During	O
reprogramming,	O
somatic	O
cell-specific	O
genes	O
are	O
suppressed,	O
while	O
embryonic	B
stem	I
cell	I
(ESC)-specific	O
pluripotency	O
genes	O
are	O
induced,	O
leading	O
to	O
the	O
generation	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
with	O
undifferentiated	O
states	O
and	O
pluripotency	O
(Stadtfeld	O
et	O
al.,	O
2008).	O

This	O
method	O
is	O
not	O
to	O
be	O
confused	O
with	O
somatic	O
cell	O
reprogramming	O
which	O
involves	O
generation	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSCs)	O
from	O
somatic	O
cells	O
using	O
techniques	O
such	O
as	O
somatic	O
cell	O
nuclear	O
transfer	O
(SCNT),	O
cell-cell	O
fusion,	O
exposure	O
to	O
extracts	O
of	O
pluripotent	O
cells,	O
or	O
iPSC	O
technology	O
[26].	O

This	O
could	O
be	O
explained	O
by	O
the	O
leukemia	B
stem	I
cell	I
(LSC)	O
theory	O
in	O
which	O
rare	O
leukemic	O
blasts	O
are	O
thought	O
to	O
be	O
responsible	O
for	O
relapse	O
and	O
for	O
maintaining	O
AML.	O

In	O
order	O
to	O
understand	O
the	O
role	O
of	O
telomerase	O
in	O
leukemia	B
stem	I
cell	I
(LSC)	O
generation	O
and	O
maintenance,	O
we	O
have	O
taken	O
advantage	O
of	O
our	O
Sca1-BCR-ABLp210	O
mouse	O
model	O
of	O
human	O
chronic	O
myeloid	O
leukaemia	O
(CML),	O
a	O
paradigmatic	O
stem-cell	O
disorder	O
[23,	O
24].	O

To	O
date,	O
the	O
majority	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
studies	O
are	O
conducted	O
using	O
human	O
tumors	O
inoculated	O
into	O
severely	O
immunosuppressed	O
hosts	O
(e.g.	O

In	O
recent	O
years,	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
theory	O
has	O
emerged	O
as	O
an	O
attractive	O
hypothesis	O
for	O
tumor	O
development	O
and	O
progression.	O

Recently,	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
theory	O
has	O
emerged	O
as	O
an	O
attractive	O
hypothesis	O
for	O
tumor	O
development	O
and	O
progression.	O

Preclinical	O
efficacy	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
in	O
animal	O
models	O
for	O
systemic	O
lupus	O
erythematosus.	O

Neural	B
stem	I
cells	I
(NSCs)	O
have	O
been	O
successfully	O
derived	O
from	O
PSCs	O
and	O
several	O
protocols	O
for	O
PSCs	O
differentiation	O
into	O
a	O
broad	O
variety	O
of	O
mature	O
neurons	O
and	O
glial	O
cell	O
subtypes	O
have	O
been	O
published	O
(Srikanth	O
and	O
Young-Pearse,	O
2014).	O

Mesenchymal	B
stem	I
cell	I
(MSC)	O
gene	O
therapy	O
have	O
been	O
widely	O
used	O
in	O
clinical	O
trials	O
due	O
to	O
their	O
heterogenetic	O
properties	O
(Bianco	O
2014).	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
attenuate	O
cutaneous	O
sclerodermatous	O
graft-versus-host	O
disease	O
(Scl-GVHD)	O
through	O
inhibition	O
of	O
immune	O
cell	O
infiltration	O
in	O
a	O
mouse	O
model.	O

Recent	O
advances	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
research	O
have	O
turned	O
limitations	O
of	O
prior	O
and	O
current	O
research	O
into	O
possibilities.	O

In	O
another	O
study,	O
functional	O
DA	O
neurons	O
were	O
generated	O
from	O
neuroepithelial	B
stem	I
cells	I
(NESCs)	O
derived	O
from	O
hiPSCs	O
using	O
a	O
phase-guided	O
3D	O
cell	O
culture	O
microfluidic	O
bioreactor.	O

Notch	O
signaling	O
augments	O
BMP9-induced	O
bone	O
formation	O
by	O
promoting	O
the	O
osteogenesis-angiogenesis	O
coupling	O
process	O
in	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
Cell.	O

However,	O
the	O
sg2/sg3	O
MA9	O
cells	O
showed	O
a	O
significantly	O
larger	O
population	O
of	O
cells	O
expressing	O
the	O
c-Kit	O
progenitor	O
marker	O
(Figure	O
3F,H),	O
which	O
has	O
been	O
associated	O
with	O
the	O
leukaemia	B
stem	I
cell	I
(LSC)	O
in	O
AMLs	O
including	O
MA9	O
[36,37].	O

Development	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
using	O
forced	O
expression	O
of	O
specific	O
sets	O
of	O
transcription	O
factors	O
has	O
changed	O
the	O
field	O
of	O
stem	O
cell	O
research	O
extensively.	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
mouse	O
[10]	O
and	O
subsequently	O
from	O
human	O
blastocysts	O
[11]	O
are	O
considered	O
pluripotent.	O

MNCs	O
of	O
normal	O
A	O
and	O
normal	O
B	O
were	O
enriched	O
for	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
by	O
CD34	O
cell	O
surface	O
marker	O
selection	O
using	O
the	O
CD34	O
MicroBead	O
kit,	O
human	O
(Miltenyi	O
Biotec)	O
according	O
to	O
the	O
manufacturer’s	O
instructions.	O

Therefore,	O
we	O
hypothesized	O
that	O
this	O
tumor	O
reprogramming	O
fate	O
at	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
level	O
should	O
be	O
the	O
target	O
where,	O
at	O
least	O
partly,	O
the	O
action	O
of	O
those	O
genetic	O
determinants	O
takes	O
place,	O
such	O
as	O
modifier	O
genes,	O
which	O
determine	O
the	O
differences	O
among	O
individuals	O
regarding	O
tumor	O
susceptibility,	O
treatment	O
response,	O
and	O
evolution..	O

At	O
the	O
base	O
of	O
the	O
crypts,	O
the	O
intestinal	B
stem	I
cell	I
(ISC)	O
niche	O
enables	O
the	O
constant	O
regeneration	O
of	O
the	O
intestinal	O
lining	O
(e.g.	O

The	O
sox	O
family	O
of	O
transcription	O
factors:	O
versatile	O
regulators	O
of	O
stem	O
and	O
progenitor	O
cell	O
fate.	O
In	O
this	O
context,	O
human	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
are	O
revolutionising	O
models	O
for	O
probing	O
biological	O
questions	O
in	O
multiple	O
fields,	O
as	O
well	O
as	O
being	O
hailed	O
as	O
future	O
treatments	O
for	O
a	O
multitude	O
of	O
diseases	O
with	O
the	O
potential	O
to	O
more	O
accurately	O
reflect	O
in	O
vivo	O
human	O
cell	O
types	O
(Hyman	O
and	O
Simons,	O
2011;	O
Zhang	O
and	O
Reilly,	O
2017).	O

To	O
investigate	O
the	O
role	O
of	O
matrix	O
rigidity	O
on	O
satellite	O
cell	O
fate,	O
freshly	O
isolated	O
and	O
FACS	O
(fluorescence	O
activated	O
cell	O
sorting)	O
enriched	O
muscle	B
stem	I
cells	I
(MuSCs)	O
were	O
cultured	O
on	O
PEG	O
hydrogels	O
with	O
differing	O
mechanical	O
properties	O
but	O
constant	O
ligand	O
density	O
[9].	O

A	O
biomimetic	O
biomaterials	O
approach	O
in	O
conjunction	O
with	O
functional	O
assays	O
in	O
mice	O
demonstrated	O
that	O
muscle	B
stem	I
cell	I
(MuSC)	O
self-renewal	O
can	O
be	O
maintained	O
in	O
culture	O
if	O
cells	O
are	O
propagated	O
upon	O
a	O
substrate	O
that	O
recapitulates	O
the	O
mechanical	O
properties	O
of	O
the	O
native	O
skeletal	O
muscle	O
tissue,	O
a	O
physical	O
property	O
of	O
the	O
stem	O
cell	O
niche	O
[9].	O

The	O
intestinal	O
epithelium	O
is	O
the	O
most	O
rapidly	O
self-renewing	O
tissue	O
in	O
adult	O
mammals,	O
which	O
renews	O
every	O
3–5	O
days	O
in	O
mice.1	O
Homeostasis	O
of	O
the	O
intestinal	O
epithelium	O
is	O
dependent	O
on	O
intestinal	B
stem	I
cells	I
(ISCs)	O
and	O
a	O
balance	O
among	O
cell	O
proliferation,	O
migration,	O
differentiation,	O
and	O
cell	O
death.1,	O
2	O
Several	O
ISC	O
populations	O
with	O
possible	O
overlap	O
have	O
recently	O
been	O
identified	O
in	O
mouse,	O
including	O
the	O
actively	O
cycling	O
columnar	O
cells	O
at	O
the	O
crypt	O
base	O
(CBCs)	O
marked	O
by	O
Lgr5	O
or	O
CD133,	O
and	O
the	O
slow	O
cycling	O
cells	O
in	O
the	O
+4	O
area	O
marked	O
by	O
Bmi1,	O
DCLK-1	O
(also	O
known	O
as	O
DCAMKL-1),	O
or	O
mTERT.	O

In	O
contrast,	O
the	O
self-renewal	O
and	O
differentiation	O
potential	O
of	O
human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
make	O
them	O
a	O
promising	O
alternative	O
cell	O
source	O
for	O
cell	O
replacement	O
therapy	O
for	O
PD.	O

Human	B
embryonic	I
stem	I
cells	I
(hESCs)	O
and	O
adult	O
stem	O
cell	O
sources	O
such	O
as	O
mesenchymal	O
stem	O
cells	O
have	O
been	O
shown	O
to	O
be	O
capable	O
of	O
generating	O
DA	O
neurons	O
in	O
cell	O
culture	O
models.	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
belong	O
to	O
a	O
category	O
of	O
clinically	O
relevant	O
cell	O
types	O
that	O
have	O
the	O
potential	O
to	O
be	O
utilized	O
for	O
cell-based	O
therapies,	O
because	O
complicated	O
culturing	O
or	O
handling	O
techniques	O
are	O
not	O
required	O
to	O
yield	O
clinically	O
practical	O
quantities.	O

Importantly,	O
Wwp2-mediated	O
Oct4	O
repression	O
could	O
impede	O
stemness	O
re-establishment	O
since	O
both	O
Wwp2	O
knockout	O
and	O
mutation	O
in	O
the	O
Oct4	O
ubiquitination	O
site	O
increase	O
the	O
efficiency	O
of	O
somatic	O
cell	O
reprogramming	O
into	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
[74].	O

Neural-like	O
cell	O
lines	O
developed	O
to	O
study	O
ASD	O
have	O
been	O
obtained	O
by	O
the	O
differentiation	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
from	O
patients	O
or	O
by	O
the	O
inactivation	O
of	O
the	O
selected	O
ASD-associated	O
gene	O
in	O
controls,	O
using	O
genomic	O
editing	O
systems..	O

We	O
also	O
discuss	O
the	O
breast's	B
stem	I
cell	I
populations	O
and	O
their	O
relevance	O
to	O
cancer	O
stem	O
cells	O
(CSCs)	O
and	O
cancer	O
development.	O

ECM	O
proteins	O
in	O
the	O
BM	O
connect	O
the	O
basal	B
stem	I
cells	I
through	O
various	O
anchoring	O
complexes,	O
which	O
coordinate	O
the	O
actin	O
and	O
microtubule	O
network	O
and	O
establish	O
cell	O
polarity,	O
so	O
that	O
the	O
basal	O
stem	O
cells	O
(EpSCs)	O
differentiate	O
and	O
proliferate	O
[2].	O

The	O
number	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
(hiPSC)	O
lines	O
established	O
from	O
each	O
sample	O
is	O
also	O
shown.	O

Establishment	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
line	O
from	O
a	O
75-year	O
old	O
patient	O
with	O
late	O
onset	O
Alzheimer’s	O
disease	O
(LOAD)	O
Stem	O
Cell	O
Res.	O

(7)	O
Melatonin	O
rescues	O
the	O
inhibitory	O
effects	O
of	O
miR‐363	O
on	O
neural	B
stem	I
cell	I
(NSC)	O
proliferation	O
and	O
neuronal	O
differentiation	O
in	O
vitamin	O
A	O
deficiency-	O
(VAD-)	O
associated	O
congenital	O
spinal	O
deformities.	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
have	O
generated	O
a	O
great	O
deal	O
of	O
interest	O
and	O
promise	O
as	O
a	O
potential	O
source	O
of	O
cells	O
for	O
cell-based	O
therapeutic	O
strategies	O
for	O
tissue	O
repair	O
and	O
regenerative	O
diseases,	O
primarily	O
owing	O
to	O
their	O
intrinsic	O
ability	O
to	O
self	O
renew	O
and	O
differentiate	O
into	O
functional	O
cell	O
types	O
that	O
constitute	O
the	O
tissue	O
in	O
which	O
they	O
exist.	O

Unexpected	O
evidence	O
that	O
chronic	O
IGF-1	O
deficiency	O
in	O
Laron	O
dwarf	O
mice	O
maintains	O
high	O
levels	O
of	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
in	O
BM	O
-	O
are	O
HSCs	O
gradually	O
depleted	O
from	O
BM	O
with	O
age	O
in	O
an	O
IGF-1-dependent	O
manner?	O
Implications	O
for	O
the	O
novel	O
effect	O
of	O
caloric	O
restriction	O
on	O
the	O
hematopoietic	O
stem	O
cell	O
compartment	O
and	O
longevity.	O

GDNF	O
deletion	O
in	O
TPCs	O
disrupts	O
spermatogonia	O
development,	O
indicating	O
an	O
essential	O
role	O
of	O
TPCs	O
in	O
maintaining	O
the	O
spermatogonial	B
stem	I
cell	I
(SSC)	O
niche	O
[14].	O

We	O
have	O
begun	O
to	O
establish	O
in	O
vitro	O
BBB	O
models	O
from	O
inducible	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
of	O
MS	O
patients	O
to	O
explore	O
the	O
impact	O
of	O
MS	O
patients	O
specific	O
brain	O
barrier	O
alterations	O
in	O
directing	O
T	O
cell	O
migration	O
into	O
the	O
CNS..	O

We	O
have	O
previously	O
described	O
the	O
generation	O
and	O
characterization	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
from	O
fibroblasts	O
of	O
NS	O
patients,	O
who	O
did	O
(NS/JMML)	O
and	O
did	O
not	O
(NS)	O
go	O
on	O
to	O
develop	O
JMML,	O
which	O
faithfully	O
model	O
leukemia	O
progression	O
after	O
differentiation	O
into	O
myeloid	O
cells.23	O
Derivation	O
of	O
iPSCs	O
from	O
noncancerous	O
cells	O
allows	O
the	O
investigation	O
of	O
these	O
PTPN11	O
mutations	O
in	O
the	O
absence	O
of	O
secondary	O
or	O
additional	O
genomic	O
alterations	O
that	O
frequently	O
occur	O
during	O
leukemia	O
progression.24	O
This	O
overcomes	O
the	O
issue	O
of	O
the	O
limited	O
availability	O
of	O
primary	O
cell	O
material	O
for	O
studies	O
of	O
this	O
disease..	O

The	O
use	O
of	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
for	O
tissue	O
engineering	O
and	O
regenerative	O
medicine	O
applications	O
is	O
attractive,	O
in	O
part	O
due	O
to	O
their	O
ability	O
to	O
differentiate	O
into	O
multiple	O
cell	O
types	O
and	O
their	O
ease	O
of	O
expansion	O
in	O
vitro.	O

GSEA	O
analysis	O
of	O
8227	O
AML	O
fractions	O
and	O
the	O
leukemia	B
stem	I
cell	I
(LSC)	O
signatures	O
were	O
performed	O
using	O
the	O
control	O
sample	O
data	O
from	O
GSE55814.	O

The	O
risk	O
of	O
tumorigenicity	O
in	B
the	I
stem	I
cell	I
platform	O
has	O
been	O
highlighted	O
in	O
many	O
studies,	O
including	O
preclinical	O
dose-escalation	O
tests	O
for	O
the	O
first-in-human	O
induced	O
pluripotent	O
stem	O
cells	O
(iPSC)	O
clinical	O
trial	O
to	O
be	O
approved	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
in	O
2009.	O

We	O
performed	O
RT-qPCR	O
in	O
MG-63	O
cells	O
seeded	O
in	O
the	O
3D	O
scaffold,	O
treated	O
for	O
72	O
h	O
with	O
non-lethal	O
doses	O
of	O
PAR	O
30,	O
60	O
and	O
120	O
s	O
to	O
analyze	O
the	O
expression	O
of	O
genes	O
with	O
well-known	O
functions	O
of	O
cancer	B
stem	I
cell	I
(CLSC)	O
phenotype.	O

Nanomedicine	O
has	O
a	O
leading	O
role	O
in	O
pharmaceutical	O
research	O
and	O
development	O
of	O
clinical	O
protocols,	O
mainly	O
in	O
the	O
form	O
of	O
nanoparticle-based	O
delivery	O
systems	O
for	O
drugs	O
and	O
imaging	O
agents,	O
especially	O
in	O
the	O
field	O
of	O
stem	B
cell	I
(SC)	O
therapies	O
[1].	O

Regarding	O
therapeutic	O
application,	O
iPSCs	O
overcame	O
the	O
practical	O
and	O
ethical	O
difficulties	O
associated	O
with	O
the	O
use	O
of	O
embryonic	B
stem	I
cells	I
(ESCs)	O
for	O
cell	O
replacement	O
therapies	O
(CRTs)	O
(Takahashi	O
et	O
al.,	O
2007).	O

Takahashi	O
and	O
Yamanaka’s	O
pioneering	O
studies	O
in	O
the	O
2000s	O
[13]	O
led	O
to	O
rapid	O
expansion	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technologies,	O
and	O
opened	O
unprecedented	O
opportunities	O
for	O
disease	O
modeling.	O

Bone	B
marrow	I
mesenchymal	I
stem	I
cells	I
(BMMSCs)	O
are	O
a	O
cell	O
population	O
characterized	O
by	O
rapid	O
proliferation,	O
low	O
immunogenicity,	O
pluripotency,	O
tissue	O
repair	O
ability,	O
and	O
immunosuppression13,14.	O

The	O
advent	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
(Takahashi	O
&	O
Yamanaka,	O
2006)	O
has	O
made	O
it	O
possible	O
to	O
reprogram	O
human	O
somatic	O
cells	O
to	O
pluripotency	O
(Park	O
et	O
al,	O
2008b;	O
Takahashi	O
et	O
al,	O
2007;	O
Yu	O
et	O
al,	O
2007),	O
thus	O
enabling	O
the	O
generation	O
of	O
disease-specific	O
iPSC	O
(Lee	O
&	O
Studer,	O
2010).	O

In	O
the	O
following	O
sections,	O
we	O
will	O
focus	O
mostly	O
on	O
the	O
biological	O
actions	O
of	O
TGFβ	O
but	O
also	O
make	O
reference	O
to	O
signalling	O
and	O
mechanistic	O
details	O
wherever	O
possible,	O
pointing	O
out	O
how	O
TGFβ	O
can	O
contribute	O
to	O
the	O
biology	O
of	O
cancer	B
stem	I
cells	I
(CSCs)	O
and	O
various	O
stromal	O
cell	O
types	O
in	O
order	O
to	O
facilitate	O
cancer	O
metastasis.	O

Chromatin	O
signatures	O
obtained	O
by	O
epigenomic	O
profiling	O
of	O
a	O
cohort	O
of	O
human	B
embryonic	I
stem	I
cell	I
(hESC)	O
lines	O
can	O
be	O
used	O
to	O
generate	O
hESC	O
reference	O
epigenomes	O
(left	O
panels).	O

We	O
have	O
witnessed	O
remarkable	O
developments	O
in	O
pluripotent	B
stem	I
cell	I
(PSC)	O
technologies	O
over	O
the	O
past	O
few	O
decades.	O

Generation	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
line	O
from	O
a	O
patient	O
with	O
triple	O
negative	O
breast	O
cancer	O
with	O
hereditary	O
exon	O
17	O
deletion	O
of	O
BRCA1	O
gene.	O

The	O
generation	O
of	O
human	B
embryonic	I
stem	I
cell	I
(hESC)	O
lines	O
(Shamblott	O
et	O
al.	O

The	O
advent	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
(Takahashi	O
et	O
al.	O

To	O
seek	O
replication	O
for	O
the	O
predicted	O
therapeutic	O
effect	O
of	O
VPA	O
on	O
M30	O
gene	O
expression,	O
and	O
to	O
assess	O
the	O
relevance	O
of	O
gene	O
expression	O
changes	O
observed	O
in	O
the	O
cancer	O
cell	O
lines	O
used	O
by	O
CMap	O
to	O
neurons,	O
we	O
analysed	O
gene	O
expression	O
changes	O
in	O
16	O
day	O
neurons	O
differentiated	O
from	O
mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
before	O
and	O
after	O
treatment	O
with	O
VPA	O
(here	O
studying	O
VPA	O
as	O
its	O
sodium	O
salt	O
which	O
is	O
therapeutically	O
equivalent	O
to	O
VPA)	O
(see	O
‘Methods’).	O

However,	O
cell	O
expansion	O
in	O
culture	O
can	O
lead	O
to	O
unwanted	O
cellular	O
differentiation,	O
particularly	O
in	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
13.	O

A	O
subpopulation	O
of	O
tumour	O
cells,	O
identified	O
by	O
co-expression	O
of	O
epithelial	O
cell	O
adhesion	O
molecule	O
(EPCAM),	O
the	O
basal	O
cell	O
marker	O
NGFR,	O
and	O
the	O
bronchioalveolar	B
stem	I
cell	I
(BASC)	O
marker	O
stem	O
cell	O
antigen-1	O
(SCA1,	O
also	O
known	O
as	O
LY6A),	O
was	O
found	O
to	O
have	O
the	O
ability	O
to	O
propagate	O
the	O
tumour	O
upon	O
implantation	O
into	O
immunocompromised	O
mice73.	O

Indeed,	O
the	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
pioneered	O
by	O
Shinya	O
Yamanaka	O
in	O
2006	O
has	O
potential	O
for	O
unlimited	O
expansion	O
and	O
can	O
generate	O
the	O
cells	O
of	O
all	O
three	O
germ	O
layers27.	O

Induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
generation	O
by	O
Sendai	O
virus-mediated	O
gene	O
transfer.	O

miR-1306-3p	O
Neurons	O
generated	O
from	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
derived	O
from	O
6	O
control	O
subjects	O
and	O
6	O
schizophrenia	O
subjects.	O

Neurons	O
produced	O
from	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
derived	O
from	O
controls	O
and	O
SCZ.	O

Neurons	O
generated	O
from	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
derived	O
from	O
controls	O
and	O
SCZ.	O

The	O
use	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
therapy	O
to	O
treat	O
clinical	O
disease	O
may	O
be	O
optimized	O
through	O
selection	O
and	O
pre‐conditioning	O
methods	O
that	O
would	O
enhance	O
their	O
immunomodulatory	O
functions.	O

Mesenchymal	B
stem	I
cell	I
(MSC)	O
therapy	O
may	O
reduce	O
intra‐renal	O
inflammation	O
and	O
fibrosis	O
following	O
systemic	O
delivery	O
and	O
has	O
demonstrated	O
modest	O
effects	O
in	O
feline	O
CKD	O
following	O
intravenous	O
delivery.	O

Accumulating	O
evidence	O
indicates	O
that	O
understanding	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
behaviors	O
holds	O
great	O
promise	O
for	O
the	O
treatment	O
of	O
human	O
cancers.	O

Induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
specifically	O
bypass	O
the	O
need	O
for	O
embryonic	O
tissue	O
as	O
they	O
can	O
be	O
generated	O
by	O
reprogramming	O
any	O
somatic	O
cell	O
42,	O
43.	O

Human	B
mesenchymal	I
stem	I
cell	I
(hMSCs)	O
(Lonza,	O
Walkersville,	O
MD,	O
USA)	O
were	O
cultured	O
in	O
Minimum	O
Essential	O
Medium	O
(Gibco,	O
Invitrogen,	O
USA),	O
containing	O
10%	O
FBS	O
(Gibco,	O
Invitrogen,	O
USA)	O
and	O
100	O
U/ml	O
penicillin,	O
100	O
mg/ml	O
streptomycin	O
sulfate	O
(Gibco,	O
Grand	O
Island,	O
NY,	O
USA).	O

(B)	O
Generation	O
of	O
embryonic	B
stem	I
cells	I
(ESCs)	O
by	O
selection	O
of	O
inner	O
cell	O
mass	O
from	O
a	O
blastocyst,	O
culture,	O
and	O
then	O
reprogramming/genome	O
editing.90,93.	O

Some	O
of	O
the	O
regulatory	O
roles	O
played	O
by	O
linc-ROR	O
are	O
the	O
maintenance	O
of	B
stem	I
cell	I
pluripotency,	O
triggering	O
the	O
epithelial-mesenchymal	O
transition	O
(EMT)	O
[105],	O
hypoxia,	O
in	O
the	O
proliferation	O
of	O
cancerous	O
cells	O
acting	O
both	O
as	O
promotor/inhibitor	O
and	O
in	O
self-renewal	O
of	O
glioma	O
stem	O
cells	O
(GSCs)	O
via	O
inhibition	O
of	O
KLF4	O
expression.	O

(a,b)	O
Normalized	O
gene	O
expression	O
levels	O
of	O
CSPG4,	O
in	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
and	O
OSA	O
biopsies	O
as	O
compared	O
with	O
normal	O
osteoblasts	O
in	O
toto	O
(mean	O
±	O
SD)	O
(a)	O
or	O
divided	O
according	O
to	O
the	O
Huvos	O
system	O
grading	O
(geometric	O
mean)	O
(b).	O

There	O
is	O
concern	O
that	O
the	O
stresses	O
of	O
inducing	O
pluripotency	O
may	O
lead	O
to	O
deleterious	O
DNA	O
mutations	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
lines,	O
which	O
would	O
compromise	O
their	O
use	O
for	O
cell	O
therapies.	O

Immunohistochemistry	O
and	O
flow	O
cytometry	O
analysis	O
of	O
12	O
tumor	O
samples	O
obtained	O
from	O
patients	O
with	O
high	O
grade	O
gliomas	O
revealed	O
that	O
a	O
considerable	O
population	O
(2–19%)	O
of	O
cells	O
in	O
all	O
malignant	O
gliomas	O
expressed	O
IL-17RA,	O
with	O
remarkable	O
co-expression	O
of	O
the	O
glioma	B
stem	I
cell	I
(GSC)	O
markers	O
CD133,	O
Nestin,	O
and	O
Sox2.	O

The	O
more	O
severely	O
affected	O
twin	O
(designated	O
as	O
the	O
affected	O
proband,	O
AP,	O
and	O
from	O
whom	O
the	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
model	O
of	O
severe	O
ASD	O
affectation	O
was	O
acquired)	O
began	O
to	O
exhibit	O
delays	O
in	O
development	O
by	O
9	O
months	O
of	O
age.	O

Melanocyte	B
stem	I
cells	I
(McSCs)	O
and	O
mouse	O
models	O
of	O
hair	O
graying	O
serve	O
as	O
useful	O
systems	O
to	O
uncover	O
mechanisms	O
involved	O
in	O
stem	O
cell	O
self-renewal	O
and	O
the	O
maintenance	O
of	O
regenerating	O
tissues.	O

Human	B
mesenchymal	I
stem	I
cell	I
(hMSC)	O
markers	O
were	O
observed	O
on	O
CD105+	O
isolated	O
cells.	O

Single	O
cell	O
sequencing	O
of	O
neural	B
stem	I
cells	I
(NSCs)	O
demonstrated	O
that	O
in	O
response	O
to	O
injury,	O
there	O
is	O
a	O
dramatic	O
increase	O
in	O
transcription	O
of	O
the	O
genes	O
involved	O
in	O
ribosome	O
biogenesis	O
(Llorens-Bobadilla	O
et	O
al.,	O
2015).	O

A	O
balance	O
between	O
quiescence	O
and	O
proliferation	O
is	O
critical	O
for	O
proper	O
maintenance	O
of	O
the	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
pool.	O

Generation	O
and	O
characterization	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
(hiPSC)	O
lines	O
from	O
an	O
Alzheimer's	O
disease	O
(ASUi003-A)	O
and	O
non-demented	O
control	O
(ASUi004-A)	O
patient	O
homozygous	O
for	O
the	O
Apolipoprotein	O
e4	O
(APOE4)	O
risk	O
variant.	O

Generation	O
and	O
characterization	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
(hiPSC)	O
lines	O
from	O
an	O
Alzheimer's	O
disease	O
(ASUi001-A)	O
and	O
non-demented	O
control	O
(ASUi002-A)	O
patient	O
homozygous	O
for	O
the	O
Apolipoprotein	O
e4	O
(APOE4)	O
risk	O
variant.	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
are	O
pluripotent	O
cells	O
located	O
in	O
the	O
inner	O
cell	O
mass	O
of	O
early	O
embryos	O
that	O
have	O
the	O
capacity	O
for	O
long-term	O
self-renewal	O
and	O
the	O
ability	O
to	O
form	O
all	O
cell	O
types	O
of	O
the	O
embryo	O
proper.	O

Induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
Patient-specific	O
genotype	O
Cells	O
can	O
be	O
differentiated	O
to	O
better	O
reflect	O
photoreceptor	O
cell	O
morphology	O
and	O
gene	O
expression	O
profiles.	O

(C):	O
Immnoblotting	O
analysis	O
was	O
used	O
to	O
examine	O
the	O
activation	O
of	O
Hedgehog	O
signaling	O
and	O
expression	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
markers	O
in	O
the	O
cells	O
described	O
in	O
(B).	O

Human	B
pluripotent	I
stem	I
cell	I
(hPSC)	O
technology	O
has	O
the	O
potential	O
to	O
overcome	O
those	O
challenges	O
and	O
to	O
present	O
a	O
fully	O
human,	O
defined	O
and	O
scalable	O
platform	O
to	O
study	O
neuroinflammation.	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
have	O
been	O
broadly	O
used	O
in	O
cell	O
therapies	O
based	O
on	O
various	O
preclinical	O
and	O
clinical	O
studies	O
regarding	O
their	O
safety	O
and	O
efficacy	O
(Kamen	O
et	O
al.,	O
2018;	O
Wilson	O
et	O
al.,	O
2015).	O

Several	O
cell	O
types,	O
such	O
as	O
T	O
cells,	O
HSCs,	O
and	O
fibroblasts,	O
can	O
be	O
reprogramed	O
into	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
by	O
transducing	O
these	O
cells	O
with	O
a	O
SIN-lentiviral	O
vector	O
expressing	O
three	O
pluripotency	O
genes,	O
OCT4,	O
SOX2,	O
and	O
KLF4	O
(88–90).	O

In	O
light	O
of	O
the	O
latest	O
advances	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology,	O
future	O
epigenomic	O
brain	O
approaches	O
will	O
involve	O
the	O
study	O
of	O
specific	O
neuronal	O
populations	O
derived	O
from	O
patient-cells,	O
allowing	O
a	O
better	O
understanding	O
of	O
the	O
disorder	O
by	O
disease	O
modelling	O
and	O
a	O
faster	O
drug	O
screening/repurposing	O
in	O
a	O
personalized	O
manner	O
[200]..	O

Human	B
mesenchymal	I
stem	I
cells	I
(hMSCs)	O
possess	O
the	O
potential	O
to	O
differentiate	O
into	O
numerous	O
cell	O
lineages,	O
such	O
as	O
adipocytes,	O
osteoblasts,	O
fibroblasts	O
and	O
chondrocytes.	O

This	O
leads	O
enhanced	O
Igf2	O
expression	O
and	O
Igfr1	O
translation,	O
playing	O
a	O
significant	O
role	O
in	O
the	O
increased	O
activation	O
and	O
proliferation	O
of	O
hematopoietic	B
stem	I
cell	I
(HSCs)	O
[61]..	O

These	O
mechanisms	O
may	O
not	O
be	O
limited	O
to	O
interactions	O
between	O
tumor	O
cells	O
and	O
fibroblasts,	O
but	O
also	O
have	O
been	O
noted	O
in	O
a	O
two-way	O
regulation	O
in	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
differentiation	O
to	O
CAFs	O
by	O
factors	O
from	O
mammary	O
cancer	O
cells	O
and	O
CAFs	O
in	O
turn	O
promoting	O
cancer	O
development.	O

Supporting	O
the	O
leukemia	O
evidence	O
for	O
a	O
critical	O
role	O
of	O
MLL1	O
in	O
hematopoiesis,	O
mouse	O
knockout	O
studies	O
showed	O
that	O
Mll1	O
is	O
required	O
for	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
function	O
(Ernst	O
et	O
al.,	O
2004;	O
Jude	O
et	O
al.,	O
2007).	O

Menin-null	O
(Men1-KO)	O
mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
can	O
undergo	O
in	O
vitro	O
differentiation	O
into	O
adipocytes	O
and	O
show	O
increased	O
adipocyte	O
cell	O
size.	O

Cancer	B
stem	I
cells	I
(CSCs)	O
are	O
a	O
small	O
subpopulation	O
of	O
cancer	O
cells	O
with	O
increased	O
renewal	O
capacity	O
that	O
play	O
roles	O
in	O
tumor	O
growth,	O
cell	O
and	O
molecular	O
heterogeneity,	O
differentiation,	O
and	O
metastasis	O
[255,256].	O

However,	O
the	O
role	O
of	O
circRNAs	O
in	O
neural	B
stem	I
cell	I
(NSC)	O
differentiation	O
and	O
the	O
treatment	O
of	O
ischaemic	O
stroke	O
remains	O
unknown..	O

The	O
classical	O
approach	O
to	O
developing	O
a	O
protocol	O
for	O
the	O
human	O
mDA	O
neuronal	O
differentiation	O
from	O
hPSCs	O
was	O
based	O
on	O
adaptations	O
of	O
mouse	B
neural	I
stem	I
cell	I
(mNSC)	O
and	O
mESC	O
protocols,	O
which	O
required	O
co-culture	O
with	O
feeder	O
cells	O
(37).	O

Induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
are	O
somatic	O
cells	O
that	O
have	O
been	O
transcriptionally	O
reprogrammed	O
to	O
an	O
embryonic	O
stem	O
cell	O
(ESC)-like	O
state.	O

Induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
are	O
somatic	O
cells	O
that	O
have	O
been	O
transcriptionally	O
reprogrammed	O
to	O
an	O
embryonic	O
stem	O
cell	O
(ESC)-like	O
state.	O

Hematopoietic	B
stem	I
cells	I
(HSCs)	O
differentiate	O
into	O
common	O
lymphoid	O
progenitors	O
(CLPs),	O
and	O
then	O
differentiate	O
into	O
NK	O
cell	O
progenitors	O
(NKPs).	O

Moreover,	O
the	O
Lange	O
laboratory	O
demonstrated	O
that	O
PR-A	O
was	O
a	O
driver	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
expansion	O
in	O
BCa	O
cells	O
and	O
that	O
phosphorylation	O
of	O
PR-A	O
was	O
required	O
for	O
the	O
expression	O
of	O
CSC-associated	O
genes	O
(Truong	O
et	O
al.	O

We	O
then	O
performed	O
transcriptome	O
analysis	O
of	O
hematopoieitic	B
stem	I
cell	I
(HSC)	O
and	O
myeloid	O
progenitor	O
cell-enriched	O
populations	O
from	O
the	O
bone	O
marrow	O
of	O
Ts(1716)65Dn	O
mice	O
to	O
define	O
the	O
relevant	O
biological	O
and	O
genetic	O
changes	O
by	O
which	O
trisomy	O
predisposes	O
to	O
development	O
of	O
myeloproliferation	O
in	O
this	O
DS	O
model	O
[20].	O

In	O
this	O
review,	O
we	O
will	O
use	O
the	O
word	O
“reprogramming”	O
specifically	O
in	O
reference	O
to	O
the	O
formation	O
of	O
pluripotent	B
stem	I
cells	I
(PSCs)	O
from	O
differentiated	O
cell	O
states,	O
especially	O
focusing	O
on	O
the	O
iPSC	O
technology.	O

All	O
myeloid	O
and	O
lymphoid	O
blood	O
lineages	O
are	O
differentiated	O
from	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
(Chao	O
et	O
al.,	O
2008),	O
during	O
which	O
the	O
activity	O
of	O
genes	O
(e.g.,	O
KCNH2,	O
SUSD3)	O
that	O
control	O
cell	O
fate	O
is	O
highly	O
regulated	O
by	O
methylation	O
status	O
(Farlik	O
et	O
al.,	O
2016).	O

Over	O
the	O
past	O
decade,	O
the	O
development	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
has	O
provided	O
a	O
novel	O
means	O
to	O
generate	O
disease-relevant	O
cells	O
for	O
in	O
vitro	O
investigation	O
of	O
the	O
molecular	O
and	O
cellular	O
mechanisms	O
underpinning	O
human	O
complex	O
disorders	O
[1,2].	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
cultured	O
in	O
spheroids	O
have	O
enhanced	O
anti-inflammatory,	O
angiogenic,	O
and	O
tissue	O
reparative/regenerative	O
effects	O
with	O
improved	O
cell	O
survival	O
after	O
transplantation.	O

It	O
causes	O
drastic	O
changes	O
in	O
gene	O
expression	O
profiles,	O
as	O
best	O
exemplified	O
in	O
the	O
fertilization	O
process	O
and	O
the	O
somatic	O
cell	O
reprogramming	O
process	O
during	O
the	O
development	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
[137].	O

Neural	B
stem	I
cells	I
(NSCs)	O
generate	O
all	O
major	O
neural	O
cell	O
types	O
in	O
the	O
central	O
nervous	O
system	O
(CNS),	O
including	O
neurons,	O
astrocytes,	O
and	O
oligodendrocytes	O
[1–3].	O

Cancer	B
stem	I
cells	I
(CSCs)	O
displaying	O
a	O
CD44+	O
(high)/CD24-(low)	O
cell	O
surface	O
antigen	O
expression	O
profile	O
may	O
act	O
as	O
tumor-initiating	O
cells	O
[120]	O
and	O
contribute	O
to	O
intra-tumoral	O
heterogeneity	O
[29,79].	O

Human	O
RPE	O
cells	O
have	O
been	O
generated	O
from	O
embryonic	B
stem	I
cells	I
(ESCs)	O
and	O
iPS	O
cells	O
offering	O
new	O
promise	O
for	O
cell	O
replacement	O
therapy	O
in	O
AMD	O
[13,15,18,70].	O

However,	O
the	O
most	O
compelling	O
evidence	O
that	O
SMCs	O
and	O
Mϕs	O
are	O
being	O
misidentified	O
within	O
human	O
advanced	O
coronary	O
lesions	O
comes	O
from	O
studies	O
of	O
cross	O
gender	O
bone	O
marrow	O
transplant	O
subjects	O
showing	O
that	O
>	O
10%	O
of	O
ACTA2+	O
cells	O
within	O
lesions	O
are	O
of	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
and	O
not	O
SMC	O
origin14.	O

Human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
have	O
the	O
capacity	O
to	O
differentiate	O
into	O
the	O
three	O
somatic	O
germ	O
layers	O
and	O
all	O
cell	O
types	O
of	O
the	O
body,	O
and	O
are	O
an	O
alternative	O
and	O
renewable	O
source	O
of	O
hepatocytes	O
that	O
could	O
be	O
used	O
for	O
drug	O
toxicity	O
and	O
metabolization	O
studies.	O

Transcriptome-wide	O
identification	O
of	O
CTCF-binding	O
RNA	O
sites	O
was	O
performed	O
in	O
two	O
previous	O
studies:	O
one	O
for	O
human	O
bone	O
osteosarcoma	O
epithelial	O
cells	O
(U2OS	O
cells)	O
with	O
two	O
biological	O
replicates	O
using	O
photoactivatable	O
ribonucleoside-enhanced	O
cross-linking	O
and	O
immunoprecipitation	O
followed	O
by	O
deep	O
sequencing	O
(14),	O
and	O
the	O
other	O
for	O
mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
with	O
two	O
biological	O
replicates	O
on	O
Days	O
0	O
and	O
3	O
of	O
cell	O
differentiation	O
by	O
CLIP-seq	O
(13).	O

Brain-specific	O
ablation	O
of	O
FoxO3a	O
or	O
combined	O
inactivation	O
of	O
FoxO1a/3a/4	O
in	O
mice	O
resulted	O
in	O
a	O
phenotype	O
that	O
resembled	O
age-dependent	O
depletion	O
of	O
the	O
neural	B
stem	I
cell	I
(NSC)	O
population	O
[290,291].	O

The	O
functional	O
potential	O
of	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
declines	O
during	O
aging,	O
and	O
it	O
contributes	O
to	O
hematopoietic	O
pathophysiology	O
in	O
the	O
elderly	O
and	O
loss	O
of	O
the	O
hematopoietic	O
cell	O
pool	O
[156,	O
157].	O

Dental	B
pulp	I
stem	I
cells	I
(DPSCs)	O
have	O
the	O
capacity	O
to	O
differentiate	O
under	O
appropriate	O
conditions	O
into	O
different	O
somatic	O
cell	O
types	O
of	O
the	O
three	O
germ	O
layers:	O
endoderm,	O
mesoderm,	O
and	O
ectoderm..	O

Dek	O
expression	O
positively	O
correlates	O
with	O
breast	B
cancer	I
stem	I
cell	I
(BCSC)	O
phenotypes.	O

After	O
the	O
identification	O
of	O
embryonic	B
stem	I
cells	I
(ESCs)	O
and	O
embryonic	O
germ	O
cells	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
blastocysts	O
and	O
post	O
implantation	O
embryos,	O
respectively,	O
the	O
next	O
advance	O
came	O
with	O
the	O
generation	O
of	O
induced	O
pluripotent	O
stem	O
cells	O
(Fig..	O

Hematopoietic	B
stem	I
cells	I
(HSCs)	O
have	O
the	O
ability	O
to	O
self-renew	O
and	O
produce	O
identical,	O
multipotent	O
daughter	O
HSCs	O
or	O
undergo	O
differentiation	O
to	O
form	O
any	O
and	O
every	O
cell	O
type	O
in	O
the	O
blood	O
system.	O

Indeed,	O
it	O
was	O
confirmed	O
that	O
SV2	O
levels	O
are	O
reduced	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
lines	O
of	O
C9ORF72	O
ALS	O
patients	O
and	O
in	O
the	O
spinal	O
cord	O
and	O
neuromuscular	O
junctions	O
of	O
poly-GA–overexpressing	O
transgenic	O
mice.	O

But	O
now	O
this	O
obstacle	O
can	O
be	O
easily	O
overcome	O
with	O
the	O
usage	O
to	O
the	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSCs)	O
technology,	O
which	O
allows	O
to	O
unveil	O
the	O
mechanisms	O
underlying	O
nucleoskeletal	O
organization	O
and	O
modulation	O
before	O
and	O
after	O
differentiation..	O

Introduction:	O
MSC	O
exosome	O
is	O
increasingly	O
accepted	O
as	O
the	O
principal	O
agent	O
that	O
underpins	O
the	O
therapeutic	O
efficacy	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
in	O
tissue	O
repair.	O

Mesenchymal	B
stem	I
cell	I
(MSC)	O
is	O
a	O
heterogeneous	O
multipotent	O
stem	O
cell	O
found	O
within	O
the	O
tumour	O
microenvironment	O
and	O
can	O
regulating	O
the	O
immune	O
system.	O

In	O
this	O
study,	O
we	O
characterize	O
the	O
microRNA,	O
tRNA,	O
and	O
piRNA	O
composition	O
of	O
EVs	O
secreted	O
from	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
(hiPSCs)	O
–	O
derived	O
3D	O
retinas	O
at	O
three	O
developmental	O
time	O
points	O
that	O
correlate	O
with	O
hallmarks	O
of	O
retinal	O
cell	O
differentiation	O
and	O
lamination	O
in	O
vivo..	O

The	O
cell	O
of	O
origin	O
for	O
OS	O
also	O
remain	O
unknown	O
but	O
cells	O
of	O
the	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
osteogenic	O
lineage	O
are	O
likely	O
candidates,	O
thus	O
indicating	O
that	O
MSCs	O
and	O
the	O
OS	O
stroma	O
cells	O
may	O
be	O
related	O
cell	O
types.	O

Cell	O
therapy	O
based	O
on	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
is	O
one	O
of	O
the	O
attractive	O
options.	O

Adipose-derived	B
stem	I
cells	I
(ASCs)	O
have	O
been	O
reported	O
as	O
an	O
important	O
component	O
of	O
regenerative	O
medicine	O
and	O
cell	O
therapy	O
for	O
hair	O
loss.	O

Introduction:	O
Immunoregulatory	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
is	O
attributed	O
to	O
extracellular	O
vesicles	O
(EVs)	O
secretion.	O

The	O
year	O
2006	O
will	O
be	O
remembered	O
monumentally	O
in	O
science,	O
particularly	O
in	B
the	I
stem	I
cell	I
biology	O
field,	O
for	O
the	O
first	O
instance	O
of	O
generation	O
of	O
induced	O
pluripotent	O
stem	O
cells	O
(iPSCs)	O
from	O
mouse	O
embryonic/adult	O
fibroblasts	O
being	O
reported	O
by	O
Takahashi	O
and	O
Yamanaka.	O

Reprogramming	O
differentiated	O
somatic	O
cells	O
to	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
enables	O
re-differentiation	O
to	O
a	O
wide	O
array	O
of	O
cell	O
types	O
(Yamanaka,	O
2012)	O
and	O
is	O
of	O
considerable	O
value	O
for	O
disease	O
modeling,	O
functional	O
genomics,	O
drug	O
discovery,	O
and	O
regenerative	O
medicine.	O

In	O
the	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
-derived	O
neural	O
cell	O
lines,	O
imbalances	O
were	O
reflected	O
in	O
an	O
attenuated	O
capacity	O
of	O
cells	O
to	O
suppress	O
accumulation	O
of	O
unfolded	O
proteins	O
upon	O
interference	O
of	O
proteostasis	O
with	O
thapsigargin.	O

Directed	O
differentiation	O
of	O
human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
combined	O
with	O
gene	O
editing	O
provides	O
a	O
powerful	O
system	O
to	O
define	O
precise	O
temporal	O
gene	O
requirements	O
for	O
progressive	O
chromatin	O
changes	O
during	O
cell	O
fate	O
transitions.	O

The	O
genomic	O
regions	O
co-bound	O
by	O
the	O
embryonic	B
stem	I
cell	I
(ESC)	O
pluripotency	O
TFs	O
Oct4,	O
Sox2,	O
and	O
Nanog	O
(OSN)	O
have	O
shown	O
robust	O
enhancer	O
activity16.	O

In	O
contrast	O
to	O
the	O
difficulty	O
of	O
obtaining	O
neuronal	O
and	O
muscle	O
cell	O
models,	O
the	O
development	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
has	O
shed	O
light	O
on	O
the	O
study	O
of	O
mitochondrial	O
diseases.	O

For	O
biomarker	O
discovery,	O
plasma	O
represents	O
the	O
best	O
source	O
for	O
repeated	O
measures	O
while	O
the	O
utilization	O
of	O
skin	O
fibroblasts	O
provides	O
an	O
outstanding	O
opportunities	O
for	O
longitudinal	O
mechanistic	O
studies	O
because	O
they	O
could	O
be	O
kept	O
in	O
culture	O
for	O
a	O
long	O
time,	O
do	O
not	O
need	O
to	O
be	O
transformed,	O
and	O
could	O
be	O
differentiated	O
into	O
disease-	O
and	O
patient-specific	O
neural	O
cell	O
lines	O
using	O
inducible	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
[52].	O

Although	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
hold	O
great	O
potential	O
for	O
the	O
study	O
of	O
human	O
diseases	O
affecting	O
disparate	O
cell	O
types,	O
they	O
have	O
been	O
underutilized	O
in	O
seeking	O
mechanistic	O
insights	O
into	O
the	O
pathogenesis	O
of	O
congenital	O
craniofacial	O
disorders.	O

The	O
emergence	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
as	O
a	O
tool	O
for	O
human	O
disease	O
modeling	O
(Takahashi	O
et	O
al.,	O
2007,	O
Takahashi	O
and	O
Yamanaka,	O
2006,	O
Tiscornia	O
et	O
al.,	O
2011,	O
Yu	O
et	O
al.,	O
2007)	O
holds	O
great	O
promise	O
for	O
improving	O
our	O
cellular	O
understanding	O
of	O
craniofacial	O
diseases,	O
as	O
hiPSCs	O
can	O
be	O
differentiated	O
into	O
patient-specific,	O
disease-relevant	O
cell	O
types.	O

Liver	O
cell	O
types	O
derived	O
from	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
share	O
the	O
potential	O
to	O
investigate	O
development,	O
toxicity,	O
as	O
well	O
as	O
genetic	O
and	O
infectious	O
disease	O
in	O
ways	O
currently	O
limited	O
by	O
the	O
availability	O
of	O
primary	O
tissue.	O

A	O
different	O
and	O
novel	O
approach	O
developed	O
by	O
the	O
Takebe	O
laboratory	O
used	O
a	O
combination	O
of	O
iPSC	O
derived	O
hepatic	O
endoderm	O
and	O
immature	O
non-parenchymal	O
liver	O
cell	O
analogs	O
[mesenchymal	B
stem	I
cells	I
(MSC)	O
and	O
endothelial	O
cells],	O
to	O
mimic	O
the	O
formation	O
of	O
the	O
liver	O
bud	O
(101).	O

Hematopoietic	B
stem	I
cells	I
(HSCs)	O
generate	O
highly	O
dividing	O
hematopoietic	O
progenitor	O
cells	O
(HPCs),	O
which	O
produce	O
all	O
blood	O
cell	O
lineages.	O

This	O
ultimately	O
led	O
to	O
the	O
derivation	O
of	O
mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
(Evans	O
and	O
Kaufman,	O
1981;	O
Martin,	O
1981),	O
a	O
discovery	O
that	O
rendered	O
EC	O
cell	O
research	O
largely	O
redundant.	O

Gene	O
expression	O
of	O
FREM2	O
and	O
SPRY1	O
was	O
measured	O
in	O
the	O
mature	O
glioblastoma	O
cell	O
lines	O
U251MG	O
and	O
U87MG,	O
in	O
the	O
stem-like	O
NCH	O
cells—a	O
co-culture	O
of	O
the	O
glioblastoma	O
stem-like	O
cell	O
lines	O
NCH644	O
and	O
NCH421K	O
—as	O
well	O
as	O
in	O
neural	B
stem	I
cells	I
(NSC)	O
and	O
astrocytes.	O

Finally,	O
concentrated	O
cells	O
may	O
form	O
aggregates	O
and	O
lead	O
to	O
pulmonary	O
emboli	O
or	O
infarctions	O
following	O
administration	O
48,	O
especially	O
when	O
intravenously	O
infused,	O
as	O
demonstrated	O
in	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
transplants	O
49.	O

However,	O
the	O
role	O
of	O
IFN-I	O
is	O
a	O
double-edged	O
sword,	O
as	O
its	O
excessive	O
expression	O
can	O
elicit	O
destructive	O
inflammatory	O
responses	O
and	O
cause	O
haematopoietic	B
stem	I
cell	I
(HSC)	O
exhaustion.	O

A	O
current	O
consensus	O
asserts	O
that	O
the	O
tumor	O
invasion-associated	O
epithelial-mesenchymal	O
transition	O
(EMT)	O
intimately	O
correlates	O
with	O
cancer	B
stem	I
cell	I
(CSC)	O
phenotypes	O
[30].	O

Directed	O
differentiation	O
protocols	O
to	O
manufacture	O
specific	O
cell	O
populations	O
from	O
pluripotent	B
stem	I
cells	I
(PSCs)	O
have	O
been	O
developed	O
to	O
meet	O
the	O
need	O
for	O
a	O
homogeneous	O
human	O
cell	O
source.	O

Pro-inflammatory	O
cytokines	O
are	O
also	O
crucially	O
important	O
for	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
maintenance,	O
proliferation,	O
and	O
differentiation	O
[4].	O

For	O
example,	O
the	O
cycloaddition	O
of	O
Arg-Gly-Asp-D-Try-Lys	O
peptide	O
was	O
added	O
to	O
the	O
surface	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
derived	O
sEVs	O
[581].	O

Early	O
work	O
on	O
this	O
topic	O
was	O
inspired	O
by	O
the	O
idea	O
that	O
if	O
homing	O
receptors	O
exist	O
for	O
immune	O
cell	O
infiltration	O
into	O
the	O
periphery,	O
homologous	O
mechanisms	O
must	O
exist	O
for	O
the	O
entry	O
of	O
haematopoietic	B
stem	I
cells	I
(HSCs)	O
into	O
the	O
marrow	O
following	O
bone	O
marrow	O
transplantation.	O

The	O
emergence	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
revolutionizes	O
the	O
paradigm	O
of	O
drug	O
discovery.	O

The	O
distinctive	O
feature	O
of	O
embryonic	B
stem	I
cell	I
(ESC)	O
being	O
able	O
to	O
self‐renew,	O
coupled	O
with	O
its	O
potential	O
to	O
differentiate	O
into	O
any	O
adult	O
cell	O
type	O
in	O
the	O
body,	O
has	O
made	O
it	O
a	O
promising	O
candidate	O
for	O
use	O
in	O
tissue	O
regeneration.	O

Physiologic	O
hypoxia	O
supports	O
and	O
maintains	O
the	O
glioma	B
stem	I
cell	I
(GSC)	O
phenotype	O
and	O
has	O
a	O
vital	O
role	O
in	O
tumor	O
development,	O
invasiveness,	O
and	O
resistance	O
to	O
chemotherapy	O
and	O
radiation.	O

Advent	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
[22]	O
and	O
differentiation	O
systems	O
have	O
made	O
it	O
possible	O
to	O
examine	O
the	O
relationship	O
of	O
specific	O
mutations	O
with	O
disease	O
phenotypes.	O

Central	O
to	O
the	B
stem	I
cell	I
(CSC)	O
concept	O
is	O
the	O
observation	O
that	O
not	O
all	O
cells	O
in	O
tumours	O
are	O
equal.	O

Developed	O
over	O
a	O
decade	O
ago,	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
theory	O
posits	O
that	O
the	O
tumor	O
has	O
its	O
own	O
stem	O
cells	O
with	O
self-renewal	O
ability	O
and	O
ascribes	O
the	O
origin	O
of	O
these	O
malignant	O
cells	O
to	O
alterations	O
of	O
regulation	O
pathways	O
through	O
genetic	O
mutations	O
of	O
the	O
healthy	O
stem	O
cell	O
population	O
[34].	O

Cell	O
transplant	O
models	O
(CTMs)	O
represent	O
a	O
distinct	O
subset	O
of	O
GEMMs	O
applied	O
primarily	O
to	O
studies	O
of	O
hematologic	O
cancers,	O
such	O
as	O
myeloproliferative	O
neoplasms	O
and	O
leukemia	O
that	O
arise	O
from	O
mutations	O
arising	O
in	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
and	O
progenitor	O
cells.	O

PCa	O
cells	O
home	O
toward	O
areas	O
in	O
the	O
bone	O
marrow	O
rich	O
in	O
osteoblasts	O
where	O
the	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
niche	O
resides.	O

Consistent	O
with	O
concepts	O
borrowed	O
from	O
the	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
transplant	O
field,	O
prior	O
lymphodepleting	O
chemotherapy	O
(so-called	O
“conditioning”)	O
appears	O
to	O
also	O
have	O
important	O
effects	O
on	O
both	O
the	O
Cmax	O
and	O
maintenance	O
of	O
adoptively	O
transferred	O
T	O
cells	O
over	O
time.32,	O
33,	O
34,	O
35	O
The	O
mechanisms	O
that	O
underlie	O
the	O
effect	O
of	O
conditioning	O
on	O
T	O
cell	O
kinetics	O
are	O
not	O
fully	O
understood.	O

Cancer	B
stem	I
cells	I
(CSCs)	O
represent	O
rare	O
tumor	O
cell	O
populations	O
capable	O
of	O
self-renewal,	O
differentiation,	O
and	O
tumor	O
initiation	O
and	O
are	O
highly	O
resistant	O
to	O
chemotherapy	O
and	O
radiotherapy.	O

Background:	O
Immunoregulatory	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
is	O
attributed	O
to	O
extracellular	O
vesicles	O
(EV)	O
secretion.	O

We	O
examined	O
the	O
epigenetic	O
influence	O
of	O
OS-extracellular	O
vesicles	O
(EVs)	O
on	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
and	O
pre-osteoblast,	O
and	O
the	O
consequences	O
of	O
OS-EVs	O
treatment	O
on	O
the	O
epigenetic	O
reprograming	O
of	O
MSCs..	O

Background:	O
Immunoregulatory	O
effect	O
of	O
Mesenchymal	B
stem	I
cell	I
(MSC)	O
is	O
attributed	O
to	O
Extracellular	O
vesicles	O
(EVs)	O
secretion.	O

ECs	O
derived	O
from	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
represent	O
an	O
alternative	O
and	O
potentially	O
superior	O
cell	O
source,	O
but	O
traditional	O
culture	O
approaches	O
and	O
2D	O
differentiation	O
protocols	O
hardly	O
allow	O
for	O
production	O
of	O
large	O
cell	O
numbers.	O

Hypothetically,	O
a	O
physiological	O
connection	O
between	O
Hh	O
signaling	O
and	O
DYRK1A	O
might	O
also	O
exist	O
in	O
the	O
case	O
of	O
neural	B
stem	I
cell	I
(NSC)	O
division.	O

Intestinal	B
stem	I
cells	I
(ISCs)	O
are	O
supported	O
by	O
Paneth	O
cells	O
that	O
are	O
specialized	O
epithelial	O
cells	O
localized	O
in	O
the	O
stem	O
cell	O
niche.	O

(A)	O
Experimental	O
design	O
and	O
optimization	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSCs)	O
differentiation	O
into	O
podocytes.	O

In	O
this	O
study,	O
we	O
explored	O
the	O
potentiality	O
of	O
human	O
arginine	O
decarboxylase	O
(ADC)	O
to	O
enhance	O
the	O
survival	O
of	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
against	O
unfavorable	O
milieu	O
of	O
host	O
tissues	O
as	O
the	O
low	O
survival	O
of	O
MSCs	O
is	O
the	O
issue	O
in	O
cell	O
transplantation	O
therapy.	O

Neural	B
stem	I
cells	I
(NSCs)	O
are	O
considered	O
as	O
a	O
potential	O
source	O
for	O
oligodendrocyte	O
precursor	O
cells	O
(OPCs)	O
to	O
be	O
used	O
in	O
cell	O
based	O
remyelination	O
therapy	O
for	O
multiple	O
sclerosis	O
(MS).	O

Since	O
the	O
emergence	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology,	O
a	O
little	O
over	O
a	O
decade	O
ago,	O
iPSC	O
models	O
have	O
held	O
the	O
potential	O
to	O
bridge	O
these	O
two	O
worlds	O
–	O
primary	O
patient	O
cells	O
and	O
conventional	O
disease	O
models	O
–	O
by	O
affording	O
direct	O
relevance	O
to	O
human	O
disease,	O
being	O
patient-derived,	O
while	O
enabling	O
precise,	O
controlled	O
and	O
scalable	O
experiments	O
that	O
were	O
hitherto	O
only	O
possible	O
using	O
traditional	O
model	O
systems.	O

The	O
unrestrained	O
activation	O
of	O
the	O
p53-p21	O
axis	O
has	O
been	O
associated	O
with	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
attrition	O
that	O
characterizes	O
inherited	O
bone	O
marrow	O
failure	O
(iBMF)	O
syndromes,	O
including	O
dyskeratosis	O
congenita	O
(DC),	O
Shwachman-Diamond	O
syndrome	O
(SDS),	O
Diamond-Blackfan	O
anemia	O
(DBA),	O
and	O
Fanconi	O
anemia	O
(FA),	O
the	O
most	O
frequent	O
and	O
genetically	O
heterogeneous	O
iBMF	O
syndrome.	O

In	O
a	O
homozygous	O
knockout	O
neuronal	O
cell	O
line,	O
embryoid	O
bodies	O
(EBs)	O
derived	O
from	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
were	O
significantly	O
smaller	O
(88),	O
supporting	O
a	O
role	O
for	O
Foxg1	O
in	O
cell	O
survival.	O

PRDM14	O
functions	O
in	O
embryonic	B
stem	I
cell	I
(ESC)	O
maintenance	O
to	O
promote	O
the	O
expression	O
of	O
pluripotency-associated	O
genes	O
while	O
suppressing	O
differentiation	O
genes.	O

Models	O
utilizing	O
micromolding	O
and	O
bioprinting	O
techniques	O
have	O
been	O
used	O
to	O
fabricate	O
endothelialized	O
tissue	O
constructs	O
to	O
visualize	O
real-time	O
endothelial	O
cord	O
formation	O
during	O
tubulogenesis.40	O
Others	O
have	O
incorporated	O
a	O
layer	O
of	O
human	O
bone	O
marrow	O
stromal	O
cells	O
surrounding	O
the	O
channels	O
to	O
recapitulate	O
perivascular-mediated	O
barrier	O
function.41	O
Compared	O
with	O
earlier	O
models,	O
the	O
most	O
recent	O
systems	O
endow	O
more	O
accurate	O
control	O
of	O
growth	O
factor	O
gradients	O
and	O
fluid	O
flow,	O
making	O
them	O
ideal	O
for	O
patient-specific	O
models.42,43	O
For	O
example,	O
a	O
recent	O
microfluidic	O
angiogenic	O
model	O
promoted	O
human-induced	O
pluripotent	B
stem	I
cell	I
(hiPSC)	O
differentiation	O
into	O
endothelial	O
cells	O
which	O
assembled	O
into	O
perfusable,	O
capillary-like	O
networks,	O
and	O
capturing	O
endothelial	O
response	O
to	O
different	O
environmental	O
biochemical	O
and	O
biophysical	O
cues.43	O
Incorporation	O
of	O
patient-derived	O
hiPSCs	O
in	O
platforms	O
such	O
as	O
these	O
lays	O
the	O
foundation	O
for	O
personalized	O
characterization	O
of	O
tumor	O
angiogenesis	O
and	O
endothelial	O
cell	O
response	O
to	O
cancer	O
therapeutics.	O

Random	O
genomic	O
alterations	O
are	O
frequently	O
observed	O
in	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
during	O
cell	O
reprogramming	O
essentially	O
due	O
to	O
the	O
massive	O
genome	O
remodeling	O
and	O
it	O
is	O
therefore	O
of	O
major	O
interest	O
to	O
evaluate	O
the	O
genomic	O
status	O
of	O
the	O
cells	O
for	O
clinical	O
use	O
in	O
order	O
to	O
determine	O
that	O
they	O
are	O
free	O
from	O
cancer-associated	O
genomic	O
alterations.	O

Embryonic	B
stem	I
cells	I
(ESC)	O
have	O
been	O
used	O
for	O
decades	O
to	O
generate	O
cardiomyocytes	O
and	O
recent	O
advances	O
in	O
cell	O
culture	O
techniques	O
significantly	O
increased	O
the	O
yield	O
of	O
cardiomyocytes	O
in	O
these	O
cultures.	O

Comparison	O
between	O
the	O
cultures	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
on	O
feeder-and	O
serum-free	O
system	O
(Matrigel	O
matrix),	O
MEF	O
and	O
HDF	O
feeder	O
cell	O
lines.	O

The	O
use	O
of	O
pluripotent	O
or	O
multipotent	O
cells	O
for	O
the	O
restoration	O
of	O
damaged	O
neuronal	O
networks	O
is	O
one	O
of	O
the	O
factors	O
that	O
holds	O
promise	O
from	O
a	O
translational	O
medicine	O
perspective	O
and	O
a	O
relevant	O
part	O
of	O
the	O
strongest	O
forces	O
driving	O
research	O
in	O
stem	B
cell	I
(SC)	O
biology	O
applied	O
to	O
neurodegenerative	O
diseases.	O

We	O
and	O
others	O
have	O
shown	O
that	O
Mof	O
plays	O
important	O
function	O
in	O
embryonic	B
stem	I
cell	I
(ESC)	O
self-renewal	O
(13,	O
14),	O
DNA	O
damage	O
repair	O
(15,	O
16),	O
senescence	O
(17),	O
and	O
autophagy	O
(18).	O

This	O
is	O
because	O
non-activated	O
fibroblasts	O
possess	O
characteristics	O
that	O
are	O
similar	O
to	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
precursors.	O

Although	O
there	O
have	O
been	O
many	O
reports	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
transplantation	O
for	O
the	O
treatment	O
of	O
ischemic	O
heart	O
disease	O
(IHD),	O
relatively	O
few	O
studies	O
have	O
investigated	O
the	O
roles	O
of	O
CF-EXOs.	O

Neural	B
stem	I
cell	I
(NSC)	O
therapy	O
can	O
be	O
used	O
for	O
nerve	O
and	O
brain	O
regeneration.	O

Induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
make	O
up	O
a	O
recent	O
powerful	O
addition	O
to	O
the	O
arsenal	O
of	O
the	O
cell	O
and	O
lipid	O
biologist.	O

This	O
is	O
especially	O
visible	O
when	O
the	O
dyes	O
are	O
applied	O
to	O
cell	O
types	O
that	O
naturally	O
form	O
clumps	O
such	O
as	O
embryoid	O
bodies	O
(EBs)	O
derived	O
from	O
embryonic	B
stem	I
cells	I
(ESCs)	O
and	O
iPSCs,	O
due	O
to	O
nonspecific	O
uptake	O
of	O
the	O
dyes	O
into	O
the	O
cell	O
clumps.	O

Notably,	O
the	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
generates	O
exosomal	O
miRNA-1470,	O
which	O
remains	O
important	O
in	O
CD4+CD25+Foxp3+Treg	O
differentiation	O
[163].	O

Fertilization	O
of	O
the	O
reconstructed	O
oocyte	O
should	O
lead	O
to	O
a	O
blastocyst,	O
which	O
can	O
be	O
used	O
for	O
embryonic	B
stem	I
cell	I
(ESC)	O
derivation.	O

Induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
lines	O
were	O
derived	O
from	O
three	O
PD	O
patients	O
carrying	O
a	O
LRRK2-G2019S	O
heterozygous	O
mutation,	O
and	O
three	O
healthy	O
control	O
individuals	O
(Materials	O
and	O
Methods),	O
from	O
the	O
Oxford	O
Parkinson’s	O
Disease	O
Centre	O
(OPDC)	O
Discovery	O
Cohort	O
(Table	O
1)	O
(Materials	O
and	O
Methods,	O
Supplementary	O
Material,	O
Fig.	O

Induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
lines	O
were	O
derived	O
from	O
three	O
PD	O
patients	O
carrying	O
a	O
LRRK2-G2019S	O
heterozygous	O
mutation,	O
and	O
three	O
healthy	O
control	O
individuals,	O
from	O
the	O
Oxford	O
Parkinson’s	O
Disease	O
Centre	O
(OPDC)	O
Discovery	O
Cohort	O
(Table	O
1)..	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
have	O
not	O
been	O
discussed	O
in	O
this	O
review	O
article,	O
however,	O
they	O
can	O
be	O
derived	O
from	O
several	O
sources	O
and	O
differentiate	O
into	O
diverse	O
cell	O
types.	O

The	O
extracellular	O
matrix	O
(ECM)	O
is	O
known	O
to	O
play	O
an	O
integral	O
role	O
in	O
human	B
pluripotent	I
stem	I
cell	I
(hPSC)	O
culture	O
and	O
maintenance.	O

However,	O
emerging	O
evidence	O
suggests	O
that	O
the	O
proportion	O
of	O
cells	O
with	O
high	O
expression	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
markers	O
among	O
the	O
surviving	O
cells	O
is	O
significantly	O
increased	O
in	O
response	O
to	O
5‐Fu,	O
resulting	O
in	O
drug	O
resistance	O
and	O
disease	O
relapse.	O

We	O
utilized	O
the	O
Drosophila	O
testis	O
as	O
an	O
in	O
vivo	O
model	O
to	O
examine	O
the	O
effects	O
of	O
ROS	O
on	O
germline	B
stem	I
cell	I
(GSC)	O
maintenance.	O

Hematopoiesis	O
is	O
a	O
process	O
through	O
which	O
all	O
the	O
blood	O
cells	O
are	O
generated	O
through	O
sequential	O
cell	O
divisions	O
and	O
differentiation	O
of	O
progeny	O
that	O
originate	O
from	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
(Kondo	O
et	O
al.,	O
2003).	O

The	O
authors	O
initially	O
quantified	O
protein	O
levels	O
and	O
fluctuations	O
by	O
measuring	O
single	O
cell	O
fluorescence	O
of	O
mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
transiently	O
transfected	O
with	O
a	O
fluorescent	O
reporter	O
with	O
miRNA	O
binding	O
sites	O
in	O
the	O
3'UTR.	O

Human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
provide	O
an	O
unlimited	O
cell	O
source	O
for	O
regenerative	O
medicine.	O

Another	O
capture	O
array–specific	O
transcript	O
is	O
represented	O
by	O
the	O
benign	O
gonial	O
cell	O
neoplasm	O
gene	O
(bgcn,	O
FlyBase	O
ID:	O
FBgn0004581),	O
which	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
germline	B
stem	I
cell	I
(GSC)	O
maintenance	O
(Li	O
et	O
al.	O

Chronic	O
myeloid	O
leukemia	O
(CML)	O
is	O
a	O
myeloproliferative	O
disorder	O
of	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
origin	O
caused	O
by	O
the	O
t(9;22)	O
chromosomal	O
translocation.	O

Development	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
to	O
obtain	O
terminally	O
differentiated	O
neurons	O
from	O
adult	O
somatic	O
cells	O
revolutionized	O
the	O
study	O
of	O
AD,	O
providing	O
a	O
powerful	O
tool	O
for	O
modelling	O
the	O
disease	O
and	O
for	O
screening	O
candidate	O
drugs.	O

In	O
particular,	O
the	O
use	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
can	O
be	O
used	O
to	O
generate	O
the	O
necessary	O
cell	O
types	O
to	O
mimic	O
the	O
adult	O
liver	O
and	O
model	O
disease	O
states.	O

Recent	O
findings	O
have	O
revealed	O
that	O
molecular	O
mechanisms	O
underlying	O
the	O
maintenance	O
of	O
embryonic	B
stem	I
cell	I
(ESC)	O
pluripotency	O
and	O
cellular	O
reprogramming	O
have	O
been	O
linked	O
to	O
miRNAs	O
[1,	O
7].	O

Members	O
of	O
the	O
miR-290	O
cluster	O
are	O
the	O
most	O
highly	O
expressed	O
miRNAs	O
in	O
mESCs	O
comprising	O
more	O
than	O
60–70	O
%	O
of	O
the	O
total	O
miRNAs	O
expressed	O
and	O
are	O
studied	O
extensively	O
in	O
various	O
backgrounds	O
[54]	O
including	O
DNA	O
methylation,	O
maintenance	O
of	O
pluripotency,	O
germ	O
cell	O
development,	O
and	O
generation	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
[55,	O
56]..	O

Functions	O
of	O
microRNAs	O
(miRNAs)	O
in	O
embryonic	B
stem	I
cell	I
(ESC)	O
self-renewal,	O
differentiation,	O
and	O
cellular	O
reprogramming.	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
are	O
typical	O
PSCs	O
that	O
derive	O
from	O
inner	O
cell	O
mass	O
(ICM)	O
of	O
blastocysts,	O
and	O
ESCs	O
show	O
difficulty	O
in	O
efficient	O
genome	O
editing.	O

Mesenchymal	B
stem	I
cells	I
(MSC)	O
are	O
multipotent	O
cells,	O
functioning	O
as	O
precursors	O
to	O
a	O
variety	O
of	O
cell	O
types	O
including	O
adipocytes,	O
osteoblasts,	O
and	O
chondrocytes.	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
display	O
immunemodulatory	O
and	O
neuroprotective	O
activities	O
and	O
promote	O
oligodendrocyte	O
differentiation	O
of	O
neural	O
progenitors	O
(NPCs)	O
and	O
are	O
thus	O
interesting	O
candidates	O
for	O
autologous	O
cell	O
therapy	O
in	O
MS.	O

To	O
further	O
study	O
the	O
routes	O
of	O
degradation	O
and	O
the	O
possibilities	O
to	O
speed	O
up	O
this	O
process	O
we	O
have	O
used	O
a	O
cell	O
culture	O
model	O
where	O
UV‐treated,	O
dead	O
cells	O
are	O
added	O
to	O
stem	O
cell‐derived	O
astrocytes.	O
Grafting	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
derived	O
dopaminergic	O
(DA)	O
neurons	O
has	O
great	O
potential	O
for	O
cell	O
based	O
therapies	O
for	O
Parkinson's	O
disease	O
(PD).	O

Mesenchymal	B
stem	I
cells	I
(MSC)	O
were	O
shown	O
to	O
exert	O
positive	O
immunomodulatory	O
effects,	O
to	O
reduce	O
demyelination,	O
to	O
increase	O
neuroprotection	O
and	O
to	O
promote	O
adult	O
neural	O
stem	O
cell	O
differentiation	O
towards	O
the	O
oligodendroglial	O
lineage.	O

The	O
use	O
of	O
human	B
embryonic	I
stem	I
cells	I
(hESCs)	O
in	O
cell	O
replacement	O
therapies	O
(CRTs)	O
has	O
been	O
limited	O
due	O
to	O
several	O
technical	O
and	O
ethical	O
issues.	O

In	O
keeping	O
with	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
hypothesis	O
(4),	O
these	O
cells	O
possess	O
self-renewing	O
capacity,	O
an	O
especially	O
high	O
resistance	O
to	O
death-promoting	O
signals,	O
and	O
the	O
ability	O
to	O
effect	O
regeneration	O
of	O
the	O
overall	O
tumor	O
mass	O
(56,	O
140).	O

[162]	O
has	O
used	O
a	O
mouse	O
model	O
for	O
showing	O
that	O
plasma	O
levels	O
of	O
miRs	O
371/302/C19MC	O
were	O
accurate	O
in	O
detecting	O
undifferentiated	O
and	O
malignant	O
components	O
arising	O
in	O
xenografts	O
derived	O
from	O
mice	O
injected	O
with	O
human	B
pluripotent	I
stem	I
cell	I
(hPSC)	O
lines	O
and	O
human	O
malignant	O
GCT	O
cell	O
lines.	O

The	O
diverse	O
Ras-pathways	O
that	O
are	O
relevant	O
for	O
stemness	O
may	O
be	O
gleaned	O
from	O
E-Ras,	O
which	O
is	O
specifically	O
expressed	O
in	O
embryonic	B
stem	I
cells	I
(ESC)	O
and	O
few	O
adult	O
cells,	O
such	O
as	O
the	O
hepatic	O
stellate	O
cells	O
(HSC),	O
a	O
liver	O
resident	O
stem	O
cell	O
population	O
[61].	O

The	O
advent	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
has	O
opened	O
an	O
unprecedented	O
avenue	O
to	O
study	O
the	O
mechanism	O
of	O
rare	O
human	O
genetic	O
diseases,	O
including	O
those	O
caused	O
by	O
defects	O
in	O
DNA	O
damage	O
repair	O
machineries	O
(Cockayne	O
syndrome	O
(Andrade	O
et	O
al.,	O
2012),	O
Fanconi	O
anemia	O
(Liu	O
et	O
al.,	O
2014),	O
Werner	O
syndrome	O
(Shimamoto	O
et	O
al.,	O
2014;	O
Cheung	O
et	O
al.,	O
2014)).	O

Methods:	O
We	O
harnessed	O
the	O
capacity	O
of	O
human	B
pluripotent	I
stem	I
cells	I
(hPSC)	O
to	O
differentiate	O
into	O
virtually	O
any	O
cell	O
type	O
by	O
subjecting	O
hPSC	O
to	O
a	O
wide	O
variety	O
of	O
media	O
and	O
culture	O
conditions	O
to	O
maximize	O
the	O
diversity	O
of	O
partially	O
differentiated	O
cells.	O

Mesenchymal	B
stem	I
cell	I
(MSC)	O
was	O
found	O
to	O
secretes	O
potential	O
growth	O
factors	O
such	O
as	O
VEGF	O
when	O
cultured	O
in	O
vitro.	O

Mesenchymal	B
stem	I
cell	I
(MSCs)	O
modification	O
towards	O
an	O
osteogenic	O
path	O
can	O
occur	O
by	O
uptake	O
of	O
exosomes	O
from	O
other	O
cells.	O

Here	O
we	O
show	O
that	O
Vibrio	O
cholerae	O
and	O
cholera	O
toxin	O
suppress	O
intestinal	B
stem	I
cell	I
(ISC)	O
division.	O

With	O
the	O
discovery	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
a	O
novel	O
and	O
promising	O
technique	O
to	O
generate	O
disease-relevant	O
and	O
patient-specific	O
cell	O
types	O
arose	O
(Takahashi	O
and	O
Yamanaka,	O
2006).	O

For	O
example,	O
while	O
dengue	O
virus	O
infection	O
in	O
Aedes	O
aegypti	O
causes	O
apoptosis	O
in	O
the	O
midgut,	O
mosquito	O
hosts	O
improve	O
the	O
maintenance	O
of	O
midgut	O
homeostasis	O
and	O
tissue	O
integrity	O
via	O
careful	O
regulation	O
of	O
interstitial	B
stem	I
cell	I
(ISC)	O
proliferation,	O
tolerating	O
the	O
effects	O
of	O
viral	O
infection	O
(Oliveira	O
et	O
al.,	O
2020).	O

Wnt	O
signaling	O
plays	O
crucial	O
roles	O
in	O
the	O
regulation	O
of	O
diverse	O
processes,	O
including	O
cell	O
proliferation,	O
survival,	O
migration	O
and	O
polarization,	O
embryonic	O
development,	O
specification	O
of	O
cell	O
fate,	O
and	O
self-renewal	O
in	O
stem	O
cells[5].	O
Thanks	O
to	O
the	O
forced	O
reprogramming	O
of	O
human	O
somatic	O
cells	O
into	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
47,	O
human	O
neurons	O
(or	O
any	O
other	O
cell	O
type)	O
can	O
be	O
generated	O
from	O
cells	O
of	O
patients	O
with	O
RTT	O
and	O
be	O
used	O
to	O
study	O
RTT.	O

Neural	B
crest	I
stem	I
cells	I
(NCSCs)	O
represent	O
a	O
transient	O
and	O
multipotent	O
cell	O
population	O
that	O
contributes	O
to	O
numerous	O
anatomical	O
structures	O
such	O
as	O
peripheral	O
nervous	O
system,	O
teeth,	O
and	O
cornea.	O

Outline	O
of	O
contribution	O
of	O
epithelial-mesenchymal	O
plasticity	O
(EMP)	O
and	O
acquisition	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
properties	O
to	O
tumor	O
initiation	O
and	O
components	O
of	O
the	O
metastatic	O
cascade,	O
including	O
intravasation,	O
extravasation,	O
and	O
metastatic	O
colonization/outgrowth.	O

The	O
critical	O
cellular	O
pathways,	O
mitogen-activated	O
protein	O
kinase	O
(MAPK),	O
phosphoinositide	O
3-kinase—protein	O
kinase	O
B—mammalian	O
target	O
of	O
rapamycin	O
(PI3K—AKT—MTOR),	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(STAT3),	O
Wnt,	O
Hedgehog,	O
and	O
Notch	O
each	O
have	O
been	O
demonstrated	O
to	O
play	O
key	O
roles	O
in	O
promotion	O
of	O
epithelial-mesenchymal	O
plasticity	O
(EMP)	O
and	O
acquisition	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
properties.	O

The	O
heterogeneous	O
cell	O
populations	O
found	O
within	O
GBM	O
contains	O
subpopulations	O
of	O
stem	O
cell-like	O
tumor	O
cells	O
supported	O
by	O
tumor	O
vasculature.	O
Human	O
high-grade	O
glioma	O
tissue	O
samples	O
cultured	O
in	O
stem	O
cell-enriching	O
medium	O
grow	O
as	O
tumor	O
spheroids	O
rich	O
in	O
two	O
distinct	O
subpopulations	O
of	O
glioma	O
stem-like	O
cells	O
(GSCs)—proneural	O
and	O
mesenchymal—with	O
proteome	O
analyses	O
recapitulated	O
differential	O
protein	O
expression	O
patterns	O
among	O
the	O
cell	O
subtypes	O
[120].	O
Human	O
HT29	O
and	O
HCT15	O
and	O
murine	O
CT26	O
CRC	O
cell	O
lines	O
can	O
be	O
cultured	O
in	B
stem	I
cell	I
medium	O
and	O
expanded	O
as	O
cancer	O
spheroids,	O
or	O
colonospheres,	O
containing	O
CRC	O
stem	O
cells	O
(CRCSCs)	O
[123].	O

The	O
fly	O
midgut	O
is	O
maintained	O
by	O
a	O
population	O
of	O
intestinal	B
stem	I
cells	I
(ISCs)	O
that	O
divide	O
to	O
self‐renew	O
and	O
give	O
rise	O
to	O
two	O
differentiated	O
cell	O
types:	O
absorptive	O
enterocytes	O
(ECs)	O
and	O
secretory	O
enteroendocrine	O
cells	O
(EEs)	O
(Micchelli	O
&	O
Perrimon,	O
2006;	O
Ohlstein	O
&	O
Spradling,	O
2006).	O

During	O
the	O
repeated	O
cycles	O
of	O
damage	O
and	O
repair	O
in	O
many	O
muscle	O
disorders,	O
including	O
Duchenne	O
muscular	O
dystrophy	O
(DMD),	O
the	O
muscle	B
stem	I
cell	I
(MuSC)	O
pool	O
becomes	O
less	O
efficient	O
at	O
responding	O
to	O
and	O
repairing	O
damage.	O

Since	O
tert	O
transcripts	O
are	O
detectable	O
in	O
embryonic	B
stem	I
cells	I
(ESCs)	O
within	O
the	O
same	O
reaction	O
(technical	O
control),	O
our	O
data	O
suggest	O
that	O
tert	O
is	O
either	O
present	O
at	O
very	O
low	O
(undetectable)	O
levels	O
or	O
expressed	O
transiently	O
in	O
freshly	O
isolated	O
MuSCs,	O
in	O
contrast	O
to	O
what	O
is	O
known	O
for	O
cancer	O
cell	O
lines	O
(Yin	O
et	O
al.,	O
2000;	O
Zuo	O
et	O
al.,	O
2011).	O

DMT	O
development	O
has	O
been	O
struggling	O
with	O
a	O
poor	O
translatability	O
of	O
preclinical	O
and	O
animal	O
models	O
to	O
human	O
disease	O
[15],	O
though	O
in	O
the	O
past	O
decade,	O
great	O
advances	O
have	O
been	O
with	O
neurons	O
derived	O
from	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
and	O
3D	O
cell	O
cultures	O
technologies	O
as	O
pre-clinical	O
models	O
for	O
neurodegenerative	O
diseases	O
[198].	O

By	O
contrast,	O
successful	O
induction	O
of	O
pluripotent	B
stem	I
cell	I
(iPSC)	O
lines	O
is	O
marked	O
by	O
a	O
reduction	O
of	O
ETC	O
function	O
[58].	O

The	O
utility	O
of	O
CD44,	O
CD117	O
and	O
CD133	O
in	O
identification	O
of	O
cancer	B
stem	I
cells	I
(CSC)	O
in	O
oral	O
squamous	O
cell	O
carcinomas	O
(OSCC)	O
Rom.	O

The	O
GATA	O
family	O
is	O
a	O
group	O
of	O
zinc	O
finger	O
DNA-binding	O
protein	O
TFs	O
that	O
control	O
differentiation	O
of	O
the	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
into	O
different	O
cell	O
types	O
and	O
has	O
six	O
members	O
from	O
GATA1	O
to	O
6.37	O
GATA3	O
plays	O
a	O
role	O
in	O
T	O
cell	O
development	O
by	O
inducing	O
Th2	O
development	O
and	O
Th1	O
suppression.38	O
Yao	O
et	O
al.	O

Spermatogonia	B
stem	I
cell	I
(SSC)	O
were	O
isolated	O
from	O
6-days	O
postpartum	O
(dpp)	O
using	O
enzymatic	O
digestion	O
and	O
magnetic-activated	O
cell	O
sorting34.	O

Immune	O
cells	O
in	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
and	O
cancer	O
cell	O
microenvironment.	O

In	O
this	O
experimental	O
study,	O
we	O
examined	O
the	O
erythroid	O
differentiation	O
potential	O
of	O
normal	O
Bombay	O
hiPSCs	O
(B-hiPSCs)	O
and	O
compared	O
results	O
to	O
human	B
embryonic	I
stem	I
cell	I
(hESC)	O
lines.	O

The	O
main	O
effects	O
elicited	O
by	O
HSP	O
inhibitors	O
on	O
GBM	O
are	O
cell	O
growth	O
inhibition,	O
radio-	O
and/or	O
chemo-sensitization,	O
cytotoxicity,	O
migration	O
and	O
invasion	O
impairment,	O
glioma	B
stem	I
cells	I
(GSCs)	O
stemness	O
and	O
self-renewal	O
suppression,	O
and	O
anti-angiogenic	O
effect.	O

The	O
barriers	O
to	O
cell	O
fate	O
conversion	O
between	O
somatic	O
cells	O
and	O
pluripotent	O
cells	O
had	O
a	O
breakthrough	O
with	O
the	O
proposition	O
of	O
the	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
reprogramming	O
strategy	O
in	O
2006,	O
when	O
Takahashi	O
et	O
al[1,2]	O
reported	O
a	O
significant	O
discovery	O
that	O
the	O
ectopic	O
expression	O
of	O
four	O
defined	O
transcription	O
factors	O
(TFs;	O
Oct4,	O
Sox2,	O
Klf4a,	O
and	O
c-Myc)	O
could	O
force	O
the	O
cell	O
fate	O
conversion.	O

Of	O
note,	O
despite	O
different	O
cell	O
origins,	O
the	O
similar	O
activation	O
of	O
the	O
XEN-like	O
program	O
was	O
reported	O
during	O
the	O
early	O
stage	O
of	O
reprogramming	O
from	O
neural	B
stem	I
cells	I
(NSCs)	O
and	O
small	O
intestinal	O
epithelial	O
cells	O
(IECs)[26],	O
highlighting	O
that	O
the	O
XEN-like	O
state	O
serves	O
as	O
a	O
vital	O
and	O
exclusive	O
bridge	O
toward	O
pluripotency.	O

Scheme	O
showing	O
the	O
essential	O
functions	O
of	O
Notch	O
in	O
blood	O
and	O
vascular	O
cell	O
types	O
(a)	O
Osteocyte	O
Dll/Jag-induced	O
Notch	O
signaling	O
in	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
is	O
involved	O
in	O
their	O
generation	O
and	O
self-renewal	O
in	O
the	O
adult.	O

Indeed,	O
a	O
lung	O
tumor	O
mass	O
is	O
composed	O
of	O
stromal	O
cells,	O
endothelial	O
cells,	O
cancerous	O
differentiated	O
lung	O
cells	O
that	O
are	O
highly	O
proliferative	O
and	O
another	O
small	O
subpopulation	O
sharing	O
cancer	B
stem	I
cell	I
(CSC)	O
features:	O
the	O
initiating	O
tumoral	O
cells	O
(TICs)	O
also	O
called	O
drug-tolerant	O
persister	O
cells	O
(DTPs)	O
[52].	O

Since	O
the	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
niche	O
provides	O
protection	O
and	O
regulation	O
of	O
self-renewal	O
and	O
differentiation	O
of	O
HSC	O
into	O
blood	O
cells,	O
this	O
difference	O
may	O
be	O
important	O
in	O
non-cell	O
autonomous	O
processes..	O

Human	B
mesenchymal	I
stem	I
cells	I
(hMSC)	O
were	O
the	O
only	O
cell	O
type	O
found	O
to	O
provide	O
an	O
appropriate	O
cellular	O
context	O
for	O
EWSR1-FLI1	O
expression,	O
supporting	O
the	O
notion	O
that	O
Ewing's	O
sarcoma	O
is	O
derived	O
from	O
hMSCs	O
20,	O
21.	O

Dental	B
pulp	I
stem	I
cells	I
(DPSCs)	O
have	O
great	O
potential	O
for	O
a	O
range	O
of	O
applications	O
in	O
stem	O
cell	O
research	O
and	O
regenerative	O
medicine.	O

Mechanisms	O
underlying	O
the	O
loss	O
of	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
during	O
BMF	O
include	O
increased	O
apoptosis	O
and	O
enhanced	O
stem	O
cell	O
activity	O
resulting	O
in	O
exhaustion.	O

Recent	O
news	O
of	O
human	B
embryonic	I
stem	I
cell	I
(hESC)	O
research	O
in	O
Seoul	O
has	O
made	O
headlines	O
around	O
the	O
world.	O

Human	B
umbilical	I
cord	I
mesenchymal	I
stem	I
cells	I
(hUCMSCs)	O
grow	O
as	O
adherent	O
cells	O
with	O
mesenchymal	O
morphology,	O
have	O
self-renewing,	O
express	O
cell	O
surface	O
markers	O
displayed	O
by	O
MSCs,	O
and	O
may	O
be	O
differentiated	O
into	O
bone,	O
cartilage,	O
adipose,	O
muscle,	O
and	O
neural	O
cells,	O
etc.	O

Thus,	O
when	O
patient-specific	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
therapy	O
was	O
developed,	O
exploration	O
of	O
disease	O
pathophysiology,	O
novel	O
drug	O
development,	O
and	O
the	O
possibility	O
of	O
stem	O
cell	O
therapy	O
in	O
retinal	O
disorders	O
were	O
forever	O
changed	O
[1]..	O

Homology-directed	O
replacement	O
of	O
an	O
expanded	O
CAG	O
repeat	O
in	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSC)	O
derived	O
from	O
Huntington	O
disease	O
patients	O
improved	O
suceptibility	O
to	O
cell	O
death	O
and	O
mitochondrial	O
defects67.	O

Identification	O
and	O
isolation	O
of	O
spermatogonial	B
stem	I
cells	I
(SSCs)	O
could	O
be	O
useful	O
for	O
achieving	O
genetic	O
gain	O
or	O
restore	O
fertility,	O
and	O
genetic	O
modification	O
of	O
SSCs	O
combined	O
with	O
germ	O
cell	O
transplantation	O
provides	O
the	O
possibility	O
to	O
produce	O
transgenic	O
animals.	O

Mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
are	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
(ICM)	O
of	O
a	O
mouse	O
blastocyst	O
and	O
have	O
the	O
ability	O
to	O
self-renew	O
and	O
differentiate	O
into	O
all	O
types	O
of	O
cells	O
in	O
the	O
body15,16.	O

Human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
are	O
increasingly	O
gaining	O
attention	O
in	O
biomedicine	O
as	O
valuable	O
resources	O
to	O
establish	O
patient-derived	O
cell	O
culture	O
models	O
of	O
the	O
cell	O
type	O
known	O
to	O
express	O
the	O
primary	O
pathology.	O

Recent	O
developments	O
in	O
human	B
pluripotent	I
stem	I
cell	I
(hPSC)	O
research	O
are	O
most	O
promising	O
and	O
could	O
provide	O
cellular	O
models	O
eventually	O
mimicking	O
“a	O
patient	O
in	O
a	O
dish”.	O

Notch	O
signaling	O
augments	O
BMP9-induced	O
bone	O
formation	O
by	O
promoting	O
the	O
osteogenesis-angiogenesis	O
coupling	O
process	O
in	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
Cell	O
Physiol	O
Biochem.	O

The	O
differentiation	O
of	O
human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
into	O
specific	O
cell	O
populations	O
is	O
a	O
major	O
avenue	O
for	O
developmental	O
studies,	O
disease	O
modeling	O
and	O
regenerative	O
medicine1,2.	O

Cancer	B
stem	I
cells	I
(CSCs)	O
are	O
self-renewing	O
cell	O
types	O
that	O
contribute	O
to	O
tumor	O
onset,	O
expansion,	O
drug	O
resistance,	O
recurrence,	O
and	O
metastasis	O
after	O
treatment	O
(Reya	O
et	O
al.,	O
2001;	O
Ward	O
and	O
Dirks,	O
2007).	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
have	O
attracted	O
attention	O
due	O
to	O
their	O
powerful	O
intrinsic	O
cell	O
therapy	O
properties,	O
although	O
the	O
molecular	O
mechanisms	O
of	O
their	O
physiological	O
action	O
have	O
not	O
yet	O
been	O
clarified.	O

Earlier	O
research	O
primarily	O
attributed	O
the	O
effects	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
therapies	O
to	O
their	O
capacity	O
for	O
local	O
engrafting	O
and	O
differentiating	O
into	O
multiple	O
tissue	O
types.	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
are	O
a	O
type	O
of	O
pluripotent	O
stem	O
cell	O
(PSC)	O
that	O
posses	O
the	O
greatest	O
potency	O
in	O
vitro,	O
responding	O
predictably	O
to	O
developmental	O
cues.	O

In	O
acute	O
myeloid	O
leukemia	O
(AML),	O
a	O
low	O
level	O
of	O
reactive	O
oxygen	O
species	O
(ROS)	O
is	O
associated	O
with	O
leukemic	B
stem	I
cell	I
(LSC)	O
quiescence,	O
whereas	O
a	O
high	O
level	O
promotes	O
blast	O
proliferation.	O

Embryonic	B
stem	I
cells	I
(ESC)	O
Inner	O
cell	O
mass	O
of	O
blastocyst	O
•	O
Autogous	O
transplantation	O
possible	O
via	O
therapeutic	O
cloning	O
•	O
Social	O
and	O
ethical	O
concerns.	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
have	O
the	O
potential	O
to	O
indefinitely	O
self-renew	O
and	O
differentiate	O
into	O
any	O
cell	O
type	O
[1],	O
and	O
extensive	O
studies	O
have	O
been	O
carried	O
out	O
to	O
take	O
advantage	O
of	O
these	O
unique	O
characteristics	O
including	O
tissue	O
regeneration	O
and	O
repair	O
[2-5].	O

In	O
conclusion,	O
for	O
the	O
brain	O
model	O
to	O
be	O
functional,	O
combining	O
engineered	O
microsystems	O
with	B
stem	I
cell	I
(hiPSC)	O
technology	O
is	O
specifically	O
beneficial	O
because	O
hiPSCs	O
can	O
contribute	O
to	O
the	O
complexity	O
of	O
tissue	O
architecture	O
based	O
on	O
their	O
level	O
of	O
differentiation	O
and	O
thereby,	O
biology	O
itself..	O

These	O
cells	O
exhibit	O
features	O
similar	O
to	O
those	O
found	O
in	O
embryonic	B
stem	I
cells	I
(ESCs)	O
and	O
can	O
be	O
potentially	O
derived	O
from	O
different	O
somatic	O
cell	O
types.	O

A	O
similar	O
study	O
demonstrated	O
that	O
the	O
Synthemax®	O
Surface	O
peptide	O
recapitulates	O
integrin-ECM	O
engagement	O
of	O
human	B
embryonic	I
stem	I
cell	I
(hESC)	O
comparable	O
to	O
those	O
grown	O
on	O
Matrigel-coated	O
substrates	O
(Jin	O
et	O
al.,	O
2012).	O

This	O
review	O
will	O
also	O
discuss	O
some	O
of	O
the	O
disease	O
models	O
that	O
are	O
currently	O
being	O
used	O
to	O
study	O
LS,	O
the	O
challenges	O
associated	O
with	O
these	O
models,	O
and	O
the	O
potential	O
for	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technologies	O
contributing	O
to	O
novel	O
models	O
for	O
understanding	O
the	O
pathophysiology	O
of	O
LS.	O

Human	B
embryonic	I
stem	I
cells	I
(hESC)	O
are	O
pluripotent	O
cell	O
lines	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
human	O
blastocysts.1	O
A	O
few	O
years	O
ago,	O
the	O
group	O
of	O
Dr.	O

Moreover,	O
the	O
ability	O
to	O
grow	O
in	O
soft	O
agar	O
is	O
typically	O
associated	O
with	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
population	O
of	O
a	O
transformed	O
culture	O
(Colburn	O
et	O
al.,	O
1978).	O

Human	O
endogenous	O
retrovirus	O
H	O
(HERV-H)	O
family	O
of	O
lincRNA	O
has	O
been	O
linked	O
to	O
human	B
embryonic	I
stem	I
cell	I
(hESC)	O
pluripotency	O
[41],	O
whereas	O
HERV-V	O
and	O
HERV-K	O
families	O
are	O
involved	O
in	O
the	O
pre-implantation	O
embryo	O
development	O
[42].	O

Despite	O
the	O
fast	O
transcriptional	O
changes	O
at	O
early	O
stages	O
of	O
reprogramming	O
(Gascón	O
et	O
al.,	O
2016;	O
Masserdotti	O
et	O
al.,	O
2015),	O
genes	O
associated	O
with	O
lipid	O
metabolism	O
(e.g.,	O
Cpt1a)	O
are	O
not	O
yet	O
downregulated	O
after	O
48	O
h	O
(Gascón	O
et	O
al.,	O
2016;	O
Masserdotti	O
et	O
al.,	O
2015),	O
suggesting	O
slow	O
metabolic	O
conversion,	O
a	O
limiting	O
factor	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
reprogramming	O
(Wu	O
et	O
al.,	O
2016).	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
are	O
pluripotent	O
cells	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
preimplantation	O
embryos	O
[1].	O

Core	O
tip:	O
Induced	B
pluripotent	I
stem	I
cells	I
(iPSC)	O
have	O
opened	O
up	O
the	O
possibility	O
of	O
converting	O
literally	O
any	O
mature	O
cell	O
type	O
into	O
an	O
embryonic	O
like	O
pluripotent	O
state.	O

The	O
ability	O
to	O
differentiate	O
into	O
any	O
given	O
cell	O
type	O
within	O
an	O
organism	O
was	O
limited	O
solely	O
to	O
embryonic	B
stem	I
cells	I
(ESC)	O
until	O
2006.	O

Tissues	O
derived	O
from	O
human	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
has	O
the	O
potential	O
to	O
overcome	O
many	O
inherent	O
limitations	O
of	O
animal	O
and	O
cell	O
culture	O
models	O
and	O
provide	O
an	O
unprecedented	O
new	O
paradigm	O
to	O
model	O
human	O
diseases..	O

Recent	O
breakthroughs	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
circumvent	O
many	O
of	O
these	O
drawbacks..	O

Atypical	O
neurogenesis	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
from	O
autistic	O
individuals.	O

The	O
stem/progenitor	O
cell	O
marker	O
esg>GFP	O
(esg::Gal4,	O
UAS::GFP)	O
is	O
only	O
expressed	O
in	O
intestinal	B
stem	I
cells	I
(ISCs)	O
and	O
enteroblasts	O
(EBs)	O
during	O
homeostasis,	O
whereas,	O
in	O
the	O
dysplastic	O
condition,	O
esg>GFP	O
begins	O
to	O
be	O
expressed	O
in	O
differentiated	O
cells,	O
including	O
enterocyte	O
(EC)-like	O
cells	O
and	O
enteroendocrine	O
cells	O
(EEs).	O

In	O
bone	O
marrow,	O
NK	O
cells	O
develop	O
from	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
through	O
common	O
lymphoid	O
progenitors	O
(CLPs)	O
and	O
NK	O
cell	O
precursors	O
(NKPs),	O
and	O
then	O
migrate	O
to	O
peripheral	O
blood	O
(cNK	O
cells)	O
or	O
tissue	O
(trNK	O
cells).	O

Using	O
human	O
disease	O
modeling	O
in	O
neuroepithelial	O
and	O
renal	O
cell	O
types	O
generated	O
from	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
of	O
both	O
individuals,	O
we	O
document	O
that	O
mutation	O
LRP2R3192Q	O
disrupts	O
the	O
ability	O
of	O
megalin	O
to	O
properly	O
discharge	O
internalized	O
ligand.	O

(a)	O
Immunodetection	O
of	O
megalin	O
(red)	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
lines	O
at	O
the	O
indicated	O
time	O
points	O
of	O
neuroectodermal	O
differentiation.	O

Induced	B
pluripotent	I
stem	I
cells	I
(iPSC)	O
have	O
revolutionized	O
the	O
field	O
of	O
biological	O
sciences	O
and	O
proteomics	O
and,	O
in	O
particular,	O
has	O
been	O
instrumental	O
in	O
identifying	O
key	O
elements	O
operating	O
during	O
the	O
maintenance	O
of	O
the	O
pluripotent	O
state	O
and	O
the	O
differentiation	O
process	O
to	O
the	O
diverse	O
cell	O
types	O
that	O
form	O
organisms.	O

The	O
pluripotent	O
potential	O
of	O
iPSC	O
is	O
represented	O
by	O
their	O
capability	O
to	O
differentiate	O
into	O
cell	O
types	O
from	O
the	O
3	O
embryonic	O
germ	O
layers:	O
ectoderm,	O
mesoderm,	O
and	O
endoderm,	O
a	O
property	O
initially	O
limited	O
to	O
embryonic	B
stem	I
cells	I
(ESC)	O
[22,23,31].	O

Many	O
of	O
the	O
age‐related	O
changes	O
observed	O
in	O
old	O
blood	O
have	O
roots	O
in	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
aging	O
(Kim,	O
Moon,	O
&	O
Spangrude,	O
2003;	O
Pang	O
et	O
al.,	O
2011).	O

Constitutive	O
KLF1	O
expression	O
in	O
human	B
embryonic	I
stem	I
cells	I
(hESCs)	O
results	O
in	O
reduced	O
proliferation	O
and	O
hematopoietic	O
progenitor	O
cell	O
production.	O

Cancer	B
stem	I
cells	I
(CSCs)	O
of	O
different	O
origins	O
suffer	O
disturbances	O
related	O
to	O
the	O
expression	O
of	O
cell	O
surface	O
markers,	O
enzymes,	O
and	O
transcription	O
factors	O
after	O
ethanol	O
exposure	O
with	O
the	O
consequent	O
dysregulation	O
of	O
mechanisms	O
related	O
to	O
cancer	O
metastasis	O
or	O
resistance	O
to	O
treatments.	O

Role	O
of	O
microRNA	O
21	O
in	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
differentiation:	O
a	O
powerful	O
biomarker	O
in	O
MSCs	O
derived	O
cells.	O

A	O
more	O
specific	O
set	O
of	O
299	O
human	O
genes	O
associated	O
to	O
stem	B
cell	I
(SC)	O
function	O
was	O
also	O
mapped	O
to	O
the	O
MSC	O
genes,	O
finding	O
139	O
positives.	O

Two	O
of	O
these	O
depicted	O
meta-regulators,	O
KLF4	O
and	O
MYC,	O
are	O
included	O
in	O
the	O
well-known	O
set	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
factors	O
(i.e.	O

When	O
tested	O
for	O
the	O
effect	O
of	O
chitosan	O
on	O
the	O
differentiation	O
of	O
brown	B
adipose-derived	I
stem	I
cell	I
(BASC)	O
to	O
CM,	O
the	O
expression	O
of	O
cardiac	O
markers	O
such	O
as	O
GATA-4,	O
Nkx2.5,	O
Myl7,	O
Myh6,	O
cTnI,	O
and	O
Cacna1a	O
was	O
noted	O
[38].	O

Human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
of	O
embryonic	O
(ESC)	O
or	O
induced	O
(iPSC)	O
origin	O
resemble	O
the	O
inner	O
cell	O
mass	O
(ICM)	O
of	O
the	O
early	O
post-implantation	O
embryo	O
and	O
have	O
become	O
a	O
cornerstone	O
for	O
modeling	O
human	O
disease	O
in	O
vitro	O
(Chamberlain,	O
2016).	O

Previously,	O
the	O
glycosylation	O
of	O
hESC	O
has	O
been	O
studied	O
with	O
lectins	O
and	O
antibodies	O
[25-27],	O
and	O
a	O
preliminary	O
report	O
has	O
been	O
published	O
on	O
mass	O
spectrometric	O
profiling	O
of	O
mouse	B
embryonic	I
stem	I
cell	I
(mESC)	O
N-glycans	O
[28].	O

All	O
MEFs	O
were	O
derived	O
from	O
13.5-day	O
mouse	O
embryos	O
and	O
used	O
for	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
generation	O
before	O
passage	O
4..	O

Here	O
we	O
report	O
a	O
novel	O
function	O
of	O
enteroendocrine	O
cells	O
acting	O
as	O
local	O
regulators	O
of	O
intestinal	B
stem	I
cell	I
(ISC)	O
proliferation	O
through	O
modulation	O
of	O
the	O
mesenchymal	O
stem	O
cell	O
niche	O
in	O
the	O
Drosophila	O
midgut.	O

B-type	O
lamins	O
are	O
ubiquitously	O
expressed	O
and	O
considered	O
essential	O
for	O
cell	O
survival,	O
whereas	O
A-type	O
lamins	O
change	O
during	O
development	O
and	O
cell	O
differentiation	O
stages,	O
being	O
absent	O
in	B
embryonic	I
stem	I
cells	I
as	O
well	O
as	O
in	O
induced	O
pluripotent	O
stem	O
cells	O
(iPSCs)	O
[7,8,9].	O

Gliomas	O
which	O
may	O
arise	O
from	O
tumorigenic	O
events	O
within	O
all	O
steps	O
of	O
maturation	O
from	O
neural	B
stem	I
cell	I
(NSC)	O
to	O
neurons	O
or	O
glia	O
display	O
diverse	O
expression	O
profiles	O
of	O
the	O
Notch	O
signaling,	O
reflecting	O
the	O
cell	O
of	O
origin.	O

The	O
differentiation	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
into	O
T	O
and	O
natural	O
killer	O
(NK)	O
lymphocytes	O
opens	O
novel	O
possibilities	O
for	O
developmental	O
studies	O
of	O
immune	O
cells	O
and	O
in-vitro	O
generation	O
of	O
cell	O
therapy	O
products.	O

These	O
data	O
are	O
supportive	O
of	O
the	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
origin	O
of	O
ES.	O

Involvement	O
of	O
Tip60	O
in	O
transcriptional	O
repression	O
is	O
not	O
unprecedented,	O
with	O
a	O
previous	O
study	O
supporting	O
a	O
critical	O
role	O
for	O
Tip60	O
in	O
epigenetically	O
repressing	O
a	O
large	O
number	O
of	O
developmental	O
genes	O
essential	O
for	O
embryonic	B
stem	I
cell	I
(ESC)	O
differentiation	O
[25].	O

Next,	O
we	O
tested	O
whether	O
HuR-telomerase	O
regulatory	O
process	O
impacts	O
on	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
function.	O

Wild	O
type	O
(WT)	O
and	O
CFTR	O
knockout	O
(KO)	O
mouse	O
pancreatic	O
ductal	O
(PDEC)	O
and	O
acinar	O
cells	O
(PAC),	O
human	O
CF	O
pancreatic	O
cell	O
line	O
(CFPAC-1)	O
and	O
human	O
pancreatic	O
organoids	O
generated	O
from	O
induced	B
pluripotent	I
stem	I
cells	I
(IPSC)	O
of	O
controls	O
and	O
CF	O
patients	O
were	O
used	O
in	O
the	O
study.	O

A	O
defined	O
set	O
of	O
master	O
transcription	O
factors	O
(TFs),	O
namely	O
OCT4,	O
SOX2,	O
KLF4,	O
and	O
MYC	O
(called	O
“OSKM”	O
hereafter),	O
can	O
reprogram	O
somatic	O
cells	O
into	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
and	O
allow	O
the	O
study	O
of	O
dynamic	O
events	O
that	O
occur	O
during	O
cell	O
fate	O
decisions	O
(Takahashi	O
and	O
Yamanaka,	O
2006,	O
Takahashi	O
et	O
al.,	O
2007).	O

Shinya	O
Yamanaka	O
reported	O
one	O
of	O
the	O
greatest	O
breakthroughs	B
in	I
stem	I
cell	I
research:	O
the	O
reprogramming	O
of	O
mouse	O
somatic	O
cells	O
into	O
induced	O
pluripotent	O
stem	O
cells	O
(iPSCs)	O
[1].	O

For	O
example,	O
cell	O
therapeutics	O
with	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
have	O
proven	O
evidence	O
for	O
efficacy	O
and	O
safety	O
in	O
animal	O
models.	O

Of	O
these,	O
the	O
cell	O
type	O
that	O
is	O
likely	O
to	O
give	O
rise	O
to	O
defects	O
in	O
multiple	O
organs	O
is	O
the	B
stem	I
cell	I
and	O
since	O
bone	O
marrow	O
failure	O
is	O
the	O
cause	O
of	O
most	O
DC-related	O
mortality	O
it	O
is	O
the	O
haematopoietic	O
stem	O
cell	O
(HSC)	O
that	O
has	O
received	O
the	O
most	O
research	O
attention	O
with	O
defects	O
having	O
been	O
identified	O
in	O
several	O
studies.	O

Hematopoietic	B
stem	I
cell	I
(HSC)	O
gene	O
therapy	O
using	O
retroviral	O
vectors	O
has	O
immense	O
potential,	O
but	O
vector-mediated	O
genotoxicity	O
limits	O
use	O
in	O
the	O
clinic.	O

As	O
to	O
the	O
role	O
of	O
Gomafu	B
in	I
stem	I
cell	I
biology,	O
it	O
has	O
been	O
suggested	O
that	O
Gomafu	O
and	O
Oct4	O
establish	O
an	O
autofeedback	O
loop	O
to	O
maintain	O
pluripotency	O
of	O
mouse	O
embryonic	O
stem	O
cells	O
(mESCs)	O
[35].	O

The	O
most	O
striking	O
evidence	O
supporting	O
the	O
use	O
of	O
exosomes	O
in	O
cell-free	O
therapy	O
and	O
tissue	O
engineering	O
come	O
from	O
the	O
results	O
obtained	O
from	O
a	O
series	O
of	O
studies	O
on	O
mesenchymal	B
stem	I
cell	I
(MSCs)	O
transplantation	O
for	O
tissue	O
regeneration	O
[122,123]..	O

The	O
emergence	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technologies	O
offers	O
an	O
attractive	O
alternative	O
to	O
humanized	O
mice	O
that	O
allows	O
the	O
interrogation	O
of	O
underlying	O
genetic	O
defects	O
using	O
a	O
vast	O
array	O
of	O
relevant	O
biological	O
tissues	O
and	O
cell	O
types	O
avoiding	O
both	O
allo-	O
and	O
xenogeneic	O
responses..	O

Induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
stable	O
cell	O
lines	O
can	O
be	O
generated	O
from	O
several	O
different	O
somatic	O
cell	O
types	O
depending	O
on	O
specimen	O
availability.	O

Gene	O
modification	O
strategies	O
for	O
use	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
lines.	O

Induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
reprogramming	O
schematic	O
from	O
CD34+	O
cells	O
using	O
Sendai	O
virus.	O

BMPs	O
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
pluripotent	B
stem	I
cell	I
(PSC)	O
regulation.	O

The	O
advent	O
and	O
maturation	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
presents	O
a	O
valuable	O
opportunity	O
to	O
solve	O
this	O
problem	O
by	O
offering	O
a	O
human	O
cell	O
model.	O

With	O
the	O
advent	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology,	O
the	O
researchers	O
have	O
also	O
been	O
able	O
to	O
generate	O
alternative	O
cell	O
models	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
the	O
diseases.	O

Embryonic	B
stem	I
cell	I
(ESC)	O
pluripotency	O
and	O
differentiation	O
are	O
controlled	O
by	O
the	O
coordinated	O
action	O
of	O
multiple	O
epigenetic	O
factors	O
that	O
affect	O
the	O
structure	O
of	O
chromatin	O
and	O
regulate	O
gene	O
expression.	O

Compelling	O
evidence	O
during	O
the	O
last	O
decades	O
has	O
demonstrated	O
the	O
existence	O
of	O
stem	B
cells	I
(SCs)	O
within	O
the	O
vertebrate’s	O
pituitary	O
with	O
capacity	O
to	O
divide	O
and	O
self-renew,	O
and	O
later	O
to	O
differentiate	O
into	O
specialized	O
cell	O
types.	O

Generation,	O
expansion,	O
and	O
differentiation	O
of	O
human	B
pluripotent	I
stem	I
cell	I
(hPSC)	O
derived	O
neural	O
progenitor	O
cells	O
(NPCs)	O
Methods	O
Mol.	O

Osteoblasts	O
differentiate	O
from	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
precursors,	O
initially	O
expressing	O
runx2	O
before	O
downregulating	O
runx2	O
and	O
expressing	O
the	O
transcription	O
factor	O
osterix	O
(osx).	O

Melanocytes	O
derive	O
from	O
neural	B
crest	I
stem	I
cells	I
(NCSCs)	O
that	O
disseminate	O
into	O
the	O
embryo	O
to	O
form	O
an	O
array	O
of	O
diverse	O
cell	O
lineages	O
[139].	O

The	O
generation	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
by	O
somatic	O
cellular	O
reprogramming	O
technology	O
using	O
a	O
combination	O
of	O
defined	O
reprogramming	O
factors	O
termed	O
the	O
“Yamanaka	O
factors”	O
(Oct-4,	O
Sox-2,	O
Klf-4,	O
and	O
c-Myc	O
(OSKM))	O
represents	O
a	O
major	O
breakthrough	O
in	O
stem	O
cell	O
biology	O
and	O
regenerative	O
medicine	O
[10,11].	O

Thus	O
the	O
seam	O
cells	O
and	O
germ	O
cells	O
both	O
have	O
stem-like	O
properties,	O
although	O
only	O
the	O
germline	B
stem	I
cells	I
(GSC)	O
have	O
a	O
recognizable	O
niche,	O
regulated	O
by	O
a	O
notch	O
signal	O
emanating	O
from	O
the	O
distal	O
tip	O
cell	O
(DTC)	O
that	O
maintains	O
the	O
mitotic	O
zone	O
[6],	O
[7].	O

In	O
this	O
article,	O
we	O
review	O
the	O
insight	O
into	O
the	O
mTOR	O
activity	O
in	O
neural	B
stem	I
cell	I
(NSC)	O
functions	O
thereby	O
illustrating	O
the	O
close	O
relationship	O
between	O
mTOR	O
and	O
the	O
pathological	O
events	O
which	O
are	O
mainly	O
occurred	O
in	O
brain	O
developmental	O
disorders	O
and	O
pediatric	O
brain	O
tumors..	O

The	O
impact	O
of	O
such	O
delay	O
on	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
function	O
is	O
unclear	O
since	O
most	O
studies	O
have	O
not	O
used	O
transplantation	O
assays	O
that	O
measure	O
HSC	O
key	O
properties	O
and	O
activities.	O

Background/Case	O
Studies:	O
Hematopoietic	B
stem	I
cell	I
(HSC)	O
donors	O
and	O
their	O
recipients	O
need	O
not	O
have	O
a	O
matching	O
blood	O
type.	O

More	O
experience	O
accumulates	O
in	O
the	O
immunomodulatory	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
infusion	O
in	O
numerous	O
immunopathological	O
disorders	O
–	O
such	O
as	O
GvHD	O
–	O
and	O
signals.	O

Neural	B
stem	I
cells	I
(NSC)	O
with	O
self-renewal	O
and	O
multipotent	O
properties	O
serve	O
as	O
an	O
ideal	O
cell	O
source	O
for	O
transplantation	O
to	O
treat	O
neurodegenerative	O
insults	O
such	O
as	O
Parkinson's	O
disease.	O

Mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
are	O
the	O
first	O
pluripotent	O
stem	O
cell	O
type	O
that	O
was	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
the	O
developing	O
blastocyst	O
[1,2].	O

Cells	O
derived	O
from	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
sources	O
(HM,	O
HO,	O
and	O
HN)	O
were	O
utilized	O
in	O
several	O
instances	O
to	O
establish	O
potential	O
patient-specific	O
and	O
disease	O
applications.	O

Therapeutic	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
largely	O
depends	O
on	O
the	O
paracrine	O
efficiency	O
of	O
MSC,	O
and	O
gingiva-derived	O
MSC	O
(GMSC)	O
have	O
unique	O
capacity	O
to	O
secret	O
large	O
amount	O
of	O
exosomes	O
and,	O
moreover,	O
are	O
easier	O
to	O
isolate.	O

POLG	O
mice	O
develop	O
progressive,	O
ultimately	O
fatal	O
megaloblastic	O
anemia	O
due	O
to	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
deficits,	O
impaired	O
erythrocyte	O
maturation,	O
and	O
increased	O
erythrocyte	O
destruction	O
by	O
splenic	O
macrophages	O
(30,	O
69,	O
70).	O

Recent	O
progress	O
in	O
the	O
biology	O
of	O
neural	B
stem	I
cells	I
(NSCs)	O
and	O
oligodendrocyte	O
precursor	O
cells	O
(OPCs)	O
provides	O
new	O
insights	O
into	O
their	O
candidacy	O
as	O
the	O
cell	O
of	O
origin	O
for	O
human	O
glioblastoma.	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
are	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
the	O
blastocysts	O
and	O
are	O
characterized	O
by	O
the	O
ability	O
to	O
renew	O
themselves	O
(self-renewal)	O
and	O
the	O
capability	O
to	O
generate	O
all	O
the	O
cells	O
within	O
the	O
human	O
body.	O

A	O
second	O
message	O
is	O
the	O
use	O
of	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
as	O
alternatives	O
to	O
the	O
stem	O
cell	O
sources	O
described	O
above.	O

There	O
are	O
limited	O
comprehensive	O
studies	O
on	O
toxicity	O
of	O
inhaled	O
FA	O
in	O
bone	O
marrow	O
(BM),	O
the	O
site	O
of	O
origination	O
of	O
all	O
blood	O
cells	O
from	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
[14]	O
and	O
target	O
site	O
for	O
leukemia	O
induction,	O
have	O
been	O
reported.	O

Hematopoietic	B
stem	I
cell	I
(HSC)	O
differentiation	O
is	O
a	O
prominent	O
example	O
of	O
a	O
dynamic	O
process	O
that	O
is	O
heavily	O
genetically	O
regulated	O
[9],	O
[29]–[32].	O

Cancer	B
stem	I
cells	I
(CSC)	O
have	O
enhanced	O
capacities	O
for	O
self-renewal,	O
cell	O
plasticity,	O
and	O
the	O
ability	O
to	O
adapt	O
to	O
harsh	O
environments	O
[277,278,279].	O

The	O
ability	O
of	O
the	O
tumor	O
suppressor	O
p53	O
under	O
stress	O
to	O
differentially	O
regulate	O
its	O
target	O
genes	O
which	O
regulate	O
cell-cycle	O
arrest,	O
apoptosis	O
or	O
senescence	O
of	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
could	O
be	O
a	O
possible	O
treatment	O
target	O
for	O
leukemia	O
[64].	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
are	O
a	O
kind	O
of	O
pluripotent	O
stem	O
cells	O
that	O
can	O
be	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
the	O
early	O
embryo	O
[5].	O

Compared	O
with	O
the	O
adult	B
stem	I
cells	I
(ASCs)	O
found	O
in	O
adults,	O
ESCs	O
are	O
able	O
to	O
replicate	O
indefinitely	O
and	O
to	O
differentiate	O
into	O
all	O
three	O
primary	O
germ	O
layers	O
cell	O
lines	O
and	O
eventually	O
generate	O
all	O
cell	O
types	O
in	O
the	O
body	O
[37].	O

Finally,	O
since	O
the	O
onset	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
[60],	O
mesenchymal	O
cells	O
have	O
been	O
investigated	O
[61,	O
62]	O
due	O
to	O
their	O
relatively	O
easy	O
harvest	O
and	O
higher	O
potency	O
than	O
other	O
cell	O
types	O
(e.g.,	O
dermal	O
fibroblasts),	O
which	O
show	O
an	O
increased	O
efficiency,	O
even	O
in	O
the	O
absence	O
of	O
the	O
oncogene	O
c-Myc.	O

In	O
general,	O
DNMT3A	O
or	O
DNMT3B	O
have	O
roles	O
in	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
self-renewal,	O
maturation,	O
and	O
differentiation	O
[85].	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
have	O
been	O
widely	O
used	O
for	O
stem	O
cell	O
therapy,	O
and	O
serial	O
passage	O
of	O
stem	O
cells	O
is	O
often	O
required	O
to	O
obtain	O
sufficient	O
cell	O
numbers	O
for	O
practical	O
applications	O
in	O
regenerative	O
medicine.	O

The	O
discovery	O
of	O
human	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
in	O
2006	O
completely	O
revolutionized	O
the	O
field	O
of	O
stem	O
cell	O
biology,	O
and	O
these	O
cells	O
are	O
expected	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
many	O
regenerative	O
medicine	O
therapies.	O

Generation	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
line	O
from	O
a	O
patient	O
with	O
triple	O
negative	O
breast	O
cancer	O
with	O
hereditary	O
exon	O
17	O
deletion	O
of	O
BRCA1	O
gene.	O

The	O
integration	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
with	O
advanced	O
bioprinting	O
systems	O
can	O
potentially	O
deliver	O
a	O
new	O
generation	O
of	O
disease	O
models	O
and	O
tissue	O
constructs	O
for	O
the	O
development	O
and	O
testing	O
of	O
personalized	O
therapies	O
with	O
enhanced	O
efficacy	O
and	O
reduced	O
costs.31,32	O
This	O
is	O
especially	O
so	O
when	O
combined	O
with	O
incorporation	O
of	O
patient-derived	O
iPSCs	O
carrying	O
heritable	O
mutations.	O

Human	B
embryonic	I
stem	I
cells	I
(hESC)	O
are	O
stem	O
cells	O
derived	O
directly	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
preimplantation	O
embryo,347	O
which	O
in	O
humans	O
comprises	O
less	O
than	O
a	O
dozen	O
cells	O
found	O
at	O
day	O
5–6	O
of	O
development.	O

HESCs	O
are	O
widely	O
used	O
in	O
medical	O
research	O
and	O
clinical	O
grade	O
hESCs,	O
suitable	O
for	O
therapeutic	O
applications,	O
are	O
readily	O
available.348−350	O
Induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
have	O
similar	O
properties	O
of	O
continuous	O
replication	O
without	O
differentiation	O
(i.e.,	O
self-renewal)	O
and	O
have	O
shown	O
the	O
ability	O
to	O
generate	O
virtually	O
any	O
cell	O
type	O
in	O
the	O
body	O
(i.e.,	O
they	O
are	O
pluripotent)	O
if	O
given	O
the	O
correct	O
induction	O
cues.	O

Our	O
previous	O
results	O
showed	O
that	O
hyaluronan	O
(HA)	O
preserved	O
human	O
placenta-derived	O
mesenchymal	B
stem	I
cells	I
(PDMSC)	O
in	O
a	O
slow	O
cell	O
cycling	O
mode	O
similar	O
to	O
quiescence,	O
the	O
pristine	O
state	O
of	O
stem	O
cells	O
in	O
vivo,	O
and	O
HA	O
was	O
found	O
to	O
prevent	O
murine	O
adipose-derived	O
mesenchymal	O
stem	O
cells	O
from	O
senescence.	O

A	O
goal	O
in	O
human	B
embryonic	I
stem	I
cell	I
(hESC)	O
research	O
is	O
the	O
faithful	O
differentiation	O
to	O
given	O
cell	O
types	O
such	O
as	O
neural	O
lineages.	O

During	O
reprogramming,	O
somatic	O
cell-specific	O
genes	O
are	O
suppressed,	O
while	B
embryonic	I
stem	I
cell	I
(ESC)-specific	O
pluripotency	O
genes	O
are	O
induced,	O
leading	O
to	O
the	O
generation	O
of	O
induced	O
pluripotent	O
stem	O
cells	O
(iPSCs)	O
with	O
undifferentiated	O
states	O
and	O
pluripotency	O
(Stadtfeld	O
et	O
al.,	O
2008).	O

This	O
method	O
is	O
not	O
to	O
be	O
confused	O
with	O
somatic	O
cell	O
reprogramming	O
which	O
involves	O
generation	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSCs)	O
from	O
somatic	O
cells	O
using	O
techniques	O
such	O
as	O
somatic	O
cell	O
nuclear	O
transfer	O
(SCNT),	O
cell-cell	O
fusion,	O
exposure	O
to	O
extracts	O
of	O
pluripotent	O
cells,	O
or	O
iPSC	O
technology	O
[26].	O

This	O
could	O
be	O
explained	O
by	O
the	O
leukemia	B
stem	I
cell	I
(LSC)	O
theory	O
in	O
which	O
rare	O
leukemic	O
blasts	O
are	O
thought	O
to	O
be	O
responsible	O
for	O
relapse	O
and	O
for	O
maintaining	O
AML.	O

In	O
order	O
to	O
understand	O
the	O
role	O
of	O
telomerase	O
in	O
leukemia	B
stem	I
cell	I
(LSC)	O
generation	O
and	O
maintenance,	O
we	O
have	O
taken	O
advantage	O
of	O
our	O
Sca1-BCR-ABLp210	O
mouse	O
model	O
of	O
human	O
chronic	O
myeloid	O
leukaemia	O
(CML),	O
a	O
paradigmatic	O
stem-cell	O
disorder	O
[23,	O
24].	O

To	O
date,	O
the	O
majority	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
studies	O
are	O
conducted	O
using	O
human	O
tumors	O
inoculated	O
into	O
severely	O
immunosuppressed	O
hosts	O
(e.g.	O

In	O
recent	O
years,	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
theory	O
has	O
emerged	O
as	O
an	O
attractive	O
hypothesis	O
for	O
tumor	O
development	O
and	O
progression.	O

Recently,	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
theory	O
has	O
emerged	O
as	O
an	O
attractive	O
hypothesis	O
for	O
tumor	O
development	O
and	O
progression.	O

Preclinical	O
efficacy	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
in	O
animal	O
models	O
for	O
systemic	O
lupus	O
erythematosus.	O

Neural	B
stem	I
cells	I
(NSCs)	O
have	O
been	O
successfully	O
derived	O
from	O
PSCs	O
and	O
several	O
protocols	O
for	O
PSCs	O
differentiation	O
into	O
a	O
broad	O
variety	O
of	O
mature	O
neurons	O
and	O
glial	O
cell	O
subtypes	O
have	O
been	O
published	O
(Srikanth	O
and	O
Young-Pearse,	O
2014).	O

Mesenchymal	B
stem	I
cell	I
(MSC)	O
gene	O
therapy	O
have	O
been	O
widely	O
used	O
in	O
clinical	O
trials	O
due	O
to	O
their	O
heterogenetic	O
properties	O
(Bianco	O
2014).	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
attenuate	O
cutaneous	O
sclerodermatous	O
graft-versus-host	O
disease	O
(Scl-GVHD)	O
through	O
inhibition	O
of	O
immune	O
cell	O
infiltration	O
in	O
a	O
mouse	O
model.	O

Here,	O
we	O
generated	O
mouse	B
embryonic	I
stem	I
cell	I
(mESC)	O
line	O
lacking	O
Wnt4	O
by	O
applying	O
the	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
(CRISPR)/CRISPR-associated	O
systems	O
9	O
(Cas9).	O

Recent	O
advances	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
research	O
have	O
turned	O
limitations	O
of	O
prior	O
and	O
current	O
research	O
into	O
possibilities.	O

In	O
another	O
study,	O
functional	O
DA	O
neurons	O
were	O
generated	O
from	O
neuroepithelial	B
stem	I
cells	I
(NESCs)	O
derived	O
from	O
hiPSCs	O
using	O
a	O
phase-guided	O
3D	O
cell	O
culture	O
microfluidic	O
bioreactor.	O

Notch	O
signaling	O
augments	O
BMP9-induced	O
bone	O
formation	O
by	O
promoting	O
the	O
osteogenesis-angiogenesis	O
coupling	O
process	O
in	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
Cell.	O

However,	O
the	O
sg2/sg3	O
MA9	O
cells	O
showed	O
a	O
significantly	O
larger	O
population	O
of	O
cells	O
expressing	O
the	O
c-Kit	O
progenitor	O
marker	O
(Figure	O
3F,H),	O
which	O
has	O
been	O
associated	O
with	O
the	O
leukaemia	B
stem	I
cell	I
(LSC)	O
in	O
AMLs	O
including	O
MA9	O
[36,37].	O

Development	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
using	O
forced	O
expression	O
of	O
specific	O
sets	O
of	O
transcription	O
factors	O
has	O
changed	O
the	O
field	O
of	O
stem	O
cell	O
research	O
extensively.	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
mouse	O
[10]	O
and	O
subsequently	O
from	O
human	O
blastocysts	O
[11]	O
are	O
considered	O
pluripotent.	O

MNCs	O
of	O
normal	O
A	O
and	O
normal	O
B	O
were	O
enriched	O
for	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
by	O
CD34	O
cell	O
surface	O
marker	O
selection	O
using	O
the	O
CD34	O
MicroBead	O
kit,	O
human	O
(Miltenyi	O
Biotec)	O
according	O
to	O
the	O
manufacturer’s	O
instructions.	O

Therefore,	O
we	O
hypothesized	O
that	O
this	O
tumor	O
reprogramming	O
fate	O
at	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
level	O
should	O
be	O
the	O
target	O
where,	O
at	O
least	O
partly,	O
the	O
action	O
of	O
those	O
genetic	O
determinants	O
takes	O
place,	O
such	O
as	O
modifier	O
genes,	O
which	O
determine	O
the	O
differences	O
among	O
individuals	O
regarding	O
tumor	O
susceptibility,	O
treatment	O
response,	O
and	O
evolution..	O

At	O
the	O
base	O
of	O
the	O
crypts,	O
the	O
intestinal	B
stem	I
cell	I
(ISC)	O
niche	O
enables	O
the	O
constant	O
regeneration	O
of	O
the	O
intestinal	O
lining	O
(e.g.	O

The	O
sox	O
family	O
of	O
transcription	O
factors:	O
versatile	O
regulators	O
of	O
stem	O
and	O
progenitor	O
cell	O
fate.	O
In	O
this	O
context,	O
human	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
are	O
revolutionising	O
models	O
for	O
probing	O
biological	O
questions	O
in	O
multiple	O
fields,	O
as	O
well	O
as	O
being	O
hailed	O
as	O
future	O
treatments	O
for	O
a	O
multitude	O
of	O
diseases	O
with	O
the	O
potential	O
to	O
more	O
accurately	O
reflect	O
in	O
vivo	O
human	O
cell	O
types	O
(Hyman	O
and	O
Simons,	O
2011;	O
Zhang	O
and	O
Reilly,	O
2017).	O

To	O
investigate	O
the	O
role	O
of	O
matrix	O
rigidity	O
on	O
satellite	O
cell	O
fate,	O
freshly	O
isolated	O
and	O
FACS	O
(fluorescence	O
activated	O
cell	O
sorting)	O
enriched	O
muscle	B
stem	I
cells	I
(MuSCs)	O
were	O
cultured	O
on	O
PEG	O
hydrogels	O
with	O
differing	O
mechanical	O
properties	O
but	O
constant	O
ligand	O
density	O
[9].	O

A	O
biomimetic	O
biomaterials	O
approach	O
in	O
conjunction	O
with	O
functional	O
assays	O
in	O
mice	O
demonstrated	O
that	O
muscle	B
stem	I
cell	I
(MuSC)	O
self-renewal	O
can	O
be	O
maintained	O
in	O
culture	O
if	O
cells	O
are	O
propagated	O
upon	O
a	O
substrate	O
that	O
recapitulates	O
the	O
mechanical	O
properties	O
of	O
the	O
native	O
skeletal	O
muscle	O
tissue,	O
a	O
physical	O
property	O
of	O
the	O
stem	O
cell	O
niche	O
[9].	O

The	O
intestinal	O
epithelium	O
is	O
the	O
most	O
rapidly	O
self-renewing	O
tissue	O
in	O
adult	O
mammals,	O
which	O
renews	O
every	O
3–5	O
days	O
in	O
mice.1	O
Homeostasis	O
of	O
the	O
intestinal	O
epithelium	O
is	O
dependent	O
on	O
intestinal	B
stem	I
cells	I
(ISCs)	O
and	O
a	O
balance	O
among	O
cell	O
proliferation,	O
migration,	O
differentiation,	O
and	O
cell	O
death.1,	O
2	O
Several	O
ISC	O
populations	O
with	O
possible	O
overlap	O
have	O
recently	O
been	O
identified	O
in	O
mouse,	O
including	O
the	O
actively	O
cycling	O
columnar	O
cells	O
at	O
the	O
crypt	O
base	O
(CBCs)	O
marked	O
by	O
Lgr5	O
or	O
CD133,	O
and	O
the	O
slow	O
cycling	O
cells	O
in	O
the	O
+4	O
area	O
marked	O
by	O
Bmi1,	O
DCLK-1	O
(also	O
known	O
as	O
DCAMKL-1),	O
or	O
mTERT.	O

In	O
contrast,	O
the	O
self-renewal	O
and	O
differentiation	O
potential	O
of	O
human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
make	O
them	O
a	O
promising	O
alternative	O
cell	O
source	O
for	O
cell	O
replacement	O
therapy	O
for	O
PD.	O

Human	B
embryonic	I
stem	I
cells	I
(hESCs)	O
and	O
adult	O
stem	O
cell	O
sources	O
such	O
as	O
mesenchymal	O
stem	O
cells	O
have	O
been	O
shown	O
to	O
be	O
capable	O
of	O
generating	O
DA	O
neurons	O
in	O
cell	O
culture	O
models.	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
belong	O
to	O
a	O
category	O
of	O
clinically	O
relevant	O
cell	O
types	O
that	O
have	O
the	O
potential	O
to	O
be	O
utilized	O
for	O
cell-based	O
therapies,	O
because	O
complicated	O
culturing	O
or	O
handling	O
techniques	O
are	O
not	O
required	O
to	O
yield	O
clinically	O
practical	O
quantities.	O

Importantly,	O
Wwp2-mediated	O
Oct4	O
repression	O
could	O
impede	O
stemness	O
re-establishment	O
since	O
both	O
Wwp2	O
knockout	O
and	O
mutation	O
in	O
the	O
Oct4	O
ubiquitination	O
site	O
increase	O
the	O
efficiency	O
of	O
somatic	O
cell	O
reprogramming	O
into	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
[74].	O

Neural-like	O
cell	O
lines	O
developed	O
to	O
study	O
ASD	O
have	O
been	O
obtained	O
by	O
the	O
differentiation	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
from	O
patients	O
or	O
by	O
the	O
inactivation	O
of	O
the	O
selected	O
ASD-associated	O
gene	O
in	O
controls,	O
using	O
genomic	O
editing	O
systems..	O

We	O
also	O
discuss	O
the	O
breast's	B
stem	I
cell	I
populations	O
and	O
their	O
relevance	O
to	O
cancer	O
stem	O
cells	O
(CSCs)	O
and	O
cancer	O
development.	O

ECM	O
proteins	O
in	O
the	O
BM	O
connect	O
the	O
basal	B
stem	I
cells	I
through	O
various	O
anchoring	O
complexes,	O
which	O
coordinate	O
the	O
actin	O
and	O
microtubule	O
network	O
and	O
establish	O
cell	O
polarity,	O
so	O
that	O
the	O
basal	O
stem	O
cells	O
(EpSCs)	O
differentiate	O
and	O
proliferate	O
[2].	O

The	O
number	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
(hiPSC)	O
lines	O
established	O
from	O
each	O
sample	O
is	O
also	O
shown.	O

Establishment	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
line	O
from	O
a	O
75-year	O
old	O
patient	O
with	O
late	O
onset	O
Alzheimer’s	O
disease	O
(LOAD)	O
Stem	O
Cell	O
Res.	O

(7)	O
Melatonin	O
rescues	O
the	O
inhibitory	O
effects	O
of	O
miR‐363	O
on	O
neural	B
stem	I
cell	I
(NSC)	O
proliferation	O
and	O
neuronal	O
differentiation	O
in	O
vitamin	O
A	O
deficiency-	O
(VAD-)	O
associated	O
congenital	O
spinal	O
deformities.	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
have	O
generated	O
a	O
great	O
deal	O
of	O
interest	O
and	O
promise	O
as	O
a	O
potential	O
source	O
of	O
cells	O
for	O
cell-based	O
therapeutic	O
strategies	O
for	O
tissue	O
repair	O
and	O
regenerative	O
diseases,	O
primarily	O
owing	O
to	O
their	O
intrinsic	O
ability	O
to	O
self	O
renew	O
and	O
differentiate	O
into	O
functional	O
cell	O
types	O
that	O
constitute	O
the	O
tissue	O
in	O
which	O
they	O
exist.	O

Unexpected	O
evidence	O
that	O
chronic	O
IGF-1	O
deficiency	O
in	O
Laron	O
dwarf	O
mice	O
maintains	O
high	O
levels	O
of	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
in	O
BM	O
-	O
are	O
HSCs	O
gradually	O
depleted	O
from	O
BM	O
with	O
age	O
in	O
an	O
IGF-1-dependent	O
manner?	O
Implications	O
for	O
the	O
novel	O
effect	O
of	O
caloric	O
restriction	O
on	O
the	O
hematopoietic	O
stem	O
cell	O
compartment	O
and	O
longevity.	O

GDNF	O
deletion	O
in	O
TPCs	O
disrupts	O
spermatogonia	O
development,	O
indicating	O
an	O
essential	O
role	O
of	O
TPCs	O
in	O
maintaining	O
the	O
spermatogonial	B
stem	I
cell	I
(SSC)	O
niche	O
[14].	O

We	O
have	O
previously	O
described	O
the	O
generation	O
and	O
characterization	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
from	O
fibroblasts	O
of	O
NS	O
patients,	O
who	O
did	O
(NS/JMML)	O
and	O
did	O
not	O
(NS)	O
go	O
on	O
to	O
develop	O
JMML,	O
which	O
faithfully	O
model	O
leukemia	O
progression	O
after	O
differentiation	O
into	O
myeloid	O
cells.23	O
Derivation	O
of	O
iPSCs	O
from	O
noncancerous	O
cells	O
allows	O
the	O
investigation	O
of	O
these	O
PTPN11	O
mutations	O
in	O
the	O
absence	O
of	O
secondary	O
or	O
additional	O
genomic	O
alterations	O
that	O
frequently	O
occur	O
during	O
leukemia	O
progression.24	O
This	O
overcomes	O
the	O
issue	O
of	O
the	O
limited	O
availability	O
of	O
primary	O
cell	O
material	O
for	O
studies	O
of	O
this	O
disease..	O

The	O
use	O
of	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
for	O
tissue	O
engineering	O
and	O
regenerative	O
medicine	O
applications	O
is	O
attractive,	O
in	O
part	O
due	O
to	O
their	O
ability	O
to	O
differentiate	O
into	O
multiple	O
cell	O
types	O
and	O
their	O
ease	O
of	O
expansion	O
in	O
vitro.	O

GSEA	O
analysis	O
of	O
8227	O
AML	O
fractions	O
and	O
the	O
leukemia	B
stem	I
cell	I
(LSC)	O
signatures	O
were	O
performed	O
using	O
the	O
control	O
sample	O
data	O
from	O
GSE55814.	O

The	O
risk	O
of	O
tumorigenicity	O
in	B
the	I
stem	I
cell	I
platform	O
has	O
been	O
highlighted	O
in	O
many	O
studies,	O
including	O
preclinical	O
dose-escalation	O
tests	O
for	O
the	O
first-in-human	O
induced	O
pluripotent	O
stem	O
cells	O
(iPSC)	O
clinical	O
trial	O
to	O
be	O
approved	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
in	O
2009.	O

We	O
performed	O
RT-qPCR	O
in	O
MG-63	O
cells	O
seeded	O
in	O
the	O
3D	O
scaffold,	O
treated	O
for	O
72	O
h	O
with	O
non-lethal	O
doses	O
of	O
PAR	O
30,	O
60	O
and	O
120	O
s	O
to	O
analyze	O
the	O
expression	O
of	O
genes	O
with	O
well-known	O
functions	O
of	O
cancer	B
stem	I
cell	I
(CLSC)	O
phenotype.	O

Nanomedicine	O
has	O
a	O
leading	O
role	O
in	O
pharmaceutical	O
research	O
and	O
development	O
of	O
clinical	O
protocols,	O
mainly	O
in	O
the	O
form	O
of	O
nanoparticle-based	O
delivery	O
systems	O
for	O
drugs	O
and	O
imaging	O
agents,	O
especially	O
in	O
the	O
field	O
of	O
stem	B
cell	I
(SC)	O
therapies	O
[1].	O

Regarding	O
therapeutic	O
application,	O
iPSCs	O
overcame	O
the	O
practical	O
and	O
ethical	O
difficulties	O
associated	O
with	O
the	O
use	O
of	O
embryonic	B
stem	I
cells	I
(ESCs)	O
for	O
cell	O
replacement	O
therapies	O
(CRTs)	O
(Takahashi	O
et	O
al.,	O
2007).	O

Takahashi	O
and	O
Yamanaka’s	O
pioneering	O
studies	O
in	O
the	O
2000s	O
[13]	O
led	O
to	O
rapid	O
expansion	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technologies,	O
and	O
opened	O
unprecedented	O
opportunities	O
for	O
disease	O
modeling.	O

Bone	B
marrow	I
mesenchymal	I
stem	I
cells	I
(BMMSCs)	O
are	O
a	O
cell	O
population	O
characterized	O
by	O
rapid	O
proliferation,	O
low	O
immunogenicity,	O
pluripotency,	O
tissue	O
repair	O
ability,	O
and	O
immunosuppression13,14.	O

The	O
advent	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
(Takahashi	O
&	O
Yamanaka,	O
2006)	O
has	O
made	O
it	O
possible	O
to	O
reprogram	O
human	O
somatic	O
cells	O
to	O
pluripotency	O
(Park	O
et	O
al,	O
2008b;	O
Takahashi	O
et	O
al,	O
2007;	O
Yu	O
et	O
al,	O
2007),	O
thus	O
enabling	O
the	O
generation	O
of	O
disease-specific	O
iPSC	O
(Lee	O
&	O
Studer,	O
2010).	O

In	O
the	O
following	O
sections,	O
we	O
will	O
focus	O
mostly	O
on	O
the	O
biological	O
actions	O
of	O
TGFβ	O
but	O
also	O
make	O
reference	O
to	O
signalling	O
and	O
mechanistic	O
details	O
wherever	O
possible,	O
pointing	O
out	O
how	O
TGFβ	O
can	O
contribute	O
to	O
the	O
biology	O
of	O
cancer	B
stem	I
cells	I
(CSCs)	O
and	O
various	O
stromal	O
cell	O
types	O
in	O
order	O
to	O
facilitate	O
cancer	O
metastasis.	O

Chromatin	O
signatures	O
obtained	O
by	O
epigenomic	O
profiling	O
of	O
a	O
cohort	O
of	O
human	B
embryonic	I
stem	I
cell	I
(hESC)	O
lines	O
can	O
be	O
used	O
to	O
generate	O
hESC	O
reference	O
epigenomes	O
(left	O
panels).	O

We	O
have	O
witnessed	O
remarkable	O
developments	O
in	O
pluripotent	B
stem	I
cell	I
(PSC)	O
technologies	O
over	O
the	O
past	O
few	O
decades.	O

Generation	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
line	O
from	O
a	O
patient	O
with	O
triple	O
negative	O
breast	O
cancer	O
with	O
hereditary	O
exon	O
17	O
deletion	O
of	O
BRCA1	O
gene.	O

The	O
generation	O
of	O
human	B
embryonic	I
stem	I
cell	I
(hESC)	O
lines	O
(Shamblott	O
et	O
al.	O

The	O
advent	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
(Takahashi	O
et	O
al.	O

To	O
seek	O
replication	O
for	O
the	O
predicted	O
therapeutic	O
effect	O
of	O
VPA	O
on	O
M30	O
gene	O
expression,	O
and	O
to	O
assess	O
the	O
relevance	O
of	O
gene	O
expression	O
changes	O
observed	O
in	O
the	O
cancer	O
cell	O
lines	O
used	O
by	O
CMap	O
to	O
neurons,	O
we	O
analysed	O
gene	O
expression	O
changes	O
in	O
16	O
day	O
neurons	O
differentiated	O
from	O
mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
before	O
and	O
after	O
treatment	O
with	O
VPA	O
(here	O
studying	O
VPA	O
as	O
its	O
sodium	O
salt	O
which	O
is	O
therapeutically	O
equivalent	O
to	O
VPA)	O
(see	O
‘Methods’).	O

However,	O
cell	O
expansion	O
in	O
culture	O
can	O
lead	O
to	O
unwanted	O
cellular	O
differentiation,	O
particularly	O
in	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
13.	O

A	O
subpopulation	O
of	O
tumour	O
cells,	O
identified	O
by	O
co-expression	O
of	O
epithelial	O
cell	O
adhesion	O
molecule	O
(EPCAM),	O
the	O
basal	O
cell	O
marker	O
NGFR,	O
and	O
the	O
bronchioalveolar	B
stem	I
cell	I
(BASC)	O
marker	O
stem	O
cell	O
antigen-1	O
(SCA1,	O
also	O
known	O
as	O
LY6A),	O
was	O
found	O
to	O
have	O
the	O
ability	O
to	O
propagate	O
the	O
tumour	O
upon	O
implantation	O
into	O
immunocompromised	O
mice73.	O

Indeed,	O
the	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
pioneered	O
by	O
Shinya	O
Yamanaka	O
in	O
2006	O
has	O
potential	O
for	O
unlimited	O
expansion	O
and	O
can	O
generate	O
the	O
cells	O
of	O
all	O
three	O
germ	O
layers27.	O

Induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
generation	O
by	O
Sendai	O
virus-mediated	O
gene	O
transfer.	O

miR-1306-3p	O
Neurons	O
generated	O
from	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
derived	O
from	O
6	O
control	O
subjects	O
and	O
6	O
schizophrenia	O
subjects.	O

Neurons	O
produced	O
from	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
derived	O
from	O
controls	O
and	O
SCZ.	O

Neurons	O
generated	O
from	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
derived	O
from	O
controls	O
and	O
SCZ.	O

The	O
use	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
therapy	O
to	O
treat	O
clinical	O
disease	O
may	O
be	O
optimized	O
through	O
selection	O
and	O
pre‐conditioning	O
methods	O
that	O
would	O
enhance	O
their	O
immunomodulatory	O
functions.	O

Mesenchymal	B
stem	I
cell	I
(MSC)	O
therapy	O
may	O
reduce	O
intra‐renal	O
inflammation	O
and	O
fibrosis	O
following	O
systemic	O
delivery	O
and	O
has	O
demonstrated	O
modest	O
effects	O
in	O
feline	O
CKD	O
following	O
intravenous	O
delivery.	O

Accumulating	O
evidence	O
indicates	O
that	O
understanding	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
behaviors	O
holds	O
great	O
promise	O
for	O
the	O
treatment	O
of	O
human	O
cancers.	O

Induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
specifically	O
bypass	O
the	O
need	O
for	O
embryonic	O
tissue	O
as	O
they	O
can	O
be	O
generated	O
by	O
reprogramming	O
any	O
somatic	O
cell	O
42,	O
43.	O

Human	B
mesenchymal	I
stem	I
cell	I
(hMSCs)	O
(Lonza,	O
Walkersville,	O
MD,	O
USA)	O
were	O
cultured	O
in	O
Minimum	O
Essential	O
Medium	O
(Gibco,	O
Invitrogen,	O
USA),	O
containing	O
10%	O
FBS	O
(Gibco,	O
Invitrogen,	O
USA)	O
and	O
100	O
U/ml	O
penicillin,	O
100	O
mg/ml	O
streptomycin	O
sulfate	O
(Gibco,	O
Grand	O
Island,	O
NY,	O
USA).	O

(B)	O
Generation	O
of	O
embryonic	B
stem	I
cells	I
(ESCs)	O
by	O
selection	O
of	O
inner	O
cell	O
mass	O
from	O
a	O
blastocyst,	O
culture,	O
and	O
then	O
reprogramming/genome	O
editing.90,93.	O

Some	O
of	O
the	O
regulatory	O
roles	O
played	O
by	O
linc-ROR	O
are	O
the	O
maintenance	O
of	B
stem	I
cell	I
pluripotency,	O
triggering	O
the	O
epithelial-mesenchymal	O
transition	O
(EMT)	O
[105],	O
hypoxia,	O
in	O
the	O
proliferation	O
of	O
cancerous	O
cells	O
acting	O
both	O
as	O
promotor/inhibitor	O
and	O
in	O
self-renewal	O
of	O
glioma	O
stem	O
cells	O
(GSCs)	O
via	O
inhibition	O
of	O
KLF4	O
expression.	O

(a,b)	O
Normalized	O
gene	O
expression	O
levels	O
of	O
CSPG4,	O
in	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
and	O
OSA	O
biopsies	O
as	O
compared	O
with	O
normal	O
osteoblasts	O
in	O
toto	O
(mean	O
±	O
SD)	O
(a)	O
or	O
divided	O
according	O
to	O
the	O
Huvos	O
system	O
grading	O
(geometric	O
mean)	O
(b).	O

There	O
is	O
concern	O
that	O
the	O
stresses	O
of	O
inducing	O
pluripotency	O
may	O
lead	O
to	O
deleterious	O
DNA	O
mutations	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
lines,	O
which	O
would	O
compromise	O
their	O
use	O
for	O
cell	O
therapies.	O

Immunohistochemistry	O
and	O
flow	O
cytometry	O
analysis	O
of	O
12	O
tumor	O
samples	O
obtained	O
from	O
patients	O
with	O
high	O
grade	O
gliomas	O
revealed	O
that	O
a	O
considerable	O
population	O
(2–19%)	O
of	O
cells	O
in	O
all	O
malignant	O
gliomas	O
expressed	O
IL-17RA,	O
with	O
remarkable	O
co-expression	O
of	O
the	O
glioma	B
stem	I
cell	I
(GSC)	O
markers	O
CD133,	O
Nestin,	O
and	O
Sox2.	O

The	O
more	O
severely	O
affected	O
twin	O
(designated	O
as	O
the	O
affected	O
proband,	O
AP,	O
and	O
from	O
whom	O
the	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
model	O
of	O
severe	O
ASD	O
affectation	O
was	O
acquired)	O
began	O
to	O
exhibit	O
delays	O
in	O
development	O
by	O
9	O
months	O
of	O
age.	O

Melanocyte	B
stem	I
cells	I
(McSCs)	O
and	O
mouse	O
models	O
of	O
hair	O
graying	O
serve	O
as	O
useful	O
systems	O
to	O
uncover	O
mechanisms	O
involved	O
in	O
stem	O
cell	O
self-renewal	O
and	O
the	O
maintenance	O
of	O
regenerating	O
tissues.	O

Human	B
mesenchymal	I
stem	I
cell	I
(hMSC)	O
markers	O
were	O
observed	O
on	O
CD105+	O
isolated	O
cells.	O

Single	O
cell	O
sequencing	O
of	O
neural	B
stem	I
cells	I
(NSCs)	O
demonstrated	O
that	O
in	O
response	O
to	O
injury,	O
there	O
is	O
a	O
dramatic	O
increase	O
in	O
transcription	O
of	O
the	O
genes	O
involved	O
in	O
ribosome	O
biogenesis	O
(Llorens-Bobadilla	O
et	O
al.,	O
2015).	O

A	O
balance	O
between	O
quiescence	O
and	O
proliferation	O
is	O
critical	O
for	O
proper	O
maintenance	O
of	O
the	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
pool.	O

Generation	O
and	O
characterization	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
(hiPSC)	O
lines	O
from	O
an	O
Alzheimer's	O
disease	O
(ASUi003-A)	O
and	O
non-demented	O
control	O
(ASUi004-A)	O
patient	O
homozygous	O
for	O
the	O
Apolipoprotein	O
e4	O
(APOE4)	O
risk	O
variant.	O

Generation	O
and	O
characterization	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
(hiPSC)	O
lines	O
from	O
an	O
Alzheimer's	O
disease	O
(ASUi001-A)	O
and	O
non-demented	O
control	O
(ASUi002-A)	O
patient	O
homozygous	O
for	O
the	O
Apolipoprotein	O
e4	O
(APOE4)	O
risk	O
variant.	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
are	O
pluripotent	O
cells	O
located	O
in	O
the	O
inner	O
cell	O
mass	O
of	O
early	O
embryos	O
that	O
have	O
the	O
capacity	O
for	O
long-term	O
self-renewal	O
and	O
the	O
ability	O
to	O
form	O
all	O
cell	O
types	O
of	O
the	O
embryo	O
proper.	O

Induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
Patient-specific	O
genotype	O
Cells	O
can	O
be	O
differentiated	O
to	O
better	O
reflect	O
photoreceptor	O
cell	O
morphology	O
and	O
gene	O
expression	O
profiles.	O

(C):	O
Immnoblotting	O
analysis	O
was	O
used	O
to	O
examine	O
the	O
activation	O
of	O
Hedgehog	O
signaling	O
and	O
expression	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
markers	O
in	O
the	O
cells	O
described	O
in	O
(B).	O

Human	B
pluripotent	I
stem	I
cell	I
(hPSC)	O
technology	O
has	O
the	O
potential	O
to	O
overcome	O
those	O
challenges	O
and	O
to	O
present	O
a	O
fully	O
human,	O
defined	O
and	O
scalable	O
platform	O
to	O
study	O
neuroinflammation.	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
have	O
been	O
broadly	O
used	O
in	O
cell	O
therapies	O
based	O
on	O
various	O
preclinical	O
and	O
clinical	O
studies	O
regarding	O
their	O
safety	O
and	O
efficacy	O
(Kamen	O
et	O
al.,	O
2018;	O
Wilson	O
et	O
al.,	O
2015).	O

Several	O
cell	O
types,	O
such	O
as	O
T	O
cells,	O
HSCs,	O
and	O
fibroblasts,	O
can	O
be	O
reprogramed	O
into	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
by	O
transducing	O
these	O
cells	O
with	O
a	O
SIN-lentiviral	O
vector	O
expressing	O
three	O
pluripotency	O
genes,	O
OCT4,	O
SOX2,	O
and	O
KLF4	O
(88–90).	O

In	O
light	O
of	O
the	O
latest	O
advances	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology,	O
future	O
epigenomic	O
brain	O
approaches	O
will	O
involve	O
the	O
study	O
of	O
specific	O
neuronal	O
populations	O
derived	O
from	O
patient-cells,	O
allowing	O
a	O
better	O
understanding	O
of	O
the	O
disorder	O
by	O
disease	O
modelling	O
and	O
a	O
faster	O
drug	O
screening/repurposing	O
in	O
a	O
personalized	O
manner	O
[200]..	O

Human	B
mesenchymal	I
stem	I
cells	I
(hMSCs)	O
possess	O
the	O
potential	O
to	O
differentiate	O
into	O
numerous	O
cell	O
lineages,	O
such	O
as	O
adipocytes,	O
osteoblasts,	O
fibroblasts	O
and	O
chondrocytes.	O

This	O
leads	O
enhanced	O
Igf2	O
expression	O
and	O
Igfr1	O
translation,	O
playing	O
a	O
significant	O
role	O
in	O
the	O
increased	O
activation	O
and	O
proliferation	O
of	O
hematopoietic	B
stem	I
cell	I
(HSCs)	O
[61]..	O

These	O
mechanisms	O
may	O
not	O
be	O
limited	O
to	O
interactions	O
between	O
tumor	O
cells	O
and	O
fibroblasts,	O
but	O
also	O
have	O
been	O
noted	O
in	O
a	O
two-way	O
regulation	O
in	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
differentiation	O
to	O
CAFs	O
by	O
factors	O
from	O
mammary	O
cancer	O
cells	O
and	O
CAFs	O
in	O
turn	O
promoting	O
cancer	O
development.	O

Supporting	O
the	O
leukemia	O
evidence	O
for	O
a	O
critical	O
role	O
of	O
MLL1	O
in	O
hematopoiesis,	O
mouse	O
knockout	O
studies	O
showed	O
that	O
Mll1	O
is	O
required	O
for	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
function	O
(Ernst	O
et	O
al.,	O
2004;	O
Jude	O
et	O
al.,	O
2007).	O

Menin-null	O
(Men1-KO)	O
mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
can	O
undergo	O
in	O
vitro	O
differentiation	O
into	O
adipocytes	O
and	O
show	O
increased	O
adipocyte	O
cell	O
size.	O

Cancer	B
stem	I
cells	I
(CSCs)	O
are	O
a	O
small	O
subpopulation	O
of	O
cancer	O
cells	O
with	O
increased	O
renewal	O
capacity	O
that	O
play	O
roles	O
in	O
tumor	O
growth,	O
cell	O
and	O
molecular	O
heterogeneity,	O
differentiation,	O
and	O
metastasis	O
[255,256].	O

However,	O
the	O
role	O
of	O
circRNAs	O
in	O
neural	B
stem	I
cell	I
(NSC)	O
differentiation	O
and	O
the	O
treatment	O
of	O
ischaemic	O
stroke	O
remains	O
unknown..	O

The	O
classical	O
approach	O
to	O
developing	O
a	O
protocol	O
for	O
the	O
human	O
mDA	O
neuronal	O
differentiation	O
from	O
hPSCs	O
was	O
based	O
on	O
adaptations	O
of	O
mouse	B
neural	I
stem	I
cell	I
(mNSC)	O
and	O
mESC	O
protocols,	O
which	O
required	O
co-culture	O
with	O
feeder	O
cells	O
(37).	O

Induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
are	O
somatic	O
cells	O
that	O
have	O
been	O
transcriptionally	O
reprogrammed	O
to	O
an	O
embryonic	O
stem	O
cell	O
(ESC)-like	O
state.	O

Induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
are	O
somatic	O
cells	O
that	O
have	O
been	O
transcriptionally	O
reprogrammed	O
to	O
an	O
embryonic	O
stem	O
cell	O
(ESC)-like	O
state.	O

Hematopoietic	B
stem	I
cells	I
(HSCs)	O
differentiate	O
into	O
common	O
lymphoid	O
progenitors	O
(CLPs),	O
and	O
then	O
differentiate	O
into	O
NK	O
cell	O
progenitors	O
(NKPs).	O

Moreover,	O
the	O
Lange	O
laboratory	O
demonstrated	O
that	O
PR-A	O
was	O
a	O
driver	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
expansion	O
in	O
BCa	O
cells	O
and	O
that	O
phosphorylation	O
of	O
PR-A	O
was	O
required	O
for	O
the	O
expression	O
of	O
CSC-associated	O
genes	O
(Truong	O
et	O
al.	O

By	O
employing	O
the	O
human	B
embryonic	I
stem	I
cell	I
(hESC)	O
to	O
cardiomyocyte	O
differentiation	O
system	O
and	O
generating	O
QKI-deficient	O
hESCs	O
(hESCs-QKIdel)	O
using	O
CRISPR/Cas9	O
gene	O
editing	O
technology,	O
we	O
analyze	O
the	O
physiological	O
role	O
of	O
QKI	O
in	O
cardiomyocyte	O
differentiation,	O
maturation,	O
and	O
contractile	O
function.	O

We	O
then	O
performed	O
transcriptome	O
analysis	O
of	O
hematopoieitic	B
stem	I
cell	I
(HSC)	O
and	O
myeloid	O
progenitor	O
cell-enriched	O
populations	O
from	O
the	O
bone	O
marrow	O
of	O
Ts(1716)65Dn	O
mice	O
to	O
define	O
the	O
relevant	O
biological	O
and	O
genetic	O
changes	O
by	O
which	O
trisomy	O
predisposes	O
to	O
development	O
of	O
myeloproliferation	O
in	O
this	O
DS	O
model	O
[20].	O

In	O
this	O
review,	O
we	O
will	O
use	O
the	O
word	O
“reprogramming”	O
specifically	O
in	O
reference	O
to	O
the	O
formation	O
of	O
pluripotent	B
stem	I
cells	I
(PSCs)	O
from	O
differentiated	O
cell	O
states,	O
especially	O
focusing	O
on	O
the	O
iPSC	O
technology.	O

All	O
myeloid	O
and	O
lymphoid	O
blood	O
lineages	O
are	O
differentiated	O
from	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
(Chao	O
et	O
al.,	O
2008),	O
during	O
which	O
the	O
activity	O
of	O
genes	O
(e.g.,	O
KCNH2,	O
SUSD3)	O
that	O
control	O
cell	O
fate	O
is	O
highly	O
regulated	O
by	O
methylation	O
status	O
(Farlik	O
et	O
al.,	O
2016).	O

Over	O
the	O
past	O
decade,	O
the	O
development	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
has	O
provided	O
a	O
novel	O
means	O
to	O
generate	O
disease-relevant	O
cells	O
for	O
in	O
vitro	O
investigation	O
of	O
the	O
molecular	O
and	O
cellular	O
mechanisms	O
underpinning	O
human	O
complex	O
disorders	O
[1,2].	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
cultured	O
in	O
spheroids	O
have	O
enhanced	O
anti-inflammatory,	O
angiogenic,	O
and	O
tissue	O
reparative/regenerative	O
effects	O
with	O
improved	O
cell	O
survival	O
after	O
transplantation.	O

It	O
causes	O
drastic	O
changes	O
in	O
gene	O
expression	O
profiles,	O
as	O
best	O
exemplified	O
in	O
the	O
fertilization	O
process	O
and	O
the	O
somatic	O
cell	O
reprogramming	O
process	O
during	O
the	O
development	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
[137].	O

Neural	B
stem	I
cells	I
(NSCs)	O
generate	O
all	O
major	O
neural	O
cell	O
types	O
in	O
the	O
central	O
nervous	O
system	O
(CNS),	O
including	O
neurons,	O
astrocytes,	O
and	O
oligodendrocytes	O
[1–3].	O

Cancer	B
stem	I
cells	I
(CSCs)	O
displaying	O
a	O
CD44+	O
(high)/CD24-(low)	O
cell	O
surface	O
antigen	O
expression	O
profile	O
may	O
act	O
as	O
tumor-initiating	O
cells	O
[120]	O
and	O
contribute	O
to	O
intra-tumoral	O
heterogeneity	O
[29,79].	O

Human	O
RPE	O
cells	O
have	O
been	O
generated	O
from	O
embryonic	B
stem	I
cells	I
(ESCs)	O
and	O
iPS	O
cells	O
offering	O
new	O
promise	O
for	O
cell	O
replacement	O
therapy	O
in	O
AMD	O
[13,15,18,70].	O

However,	O
the	O
most	O
compelling	O
evidence	O
that	O
SMCs	O
and	O
Mϕs	O
are	O
being	O
misidentified	O
within	O
human	O
advanced	O
coronary	O
lesions	O
comes	O
from	O
studies	O
of	O
cross	O
gender	O
bone	O
marrow	O
transplant	O
subjects	O
showing	O
that	O
>	O
10%	O
of	O
ACTA2+	O
cells	O
within	O
lesions	O
are	O
of	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
and	O
not	O
SMC	O
origin14.	O

Human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
have	O
the	O
capacity	O
to	O
differentiate	O
into	O
the	O
three	O
somatic	O
germ	O
layers	O
and	O
all	O
cell	O
types	O
of	O
the	O
body,	O
and	O
are	O
an	O
alternative	O
and	O
renewable	O
source	O
of	O
hepatocytes	O
that	O
could	O
be	O
used	O
for	O
drug	O
toxicity	O
and	O
metabolization	O
studies.	O

Transcriptome-wide	O
identification	O
of	O
CTCF-binding	O
RNA	O
sites	O
was	O
performed	O
in	O
two	O
previous	O
studies:	O
one	O
for	O
human	O
bone	O
osteosarcoma	O
epithelial	O
cells	O
(U2OS	O
cells)	O
with	O
two	O
biological	O
replicates	O
using	O
photoactivatable	O
ribonucleoside-enhanced	O
cross-linking	O
and	O
immunoprecipitation	O
followed	O
by	O
deep	O
sequencing	O
(14),	O
and	O
the	O
other	O
for	O
mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
with	O
two	O
biological	O
replicates	O
on	O
Days	O
0	O
and	O
3	O
of	O
cell	O
differentiation	O
by	O
CLIP-seq	O
(13).	O

Brain-specific	O
ablation	O
of	O
FoxO3a	O
or	O
combined	O
inactivation	O
of	O
FoxO1a/3a/4	O
in	O
mice	O
resulted	O
in	O
a	O
phenotype	O
that	O
resembled	O
age-dependent	O
depletion	O
of	O
the	O
neural	B
stem	I
cell	I
(NSC)	O
population	O
[290,291].	O

The	O
functional	O
potential	O
of	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
declines	O
during	O
aging,	O
and	O
it	O
contributes	O
to	O
hematopoietic	O
pathophysiology	O
in	O
the	O
elderly	O
and	O
loss	O
of	O
the	O
hematopoietic	O
cell	O
pool	O
[156,	O
157].	O

Dental	B
pulp	I
stem	I
cells	I
(DPSCs)	O
have	O
the	O
capacity	O
to	O
differentiate	O
under	O
appropriate	O
conditions	O
into	O
different	O
somatic	O
cell	O
types	O
of	O
the	O
three	O
germ	O
layers:	O
endoderm,	O
mesoderm,	O
and	O
ectoderm..	O

Dek	O
expression	O
positively	O
correlates	O
with	O
breast	B
cancer	I
stem	I
cell	I
(BCSC)	O
phenotypes.	O

After	O
the	O
identification	O
of	O
embryonic	B
stem	I
cells	I
(ESCs)	O
and	O
embryonic	O
germ	O
cells	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
blastocysts	O
and	O
post	O
implantation	O
embryos,	O
respectively,	O
the	O
next	O
advance	O
came	O
with	O
the	O
generation	O
of	O
induced	O
pluripotent	O
stem	O
cells	O
(Fig..	O

Hematopoietic	B
stem	I
cells	I
(HSCs)	O
have	O
the	O
ability	O
to	O
self-renew	O
and	O
produce	O
identical,	O
multipotent	O
daughter	O
HSCs	O
or	O
undergo	O
differentiation	O
to	O
form	O
any	O
and	O
every	O
cell	O
type	O
in	O
the	O
blood	O
system.	O

Indeed,	O
it	O
was	O
confirmed	O
that	O
SV2	O
levels	O
are	O
reduced	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
lines	O
of	O
C9ORF72	O
ALS	O
patients	O
and	O
in	O
the	O
spinal	O
cord	O
and	O
neuromuscular	O
junctions	O
of	O
poly-GA–overexpressing	O
transgenic	O
mice.	O

But	O
now	O
this	O
obstacle	O
can	O
be	O
easily	O
overcome	O
with	O
the	O
usage	O
to	O
the	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSCs)	O
technology,	O
which	O
allows	O
to	O
unveil	O
the	O
mechanisms	O
underlying	O
nucleoskeletal	O
organization	O
and	O
modulation	O
before	O
and	O
after	O
differentiation..	O

Introduction:	O
MSC	O
exosome	O
is	O
increasingly	O
accepted	O
as	O
the	O
principal	O
agent	O
that	O
underpins	O
the	O
therapeutic	O
efficacy	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
in	O
tissue	O
repair.	O

Mesenchymal	B
stem	I
cell	I
(MSC)	O
is	O
a	O
heterogeneous	O
multipotent	O
stem	O
cell	O
found	O
within	O
the	O
tumour	O
microenvironment	O
and	O
can	O
regulating	O
the	O
immune	O
system.	O

In	O
this	O
study,	O
we	O
characterize	O
the	O
microRNA,	O
tRNA,	O
and	O
piRNA	O
composition	O
of	O
EVs	O
secreted	O
from	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
(hiPSCs)	O
–	O
derived	O
3D	O
retinas	O
at	O
three	O
developmental	O
time	O
points	O
that	O
correlate	O
with	O
hallmarks	O
of	O
retinal	O
cell	O
differentiation	O
and	O
lamination	O
in	O
vivo..	O

The	O
cell	O
of	O
origin	O
for	O
OS	O
also	O
remain	O
unknown	O
but	O
cells	O
of	O
the	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
osteogenic	O
lineage	O
are	O
likely	O
candidates,	O
thus	O
indicating	O
that	O
MSCs	O
and	O
the	O
OS	O
stroma	O
cells	O
may	O
be	O
related	O
cell	O
types.	O

Cell	O
therapy	O
based	O
on	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
is	O
one	O
of	O
the	O
attractive	O
options.	O

Adipose-derived	B
stem	I
cells	I
(ASCs)	O
have	O
been	O
reported	O
as	O
an	O
important	O
component	O
of	O
regenerative	O
medicine	O
and	O
cell	O
therapy	O
for	O
hair	O
loss.	O

Introduction:	O
Immunoregulatory	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
is	O
attributed	O
to	O
extracellular	O
vesicles	O
(EVs)	O
secretion.	O

The	O
year	O
2006	O
will	O
be	O
remembered	O
monumentally	O
in	O
science,	O
particularly	O
in	B
the	I
stem	I
cell	I
biology	O
field,	O
for	O
the	O
first	O
instance	O
of	O
generation	O
of	O
induced	O
pluripotent	O
stem	O
cells	O
(iPSCs)	O
from	O
mouse	O
embryonic/adult	O
fibroblasts	O
being	O
reported	O
by	O
Takahashi	O
and	O
Yamanaka.	O

Reprogramming	O
differentiated	O
somatic	O
cells	O
to	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
enables	O
re-differentiation	O
to	O
a	O
wide	O
array	O
of	O
cell	O
types	O
(Yamanaka,	O
2012)	O
and	O
is	O
of	O
considerable	O
value	O
for	O
disease	O
modeling,	O
functional	O
genomics,	O
drug	O
discovery,	O
and	O
regenerative	O
medicine.	O

In	O
the	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
-derived	O
neural	O
cell	O
lines,	O
imbalances	O
were	O
reflected	O
in	O
an	O
attenuated	O
capacity	O
of	O
cells	O
to	O
suppress	O
accumulation	O
of	O
unfolded	O
proteins	O
upon	O
interference	O
of	O
proteostasis	O
with	O
thapsigargin.	O

Directed	O
differentiation	O
of	O
human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
combined	O
with	O
gene	O
editing	O
provides	O
a	O
powerful	O
system	O
to	O
define	O
precise	O
temporal	O
gene	O
requirements	O
for	O
progressive	O
chromatin	O
changes	O
during	O
cell	O
fate	O
transitions.	O

The	O
genomic	O
regions	O
co-bound	O
by	O
the	O
embryonic	B
stem	I
cell	I
(ESC)	O
pluripotency	O
TFs	O
Oct4,	O
Sox2,	O
and	O
Nanog	O
(OSN)	O
have	O
shown	O
robust	O
enhancer	O
activity16.	O

In	O
contrast	O
to	O
the	O
difficulty	O
of	O
obtaining	O
neuronal	O
and	O
muscle	O
cell	O
models,	O
the	O
development	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
has	O
shed	O
light	O
on	O
the	O
study	O
of	O
mitochondrial	O
diseases.	O

The	O
emergence	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
as	O
a	O
tool	O
for	O
human	O
disease	O
modeling	O
(Takahashi	O
et	O
al.,	O
2007,	O
Takahashi	O
and	O
Yamanaka,	O
2006,	O
Tiscornia	O
et	O
al.,	O
2011,	O
Yu	O
et	O
al.,	O
2007)	O
holds	O
great	O
promise	O
for	O
improving	O
our	O
cellular	O
understanding	O
of	O
craniofacial	O
diseases,	O
as	O
hiPSCs	O
can	O
be	O
differentiated	O
into	O
patient-specific,	O
disease-relevant	O
cell	O
types.	O

Liver	O
cell	O
types	O
derived	O
from	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
share	O
the	O
potential	O
to	O
investigate	O
development,	O
toxicity,	O
as	O
well	O
as	O
genetic	O
and	O
infectious	O
disease	O
in	O
ways	O
currently	O
limited	O
by	O
the	O
availability	O
of	O
primary	O
tissue.	O

A	O
different	O
and	O
novel	O
approach	O
developed	O
by	O
the	O
Takebe	O
laboratory	O
used	O
a	O
combination	O
of	O
iPSC	O
derived	O
hepatic	O
endoderm	O
and	O
immature	O
non-parenchymal	O
liver	O
cell	O
analogs	O
[mesenchymal	B
stem	I
cells	I
(MSC)	O
and	O
endothelial	O
cells],	O
to	O
mimic	O
the	O
formation	O
of	O
the	O
liver	O
bud	O
(101).	O

Hematopoietic	B
stem	I
cells	I
(HSCs)	O
generate	O
highly	O
dividing	O
hematopoietic	O
progenitor	O
cells	O
(HPCs),	O
which	O
produce	O
all	O
blood	O
cell	O
lineages.	O

This	O
ultimately	O
led	O
to	O
the	O
derivation	O
of	O
mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
(Evans	O
and	O
Kaufman,	O
1981;	O
Martin,	O
1981),	O
a	O
discovery	O
that	O
rendered	O
EC	O
cell	O
research	O
largely	O
redundant.	O

Gene	O
expression	O
of	O
FREM2	O
and	O
SPRY1	O
was	O
measured	O
in	O
the	O
mature	O
glioblastoma	O
cell	O
lines	O
U251MG	O
and	O
U87MG,	O
in	O
the	O
stem-like	O
NCH	O
cells—a	O
co-culture	O
of	O
the	O
glioblastoma	O
stem-like	O
cell	O
lines	O
NCH644	O
and	O
NCH421K	O
—as	O
well	O
as	O
in	O
neural	B
stem	I
cells	I
(NSC)	O
and	O
astrocytes.	O

Finally,	O
concentrated	O
cells	O
may	O
form	O
aggregates	O
and	O
lead	O
to	O
pulmonary	O
emboli	O
or	O
infarctions	O
following	O
administration	O
48,	O
especially	O
when	O
intravenously	O
infused,	O
as	O
demonstrated	O
in	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
transplants	O
49.	O

However,	O
the	O
role	O
of	O
IFN-I	O
is	O
a	O
double-edged	O
sword,	O
as	O
its	O
excessive	O
expression	O
can	O
elicit	O
destructive	O
inflammatory	O
responses	O
and	O
cause	O
haematopoietic	B
stem	I
cell	I
(HSC)	O
exhaustion.	O

Human	O
Pluripotent	O
Stem	O
Cell-Derived	O
Cardiac	O
Cells:	O
Application	O
in	O
Disease	O
Modeling,	O
Cell	O
Therapy,	O
and	O
Drug	O
Discovery.	O
Human	O
Pluripotent	O
Stem	O
Cell-Derived	O
Cardiac	O
Cells:	O
Application	O
in	O
Disease	O
Modeling,	O
Cell	O
Therapy,	O
and	O
Drug	O
Discovery.	O
The	O
development	O
of	O
human	B
pluripotent	I
stem	I
cell	I
(hPSC)	O
technology	O
in	O
theory	O
guarantees	O
an	O
unlimited	O
source	O
of	O
human	O
cardiac	O
cells.	O

A	O
current	O
consensus	O
asserts	O
that	O
the	O
tumor	O
invasion-associated	O
epithelial-mesenchymal	O
transition	O
(EMT)	O
intimately	O
correlates	O
with	O
cancer	B
stem	I
cell	I
(CSC)	O
phenotypes	O
[30].	O

Directed	O
differentiation	O
protocols	O
to	O
manufacture	O
specific	O
cell	O
populations	O
from	O
pluripotent	B
stem	I
cells	I
(PSCs)	O
have	O
been	O
developed	O
to	O
meet	O
the	O
need	O
for	O
a	O
homogeneous	O
human	O
cell	O
source.	O

Pro-inflammatory	O
cytokines	O
are	O
also	O
crucially	O
important	O
for	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
maintenance,	O
proliferation,	O
and	O
differentiation	O
[4].	O

For	O
example,	O
the	O
cycloaddition	O
of	O
Arg-Gly-Asp-D-Try-Lys	O
peptide	O
was	O
added	O
to	O
the	O
surface	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
derived	O
sEVs	O
[581].	O

Early	O
work	O
on	O
this	O
topic	O
was	O
inspired	O
by	O
the	O
idea	O
that	O
if	O
homing	O
receptors	O
exist	O
for	O
immune	O
cell	O
infiltration	O
into	O
the	O
periphery,	O
homologous	O
mechanisms	O
must	O
exist	O
for	O
the	O
entry	O
of	O
haematopoietic	B
stem	I
cells	I
(HSCs)	O
into	O
the	O
marrow	O
following	O
bone	O
marrow	O
transplantation.	O

The	O
emergence	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
revolutionizes	O
the	O
paradigm	O
of	O
drug	O
discovery.	O

The	O
distinctive	O
feature	O
of	O
embryonic	B
stem	I
cell	I
(ESC)	O
being	O
able	O
to	O
self‐renew,	O
coupled	O
with	O
its	O
potential	O
to	O
differentiate	O
into	O
any	O
adult	O
cell	O
type	O
in	O
the	O
body,	O
has	O
made	O
it	O
a	O
promising	O
candidate	O
for	O
use	O
in	O
tissue	O
regeneration.	O

Physiologic	O
hypoxia	O
supports	O
and	O
maintains	O
the	O
glioma	B
stem	I
cell	I
(GSC)	O
phenotype	O
and	O
has	O
a	O
vital	O
role	O
in	O
tumor	O
development,	O
invasiveness,	O
and	O
resistance	O
to	O
chemotherapy	O
and	O
radiation.	O

Advent	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
[22]	O
and	O
differentiation	O
systems	O
have	O
made	O
it	O
possible	O
to	O
examine	O
the	O
relationship	O
of	O
specific	O
mutations	O
with	O
disease	O
phenotypes.	O

Central	O
to	O
the	B
stem	I
cell	I
(CSC)	O
concept	O
is	O
the	O
observation	O
that	O
not	O
all	O
cells	O
in	O
tumours	O
are	O
equal.	O

Developed	O
over	O
a	O
decade	O
ago,	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
theory	O
posits	O
that	O
the	O
tumor	O
has	O
its	O
own	O
stem	O
cells	O
with	O
self-renewal	O
ability	O
and	O
ascribes	O
the	O
origin	O
of	O
these	O
malignant	O
cells	O
to	O
alterations	O
of	O
regulation	O
pathways	O
through	O
genetic	O
mutations	O
of	O
the	O
healthy	O
stem	O
cell	O
population	O
[34].	O

Cell	O
transplant	O
models	O
(CTMs)	O
represent	O
a	O
distinct	O
subset	O
of	O
GEMMs	O
applied	O
primarily	O
to	O
studies	O
of	O
hematologic	O
cancers,	O
such	O
as	O
myeloproliferative	O
neoplasms	O
and	O
leukemia	O
that	O
arise	O
from	O
mutations	O
arising	O
in	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
and	O
progenitor	O
cells.	O

PCa	O
cells	O
home	O
toward	O
areas	O
in	O
the	O
bone	O
marrow	O
rich	O
in	O
osteoblasts	O
where	O
the	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
niche	O
resides.	O

Consistent	O
with	O
concepts	O
borrowed	O
from	O
the	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
transplant	O
field,	O
prior	O
lymphodepleting	O
chemotherapy	O
(so-called	O
“conditioning”)	O
appears	O
to	O
also	O
have	O
important	O
effects	O
on	O
both	O
the	O
Cmax	O
and	O
maintenance	O
of	O
adoptively	O
transferred	O
T	O
cells	O
over	O
time.32,	O
33,	O
34,	O
35	O
The	O
mechanisms	O
that	O
underlie	O
the	O
effect	O
of	O
conditioning	O
on	O
T	O
cell	O
kinetics	O
are	O
not	O
fully	O
understood.	O

Cancer	B
stem	I
cells	I
(CSCs)	O
represent	O
rare	O
tumor	O
cell	O
populations	O
capable	O
of	O
self-renewal,	O
differentiation,	O
and	O
tumor	O
initiation	O
and	O
are	O
highly	O
resistant	O
to	O
chemotherapy	O
and	O
radiotherapy.	O

Background:	O
Immunoregulatory	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
is	O
attributed	O
to	O
extracellular	O
vesicles	O
(EV)	O
secretion.	O

We	O
examined	O
the	O
epigenetic	O
influence	O
of	O
OS-extracellular	O
vesicles	O
(EVs)	O
on	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
and	O
pre-osteoblast,	O
and	O
the	O
consequences	O
of	O
OS-EVs	O
treatment	O
on	O
the	O
epigenetic	O
reprograming	O
of	O
MSCs..	O

Background:	O
Immunoregulatory	O
effect	O
of	O
Mesenchymal	B
stem	I
cell	I
(MSC)	O
is	O
attributed	O
to	O
Extracellular	O
vesicles	O
(EVs)	O
secretion.	O

ECs	O
derived	O
from	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
represent	O
an	O
alternative	O
and	O
potentially	O
superior	O
cell	O
source,	O
but	O
traditional	O
culture	O
approaches	O
and	O
2D	O
differentiation	O
protocols	O
hardly	O
allow	O
for	O
production	O
of	O
large	O
cell	O
numbers.	O

Hypothetically,	O
a	O
physiological	O
connection	O
between	O
Hh	O
signaling	O
and	O
DYRK1A	O
might	O
also	O
exist	O
in	O
the	O
case	O
of	O
neural	B
stem	I
cell	I
(NSC)	O
division.	O

Intestinal	B
stem	I
cells	I
(ISCs)	O
are	O
supported	O
by	O
Paneth	O
cells	O
that	O
are	O
specialized	O
epithelial	O
cells	O
localized	O
in	O
the	O
stem	O
cell	O
niche.	O

(A)	O
Experimental	O
design	O
and	O
optimization	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSCs)	O
differentiation	O
into	O
podocytes.	O

In	O
this	O
study,	O
we	O
explored	O
the	O
potentiality	O
of	O
human	O
arginine	O
decarboxylase	O
(ADC)	O
to	O
enhance	O
the	O
survival	O
of	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
against	O
unfavorable	O
milieu	O
of	O
host	O
tissues	O
as	O
the	O
low	O
survival	O
of	O
MSCs	O
is	O
the	O
issue	O
in	O
cell	O
transplantation	O
therapy.	O

Neural	B
stem	I
cells	I
(NSCs)	O
are	O
considered	O
as	O
a	O
potential	O
source	O
for	O
oligodendrocyte	O
precursor	O
cells	O
(OPCs)	O
to	O
be	O
used	O
in	O
cell	O
based	O
remyelination	O
therapy	O
for	O
multiple	O
sclerosis	O
(MS).	O

Since	O
the	O
emergence	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology,	O
a	O
little	O
over	O
a	O
decade	O
ago,	O
iPSC	O
models	O
have	O
held	O
the	O
potential	O
to	O
bridge	O
these	O
two	O
worlds	O
–	O
primary	O
patient	O
cells	O
and	O
conventional	O
disease	O
models	O
–	O
by	O
affording	O
direct	O
relevance	O
to	O
human	O
disease,	O
being	O
patient-derived,	O
while	O
enabling	O
precise,	O
controlled	O
and	O
scalable	O
experiments	O
that	O
were	O
hitherto	O
only	O
possible	O
using	O
traditional	O
model	O
systems.	O

The	O
unrestrained	O
activation	O
of	O
the	O
p53-p21	O
axis	O
has	O
been	O
associated	O
with	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
attrition	O
that	O
characterizes	O
inherited	O
bone	O
marrow	O
failure	O
(iBMF)	O
syndromes,	O
including	O
dyskeratosis	O
congenita	O
(DC),	O
Shwachman-Diamond	O
syndrome	O
(SDS),	O
Diamond-Blackfan	O
anemia	O
(DBA),	O
and	O
Fanconi	O
anemia	O
(FA),	O
the	O
most	O
frequent	O
and	O
genetically	O
heterogeneous	O
iBMF	O
syndrome.	O

In	O
a	O
homozygous	O
knockout	O
neuronal	O
cell	O
line,	O
embryoid	O
bodies	O
(EBs)	O
derived	O
from	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
were	O
significantly	O
smaller	O
(88),	O
supporting	O
a	O
role	O
for	O
Foxg1	O
in	O
cell	O
survival.	O

PRDM14	O
functions	O
in	O
embryonic	B
stem	I
cell	I
(ESC)	O
maintenance	O
to	O
promote	O
the	O
expression	O
of	O
pluripotency-associated	O
genes	O
while	O
suppressing	O
differentiation	O
genes.	O

Models	O
utilizing	O
micromolding	O
and	O
bioprinting	O
techniques	O
have	O
been	O
used	O
to	O
fabricate	O
endothelialized	O
tissue	O
constructs	O
to	O
visualize	O
real-time	O
endothelial	O
cord	O
formation	O
during	O
tubulogenesis.40	O
Others	O
have	O
incorporated	O
a	O
layer	O
of	O
human	O
bone	O
marrow	O
stromal	O
cells	O
surrounding	O
the	O
channels	O
to	O
recapitulate	O
perivascular-mediated	O
barrier	O
function.41	O
Compared	O
with	O
earlier	O
models,	O
the	O
most	O
recent	O
systems	O
endow	O
more	O
accurate	O
control	O
of	O
growth	O
factor	O
gradients	O
and	O
fluid	O
flow,	O
making	O
them	O
ideal	O
for	O
patient-specific	O
models.42,43	O
For	O
example,	O
a	O
recent	O
microfluidic	O
angiogenic	O
model	O
promoted	O
human-induced	O
pluripotent	B
stem	I
cell	I
(hiPSC)	O
differentiation	O
into	O
endothelial	O
cells	O
which	O
assembled	O
into	O
perfusable,	O
capillary-like	O
networks,	O
and	O
capturing	O
endothelial	O
response	O
to	O
different	O
environmental	O
biochemical	O
and	O
biophysical	O
cues.43	O
Incorporation	O
of	O
patient-derived	O
hiPSCs	O
in	O
platforms	O
such	O
as	O
these	O
lays	O
the	O
foundation	O
for	O
personalized	O
characterization	O
of	O
tumor	O
angiogenesis	O
and	O
endothelial	O
cell	O
response	O
to	O
cancer	O
therapeutics.	O

Random	O
genomic	O
alterations	O
are	O
frequently	O
observed	O
in	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
during	O
cell	O
reprogramming	O
essentially	O
due	O
to	O
the	O
massive	O
genome	O
remodeling	O
and	O
it	O
is	O
therefore	O
of	O
major	O
interest	O
to	O
evaluate	O
the	O
genomic	O
status	O
of	O
the	O
cells	O
for	O
clinical	O
use	O
in	O
order	O
to	O
determine	O
that	O
they	O
are	O
free	O
from	O
cancer-associated	O
genomic	O
alterations.	O

Embryonic	B
stem	I
cells	I
(ESC)	O
have	O
been	O
used	O
for	O
decades	O
to	O
generate	O
cardiomyocytes	O
and	O
recent	O
advances	O
in	O
cell	O
culture	O
techniques	O
significantly	O
increased	O
the	O
yield	O
of	O
cardiomyocytes	O
in	O
these	O
cultures.	O

Comparison	O
between	O
the	O
cultures	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
on	O
feeder-and	O
serum-free	O
system	O
(Matrigel	O
matrix),	O
MEF	O
and	O
HDF	O
feeder	O
cell	O
lines.	O

The	O
use	O
of	O
pluripotent	O
or	O
multipotent	O
cells	O
for	O
the	O
restoration	O
of	O
damaged	O
neuronal	O
networks	O
is	O
one	O
of	O
the	O
factors	O
that	O
holds	O
promise	O
from	O
a	O
translational	O
medicine	O
perspective	O
and	O
a	O
relevant	O
part	O
of	O
the	O
strongest	O
forces	O
driving	O
research	O
in	O
stem	B
cell	I
(SC)	O
biology	O
applied	O
to	O
neurodegenerative	O
diseases.	O

explored	O
the	O
role	O
of	O
ROS	O
in	O
bone	O
marrow	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
aging	O
finding	O
the	O
aged	O
mice	O
cells	O
(24	O
month	O
aged)	O
had	O
increased	O
intracellular	O
concentrations	O
of	O
the	O
following	O
compounds:	O
O2·−	O
(1.4-fold),	O
H2O2	O
(2-fold),	O
and	O
NO	O
(1.6-fold),	O
peroxynitrite/OH·	O
(2.5-fold)	O
comparing	O
with	O
young	O
mice	O
cells	O
(2	O
months	O
old)	O
[104].	O

We	O
and	O
others	O
have	O
shown	O
that	O
Mof	O
plays	O
important	O
function	O
in	O
embryonic	B
stem	I
cell	I
(ESC)	O
self-renewal	O
(13,	O
14),	O
DNA	O
damage	O
repair	O
(15,	O
16),	O
senescence	O
(17),	O
and	O
autophagy	O
(18).	O

This	O
is	O
because	O
non-activated	O
fibroblasts	O
possess	O
characteristics	O
that	O
are	O
similar	O
to	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
precursors.	O

Although	O
there	O
have	O
been	O
many	O
reports	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
transplantation	O
for	O
the	O
treatment	O
of	O
ischemic	O
heart	O
disease	O
(IHD),	O
relatively	O
few	O
studies	O
have	O
investigated	O
the	O
roles	O
of	O
CF-EXOs.	O

Neural	B
stem	I
cell	I
(NSC)	O
therapy	O
can	O
be	O
used	O
for	O
nerve	O
and	O
brain	O
regeneration.	O

Induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
make	O
up	O
a	O
recent	O
powerful	O
addition	O
to	O
the	O
arsenal	O
of	O
the	O
cell	O
and	O
lipid	O
biologist.	O

This	O
is	O
especially	O
visible	O
when	O
the	O
dyes	O
are	O
applied	O
to	O
cell	O
types	O
that	O
naturally	O
form	O
clumps	O
such	O
as	O
embryoid	O
bodies	O
(EBs)	O
derived	O
from	O
embryonic	B
stem	I
cells	I
(ESCs)	O
and	O
iPSCs,	O
due	O
to	O
nonspecific	O
uptake	O
of	O
the	O
dyes	O
into	O
the	O
cell	O
clumps.	O

Notably,	O
the	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
generates	O
exosomal	O
miRNA-1470,	O
which	O
remains	O
important	O
in	O
CD4+CD25+Foxp3+Treg	O
differentiation	O
[163].	O

Fertilization	O
of	O
the	O
reconstructed	O
oocyte	O
should	O
lead	O
to	O
a	O
blastocyst,	O
which	O
can	O
be	O
used	O
for	O
embryonic	B
stem	I
cell	I
(ESC)	O
derivation.	O

Induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
lines	O
were	O
derived	O
from	O
three	O
PD	O
patients	O
carrying	O
a	O
LRRK2-G2019S	O
heterozygous	O
mutation,	O
and	O
three	O
healthy	O
control	O
individuals	O
(Materials	O
and	O
Methods),	O
from	O
the	O
Oxford	O
Parkinson’s	O
Disease	O
Centre	O
(OPDC)	O
Discovery	O
Cohort	O
(Table	O
1)	O
(Materials	O
and	O
Methods,	O
Supplementary	O
Material,	O
Fig.	O

Induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
lines	O
were	O
derived	O
from	O
three	O
PD	O
patients	O
carrying	O
a	O
LRRK2-G2019S	O
heterozygous	O
mutation,	O
and	O
three	O
healthy	O
control	O
individuals,	O
from	O
the	O
Oxford	O
Parkinson’s	O
Disease	O
Centre	O
(OPDC)	O
Discovery	O
Cohort	O
(Table	O
1)..	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
have	O
not	O
been	O
discussed	O
in	O
this	O
review	O
article,	O
however,	O
they	O
can	O
be	O
derived	O
from	O
several	O
sources	O
and	O
differentiate	O
into	O
diverse	O
cell	O
types.	O

Substrate	O
composition	O
significantly	O
impacts	O
human	B
pluripotent	I
stem	I
cell	I
(hPSC)	O
self-renewal	O
and	O
differentiation,	O
but	O
relatively	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
endogenously	O
produced	O
extracellular	O
matrix	O
(ECM)	O
components	O
in	O
regulating	O
hPSC	O
fates.	O

The	O
extracellular	O
matrix	O
(ECM)	O
is	O
known	O
to	O
play	O
an	O
integral	O
role	O
in	O
human	B
pluripotent	I
stem	I
cell	I
(hPSC)	O
culture	O
and	O
maintenance.	O

However,	O
emerging	O
evidence	O
suggests	O
that	O
the	O
proportion	O
of	O
cells	O
with	O
high	O
expression	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
markers	O
among	O
the	O
surviving	O
cells	O
is	O
significantly	O
increased	O
in	O
response	O
to	O
5‐Fu,	O
resulting	O
in	O
drug	O
resistance	O
and	O
disease	O
relapse.	O

We	O
utilized	O
the	O
Drosophila	O
testis	O
as	O
an	O
in	O
vivo	O
model	O
to	O
examine	O
the	O
effects	O
of	O
ROS	O
on	O
germline	B
stem	I
cell	I
(GSC)	O
maintenance.	O

Hematopoiesis	O
is	O
a	O
process	O
through	O
which	O
all	O
the	O
blood	O
cells	O
are	O
generated	O
through	O
sequential	O
cell	O
divisions	O
and	O
differentiation	O
of	O
progeny	O
that	O
originate	O
from	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
(Kondo	O
et	O
al.,	O
2003).	O

The	O
authors	O
initially	O
quantified	O
protein	O
levels	O
and	O
fluctuations	O
by	O
measuring	O
single	O
cell	O
fluorescence	O
of	O
mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
transiently	O
transfected	O
with	O
a	O
fluorescent	O
reporter	O
with	O
miRNA	O
binding	O
sites	O
in	O
the	O
3'UTR.	O

Human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
provide	O
an	O
unlimited	O
cell	O
source	O
for	O
regenerative	O
medicine.	O

Another	O
capture	O
array–specific	O
transcript	O
is	O
represented	O
by	O
the	O
benign	O
gonial	O
cell	O
neoplasm	O
gene	O
(bgcn,	O
FlyBase	O
ID:	O
FBgn0004581),	O
which	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
germline	B
stem	I
cell	I
(GSC)	O
maintenance	O
(Li	O
et	O
al.	O

Chronic	O
myeloid	O
leukemia	O
(CML)	O
is	O
a	O
myeloproliferative	O
disorder	O
of	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
origin	O
caused	O
by	O
the	O
t(9;22)	O
chromosomal	O
translocation.	O

Development	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
to	O
obtain	O
terminally	O
differentiated	O
neurons	O
from	O
adult	O
somatic	O
cells	O
revolutionized	O
the	O
study	O
of	O
AD,	O
providing	O
a	O
powerful	O
tool	O
for	O
modelling	O
the	O
disease	O
and	O
for	O
screening	O
candidate	O
drugs.	O

In	O
particular,	O
the	O
use	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
can	O
be	O
used	O
to	O
generate	O
the	O
necessary	O
cell	O
types	O
to	O
mimic	O
the	O
adult	O
liver	O
and	O
model	O
disease	O
states.	O

Recent	O
findings	O
have	O
revealed	O
that	O
molecular	O
mechanisms	O
underlying	O
the	O
maintenance	O
of	O
embryonic	B
stem	I
cell	I
(ESC)	O
pluripotency	O
and	O
cellular	O
reprogramming	O
have	O
been	O
linked	O
to	O
miRNAs	O
[1,	O
7].	O

Members	O
of	O
the	O
miR-290	O
cluster	O
are	O
the	O
most	O
highly	O
expressed	O
miRNAs	O
in	O
mESCs	O
comprising	O
more	O
than	O
60–70	O
%	O
of	O
the	O
total	O
miRNAs	O
expressed	O
and	O
are	O
studied	O
extensively	O
in	O
various	O
backgrounds	O
[54]	O
including	O
DNA	O
methylation,	O
maintenance	O
of	O
pluripotency,	O
germ	O
cell	O
development,	O
and	O
generation	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
[55,	O
56]..	O

Functions	O
of	O
microRNAs	O
(miRNAs)	O
in	O
embryonic	B
stem	I
cell	I
(ESC)	O
self-renewal,	O
differentiation,	O
and	O
cellular	O
reprogramming.	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
are	O
typical	O
PSCs	O
that	O
derive	O
from	O
inner	O
cell	O
mass	O
(ICM)	O
of	O
blastocysts,	O
and	O
ESCs	O
show	O
difficulty	O
in	O
efficient	O
genome	O
editing.	O

Mesenchymal	B
stem	I
cells	I
(MSC)	O
are	O
multipotent	O
cells,	O
functioning	O
as	O
precursors	O
to	O
a	O
variety	O
of	O
cell	O
types	O
including	O
adipocytes,	O
osteoblasts,	O
and	O
chondrocytes.	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
display	O
immunemodulatory	O
and	O
neuroprotective	O
activities	O
and	O
promote	O
oligodendrocyte	O
differentiation	O
of	O
neural	O
progenitors	O
(NPCs)	O
and	O
are	O
thus	O
interesting	O
candidates	O
for	O
autologous	O
cell	O
therapy	O
in	O
MS.	O

To	O
further	O
study	O
the	O
routes	O
of	O
degradation	O
and	O
the	O
possibilities	O
to	O
speed	O
up	O
this	O
process	O
we	O
have	O
used	O
a	O
cell	O
culture	O
model	O
where	O
UV‐treated,	O
dead	O
cells	O
are	O
added	O
to	O
stem	O
cell‐derived	O
astrocytes.	O
Grafting	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
derived	O
dopaminergic	O
(DA)	O
neurons	O
has	O
great	O
potential	O
for	O
cell	O
based	O
therapies	O
for	O
Parkinson's	O
disease	O
(PD).	O

Mesenchymal	B
stem	I
cells	I
(MSC)	O
were	O
shown	O
to	O
exert	O
positive	O
immunomodulatory	O
effects,	O
to	O
reduce	O
demyelination,	O
to	O
increase	O
neuroprotection	O
and	O
to	O
promote	O
adult	O
neural	O
stem	O
cell	O
differentiation	O
towards	O
the	O
oligodendroglial	O
lineage.	O

The	O
use	O
of	O
human	B
embryonic	I
stem	I
cells	I
(hESCs)	O
in	O
cell	O
replacement	O
therapies	O
(CRTs)	O
has	O
been	O
limited	O
due	O
to	O
several	O
technical	O
and	O
ethical	O
issues.	O

In	O
keeping	O
with	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
hypothesis	O
(4),	O
these	O
cells	O
possess	O
self-renewing	O
capacity,	O
an	O
especially	O
high	O
resistance	O
to	O
death-promoting	O
signals,	O
and	O
the	O
ability	O
to	O
effect	O
regeneration	O
of	O
the	O
overall	O
tumor	O
mass	O
(56,	O
140).	O

[162]	O
has	O
used	O
a	O
mouse	O
model	O
for	O
showing	O
that	O
plasma	O
levels	O
of	O
miRs	O
371/302/C19MC	O
were	O
accurate	O
in	O
detecting	O
undifferentiated	O
and	O
malignant	O
components	O
arising	O
in	O
xenografts	O
derived	O
from	O
mice	O
injected	O
with	O
human	B
pluripotent	I
stem	I
cell	I
(hPSC)	O
lines	O
and	O
human	O
malignant	O
GCT	O
cell	O
lines.	O

The	O
diverse	O
Ras-pathways	O
that	O
are	O
relevant	O
for	O
stemness	O
may	O
be	O
gleaned	O
from	O
E-Ras,	O
which	O
is	O
specifically	O
expressed	O
in	O
embryonic	B
stem	I
cells	I
(ESC)	O
and	O
few	O
adult	O
cells,	O
such	O
as	O
the	O
hepatic	O
stellate	O
cells	O
(HSC),	O
a	O
liver	O
resident	O
stem	O
cell	O
population	O
[61].	O

The	O
advent	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
has	O
opened	O
an	O
unprecedented	O
avenue	O
to	O
study	O
the	O
mechanism	O
of	O
rare	O
human	O
genetic	O
diseases,	O
including	O
those	O
caused	O
by	O
defects	O
in	O
DNA	O
damage	O
repair	O
machineries	O
(Cockayne	O
syndrome	O
(Andrade	O
et	O
al.,	O
2012),	O
Fanconi	O
anemia	O
(Liu	O
et	O
al.,	O
2014),	O
Werner	O
syndrome	O
(Shimamoto	O
et	O
al.,	O
2014;	O
Cheung	O
et	O
al.,	O
2014)).	O

Methods:	O
We	O
harnessed	O
the	O
capacity	O
of	O
human	B
pluripotent	I
stem	I
cells	I
(hPSC)	O
to	O
differentiate	O
into	O
virtually	O
any	O
cell	O
type	O
by	O
subjecting	O
hPSC	O
to	O
a	O
wide	O
variety	O
of	O
media	O
and	O
culture	O
conditions	O
to	O
maximize	O
the	O
diversity	O
of	O
partially	O
differentiated	O
cells.	O

Mesenchymal	B
stem	I
cell	I
(MSC)	O
was	O
found	O
to	O
secretes	O
potential	O
growth	O
factors	O
such	O
as	O
VEGF	O
when	O
cultured	O
in	O
vitro.	O

Mesenchymal	B
stem	I
cell	I
(MSCs)	O
modification	O
towards	O
an	O
osteogenic	O
path	O
can	O
occur	O
by	O
uptake	O
of	O
exosomes	O
from	O
other	O
cells.	O

Here	O
we	O
show	O
that	O
Vibrio	O
cholerae	O
and	O
cholera	O
toxin	O
suppress	O
intestinal	B
stem	I
cell	I
(ISC)	O
division.	O

With	O
the	O
discovery	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
a	O
novel	O
and	O
promising	O
technique	O
to	O
generate	O
disease-relevant	O
and	O
patient-specific	O
cell	O
types	O
arose	O
(Takahashi	O
and	O
Yamanaka,	O
2006).	O

I/R	O
results	O
in	O
consumption	O
of	O
intracellular	O
ATP	O
to	O
a	O
large	O
extent,	O
and	O
exosomes	O
from	O
adipose-derived	B
stem	I
cells	I
(ADSCs)	O
were	O
observed	O
to	O
supplement	O
intracellular	O
ATP,	O
NADH,	O
phosphorylated	O
AKT,	O
and	O
phosphorylated	O
GSK-3β	O
levels,	O
while	O
reducing	O
phosphorylated	O
c-JNK	O
and	O
recovering	O
cell	O
bioenergy	O
[165].	O

For	O
example,	O
while	O
dengue	O
virus	O
infection	O
in	O
Aedes	O
aegypti	O
causes	O
apoptosis	O
in	O
the	O
midgut,	O
mosquito	O
hosts	O
improve	O
the	O
maintenance	O
of	O
midgut	O
homeostasis	O
and	O
tissue	O
integrity	O
via	O
careful	O
regulation	O
of	O
interstitial	B
stem	I
cell	I
(ISC)	O
proliferation,	O
tolerating	O
the	O
effects	O
of	O
viral	O
infection	O
(Oliveira	O
et	O
al.,	O
2020).	O

Wnt	O
signaling	O
plays	O
crucial	O
roles	O
in	O
the	O
regulation	O
of	O
diverse	O
processes,	O
including	O
cell	O
proliferation,	O
survival,	O
migration	O
and	O
polarization,	O
embryonic	O
development,	O
specification	O
of	O
cell	O
fate,	O
and	O
self-renewal	O
in	O
stem	O
cells[5].	O
Thanks	O
to	O
the	O
forced	O
reprogramming	O
of	O
human	O
somatic	O
cells	O
into	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
47,	O
human	O
neurons	O
(or	O
any	O
other	O
cell	O
type)	O
can	O
be	O
generated	O
from	O
cells	O
of	O
patients	O
with	O
RTT	O
and	O
be	O
used	O
to	O
study	O
RTT.	O

Neural	B
crest	I
stem	I
cells	I
(NCSCs)	O
represent	O
a	O
transient	O
and	O
multipotent	O
cell	O
population	O
that	O
contributes	O
to	O
numerous	O
anatomical	O
structures	O
such	O
as	O
peripheral	O
nervous	O
system,	O
teeth,	O
and	O
cornea.	O

Outline	O
of	O
contribution	O
of	O
epithelial-mesenchymal	O
plasticity	O
(EMP)	O
and	O
acquisition	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
properties	O
to	O
tumor	O
initiation	O
and	O
components	O
of	O
the	O
metastatic	O
cascade,	O
including	O
intravasation,	O
extravasation,	O
and	O
metastatic	O
colonization/outgrowth.	O

The	O
critical	O
cellular	O
pathways,	O
mitogen-activated	O
protein	O
kinase	O
(MAPK),	O
phosphoinositide	O
3-kinase—protein	O
kinase	O
B—mammalian	O
target	O
of	O
rapamycin	O
(PI3K—AKT—MTOR),	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(STAT3),	O
Wnt,	O
Hedgehog,	O
and	O
Notch	O
each	O
have	O
been	O
demonstrated	O
to	O
play	O
key	O
roles	O
in	O
promotion	O
of	O
epithelial-mesenchymal	O
plasticity	O
(EMP)	O
and	O
acquisition	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
properties.	O

The	O
heterogeneous	O
cell	O
populations	O
found	O
within	O
GBM	O
contains	O
subpopulations	O
of	O
stem	O
cell-like	O
tumor	O
cells	O
supported	O
by	O
tumor	O
vasculature.	O
Human	O
high-grade	O
glioma	O
tissue	O
samples	O
cultured	O
in	O
stem	O
cell-enriching	O
medium	O
grow	O
as	O
tumor	O
spheroids	O
rich	O
in	O
two	O
distinct	O
subpopulations	O
of	O
glioma	O
stem-like	O
cells	O
(GSCs)—proneural	O
and	O
mesenchymal—with	O
proteome	O
analyses	O
recapitulated	O
differential	O
protein	O
expression	O
patterns	O
among	O
the	O
cell	O
subtypes	O
[120].	O
Human	O
HT29	O
and	O
HCT15	O
and	O
murine	O
CT26	O
CRC	O
cell	O
lines	O
can	O
be	O
cultured	O
in	B
stem	I
cell	I
medium	O
and	O
expanded	O
as	O
cancer	O
spheroids,	O
or	O
colonospheres,	O
containing	O
CRC	O
stem	O
cells	O
(CRCSCs)	O
[123].	O

The	O
fly	O
midgut	O
is	O
maintained	O
by	O
a	O
population	O
of	O
intestinal	B
stem	I
cells	I
(ISCs)	O
that	O
divide	O
to	O
self‐renew	O
and	O
give	O
rise	O
to	O
two	O
differentiated	O
cell	O
types:	O
absorptive	O
enterocytes	O
(ECs)	O
and	O
secretory	O
enteroendocrine	O
cells	O
(EEs)	O
(Micchelli	O
&	O
Perrimon,	O
2006;	O
Ohlstein	O
&	O
Spradling,	O
2006).	O

During	O
the	O
repeated	O
cycles	O
of	O
damage	O
and	O
repair	O
in	O
many	O
muscle	O
disorders,	O
including	O
Duchenne	O
muscular	O
dystrophy	O
(DMD),	O
the	O
muscle	B
stem	I
cell	I
(MuSC)	O
pool	O
becomes	O
less	O
efficient	O
at	O
responding	O
to	O
and	O
repairing	O
damage.	O

Since	O
tert	O
transcripts	O
are	O
detectable	O
in	O
embryonic	B
stem	I
cells	I
(ESCs)	O
within	O
the	O
same	O
reaction	O
(technical	O
control),	O
our	O
data	O
suggest	O
that	O
tert	O
is	O
either	O
present	O
at	O
very	O
low	O
(undetectable)	O
levels	O
or	O
expressed	O
transiently	O
in	O
freshly	O
isolated	O
MuSCs,	O
in	O
contrast	O
to	O
what	O
is	O
known	O
for	O
cancer	O
cell	O
lines	O
(Yin	O
et	O
al.,	O
2000;	O
Zuo	O
et	O
al.,	O
2011).	O

DMT	O
development	O
has	O
been	O
struggling	O
with	O
a	O
poor	O
translatability	O
of	O
preclinical	O
and	O
animal	O
models	O
to	O
human	O
disease	O
[15],	O
though	O
in	O
the	O
past	O
decade,	O
great	O
advances	O
have	O
been	O
with	O
neurons	O
derived	O
from	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
and	O
3D	O
cell	O
cultures	O
technologies	O
as	O
pre-clinical	O
models	O
for	O
neurodegenerative	O
diseases	O
[198].	O

By	O
contrast,	O
successful	O
induction	O
of	O
pluripotent	B
stem	I
cell	I
(iPSC)	O
lines	O
is	O
marked	O
by	O
a	O
reduction	O
of	O
ETC	O
function	O
[58].	O

The	O
utility	O
of	O
CD44,	O
CD117	O
and	O
CD133	O
in	O
identification	O
of	O
cancer	B
stem	I
cells	I
(CSC)	O
in	O
oral	O
squamous	O
cell	O
carcinomas	O
(OSCC)	O
Rom.	O

The	O
GATA	O
family	O
is	O
a	O
group	O
of	O
zinc	O
finger	O
DNA-binding	O
protein	O
TFs	O
that	O
control	O
differentiation	O
of	O
the	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
into	O
different	O
cell	O
types	O
and	O
has	O
six	O
members	O
from	O
GATA1	O
to	O
6.37	O
GATA3	O
plays	O
a	O
role	O
in	O
T	O
cell	O
development	O
by	O
inducing	O
Th2	O
development	O
and	O
Th1	O
suppression.38	O
Yao	O
et	O
al.	O

Spermatogonia	B
stem	I
cell	I
(SSC)	O
were	O
isolated	O
from	O
6-days	O
postpartum	O
(dpp)	O
using	O
enzymatic	O
digestion	O
and	O
magnetic-activated	O
cell	O
sorting34.	O

Immune	O
cells	O
in	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
and	O
cancer	O
cell	O
microenvironment.	O

In	O
this	O
experimental	O
study,	O
we	O
examined	O
the	O
erythroid	O
differentiation	O
potential	O
of	O
normal	O
Bombay	O
hiPSCs	O
(B-hiPSCs)	O
and	O
compared	O
results	O
to	O
human	B
embryonic	I
stem	I
cell	I
(hESC)	O
lines.	O

The	O
main	O
effects	O
elicited	O
by	O
HSP	O
inhibitors	O
on	O
GBM	O
are	O
cell	O
growth	O
inhibition,	O
radio-	O
and/or	O
chemo-sensitization,	O
cytotoxicity,	O
migration	O
and	O
invasion	O
impairment,	O
glioma	B
stem	I
cells	I
(GSCs)	O
stemness	O
and	O
self-renewal	O
suppression,	O
and	O
anti-angiogenic	O
effect.	O

The	O
barriers	O
to	O
cell	O
fate	O
conversion	O
between	O
somatic	O
cells	O
and	O
pluripotent	O
cells	O
had	O
a	O
breakthrough	O
with	O
the	O
proposition	O
of	O
the	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
reprogramming	O
strategy	O
in	O
2006,	O
when	O
Takahashi	O
et	O
al[1,2]	O
reported	O
a	O
significant	O
discovery	O
that	O
the	O
ectopic	O
expression	O
of	O
four	O
defined	O
transcription	O
factors	O
(TFs;	O
Oct4,	O
Sox2,	O
Klf4a,	O
and	O
c-Myc)	O
could	O
force	O
the	O
cell	O
fate	O
conversion.	O

Of	O
note,	O
despite	O
different	O
cell	O
origins,	O
the	O
similar	O
activation	O
of	O
the	O
XEN-like	O
program	O
was	O
reported	O
during	O
the	O
early	O
stage	O
of	O
reprogramming	O
from	O
neural	B
stem	I
cells	I
(NSCs)	O
and	O
small	O
intestinal	O
epithelial	O
cells	O
(IECs)[26],	O
highlighting	O
that	O
the	O
XEN-like	O
state	O
serves	O
as	O
a	O
vital	O
and	O
exclusive	O
bridge	O
toward	O
pluripotency.	O

Scheme	O
showing	O
the	O
essential	O
functions	O
of	O
Notch	O
in	O
blood	O
and	O
vascular	O
cell	O
types	O
(a)	O
Osteocyte	O
Dll/Jag-induced	O
Notch	O
signaling	O
in	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
is	O
involved	O
in	O
their	O
generation	O
and	O
self-renewal	O
in	O
the	O
adult.	O

Indeed,	O
a	O
lung	O
tumor	O
mass	O
is	O
composed	O
of	O
stromal	O
cells,	O
endothelial	O
cells,	O
cancerous	O
differentiated	O
lung	O
cells	O
that	O
are	O
highly	O
proliferative	O
and	O
another	O
small	O
subpopulation	O
sharing	O
cancer	B
stem	I
cell	I
(CSC)	O
features:	O
the	O
initiating	O
tumoral	O
cells	O
(TICs)	O
also	O
called	O
drug-tolerant	O
persister	O
cells	O
(DTPs)	O
[52].	O

Since	O
the	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
niche	O
provides	O
protection	O
and	O
regulation	O
of	O
self-renewal	O
and	O
differentiation	O
of	O
HSC	O
into	O
blood	O
cells,	O
this	O
difference	O
may	O
be	O
important	O
in	O
non-cell	O
autonomous	O
processes..	O

Human	B
mesenchymal	I
stem	I
cells	I
(hMSC)	O
were	O
the	O
only	O
cell	O
type	O
found	O
to	O
provide	O
an	O
appropriate	O
cellular	O
context	O
for	O
EWSR1-FLI1	O
expression,	O
supporting	O
the	O
notion	O
that	O
Ewing's	O
sarcoma	O
is	O
derived	O
from	O
hMSCs	O
20,	O
21.	O

Dental	B
pulp	I
stem	I
cells	I
(DPSCs)	O
have	O
great	O
potential	O
for	O
a	O
range	O
of	O
applications	O
in	O
stem	O
cell	O
research	O
and	O
regenerative	O
medicine.	O

Mechanisms	O
underlying	O
the	O
loss	O
of	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
during	O
BMF	O
include	O
increased	O
apoptosis	O
and	O
enhanced	O
stem	O
cell	O
activity	O
resulting	O
in	O
exhaustion.	O

Recent	O
news	O
of	O
human	B
embryonic	I
stem	I
cell	I
(hESC)	O
research	O
in	O
Seoul	O
has	O
made	O
headlines	O
around	O
the	O
world.	O

Human	B
umbilical	I
cord	I
mesenchymal	I
stem	I
cells	I
(hUCMSCs)	O
grow	O
as	O
adherent	O
cells	O
with	O
mesenchymal	O
morphology,	O
have	O
self-renewing,	O
express	O
cell	O
surface	O
markers	O
displayed	O
by	O
MSCs,	O
and	O
may	O
be	O
differentiated	O
into	O
bone,	O
cartilage,	O
adipose,	O
muscle,	O
and	O
neural	O
cells,	O
etc.	O

Thus,	O
when	O
patient-specific	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
therapy	O
was	O
developed,	O
exploration	O
of	O
disease	O
pathophysiology,	O
novel	O
drug	O
development,	O
and	O
the	O
possibility	O
of	O
stem	O
cell	O
therapy	O
in	O
retinal	O
disorders	O
were	O
forever	O
changed	O
[1]..	O

Homology-directed	O
replacement	O
of	O
an	O
expanded	O
CAG	O
repeat	O
in	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSC)	O
derived	O
from	O
Huntington	O
disease	O
patients	O
improved	O
suceptibility	O
to	O
cell	O
death	O
and	O
mitochondrial	O
defects67.	O

Identification	O
and	O
isolation	O
of	O
spermatogonial	B
stem	I
cells	I
(SSCs)	O
could	O
be	O
useful	O
for	O
achieving	O
genetic	O
gain	O
or	O
restore	O
fertility,	O
and	O
genetic	O
modification	O
of	O
SSCs	O
combined	O
with	O
germ	O
cell	O
transplantation	O
provides	O
the	O
possibility	O
to	O
produce	O
transgenic	O
animals.	O

Mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
are	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
(ICM)	O
of	O
a	O
mouse	O
blastocyst	O
and	O
have	O
the	O
ability	O
to	O
self-renew	O
and	O
differentiate	O
into	O
all	O
types	O
of	O
cells	O
in	O
the	O
body15,16.	O

Human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
are	O
increasingly	O
gaining	O
attention	O
in	O
biomedicine	O
as	O
valuable	O
resources	O
to	O
establish	O
patient-derived	O
cell	O
culture	O
models	O
of	O
the	O
cell	O
type	O
known	O
to	O
express	O
the	O
primary	O
pathology.	O

Recent	O
developments	O
in	O
human	B
pluripotent	I
stem	I
cell	I
(hPSC)	O
research	O
are	O
most	O
promising	O
and	O
could	O
provide	O
cellular	O
models	O
eventually	O
mimicking	O
“a	O
patient	O
in	O
a	O
dish”.	O

Notch	O
signaling	O
augments	O
BMP9-induced	O
bone	O
formation	O
by	O
promoting	O
the	O
osteogenesis-angiogenesis	O
coupling	O
process	O
in	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
Cell	O
Physiol	O
Biochem.	O

The	O
differentiation	O
of	O
human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
into	O
specific	O
cell	O
populations	O
is	O
a	O
major	O
avenue	O
for	O
developmental	O
studies,	O
disease	O
modeling	O
and	O
regenerative	O
medicine1,2.	O

Cancer	B
stem	I
cells	I
(CSCs)	O
are	O
self-renewing	O
cell	O
types	O
that	O
contribute	O
to	O
tumor	O
onset,	O
expansion,	O
drug	O
resistance,	O
recurrence,	O
and	O
metastasis	O
after	O
treatment	O
(Reya	O
et	O
al.,	O
2001;	O
Ward	O
and	O
Dirks,	O
2007).	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
have	O
attracted	O
attention	O
due	O
to	O
their	O
powerful	O
intrinsic	O
cell	O
therapy	O
properties,	O
although	O
the	O
molecular	O
mechanisms	O
of	O
their	O
physiological	O
action	O
have	O
not	O
yet	O
been	O
clarified.	O

Earlier	O
research	O
primarily	O
attributed	O
the	O
effects	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
therapies	O
to	O
their	O
capacity	O
for	O
local	O
engrafting	O
and	O
differentiating	O
into	O
multiple	O
tissue	O
types.	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
are	O
a	O
type	O
of	O
pluripotent	O
stem	O
cell	O
(PSC)	O
that	O
posses	O
the	O
greatest	O
potency	O
in	O
vitro,	O
responding	O
predictably	O
to	O
developmental	O
cues.	O

In	O
acute	O
myeloid	O
leukemia	O
(AML),	O
a	O
low	O
level	O
of	O
reactive	O
oxygen	O
species	O
(ROS)	O
is	O
associated	O
with	O
leukemic	B
stem	I
cell	I
(LSC)	O
quiescence,	O
whereas	O
a	O
high	O
level	O
promotes	O
blast	O
proliferation.	O

Embryonic	B
stem	I
cells	I
(ESC)	O
Inner	O
cell	O
mass	O
of	O
blastocyst	O
•	O
Autogous	O
transplantation	O
possible	O
via	O
therapeutic	O
cloning	O
•	O
Social	O
and	O
ethical	O
concerns.	O

The	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
(hiPSC)	O
technology	O
allows	O
the	O
investigation	O
of	O
pathological	O
and	O
molecular	O
changes	O
in	O
an	O
individual	O
cell	O
type,	O
using	O
cells	O
derived	O
from	O
patients.	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
have	O
the	O
potential	O
to	O
indefinitely	O
self-renew	O
and	O
differentiate	O
into	O
any	O
cell	O
type	O
[1],	O
and	O
extensive	O
studies	O
have	O
been	O
carried	O
out	O
to	O
take	O
advantage	O
of	O
these	O
unique	O
characteristics	O
including	O
tissue	O
regeneration	O
and	O
repair	O
[2-5].	O

In	O
conclusion,	O
for	O
the	O
brain	O
model	O
to	O
be	O
functional,	O
combining	O
engineered	O
microsystems	O
with	B
stem	I
cell	I
(hiPSC)	O
technology	O
is	O
specifically	O
beneficial	O
because	O
hiPSCs	O
can	O
contribute	O
to	O
the	O
complexity	O
of	O
tissue	O
architecture	O
based	O
on	O
their	O
level	O
of	O
differentiation	O
and	O
thereby,	O
biology	O
itself..	O

These	O
cells	O
exhibit	O
features	O
similar	O
to	O
those	O
found	O
in	O
embryonic	B
stem	I
cells	I
(ESCs)	O
and	O
can	O
be	O
potentially	O
derived	O
from	O
different	O
somatic	O
cell	O
types.	O

A	O
similar	O
study	O
demonstrated	O
that	O
the	O
Synthemax®	O
Surface	O
peptide	O
recapitulates	O
integrin-ECM	O
engagement	O
of	O
human	B
embryonic	I
stem	I
cell	I
(hESC)	O
comparable	O
to	O
those	O
grown	O
on	O
Matrigel-coated	O
substrates	O
(Jin	O
et	O
al.,	O
2012).	O

This	O
review	O
will	O
also	O
discuss	O
some	O
of	O
the	O
disease	O
models	O
that	O
are	O
currently	O
being	O
used	O
to	O
study	O
LS,	O
the	O
challenges	O
associated	O
with	O
these	O
models,	O
and	O
the	O
potential	O
for	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technologies	O
contributing	O
to	O
novel	O
models	O
for	O
understanding	O
the	O
pathophysiology	O
of	O
LS.	O

Human	B
embryonic	I
stem	I
cells	I
(hESC)	O
are	O
pluripotent	O
cell	O
lines	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
human	O
blastocysts.1	O
A	O
few	O
years	O
ago,	O
the	O
group	O
of	O
Dr.	O

Moreover,	O
the	O
ability	O
to	O
grow	O
in	O
soft	O
agar	O
is	O
typically	O
associated	O
with	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
population	O
of	O
a	O
transformed	O
culture	O
(Colburn	O
et	O
al.,	O
1978).	O

Human	O
endogenous	O
retrovirus	O
H	O
(HERV-H)	O
family	O
of	O
lincRNA	O
has	O
been	O
linked	O
to	O
human	B
embryonic	I
stem	I
cell	I
(hESC)	O
pluripotency	O
[41],	O
whereas	O
HERV-V	O
and	O
HERV-K	O
families	O
are	O
involved	O
in	O
the	O
pre-implantation	O
embryo	O
development	O
[42].	O

Despite	O
the	O
fast	O
transcriptional	O
changes	O
at	O
early	O
stages	O
of	O
reprogramming	O
(Gascón	O
et	O
al.,	O
2016;	O
Masserdotti	O
et	O
al.,	O
2015),	O
genes	O
associated	O
with	O
lipid	O
metabolism	O
(e.g.,	O
Cpt1a)	O
are	O
not	O
yet	O
downregulated	O
after	O
48	O
h	O
(Gascón	O
et	O
al.,	O
2016;	O
Masserdotti	O
et	O
al.,	O
2015),	O
suggesting	O
slow	O
metabolic	O
conversion,	O
a	O
limiting	O
factor	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
reprogramming	O
(Wu	O
et	O
al.,	O
2016).	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
are	O
pluripotent	O
cells	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
preimplantation	O
embryos	O
[1].	O

Core	O
tip:	O
Induced	B
pluripotent	I
stem	I
cells	I
(iPSC)	O
have	O
opened	O
up	O
the	O
possibility	O
of	O
converting	O
literally	O
any	O
mature	O
cell	O
type	O
into	O
an	O
embryonic	O
like	O
pluripotent	O
state.	O

The	O
ability	O
to	O
differentiate	O
into	O
any	O
given	O
cell	O
type	O
within	O
an	O
organism	O
was	O
limited	O
solely	O
to	O
embryonic	B
stem	I
cells	I
(ESC)	O
until	O
2006.	O

Tissues	O
derived	O
from	O
human	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
has	O
the	O
potential	O
to	O
overcome	O
many	O
inherent	O
limitations	O
of	O
animal	O
and	O
cell	O
culture	O
models	O
and	O
provide	O
an	O
unprecedented	O
new	O
paradigm	O
to	O
model	O
human	O
diseases..	O

Recent	O
breakthroughs	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
circumvent	O
many	O
of	O
these	O
drawbacks..	O

Atypical	O
neurogenesis	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
from	O
autistic	O
individuals.	O

The	O
stem/progenitor	O
cell	O
marker	O
esg>GFP	O
(esg::Gal4,	O
UAS::GFP)	O
is	O
only	O
expressed	O
in	O
intestinal	B
stem	I
cells	I
(ISCs)	O
and	O
enteroblasts	O
(EBs)	O
during	O
homeostasis,	O
whereas,	O
in	O
the	O
dysplastic	O
condition,	O
esg>GFP	O
begins	O
to	O
be	O
expressed	O
in	O
differentiated	O
cells,	O
including	O
enterocyte	O
(EC)-like	O
cells	O
and	O
enteroendocrine	O
cells	O
(EEs).	O

In	O
bone	O
marrow,	O
NK	O
cells	O
develop	O
from	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
through	O
common	O
lymphoid	O
progenitors	O
(CLPs)	O
and	O
NK	O
cell	O
precursors	O
(NKPs),	O
and	O
then	O
migrate	O
to	O
peripheral	O
blood	O
(cNK	O
cells)	O
or	O
tissue	O
(trNK	O
cells).	O

Using	O
human	O
disease	O
modeling	O
in	O
neuroepithelial	O
and	O
renal	O
cell	O
types	O
generated	O
from	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
of	O
both	O
individuals,	O
we	O
document	O
that	O
mutation	O
LRP2R3192Q	O
disrupts	O
the	O
ability	O
of	O
megalin	O
to	O
properly	O
discharge	O
internalized	O
ligand.	O

(a)	O
Immunodetection	O
of	O
megalin	O
(red)	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
lines	O
at	O
the	O
indicated	O
time	O
points	O
of	O
neuroectodermal	O
differentiation.	O

Induced	B
pluripotent	I
stem	I
cells	I
(iPSC)	O
have	O
revolutionized	O
the	O
field	O
of	O
biological	O
sciences	O
and	O
proteomics	O
and,	O
in	O
particular,	O
has	O
been	O
instrumental	O
in	O
identifying	O
key	O
elements	O
operating	O
during	O
the	O
maintenance	O
of	O
the	O
pluripotent	O
state	O
and	O
the	O
differentiation	O
process	O
to	O
the	O
diverse	O
cell	O
types	O
that	O
form	O
organisms.	O

The	O
pluripotent	O
potential	O
of	O
iPSC	O
is	O
represented	O
by	O
their	O
capability	O
to	O
differentiate	O
into	O
cell	O
types	O
from	O
the	O
3	O
embryonic	O
germ	O
layers:	O
ectoderm,	O
mesoderm,	O
and	O
endoderm,	O
a	O
property	O
initially	O
limited	O
to	O
embryonic	B
stem	I
cells	I
(ESC)	O
[22,23,31].	O

Many	O
of	O
the	O
age‐related	O
changes	O
observed	O
in	O
old	O
blood	O
have	O
roots	O
in	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
aging	O
(Kim,	O
Moon,	O
&	O
Spangrude,	O
2003;	O
Pang	O
et	O
al.,	O
2011).	O

Constitutive	O
KLF1	O
expression	O
in	O
human	B
embryonic	I
stem	I
cells	I
(hESCs)	O
results	O
in	O
reduced	O
proliferation	O
and	O
hematopoietic	O
progenitor	O
cell	O
production.	O

Cancer	B
stem	I
cells	I
(CSCs)	O
of	O
different	O
origins	O
suffer	O
disturbances	O
related	O
to	O
the	O
expression	O
of	O
cell	O
surface	O
markers,	O
enzymes,	O
and	O
transcription	O
factors	O
after	O
ethanol	O
exposure	O
with	O
the	O
consequent	O
dysregulation	O
of	O
mechanisms	O
related	O
to	O
cancer	O
metastasis	O
or	O
resistance	O
to	O
treatments.	O

Role	O
of	O
microRNA	O
21	O
in	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
differentiation:	O
a	O
powerful	O
biomarker	O
in	O
MSCs	O
derived	O
cells.	O

A	O
more	O
specific	O
set	O
of	O
299	O
human	O
genes	O
associated	O
to	O
stem	B
cell	I
(SC)	O
function	O
was	O
also	O
mapped	O
to	O
the	O
MSC	O
genes,	O
finding	O
139	O
positives.	O

Two	O
of	O
these	O
depicted	O
meta-regulators,	O
KLF4	O
and	O
MYC,	O
are	O
included	O
in	O
the	O
well-known	O
set	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
factors	O
(i.e.	O

When	O
tested	O
for	O
the	O
effect	O
of	O
chitosan	O
on	O
the	O
differentiation	O
of	O
brown	B
adipose-derived	I
stem	I
cell	I
(BASC)	O
to	O
CM,	O
the	O
expression	O
of	O
cardiac	O
markers	O
such	O
as	O
GATA-4,	O
Nkx2.5,	O
Myl7,	O
Myh6,	O
cTnI,	O
and	O
Cacna1a	O
was	O
noted	O
[38].	O

Human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
of	O
embryonic	O
(ESC)	O
or	O
induced	O
(iPSC)	O
origin	O
resemble	O
the	O
inner	O
cell	O
mass	O
(ICM)	O
of	O
the	O
early	O
post-implantation	O
embryo	O
and	O
have	O
become	O
a	O
cornerstone	O
for	O
modeling	O
human	O
disease	O
in	O
vitro	O
(Chamberlain,	O
2016).	O

Previously,	O
the	O
glycosylation	O
of	O
hESC	O
has	O
been	O
studied	O
with	O
lectins	O
and	O
antibodies	O
[25-27],	O
and	O
a	O
preliminary	O
report	O
has	O
been	O
published	O
on	O
mass	O
spectrometric	O
profiling	O
of	O
mouse	B
embryonic	I
stem	I
cell	I
(mESC)	O
N-glycans	O
[28].	O

All	O
MEFs	O
were	O
derived	O
from	O
13.5-day	O
mouse	O
embryos	O
and	O
used	O
for	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
generation	O
before	O
passage	O
4..	O

Here	O
we	O
report	O
a	O
novel	O
function	O
of	O
enteroendocrine	O
cells	O
acting	O
as	O
local	O
regulators	O
of	O
intestinal	B
stem	I
cell	I
(ISC)	O
proliferation	O
through	O
modulation	O
of	O
the	O
mesenchymal	O
stem	O
cell	O
niche	O
in	O
the	O
Drosophila	O
midgut.	O

B-type	O
lamins	O
are	O
ubiquitously	O
expressed	O
and	O
considered	O
essential	O
for	O
cell	O
survival,	O
whereas	O
A-type	O
lamins	O
change	O
during	O
development	O
and	O
cell	O
differentiation	O
stages,	O
being	O
absent	O
in	B
embryonic	I
stem	I
cells	I
as	O
well	O
as	O
in	O
induced	O
pluripotent	O
stem	O
cells	O
(iPSCs)	O
[7,8,9].	O

Gliomas	O
which	O
may	O
arise	O
from	O
tumorigenic	O
events	O
within	O
all	O
steps	O
of	O
maturation	O
from	O
neural	B
stem	I
cell	I
(NSC)	O
to	O
neurons	O
or	O
glia	O
display	O
diverse	O
expression	O
profiles	O
of	O
the	O
Notch	O
signaling,	O
reflecting	O
the	O
cell	O
of	O
origin.	O

The	O
differentiation	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
into	O
T	O
and	O
natural	O
killer	O
(NK)	O
lymphocytes	O
opens	O
novel	O
possibilities	O
for	O
developmental	O
studies	O
of	O
immune	O
cells	O
and	O
in-vitro	O
generation	O
of	O
cell	O
therapy	O
products.	O

These	O
data	O
are	O
supportive	O
of	O
the	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
origin	O
of	O
ES.	O

Involvement	O
of	O
Tip60	O
in	O
transcriptional	O
repression	O
is	O
not	O
unprecedented,	O
with	O
a	O
previous	O
study	O
supporting	O
a	O
critical	O
role	O
for	O
Tip60	O
in	O
epigenetically	O
repressing	O
a	O
large	O
number	O
of	O
developmental	O
genes	O
essential	O
for	O
embryonic	B
stem	I
cell	I
(ESC)	O
differentiation	O
[25].	O

Next,	O
we	O
tested	O
whether	O
HuR-telomerase	O
regulatory	O
process	O
impacts	O
on	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
function.	O

Wild	O
type	O
(WT)	O
and	O
CFTR	O
knockout	O
(KO)	O
mouse	O
pancreatic	O
ductal	O
(PDEC)	O
and	O
acinar	O
cells	O
(PAC),	O
human	O
CF	O
pancreatic	O
cell	O
line	O
(CFPAC-1)	O
and	O
human	O
pancreatic	O
organoids	O
generated	O
from	O
induced	B
pluripotent	I
stem	I
cells	I
(IPSC)	O
of	O
controls	O
and	O
CF	O
patients	O
were	O
used	O
in	O
the	O
study.	O

A	O
defined	O
set	O
of	O
master	O
transcription	O
factors	O
(TFs),	O
namely	O
OCT4,	O
SOX2,	O
KLF4,	O
and	O
MYC	O
(called	O
“OSKM”	O
hereafter),	O
can	O
reprogram	O
somatic	O
cells	O
into	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
and	O
allow	O
the	O
study	O
of	O
dynamic	O
events	O
that	O
occur	O
during	O
cell	O
fate	O
decisions	O
(Takahashi	O
and	O
Yamanaka,	O
2006,	O
Takahashi	O
et	O
al.,	O
2007).	O

Shinya	O
Yamanaka	O
reported	O
one	O
of	O
the	O
greatest	O
breakthroughs	B
in	I
stem	I
cell	I
research:	O
the	O
reprogramming	O
of	O
mouse	O
somatic	O
cells	O
into	O
induced	O
pluripotent	O
stem	O
cells	O
(iPSCs)	O
[1].	O

For	O
example,	O
cell	O
therapeutics	O
with	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
have	O
proven	O
evidence	O
for	O
efficacy	O
and	O
safety	O
in	O
animal	O
models.	O

Of	O
these,	O
the	O
cell	O
type	O
that	O
is	O
likely	O
to	O
give	O
rise	O
to	O
defects	O
in	O
multiple	O
organs	O
is	O
the	B
stem	I
cell	I
and	O
since	O
bone	O
marrow	O
failure	O
is	O
the	O
cause	O
of	O
most	O
DC-related	O
mortality	O
it	O
is	O
the	O
haematopoietic	O
stem	O
cell	O
(HSC)	O
that	O
has	O
received	O
the	O
most	O
research	O
attention	O
with	O
defects	O
having	O
been	O
identified	O
in	O
several	O
studies.	O

Hematopoietic	B
stem	I
cell	I
(HSC)	O
gene	O
therapy	O
using	O
retroviral	O
vectors	O
has	O
immense	O
potential,	O
but	O
vector-mediated	O
genotoxicity	O
limits	O
use	O
in	O
the	O
clinic.	O

As	O
to	O
the	O
role	O
of	O
Gomafu	B
in	I
stem	I
cell	I
biology,	O
it	O
has	O
been	O
suggested	O
that	O
Gomafu	O
and	O
Oct4	O
establish	O
an	O
autofeedback	O
loop	O
to	O
maintain	O
pluripotency	O
of	O
mouse	O
embryonic	O
stem	O
cells	O
(mESCs)	O
[35].	O

The	O
most	O
striking	O
evidence	O
supporting	O
the	O
use	O
of	O
exosomes	O
in	O
cell-free	O
therapy	O
and	O
tissue	O
engineering	O
come	O
from	O
the	O
results	O
obtained	O
from	O
a	O
series	O
of	O
studies	O
on	O
mesenchymal	B
stem	I
cell	I
(MSCs)	O
transplantation	O
for	O
tissue	O
regeneration	O
[122,123]..	O

The	O
emergence	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technologies	O
offers	O
an	O
attractive	O
alternative	O
to	O
humanized	O
mice	O
that	O
allows	O
the	O
interrogation	O
of	O
underlying	O
genetic	O
defects	O
using	O
a	O
vast	O
array	O
of	O
relevant	O
biological	O
tissues	O
and	O
cell	O
types	O
avoiding	O
both	O
allo-	O
and	O
xenogeneic	O
responses..	O

Induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
stable	O
cell	O
lines	O
can	O
be	O
generated	O
from	O
several	O
different	O
somatic	O
cell	O
types	O
depending	O
on	O
specimen	O
availability.	O

Gene	O
modification	O
strategies	O
for	O
use	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
lines.	O

Induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
reprogramming	O
schematic	O
from	O
CD34+	O
cells	O
using	O
Sendai	O
virus.	O

BMPs	O
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
pluripotent	B
stem	I
cell	I
(PSC)	O
regulation.	O

The	O
advent	O
and	O
maturation	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
presents	O
a	O
valuable	O
opportunity	O
to	O
solve	O
this	O
problem	O
by	O
offering	O
a	O
human	O
cell	O
model.	O

With	O
the	O
advent	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology,	O
the	O
researchers	O
have	O
also	O
been	O
able	O
to	O
generate	O
alternative	O
cell	O
models	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
the	O
diseases.	O

Embryonic	B
stem	I
cell	I
(ESC)	O
pluripotency	O
and	O
differentiation	O
are	O
controlled	O
by	O
the	O
coordinated	O
action	O
of	O
multiple	O
epigenetic	O
factors	O
that	O
affect	O
the	O
structure	O
of	O
chromatin	O
and	O
regulate	O
gene	O
expression.	O

Compelling	O
evidence	O
during	O
the	O
last	O
decades	O
has	O
demonstrated	O
the	O
existence	O
of	O
stem	B
cells	I
(SCs)	O
within	O
the	O
vertebrate’s	O
pituitary	O
with	O
capacity	O
to	O
divide	O
and	O
self-renew,	O
and	O
later	O
to	O
differentiate	O
into	O
specialized	O
cell	O
types.	O

Generation,	O
expansion,	O
and	O
differentiation	O
of	O
human	B
pluripotent	I
stem	I
cell	I
(hPSC)	O
derived	O
neural	O
progenitor	O
cells	O
(NPCs)	O
Methods	O
Mol.	O

Osteoblasts	O
differentiate	O
from	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
precursors,	O
initially	O
expressing	O
runx2	O
before	O
downregulating	O
runx2	O
and	O
expressing	O
the	O
transcription	O
factor	O
osterix	O
(osx).	O

Melanocytes	O
derive	O
from	O
neural	B
crest	I
stem	I
cells	I
(NCSCs)	O
that	O
disseminate	O
into	O
the	O
embryo	O
to	O
form	O
an	O
array	O
of	O
diverse	O
cell	O
lineages	O
[139].	O

The	O
generation	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
by	O
somatic	O
cellular	O
reprogramming	O
technology	O
using	O
a	O
combination	O
of	O
defined	O
reprogramming	O
factors	O
termed	O
the	O
“Yamanaka	O
factors”	O
(Oct-4,	O
Sox-2,	O
Klf-4,	O
and	O
c-Myc	O
(OSKM))	O
represents	O
a	O
major	O
breakthrough	O
in	O
stem	O
cell	O
biology	O
and	O
regenerative	O
medicine	O
[10,11].	O

Thus	O
the	O
seam	O
cells	O
and	O
germ	O
cells	O
both	O
have	O
stem-like	O
properties,	O
although	O
only	O
the	O
germline	B
stem	I
cells	I
(GSC)	O
have	O
a	O
recognizable	O
niche,	O
regulated	O
by	O
a	O
notch	O
signal	O
emanating	O
from	O
the	O
distal	O
tip	O
cell	O
(DTC)	O
that	O
maintains	O
the	O
mitotic	O
zone	O
[6],	O
[7].	O

In	O
this	O
article,	O
we	O
review	O
the	O
insight	O
into	O
the	O
mTOR	O
activity	O
in	O
neural	B
stem	I
cell	I
(NSC)	O
functions	O
thereby	O
illustrating	O
the	O
close	O
relationship	O
between	O
mTOR	O
and	O
the	O
pathological	O
events	O
which	O
are	O
mainly	O
occurred	O
in	O
brain	O
developmental	O
disorders	O
and	O
pediatric	O
brain	O
tumors..	O

The	O
impact	O
of	O
such	O
delay	O
on	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
function	O
is	O
unclear	O
since	O
most	O
studies	O
have	O
not	O
used	O
transplantation	O
assays	O
that	O
measure	O
HSC	O
key	O
properties	O
and	O
activities.	O

More	O
experience	O
accumulates	O
in	O
the	O
immunomodulatory	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
infusion	O
in	O
numerous	O
immunopathological	O
disorders	O
–	O
such	O
as	O
GvHD	O
–	O
and	O
signals.	O

Neural	B
stem	I
cells	I
(NSC)	O
with	O
self-renewal	O
and	O
multipotent	O
properties	O
serve	O
as	O
an	O
ideal	O
cell	O
source	O
for	O
transplantation	O
to	O
treat	O
neurodegenerative	O
insults	O
such	O
as	O
Parkinson's	O
disease.	O

Mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
are	O
the	O
first	O
pluripotent	O
stem	O
cell	O
type	O
that	O
was	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
the	O
developing	O
blastocyst	O
[1,2].	O

Cells	O
derived	O
from	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
sources	O
(HM,	O
HO,	O
and	O
HN)	O
were	O
utilized	O
in	O
several	O
instances	O
to	O
establish	O
potential	O
patient-specific	O
and	O
disease	O
applications.	O

Therapeutic	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
largely	O
depends	O
on	O
the	O
paracrine	O
efficiency	O
of	O
MSC,	O
and	O
gingiva-derived	O
MSC	O
(GMSC)	O
have	O
unique	O
capacity	O
to	O
secret	O
large	O
amount	O
of	O
exosomes	O
and,	O
moreover,	O
are	O
easier	O
to	O
isolate.	O

POLG	O
mice	O
develop	O
progressive,	O
ultimately	O
fatal	O
megaloblastic	O
anemia	O
due	O
to	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
deficits,	O
impaired	O
erythrocyte	O
maturation,	O
and	O
increased	O
erythrocyte	O
destruction	O
by	O
splenic	O
macrophages	O
(30,	O
69,	O
70).	O

Recent	O
progress	O
in	O
the	O
biology	O
of	O
neural	B
stem	I
cells	I
(NSCs)	O
and	O
oligodendrocyte	O
precursor	O
cells	O
(OPCs)	O
provides	O
new	O
insights	O
into	O
their	O
candidacy	O
as	O
the	O
cell	O
of	O
origin	O
for	O
human	O
glioblastoma.	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
are	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
the	O
blastocysts	O
and	O
are	O
characterized	O
by	O
the	O
ability	O
to	O
renew	O
themselves	O
(self-renewal)	O
and	O
the	O
capability	O
to	O
generate	O
all	O
the	O
cells	O
within	O
the	O
human	O
body.	O

A	O
second	O
message	O
is	O
the	O
use	O
of	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
as	O
alternatives	O
to	O
the	O
stem	O
cell	O
sources	O
described	O
above.	O

There	O
are	O
limited	O
comprehensive	O
studies	O
on	O
toxicity	O
of	O
inhaled	O
FA	O
in	O
bone	O
marrow	O
(BM),	O
the	O
site	O
of	O
origination	O
of	O
all	O
blood	O
cells	O
from	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
[14]	O
and	O
target	O
site	O
for	O
leukemia	O
induction,	O
have	O
been	O
reported.	O

Hematopoietic	B
stem	I
cell	I
(HSC)	O
differentiation	O
is	O
a	O
prominent	O
example	O
of	O
a	O
dynamic	O
process	O
that	O
is	O
heavily	O
genetically	O
regulated	O
[9],	O
[29]–[32].	O

Cancer	B
stem	I
cells	I
(CSC)	O
have	O
enhanced	O
capacities	O
for	O
self-renewal,	O
cell	O
plasticity,	O
and	O
the	O
ability	O
to	O
adapt	O
to	O
harsh	O
environments	O
[277,278,279].	O

The	O
ability	O
of	O
the	O
tumor	O
suppressor	O
p53	O
under	O
stress	O
to	O
differentially	O
regulate	O
its	O
target	O
genes	O
which	O
regulate	O
cell-cycle	O
arrest,	O
apoptosis	O
or	O
senescence	O
of	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
could	O
be	O
a	O
possible	O
treatment	O
target	O
for	O
leukemia	O
[64].	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
are	O
a	O
kind	O
of	O
pluripotent	O
stem	O
cells	O
that	O
can	O
be	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
the	O
early	O
embryo	O
[5].	O

Compared	O
with	O
the	O
adult	B
stem	I
cells	I
(ASCs)	O
found	O
in	O
adults,	O
ESCs	O
are	O
able	O
to	O
replicate	O
indefinitely	O
and	O
to	O
differentiate	O
into	O
all	O
three	O
primary	O
germ	O
layers	O
cell	O
lines	O
and	O
eventually	O
generate	O
all	O
cell	O
types	O
in	O
the	O
body	O
[37].	O

Finally,	O
since	O
the	O
onset	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
[60],	O
mesenchymal	O
cells	O
have	O
been	O
investigated	O
[61,	O
62]	O
due	O
to	O
their	O
relatively	O
easy	O
harvest	O
and	O
higher	O
potency	O
than	O
other	O
cell	O
types	O
(e.g.,	O
dermal	O
fibroblasts),	O
which	O
show	O
an	O
increased	O
efficiency,	O
even	O
in	O
the	O
absence	O
of	O
the	O
oncogene	O
c-Myc.	O

In	O
general,	O
DNMT3A	O
or	O
DNMT3B	O
have	O
roles	O
in	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
self-renewal,	O
maturation,	O
and	O
differentiation	O
[85].	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
have	O
been	O
widely	O
used	O
for	O
stem	O
cell	O
therapy,	O
and	O
serial	O
passage	O
of	O
stem	O
cells	O
is	O
often	O
required	O
to	O
obtain	O
sufficient	O
cell	O
numbers	O
for	O
practical	O
applications	O
in	O
regenerative	O
medicine.	O

The	O
discovery	O
of	O
human	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
in	O
2006	O
completely	O
revolutionized	O
the	O
field	O
of	O
stem	O
cell	O
biology,	O
and	O
these	O
cells	O
are	O
expected	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
many	O
regenerative	O
medicine	O
therapies.	O

Generation	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
line	O
from	O
a	O
patient	O
with	O
triple	O
negative	O
breast	O
cancer	O
with	O
hereditary	O
exon	O
17	O
deletion	O
of	O
BRCA1	O
gene.	O

The	O
integration	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
with	O
advanced	O
bioprinting	O
systems	O
can	O
potentially	O
deliver	O
a	O
new	O
generation	O
of	O
disease	O
models	O
and	O
tissue	O
constructs	O
for	O
the	O
development	O
and	O
testing	O
of	O
personalized	O
therapies	O
with	O
enhanced	O
efficacy	O
and	O
reduced	O
costs.31,32	O
This	O
is	O
especially	O
so	O
when	O
combined	O
with	O
incorporation	O
of	O
patient-derived	O
iPSCs	O
carrying	O
heritable	O
mutations.	O

Human	B
embryonic	I
stem	I
cells	I
(hESC)	O
are	O
stem	O
cells	O
derived	O
directly	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
preimplantation	O
embryo,347	O
which	O
in	O
humans	O
comprises	O
less	O
than	O
a	O
dozen	O
cells	O
found	O
at	O
day	O
5–6	O
of	O
development.	O

HESCs	O
are	O
widely	O
used	O
in	O
medical	O
research	O
and	O
clinical	O
grade	O
hESCs,	O
suitable	O
for	O
therapeutic	O
applications,	O
are	O
readily	O
available.348−350	O
Induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
have	O
similar	O
properties	O
of	O
continuous	O
replication	O
without	O
differentiation	O
(i.e.,	O
self-renewal)	O
and	O
have	O
shown	O
the	O
ability	O
to	O
generate	O
virtually	O
any	O
cell	O
type	O
in	O
the	O
body	O
(i.e.,	O
they	O
are	O
pluripotent)	O
if	O
given	O
the	O
correct	O
induction	O
cues.	O

Our	O
previous	O
results	O
showed	O
that	O
hyaluronan	O
(HA)	O
preserved	O
human	O
placenta-derived	O
mesenchymal	B
stem	I
cells	I
(PDMSC)	O
in	O
a	O
slow	O
cell	O
cycling	O
mode	O
similar	O
to	O
quiescence,	O
the	O
pristine	O
state	O
of	O
stem	O
cells	O
in	O
vivo,	O
and	O
HA	O
was	O
found	O
to	O
prevent	O
murine	O
adipose-derived	O
mesenchymal	O
stem	O
cells	O
from	O
senescence.	O

A	O
goal	O
in	O
human	B
embryonic	I
stem	I
cell	I
(hESC)	O
research	O
is	O
the	O
faithful	O
differentiation	O
to	O
given	O
cell	O
types	O
such	O
as	O
neural	O
lineages.	O

Furthermore,	O
E4F1	O
was	O
recently	O
shown	O
to	O
be	O
essential	O
for	O
epidermal	B
stem	I
cell	I
maintenance	O
and	O
proper	O
skin	O
homeostasis	O
in	O
murine	O
epidermis	O
(Lacroix	O
et	O
al.,	O
2010)..	O

Transcription	O
factor	O
E4F1	O
is	O
essential	O
for	O
epidermal	B
stem	I
cell	I
maintenance	O
and	O
skin	O
homeostasis.	O

It	O
is	O
clear	O
that	O
Lyn	O
has	O
important	O
functions	O
in	O
numerous	O
hematopoietic	O
cell	O
types,	O
from	O
early	O
(signaling	O
via	O
the	O
stem	B
cell	I
factor	O
receptor/c-kit	O
[27])	O
through	O
to	O
multiple	O
lineages	O
of	O
the	O
lymphoid	O
system	O
(e.g.	O

Furthermore,	O
the	O
pathophysiology	O
of	O
AT	O
might	O
be	O
associated	O
with	O
dysregulation	O
of	O
the	O
reservoir	O
of	O
adult	B
stem	I
cell	I
populations	O
(Wong	O
et	O
al.,	O
2003).	O

Effects	O
of	O
telomerase	O
and	O
telomere	O
length	O
on	O
epidermal	B
stem	I
cell	I
behavior.	O

One	O
such	O
challenge	O
is	O
the	O
expansion	O
of	O
a	O
homogeneous,	O
self-renewing	O
population	O
of	O
stem	B
cells	I
in	O
a	O
regulatory-friendly,	O
economically	O
feasible,	O
and	O
scalable	O
cell	O
culture	O
medium.5,6	O
Protein	O
supplementation,	O
such	O
as	O
with	O
serum	O
albumin	O
and	O
transferrin	O
required	O
to	O
maintain	O
adequate	O
cell	O
proliferation	O
and	O
high	O
viability	O
in	O
vitro,	O
has	O
traditionally	O
been	O
met	O
using	O
bovine-derived	O
serum	O
or	O
isolated	O
proteins.	O

However,	O
it	O
proves	O
costly	O
due	O
to	O
the	O
combination	O
of	O
relatively	O
high	O
protein	O
concentrations	O
required	O
in	O
medium	O
formulations,8	O
the	O
cost	O
of	O
the	O
recombinant	O
protein,9	O
and	O
the	O
volumes	O
of	O
growth	O
medium	O
needed	O
to	O
produce	O
a	O
clinically	O
relevant	O
doses	O
of	O
stem	O
cells	O
per	O
patient.10	O
Thus,	O
current	O
mainstream	O
platforms	O
for	O
the	O
production	O
of	O
recombinant	O
proteins,	O
although	O
suitable	O
for	O
producing	O
regulatory-friendly	O
human	O
proteins	O
with	O
consistent	O
performance,	O
lack	O
the	O
economical	B
sustainability	I
for	I
therapeutic	I
stem	I
cell	I
expansion..	O

Our	O
previous	O
study	O
demonstrated	O
that	O
the	O
biological	O
activity	O
of	O
the	O
rhLIF	O
protein	O
was	O
equivalent	O
in	O
a	O
modified	O
M1	O
cell	O
proliferation	O
inhibition	O
assay	O
as	O
well	O
as	O
in	O
the	O
C57BL/6	O
N	O
Lex3.13	O
mouse	O
embryonic	O
stem	O
cell	O
system.12	O
To	O
provide	O
further	O
evidence	O
of	O
application	O
of	O
the	O
rhLIF	O
in	O
stem	B
cell	I
systems,	O
we	O
tested	O
the	O
ability	O
of	O
rice-derived	O
rhLIF	O
to	O
maintain	O
pluripotency	O
in	O
mouse	O
iPS	O
cells.	O

Like	O
mouse	O
ESCs,	O
iPS	O
cells	O
require	O
the	O
presence	O
of	O
LIF	O
to	O
maintain	O
the	O
stem	B
cell	I
state	O
in	O
culture.	O

coli-derived	O
rhLIF	O
in	O
the	O
expression	O
of	O
mRNAs	O
encoding	O
the	O
stem	B
cell	I
state	O
regulators	O
in	O
mouse	O
iPS	O
cells	O
(Fig.	O

Given	O
the	O
reported	O
successes	O
of	O
stem	O
cell-based	O
therapies	O
in	O
animal	O
models,	O
it	O
is	O
anticipated	O
that	O
increasing	O
numbers	O
of	O
stem	O
cell	O
based	O
therapies	O
will	O
enter	O
clinical	O
testing	O
in	O
the	O
near	O
future.	O
Translation	O
of	O
stem	B
cell	I
therapy	O
to	O
the	O
clinic	O
will	O
necessitate	O
the	O
generation	O
of	O
scalable,	O
high	O
performance,	O
and	O
economically	O
feasible	O
animal	O
component-free	O
media.	O

Using	O
the	O
rhLIF	O
protein	O
as	O
a	O
proof-of-principle,	O
we	O
provide	O
justification	O
for	O
inclusion	O
of	O
ExpressTec-derived	O
recombinant	O
proteins	O
in	O
stem	B
cell	I
culture	O
medium.	O

Further,	O
we	O
demonstrate	O
equivalency	O
in	O
biological	O
activity	O
in	O
a	O
variety	O
of	O
stem	B
cell	I
systems	O
of	O
both	O
human	O
and	O
mouse	O
origin	O
in	O
comparison	O
to	O
the	O
E.	O

Thus	O
inclusion	O
of	O
ExpressTec-derived	O
proteins	O
in	O
stem	O
cell	O
mediums	O
can	O
enhance	O
the	O
safety,	O
affordability,	O
and	O
reliability	O
of	O
novel	O
stem	B
cell	I
therapies	O
and	O
potentially	O
facilitate	O
the	O
translation	O
of	O
these	O
new	O
therapies	O
to	O
first	O
line	O
treatments	O
for	O
many	O
devastating	O
diseases..	O

In	O
Table	O
1,	O
the	O
diagnosis	O
of	O
acute	O
leukemia	O
was	O
compared	O
to	O
all	O
other	O
diagnoses	O
and	O
for	O
stem	B
cell	I
source,	O
PBSC	O
were	O
compared	O
to	O
BM	O
and	O
BM	O
plus	O
PBSC..	O

Our	O
lab	O
succeeded	O
in	O
isolating	O
fetal	O
and	O
adult	O
cardiomyocyte	O
progenitor	O
cells	O
(CMPC)	O
from	O
mouse	O
and	O
human	O
hearts	O
based	O
on	O
the	O
stem	B
cell	I
antigen	O
Sca-1.[2]	O
CMPCs	O
can	O
successfully	O
been	O
differentiated	O
in	O
cardiomyocytes,	O
endothelial	O
cells	O
and	O
smooth	O
muscle	O
cells	O
in	O
vitro.	O

A	O
direct	O
comparison	O
of	O
efficacy	O
of	O
stem	B
cells	I
in	O
acute	O
versus	O
chronic	O
ischemic	O
heart	O
disease	O
has	O
never	O
been	O
performed,	O
but	O
safety	O
is	O
at	O
least	O
similar	O
in	O
acute	O
and	O
chronic	O
patients.[24]	O
Table	O
3	O
shows	O
negative	O
and	O
positive	O
results	O
of	O
cardiac	O
cell	O
therapy	O
in	O
both	O
acute	O
and	O
chronic	O
settings..	O

(2011)	O
Human	O
relevance	O
of	O
pre-clinical	O
studies	O
in	O
stem	B
cell	I
therapy:	O
systematic	O
review	O
and	O
meta-analysis	O
of	O
large	O
animal	O
models	O
of	O
ischaemic	O
heart	O
disease.	O

(2006)	O
A	O
quantitative,	O
randomized	O
study	O
evaluating	O
three	O
methods	O
of	O
mesenchymal	B
stem	I
cell	I
delivery	O
following	O
myocardial	O
infarction.	O

Gnecchi	O
M,	O
Zhang	O
Z,	O
Ni	O
A,	O
Dzau	O
VJ	O
(2008)	O
Paracrine	O
mechanisms	O
in	O
adult	B
stem	I
cell	I
signaling	O
and	O
therapy.	O

There	O
are	O
many	O
safety	O
concerns,	O
however,	O
in	O
the	O
use	O
of	O
stem	B
cell	I
therapy	O
in	O
the	O
treatment	O
of	O
human	O
disease.	O

(2009)	O
Granulocyte-macrophage	O
colony-stimulating	O
factor	O
(GM-CSF)-secreting	O
cellular	O
immunotherapy	O
in	O
combination	O
with	O
autologous	B
stem	I
cell	I
transplantation	O
(ASCT)	O
as	O
postremission	O
therapy	O
for	O
acute	O
myeloid	O
leukemia	O
(AML).	O

In	O
the	O
setting	O
of	O
haematopoietic	B
stem	I
cell	I
transplantation,	O
severe	O
BKV	O
haemorrhagic	O
cystitis	O
may	O
be	O
lethal.	O

The	O
reduced	O
levels	O
of	O
GATA2	O
observed	O
in	O
−77−/−	O
hematopoietic	O
progenitors	O
were	O
rescued	O
by	O
infection	O
of	O
E14.5	O
Lin−	O
fetal	O
liver	O
cells	O
with	O
retrovirus	O
carrying	O
the	O
murine	O
Gata2	O
cDNA	O
in	O
the	O
murine	B
stem	I
cell	I
virus	O
plasmid	O
(pMSCV;	O
Katsumura	O
et	O
al.,	O
2018).	O

Mesenchymal	B
stem	I
cell	I
delivery	O
strategies	O
to	O
promote	O
cardiac	O
regeneration	O
following	O
ischemic	O
injury.	O

Nerve	O
growth	O
factor	O
induces	O
cord	O
formation	O
of	O
mesenchymal	B
stem	I
cell	I
by	O
promoting	O
proliferation	O
and	O
activating	O
the	O
PI3K/Akt	O
signaling	O
pathway.	O

Paradoxical	O
dysregulation	O
of	O
the	O
neural	B
stem	I
cell	I
pathway	O
sonic	O
hedgehog-Gli1	O
in	O
autoimmune	O
encephalomyelitis	O
and	O
multiple	O
sclerosis.	O

Hans	O
Clevers	O
defined	O
an	O
organoid	O
as	O
“a	O
3D	O
structure	O
grown	B
from	I
stem	I
cells	I
and	O
consisting	O
of	O
organ-specific	O
cell	O
types	O
that	O
self-organize	O
through	O
cell	O
sorting	O
and	O
spatially	O
restricted	O
lineage	O
commitment”	O
[24].	O

Furthermore,	O
BCOR’s	O
major	O
role	O
in	O
embryonic	B
stem	I
cell	I
differentiation	O
may	O
be	O
significantly	O
altered	O
by	O
inheritance	O
of	O
downregulated	O
expression	O
as	O
a	O
result	O
of	O
maternal	O
smoking	O
[43]..	O

Role	O
of	O
the	O
transcriptional	O
corepressor	O
Bcor	O
in	O
embryonic	B
stem	I
cell	I
differentiation	O
and	O
early	O
embryonic	O
development.	O

microRNAs	O
as	O
novel	O
regulators	O
of	O
stem	B
cell	I
pluripotency	O
and	O
somatic	O
cell	O
reprogramming.	O

(2010)	O
Anthracycline	O
cardiomyopathy	O
is	O
mediated	O
by	O
depletion	O
of	O
the	O
cardiac	B
stem	I
cell	I
pool	O
and	O
is	O
rescued	O
by	O
restoration	O
of	O
progenitor	O
cell	O
function.	O

Numb	O
is	O
a	O
signal	O
transduction	O
factor	O
involved	O
in	O
stem	B
cell	I
maintenance	O
and	O
differentiation,	O
as	O
well	O
as	O
in	O
neuritogenesis,	O
by	O
antagonizing	O
Notch-1	O
signalling	O
[31–34].	O

Mesenchymal	B
stem	I
cells	I
inhibit	O
human	O
Th17	O
cell	O
differentiation	O
and	O
function	O
and	O
induce	O
a	O
T	O
regulatory	O
cell	O
phenotype.	O

Mesenchymal	B
stem	I
cells	I
generate	O
a	O
CD4+CD25+Foxp3+	O
regulatory	O
T	O
cell	O
population	O
during	O
the	O
differentiation	O
process	O
of	O
Th1	O
and	O
Th17	O
cells.	O

Inflammatory	O
cytokine-induced	O
intercellular	O
adhesion	O
molecule-1	O
and	O
vascular	O
cell	O
adhesion	O
molecule-1	O
in	O
mesenchymal	B
stem	I
cells	I
are	O
critical	O
for	O
immunosuppression.	O

CD8	O
T	O
cell/indoleamine	O
2,3-dioxygenase	O
axis	O
is	O
required	O
for	O
mesenchymal	B
stem	I
cell	I
suppression	O
of	O
human	O
systemic	O
lupus	O
erythematosus.	O

The	O
therapeutic	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
transplantation	O
in	O
experimental	O
autoimmune	O
encephalomyelitis	O
is	O
mediated	O
by	O
peripheral	O
and	O
central	O
mechanisms.	O

Safety	O
and	O
immunological	O
effects	O
of	O
mesenchymal	B
stem	I
cell	I
transplantation	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
and	O
amyotrophic	O
lateral	O
sclerosis.	O

Mesenchymal	B
stem	I
cell	I
transplantation	O
in	O
amyotrophic	O
lateral	O
sclerosis:	O
a	O
phase	O
I	O
clinical	O
trial.	O

The	O
comprehensive	O
analysis	O
of	O
highly	O
cited	O
articles	O
in	O
the	O
stem	B
cell	I
field	O
could	O
identify	O
milestones	O
and	O
important	O
contributors,	O
giving	O
a	O
historic	O
perspective	O
on	O
scientific	O
progress..	O

The	O
most	O
recent	O
bibliometric	O
analysis	O
of	O
stem	B
cell	I
research	O
was	O
reported	O
in	O
2003	O
(13).	O

In	O
2012,	O
several	O
bibliometric	O
analyses	O
of	O
applications	O
relating	O
to	O
stem	B
cell	I
transplantation	O
technology	O
were	O
reported	O
for	O
diseases	O
such	O
as	O
Parkinson’s	O
disease	O
(15),	O
cerebral	O
ischemia	O
(16),	O
spinal	O
cord	O
injury	O
(17),	O
Duchenne	O
muscular	O
dystrophy	O
(18)	O
and	O
epilepsy	O
(19).	O

A	O
sharp	O
increase	O
in	O
stem	B
cell	I
research	O
has	O
been	O
observed	O
since	O
1991	O
(14).	O

In	O
this	O
research,	O
the	O
pluripotent	B
stem	I
cell	I
literature	O
published	O
from	O
1991	O
to	O
2012	O
was	O
screened,	O
and	O
highly	O
cited	O
articles	O
in	O
total	O
citations	O
as	O
well	O
as	O
citations	O
in	O
last	O
year	O
and	O
publication	O
year	O
were	O
identified	O
and	O
compared	O
for	O
impact	O
in	O
literature..	O

The	O
abbreviation	O
has	O
become	O
acceptable	O
for	O
use	O
in	O
pluripotent	B
stem	I
cell	I
research	O
and	O
is	O
gaining	O
popularity	O
(Fig.4)..	O

As	O
seen	O
by	O
the	O
popularity	O
of	O
stem	O
cell	O
research	O
in	O
various	O
countries	O
and	O
the	O
acknowledgment	O
of	O
the	O
potential	O
of	O
pluripotent	B
stem	I
cells	I
to	O
aid	O
in	O
patient	O
specific	O
therapies	O
in	O
our	O
ever	O
increasing	O
elderly	O
population,	O
regenerative	O
medicine	O
will	O
continue	O
to	O
progress	O
with	O
the	O
advent	O
of	O
new	O
research	O
findings..	O

Use	O
of	O
stem	B
cell	I
transplantation	O
to	O
treat	O
epilepsy:	O
a	O
Web	O
of	O
Science-based	O
literature	O
analysis.	O

Mir-29b	O
Mediates	O
the	O
Neural	O
Tube	O
versus	O
Neural	O
Crest	O
Fate	O
Decision	O
during	B
Embryonic	I
Stem	I
Cell	I
Neural	O
Differentiation.	O

Surprisingly,	O
however,	O
we	O
discover	O
that	O
(i)	O
teenage	O
fathers	O
already	O
set	O
out	O
from	O
a	O
much	O
higher	O
mutation	O
rate	O
than	O
teenage	O
mothers	O
(potentially	O
equivalent	O
to	O
77–196	O
male	O
germline	O
cell	O
divisions	O
by	O
puberty);	O
and	O
(ii)	O
ageing	O
men	O
maintain	O
sperm	O
DNA	O
quality	O
similar	O
to	O
that	O
of	O
teenagers,	O
presumably	O
by	O
using	O
fresh	O
batches	O
of	O
stem	B
cells	I
known	O
as	O
‘A-dark	O
spermatogonia’..	O

Increasing	O
cell	O
survival	O
in	O
stem	B
cell	I
therapy	O
is	O
an	O
important	O
challenge	O
for	O
the	O
field	O
of	O
regenerative	O
medicine.	O

These	O
nanoparticles	O
can	O
be	O
used	O
for	O
real	B
time	I
stem	I
cell	I
imaging	O
and	O
quantitation	O
with	O
ultrasound	O
to	O
avoid	O
delivery	O
into	O
fibrotic	O
tissue	O
16,	O
22.	O

Here,	O
we	O
report	O
the	O
construction	O
and	O
validation	O
of	O
mesoporous	O
silica	O
nanoparticles	O
as	O
a	O
theranostic	O
tool	O
for	O
stem	B
cell	I
therapy.	O

We	O
used	O
insulin-like	O
growth	O
factor	O
(IGF)	O
as	O
a	O
model	O
pro-survival	O
agent	O
because	O
of	O
its	O
established	O
role	O
in	O
cardiac	B
stem	I
cell	I
therapy	O
33,	O
34.	O

This	O
approach	O
may	O
offer	O
important	O
advantages	O
for	O
cardiac	B
stem	I
cell	I
therapy	O
as	O
well	O
as	O
abdominal	O
applications	O
of	O
regenerative	O
medicine	O
amenable	O
to	O
ultrasound	O
imaging..	O

Our	O
goal	O
was	O
to	O
deploy	O
the	O
established	O
utility	O
of	O
MSNs	O
in	O
both	O
imaging	O
and	O
drug	O
delivery	O
to	O
cardiac	B
stem	I
cell	I
therapy	O
(Fig..	O

FOXM1	O
is	O
a	O
known	O
master	O
regulator	O
of	O
cancer	O
metastasis,	O
the	O
expression	O
of	O
multiple	B
stem	I
cell	I
genes,	O
as	O
well	O
as	O
MYCN	O
and	O
AURK	O
(Raychaudhuri	O
&	O
Park	O
2011).	O

Vascular-derived	O
TGF-beta	O
increases	O
in	O
the	O
stem	B
cell	I
niche	O
and	O
perturbs	O
neurogenesis	O
during	O
aging	O
and	O
following	O
irradiation	O
in	O
the	O
adult	O
mouse	O
brain.	O

Additionally,	O
its	O
replenishment	O
therapy	O
reduced	O
the	O
cancer	B
stem	I
cell	I
markers	O
and	O
induced	O
the	O
sensitization	O
to	O
gemcitabine	O
(GEM)	O
therapy.	O

Chromosome	O
number	O
variation	O
in	O
three	O
mouse	B
embryonic	I
stem	I
cell	I
lines	O
during	O
culture.	O

Current	O
status	O
of	O
chromosomal	O
abnormalities	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
lines	O
used	O
in	O
Japan.	O

While	O
neural	O
crest	O
development	O
is	O
a	O
complex	O
process	O
involving	O
numerous	O
steps,	O
here	O
we	O
focus	O
on	O
the	O
genetics	O
of	O
this	O
stem	B
cell	I
population	O
in	O
the	O
context	O
of	O
ocular	O
development..	O

While	O
neural	O
plate	O
border	O
specifiers	O
show	O
continued	O
expression,	O
additional	O
factors,	O
including	O
Sox10,	O
Foxd3,	O
Snai1/2,	O
and	O
Ets1	O
are	O
activated	O
at	O
this	O
stage	O
to	O
maintain	O
the	O
stem	B
cell	I
qualities	O
of	O
the	O
pre-migratory	O
neural	O
crest	O
cells	O
[53,142].	O

Induction	O
of	O
the	O
neural	O
crest	O
state:	O
Control	O
of	O
stem	B
cell	I
attributes	O
by	O
gene	O
regulatory,	O
post-transcriptional	O
and	O
epigenetic	O
interactions.	O

There	O
was	O
also	O
increased	O
expression	O
of	O
neuronal	B
stem	I
cell	I
markers	O
such	O
as	O
nestin	O
and	O
the	O
number	O
of	O
proliferating	O
cells	O
in	O
the	O
subgranular	O
zone	O
(SGZ).	O

In	O
addition	O
to	O
the	O
stem	B
cell	I
model,	O
several	O
studies	O
have	O
shown	O
a	O
positive	O
activating	O
role	O
for	O
DAX-1	O
in	O
gene	O
transcription	O
rather	O
than	O
repressor	O
role.	O

A	O
better	O
understanding	O
of	O
DAX-1	O
and	O
SF-1	O
in	O
development	O
and	O
tumorigenesis	O
is	O
needed,	O
especially	O
in	O
relation	O
to	O
stem	B
cell	I
biology.	O

Mesenchymal	B
stem	I
cell	I
migration	O
is	O
regulated	O
by	O
fibronectin	O
through	O
alpha5beta1-integrin-mediated	O
activation	O
of	O
PDGFR-beta	O
and	O
potentiation	O
of	O
growth	O
factor	O
signals.	O

Increased	O
expression	O
of	O
Syne1/nesprin-1	O
facilitates	O
nuclear	O
envelope	O
structure	O
changes	O
in	O
embryonic	B
stem	I
cell	I
differentiation.	O

Unveiling	O
the	O
critical	O
role	O
of	O
REX1	O
in	O
the	O
regulation	O
of	O
human	B
stem	I
cell	I
pluripotency.	O

Our	O
results	O
reveal	O
that	O
the	O
UPR	O
in	O
HSCs	O
can	O
be	O
modulated	O
by	O
systemic	O
factors,	O
extending	O
the	O
systemic	O
activation	O
of	O
the	O
UPR	O
to	O
tissue	B
stem	I
cell	I
biology..	O

Direct	O
control	O
of	O
germline	B
stem	I
cell	I
division	O
and	O
cyst	O
growth	O
by	O
neural	O
insulin	O
in	O
Drosophila.	O

Moreover,	O
some	O
studies	O
suggest	O
that	O
the	O
MSC	O
secretome	O
may	O
be	O
as	O
effective	O
as	O
MSC	O
themselves,	O
raising	O
questions	O
about	O
their	O
mechanism	O
of	O
action	O
and	O
possibly	O
negating	O
the	O
risk	O
of	O
stem	B
cell	I
infusion	O
(7).	O

Tumor	O
promotion	O
through	O
the	O
mesenchymal	B
stem	I
cell	I
compartment	O
in	O
human	O
hepatocellular	O
carcinoma.	O

Randomized	O
placebo-controlled	O
trial	O
of	O
mesenchymal	B
stem	I
cell	I
transplantation	O
in	O
decompensated	O
cirrhosis.	O

Mesenchymal	B
stem	I
cells	I
inhibit	O
dendritic	O
cell	O
differentiation	O
and	O
function	O
by	O
preventing	O
entry	O
into	O
the	O
cell	O
cycle.	O

The	O
effect	O
of	O
mesenchymal	B
stem	I
cells	I
on	O
dynamic	O
changes	O
of	O
T	O
cell	O
subsets	O
in	O
experimental	O
autoimmune	O
uveoretinitis.	O

The	O
expression	O
of	O
stem	B
cell	I
markers,	O
such	O
as	O
Sca-1	O
and	O
Keratin	O
6,	O
is	O
greatly	O
increased	O
in	O
the	O
hyperplastic	O
mammary	O
ducts	O
of	O
Cav-1	O
deficient	O
mice,	O
as	O
well	O
as	O
in	O
3D	O
cultures	O
of	O
Cav-1	O
(−/−)	O
primary	O
mammary	O
epithelial	O
cells.	O

The	O
gold	O
standard	O
treatment	O
consists	O
of	O
induction	O
chemotherapy	O
(cytarabine	O
in	O
combination	O
with	O
anthracyclines)	O
to	O
achieve	O
remission,	O
followed	O
by	O
consolidation	O
chemotherapy	O
and,	O
if	O
possible,	O
either	O
allogeneic	O
or	O
autologous	B
stem	I
cell	I
transplantation	O
[2,5,6].	O

Sox9	O
regulates	O
self-renewal	O
and	O
tumorigenicity	O
by	O
promoting	O
symmetrical	O
cell	O
division	O
of	O
cancer	B
stem	I
cells	I
in	O
hepatocellular	O
carcinoma.	O

To	O
investigate	O
further	O
the	O
observed	O
effect	O
of	O
WDR62	O
depletion	O
resulting	O
in	O
NSP	O
size	O
reduction,	O
we	O
analysed	O
the	O
expression	O
of	O
neural	B
stem	I
cell	I
and	O
progenitor	O
markers	O
in	O
Dox-treated	O
hPSC-H15	O
cultures	O
by	O
Q-PCR	O
at	O
both	O
the	O
neural	O
induction	O
and	O
NSP	O
stages	O
of	O
differentiation.	O

Primary	O
cell	O
lines	O
([A]	O
GBM-1,	O
from	O
a	O
recurrent	O
tumor,	O
and	O
[B]	O
GBM-6,	O
from	O
a	O
primary	O
tumor)	O
were	O
generated	O
in	O
stem	B
cell	I
medium	O
and	O
were	O
cultured	O
as	O
‘neurospheres’.	O

Basically,	O
given	O
the	O
difference	O
of	O
telomere	O
and	O
telomerase	O
activity	O
in	O
human	O
and	O
mouse	O
cells,	O
the	O
telomere	O
and	O
telomerase	O
status	O
in	O
stem	B
cell	I
populations	O
is	O
different	O
between	O
humans	O
and	O
mice	O
(Harrington,	O
2004).	O

These	O
data	O
support	O
the	O
idea	O
that	O
replicative	O
potential	O
of	O
HSCs	O
could	O
be	O
limited	O
by	O
progressive	O
telomere	O
shortening	O
and	O
that	O
telomere	O
length	O
can	O
be	O
used	O
as	O
an	O
indirect	O
indicator	O
of	O
stem	B
cell	I
proliferative	O
history	O
and	O
potential.	O

Mesenchymal	B
stem	I
cells	I
could	O
differentiate	O
into	O
multiple	O
mesoderm-type	O
cell	O
lineages	O
(Prockop,	O
1997),	O
such	O
as	O
fibroblasts,	O
adipocytes,	O
osteoblasts,	O
chondrocytes,	O
and	O
endothelial	O
cells,	O
as	O
well	O
as	O
into	O
non-mesoderm-type	O
lineages,	O
such	O
as	O
neuronal-like	O
cells.	O

In	O
low	O
confinement	O
(high-stress)	O
conditions,	O
filamentous	O
actin	O
(F-actin)	O
is	O
polymerized	O
actively	O
in	O
the	O
cytoplasm	O
to	O
maintain	O
cell	O
shape	O
and	O
movement,	O
and	O
this	O
prevents	O
epidermal	B
stem	I
cell	I
differentiation.	O

These	O
efforts	O
will	O
be	O
crucial	O
for	O
the	O
design	O
of	O
next-generation	O
pharmacological	O
approaches	O
which	O
attempt	O
to	O
reestablish	O
cell	O
differentiation	O
in	O
the	O
treatment	O
of	O
epithelial	O
diseases	O
such	O
as	O
cancer,	O
as	O
well	O
as	O
in	O
the	O
development	O
of	O
more	O
robust	O
strategies	O
for	O
stem	B
cell	I
culture	O
and	O
targeted	O
differentiation..	O

(2012)	O
Fine-tuning	O
the	O
degree	O
of	O
stem	B
cell	I
polarization	O
and	O
alignment	O
on	O
ordered	O
arrays	O
of	O
high-aspect-ratio	O
nanopillars.	O

Our	O
results	O
add	O
the	O
telomerase	O
pathway	O
as	O
a	O
potential	O
therapeutic	O
target	O
whose	O
inactivation	O
can	O
lead	O
to	O
CML	B
stem	I
cell	I
eradication..	O

Cancer	O
induction	O
by	O
restriction	O
of	O
oncogene	O
expression	O
to	O
the	O
stem	B
cell	I
compartment.	O

Furthermore,	O
gene	O
expression	O
analysis	O
of	O
stem	B
cell	I
markers	O
(Lgr5,	O
Bmi,	O
and	O
Oflm4)	O
from	O
sorted	O
cells	O
were	O
similar	O
in	O
Vil-Cre	O
mir-802fl/fl	O
and	O
control	O
mice,	O
thereby	O
confirming	O
the	O
OLFM4	O
cell	O
quantification	O
(Fig.	O

In	O
conclusion,	O
we	O
identified	O
and	O
validated	O
six	O
miR-802	O
targets	O
related	O
to	O
Wnt	O
signaling	O
with	O
a	O
possible	O
role	O
in	O
the	O
regulation	O
of	O
intestinal	B
stem	I
cell	I
proliferation..	O

There	O
is	O
increasing	O
evidence	O
that	O
an	O
intricate	O
functional	O
relationship	O
exists	O
between	O
Wnt	O
and	O
Notch	O
signaling	O
during	O
the	O
assignment	O
of	O
particular	O
cell	O
fates,	O
for	O
stem	B
cell	I
maintenance,	O
and	O
a	O
proper	O
balance	O
of	O
differentiation	O
between	O
secretory	O
and	O
absorptive	O
cell	O
lineages15.	O

Intestinal	B
stem	I
cells	I
were	O
isolated	O
as	O
Lgr5-EGFP+	O
Epcam+	O
CD24low/CD31−	O
Ter119−	O
CD45–Efluoro780− 81	O
Paneth	O
cells	O
were	O
isolated	O
as	O
CD24hiSideScatterhiLgr5-EGFP−EPCAM+/	O
CD31−Ter119−	O
CD45−Efluoro780−,	O
enriched	O
enterocyte	O
population	O
was	O
isolated	O
as	O
CD24–	O
Lgr5-EGFP–EPCAM+/	O
CD31−Ter119−CD45–Efluoro780−	O
with	O
a	O
BD	O
FACS	O
Aria	O
II	O
SORP	O
cell	O
sorter.	O

Cancer	O
Stem	O
Cell	O
Vaccination	O
Confers	O
Significant	O
Anti-Tumor	O
Immunity	O
by	O
Selectively	O
Targeting	O
Cancer	B
Stem	I
Cells.	I

The	O
resulting	O
pellet	O
was	O
resuspended	O
in	O
a	O
specific	O
growth	O
medium	O
for	O
murine	O
MSCs,	O
Complete	O
MesenCult®	O
Medium	O
–	O
that	O
is,	O
MesenCult®	O
Basal	O
Medium	O
supplemented	O
with	O
MESENCULT®	B
Mesenchymal	I
Stem	I
Cell	I
Stimulatory	O
Supplements	O
(both	O
STEMCELLS	O
Technologies,	O
Grenoble,	O
France)	O
–	O
streptomycin	O
and	O
penicillin	O
(PAA	O
Laboratories	O
GmbH,	O
Pasching,	O
Austria),	O
and	O
thereafter	O
seeded	O
in	O
culture	O
plates	O
(1 × 106	O
cells	O
per	O
9.6	O
cm2	O
dish)	O
until	O
the	O
cell	O
culture	O
reached	O
100%	O
confluence..	O

Freedman	O
MS,	O
Bar-Or	O
A,	O
Atkins	O
HL,	O
Karussis	O
D,	O
Frassoni	O
F,	O
Lazarus	O
H,	O
Scolding	O
N,	O
Slavin	O
S,	O
Le	O
Blanc	O
K,	O
Uccelli	O
A,	O
MSCT	O
Study	O
Group	O
The	O
therapeutic	O
potential	O
of	O
mesenchymal	B
stem	I
cell	I
transplantation	O
as	O
a	O
treatment	O
for	O
multiple	O
sclerosis:	O
consensus	O
report	O
of	O
the	O
International	O
MSCT	O
Study	O
Group.	O

Thus,	O
primary	O
cell	O
metabolism	O
can	O
define	O
the	O
fate	O
of	O
stem	B
cells	I
in	O
a	O
developing	O
organism..	O

In	O
vitro	O
effect	O
of	O
fludarabine,	O
cyclophosphamide,	O
and	O
cytosine	O
arabinoside	O
on	O
chromosome	O
breakage	O
in	O
Fanconi	O
anemia	O
patients:	O
relevance	O
to	O
stem	B
cell	I
transplantation.	O

Bone	O
marrow-derived	O
myofibroblasts	O
contribute	O
to	O
the	O
mesenchymal	B
stem	I
cell	I
niche	O
and	O
promote	O
tumor	O
growth.	O

Thus,	O
we	O
can	O
further	O
suppose	O
that	O
the	O
ablation	O
of	O
Tis21	O
enhances	O
the	O
stem	B
cell	I
character	O
of	O
the	O
Shh–activated	O
GCPs	O
as	O
a	O
preliminary	O
step	O
to	O
possible	O
lineage	O
shifts..	O

Neuropathy	O
of	O
haematopoietic	B
stem	I
cell	I
niche	O
is	O
essential	O
for	O
myeloproliferative	O
neoplasms.	O

Zhang	O
D,	O
Chan	O
JD,	O
Nogi	O
T,	O
Marchant	O
JS	O
(2011)	O
Opposing	O
roles	O
of	O
voltage-gated	O
Ca2+	O
channels	O
in	O
neuronal	O
control	O
of	O
stem	B
cell	I
differentiation	O
in	O
vivo	O
.	O

Induction	O
of	O
T	O
cell	O
development	O
and	O
establishment	O
of	O
T	O
cell	O
competence	O
from	O
embryonic	B
stem	I
cells	I
differentiated	O
in	O
vitro.	O

Because	O
desensitization	O
for	O
stem	B
cell	I
transplantation	O
is	O
a	O
relatively	O
recent	O
development	O
with	O
special	O
considerations,	O
we	O
have	O
dealt	O
with	O
that	O
topic	O
in	O
a	O
separate	O
section..	O

In	O
general,	O
unless	O
the	O
stem	B
cell	I
grafts	O
are	O
depleted	O
of	O
T	O
lymphocytes,	O
increasing	O
degrees	O
of	O
HLA	O
mismatch	O
have	O
been	O
associated	O
with	O
increased	O
rates	O
of	O
severe	O
acute	O
and	O
chronic	O
GVHD.	O

Other	O
factors,	O
including	O
the	O
underlying	O
disease,	O
the	O
degree	O
of	O
HLA	O
mismatch,	O
the	O
stem	B
cell	I
source,	O
the	O
timing	O
of	O
the	O
transplant,	O
the	O
pre-transplant	O
conditioning	O
regimen,	O
and	O
post-transplant	O
immunosuppression	O
135,140,142,148–150,	O
all	O
significantly	O
affect	O
HSCT	O
outcomes	O
and	O
HLA-DSA	O
may	O
increase	O
significantly	O
the	O
risk	O
of	O
adverse	O
outcomes.	O

The	O
presence	O
of	O
HLA-specific	O
antibodies	O
among	O
UCB	O
candidates	O
has	O
been	O
the	O
subject	O
of	O
several	O
recent	O
reports,	O
as	O
the	O
degree	O
of	O
HLA	O
mismatching	O
is	O
usually	O
higher	O
with	O
UCB	O
transplants	O
than	O
those	O
with	O
unrelated	O
donors	O
and	O
because	O
the	O
cell	O
dose	O
of	O
stem	B
cells	I
in	O
UCB	O
may	O
be	O
less	O
than	O
optimal	O
and,	O
consequently,	O
more	O
susceptible	O
to	O
antibody-mediated	O
rejection	O
156–160.	O

While	O
there	O
is	O
clear	O
evidence	O
of	O
the	O
detrimental	O
impact	O
of	O
HLA	O
antibodies	O
on	O
engraftment,	O
it	O
should	O
be	O
noted	O
that	O
patients	O
with	O
DSA	O
are	O
also	O
likely	O
to	O
have	O
increased	O
numbers	O
of	O
alloreactive	O
memory	O
T	O
cells	O
which	O
also	O
can	O
mediate	O
rejection	O
of	O
stem	B
cell	I
grafts.	O

There	O
are	O
two	O
general	O
approaches	O
for	O
management	O
of	O
major	O
ABOi	O
HSCT	O
175:	O
removal	O
of	O
the	O
anti-donor	O
isoagglutinins,	O
and	O
depletion	O
of	O
RBCs	O
from	O
the	O
stem	B
cell	I
product.	O

Depletion	O
of	O
RBC	O
from	O
the	O
stem	B
cell	I
infusion	O
component	O
can	O
be	O
achieved	O
by	O
gravity	O
sedimentation,	O
centrifugation,	O
Ficoll-Hypaque	O
gradients,	O
or	O
continuous	O
flow	O
blood	O
cell	O
separation.	O

For	O
patients	O
with	O
high	O
IgG	O
isoagglutinin	O
titers	O
(>1:256),	O
PE	O
or	O
IA	O
in	O
addition	O
to	O
red	O
cell	O
depletion	O
of	O
the	O
stem	B
cell	I
component	O
has	O
been	O
recommended	O
173.	O

Impact	O
of	O
donor-recipient	O
major	O
ABO	O
mismatch	O
on	O
allogeneic	O
transplantation	O
outcome	O
according	O
to	O
stem	B
cell	I
source.	O

Clinical	O
significance	O
of	O
recipient	O
antibodies	O
to	O
stem	B
cell	I
donor	O
mismatched	O
class	O
I	O
HLA	O
antigens.	O

Expression	O
of	O
cancer	B
stem	I
cell	I
markers	O
ALDH1,	O
CD44	O
and	O
CD133	O
in	O
primary	O
tumor	O
and	O
lymph	O
node	O
metastasis	O
of	O
gastric	O
cancer.	O

14S,21R-Dihydroxy-Docosahexaenoic	O
Acid	O
Treatment	O
Enhances	O
Mesenchymal	B
Stem	I
Cell	I
Amelioration	O
of	O
Renal	O
Ischemia/Reperfusion	O
Injury.	O

The	O
detection	O
of	O
prominin-1	O
in	O
human	O
cancer-initiating	O
cells	O
from	O
various	O
organs	O
brought	O
an	O
international	O
interest	O
to	O
this	O
molecule	O
as	O
a	O
specific	O
biomarker	O
of	O
cells	O
with	O
stem	B
cell	I
properties,	O
and,	O
excitingly,	O
as	O
a	O
potential	O
target	O
for	O
cancer	O
eradication	O
[13,	O
16–19]..	O

Nonetheless,	O
the	O
use	O
of	O
anti-human	O
prominin-1	O
antibodies	O
and	O
the	O
interpretation	O
of	O
data	O
need	O
to	O
be	O
considered	O
with	O
caution	O
because	O
discrepancies	O
in	O
immunohistochemical	O
expression	O
patterns	O
of	O
prominin-1	O
in	O
human	O
samples	O
have	O
been	O
observed	O
in	O
stem	B
cell	I
niches	O
and	O
cancerous	O
tissues	O
[59].	O

Midbody	O
and	O
primary	O
cilium	O
of	O
neural	O
progenitors	O
release	O
extracellular	O
membrane	O
particles	O
enriched	O
in	O
the	O
stem	B
cell	I
marker	O
prominin-1.	O

Isolation	O
of	O
canine	O
mammary	O
cells	O
with	O
stem	B
cell	I
properties	O
and	O
tumour-initiating	O
potential.	O

Evaluation	O
of	O
stem	B
cell	I
marker	O
gene	O
expression	O
in	O
canine	O
prostate	O
carcinoma-	O
and	O
prostate	O
cyst-derived	O
cell	O
lines.	O

Comparison	O
of	O
cancer	B
stem	I
cell	I
antigen	O
expression	O
by	O
tumor	O
cell	O
lines	O
and	O
by	O
tumor	O
biopsies	O
from	O
dogs	O
with	O
melanoma	O
and	O
osteosarcoma.	O

Comparative	O
characterization	O
of	O
stem	B
cell	I
marker	O
expression,	O
metabolic	O
activity	O
and	O
resistance	O
to	O
doxorubicin	O
in	O
adherent	O
and	O
spheroid	O
cells	O
derived	O
from	O
the	O
canine	O
prostate	O
adenocarcinoma	O
cell	O
line	O
CT1258.	O

The	B
stem	I
cell	I
marker	O
CD133	O
(prominin-1)	O
is	O
phosphorylated	O
on	O
cytoplasmic	O
tyrosine-828	O
and	O
tyrosine-852	O
by	O
Src	O
and	O
Fyn	O
tyrosine	O
kinases.	O

Allo-Reactivity	B
of	I
Mesenchymal	I
Stem	O
Cells	O
in	O
Rhesus	O
Macaques	O
Is	O
Dose	O
and	O
Haplotype	O
Dependent	O
and	O
Limits	O
Durable	O
Cell	O
Engraftment	O
In	O
Vivo.	O

Allo-Reactivity	B
of	I
Mesenchymal	I
Stem	O
Cells	O
in	O
Rhesus	O
Macaques	O
Is	O
Dose	O
and	O
Haplotype	O
Dependent	O
and	O
Limits	O
Durable	O
Cell	O
Engraftment	O
In	O
Vivo.	O

Isakova	O
IA,	O
Baker	O
K,	O
Dufour	O
J,	O
Gaupp	O
D,	O
Phinney	O
DG	O
(2006)	O
Preclinical	O
evaluation	O
of	O
adult	B
stem	I
cell	I
engraftment	O
and	O
toxicity	O
in	O
the	O
CNS	O
of	O
rhesus	O
macaques.	O

The	O
method	O
of	O
stem	B
cell	I
culture	O
and	O
neuronal	O
differentiation	O
employed	O
in	O
this	O
study	O
gives	O
rise	O
to	O
neurons	O
with	O
a	O
mature	O
projecting	O
phenotype	O
(Fig. 1)	O
that	O
express	O
the	O
markers	O
β	O
III	O
tubulin,	O
microtubule-associated	O
protein	O
2	O
(MAP2),	O
and	O
neural	O
nuclei	O
(NeuN).	O

This	O
study	O
provides	O
the	O
first	O
description	O
of	O
protection	O
of	O
embryonic	B
stem	I
cell	I
derived	O
human	O
neurons	O
by	O
hypothermia.	O

Murine	O
lines	O
were	O
maintained	O
in	O
stem	B
cell	I
media	O
(40%	O
IMDM,	O
40%	O
DMEM,	O
20%	O
FBS,	O
with	O
or	O
without	O
murine	O
SCF	O
10	O
ng/mL,	O
murine	O
IL-6	O
2	O
ng/mL,	O
and	O
murine	O
IL-3	O
0.4	O
ng/mL).	O

[18F]FDG	O
labeling	O
of	O
neural	B
stem	I
cells	I
for	O
in	O
vivo	O
cell	O
tracking	O
with	O
positron	O
emission	O
tomography:	O
inhibition	O
of	O
tracer	O
release	O
by	O
phloretin.	O

Mesenchymal	B
stem	I
cells	I
are	O
an	O
attractive	O
cell	O
population	O
for	O
regeneration	O
of	O
musculoskeletal	O
tissues	O
and	O
wound	O
healing	O
[23]–[25].	O

Horses,	O
in	O
contrast,	O
suffer	O
naturally-occurring	O
flexor	O
tendon	O
injury	O
with	O
many	O
similarities	O
to	O
human	O
Achilles	O
tendinopathy,	O
making	O
the	O
horse	O
a	O
useful	O
translational	O
model	O
for	O
stem	B
cell	I
therapies.	O

The	O
ability	O
of	O
muscle	O
fibers	O
to	O
repair	O
damage	O
and	O
regenerate	O
comes	O
from	O
the	O
presence	O
of	O
stem	B
cell	I
populations	O
that	O
cooperate	O
in	O
the	O
myogenic	O
process.	O

Targeting	O
of	O
the	O
stem	B
cell	I
population	O
responsible	O
for	O
the	O
regeneration	O
of	O
muscle	O
tissue,	O
known	O
as	O
satellite	O
cells,	O
seems	O
a	O
possible	O
way	O
to	O
ensure	O
the	O
healing	O
of	O
the	O
muscle	O
fiber	O
from	O
an	O
early	O
stage..	O

Isolation	O
of	O
muscle	B
stem	I
cells	I
by	O
fluorescence	O
activated	O
cell	O
sorting	O
cytometry.	O

Increasing	O
Nde1	O
expression	O
in	O
this	O
neural	B
stem	I
cell	I
line	O
led	O
to	O
increased	O
neuronal	O
differentiation	O
while	O
decreasing	O
levels	O
of	O
astroglial	O
differentiation.	O

Because	O
Nde1	O
functions	O
in	O
stem	O
cell	O
mitosis	O
(Feng	O
and	O
Walsh,	O
2004),	O
we	O
hypothesized	O
that	O
Nde1	O
may	O
be	O
expressed	O
in	O
the	O
adult	B
stem	I
cells	I
of	O
SVZ	O
in	O
vivo.	O

These	O
data	O
suggest	O
that	O
Nde1	O
is	O
more	O
likely	O
than	O
Ndel1	O
to	O
be	O
involved	O
in	O
adult	B
neural	I
stem	I
cell	I
function.	O

Neural	B
stem	I
cell	I
proliferation	O
is	O
decreased	O
in	O
schizophrenia,	O
but	O
not	O
in	O
depression.	O

Therefore,	O
ECM	O
modulates	O
self-renewal	O
and	O
differentiation	O
of	O
stem	O
cells	O
and	O
represents	O
an	O
essential	O
part	O
of	O
the	O
stem	B
cell	I
niche	O
(Nikolova	O
et	O
al.,	O
2007;	O
Brizzi	O
et	O
al.,	O
2012;	O
Ahmed	O
and	O
Ffrench-Constant,	O
2016).	O

Extracellular	O
matrix,	O
integrins,	O
and	O
growth	O
factors	O
as	O
tailors	O
of	O
the	O
stem	B
cell	I
niche.	O

Repair	O
and	O
regeneration	O
of	O
the	O
respiratory	O
system:	O
complexity,	O
plasticity,	O
and	O
mechanisms	O
of	O
lung	B
stem	I
cell	I
function.	O

Lung	B
stem	I
cell	I
differentiation	O
in	O
mice	O
directed	O
by	O
endothelial	O
cells	O
via	O
a	O
BMP4-NFATc1-thrombospondin-1	O
axis.	O

Some	O
cell	O
types,	O
such	O
as	O
hematopoietic	O
cells	O
[2]	O
and	O
certain	O
types	O
of	O
stem	B
cells	I
[3],	O
[4],	O
express	O
telomerase,	O
which	O
can	O
slow	O
the	O
rate	O
of	O
telomere	O
attrition.	O

Mesenchymal	B
stem	I
cell	I
transplantation	O
inhibits	O
abnormal	O
activation	O
of	O
Akt/GSK3beta	O
signaling	O
pathway	O
in	O
T	O
cells	O
from	O
systemic	O
lupus	O
erythematosus	O
mice.	O

Interferon-gamma-dependent	O
inhibition	O
of	O
B	O
cell	O
activation	O
by	O
bone	B
marrow-derived	I
mesenchymal	I
stem	I
cells	I
in	O
a	O
murine	O
model	O
of	O
systemic	O
lupus	O
erythematosus.	O

Cell	O
therapy	O
using	O
allogeneic	O
bone	B
marrow	I
mesenchymal	I
stem	I
cells	I
prevents	O
tissue	O
damage	O
in	O
collagen-induced	O
arthritis.	O

Inflammatory	O
cytokine-induced	O
intercellular	O
adhesion	O
molecule-1	O
and	O
vascular	O
cell	O
adhesion	O
molecule-1	O
in	O
mesenchymal	B
stem	I
cells	I
are	O
critical	O
for	O
immunosuppression.	O

Finally	O
we	O
examined	O
the	O
presence	O
of	O
translated	O
uORFs	O
in	O
transcripts	O
critically	O
involved	O
in	O
embryonic	B
stem	I
cell	I
pluripotency	O
and	O
self-renewal.	O

Besides	O
for	O
Nanog,	O
we	O
observed	O
DMDA-PatA-sensitive	O
ribosome	O
footprint	O
profiles	O
that	O
suggest	O
uORF	O
translation	O
for	O
several	O
other	O
transcripts	O
that	O
code	O
for	O
proteins	O
critically	O
involved	O
in	O
stem	B
cell	I
renewal	O
and	O
identity	O
such	O
as	O
CTCF,	O
Dicer1,	O
Lin28b	O
and	O
Trim71	O
(Lin41)	O
(Fig.	O

Translated	O
uORFs	O
in	O
transcripts	O
implicated	O
in	O
stem	B
cell	I
self-renewal	O
and	O
identity.	O

It	O
seems	O
likely	O
that	O
the	O
translated	O
uORFs	O
in	O
transcripts	O
critical	O
for	O
stem	B
cell	I
identity	O
affect	O
protein	O
output	O
and	O
are	O
part	O
of	O
the	O
network	O
that	O
post-transcriptionally	O
fine	O
tunes	O
the	O
ES	O
cell	O
proteome	O
for	O
maintenance	O
of	O
pluripotency	O
and	O
self	O
renewal..	O

T1D	O
is	O
in	O
essence	O
a	O
curable	O
autoimmune	O
disease,	O
as	O
evidenced	O
by	O
immunosuppression	O
trials	O
decades	O
ago	O
[12]	O
and	O
more	O
recently	O
by	O
non-myeloablative	B
stem	I
cell	I
transfers	O
[13].	O

Thus,	O
we	O
believe	O
that	O
a	O
more	O
likely	O
and	O
stringent	O
interpretation	O
is	O
that	O
these	O
apparent	O
abnormalities	O
are	O
secondary	O
to	O
the	O
small	O
numbers	O
of	O
stem	B
cell	I
clones	O
operating	O
to	O
support	O
hematopoiesis	O
in	O
this	O
BM	O
failure	O
syndrome..	O

Tripartite	O
polyionic	O
complex	O
(PIC)	O
micelles	O
as	O
non-viral	O
vectors	O
for	O
mesenchymal	B
stem	I
cell	I
siRNA	O
transfection.	O

Acute	O
myeloid	O
leukemia	O
originates	O
from	O
a	O
hierarchy	O
of	O
leukemic	B
stem	I
cell	I
classes	O
that	O
differ	O
in	O
self-renewal	O
capacity.	O

Cancer	O
induction	O
by	O
restriction	O
of	O
oncogene	O
expression	O
to	O
the	O
stem	B
cell	I
compartment.	O

The	O
underlying	O
mechanisms	O
that	O
control	O
this	O
delicate	O
balance	O
are	O
fundamental	O
to	O
understanding	O
stem	O
cell	O
regulation	O
and	O
the	O
therapeutic	O
use	O
of	O
stem	B
cells	I
in	O
human	O
disease..	O

While	O
all	O
NSCs	O
in	O
the	O
SVZ	O
of	O
the	O
forebrain	O
express	O
the	O
stem	B
cell	I
markers	O
Nestin,	O
Sox2	O
and	O
GFAP,	O
in	O
the	O
spinal	O
cord	O
only	O
dorsally	O
situated	O
ependymal	O
cells	O
express	O
Nestin/GFAP,	O
while	O
Sox2	O
is	O
expressed	O
in	O
all	O
ependymal	O
cells	O
(Sabourin	O
et	O
al.,	O
2009;	O
Barnabe-Heider	O
et	O
al.,	O
2010;	O
Alfaro-Cervello	O
et	O
al.,	O
2012).	O

(E)	O
qRT–PCR	O
results	O
show	O
the	O
expression	O
level	O
of	O
the	O
stem	B
cell	I
markers	O
(Sox2,	O
Oct4,	O
Nanog)	O
–	O
no	O
significant	O
differences	O
between	O
wild	O
type	O
mESCs	O
and	O
Wnt4	O
knockout	O
mESCs	O
can	O
be	O
observed..	O

Embryonic	B
stem	I
cell	I
differentiation:	O
emergence	O
of	O
a	O
new	O
era	O
in	O
biology	O
and	O
medicine.	O

The	O
iN	O
cells	O
barely	O
expressed	O
the	O
pluripotent	B
stem	I
cell	I
marker	O
(OCT4)	O
and	O
the	O
progenitor	O
cell	O
marker	O
(NESTIN).	O

The	O
establishment	O
of	O
the	O
AD-hiPSC	O
lines	O
followed	O
the	O
Policy	O
Instructions	O
of	O
the	O
Ethics	O
of	O
Human	O
Embryo	O
and	O
Embryonic	B
Stem	I
Cell	I
Research	O
in	O
Taiwan.	O

After	O
12	O
days	O
EBs	O
were	O
collected	O
and	O
assessed	O
by	O
RT-PCR	O
for	O
expression	O
of	O
stem	B
cell	I
and	O
differentiation	O
markers..	O

In	O
silico	O
identification	O
of	O
thiostrepton	O
as	O
an	O
inhibitor	O
of	O
cancer	B
stem	I
cell	I
growth	O
and	O
an	O
enhancer	O
for	O
chemotherapy	O
in	O
non–small‐cell	O
lung	O
cancer.	O

Transmission	O
electron	O
microscopy	O
and	O
electron	O
tomography	O
revealed	O
complex	O
junctions	O
between	O
TC	O
and	O
cardiomyocytes,	O
as	O
well	O
as	O
nanostructural	O
junctions	O
between	O
TC	O
and	O
resident	O
progenitor	O
cells,	O
at	O
the	O
level	O
of	O
epicardial	B
stem	I
cell	I
niches	O
(Gherghiceanu	O
and	O
Popescu	O
2010,	O
2011).	O

It	O
is	O
worthy	O
of	O
note	O
that	O
close	O
contacts	O
between	O
TC	O
and	O
putative	O
progenitor	O
cells	O
were	O
also	O
found	O
at	O
the	O
level	O
of	O
interstitial	B
stem	I
cell	I
niches	O
in	O
lungs	O
(Popescu	O
et	O
al.	O

Gherghiceanu	O
M,	O
Popescu	O
LM	O
(2010)	O
Cardiomyocyte	O
precursors	O
and	O
telocytes	O
in	O
epicardial	B
stem	I
cell	I
niche:	O
electron	O
microscope	O
images.	O

Gherghiceanu	O
M,	O
Popescu	O
LM	O
(2010)	O
Cardiomyocyte	O
precursors	O
and	O
telocytes	O
in	O
epicardial	B
stem	I
cell	I
niche:	O
electron	O
microscope	O
images.	O

Differentiation	O
of	O
stem	B
cells	I
into	O
nervous	O
cells	O
has	O
been	O
prevalent	O
among	O
all	O
cell	O
types	O
studied.	O

Human	O
ES	O
cell-derived	O
neural	O
rosettes	O
reveal	O
a	O
functionally	O
distinct	O
early	O
neural	B
stem	I
cell	I
stage.	O

The	O
effects	O
of	O
topographical	O
patterns	O
and	O
sizes	O
on	O
neural	B
stem	I
cell	I
behavior.	O

Human	O
Mesenchymal	O
Stem	O
Cells	O
(hMSCs)	O
have	O
emerged	O
in	O
the	B
last	I
few	I
years	O
as	O
one	O
of	O
the	O
most	O
promising	O
therapeutic	O
cell	O
sources	O
and,	O
in	O
particular,	O
as	O
an	O
important	O
tool	O
for	O
regenerative	O
medicine	O
of	O
skeletal	O
tissues.	O

Mesenchymal	O
Stem	O
Cells	O
(MSCs)	O
are	O
capable	O
of	O
self-renewing	O
to	B
produce	I
more	I
hMSCs	O
but	O
also,	O
of	O
dividing	O
asymmetrically	O
producing	O
lineage-committed	O
progenitors	O
that	O
will	O
differentiate	O
into	O
the	O
required	O
cell	O
types.	O

Differentiation	O
of	O
stem	B
cells	I
requires	O
the	O
activation	O
of	O
genes	O
involved	O
in	O
the	O
developing	O
of	O
a	O
specific	O
cell	O
type	O
on	O
one	O
hand	O
and	O
the	O
suppression	O
of	O
specific	O
sets	O
of	O
genes	O
responsible	O
for	O
cell	O
stemness	O
on	O
the	O
other	O
hand	O
[21].	O

Once	O
in	O
place,	O
epigenetic	O
changes	O
can	O
direct	O
gene	O
expression	O
by	O
modifying	O
the	O
accessibility	O
of	O
gene	O
promoters	O
and	O
therefore	O
facilitating	O
(or	O
avoiding)	O
the	O
recruitment	O
of	O
additional	O
chromatin	O
modifying	O
enzymes	O
or	O
transcriptional	O
regulators	O
that	O
would	O
drive	B
stem	I
cell	I
differentiation	O
[24-28].	O

CDK1	O
is	O
one	O
of	O
the	O
major	O
kinases	O
controlling	O
the	O
transition	O
from	O
the	O
G2	O
to	O
the	O
M	O
phase	O
of	O
the	O
cell	O
cycle	O
and	O
has	O
a	O
key	O
role	O
in	O
regulating	O
proliferation	O
and	O
lineage	O
specification	O
in	O
stem	B
cells	I
[83].	O

(2012)	O
have	O
described	O
the	O
regulation	O
by	O
DNA	O
methylation	O
of	O
PIWIL2,	O
(Piwi-like	O
RNA-Mediated	O
Gene	O
Silencing	O
2),	O
another	O
gene	O
involved	O
in	O
stem	B
cell	I
maintenance	O
[126].	O

The	O
DNM	O
rate	O
for	O
SNV	O
in	O
the	O
paternal	O
germline	O
is	O
about	O
four	O
times	O
greater	O
than	O
that	O
in	O
the	O
maternal	O
germline;	O
it	O
increases	O
linearly	O
by	O
about	O
two	O
DNMs	O
per	O
year	O
in	O
line	O
with	O
spermatogonial	B
stem	I
cell	I
turnover	O
after	O
puberty	O
[7].	O

Cells	O
with	O
stem	B
cell	I
properties	O
have	O
been	O
shown	O
to	O
exist	O
in	O
the	O
perivascular	O
structures	O
of	O
both	O
medulloblastomas	O
and	O
gliomas	O
(Calabrese	O
et	O
al.,	O
2007).	O

It	O
will	O
be	O
interesting	O
to	O
see	O
whether	O
further	O
insights	O
into	O
TERRA	O
regulation	O
will	O
advance	O
our	O
understanding	O
of	O
mechanisms	O
that	O
are	O
central	O
to	O
stem	B
cell	I
biology.	O

Epidemiology	O
and	O
risk	O
factors	O
for	O
serious	O
infections	O
in	O
the	O
stem	B
cell	I
transplant	O
setting.	O

Effectiveness	O
of	O
ganciclovir	O
against	O
human	O
herpesvirus‐6	O
excreted	O
in	O
saliva	O
in	O
stem	B
cell	I
transplant	O
recipients.	O

The	O
Hippo	O
pathway	O
is	O
a	O
highly	O
conserved	O
regulator	O
of	O
organ	O
size	O
as	O
well	O
as	O
of	O
stem	B
cell	I
proliferation	O
and	O
maintenance	O
(6,	O
14,	O
21).	O

In	O
microarray	O
datasets	O
of	O
colorectal	O
cancer	O
patients,	O
an	O
increased	O
expression	O
of	O
gene	O
signatures	O
for	O
YAP	O
activity	O
related	O
to	O
a	O
high	O
histological	O
grade,	O
an	O
enrichment	O
of	O
colon	B
stem	I
cell	I
signatures,	O
metastasis	O
characteristics,	O
and	O
cancer	O
progression.	O

Characterization	O
of	O
TAZ	O
domains	O
important	O
for	O
the	O
induction	O
of	O
breast	B
cancer	I
stem	I
cell	I
properties	O
and	O
tumorigenesis.	O

Horne	O
A,	O
Janka	O
G,	O
Maarten	O
Egeler	O
R,	O
et	O
al	O
Haematopoietic	B
stem	I
cell	I
transplantation	O
in	O
haemophagocytic	O
lymphohistiocytosis.	O

Unfortunately,	O
the	O
current	O
status	O
of	O
stem	B
cell	I
research	O
does	O
not	O
allow	O
us	O
to	O
substitute	O
for	O
whole	O
animal	O
testing,	O
as	O
seen	O
with	O
animal	O
models.	O

CD90	O
and	O
CD110	O
correlate	O
with	O
cancer	B
stem	I
cell	I
potentials	O
in	O
human	O
T-acute	O
lymphoblastic	O
leukemia	O
cells.	O

A	O
genome-wide	O
RNAi	O
screen	O
reveals	O
determinants	O
of	O
human	B
embryonic	I
stem	I
cell	I
identity.	O

Non-small	O
cell	O
lung	O
cancer	O
cells	O
expressing	O
CD44	O
are	O
enriched	O
for	O
stem	O
cell-like	O
properties.	O
Identification	O
and	O
characterization	O
of	O
cells	O
with	O
cancer	O
stem	B
cell	I
properties	O
in	O
human	O
primary	O
lung	O
cancer	O
cell	O
lines.	O

Activation	O
of	O
hepatic	B
stem	I
cell	I
compartment	O
in	O
the	O
rat:	O
role	O
of	O
transforming	O
growth	O
factor	O
alpha,	O
hepatocyte	O
growth	O
factor,	O
and	O
acidic	O
fibroblast	O
growth	O
factor	O
in	O
early	O
proliferation.	O

Highly	O
expressed	O
BMP9/GDF2	O
in	O
postnatal	O
mouse	O
liver	O
and	O
lungs	O
may	O
account	O
for	O
its	O
pleiotropic	O
effects	O
on	O
stem	B
cell	I
differentiation,	O
angiogenesis,	O
tumor	O
growth	O
and	O
metabolism.	O

A	O
pH-triggered,	O
self-assembled,	O
and	O
bioprintable	O
hybrid	O
hydrogel	O
scaffold	O
for	O
mesenchymal	B
stem	I
cell	I
based	O
bone	O
tissue	O
engineering.	O

Leucine-rich-repeat-containing	O
G	O
protein-coupled	O
receptor	O
6	O
(LGR6)	O
has	O
been	O
identified	O
as	O
the	O
stem	B
cell	I
marker	O
in	O
multiple	O
normal	O
tissues	O
and	O
malignancies.	O

Numerous	O
studies	O
have	O
revealed	O
the	O
significant	O
role	O
of	O
LGR5	O
in	O
stem	B
cell	I
identification	O
and	O
stemness	O
maintenance	O
in	O
both	O
normal	O
tissues	O
and	O
cancers.22,	O
23,	O
24	O
However,	O
subsequent	O
research	O
found	O
that	O
although	O
homologs,	O
LGR6	O
and	O
LGR5	O
may	O
have	O
distinctly	O
different	O
distribution	O
and	O
function.	O

Experimental	O
therapy	O
in	O
humans	O
is	O
limited	O
by	O
technical	O
and	O
ethical	O
considerations,	O
and	O
studies	O
in	O
closely	O
related	O
nonhuman	O
primates	O
are	O
constrained	O
by	O
high	O
cost,	O
limited	O
availability,	O
paucity	O
of	O
genetic	O
models	O
for	O
human	O
diseases,	O
and	O
lack	O
of	O
genetically	O
inbred	O
strains	O
suitable	O
for	O
stem	B
cell	I
or	O
tissue	O
transplantation.	O

In	O
contrast,	O
studies	O
in	O
mice	O
have	O
provided	O
proof	O
of	O
principle	O
for	O
stem	B
cell	I
transplantation	O
and	O
other	O
therapies.	O

PBX3	O
is	O
essential	O
for	O
leukemia	B
stem	I
cell	I
maintenance	O
in	O
MLL-rearranged	O
leukemia.	O

Inborn	O
Errors	O
of	O
Long-Chain	O
Fatty	O
Acid	O
beta-Oxidation	O
Link	O
Neural	B
Stem	I
Cell	I
Self-Renewal	O
to	O
Autism.	O

Paradoxical	O
dysregulation	O
of	O
the	O
neural	B
stem	I
cell	I
pathway	O
sonic	O
hedgehog-Gli1	O
in	O
autoimmune	O
encephalomyelitis	O
and	O
multiple	O
sclerosis.	O

Moreover,	O
production	O
of	O
more	O
mature	O
cell	O
types	O
from	O
pluripotent	B
stem	I
cells	I
can	O
be	O
beneficial	O
for	O
use	O
as	O
a	O
model	O
system	O
for	O
adult	O
human	O
organs	O
in	O
pharmacological	O
and	O
toxicological	O
studies.	O

Mouse	B
embryonic	I
stem	I
cell	I
expansion	O
in	O
a	O
microcarrier-based	O
stirred	O
culture	O
system.	O

edgeR	O
for	O
differential	O
RNA-seq	O
and	O
ChIP-seq	O
analysis:	O
an	O
application	O
to	O
stem	B
cell	I
biology.	O

PKC412	O
inhibits	O
the	O
zinc	O
finger	O
198-fibroblast	O
growth	O
factor	O
receptor	O
1	O
fusion	O
tyrosine	O
kinase	O
and	O
is	O
active	O
in	O
treatment	O
of	O
stem	B
cell	I
myeloproliferative	O
disorder.	O

Identification	O
of	O
such	O
modules	O
across	O
multiple	O
species	O
using	O
gene	O
networks	O
in	O
stem	B
cell	I
differentiation	O
has	O
provided	O
new	O
insights	O
into	O
evolutionary	O
conserved	O
developmental	O
pathways	O
and	O
conserved	O
pioneer	O
factors.	O

The	O
breast	B
cancer	I
stem	I
cell	I
hypotheses	O
suggest	O
that	O
breast	O
cancer	O
is	O
derived	O
from	O
a	O
single	O
cell	O
with	O
stem-like	O
properties	O
that	O
is	O
capable	O
of	O
tumor	O
initiation	O
and	O
formation.	O

Kruppel-like	O
factor	O
4	O
(KLF4)	O
is	O
required	O
for	O
maintenance	O
of	O
breast	B
cancer	I
stem	I
cells	I
and	O
for	O
cell	O
migration	O
and	O
invasion.	O

P19	O
cells	O
are	O
pluripotent	O
embryonic	O
carcinoma	O
cells	O
with	O
stem	B
cell	I
properties	O
that	O
can	O
be	O
differentiated	O
into	O
three	O
germ	O
layers	O
upon	O
stimulation23.	O

Cancer	O
stem	O
cells	O
are	O
a	O
small	O
subset	O
of	O
immortal	O
cancer	O
cells	O
with	O
stem	B
cell	I
properties	O
such	O
as	O
its	O
unlimited	O
cell	O
proliferation	O
and	O
ability	O
to	O
differentiate.	O

Bone	O
marrow-derived	O
myofibroblasts	O
contribute	O
to	O
the	O
mesenchymal	B
stem	I
cell	I
niche	O
and	O
promote	O
tumor	O
growth.	O

Immunohistochemical	O
markers	O
in	O
breast	O
cancer	O
brain	O
metastases:	O
the	O
role	O
of	O
the	O
cancer	B
stem	I
cell	I
marker	O
CD44	O
in	O
prognosis.	O

Now	O
myocardium	O
has	O
become	O
an	O
attractive	O
target	O
of	O
stem	B
cell	I
therapy	O
with	O
vessels,	O
valves,	O
and	O
even	O
conducting	O
systems	O
in	O
the	O
cardiovascular	O
system..	O

Although	O
considerable	O
research	O
has	O
been	O
done,	O
there	O
has	O
still	O
been	O
no	O
definite	O
advance	O
in	O
the	O
practical	O
human	O
application	O
of	O
stem	B
cell	I
therapy.	O

The	O
frequently	O
used	O
terms	O
in	O
stem	B
cell	I
biology	O
are	O
listed	O
and	O
defined	O
in	O
Table	O
2.	O

In	O
order	O
for	O
the	O
novel	O
concept	O
of	O
stem	B
cell	I
therapy	O
to	O
be	O
realized,	O
well-regulated,	O
ethically	O
proven,	O
randomized	O
clinical	O
trials	O
are	O
needed	O
to	O
obtain	O
background	O
on	O
the	O
therapeutic	O
mechanisms.	O

The	O
balance	O
between	O
safety	O
and	O
efficacy	O
is	O
the	O
first	O
priority	O
for	O
stem	B
cell	I
therapy	O
to	O
be	O
approved	O
clinically	O
in	O
human	O
disease..	O

Ensuring	O
genomic	O
stability	O
in	O
stem	B
cell	I
lines	O
is	O
required	O
to	O
achieve	O
the	O
quality	O
control	O
standards	O
for	O
safe	O
clinical	O
application..	O

Additionally,	O
mechanisms	O
to	O
protect	B
stem	I
cell	I
genomes	O
from	O
endogenous	O
and	O
exogenous	O
genotoxic	O
stresses	O
have	O
been	O
outlined	O
[2].	O

In	O
the	O
promising	O
era	O
of	O
stem	O
cell	O
research	O
and	O
therapy,	O
ensuring	O
genomic	O
stability	O
of	O
stem	B
cells	I
remains	O
one	O
of	O
the	O
highest	O
priorities	O
prior	O
to	O
clinical	O
translation.	O

Damage	O
to	O
genomic	O
DNA	O
in	O
multipotent	B
stem	I
cells	I
elicits	O
activation	O
of	O
the	O
DNA	O
damage	O
response	O
and	O
initiates	O
DNA	O
repair,	O
cell	O
cycle	O
arrest,	O
and	O
ultimately	O
apoptosis	O
or	O
cellular	O
senescence	O
[79,80].	O

Overall,	O
DNA	O
repair	O
is	O
observed	O
to	O
be	O
faster	O
and	O
more	O
accurate	O
in	O
stem	B
cell	I
populations	O
when	O
compared	O
to	O
the	O
DNA	O
repair	O
of	O
their	O
differentiated	O
counterparts.	O

Reduced	O
DNA	O
damage	O
response	O
and	O
cell	O
cycle	O
checkpoints	O
lead	O
to	O
mutation	O
accumulation	O
in	O
stem	B
cell	I
lines.	O

mutation-prone	B
stem	I
cell	I
clones	O
will	O
be	O
essential	O
to	O
guarantee	O
genomic	O
stability.	O

Systems-based	O
technologies	O
in	O
profiling	O
the	O
stem	B
cell	I
molecular	O
framework	O
for	O
cardioregenerative	O
medicine.	O

Lessons	O
from	O
human	O
teratomas	O
to	O
guide	O
development	O
of	O
safe	B
stem	I
cell	I
therapies.	O

Functional	O
data	O
supporting	O
a	O
hierarchy	O
of	O
tumour	O
cell	O
malignancy	O
came	O
via	O
improved	O
methods	O
for	O
fractionating	O
tumour	O
populations	O
based	O
on	O
neural	B
stem	I
cell	I
markers	O
and	O
interrogating	O
their	O
potency	O
in	O
immunocompromised	O
mice	O
(Singh	O
et	O
al.,	O
2004).	O

Primary	O
human	O
NS	O
cells	O
provide	O
the	O
genetically	O
normal	O
controls	O
for	O
functional	O
studies	O
and	O
comparison	O
with	O
glioma	B
stem	I
cell	I
cultures	O
(Fig.	O

Each	O
cell	O
type	O
gives	O
an	O
orthogonal	O
view	O
of	O
neural	B
stem	I
cells	I
in	O
development	O
and	O
disease.	O

This	O
is	O
particularly	O
useful	O
in	O
stem	B
cell	I
based	O
models	O
where	O
cell	O
heterogeneity	O
and	O
shifts	O
in	O
differentiation	O
status	O
mean	O
individual	O
cell	O
behavior	O
must	O
be	O
tracked..	O

Long-term	O
image-based	O
kinetic	O
analysis	O
of	O
cell	O
phenotypes	O
facilitates	O
quantification	O
of	O
stem	B
cell	I
differentiation	O
and	O
cell	O
fate.	O

This	O
may	O
include	O
the	O
selection	O
of	O
the	O
most	O
optimal	O
time-point	O
or	O
time-points	O
to	O
measure	O
transient	O
phenotypic	O
response	O
or	O
selection	O
of	O
earliest	O
time-point/phenotypic	O
measure	O
predictive	O
of	O
long-term	O
stem	O
cell	O
fate	O
to	O
accelerate	O
stem	B
cell	I
screening	O
studies.	O

Human	O
ES	O
cell-derived	O
neural	O
rosettes	O
reveal	O
a	O
functionally	O
distinct	O
early	O
neural	B
stem	I
cell	I
stage.	O

Tumor	B
stem	I
cells	I
derived	O
from	O
glioblastomas	O
cultured	O
in	O
bFGF	O
and	O
EGF	O
more	O
closely	O
mirror	O
the	O
phenotype	O
and	O
genotype	O
of	O
primary	O
tumors	O
than	O
do	O
serum-cultured	O
cell	O
lines.	O

Glioma	B
stem	I
cell	I
lines	O
expanded	O
in	O
adherent	O
culture	O
have	O
tumor-specific	O
phenotypes	O
and	O
are	O
suitable	O
for	O
chemical	O
and	O
genetic	O
screens.	O

Recent	O
advances	O
in	O
stem	B
cell	I
technologies	O
have	O
enabled	O
the	O
use	O
of	O
hESC-	O
and	O
iPSC-derived	O
cells	O
as	O
disease	O
model	O
systems	O
for	O
drug	O
discovery.	O

In	O
aging	O
telomerase	O
knockout	O
mice	O
(G4mTerc−/−),	O
telomere	O
dysfunction	O
is	O
associated	O
with	O
a	O
decline	O
in	O
stem	B
cell	I
function,	O
impaired	O
organ	O
maintenance,	O
and	O
a	O
shortened	O
lifespan	O
[8–11].	O

Targeting	O
exosomes	O
from	O
preadipocytes	O
inhibits	O
preadipocyte	O
to	O
cancer	B
stem	I
cell	I
signaling	O
in	O
early-stage	O
breast	O
cancer.	O

Hypoxia	O
induces	O
the	O
breast	B
cancer	I
stem	I
cell	I
phenotype	O
by	O
HIF-dependent	O
and	O
ALKBH5-mediated	O
m(6)A-demethylation	O
of	O
NANOG	O
mRNA.	O

Allende	O
reported	O
that	O
Sox2,	O
a	O
gene	O
encoding	O
a	O
transcription	O
factor	O
expressed	O
early	O
in	O
neural	O
tissue	O
and	O
involved	O
in	O
stem	B
cell	I
maintenance,	O
is	O
expressed	O
in	O
support	O
cells	O
within	O
the	O
neuromast	O
(Figure.	O

Telomerase	O
activity	O
is	O
generally	O
limited	O
to	O
stem	B
cell	I
populations	O
and	O
immortalized	O
tumor	O
cells	O
and	O
is	O
suppressed	O
in	O
normal	O
cells	O
(Kim	O
et	O
al	O
1994).	O

Prostate	O
cancer	O
cells	O
with	O
stem	B
cell	I
characteristics	O
reconstitute	O
the	O
original	O
human	O
tumor	O
in	O
vivo.	O

High	O
levels	O
of	O
some	O
miRNA	O
have	O
been	O
linked	O
to	O
stem	B
cell	I
promotion	O
[16-18],	O
while	O
others	O
exhibit	O
a	O
reduced	O
expression	O
of	O
many,	O
promoting	O
loss	O
of	O
differentiation	O
[19,20].	O

Nevertheless,	O
the	O
importance	O
of	O
stem	B
cell	I
biology	O
for	O
understanding	O
basic	O
lung	O
biology	O
and	O
for	O
the	O
treatment	O
of	O
respiratory	O
diseases	O
has	O
now	O
been	O
recognized.	O

While	O
alpha-1-antitrypsin	O
deficiency	O
in	O
early	O
stages	O
may	O
be	O
treatable	O
by	O
transplantation	O
of	O
transgenic	B
stem	I
cell	I
derivatives,	O
this	O
possibility	O
appears	O
less	O
likely	O
in	O
advanced	O
stage	O
cases	O
after	O
massive	O
development	O
of	O
emphysema.	O

Further	O
problems	O
in	O
the	O
field	O
include	O
the	O
lack	O
of	O
suitable	O
animal	O
models	O
that	O
closely	O
mirror	O
important	O
human	O
diseases	O
and	O
enable	O
proof	O
of	O
functionality	O
of	O
stem	B
cell	I
derivatives.	O

In	O
this	O
study,	O
we	O
show	O
that	O
the	O
genetic	O
background	O
influences	O
this	O
tumoral	O
stem	O
cell	O
reprogramming	O
capacity	O
of	O
the	O
oncogenes	O
using	O
as	O
a	O
model	O
the	O
Sca1-BCRABLp210	O
mice,	O
where	O
the	O
type	O
of	O
tumor	O
they	O
develop,	O
chronic	O
myeloid	O
leukemia	O
(CML),	O
is	O
a	O
function	O
of	O
tumoral	B
stem	I
cell	I
reprogramming.	O

In	O
order	O
to	O
probe	O
whether	O
the	O
genetic	O
background	O
could	O
influence	O
the	O
tumoral	O
stem	O
cell	O
reprogramming	O
fate,	O
we	O
have	O
used	O
as	O
a	O
model	O
the	O
Sca1-BCR-ABLp210	O
mice,	O
because	O
the	O
type	O
of	O
tumor	O
that	O
develops	O
is	O
a	O
function	O
of	O
stem	O
cell	O
reprogramming.4-8,17	O
In	O
this	O
model	O
the	O
restricted	O
expression	O
of	O
the	O
BCR-ABL	O
oncogene,	O
linked	O
to	O
chronic	O
myeloid	O
leukemia	O
(CML)	O
disease,	O
to	O
the	O
hematopoietic	O
stem	O
cell	O
compartment	O
is	O
capable	O
of	O
generating	O
a	O
full-blown	O
tumor	O
with	O
all	O
its	O
differentiated	O
cellular	O
components,	O
showing	O
a	O
hands-off	O
role	O
for	O
BCR-ABL	O
in	O
regulating	O
CML	O
formation.4-8,17	O
BCR-ABL	O
oncogene	O
inactivation	O
could	O
not	O
change	O
this	O
tumor	O
reprogramming	O
fate	O
at	O
the	O
CSC	O
level,	O
in	O
agreement	O
with	O
the	O
common	O
occurrence	O
of	O
tumor	O
relapse	O
by	O
which	O
human	O
CML	O
evolves	O
to	O
escape	O
BCR-ABL	O
pharmacological	O
inactivation.18-21	O
These	O
observations	O
suggest	O
that	O
the	O
susceptibility	O
to	O
development	O
of	O
CML	O
is	O
intrinsic	O
to	O
the	O
BCR-ABLp210-induced	O
reprogramming	O
of	O
stem	B
cells.	I

In	O
order	O
to	O
probe	O
if	O
the	O
genetic	O
background	O
could	O
affect	O
the	O
tumoral	B
stem	I
cell	I
reprogramming	O
fate,	O
we	O
have	O
taken	O
advantage	O
of	O
our	O
Sca1-BCRABLp210	O
mouse	O
model	O
of	O
human	O
chronic	O
myeloid	O
leukemia	O
(CML).	O

Thus	O
the	O
genetic	O
background	O
influences	O
the	O
tumoral	B
stem	I
cell	I
reprogramming	O
ability	O
of	O
the	O
BCRABLp210	O
oncogene..	O

Molecular	O
identification	O
of	O
such	O
loci	O
should	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
stem	B
cell	I
reprogramming	O
development.	O

Leukemic	B
stem	I
cell	I
persistence	O
in	O
chronic	O
myeloid	O
leukemia	O
patients	O
with	O
sustained	O
undetectable	O
molecular	O
residual	O
disease.	O

Hypoxia	O
induces	O
the	O
breast	B
cancer	I
stem	I
cell	I
phenotype	O
by	O
HIF-dependent	O
and	O
ALKBH5-mediated	O
m6A-demethylation	O
of	O
NANOG	O
mRNA.	O

Multiple	O
myeloma	O
remains	O
an	O
incurable	O
disease	O
even	O
with	O
the	O
use	O
of	O
proteasome	O
inhibitor	O
bortezomib,	O
immuno-modulatory	O
drugs	O
(thalidomide	O
or	O
lenalidomide),	O
and	O
high-dose	O
chemotherapy	O
associated	O
to	O
autologous	B
stem	I
cell	I
transplantation,	O
as	O
part	O
of	O
first-line	O
therapy	O
[6].	O

We	O
focus	O
especially	O
on	O
intestinal	B
stem	I
cell	I
proliferation,	O
cell	O
junction	O
formation,	O
remodelling,	O
hypoxia,	O
the	O
impact	O
of	O
intestinal	O
microbiota,	O
the	O
immune	O
system,	O
inflammation,	O
and	O
metabolism.	O

The	O
large	O
intestine	O
is	O
composed	O
of	O
intestinal	O
epithelial	O
cells,	O
which	O
arise	O
from	O
the	O
intestinal	B
stem	I
cells	I
localised	O
at	O
the	O
bottom	O
of	O
the	O
crypts	O
and	O
differentiate	O
into	O
several	O
cell	O
types	O
such	O
as	O
goblet	O
cells,	O
enteroendocrine	O
cells,	O
tuft	O
cells	O
or	O
enterocytes.	O

Indeed,	O
EGF,	O
which	O
is	O
produced	O
by	O
Paneth	O
cells	O
and	O
located	O
in	O
the	O
stem	B
cell	I
niches	O
(where	O
EGF	O
receptors	O
are	O
highly	O
expressed),	O
and	O
others	O
such	O
as	O
signaling	O
molecules	O
found	O
in	O
the	O
environment	O
can	O
control	O
the	O
activity	O
of	O
ISCs	O
[36].	O

KRAS	O
mutant	O
proteins	O
have	O
a	O
major	O
role	O
in	O
stem	B
cell	I
activities.	O

Role	O
of	O
oncogenic	O
K-Ras	O
in	O
cancer	B
stem	I
cell	I
activation	O
by	O
aberrant	O
Wnt/beta-catenin	O
signaling.	O

Dietary	O
and	O
metabolic	O
control	O
of	O
stem	B
cell	I
function	O
in	O
physiology	O
and	O
cancer.	O

Cells	O
were	O
cultured	O
as	O
floating	O
tumor-spheres	O
in	O
neural	B
stem	I
cell	I
medium	O
(serum-free),	O
consisting	O
of	O
Neurobasal-A	O
Medium	O
(1×,	O
ThermoFisher,	O
Waltham,	O
MA,	O
USA),	O
plus	O
DMEM/F-12	O
(1×,	O
ThermoFisher,	O
Waltham,	O
MA,	O
USA)	O
supplemented	O
with	O
HEPES	O
Buffer	O
Solution	O
(1M,	O
ThermoFisher,	O
Waltham,	O
MA,	O
USA),	O
Sodium	O
pyruvate	O
mem	O
100	O
mM	O
(CE,	O
ThermoFisher,	O
Waltham,	O
MA,	O
USA),	O
MEM	O
Non-essential	O
Amino	O
Acids	O
Solution	O
10	O
mM	O
(100×,	O
ThermoFisher,	O
Waltham,	O
MA,	O
USA),	O
GlutaMAX-I	O
Supplement	O
(100×,	O
ThermoFisher,	O
Waltham,	O
MA,	O
USA),	O
Antibiotic-Antimycotic	O
(100×,	O
ThermoFisher,	O
Waltham,	O
MA,	O
USA)	O
B27	O
Supplement	O
Minus	O
Vitamin-A	O
(50×,	O
ThermoFisher,	O
Waltham,	O
MA,	O
USA),	O
Recombinant	O
Human-basic	O
FGF	O
(20	O
ng/mL,	O
Peprotech,	O
Cranbury,	O
NJ,	O
USA),	O
Recombinat	O
Human	O
EGF	O
(20	O
ng/mL,	O
Peprotech,	O
Cranbury,	O
NJ,	O
USA),	O
Human	O
PDGF-AA	O
(20ng/mL,	O
Peprotech,	O
Cranbury,	O
NJ,	O
USA),	O
Human	O
PDGF-BB	O
(10	O
ng/mL,	O
Peprotech,	O
Cranbury,	O
NJ,	O
USA)	O
and	O
Heparin	O
Solution	O
0.2%	O
(2	O
µg/mL,	O
Sigma	O
Aldrich,	O
St.	O

These	O
effects	O
of	O
telomerase	O
and	O
telomere	O
length	O
on	O
stem	B
cell	I
behaviour	O
anticipate	O
the	O
premature	O
ageing	O
and	O
cancer	O
phenotypes	O
of	O
telomerase	O
mutant	O
mice.	O

Robust	O
telomerase	O
expression	O
is	O
a	O
feature	O
of	O
pluripotent	O
stem	O
cells	O
and	O
early	O
stages	O
of	O
embryonic	O
development,	O
although	O
telomerase	O
activity	O
is	O
also	O
present	O
in	O
adult	B
stem	I
cell	I
compartments	O
[4].	O

As	O
telomerase	O
expression	O
is	O
restricted	O
to	O
stem	O
cell	O
compartments	O
in	O
the	O
context	O
of	O
the	O
adult	O
organism,	O
it	O
is	O
of	O
interest	O
to	O
determine	O
the	O
impact	O
of	O
telomere	O
shortening	O
on	O
stem	B
cell	I
ageing.	O

A.2005Effects	O
of	O
telomerase	O
and	O
telomere	O
length	O
on	O
epidermal	B
stem	I
cell	I
behavior.	O

A.2007Telomerase	O
reverses	O
epidermal	O
hair	B
follicle	I
stem	I
cell	I
defects	O
and	O
loss	O
of	O
long-term	O
survival	O
associated	O
with	O
critically	O
short	O
telomeres.	O

A.2008The	O
longest	O
telomeres:	O
a	O
general	O
signature	O
of	O
adult	B
stem	I
cell	I
compartments.	O

This	O
review	O
will	O
discuss	O
the	O
methodology	O
that	O
should	O
be	O
used	O
in	O
the	O
stem	B
cell	I
banks	O
in	O
order	O
to	O
assure	O
the	O
quality	O
of	O
cell	O
and	O
biotechnological	O
products	O
and	O
avoid	O
the	O
transmission	O
of	O
infections,	O
in	O
particular	O
those	O
that	O
involve	O
virus	O
and	O
prion	O
particles..	O

In	O
addition,	O
infected	O
laboratory	O
workers	O
may	O
cause	O
contamination	O
of	O
stem	B
cell	I
lines	O
during	O
culture	O
manipulation..	O

The	O
use	O
of	O
bovine	O
fetal	O
serum	O
in	O
stem	B
cell	I
cultures	O
requires	O
an	O
urgent	O
need	O
for	O
a	O
risk	O
assessment	O
for	O
Transmissible	O
Spongiform	O
Encephalopathies	O
(TSEs)	O
by	O
means	O
of	O
a	O
sensitive	O
and	O
specific	O
test	O
in	O
all	O
products	O
derived	O
from	O
ruminants	O
(U.S.	O

The	O
addition	O
of	O
nucleic	O
acid	O
test	O
methods	O
to	O
screening	O
of	O
tissue	O
donors,	O
and	O
to	O
the	O
testing	O
of	O
derived	O
cell	O
lines,	O
should	O
reduce	O
the	O
risk	O
of	O
these	O
infections	O
among	O
recipients	O
of	O
stem	B
cell	I
lines	O
(Zou	O
et	O
al.,	O
2004)..	O

This	O
method	O
is	O
not	O
to	O
be	O
confused	O
with	O
somatic	O
cell	O
reprogramming	O
which	O
involves	O
generation	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSCs)	O
from	O
somatic	O
cells	O
using	O
techniques	O
such	O
as	O
somatic	O
cell	O
nuclear	O
transfer	O
(SCNT),	O
cell-cell	O
fusion,	O
exposure	O
to	O
extracts	O
of	O
pluripotent	O
cells,	O
or	O
iPSC	O
technology	O
[26].	O

This	O
could	O
be	O
explained	O
by	O
the	O
leukemia	B
stem	I
cell	I
(LSC)	O
theory	O
in	O
which	O
rare	O
leukemic	O
blasts	O
are	O
thought	O
to	O
be	O
responsible	O
for	O
relapse	O
and	O
for	O
maintaining	O
AML.	O

In	O
order	O
to	O
understand	O
the	O
role	O
of	O
telomerase	O
in	O
leukemia	B
stem	I
cell	I
(LSC)	O
generation	O
and	O
maintenance,	O
we	O
have	O
taken	O
advantage	O
of	O
our	O
Sca1-BCR-ABLp210	O
mouse	O
model	O
of	O
human	O
chronic	O
myeloid	O
leukaemia	O
(CML),	O
a	O
paradigmatic	O
stem-cell	O
disorder	O
[23,	O
24].	O

To	O
date,	O
the	O
majority	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
studies	O
are	O
conducted	O
using	O
human	O
tumors	O
inoculated	O
into	O
severely	O
immunosuppressed	O
hosts	O
(e.g.	O

In	O
recent	O
years,	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
theory	O
has	O
emerged	O
as	O
an	O
attractive	O
hypothesis	O
for	O
tumor	O
development	O
and	O
progression.	O

Recently,	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
theory	O
has	O
emerged	O
as	O
an	O
attractive	O
hypothesis	O
for	O
tumor	O
development	O
and	O
progression.	O

Preclinical	O
efficacy	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
in	O
animal	O
models	O
for	O
systemic	O
lupus	O
erythematosus.	O

Neural	B
stem	I
cells	I
(NSCs)	O
have	O
been	O
successfully	O
derived	O
from	O
PSCs	O
and	O
several	O
protocols	O
for	O
PSCs	O
differentiation	O
into	O
a	O
broad	O
variety	O
of	O
mature	O
neurons	O
and	O
glial	O
cell	O
subtypes	O
have	O
been	O
published	O
(Srikanth	O
and	O
Young-Pearse,	O
2014).	O

Mesenchymal	B
stem	I
cell	I
(MSC)	O
gene	O
therapy	O
have	O
been	O
widely	O
used	O
in	O
clinical	O
trials	O
due	O
to	O
their	O
heterogenetic	O
properties	O
(Bianco	O
2014).	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
attenuate	O
cutaneous	O
sclerodermatous	O
graft-versus-host	O
disease	O
(Scl-GVHD)	O
through	O
inhibition	O
of	O
immune	O
cell	O
infiltration	O
in	O
a	O
mouse	O
model.	O

Recent	O
advances	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
research	O
have	O
turned	O
limitations	O
of	O
prior	O
and	O
current	O
research	O
into	O
possibilities.	O

In	O
another	O
study,	O
functional	O
DA	O
neurons	O
were	O
generated	O
from	O
neuroepithelial	B
stem	I
cells	I
(NESCs)	O
derived	O
from	O
hiPSCs	O
using	O
a	O
phase-guided	O
3D	O
cell	O
culture	O
microfluidic	O
bioreactor.	O

Notch	O
signaling	O
augments	O
BMP9-induced	O
bone	O
formation	O
by	O
promoting	O
the	O
osteogenesis-angiogenesis	O
coupling	O
process	O
in	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
Cell.	O

However,	O
the	O
sg2/sg3	O
MA9	O
cells	O
showed	O
a	O
significantly	O
larger	O
population	O
of	O
cells	O
expressing	O
the	O
c-Kit	O
progenitor	O
marker	O
(Figure	O
3F,H),	O
which	O
has	O
been	O
associated	O
with	O
the	O
leukaemia	B
stem	I
cell	I
(LSC)	O
in	O
AMLs	O
including	O
MA9	O
[36,37].	O

Development	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
using	O
forced	O
expression	O
of	O
specific	O
sets	O
of	O
transcription	O
factors	O
has	O
changed	O
the	O
field	O
of	O
stem	O
cell	O
research	O
extensively.	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
mouse	O
[10]	O
and	O
subsequently	O
from	O
human	O
blastocysts	O
[11]	O
are	O
considered	O
pluripotent.	O

MNCs	O
of	O
normal	O
A	O
and	O
normal	O
B	O
were	O
enriched	O
for	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
by	O
CD34	O
cell	O
surface	O
marker	O
selection	O
using	O
the	O
CD34	O
MicroBead	O
kit,	O
human	O
(Miltenyi	O
Biotec)	O
according	O
to	O
the	O
manufacturer’s	O
instructions.	O

Therefore,	O
we	O
hypothesized	O
that	O
this	O
tumor	O
reprogramming	O
fate	O
at	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
level	O
should	O
be	O
the	O
target	O
where,	O
at	O
least	O
partly,	O
the	O
action	O
of	O
those	O
genetic	O
determinants	O
takes	O
place,	O
such	O
as	O
modifier	O
genes,	O
which	O
determine	O
the	O
differences	O
among	O
individuals	O
regarding	O
tumor	O
susceptibility,	O
treatment	O
response,	O
and	O
evolution..	O

At	O
the	O
base	O
of	O
the	O
crypts,	O
the	O
intestinal	B
stem	I
cell	I
(ISC)	O
niche	O
enables	O
the	O
constant	O
regeneration	O
of	O
the	O
intestinal	O
lining	O
(e.g.	O

The	O
sox	O
family	O
of	O
transcription	O
factors:	O
versatile	O
regulators	O
of	O
stem	O
and	O
progenitor	O
cell	O
fate.	O
In	O
this	O
context,	O
human	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
are	O
revolutionising	O
models	O
for	O
probing	O
biological	O
questions	O
in	O
multiple	O
fields,	O
as	O
well	O
as	O
being	O
hailed	O
as	O
future	O
treatments	O
for	O
a	O
multitude	O
of	O
diseases	O
with	O
the	O
potential	O
to	O
more	O
accurately	O
reflect	O
in	O
vivo	O
human	O
cell	O
types	O
(Hyman	O
and	O
Simons,	O
2011;	O
Zhang	O
and	O
Reilly,	O
2017).	O

To	O
investigate	O
the	O
role	O
of	O
matrix	O
rigidity	O
on	O
satellite	O
cell	O
fate,	O
freshly	O
isolated	O
and	O
FACS	O
(fluorescence	O
activated	O
cell	O
sorting)	O
enriched	O
muscle	B
stem	I
cells	I
(MuSCs)	O
were	O
cultured	O
on	O
PEG	O
hydrogels	O
with	O
differing	O
mechanical	O
properties	O
but	O
constant	O
ligand	O
density	O
[9].	O

A	O
biomimetic	O
biomaterials	O
approach	O
in	O
conjunction	O
with	O
functional	O
assays	O
in	O
mice	O
demonstrated	O
that	O
muscle	B
stem	I
cell	I
(MuSC)	O
self-renewal	O
can	O
be	O
maintained	O
in	O
culture	O
if	O
cells	O
are	O
propagated	O
upon	O
a	O
substrate	O
that	O
recapitulates	O
the	O
mechanical	O
properties	O
of	O
the	O
native	O
skeletal	O
muscle	O
tissue,	O
a	O
physical	O
property	O
of	O
the	O
stem	O
cell	O
niche	O
[9].	O

The	O
intestinal	O
epithelium	O
is	O
the	O
most	O
rapidly	O
self-renewing	O
tissue	O
in	O
adult	O
mammals,	O
which	O
renews	O
every	O
3–5	O
days	O
in	O
mice.1	O
Homeostasis	O
of	O
the	O
intestinal	O
epithelium	O
is	O
dependent	O
on	O
intestinal	B
stem	I
cells	I
(ISCs)	O
and	O
a	O
balance	O
among	O
cell	O
proliferation,	O
migration,	O
differentiation,	O
and	O
cell	O
death.1,	O
2	O
Several	O
ISC	O
populations	O
with	O
possible	O
overlap	O
have	O
recently	O
been	O
identified	O
in	O
mouse,	O
including	O
the	O
actively	O
cycling	O
columnar	O
cells	O
at	O
the	O
crypt	O
base	O
(CBCs)	O
marked	O
by	O
Lgr5	O
or	O
CD133,	O
and	O
the	O
slow	O
cycling	O
cells	O
in	O
the	O
+4	O
area	O
marked	O
by	O
Bmi1,	O
DCLK-1	O
(also	O
known	O
as	O
DCAMKL-1),	O
or	O
mTERT.	O

In	O
contrast,	O
the	O
self-renewal	O
and	O
differentiation	O
potential	O
of	O
human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
make	O
them	O
a	O
promising	O
alternative	O
cell	O
source	O
for	O
cell	O
replacement	O
therapy	O
for	O
PD.	O

Human	B
embryonic	I
stem	I
cells	I
(hESCs)	O
and	O
adult	O
stem	O
cell	O
sources	O
such	O
as	O
mesenchymal	O
stem	O
cells	O
have	O
been	O
shown	O
to	O
be	O
capable	O
of	O
generating	O
DA	O
neurons	O
in	O
cell	O
culture	O
models.	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
belong	O
to	O
a	O
category	O
of	O
clinically	O
relevant	O
cell	O
types	O
that	O
have	O
the	O
potential	O
to	O
be	O
utilized	O
for	O
cell-based	O
therapies,	O
because	O
complicated	O
culturing	O
or	O
handling	O
techniques	O
are	O
not	O
required	O
to	O
yield	O
clinically	O
practical	O
quantities.	O

Importantly,	O
Wwp2-mediated	O
Oct4	O
repression	O
could	O
impede	O
stemness	O
re-establishment	O
since	O
both	O
Wwp2	O
knockout	O
and	O
mutation	O
in	O
the	O
Oct4	O
ubiquitination	O
site	O
increase	O
the	O
efficiency	O
of	O
somatic	O
cell	O
reprogramming	O
into	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
[74].	O

Neural-like	O
cell	O
lines	O
developed	O
to	O
study	O
ASD	O
have	O
been	O
obtained	O
by	O
the	O
differentiation	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
from	O
patients	O
or	O
by	O
the	O
inactivation	O
of	O
the	O
selected	O
ASD-associated	O
gene	O
in	O
controls,	O
using	O
genomic	O
editing	O
systems..	O

We	O
also	O
discuss	O
the	O
breast's	B
stem	I
cell	I
populations	O
and	O
their	O
relevance	O
to	O
cancer	O
stem	O
cells	O
(CSCs)	O
and	O
cancer	O
development.	O

ECM	O
proteins	O
in	O
the	O
BM	O
connect	O
the	O
basal	B
stem	I
cells	I
through	O
various	O
anchoring	O
complexes,	O
which	O
coordinate	O
the	O
actin	O
and	O
microtubule	O
network	O
and	O
establish	O
cell	O
polarity,	O
so	O
that	O
the	O
basal	O
stem	O
cells	O
(EpSCs)	O
differentiate	O
and	O
proliferate	O
[2].	O

The	O
number	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
(hiPSC)	O
lines	O
established	O
from	O
each	O
sample	O
is	O
also	O
shown.	O

Establishment	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
line	O
from	O
a	O
75-year	O
old	O
patient	O
with	O
late	O
onset	O
Alzheimer’s	O
disease	O
(LOAD)	O
Stem	O
Cell	O
Res.	O

(7)	O
Melatonin	O
rescues	O
the	O
inhibitory	O
effects	O
of	O
miR‐363	O
on	O
neural	B
stem	I
cell	I
(NSC)	O
proliferation	O
and	O
neuronal	O
differentiation	O
in	O
vitamin	O
A	O
deficiency-	O
(VAD-)	O
associated	O
congenital	O
spinal	O
deformities.	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
have	O
generated	O
a	O
great	O
deal	O
of	O
interest	O
and	O
promise	O
as	O
a	O
potential	O
source	O
of	O
cells	O
for	O
cell-based	O
therapeutic	O
strategies	O
for	O
tissue	O
repair	O
and	O
regenerative	O
diseases,	O
primarily	O
owing	O
to	O
their	O
intrinsic	O
ability	O
to	O
self	O
renew	O
and	O
differentiate	O
into	O
functional	O
cell	O
types	O
that	O
constitute	O
the	O
tissue	O
in	O
which	O
they	O
exist.	O

Unexpected	O
evidence	O
that	O
chronic	O
IGF-1	O
deficiency	O
in	O
Laron	O
dwarf	O
mice	O
maintains	O
high	O
levels	O
of	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
in	O
BM	O
-	O
are	O
HSCs	O
gradually	O
depleted	O
from	O
BM	O
with	O
age	O
in	O
an	O
IGF-1-dependent	O
manner?	O
Implications	O
for	O
the	O
novel	O
effect	O
of	O
caloric	O
restriction	O
on	O
the	O
hematopoietic	O
stem	O
cell	O
compartment	O
and	O
longevity.	O

GDNF	O
deletion	O
in	O
TPCs	O
disrupts	O
spermatogonia	O
development,	O
indicating	O
an	O
essential	O
role	O
of	O
TPCs	O
in	O
maintaining	O
the	O
spermatogonial	B
stem	I
cell	I
(SSC)	O
niche	O
[14].	O

We	O
have	O
previously	O
described	O
the	O
generation	O
and	O
characterization	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
from	O
fibroblasts	O
of	O
NS	O
patients,	O
who	O
did	O
(NS/JMML)	O
and	O
did	O
not	O
(NS)	O
go	O
on	O
to	O
develop	O
JMML,	O
which	O
faithfully	O
model	O
leukemia	O
progression	O
after	O
differentiation	O
into	O
myeloid	O
cells.23	O
Derivation	O
of	O
iPSCs	O
from	O
noncancerous	O
cells	O
allows	O
the	O
investigation	O
of	O
these	O
PTPN11	O
mutations	O
in	O
the	O
absence	O
of	O
secondary	O
or	O
additional	O
genomic	O
alterations	O
that	O
frequently	O
occur	O
during	O
leukemia	O
progression.24	O
This	O
overcomes	O
the	O
issue	O
of	O
the	O
limited	O
availability	O
of	O
primary	O
cell	O
material	O
for	O
studies	O
of	O
this	O
disease..	O

The	O
use	O
of	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
for	O
tissue	O
engineering	O
and	O
regenerative	O
medicine	O
applications	O
is	O
attractive,	O
in	O
part	O
due	O
to	O
their	O
ability	O
to	O
differentiate	O
into	O
multiple	O
cell	O
types	O
and	O
their	O
ease	O
of	O
expansion	O
in	O
vitro.	O

GSEA	O
analysis	O
of	O
8227	O
AML	O
fractions	O
and	O
the	O
leukemia	B
stem	I
cell	I
(LSC)	O
signatures	O
were	O
performed	O
using	O
the	O
control	O
sample	O
data	O
from	O
GSE55814.	O

The	O
types	B
of	I
stem	I
cell	I
utilized	O
include	O
amnion	O
epithelial	O
cells	O
(AECs),	O
MSCs	O
and	O
induced	O
pluripotent	O
stem	O
cells	O
(iPSCs)	O
(Möbius	O
and	O
Thébaud,	O
2015).	O

The	O
risk	O
of	O
tumorigenicity	O
in	B
the	I
stem	I
cell	I
platform	O
has	O
been	O
highlighted	O
in	O
many	O
studies,	O
including	O
preclinical	O
dose-escalation	O
tests	O
for	O
the	O
first-in-human	O
induced	O
pluripotent	O
stem	O
cells	O
(iPSC)	O
clinical	O
trial	O
to	O
be	O
approved	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
in	O
2009.	O

We	O
performed	O
RT-qPCR	O
in	O
MG-63	O
cells	O
seeded	O
in	O
the	O
3D	O
scaffold,	O
treated	O
for	O
72	O
h	O
with	O
non-lethal	O
doses	O
of	O
PAR	O
30,	O
60	O
and	O
120	O
s	O
to	O
analyze	O
the	O
expression	O
of	O
genes	O
with	O
well-known	O
functions	O
of	O
cancer	B
stem	I
cell	I
(CLSC)	O
phenotype.	O

Nanomedicine	O
has	O
a	O
leading	O
role	O
in	O
pharmaceutical	O
research	O
and	O
development	O
of	O
clinical	O
protocols,	O
mainly	O
in	O
the	O
form	O
of	O
nanoparticle-based	O
delivery	O
systems	O
for	O
drugs	O
and	O
imaging	O
agents,	O
especially	O
in	O
the	O
field	O
of	O
stem	B
cell	I
(SC)	O
therapies	O
[1].	O

Via	O
transposon-mediated	O
overexpression	O
of	O
six	O
reprogramming	O
factors,	O
we	O
generated	O
five	O
baboon	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
lines.	O

Regarding	O
therapeutic	O
application,	O
iPSCs	O
overcame	O
the	O
practical	O
and	O
ethical	O
difficulties	O
associated	O
with	O
the	O
use	O
of	O
embryonic	B
stem	I
cells	I
(ESCs)	O
for	O
cell	O
replacement	O
therapies	O
(CRTs)	O
(Takahashi	O
et	O
al.,	O
2007).	O

Takahashi	O
and	O
Yamanaka’s	O
pioneering	O
studies	O
in	O
the	O
2000s	O
[13]	O
led	O
to	O
rapid	O
expansion	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technologies,	O
and	O
opened	O
unprecedented	O
opportunities	O
for	O
disease	O
modeling.	O

Bone	B
marrow	I
mesenchymal	I
stem	I
cells	I
(BMMSCs)	O
are	O
a	O
cell	O
population	O
characterized	O
by	O
rapid	O
proliferation,	O
low	O
immunogenicity,	O
pluripotency,	O
tissue	O
repair	O
ability,	O
and	O
immunosuppression13,14.	O

The	O
advent	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
(Takahashi	O
&	O
Yamanaka,	O
2006)	O
has	O
made	O
it	O
possible	O
to	O
reprogram	O
human	O
somatic	O
cells	O
to	O
pluripotency	O
(Park	O
et	O
al,	O
2008b;	O
Takahashi	O
et	O
al,	O
2007;	O
Yu	O
et	O
al,	O
2007),	O
thus	O
enabling	O
the	O
generation	O
of	O
disease-specific	O
iPSC	O
(Lee	O
&	O
Studer,	O
2010).	O

In	O
the	O
following	O
sections,	O
we	O
will	O
focus	O
mostly	O
on	O
the	O
biological	O
actions	O
of	O
TGFβ	O
but	O
also	O
make	O
reference	O
to	O
signalling	O
and	O
mechanistic	O
details	O
wherever	O
possible,	O
pointing	O
out	O
how	O
TGFβ	O
can	O
contribute	O
to	O
the	O
biology	O
of	O
cancer	B
stem	I
cells	I
(CSCs)	O
and	O
various	O
stromal	O
cell	O
types	O
in	O
order	O
to	O
facilitate	O
cancer	O
metastasis.	O

Chromatin	O
signatures	O
obtained	O
by	O
epigenomic	O
profiling	O
of	O
a	O
cohort	O
of	O
human	B
embryonic	I
stem	I
cell	I
(hESC)	O
lines	O
can	O
be	O
used	O
to	O
generate	O
hESC	O
reference	O
epigenomes	O
(left	O
panels).	O

We	O
have	O
witnessed	O
remarkable	O
developments	O
in	O
pluripotent	B
stem	I
cell	I
(PSC)	O
technologies	O
over	O
the	O
past	O
few	O
decades.	O

Generation	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
line	O
from	O
a	O
patient	O
with	O
triple	O
negative	O
breast	O
cancer	O
with	O
hereditary	O
exon	O
17	O
deletion	O
of	O
BRCA1	O
gene.	O

The	O
generation	O
of	O
human	B
embryonic	I
stem	I
cell	I
(hESC)	O
lines	O
(Shamblott	O
et	O
al.	O

The	O
advent	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
(Takahashi	O
et	O
al.	O

To	O
seek	O
replication	O
for	O
the	O
predicted	O
therapeutic	O
effect	O
of	O
VPA	O
on	O
M30	O
gene	O
expression,	O
and	O
to	O
assess	O
the	O
relevance	O
of	O
gene	O
expression	O
changes	O
observed	O
in	O
the	O
cancer	O
cell	O
lines	O
used	O
by	O
CMap	O
to	O
neurons,	O
we	O
analysed	O
gene	O
expression	O
changes	O
in	O
16	O
day	O
neurons	O
differentiated	O
from	O
mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
before	O
and	O
after	O
treatment	O
with	O
VPA	O
(here	O
studying	O
VPA	O
as	O
its	O
sodium	O
salt	O
which	O
is	O
therapeutically	O
equivalent	O
to	O
VPA)	O
(see	O
‘Methods’).	O

However,	O
cell	O
expansion	O
in	O
culture	O
can	O
lead	O
to	O
unwanted	O
cellular	O
differentiation,	O
particularly	O
in	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
13.	O

A	O
subpopulation	O
of	O
tumour	O
cells,	O
identified	O
by	O
co-expression	O
of	O
epithelial	O
cell	O
adhesion	O
molecule	O
(EPCAM),	O
the	O
basal	O
cell	O
marker	O
NGFR,	O
and	O
the	O
bronchioalveolar	B
stem	I
cell	I
(BASC)	O
marker	O
stem	O
cell	O
antigen-1	O
(SCA1,	O
also	O
known	O
as	O
LY6A),	O
was	O
found	O
to	O
have	O
the	O
ability	O
to	O
propagate	O
the	O
tumour	O
upon	O
implantation	O
into	O
immunocompromised	O
mice73.	O

Indeed,	O
the	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
pioneered	O
by	O
Shinya	O
Yamanaka	O
in	O
2006	O
has	O
potential	O
for	O
unlimited	O
expansion	O
and	O
can	O
generate	O
the	O
cells	O
of	O
all	O
three	O
germ	O
layers27.	O

Induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
generation	O
by	O
Sendai	O
virus-mediated	O
gene	O
transfer.	O

miR-1306-3p	O
Neurons	O
generated	O
from	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
derived	O
from	O
6	O
control	O
subjects	O
and	O
6	O
schizophrenia	O
subjects.	O

Neurons	O
produced	O
from	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
derived	O
from	O
controls	O
and	O
SCZ.	O

Neurons	O
generated	O
from	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
derived	O
from	O
controls	O
and	O
SCZ.	O

The	O
use	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
therapy	O
to	O
treat	O
clinical	O
disease	O
may	O
be	O
optimized	O
through	O
selection	O
and	O
pre‐conditioning	O
methods	O
that	O
would	O
enhance	O
their	O
immunomodulatory	O
functions.	O

Mesenchymal	B
stem	I
cell	I
(MSC)	O
therapy	O
may	O
reduce	O
intra‐renal	O
inflammation	O
and	O
fibrosis	O
following	O
systemic	O
delivery	O
and	O
has	O
demonstrated	O
modest	O
effects	O
in	O
feline	O
CKD	O
following	O
intravenous	O
delivery.	O

Accumulating	O
evidence	O
indicates	O
that	O
understanding	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
behaviors	O
holds	O
great	O
promise	O
for	O
the	O
treatment	O
of	O
human	O
cancers.	O

Induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
specifically	O
bypass	O
the	O
need	O
for	O
embryonic	O
tissue	O
as	O
they	O
can	O
be	O
generated	O
by	O
reprogramming	O
any	O
somatic	O
cell	O
42,	O
43.	O

Human	B
mesenchymal	I
stem	I
cell	I
(hMSCs)	O
(Lonza,	O
Walkersville,	O
MD,	O
USA)	O
were	O
cultured	O
in	O
Minimum	O
Essential	O
Medium	O
(Gibco,	O
Invitrogen,	O
USA),	O
containing	O
10%	O
FBS	O
(Gibco,	O
Invitrogen,	O
USA)	O
and	O
100	O
U/ml	O
penicillin,	O
100	O
mg/ml	O
streptomycin	O
sulfate	O
(Gibco,	O
Grand	O
Island,	O
NY,	O
USA).	O

(B)	O
Generation	O
of	O
embryonic	B
stem	I
cells	I
(ESCs)	O
by	O
selection	O
of	O
inner	O
cell	O
mass	O
from	O
a	O
blastocyst,	O
culture,	O
and	O
then	O
reprogramming/genome	O
editing.90,93.	O

Some	O
of	O
the	O
regulatory	O
roles	O
played	O
by	O
linc-ROR	O
are	O
the	O
maintenance	O
of	B
stem	I
cell	I
pluripotency,	O
triggering	O
the	O
epithelial-mesenchymal	O
transition	O
(EMT)	O
[105],	O
hypoxia,	O
in	O
the	O
proliferation	O
of	O
cancerous	O
cells	O
acting	O
both	O
as	O
promotor/inhibitor	O
and	O
in	O
self-renewal	O
of	O
glioma	O
stem	O
cells	O
(GSCs)	O
via	O
inhibition	O
of	O
KLF4	O
expression.	O

(a,b)	O
Normalized	O
gene	O
expression	O
levels	O
of	O
CSPG4,	O
in	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
and	O
OSA	O
biopsies	O
as	O
compared	O
with	O
normal	O
osteoblasts	O
in	O
toto	O
(mean	O
±	O
SD)	O
(a)	O
or	O
divided	O
according	O
to	O
the	O
Huvos	O
system	O
grading	O
(geometric	O
mean)	O
(b).	O

There	O
is	O
concern	O
that	O
the	O
stresses	O
of	O
inducing	O
pluripotency	O
may	O
lead	O
to	O
deleterious	O
DNA	O
mutations	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
lines,	O
which	O
would	O
compromise	O
their	O
use	O
for	O
cell	O
therapies.	O

Immunohistochemistry	O
and	O
flow	O
cytometry	O
analysis	O
of	O
12	O
tumor	O
samples	O
obtained	O
from	O
patients	O
with	O
high	O
grade	O
gliomas	O
revealed	O
that	O
a	O
considerable	O
population	O
(2–19%)	O
of	O
cells	O
in	O
all	O
malignant	O
gliomas	O
expressed	O
IL-17RA,	O
with	O
remarkable	O
co-expression	O
of	O
the	O
glioma	B
stem	I
cell	I
(GSC)	O
markers	O
CD133,	O
Nestin,	O
and	O
Sox2.	O

The	O
more	O
severely	O
affected	O
twin	O
(designated	O
as	O
the	O
affected	O
proband,	O
AP,	O
and	O
from	O
whom	O
the	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
model	O
of	O
severe	O
ASD	O
affectation	O
was	O
acquired)	O
began	O
to	O
exhibit	O
delays	O
in	O
development	O
by	O
9	O
months	O
of	O
age.	O

Melanocyte	B
stem	I
cells	I
(McSCs)	O
and	O
mouse	O
models	O
of	O
hair	O
graying	O
serve	O
as	O
useful	O
systems	O
to	O
uncover	O
mechanisms	O
involved	O
in	O
stem	O
cell	O
self-renewal	O
and	O
the	O
maintenance	O
of	O
regenerating	O
tissues.	O

Human	B
mesenchymal	I
stem	I
cell	I
(hMSC)	O
markers	O
were	O
observed	O
on	O
CD105+	O
isolated	O
cells.	O

Single	O
cell	O
sequencing	O
of	O
neural	B
stem	I
cells	I
(NSCs)	O
demonstrated	O
that	O
in	O
response	O
to	O
injury,	O
there	O
is	O
a	O
dramatic	O
increase	O
in	O
transcription	O
of	O
the	O
genes	O
involved	O
in	O
ribosome	O
biogenesis	O
(Llorens-Bobadilla	O
et	O
al.,	O
2015).	O

A	O
balance	O
between	O
quiescence	O
and	O
proliferation	O
is	O
critical	O
for	O
proper	O
maintenance	O
of	O
the	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
pool.	O

Generation	O
and	O
characterization	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
(hiPSC)	O
lines	O
from	O
an	O
Alzheimer's	O
disease	O
(ASUi003-A)	O
and	O
non-demented	O
control	O
(ASUi004-A)	O
patient	O
homozygous	O
for	O
the	O
Apolipoprotein	O
e4	O
(APOE4)	O
risk	O
variant.	O

Generation	O
and	O
characterization	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
(hiPSC)	O
lines	O
from	O
an	O
Alzheimer's	O
disease	O
(ASUi001-A)	O
and	O
non-demented	O
control	O
(ASUi002-A)	O
patient	O
homozygous	O
for	O
the	O
Apolipoprotein	O
e4	O
(APOE4)	O
risk	O
variant.	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
are	O
pluripotent	O
cells	O
located	O
in	O
the	O
inner	O
cell	O
mass	O
of	O
early	O
embryos	O
that	O
have	O
the	O
capacity	O
for	O
long-term	O
self-renewal	O
and	O
the	O
ability	O
to	O
form	O
all	O
cell	O
types	O
of	O
the	O
embryo	O
proper.	O

Induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
Patient-specific	O
genotype	O
Cells	O
can	O
be	O
differentiated	O
to	O
better	O
reflect	O
photoreceptor	O
cell	O
morphology	O
and	O
gene	O
expression	O
profiles.	O

(C):	O
Immnoblotting	O
analysis	O
was	O
used	O
to	O
examine	O
the	O
activation	O
of	O
Hedgehog	O
signaling	O
and	O
expression	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
markers	O
in	O
the	O
cells	O
described	O
in	O
(B).	O

Human	B
pluripotent	I
stem	I
cell	I
(hPSC)	O
technology	O
has	O
the	O
potential	O
to	O
overcome	O
those	O
challenges	O
and	O
to	O
present	O
a	O
fully	O
human,	O
defined	O
and	O
scalable	O
platform	O
to	O
study	O
neuroinflammation.	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
have	O
been	O
broadly	O
used	O
in	O
cell	O
therapies	O
based	O
on	O
various	O
preclinical	O
and	O
clinical	O
studies	O
regarding	O
their	O
safety	O
and	O
efficacy	O
(Kamen	O
et	O
al.,	O
2018;	O
Wilson	O
et	O
al.,	O
2015).	O

Several	O
cell	O
types,	O
such	O
as	O
T	O
cells,	O
HSCs,	O
and	O
fibroblasts,	O
can	O
be	O
reprogramed	O
into	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
by	O
transducing	O
these	O
cells	O
with	O
a	O
SIN-lentiviral	O
vector	O
expressing	O
three	O
pluripotency	O
genes,	O
OCT4,	O
SOX2,	O
and	O
KLF4	O
(88–90).	O

In	O
light	O
of	O
the	O
latest	O
advances	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology,	O
future	O
epigenomic	O
brain	O
approaches	O
will	O
involve	O
the	O
study	O
of	O
specific	O
neuronal	O
populations	O
derived	O
from	O
patient-cells,	O
allowing	O
a	O
better	O
understanding	O
of	O
the	O
disorder	O
by	O
disease	O
modelling	O
and	O
a	O
faster	O
drug	O
screening/repurposing	O
in	O
a	O
personalized	O
manner	O
[200]..	O

Human	B
mesenchymal	I
stem	I
cells	I
(hMSCs)	O
possess	O
the	O
potential	O
to	O
differentiate	O
into	O
numerous	O
cell	O
lineages,	O
such	O
as	O
adipocytes,	O
osteoblasts,	O
fibroblasts	O
and	O
chondrocytes.	O

This	O
leads	O
enhanced	O
Igf2	O
expression	O
and	O
Igfr1	O
translation,	O
playing	O
a	O
significant	O
role	O
in	O
the	O
increased	O
activation	O
and	O
proliferation	O
of	O
hematopoietic	B
stem	I
cell	I
(HSCs)	O
[61]..	O

These	O
mechanisms	O
may	O
not	O
be	O
limited	O
to	O
interactions	O
between	O
tumor	O
cells	O
and	O
fibroblasts,	O
but	O
also	O
have	O
been	O
noted	O
in	O
a	O
two-way	O
regulation	O
in	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
differentiation	O
to	O
CAFs	O
by	O
factors	O
from	O
mammary	O
cancer	O
cells	O
and	O
CAFs	O
in	O
turn	O
promoting	O
cancer	O
development.	O

Supporting	O
the	O
leukemia	O
evidence	O
for	O
a	O
critical	O
role	O
of	O
MLL1	O
in	O
hematopoiesis,	O
mouse	O
knockout	O
studies	O
showed	O
that	O
Mll1	O
is	O
required	O
for	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
function	O
(Ernst	O
et	O
al.,	O
2004;	O
Jude	O
et	O
al.,	O
2007).	O

Menin-null	O
(Men1-KO)	O
mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
can	O
undergo	O
in	O
vitro	O
differentiation	O
into	O
adipocytes	O
and	O
show	O
increased	O
adipocyte	O
cell	O
size.	O

Cancer	B
stem	I
cells	I
(CSCs)	O
are	O
a	O
small	O
subpopulation	O
of	O
cancer	O
cells	O
with	O
increased	O
renewal	O
capacity	O
that	O
play	O
roles	O
in	O
tumor	O
growth,	O
cell	O
and	O
molecular	O
heterogeneity,	O
differentiation,	O
and	O
metastasis	O
[255,256].	O

However,	O
the	O
role	O
of	O
circRNAs	O
in	O
neural	B
stem	I
cell	I
(NSC)	O
differentiation	O
and	O
the	O
treatment	O
of	O
ischaemic	O
stroke	O
remains	O
unknown..	O

The	O
classical	O
approach	O
to	O
developing	O
a	O
protocol	O
for	O
the	O
human	O
mDA	O
neuronal	O
differentiation	O
from	O
hPSCs	O
was	O
based	O
on	O
adaptations	O
of	O
mouse	B
neural	I
stem	I
cell	I
(mNSC)	O
and	O
mESC	O
protocols,	O
which	O
required	O
co-culture	O
with	O
feeder	O
cells	O
(37).	O

Induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
are	O
somatic	O
cells	O
that	O
have	O
been	O
transcriptionally	O
reprogrammed	O
to	O
an	O
embryonic	O
stem	O
cell	O
(ESC)-like	O
state.	O

Induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
are	O
somatic	O
cells	O
that	O
have	O
been	O
transcriptionally	O
reprogrammed	O
to	O
an	O
embryonic	O
stem	O
cell	O
(ESC)-like	O
state.	O

Hematopoietic	B
stem	I
cells	I
(HSCs)	O
differentiate	O
into	O
common	O
lymphoid	O
progenitors	O
(CLPs),	O
and	O
then	O
differentiate	O
into	O
NK	O
cell	O
progenitors	O
(NKPs).	O

Moreover,	O
the	O
Lange	O
laboratory	O
demonstrated	O
that	O
PR-A	O
was	O
a	O
driver	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
expansion	O
in	O
BCa	O
cells	O
and	O
that	O
phosphorylation	O
of	O
PR-A	O
was	O
required	O
for	O
the	O
expression	O
of	O
CSC-associated	O
genes	O
(Truong	O
et	O
al.	O

We	O
then	O
performed	O
transcriptome	O
analysis	O
of	O
hematopoieitic	B
stem	I
cell	I
(HSC)	O
and	O
myeloid	O
progenitor	O
cell-enriched	O
populations	O
from	O
the	O
bone	O
marrow	O
of	O
Ts(1716)65Dn	O
mice	O
to	O
define	O
the	O
relevant	O
biological	O
and	O
genetic	O
changes	O
by	O
which	O
trisomy	O
predisposes	O
to	O
development	O
of	O
myeloproliferation	O
in	O
this	O
DS	O
model	O
[20].	O

In	O
this	O
review,	O
we	O
will	O
use	O
the	O
word	O
“reprogramming”	O
specifically	O
in	O
reference	O
to	O
the	O
formation	O
of	O
pluripotent	B
stem	I
cells	I
(PSCs)	O
from	O
differentiated	O
cell	O
states,	O
especially	O
focusing	O
on	O
the	O
iPSC	O
technology.	O

All	O
myeloid	O
and	O
lymphoid	O
blood	O
lineages	O
are	O
differentiated	O
from	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
(Chao	O
et	O
al.,	O
2008),	O
during	O
which	O
the	O
activity	O
of	O
genes	O
(e.g.,	O
KCNH2,	O
SUSD3)	O
that	O
control	O
cell	O
fate	O
is	O
highly	O
regulated	O
by	O
methylation	O
status	O
(Farlik	O
et	O
al.,	O
2016).	O

Over	O
the	O
past	O
decade,	O
the	O
development	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
has	O
provided	O
a	O
novel	O
means	O
to	O
generate	O
disease-relevant	O
cells	O
for	O
in	O
vitro	O
investigation	O
of	O
the	O
molecular	O
and	O
cellular	O
mechanisms	O
underpinning	O
human	O
complex	O
disorders	O
[1,2].	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
cultured	O
in	O
spheroids	O
have	O
enhanced	O
anti-inflammatory,	O
angiogenic,	O
and	O
tissue	O
reparative/regenerative	O
effects	O
with	O
improved	O
cell	O
survival	O
after	O
transplantation.	O

It	O
causes	O
drastic	O
changes	O
in	O
gene	O
expression	O
profiles,	O
as	O
best	O
exemplified	O
in	O
the	O
fertilization	O
process	O
and	O
the	O
somatic	O
cell	O
reprogramming	O
process	O
during	O
the	O
development	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
[137].	O

Neural	B
stem	I
cells	I
(NSCs)	O
generate	O
all	O
major	O
neural	O
cell	O
types	O
in	O
the	O
central	O
nervous	O
system	O
(CNS),	O
including	O
neurons,	O
astrocytes,	O
and	O
oligodendrocytes	O
[1–3].	O

Cancer	B
stem	I
cells	I
(CSCs)	O
displaying	O
a	O
CD44+	O
(high)/CD24-(low)	O
cell	O
surface	O
antigen	O
expression	O
profile	O
may	O
act	O
as	O
tumor-initiating	O
cells	O
[120]	O
and	O
contribute	O
to	O
intra-tumoral	O
heterogeneity	O
[29,79].	O

Human	O
RPE	O
cells	O
have	O
been	O
generated	O
from	O
embryonic	B
stem	I
cells	I
(ESCs)	O
and	O
iPS	O
cells	O
offering	O
new	O
promise	O
for	O
cell	O
replacement	O
therapy	O
in	O
AMD	O
[13,15,18,70].	O

However,	O
the	O
most	O
compelling	O
evidence	O
that	O
SMCs	O
and	O
Mϕs	O
are	O
being	O
misidentified	O
within	O
human	O
advanced	O
coronary	O
lesions	O
comes	O
from	O
studies	O
of	O
cross	O
gender	O
bone	O
marrow	O
transplant	O
subjects	O
showing	O
that	O
>	O
10%	O
of	O
ACTA2+	O
cells	O
within	O
lesions	O
are	O
of	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
and	O
not	O
SMC	O
origin14.	O

Human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
have	O
the	O
capacity	O
to	O
differentiate	O
into	O
the	O
three	O
somatic	O
germ	O
layers	O
and	O
all	O
cell	O
types	O
of	O
the	O
body,	O
and	O
are	O
an	O
alternative	O
and	O
renewable	O
source	O
of	O
hepatocytes	O
that	O
could	O
be	O
used	O
for	O
drug	O
toxicity	O
and	O
metabolization	O
studies.	O

Transcriptome-wide	O
identification	O
of	O
CTCF-binding	O
RNA	O
sites	O
was	O
performed	O
in	O
two	O
previous	O
studies:	O
one	O
for	O
human	O
bone	O
osteosarcoma	O
epithelial	O
cells	O
(U2OS	O
cells)	O
with	O
two	O
biological	O
replicates	O
using	O
photoactivatable	O
ribonucleoside-enhanced	O
cross-linking	O
and	O
immunoprecipitation	O
followed	O
by	O
deep	O
sequencing	O
(14),	O
and	O
the	O
other	O
for	O
mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
with	O
two	O
biological	O
replicates	O
on	O
Days	O
0	O
and	O
3	O
of	O
cell	O
differentiation	O
by	O
CLIP-seq	O
(13).	O

Brain-specific	O
ablation	O
of	O
FoxO3a	O
or	O
combined	O
inactivation	O
of	O
FoxO1a/3a/4	O
in	O
mice	O
resulted	O
in	O
a	O
phenotype	O
that	O
resembled	O
age-dependent	O
depletion	O
of	O
the	O
neural	B
stem	I
cell	I
(NSC)	O
population	O
[290,291].	O

The	O
functional	O
potential	O
of	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
declines	O
during	O
aging,	O
and	O
it	O
contributes	O
to	O
hematopoietic	O
pathophysiology	O
in	O
the	O
elderly	O
and	O
loss	O
of	O
the	O
hematopoietic	O
cell	O
pool	O
[156,	O
157].	O

Dental	B
pulp	I
stem	I
cells	I
(DPSCs)	O
have	O
the	O
capacity	O
to	O
differentiate	O
under	O
appropriate	O
conditions	O
into	O
different	O
somatic	O
cell	O
types	O
of	O
the	O
three	O
germ	O
layers:	O
endoderm,	O
mesoderm,	O
and	O
ectoderm..	O

Dek	O
expression	O
positively	O
correlates	O
with	O
breast	B
cancer	I
stem	I
cell	I
(BCSC)	O
phenotypes.	O

Hematopoietic	B
stem	I
cells	I
(HSCs)	O
have	O
the	O
ability	O
to	O
self-renew	O
and	O
produce	O
identical,	O
multipotent	O
daughter	O
HSCs	O
or	O
undergo	O
differentiation	O
to	O
form	O
any	O
and	O
every	O
cell	O
type	O
in	O
the	O
blood	O
system.	O

Indeed,	O
it	O
was	O
confirmed	O
that	O
SV2	O
levels	O
are	O
reduced	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
lines	O
of	O
C9ORF72	O
ALS	O
patients	O
and	O
in	O
the	O
spinal	O
cord	O
and	O
neuromuscular	O
junctions	O
of	O
poly-GA–overexpressing	O
transgenic	O
mice.	O

But	O
now	O
this	O
obstacle	O
can	O
be	O
easily	O
overcome	O
with	O
the	O
usage	O
to	O
the	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSCs)	O
technology,	O
which	O
allows	O
to	O
unveil	O
the	O
mechanisms	O
underlying	O
nucleoskeletal	O
organization	O
and	O
modulation	O
before	O
and	O
after	O
differentiation..	O

Introduction:	O
MSC	O
exosome	O
is	O
increasingly	O
accepted	O
as	O
the	O
principal	O
agent	O
that	O
underpins	O
the	O
therapeutic	O
efficacy	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
in	O
tissue	O
repair.	O

Mesenchymal	B
stem	I
cell	I
(MSC)	O
is	O
a	O
heterogeneous	O
multipotent	O
stem	O
cell	O
found	O
within	O
the	O
tumour	O
microenvironment	O
and	O
can	O
regulating	O
the	O
immune	O
system.	O

In	O
this	O
study,	O
we	O
characterize	O
the	O
microRNA,	O
tRNA,	O
and	O
piRNA	O
composition	O
of	O
EVs	O
secreted	O
from	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
(hiPSCs)	O
–	O
derived	O
3D	O
retinas	O
at	O
three	O
developmental	O
time	O
points	O
that	O
correlate	O
with	O
hallmarks	O
of	O
retinal	O
cell	O
differentiation	O
and	O
lamination	O
in	O
vivo..	O

The	O
cell	O
of	O
origin	O
for	O
OS	O
also	O
remain	O
unknown	O
but	O
cells	O
of	O
the	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
osteogenic	O
lineage	O
are	O
likely	O
candidates,	O
thus	O
indicating	O
that	O
MSCs	O
and	O
the	O
OS	O
stroma	O
cells	O
may	O
be	O
related	O
cell	O
types.	O

Cell	O
therapy	O
based	O
on	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
is	O
one	O
of	O
the	O
attractive	O
options.	O

Adipose-derived	B
stem	I
cells	I
(ASCs)	O
have	O
been	O
reported	O
as	O
an	O
important	O
component	O
of	O
regenerative	O
medicine	O
and	O
cell	O
therapy	O
for	O
hair	O
loss.	O

Introduction:	O
Immunoregulatory	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
is	O
attributed	O
to	O
extracellular	O
vesicles	O
(EVs)	O
secretion.	O

The	O
year	O
2006	O
will	O
be	O
remembered	O
monumentally	O
in	O
science,	O
particularly	O
in	B
the	I
stem	I
cell	I
biology	O
field,	O
for	O
the	O
first	O
instance	O
of	O
generation	O
of	O
induced	O
pluripotent	O
stem	O
cells	O
(iPSCs)	O
from	O
mouse	O
embryonic/adult	O
fibroblasts	O
being	O
reported	O
by	O
Takahashi	O
and	O
Yamanaka.	O

Reprogramming	O
differentiated	O
somatic	O
cells	O
to	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
enables	O
re-differentiation	O
to	O
a	O
wide	O
array	O
of	O
cell	O
types	O
(Yamanaka,	O
2012)	O
and	O
is	O
of	O
considerable	O
value	O
for	O
disease	O
modeling,	O
functional	O
genomics,	O
drug	O
discovery,	O
and	O
regenerative	O
medicine.	O

In	O
the	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
-derived	O
neural	O
cell	O
lines,	O
imbalances	O
were	O
reflected	O
in	O
an	O
attenuated	O
capacity	O
of	O
cells	O
to	O
suppress	O
accumulation	O
of	O
unfolded	O
proteins	O
upon	O
interference	O
of	O
proteostasis	O
with	O
thapsigargin.	O

Directed	O
differentiation	O
of	O
human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
combined	O
with	O
gene	O
editing	O
provides	O
a	O
powerful	O
system	O
to	O
define	O
precise	O
temporal	O
gene	O
requirements	O
for	O
progressive	O
chromatin	O
changes	O
during	O
cell	O
fate	O
transitions.	O

The	O
genomic	O
regions	O
co-bound	O
by	O
the	O
embryonic	B
stem	I
cell	I
(ESC)	O
pluripotency	O
TFs	O
Oct4,	O
Sox2,	O
and	O
Nanog	O
(OSN)	O
have	O
shown	O
robust	O
enhancer	O
activity16.	O

In	O
contrast	O
to	O
the	O
difficulty	O
of	O
obtaining	O
neuronal	O
and	O
muscle	O
cell	O
models,	O
the	O
development	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
has	O
shed	O
light	O
on	O
the	O
study	O
of	O
mitochondrial	O
diseases.	O

For	O
biomarker	O
discovery,	O
plasma	O
represents	O
the	O
best	O
source	O
for	O
repeated	O
measures	O
while	O
the	O
utilization	O
of	O
skin	O
fibroblasts	O
provides	O
an	O
outstanding	O
opportunities	O
for	O
longitudinal	O
mechanistic	O
studies	O
because	O
they	O
could	O
be	O
kept	O
in	O
culture	O
for	O
a	O
long	O
time,	O
do	O
not	O
need	O
to	O
be	O
transformed,	O
and	O
could	O
be	O
differentiated	O
into	O
disease-	O
and	O
patient-specific	O
neural	O
cell	O
lines	O
using	O
inducible	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
[52].	O

Although	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
hold	O
great	O
potential	O
for	O
the	O
study	O
of	O
human	O
diseases	O
affecting	O
disparate	O
cell	O
types,	O
they	O
have	O
been	O
underutilized	O
in	O
seeking	O
mechanistic	O
insights	O
into	O
the	O
pathogenesis	O
of	O
congenital	O
craniofacial	O
disorders.	O

The	O
emergence	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
as	O
a	O
tool	O
for	O
human	O
disease	O
modeling	O
(Takahashi	O
et	O
al.,	O
2007,	O
Takahashi	O
and	O
Yamanaka,	O
2006,	O
Tiscornia	O
et	O
al.,	O
2011,	O
Yu	O
et	O
al.,	O
2007)	O
holds	O
great	O
promise	O
for	O
improving	O
our	O
cellular	O
understanding	O
of	O
craniofacial	O
diseases,	O
as	O
hiPSCs	O
can	O
be	O
differentiated	O
into	O
patient-specific,	O
disease-relevant	O
cell	O
types.	O

Liver	O
cell	O
types	O
derived	O
from	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
share	O
the	O
potential	O
to	O
investigate	O
development,	O
toxicity,	O
as	O
well	O
as	O
genetic	O
and	O
infectious	O
disease	O
in	O
ways	O
currently	O
limited	O
by	O
the	O
availability	O
of	O
primary	O
tissue.	O

A	O
different	O
and	O
novel	O
approach	O
developed	O
by	O
the	O
Takebe	O
laboratory	O
used	O
a	O
combination	O
of	O
iPSC	O
derived	O
hepatic	O
endoderm	O
and	O
immature	O
non-parenchymal	O
liver	O
cell	O
analogs	O
[mesenchymal	B
stem	I
cells	I
(MSC)	O
and	O
endothelial	O
cells],	O
to	O
mimic	O
the	O
formation	O
of	O
the	O
liver	O
bud	O
(101).	O

Hematopoietic	B
stem	I
cells	I
(HSCs)	O
generate	O
highly	O
dividing	O
hematopoietic	O
progenitor	O
cells	O
(HPCs),	O
which	O
produce	O
all	O
blood	O
cell	O
lineages.	O

This	O
ultimately	O
led	O
to	O
the	O
derivation	O
of	O
mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
(Evans	O
and	O
Kaufman,	O
1981;	O
Martin,	O
1981),	O
a	O
discovery	O
that	O
rendered	O
EC	O
cell	O
research	O
largely	O
redundant.	O

Gene	O
expression	O
of	O
FREM2	O
and	O
SPRY1	O
was	O
measured	O
in	O
the	O
mature	O
glioblastoma	O
cell	O
lines	O
U251MG	O
and	O
U87MG,	O
in	O
the	O
stem-like	O
NCH	O
cells—a	O
co-culture	O
of	O
the	O
glioblastoma	O
stem-like	O
cell	O
lines	O
NCH644	O
and	O
NCH421K	O
—as	O
well	O
as	O
in	O
neural	B
stem	I
cells	I
(NSC)	O
and	O
astrocytes.	O

Finally,	O
concentrated	O
cells	O
may	O
form	O
aggregates	O
and	O
lead	O
to	O
pulmonary	O
emboli	O
or	O
infarctions	O
following	O
administration	O
48,	O
especially	O
when	O
intravenously	O
infused,	O
as	O
demonstrated	O
in	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
transplants	O
49.	O

However,	O
the	O
role	O
of	O
IFN-I	O
is	O
a	O
double-edged	O
sword,	O
as	O
its	O
excessive	O
expression	O
can	O
elicit	O
destructive	O
inflammatory	O
responses	O
and	O
cause	O
haematopoietic	B
stem	I
cell	I
(HSC)	O
exhaustion.	O

Human	O
Pluripotent	O
Stem	O
Cell-Derived	O
Cardiac	O
Cells:	O
Application	O
in	O
Disease	O
Modeling,	O
Cell	O
Therapy,	O
and	O
Drug	O
Discovery.	O
Human	O
Pluripotent	O
Stem	O
Cell-Derived	O
Cardiac	O
Cells:	O
Application	O
in	O
Disease	O
Modeling,	O
Cell	O
Therapy,	O
and	O
Drug	O
Discovery.	O
The	O
development	O
of	O
human	B
pluripotent	I
stem	I
cell	I
(hPSC)	O
technology	O
in	O
theory	O
guarantees	O
an	O
unlimited	O
source	O
of	O
human	O
cardiac	O
cells.	O

A	O
current	O
consensus	O
asserts	O
that	O
the	O
tumor	O
invasion-associated	O
epithelial-mesenchymal	O
transition	O
(EMT)	O
intimately	O
correlates	O
with	O
cancer	B
stem	I
cell	I
(CSC)	O
phenotypes	O
[30].	O

Directed	O
differentiation	O
protocols	O
to	O
manufacture	O
specific	O
cell	O
populations	O
from	O
pluripotent	B
stem	I
cells	I
(PSCs)	O
have	O
been	O
developed	O
to	O
meet	O
the	O
need	O
for	O
a	O
homogeneous	O
human	O
cell	O
source.	O

Pro-inflammatory	O
cytokines	O
are	O
also	O
crucially	O
important	O
for	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
maintenance,	O
proliferation,	O
and	O
differentiation	O
[4].	O

For	O
example,	O
the	O
cycloaddition	O
of	O
Arg-Gly-Asp-D-Try-Lys	O
peptide	O
was	O
added	O
to	O
the	O
surface	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
derived	O
sEVs	O
[581].	O

Early	O
work	O
on	O
this	O
topic	O
was	O
inspired	O
by	O
the	O
idea	O
that	O
if	O
homing	O
receptors	O
exist	O
for	O
immune	O
cell	O
infiltration	O
into	O
the	O
periphery,	O
homologous	O
mechanisms	O
must	O
exist	O
for	O
the	O
entry	O
of	O
haematopoietic	B
stem	I
cells	I
(HSCs)	O
into	O
the	O
marrow	O
following	O
bone	O
marrow	O
transplantation.	O

The	O
emergence	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
revolutionizes	O
the	O
paradigm	O
of	O
drug	O
discovery.	O

The	O
distinctive	O
feature	O
of	O
embryonic	B
stem	I
cell	I
(ESC)	O
being	O
able	O
to	O
self‐renew,	O
coupled	O
with	O
its	O
potential	O
to	O
differentiate	O
into	O
any	O
adult	O
cell	O
type	O
in	O
the	O
body,	O
has	O
made	O
it	O
a	O
promising	O
candidate	O
for	O
use	O
in	O
tissue	O
regeneration.	O

Physiologic	O
hypoxia	O
supports	O
and	O
maintains	O
the	O
glioma	B
stem	I
cell	I
(GSC)	O
phenotype	O
and	O
has	O
a	O
vital	O
role	O
in	O
tumor	O
development,	O
invasiveness,	O
and	O
resistance	O
to	O
chemotherapy	O
and	O
radiation.	O

Advent	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
[22]	O
and	O
differentiation	O
systems	O
have	O
made	O
it	O
possible	O
to	O
examine	O
the	O
relationship	O
of	O
specific	O
mutations	O
with	O
disease	O
phenotypes.	O

Central	O
to	O
the	B
stem	I
cell	I
(CSC)	O
concept	O
is	O
the	O
observation	O
that	O
not	O
all	O
cells	O
in	O
tumours	O
are	O
equal.	O

Developed	O
over	O
a	O
decade	O
ago,	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
theory	O
posits	O
that	O
the	O
tumor	O
has	O
its	O
own	O
stem	O
cells	O
with	O
self-renewal	O
ability	O
and	O
ascribes	O
the	O
origin	O
of	O
these	O
malignant	O
cells	O
to	O
alterations	O
of	O
regulation	O
pathways	O
through	O
genetic	O
mutations	O
of	O
the	O
healthy	O
stem	O
cell	O
population	O
[34].	O

Cell	O
transplant	O
models	O
(CTMs)	O
represent	O
a	O
distinct	O
subset	O
of	O
GEMMs	O
applied	O
primarily	O
to	O
studies	O
of	O
hematologic	O
cancers,	O
such	O
as	O
myeloproliferative	O
neoplasms	O
and	O
leukemia	O
that	O
arise	O
from	O
mutations	O
arising	O
in	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
and	O
progenitor	O
cells.	O

PCa	O
cells	O
home	O
toward	O
areas	O
in	O
the	O
bone	O
marrow	O
rich	O
in	O
osteoblasts	O
where	O
the	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
niche	O
resides.	O

Consistent	O
with	O
concepts	O
borrowed	O
from	O
the	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
transplant	O
field,	O
prior	O
lymphodepleting	O
chemotherapy	O
(so-called	O
“conditioning”)	O
appears	O
to	O
also	O
have	O
important	O
effects	O
on	O
both	O
the	O
Cmax	O
and	O
maintenance	O
of	O
adoptively	O
transferred	O
T	O
cells	O
over	O
time.32,	O
33,	O
34,	O
35	O
The	O
mechanisms	O
that	O
underlie	O
the	O
effect	O
of	O
conditioning	O
on	O
T	O
cell	O
kinetics	O
are	O
not	O
fully	O
understood.	O

Cancer	B
stem	I
cells	I
(CSCs)	O
represent	O
rare	O
tumor	O
cell	O
populations	O
capable	O
of	O
self-renewal,	O
differentiation,	O
and	O
tumor	O
initiation	O
and	O
are	O
highly	O
resistant	O
to	O
chemotherapy	O
and	O
radiotherapy.	O

Background:	O
Immunoregulatory	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
is	O
attributed	O
to	O
extracellular	O
vesicles	O
(EV)	O
secretion.	O

We	O
examined	O
the	O
epigenetic	O
influence	O
of	O
OS-extracellular	O
vesicles	O
(EVs)	O
on	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
and	O
pre-osteoblast,	O
and	O
the	O
consequences	O
of	O
OS-EVs	O
treatment	O
on	O
the	O
epigenetic	O
reprograming	O
of	O
MSCs..	O

Background:	O
Immunoregulatory	O
effect	O
of	O
Mesenchymal	B
stem	I
cell	I
(MSC)	O
is	O
attributed	O
to	O
Extracellular	O
vesicles	O
(EVs)	O
secretion.	O

ECs	O
derived	O
from	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
represent	O
an	O
alternative	O
and	O
potentially	O
superior	O
cell	O
source,	O
but	O
traditional	O
culture	O
approaches	O
and	O
2D	O
differentiation	O
protocols	O
hardly	O
allow	O
for	O
production	O
of	O
large	O
cell	O
numbers.	O

Hypothetically,	O
a	O
physiological	O
connection	O
between	O
Hh	O
signaling	O
and	O
DYRK1A	O
might	O
also	O
exist	O
in	O
the	O
case	O
of	O
neural	B
stem	I
cell	I
(NSC)	O
division.	O

Intestinal	B
stem	I
cells	I
(ISCs)	O
are	O
supported	O
by	O
Paneth	O
cells	O
that	O
are	O
specialized	O
epithelial	O
cells	O
localized	O
in	O
the	O
stem	O
cell	O
niche.	O

(A)	O
Experimental	O
design	O
and	O
optimization	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSCs)	O
differentiation	O
into	O
podocytes.	O

In	O
this	O
study,	O
we	O
explored	O
the	O
potentiality	O
of	O
human	O
arginine	O
decarboxylase	O
(ADC)	O
to	O
enhance	O
the	O
survival	O
of	O
mesenchymal	B
stem	I
cells	I
(MSCs)	O
against	O
unfavorable	O
milieu	O
of	O
host	O
tissues	O
as	O
the	O
low	O
survival	O
of	O
MSCs	O
is	O
the	O
issue	O
in	O
cell	O
transplantation	O
therapy.	O

Neural	B
stem	I
cells	I
(NSCs)	O
are	O
considered	O
as	O
a	O
potential	O
source	O
for	O
oligodendrocyte	O
precursor	O
cells	O
(OPCs)	O
to	O
be	O
used	O
in	O
cell	O
based	O
remyelination	O
therapy	O
for	O
multiple	O
sclerosis	O
(MS).	O

Since	O
the	O
emergence	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology,	O
a	O
little	O
over	O
a	O
decade	O
ago,	O
iPSC	O
models	O
have	O
held	O
the	O
potential	O
to	O
bridge	O
these	O
two	O
worlds	O
–	O
primary	O
patient	O
cells	O
and	O
conventional	O
disease	O
models	O
–	O
by	O
affording	O
direct	O
relevance	O
to	O
human	O
disease,	O
being	O
patient-derived,	O
while	O
enabling	O
precise,	O
controlled	O
and	O
scalable	O
experiments	O
that	O
were	O
hitherto	O
only	O
possible	O
using	O
traditional	O
model	O
systems.	O

The	O
unrestrained	O
activation	O
of	O
the	O
p53-p21	O
axis	O
has	O
been	O
associated	O
with	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
attrition	O
that	O
characterizes	O
inherited	O
bone	O
marrow	O
failure	O
(iBMF)	O
syndromes,	O
including	O
dyskeratosis	O
congenita	O
(DC),	O
Shwachman-Diamond	O
syndrome	O
(SDS),	O
Diamond-Blackfan	O
anemia	O
(DBA),	O
and	O
Fanconi	O
anemia	O
(FA),	O
the	O
most	O
frequent	O
and	O
genetically	O
heterogeneous	O
iBMF	O
syndrome.	O

In	O
a	O
homozygous	O
knockout	O
neuronal	O
cell	O
line,	O
embryoid	O
bodies	O
(EBs)	O
derived	O
from	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
were	O
significantly	O
smaller	O
(88),	O
supporting	O
a	O
role	O
for	O
Foxg1	O
in	O
cell	O
survival.	O

PRDM14	O
functions	O
in	O
embryonic	B
stem	I
cell	I
(ESC)	O
maintenance	O
to	O
promote	O
the	O
expression	O
of	O
pluripotency-associated	O
genes	O
while	O
suppressing	O
differentiation	O
genes.	O

Models	O
utilizing	O
micromolding	O
and	O
bioprinting	O
techniques	O
have	O
been	O
used	O
to	O
fabricate	O
endothelialized	O
tissue	O
constructs	O
to	O
visualize	O
real-time	O
endothelial	O
cord	O
formation	O
during	O
tubulogenesis.40	O
Others	O
have	O
incorporated	O
a	O
layer	O
of	O
human	O
bone	O
marrow	O
stromal	O
cells	O
surrounding	O
the	O
channels	O
to	O
recapitulate	O
perivascular-mediated	O
barrier	O
function.41	O
Compared	O
with	O
earlier	O
models,	O
the	O
most	O
recent	O
systems	O
endow	O
more	O
accurate	O
control	O
of	O
growth	O
factor	O
gradients	O
and	O
fluid	O
flow,	O
making	O
them	O
ideal	O
for	O
patient-specific	O
models.42,43	O
For	O
example,	O
a	O
recent	O
microfluidic	O
angiogenic	O
model	O
promoted	O
human-induced	O
pluripotent	B
stem	I
cell	I
(hiPSC)	O
differentiation	O
into	O
endothelial	O
cells	O
which	O
assembled	O
into	O
perfusable,	O
capillary-like	O
networks,	O
and	O
capturing	O
endothelial	O
response	O
to	O
different	O
environmental	O
biochemical	O
and	O
biophysical	O
cues.43	O
Incorporation	O
of	O
patient-derived	O
hiPSCs	O
in	O
platforms	O
such	O
as	O
these	O
lays	O
the	O
foundation	O
for	O
personalized	O
characterization	O
of	O
tumor	O
angiogenesis	O
and	O
endothelial	O
cell	O
response	O
to	O
cancer	O
therapeutics.	O

Random	O
genomic	O
alterations	O
are	O
frequently	O
observed	O
in	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
during	O
cell	O
reprogramming	O
essentially	O
due	O
to	O
the	O
massive	O
genome	O
remodeling	O
and	O
it	O
is	O
therefore	O
of	O
major	O
interest	O
to	O
evaluate	O
the	O
genomic	O
status	O
of	O
the	O
cells	O
for	O
clinical	O
use	O
in	O
order	O
to	O
determine	O
that	O
they	O
are	O
free	O
from	O
cancer-associated	O
genomic	O
alterations.	O

Embryonic	B
stem	I
cells	I
(ESC)	O
have	O
been	O
used	O
for	O
decades	O
to	O
generate	O
cardiomyocytes	O
and	O
recent	O
advances	O
in	O
cell	O
culture	O
techniques	O
significantly	O
increased	O
the	O
yield	O
of	O
cardiomyocytes	O
in	O
these	O
cultures.	O

Comparison	O
between	O
the	O
cultures	O
of	O
human	B
induced	I
pluripotent	I
stem	I
cells	I
(hiPSCs)	O
on	O
feeder-and	O
serum-free	O
system	O
(Matrigel	O
matrix),	O
MEF	O
and	O
HDF	O
feeder	O
cell	O
lines.	O

The	O
use	O
of	O
pluripotent	O
or	O
multipotent	O
cells	O
for	O
the	O
restoration	O
of	O
damaged	O
neuronal	O
networks	O
is	O
one	O
of	O
the	O
factors	O
that	O
holds	O
promise	O
from	O
a	O
translational	O
medicine	O
perspective	O
and	O
a	O
relevant	O
part	O
of	O
the	O
strongest	O
forces	O
driving	O
research	O
in	O
stem	B
cell	I
(SC)	O
biology	O
applied	O
to	O
neurodegenerative	O
diseases.	O

explored	O
the	O
role	O
of	O
ROS	O
in	O
bone	O
marrow	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
aging	O
finding	O
the	O
aged	O
mice	O
cells	O
(24	O
month	O
aged)	O
had	O
increased	O
intracellular	O
concentrations	O
of	O
the	O
following	O
compounds:	O
O2·−	O
(1.4-fold),	O
H2O2	O
(2-fold),	O
and	O
NO	O
(1.6-fold),	O
peroxynitrite/OH·	O
(2.5-fold)	O
comparing	O
with	O
young	O
mice	O
cells	O
(2	O
months	O
old)	O
[104].	O

We	O
and	O
others	O
have	O
shown	O
that	O
Mof	O
plays	O
important	O
function	O
in	O
embryonic	B
stem	I
cell	I
(ESC)	O
self-renewal	O
(13,	O
14),	O
DNA	O
damage	O
repair	O
(15,	O
16),	O
senescence	O
(17),	O
and	O
autophagy	O
(18).	O

Recent	O
evidence	O
suggests	O
that	O
several	O
of	O
the	O
beneficial	O
effects	O
of	O
human	B
mesenchymal	I
stem	I
cell	I
(HMSC)	O
therapy	O
can	O
be	O
attributed	O
to	O
paracrine	O
effects	O
of	O
the	O
HMSC	O
secretome	O
(Dai	O
et	O
al.,	O
2007;	O
Gnecchi	O
et	O
al.,	O
2008;	O
Yao	O
et	O
al.,	O
2015).	O

This	O
is	O
because	O
non-activated	O
fibroblasts	O
possess	O
characteristics	O
that	O
are	O
similar	O
to	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
precursors.	O

Although	O
there	O
have	O
been	O
many	O
reports	O
of	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
transplantation	O
for	O
the	O
treatment	O
of	O
ischemic	O
heart	O
disease	O
(IHD),	O
relatively	O
few	O
studies	O
have	O
investigated	O
the	O
roles	O
of	O
CF-EXOs.	O

Neural	B
stem	I
cell	I
(NSC)	O
therapy	O
can	O
be	O
used	O
for	O
nerve	O
and	O
brain	O
regeneration.	O

Induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
make	O
up	O
a	O
recent	O
powerful	O
addition	O
to	O
the	O
arsenal	O
of	O
the	O
cell	O
and	O
lipid	O
biologist.	O

This	O
is	O
especially	O
visible	O
when	O
the	O
dyes	O
are	O
applied	O
to	O
cell	O
types	O
that	O
naturally	O
form	O
clumps	O
such	O
as	O
embryoid	O
bodies	O
(EBs)	O
derived	O
from	O
embryonic	B
stem	I
cells	I
(ESCs)	O
and	O
iPSCs,	O
due	O
to	O
nonspecific	O
uptake	O
of	O
the	O
dyes	O
into	O
the	O
cell	O
clumps.	O

Notably,	O
the	O
mesenchymal	B
stem	I
cell	I
(MSC)	O
generates	O
exosomal	O
miRNA-1470,	O
which	O
remains	O
important	O
in	O
CD4+CD25+Foxp3+Treg	O
differentiation	O
[163].	O

Fertilization	O
of	O
the	O
reconstructed	O
oocyte	O
should	O
lead	O
to	O
a	O
blastocyst,	O
which	O
can	O
be	O
used	O
for	O
embryonic	B
stem	I
cell	I
(ESC)	O
derivation.	O

Induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
lines	O
were	O
derived	O
from	O
three	O
PD	O
patients	O
carrying	O
a	O
LRRK2-G2019S	O
heterozygous	O
mutation,	O
and	O
three	O
healthy	O
control	O
individuals	O
(Materials	O
and	O
Methods),	O
from	O
the	O
Oxford	O
Parkinson’s	O
Disease	O
Centre	O
(OPDC)	O
Discovery	O
Cohort	O
(Table	O
1)	O
(Materials	O
and	O
Methods,	O
Supplementary	O
Material,	O
Fig.	O

Induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
lines	O
were	O
derived	O
from	O
three	O
PD	O
patients	O
carrying	O
a	O
LRRK2-G2019S	O
heterozygous	O
mutation,	O
and	O
three	O
healthy	O
control	O
individuals,	O
from	O
the	O
Oxford	O
Parkinson’s	O
Disease	O
Centre	O
(OPDC)	O
Discovery	O
Cohort	O
(Table	O
1)..	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
have	O
not	O
been	O
discussed	O
in	O
this	O
review	O
article,	O
however,	O
they	O
can	O
be	O
derived	O
from	O
several	O
sources	O
and	O
differentiate	O
into	O
diverse	O
cell	O
types.	O

Substrate	O
composition	O
significantly	O
impacts	O
human	B
pluripotent	I
stem	I
cell	I
(hPSC)	O
self-renewal	O
and	O
differentiation,	O
but	O
relatively	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
endogenously	O
produced	O
extracellular	O
matrix	O
(ECM)	O
components	O
in	O
regulating	O
hPSC	O
fates.	O

The	O
extracellular	O
matrix	O
(ECM)	O
is	O
known	O
to	O
play	O
an	O
integral	O
role	O
in	O
human	B
pluripotent	I
stem	I
cell	I
(hPSC)	O
culture	O
and	O
maintenance.	O

However,	O
emerging	O
evidence	O
suggests	O
that	O
the	O
proportion	O
of	O
cells	O
with	O
high	O
expression	O
of	O
cancer	B
stem	I
cell	I
(CSC)	O
markers	O
among	O
the	O
surviving	O
cells	O
is	O
significantly	O
increased	O
in	O
response	O
to	O
5‐Fu,	O
resulting	O
in	O
drug	O
resistance	O
and	O
disease	O
relapse.	O

We	O
utilized	O
the	O
Drosophila	O
testis	O
as	O
an	O
in	O
vivo	O
model	O
to	O
examine	O
the	O
effects	O
of	O
ROS	O
on	O
germline	B
stem	I
cell	I
(GSC)	O
maintenance.	O

In	O
this	O
study,	O
we	O
examined	O
the	O
role	O
of	O
Keap1/Nrf2	O
signaling	O
in	O
the	O
regulation	O
of	O
ROS	O
levels	O
and	O
assessed	O
whether	O
redox	O
states	O
can	O
influence	O
germline	B
stem	I
cell	I
(GSC)	O
maintenance	O
in	O
the	O
Drosophila	O
testis.	O

Extrusion	O
bioprinting	O
was	O
used	O
to	O
prepare	O
human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
derived	O
from	O
renal	O
progenitor	O
cells	O
in	O
6-well	O
and	O
96-well	O
plates	O
and	O
they	O
developed	O
into	O
initial	O
cellular	O
microclusters	O
of	O
kidney	O
organoids,	O
which	O
were	O
then	O
cultured	O
for	O
20	O
days	O
to	O
obtain	O
kidney	O
organoids	O
with	O
morphology,	O
cell	O
type,	O
and	O
gene	O
expression	O
levels	O
comparable	O
to	O
those	O
previously	O
reported	O
for	O
kidney	O
organoids	O
in	O
artificial	O
culture.	O

Hematopoiesis	O
is	O
a	O
process	O
through	O
which	O
all	O
the	O
blood	O
cells	O
are	O
generated	O
through	O
sequential	O
cell	O
divisions	O
and	O
differentiation	O
of	O
progeny	O
that	O
originate	O
from	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
(Kondo	O
et	O
al.,	O
2003).	O

The	O
authors	O
initially	O
quantified	O
protein	O
levels	O
and	O
fluctuations	O
by	O
measuring	O
single	O
cell	O
fluorescence	O
of	O
mouse	B
embryonic	I
stem	I
cells	I
(mESCs)	O
transiently	O
transfected	O
with	O
a	O
fluorescent	O
reporter	O
with	O
miRNA	O
binding	O
sites	O
in	O
the	O
3'UTR.	O

Human	B
pluripotent	I
stem	I
cells	I
(hPSCs)	O
provide	O
an	O
unlimited	O
cell	O
source	O
for	O
regenerative	O
medicine.	O

Another	O
capture	O
array–specific	O
transcript	O
is	O
represented	O
by	O
the	O
benign	O
gonial	O
cell	O
neoplasm	O
gene	O
(bgcn,	O
FlyBase	O
ID:	O
FBgn0004581),	O
which	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
germline	B
stem	I
cell	I
(GSC)	O
maintenance	O
(Li	O
et	O
al.	O

Chronic	O
myeloid	O
leukemia	O
(CML)	O
is	O
a	O
myeloproliferative	O
disorder	O
of	O
hematopoietic	B
stem	I
cell	I
(HSC)	O
origin	O
caused	O
by	O
the	O
t(9;22)	O
chromosomal	O
translocation.	O

Development	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
technology	O
to	O
obtain	O
terminally	O
differentiated	O
neurons	O
from	O
adult	O
somatic	O
cells	O
revolutionized	O
the	O
study	O
of	O
AD,	O
providing	O
a	O
powerful	O
tool	O
for	O
modelling	O
the	O
disease	O
and	O
for	O
screening	O
candidate	O
drugs.	O

In	O
particular,	O
the	O
use	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
can	O
be	O
used	O
to	O
generate	O
the	O
necessary	O
cell	O
types	O
to	O
mimic	O
the	O
adult	O
liver	O
and	O
model	O
disease	O
states.	O

Recent	O
findings	O
have	O
revealed	O
that	O
molecular	O
mechanisms	O
underlying	O
the	O
maintenance	O
of	O
embryonic	B
stem	I
cell	I
(ESC)	O
pluripotency	O
and	O
cellular	O
reprogramming	O
have	O
been	O
linked	O
to	O
miRNAs	O
[1,	O
7].	O

Members	O
of	O
the	O
miR-290	O
cluster	O
are	O
the	O
most	O
highly	O
expressed	O
miRNAs	O
in	O
mESCs	O
comprising	O
more	O
than	O
60–70	O
%	O
of	O
the	O
total	O
miRNAs	O
expressed	O
and	O
are	O
studied	O
extensively	O
in	O
various	O
backgrounds	O
[54]	O
including	O
DNA	O
methylation,	O
maintenance	O
of	O
pluripotency,	O
germ	O
cell	O
development,	O
and	O
generation	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
(iPSCs)	O
[55,	O
56]..	O

Functions	O
of	O
microRNAs	O
(miRNAs)	O
in	O
embryonic	B
stem	I
cell	I
(ESC)	O
self-renewal,	O
differentiation,	O
and	O
cellular	O
reprogramming.	O

Embryonic	B
stem	I
cells	I
(ESCs)	O
are	O
typical	O
PSCs	O
that	O
derive	O
from	O
inner	O
cell	O
mass	O
(ICM)	O
of	O
blastocysts,	O
and	O
ESCs	O
show	O
difficulty	O
in	O
efficient	O
genome	O
editing.	O

Mesenchymal	B
stem	I
cells	I
(MSC)	O
are	O
multipotent	O
cells,	O
functioning	O
as	O
precursors	O
to	O
a	O
variety	O
of	O
cell	O
types	O
including	O
adipocytes,	O
osteoblasts,	O
and	O
chondrocytes.	O

Mesenchymal	B
stem	I
cells	I
(MSCs)	O
display	O
immunemodulatory	O
and	O
neuroprotective	O
activities	O
and	O
promote	O
oligodendrocyte	O
differentiation	O
of	O
neural	O
progenitors	O
(NPCs)	O
and	O
are	O
thus	O
interesting	O
candidates	O
for	O
autologous	O
cell	O
therapy	O
in	O
MS.	O

To	O
further	O
study	O
the	O
routes	O
of	O
degradation	O
and	O
the	O
possibilities	O
to	O
speed	O
up	O
this	O
process	O
we	O
have	O
used	O
a	O
cell	O
culture	O
model	O
where	O
UV‐treated,	O
dead	O
cells	O
are	O
added	O
to	O
stem	O
cell‐derived	O
astrocytes.	O
Grafting	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
derived	O
dopaminergic	O
(DA)	O
neurons	O
has	O
great	O
potential	O
for	O
cell	O
based	O
therapies	O
for	O
Parkinson's	O
disease	O
(PD).	O

Mesenchymal	B
stem	I
cells	I
(MSC)	O
were	O
shown	O
to	O
exert	O
positive	O
immunomodulatory	O
effects,	O
to	O
reduce	O
demyelination,	O
to	O
increase	O
neuroprotection	O
and	O
to	O
promote	O
adult	O
neural	O
stem	O
cell	O
differentiation	O
towards	O
the	O
oligodendroglial	O
lineage.	O

The	O
use	O
of	O
human	B
embryonic	I
stem	I
cells	I
(hESCs)	O
in	O
cell	O
replacement	O
therapies	O
(CRTs)	O
has	O
been	O
limited	O
due	O
to	O
several	O
technical	O
and	O
ethical	O
issues.	O

In	O
keeping	O
with	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
hypothesis	O
(4),	O
these	O
cells	O
possess	O
self-renewing	O
capacity,	O
an	O
especially	O
high	O
resistance	O
to	O
death-promoting	O
signals,	O
and	O
the	O
ability	O
to	O
effect	O
regeneration	O
of	O
the	O
overall	O
tumor	O
mass	O
(56,	O
140).	O

[162]	O
has	O
used	O
a	O
mouse	O
model	O
for	O
showing	O
that	O
plasma	O
levels	O
of	O
miRs	O
371/302/C19MC	O
were	O
accurate	O
in	O
detecting	O
undifferentiated	O
and	O
malignant	O
components	O
arising	O
in	O
xenografts	O
derived	O
from	O
mice	O
injected	O
with	O
human	B
pluripotent	I
stem	I
cell	I
(hPSC)	O
lines	O
and	O
human	O
malignant	O
GCT	O
cell	O
lines.	O

The	O
diverse	O
Ras-pathways	O
that	O
are	O
relevant	O
for	O
stemness	O
may	O
be	O
gleaned	O
from	O
E-Ras,	O
which	O
is	O
specifically	O
expressed	O
in	O
embryonic	B
stem	I
cells	I
(ESC)	O
and	O
few	O
adult	O
cells,	O
such	O
as	O
the	O
hepatic	O
stellate	O
cells	O
(HSC),	O
a	O
liver	O
resident	O
stem	O
cell	O
population	O
[61].	O

The	O
implementation	O
of	O
a	O
similar	O
blood-detection	O
procedure	O
for	O
humans	O
and	O
culture-detection	O
method	O
for	O
stem	B
cell	I
lines	O
undoubtedly	O
contributes	O
to	O
minimizing	O
the	O
risk	O
of	O
infection	O
with	O
agents	O
causing	O
transmissible	O
spongiform	O
encephalopathies..	O

Selecting	O
and	O
testing	O
of	O
stem	B
cell	I
lines	O
and	O
biotechnological	O
products	O
(e.g.	O

murine)	O
for	O
embryonic	B
stem	I
cell	I
culture,	O
there	O
is	O
a	O
need	O
to	O
evaluate	O
several	O
viruses	O
that	O
are	O
capable	O
of	O
infecting	O
humans	O
or	O
primates	O
and	O
that	O
potentially	O
can	O
cause	O
serious	O
infections	O
in	O
laboratory	O
workers.	O

In	O
our	O
opinion,	O
there	O
is	O
a	O
need	O
to	O
design	O
and	O
to	O
implement	O
this	O
methodology	O
in	O
stem	B
cell	I
cultures,	O
so	O
new	O
research	O
will	O
be	O
needed..	O

SERUM-free	O
derivation	O
of	O
human	B
embryonic	I
stem	I
cell	I
lines	O
of	O
human	O
placental	O
fibroblast	O
feeders.	O

It	O
will	O
be	O
important	O
to	O
determine	O
whether	O
Dicer	O
is	O
required	O
for	O
earlier	O
steps	O
of	O
cardiogenesis	O
(before	O
E8.5),	O
such	O
as	O
cardiac	O
lineage	O
specification,	O
because	O
Dicer	O
is	O
required	O
for	O
embryonic	B
stem	I
cell	I
differentiation	O
[21,	O
35].	O

Without	O
question,	O
the	O
scarce	O
supply	O
of	O
human	O
ESCs	O
combined	O
with	O
the	O
technical	O
challenges	O
associated	O
with	O
interspecies	O
translation	O
of	O
stem	B
cell	I
derivation	O
contributed	O
to	O
the	O
long	O
interval	O
between	O
these	O
reports.	O

Public	O
sharing	O
of	O
information	O
about	O
the	O
basic	O
science	O
of	O
ESCs	O
has	O
proven	O
to	O
be	O
important,	O
since	O
those	O
who	O
are	O
aware	O
of	O
the	O
stem	B
cell	I
debate	O
tend	O
to	O
be	O
more	O
supportive	O
of	O
research	O
in	O
this	O
area	O
compared	O
to	O
those	O
less	O
familiar	O
with	O
the	O
topic	O
[24].	O

Embryonic	B
stem	I
cell	I
harvesting	O
is	O
enhanced	O
by	O
a	O
chemically-defined	O
medium	O
(abstract	O
O-019)	O
Hum	O
Reprod.	O

Also,	O
stimulation	O
of	O
mTOR	O
in	O
normal	B
stem	I
cells	I
causes	O
hyper-proliferation,	O
pro-gerogenic	O
conversion	O
and	O
cell	O
exhaustion	O
[79-84],	O
contributing	O
to	O
aging..	O

mTORC1-dependent	O
and	O
-independent	O
regulation	O
of	O
stem	B
cell	I
renewal,	O
differentiation,	O
and	O
mobilization.	O

Haematopoietic	B
stem	I
cell	I
transplantation	O
for	O
vasculitis	O
including	O
Behcet's	O
disease	O
and	O
polychondritis:	O
a	O
retrospective	O
analysis	O
of	O
patients	O
recorded	O
in	O
the	O
European	O
Bone	O
Marrow	O
Transplantation	O
and	O
European	O
League	O
Against	O
Rheumatism	O
databases	O
and	O
a	O
review	O
of	O
the	O
literature.	O

If	O
we	O
instead	O
batch	O
download	O
as	O
a	O
tab	O
separated	O
file	O
and	O
open	O
as	O
a	O
spreadsheet,	O
we	O
can	O
rapidly	O
determine	O
that	O
513	O
of	O
the	O
746	O
fly	O
genes	O
implicated	O
in	O
stem	B
cell	I
biology	O
have	O
at	O
least	O
one	O
identified	O
human	O
ortholog..	O

10000-fold	O
dilution	O
of	O
CKα	O
antiserum	O
was	O
used	O
for	O
detection	O
of	O
mouse	O
CKα	O
in	O
50	O
µg	O
of	O
mouse	B
embryonic	I
stem	I
cell	I
protein	O
lysate	O
(E),	O
using	O
50	O
µg	O
of	O
HeLa	O
cell	O
protein	O
extract	O
as	O
the	O
positive	O
control	O
(H).	O

The	O
specificity	O
of	O
the	O
CKα	O
antiserum	O
when	O
tested	O
on	O
a	O
series	O
of	O
human	O
cell	O
lysates	O
and	O
mouse	B
embryonic	I
stem	I
cell	I
extract	O
supported	O
its	O
use	O
in	O
non-homogeneous	O
samples	O
such	O
as	O
for	O
protein	O
dot	O
blot	O
analysis	O
of	O
total	O
CKα.	O

Importantly,	O
the	O
presence	O
of	O
stem	B
cell	I
marker	O
reads	O
was	O
minimal	O
(Fig.	O

Consistent	O
with	O
the	O
increased	O
stem	O
cell	O
proliferation,	O
competitive	O
repopulation	O
assays	O
demonstrated	O
that	O
chronic	O
OXM	O
therapy	O
eventually	O
resulted	O
in	O
stem	B
cell	I
exhaustion.	O

In	O
fact,	O
our	O
data	O
show	O
that	O
chronic	O
OXM	O
administration	O
eventually	O
results	O
in	O
stem	B
cell	I
exhaustion.	O

We	O
have	O
previously	O
shown	O
that	O
FA	O
HSPCs	O
already	O
have	O
an	O
accelerated	O
cell	O
cycle	O
and	O
interpreted	O
this	O
finding	O
as	O
a	O
homeostatic	O
mechanism	O
that	O
compensates	O
for	O
the	O
increased	O
loss	O
of	O
stem	B
cells	I
in	O
this	O
disease	O
(Zhang	O
et	O
al.,	O
2010).	O

Furthermore,	O
enhanced	O
expression	O
of	O
telomerase,	O
even	O
if	O
present,	O
would	O
not	O
explain	O
the	O
observed	O
effect	O
on	O
stem	B
cell	I
quiescence.	O

Our	O
data	O
indicate	O
that	O
this	O
protein	O
may	O
also	O
have	O
a	O
cell	O
autonomous	O
effect	O
in	O
stem	O
cells.	O
Others	O
have	O
found	O
that	O
the	O
hypersensitivity	O
of	O
FA	O
cells	O
to	O
acetaldehyde	O
is	O
also	O
uniquely	O
limited	O
to	O
HSPCs	O
(Garaycoechea	O
et	O
al.,	O
2012)	O
and	O
that	O
it	O
is	O
possible	O
that	O
the	O
lack	O
of	O
stem	B
cell	I
quiescence	O
is	O
mediated	O
by	O
aldehyde	O
toxicity.	O

The	O
changes	O
in	O
cell	O
cycle-related	O
genes	O
and	O
genes	O
involved	O
in	O
DNA	O
damage	O
responses	O
were	O
not	O
surprising,	O
given	O
the	O
obvious	O
lack	O
of	O
stem	B
cell	I
quiescence	O
and	O
the	O
known	O
role	O
of	O
the	O
FA	O
pathway	O
in	O
DNA	O
repair	O
(Kim	O
and	O
D’Andrea,	O
2012).	O

Differential	O
expression	O
of	O
stem	B
cell	I
mobilization-associated	O
molecules	O
on	O
multi-lineage	O
cells	O
from	O
adipose	O
tissue	O
and	O
bone	O
marrow.	O

4Mu	O
Decreases	O
CD47	O
Expression	B
on	I
Hepatic	O
Cancer	O
Stem	O
Cells	O
and	O
Primes	O
a	O
Potent	O
Antitumor	O
T	O
Cell	O
Response	O
Induced	O
by	O
Interleukin-12.	O

Wang	O
Y,	O
Medvid	O
R,	O
Melton	O
C,	O
Jaenisch	O
R,	O
Blelloch	O
R	O
(2007)	O
DGCR8	O
is	O
essential	O
for	O
microRNA	O
biogenesis	O
and	O
silencing	O
of	O
embryonic	B
stem	I
cell	I
self-renewal.	O

Swine	O
are	O
gaining	O
popularity	O
as	O
a	O
useful	O
large	O
animal	O
model	O
for	O
stem	B
cell	I
therapy	O
for	O
important	O
human	O
diseases	O
or	O
conditions	O
such	O
as	O
myocardial	O
infarction,	O
diabetes,	O
atherosclerosis,	O
traumatic	O
brain	O
injury,	O
retinal	O
damage,	O
and	O
tooth	O
regeneration	O
[21],	O
[22],	O
[23],	O
[24],	O
[25].	O

To	O
characterize	O
epithelial	O
colony	O
cells,	O
we	O
expanded	O
individual	O
colonies	O
in	O
vitro	O
and	O
performed	O
immunocytochemistry	O
by	O
using	O
a	O
panel	O
of	O
stem	B
cell	I
and	O
epithelial	O
cell-specific	O
antibodies.	O

Expression	O
of	O
stem	B
cell	I
markers	O
in	O
progenitor	O
epithelial	O
cells	O
may,	O
therefore,	O
be	O
associated	O
with	O
differentiation	O
potential	O
of	O
these	O
cells..	O

Mesenchymal	B
stem	I
cell	I
engraftment	O
in	O
lung	O
is	O
enhanced	O
in	O
response	O
to	O
bleomycin	O
exposure	O
and	O
ameliorates	O
its	O
fibrotic	O
effects.	O

Terminal	O
bronchioles	O
harbor	O
a	O
unique	O
airway	B
stem	I
cell	I
population	O
that	O
localizes	O
to	O
the	O
bronchoalveolar	O
duct	O
junction.	O

Mesenchymal	B
stem	I
cell	I
implantation	O
in	O
a	O
swine	O
myocardial	O
infarct	O
model:	O
engraftment	O
and	O
functional	O
effects.	O

Reduced	O
inflammation,	O
decreased	O
levels	O
of	O
growth-promoting	O
hormones,	O
enhanced	O
glucose	O
homeostasis,	O
decreased	O
adiposity,	O
protection	O
from	O
a	O
variety	O
of	O
cancers,	O
and	O
preservation	O
of	O
stem	B
cell	I
function	O
have	O
each	O
been	O
proposed	O
to	O
be	O
an	O
important	O
part	O
of	O
the	O
“dietary	O
restriction	O
effect”..	O

This	O
decline	O
is	O
associated	O
with	O
several	O
changes	O
such	O
as	O
tissue	O
deterioration	O
and	O
disorganization,	O
organ	O
dysfunction,	O
and	O
loss	O
of	O
stem	B
cell	I
renewal,	O
the	O
latter	O
contributing	O
to	O
age‐associated	O
immunodeficiency.	O

(2006)	O
showed	O
that	O
microvesicles	O
derived	O
from	O
embryonic	O
stem	O
cells	O
can	O
enhance	O
the	O
survival	O
and	O
expansion	O
of	O
mouse	O
hematopoietic	O
progenitor	O
cells,	O
and	O
are	O
enriched	O
in	O
stem	B
cell	I
related	O
transcripts	O
including	O
Oct-4,	O
Rex-1,	O
Nanog,	O
SCL,	O
and	O
GATA-2.	O

The	O
marriage	O
of	O
stem	O
cell	O
biology	O
with	O
creative	O
bioengineering	O
technology	O
has	O
the	O
potential	O
to	O
expand	O
our	O
basic	O
understanding	O
of	O
stem	B
cell	I
regulation	O
imposed	O
by	O
the	O
niche	O
and	O
to	O
develop	O
novel	O
regenerative	O
medicine	O
applications..	O

First	O
formally	O
described	O
in	O
the	O
fruit	O
fly,	O
Drosophila	O
[3,4],	O
the	O
stem	B
cell	I
niche,	O
or	O
microenvironment,	O
is	O
composed	O
of	O
both	O
biochemical	O
(growth	O
factors,	O
cytokines,	O
receptor	O
ligands,	O
and	O
so	O
on)	O
and	O
biophysical	O
(matrix	O
stiffness,	O
topography/architecture,	O
fluidity,	O
and	O
so	O
on)	O
factors	O
that	O
act	O
singly	O
and	O
in	O
concert	O
to	O
continuously	O
modulate	O
cell	O
fate.	O

By	O
advancing	O
our	O
understanding	O
of	O
stem	B
cell	I
niche	O
regulation	O
we	O
can	O
begin	O
to	O
envision	O
regenerative	O
medicine	O
applications	O
built	O
on	O
principles	O
derived	O
from	O
fundamental	O
niche	O
biology..	O

Importantly,	O
these	O
approaches	O
are	O
all	O
amenable	O
to	O
highthroughput	O
screening	O
and	O
time-lapse	O
microscopy	O
to	O
assess	O
co-culture	O
effects	O
on	O
stem	B
cell	I
behavior	O
and	O
fate	O
changes	O
over	O
time,	O
such	O
as	O
division	O
resulting	O
in	O
symmetric	O
or	O
asymmetric	O
self-renewal,	O
differentiation	O
and	O
changes	O
in	O
viability..	O

More	O
recently,	O
the	O
molecular	O
mechanisms	O
and	O
signaling	O
pathways	O
driving	O
cell	O
shape-mediated	O
effects	O
on	O
stem	B
cell	I
populations	O
have	O
been	O
described	O
[28,29].	O

While	O
two-dimensional	O
approaches	O
enable	O
well	O
controlled	O
interrogation	O
of	O
single	O
putative	O
niche	O
elements	O
on	O
cell	O
fate,	O
the	O
focus	O
of	O
three-dimensional	O
tissue	O
engineering	O
is	O
to	O
reconstruct	O
the	O
complex	O
architecture	O
of	O
stem	B
cells	I
within	O
a	O
three-dimensional	O
matrix	O
to	O
achieve	O
a	O
physiologically	O
relevant	O
structure.	O

Extending	O
this	O
to	O
permit	O
matrix	O
tunability	O
over	O
time	O
in	O
a	O
spatial	O
and	O
temporal	O
manner	O
has	O
the	O
potential	O
to	O
enable	O
exquisite	O
study	O
of	O
stem	O
cell	O
fate	O
changes	O
as	O
they	O
may	O
occur	O
during	O
disease	O
progression	O
[58]	O
Through	O
the	O
careful	O
design	O
and	O
thoughtful	O
characterization	O
of	O
the	O
parameters	O
described	O
above	O
it	O
is	O
now	O
possible	O
to	O
produce	O
biomaterials	O
that	O
promote	O
longterm	O
survival,	O
proliferation	O
and	O
differentiation	O
of	O
stem	B
cells	I
in	O
three	O
dimensions..	O

The	O
integration	O
of	O
bioengineering	O
approaches	O
with	O
stem	B
cell	I
biology	O
has	O
the	O
potential	O
to	O
substantially	O
change	O
the	O
practice	O
of	O
medicine	O
as	O
we	O
know	O
it	O
today.	O

A	O
tissue-engineering	O
approach	O
based	O
upon	O
the	O
principle	O
of	O
designing	B
stem	I
cell	I
microenvironments	O
that	O
incorporate	O
the	O
cell	O
types,	O
signaling	O
cues	O
and	O
structure	O
required	O
for	O
long-term	O
physiological	O
function	O
and	O
incorporation	O
in	O
a	O
living	O
patient	O
has	O
the	O
potential	O
to	O
substantially	O
reduce	O
the	O
current	O
reliance	O
on	O
organ	O
donors	O
to	O
provide	O
tissues	O
to	O
patients	O
in	O
critical	O
need.	O

More	O
importantly,	O
current	O
biomaterials	O
technologies	O
and	O
the	O
inevitable	O
future	O
technological	O
advances	O
in	O
the	O
field	O
provide	O
a	O
novel	O
toolbox	O
for	O
stem	B
cell	I
biologists	O
to	O
investigate	O
the	O
impact	O
of	O
niche	O
biochemical	O
and	O
biophysical	O
properties	O
in	O
unprecedented	O
ways.	O

Functional	O
immobilization	O
of	O
signaling	O
proteins	O
enables	O
control	O
of	O
stem	B
cell	I
fate.	O

Mimicking	O
cell-cell	O
interactions	O
at	O
the	O
biomaterial-cell	O
interface	O
for	O
control	O
of	O
stem	B
cell	I
differentiation.	O

Control	O
of	O
stem	B
cell	I
fate	O
by	O
physical	O
interactions	O
with	O
the	O
extracellular	O
matrix.	O

Potency	O
and	O
fate	O
specification	O
in	O
CNS	B
stem	I
cell	I
populations	O
in	O
vitro.	O

Embryonic	B
stem	I
cell	I
differentiation:	O
emergence	O
of	O
a	O
new	O
era	O
in	O
biology	O
and	O
medicine.	O

Neural	B
stem	I
cell	I
Ad	O
GBM	O
Single	O
administration	O
of	O
oncolytic	O
virus-loaded	O
NSCs	O
allows	O
for	O
up	O
to	O
31%	O
coverage	O
of	O
intracranial	O
tumors	O
29.	O

Increased	O
Müller	O
cell	O
de-differentiation	O
after	O
grafting	O
of	O
retinal	B
stem	I
cell	I
in	O
the	O
sub-retinal	O
space	O
of	O
royal	O
college	O
of	O
surgeons	O
rats.	O

Differences	O
between	O
the	O
neurogenic	O
and	O
proliferative	O
abilities	O
of	O
Müller	O
glia	O
with	O
stem	B
cell	I
characteristics	O
and	O
the	O
ciliary	O
epithelium	O
from	O
the	O
adult	O
human	O
eye.	O

Combinations	O
of	O
genetic	O
mutations	O
in	O
the	O
adult	B
neural	I
stem	I
cell	I
compartment	O
determine	O
brain	O
tumour	O
phenotypes.	O

The	O
Inhibitory	O
Effect	O
of	O
Mesenchymal	B
Stem	I
Cell	I
on	O
Blood-Brain	O
Barrier	O
Disruption	O
Following	O
Intracerebral	O
Hemorrhage	O
in	O
Rats:	O
Contribution	O
of	O
TSG-6.	O

Notch	O
acts	O
as	O
a	O
key	O
regulator	O
of	O
plasticity	O
in	O
the	O
brain,	O
balancing	O
the	O
number	O
of	O
NSCs	O
and	O
their	O
progenies	O
to	O
maintain	O
the	O
stem	B
cell	I
niche,	O
by	O
regulating	O
the	O
cell	O
cycle	O
(55,56).	O

Thus,	O
Wnt	O
signaling	O
could	O
regulate	O
the	O
size	O
of	O
the	O
stem	B
cell	I
pool	O
(59).	O

Epidermal	O
growth	O
factor	O
receptor	O
and	O
Ink4a/Arf:	O
convergent	O
mechanisms	O
governing	O
terminal	O
differentiation	O
and	O
transformation	O
along	O
the	O
neural	B
stem	I
cell	I
to	O
astrocyte	O
axis.	O

(2017)	O
Untangling	O
the	O
biology	O
of	O
genetic	O
cardiomyopathies	O
with	O
pluripotent	B
stem	I
cell	I
disease	O
models.	O

Such	O
capability	O
would	O
be	O
especially	O
useful	O
for	O
the	O
stem	O
cell	O
field	O
where	O
spatially	O
separated	O
and	O
often	O
functionally	O
specialized	O
populations	O
of	O
stem	B
cells	I
and	O
progenitors	O
are	O
the	O
research	O
target	O
[17],	O
[18],	O
[19],	O
[20],	O
[21].	O

An	O
update	O
review	O
of	O
stem	B
cell	I
applications	O
in	O
burns	O
and	O
wound	O
care.	O

An	O
update	O
review	O
of	O
stem	B
cell	I
applications	O
in	O
burns	O
and	O
wound	O
care.	O

This	O
review	O
seeks	O
to	O
give	O
an	O
updated	O
overview	O
of	O
the	O
applications	O
of	O
stem	B
cell	I
therapy	O
in	O
burns	O
and	O
wound	O
management	O
since	O
our	O
previous	O
review	O
of	O
the	O
“stem	O
cell	O
strategies	O
in	O
burns	O
care”..	O

At	O
the	O
end	O
a	O
diagrammatic	O
overview	O
of	O
the	O
stem	B
cell	I
strategies	O
in	O
modulating	O
wound	O
healing	O
and	O
skin	O
regeneration	O
was	O
proposed,	O
which	O
is	O
reproduced	O
herein	O
with	O
a	O
few	O
modifications	O
as	O
shown	O
in	O
Figure	O
1..	O

The	O
main	O
clinical	O
focus	O
of	O
stem	B
cell	I
application	O
in	O
burns	O
and	O
wound	O
care	O
is	O
to	O
target	O
an	O
improved	O
quality	O
of	O
wound	O
healing.	O

Of	O
note,	O
different	O
means	O
of	O
transplantation	O
of	O
MSC	O
have	O
been	O
described	O
in	O
stem	B
cell	I
therapy.	O

human	O
umbilical	O
cord	O
blood	O
(HUCB),	O
to	O
meet	O
acute	O
response	O
demand	O
whilst	O
protecting	O
the	O
autogenic	B
stem	I
cell	I
bank,	O
the	O
bone	O
marrow[1]	O
.	O

Phenotypic	O
indications	O
that	O
human	O
sweat	O
glands	O
are	O
a	O
rich	O
source	O
of	O
nestin-positive	B
stem	I
cell	I
populations.	O

Despite	O
such	O
progress	O
in	O
stem	B
cell	I
research,	O
ethical,	O
regulatory,	O
safety,	O
and	O
technical	O
difficulties	O
still	O
remain	O
a	O
challenge	O
for	O
the	O
transformation	O
of	O
this	O
technique	O
into	O
a	O
standard	O
clinical	O
approach.	O

Many	O
of	O
the	O
mouse	O
models	O
discussed	O
here	O
are	O
tested	O
for	O
stem	B
cell	I
therapies	O
using	O
cell	O
suspension	O
injections	O
[89,	O
119].	O

Housing,	O
maintenance,	O
costs,	O
and	O
ethical	O
concerns	O
due	O
to	O
a	O
close	O
evolutionary	O
relationship	O
to	O
humans	O
further	O
make	O
the	O
nonhuman	O
primate	O
models	O
less	O
appealing	O
for	O
stem	B
cell	I
researchers	O
[194,	O
195]..	O

Although	O
multifocal	O
ERG	O
(mfERG)	O
is	O
also	O
considered	O
an	O
equally	O
efficient	O
tool	O
to	O
analyze	O
focal	O
retinal	O
changes,	O
its	O
application	O
in	O
stem	B
cell	I
research	O
is	O
still	O
not	O
well	O
established.	O

Current	O
approaches	O
and	O
future	O
prospects	O
for	O
stem	B
cell	I
rescue	O
and	O
regeneration	O
of	O
the	O
retina	O
and	O
optic	O
nerve.	O

Non-invasive	B
stem	I
cell	I
therapy	O
in	O
a	O
rat	O
model	O
for	O
retinal	O
degeneration	O
and	O
vascular	O
pathology.	O

Trp53ΔEC	O
and	O
RbΔEC;	O
Trp53ΔEC	O
mouse	O
tumors	O
are	O
enriched	O
in	B
human	I
stem	I
cell	I
genes.	O

GSEA	O
[20,21]	O
was	O
used	O
to	O
analyze	O
the	O
enrichment	O
of	O
human	B
embryonic	I
stem	I
cell	I
gene	O
signatures	O
within	O
the	O
mouse	O
tumors	O
when	O
compared	O
to	O
normal	O
skin.	O

Recombinant	O
GDNF	O
has	O
also	O
been	O
used	O
as	O
a	O
supplement	O
in	O
mammalian	O
ovarian	B
germline	I
stem	I
cell	I
cultures	O
[33].	O

(1998)	O
A	O
novel	O
class	O
of	O
evolutionarily	O
conserved	O
genes	O
defined	O
by	O
piwi	O
are	O
essential	O
for	O
stem	B
cell	I
self-renewal.	O

Tadokoro	O
Y,	O
Yomogida	O
K,	O
Ohta	O
H,	O
Tohda	O
A,	O
Nishimune	O
Y	O
(2002)	O
Homeostatic	O
regulation	O
of	O
germinal	O
stem	B
cell	I
proliferation	O
by	O
the	O
GDNF/FSH	O
pathway.	O

Yomogida	O
K,	O
Yagura	O
Y,	O
Tadokoro	O
Y,	O
Nishimune	O
Y	O
(2003)	O
Dramatic	O
expansion	O
of	O
germinal	B
stem	I
cells	I
by	O
ectopically	O
expressed	O
human	O
glial	O
cell	O
line-derived	O
neurotrophic	O
factor	O
in	O
mouse	O
Sertoli	O
cells.	O

The	O
understanding	O
gained	O
will	O
assist	O
in	O
successfully	O
leveraging	O
PSI-derived	O
structural	O
genomics	O
methods	O
into	O
more	O
complicated,	O
but	O
highly	O
relevant,	O
biological	O
topics	O
such	O
as	O
alternative	O
splicing	O
patterns,	O
temporal	O
patterns	O
of	O
gene	O
expression	O
in	O
stem	B
cell	I
differentiation,	O
tumor	O
cell	O
biogenesis,	O
and	O
many	O
other	O
biological	O
phenomena	O
that	O
are	O
unique	O
to	O
eukaryotes..	O

The	O
proapoptotic	O
activities	O
of	O
Bax	O
and	O
Bak	O
limit	O
the	O
size	O
of	O
the	O
neural	B
stem	I
cell	I
pool.	O

(A	O
and	O
B)	O
The	O
old	O
centrosome,	O
which	O
contains	O
the	O
oldest	O
centriole,	O
segregated	O
preferentially	O
in	O
the	O
daughter	O
cell	O
that	O
maintains	O
the	O
stem	O
cell–like	O
fate	O
in	O
both	O
the	O
male	O
Drosophila	O
germ	O
line	O
(A)	O
and	O
in	O
the	O
mouse	O
neuroblast	O
(B).	O
Dividing	O
cellular	O
asymmetry:	O
Asymmetric	O
cell	O
division	O
and	O
its	O
implications	O
for	O
stem	B
cells	I
and	O
cancer.	O

Asymmetric	O
inheritance	O
of	O
mother	O
versus	O
daughter	O
centrosome	O
in	O
stem	B
cell	I
division.	O

Dicer	O
is	O
required	O
for	O
neural	B
stem	I
cell	I
multipotency	O
and	O
lineage	O
progression	O
during	O
cerebral	O
cortex	O
development.	O

Mesenchymal	B
Stem	I
Cell	I
Derived	O
Extracellular	O
Vesicles	O
for	O
Tissue	O
Engineering	O
and	O
Regenerative	O
Medicine	O
Applications.	O

Tsai	O
RYL	O
&	O
McKay	O
RDG	O
A	O
nucleolar	O
mechanism	O
controlling	O
cell	O
proliferation	O
in	O
stem	B
cells	I
and	O
cancer	O
cells.	O

To	O
date,	O
posaconazole	O
has	O
been	O
approved	O
for	O
prophylaxis	O
of	O
invasive	O
fungal	O
infections	O
in	O
stem	B
cell	I
transplant	O
recipients	O
with	O
acute	O
graft	O
versus	O
host	O
disease	O
(GVHD)	O
and	O
neutropenic	O
patients	O
receiving	O
intensive	O
induction	O
chemotherapy	O
for	O
acute	O
myelogenous	O
leukemia	O
and	O
myelodys-plastic	O
syndrome.	O

Risks,	O
diagnosis	O
and	O
outcomes	O
of	O
invasive	O
fungal	O
infections	O
in	O
haematopoietic	B
stem	I
cell	I
transplant	O
recipients.	O

Some	O
studies	O
reported	O
Sal-B	O
protected	O
the	O
SH-SY5Y	O
neuroblastoma	O
cells,	O
hepatocyte	O
and	O
bone	B
marrow	I
stem	I
cells	I
against	O
apoptosis	O
by	O
relieving	O
oxidative	O
stress	O
and	O
modulating	O
the	O
apoptotic	O
process	O
[93–95];	O
on	O
the	O
other	O
hand,	O
Sal-B	O
has	O
been	O
revealed	O
to	O
activate	O
apoptosis	O
pathways	O
in	O
order	O
to	O
inhibit	O
cancer	O
cell	O
proliferation	O
[24,	O
25].	O

Bispecific	O
single-chain	O
antibodies	O
as	O
effective	O
tools	O
for	O
eliminating	O
epithelial	O
cancer	O
cells	O
from	O
human	B
stem	I
cell	I
preparations	O
by	O
redirected	O
cell	O
cytotoxicity.	O

Novel	O
humanized	O
and	O
highly	O
efficient	O
bispecific	O
antibodies	O
mediate	O
killing	O
of	O
prostate	B
stem	I
cell	I
antigen-expressing	O
tumor	O
cells	O
by	O
CD8+	O
and	O
CD4+	O
T	O
cells.	O

Over	O
the	O
past	O
decade,	O
the	O
advances	O
in	O
the	O
understanding	O
of	O
stem	O
cell	O
biology	O
and	O
the	O
role	O
of	O
stem	B
cells	I
in	O
diseases,	O
such	O
as	O
CRC,	O
have	O
been	O
remarkable.	O

In	O
particular,	O
discoveries	O
related	O
to	O
the	O
control	O
of	O
stem	B
cell	I
proliferation	O
and	O
how	O
dysregulation	O
of	O
proliferation	O
leads	O
to	O
oncogenesis	O
have	O
been	O
foremost.	O

A	O
paradigm	O
of	O
abnormal	B
stem	I
cell	I
biology	O
is	O
illustrated	O
by	O
patients	O
with	O
FAP,	O
who	O
have	O
mutations	O
in	O
the	O
adenomatous	O
polyposis	O
coli	O
(APC)	O
gene.	O

Therefore,	O
whereas	O
the	O
stem	B
cell	I
that	O
is	O
the	O
likely	O
oncogenic	O
precursor	O
must	O
have	O
originated	O
in	O
the	O
base	O
or	O
depths	O
of	O
the	O
crypt,	O
the	O
polyp	O
originates	O
in	O
the	O
top	O
of	O
the	O
crypt	O
or	O
in	O
the	O
space	O
between	O
the	O
crypts.	O

In	O
OAT	O
+/−	O
individuals	O
with	O
FAP,	O
there	O
are	O
increased	O
rates	O
of	O
stem	B
cell	I
mutation	O
and	O
clustering	O
of	O
mutated	O
crypts	O
consistent	O
with	O
the	O
‘bottom-up’	O
model.[28].	O

Another	O
area	O
of	O
expertise	O
is	O
in	O
phenotypic	O
assays	O
for	O
stem	B
cell	I
differentiation,	O
using	O
fluorescent	O
reporters.	O

Telocytes	O
have	O
been	O
described	O
in	O
all	O
cardiac	O
layers	O
and	O
in	O
the	O
stem	B
cell	I
niches	O
[225].	O

The	O
current	O
status	O
of	O
stem	B
cell	I
therapy	O
in	O
ischemic	O
heart	O
disease.	O

Prospects	O
of	O
stem	B
cell	I
therapy	O
for	O
replacing	O
dopamine	O
neurons	O
in	O
Parkinson's	O
disease.	O

Bone	O
marrow-derived	O
myofibroblasts	O
contribute	O
to	O
the	O
mesenchymal	B
stem	I
cell	I
niche	O
and	O
promote	O
tumor	O
growth.	O

de	O
la	O
Fuente	O
J,	O
Dokal	O
I	O
(2007)	O
Dyskeratosis	O
congenita:	O
advances	O
in	O
the	O
understanding	O
of	O
the	O
telomerase	O
defect	O
and	O
the	O
role	O
of	O
stem	B
cell	I
transplantation.	O

Specifically,	O
the	O
assembly	O
of	O
stem	B
cells	I
themselves	O
into	O
multicellular	O
aggregates	O
exerts	O
strong	O
influences	O
on	O
cell	O
self-renewal	O
or	O
differentiation,	O
as	O
the	O
cells	O
actively	O
secrete	O
factors	O
and	O
modulate	O
local	O
biological	O
transport	O
properties	O
in	O
ways	O
that	O
impact	O
their	O
neighbors.	O

Collectively,	O
these	O
results	O
demonstrate	O
that	O
spatial	O
organization	O
of	O
molecules	O
and	O
cells	O
can	O
play	O
critical	O
roles	O
in	O
modulating	B
stem	I
cell	I
fate	O
and	O
can	O
therefore	O
serve	O
as	O
important	O
tools	O
to	O
exert	O
exogenous	O
control	O
over	O
these	O
processes..	O

The	O
earliest	O
study	O
of	O
shear	O
on	O
stem	B
cell	I
fate	O
determined	O
that	O
flow	O
promotes	O
maturation	O
and	O
capillary	O
assembly	O
of	O
endothelial	O
progenitor	O
cells	O
[61].	O

Physical	O
orientation	O
of	O
stem	B
cells	I
450-μm	O
cell	O
cluster	O
size/150-μm	O
cell	O
cluster	O
size;	O
decreased	O
cell	O
colony	O
size	O
mESCs;	O
hESCs	O
Cardiogenesis/endothelial	O
cell	O
differentiation;	O
increased	O
endodermal	O
differentiation	O
[31];	O
[32].	O

While	O
technological	O
limitations	O
in	O
the	O
ability	O
to	O
control,	O
quantify,	O
and	O
image	O
these	O
properties	O
currently	O
exist,	O
advances	O
in	O
super-resolution	O
microscopy	O
may	O
be	O
combined	O
with	O
stem	B
cell	I
research	O
to	O
enable	O
considerable	O
progress	O
[67]..	O

Furthermore,	O
an	O
appreciation	O
of	O
these	O
interactive	O
processes	O
in	O
natural	O
tissue	O
may	O
greatly	O
aid	O
the	O
development	O
of	O
stem	B
cell	I
therapies	O
to	O
treat	O
numerous	O
human	O
diseases.	O

Functional	O
immobilization	O
of	O
signaling	O
proteins	O
enables	O
control	O
of	O
stem	B
cell	I
fate.	O

Control	O
of	O
human	B
embryonic	I
stem	I
cell	I
colony	O
and	O
aggregate	O
size	O
heterogeneity	O
influences	O
differentiation	O
trajectories.	O

TGFbeta/Activin/Nodal	O
pathway	O
in	O
inhibition	O
of	O
human	B
embryonic	I
stem	I
cell	I
differentiation	O
by	O
mechanical	O
strain.	O

In	O
addition,	O
although	O
the	O
composition	O
of	O
culture	O
media	O
is	O
similar	O
to	O
fluids	O
present	O
in	O
vivo,	O
it	O
does	O
not	O
supply	O
all	O
of	O
the	O
bioactive	O
factors	O
present	O
in	O
the	O
stem	B
cell	I
niche	O
(Watt	O
and	O
Hogan,	O
2000).	O

From	O
a	O
practical	O
perspective,	O
MSCs	O
seem	O
to	O
be	O
a	O
very	O
promising	O
cell	O
source	O
for	O
use	O
in	O
stem	B
cell	I
therapies	O
for	O
tissue	O
impairment,	O
given	O
that	O
MSCs	O
can	O
home	O
to	O
inflamed	O
or	O
injured	O
tissues,	O
as	O
well	O
as	O
tumors,	O
likely	O
without	O
differentiating	O
into	O
somatic	O
cells.	O

Mesenchymal	B
stem	I
cell	I
targeting	O
of	O
microscopic	O
tumors	O
and	O
tumor	O
stroma	O
development	O
monitored	O
by	O
noninvasive	O
in	O
vivo	O
positron	O
emission	O
tomography	O
imaging.	O

Bone	O
marrow-derived	O
myofibroblasts	O
contribute	O
to	O
the	O
mesenchymal	B
stem	I
cell	I
niche	O
and	O
promote	O
tumor	O
growth.	O

Immunocompromised	O
patients,	O
particularly	O
hematopoietic	B
stem	I
cell	I
transplant	O
(HSCT)	O
and	O
solid-organ	O
transplant	O
recipients,	O
are	O
susceptible	O
to	O
severe	O
and	O
potentially	O
fatal	O
adenovirus	O
disease,3.,	O
4.,	O
5.	O

Adenovirus	O
infections	O
in	O
stem	B
cell	I
transplant	O
recipients:	O
recent	O
developments	O
in	O
understanding	O
of	O
pathogenesis,	O
diagnosis	O
and	O
management.	O

Despite	O
the	O
enthusiasm	O
for	O
stem	B
cell	I
therapy,	O
there	O
remain	O
a	O
number	O
of	O
unaddressed,	O
fundamental	O
problems	O
in	O
using	O
allogeneic	O
cells	O
as	O
a	O
donor	O
source	O
in	O
cell	O
therapy	O
for	O
AMD.	O

However,	O
the	O
holy	O
grail	O
of	O
accomplishing	O
complete	O
human	O
organ	O
replacement	O
is	O
still	O
a	O
high	O
aspiration	O
target	O
of	O
stem	B
cell	I
biology,	O
and	O
this	O
highlights	O
an	O
additional	O
level	O
of	O
complexity	O
required	O
in	O
the	O
coordinated	O
differentiation	O
and	O
integration	O
of	O
such	O
with	O
pre-existing	O
host	O
tissues.	O

Therefore,	O
they	O
represent	O
an	O
essential	O
model	O
for	O
cancer	B
stem	I
cell	I
research	O
as	O
well.	O

The	O
Role	O
of	O
Ubiquitination	O
in	O
Regulating	O
Embryonic	B
Stem	I
Cell	I
Maintenance	O
and	O
Cancer	O
Development.	O

The	O
Role	O
of	O
Ubiquitination	O
in	O
Regulating	O
Embryonic	B
Stem	I
Cell	I
Maintenance	O
and	O
Cancer	O
Development.	O

In	O
this	O
review,	O
we	O
provide	O
an	O
overview	O
of	O
the	O
ubiquitination	O
machinery	O
and	O
discuss	O
the	O
recent	O
progresses	O
in	O
the	O
ubiquitination-mediated	O
regulation	O
of	O
embryonic	B
stem	I
cell	I
maintenance	O
and	O
cancer	O
biology..	O

To	O
suppress	O
the	O
poor	O
differentiation	O
properties	O
through	O
eliminating	O
the	O
excessive	O
expression	O
of	O
stem	B
cell	I
markers	O
could	O
serve	O
as	O
an	O
avenue	O
for	O
a	O
better	O
treatment	O
of	O
OS.	O

E3	O
MDM2	O
is	O
involved	O
in	O
maintaining	O
the	O
stem	B
cell	I
properties	O
of	O
OS	O
cells.	O

Itch,	O
an	O
E3	O
ligase	O
of	O
Oct4,	O
is	O
required	O
for	O
embryonic	B
stem	I
cell	I
self-renewal	O
and	O
pluripotency	O
induction.	O

Deubiquitylating	O
Nanog:	O
Novel	O
role	O
of	O
USP21	O
in	O
embryonic	B
stem	I
cell	I
maintenance.	O

Regulation	O
of	O
embryonic	B
stem	I
cell	I
self-renewal	O
and	O
pluripotency	O
by	O
leukaemia	O
inhibitory	O
factor.	O

RNF12	O
Controls	O
Embryonic	B
Stem	I
Cell	I
Fate	O
and	O
Morphogenesis	O
in	O
Zebrafish	O
Embryos	O
by	O
Targeting	O
Smad7	O
for	O
Degradation.	O

siRNA	O
delivery	O
with	O
stem	B
cell	I
membrane-coated	O
magnetic	O
nanoparticles	O
for	O
imaging-guided	O
photothermal	O
therapy	O
and	O
gene	O
therapy.	O

To	O
probe	O
periosteum-associated	O
IL-17	O
biology,	O
we	O
used	O
an	O
hPDC	O
model	O
that	O
recapitulates	O
in	O
vivo-type	O
bone	O
formation	O
in	O
vitro	O
through	O
the	O
use	O
of	O
a	O
defined	O
osteogenic	O
GFC.9	O
During	O
differentiation,	O
the	O
expression	O
of	O
the	O
periosteal	B
stem	I
cell	I
marker	O
SOSTDC1	O
peaked	O
at	O
day	O
3	O
and	O
then	O
subsequently	O
decreased	O
over	O
time	O
indicating	O
differentiation	O
away	O
from	O
a	O
‘stem	O
cell’	O
phenotype	O
(p<0.05	O
at	O
all	O
timepoints	O
vs	O
GM).	O

Uncovering	O
the	O
periosteum	O
for	O
skeletal	O
regeneration:	O
the	O
stem	B
cell	I
that	O
lies	O
beneath.	O

Mouse	B
embryonic	I
stem	I
cell	I
line	O
R1	O
was	O
obtained	O
from	O
the	O
American	O
Type	O
Culture	O
Collection	O
(ATCC;	O
Manassas,	O
VA).	O

Functional	O
impacts	O
of	O
NRXN1	O
knockdown	O
on	O
neurodevelopment	O
in	O
stem	B
cell	I
models.	O

These	O
similarities	O
suggested	O
the	O
stem	B
cell	I
origin	O
of	O
the	O
cancer	O
cells,	O
long	O
before	O
the	O
discovery	O
of	O
CSCs	O
in	O
the	O
breast	O
[94,95].	O

Embryonic	B
stem	I
cell	I
genes	O
such	O
as	O
MYC,	O
NANOG,	O
OCT4,	O
and	O
SOX2	O
are	O
overexpressed	O
in	O
poorly	O
differentiated	O
basal-like	O
subtype	O
[181].	O

Identification	O
of	O
breast	B
cancer	I
stem	I
cell	I
related	O
genes	O
using	O
functional	O
cellular	O
assays	O
combined	O
with	O
single-cell	O
RNA	O
sequencing	O
in	O
MDA-MB-231	O
cells.	O

Dissociation	O
of	O
estrogen	O
receptor	O
expression	O
and	O
in	B
vivo	I
stem	I
cell	I
activity	O
in	O
the	O
mammary	O
gland.	O

Crigler	O
L,	O
Robey	O
RC,	O
Asawachaicharn	O
A,	O
Gaupp	O
D,	O
Phinney	O
DG	O
(2006)	O
Human	B
mesenchymal	I
stem	I
cell	I
subpopulations	O
express	O
a	O
variety	O
of	O
neuro-regulatory	O
molecules	O
and	O
promote	O
neuronal	O
cell	O
survival	O
and	O
neuritogenesis.	O

(2013)	O
Characterization	O
of	O
mesenchymal	B
stem	I
cell	I
subpopulations	O
from	O
human	O
amniotic	O
membrane	O
with	O
dissimilar	O
osteoblastic	O
potential.	O

Reconstituting	O
vascular	O
microenvironment	O
of	O
neural	B
stem	I
cell	I
niche	O
in	O
three-dimensional	O
extracellular	O
matrix.	O

The	O
relevance	O
and	O
potential	O
of	O
ASCs	O
in	O
tissue	O
engineering	O
and,	O
potentially,	O
in	O
the	O
treatment	O
of	O
“immune-mediated”	O
conditions	O
may	O
be	O
better	O
appreciated	O
when	O
the	O
stem	B
cell	I
yield	O
of	O
adipose	O
tissue	O
is	O
examined.	O

When	O
cultured	O
in	O
suspension,	O
a	O
cell	O
population	O
within	O
adipose	O
tissue	O
maintains	O
most	O
of	O
the	O
stem	B
cell	I
biological	O
characteristics	O
and,	O
if	O
plated	O
under	O
differentiating	O
conditions,	O
undergoes	O
adherence	O
and	O
change	O
in	O
their	O
surface	O
molecule	O
expression	O
(manuscript	O
submitted).	O

Mesenchymal	B
stem	I
cells	I
derived	O
from	O
human	O
adipose	O
tissues	O
favor	O
tumor	O
cell	O
growth	O
in	O
vivo.	O

Multiple	O
RBC	O
transfusions	O
inevitably	O
lead	O
to	O
a	O
state	O
of	O
iron	O
overload	O
before	O
and	O
after	O
high-dose	O
chemotherapy	O
and	O
autologous	B
stem	I
cell	I
transplantation	O
(HDCT/autoSCT).	O

The	O
use	O
of	O
high-dose	O
chemotherapy	O
in	O
conjunction	O
with	O
autologous	B
stem	I
cell	I
transplantation	O
(HDCT/autoSCT)	O
has	O
been	O
demonstrated	O
to	O
increase	O
the	O
survival	O
rate	O
of	O
children	O
with	O
high-risk	O
solid	O
tumors	O
(1).	O

Iron	O
overload	O
might	O
increase	O
transplant-related	O
mortality	O
in	O
haematopoietic	B
stem	I
cell	I
transplantation.	O

In	O
vivo	O
clonal	O
analysis	O
reveals	O
self-renewing	O
and	O
multipotent	O
adult	B
neural	I
stem	I
cell	I
characteristics.	O

In	O
addition,	O
a	O
recent	O
exome	O
sequencing	O
of	O
381	O
infants	O
with	O
congenital	O
hydrocephalus	O
identified	O
a	O
predominance	O
of	O
de	O
novo	O
mutations	O
in	O
genes	O
associated	O
with	O
neural	B
stem	I
cell	I
differentiation	O
(Jin	O
et	O
al.,	O
2020).	O

A	O
cell	O
junction	O
pathology	O
of	O
neural	B
stem	I
cells	I
Is	O
associated	O
to	O
ventricular	O
zone	O
disruption,	O
hydrocephalus	O
and	O
neurogenesis	O
abnormalities.	O

Cell	O
junction	O
pathology	O
of	O
neural	B
stem	I
cells	I
is	O
associated	O
with	O
ventricular	O
zone	O
disruption,	O
hydrocephalus,	O
and	O
abnormal	O
neurogenesis.	O

A	O
cell	O
junction	O
pathology	O
of	O
neural	B
stem	I
cells	I
leads	O
to	O
abnormal	O
neurogenesis	O
and	O
hydrocephalus.	O

With	O
the	O
development	O
of	O
the	O
stem	B
cell	I
industry,	O
functional	O
seed	O
cells	O
are	O
needed	O
to	O
treat	O
patients	O
with	O
skin	O
diseases	O
or	O
for	O
drug	O
screening.	O

The	O
Wnt	O
signaling	O
pathway	O
is	O
essential	O
for	O
epidermal	B
stem	I
cell	I
self-renewal	O
[32].	O

Organoids:	O
modeling	O
development	O
and	O
the	O
stem	B
cell	I
niche	O
in	O
a	O
dish.	O

In	O
vitro	O
cultivation	O
of	O
fetal	O
brain	O
cells	O
induces	O
aneuploidy:	O
a	O
caution	O
for	O
neural	B
stem	I
cell	I
therapy?	O
Int	O
J	O
Neuroprotec	O
Neuroregenerat.	O

6d),	O
suggesting	O
that,	O
unlike	O
in	O
embryonic	B
stem	I
cells	I
[32],	O
adult	O
NPCs	O
are	O
not	O
the	O
main	O
source	O
of	O
secreted	O
GDF3	O
and	O
adult	O
hippocampal	O
GDF3	O
likely	O
derives	O
from	O
mature	O
cell	O
types	O
[28].	O

Given	O
that	O
GDF3	O
has	O
been	O
implicated	O
in	O
embryonic	B
stem	I
cell	I
fate	O
[29,	O
30]	O
and	O
is	O
capable	O
of	O
differentiating	O
PC12	O
cells	O
[33],	O
we	O
next	O
investigated	O
whether	O
GDF3	O
promotes	O
neuronal	O
differentiation.	O

GDF3,	O
a	O
BMP	O
inhibitor,	O
regulates	O
cell	O
fate	O
in	O
stem	B
cells	I
and	O
early	O
embryos.	O

Evidence	O
for	O
the	O
stem	B
cell	I
origin	O
of	O
hepatocellular	O
carcinoma	O
and	O
cholangiocarcinoma.	O

Investigation	O
of	O
the	O
microRNAs	O
with	O
the	O
most	O
variable	O
expression	O
between	O
patients	O
in	O
different	O
runs	O
yielded	O
a	O
list	O
of	O
31	O
microRNAs,	O
eight	O
of	O
which	O
are	O
associated	O
with	O
stem	B
cell	I
characteristics..	O

We	O
identified	O
a	O
sub-group	O
of	O
Tamoxifen-treated	O
breast	O
cancer	O
patients	O
with	O
miRNA-expressing	O
tumors	O
associated	O
with	O
cancer	B
stem	I
cell	I
characteristics..	O

Eight	O
of	O
these	O
miRNAs,	O
miR-141,	O
miR-200a,	O
miR-200b,	O
miR-200c,	O
let-7a,	O
let-7b,	O
let-7c	O
and	O
miR-205,	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
cancer	B
stem	I
cell	I
characteristics,	O
such	O
as	O
epithelial-mesenchymal	O
transition	O
(EMT)	O
and	O
self-renewal..	O

Glial	O
influences	O
on	O
neural	B
stem	I
cell	I
development:	O
cellular	O
niches	O
for	O
adult	O
neurogenesis.	O

Effect	O
of	O
cell	O
number	O
on	O
mesenchymal	B
stem	I
cell	I
transplantation	O
in	O
a	O
canine	O
disc	O
degeneration	O
model.	O

Orange	O
coloured	O
icons	O
represent	O
E3	O
ligase	O
functions	O
identified	O
in	O
neural	B
stem	I
cell	I
or	O
GB	O
models..	O

BMI1	O
complexes	O
with	O
RING1A/B	O
and	O
the	O
E2	O
UbcH5c	O
to	O
form	O
the	O
active	O
ligase	O
which	O
has	O
critical	O
roles	O
in	O
maintaining	O
the	O
stem	B
cell	I
phenotype	O
of	O
GSCs	O
[74,	O
75].	O

Moreover,	O
shRNA	O
of	O
BMI1	O
in	O
GSCs	O
demonstrated	O
that	O
it	O
suppresses	O
multiple	O
tumour	O
suppressor	O
pathways,	O
including	O
the	O
major	O
histocompatibility	O
complex	O
(MHC)	O
cluster	O
and	O
Notch	O
signalling,	O
and	O
is	O
critical	O
in	O
maintaining	B
stem	I
cell	I
renewal	O
[84].	O

For	O
example,	O
it	O
enhances	O
the	O
expression	O
of	O
stem	B
cell	I
markers	O
such	O
as	O
Sex	O
determining	O
region	O
Y-box	O
2	O
(SOX2)	O
and	O
CD133	O
by	O
suppressing	O
the	O
expression	O
of	O
the	O
inhibitor	O
of	O
STAT3,	O
protein	O
inhibitor	O
of	O
activated	O
STAT1	O
(PIAS1).	O

In	O
patient-derived	O
GSCs,	O
APC/CCDC20﻿	O
stabilised	O
SOX2	O
and	O
was	O
enriched	O
in	O
stem	B
cell	I
populations	O
[103,	O
104].	O

The	O
NFκB	O
signalling	O
pathway	O
has	O
multiple	O
pro-tumorigenic	O
roles	O
including	O
cell	O
proliferation,	O
angiogenesis	O
and	O
maintenance	O
of	O
cancer	B
stem	I
cells	I
[120].	O

[73],	O
the	O
field	O
of	O
stem	B
cell	I
research	O
caught	O
the	O
scientific	O
and	O
public	O
domain’s	O
attention,	O
bringing	O
an	O
understandable	O
high	O
level	O
of	O
hope	O
for	O
new	O
breakthroughs	O
in	O
regenerative	O
medicine.	O

Embryonic	B
stem	I
cells	I
are	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
the	O
blastocyst	O
~5	O
days	O
post	O
fertilization.	O

Embryonic	O
stem	O
cell	O
marker	O
expression	O
pattern	O
in	O
human	O
mesenchymal	B
stem	I
cells	I
derived	O
from	O
bone	O
marrow,	O
adipose	O
tissue,	O
heart	O
and	O
dermis.	O

Matrix	O
assembly,	O
regulation,	O
and	O
survival	O
functions	O
of	O
laminin	O
and	O
its	O
receptors	O
in	O
embryonic	B
stem	I
cell	I
differentiation.	O

An	O
important	O
cell	O
source	O
during	O
regular	O
tissue	O
turnover,	O
but	O
also	O
during	O
repair	O
is	O
the	O
pool	O
of	O
resident	B
stem	I
cells	I
within	O
the	O
dental	O
pulp.	O

The	O
number	O
and	O
proliferation	O
potential	O
of	O
stem	B
cell	I
populations,	O
including	O
those	O
of	O
the	O
intestinal	O
crypt	O
and	O
muscle,	O
decrease	O
with	O
age,	O
leading	O
to	O
a	O
progressive	O
deterioration	O
of	O
tissue	O
and	O
organ	O
maintenance	O
and	O
function	O
[120,121].	O

Notably,	O
cell	O
therapy,	O
including	O
cell	O
transplantation	O
and	O
stimulating	O
potential	B
stem	I
cell	I
differentiation,	O
is	O
a	O
potential	O
SCI	O
treatment	O
[120,	O
121]..	O

Regenerative	O
medicine	O
is	O
a	O
distinct	O
major	O
advancement	O
in	O
medical	O
treatment	O
which	O
is	O
based	O
on	O
the	O
principles	O
of	O
stem	B
cell	I
technology	O
and	O
tissue	O
engineering	O
in	O
order	O
to	O
replace	O
or	O
regenerate	O
human	O
tissues	O
and	O
organs	O
and	O
restore	O
their	O
functions.	O

Embryonic	B
stem	I
cells	I
are	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
a	O
blastocyst.	O

These	O
can	O
be	O
classified	O
according	O
to	O
their	O
morphologies	O
and	O
correspond	O
to	O
three	O
main	O
maturation	O
stages:	O
Adark	O
spermatogonia,	O
which	O
are	O
considered	O
to	O
represent	O
the	O
reserve	B
stem	I
cell	I
population;	O
highly	O
proliferating	O
Apale	O
spermatogonia;	O
and	O
more	O
mature	O
B	O
spermatogonia	O
that	O
give	O
rise	O
to	O
primary	O
spermatocytes.	O

Immunodepleted	O
mMSCs	O
(ID-mMSCs)	O
are	O
uniformly	O
positive	O
for	O
stem	B
cell	I
antigen-1	O
(Sca-1),	O
CD90,	O
CD105	O
and	O
CD73	O
cell	O
surface	O
markers,	O
but	O
negative	O
for	O
the	O
hematopoietic	O
surface	O
markers	O
CD14,	O
CD34	O
and	O
CD45.	O

Mesenchymal	B
stem	I
cells	I
are	O
self-renewing	O
and	O
multipotent	O
progenitors	O
that	O
can	O
differentiate	O
into	O
a	O
variety	O
of	O
cell	O
types,	O
including	O
adipocytes,	O
osteoblasts,	O
chondrocytes,	O
myocytes,	O
hepatocytes,	O
cardiomyocytes,	O
neurons,	O
and	O
beta-pancreatic	O
islets	O
cells	O
[1–4].BM	O
is	O
the	O
most	O
common	O
source	O
of	O
MSCs.	O

We	O
compared	O
medium	O
with	O
fetal	O
bovine	O
serum	O
(FBS)	O
to	O
medium	O
with	O
mesenchymal	O
stem	O
cell	O
stimulatory	O
supplements	O
(mouse)	O
from	O
Stem	O
cell	O
technologies	O
and	O
found	O
that	O
cells	O
cultured	O
with	O
Mesenchymal	B
Stem	I
Cell	I
Stimulatory	O
Supplements	O
showed	O
a	O
higher	O
proliferation	O
rate	O
(Figure	O
3)..	O

Passage	O
1	O
cells	O
show	O
a	O
higher	O
growth	O
rate	O
in	O
medium	O
with	O
mesenchymal	B
stem	I
cell	I
stimulatory	O
supplements	O
as	O
compared	O
to	O
the	O
proliferation	O
rate	O
observed	O
in	O
medium	O
with	O
the	O
10%	O
FBS.	O

Patient-derived	O
xenografts,	O
the	O
cancer	B
stem	I
cell	I
paradigm,	O
and	O
cancer	O
pathobiology	O
in	O
the	O
21st	O
century.	O

Primary	O
high	O
grade	O
human	O
glioma	O
(glioblastoma)	O
tissue	O
was	O
acquired	O
surgically,	O
dissociated,	O
and	O
cultured	O
in	O
stem	B
cell	I
selection	O
media	O
to	O
form	O
tumorspheres..	O

Tumor	B
stem	I
cells	I
derived	O
from	O
glioblastomas	O
cultured	O
in	O
bFGF	O
and	O
EGF	O
more	O
closely	O
mirror	O
the	O
phenotype	O
and	O
genotype	O
of	O
primary	O
tumors	O
than	O
do	O
serum-cultured	O
cell	O
lines.	O

Epidermal	O
growth	O
factor	O
receptor	O
and	O
Ink4a/Arf:	O
convergent	O
mechanisms	O
governing	O
terminal	O
differentiation	O
and	O
transformation	O
along	O
the	O
neural	B
stem	I
cell	I
to	O
astrocyte	O
axis.	O

Looking	O
at	O
the	O
hierarchy	O
of	O
the	O
stem	B
cell	I
compartment	O
and	O
its	O
developmental	O
specification,	O
an	O
important	O
question	O
emerges.	O

Is	O
the	O
differentiation	O
of	O
SCs	O
a	O
“one	O
way	O
street”,	O
where	O
during	O
embryogenesis	O
all	O
PSCs	O
gradually	O
disappear,	O
giving	O
rise	O
to	O
TCSCs	O
or,	O
alternatively,	O
do	O
some	O
epiblast-derived	O
PSCs	O
survive	O
beyond	O
embryonic	O
development	O
into	O
adulthood	O
and	O
remain	O
as	O
a	O
“hibernating”	O
backup	O
population	O
for	O
TCSCs?	O
This	O
possibility	O
would	O
somewhat	O
mimic	O
the	O
organization	O
of	O
the	O
stem	B
cell	I
compartment	O
in	O
urodeles,	O
where	O
a	O
population	O
of	O
the	O
precursors	O
of	O
pluripotent	O
blastema	O
SCs	O
is	O
left	O
dormant	O
during	O
development	O
in	O
adult	O
tissues	O
[9]..	O

Since	O
the	O
plasma	O
Igf-1	O
level	O
is	O
regulated	O
in	O
mice	O
by	O
caloric	O
uptake	O
and	O
in	O
humans	O
by	O
calorie	O
uptake	O
if	O
in	O
particular	O
protein	O
content	O
in	O
the	O
diet	O
is	O
low	O
[30],	O
these	O
data	O
shed	O
new	O
light	O
on	O
caloric	O
restriction,	O
senescence,	O
and	O
the	O
size	O
of	O
hematopoietic	B
stem	I
cell	I
compartment.	O

Based	O
on	O
our	O
data,	O
we	O
postulate	O
novel	O
linkages	O
between	O
the	O
Igf-1	O
level,	O
aging,	O
and	O
the	O
stem	B
cell	I
compartment.	O

Recently,	O
the	O
potential	O
role	O
of	O
stem	B
cells	I
and	O
of	O
regulatory	O
cells	O
has	O
received	O
attention,	O
with	O
enhancement	O
of	O
ARDS	O
resolution	O
by	O
cell	O
therapy	O
being	O
explored..	O

A	O
transient	O
phase	O
then	O
follows,	O
whereby	O
a	O
reduced	O
group	O
of	O
cells	O
upregulates	B
early	I
stem	I
cell	I
markers.	O

Recent	O
developments	O
in	O
stem	O
cell	O
research	O
and	O
derived	O
clinical	O
stem	B
cell	I
therapies	O
have	O
given	O
reason	O
to	O
believe	O
that	O
such	O
cell-based	O
treatments	O
will	O
become	O
generally	O
available	O
in	O
the	O
near	O
future.	O

Mesenchymal	B
stem	I
cell	I
engraftment	O
in	O
lung	O
is	O
enhanced	O
in	O
response	O
to	O
bleomycin	O
exposure	O
and	O
ameliorates	O
its	O
fibrotic	O
effects.	O

Testicular	O
peritubular	O
cells	O
fulfill	O
essential	O
functions,	O
including	O
sperm	O
transport,	O
contributions	O
to	O
the	O
spermatogonial	B
stem	I
cell	I
niche,	O
and	O
paracrine	O
interactions	O
within	O
the	O
testis.	O

Glial	O
cell	O
line-derived	O
neurotrophic	O
factor	O
is	O
constitutively	O
produced	O
by	O
human	O
testicular	O
peritubular	O
cells	O
and	O
may	O
contribute	O
to	O
the	O
spermatogonial	B
stem	I
cell	I
niche	O
in	O
man.	O

Peritubular	O
myoid	O
cells	O
participate	O
in	O
male	B
mouse	I
spermatogonial	I
stem	I
cell	I
maintenance.	O

Secretome	O
analysis	O
of	O
testicular	O
peritubular	O
cells:	O
A	O
window	O
into	O
the	O
human	O
testicular	O
microenvironment	O
and	O
the	O
spermatogonial	B
stem	I
cell	I
niche	O
in	O
man.	O

The	O
ALK5	O
kinase	O
inhibitor	O
SB-431542	O
facilitated	O
proliferation	O
and	O
sheet	O
formation	O
of	O
embryonic	B
stem	I
cell	I
derived	O
endothelial	O
cells	O
and	O
in	O
fetal	O
mouse	O
metatarsal	O
assays	O
(Watabe	O
et	O
al.	O

Within	O
the	O
group	O
of	O
pALL	O
patients	O
that	O
are	O
medically	O
refractory	O
and	O
considered	O
for	O
stem	B
cell	I
transplantation,	O
the	O
precursor	O
B	O
cell	O
versus	O
precursor	O
T	O
cell	O
lineages	O
mirror	O
the	O
frequency	O
of	O
these	O
types	O
in	O
the	O
pALL	O
population	O
as	O
a	O
whole.	O

It	O
is	O
often	O
difficult	O
to	O
get	O
T	O
cell	O
lineage	O
pALL	O
patients	O
into	O
remission	O
after	O
relapse,	O
as	O
required	O
for	O
transplantation,	O
leaving	O
the	O
majority	O
of	O
the	O
patients	O
advancing	O
to	O
stem	B
cell	I
transplantation	O
with	O
pre-B	O
cell	O
leukemia..	O

MiR-296	O
suppresses	O
the	O
expression	O
of	O
Trp53inp1,	O
a	O
protein	O
known	O
to	O
repress	O
the	O
proliferation	O
in	O
neural	B
stem	I
cell	I
[117],	O
as	O
well	O
as	O
Itm2a,	O
a	O
protein	O
essential	O
for	O
chondrogenic	O
cellular	O
differentiation	O
[118].	O

Alcohol	O
Alters	O
DNA	O
Methylation	O
Patterns	O
and	O
Inhibits	O
Neural	B
Stem	I
Cell	I
Differentiation.	O

mTORC1-dependent	O
and	O
-independent	O
regulation	O
of	O
stem	B
cell	I
renewal,	O
differentiation,	O
and	O
mobilization.	O

CCND2	O
has	O
been	O
shown	O
to	O
be	O
important	O
for	O
long-term	O
maintenance	O
of	O
spermatogonial	B
stem	I
cell	I
self-renewal73,	O
whereas	O
Ccnd1	O
expression	O
is	O
predominantly	O
associated	O
with	O
differentiating	O
subsets	O
of	O
spermatogonia37.	O

Germline	B
stem	I
cell	I
activity	O
is	O
sustained	O
by	O
SALL4-dependent	O
silencing	O
of	O
distinct	O
tumor	O
suppressor	O
genes.	O

Spermatogonial	B
stem	I
cell	I
self-renewal	O
requires	O
ETV5-mediated	O
downstream	O
activation	O
of	O
brachyury	O
in	O
mice.	O

Digital	O
DNA	O
methylation	O
analysis	O
of	O
stem	B
cell	I
reprogramming	O
by	O
targeted	O
bisulfite	O
sequencing.	O

The	O
influence	O
of	O
fiber	O
diameter	O
of	O
electrospun	O
substrates	O
on	O
neural	B
stem	I
cell	I
differentiation	O
and	O
proliferation.	O

Micro-	O
and	O
nanoengineering	O
for	O
stem	B
cell	I
biology:	O
The	O
promise	O
with	O
a	O
caution.	O

A	O
key	O
advantage	O
with	O
stem	B
cell	I
derived	O
macrophages	O
is	O
the	O
ability	O
to	O
create	O
genetically	O
modified	O
macrophages	O
lines.	O

Advances	O
in	O
the	O
stem	B
cell	I
biology	O
field	O
will	O
likely	O
increase	O
the	O
prevalence	O
of	O
this	O
model	O
system	O
in	O
the	O
future..	O

Indications	O
were:	O
recurrent	O
obstruction	O
after	O
slide	O
tracheoplasty	O
(2),	O
persistent	O
airway	O
compression	O
after	O
correction	O
of	O
a	O
congenital	O
cardiac	O
lesion	O
(2),	O
collapse	O
of	O
stem	B
cell	I
supported	O
tracheal	O
homograft,	O
tracheomegaly	O
following	O
fetal	O
balloon	O
insertion,	O
and	O
syndromic	O
tracheobronchomalacia	O
(TBM).	O

Advanced	O
sequencing	O
technologies,	O
genome	O
modification	O
techniques,	O
and	O
the	O
development	O
of	O
embryonic	B
stem	I
cell	I
protocols	O
ensure	O
the	O
rat	O
remains	O
an	O
important	O
mammalian	O
model	O
for	O
disease	O
studies.	O

Advanced	O
sequencing	O
technologies,	O
genome	O
modification	O
techniques,	O
and	O
the	O
development	O
of	O
embryonic	B
stem	I
cell	I
protocols	O
ensure	O
the	O
rat	O
remains	O
an	O
important	O
mammalian	O
model	O
for	O
disease	O
studies.	O

However,	O
the	O
protocols	O
for	O
human	B
stem	I
cell	I
reprogramming	O
and	O
differentiation	O
are	O
still	O
challenging,	O
and	O
the	O
obtained	O
neurons	O
have	O
embryonic	O
or	O
early	O
postnatal	O
phenotype,	O
rather	O
than	O
adult	O
neurons	O
affected	O
by	O
neurodegeneration	O
in	O
patients.	O

Neural	B
stem	I
cell	I
transplantation	O
and	O
melatonin	O
treatment	O
in	O
a	O
6-hydroxydopamine	O
model	O
of	O
Parkinson’s	O
disease.	O

Glioma	B
stem	I
cell	I
lines	O
expanded	O
in	O
adherent	O
culture	O
have	O
tumor-specific	O
phenotypes	O
and	O
are	O
suitable	O
for	O
chemical	O
and	O
genetic	O
screens.	O

B,	O
Western	O
blot	O
analysis	O
of	O
non-GICs	O
and	O
GICs	O
showing	O
the	O
expression	O
of	O
stem	B
cell	I
markers	O
CD133,	O
CD44,	O
Nestin,	O
Sox-2,	O
proliferation	O
marker	O
Ki67,	O
and	O
the	O
lineage	O
markers	O
GFAP	O
and	O
Tuj-1.	O

CD133	O
has	O
been	O
used	O
to	O
isolate	O
populations	O
of	O
cancer	O
stem	O
cells	O
with	O
enhanced	O
stem	B
cell	I
phenotypes	O
from	O
multiple	O
types	O
of	O
brain	O
cancer	O
and	O
these	O
CD133+	O
cells	O
from	O
glioblastoma	O
are	O
capable	O
of	O
multi-lineage	O
differentiation	O
and	O
had	O
a	O
high	O
capacity	O
for	O
neurosphere	O
formation	O
(15,16)..	O

This	O
patterning	O
has	O
been	O
observed	O
in	O
stem	B
cell	I
marker	O
studies	O
where	O
an	O
umbrella-like	O
surface	O
of	O
progeny	O
is	O
visible	O
from	O
a	O
labelled	O
intrafollicular	O
basal	O
cell	O
(Reference	O
[33]-Fig	O
7D)..	O

Distinct	O
functions	O
for	O
Wnt/beta-catenin	O
in	O
hair	B
follicle	I
stem	I
cell	I
proliferation	O
and	O
survival	O
and	O
interfollicular	O
epidermal	O
homeostasis.	O

Cancer	O
Stem	O
Cells	O
in	O
Head	O
and	B
Neck	I
Squamous	I
Cell	I
Carcinoma:	O
Identification,	O
Characterization	O
and	O
Clinical	O
Implications.	O

Paneth	O
cells	O
are	O
specialized	O
IECs	O
located	O
adjacent	O
to	O
the	O
stem	B
cell	I
zone	O
in	O
the	O
base	O
of	O
the	O
crypts	O
in	O
the	O
small	O
intestine.	O

Nucleotide-binding	O
oligomerization	O
domain	O
2	O
has	O
been	O
reported	O
to	O
account	O
for	O
stem	O
cell	O
protection	O
and	O
to	O
contribute	O
to	O
stem	B
cells	I
regeneration	O
via	O
responses	O
triggered	O
by	O
MDP	O
recognition	O
and	O
leading	O
to	O
the	O
recruitment	O
of	O
NF-κB	O
at	O
the	O
membrane	O
surface	O
of	O
IECs	O
(136–139).	O

Microenvironmental	O
control	O
of	O
stem	B
cell	I
fate	O
in	O
intestinal	O
homeostasis	O
and	O
disease.	O

Microenvironmental	O
control	O
of	O
stem	B
cell	I
fate	O
in	O
intestinal	O
homeostasis	O
and	O
disease.	O

This	O
paper	O
reviews	O
the	O
exciting	O
developments	O
in	O
the	O
study	O
of	O
stem	B
cell	I
dynamics	O
in	O
homeostasis,	O
intestinal	O
regeneration,	O
and	O
carcinogenesis,	O
and	O
explores	O
the	O
implications	O
for	O
human	O
disease	O
and	O
cancer	O
therapies.	O

This	O
review	O
will	O
explore	O
some	O
of	O
the	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
the	O
control	O
of	O
the	O
intestinal	B
stem	I
cell	I
and	O
daughter	O
cell	O
fate	O
determination	O
in	O
intestinal	O
homeostasis	O
and	O
assess	O
the	O
implications	O
for	O
colorectal	O
carcinogenesis..	O

Paneth	O
cells,	O
although	O
differentiated,	O
reside	O
at	O
the	O
crypt	O
base	O
and	O
secrete	O
antimicrobial	O
peptides	O
as	O
well	O
as	O
growth	O
factors	O
to	O
maintain	O
the	O
stem	B
cell	I
niche.	O

However,	O
this	O
technique	O
requires	O
prior	O
knowledge	O
of	O
the	O
marker	O
to	O
be	O
tested	O
and	O
cannot	O
assess	O
the	O
stem	B
cell	I
capacity	O
of	O
cells	O
not	O
expressing	O
the	O
candidate	O
gene.	O

Rather	O
than	O
relying	O
on	O
putative	O
marker	O
expression,	O
Buczacki	O
et	O
al	O
focused	O
on	O
cells	O
with	O
functional	O
label	O
retention	O
properties	O
and	O
in	O
a	O
series	O
of	O
elegant	O
experiments,	O
demonstrated	O
that	O
these	O
cells	O
are	O
committed	O
secretory	O
cell	O
precursors	O
that	O
retain	O
the	O
capability	O
of	O
returning	O
to	O
stem	B
cell	I
function	O
in	O
the	O
event	O
of	O
intestinal	O
damage	O
and	O
regeneration	O
18.	O

Wnt	O
ligands,	O
secreted	O
from	O
the	O
intestinal	O
subepithelial	O
myofibrobasts	O
and	O
the	O
Paneth	O
cells,	O
act	O
predominantly	O
at	O
the	O
base	O
of	O
the	O
crypt	O
(red	O
cells)	O
to	O
maintain	B
stem	I
cell	I
function	O
and	O
transit	O
amplifying	O
cell	O
proliferation;	O
(B)	O
Bone	O
morphogenetic	O
protein	O
signalling.	O

Notch	O
regulates	O
cell	O
fate	O
through	O
cell‐to‐cell	O
contact	O
in	O
the	O
stem	B
cell	I
and	O
transit	O
amplifying	O
zone	O
at	O
the	O
base	O
of	O
the	O
crypt	O
(yellow	O
cells).	O

Notch	O
signalling	O
is	O
also	O
involved	O
in	O
the	O
control	O
of	O
stem	B
cells	I
and	O
transit	O
amplifying	O
cell	O
division	O
28,	O
29.	O

This	O
indicates	O
that	O
there	O
is	O
a	O
spectrum	O
of	O
stem	B
cell	I
function	O
even	O
within	O
cells	O
expressing	O
the	O
Lgr5	O
marker	O
and	O
that	O
these	O
cells	O
transit	O
reversibly	O
between	O
states	O
of	O
variable	O
competence	O
influenced	O
by	O
proximity	O
to	O
niche‐derived	O
signals.	O

Regulated	O
disruption	O
of	O
these	O
epithelial,	O
stromal,	O
and	O
immunological	O
morphogen	O
gradients	O
with	O
resultant	O
change	O
in	O
epithelial	B
stem	I
cell	I
function	O
is	O
a	O
key	O
feature	O
of	O
the	O
response	O
to	O
damage	O
and	O
underpins	O
the	O
regenerative	O
and	O
reparative	O
capacity	O
of	O
the	O
intestinal	O
epithelium.	O

Recent	O
work	O
has	O
shown	O
that	O
this	O
disruption	O
of	O
the	O
crypt	O
microenvironment	O
can	O
provoke	O
a	O
return	O
to	O
stem	O
cell	O
function	O
from	O
cells	O
that	O
have	O
ostensibly	O
exited	O
the	O
stem	B
cell	I
niche.	O

Metcalfe	O
et	O
al	O
showed	O
that	O
intestinal	O
architecture	O
can	O
regenerate	O
if	O
either	O
the	O
stem	B
cell	I
or	O
the	O
progenitor	O
zone	O
remains	O
intact	O
following	O
injury;	O
however,	O
if	O
both	O
cell	O
populations	O
are	O
damaged/ablated	O
simultaneously,	O
the	O
intestinal	O
architecture	O
is	O
irreversibly	O
perturbed	O
37..	O

If	O
progenitor	O
cells	O
are	O
capable	O
of	O
dedifferentiation	O
and	O
return	O
to	O
stem	B
cell	I
function	O
following	O
injury,	O
is	O
the	O
fate	O
of	O
fully	O
differentiated	O
cells	O
fixed?	O
Westphalen	O
et	O
al	O
used	O
a	O
doublecortin‐like	O
kinase1	O
transgenic	O
mouse	O
to	O
label	O
and	O
trace	O
the	O
fate	O
of	O
mature	O
tuft	O
cells	O
in	O
the	O
murine	O
colon.	O

The	O
‘top	O
down’	O
model	O
was	O
based	O
on	O
the	O
observation	O
that	O
some	O
early	O
adenomatous	O
lesions	O
develop	O
on	O
the	O
luminal	O
surface	O
without	O
any	O
obvious	O
contact	O
to	O
the	O
crypt	O
base	O
and	O
proposed	O
an	O
intercrypt	O
location	O
for	O
the	O
stem	B
cell	I
niche.	O

The	O
work	O
in	O
this	O
review	O
highlights	O
that	O
the	O
stem	O
cell	O
pool	O
should	O
be	O
thought	O
of	O
as	O
a	O
functional	O
collective,	O
comprising	O
a	O
dynamic	O
and	O
heterogeneous	O
population	O
of	O
cells	O
with	O
variable	O
stem	B
cell	I
competence	O
imposed	O
by	O
position	O
within	O
the	O
niche	O
and	O
microenvironmental	O
morphogen	O
context..	O

There	O
is,	O
however,	O
compelling	O
evidence	O
and	O
increasing	O
acceptance	O
in	O
the	O
cancer	O
stem	O
cell	O
field	O
that	O
stemness	O
is	O
a	O
dynamic	O
state	O
with	O
cancer	O
stem	B
cell	I
plasticity	O
multifactorially	O
driven	O
by	O
cell‐intrinsic	O
factors,	O
microenvironmental	O
signals,	O
and	O
evolutionary	O
pressures.	O

Cancer	B
stem	I
cell	I
plasticity	O
bestows	O
a	O
considerable	O
evolutionary	O
advantage	O
on	O
a	O
tumour	O
by	O
allowing	O
it	O
to	O
adapt	O
to	O
a	O
changing	O
environment	O
and	O
selective	O
pressures	O
imposed	O
by	O
tumour	O
context,	O
immune	O
activation,	O
and	O
chemotherapy.	O

In	O
contrast	O
to	O
the	O
exquisitely	O
controlled	O
and	O
balanced	O
morphogen	O
signalling	O
seen	O
in	O
intestinal	O
homeostasis,	O
the	O
cancer	B
stem	I
cell	I
microenvironment	O
is	O
a	O
disorganized	O
and	O
chaotic	O
signalling	O
mix,	O
originating	O
from	O
cancer‐associated	O
fibroblasts,	O
infiltrating	O
immunocytes,	O
and	O
endothelial	O
cells.	O

Even	O
tumour‐associated	O
endothelial	O
cells	O
have	O
recently	O
been	O
shown	O
to	O
have	O
an	O
effect	O
on	O
the	O
cancer	B
stem	I
cell	I
phenotype	O
by	O
paracrine	O
secretion	O
of	O
the	O
Notch	O
ligand	O
Jagged1	O
61	O
(Figure.	O

To	O
understand	O
and	O
then	O
target	O
the	O
factors	O
that	O
discriminate	O
the	O
neoplastic	O
from	O
the	O
normal	B
stem	I
cell	I
niche	O
will	O
be	O
the	O
next	O
step..	O

Aberrant	O
epithelial	O
GREM1	O
expression	O
initiates	O
colonic	O
tumorigenesis	O
from	O
cells	O
outside	O
the	O
stem	B
cell	I
niche.	O

Endothelial	O
cells	O
promote	O
the	O
colorectal	B
cancer	I
stem	I
cell	I
phenotype	O
through	O
a	O
soluble	O
form	O
of	O
Jagged‐1.	O

Cav-1	O
is	O
a	O
protein	O
that	O
localizes	O
to	O
caveolae,	O
invaginations	O
of	O
the	O
plasma	O
membrane	O
which	O
are	O
found	O
in	O
most	O
cells	O
and	O
is	O
particularly	O
important	O
for	O
vesicular	O
trafficking	O
in	O
endothelial	O
cells.[28]	O
Cav-1	O
also	O
regulates	O
eNOS	O
activity	O
and	O
may	O
play	O
a	O
role	O
in	O
PAH	O
pathogenesis.[27]	O
CD34	O
is	O
a	O
cell	O
surface	O
protein	O
implicated	O
in	O
cell	O
migration	O
and	O
halting	O
of	O
differentiation	O
that	O
has	O
been	O
documented	O
to	O
be	O
expressed	O
in	O
ECFC	O
and	O
PAEC,	O
and	O
which	O
has	O
served	O
most	O
commonly	O
as	O
a	O
hematopoietic	B
stem	I
cell	I
marker.[8,29].	O

Despite	O
the	O
immaturity	O
of	O
stem	O
cell-derived	O
differentiated	O
cell	O
types,	O
investigating	O
how	O
the	O
changes	O
occur	O
in	O
remodelling	O
contributes	O
to	O
the	O
pathogenesis	O
of	O
heart	O
failure	O
using	O
models	O
that	O
utilize	O
these	O
cells,	O
especially	O
hiPSC-CMs,	O
and	O
offers	O
huge	O
potential	O
in	O
mapping	O
this	O
complex	O
disease..	O
The	O
advancements	O
in	O
stem	B
cell	I
biology	O
and	O
tissue	O
engineering	O
have	O
spearheaded	O
the	O
development	O
of	O
in	O
vitro	O
cardiac	O
models	O
that	O
can	O
employ	O
patient-	O
or	O
disease-specific	O
CMs	O
and	O
non-myocytes	O
in	O
culture.	O

This	O
agrees	O
with	O
evidence	O
from	O
stem	B
cells	I
and	O
cell	O
lines	O
indicates	O
that	O
patterns	O
of	O
gene	O
expression	O
thought	O
to	O
be	O
under	O
epigenetic	O
control	O
can	O
be	O
reversed	O
[2,62]..	O

CKIT	O
is	O
the	O
receptor	O
for	O
the	O
stem	B
cell	I
growth	O
factor	O
(SCF)	O
and	O
belongs	O
to	O
the	O
platelet-derived	O
growth	O
factor	O
receptor	O
(PDGFR)	O
family.	O

The	O
methylase	O
METTL3	O
can	O
participate	O
in	O
the	O
regulation	O
of	O
stem	B
cell	I
self‐renewal	O
and	O
differentiation	O
[14].	O

The	O
epigenetic	O
modification	O
RNA	O
plays	O
key	O
roles	O
in	O
the	O
stem	B
cell	I
differentiation.	O

(2019)	O
Osteogenesis	O
depends	O
on	O
commissioning	O
of	O
a	O
network	O
of	O
stem	B
cell	I
transcription	O
factors	O
that	O
act	O
as	O
repressors	O
of	O
adipogenesis.	O

Advances	O
in	O
stem	B
cell	I
technology	O
have	O
also	O
explored	O
the	O
possibility	O
of	O
restoring	O
type	O
IV	O
collagen	O
network	O
to	O
the	O
GBM	O
in	O
Alport	O
AS.	O

The	O
molecular	O
mechanisms	O
of	O
atherothrombosis	O
will	O
soon	O
be	O
uncovered	O
via	O
the	O
rapid	O
accumulation	O
of	O
molecular	O
information	O
and	O
progress	O
in	O
stem	B
cell	I
technology..	O

To	O
validate	O
our	O
biochip	O
we	O
cultured	O
the	O
hCMEC/D3	O
human	O
brain	O
endothelial	O
cell	O
line	O
and	O
the	O
stem	B
cell	I
derived	O
CD34+	O
human	O
endothelial	O
cells	O
in	O
co-culture	O
with	O
bovine	O
pericytes..	O

A	O
retinoic	O
acid-enhanced,	O
multicellular	O
human	O
blood–brain	O
barrier	O
model	O
derived	O
from	O
stem	B
cell	I
sources.	O

Orkin	O
SH,	O
Zon	O
LI	O
(2008)	O
Hematopoiesis:	O
an	O
evolving	O
paradigm	O
for	O
stem	B
cell	I
biology.	O

(F)	O
Expression	O
of	O
neural	B
stem	I
cell	I
markers	O
reveals	O
that	O
the	O
cells	O
have	O
a	O
neural	O
progenitor	O
phenotype.	O

That	O
is	O
to	O
say,	O
the	O
cancer	B
stem	I
cell	I
[11]	O
is	O
'born'	O
at	O
the	O
precancer	O
stage.	O

Our	O
data	O
support	O
a	O
modified	O
model,	O
in	O
which	O
the	O
programming	O
stabilized	O
in	O
the	O
precancer	B
stem	I
cell	I
might	O
be	O
epigenetic	O
as	O
well	O
as	O
genetic.	O

Here	O
we	O
summarize	O
existing	O
commercial	O
NPs	O
which	O
can	O
act	O
as	O
contrast	O
agents	O
of	O
three	O
commonly	O
used	O
imaging	O
modalities,	O
including	O
fluorescence	O
imaging,	O
magnetic	O
resonance	O
imaging	O
and	O
photoacoustic	O
imaging,	O
for	O
stem	B
cell	I
labeling	O
and	O
tracking.	O

Specifically,	O
we	O
go	O
through	O
their	O
technologies,	O
industry	O
distributors,	O
applications	O
and	O
existing	O
concerns	O
in	O
stem	B
cell	I
research.	O

Finally,	O
we	O
also	O
discuss	O
the	O
concerns	O
of	O
existing	O
NP	O
products	O
and	O
the	O
future	O
of	O
development	O
of	O
new	O
NP	O
products	O
for	O
stem	B
cell	I
tracking..	O

Amongst	O
the	O
numerous	O
QD	O
products,	O
Qdot®	O
(Invitrogen)	O
is	O
most	O
frequently	O
used	O
for	O
stem	B
cell	I
labeling	O
and	O
tracking,	O
seconded	O
by	O
efluor®	O
(eBioscience).	O

So	O
far,	O
there	O
is	O
no	O
report	O
applying	O
fluorescent	O
silica	O
NPs	O
for	O
stem	B
cell	I
labeling	O
and	O
tracking.	O

SPIOs	O
have	O
been	O
used	O
as	O
MRI	O
contrast	O
agents	O
since	O
1990.72	O
Currently,	O
they	O
are	O
clinically	O
used	O
for	O
liver	O
imaging,70,	O
72	O
lymph	O
nodes	O
imaging,70	O
and	O
blood	O
pool	O
agent.70	O
Although	O
not	O
initially	O
developed	O
for	O
stem	O
cell	O
labeling	O
and	O
tracking,70-78	O
they	O
have	B
been	I
successfully	I
adapted	I
for	I
tracking	I
stem	I
cells	I
post	O
implantation.78,	O
79	O
Among	O
them,	O
Ferumoxides	O
and	O
ferucarbotran	O
are	O
most	O
frequently	O
usedprobably	O
because	O
of	O
the	O
regulation	O
by	O
U.S.	O

The	O
number	O
of	O
publications	O
using	O
SPIO	O
in	O
stem	B
cell	I
labeling	O
or	O
tracking	O
increased	O
exponentially	O
in	O
recent	O
years	O
(Figure.	O

The	O
significant	O
increase	O
of	O
the	O
number	O
of	O
publications	O
indicates	O
the	O
great	O
potentials	O
of	O
SPIOs	O
and	O
a	O
rising	O
“market	O
share”	O
in	O
the	O
field	O
of	O
stem	B
cell	I
labeling	O
and	O
tracking.	O

Survey	O
of	O
publications	O
related	O
to	O
“superparamagnetic	O
iron	O
oxide	O
nanoparticle	O
in	O
stem	B
cell	I
research”	O
in	O
the	O
Web	O
of	O
Science	O
database	O
as	O
a	O
function	O
of	O
publication	O
years	O
(3	O
years	O
as	O
a	O
data	O
point)	O
for	O
the	O
indicated	O
combination	O
of	O
words	O
in	O
the	O
title	O
and/or	O
abstract.	O

The	O
number	O
of	O
publications	O
shows	O
the	O
rapid	O
increasing	O
interest	O
in	O
stem	B
cell	I
and	O
particle	O
tracking	O
in	O
the	O
literature.	O

In	O
other	O
words,	O
the	O
trend	O
of	O
increasing	O
number	O
of	O
publications	O
indicates	O
a	O
rising	O
“market	O
share”	O
of	O
superparamagnetic	O
iron	O
oxide	O
in	O
stem	B
cell	I
related	O
research..	O

Prior	O
to	O
apply	O
gadolinium	O
NPs	O
in	O
stem	O
cell	O
therapy,	O
their	O
effects	O
on	O
stem	B
cell	I
function	O
needs	O
to	O
be	O
fully	O
investigated..	O

Gold	O
(Au)	O
NPs,	O
Au	O
nanorod,	O
and	O
single	O
walled	O
carbon	O
nanotubes	O
(SWNTs)	O
are	O
potential	O
contrast	O
agents	O
for	O
photoacoustic	O
imaging.93,	O
94	O
Concerning	O
the	O
safety	O
issue,	O
SWNTs	O
have	O
not	O
been	O
utilized	O
for	O
stem	B
cell	I
labeling	O
and	O
tracking.	O

Research	O
of	O
using	O
QDs	O
in	O
stem	B
cell	I
therapy	O
is	O
extensively	O
investigated.	O

With	O
the	O
rapid	O
development	O
of	O
nanotechnology	O
in	O
stem	B
cell	I
therapy,	O
the	O
list	O
of	O
commercial	O
NP	O
products	O
will	O
quickly	O
expand..	O

Xu	O
etc	O
demonstrated	O
the	O
possibility	O
of	O
single	O
particle	O
single	O
cell	O
detection	O
for	O
stem	B
cell	I
therapy.	O

We	O
summarize	O
existing	O
commercial	O
NPs	O
which	O
can	O
act	O
as	O
contrast	O
agents	O
for	O
three	O
commonly	O
used	O
imaging	O
modalities	O
for	O
stem	B
cell	I
labeling	O
and	O
tracking.	O

We	O
overviewed	O
the	O
technology,	O
current	O
market	O
status	O
and	O
their	O
applications	O
in	O
stem	B
cell	I
labeling	O
and	O
tracking.	O

We	O
also	O
discussed	O
the	O
concerns	O
and	O
limitations	O
of	O
existing	O
commercial	O
NPs	O
and	O
provide	O
perspectives	O
for	O
the	O
development	O
of	O
future	O
NP	O
products	O
for	O
stem	B
cell	I
therapy.	O

Prior	O
to	O
the	O
extensive	O
use	O
of	O
commercial	O
NP	O
in	O
stem	B
cell	I
therapy	O
in	O
humans,	O
concerns	O
of	O
NPs	O
including	O
the	O
unclear	O
safety	O
profile,	O
signal	O
loss	O
in	O
longitudinal	O
tracking,	O
insufficient	O
to	O
attain	O
all	O
necessary	O
information	O
of	O
transplanted	O
cells	O
for	O
single	O
modality	O
NPs	O
and	O
limited	O
capability	O
to	O
report	O
cell	O
functionality	O
and	O
viability	O
will	O
have	O
to	O
be	O
clearly	O
resolved.	O

The	O
hMSCs	O
and	O
their	O
transforming	O
derivatives	O
were	O
cultured	O
in	O
mesenchymal	B
stem	I
cell	I
growth	O
media	O
(Lonza),	O
as	O
previously	O
described	O
[19].	O

The	O
effects	O
of	O
Mg	O
ions	O
of	O
various	O
concentrations	O
on	O
the	O
pluripotency	O
of	O
hESCs	O
were	O
examined	O
for	O
the	O
first	O
time	O
in	O
this	O
study	O
to	O
determine	O
the	O
feasibility	O
of	O
Mg-based	O
biodegradable	O
scaffolds	O
for	O
maintaining	O
hESC	O
pluripotency	O
for	O
potential	B
stem	I
cell	I
therapies.	O

In	O
closing,	O
Meier	O
and	O
Rosenkranz	O
focus	O
on	O
the	O
modulation	O
of	O
“Cx43	O
expression	O
observed	O
after	O
transplantation	O
of	O
stem	O
cells	O
in	O
animal	O
models	O
of	O
traumatic	O
and	O
hypoxic	O
brain	O
injury.”	O
The	O
authors	O
develop	O
the	O
intriguing	O
hypothesis	O
that	O
these	O
changes	O
in	O
gap	O
junctional	O
communication	O
might	O
provide	O
one	O
possible	O
explanation	O
for	O
the	O
beneficial	O
effects	O
associated	O
with	O
exogenous	B
stem	I
cell	I
application	O
(Meier	O
and	O
Rosenkranz,	O
2014).	O

Cx43	O
expression	O
and	O
function	O
in	O
the	O
nervous	O
system-implications	O
for	O
stem	B
cell	I
mediated	O
regeneration.	O

Mesenchymal	B
stem	I
cell	I
engraftment	O
in	O
lung	O
is	O
enhanced	O
in	O
response	O
to	O
bleomycin	O
exposure	O
and	O
ameliorates	O
its	O
fibrotic	O
effects.	O

Human	O
embryonic	O
stem	O
cell-derived	O
oligodendrocyte	O
progenitor	O
cell	O
transplants	O
remyelinate	O
and	O
restore	O
locomotion	O
after	O
spinal	O
cord	O
injury.	O
Human	O
embryonic	O
stem	O
cell-derived	O
oligodendrocyte	O
progenitor	O
cell	O
transplants	O
improve	O
recovery	O
after	O
cervical	O
spinal	O
cord	O
injury.	O
Effect	O
of	O
_Zhichan_	O
Decoction	O
on	B
Neural	I
Stem	I
Cell	I
Differentiation	O
in	O
Parkinson's	O
Disease	O
Model	O
Rats.	O

Morris	O
LX,	O
Spradling	O
AC	O
(2011)	O
Long-term	O
live	O
imaging	O
provides	O
new	O
insight	O
into	O
stem	B
cell	I
regulation	O
and	O
germline-soma	O
coordination	O
in	O
the	O
Drosophila	O
ovary.	O

Davies	O
EL,	O
Fuller	O
MT	O
(2008)	O
Regulation	O
of	O
self-renewal	O
and	O
differentiation	O
in	O
adult	B
stem	I
cell	I
lineages:	O
lessons	O
from	O
the	O
Drosophila	O
male	O
germ	O
line.	O

Transplanted	O
murine	O
long-term	O
repopulating	O
hematopoietic	O
cells	O
can	O
differentiate	O
to	O
osteoblasts	O
in	O
the	B
marrow	I
stem	I
cell	I
niche.	O

Hippo	O
signaling	O
is	O
known	O
to	O
be	O
involved	O
in	O
stem	B
cell	I
and	O
progenitor	O
cell	O
maintenance,	O
renewal,	O
and	O
expansion	O
in	O
a	O
variety	O
of	O
tissues	O
to	O
play	O
a	O
crucial	O
role	O
in	O
regeneration	O
and	O
repair	O
(Wang	O
et	O
al.,	O
2017;	O
Moya	O
and	O
Halder,	O
2019).	O

Leukaemogenic	O
effects	O
of	O
Ptpn11	O
activating	O
mutations	O
in	O
the	O
stem	B
cell	I
microenvironment.	O

Adenovirus	O
infections	O
in	O
stem	B
cell	I
transplant	O
recipients:	O
recent	O
developments	O
in	O
understanding	O
of	O
pathogenesis,	O
diagnosis	O
and	O
management.	O

Treatment	O
of	O
adenovirus	O
disease	O
in	O
stem	B
cell	I
transplant	O
recipients	O
with	O
cidofovir.	O

PU.1-mediated	O
upregulation	O
of	O
CSF1R	O
is	O
crucial	O
for	O
leukemia	B
stem	I
cell	I
potential	O
induced	O
by	O
MOZ-TIF2.	O

Cytoskeletal	O
and	O
focal	O
adhesion	O
influences	O
on	O
mesenchymal	B
stem	I
cell	I
shape,	O
mechanical	O
properties,	O
and	O
differentiation	O
down	O
osteogenic,	O
adipogenic,	O
and	O
chondrogenic	O
pathways.	O

Cell	O
adhesion	O
and	O
mechanical	O
stimulation	O
in	O
the	O
regulation	O
of	O
mesenchymal	B
stem	I
cell	I
differentiation.	O

Recent	O
progresses	O
in	O
stem	B
cell	I
research	O
allow	O
investigators	O
to	O
study	O
cell-based	O
therapies	O
in	O
the	O
treatment	O
of	O
lung	O
diseases.	O

Lung	B
stem	I
cell	I
research	O
slightly	O
lags	O
behind	O
studies	O
on	O
other	O
organs.	O

This	O
review	O
will	O
briefly	O
highlight	O
the	O
recent	O
progresses	O
on	O
mouse	B
lung	I
stem	I
cell	I
research	O
and	O
its	O
applications	O
in	O
some	O
clinical	O
trials	O
for	O
specific	O
lung	O
diseases	O
such	O
as	O
IPF	O
and	O
COPD.	O

Repairing	O
the	O
destroyed	O
lung	O
structure	O
with	O
stem	B
cell	I
therapies	O
becomes	O
an	O
extremely	O
attractive	O
choice	O
to	O
treat	O
COPD.	O

Mesenchymal	B
stem	I
cells	I
promote	O
alveolar	O
epithelial	O
cell	O
wound	O
repair	O
in	O
vitro	O
through	O
distinct	O
migratory	O
and	O
paracrine	O
mechanisms.	O

Mesenchymal	B
stem	I
cell	I
engraftment	O
in	O
lung	O
is	O
enhanced	O
in	O
response	O
to	O
bleomycin	O
exposure	O
and	O
ameliorates	O
its	O
fibrotic	O
effects.	O

Mesenchymal	B
stem	I
cell	I
therapy	O
for	O
the	O
treatment	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease.	O

When	O
the	O
stem	O
cell	O
colony	O
reaches	O
a	O
certain	O
size,	O
the	O
stem	B
cells	I
on	O
the	O
colony	O
edge	O
will	O
differentiate	O
to	O
TA	O
cells.	O

Generating	O
large	O
numbers	O
of	O
bona	O
fide	O
mDAs	O
is	O
a	O
key	O
goal	O
of	O
stem	B
cell	I
based	O
approaches	O
towards	O
Parkinson's	O
disease	O
treatment.	O

In	O
recent	O
years	O
there	O
has	O
been	O
significant	O
progress	O
in	O
defining	O
common	O
strategies	O
of	O
stem	B
cell	I
self-renewal	O
using	O
lineage	O
tracing	O
assays	O
in	O
mice	O
(Simons	O
and	O
Clevers,	O
2011).	O

By	O
tracing	O
the	O
clonal	O
evolution	O
of	O
marked	O
cells	O
following	O
genetic	O
pulse-labelling	O
of	O
transgenic	O
animals,	O
statistical	O
methods	O
have	O
been	O
used	O
to	O
discern	O
the	O
pattern	O
of	O
adult	B
stem	I
cell	I
fate	O
in	O
several	O
actively	O
cycling	O
mammalian	O
tissues.	O

However,	O
although	O
such	O
approaches	O
provide	O
key	O
insights	O
into	O
the	O
mechanisms	O
of	O
stem	B
cell	I
maintenance	O
in	O
transgenic	O
animal	O
models,	O
their	O
relevance	O
and	O
application	O
to	O
human	O
tissues	O
is	O
unknown..	O

However,	O
the	O
range	O
and	O
identity	O
of	O
the	O
stem	O
cell	O
compartment,	O
and	O
the	O
frequency	O
of	O
stem	B
cell	I
loss	O
and	O
replacement,	O
has	O
not	O
been	O
quantified.	O

Locating	O
the	O
stem	B
cell	I
niche	O
and	O
tracing	O
hepatocyte	O
lineages	O
in	O
human	O
liver.	O

First,	O
the	O
proliferative	O
activity	O
of	O
stem	B
cells	I
and/or	O
their	O
differentiating	O
progenitor	O
cell	O
progeny	O
could	O
change	O
as	O
a	O
result	O
of	O
ageing.	O

Notably,	O
K8	O
and	O
K18	O
are	O
the	O
ancestral	O
genes	O
for	O
the	O
multiple	O
specialized	O
Type	O
II	O
and	O
Type	O
I	O
keratin	O
classes,	O
respectively,	O
and	O
constitute	O
the	O
first	O
cytoplasmic	O
IF	O
genes	O
expressed	O
in	O
the	O
embryo,	O
at	O
the	O
time	O
of	O
stem	B
cell	I
differentiation	O
along	O
the	O
different	O
cell	O
lineages	O
[16],	O
[17].	O

At	O
this	O
point,	O
with	O
low	O
tumor	O
burden	O
and	O
fairly	O
uniform	O
cancer	O
cell	O
population,	O
the	O
patient	O
could	O
be	O
treated	O
with	O
a	O
cancer	O
vaccine	O
targeting	O
specific	O
proteins	O
essential	O
to	O
the	O
stem	B
cell	I
survival..	O

We	O
have	O
now	O
incorporated	O
the	O
reserve	B
stem	I
cell	I
possibility	O
into	O
our	O
model	O
for	O
mutation	O
in	O
the	O
germ-line,	O
and	O
simulations	O
from	O
the	O
modified	O
model	O
reproduce	O
the	O
middle	O
age	O
decrease.	O

Involvement	O
of	O
aldehyde	O
dehydrogenase	O
1A2	O
in	O
the	O
regulation	O
of	O
cancer	B
stem	I
cell	I
properties	O
in	O
neuroblastoma.	O

Greiner	O
DL,	O
Hesselton	O
RA,	O
Shultz	O
LD	O
(1998)	O
SCID	O
mouse	O
models	O
of	O
human	B
stem	I
cell	I
engraftment.	O

Increasing	O
studies	O
have	O
revealed	O
that	O
LncRNAs	O
play	O
an	O
essential	O
role	O
in	O
gene	O
silencing,	O
as	O
trans-regulatory	O
elements	O
affecting	O
multiple	O
gene	O
transcription,	O
as	O
scaffolds	O
for	O
histone	O
modification,	O
enhancers	O
to	O
modify	O
gene	O
expression,	O
participators	O
in	O
genomic	O
reprogramming	O
involved	O
in	O
stem	B
cell	I
differentiation	O
and	O
nucleators	O
to	O
generate	O
the	O
dynamic	O
assembly	O
of	O
the	O
nuclear	O
structure	O
(reviewed	O
in	O
[4]).	O

Initially,	O
the	O
sustained	O
culture	O
of	O
pluripotent	B
stem	I
cells	I
required	O
growth	O
on	O
a	O
layer	O
of	O
mouse	O
embryonic	O
fibroblasts	O
(MEF),	O
which	O
presumably	O
provide	O
factors	O
that	O
sustain	O
cell	O
pluripotency	O
and	O
viability	O
[1].	O

Historically,	O
integrin-mediated	O
cell-ECM	O
interactions	O
have	O
been	O
considered	O
essential	O
for	O
maintenance	O
of	O
stem	B
cell	I
pluripotency	O
and	O
viability	O
[24-26].	O

The	O
absence	O
of	O
integrin	O
binding	O
proteins	O
within	O
the	O
hE-cad-Fc	O
substratum	O
may	O
indicate	O
that	O
integrin-mediated	O
signalling	O
is	O
dispensable	O
for	O
stem	B
cell	I
maintenance.	O

Control	O
of	O
stem	B
cell	I
fate	O
by	O
physical	O
interactions	O
with	O
the	O
extracellular	O
matrix.	O

Laminin-511	O
but	O
not	O
-332,	O
-111,	O
or	O
-411	O
enables	O
mouse	B
embryonic	I
stem	I
cell	I
self-renewal	O
in	O
vitro.	O

Leukemic	B
stem	I
cell	I
signatures	O
identify	O
novel	O
therapeutics	O
targeting	O
acute	O
myeloid	O
leukemia.	O

Revealing	O
a	O
core	O
signaling	O
regulatory	O
mechanism	O
for	O
pluripotent	B
stem	I
cell	I
survival	O
and	O
self-renewal	O
by	O
small	O
molecules.	O

E-cadherin	O
is	O
crucial	O
for	O
embryonic	B
stem	I
cell	I
pluripotency	O
and	O
can	O
replace	O
OCT4	O
during	O
somatic	O
cell	O
reprogramming.	O

Treatment	O
of	O
adenovirus	O
disease	O
in	O
stem	B
cell	I
transplant	O
recipients	O
with	O
cidofovir.	O

Adenovirus	O
infections	O
in	O
stem	B
cell	I
transplant	O
recipients:	O
recent	O
developments	O
in	O
understanding	O
of	O
pathogenesis,	O
diagnosis	O
and	O
management.	O

While	O
we	O
did	O
not	O
address	O
the	O
role	O
of	O
hypoxia	O
in	O
leukemogenesis	O
and	O
chemoresistance	O
in	O
current	O
work,	O
the	O
reports	O
from	O
our	O
group	O
and	O
others	O
have	O
demonstrated	O
prevalence	O
of	O
hypoxia	O
in	O
human	O
leukemic	O
BM	O
and	O
negative	O
prognostic	O
impact	O
of	O
HIF-1α	O
expression	O
in	O
newly	O
diagnosed	O
patients	O
with	O
pre-B-ALL	O
(3);	O
in	O
vitro	O
observation	O
of	O
hypoxia	O
promoting	O
chemoresistance	O
in	O
ALL	O
(50,	O
51)	O
and	O
in	O
AML	O
(52–55);	O
link	O
between	O
the	O
poorly	O
oxygenated	O
niche,	O
the	O
hypoxia-induced	O
glycolytic	O
metabolism	O
and	O
chemoresistance	O
in	O
B-ALL	O
and	O
T-ALL	O
(56,	O
57);	O
and	O
requirements	O
for	O
HIF1α	O
signaling	O
for	O
leukemia	B
stem	I
cell	I
maintenance	O
in	O
T-ALL	O
(58).	O

hRANKL	O
was	O
cloned	O
into	O
the	O
pCL10.1	O
bicistronic	O
expression	O
vector	O
upstream	O
of	O
the	O
sequence	O
encoding	O
enhanced	O
green	O
fluorescent	O
protein	O
(eGFP	O
-	O
Aequorea	O
victoria),	O
in	O
which	O
co-expression	O
is	O
controlled	O
by	O
the	O
murine	B
stem	I
cell	I
virus	O
promoter.	O

Taken	O
together,	O
the	O
data	O
suggest	O
that	O
TRIM32-mediated	O
targeting	O
of	O
myc	O
proteins	O
may	O
provide	O
new	O
avenues	O
for	O
stem	B
cell	I
cancer	O
drug	O
therapy..	O

• Standardize	O
the	O
route	O
and	O
frequency	O
of	O
stem	B
cell	I
administration	O
in	O
in	O
vivo	O
treatments..	O

Harnessing	O
the	O
immunomodulatory	O
and	O
tissue	O
repair	O
properties	O
of	O
mesenchymal	B
stem	I
cells	I
to	O
restore	O
β	O
cell	O
function.	O

Tanaka	O
S,	O
Kunath	O
T,	O
Hadjantonakis	O
AK,	O
Nagy	O
A,	O
Rossant	O
J	O
(1998)	O
Promotion	O
of	O
trophoblast	B
stem	I
cell	I
proliferation	O
by	O
FGF4.	O

Ophthalmic	O
conditions,	O
some	O
of	O
which	O
are	O
leading	O
causes	O
of	O
blindness	O
worldwide,	O
are	O
being	O
treated	O
with	O
stem	B
cell	I
therapies.	O

Given	O
the	O
therapeutic	O
potential	O
of	O
the	O
stem	B
cell	I
platform,	O
cord	O
blood	O
banking	O
is	O
increasingly	O
being	O
touted	O
as	O
a	O
viable	O
option	O
to	O
treat	O
disorders	O
that	O
may	O
arise	O
later	O
in	O
a	O
person’s	O
life,	O
with	O
cord	O
blood	O
also	O
being	O
used	O
in	O
transplantation	O
to	O
overcome	O
human	O
leukocyte	O
antigen	O
(HLA)	O
incompatibility	O
[4]..	O

As	O
a	O
result	O
of	O
the	O
recent	O
advances	O
in	O
stem	B
cell	I
technologies,	O
we	O
are	O
now	O
able	O
to	O
study	O
the	O
mechanisms	O
of	O
human	O
disease	O
more	O
effectively.	O

Various	O
factors	O
can	O
be	O
modified	O
to	O
promote	O
the	O
differentiation	O
and	O
growth	O
of	O
stem	B
cells	I
into	O
complex	O
tissues	O
composed	O
of	O
different	O
cell	O
types	O
due	O
to	O
their	O
multilineage	O
differentiation	O
capabilities.	O

Multiple	O
sclerosis,	O
a	O
demyelinating	O
disease	O
characterized	O
by	O
a	O
progressive	O
decline	O
in	O
function,	O
is	O
a	O
devastating	O
disease	O
for	O
patients	O
but	O
one	O
to	O
which	O
the	O
stem	B
cell	I
platform	O
can	O
be	O
applied.	O

Despite	O
the	O
great	O
potential	O
of	O
the	O
stem	B
cell	I
platform,	O
the	O
field	O
in	O
which	O
this	O
potential	O
is	O
being	O
fully	O
explored	O
is	O
oncology.	O

The	O
main	O
goal	O
of	O
stem	B
cell	I
therapies	O
in	O
neurological	O
disorders	O
is	O
to	O
replace	O
damaged	O
and	O
non-functional	O
tissues,	O
improving	O
neurological	O
outcomes.	O

Similarly,	O
the	O
manipulation	O
of	O
somatic	O
cell	O
DNA	O
may	O
give	O
rise	O
to	O
safety	O
concerns	O
in	O
patient-specific	B
stem	I
cell	I
lines..	O

However,	O
SCNT	O
faces	O
many	O
hurdles	O
that	O
stop	O
it	O
from	O
being	O
a	O
widespread	O
methodology	O
in	O
stem	B
cell	I
research.	O

As	O
of	O
late,	O
a	O
new	O
system	O
of	O
research	O
oversight	O
in	O
stem	B
cell	I
research	O
has	O
evolved.	O

Lastly,	O
any	O
potentially	O
remaining	O
Cancer	B
Stem	I
Cell	I
subpopulations	O
were	O
isolated	O
and	O
characterized..	O

CXCR4	O
signaling	O
in	O
the	O
regulation	O
of	O
stem	B
cell	I
migration	O
and	O
development.	O

Intra-cellular	O
delivery	O
of	O
even	O
moderate	O
levels	O
of	O
iron	O
oxide	O
nanoparticles	O
(iron	O
concentration	O
from	O
0.15	O
to	O
15	O
mM)	O
adversely	O
affects	O
cell	O
functions	O
of	O
the	O
rat	O
pheochromocytoma	O
cell	O
line	O
(PC	O
12),	O
an	O
ideal	O
model	O
system	O
for	O
the	O
study	O
of	O
neural	B
stem	I
cell	I
development	O
and	O
differentiation.	O

(2012)	O
Nano-regenerative	O
medicine	O
towards	O
clinical	O
outcome	O
of	O
stem	B
cell	I
and	O
tissue	O
engineering	O
in	O
humans.	O

Janowski	O
M,	O
Bulte	O
JW,	O
Walczak	O
P	O
(2012)	O
Personalized	O
nanomedicine	O
advancements	O
for	O
stem	B
cell	I
tracking.	O

(2013)	O
Cell	O
motility	O
of	O
neural	B
stem	I
cells	I
is	O
reduced	O
after	O
SPIO-labeling,	O
which	O
is	O
mitigated	O
after	O
exocytosis.	O

C	O
and	O
Additional	O
Figure	O
2B–D)	O
revealed	O
that	O
a	O
small	O
portion	O
of	O
tdTomato-expressing	O
cells	O
co-label	O
with	O
the	O
hair	B
root	I
stem	I
cell	I
marker	O
K15.	O

Examination	O
by	O
confocal	O
microscopy	O
revealed	O
that	O
a	O
very	O
small	O
proportion	O
of	O
these	O
cells	O
were	O
positive	O
for	O
a	O
hair	B
follicle	I
stem	I
cell	I
marker	O
(K15).	O

Cell	O
fusion-independent	O
differentiation	O
of	O
neural	B
stem	I
cells	I
to	O
the	O
endothelial	O
lineage.	O

Lymphokine-activated	O
killer	O
cells	O
selectively	O
kill	O
tumor	O
cells	O
in	O
bone	O
marrow	O
without	O
compromising	O
bone	B
marrow	I
stem	I
cell	I
function	O
in	O
vitro.	O

Gene	O
targeting	O
was	O
performed	O
in	O
the	O
mouse	O
embryonic	O
stem	O
(ES)	O
cell	O
line	O
JM8A3	O
(Pettitt	O
et	O
al.,	O
2009)	O
by	O
electroporation	O
of	O
the	O
linearized	O
gene	O
targeting	O
construct	O
followed	O
by	O
selection	O
with	O
G418	O
(Life	O
Technologies)	O
and	O
Ganciclovir.	O
The	O
method	O
may	O
provide	O
particular	O
benefits	B
in	I
stem	I
cell	I
and	O
embryonic	O
research,	O
where	O
aneuploidies	O
are	O
known	O
to	O
be	O
common	O
[2,	O
7,	O
38]	O
and	O
single-cell	O
approaches	O
have	O
been	O
widely	O
applied.	O

cells	O
per	O
plate)	O
and	O
cultured	O
in	O
embryonic	B
stem	I
cell	I
medium	O
(ESM)	O
(KO-DMEM,	O
Gibco;	O
20 %,.	O

Establishment	O
and	O
characterization	O
of	O
baboon	B
embryonic	I
stem	I
cell	I
lines:	O
An	O
Old	O
World	O
Primate	O
model	O
for	O
regeneration	O
and	O
transplantation	O
research.	O

In	O
PVL,	O
the	O
stem	B
cell	I
immunomarker	O
to	O
nestin	O
demonstrates	O
its	O
increased	O
expression	O
in	O
glia	O
and	O
neurons,	O
attributed	O
to	O
nestin	O
upregulation	O
in	O
response	O
to	O
injury	O
rather	O
than	O
regeneration	O
of	O
new	O
cells	O
[79].	O

Extended	O
study	O
in	O
the	O
colon	O
demonstrated	O
that,	O
in	O
addition	O
to	O
disruption	O
of	O
normal	O
crypt	O
morphology,	O
loss	O
of	O
ATP6AP2	O
led	O
to	O
generation	O
of	O
microadenomas	O
concurrent	O
with	O
loss	O
of	O
the	O
intestinal	B
stem	I
cell	I
marker,	O
Lgr5.	O

(D)	O
Relative	O
contribution	O
of	O
different	O
genotypes	O
to	O
stem	B
cell	I
and	O
progenitor	O
pools	O
in	O
bone-marrow	O
of	O
reconstituted	O
animals	O
expressed	O
as	O
a	O
percentage	O
arising	O
from	O
Atp6ap2	O
cKO	O
(MUT)	O
reconstituted	O
animals	O
over	O
those	O
of	O
wild-type	O
(WT)	O
[N = 10];	O
Statistical	O
significances	O
presented	O
are	O
results	O
of	O
Student’s	O
t-test	O
for	O
effect	O
of	O
genotype	O
in	O
the	O
reconstituted	O
animals	O
after	O
TAM	O
treatment.;	O
***p < 0.001..	O

Since	O
Lgr5	O
is	O
an	O
important	O
regulator	O
of	O
stem	B
cell	I
maintenance	O
in	O
the	O
intestine,	O
these	O
data	O
suggest	O
that	O
the	O
disorganization	O
and	O
general	O
dysfunction	O
of	O
the	O
intestine	O
upon	O
loss	O
of	O
ATP6AP2	O
may	O
be	O
due	O
to	O
altered	O
Lgr5	O
signaling	O
causing	O
dysregulated	O
proliferation	O
and	O
increased	O
activation	O
of	O
cell	O
death	O
pathways..	O

While	O
understanding	O
pathway(s)	O
are	O
not	O
crucial	O
to	O
assess	O
the	O
value	O
of	O
a	O
gene	O
product	O
as	O
a	O
potential	O
drug	O
target,	O
it	O
is	O
clearly	O
evident	O
that	O
loss	O
of	O
ATP6AP2	O
product	O
results	O
in	O
widespread	O
cell	O
viability	O
problems,	O
notably	O
in	O
stem	B
cell	I
compartments..	O

Our	O
results	O
are	O
consistent	O
with	O
the	O
established	O
role	O
of	O
multiple	O
Sox	O
genes	O
in	O
the	O
maintenance	O
of	O
stem	B
cell	I
pools.	O

In	O
light	O
of	O
recent	O
phylogenetic	O
evidence	O
that	O
Ctenophora	O
is	O
the	O
earliest-branching	O
animal	O
lineage,	O
our	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
ancient	O
primary	O
function	O
of	O
Sox	O
family	O
genes	O
was	O
to	O
regulate	O
the	O
maintenance	O
of	O
stem	B
cells	I
and	O
function	O
in	O
cell	O
fate	O
determination..	O

Overall,	O
however,	O
the	O
well-established	O
role	O
of	O
the	O
Sox	O
family	O
in	O
the	O
maintenance	O
of	O
stem	B
cell	I
pools	O
during	O
development	O
[53]	O
seems	O
to	O
be	O
conserved	O
in	O
ctenophores,	O
at	O
least	O
as	O
much	O
as	O
can	O
be	O
indicated	O
by	O
the	O
zones	O
of	O
cell	O
proliferation	O
seen	O
in	O
both	O
Mnemiopsis	O
and	O
Pleurobrachia	O
in	O
the	O
apical	O
sense	O
organ,	O
upper	O
tentacle	O
bulbs,	O
and	O
comb	O
rows,	O
which	O
overlap	O
with	O
regions	O
of	O
Sox	O
gene	O
expression	O
in	O
both	O
species.	O

Soluble	O
mediators	O
from	O
mesenchymal	B
stem	I
cells	I
suppress	O
T	O
cell	O
proliferation	O
by	O
inducing	O
IL-10.	O

THAP11	O
was	O
reported	O
to	O
be	O
essential	O
for	O
mouse	B
embryonic	I
stem	I
cell	I
self-renewal	O
and	O
cell-growth	O
regulation	O
in	O
human	O
colon	O
cancer	O
cells	O
(47,	O
49,	O
50).	O

Runx1	O
modulates	O
adult	O
hair	B
follicle	I
stem	I
cell	I
emergence	O
and	O
maintenance	O
from	O
distinct	O
embryonic	O
skin	O
compartments.	O

The	O
tortoise	O
and	O
the	O
hair:	O
slow-cycling	O
cells	O
in	O
the	O
stem	B
cell	I
race.	O

Hair	O
follicle	O
renewal:	O
authentic	O
morphogenesis	O
that	O
depends	O
on	O
a	O
complex	O
progression	O
of	O
stem	B
cell	I
lineages.	O

Sox9	O
is	O
essential	O
for	O
outer	O
root	O
sheath	O
differentiation	O
and	O
the	O
formation	O
of	O
the	O
hair	B
stem	I
cell	I
compartment.	O

LRCs	O
were	O
also	O
positive	O
for	O
stem	B
cell	I
markers	O
c-Kit	O
and	O
Oct4	O
(Cervello	O
et	O
al.,	O
2007).	O

Bone	B
marrow	I
stem	I
cells	I
do	O
not	O
contribute	O
to	O
endometrial	O
cell	O
lineages	O
in	O
chimeric	O
mouse	O
models.	O

Comparative	B
analysis	I
of	I
human	I
Mesenchymal	O
Stem	O
Cells	O
from	O
Umbilical	O
Cord,	O
Dental	O
Pulp,	O
and	O
Menstrual	O
blood	O
as	O
sources	O
for	O
cell	O
therapy.	O

Endometrial	B
stem	I
cell	I
transplantation	O
restores	O
dopamine	O
production	O
in	O
a	O
Parkinson’s	O
disease	O
model.	O

Endometrial	B
stem	I
cell	I
transplantation	O
in	O
MPTP-	O
exposed	O
primates:	O
an	O
alternative	O
cell	O
source	O
for	O
treatment	O
of	O
Parkinson’s	O
disease.	O

Mesenchymal	B
stem	I
cell	I
surface	O
antigen	O
SB-10	O
corresponds	O
to	O
activated	O
leukocyte	O
cell	O
adhesion	O
molecule	O
and	O
is	O
involved	O
in	O
osteogenic	O
differentiation.	O

Role	O
of	O
retinoic	O
acid	O
and	O
oxidative	O
stress	O
in	O
embryonic	B
stem	I
cell	I
death	O
and	O
neuronal	O
differentiation.	O

Oxidative	O
stress	O
promotes	O
exit	O
from	O
the	O
stem	B
cell	I
state	O
and	O
spontaneous	O
neuronal	O
differentiation.	O

Treatment	O
of	O
adenovirus	O
disease	O
in	O
stem	B
cell	I
transplant	O
recipients	O
with	O
cidofovir.	O

S1;	O
Additional	O
files	O
2,	O
3,	O
4:	O
Table	O
S1–3),	O
human	O
cell	O
lines	O
[24],	O
and	O
mouse	B
embryonic	I
stem	I
cells	I
[29].	O

Such	O
a	O
concept	O
of	O
phenotypic	O
changes	O
does	O
not	O
reflect	O
great	O
flexibility	O
in	O
terms	O
of	O
the	O
functions	O
of	O
differentiated	O
cells	O
for	O
which	O
compelling	O
evidence	O
has	O
already	O
been	O
accumulated,	O
including	O
in	O
vitro-induced	O
pluripotent	O
SCs	O
67,	O
68,	O
and	O
is	O
fast	O
growing	O
as	O
the	O
stem	B
cell	I
research	O
prospers.	O

:	O
Cell	O
fusion-independent	O
differentiation	O
of	O
neural	B
stem	I
cells	I
to	O
the	O
endothelial	O
lineage.	O

Neutrophil	O
progenitor	O
cells	O
are	O
immortalised	O
by	O
a	O
fusion	O
protein	O
of	O
the	O
estrogen	O
receptor	O
and	O
the	O
oncoprotein	O
Hoxb8,	O
allowing	O
unlimited	O
expansion	O
of	O
these	O
progenitors	O
in	O
the	O
presence	O
of	O
stem	B
cell	I
factor	O
(SCF).	O

25,000	O
BMCs	O
were	O
cultured	O
with	O
stem	B
cell	I
factor,	O
IL-3,	O
and	O
erythropoietin	O
in	O
semisolid	O
agar	O
for	O
7	O
d.	O

Recently	O
it	O
has	O
been	O
proposed	O
that	O
BMP	O
permits	O
the	O
cancer	B
stem	I
cell	I
in	O
GBM	O
to	O
remain	O
quiescent	O
and	O
resist	O
treatment.	O

Single‐cell	O
transcriptomic	O
analysis	O
defines	O
heterogeneity	O
and	O
transcriptional	O
dynamics	O
in	O
the	O
adult	B
neural	I
stem	I
cell	I
lineage.	O

BMP	O
signaling	O
mediates	O
glioma	B
stem	I
cell	I
quiescence	O
and	O
confers	O
treatment	O
resistance	O
in	O
glioblastoma.	O

Bone	O
tissue	O
engineering	O
strategies	O
rely	O
on	O
three-dimensional	O
scaffolds	O
that	O
constitute	O
an	O
inductive/conductive	O
extracellular	O
microenvironment	O
for	O
stem	B
cell	I
function	O
as	O
well	O
as	O
a	O
delivery	O
vehicle	O
and	O
3D	O
scaffold	O
of	O
clinically	O
relevant	O
properties	O
and	O
proportions.	O

In	O
fulfilling	O
these	O
dual	O
criteria	O
the	O
biomimetic	O
scaffold	O
plays	O
a	O
critical	O
role	O
bridging	O
the	O
gap	O
between	O
the	O
developmental	O
context	O
of	O
stem	B
cell	I
mediated	O
tissue	O
formation	O
and	O
the	O
adult	O
context	O
of	O
injury	O
and	O
disease.	O

Nephrotoxicity	O
of	O
cyclosporine	O
A	O
and	O
amphotericin	O
B-deoxycholate	O
as	O
continuous	O
infusion	O
in	O
allogenic	B
stem	I
cell	I
transplantation.	O

Fluid	O
overload	O
and	O
acute	O
renal	O
failure	O
in	O
pediatric	B
stem	I
cell	I
transplant	O
patients.	O

The	O
control	O
of	O
stem	B
cell	I
homeostasis	O
within	O
tissues	O
such	O
as	O
the	O
balance	O
between	O
proliferation,	O
differentiation,	O
apoptosis	O
and	O
senescence	O
is	O
strictly	O
linked	O
to	O
the	O
regulation	O
of	O
tissue	O
repair	O
and	O
regeneration.	O

Microbubble-mediated	O
ultrasound	O
promotes	O
accumulation	O
of	O
bone	B
marrow	I
mesenchymal	I
stem	I
cell	I
to	O
the	O
prostate	O
for	O
treating	O
chronic	O
bacterial	O
prostatitis	O
in	O
rats.	O

Microbubble-mediated	O
ultrasound	O
promotes	O
accumulation	O
of	O
bone	B
marrow	I
mesenchymal	I
stem	I
cell	I
to	O
the	O
prostate	O
for	O
treating	O
chronic	O
bacterial	O
prostatitis	O
in	O
rats.	O

Microbubble-mediated	O
ultrasound	O
promotes	O
accumulation	O
of	O
bone	B
marrow	I
mesenchymal	I
stem	I
cell	I
to	O
the	O
prostate	O
for	O
treating	O
chronic	O
bacterial	O
prostatitis	O
in	O
rats.	O

H19/let-7/LIN28	O
reciprocal	O
negative	O
regulatory	O
circuit	O
promotes	O
breast	B
cancer	I
stem	I
cell	I
maintenance.	O

JAK/STAT-1	O
Signaling	O
Is	O
Required	O
for	O
Reserve	O
Intestinal	B
Stem	I
Cell	I
Activation	O
during	O
Intestinal	O
Regeneration	O
Following	O
Acute	O
Inflammation.	O

Human	O
breast	B
cancer	I
stem	I
cell	I
complete	O
growth	O
medium	O
was	O
from	O
Celprogen	O
(Torrance,	O
CA).	O

(A)	O
Equal	O
numbers	O
of	O
MCF-7,	O
T-47D,	O
MDA-MB-231,	O
HCC-1806,	O
or	O
breast	B
cancer	I
stem	I
cells	I
were	O
grown	O
in	O
medium	O
containing	O
0	O
or	O
5	O
μM	O
FND-4b	O
for	O
72	O
h	O
followed	O
by	O
cell	O
counting.	O

Shh	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
and	O
suggested	O
as	O
treatment	O
of	O
other	O
neurodegenerative	O
diseases	O
including	O
Parkinson’s	O
and	O
Alzheimer’s	O
disease,	O
in	O
part	O
but	O
not	O
exclusively	O
because	O
of	O
its	O
role	O
in	O
the	O
maintenance	O
of	O
stem	B
cell	I
niches	O
in	O
adult	O
organisms	O
6.	O

Bone	O
marrow-derived	O
myofibroblasts	O
contribute	O
to	O
the	O
mesenchymal	B
stem	I
cell	I
niche	O
and	O
promote	O
tumor	O
growth.	O

Regulation	O
of	O
mouse	B
embryonic	I
stem	I
cell	I
self-renewal	O
by	O
a	O
Yes-YAP-TEAD2	O
signaling	O
pathway	O
downstream	O
of	O
LIF.	O

However,	O
it	O
is	O
notable	O
that	O
in	O
the	O
cohort	O
of	O
patients	O
that	O
did	O
not	O
receive	O
the	O
stem	O
cell	O
infusions	O
there	O
were	O
significantly	O
more	O
episodes	O
of	O
cholangitis	O
which	O
may	O
accelerate	O
the	O
hepatic	O
decline	O
in	O
biliary	O
atresia	O
and	O
may	O
be	O
a	O
confounding	O
factor	O
in	O
this	O
study,	O
and	O
also	O
there	O
was	O
a	O
high	O
mortality	O
rate	O
in	O
this	O
series	O
and	O
no	O
significant	O
difference	O
in	O
median	O
post-operative	O
survival	O
time,	O
though	O
the	O
authors	O
proposed	O
the	O
stem	B
cell	I
infusions	O
may	O
have	O
prolonged	O
life	O
in	O
early	O
infancy.	O

The	O
emerging	O
functions	O
of	O
the	O
p53-miRNA	O
network	O
in	O
stem	B
cell	I
biology.	O

p38	O
MAPK	O
signaling	O
underlies	O
a	O
cell-autonomous	O
loss	O
of	O
stem	B
cell	I
self-renewal	O
in	O
skeletal	O
muscle	O
of	O
aged	O
mice.	O

Intrinsic	O
changes	O
and	O
extrinsic	O
influences	O
of	O
myogenic	B
stem	I
cell	I
function	O
during	O
aging.	O

Dysfunctional	O
autophagy	O
is	O
a	O
driver	O
of	O
muscle	B
stem	I
cell	I
functional	O
decline	O
with	O
aging.	O

Induction	O
of	O
autophagy	O
supports	O
the	O
bioenergetic	O
demands	O
of	O
quiescent	B
muscle	I
stem	I
cell	I
activation.	O

These	O
studies	O
strongly	O
suggest	O
that	O
wasting	O
and	O
lethality	O
in	O
acrodermatitis	O
enteropathica	O
patients	O
reflects	O
the	O
loss-of-function	O
of	O
the	O
intestine	O
zinc	O
transporter	O
ZIP4,	O
which	O
leads	O
to	O
abnormal	O
Paneth	O
cell	O
gene	O
expression,	O
disruption	O
of	O
the	O
intestinal	B
stem	I
cell	I
niche,	O
and	O
diminished	O
function	O
of	O
the	O
intestinal	O
mucosa.	O

Our	O
studies	O
demonstrate	O
the	O
paramount	O
importance	O
of	O
ZIP4	O
in	O
the	O
intestine	O
in	O
this	O
disease	O
and	O
reveal	O
that	O
a	O
root	O
cause	O
of	O
lethality	O
is	O
disruption	O
of	O
the	O
intestine	B
stem	I
cell	I
niche	O
and	O
impaired	O
function	O
of	O
the	O
small	O
intestine.	O

The	O
Zip4	O
gene	O
remained	O
knocked	O
out	O
for	O
4	O
weeks	O
in	O
these	O
mice	O
(Figure	O
2E,	O
inset)	O
which	O
indicates	O
that	O
it	O
was	O
also	O
knocked	O
out	O
in	O
the	O
intestinal	B
stem	I
cell	I
population,	O
as	O
reported	O
previously	O
using	O
the	O
vil-CreERT2	O
system	O
[11].	O

The	O
relative	O
amount	O
of	O
cell	O
division	O
in	O
the	O
small	O
intestine	O
was	O
determined	O
since	O
Sox9	O
plays	O
a	O
role	O
in	O
intestinal	B
stem	I
cell	I
proliferation	O
and	O
the	O
crypts	O
are	O
critical	O
for	O
renewal	O
of	O
the	O
epithelium.	O

Remarkably	O
this	O
is	O
accompanied	O
by	O
enhanced	O
mTOR1	O
activity	O
in	O
the	O
stem	B
cell	I
niche,	O
but	O
not	O
in	O
Paneth	O
cells..	O

Therefore,	O
impaired	O
Paneth	O
cell	O
function	O
contributes	O
to	O
reduced	O
cell	O
division	O
in	O
the	O
small	O
intestine	O
through	O
its	O
effects	O
on	O
the	O
stem	B
cell	I
niche..	O

The	O
results	O
suggest	O
that	O
Paneth	O
cell	O
dysfunction	O
leading	O
to	O
disruption	O
of	O
the	O
stem	B
cell	I
niche	O
and	O
loss	O
of	O
villus	O
enterocyte	O
integrity	O
are	O
primary	O
causes	O
of	O
AE.	O

Revealing	O
the	O
complex	O
immunological	O
dysregulation	O
in	O
MM,	O
the	O
neutrophil-to-lymphocyte	O
ratio	O
at	O
diagnosis	O
or	O
after	O
100	O
days	O
from	O
autologous	B
stem	I
cell	I
transplantation	O
can	O
predict	O
outcome	O
in	O
MM	O
patients,	O
even	O
if	O
the	O
novel	O
agents	O
era16–22	O
In	O
cancer,	O
neutrophils	O
can	O
integrate	O
the	O
environmental	O
signals	O
towards	O
an	O
adaptive	O
response	O
to	O
the	O
tumor-associated	O
sterile	O
inflammation,	O
generally	O
associated	O
to	O
a	O
pro-tumoral	O
phenotype13,23–26.	O

Between	O
January	O
2012	O
and	O
April	O
2013,	O
43	O
consecutive	O
newly	O
diagnosed	O
MM	O
patients	O
(Supplementary	O
Table	O
4),	O
candidates	O
to	O
autologous	B
stem	I
cell	I
transplantation,	O
received	O
first-line	O
treatment	O
based	O
on	O
bortezomib,	O
thalidomide	O
and	O
dexamethasone	O
(VTD).	O

Phagocyte	O
function	O
decreases	O
after	O
high-dose	O
treatment	O
with	O
melphalan	O
and	O
autologous	B
stem	I
cell	I
transplantation	O
in	O
patients	O
with	O
multiple	O
myeloma.	O

Thus,	O
the	O
act	O
of	O
establishing	O
conditions	O
to	O
maintain	O
organoids	O
is	O
in	O
itself	O
informative	O
for	O
understanding	O
how	O
the	O
stem	O
cell	O
niche	O
regulates	O
the	O
behavior	O
of	O
stem	B
cells	I
in	O
normal	O
and	O
pathological	O
states	O
across	O
many	O
different	O
organ	O
systems..	O

It	O
is	O
remarkable	O
how	O
far	O
hPSC-derived	O
organoids	O
have	O
come	O
in	O
the	O
approximately	O
20	O
years	O
since	O
the	O
derivation	O
of	O
the	O
first	O
human	B
pluripotent	I
stem	I
cell	I
line	O
[46]:	O
from	O
essential	O
discoveries	O
of	O
how	O
to	O
coax	O
hPSCs	O
to	O
differentiate	O
towards	O
specific	O
germ	O
layers,	O
to	O
identification	O
of	O
signaling	O
pathways	O
that	O
promote	O
the	O
emergence	O
of	O
particular	O
organ	O
progenitors,	O
to	O
the	O
creation	O
of	O
3D	O
models	O
of	O
organ	O
development	O
and	O
function.	O

Human	B
embryonic	I
stem	I
cell	I
cultivation:	O
historical	O
perspective	O
and	O
evolution	O
of	O
xeno-free	O
culture	O
systems.	O

A	O
bioengineered	O
niche	O
promotes	O
in	O
vivo	O
engraftment	O
and	O
maturation	O
of	O
pluripotent	B
stem	I
cell	I
derived	O
human	O
lung	O
organoids.	O

Dissecting	O
the	O
stem	B
cell	I
niche	O
with	O
organoid	O
models:	O
an	O
engineering-based	O
approach.	O

The	O
concept	O
of	O
stem	B
cell	I
niches	O
has	O
been	O
introduced	O
for	O
the	O
first	O
time	O
by	O
Schofield	O
[5].	O

Identification	O
of	O
the	O
haematopoietic	B
stem	I
cell	I
niche	O
and	O
control	O
of	O
the	O
niche	O
size.	O

Leukaemogenic	O
effects	O
of	O
Ptpn11	O
activating	O
mutations	O
in	O
the	O
stem	B
cell	I
microenvironment.	O

Neuropathy	O
of	O
haematopoietic	B
stem	I
cell	I
niche	O
is	O
essential	O
for	O
myeloproliferative	O
neoplasms.	O

Genetic	O
evaluation	O
of	O
mesenchymal	B
stem	I
cells	I
by	O
G-banded	O
karyotyping	O
in	O
a	O
Cell	O
Technology	O
Center.	O

SF3B1	O
mutant	O
MDS-initiating	O
cells	O
may	O
arise	O
from	O
the	O
haematopoietic	B
stem	I
cell	I
compartment.	O

Interestingly,	O
PIWI	O
genes	O
are	O
associated	O
with	O
stem	O
cell	O
self-renewal	O
and	O
are	O
re-expressed	O
in	O
precancerous	O
stem	B
cells	I
that	O
have	O
the	O
potential	O
for	O
malignant	O
differentiation	O
[30,	O
31].	O

Knockdown	O
of	O
PIWIL1	O
compromised	O
sphere	O
formation	O
ability	O
in	O
the	O
stem	B
cell	I
population	O
SSClo	O
Aldebr	O
and	O
in	O
vivo	O
tumor	O
growth	O
in	O
a	O
nude	O
mice	O
model	O
[39].	O

Expression	O
of	O
the	O
stem	B
cell	I
self-renewal	O
gene	O
Hiwi	O
and	O
risk	O
of	O
tumour-related	O
death	O
in	O
patients	O
with	O
soft-tissue	O
sarcoma.	O

A	O
novel	O
class	O
of	O
evolutionarily	O
conserved	O
genes	O
defined	O
by	O
piwi	O
are	O
essential	O
for	O
stem	B
cell	I
self-renewal.	O

Short-term	B
stem	I
cell	I
capacity	O
as	O
measured	O
by	O
transplantation	O
analysis	O
was	O
also	O
comparable	O
between	O
wild-type	O
and	O
mutant	O
groups.	O

Apart	O
from	O
Pax7,	O
these	O
52	O
genes,	O
were	O
not	O
differentially	O
expressed;	O
yet,	O
the	O
stem	B
cell	I
marker	O
genes	O
trended	O
toward	O
slight	O
down-regulation	O
and	O
the	O
differentiation	O
markers	O
exhibited	O
slight	O
up-regulation	O
in	O
the	O
MUT	O
group	O
(Fig	O
6B).	O

For	O
in	O
vivo	O
genetic	O
manipulation	O
of	O
the	O
Aundiff,	O
which	O
contain	O
the	O
stem	B
cell	I
pool,	O
only	O
a	O
handful	O
cre	O
driver	O
lines	O
have	O
been	O
described,	O
including	O
Vasa-cre	O
and	O
Stra8-cre.	O

Exosomal	O
microRNA-139-5p	O
from	O
mesenchymal	B
stem	I
cells	I
accelerates	O
trophoblast	O
cell	O
invasion	O
and	O
migration	O
by	O
motivation	O
of	O
the	O
ERK/MMP-2	O
pathway	O
via	O
downregulation	O
of	O
protein	O
tyrosine	O
phosphatase.	O

The	O
extended	O
passage	O
and	O
tissue	O
culture	O
can	O
result	O
in	O
the	O
acquisition	O
of	O
adaptive	O
mutations	O
from	O
cell-culture	O
conditions,	O
as	O
seen	O
in	O
long-term	O
culturing	O
of	O
embryonic	B
stem	I
cells	I
and	O
lung	O
cancer	O
cell	O
lines	O
[164-166].	O

It	O
is	O
important	O
to	O
note	O
that	O
the	O
cancer	O
cell	O
of	O
origin	O
is	O
not	O
necessarily	O
related	O
to	O
the	O
origin	O
of	O
the	O
cancer	B
stem	I
cell	I
[190].	O

In	O
hepatocellular	O
carcinoma	O
(HCC),	O
TGFβ	O
upregulates	O
the	O
expression	O
of	O
the	O
stem	B
cell	I
marker	O
CD133,	O
via	O
a	O
Smad-dependent	O
transcriptional	O
mechanism	O
and	O
by	O
promoting	O
CD133	O
promoter	O
demethylation	O
based	O
on	O
a	O
negative	O
effect	O
on	O
the	O
DNA	O
methyltransferases	O
DNMT1	O
and	O
DNMT3β,	O
thus	O
enhancing	O
the	O
tumourigenic	O
potential	O
of	O
the	O
CD133+	O
population	O
in	O
vivo	O
(You	O
et	O
al,	O
2010).	O

Attempting	O
to	O
genetically	O
silence	O
musashi-2	O
in	O
these	O
lung	O
CSCs	O
depleted	O
the	O
stem	B
cell	I
pool	O
in	O
part	O
by	O
causing	O
induction	O
of	O
epithelial	O
proteins,	O
such	O
as	O
the	O
junctional	O
claudins,	O
and	O
by	O
suppressing	O
the	O
translation	O
of	O
mRNAs	O
for	O
TβRI	O
and	O
Smad3	O
and	O
of	O
Snail1	O
and	O
Snail2,	O
transcriptional	O
mediators	O
of	O
EMT	O
(Kudinov	O
et	O
al,	O
2016).	O

Quante	O
M,	O
Tu	O
SP,	O
Tomita	O
H,	O
Gonda	O
T,	O
Wang	O
SS,	O
Takashi	O
S,	O
Baik	O
GH,	O
Shibata	O
W,	O
Diprete	O
B,	O
Betz	O
KS,	O
Friedman	O
R,	O
Varro	O
A,	O
Tycko	O
B,	O
Wang	O
TC	O
(2011)	O
Bone	O
marrow-derived	O
myofibroblasts	O
contribute	O
to	O
the	O
mesenchymal	B
stem	I
cell	I
niche	O
and	O
promote	O
tumor	O
growth.	O

Posttranscriptional	O
control	O
of	O
the	O
stem	B
cell	I
and	O
neurogenic	O
programs	O
by	O
the	O
nonsense-mediated	O
RNA	O
decay	O
pathway.	O

MiR-125b	O
functions	O
as	O
a	O
key	O
mediator	O
for	O
snail-induced	B
stem	I
cell	I
propagation	O
and	O
chemoresistance.	O

Specifically,	O
miRNAs	O
act	O
in	O
stem	B
cell	I
differentiation,	O
cell	O
division,	O
immunological	O
cell	O
function,	O
organogenesis	O
and	O
cell	O
identity.	O

Besides,	O
hedgehog	O
signaling	O
plays	O
a	O
vital	O
role	O
in	O
the	O
development	O
and	O
the	O
maintenance	O
of	O
stem	B
cell	I
populations	O
(12,	O
13)..	O

Sonic	O
hedgehog	O
is	O
required	O
for	O
progenitor	O
cell	O
maintenance	O
in	O
telencephalic	B
stem	I
cell	I
niches.	O

Tug	O
of	O
war	O
in	O
the	O
haematopoietic	B
stem	I
cell	I
niche:	O
Do	O
myeloma	O
plasma	O
cells	O
compete	O
for	O
the	O
HSC	O
niche?	O
Blood	O
Cancer	O
J.	O

For	O
example,	O
cell	O
fate	O
specification	O
of	O
neural	B
stem	I
cells	I
along	O
the	O
neuroependymal	O
lining	O
depends	O
upon	O
the	O
actin	O
cytoskeleton	O
to	O
direct	O
cytokinesis	O
and	O
localization	O
of	O
cell	O
fate	O
determining	O
proteins.	O

Stem	B
cell	I
factor	O
induces	O
heterotopic	O
accumulation	O
of	O
cells	O
(heterotopia)	O
in	O
the	O
mouse	O
cerebral	O
cortex.	O

Induction	O
of	O
stem	B
cell	I
markers	O
in	O
Rb1−/−	O
MEF	O
sublines	O
expressing	O
RB	O
and	O
S18-2.	O

Galderisi	O
U.,	O
Cipollaro	O
M.,	O
Giordano	O
A.,	O
The	O
retinoblastoma	O
gene	O
is	O
involved	O
in	O
multiple	O
aspects	O
of	O
stem	B
cell	I
biology.	O

.,	O
StemMapper:	O
A	O
curated	O
gene	O
expression	O
database	O
for	O
stem	B
cell	I
lineage	O
analysis.	O

NCT04602104	O
A	O
Clinical	O
Study	O
of	O
Mesenchymal	B
Stem	I
Cell	I
Exosomes	O
Nebulizer	O
for	O
the	O
Treatment	O
of	O
ARDS	O
October	O
2020	O
Acute	O
Respiratory	O
Distress	O
Syndrome.	O

DNA	O
methylation	O
plays	O
an	O
important	O
role	O
in	O
main	O
tenance	O
of	O
genome	O
integrity	O
(by	O
silencing	O
of	O
repetitive	O
sequences,	O
endogenous	O
retroviruses,	O
selfish	O
genetic	O
elements	O
like	O
transposons)	O
and	O
contributes	O
significantly	O
towards	O
X-chromosome	O
inactivation,	O
tissue-specific	O
gene	O
expression,	O
and	O
induction	O
of	O
stem	B
cell	I
differentiation	O
[5-8]..	O

The	O
contributions	O
of	O
TRIM28	O
to	O
cancer	O
are	O
complex	O
and	O
mediated	O
by	O
different	O
mechanisms	O
including	O
the	O
inhibition	O
of	O
p53	O
activity,	O
the	O
activation	O
of	O
DNA	O
damage	O
repair	O
mechanisms,	O
induction	O
of	O
EMT,	O
and	O
maintenance	O
of	O
stem	B
cell	I
pluripotency,	O
just	O
to	O
cite	O
a	O
few	O
examples	O
[93].	O

The	O
role	O
of	O
TRIM	O
family	O
proteins	O
in	O
the	O
regulation	O
of	O
cancer	B
stem	I
cell	I
self-renewal.	O

Gene	O
expression	O
in	O
human	B
embryonic	I
stem	I
cell	I
lines:	O
Unique	O
molecular	O
signature.	O

Roles	O
of	O
FGF	O
signaling	O
in	O
stem	B
cell	I
self-renewal,	O
senescence	O
and	O
aging.	O

ICN1-expressing	O
ERMS	O
also	O
expressed	O
significantly	O
higher	O
levels	O
of	O
muscle	B
stem	I
cell	I
genes,	O
including	O
myf5,	O
pax7a,	O
and	O
c-met	O
(Figure	O
1H).	O

Plasticity	O
of	O
the	O
stem	B
cell	I
fate	O
is	O
an	O
uncommon	O
phenomenon,	O
with	O
only	O
a	O
few	O
reports	O
published	O
in	O
normal	O
and	O
malignant	O
contexts.	O

In	O
this	O
section,	O
we	O
envision	O
how	O
recent	O
advances	O
in	O
epigenomics	O
can	O
be	O
used	O
to	O
gain	O
insight	O
into	O
human	O
development	O
and	O
disease,	O
and	O
to	O
facilitate	O
the	O
transition	O
of	O
stem	B
cell	I
technologies	O
towards	O
clinical	O
applications..	O

The	O
combination	O
of	O
stem	B
cell	I
models	O
and	O
epigenomics	O
in	O
studies	O
of	O
the	O
role	O
of	O
non-coding	O
mutations	O
in	O
human	O
disease.	O

In	O
addition,	O
miR-145	O
acts	O
to	O
silence	O
multiple	O
pluripotency	O
factors	O
during	O
the	O
switch	O
from	O
stem	B
cell	I
self-renewal	O
to	O
lineage	O
commitment	O
(35).	O

Interaction	O
domains	O
of	O
Sos1/Grb2	O
are	O
finely	O
tuned	O
for	O
cooperative	O
control	O
of	O
embryonic	B
stem	I
cell	I
fate.	O

Dysregulation	O
of	O
haematopoietic	B
stem	I
cell	I
regulatory	O
programs	O
in	O
acute	O
myeloid	O
leukaemia.	O

Using	O
MLL	O
as	O
an	O
example,	O
we	O
explore	O
important	O
questions	O
of	O
wider	O
significance	O
that	O
are	O
still	O
under	O
debate,	O
including	O
the	O
importance	O
of	O
cell	O
of	O
origin,	O
to	O
what	O
extent	O
leukaemia	O
oncogenes	O
impose	O
specific	O
regulatory	O
programs	O
and	O
the	O
relevance	O
of	O
leukaemia	B
stem	I
cells	I
for	O
disease	O
development	O
and	O
prognosis.	O

Finally,	O
we	O
suggest	O
that	O
disruption	O
of	O
stem	B
cell	I
regulatory	O
programs	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
many	O
other	O
pathologies	O
including	O
ageing-associated	O
regenerative	O
failure..	O

Much	O
remains	O
to	O
be	O
learnt	O
about	O
the	O
complex	O
regulatory	O
programs	O
that	O
are	O
responsible	O
for	O
stem	B
cell	I
function	O
during	O
both	O
tissue	O
maintenance	O
and	O
repair.	O

While	O
current	O
research	O
efforts	O
are	O
largely	O
aimed	O
at	O
improving	O
our	O
understanding	O
of	O
perturbations	O
that	O
corrupt	O
normal	O
HSPCs	O
towards	O
creating	O
a	O
malignant	O
state,	O
many	O
of	O
the	O
underlying	O
principles	O
will	O
be	O
widely	O
applicable	O
to	O
other	O
instances	O
of	O
stem	B
cell	I
state	O
subversion.	O

A	O
better	O
understanding	O
of	O
the	O
mechanisms	O
that	O
underlie	O
the	O
corruption	O
of	O
stem	B
cell	I
regulatory	O
programs	O
is	O
therefore	O
of	O
broad	O
therapeutic	O
relevance	O
[102]..	O

Acute	O
myeloid	O
leukemia	O
originates	O
from	O
a	O
hierarchy	O
of	O
leukemic	B
stem	I
cell	I
classes	O
that	O
differ	O
in	O
self-renewal	O
capacity.	O

Endothelial-mesenchymal	O
transition	O
and	O
its	O
contribution	O
to	O
the	O
emergence	O
of	O
stem	B
cell	I
phenotype.	O

Spontaneous	O
development	O
of	O
hepatocellular	O
carcinoma	O
with	O
cancer	B
stem	I
cell	I
properties	O
in	O
PR-SET7-deficient	O
livers.	O

Revolutionary	O
advances	O
in	O
stem	B
cell	I
biology	O
during	O
the	O
last	O
decade	O
made	O
human	O
somatic	O
cells	O
accessible	O
in	O
a	O
large	O
scale	O
for	O
the	O
study	O
of	O
human	O
diseases.	O

Annelie	O
E	O
Abrahamssona,	O
Ifat	O
Gerona	O
(2009)	O
GSK-3b	O
missplicing	O
contributes	O
to	O
leukemia	B
stem	I
cell	I
generation.	O

Buettner	O
data	O
set	O
[14]	O
consists	O
of	O
embryonic	B
stem	I
cells	I
in	O
different	O
cell	O
cycle	O
stages.	O

Secondary	O
to	O
the	O
underlying	O
genetic	O
cause	O
of	O
DC,	O
patients	O
are	O
highly	O
susceptible	O
to	O
BMF	O
(up	O
to	O
80%	O
of	O
patients)	O
with	O
hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
as	O
definitive	O
therapy	O
[16,	O
17].	O

When	O
considering	O
the	O
impact	O
of	O
limbal	B
stem	I
cell	I
deficiency	O
on	O
healing,	O
in	O
conjunction	O
with	O
allogeneic	O
transplant	O
complications,	O
we	O
do	O
not	O
recommend	O
elective	O
corneal	O
refractive	O
surgery	O
such	O
as	O
LASIK,	O
PRK,	O
or	O
SMILE	O
in	O
patients	O
with	O
DC..	O

De	O
novo	O
prediction	O
of	O
stem	B
cell	I
identity	O
using	O
single-cell	O
transcriptome	O
data.	O

Skeletal	O
muscle	O
fiber-specific	O
green	O
autofluorescence:	O
potential	O
for	O
stem	B
cell	I
engraftment	O
artifacts.	O

POU5F1,	O
encoding	O
a	O
key	O
regulator	O
of	O
stem	B
cell	I
pluripotency,	O
is	O
fused	O
to	O
EWSR1	O
in	O
hidradenoma	O
of	O
the	O
skin	O
and	O
mucoepidermoid	O
carcinoma	O
of	O
the	O
salivary	O
glands.	O

Beyond	O
that,	O
just	O
to	O
indicate	O
the	O
scope	O
of	O
miRNA	O
dependent	O
regulation,	O
the	O
impact	O
of	O
miRNAs	O
during	O
heart	O
development	O
in	O
general	O
has	O
been	O
proven	O
by	O
inhibiting	O
miRNA	O
maturation	O
in	O
mouse	O
models	O
and	O
for	O
miR-155,	O
miR-221	O
and	O
miR-222	O
a	O
pivotal	O
role	O
for	O
the	O
development	O
of	O
obesity	O
during	O
of	O
the	O
differentiation	O
of	O
stem	B
cell	I
progenitors	O
into	O
adipocytes	O
have	O
been	O
shown.72,73	O
Furthermore	O
let-7	O
inhibition	O
might	O
be	O
used	O
obesity	O
and	O
type	O
2	O
diabetes	O
treatment..	O

Because	O
lack	O
of	O
A-type	O
lamins	O
or	O
the	O
expression	O
of	O
disease-causing	O
mutant	O
lamin	O
A	O
affect	O
the	O
cell	O
cycle,	O
as	O
well	O
as	O
differentiation	O
of	O
myocytes	O
and	O
adipocytes	O
[117–119],	O
it	O
has	O
been	O
proposed	O
that	O
lamins	O
A	O
and	O
C-LAP-2α	O
complexes	O
also	O
control	O
the	O
balance	O
between	O
proliferation	O
and	O
differentiation	O
of	O
adult	B
stem	I
cells	I
in	O
tissue	O
homeostasis	O
and	O
regeneration	O
(see	O
below)	O
[120,	O
121].	O

Although	O
the	O
exact	O
regulation	O
of	O
lamin	O
A	O
deposition	O
in	O
the	O
nuclear	O
lamina	O
during	O
ESC	O
differentiation	O
has	O
not	O
been	O
studied,	O
there	O
is	O
a	O
growing	O
body	O
of	O
evidence	O
linking	O
lamin	O
A	O
to	O
somatic	B
stem	I
cell	I
regulation	O
and	O
differentiation..	O

Thus,	O
the	O
decreased	O
epidermal	B
stem	I
cell	I
proliferation	O
observed	O
in	O
the	O
Zmpste24−/−-	O
mice	O
is	O
likely	O
a	O
result	O
of	O
the	O
absence	O
of	O
Wnt	O
signalling	O
in	O
these	O
cells.	O

No	O
place	O
like	O
home:	O
anatomy	O
and	O
function	O
of	O
the	O
stem	B
cell	I
niche.	O

Following	O
the	O
discovery	O
of	O
tumor-initiating	O
cells	O
for	O
AML,	O
tumor-initiating	O
cells	O
with	O
stem	B
cell	I
properties	O
have	O
been	O
isolated	O
for	O
a	O
variety	O
of	O
cancers	O
(Li	O
et	O
al.,	O
2007;	O
Eramo	O
et	O
al.,	O
2008;	O
Collins	O
et	O
al.,	O
2005;	O
Bapat	O
et	O
al.,	O
2005;	O
Singh	O
et	O
al.,	O
2003;	O
Yuan	O
et	O
al.,	O
2004;	O
Gibbs	O
et	O
al.,	O
2005;	O
Wu	O
et	O
al.,	O
2007;	O
Al-Hajj	O
et	O
al.,	O
2003).	O

Immunohistochemical	O
expression	O
of	O
embryonic	B
stem	I
cell	I
markers	O
in	O
malignant	O
rhabdoid	O
tumors.	O

showed	O
in	O
a	O
mouse	O
blast	O
crisis	O
(BC)	O
model	O
that	O
let-7	O
microRNA	O
editing	O
is	O
a	O
pivotal	O
process	O
in	O
leukemia	B
stem	I
cell	I
self-renewal.	O

Cell	O
fate	O
determination	O
factor	O
Dachshund	O
reprograms	O
breast	B
cancer	I
stem	I
cell	I
function.	O

Human	O
ES	O
cell-derived	O
neural	O
rosettes	O
reveal	O
a	O
functionally	O
distinct	O
early	O
neural	B
stem	I
cell	I
stage.	O

The	O
Kumar	O
data	O
consists	O
of	O
mouse	B
embryonic	I
stem	I
cells	I
cultured	O
in	O
three	O
different	O
media	O
while	O
the	O
PBMC3k	O
data	O
consists	O
of	O
11	O
blood	O
cell	O
types	O
(data	O
details	O
in	O
the	O
Additional	O
file	O
1).	O

Conditional	O
expression	O
of	O
K-ras	O
in	O
an	O
epithelial	O
compartment	O
that	O
includes	O
the	O
stem	B
cells	I
is	O
sufficient	O
to	O
promote	O
squamous	O
cell	O
carcinogenesis.	O

The	O
advent	O
of	O
stem	B
cell	I
technology	O
to	O
generate	O
human	O
neurons	O
(Brennand	O
et	O
al.,	O
2015)	O
has	O
boosted	O
cell	O
culture-based	O
research	O
of	O
brain	O
function	O
as	O
well	O
as	O
human	O
disease	O
modeling	O
(Sandoe	O
and	O
Eggan,	O
2013).	O

This	O
suggested	O
that	O
NSPCs	O
with	O
elevated	O
DNA	O
DSBs	O
might	O
lose	O
the	O
stem	B
cell	I
identity	O
instead	O
of	O
undergoing	O
apoptosis	O
in	O
vivo.	O

The	O
success	O
of	O
this	O
approach	O
demonstrated	O
the	O
potential	O
for	O
CRISPR-Cas9-induced	O
gene	O
correction	O
of	O
epidermal	B
stem	I
cells	I
in	O
vivo	O
without	O
the	O
cost	O
and	O
technical	O
challenge	O
of	O
ex	O
vivo	O
cell	O
modification.	O

successfully	O
established	O
cell	O
lines	O
from	O
primary	O
patient	O
samples	O
of	O
lung	O
BMs,	O
where	O
specific	O
in	O
vitro	O
culture	O
conditions	O
were	O
utilized	O
to	O
enrich	O
for	O
a	O
metastatic	O
subpopulation	O
of	O
cancer	B
stem	I
cells	I
within	O
these	O
BM,	O
termed	O
brain	O
metastasis-initiating	O
cells	O
(BMICs).	O

A	O
total	O
of	O
23	O
essential	O
genes	O
were	O
identified	O
through	O
experimental	O
analysis	O
as	O
essential	O
for	O
mouse	B
embryonic	I
stem	I
cell	I
survival.	O

Cells	O
were	O
cultured	O
(over	O
night)	O
in	B
serum-free	I
stem	I
cells	I
maintaining	O
medium	O
(STEM	O
CELL	O
technologies,	O
09650)	O
supplemented	O
with	O
cytokines	O
mSCF	O
(50	O
ng/ml;	O
Peprotech,	O
250-03)	O
and	O
TPO	O
(50	O
ng/ml;	O
Peprotech,	O
315-14).	O

Twelve	O
hours	O
later,	O
medium	O
was	O
changed	O
with	O
stem	B
cell	I
maintaining	O
medium	O
and	O
kept	O
in	O
culture.	O

Graft-versus	O
host	O
disease	O
(GVHD)	O
is	O
a	O
complication	O
of	O
stem	B
cell	I
transplantation	O
associated	O
with	O
significant	O
morbidity	O
and	O
mortality.	O

Identifying	O
molecular	O
targets	O
against	O
GVHD	O
is	O
critical	O
to	O
reduce	O
therapy-related	O
mortality	O
in	O
stem	B
cell	I
transplantation.	O

In	O
addition,	O
resistance	O
occurs	O
and	O
this,	O
together	O
with	O
stem	B
cell	I
persistence,	O
facilitates	O
disease	O
transformation.	O

The	O
expression	O
pattern	O
of	O
erythrocyte/megakaryocyte-related	O
transcription	O
factors	O
GATA-1	O
and	O
the	O
stem	B
cell	I
leukemia	O
gene	O
correlates	O
with	O
hematopoietic	O
differentiation	O
and	O
is	O
associated	O
with	O
outcome	O
of	O
acute	O
myeloid	O
leukemia.	O

Altogether	O
these	O
data	O
suggest	O
that	O
TE-derived	O
enhancers	O
play	O
an	O
essential	O
role	O
in	O
the	O
species	O
speciation	O
and	O
tissue-specific	O
re-wiring	O
of	O
the	O
transcriptional	O
network	O
in	O
stem	B
cells	I
and	O
differentiated	O
cell	O
lineages	O
[85].	O

Potential	O
Gene	O
Interactions	O
in	O
the	O
Cell	O
Cycles	O
of	O
Gametes,	O
Zygotes,	O
Embryonic	O
Stem	O
Cells	O
and	O
the	O
Development	O
of	O
Cancer.	O

Potential	O
Gene	O
Interactions	O
in	O
the	O
Cell	O
Cycles	O
of	O
Gametes,	O
Zygotes,	O
Embryonic	O
Stem	O
Cells	O
and	O
the	O
Development	O
of	O
Cancer.	O

Thus,	O
interactions	O
of	O
parental	O
genes	O
in	O
the	O
zygote	O
reprogram	O
PEGCs	O
as	O
a	O
key	O
source	O
for	O
stem	B
cell	I
memory	O
persisting	O
throughout	O
life	O
(28,	O
86).	O

Activity	O
of	O
a	O
heptad	O
of	O
transcription	O
factors	O
is	O
associated	O
with	O
stem	B
cell	I
programs	O
and	O
clinical	O
outcome	O
in	O
acute	O
myeloid	O
leukemia.	O

Itch,	O
an	O
E3	O
ligase	O
of	O
Oct4,	O
is	O
required	O
for	O
embryonic	B
stem	I
cell	I
self-renewal	O
and	O
pluripotency	O
induction.	O

Novel	O
insight	O
into	O
embryonic	B
stem	I
cell	I
self-renewal	O
through	O
comparative	O
human	O
and	O
mouse	O
system	O
biological	O
networks.	O

Embryonic	B
stem	I
cell	I
markers	O
Sox2	O
and	O
Oct4	O
expression	O
and	O
their	O
correlation	O
with	O
Wnt	O
signal	O
pathway	O
in	O
cervical	O
squamous	O
cell	O
carcinoma.	O

Material	O
for	O
HSCT	O
in	O
humans	O
is	O
now	O
most	O
commonly	O
derived	O
from	O
mobilized	B
stem	I
cell	I
products	O
and	O
contains	O
donor	O
immune	O
cells	O
from	O
the	O
circulation.	O

Efficient	O
definitive	O
endoderm	O
induction	O
from	O
mouse	B
embryonic	I
stem	I
cell	I
adherent	O
cultures:	O
a	O
rapid	O
screening	O
model	O
for	O
differentiation	O
studies.	O

Furthermore,	O
it	O
has	O
been	O
described	O
to	O
favor	O
the	O
establishment	O
of	O
cancer	B
stem	I
cell	I
phenotypes,	O
responsible	O
by	O
recapitulating	O
tumor	O
heterogeneity	O
after	O
treatment	O
[16].	O

A	O
significant	O
number	O
of	O
genes	O
involved	O
in	O
stem	B
cell	I
maintenance,	O
differentiation,	O
and	O
asymmetric	O
division	O
were	O
also	O
identified	O
among	O
the	O
differentially	O
expressed	O
genes	O
in	O
overexpression,	O
consistent	O
with	O
TBPH	O
playing	O
some	O
role	O
in	O
neuronal	O
differentiation	O
and	O
death..	O

Cellular	O
functions	O
of	O
stem	B
cell	I
factors	O
mediated	O
by	O
the	O
ubiquitin-proteasome	O
system.	O

These	O
cells	O
make	O
up	O
the	O
connective	O
tissue	O
in	O
the	O
lung	O
and	O
exhibit	O
diverse	O
functions	O
including	O
regulation	O
of	O
the	O
ECM,	O
production	O
of	O
growth	O
factors,	O
cytokines	O
and	O
chemokines,	O
and	O
the	O
generation	O
of	O
stem	B
cell	I
niches,	O
among	O
others165.	O

This	O
suggests	O
that	O
the	O
cisd-3.2(pnIs68)	O
mutant	O
has	O
abnormalities	O
within	O
the	O
stem	B
cell	I
niche	O
region	O
of	O
the	O
gonad.	O

It	O
will	O
be	O
of	O
interest	O
to	O
further	O
examine	O
the	O
role	O
of	O
mitochondria	O
homeostasis	O
with	O
the	O
maintenance	O
of	O
the	O
stem	B
cell	I
niche.	O

Analysis	O
of	O
Germline	B
Stem	I
Cell	I
Differentiation	O
Following	O
Loss	O
of	O
GLP-1	O
Notch	O
Activity	O
in	O
Caenorhabditis	O
elegans.	O

We	O
previously	O
explored	O
the	O
potential	O
treatment	O
mechanism	O
of	O
MSC	O
by	O
monitoring	O
the	O
fate	O
of	O
transplanted	O
BM-MSC	O
using	O
molecular	O
imaging	O
strategy,	O
which	O
provided	O
valuable	O
insight	O
into	O
the	O
in	O
vivo	O
kinetics	O
of	O
engrafted	O
cells.17,31	O
BLI	O
is	O
an	O
accurate,	O
sensitive,	O
approach	O
for	O
noninvasive	B
stem	I
cell	I
tracking.	O

Therefore,	O
our	O
findings	O
may	O
facilitate	O
the	O
further	O
application	O
of	O
stem	B
cell	I
for	O
the	O
biological	O
treatment	O
of	O
sepsis..	O

In	O
vivo	O
visualization	O
of	O
embryonic	B
stem	I
cell	I
survival,	O
proliferation,	O
and	O
migration	O
after	O
cardiac	O
delivery.	O

RBPJ	O
in	O
mouse	O
Sertoli	O
cells	O
is	O
required	O
for	O
proper	O
regulation	O
of	O
the	O
testis	B
stem	I
cell	I
niche.	O

miR-205hg	O
was	O
associated	O
with	O
cutaneous	O
squamous	O
cell	O
carcinoma	O
[102]	O
and	O
controls	O
neonatal	O
expansion	O
of	O
skin	B
stem	I
cells	I
by	O
regulating	O
the	O
PI(3)K	O
pathway	O
[103]..	O

To	O
further	O
characterize	O
the	O
effect	O
of	O
TEL–SYK	O
on	B
the	I
stem	I
cell	I
compartment,	O
we	O
sorted	O
TEL–SYK+	O
LT-HSCs	O
(Lin-Kit+Sca+CD150+FLT3-)	O
and	O
ST-HSCs	O
(Lin-Kit+Sca+CD150-FLT3-)	O
and	O
compared	O
them	O
with	O
control	O
counterparts	O
by	O
gene	O
expression	O
profiling.	O

CS,	O
HM,	O
DB,	O
TAM,	O
JH,	O
SK	O
and	O
JA	O
performed	O
the	O
experiments;	O
CK	O
established	O
flow	O
cytometry	O
analysis	O
of	O
stem	B
cell	I
populations;	O
DP	O
performed	O
gene	O
expression	O
analysis;	O
CD,	O
JD,	O
TB	O
and	O
HJ	O
designed	O
the	O
research;	O
CD	O
and	O
CS	O
wrote	O
the	O
manuscript.	O

Examples	O
of	O
such	O
processes	O
are	O
the	O
cell's	O
response	O
to	O
starvation	O
and	O
other	O
stresses,4	O
removal	O
of	O
bacteria	O
and	O
viruses,5	O
elimination	O
of	O
damaged	O
proteins	O
and	O
organelles	O
that	O
occur	O
during	O
aging,6	O
and	O
maintenance	O
of	O
stem	B
cell	I
homeostasis.7	O
Given	O
the	O
numerous	O
ways	O
that	O
autophagy	O
impacts	O
cellular	O
homeostasis,	O
it	O
is	O
not	O
remarkable	O
that	O
this	O
cellular	O
process	O
has	O
been	O
implicated	O
in	O
ocular	O
health	O
and	O
disease	O
(see	O
prior	O
reviews8,9).	O

Induction	O
of	O
autophagy	O
supports	O
the	O
bioenergetic	O
demands	O
of	O
quiescent	B
muscle	I
stem	I
cell	I
activation.	O

Congenital	O
muscular	O
dystrophy-associated	O
inflammatory	O
chemokines	O
provide	O
axes	O
for	O
effective	O
recruitment	O
of	O
therapeutic	B
adult	I
stem	I
cell	I
into	O
muscles.	O

Witness	O
the	O
visceral	O
reactions	O
after	O
Tomasetti	O
and	O
Vogelstein	O
published,	O
“Variation	O
in	O
cancer	O
risk	O
among	O
tissues	O
can	O
be	O
explained	O
by	O
the	O
number	O
of	O
stem	B
cell	I
divisions”	O
[2].	O

Variation	O
in	O
cancer	O
risk	O
among	O
tissues	O
can	O
be	O
explained	O
by	O
the	O
number	O
of	O
stem	B
cell	I
divisions.	O

Calcium	O
dependent	O
CAMTA1	O
in	O
adult	B
stem	I
cell	I
commitment	O
to	O
a	O
myocardial	O
lineage.	O

In	O
addition	O
to	O
demonstrating	O
the	O
stem	B
cell	I
nature	O
of	O
pre-migratory	O
and	O
migratory	O
NC	O
cells,	O
in	O
vitro	O
studies	O
have	O
also	O
revealed	O
environmental	O
signals	O
regulating	O
multipotential	O
maintenance	O
in	O
NC	O
cells	O
[19].	O

As	O
NC	O
cells	O
migrate	O
away	O
from	O
the	O
dorsal	O
neural	O
tube,	O
expression	O
of	O
Lin28a	O
decreases,	O
leading	O
to	O
increased	O
let7	O
activation,	O
resulting	O
in	O
a	O
loss	O
of	O
stem	B
cell	I
identity	O
[209]..	O

The	O
role	O
of	O
stem	B
cell	I
therapy	O
in	O
regeneration	O
of	O
dentine-pulp	O
complex:	O
a	O
systematic	O
review.	O

In	O
the	O
present	O
paper	O
we	O
describe	O
the	O
main	O
findings	O
about	O
the	O
alterations	O
of	O
cell	O
signaling	O
pathways	O
in	O
the	O
most	O
aggressive	O
glioma	O
in	O
the	O
adult	O
population,	O
namely,	O
glioblastoma,	O
in	O
which	O
epigenetic	O
mechanisms	O
and	O
the	O
emerging	O
role	O
of	O
cancer	B
stem	I
cell	I
play	O
a	O
crucial	O
function	O
in	O
the	O
development	O
of	O
new	O
biomarkers	O
for	O
its	O
detection	O
and	O
prognosis	O
and	O
the	O
corresponding	O
development	O
of	O
new	O
pharmacological	O
strategies..	O

In	O
particular,	O
Wnt/β-catenin	O
signaling	O
controls	O
intestinal	O
crypt	O
cell	O
division,	O
survival	O
and	O
maintenance	O
of	O
the	O
stem	B
cell	I
niche.	O

These	O
results	O
suggest	O
that	O
LRP6	O
is	O
much	O
more	O
important	O
than	O
LRP5	O
for	O
the	O
control	O
of	O
intestinal	B
stem	I
cell	I
renewal	O
and	O
crypt	O
regeneration,	O
at	O
least	O
ex	O
vivo..	O

While	O
no	O
alteration	O
in	O
stem	B
cell	I
numbers	O
and	O
Wnt	O
signaling,	O
as	O
assessed	O
by	O
measuring	O
active	O
β-catenin	O
levels,	O
was	O
observed	O
in	O
vivo,	O
enteroids	O
derived	O
from	O
these	O
KO	O
mice	O
could	O
not	O
grow	O
[27,28].	O

Thus,	O
these	O
studies	O
have	O
revealed	O
that	O
Paneth	O
cell-secreted	O
Wnt3	O
is	O
not	O
the	O
only	O
niche	O
factor	O
involved	O
in	O
stem	B
cell	I
maintenance	O
in	O
vivo,	O
suggesting	O
that	O
redundant	O
Wnt	O
signals	O
exist	O
in	O
mice	O
to	O
ensure	O
intestinal	O
homeostasis.	O

Indeed,	O
intestinal	O
stromal	O
cells	O
act	O
as	O
important	O
regulators	O
of	O
the	O
stem	B
cell	I
niche,	O
by	O
producing	O
and	O
secreting	O
several	O
Wnt	O
factors,	O
notably	O
Wnt2b	O
and	O
Wnt4	O
[29,30,31,32,33].	O

4.2	O
Therapeutic	O
effect	O
of	O
miRNA	O
in	O
exosomes	O
are	O
found	O
in	O
stem	B
cell	I
therapies.	O

The	O
effectiveness	O
of	O
stem	B
cell	I
therapies	O
is	O
always	O
influenced	O
by	O
aging-related	O
environmental	O
changes.	O

Cfa‐miR‐196b	O
(involved	O
in	O
stem	B
cell	I
differentiation)	O
was	O
the	O
most	O
highly	O
expressed	O
and	O
cfa‐miR‐208a	O
(associated	O
with	O
cardiac	O
hypertrophy)	O
the	O
most	O
negatively	O
regulated	O
miRNAs	O
on	O
the	O
mitral	O
valve	O
of	O
MR	O
dogs	O
as	O
quantified	O
by	O
RNA	O
sequencing	O
(P	O
<	O
0.001).	O

Rbfox1	O
is	O
expressed	O
in	O
heart,	O
skeletal	O
muscle,	O
and	O
neuronal	O
tissues,	O
while	O
Rbfox2	O
is	O
ubiquitously	O
expressed	O
in	O
many	O
tissues	O
from	O
the	O
embryonic	B
stem	I
cell	I
stage	O
through	O
adulthood1,8,13,14.	O

Hypoxia	O
induces	O
EMT	O
in	O
low	O
and	O
highly	O
aggressive	O
pancreatic	O
tumor	O
cells	O
but	O
only	O
cells	O
with	O
cancer	B
stem	I
cell	I
characteristics	O
acquire	O
pronounced	O
migratory	O
potential.	O

These	O
cells	O
are	O
maintained	O
in	O
sufficient	O
quantities	O
predominantly	O
by	O
their	O
own	O
self-renewal,	O
rather	O
than	O
by	O
replacement	O
from	O
neural	B
stem	I
cell	I
niches	O
in	O
the	O
CNS	O
[50,	O
51]..	O

During	O
development,	O
Wnt	O
signaling	O
is	O
involved	O
in	O
cell	O
fate	O
specification,	O
proliferation	O
and	O
migration,	O
and	O
in	O
the	O
adult	O
this	O
pathway	O
is	O
involved	O
in	O
maintaining	O
homeostasis	O
in	O
tissues	O
such	O
as	O
the	O
intestine,	O
where	O
Wnt	O
signaling	O
is	O
critical	O
for	O
stem	B
cell	I
function	O
(Dorsky	O
et	O
al.,	O
1998;	O
Loebel	O
et	O
al.,	O
2003).	O

At	O
present,	O
lineage	O
tracing	O
offers	O
the	O
most	O
robust	O
method	O
of	O
addressing	O
the	O
cancer	B
stem	I
cell	I
hypothesis	O
in	O
vivo.	O

Basal	O
cell	O
carcinomas	O
arise	O
from	O
hair	B
follicle	I
stem	I
cells	I
in	O
Ptch1(+/−)	O
mice.	O

A	O
xenograft	O
transplantation	O
in	O
immune-deficient	O
mice	O
was	O
performed,	O
and	O
the	O
estimated	O
stem	O
cell	O
ratio	O
in	O
sphere-cultured	O
cells	O
was	O
1	O
in	O
185	O
cells,	O
whereas	O
the	O
estimated	O
stem	O
cell	O
ratio	O
in	O
adherent-culture	O
cells	O
was	O
1	O
in	O
770;	O
however,	O
the	O
difference	O
in	O
stem	B
cell	I
ratios	O
did	O
not	O
reach	O
statistical	O
significance	O
(Figure.	O

ELDA:	O
extreme	O
limiting	O
dilution	O
analysis	O
for	O
comparing	O
depleted	O
and	O
enriched	O
populations	O
in	O
stem	B
cell	I
and	O
other	O
assays.	O

By	O
using	O
p63,	O
Foxi3a/-b,	O
and	O
Gcm2	O
as	O
markers,	O
cortisol	O
treatment	O
for	O
as	O
short	O
as	O
14-24	O
h	O
was	O
found	O
to	O
increase	O
the	O
densities	O
of	O
both	O
progenitor	O
and	O
mature	O
ionocytes	O
in	O
embryos	O
or	O
isolated	O
adult	O
gills,	O
but	O
the	O
same	O
treatment	O
(even	O
for	O
a	O
longer	O
period,	O
48	O
h)	O
did	O
not	O
affect	O
those	O
of	O
stem	B
cells	I
and	O
dividing	O
cells	O
(examined	O
using	O
PH3	O
as	O
a	O
marker),	O
indicating	O
that	O
cortisol	O
acts	O
on	O
cell	O
differentiation,	O
but	O
not	O
on	O
cell	O
proliferation	O
(Cruz	O
et	O
al.,	O
2013[31],	O
[32]).	O

We	O
present	O
new	O
data	O
that	O
implicate	O
imprinted	O
gene	O
networks	O
in	O
the	O
development	O
of	O
the	O
gland	O
and	O
in	O
the	O
stem	B
cell	I
compartment.	O

By	O
e11.5,	O
the	O
RP	O
appears	O
as	O
a	O
defined	O
structure	O
that	O
largely	O
consists	O
of	O
a	O
central	O
lumen	O
surrounded	O
by	O
highly	O
proliferative	O
epithelial	O
progenitors	O
expressing	O
the	O
stem	B
cell	I
marker,	O
sex-determining	O
region	O
Y-related	O
HMG	O
box	O
2	O
(SOX2)	O
[63].	O

Notably,	O
the	O
periluminal	O
region	O
(also	O
known	O
as	O
marginal	O
zone,	O
MZ)	O
is	O
described	O
as	O
the	O
stem	B
cell	I
niche	O
of	O
the	O
pituitary	O
gland	O
[63,81,82].	O

Importantly,	O
several	O
members	O
of	O
the	O
IGN	O
are	O
expressed	O
in	O
somatic	B
stem	I
cell	I
niches	O
and	O
contribute	O
to	O
postnatal	O
tissue	O
homeostasis,	O
including	O
Igf2	O
[102],	O
Dlk1	O
[103],	O
H19	O
[104]	O
and	O
paternally	O
expressed	O
gene	O
3	O
(Peg3)	O
[105,106].	O

By	O
e18.5	O
and	O
in	O
the	O
postnatal	O
stages	O
(Ag–Aj),	O
SOX2	O
staining	O
was	O
clearly	O
observed	O
in	O
the	O
marginal	O
zone	O
(MZ)	O
around	O
the	O
cleft,	O
considered	O
to	O
be	O
the	O
stem	B
cell	I
niche	O
of	O
the	O
pituitary	O
gland.	O

IGN	O
genes	O
could	O
represent	O
a	O
transcriptional	O
programme	O
that	O
confers	O
potency	O
to	O
regenerate	O
adult	O
organs	O
[107],	O
an	O
idea	O
supported	O
by	O
the	O
finding	O
that	O
imprinted	O
genes	O
are	O
necessary	O
for	O
adult	B
stem	I
cell	I
homeostasis	O
in	O
multiple	O
contexts	O
[102,103,104,105].	O

Utilising	O
single-cell	O
RNA	O
sequencing	O
data	O
from	O
adult	O
mouse	O
pituitaries	O
[44],	O
we	O
asked	O
if	O
our	O
embryo	O
high	O
genes	O
were	O
also	O
expressed	O
in	O
the	O
pituitary	B
stem	I
cell	I
compartment.	O

Peg3	O
was	O
enriched	O
in	O
the	O
stem	B
cell	I
compartment,	O
as	O
were	O
neighbouring	O
genes	O
in	O
the	O
same	O
imprinting	O
cluster,	O
Zim1	O
and	O
Usp29.	O

High-resolution	O
DNA	O
analysis	O
of	O
human	B
embryonic	I
stem	I
cell	I
lines	O
reveals	O
culture-induced	O
copy	O
number	O
changes	O
and	O
loss	O
of	O
heterozygosity.	O

miRNAs	O
regulate	O
SIRT1	O
expression	O
during	O
mouse	B
embryonic	I
stem	I
cell	I
differentiation	O
and	O
in	O
adult	O
mouse	O
tissues.	O

Mounting	O
evidence	O
indicates	O
that	O
microRNAs	O
play	O
important	O
roles	O
in	O
stress-activated	O
pathways	O
(Leung	O
and	O
Sharp,	O
2010;	O
Mendell	O
and	O
Olson,	O
2012;	O
Emde	O
and	O
Hornstein,	O
2014)	O
and	O
in	O
control	O
of	O
somatic	B
stem	I
cell	I
fate	O
and	O
tumorigenesis	O
(Gangaraju	O
and	O
Lin,	O
2009;	O
Sun	O
and	O
Lai,	O
2013;	O
Yi	O
and	O
Fuchs,	O
2011).	O

In	O
summary,	O
we	O
propose	O
a	O
model	O
in	O
which	O
miR-31	O
functions	O
as	O
a	O
cell-intrinsic	O
master	O
modulator	O
of	O
the	O
intestinal	B
stem	I
cell	I
niche	O
signaling	O
during	O
normal	O
homeostasis,	O
regeneration	O
and	O
tumorigenesis	O
(Figure	O
9).	O

However,	O
they	O
do	O
not	O
fully	O
describe	O
the	O
consequences	O
of	O
these	O
changes	O
in	O
stem	B
cell	I
numbers	O
under	O
normal	O
circumstances.	O

8)	O
Figure	O
1—figure	O
supplement	O
2F:	O
Showing	O
an	O
image	O
of	O
a	O
single	O
crypt	O
is	O
not	O
sufficient	O
to	O
make	O
the	O
point	O
that	O
the	O
stem	B
cell	I
compartment	O
is	O
expanded	O
in	O
TRE-miR-31	O
colon.	O

To	O
properly	O
document	O
an	O
increase	O
in	O
Lgr5+	B
stem	I
cell	I
activity,	O
in	O
vivo	O
lineage	O
tracing	O
must	O
be	O
performed.	O

I	O
don't	O
see	O
how	O
you	O
can	O
conclude	O
that	O
miR-31	O
is	O
required	O
for	O
reserve	B
stem	I
cell	I
activity.	O

What	O
happens	O
within	O
the	O
epithelium	O
following	O
miR-31	O
deletion?	O
Is	O
the	O
phenotype	O
more	O
general	O
TA	O
cell	O
driven	O
or	O
does	O
it	O
originate	O
from	O
within	O
the	O
stem	B
cell	I
compartment?	O
Apoptosis	O
evident	O
as	O
observed	O
with	O
the	O
miR31	O
null	O
mice?.	O

Are	O
the	O
target	O
genes	O
first	O
changing	O
within	O
the	O
stem	B
cell	I
compartment	O
or	O
is	O
it	O
a	O
more	O
general	O
response?	O
Are	O
similar	O
changes	O
found	O
in	O
both	O
the	O
small	O
intestine	O
and	O
colon?.	O

However,	O
they	O
do	O
not	O
fully	O
describe	O
the	O
consequences	O
of	O
these	O
changes	O
in	O
stem	B
cell	I
numbers	O
under	O
normal	O
circumstances.	O

8)	O
Figure	O
1—figure	O
supplement	O
2F:	O
Showing	O
an	O
image	O
of	O
a	O
single	O
crypt	O
is	O
not	O
sufficient	O
to	O
make	O
the	O
point	O
that	O
the	O
stem	B
cell	I
compartment	O
is	O
expanded	O
in	O
TRE-miR-31	O
colon.	O

A	O
detailed	O
time-course	O
with	O
early	O
time-points	O
is	O
needed	O
to	O
determine	O
when	O
the	O
phenotype	O
first	O
presents	O
and	O
in	O
which	O
cell-type	O
(using	O
lineage	O
markers)	O
–	O
is	O
it	O
selectively	O
driven	O
from	O
the	O
stem	B
cell	I
compartment?.	O

Any	O
effect	O
on	O
the	O
Paneth	O
cells	O
(important	O
regulators	O
of	O
stem	B
cell	I
activity)?.	O

To	O
properly	O
document	O
an	O
increase	O
in	O
Lgr5+	B
stem	I
cell	I
activity,	O
in	O
vivo	O
lineage	O
tracing	O
must	O
be	O
performed.	O

I	O
don't	O
see	O
how	O
you	O
can	O
conclude	O
that	O
miR-31	O
is	O
required	O
for	O
reserve	B
stem	I
cell	I
activity.	O

Is	O
the	O
phenotype	O
more	O
general	O
TA	O
cell	O
driven	O
or	O
does	O
it	O
originate	O
from	O
within	O
the	O
stem	B
cell	I
compartment?.	O

Are	O
the	O
target	O
genes	O
first	O
changing	O
within	O
the	O
stem	B
cell	I
compartment	O
or	O
is	O
it	O
a	O
more	O
general	O
response?	O
Are	O
similar	O
changes	O
found	O
in	O
both	O
the	O
small	O
intestine	O
and	O
colon?.	O

Many	O
signaling	O
pathways	O
have	O
been	O
linked	O
to	O
stem	B
cell	I
behaviors	O
or	O
self-renewal	O
abilities.	O

We	O
also	O
detail	O
immune	O
reconstitution	O
studies	O
that	O
have	O
been	O
integrated	O
into	O
the	O
randomized	B
controlled	I
Autologous	I
Stem	I
cell	I
Transplantation	O
In	O
refractory	O
CD—Low	O
Intensity	O
Therapy	O
Evaluation	O
trial,	O
which	O
is	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
auto-HSCT	O
using	O
reduced	O
intensity	O
mobilization	O
and	O
conditioning	O
regimens	O
will	O
be	O
a	O
safe	O
and	O
effective	O
means	O
of	O
inducing	O
sustained	O
control	O
in	O
refractory	O
CD	O
compared	O
to	O
standard	O
of	O
care.	O

Pre-specified	O
interim	O
analyses	O
will	O
be	O
undertaken	O
to	O
confirm	O
that	O
the	O
mobilization	O
regimen	O
is	O
effective	O
for	O
stem	B
cell	I
harvest	O
with	O
no	O
negative	O
impact	O
on	O
disease	O
activity.	O

During	O
differentiation,	O
cell	O
identity	O
switches	O
from	O
proliferating	B
stem	I
cell	I
to	O
a	O
specialized	O
cell	O
with	O
distinct	O
physiological	O
function.	O

The	O
miRNA	O
regulation	O
may	O
be	O
involved	O
in	O
the	O
maintenance	O
of	O
the	O
cancer	B
stem	I
cell	I
phenotype.[73,74]	O
One	O
of	O
the	O
HIF-regulating	O
factors,	O
EPO,	O
has	O
been	O
shown	O
to	O
promote	O
tumorigenesis	O
by	O
activating	O
Janus	O
kinase	O
(JAK)/STAT	O
signaling.[75]	O
In	O
Hodgkin	O
and	O
Reed-Sternberg	O
tumor	O
cells,	O
Notch-1	O
and	O
JAK/STAT	O
pathway	O
are	O
activated,	O
whose	O
inhibition	O
results	O
in	O
apoptosis	O
for	O
treating	O
classical	O
Hodgkin	O
lymphoma.[76]	O
In	O
an	O
experimental	O
glioma	O
model,	O
tumor	O
cells	O
expressed	O
CD133,	O
nestin,	O
VEGF,	O
sodium	O
calcium	O
ex-changers,	O
and	O
showed	O
hybrid	O
cell	O
death	O
after	O
chemotherapy	O
drug	O
treatment.[77,78]	O
Hypoxia	O
also	O
inhibits	O
HIF-1α	O
degradation,	O
which	O
is	O
BMP	O
dependent.[79]	O
Further	O
studies	O
suggest	O
HIF-1	O
and	O
VEGF	O
as	O
two	O
angiogenic	O
targets	O
that	O
can	O
be	O
used	O
for	O
diagnosis	O
and	O
blocked	O
for	O
treating	O
cancers.[80,81,82]	O
Anthracycline	O
chemotherapy	O
is	O
effective	O
in	O
inhibiting	O
HIF-1,	O
which	O
blocks	O
the	O
mobilization	O
of	O
circulating	O
progenitors	O
to	O
the	O
tumor	O
angiogenesis.[83].	O

The	O
success	O
in	O
generation	O
and	O
culture	O
of	O
ESCs	O
from	O
mice,	O
primates,	O
and	O
human	O
embryos	O
has	O
been	O
considered	O
a	O
milestone	O
of	O
stem	B
cell	I
research.	O

Primed	O
for	O
lethal	O
battle:	O
A	O
step	O
forward	O
to	O
enhance	O
the	O
efficacy	O
and	O
efficiency	O
of	O
stem	B
cell	I
transplantation	O
therapy.	O

Delayed	O
intranasal	O
delivery	O
of	O
hypoxic-preconditioned	B
bone	I
marrow	I
mesenchymal	I
stem	I
cells	I
enhanced	O
cell	O
homing	O
and	O
therapeutic	O
benefits	O
after	O
ischemic	O
stroke	O
in	O
mice.	O

The	O
endogenous	O
regenerative	O
capacity	O
of	O
the	O
damaged	O
newborn	O
brain:	O
Boosting	O
neurogenesis	O
with	O
mesenchymal	B
stem	I
cell	I
treatment.	O

Finally,	O
numerous	O
recent	O
studies	O
have	O
revealed	O
that	O
the	O
methylation	O
of	O
H3K27	O
by	O
Polycomb	O
proteins	O
is	O
critical	O
for	O
the	O
maintenance	O
of	O
stem	B
cell	I
pluripotency	O
in	O
mammals	O
[74].	O

By	O
counteracting	O
H3K27	O
methylation,	O
CHD7	O
may	O
promote	O
the	O
differentiation	O
of	O
pluripotent	B
stem	I
cells	I
into	O
specialized	O
cell	O
types.	O

Human	O
Cytomegalovirus	O
IE2	O
Protein	O
Disturbs	O
Brain	O
Development	O
by	O
the	O
Dysregulation	O
of	O
Neural	B
Stem	I
Cell	I
Maintenance	O
and	O
the	O
Polarization	O
of	O
Migrating	O
Neurons.	O

This	O
gene	O
encodes	O
an	O
orphan	O
nuclear	O
receptor	O
(also	O
known	O
as	O
TLX)	O
that	O
is	O
highly	O
conserved	O
between	O
human	O
and	O
mouse,	O
and	O
has	O
an	O
important	O
role	O
in	O
the	O
maintenance	O
of	O
the	O
neural/progenitor	B
stem	I
cell	I
populations	O
of	O
both	O
the	O
forebrain	O
and	O
retina	O
[76]–[80].	O

Nuclear	O
receptor	O
TLX	O
regulates	O
cell	O
cycle	O
progression	O
in	O
neural	B
stem	I
cells	I
of	O
the	O
developing	O
brain.	O

Separation	O
of	O
stem	B
cell	I
maintenance	O
and	O
transposon	O
silencing	O
functions	O
of	O
Piwi	O
protein.	O

A	O
novel	O
class	O
of	O
evolutionarily	O
conserved	O
genes	O
defined	O
by	O
piwi	O
are	O
essential	O
for	O
stem	B
cell	I
self-renewal.	O

eDEV500	O
does	O
not	O
rank	O
among	O
the	O
top	O
gene	O
sets,	O
nor	O
do	O
any	O
of	O
the	O
stem	B
cell	I
signatures.	O

The	O
top-scoring	O
genes	O
in	O
this	O
comparison	O
are	O
related	O
to	O
proliferation	O
and	O
DNA	O
repair	O
and	O
also	O
include	O
transcripts	O
coding	O
for	O
chromatin	O
remodeling	O
proteins	O
(EZH2),	O
a	O
histone	O
variant	O
that	O
has	O
recently	O
been	O
linked	O
with	O
stem	B
cell	I
proliferation	O
[28]	O
(H2AFX)	O
and	O
RNA-interacting	O
proteins	O
(ELAVL1,	O
SNRPA).	O

Although	O
how	O
estrogen	O
contributes	O
to	O
malignant	O
progression	O
is	O
still	O
unclear,	O
increasing	O
evidence	O
has	O
shown	O
that	O
higher	O
levels	O
lead	O
to	O
higher	O
genotoxic	O
and	O
mutagenic	O
metabolites	O
of	O
estrogen,	O
expression	O
of	O
stem	B
cell	I
markers	O
and	O
ERα-independent	O
signaling	O
[75,76,82].	O

FLCN/FNIP	O
loss	O
impacts	O
upon	O
on	O
cell	O
migration/adhesion	O
43,	O
44,	O
TGF‐β	O
signalling	O
45,	O
46,	O
HIF1‐α	O
transcription	O
47,	O
autophagy	O
48,	O
49,	O
ciliogenesis	O
50	O
and,	O
via	O
mTORC1	O
and	O
TFEB/TFE3,	O
regulates	O
lysosome	O
biogenesis	O
and	O
exit	O
of	O
stem	B
cells	I
from	O
pluripotency	O
37,	O
39,	O
51,	O
52	O
and	O
several	O
others,	O
reviewed	O
in	O
53.	O

Wnt	O
signaling	O
is	O
essential	O
in	O
maintaining	O
the	O
stem	O
cell	O
niche,	O
and	O
high	O
Wnt	O
activity	O
was	O
reported	O
to	O
accurately	O
define	O
the	O
CRC	O
stem	B
cell	I
population	O
[24].	O

RACE	O
Interacts	O
with	O
Dnmt3a,	O
HDAC1,	O
and	O
PHB2E	O
to	O
epigenetically	O
silences	O
miR-34a	O
expression,	O
resulting	O
in	O
CRC	B
stem	I
cell	I
asymmetric	O
division.	O

Mouse	O
studies	O
proved	O
the	O
function	O
of	O
Lnc34a	O
in	O
regulating	O
self-renewal	O
of	O
cancer	B
stem	I
cell	I
and	O
CRC	O
growth	O
[73].	O

This	O
provides	O
an	O
example	O
of	O
lncRNA-miRNA	O
interaction	O
in	O
maintenance	O
of	O
cancer	B
stem	I
cell	I
feature	O
by	O
regulating	O
Wnt	O
and	O
Notch	O
signaling..	O

De	O
novo	O
prediction	O
of	O
stem	B
cell	I
identity	O
using	O
single-cell	O
transcriptome	O
data.	O

Functional	O
connectivity	O
of	O
these	O
genes	O
was	O
linked	O
to	O
embryonic	B
stem	I
cell	I
pluripotency.	O

These	O
validated	O
genes	O
have	O
functional	O
connectivity	O
associated	O
with	O
stem	B
cell	I
pluripotency.	O

While	O
only	O
4	O
of	O
the	O
7	O
genes	O
have	O
been	O
functionally	O
characterized	O
in	O
PCa	O
cells	O
and	O
tissues,	O
all	O
genes,	O
except	O
PAQR4,	O
are	O
related	O
to	O
stem	B
cell	I
proliferation,	O
cancer	O
cell	O
proliferation	O
migration,	O
and/or	O
tumorigenesis	O
(reported	O
bio-functions	O
are	O
summarized	O
in	O
Table	O
3)..	O

In	O
concordance,	O
our	O
current	O
study	O
showed	O
that	O
neonatal	O
exposure	O
to	O
xenoestrogens	O
led	O
to	O
the	O
dysregulation	O
of	O
a	O
panel	O
of	O
stem	B
cell	I
function-related	O
genes	O
through	O
DNA	O
methylation	O
in	O
the	O
adult	O
prostate,	O
lending	O
further	O
credence	O
to	O
this	O
hypothesis.	O

Distinct	O
histone	O
modifications	O
in	O
stem	B
cell	I
lines	O
and	O
tissue	O
lineages	O
from	O
the	O
early	O
mouse	O
embryo.	O

[8]	O
investigated	O
how	O
alteration	O
in	O
methylation	O
at	O
the	O
level	O
of	O
stem	O
cell	O
methylation	O
can	O
be	O
responsible	O
for	O
active	O
variations	O
in	O
stem	B
cell	I
populations	O
which	O
leads	O
to	O
abnormal	O
plasticity	O
of	O
the	O
uterine	O
endometrium	O
and	O
consequently	O
pregnancy	O
loss.	O

These	O
techniques	O
have	O
been	O
applied	O
successfully	O
to	O
understand	O
molecular	O
and	O
cellular	O
pathways	O
involved	O
in	O
stem	B
cell	I
differentiation	O
by	O
identifying	O
the	O
expressed	O
genes	O
causing	O
lineage	O
commitment	O
into	O
megakaryocytes,	O
erythrocytes,	O
and	O
granulocytes,	O
which	O
play	O
different	O
roles	O
in	O
atherosclerosis	O
disease	O
developmental	O
and	O
disease	O
progression	O
[19]..	O

Reconstituting	O
vascular	O
microenvironment	O
of	O
neural	B
stem	I
cell	I
niche	O
in	O
three-dimensional	O
extracellular	O
matrix.	O

Mesenchymal	B
stem	I
cell	I
senescence	O
alleviates	O
their	O
intrinsic	O
and	O
seno-suppressive	O
paracrine	O
properties	O
contributing	O
to	O
osteoarthritis	O
development.	O

Mesenchymal	B
stem	I
cell	I
senescence	O
alleviates	O
their	O
intrinsic	O
and	O
seno-suppressive	O
paracrine	O
properties	O
contributing	O
to	O
osteoarthritis	O
development.	O

During	O
aging,	O
this	O
equilibrium	O
is	O
progressively	O
lost	O
as	O
a	O
result	O
of	O
time-	O
dependent	O
decrease	O
in	O
stem	B
cell	I
functions,	O
such	O
as	O
self-renewal,	O
differentiation,	O
and	O
tissue	O
repair	O
capacities	O
[1].	O

Moreover,	O
it	O
is	O
known	O
that	O
the	O
expression	O
of	O
miR371	O
cluster	O
is	O
downregulated	O
before	O
that	O
of	O
the	O
mir-302/367	O
cluster,	O
during	O
the	B
stem	I
cell	I
differentiation55,	O
and	O
that	O
miR-302/372	O
target	O
MBD254.	O

NANOS2:	O
encodes	O
an	O
RNA-binding	O
protein	O
that	O
contribute	O
to	O
the	O
maintenance	O
of	O
the	O
spermatogonial	B
stem	I
cell	I
population	O
and	O
suppression	O
of	O
meiotic	O
entry	O
[163].	O

Interestingly,	O
Taf4b	O
KO	O
mice	O
are	O
subfertile	O
with	O
extensive	O
pre-meiotic	O
germ	O
cell	O
loss	O
due	O
to	O
altered	O
differentiation	O
and	O
self-renewal	O
of	O
the	O
spermatogonial	B
stem	I
cell	I
pool	O
[107]..	O

Wnt/beta-catenin	O
signaling	O
plays	O
an	O
ever-expanding	O
role	O
in	O
stem	B
cell	I
self-renewal,	O
tumorigenesis	O
and	O
cancer	O
chemoresistance.	O

In	O
the	O
best	O
characterized	O
pathway,	O
Wnt	O
interacts	O
with	O
a	O
FZD	O
and	O
a	O
single	O
transmembrane	O
LRP5	O
or	O
LRP6	O
co-receptor	O
to	O
stabilize	O
intracellular	O
βcatenin	O
and	O
regulate	O
genes	O
involved	O
in	O
tissue	B
stem	I
cell	I
proliferation	O
and	O
differentiation.	O

We	O
thus	O
anticipate	O
that	O
tailored	O
FLAgs	O
will	O
improve	O
directed	O
differentiation	O
and	O
cell	O
therapy	O
endeavors,	O
sustain	O
tissue	O
organoid	O
growth,	O
and	O
enable	O
therapeutic	O
mobilization	O
of	O
endogenous	B
stem	I
cells	I
in	O
vivo	O
to	O
promote	O
tissue	O
repair	O
after	O
injury	O
and	O
restore	O
function	O
following	O
tissue	O
degeneration..	O

Within	O
the	O
intestinal	O
stem	O
cell	O
niche,	O
Wnt	O
proteins	O
secreted	O
by	O
mesenchymal	O
cells	O
induce	O
expression	O
of	O
βcatenin	O
target	O
genes	O
in	O
stem	O
cells	O
at	O
the	O
bottom	O
of	O
the	O
crypt	O
to	O
direct	O
their	O
self-renewal,	O
and	O
the	O
target	O
gene	O
LGR5	O
is	O
frequently	O
used	O
as	O
a	O
marker	O
of	O
stem	B
cells	I
in	O
various	O
tissues.	O

(A)	O
Isolated	O
MSCs	O
are	O
positive	O
to	O
mesenchymal	B
stem	I
cell	I
markers	O
(Sca-1,	O
CD44)	O
and	O
negative	O
to	O
CD90.1,	O
macrophage	O
marker	O
F4/80	O
and	O
Flk1,	O
endothelial	O
cell	O
marker.	O

Licensing	O
by	O
Inflammatory	O
Cytokines	O
Abolishes	O
Heterogeneity	O
of	O
Immunosuppressive	O
Function	O
of	O
Mesenchymal	B
Stem	I
Cell	I
Population.	O

In	O
recent	O
years,	O
epigenetic	O
regulation	O
has	O
also	O
emerged	O
as	O
an	O
important	O
modulator	O
of	O
stem	B
cell	I
differentiation	O
[18].	O

However,	O
before	O
such	O
treatments	O
become	O
readily	O
available,	O
we	O
must	O
further	O
elucidate	O
the	O
mechanisms	O
responsible	O
for	O
stem	B
cell	I
behavior.	O

The	O
role	O
of	O
promoter	O
CpG	O
methylation	O
in	O
the	O
epigenetic	O
control	O
of	O
stem	B
cell	I
related	O
genes	O
during	O
differentiation.	O

Mutual	O
reinforcement	O
between	O
telomere	O
capping	O
and	O
canonical	O
Wnt	O
signalling	O
in	O
the	O
intestinal	B
stem	I
cell	I
niche.	O

Finally,	O
similar	O
to	O
the	O
U251	O
model,	O
U87	O
tumours	O
show	O
a	O
CD133+	O
subpopulation	O
of	O
cells	O
able	O
to	O
form	O
neurosphere	O
aggregates	O
with	O
self-propagating	O
potential,	O
of	O
interest	O
to	O
the	O
tumour	B
stem	I
cell	I
community	O
(Qiang	O
et	O
al.,	O
2009)..	O

It	O
is	O
strongly	O
expressed	O
in	O
embryonic	O
stem	B
cells	I
and	O
has	O
essential	O
roles	O
in	O
vital	O
processes	O
such	O
as	O
cell	O
cycle	O
regulation,	O
proliferation	O
and	O
apoptosis	O
[10,	O
11].	O

The	O
clinical	O
manifestations	O
of	O
TBDs	O
are	O
thought	O
to	O
arise	O
from	O
severely	O
short	O
telomeres	O
that	O
limit	O
replicative	O
capacity,	O
leading	O
to	O
the	O
loss	O
of	O
critical	B
stem	I
cell	I
pools.	O

For	O
example,	O
the	O
tissue-specific	O
macrophages	O
that	O
undergo	O
self-renewal	O
activate	O
a	O
series	O
of	O
genes	O
that	O
are	O
also	O
required	O
for	O
embryonic	B
stem	I
cell	I
self-renewal	O
(Soucie	O
et	O
al.,	O
2016).	O

We	O
discuss	O
their	O
potential	O
for	O
use	O
in	O
reproductive	O
medicine	O
and	O
for	O
gaining	O
a	O
better	O
understanding	O
of	O
stem	B
cell	I
development	O
and	O
spermatogenesis.	O

Progress	O
in	O
stem	B
cell	I
technologies	O
might	O
lead	O
to	O
new	O
cell-based	O
infertility	O
treatments	O
if	O
immunologically	O
compatible	O
patient-specific	O
cells	O
can	O
be	O
derived.	O

Spermatogonial	B
stem	I
cell	I
transplantation	O
into	O
rhesus	O
testes	O
regenerates	O
spermatogenesis	O
producing	O
functional	O
sperm.	O

(2010)	O
Sprouty1	O
is	O
a	O
critical	O
regulatory	O
switch	O
of	O
mesenchymal	B
stem	I
cell	I
lineage	O
allocation.	O

The	O
prognostic	O
role	O
of	O
the	O
cancer	B
stem	I
cell	I
marker	O
aldehyde	O
dehydrogenase	O
1	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas:	O
A	O
meta-analysis.	O

Mouse	B
embryonic	I
stem	I
cell	I
Primoridal	O
germ	O
cell	O
CRISPR	O
knockout	O
Stella-GFP	O
+	O
Esg1-tdTomato	O
Nr5a2,	O
Zfp296	O
60.	O

Mouse	B
embryonic	I
stem	I
cell	I
2C-like	O
cell	O
CRISPRa	O
scRNA-seq	O
Dppa2,	O
Smarca5	O
61.	O

It	O
has	O
been	O
shown	O
that	O
blocking	O
autocrine	O
vascular	O
endothelial	O
growth	O
factor	O
signaling	O
via	O
knocking	O
down	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
promotes	B
stem	I
cell	I
self-renewal	O
and	O
somatic	O
cell	O
reprogramming.143	O
Thus,	O
it	O
is	O
important	O
to	O
note	O
that	O
possible	O
transcriptomic	O
changes	O
driven	O
by	O
cell	O
and	O
environmental	O
interactions	O
rather	O
than	O
reprogramming	O
factors	O
can	O
increase	O
variability	O
within	O
the	O
screen.	O

Similarly,	O
missplicing	O
of	O
GSK3B,	O
involved	O
in	O
βCatenin-Wnt	O
self-renewal	O
signaling	O
pathway,	O
plays	O
a	O
role	O
in	O
the	O
acquisition	O
of	O
stem	B
cell	I
properties	O
in	O
BC	O
CML	O
progenitors	O
[100].	O

Glycogen	O
synthase	O
kinase	O
3beta	O
missplicing	O
contributes	O
to	O
leukemia	B
stem	I
cell	I
generation.	O

Retroviral	O
transduction	O
and	O
bone	O
marrow	O
transplantation	O
were	O
performed	O
as	O
previously	O
described.[26]	O
Briefly,	O
the	O
rat	O
PLCγ1	O
or	O
rat	O
PLCγ2	O
gene	O
was	O
cloned	O
into	O
a	O
bicistronic	O
retrovirus	O
MSCV-IRES-GFP	O
vector,	O
in	O
which	O
expression	O
of	O
the	O
cloned	O
gene	O
and	O
green	O
fluorescent	O
protein	O
(GFP)	O
is	O
under	O
the	O
control	O
of	O
the	O
murine	B
stem	I
cell	I
virus	O
promoter.	O

Reflecting	O
the	O
stem	B
cell	I
nature	O
of	O
the	O
disease,	O
these	O
patients	O
may	O
coincidentally	O
develop	O
T-	O
or	O
B-cell	O
lymphoma	O
[12,	O
14].	O

Research	O
towards	O
the	O
discovery	O
of	O
phenotype-specific	O
biomarkers	O
will	O
inform	O
affected	O
individuals	O
about	O
their	O
health	O
risk	O
and	O
allow	O
them	O
to	O
thoughtfully	O
consider	O
their	O
treatment	O
options	O
particularly	O
with	O
regards	O
to	O
stem	B
cell	I
transplantation	O
and	O
gene	O
therapy,	O
which	O
offer	O
the	O
promise	O
of	O
complete	O
cure	O
albeit	O
at	O
a	O
risk.	O

Embryonic	B
stem	I
cell	I
lines	O
from	O
human	O
blastocysts:	O
somatic	O
differentiation	O
in	O
vitro.	O

C)	O
GSEA	O
showing	O
enrichment	O
of	O
stem	B
cell	I
proliferation	O
in	O
SGCE	O
differentially	O
expressed	O
genes	O
based	O
on	O
TCGA.	O

Considering	O
that	O
ECM	O
is	O
closely	O
related	O
to	O
cancer	B
stem	I
cell	I
self‐renewal,	O
tumor	O
formation,	O
and	O
drug	O
resistance,[	O
70	O
,	O
71	O
,	O
72	O
]	O
we	O
speculate	O
that	O
the	O
role	O
of	O
SGCE	O
in	O
regulating	O
BCSCs	O
and	O
drug	O
resistance	O
may	O
be	O
through	O
ECM.	O

Embryonic	B
stem	I
cell	I
tumor	O
model	O
reveals	O
role	O
of	O
vascular	O
endothelial	O
receptor	O
tyrosine	O
phosphatase	O
in	O
regulating	O
Tie2	O
pathway	O
in	O
tumor	O
angiogenesis.	O

The	O
t(11;19)(q23;p13.3)	O
translocation	O
leading	O
to	O
the	O
expression	O
of	O
an	O
MLL-ENL	O
fusion	O
protein	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
alterations	O
affecting	O
the	O
mixed	O
lineage	O
leukemia	O
1	O
(MLL1)	O
gene.1	O
The	O
ENL	O
fusion	O
partner	O
is	O
a	O
transcriptional	O
elongation	O
factor	O
involved	O
in	O
controlling	O
transcription	O
in	O
lymphoid	O
and	O
myeloid	O
cells.2	O
Although	O
the	O
majority	O
of	O
the	O
human	O
MLL-ENL+	O
leukemia	O
cases	O
are	O
diagnosed	O
as	O
B-cell	O
acute	O
lymphoblastic	O
leukemia	O
(ALL),	O
several	O
studies	O
have	O
shown	O
that	O
t(11;19)	O
positive	O
tumor	O
cells	O
simultaneously	O
express	O
lymphoid	O
and	O
myeloid	O
markers	O
characterizing	O
the	O
disease	O
as	O
mixed	O
phenotype	O
or	O
mixed-lineage	O
leukemia.1,3,4	O
These	O
observations	O
suggest	O
that	O
the	O
disease	O
initiates	O
by	O
malignant	O
transformation	O
of	O
a	O
hematopoietic	O
stem	O
(HSC)	O
or	O
early	O
progenitor	O
cell	O
with	O
lymphoid	O
and	O
myeloid	O
potential	O
rather	O
than	O
of	O
a	O
lineage-restricted	O
progenitor	O
cell..	O
Cells	O
were	O
grown	O
in	O
liquid	O
cultures	O
containing	O
RPMI-1640,	O
10%	O
fetal	O
bovine	O
serum,	O
1%	O
Pen/Strep	O
supplemented	O
with	O
10 ng/mL	O
of	O
human	O
interleukin-6	O
(hIL-6),	O
6 ng/mL	O
of	O
murine	O
mIL-3,	O
10 ng/mL	O
of	O
murine	O
mIL-7,	O
100 ng/mL	O
of	O
murine	B
stem	I
cell	I
factor	O
(mSCF),	O
and	O
100 ng/mL	O
of	O
mouse	O
Flt3-ligand	O
(mFlt-3L)	O
(PeproTech	O
EC,	O
London,	O
UK)	O
in	O
the	O
presence	O
of	O
0.5 μg/mL	O
DOX	O
where	O
indicated.	O

Interestingly,	O
several	O
PcG	O
proteins	O
have	O
been	O
shown	O
to	O
be	O
involved	O
in	O
stem	B
cell	I
maintenance	O
and	O
DNA	O
damage	O
response.80.	O

There	O
are	O
several	O
important	O
design	O
criteria	O
for	O
a	O
cell	O
culture	O
platform	O
to	O
manufacture	O
functional,	O
clinically	O
relevant	O
cells	O
at	O
large	O
scale:	O
(i)	O
fully-defined,	O
xeno-free	O
culture	O
conditions	O
to	O
enhance	O
reproducibility	O
and	O
scalability,	O
(ii)	O
a	O
scalable	O
culture	O
platform,	O
such	O
as	O
a	O
3D	O
system,	O
(iii)	O
facile,	O
high	O
viability	O
cell	O
harvesting	O
for	O
passage	O
and	O
implantation,	O
(iv)	O
a	O
microenvironment	O
that	O
supports	O
efficient	O
and	O
effective	B
stem	I
cell	I
differentiation	O
and	O
maturation,	O
and	O
(v)	O
compatibility	O
with	O
long-term	O
culture	O
to	O
enable	O
cell	O
maturation.	O

Personalized	O
Medicine	O
Based	O
Approach	O
to	O
Model	O
Patterns	O
of	O
Chemoresistance,	O
and	O
Tumor	O
Recurrence	O
Using	O
Ovarian	O
Cancer	B
Stem	I
Cell	I
Spheroids.	O

Loss	O
of	O
Gata4	O
in	O
Sertoli	O
cells	O
impairs	O
the	O
spermatogonial	B
stem	I
cell	I
niche	O
and	O
causes	O
germ	O
cell	O
exhaustion	O
by	O
attenuating	O
chemokine	O
signaling.	O

GSCs	O
were	O
cultured	O
in	O
stem	B
cell	I
medium	O
with	O
IL-17	O
(100	O
ng/ml)	O
for	O
3	O
days.	O

Primary	O
glioma	O
cells,	O
obtained	O
from	O
patients	O
with	O
malignant	O
glioma,	O
were	O
cultured	O
in	O
stem	B
cell	I
medium	O
for	O
2	O
weeks	O
to	O
obtain	O
GSC	O
neurospheres,	O
as	O
described.	O

Our	O
results	O
are	O
also	O
in	O
agreement	O
with	O
recent	O
reports	O
on	O
extra-cranial	O
tumors	O
where	O
stimulation	O
of	O
cancer	B
stem	I
cell	I
by	O
IL-17	O
has	O
been	O
observed.	O

When	O
grown	O
in	O
stem	B
cell	I
maintenance	O
media,	O
there	O
were	O
minimal	O
differences	O
observed	O
in	O
the	O
expression	O
of	O
pluripotency	O
markers	O
between	O
these	O
iPSC	O
lines,	O
as	O
assessed	O
by	O
RT-qPCR	O
(Additional	O
file	O
2:	O
Figure	O
S1C)	O
and	O
immunocytochemistry	O
(ICC)	O
(Additional	O
file	O
2:	O
Figure	O
S1D).	O

To	O
determine	O
whether	O
induction	O
of	O
neural	O
differentiation	O
was	O
a	O
stressor	O
that	O
was	O
contributing	O
to	O
this	O
increase	O
in	O
apoptosis	O
in	O
the	O
IS	O
and	O
AP	O
line-derived	O
neurospheres,	O
we	O
compared	O
sphere	O
size	O
after	O
culturing	O
spheres	O
from	O
each	O
line	O
either	O
in	O
stem	B
cell	I
maintenance	O
media	O
(mTeSR)	O
or	O
in	O
neural	O
induction	O
media.	O

Loss	O
of	O
Let-7	O
up-regulates	O
EZH2	O
in	O
prostate	O
cancer	O
consistent	O
with	O
the	O
acquisition	O
of	O
cancer	B
stem	I
cell	I
signatures	O
that	O
are	O
attenuated	O
by	O
BR-DIM.	O

Down-regulation	O
of	O
stem	B
cell	I
genes,	O
including	O
those	O
in	O
a	O
200-kb	O
gene	O
cluster	O
at	O
12p13.31,	O
is	O
associated	O
with	O
in	O
vivo	O
differentiation	O
of	O
human	O
male	O
germ	O
cell	O
tumors.	O

Effective	O
differentiation	O
of	O
all	O
these	O
cell	O
lines	O
genotype	O
to	O
mDA	O
neurons	O
specified	O
that	O
knockout	O
of	O
the	O
protein	O
α‐synuclein	O
did	O
not	O
affect	O
the	O
differentiation	O
ability	O
of	O
pluripotent	B
stem	I
cells	I
in	O
this	O
neural	O
sub‐type.	O

Most	O
recently,	O
a	O
study	O
has	O
revealed	O
that	O
the	O
functional	O
benefit	O
of	O
stem	B
cell	I
therapy	O
following	O
myocardial	O
infarction	O
is	O
due	O
to	O
an	O
acute	O
inflammatory-mediated	O
wound	O
healing	O
response	O
that	O
rejuvenates	O
the	O
mechanical	O
properties	O
of	O
the	O
infarcted	O
area	O
of	O
the	O
LV	O
[109].	O

Thus,	O
current	O
knowledge	O
suggests	O
that	O
therapeutic	O
effects	O
of	O
stem	B
cell	I
therapy	O
in	O
heart	O
failure	O
are	O
mediated	O
by	O
modification	O
and	O
promotion	O
of	O
inflammation-induced	O
endogenous	O
healing	O
processes..	O

Eventually,	O
some	O
of	O
the	O
older	O
mice	O
remained	O
bald,	O
possibly	O
due	O
to	O
hair	B
follicle	I
stem	I
cell	I
depletion..	O

Furthermore,	O
some	O
evidence	O
indicates	O
that	O
natural	O
products	O
may	O
inhibit	O
tumor	O
recurrence	O
by	O
targeting	O
key	O
modulators	O
of	O
cancer	B
stem	I
cell	I
renewal	O
[35].	O

In	O
both	O
chickens	O
and	O
mice,	O
active	O
Hh	O
signaling	O
in	O
the	O
stroma	O
has	O
pro-differentiating	O
effects	O
on	O
the	O
overlying	O
epithelial	O
layer,	O
such	O
that	O
stromal	O
Hh	O
activation	O
leads	O
to	O
the	O
loss	O
of	O
epithelial	O
progenitors	O
[58,60,61],	O
while	O
reduced	O
Hh	O
signaling	O
evokes	O
an	O
expansion	O
of	O
the	O
epithelial	B
stem	I
cell	I
compartment	O
associated	O
with	O
enhanced	O
Wnt	O
signaling	O
[62,63,64].	O

First,	O
intestinal	O
stroma	O
cells	O
expressing	O
Gli1,	O
the	O
classical	O
target	O
indicating	O
active	O
downstream	O
Hh	O
signaling,	O
were	O
identified	O
as	O
the	O
source	O
of	O
the	O
Wnt	O
ligand,	O
WNT2B,	O
which	O
is	O
essential	O
for	O
maintenance	O
of	O
the	O
intestinal	B
stem	I
cell	I
state	O
[67].	O

These	O
findings	O
make	O
it	O
possible	O
to	O
reconcile	O
the	O
data	O
showing	O
that	O
Gli1+	O
cells	O
are	O
essential	O
providers	O
of	O
Wnt	O
ligands	O
in	O
the	O
colon	O
with	O
the	O
overall	O
net	O
effect	O
observed	O
in	O
other	O
models,	O
in	O
which	O
stromal	O
Hh	O
activation	O
leads	O
to	O
increased	O
differentiation	O
of	O
epithelial	O
cells,	O
rather	O
than	O
expansion	O
of	O
the	O
epithelial	B
stem	I
cell	I
compartment	O
[60,62].	O

In	O
the	O
crypt	O
region,	O
stromal	O
cells	O
provide	O
both	O
Wnt	O
ligands	O
and	O
BMP	O
inhibitors,	O
such	O
as	O
GREM1,	O
that	O
maintain	O
the	O
epithelial	B
stem	I
cell	I
state.	O

In	O
contrast	O
to	O
other	O
mesenchymal	O
cells,	O
such	O
as	O
myofibroblasts,	O
telocytes	O
produce	O
the	O
Wnt	O
ligands	O
and	O
BMP	O
antagonists	O
required	O
for	O
intestinal	B
stem	I
cell	I
maintenance.	O

Importantly,	O
these	O
mesenchymal	O
cells	O
have	O
opposing	O
functional	O
roles,	O
such	O
that	O
stromal	O
cells	O
are	O
required	O
for	O
maintenance	O
of	O
the	O
epithelial	B
stem	I
cell	I
compartment	O
in	O
the	O
crypt	O
base,	O
whereas	O
stromal	O
cells	O
located	O
towards	O
the	O
intestinal	O
lumen	O
secrete	O
factors	O
inducing	O
epithelial	O
differentiation.	O

Mouse	O
models	O
suggest	O
that	O
cells	O
further	O
downstream	O
on	O
the	O
differentiation	O
trajectory	O
(closer	O
to	O
the	O
lumen)	O
can	O
act	O
as	O
tumor-initiating	O
cells	O
only	O
when	O
“pushed	O
back”	O
towards	O
the	O
stem	B
cell	I
state	O
[77,99].	O

Extrapolating	O
from	O
its	O
role	O
as	O
a	O
strong	O
regulator	O
of	O
the	O
intestinal	O
stem	O
cell	O
state	O
in	O
development	O
and	O
homeostasis	O
[56,60,62,63,102,103],	O
it	O
is	O
likely	O
that	O
stromal	O
Hh	O
signaling	O
interacts	O
with	O
epithelial	O
Wnt	O
signaling	O
to	O
influence	O
both	O
the	O
pool	O
of	O
stem	O
cells	O
susceptible	O
to	O
malignant	O
transformation	O
and	O
the	O
cancer	B
stem	I
cell	I
state	O
in	O
the	O
tumor	O
cell	O
hierarchy.	O

Recent	O
studies	O
in	O
mice	O
have	O
shown	O
that,	O
at	O
least	O
in	O
the	O
healthy	O
colonic	O
crypt,	O
a	O
subset	O
of	O
Hh-responsive	O
cells	O
provides	O
essential	O
Wnt	O
ligands	O
that	O
uphold	O
the	O
intestinal	B
stem	I
cell	I
state	O
in	O
the	O
crypt.	O

Evaluating	O
mouse	O
models	O
of	O
hair	O
graying	O
can	O
reveal	O
key	O
aspects	O
of	O
melanocyte	B
stem	I
cell	I
biology.	O

Tg(Dct-Sox10)/0;	O
Mitfmi-vga9/+	O
mice	O
also	O
show	O
increased	O
differentiation	O
of	O
McSCs,	O
as	O
indicated	O
by	O
excessive	O
ectopic	O
pigmentation	O
within	O
the	O
stem	B
cell	I
niche	O
(hair	O
bulge)	O
of	O
their	O
hair	O
follicles.	O

A	O
Dual	O
Role	O
for	O
SOX10	O
in	O
the	O
Maintenance	O
of	O
the	O
Postnatal	O
Melanocyte	O
Lineage	O
and	O
the	O
Differentiation	O
of	O
Melanocyte	B
Stem	I
Cell	I
Progenitors.	O

According	O
to	O
cancer	B
stem	I
cell	I
hypothesis,	O
a	O
tumor	O
sustained	O
by	O
a	O
subset	O
of	O
cancer	O
cells	O
with	O
stem-cell-like	O
characteristics.	O

Gene	O
expression	O
of	O
stem	B
cell	I
genes,	O
such	O
as	O
Oct-4,	O
Ncam,	O
and	O
Nanog,	O
is	O
crucial	O
for	O
progression	O
of	O
various	O
human	O
malignancies	O
[55–57].	O

High-level	O
expression	O
of	O
stem	B
cell	I
marker	O
CD133	O
in	O
clear	O
cell	O
renal	O
cell	O
carcinoma	O
with	O
favorable	O
prognosis.	O

Application	O
of	O
hanging	O
drop	O
technique	O
for	O
stem	B
cell	I
differentiation	O
and	O
cytotoxicity	O
studies.	O

We	O
also	O
review	O
the	O
phenotypes	O
associated	O
with	O
genetic	O
mutations	O
at	O
particular	O
imprinted	O
loci	O
in	O
order	O
to	O
consider	O
the	O
impact	O
of	O
imprinted	O
genes	O
in	O
the	O
maintenance	O
and/or	O
differentiation	O
of	O
the	O
neural	B
stem	I
cell	I
pool	O
in	O
vivo	O
and	O
during	O
brain	O
tumour	O
formation..	O

Given	O
the	O
absence	O
of	O
unique,	O
decisive	O
markers	O
to	O
identify	O
the	O
neural	B
stem	I
cell	I
population	O
in	O
vivo,	O
the	O
analysis	O
of	O
NSCs	O
has	O
been	O
widely	O
based	O
on	O
the	O
ex	O
vivo	O
behaviour	O
of	O
cells	O
isolated	O
from	O
neurogenic	O
niches.	O

There	O
is	O
still	O
some	O
controversy	O
about	O
the	O
real	O
functional	O
relationship	O
between	O
neurosphere-forming	O
cells	O
and	O
the	O
stem	B
cell	I
population	O
in	O
vivo	O
[19].	O

Nevertheless,	O
this	O
system	O
represents	O
a	O
tractable	O
model	O
to	O
investigate	O
the	O
contribution	O
to	O
cell	O
fate	O
specification	O
made	O
by	O
signalling	O
pathways,	O
expression	O
or	O
epigenetic	O
mechanisms,	O
potentially	O
applicable	O
to	O
neural	B
stem	I
cells	I
for	O
restorative	O
neurogenesis	O
in	O
disease	O
or	O
trauma..	O

Biallelic	O
expression	O
of	O
Dlk1	O
is	O
required	O
for	O
stem	B
cell	I
maintenance	O
in	O
the	O
SVZ	O
and	O
final	O
neurogenesis	O
to	O
the	O
olfactory	O
bulb	O
[39].	O

However,	O
little	O
is	O
known	O
about	O
how	O
the	O
absence	O
or	O
altered	O
dosage	O
of	O
these	O
genes	O
in	O
neural	B
stem	I
cell	I
populations	O
influences	O
neuronal	O
function.	O

Imprinted	O
genes	O
of	O
maternal	O
and	O
paternal	O
origin	O
favour	O
different	O
degrees	O
of	O
neural	B
stem	I
cell	I
proliferation.	O

DLK1,	O
essential	O
for	O
maintaining	O
the	O
stem	B
cell	I
pool	O
in	O
the	O
SVZ,	O
is	O
more	O
highly	O
expressed	O
in	O
human	O
glioma	O
[82].	O

Such	O
analyses	O
may	O
prove	O
fundamental	O
in	O
understanding	O
stem	O
cell	O
regulation,	O
the	O
nature	O
of	O
cancer/tumour	O
formation,	O
and	O
the	O
future	O
therapeutic	O
use	O
of	O
stem	B
cells	I
in	O
human	O
disease..	O

It	O
now	O
becomes	O
important	O
to	O
understand	O
the	O
epigenetic	O
profile	O
and	O
some	O
of	O
the	O
molecular	O
players	O
that	O
participate	O
in	O
the	O
regulation	O
of	O
the	O
imprinting	O
status	O
in	O
NSCs,	O
as	O
well	O
as	O
the	O
role	O
of	O
these	O
imprinting	O
domains	O
in	O
the	O
maintenance	O
of	O
the	O
stem	B
cell	I
pool	O
in	O
the	O
neurogenic	O
niches	O
in	O
vivo.	O

Postnatal	O
development	O
of	O
radial	O
glia	O
and	O
the	O
ventricular	O
zone	O
(VZ):	O
A	O
continuum	O
of	O
the	O
neural	B
stem	I
cell	I
compartment.	O

Defining	O
the	O
actual	O
sensitivity	O
and	O
specificity	O
of	O
the	O
neurosphere	O
assay	O
in	O
stem	B
cell	I
biology.	O

p57	O
controls	O
adult	B
neural	I
stem	I
cell	I
quiescence	O
and	O
modulates	O
the	O
pace	O
of	O
lifelong	O
neurogenesis.	O

Altogether,	O
these	O
findings	O
demonstrate	O
that	O
translational	O
control	O
is	O
a	O
key	O
modulator	O
of	O
stem	B
cell	I
differentiation..	O

The	O
subventricular	O
zone	O
(SVZ)	O
in	O
the	O
fetal	O
and	O
adult	O
brain	O
of	O
mammals	O
harbors	O
a	O
small	O
population	O
of	O
cells	O
with	O
stem	B
cell	I
properties	O
(self-renewal	O
and	O
multipotency),	O
known	O
as	O
NSCs	O
(Figure.	O

The	O
mTORC1	O
pathway	O
also	O
regulates	O
the	O
activity	O
of	O
satellite	O
cells	O
and	O
is	O
required	O
for	O
their	O
transition	O
from	O
G0	O
quiescent	O
state	O
into	O
GAlert	O
phase	O
(an	O
“alerting”	O
state	O
of	O
quiescent	B
stem	I
cells	I
that	O
allows	O
them	O
to	O
immediately	O
enter	O
the	O
cell	O
cycle	O
and	O
respond	O
to	O
injury	O
or	O
stress)	O
(Rodgers	O
et	O
al.,	O
2014).	O

p-eIF2α	O
promotes	O
translation	O
of	O
stem	B
cell	I
factors,	O
such	O
as	O
Nanog	O
and	O
Myc	O
containing	O
uORFs	O
in	O
their	O
5′UTR.	O

Technological	O
advances	O
in	O
the	O
studies	O
of	O
translation,	O
combined	O
with	O
novel	O
genetic	O
approaches,	O
are	O
beginning	O
to	O
provide	O
the	O
essential	O
tools	O
required	O
for	O
understanding	O
this	O
critical	O
step	O
of	O
gene	O
expression	O
in	O
stem	B
cell	I
plasticity..	O

Control	O
of	O
embryonic	B
stem	I
cell	I
self-renewal	O
and	O
differentiation	O
via	O
coordinated	O
alternative	O
splicing	O
and	O
translation	O
of	O
YY2.	O

Heart	O
PEG-silane,	O
PDMS,	O
silicon	O
(cantilever)	O
Electrical	O
and	O
contractile	O
activity	O
Human	O
cardiomyocytes	O
derived	O
from	O
the	O
hESC-10-0061	B
stem	I
cell	I
line	O
2D	O
monolayer	O
Electrical	O
activity	O
sensing	O
by	O
using	O
an	O
MEA	O
and	O
contractile	O
stress	O
sensing	O
using	O
cantilevers	O
deflection	O
measured	O
by	O
a	O
photodiode	O
laser	O
and	O
a	O
photodetector.	O

Human	B
breast	I
cancer	I
stem	I
cell	I
markers	O
CD44	O
and	O
CD24:	O
enriching	O
for	O
cells	O
with	O
functional	O
properties	O
in	O
mice	O
or	O
in	O
man?	O
Breast	O
Cancer	O
Res.	O

Down-regulation	O
of	O
stem	B
cell	I
genes,	O
including	O
those	O
in	O
a	O
200-kb	O
gene	O
cluster	O
at	O
12p13.	O

The	O
presence	O
of	O
RNA	O
in	O
EVs	O
was	O
first	O
described	O
in	O
2006	O
for	O
murine	B
stem	I
cell	I
derived	O
EVs	O
and	O
in	O
2007	O
for	O
murine	O
mast	O
cell-derived	O
exosomes	O
taken	O
up	O
by	O
the	O
human	O
mast	O
cells	O
[158,159].	O

showed	O
HIF-dependent	O
expression	O
of	O
GSTO1-1	O
in	O
breast	O
cancer	O
cells	O
exposed	O
to	O
carboplatin	O
with	O
consequent	O
breast	B
cancer	I
stem	I
cell	I
enrichment,	O
mediated	O
by	O
interaction	O
between	O
GSTO1-1	O
and	O
RyR1	O
and	O
downstream	O
activation	O
of	O
PYK2/SRC/STAT3	O
signaling	O
[25].	O

Separation	O
of	O
stem	B
cell	I
maintenance	O
and	O
transposon	O
silencing	O
functions	O
of	O
Piwi	O
protein.	O

Notably,	O
epithelial	O
cells	O
from	O
outside	O
the	O
hair	O
follicle	O
can	O
migrate	O
to	O
the	O
follicular	B
stem	I
cell	I
niche.	O

The	O
degree	O
to	O
which	O
such	O
heterogeneity	O
exists	O
in	O
mesenchymal	B
stem	I
cell	I
populations	O
is	O
less	O
well	O
studied,	O
but	O
consensus	O
is	O
emerging.	O

Heterogeneity	O
and	O
plasticity	O
are	O
fundamental	O
features	O
of	O
stem	B
cell	I
systems	O
that	O
must	O
be	O
understood	O
as	O
bioengineers	O
and	O
developmental	O
biologists	O
seek	O
to	O
manipulate	O
cell	O
biology	O
for	O
regenerative	O
therapies..	O

To	O
this	O
end,	O
we	O
1)	O
identified	O
label-retaining	O
cells	O
(LRCs)	O
using	O
a	O
pulse–chase	O
strategy	O
and	O
2)	O
examined	O
the	O
activity	O
of	O
adult	B
stem	I
cell	I
markers	O
in	O
these	O
adjoining	O
structures	O
undergoing	O
lifelong	O
renewal	O
(taste	O
buds)	O
and	O
replacement	O
(teeth).	O

We	O
began	O
our	O
study	O
with	O
the	O
aim	O
of	O
identifying	O
the	O
spatial	O
location	O
of	O
putative	B
stem	I
cell	I
niches	O
in	O
both	O
renewing	O
TBs	O
and	O
successional	O
teeth	O
through	O
in	O
situ	O
hybridization	O
(ISH).	O

While	O
Sox2	O
is	O
a	O
well-known	O
TB	O
marker,	O
important	O
for	O
both	O
the	O
generation	O
of	O
TBs	O
as	O
well	O
as	O
maintenance	O
of	O
TB	B
stem	I
cell	I
populations	O
(32),	O
it	O
has	O
more	O
recently	O
been	O
implicated	O
in	O
dental	O
ESCs	O
of	O
both	O
mice	O
(7)	O
and	O
other	O
vertebrates	O
(4).	O

This	O
niche	O
has	O
been	O
understudied	O
likely	O
because	O
very	O
little	O
to	O
date	O
has	O
been	O
published	O
on	O
the	O
stem	B
cell	I
populations	O
involved	O
in	O
whole	O
tooth	O
replacement	O
in	O
a	O
one-for-one	O
replacement	O
system..	O

A	O
model	O
of	O
stem	B
cell	I
niche	O
localization	O
and	O
associated	O
stages	O
of	O
tooth	O
regeneration	O
in	O
the	O
cichlid.	O

(A)	O
During	O
maturation	O
of	O
the	O
replacement	O
tooth,	O
a	O
number	O
of	O
potential	B
stem	I
cell	I
pockets	O
are	O
identified	O
(yellow).	O

Ring	O
A.,	O
Kim	O
Y.-M.,	O
Kahn	O
M.,	O
Wnt/catenin	O
signaling	O
in	O
adult	B
stem	I
cell	I
physiology	O
and	O
disease.	O

,	O
β-Catenin	O
activation	O
regulates	O
tissue	O
growth	O
non-cell	O
autonomously	O
in	O
the	O
hair	B
stem	I
cell	I
niche.	O

Wnt/β-catenin	O
signaling	O
plays	O
an	O
ever-expanding	O
role	O
in	O
stem	B
cell	I
self-renewal,	O
tumorigenesis	O
and	O
cancer	O
chemoresistance.	O

Recent	O
research	O
points	O
at	O
mTOR	O
signaling	O
hyper-activation	O
and	O
subsequent	O
autophagy	O
suppression	O
as	O
key	O
events	O
implicated	O
in	O
GBM	B
stem	I
cell	I
maintenance,	O
tumor	O
propagation,	O
as	O
well	O
as	O
treatment	O
resistance,	O
which	O
will	O
be	O
dealt	O
with	O
in	O
the	O
following	O
sections..	O

In	O
fact,	O
normal	O
NSCs	O
undergo	O
self-renewing	O
divisions	O
to	O
propagate	O
the	O
stem	B
cell	I
pool,	O
but	O
they	O
also	O
produce	O
progenitor	O
cells,	O
which	O
then	O
differentiate	O
into	O
neurons,	O
astrocytes,	O
or	O
oligodendrocytes.	O

In	O
baseline	O
conditions,	O
mTOR	O
activity	O
is	O
finely	O
tuned	O
to	O
maintain	O
the	O
delicate	O
balance	O
between	O
proliferating	O
and	O
differentiating	O
signals	O
within	O
the	O
stem	B
cell	I
niche,	O
where	O
normal	O
NSCs	O
reside.	O

Isolation	O
of	O
cancer	B
stem	I
cells	I
from	O
three	O
human	O
glioblastoma	O
cell	O
lines:	O
Characterization	O
of	O
two	O
selected	O
clones.	O

Neural	B
stem	I
cell	I
activation	O
leads	O
to	O
neuroregeneration,	O
probably	O
via	O
P2X4R	O
and	O
P2X7R.	O

Human	B
embryonic	I
stem	I
cells	I
are	O
able	O
to	O
self-renew	O
and	O
have	O
the	O
potential	O
to	O
differentiate	O
into	O
different	O
cell	O
types,	O
including	O
cardiovascular	O
progenitor	O
cells.	O

Generation	O
of	O
a	O
variety	O
of	O
specialized	O
cell	O
types	O
from	O
stem	B
cells	I
is	O
fundamental	O
for	O
the	O
development	O
of	O
multicellular	O
organisms.	O

However,	O
none	O
of	O
these	O
proteins	O
are	O
receptors	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
stem	B
cell	I
fate,	O
consistent	O
with	O
our	O
previous	O
observation	O
that	O
the	O
p150	O
KO	O
has	O
a	O
minor	O
impact	O
on	O
ESC	O
proliferation	O
and	O
stemness..	O

Gene	O
Ontology	O
(GO)	O
analysis	O
revealed	O
that	O
Group	O
1	O
genes	O
were	O
enriched	O
in	O
genes	O
involved	O
in	O
stem	B
cell	I
population	O
maintenance,	O
DNA	O
replication	O
and	O
repair	O
(Figure.	O

Hypoxia	B
promotes	I
stem	I
cell	I
phenotypes	O
and	O
poor	O
prognosis	O
through	O
epigenetic	O
regulation	O
of	O
DICER.	O

Polycomb	O
PHF19	O
binds	O
H3K36me3	O
and	O
recruits	O
PRC2	O
and	O
demethylase	O
NO66	O
to	O
embryonic	B
stem	I
cell	I
genes	O
during	O
differentiation.	O

A	O
feedback	O
regulatory	O
loop	O
involving	O
microRNA-9	O
and	O
nuclear	O
receptor	O
TLX	O
in	O
neural	B
stem	I
cell	I
fate	O
determination.	O

Thus,	O
it	O
can	O
be	O
hypothesized	O
that	O
the	O
signaling	O
pathways	O
regulating	O
pluripotency	O
of	O
stem	B
cells	I
could	O
be	O
indicative	O
of	O
neuronal	O
reestablishment,	O
since	O
recent	O
findings	O
support	O
that	O
cerebral	O
cell	O
volume	O
in	O
patients	O
with	O
depression	O
is	O
lower	O
when	O
compared	O
to	O
healthy	O
subjects	O
(Campbell	O
et	O
al.,	O
2004),	O
perhaps	O
due	O
to	O
the	O
apoptosis	O
pathway.	O

Moreover,	O
these	O
studies	O
were	O
based	O
on	O
the	O
functions	O
of	O
E3	O
ubiquitin	O
ligases,	O
such	O
as	O
c-Cbl,	O
Itch,	O
and	O
Fbxw7,	O
and	O
the	O
role	O
of	O
deubiquitinases	O
(DUBs)	O
in	O
early	O
hematopoiesis	O
and	O
in	O
stem	B
cell	I
biology	O
needs	O
to	O
be	O
explored..	O

Intravenous	O
infusions	O
of	O
UC-MSCs	O
are	O
safe	O
in	O
this	O
population	O
and	O
suggest	O
benefits	O
in	O
surrogate	O
clinical	O
end	O
points,	O
including	O
LVEF,	O
functional	O
status,	O
and	O
quality	O
of	O
life,	O
in	O
patients	O
with	O
HFrEF	O
receiving	O
this	O
form	O
of	O
systemic	B
stem	I
cell	I
therapy..	O

Genetic	O
modification	O
of	O
mesenchymal	B
stem	I
cells	I
overexpressing	O
CCR1	O
increases	O
cell	O
viability,	O
migration,	O
engraftment,	O
and	O
capillary	O
density	O
in	O
the	O
injured	O
myocardium.	O

Alzheimer's	O
disease	O
in	O
a	O
dish:	O
promises	O
and	O
challenges	O
of	O
human	B
stem	I
cell	I
models.	O

While	O
several	O
landmark	O
papers	O
have	O
described	O
the	O
generation	O
of	O
reporter	O
lines	O
using	O
these	O
technologies	O
[20]–[22],	O
no	O
studies	O
have	O
thoroughly	O
investigated	O
the	O
effects	O
of	O
the	O
genomic	O
modification	O
on	O
stem	B
cell	I
characteristics	O
or	O
directed	O
differentiation	O
potential..	O

To	O
ensure	O
the	O
genomic	O
modification	O
and	O
our	O
targeting	O
approach	O
did	O
not	O
alter	O
the	O
stem	B
cell	I
characteristics	O
of	O
these	O
cells,	O
immunofluorescent	O
staining	O
for	O
two	O
other	O
pluripotency	O
markers,	O
NANOG	O
(Figure	O
3A)	O
and	O
SOX2	O
(Figure	O
3B)	O
was	O
performed.	O

Gerrard	O
L,	O
Zhao	O
D,	O
Clark	O
AJ,	O
Cui	O
W	O
(2005)	O
Stably	O
Transfected	B
Human	I
Embryonic	I
Stem	I
Cell	I
Clones	O
Express	O
OCT4-Specific	O
Green	O
Fluorescent	O
Protein	O
and	O
Maintain	O
Self-Renewal	O
and	O
Pluripotency.	O

The	O
epigenetic	O
modifications	O
of	O
DNA	O
or	O
histones	O
are	O
fundamental	O
to	O
the	O
maintenance	O
of	O
cancer	B
stem	I
cell	I
identity	O
[45–48].	O

Wild-type	O
ADAR1,	O
but	O
not	O
the	O
editing-defective	O
ADAR1E912	O
mutant,	O
potentiates	O
self-renewal	O
gene	O
expression	O
and	O
suppresses	O
the	O
biogenesis	O
of	O
stem	B
cell	I
inhibitory	O
microRNA	O
let-7	O
[36].	O

For	O
instance,	O
the	O
stem	B
cell	I
marker	O
gene,	O
KLF4,	O
has	O
contrasting	O
roles	O
in	O
various	O
cancer	O
types	O
as	O
reported	O
in	O
previous	O
studies	O
[87,	O
88].	O

Hypoxia	O
induces	O
the	O
breast	B
cancer	I
stem	I
cell	I
phenotype	O
by	O
HIF-dependent	O
and	O
ALKBH5-mediated	O
m	O
(6)	O
A-demethylation	O
of	O
NANOG	O
mRNA.	O

Cancer	B
stem	I
cell	I
self-renewal	O
as	O
a	O
therapeutic	O
target	O
in	O
human	O
oral	O
cancer.	O

Epigenetic	O
regulation	O
of	O
cancer	B
stem	I
cell	I
genes	O
in	O
triple-negative	O
breast	O
cancer.	O

Glycogen	O
synthase	O
kinase	O
3	O
beta	O
missplicing	O
contributes	O
to	O
leukemia	B
stem	I
cell	I
generation.	O

Expression	O
of	O
neural	B
stem	I
cell	I
surface	O
marker	O
CD133	O
in	O
balloon	O
cells	O
of	O
human	O
focal	O
cortical	O
dysplasia.	O

(2008)	O
A	O
Gata6-Wnt	O
pathway	O
required	O
for	O
epithelial	B
stem	I
cell	I
development	O
and	O
airway	O
regeneration.	O

Human	O
Müller	O
glia	O
with	O
stem	B
cell	I
characteristics	O
differentiate	O
into	O
retinal	O
ganglion	O
cell	O
(RGC)	O
precursors	O
in	O
vitro	O
and	O
partially	O
restore	O
RGC	O
function	O
in	O
vivo	O
following	O
transplantation.	O

However,	O
the	O
lower	O
range	O
of	O
doses	O
required	O
to	O
reduce	O
the	O
oxidative	O
stress	O
and	O
to	O
restore	O
the	O
expression	O
of	O
hematopoietic	B
stem	I
cell	I
and	O
lymphoid	O
markers	O
in	O
ak2	O
null	O
embryos	O
suggest	O
that	O
hematopoietic	O
cells	O
seem	O
to	O
be	O
more	O
sensitive	O
to	O
the	O
oxidative	O
stress	O
than	O
cells	O
from	O
the	O
sensory	O
system	O
(and	O
thus	O
easier	O
to	O
rescue	O
with	O
antioxidants	O
alone).	O

Solely	O
relying	O
on	O
cancer	B
stem	I
cell	I
markers	O
was	O
found	O
to	O
be	O
insufficient	O
to	O
render	O
clustering	O
analyses	O
informative	O
and	O
support	O
authors	O
conclusion.	O

While	O
the	O
authors	O
do	O
not	O
comprehensively	O
assess	O
the	O
underlying	O
processes	O
regulating	O
these	O
phenotypes,	O
they	O
demonstrate	O
that	O
cells/tumors	O
from	O
pair	O
disrupted	O
animals	O
cluster	O
together	O
based	O
on	O
the	O
expression	O
of	O
a	O
limited	O
set	O
of	O
cancer	B
stem	I
cell	I
markers.	O

Solely	O
relying	O
on	O
cancer	B
stem	I
cell	I
markers	O
was	O
found	O
to	O
be	O
insufficient	O
to	O
render	O
clustering	O
analyses	O
informative	O
and	O
support	O
authors	O
conclusion.	O

We	O
also	O
moved	O
the	O
original	O
qPCR	O
data	O
of	O
cancer	B
stem	I
cell	I
markers	O
into	O
the	O
supplementary	O
information	O
which	O
now,	O
also	O
includes	O
the	O
new	O
clustering	O
data	O
from	O
RNAseq	O
(Figure3	O
and	O
Figure	O
3—figure	O
supplement	O
2,3)..	O

Skin	O
undergoes	O
continuous	O
renewal	O
throughout	O
an	O
individual’s	O
lifetime	O
relying	O
on	O
stem	B
cell	I
functionality.	O

Control	O
of	O
the	O
epithelial	O
stem	O
cell	O
epigenome:	O
The	O
shaping	O
of	O
epithelial	B
stem	I
cell	I
identity.	O

A	O
ΔNp63α	O
is	O
an	O
oncogene	O
that	O
targets	O
chromatin	O
remodeler	O
Lsh	O
to	O
drive	B
skin	I
stem	I
cell	I
proliferation	O
and	O
tumorigenesis.	O

In	O
hESCs,	O
Mediator	O
was	O
also	O
revealed	O
to	O
be	O
important	O
in	O
the	O
maintenance	O
of	O
pluripotent	B
stem	I
cell	I
identity	O
during	O
a	O
genome-wide	O
siRNA	O
screen,	O
suggesting	O
an	O
evolutionarily	O
conserved	O
role	O
[75].	O

An	O
expanded	O
Oct4	O
interaction	O
network:	O
implications	O
for	O
stem	B
cell	I
biology,	O
development,	O
and	O
disease.	O

Wdr5	O
mediates	O
self-renewal	O
and	O
reprogramming	O
via	O
the	O
embryonic	B
stem	I
cell	I
core	O
transcriptional	O
network.	O

Evidence	O
exists	O
for	O
organization	O
of	O
chromosomes	O
into	O
topological	O
domains	O
in	O
pluripotent	B
stem	I
cells	I
that	O
then	O
remain	O
stable	O
between	O
cell	O
types	O
(de	O
Wit	O
et	O
al.,	O
2013).	O

(2006)	O
Tumor	B
stem	I
cells	I
derived	O
from	O
glioblastomas	O
cultured	O
in	O
bFGF	O
and	O
EGF	O
more	O
closely	O
mirror	O
the	O
phenotype	O
and	O
genotype	O
of	O
primary	O
tumors	O
than	O
do	O
serum-cultured	O
cell	O
lines.	O

The	O
use	O
of	O
stem	B
cell	I
therapy	O
has	O
been	O
extensively	O
studied	O
for	O
treating	O
several	O
diseases	O
such	O
as	O
cardiac,	O
immunological,	O
renal,	O
and	O
neurological	O
diseases	O
(Petrie	O
Aronin	O
and	O
Tuan,	O
2010;	O
Liu	O
et	O
al.,	O
2020).	O

Based	O
on	O
the	O
emerging	O
findings	O
in	O
HGPS,	O
it	O
is	O
tempting	O
to	O
speculate	O
that	O
a	O
misbalance	O
in	O
stem	O
cell	O
self-renewal	O
and	O
differentiation	O
coupled	O
with	O
increased	O
mechanical	O
sensitivity	O
could	O
lead	O
to	O
stem	B
cell	I
exhaustion	O
and	O
inefficient	O
repair	O
of	O
the	O
damaged	O
tissues,	O
contributing	O
to	O
many	O
of	O
the	O
phenotypes	O
in	O
HGPS	O
(Gotzman	O
and	O
Foisner	O
2006)..	O

Lamina-associated	O
polypeptide	O
(LAP)2α	O
and	O
nucleoplasmic	O
lamins	O
in	O
adult	B
stem	I
cell	I
regulation	O
and	O
disease.	O

RUNX1	O
regulates	O
the	O
transcription	O
of	O
genes	O
important	O
in	O
hematopoietic	O
stem	B
cell	I
formation	O
during	O
embryogenesis.	O

Consequently,	O
the	O
activated	O
Gli	O
family	O
of	O
zinc‐finger	O
transcription	O
factors	O
initiates	O
the	O
transcription	O
of	O
their	O
target	O
genes	O
19,	O
such	O
as	O
SOX2	O
and	O
OCT4	O
14,	O
20,	O
the	O
crucial	O
genes	O
for	O
stem	B
cell	I
function	O
21.	O

For	O
example,	O
Wnt/β‐catenin	O
signaling	O
has	O
been	O
found	O
to	O
regulate	O
the	O
self‐renewal	O
of	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
cells	O
with	O
stem	B
cell	I
characteristics,	O
and	O
this	O
phenomenon	O
occurs	O
partly	O
through	O
direct	O
Oct4	O
regulation	O
by	O
β‐catenin	O
12.	O

The	O
Notch	O
pathway	O
is	O
important	O
in	O
maintaining	O
the	O
cancer	B
stem	I
cell	I
population	O
in	O
pancreatic	O
cancer.	O

A	O
detailed	O
mammosphere	O
assay	O
protocol	O
for	O
the	O
quantification	O
of	O
breast	B
stem	I
cell	I
activity.	O

Heiden	O
KB,	O
Williamson	O
AJ,	O
Doscas	O
ME	O
et	O
al:	O
The	O
sonic	O
hedgehog	O
signaling	O
pathway	O
maintains	O
the	O
cancer	B
stem	I
cell	I
self‐renewal	O
of	O
anaplastic	O
thyroid	O
cancer	O
by	O
inducing	O
Snail	O
expression.	O

2)	O
has	O
led	O
to	O
the	O
landmark	O
discovery	O
in	O
stem	B
cell	I
research.	O

Targeted	O
genome	O
editing	O
is	O
broadly	O
applicable	O
to	O
genetically	O
engineer	O
any	O
sequence	O
of	O
interest	O
in	O
living	O
cells	O
or	O
organisms.148,149	O
Therefore,	O
the	O
combination	O
of	O
novel	O
approaches	O
in	O
human	O
iPSCs	O
and	O
CRISPR-based	O
genome	O
editing	O
can	O
improve	O
iPSC-based	O
cell	O
therapy	O
and	O
create	O
a	O
viable	O
option	O
for	O
stem	B
cell	I
therapy	O
and	O
regenerative	O
medicine..	O

Patients	O
of	O
the	O
TT2	O
cohort	O
(Arkansas,	O
newly	O
diagnosed	O
MM	O
patients	O
treated	O
by	O
High-dose	O
therapy	O
(HDT)	O
and	O
autologous	B
stem	I
cell	I
transplantation	O
(ASCT),	O
n	O
=	O
345)	O
were	O
ranked	O
according	O
to	O
expression	O
of	O
the	O
TRCs	O
resolution	O
genes	O
and	O
a	O
maximum	O
difference	O
in	O
OS	O
was	O
obtained	O
using	O
the	O
Maxstat	O
R	O
function.	O

Expression	O
of	O
8	O
TRCs	O
resolution	O
genes	O
in	O
patients	O
of	O
the	O
7	O
MM	O
molecular	O
subgroups	O
of	O
the	O
TT2	O
cohort	O
(Arkansas,	O
newly	O
diagnosed	O
MM	O
patients	O
treated	O
by	O
High	O
dose	O
therapy	O
(HDT)	O
and	O
autologous	B
stem	I
cell	I
transplantation	O
(ASCT),	O
n	O
=	O
345).	O

It	O
also	O
reduces	O
the	O
proliferation	O
of	O
neural	B
stem	I
cells	I
and	O
progenitor	O
cells	O
by	O
inducing	O
DNA	O
damage	O
and	O
cell	O
death	O
[251]..	O

In	O
all	O
studies,	O
CRISPR/Cas9	O
was	O
used	O
to	O
introduce	O
or	O
repair	O
the	O
mutation	O
in	O
the	O
gene	O
of	O
interest;	O
however,	O
the	O
pluripotent	B
stem	I
cell	I
source	O
was	O
different.	O

Murine	O
cutaneous	O
mastocytosis	O
and	O
epidermal	O
melanocytosis	O
induced	O
by	O
keratinocyte	O
expression	O
of	O
transgenic	B
stem	I
cell	I
factor.	O

Examples	O
of	O
this	O
orchestrated	O
DNA	O
methylation	O
remodeling	O
can	O
be	O
found	O
in	O
several	O
genes	O
involved	O
in	O
EMT	O
[66],	O
a	O
process	O
thought	O
to	O
drive	O
tumor	O
cell	O
dissemination	O
[67],	O
acquisition	O
of	O
stem	B
cell	I
properties	O
[68],	O
and	O
to	O
be	O
crucial	O
for	O
the	O
fate	O
of	O
CTCs	O
[69].	O

Exosomes	O
Regulate	O
the	O
Transformation	O
of	O
Cancer	O
Cells	O
in	O
Cancer	B
Stem	I
Cell	I
Homeostasis.	O

Understanding	O
breast	B
cancer	I
stem	I
cell	I
heterogeneity:	O
time	O
to	O
move	O
on	O
to	O
a	O
new	O
research	O
paradigm.	O

Both	O
SOX12	O
and	O
TMED3	O
thus	O
appear	O
required	O
for	O
normal	B
stem	I
cell	I
clonogenicity,	O
affecting	O
the	O
different	O
types	O
of	O
spheroids	O
formed,	O
but	O
only	O
TMED3	O
is	O
also	O
required	O
for	O
normal	O
clone	O
compaction/adhesion..	O

In	O
the	O
case	O
of	O
TMED3,	O
this	O
change	O
is	O
more	O
extreme	O
as	O
the	O
spheroids	O
loose	O
compaction	O
and	O
single	O
cells	O
can	O
move	O
out	O
of	O
the	O
clone,	O
perhaps	O
paralleling	O
early	O
steps	O
in	O
cancer	B
stem	I
cell	I
dissemination	O
during	O
metastases..	O

Original	O
reports	O
described	O
that	O
NSUN2	O
participates	O
in	O
catalyzing	O
biological	O
reactions	O
of	O
m5C	O
formation	O
in	O
RNAs	O
and	O
regulating	O
cell	O
cycle	O
[52],	O
linked	O
to	O
stem	B
cell	I
differentiation	O
and	O
involved	O
in	O
progression	O
[53].	O

This	O
effect	O
has	O
been	O
observed	O
in	O
human	O
leukemia	O
cell	O
lines,	O
monocytic	O
cell	O
lines,	O
osteosarcoma	O
and	O
adipocytes,	O
while	O
an	O
effect	O
on	O
stem	B
cells	I
or	O
progenitor	O
cells	O
has	O
been	O
observed	O
with	O
CDDO-Im,	O
but	O
not	O
with	O
CDDO	O
or	O
CDDO-Me	O
[59,60,61,62,63,64]..	O

Piwi	O
and	O
Aubergine	O
(Aub)	O
are	O
essential	O
for	O
germline	B
stem	I
cell	I
maintenance	O
in	O
adult	O
Drosophila	O
ovaries	O
and	O
testes.	O

2010),	O
transcription	O
activator-like	O
effector	O
nuclease	O
(TALEN)	O
(Bogdanove	O
and	O
Voytas	O
2011),	O
and	O
CRISPR/Cas,	O
have	O
the	O
advantage	O
of	O
generating	O
genetically	O
modified	O
organisms	O
by	O
directly	O
modifying	O
the	O
genome	O
in	O
the	O
zygote,	O
eliminating	O
the	O
need	O
for	O
a	B
germline	I
competent	I
embryonic	I
stem	I
cell	I
line,	O
saving	O
cost	O
and	O
shortening	O
the	O
time	O
needed	O
for	O
creating	O
mutant	O
animals..	O

This	O
networking	O
in	O
large	O
spheroid	O
is	O
useful	O
for	O
facilitating	O
cell	O
proliferation,	O
to	O
allow	O
cell	O
differentiation	O
and	O
their	O
coordination	O
during	O
the	O
following	O
morphological	O
changes,	O
as	O
well	O
as	O
to	O
supply	O
gap	O
junction	O
connections	O
that	O
are	O
formed	O
precociously	O
but	O
cannot	O
function	O
during	O
the	O
undifferentiated	O
state	O
typical	O
of	O
stem	B
cells	I
[65,66]..	O

Nonadhesive	O
Culture	O
System	O
as	O
a	O
Model	O
of	O
Rapid	O
Sphere	O
Formation	O
with	O
Cancer	B
Stem	I
Cell	I
Properties.	O

MicroRNAs	O
in	O
stem	B
cell	I
function	O
and	O
regenerative	O
therapy	O
of	O
the	O
heart.	O

Expression	O
of	O
stem	B
cell	I
factor	O
(SCF)	O
and	O
SCF	O
receptor	O
(c-kit)	O
in	O
synovial	O
membrane	O
in	O
arthritis:	O
correlation	O
with	O
synovial	O
mast	O
cell	O
hyperplasia	O
and	O
inflammation.	O

Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

The	O
polycomb	O
group	O
protein	O
Suz12	O
is	O
required	O
for	O
embryonic	B
stem	I
cell	I
differentiation.	O

In	O
reality,	O
lincRNAs	O
are	O
found	O
to	O
perform	O
important	O
functions	O
in	O
many	O
cellular	O
processes,	O
from	O
embryonic	B
stem	I
cell	I
pluripotency	O
to	O
cell	O
proliferation	O
and	O
cancer	O
progression.38,46,53,54.	O

Our	O
further	O
studies	O
will	O
focus	O
on	O
identification	O
and	O
validation	O
of	O
the	O
secreted	O
factors	O
that	O
are	O
likely	O
to	O
underlie	O
the	O
restorative	O
effects	O
of	O
transplanted	O
hNPCs,	O
which	O
may	O
guide	O
further	O
development	O
of	O
stem	B
cell	I
and	O
perhaps	O
cell-free	O
therapies	O
for	O
MS..	O

We	O
are	O
grateful	O
to	O
Duane	O
Roth	O
for	O
his	O
unwavering	O
support	O
of	O
stem	B
cell	I
research,	O
and	O
we	O
wish	O
to	O
dedicate	O
this	O
report	O
to	O
his	O
memory..	O

Hippocampal	O
injury-induced	O
cognitive	O
and	O
mood	O
dysfunction,	O
altered	O
neurogenesis,	O
and	O
epilepsy:	O
can	O
early	O
neural	B
stem	I
cell	I
grafting	O
intervention	O
provide	O
protection?	O
Epilepsy	O
Behav.	O

Lung	B
stem	I
cell	I
self-renewal	O
relies	O
on	O
BMI1-dependent	O
control	O
of	O
expression	O
at	O
imprinted	O
loci.	O

In	O
recent	O
years,	O
further	O
evidence	O
has	O
demonstrated	O
the	O
role	O
of	O
epigenetic	O
factors	O
in	O
the	O
maintenance	O
of	O
neural	B
stem	I
cell	I
renewal	O
and	O
also	O
in	O
the	O
induction	O
of	O
new	O
mature	O
neurons.	O

Variation	O
in	O
cancer	O
risk	O
among	O
tissues	O
can	O
be	O
explained	O
by	O
the	O
number	O
of	O
stem	B
cell	I
divisions.	O

In	O
mouse	O
embryonic	O
stem	O
cells,	O
phenocopying	O
Mettl14	O
silencing,	O
H3K36me3	O
depletion	O
also	O
induces	O
m6A	O
reduction	O
transcriptome-wide	O
and	O
in	O
pluripotency	O
transcripts,	O
resulting	O
in	O
increased	O
cell	O
stemness.	O
Functional	O
analysis	O
of	O
gene	O
expression	O
revealed	O
the	O
enrichment	O
of	B
stem	I
cell	I
maintenance	O
genes	O
in	O
downregulated	O
genes	O
during	O
LIF	O
withdrawal	O
and	O
in	O
upregulated	O
genes	O
upon	O
SETD2	O
silencing	O
(Extended	O
Data	O
Fig.	O

Remarkably:	O
(i)	O
a	O
large	O
diversity	O
and	O
variation	O
exist	O
in	O
epigenomes	O
both	O
across	O
cell	O
types	O
and	O
individuals	O
[23];	O
for	O
example	O
up	O
to	O
95-fold	O
variation	O
between	O
reference	O
epigenomes	O
has	O
been	O
observed	O
in	O
H3K4me3	O
signal	O
close	O
to	O
TSSs	O
in	O
humans	O
[24];	O
(ii)	O
chromatin	O
mark	O
features	O
such	O
as	O
length	O
or	O
read-enrichment	O
shape	O
have	O
proven	O
to	O
be	O
relevant	O
for	O
gene	O
expression	O
regulation	O
[25,	O
26];	O
(iii)	O
chromatin	O
marks	O
can	O
capture	O
differences	O
that	O
are	O
not	O
reflected	O
in	O
either	O
methylation	O
or	O
DNA	O
accessibility	O
[2];	O
and	O
(iv)	O
these	O
marks	O
may	O
have	O
additional	O
practical	O
applications,	O
as	O
shown	O
recently	O
by	O
the	O
histone	O
variant	O
H2A.X,	O
which	O
variability	O
can	O
be	O
used	O
as	O
an	O
indicator	O
of	O
quality	O
in	O
mouse	B
induced	I
pluripotent	I
stem	I
cells	I
[27].	O

These	O
results	O
indicate	O
that	O
Rad21	O
plays	O
a	O
critical	O
role	O
in	O
the	O
Esg-mediated	O
maintenance	O
of	O
the	O
stem	B
cell	I
state	O
in	O
the	O
ISC	O
lineage	O
(Figure	O
10).	O

Our	O
data	O
support	O
a	O
specific	O
function	O
for	O
Cohesin-mediated	O
chromatin	O
regulation	O
in	O
the	O
control	O
of	O
somatic	B
stem	I
cell	I
biology.	O

It	O
has	O
been	O
proposed	O
that	O
the	O
3-dimensional	O
genome	O
structure	O
is	O
more	O
plastic	O
in	O
stem	B
cells	I
compared	O
to	O
differentiated	O
progeny,	O
thus	O
facilitating	O
re-shaping	O
into	O
the	O
more	O
stable	O
chromatin	O
organization	O
that	O
is	O
critical	O
for	O
the	O
establishment	O
of	O
a	O
fully	O
differentiated	O
daughter	O
cell	O
with	O
a	O
specific	O
transcriptional	O
program	O
(Filion	O
et	O
al.,	O
2010;	O
Sexton	O
and	O
Cavalli,	O
2015).	O

This	O
study	O
did	O
not	O
observe	O
defects	O
in	O
stem	B
cell	I
self-renewal	O
efficiency	O
in	O
Rad21	O
heterozygotes,	O
but	O
did	O
observe	O
reduced	O
expression	O
of	O
the	O
ISC	O
marker	O
Lgr5	O
in	O
heterozygous	O
crypts.	O

Aneuploidy	O
has	O
been	O
recently	O
linked	O
to	O
stem	B
cell	I
maintenance	O
and	O
proliferation	O
(Gogendeau	O
et	O
al.,	O
2015;	O
Resende	O
et	O
al.,	O
2018).	O

Pioneer	O
factors	O
govern	O
super-enhancer	O
dynamics	O
in	O
stem	B
cell	I
plasticity	O
and	O
lineage	O
choice.	O

RAD21	O
cooperates	O
with	O
pluripotency	O
transcription	O
factors	O
in	O
the	O
maintenance	O
of	O
embryonic	B
stem	I
cell	I
identity.	O

In	O
this	O
revised	O
version	O
of	O
the	O
manuscript	O
Khaminets	O
and	O
co-workers	O
provide	O
additional	O
evidence	O
to	O
support	O
that	O
the	O
observed	O
premature	O
differentiation	O
is	O
at	O
least	O
partly	O
independent	O
of	O
possible	O
mitotic	O
defects	O
(particularly	O
highlighting	O
the	O
effect	O
on	O
single	O
cell	O
clones),	O
and	O
therefore	O
suggest	O
a	O
gene-expression	O
related	O
role	O
for	O
cohesin	O
in	O
stem	B
cell	I
identity.	O

We	O
agree	O
with	O
the	O
reviewers	O
that	O
aneuploidy	O
induced	O
by	O
Cohesin	O
depletion	O
and	O
its	O
relevance	O
in	O
stem	B
cell	I
maintenance	O
is	O
an	O
important	O
aspect	O
of	O
our	O
study	O
and	O
therefore	O
requires	O
additional	O
clarification..	O

In	O
this	O
revised	O
version	O
of	O
the	O
manuscript	O
Khaminets	O
and	O
co-workers	O
provide	O
additional	O
evidence	O
to	O
support	O
that	O
the	O
observed	O
premature	O
differentiation	O
is	O
at	O
least	O
partly	O
independent	O
of	O
possible	O
mitotic	O
defects	O
(particularly	O
highlighting	O
the	O
effect	O
on	O
single	O
cell	O
clones),	O
and	O
therefore	O
suggest	O
a	O
gene-expression	O
related	O
role	O
for	O
cohesin	O
in	O
stem	B
cell	I
identity.	O

Notably,	O
s-SHIP	O
expression	O
in	O
cap	O
cells	O
is	O
associated	O
with	O
the	O
expression	O
of	O
Par3-like	O
polarity	O
protein,	O
which	O
is	O
essential	O
for	O
mammary	B
stem	I
cell	I
maintenance	O
(Huo	O
and	O
Macara,	O
2014)..	O

ELDA:	O
extreme	O
limiting	O
dilution	O
analysis	O
for	O
comparing	O
depleted	O
and	O
enriched	O
populations	O
in	O
stem	B
cell	I
and	O
other	O
assays.	O

The	O
Par3-like	O
polarity	O
protein	O
Par3L	O
is	O
essential	O
for	O
mammary	B
stem	I
cell	I
maintenance.	O

Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

At	O
one	O
year	O
after	O
the	O
mesenchymal	B
stem	I
cell	I
infusions,	O
three	O
animals	O
regained	O
functional	O
ambulation	O
(Grade	O
I),	O
and	O
all	O
four	O
dogs	O
started	O
to	O
move	O
independently	O
(Grades	O
I	O
and	O
II).	O

The	O
US	O
Food	O
and	O
Drug	O
Administration's	O
Center	O
for	O
Veterinary	O
Medicine	O
was	O
the	O
only	O
legislative	O
body	O
to	O
formally	O
publish	O
specific	O
definitions	O
and	O
recommendations	O
for	O
stem	B
cell	I
use	O
through	O
guidelines	O
[40],	O
where	O
cell-based	O
products	O
must	O
follow	O
the	O
same	O
legal	O
requirements	O
that	O
apply	O
to	O
other	O
animal	O
drugs,	O
forcing	O
the	O
industry	O
to	O
prove	O
efficacy	O
and	O
manufacturing	O
quality	O
and	O
safety	O
prior	O
to	O
commercialization	O
[38]..	O

The	O
therapeutic	O
potential	O
of	O
mesenchymal	B
stem	I
cell	I
transplantation	O
as	O
a	O
treatment	O
for	O
multiple	O
sclerosis:	O
consensus	O
report	O
of	O
the	O
International	O
MSCT	O
Study	O
Group.	O

Safety	O
and	O
immunological	O
effects	O
of	O
mesenchymal	B
stem	I
cell	I
transplantation	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
and	O
amyotrophic	O
lateral	O
sclerosis.	O

Mesenchymal	B
stem	I
cell	I
infusion	O
for	O
the	O
treatment	O
of	O
neurological	O
sequelae	O
of	O
canine	O
distemper	O
virus:	O
a	O
clinical	O
study.	O

Extracellular	O
vesicles	O
(EVs)	O
are	O
cell	O
derivatives	O
containing	O
diverse	O
cellular	O
molecules,	O
have	O
various	O
physiological	O
properties	O
and	O
are	O
also	O
present	O
in	O
stem	B
cells	I
used	O
for	O
regenerative	O
therapy.	O

After	O
1 h	O
of	O
I/R,	O
rats	O
were	O
treated	O
with	O
ASCmiR-210	O
and	O
sacrificed	O
to	O
obtain	O
the	O
stem	B
cell	I
injection	O
site	O
after	O
3	O
weeks.	O

However,	O
in	O
this	O
study,	O
the	O
authors	O
commented	O
that	O
depletion	O
of	O
PKD2	O
or	O
-3	O
had	O
no	O
effect	O
on	O
VEGF	O
secretion	O
from	O
prostate	O
cancer	O
cells	O
or	O
mast	O
cells;	O
instead,	O
a	O
role	O
of	O
PKD2	O
and	O
PKD3	O
on	O
the	O
secretion	O
of	O
stem	B
cell	I
factor	O
and	O
chemokine	O
ligand	O
5	O
and	O
C-C	O
motif	O
chemokine	O
11	O
expression	O
was	O
implicated	O
in	O
the	O
response	O
[47].	O

Perturbations	O
in	O
the	O
normal	B
stem	I
cell	I
program	O
leading	O
to	O
neoplastic	O
growth	O
as	O
the	O
result	O
of	O
aberrant	O
expression	O
of	O
key	O
regulatory	O
genes	O
are	O
also	O
difficult	O
to	O
study	O
because	O
leukemic	O
cells	O
are	O
difficult	O
to	O
grow	O
in	O
culture.	O

Studies	O
have	O
screened	O
substrate	O
stiffness	O
to	O
determine	O
the	O
condition	O
for	O
the	O
maintenance	O
of	O
cancer	B
stem	I
cell	I
populations.	O

Though	O
neither	O
protein	O
has	O
yet	O
been	O
associated	O
with	O
hematopoietic	O
stem	O
cells	O
DC	O
is	O
associated	O
with	O
stem	B
cell	I
failure	O
in	O
other	O
systems	O
and	O
has	O
prominent	O
skin,	O
gut	O
and	O
hair	O
manifestations..	O

We	O
conclude	O
that	O
DC	O
iPS	O
cells	O
represent	O
a	O
useful	O
model	O
of	O
the	O
DC	O
stem	B
cell	I
and	O
should	O
accelerate	O
research	O
into	O
the	O
pathology	O
of	O
this	O
devastating	O
disease.	O

Taking	O
into	O
account	O
the	O
advances	O
in	O
the	O
isolation	O
of	O
new	O
subpopulation	O
of	O
stem	O
cells	O
and	O
in	O
the	O
creation	O
of	O
artificial	B
stem	I
cell	I
niches,	O
we	O
discuss	O
how	O
these	O
emerging	O
technologies	O
offer	O
great	O
promises	O
for	O
therapeutic	O
approaches	O
to	O
muscle	O
diseases	O
and	O
muscle	O
wasting	O
associated	O
with	O
aging..	O

Unfortunately,	O
the	O
use	O
of	O
stem	B
cell	I
in	O
regenerative	O
medicine	O
is	O
limited	O
by	O
the	O
poor	O
engraftment	O
and	O
persistence	O
of	O
transplanted	O
cells	O
and	O
the	O
risk	O
of	O
neoplastic	O
formation	O
(Suuronen	O
et	O
al.,	O
2008;	O
Kuraitis	O
et	O
al.,	O
2012).	O

Modulation	O
of	O
the	O
inflammatory	O
reaction	O
is	O
a	O
key	O
step	O
for	O
stem	B
cell	I
transplantation	O
(Smythe	O
et	O
al.,	O
2000):	O
myeloid	O
cells	O
(Suzuki	O
et	O
al.,	O
1999;	O
Mcnally	O
et	O
al.,	O
2000),	O
macrophages	O
(Wehling	O
et	O
al.,	O
2001;	O
Villalta	O
et	O
al.,	O
2009),	O
neutrophils	O
(Hodgetts	O
et	O
al.,	O
2006)	O
and	O
eosinophils	O
(Cai	O
et	O
al.,	O
2000)	O
actively	O
contribute	O
to	O
development	O
of	O
pathogenesis	O
in	O
several	O
myophaties	O
but	O
only	O
macrophages	O
and	O
sometimes	O
eosinophils	O
play	O
a	O
role	O
in	O
muscle	O
regeneration	O
(Tidball	O
and	O
Villalta,	O
2010).	O

Biomaterials	O
technologies	O
offer	O
great	O
opportunities	O
to	O
control	O
the	O
stem	B
cell	I
fate	O
in	O
vivo,	O
especially	O
in	O
case	O
of	O
tissue	O
damage.	O

Biomaterials	O
may	O
improve	O
the	O
effect	O
of	O
stem	B
cell	I
transplantation;	O
they	O
may	O
be	O
used	O
as	O
multifunctional	O
stem-cell	O
microenvironments.	O

Biomaterials	O
aim	O
is	O
not	O
only	O
to	O
create	O
materials	O
to	O
control	O
spatially	O
and	O
temporally	O
the	O
components	O
of	O
the	O
niche	O
but	O
also	O
to	O
study	O
microenvironmental	O
regulation	O
of	O
stem	B
cell	I
proliferation	O
and	O
fate	O
(Conboy	O
et	O
al.,	O
2005).	O

New	O
approaches	O
using	O
organisms	O
genetically	O
modified	O
and	O
transgenic	O
mouse	O
models	O
proposed	O
the	O
importance	O
of	O
the	O
microenvironment—like	O
the	O
niche	O
and	O
the	O
extrinsic	O
factors—to	O
be	O
a	O
key	O
component	O
in	O
stem	B
cell	I
regulation.	O

Investigations	O
on	O
the	O
molecular	O
nature	O
of	O
stem	B
cell	I
niche	O
signals	O
on	O
in	O
vivo	O
models	O
and	O
short-term	O
cultures	O
of	O
isolated	O
myofibers,	O
are	O
now	O
on-going.	O

Intrinsic	O
changes	O
and	O
extrinsic	O
influences	O
of	O
myogenic	B
stem	I
cell	I
function	O
during	O
aging.	O

The	O
biological	O
and	O
ethical	O
basis	O
of	O
the	O
use	O
of	O
human	B
embryonic	I
stem	I
cells	I
for	O
in	O
vitro	O
test	O
systems	O
or	O
cell	O
therapy.	O

Muscle	O
cell	O
differentiation	O
of	O
embryonic	B
stem	I
cells	I
reflects	O
myogenesis	O
in	O
vivo:	O
developmentally	O
regulated	O
expression	O
of	O
myogenic	O
determination	O
genes	O
and	O
functional	O
expression	O
of	O
ionic	O
currents.	O

Overexpression	O
of	O
miR-124	O
has	O
consistently	O
been	O
found	O
to	O
inhibit	O
the	O
CD133+	O
cell	O
subpopulation	O
of	O
the	O
neurosphere	O
and	O
to	O
downregulate	B
stem	I
cell	I
markers,	O
such	O
as	O
BMI1,	O
Nanog,	O
and	O
Nestin.	O

Notch	O
is	O
a	O
critical	O
regulator	O
of	O
cell-fate	O
during	O
development	O
and	O
also	O
of	O
normal	B
stem	I
cell	I
maintenance	O
(Fan	O
et	O
al.,	O
2006;	O
Shih	O
and	O
Holland,	O
2006;	O
Fan	O
et	O
al.,	O
2010).	O

In	O
addition,	O
miR-34a	O
induces	O
GSC	O
differentiation	O
as	O
evidenced	O
by	O
the	O
decreased	O
expression	O
of	O
stem	B
cell	I
markers	O
and	O
increased	O
expression	O
of	O
differentiation	O
markers	O
(Guessous	O
et	O
al.,	O
2010)..	O

Tumor	B
stem	I
cells	I
derived	O
from	O
glioblastomas	O
cultured	O
in	O
bFGF	O
and	O
EGF	O
more	O
closely	O
mirror	O
the	O
phenotype	O
and	O
genotype	O
of	O
primary	O
tumors	O
than	O
do	O
serum-cultured	O
cell	O
lines.	O

Therefore,	O
the	O
epigenetic	O
regulation	O
of	O
stem	B
cell	I
identity	O
in	O
intact	O
tissues	O
remains	O
poorly	O
understood.	O

Importantly,	O
in	O
rrf-1	O
mutants,	O
RNAi	O
is	O
impaired	O
in	O
the	O
somatic	O
gonad,	O
including	O
the	O
distal	O
tip	O
cell	O
(DTC),	O
which	O
constitutes	O
the	O
germline	B
stem	I
cell	I
niche	O
(Kumsta	O
and	O
Hansen,	O
2012).	O

Discovery	O
of	O
two	O
GLP-1/Notch	O
target	O
genes	O
that	O
account	O
for	O
the	O
role	O
of	O
GLP-1/Notch	O
signaling	O
in	O
stem	B
cell	I
maintenance.	O

Notch	O
signaling	O
in	O
the	O
regulation	O
of	O
stem	B
cell	I
self-renewal	O
and	O
differentiation.	O

Cytokines	O
activate	O
gene	O
transcription	O
regulators	O
that	O
are	O
involved	O
in	O
stem	B
cell	I
renewal	O
and	O
proliferation,	O
critical	O
for	O
tissue	O
repair	O
[100-103].	O

On	O
the	O
other	O
hand,	O
the	O
top	O
upregulated	O
terms	O
included	O
signaling	O
pathways	O
involved	O
in	O
regulation	O
of	O
stem	B
cell	I
quiescence,	O
differentiation,	O
and	O
inflammatory	O
signaling	O
(e.g.	O

Epigenetic	O
control	O
of	O
stem	B
cell	I
potential	O
during	O
homeostasis,	O
aging,	O
and	O
disease.	O

m6A	O
methylation	O
also	O
plays	O
important	O
roles	O
in	O
human	O
disease,	O
such	O
as	O
control	O
of	O
HIV-1	O
replication	O
and	O
interaction	O
with	O
the	O
host	O
immune	O
system	O
during	O
HIV-1	O
infection	O
of	O
T	O
cells	O
[17],	O
promoting	O
translation	O
of	O
oncogenes	O
in	O
human	O
lung	O
cancer	O
[18],	O
and	O
induction	O
of	O
breast	B
cancer	I
stem	I
cell	I
phenotype	O
[19].	O

The	O
molecular	O
mechanisms	O
by	O
which	O
lncRNAs	O
exert	O
their	O
function	O
are	O
poorly	O
understood,	O
and	O
only	O
for	O
a	O
limited	O
number	O
of	O
them	O
a	O
function	O
has	O
been	O
defined	O
that	O
implicates	O
their	O
involvement	O
in	O
numerous	O
cellular	O
processes	O
ranging	O
from	O
embryonic	B
stem	I
cell	I
pluripotency,	O
cell-cycle	O
regulation,	O
and	O
diseases.	O

Mesenchymal	B
stem	I
cells	I
Apelin	O
13	O
Activate	O
PI3K/AKT	O
signaling	O
pathways	O
enhance	O
the	O
efficacy	O
of	O
MSCs	O
in	O
cell	O
therapy	O
of	O
diabetes	O
166.	O

A	O
feedback	O
regulatory	O
loop	O
involving	O
microRNA-9	O
and	O
nuclear	O
receptor	O
TLX	O
in	O
neural	B
stem	I
cell	I
fate	O
determination.	O

EZH2	O
also	O
plays	O
vital	O
roles	O
in	O
stem	B
cell	I
maintenance	O
and	O
lineage	O
differentiation	O
[24-26].	O

AM	O
=	O
alveolar	O
macrophages,	O
BMDM	O
=	O
bone	O
marrow	O
derived	O
macrophages,	O
MDM	O
=	O
monocyte	O
derived	O
macrophages,	O
PM	O
=	O
peritoneal	O
macrophages,	O
ESDM	O
=	O
embryonic	B
stem	I
cell	I
derived	O
macrophages.	O

Conditional-ready	O
mouse	B
embryonic	I
stem	I
cell	I
derived	O
macrophages	O
enable	O
the	O
study	O
of	O
essential	O
genes	O
in	O
macrophage	O
function.	O

Injection	O
of	O
embryonic	B
stem	I
cell	I
derived	O
macrophages	O
ameliorates	O
fibrosis	O
in	O
a	O
murine	O
model	O
of	O
liver	O
injury.	O

EZH1	O
mediates	O
methylation	O
on	O
histone	O
H3	O
lysine	O
27	O
and	O
complements	O
EZH2	O
in	O
maintaining	B
stem	I
cell	I
identity	O
and	O
executing	O
pluripotency.	O

The	O
expression	O
of	O
7SL	O
RNA	O
was	O
demonstrated	O
to	O
be	O
positively	O
regulated	O
during	O
differentiation	O
of	O
mouse	B
embryonic	I
stem	I
cells	I
into	O
a	O
differentiated	O
heterogeneous	O
population	O
of	O
neurons	O
and	O
glial	O
cells	O
(Skreka	O
et	O
al.,	O
2012),	O
suggesting	O
that	O
it	O
may	O
be	O
of	O
particular	O
importance	O
in	O
these	O
cell	O
types,	O
both	O
of	O
which	O
are	O
affected	O
in	O
POLR3-related	O
disorders..	O

Identification	O
of	O
Differentially	O
Expressed	O
Non-coding	O
RNAs	O
in	O
Embryonic	B
Stem	I
Cell	I
Neural	O
Differentiation.	O

Yet,	O
to	O
date,	O
the	O
effect	O
of	O
TP53	O
pathway	O
inactivation	O
on	O
cancer	B
stem	I
cell	I
number,	O
tumor	O
progression,	O
and	O
metastasis	O
in	O
ERMS	O
is	O
not	O
fully	O
understood.	O

Conversely,	O
a	O
recent	O
study	O
showed	O
that	O
in	O
stem	B
cells	I
and	O
cancer	O
cell	O
precursors,	O
methylation	O
also	O
occurs	O
at	O
non-CpG	O
pairs	O
and	O
involves	O
introns	O
and	O
even	O
gene	O
bodies.	O

The	O
reported	O
results	O
confirm	O
the	O
ds-DNA	O
stabilizing	O
action	O
of	O
methylcytosine,	O
and,	O
in	O
the	O
future,	O
may	O
shed	O
new	O
light	O
on	O
the	O
mechanisms	O
for	O
the	O
fine	O
regulation	O
of	O
gene	O
expression	O
that	O
are	O
connected	O
to	O
the	O
non-CpG	O
intragenic	O
methylation	O
of	O
stem	B
cell	I
and	O
cancer	O
cell	O
precursor	O
genomes.	O

faecalis,	O
which	O
can	O
cause	O
colitis	O
after	O
infection,	O
can	O
express	O
TGF‐β	O
in	O
the	O
intestinal	O
epithelial	O
cells	O
of	O
wild‐type	O
mice,	O
thereby	O
activating	O
the	O
Smad	O
signaling	O
pathway.54	O
In	O
this	O
process,	O
the	O
dedifferentiation	O
of	O
TGF‐β	B
signal	I
transduction	I
enhances	I
the	I
stem	I
cell	I
characteristics	O
of	O
CRC,	O
thereby	O
promoting	O
its	O
occurrence.55	O
This	O
is	O
associated	O
with	O
the	O
deletion	O
of	O
the	O
expression	O
of	O
the	O
TLR2	O
protein	O
and	O
the	O
inhibition	O
of	O
NF‐κB‐dependent	O
pro‐inflammatory	O
gene	O
expression54	O
(Fig..	O

Embryonic	B
stem	I
cells	I
are	O
multipotent	O
and	O
able	O
to	O
commit	O
to	O
different	O
cell	O
lineages,	O
and	O
3T3-L1	O
cells	O
are	O
already	O
committed	O
to	O
the	O
adipocyte	O
lineage	O
[15,	O
24].	O

Embryonic	B
stem	I
cell	I
differentiation:	O
emergence	O
of	O
a	O
new	O
era	O
in	O
biology	O
and	O
medicine.	O

Wdr5	O
mediates	O
self-renewal	O
and	O
reprogramming	O
via	O
the	O
embryonic	B
stem	I
cell	I
core	O
transcriptional	O
network.	O

In	O
the	O
primary	O
cell	O
cultivation	O
system,	O
metacestode	O
vesicles	O
are	O
formed	O
from	O
parasite	B
stem	I
cells	I
within	O
1–2	O
weeks	O
[36].	O

multilocularis	B
stem	I
cell	I
proliferation	O
was	O
significantly	O
impaired	O
in	O
a	O
dose-dependent	O
manner	O
as	O
assessed	O
by	O
BrdU	O
incorporation	O
assays	O
(Fig.	O

3A)	O
was	O
used,	O
but	O
revealed	O
no	O
inhibition	O
of	O
Echinococcus	B
stem	I
cell	I
proliferation	O
(Fig.	O

multilocularis	B
stem	I
cell	I
proliferation	O
whereas	O
an	O
equal	O
amount	O
of	O
total	O
rabbit	O
IgG	O
failed	O
to	O
do	O
so.	O

Irrespective	O
of	O
the	O
mechanism,	O
our	O
data	O
clearly	O
indicate	O
an	O
important	O
role	O
of	O
EmTIP	O
in	O
parasite	O
development	O
during	O
the	O
onset	O
of	O
AE	O
and	O
probably	O
also	O
during	O
metastatic	O
growth	O
of	O
the	O
parasite	O
in	O
long-term	O
infections,	O
which	O
all	O
dependent	O
on	O
parasite	B
stem	I
cell	I
proliferation	O
and	O
differentiation	O
[36],	O
[37],	O
[66],	O
[67].	O

Brizzi	O
MF,	O
Tarone	O
G,	O
Defilippi	O
P	O
(2012)	O
Extracellular	O
matrix,	O
integrins,	O
and	O
growth	O
factors	O
as	O
tailors	O
of	O
the	O
stem	B
cell	I
niche.	O

Marthiens	O
V,	O
Kazanis	O
I,	O
Moss	O
L,	O
Long	O
K,	O
Ffrench-Constant	O
C	O
(2010)	O
Adhesion	O
molecules	O
in	O
the	O
stem	B
cell	I
niche–more	O
than	O
just	O
staying	O
in	O
shape?	O
J	O
Cell	O
Sci	O
123:	O
1613–1622.	O

Raymond	O
K,	O
Deugnier	O
MA,	O
Faraldo	O
MM,	O
Glukhova	O
MA	O
(2009)	O
Adhesion	O
within	O
the	O
stem	B
cell	I
niches.	O

Together,	O
these	O
observations	O
suggest	O
that	O
the	O
TLR7	O
positive	O
population	O
probably	O
represent	O
a	O
subset	O
of	O
the	O
total	O
epidermal	O
stem	O
cell	O
population	O
in	O
the	O
epidermis	O
and	O
a	O
small	O
subset	O
of	O
the	O
HF	O
stem	B
cell	I
population	O
in	O
the	O
HFs..	O

Taken	O
together,	O
our	O
data	O
provide	O
a	O
novel	O
function	O
of	O
TLR7	O
in	O
skin,	O
as	O
well	O
as	O
a	O
possible	O
application	O
of	O
TLR7	O
for	O
purification	O
of	O
skin	B
stem	I
cell	I
for	O
skin	O
transplantation	O
and	O
regeneration.	O

Measuring	B
stem	I
cell	I
frequency	O
in	O
epidermis:	O
a	O
quantitative	O
in	O
vivo	O
functional	O
assay	O
for	O
long-term	O
repopulating	O
cells.	O

To	O
accomplish	O
this	O
goal,	O
a	O
fragment	O
of	O
the	O
integrin	O
αIIb	O
(ITGA2B)	O
gene	O
promoter	O
known	O
to	O
drive	O
megakaryocyte-specific	O
gene	O
transcription17	O
was	O
employed	O
for	O
ectopic	O
expression	O
of	O
human	O
B-domain-deleted	O
Factor	O
VIII	O
(BDDFVIII)	O
because	O
megakaryocyte-targeted	O
expression	O
of	O
ITGA2B	O
and	O
integrin	O
β3	O
(ITGB3)	O
genes	O
was	O
previously	O
shown	O
to	O
be	O
useful	O
for	O
hematopoietic	B
stem	I
cell	I
gene	O
therapy	O
leading	O
to	O
correction	O
of	O
platelet	O
function	O
in	O
dogs	O
and	O
mice	O
affected	O
with	O
the	O
inherited	O
bleeding	O
disorder	O
Glanzmann	O
thrombasthenia	O
(GT)18,19.	O

A	O
recent	O
report	O
also	O
demonstrated	O
successful	O
use	O
of	O
busulfan	O
at	O
10 mg kg−1	O
for	O
hematopoietic	B
stem	I
cell	I
gene	O
transfer	O
to	O
correct	O
canine	O
leukocyte	O
adhesion	O
deficiency28,	O
followed	O
by	O
transient	O
immunosuppression	O
with	O
mycophenolate	O
mofetil	O
(MMF)	O
and	O
cyclosporine	O
(CSP)	O
after	O
major	O
histocompatibility	O
complex	O
identical	O
marrow	O
transplantation29.	O

According	O
to	O
the	O
NB	O
cell	O
line	O
used,	O
over-expression	O
of	O
miR-340	O
induced	O
either	O
apoptosis	O
or	O
differentiation	O
by	O
targeting	O
SOX2,	O
an	O
SRY	O
box	O
containing	O
a	O
transcription	O
factor	O
family	O
member	O
that	O
acts	O
in	O
regulating	O
the	O
maintenance	O
and	O
differentiation	O
of	O
neural	B
stem	I
cells	I
[109]..	O

Role	O
of	O
miRNAs	O
in	O
muscle	B
stem	I
cell	I
biology:	O
proliferation,	O
differentiation	O
and	O
death.	O

SMRT-mediated	O
repression	O
of	O
an	O
H3K27	O
demethylase	O
in	O
progression	O
from	O
neural	B
stem	I
cell	I
to	O
neuron.	O

LT-HSC–transplanted	O
recipients	O
developed	O
a	O
lethal	O
MPN	O
consistent	O
with	O
efficient	O
propagation	O
of	O
the	O
disease	O
from	O
the	O
stem	B
cell	I
compartment	O
(Supplemental	O
Figure	O
1C).	O

This	O
could	O
be	O
due	O
to	O
the	O
observation	O
that	O
JAK2/IDH-mutant	O
disease	O
remains	O
an	O
accelerated-phase	O
MPN	O
versus	O
the	O
AML	O
observed	O
in	O
combined	O
Flt3ITD-	O
and	O
Tet2/Idh2-mutant	O
disease,	O
such	O
that	O
the	O
leukemic	B
stem	I
cell	I
remains	O
in	O
the	O
LT-HSC	O
compartment	O
in	O
chronic-phase	O
disease	O
until	O
blast	O
transformation.	O

Specifically,	O
we	O
found	O
that	O
treatment	O
with	O
the	O
IDH2	O
inhibitor	O
AG221	O
showed	O
efficacy	O
in	O
Jak2/Idh2-mutant	O
MPN,	O
including	O
attenuation	O
of	O
myeloid	O
expansion,	O
reversal	O
of	O
stem	B
cell	I
expansion,	O
and	O
a	O
reduction	O
in	O
the	O
mutant	O
allele	O
burden.	O

It	O
would	O
be	O
of	O
the	O
order	O
of	O
1	O
mGy/h	O
based	O
on	O
the	O
unit	O
dose	O
of	O
a	O
single	O
photon	O
track	O
[149]	O
and	O
the	O
rate	O
of	O
DNA	O
repair	O
[150],	O
or	O
of	O
the	O
order	O
of	O
10	O
mGy/week	O
based	O
on	B
the	I
stem	I
cell	I
turnover	O
rate	O
in	O
tissues	O
(e.g.	O

By	O
mating	O
this	O
pig	O
with	O
PDX1-HES1	O
Tg	O
pig[72,73],	O
we	O
generated	O
an	O
SCID	O
pig	O
with	O
pancreatic	O
agenesis	O
that	O
can	O
greatly	O
contribute	O
to	O
preclinical	O
evaluations	O
of	O
stem	B
cell	I
transplantation	O
and	O
xenotransplantation..	O

Mesenchymal	B
stem	I
cells	I
and	O
bone	O
marrow	O
cells	O
appear	O
attractive	O
for	O
cell	O
therapy;	O
however,	O
they	O
are	O
not	O
readily	O
converted	O
into	O
functionally	O
mature	O
β-cells[85]..	O

Available	O
treatment	O
strategies	O
for	O
NB	O
patients	O
include	O
chemotherapy	O
followed	O
by	O
surgical	O
resection,	O
myeloablation	O
and	O
autologous	B
stem	I
cell	I
rescue,	O
radiation,	O
and	O
immunotherapy	O
[5,6].	O

MEK/ERK	O
signaling	O
contributes	O
to	O
the	O
maintenance	O
of	O
human	B
embryonic	I
stem	I
cell	I
self-renewal.	O

identified	O
A40s,	O
a	O
novel	O
aptamer	O
that	O
can	O
internalize	O
in	O
GBM	O
stem	O
cells	O
and	O
specifically	O
deliver	O
miR-34c	O
and	O
anti-miR10b	O
to	O
the	O
stem	B
cell	I
population.	O

Palmer	O
NP,	O
Schmid	O
PR,	O
Berger	O
B,	O
Kohane	O
IS	O
(2012)	O
A	O
gene	O
expression	O
profile	O
of	O
stem	B
cell	I
pluripotentiality	O
and	O
differentiation	O
is	O
conserved	O
across	O
diverse	O
solid	O
and	O
hematopoietic	O
cancers.	O

Paternal	O
age	O
and	O
telomere	O
length	O
in	O
twins:	O
the	O
germ	B
stem	I
cell	I
selection	O
paradigm.	O

The	O
development	O
of	O
stem	B
cell	I
differentiation	O
technology	O
has	O
led	O
to	O
the	O
efficient	O
differentiation	O
of	O
hPSCs	O
into	O
various	O
cell	O
types,	O
such	O
as	O
neurons7,	O
cardiomyocytes	O
(CMs)8,	O
hepatocytes9,	O
and	O
lung	O
airway	O
epithelial	O
cells10.	O

Furthermore,	O
advances	O
in	O
three-dimensional	O
(3D)	O
culture	O
systems	O
have	O
enabled	O
the	O
development	O
of	O
complex	O
organotypic	O
models	O
using	O
3D	O
organoids	O
that	O
differentiate	O
from	O
stem	B
cells	I
into	O
tissue-like	O
miniature	O
analogs	O
that	O
recapitulate	O
complex	O
tissue-specific	O
cell	O
compositions,	O
architectures,	O
and	O
functions11–13.	O

De	O
Novo	O
Mutation	O
in	O
Genes	O
Regulating	O
Neural	B
Stem	I
Cell	I
Fate	O
in	O
Human	O
Congenital	O
Hydrocephalus.	O

Cell	O
Junction	O
Pathology	O
of	O
Neural	O
Stem	O
Cells	B
Is	I
Associated	I
With	O
Ventricular	O
Zone	O
Disruption,	O
Hydrocephalus,	O
and	O
Abnormal	O
Neurogenesis.	O

Bailey	O
JMAlsina	O
Jet	O
al.DCLK1	O
marks	O
a	O
morphologically	O
distinct	O
subpopulation	O
of	O
cells	O
with	O
stem	B
cell	I
properties	O
in	O
preinvasive	O
pancreatic	O
cancer.	O

It	O
is	O
therefore	O
not	O
clear	O
which	O
BMPs	O
are	O
expressed	O
by	O
the	O
intestinal	O
organoid	O
cultures	O
and	O
which	O
need	O
to	O
be	O
inhibited	O
to	O
sustain	O
the	O
stem	B
cell	I
culture..	O

Since	O
inhibition	O
of	O
BMP5,6	O
is	O
not	O
required	O
for	O
intestinal	B
stem	I
cell	I
cultures,	O
future	O
in	O
vivo	O
application	O
of	O
C8,	O
would	O
prevent	O
detrimental	O
effects	O
of	O
Noggin	O
on	O
for	O
instance	O
bone	O
structures..	O

Introduction:	O
Intestinal	O
graft	O
versus	O
host	O
disease	O
(iGvHD)	O
is	O
a	O
common	O
complication	O
of	O
haematopoetic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
associated	O
with	O
significant	O
morbidity	O
and	O
mortality.	O

The	O
strategy	O
based	O
on	O
the	O
use	O
of	O
drugs	O
modifying	O
complement	O
system	O
(CS)	O
cascade	O
is	O
a	O
new	O
promising	O
therapeutic	O
option	O
allowing	O
for	O
control	O
of	O
stem	B
cell	I
mobilization	O
(1)	O
and	O
inflammatory	O
process	O
in	O
the	O
intestine	O
(2).	O

Although	O
the	O
stem	B
cell	I
mobilization	O
in	O
C3-/-mice	O
was	O
higher	O
than	O
in	O
WT	O
mice	O
no	O
significant	O
reduction	O
of	O
inflammation	O
in	O
the	O
large	O
intestine	O
was	O
observed	O
in	O
these	O
animals.	O

Conclusion:	O
We	O
have	O
determined	O
for	O
the	O
first	O
time	O
the	O
role	O
of	O
C2,	O
fB	O
and	O
C3	O
deficiency	O
in	O
stem	B
cell	I
mobilization	O
and	O
inflammatory	O
process	O
in	O
experimental	O
model	O
of	O
chronic	O
colitis.	O

C3	O
inhibitors	O
might	O
be	O
considered	O
as	O
a	O
part	O
of	O
complex	O
UC	O
therapy	O
due	O
to	O
beneficial	O
effect	O
on	O
stem	B
cell	I
mobilization,	O
but	O
shall	O
not	O
be	O
used	O
alone	O
because	O
the	O
lack	O
of	O
C3	O
has	O
no	O
effect	O
on	O
tissue	O
repair..	O

OSM	O
has	O
recently	O
been	O
identified	O
as	O
an	O
important	O
regulator	O
of	O
the	O
EMT/cancer	B
stem	I
cell	I
plasticity	O
program	O
that	O
promotes	O
tumorigenic	O
properties.(	O
29	O
)	O
Osm	O
was	O
significantly	O
increased	O
in	O
NEMO∆hepa/JNKΔhepa	O
livers..	O

New	O
tricks	O
for	O
an	O
old	O
dog:	O
Ribosome	O
biogenesis	O
contributes	O
to	O
stem	B
cell	I
homeostasis.	O

Targeting	O
miRNAs	O
involved	O
in	O
cancer	B
stem	I
cell	I
and	O
EMT	O
regulation:	O
an	O
emerging	O
concept	O
in	O
overcoming	O
drug	O
resistance.	O

Overexpressing	O
ALDH1A3	O
is	O
associated	O
with	O
cancer	B
stem	I
cell	I
characteristics	O
by	O
increasing	O
cancer	O
cell	O
proliferation.	O

Distinct	O
expression	O
levels	O
and	O
patterns	O
of	O
stem	B
cell	I
marker,	O
aldehyde	O
dehydrogenase	O
isoform	O
1	O
(ALDH1),	O
in	O
human	O
epithelial	O
cancers.	O

The	O
activity	O
of	O
PKM2	O
is	O
negatively	O
regulated	O
by	O
interaction	O
with	O
the	O
CD44	O
adhesion	O
molecule,	O
a	O
cell	O
surface	O
marker	O
for	O
cancer	B
stem	I
cells	I
[12].	O

Regenerative	O
dental	O
medicine	O
has	O
rapidly	O
progressed	O
since	O
the	O
advancement	O
of	O
stem	B
cell	I
biology	O
and	O
material	O
science.	O

These	O
include	O
the	O
hypermethylation	O
of	O
stem	B
cell	I
genes	O
(Rakyan	O
et	O
al.,	O
2010;	O
Teschendorff	O
et	O
al.,	O
2010),	O
a	O
general	O
linear	O
correlation	O
between	O
the	O
methylation	O
level	O
of	O
certain	O
CpGs	O
and	O
the	O
chronological	O
age	O
(Hannum	O
et	O
al.,	O
2013;	O
Horvath,	O
2013;	O
Weidner	O
et	O
al.,	O
2014),	O
and	O
the	O
hypermethylation	O
of	O
CpG	O
islands	O
(Yuan	O
et	O
al.,	O
2015).	O

Indeed,	O
the	O
spermatogonial	O
stem	O
cell	O
pool	O
is	O
maintained	O
through	O
a	O
high	O
rate	O
of	O
cell	O
division,	O
with	O
hence	O
a	O
higher	O
risk	O
of	O
errors	O
from	O
mitosis	O
as	O
the	O
individual	O
ages,	O
while	O
the	O
oogonial	O
stem	B
cell	I
pool	O
is	O
established	O
before	O
birth.	O

Human	B
embryonic	I
stem	I
cell	I
derived	O
hepatocyte-like	O
cells	O
as	O
a	O
tool	O
for	O
in	O
vitro	O
hazard	O
assessment	O
of	O
chemical	O
carcinogenicity.	O

The	O
researchers	O
are	O
particularly	O
interested	O
in	O
blood	B
stem	I
cell	I
colonization	O
because	O
understanding	O
this	O
key	O
but	O
poorly	O
understood	O
process	O
could	O
provide	O
insight	O
into	O
how	O
to	O
improve	O
the	O
success	O
rates	O
for	O
bone	O
marrow	O
transplants.	O

To	O
better	O
define	O
the	O
stem	B
cell	I
niche,	O
the	O
researchers	O
conducted	O
correlative	O
electron	O
microscopy	O
on	O
the	O
same	O
transgenic	O
zebrafish.	O

Surprisingly,	O
the	O
stem	B
cell	I
was	O
physically	O
attached	O
to	O
a	O
stromal	O
cell	O
(Figure	O
5).	O

They	O
also	O
saw	O
that	O
a	O
second	O
macrophage	O
is	O
responsible	O
for	O
escorting	O
the	O
stem	B
cell	I
to	O
the	O
stromal	O
cell..	O

To	O
understand	O
the	O
cellular	O
basis	O
for	O
the	O
increase	O
in	O
villus	O
height	O
and	O
crypt	O
depth	O
we	O
next	O
examined	O
the	O
expression	O
of	O
the	O
intestinal	B
stem	I
cell	I
and	O
transient	O
proliferating	O
cell	O
marker	O
Lgr5	O
in	O
preweaned	O
mouse	O
ileum.	O

Cross-linked	O
matrix	O
rigidity	O
and	O
soluble	O
retinoids	O
synergize	O
in	O
nuclear	O
lamina	O
regulation	O
of	O
stem	B
cell	I
differentiation.	O

In	O
terms	O
of	O
the	O
molecular	O
characteristics,	O
CSCs	O
exhibit	O
expression	O
patterns	O
of	O
genes	O
involved	O
in	O
the	O
regulation	O
of	O
stem	B
cell	I
self-renewal,	O
such	O
as	O
proto-oncogenes;	O
tumor	O
suppressors;	O
or	O
expression	O
of	O
signaling	O
pathway	O
components	O
involved	O
in	O
the	O
control	O
of	O
cell	O
cycle,	O
growth,	O
survival,	O
and	O
death	O
[261,262]..	O

Human	B
embryonic	I
stem	I
cell	I
derived	O
neurons	O
infected	O
with	O
shRNA	O
targeting	O
NUDT21	O
have	O
30%	O
less	O
CFIm25	O
protein..	O

The	O
skeletal	O
muscle	O
satellite	O
cell:	O
the	O
stem	B
cell	I
that	O
came	O
in	O
from	O
the	O
cold.	O

The	O
O-GlcNAc	O
transferase	O
gene	O
resides	O
on	O
the	O
X	O
chromosome	O
and	O
is	O
essential	O
for	O
embryonic	B
stem	I
cell	I
viability	O
and	O
mouse	O
ontogeny.	O

Similar	O
effects	O
had	O
already	O
been	O
reported	O
for	O
miR-23b	O
expression:	O
this	O
miRNA	O
is	O
associated	O
with	O
EXOs	O
released	O
from	O
bone	B
marrow	I
mesenchymal	I
stem	I
cells	I
and	O
promotes	O
dormancy	O
in	O
breast	O
cancer	O
cells	O
driving	O
them	O
to	O
enter	O
in	O
G0	O
phase,	O
confirming	O
that	O
exosomal	O
transfer	O
of	O
specific	O
miRNAs	O
can	O
deeply	O
affect	O
cancer	O
cell	O
dormancy	O
in	O
the	O
metastatic	O
niche	O
[95]..	O

Chicken	B
stem	I
cell	I
factor	O
enhances	O
primordial	O
germ	O
cell	O
proliferation	O
cooperatively	O
with	O
fibroblast	O
growth	O
factor	O
2.	O

Our	O
preliminary	O
study	O
found	O
that	O
there	O
is	O
a	O
binding	O
site	O
between	O
circHIPK2	O
and	O
miR-124	O
[20],	O
and	O
miR-124	O
was	O
reported	O
to	O
not	O
only	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
stem	B
cell	I
differentiation	O
but	O
also	O
to	O
promote	O
the	O
number	O
of	O
NSC-differentiated	O
neurons	O
[39,40].	O

The	O
fate,	O
homing	O
and	O
function	O
of	O
transplanted	O
NSCs	O
in	O
vivo	O
have	O
always	O
been	O
key	O
issues	O
in	O
stem	B
cell	I
therapy.	O

Neural	B
stem	I
cell	I
differentiation	O
into	O
mature	O
neurons:	O
mechanisms	O
of	O
regulation	O
and	O
biotechnological	O
applications.	O

Furthermore,	O
lncRNAs	O
play	O
a	O
key	O
role	O
in	O
stem	B
cell	I
differentiation,	O
immune	O
response,	O
epigenetic	O
regulation,	O
inflammation-related	O
diseases,	O
and	O
tumor	O
development	O
(Briggs	O
et	O
al.,	O
2015;	O
Huarte,	O
2015;	O
Boon	O
et	O
al.,	O
2016;	O
Chen	O
et	O
al.,	O
2017)..	O

iPSC	O
crowdsourcing:	O
a	O
model	O
for	O
obtaining	O
large	O
panels	O
of	O
stem	B
cell	I
lines	O
for	O
screening.	O

Stage-specific	O
optimization	O
of	O
activin/nodal	O
and	O
BMP	O
signaling	O
promotes	O
cardiac	O
differentiation	O
of	O
mouse	O
and	O
human	B
pluripotent	I
stem	I
cell	I
lines.	O

IPSC	O
crowdsourcing:	O
a	O
model	O
for	O
obtaining	O
large	O
panels	O
of	O
stem	B
cell	I
lines	O
for	O
screening.	O

Considering	O
the	O
fact	O
that	O
epigenetic	O
research	O
is	O
paving	O
the	O
way	O
for	O
many	O
new	O
breakthroughs	O
in	O
the	O
prevention,	O
diagnosis	O
and	O
treatment	O
of	O
human	O
diseases,	O
focused	O
efforts	O
on	O
the	O
detailed	O
mechanisms	O
linking	O
epigenetic	O
regulatory	O
mechanisms	O
to	O
adult	B
stem	I
cell	I
function	O
in	O
physiological/pathological	O
conditions	O
have	O
an	O
immense	O
potential	O
for	O
improving	O
human	O
health	O
and	O
welfare..	O

Chromatin	O
modifications	O
as	O
determinants	O
of	O
muscle	B
stem	I
cell	I
quiescence	O
and	O
chronological	O
aging.	O

Genome-wide	O
analysis	O
of	O
histone	O
H3	O
lysine9	O
modifications	O
in	O
human	B
mesenchymal	I
stem	I
cell	I
osteogenic	O
differentiation.	O

Control	O
of	O
embryonic	B
stem	I
cell	I
identity	O
by	O
BRD4-dependent	O
transcriptional	O
elongation	O
of	O
super-enhancer-associated	O
pluripotency	O
genes.	O

(2007)	O
demonstrated	O
that	O
Mll	O
was	O
not	O
important	O
for	O
the	O
production	O
of	O
mature	O
adult	O
hematopoietic	O
lineages,	O
but	O
it	O
was	O
required	O
for	O
stem	B
cell	I
self-renewal	O
in	O
fetal	O
liver	O
and	O
adult	O
bone	O
marrow.	O

In	O
a	O
murine	O
MLL-AF9	O
AML	O
cell	O
model,	O
shRNA	O
or	O
(+)-JQ1	O
treatments	O
induced	O
cell	O
differentiation	O
and	O
led	O
to	O
depletion	O
of	O
leukemia	B
stem	I
cells	I
and	O
a	O
global	O
reduction	O
in	O
the	O
expression	O
of	O
Myc	O
target	O
genes.	O

Depletion	O
of	O
ENL	O
results	O
in	O
down-regulation	O
of	O
key	O
leukemic	O
drivers	O
such	O
as	O
MYC,	O
cell	O
growth	O
inhibition,	O
reduced	O
expression	O
of	O
the	O
leukemia	B
stem	I
cell	I
signature,	O
and	O
terminal	O
differentiation	O
of	O
MLL-r	O
leukemia	O
cell	O
models	O
(Erb	O
et	O
al.,	O
2017;	O
Wan	O
et	O
al.,	O
2017).	O

(B)	O
Disturbances	O
in	O
Drosha/DGCR8	O
processing	O
(e.g.,	O
because	O
of	O
a	O
mutation	O
in	O
the	O
genes	O
encoding	O
these	O
enzymes)	O
may	O
reveal	O
alternate,	O
mRNA-like	O
functions	O
of	O
unprocessed	O
pri-miRNAs	O
and	O
result	O
in	O
disrupted	B
stem	I
cell	I
maturation..	O

DGCR8	O
is	O
essential	O
for	O
microRNA	O
biogenesis	O
and	O
silencing	O
of	O
embryonic	B
stem	I
cell	I
self-renewal.	O

Long	O
non-coding	O
RNA	O
TCONS_00041960	O
enhances	O
osteogenesis	O
and	O
inhibits	O
adipogenesis	O
of	O
rat	B
bone	I
marrow	I
mesenchymal	I
stem	I
cell	I
by	O
targeting	O
miR-204-5p	O
and	O
miR-125a-3p.	O

The	O
long	O
non-coding	O
RNA-ORLNC1	O
regulates	O
bone	O
mass	O
by	O
directing	O
Mesenchymal	B
stem	I
cell	I
fate.	O

Hyaluronan-CD44v3	O
interaction	O
with	O
Oct4-Sox2-Nanog	O
promotes	O
miR-302	O
expression	O
leading	O
to	O
self-renewal,	O
clonal	O
formation,	O
and	O
cisplatin	O
resistance	O
in	O
cancer	B
stem	I
cells	I
from	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma.	O

Some	O
features	O
of	O
the	O
aging	O
process	O
such	O
as	O
senescence,	O
inflammation,	O
and	O
the	O
loss	O
of	O
stem	B
cell	I
activity	O
are	O
provoked	O
by	O
mitochondria.	O

Epigenetic	O
reprogramming	O
via	O
GCN5	O
establishes	O
competency	O
for	O
shoot	O
regeneration	O
from	O
a	O
callus	O
by	O
promoting	O
the	O
expression	O
of	O
root	B
stem	I
cell	I
factors.	O

Mice	O
do	O
not	O
develop	O
the	O
symptoms	O
characteristic	O
of	O
HUS,	O
and	O
the	O
murine	O
intestinal	O
tract	O
is	O
resistant	O
to	O
Stx.18	O
Advances	O
in	O
stem	B
cell	I
biology	O
have	O
allowed	O
for	O
generation	O
of	O
genetically	O
normal,	O
differentiated	O
human	O
intestinal	O
tissues.	O

Patient-derived	O
iPS	O
cells	O
were	O
then	O
transfected	O
using	O
the	O
human	B
stem	I
cell	I
Nucleofector	O
Kit	O
1	O
(Lonza,	O
Rockville,	O
MD)	O
to	O
deliver	O
20	O
μg	O
of	O
the	O
SD/pSpCas9(BB)-2A-Puro	O
plasmid	O
and	O
100	O
pmol	O
of	O
the	O
repair	O
oligodeoxynucleotide.	O

Apelin	O
receptor	O
early	O
endogenous	O
ligand	O
(ELABELA;	O
also	O
known	O
as	O
ELA,	O
official	O
name	O
is	O
APELA)	O
is	O
a	O
circulating	O
peptide	O
hormone	O
that	O
binds	O
to	O
the	O
G-protein–coupled	O
apelin	O
receptor	O
(APLNR).9	O
It	O
has	O
roles	O
in	O
embryonic	B
stem	I
cell	I
renewal	O
in	O
mice9	O
and	O
cardiac	O
formation	O
in	O
zebrafish,10	O
but	O
in	O
adult	O
humans	O
its	O
expression	O
is	O
restricted	O
to	O
the	O
kidneys	O
and	O
the	O
placenta..	O

Mesenchymal	B
stem	I
cell	I
transplantation	O
attenuates	O
blood	O
brain	O
barrier	O
damage	O
and	O
neuroinflammation	O
and	O
protects	O
dopaminergic	O
neurons	O
against	O
MPTP	O
toxicity	O
in	O
the	O
substantia	O
nigra	O
in	O
a	O
model	O
of	O
Parkinson's	O
disease.	O

However,	O
recent	O
findings	O
have	O
shown	O
that	O
combining	O
pre-conditioning	O
with	O
stem	B
cell	I
therapy	O
provides	O
the	O
opportunity	O
of	O
clinical	O
applications	O
of	O
hypoxic	O
pre-conditioning.	O

Therefore,	O
the	O
combination	O
of	O
pre-conditioning	O
in	O
stem	O
cells	O
will	O
definitely	O
attract	O
more	O
attention	O
in	O
stem	B
cell	I
and	O
regenerative	O
translational	O
research,	O
which	O
will	O
broaden	O
the	O
possibility	O
for	O
clinical	O
applications	O
(Hu	O
et	O
al.,	O
2008;	O
Theus	O
et	O
al.,	O
2008;	O
Ogle	O
et	O
al.,	O
2009;	O
Yu	O
et	O
al.,	O
2013)..	O

Current	O
understanding	O
of	O
stem	B
cell	I
mobilization:	O
the	O
roles	O
of	O
chemokines,	O
proteolytic	O
enzymes,	O
adhesion	O
molecules,	O
cytokines,	O
and	O
stromal	O
cells.	O

Primed	O
for	O
lethal	O
battle:	O
a	O
step	O
forward	O
to	O
enhance	O
the	O
efficacy	O
and	O
efficiency	O
of	O
stem	B
cell	I
transplantation	O
therapy.	O

In	O
vitro	O
hypoxic	O
preconditioning	O
of	O
embryonic	B
stem	I
cells	I
as	O
a	O
strategy	O
of	O
promoting	O
cell	O
survival	O
and	O
functional	O
benefits	O
after	O
transplantation	O
into	O
the	O
ischemic	O
rat	O
brain.	O

Moreover,	O
it	O
has	O
been	O
observed	O
that,	O
in	O
addition	O
to	O
changes	O
in	O
stem	B
cell	I
numbers,	O
bipotential	O
erythroid-megakaryocyte	O
progenitor	O
populations	O
are	O
also	O
perturbed	O
in	O
human	O
DS	O
[15].	O

Lessons	O
learned	O
from	O
the	O
development	O
of	O
RNA-interference	O
(RNA-i)	O
therapies	O
can	O
spur	O
the	O
translation	O
of	O
genome	O
editing,	O
such	O
as	O
those	O
enabling	O
the	O
translation	O
of	O
human	B
pluripotent	I
stem	I
cell	I
engineering.	O

In	O
the	O
arena	O
of	O
inter-specific	O
chimeras,	O
a	O
team,	O
led	O
by	O
Izpisua	O
Belmonte	O
of	O
Salk	O
Institute	O
for	O
Biological	O
Studies,	O
began	O
by	O
combining	O
genome	O
editing	O
with	O
stem	B
cell	I
biology,	O
two	O
revolutionary	O
platform	O
technologies	O
117,	O
and	O
using	O
the	O
pig	O
as	O
an	O
“animal	O
incubator”.	O

One	O
of	O
the	O
earliest	O
examples	O
of	O
CRISPR	O
applications	O
in	O
stem	O
cell	O
research	O
was	O
in	O
the	O
functional	O
repair	O
of	O
cystic	O
fibrosis	O
transmembrane	O
conductor	O
receptor	O
(CFTR)	O
in	B
intestinal	I
stem	I
cell	I
organoids	O
of	O
cystic	O
fibrosis	O
patients	O
153,	O
affording	O
a	O
proof-of-concept	O
for	O
genome	O
editing	O
by	O
HDR	O
in	O
patients	O
with	O
a	O
single-gene	O
hereditary	O
defect	O
153,	O
followed	O
by	O
many	O
other	O
studies	O
involving	O
blood	O
and	O
neuromuscular	O
disorders,	O
as	O
summarized	O
in	O
a	O
recent	O
review	O
154.	O

In	O
vivo	O
dynamics	O
of	O
human	B
stem	I
cell	I
repopulation	O
in	O
NOD/SCID	O
mice.	O

Harnessing	O
the	O
mesenchymal	B
stem	I
cell	I
secretome	O
for	O
the	O
treatment	O
of	O
cardiovascular	O
disease.	O

Mesenchymal	B
stem	I
cells	I
generate	O
a	O
CD4+CD25+Foxp3+	O
regulatory	O
T	O
cell	O
population	O
during	O
the	O
differentiation	O
process	O
of	O
Th1	O
and	O
Th17	O
cells.	O

Mesenchymal	B
stem	I
cells	I
inhibit	O
dendritic	O
cell	O
differentiation	O
and	O
function	O
by	O
preventing	O
entry	O
into	O
the	O
cell	O
cycle.	O

Rationale	O
and	O
prospects	O
of	O
mesenchymal	B
stem	I
cell	I
therapy	O
for	O
liver	O
transplantation.	O

Mesenchymal	B
stem	I
cells	I
inhibit	O
human	O
Th17	O
cell	O
differentiation	O
and	O
function	O
and	O
induce	O
a	O
T	O
regulatory	O
cell	O
phenotype.	O

Mesenchymal	B
stem	I
cell	I
1	O
(MSC1)-based	O
therapy	O
attenuates	O
tumor	O
growth	O
whereas	O
MSC2-treatment	O
promotes	O
tumor	O
growth	O
and	O
metastasis.	O

Toll-like	O
receptors	O
as	O
a	O
key	O
regulator	O
of	O
mesenchymal	B
stem	I
cell	I
function:	O
an	O
up-to-date	O
review.	O

Direct	O
evidence	O
of	O
mesenchymal	B
stem	I
cell	I
tropism	O
for	O
tumor	O
and	O
wounding	O
microenvironments	O
using	O
in	O
vivo	O
bioluminescent	O
imaging.	O

Bone	O
marrow-derived	O
myofibroblasts	O
contribute	O
to	O
the	O
mesenchymal	B
stem	I
cell	I
niche	O
and	O
promote	O
tumor	O
growth.	O

Complete	O
regression	O
of	O
metastatic	O
renal	O
cell	O
carcinoma	O
by	O
multiple	O
injections	O
of	O
engineered	B
mesenchymal	I
stem	I
cells	I
expressing	O
dodecameric	O
TRAIL	O
and	O
HSV-TK.	O

Valproic	O
acid	O
enhances	O
anti-tumor	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
mediated	O
HSV-TK	O
gene	O
therapy	O
in	O
intracranial	O
glioma.	O

Novel	O
humanized	O
and	O
highly	O
efficient	O
bispecific	O
antibodies	O
mediate	O
killing	O
of	O
prostate	B
stem	I
cell	I
antigen-expressing	O
tumor	O
cells	O
by	O
CD8+	O
and	O
CD4+	O
T	O
cells.	O

ATP	O
stimulates	O
mouse	B
embryonic	I
stem	I
cell	I
proliferation	O
via	O
protein	O
kinase	O
C,	O
phosphatidylinositol	O
3-kinase/Akt,	O
and	O
mitogen-activated	O
protein	O
kinase	O
signaling	O
pathwats.	O

Thus,	O
combining	O
the	O
best	O
attributes	O
of	O
stem	B
cell	I
assays	O
and	O
Organs-on-Chips	O
technologies	O
might	O
enable	O
the	O
design	O
of	O
a	O
more	O
powerful	O
in	O
vitro	O
model	O
of	O
the	O
human	O
lung..	O

Beers	O
and	O
Moodley,	O
along	O
with	O
other	O
leading	O
experts	O
and	O
pioneers	O
in	O
the	O
lung	O
field,	O
reviewed	O
this	O
concern	O
and	O
proposed	O
a	O
set	O
of	O
standards	O
specific	O
to	O
alveolar	O
cell	O
generation	O
in	O
order	O
to	O
bridge	O
lung	O
biology	O
with	O
stem	B
cell	I
development	O
[162].	O

Once	O
such	O
benefits	O
are	O
clearly	O
established,	O
combining	O
Organs-on-Chips	O
with	O
human	B
stem	I
cells	I
in	O
which	O
all	O
cell	O
types	O
come	O
from	O
the	O
same	O
donor	O
would	O
offer	O
the	O
opportunity	O
to	O
test	O
compounds	O
that	O
correct	O
patient	O
specific	O
phenotypes	O
associated	O
with	O
defined	O
genotypes	O
or	O
genes	O
mutations,	O
thus	O
creating	O
predictive	O
platforms	O
for	O
the	O
field	O
of	O
personalized	O
medicine	O
that	O
offer	O
complementary	O
advantages	O
to	O
models	O
based	O
on	O
animals	O
and	O
immortalized	O
or	O
primary	O
cells	O
[13].	O

☆This	O
review	O
is	O
part	O
of	O
the	O
Advanced	O
Drug	O
Delivery	O
Reviews	O
theme	O
issue	O
on	O
“Human	B
stem	I
cell	I
based	O
organ-on-a-chip	O
models	O
for	O
drug	O
discovery	O
and	O
development”..	O

Lung	B
stem	I
cell	I
differentiation	O
in	O
mice	O
directed	O
by	O
endothelial	O
cells	O
via	O
a	O
BMP4-NFATc1-thrombospondin-1	O
axis.	O

A	O
bioengineered	O
niche	O
promotes	O
in	O
vivo	O
engraftment	O
and	O
maturation	O
of	O
pluripotent	B
stem	I
cell	I
derived	O
human	O
lung	O
organoids.	O

When	O
is	O
an	O
alveolar	O
type	O
2	O
cell	O
an	O
alveolar	O
type	O
2	O
cell?	O
A	O
conundrum	O
for	O
lung	B
stem	I
cell	I
biology	O
and	O
regenerative	O
medicine.	O

A	O
novel	O
class	O
of	O
evolutionarily	O
conserved	O
genes	O
defined	O
by	O
piwi	O
are	O
essential	O
for	O
stem	B
cell	I
self-renewal.	O

Separation	O
of	O
stem	B
cell	I
maintenance	O
and	O
transposon	O
silencing	O
functions	O
of	O
Piwi	O
protein.	O

MyoD	O
is	O
required	O
for	O
myogenic	B
stem	I
cell	I
function	O
in	O
adult	O
skeletal	O
muscle.	O

Mesenchymal	B
Stem	I
Cell	I
Secretome:	O
Toward	O
Cell-Free	O
Therapeutic	O
Strategies	O
in	O
Regenerative	O
Medicine.	O

Human	O
Mesenchymal	B
Stem	I
Cell	I
Microvesicles	O
for	O
Treatment	O
of	O
Escherichia	O
Coli	O
Endotoxin-Induced	O
Acute	O
Lung	O
Injury	O
in	O
Mice.	O

Mesenchymal	O
Stem	O
Cell-Conditioned	O
Media:	O
A	O
Novel	O
Alternative	O
of	O
Stem	O
Cell	O
Therapy	O
for	O
Quality	O
Wound	O
Healing.	O
Stem	O
Cell	O
Conditioned	O
Medium	O
Improves	O
Acute	O
Lung	O
Injury	O
in	O
Mice:	O
In	O
Vivo	O
Evidence	O
for	O
Stem	B
Cell	I
Paracrine	O
Action.	O

Long-Term	O
Evaluation	O
of	O
Mesenchymal	B
Stem	I
Cell	I
Therapy	O
in	O
a	O
Feline	O
Model	O
of	O
Chronic	O
Allergic	O
Asthma.	O

Nebulized	O
Mesenchymal	B
Stem	I
Cell	I
Derived	O
Conditioned	O
Medium	O
Retains	O
Antibacterial	O
Properties	O
against	O
Clinical	O
Pathogen	O
Isolates.	O

Mesenchymal	B
Stem	I
Cell	I
Exosome	O
Delivered	O
Zinc	O
Finger	O
Protein	O
Activation	O
of	O
Cystic	O
Fibrosis	O
Transmembrane	O
Conductance	O
Regulator.	O

Mesenchymal	B
Stem	I
Cells	I
Promote	O
Alveolar	O
Epithelial	O
Cell	O
Wound	O
Repair	O
in	O
Vitro	O
through	O
Distinct	O
Migratory	O
and	O
Paracrine	O
Mechanisms.	O

Plzf	O
is	O
required	O
in	O
adult	O
male	O
germ	O
cells	O
for	O
stem	B
cell	I
self-renewal.	O

Compared	O
with	O
traditional	O
2D	O
adherent	O
cell	O
culture,	O
3D	O
spheroidal	O
cell	O
aggregates,	O
or	O
spheroids,	O
are	O
regarded	O
as	O
more	O
physiological,	O
and	O
this	O
technique	O
has	O
been	O
exploited	O
in	O
the	O
field	O
of	O
oncology,	O
stem	B
cell	I
biology,	O
and	O
tissue	O
engineering.	O

Interplay	O
of	O
matrix	O
stiffness	O
and	O
protein	O
tethering	O
in	O
stem	B
cell	I
differentiation.	O

Mesenchymal	B
stem	I
cell	I
therapy	O
for	O
attenuation	O
of	O
scar	O
formation	O
during	O
wound	O
healing.	O

Cell	O
type-specific	O
loops	O
show	O
different	O
patterns	O
of	O
chromatin	O
states,	O
with	O
stem	B
cell	I
loops	O
being	O
depleted	O
of	O
active	O
promoter	O
states	O
and	O
transcription,	O
and	O
enriched	O
in	O
bivalent	O
states.	O

The	O
two	O
strongest	O
were	O
the	O
HSPC	O
migration	O
receptor	O
CXCR4	O
and	O
a	O
novel	O
protein	O
phosphatase	O
never	O
previously	O
implicated	O
in	O
stem	B
cell	I
biology.	O

Conclusions:	O
We	O
report	O
the	O
first	O
large-scale	O
analysis	O
of	O
the	O
genetic	O
architecture	O
of	O
HSPC	O
regulation,	O
with	O
potential	O
implications	O
for	O
stem	B
cell	I
transplantation	O
and	O
the	O
treatment	O
of	O
hematologic	O
malignancies..	O

BaSiC	O
software	O
allows	O
detection	O
of	O
transcription	O
factors	O
as	O
the	O
stem	B
cell	I
undergoes	O
differentiation..	O

However,	O
BaSiC	O
has	O
an	O
inbuilt	O
background	O
alteration	O
correction	O
algorithm,	O
which	O
is	O
an	O
exceptional	O
tool	O
for	O
the	O
study	O
of	O
early-onset	O
transcriptional	O
factors	O
and	O
is	O
especially	O
useful	O
in	O
stem	B
cell	I
studies.	O

A	O
high-throughput	O
platform	O
for	O
stem	B
cell	I
niche	O
co-cultures	O
and	O
downstream	O
gene	O
expression	O
analysis.	O

Likewise,	O
the	O
VEGF-A/NRP1	O
axis	O
was	O
suggested	O
to	O
confer	B
cancer	I
stem	I
cell	I
traits	O
in	O
breast	O
cancer	O
cells	O
(i.e.,	O
MCF-7,	O
MDA-MB-231)	O
by	O
activating	O
the	O
Wnt/β-catenin	O
pathway	O
[85].	O

Epigenetic	O
Regulation	O
of	O
Inflammatory	O
Cytokine-Induced	O
Epithelial-To-Mesenchymal	O
Cell	O
Transition	O
and	O
Cancer	B
Stem	I
Cell	I
Generation.	O

Pioneer	O
factors	O
govern	O
super-enhancer	O
dynamics	O
in	O
stem	B
cell	I
plasticity	O
and	O
lineage	O
choice.	O

To	O
analyze	O
the	O
intestinal	O
differentiation	O
of	O
iPSCs	O
after	O
small	O
molecule	O
treatment,	O
the	O
authors	O
considered	O
mRNA	O
expression	O
of	O
sucrase-isomaltase	O
and	O
CYP3A4,	O
which	O
were	O
both	O
markedly	O
increased,	O
while	O
those	O
of	O
intestinal	B
stem	I
cell	I
markers	O
decreased.	O

Application	O
of	O
stem	B
cell	I
derived	O
neuronal	O
cells	O
to	O
evaluate	O
neurotoxic	O
chemotherapy.	O

Several	O
studies	O
have	O
demonstrated	O
a	O
correlation	O
of	O
Wnt/beta-catenin	O
signaling	O
levels	O
with	O
embryonic	B
stem	I
cell	I
differentiation,	O
anterior	O
specification	O
during	O
mouse	O
embryogenesis,	O
adult	O
hepatic	O
homeostasis,	O
phenotypic	O
severity	O
of	O
intestinal	O
tumorigenesis,	O
and	O
lineage	O
determination	O
during	O
hematopoiesis	O
[30],	O
[31],	O
[32],	O
[33],	O
[34],	O
[35],	O
[36],	O
[37],	O
[42],	O
[43].	O

We	O
next	O
analyzed	O
the	O
effect	O
of	O
ChABC	O
treatment	O
on	O
ES	O
cell	O
morphology	O
and	O
expression	O
of	O
stem	B
cell	I
markers	O
(Figure	O
2).	O

Mechanistically,	O
CS	O
functioned	O
through	O
negative	O
regulation	O
of	O
the	O
Wnt/beta-catenin	O
signaling	O
cascade,	O
in	O
itself	O
a	O
known	O
biphasic	O
regulator	O
of	O
cardiac	B
stem	I
cell	I
differentiation	O
(Figure	O
9).	O

These	O
changes	O
represent	O
novel	O
insights	O
into	O
the	O
ageing	O
process,	O
with	O
implications	O
for	O
stem	B
cell	I
therapies	O
in	O
older	O
patients.	O

The	O
changes	O
identified	O
represented	O
novel	O
insights	O
into	O
the	O
ageing	O
process,	O
with	O
implications	O
for	O
stem	B
cell	I
therapies	O
in	O
older	O
patients..	O

Another	O
study	O
showed	O
the	O
possibility	O
of	O
spermatogonial	B
stem	I
cell	I
transplantation	O
in	O
a	O
non-human	O
primate	O
infertility	O
model[144].	O

Involvement	O
of	O
pluripotent	B
stem	I
cells	I
in	O
the	O
reproductive	O
cell	O
cycle	O
through	O
reprogramming,	O
differentiation	O
and	O
development..	O

Human	O
relevance	O
of	O
pre-clinical	O
studies	O
in	O
stem	B
cell	I
therapy:	O
systematic	O
review	O
and	O
meta-analysis	O
of	O
large	O
animal	O
models	O
of	O
ischaemic	O
heart	O
disease.	O

The	O
elevated	O
O-GlcNAcylation	O
in	O
progenitor	O
cells	O
of	O
these	O
mice	O
were	O
correlated	O
with	O
transcriptional	O
changes	O
in	O
factors	O
involved	O
in	O
adult	B
stem	I
cell	I
maintenance,	O
lineage	O
specification	O
and	O
nutrient	O
uptake	O
(Abramowitz	O
et	O
al.,	O
2019)..	O

We	O
have	O
also	O
examined	O
the	O
role	O
of	O
O-GlcNAc	O
cycling	O
in	O
stem	B
cell	I
differentiation	O
and	O
the	O
regulation	O
of	O
DNA	O
damage	O
response	O
signaling.	O

The	O
O-GlcNAc	O
transferase	O
gene	O
resides	O
on	O
the	O
X	O
chromosome	O
and	O
is	O
essential	O
for	O
embryonic	B
stem	I
cell	I
viability	O
and	O
mouse	O
ontogeny.	O

MyoD	O
is	O
required	O
for	O
myogenic	B
stem	I
cell	I
function	O
in	O
adult	O
skeletal	O
muscle.	O

H2A.Z	O
facilitates	O
access	O
of	O
active	O
and	O
repressive	O
complexes	O
to	O
chromatin	O
in	O
embryonic	B
stem	I
cell	I
self-renewal	O
and	O
differentiation.	O

Lysine	O
4	O
of	O
histone	O
H3.3	O
is	O
required	O
for	O
embryonic	B
stem	I
cell	I
differentiation,	O
histone	O
enrichment	O
at	O
regulatory	O
regions	O
and	O
transcription	O
accuracy.	O

Common	O
pitfalls	O
of	O
stem	B
cell	I
differentiation:	O
a	O
guide	O
to	O
improving	O
protocols	O
for	O
neurodegenerative	O
disease	O
models	O
and	O
research.	O

Many	O
studies	O
done	O
in	O
the	O
field	O
of	O
the	O
stem	B
cell	I
transplantation	O
have	O
indicated	O
the	O
relationships	O
between	O
SNPs	O
and	O
HSCT-related	O
complications,	O
including	O
GVHD	O
and	O
early	O
death	O
[33,	O
34].	O

Recent	O
advances	O
in	O
stem	O
cell	O
research	O
provide	O
the	O
possibility	O
of	O
combining	O
gene	O
therapy	O
with	O
ex	O
vivo	O
gene	O
transfer	O
into	O
stem	B
cells	I
for	O
angiogenesis	O
therapy,	O
as	O
will	O
be	O
discussed	O
later.	O

Haematopoiesis	O
or	O
blood	O
development	O
has	O
long	O
served	O
as	O
a	O
model	O
system	O
for	O
adult	B
stem	I
cell	I
biology.	O

A	O
bias	O
towards	O
genes	O
involved	O
in	O
development	O
has	O
been	O
seen	O
in	O
cross-sectional	O
[13,20,54,55]	O
and	O
longitudinal	O
[25,27]	O
studies	O
of	O
human	O
aging	O
and	O
in	O
a	O
study	O
of	O
embryonic	B
stem	I
cell	I
differentiation	O
[53]..	O

The	O
current	O
focus	O
on	O
stem	B
cell	I
therapy	O
and	O
regenerative	O
medicine	O
has	O
put	O
an	O
emphasis	O
on	O
the	O
protective	O
functions	O
of	O
some	O
cytokines.	O

A	O
PCR-based	O
technique	O
has	O
recently	O
been	O
adopted	O
in	O
some	O
jurisdictions	O
to	O
screen	O
newborn	O
infants	O
for	O
severe	O
combined	O
immunodeficiency	O
disease	O
[75],	O
a	O
group	O
of	O
genetic	O
disorders	O
causing	O
recurrent	O
and	O
eventually	O
lethal	O
infections	O
that	O
can	O
be	O
effectively	O
treated	O
by	O
early	B
stem	I
cell	I
transplantation.	O

Epigenetic	O
Regulation	O
of	O
Inflammatory	O
Cytokine-Induced	O
Epithelial-To-Mesenchymal	O
Cell	O
Transition	O
and	O
Cancer	B
Stem	I
Cell	I
Generation.	O

Epigenetic	O
Regulation	O
of	O
Inflammatory	O
Cytokine-Induced	O
Epithelial-To-Mesenchymal	O
Cell	O
Transition	O
and	O
Cancer	B
Stem	I
Cell	I
Generation.	O

Regulation	O
of	O
Epithelial-To-Mesenchymal	O
Cell	O
Transition	O
(EMT)	O
in	O
Cancer,	O
and	O
Its	B
Involvement	I
in	I
the	O
Generation	O
of	O
Cancer	O
Stem	O
Cells	O
(CSCs).	O

Activation	O
of	O
an	O
il6	O
inflammatory	O
loop	O
mediates	O
trastuzumab	O
resistance	O
in	O
her2+	O
breast	O
cancer	O
by	O
expanding	O
the	O
cancer	B
stem	I
cell	I
population.	O

Normal	O
bone	O
healing	O
involves	O
recruitment	O
and	O
proliferation	O
of	O
stem	B
cell	I
populations	O
at	O
the	O
injury	O
site,	O
chondrogenic	O
commitment	O
and	O
cartilage	O
differentiation,	O
formation	O
of	O
woven	O
bone	O
and	O
osteoclast-mediated	O
remodeling	O
of	O
the	O
callus	O
[11],	O
[12]	O
[11],	O
[12].	O

In	O
prostate	O
cancer,	O
tumor	O
suppressor	O
SPOP	O
interacts	O
with	O
Nanog	O
and	O
promotes	O
Nanog	O
poly-ubiquitination	O
and	O
subsequent	O
degradation,	O
but	O
Pin1	O
functions	O
as	O
an	O
upstream	O
Nanog	O
regulator	O
and	O
impairs	O
its	O
recognition	O
by	O
SPOP,	O
stabilizing	O
Nanog	O
to	O
promote	O
the	O
cancer	B
stem	I
cell	I
traits	O
and	O
tumor	O
progression	O
(Zhang	O
et	O
al.,	O
2019).	O

Lately,	O
there	O
has	O
been	O
considerable	O
enthusiasm	O
for	O
application	O
of	O
stem	B
cell	I
biology	O
for	O
both	O
disease	O
modeling	O
and	O
therapeutic	O
application.	O

Use	O
of	O
stem	B
cells	I
for	O
retinal	O
repair	O
offers	O
enormous	O
promise	O
for	O
generation	O
of	O
adequate	O
and	O
appropriate	O
cell	O
populations	O
for	O
transplantation.	O

This	O
open-label	O
Phase	O
I/II	O
trial	O
seeks	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
this	O
procedure	O
and	O
represents	O
one	O
of	O
the	O
first	O
clinical	O
trials	O
involving	O
the	O
use	O
of	O
stem	B
cell	I
transplant	O
in	O
treatment	O
of	O
macular	O
dystrophy	O
and	O
related	O
retinopathies	O
[134]..	O

Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

FACS	O
analysis	O
of	O
the	O
mutant	O
glands	O
revealed	O
an	O
increased	O
proportion	O
of	O
mammary	O
basal	O
cells	O
with	O
stem	B
cell	I
activity,	O
a	O
diminished	O
subset	O
of	O
ERα + luminal	O
cells	O
and	O
an	O
aberrant	O
commitment	O
of	O
luminal	O
cells	O
towards	O
a	O
mixed	O
basal/luminal	O
phenotype.	O

(b)	O
Isolated	O
YFP+	O
and	O
YFP−	O
MSCs	O
(SCA1+ENG+)	O
in	O
mesenchymal	B
stem	I
cell	I
media	O
10	O
days	O
post	O
plating,	O
green	O
is	O
native	O
YFP	O
signal.	O

Signaling	O
in	O
the	O
stem	B
cell	I
niche:	O
Regulating	O
cell	O
fate,	O
function	O
and	O
plasticity.	O

Zc3h13	O
regulates	O
nuclear	O
RNA	O
m(6)A	O
methylation	O
and	O
mouse	B
embryonic	I
stem	I
cell	I
self-renewal.	O

Because	O
the	O
studies	O
with	O
human	B
stem	I
cells	I
were	O
largely	O
conducted	O
in	O
vitro,	O
we	O
herein	O
sought	O
to	O
examine	O
whether	O
chronic	O
in	O
vivo	O
BPA	O
exposures	O
could	O
likewise	O
reprogram	O
the	O
stem	O
and	O
progenitor	O
cell	O
populations	O
in	O
the	O
rat	O
DLP..	O

A:	O
Experimental	O
design	O
for	O
stem	B
cell	I
assessment	O
in	O
6	O
mo	O
old	O
rat	O
dorsolateral	O
prostates	O
(DLP)	O
following	O
daily	O
gavage	O
with	O
vehicle	O
(Veh),	O
ethinyl	O
estradiol	O
(EE)	O
or	O
2.5,	O
25,	O
or.	O

We	O
therefore	O
applied	O
this	O
assay	O
in	O
the	O
current	O
study	O
and	O
directly	O
tested	O
whether	O
exposure	O
to	O
BPA	O
could	O
alter	O
the	O
stem	B
cell	I
number	O
within	O
human	O
PS.	O

Immunohistochemistry	O
for	O
BrdU	O
identifies	O
the	O
stem	B
cell	I
within	O
spheroids	O
which	O
is	O
quantified/PS.	O

This	O
increase	O
is	O
highly	O
relevant	O
because	O
cancer	O
risk	O
has	O
been	O
proposed	O
to	O
be	O
strongly	O
correlated	O
with	O
the	O
number	O
of	O
normal	B
stem	I
cell	I
divisions	O
across	O
multiple	O
tissues,	O
including	O
the	O
prostate	O
(Tomasetti	O
and	O
Vogelstein	O
2015;	O
Tomasetti	O
et	O
al.	O

dose	O
is	O
the	O
same	O
dose	O
that	O
led	O
to	O
significantly	O
greater	O
tumor	O
multiplicity	O
in	O
DLP	O
ducts,	O
the	O
present	O
findings	O
suggest	O
that	O
BPA	O
reprogramming	O
of	O
stem	B
cell	I
numbers	O
might	O
contribute	O
to	O
increased	O
susceptibility	O
to.	O

Variation	O
in	O
cancer	O
risk	O
among	O
tissues	O
can	O
be	O
explained	O
by	O
the	O
number	O
of	O
stem	B
cell	I
divisions.	O

Work	O
done	O
in	O
whole	O
chorion	O
tissues	O
indicates	O
a	O
downregulation	O
of	O
telomerase	O
activity	O
over	O
the	O
gestation,	O
also	O
supporting	O
the	O
idea	O
of	O
a	O
decline	O
of	O
primitive	B
stem	I
cell	I
features	O
with	O
aging	O
[70].	O

Functional	O
expression	O
of	O
HGF	O
and	O
HGF	O
receptor/c-met	O
in	O
adult	B
human	I
mesenchymal	I
stem	I
cells	I
suggests	O
a	O
role	O
in	O
cell	O
mobilization,	O
tissue	O
repair,	O
and	O
wound	O
healing.	O

The	O
dual	O
capacity	O
of	O
self-renewal	O
and	O
multipotent	O
differentiation	O
that	O
is	O
unique	O
to	O
stem	B
cells	I
has	O
opened	O
new	O
vistas	O
for	O
cell	O
therapy	O
and	O
regenerative	O
medicine	O
with	O
great	O
therapeutic	O
promise	O
(Ito	O
and	O
Suda,	O
2014).	O

However,	O
the	O
rate	O
of	O
self-renewal	O
declines	O
with	O
age,	O
resulting	O
in	O
stem	B
cell	I
exhaustion.	O

Bottom	O
half	O
shows	O
the	O
effect	O
of	O
altered	O
mitochondrial	O
ETC	O
complex	O
I	O
activity	O
on	O
stem	B
cell	I
differentiation..	O

Elucidating	O
mechanisms	O
that	O
regulate	O
metabolic	O
plasticity	O
of	O
stem	O
cells	O
is	O
a	O
key	O
outstanding	O
problem	O
in	O
stem	B
cell	I
biology.	O

While	O
several	O
regulators	O
of	O
energy	O
metabolism	O
are	O
known,	O
their	O
role	O
in	O
the	O
regulation	O
of	O
stem	B
cell	I
differentiation	O
is	O
not	O
well	O
investigated.	O

Therefore,	O
delineating	O
mechanisms	O
that	O
regulate	O
the	O
energy	O
metabolic	O
machinery	O
is	O
important	O
for	O
enabling	O
control	O
of	O
stem	B
cell	I
state,	O
fate,	O
and	O
reprogramming..	O

There	O
is	O
limited	O
understanding	O
of	O
metabolic	O
states	O
in	O
which	O
different	O
types	O
of	O
stem	O
and	O
precursor	O
cells	O
may	O
exist,	O
and	O
the	O
cell	O
intrinsic	O
and	O
extrinsic	O
factors	O
that	O
influence	O
them.	O
Our	O
results	O
suggest	O
that	O
normal	O
OCIAD1	O
levels	O
allow	O
metabolic	O
realignment	O
in	O
stem	B
cell	I
differentiation.	O

Identification	O
of	O
specific	O
small-molecule	O
modulators	O
of	O
OCIAD1	O
level	O
and/or	O
activity	O
should	O
help	O
directed,	O
transient,	O
and	O
reversible	O
changes	O
to	O
the	O
metabolic	O
state	O
to	O
achieve	O
the	O
desired	B
stem	I
cell	I
expansion	O
in	O
a	O
scalable	O
and	O
cost-effective	O
manner..	O

Asrij	O
maintains	O
the	O
stem	B
cell	I
niche	O
and	O
controls	O
differentiation	O
during	O
Drosophila	O
lymph	O
gland	O
hematopoiesis.	O

Enhancement	O
of	O
human	B
embryonic	I
stem	I
cell	I
pluripotency	O
through	O
inhibition	O
of	O
the	O
mitochondrial	O
respiratory	O
chain.	O

miR-34	O
cooperates	O
with	O
p53	O
in	O
suppression	O
of	O
prostate	O
cancer	O
by	O
joint	O
regulation	O
of	O
stem	B
cell	I
compartment.	O

The	O
cohorts	O
of	O
mice	O
used	O
in	O
this	O
analysis	O
were	O
comprised	O
of	O
humanized	O
mice	O
generated	O
from	O
multiple	B
stem	I
cell	I
donors	O
in	O
an	O
effort	O
to	O
diminish	O
any	O
donor	O
bias	O
and	O
thus	O
ensure	O
that	O
representative	O
immune	O
responses	O
would	O
be	O
observed.	O

(2010)	O
Generating	O
hepatic	O
cell	O
lineages	O
from	O
pluripotent	B
stem	I
cells	I
for	O
drug	O
toxicity	O
screening.	O

Chamberlain	O
SJ,	O
Yee	O
D,	O
Magnuson	O
T	O
(2008)	O
Polycomb	O
repressive	O
complex	O
2	O
is	O
dispensable	O
for	O
maintenance	O
of	O
embryonic	B
stem	I
cell	I
pluripotency.	O

Pasini	O
D,	O
Bracken	O
AP,	O
Hansen	O
JB,	O
Capillo	O
M,	O
Helin	O
K	O
(2007)	O
The	O
polycomb	O
group	O
protein	O
Suz12	O
is	O
required	O
for	O
embryonic	B
stem	I
cell	I
differentiation.	O

Christophersen	O
NS,	O
Helin	O
K	O
(2010)	O
Epigenetic	O
control	O
of	O
embryonic	B
stem	I
cell	I
fate.	O

A	O
genome-wide	O
RNAi	O
screen	O
reveals	O
determinants	O
of	O
human	B
embryonic	I
stem	I
cell	I
identity.	O

In	O
support	O
of	O
this,	O
gene	O
ontology	O
analysis	O
of	O
these	O
79	O
CpGs	O
revealed	O
overrepresentation	O
of	O
these	O
CpGs	O
at	O
genes	O
relevant	O
to	O
HSC	O
function,	O
including	O
involvement	O
in	O
stem	B
cell	I
pluripotency,	O
differentiation,	O
and	O
Wnt	O
signaling	O
pathways..	O

Interestingly,	O
three	O
of	O
the	O
four	O
CpGs	O
were	O
enriched	O
at	O
genes	O
involved	O
in	O
stem	B
cell	I
pluripotency	O
and	O
differentiation	O
(ESRP1	O
and	O
SVOPL)	O
[73,	O
76,	O
89].	O

Roles	O
of	O
FGF	O
signaling	O
in	O
stem	B
cell	I
self-renewal,	O
senescence	O
and	O
aging.	O

Although	O
many	O
applications	O
of	O
NT	O
can	O
be	O
easily	O
linked	O
to	O
NHP	O
models,	O
and	O
the	O
profound	O
impact	O
of	O
stem	B
cell	I
research	O
and	O
gene	O
targeted	O
mice	O
has	O
been	O
clearly	O
demonstrated	O
[6,88-93],	O
the	O
technical	O
barriers	O
for	O
NT	O
in	O
the	O
NHP	O
hss	O
not	O
yet	O
been	O
overcome.	O

Progress	O
in	O
gene	O
and	O
cell	O
therapy,	O
the	O
advancement	O
of	O
stem	B
cell	I
technology	O
and	O
the	O
need	O
for	O
efficacious	O
and	O
reliable	O
vaccines	O
have	O
driven	O
the	O
development	O
of	O
NHP	O
models	O
that	O
are	O
not	O
only	O
similar	O
in	O
physiology,	O
but	O
also	O
carry	O
similar	O
genetic	O
defects	O
that	O
lead	O
to	O
diseases	O
such	O
as	O
AD,	O
PD	O
and	O
HD.	O

Polycomb	O
repressive	O
complex	O
2	O
is	O
dispensable	O
for	O
maintenance	O
of	O
embryonic	B
stem	I
cell	I
pluripotency.	O

Pluripotency	O
and	O
epigenetic	O
factors	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
fate	O
regulation.	O

The	O
polycomb	O
group	O
protein	O
Suz12	O
is	O
required	O
for	O
embryonic	B
stem	I
cell	I
differentiation.	O

EZH1	O
mediates	O
methylation	O
on	O
histone	O
H3	O
lysine	O
27	O
and	O
complements	O
EZH2	O
in	O
maintaining	B
stem	I
cell	I
identity	O
and	O
executing	O
pluripotency.	O

Blocking	O
CXCR4	O
function	O
liberates	O
HSCs	O
from	O
the	O
BM,	O
and	O
CXCR4	O
antagonist	O
AMD3100	O
(Plerixafor)	O
is	O
used	O
clinically	O
to	O
mobilize	O
HSCs	O
for	O
collection	O
from	O
peripheral	O
blood	O
prior	O
to	O
autologous	B
stem	I
cell	I
transplantation	O
237..	O

Bilgin	O
YM	O
&	O
de	O
Greef	O
GE	O
(2016)	O
Plerixafor	O
for	O
stem	B
cell	I
mobilization:	O
the	O
current	O
status.	O

Without	O
prompt	O
and	O
adequate	O
therapy	O
by	O
means	O
of	O
stem	B
cell	I
transplantation,	O
they	O
have	O
a	O
significant	O
mortality	O
during	O
the	O
first	O
two	O
years	O
of	O
life	O
[41,	O
43,	O
44].	O

Schematic	O
representation	O
of	O
the	O
mechanisms	O
implicated	O
with	O
adult	B
stem	I
cell	I
senescence	O
owing	O
to	O
tissue-specific	O
stem/progenitor	O
cell	O
exhaustion	O
in	O
aging..	O

Despite	O
that	O
future	O
studies	O
are	O
required	O
to	O
evaluate	O
the	O
translational	O
potentials	O
of	O
cardiac	B
stem	I
cell	I
therapy,	O
the	O
possibility	O
to	O
manipulate	O
these	O
cells	O
to	O
express	O
growth	O
factors	O
or	O
cardioprotective	O
molecules	O
(i.e.,	O
IGF-1,	O
Pim-1,	O
Follistatin-like	O
1,	O
and	O
nucleostemin)	O
may	O
become	O
an	O
important	O
goal	O
to	O
develop	O
strategies	O
to	O
fostering	O
autologous	O
CSC	O
physiological	O
turnover	O
in	O
order	O
to	O
maintain	O
their	O
stemness	O
potential,	O
to	O
rejuvenate	O
them,	O
and	O
to	O
improve	O
their	O
beneficial	O
regenerative/reparative	O
properties..	O

Effects	O
of	O
telomerase	O
and	O
telomere	O
length	O
on	O
epidermal	B
stem	I
cell	I
behavior.	O

Cardiac	B
stem	I
cell	I
and	O
myocyte	O
aging,	O
heart	O
failure,	O
and	O
insulin-like	O
growth	O
factor-1	O
overexpression.	O

Adult	B
stem	I
cell	I
plasticity:	O
fact	O
or	O
artifact?	O
Annual	O
Review	O
of	O
Cell	O
and	O
Developmental	O
Biology.	O

Regenerating	O
the	O
skin:	O
a	O
task	O
for	O
the	O
heterogeneous	B
stem	I
cell	I
pool	O
and	O
surrounding	O
niche.	O

Ultrastructure	O
and	O
cell-cell	O
coupling	O
of	O
cardiac	O
myocytes	O
differentiating	O
in	O
embryonic	B
stem	I
cell	I
cultures.	O

Because	O
cPu	O
adducts	O
have	O
been	O
shown	O
to	O
accumulate	O
in	O
an	O
age-dependent	O
manner	O
[17],	O
it	O
is	O
reasonable	O
to	O
speculate	O
that	O
their	O
metabolism	O
will	O
have	O
important	O
consequences	O
for	O
stem	B
cell	I
dysfunction	O
with	O
aging..	O

Liu	O
L,	O
Rando	O
TA	O
(2011)	O
Manifestations	O
and	O
mechanisms	O
of	O
stem	B
cell	I
aging.	O

While	O
the	O
explant	O
method	O
is	O
based	O
on	O
the	O
migration	O
of	O
stem	B
cells	I
from	O
small	O
tissue	O
fragments	O
and	O
their	O
ability	O
to	O
adhere	O
to	O
a	O
plastic	O
surface,	O
the	O
enzymatic	O
digestion	O
method	O
involves	O
the	O
application	O
of	O
collagenase	O
and	O
dispase	O
to	O
dissociate	O
cells	O
from	O
dental	O
tissues	O
and	O
acquire	O
single	O
cell	O
suspensions	O
(Karamzadeh	O
et	O
al.,	O
2012;	O
Hilkens	O
et	O
al.,	O
2013).	O

On	O
the	O
other	O
hand,	O
the	O
use	O
of	O
HS	O
improves	O
the	O
cell	O
growth	O
of	O
DPSCs	O
and	O
provides	O
a	O
consistency	O
in	O
the	O
expression	O
of	O
stem	B
cell	I
markers,	O
as	O
well	O
as	O
an	O
osteoblastic	O
potential	O
similar	O
to	O
that	O
provided	O
by	O
common	O
differentiation	O
protocols	O
that	O
use	O
10%	O
FBS	O
(Ferro	O
et	O
al.,	O
2012a).	O

However,	O
the	O
capability	O
of	O
dental	B
stem	I
cells	I
to	O
differentiate	O
into	O
multiple	O
cell	O
lineages	O
(Figure.	O

In	O
this	O
context,	O
the	O
mechanism	O
of	O
integration	O
and	O
the	O
functions	O
of	O
dental	B
stem	I
cells	I
are	O
being	O
extensively	O
investigated	O
in	O
animal	O
models	O
before	O
these	O
cell	O
populations	O
can	O
be	O
employed	O
in	O
clinical	O
therapy.	O

Finally,	O
another	O
type	O
of	O
dental	B
stem	I
cell	I
that	O
has	O
positively	O
impacted	O
tissue	O
regeneration	O
is	O
TGPCs.	O

Such	O
transcriptional	O
events	O
in	O
stem	B
cell	I
renewal	O
and	O
fate	O
decision	O
events	O
are	O
regulated	O
by	O
epigenetic	O
modifications,	O
which	O
change	O
chromatin	O
accessibility	O
and	O
dictate	O
the	O
proper	O
instructions	O
for	O
cell	O
identity	O
(Table.	O

Therefore,	O
characterizing	O
and	O
understanding	O
multiple	O
epigenetic	O
modifications	O
during	O
the	O
establishment	O
of	O
cell	O
identity	O
and	O
the	O
differentiation	O
of	O
stem	B
cells	I
is	O
an	O
urgent	O
research	O
topic,	O
and	O
DP	O
is	O
considered	O
a	O
promising	O
starting	O
point.	O

It	O
has	O
also	O
been	O
found	O
that	O
miR-720	O
participates	O
in	O
the	O
control	O
of	O
the	O
stem	B
cell	I
phenotype	O
and	O
the	O
differentiation	O
of	O
DPCs	O
by	O
directly	O
repressing	O
NANOG	O
expression;	O
it	O
also	O
participates	O
indirectly	O
by	O
increasing	O
the	O
expression	O
of	O
DNMT3a	O
and	O
DNMT3b	O
through	O
an	O
unknown	O
mechanism,	O
and	O
these	O
genes	O
also	O
act	O
as	O
transcriptional	O
repressors	O
of	O
NANOG.	O

cMyc	O
regulates	O
the	O
size	O
of	O
the	O
premigratory	B
neural	I
crest	I
stem	I
cell	I
pool.	O

Primary	O
microcephaly	O
represents	O
a	O
recognizable	O
monogenic	O
form	O
of	O
microcephaly	O
in	O
which	O
brain	O
size	O
is	O
markedly	O
reduced	O
in	O
the	O
absence	O
of	O
other	O
malformations	O
and/or	O
significant	O
neurological	O
deficits	O
aside	O
from	O
intellectual	O
disability.6	O
Many	O
genes	O
associated	O
with	O
centrosome	O
and/or	O
mitotic	O
spindle	O
function	O
have	O
been	O
described,	O
suggesting	O
primary	O
microcephaly	O
to	O
be	O
a	O
disorder	O
of	O
neural	B
stem	I
cell	I
mitosis.7.	O

Systematic	O
gene	O
tagging	O
using	O
CRISPR/Cas9	O
in	O
human	B
stem	I
cells	I
to	O
illuminate	O
cell	O
organization.	O

Because	O
this	O
represents	O
a	O
very	O
large	O
number	O
of	O
cell	O
lines,	O
we	O
regard	O
this	O
as	O
strong	O
evidence	O
that	O
NMD	O
factors	O
are	O
highly	O
expressed	O
in	O
human	B
pluripotent	I
stem	I
cells	I
and	O
that	O
their	O
level	O
decreases	O
upon	O
loss	O
of	O
pluripotency..	O

We	O
found	O
that	O
maintenance	O
of	O
UPF1	O
expression	O
in	O
this	O
manner	O
inhibited	O
the	O
upregulation	O
of	O
the	O
endoderm	O
marker,	O
SOX17,	O
and	O
largely	O
maintained	O
expression	O
of	O
the	O
stem	B
cell	I
marker,	O
OCT4	O
(Figure	O
1E,	O
left).	O

Dissecting	O
the	O
molecular	O
hierarchy	O
for	O
mesendoderm	O
differentiation	O
through	O
a	O
combination	O
of	O
embryonic	B
stem	I
cell	I
culture	O
and	O
RNA	O
interference.	O

Posttranscriptional	O
control	O
of	O
the	O
stem	B
cell	I
and	O
neurogenic	O
programs	O
by	O
the	O
nonsense-mediated	O
RNA	O
decay	O
pathway.	O

A	O
novel	O
class	O
of	O
evolutionarily	O
conserved	O
genes	O
defined	O
by	O
piwi	O
are	O
essential	O
for	O
stem	B
cell	I
self-renewal.	O

Skeletal	O
muscle	O
is	O
a	O
source	O
of	O
myosphere-derived	O
progenitor	O
cells	O
(MDPCs),	O
which	O
are	O
multipotent	O
cells	O
that	O
express	O
a	O
number	O
of	O
embryonic	B
stem	I
cell	I
markers	O
and	O
differentiate	O
into	O
vascular	O
smooth	O
muscle	O
cells	O
and	O
mesenchymal	O
progeny.	O

Rapid	O
progress	O
in	O
stem	B
cell	I
biology	O
has	O
the	O
potential	O
to	O
revolutionize	O
various	O
areas	O
of	O
medicine.	O

Both	O
patterned	O
and	O
nonpatterned	O
organoids	O
recapitulate	O
many	O
aspects	O
of	O
embryonic	O
brain	O
development,	O
such	O
as	O
the	O
formation	O
of	O
stereotypical	B
stem	I
cell	I
niches	O
of	O
the	O
developing	O
brain	O
with	O
corresponding	O
production	O
of	O
various	O
NPC	O
subtypes	O
and	O
the	O
migration	O
of	O
neurons	O
away	O
from	O
these	O
proliferative	O
niches	O
(Fig..	O

One	O
of	O
the	O
benefits	O
of	O
stem	B
cell	I
transplantation	O
for	O
RGCs	O
neuroprotection	O
is	O
its	O
long-lasting	O
and	O
localized	O
effect	O
which	O
is	O
intended	O
to	O
improve	O
patient	O
compliance.	O

Distribution	O
of	O
Mesenchymal	O
Stem	O
Cells	O
and	B
Effects	I
on	O
Neuronal	O
Survival	O
and	O
Axon	O
Regeneration	O
after	O
Optic	O
Nerve	O
Crush	O
and	O
Cell	O
Therapy.	O

Previous	O
studies	O
reported	O
that	O
IL-17	O
increased	O
total	O
p38	O
levels	O
and	O
restricted	O
neural	B
stem	I
cell	I
differentiating	O
to	O
neurons,	O
astrocytes,	O
and	O
OPCs	O
(Li	O
et	O
al.,	O
2013).	O

Similar	O
results	O
were	O
also	O
observed	O
in	O
neural	O
stem	O
cells	O
that	O
IL-17	O
stimulated	O
neural	B
stem	I
cell	I
way	O
out	O
of	O
cell	O
cycle	O
despite	O
no	O
change	O
of	O
apoptosis	O
(Li	O
et	O
al.,	O
2013).	O

Inhibitory	O
effect	O
of	O
IL-17	O
on	O
neural	B
stem	I
cell	I
proliferation	O
and	O
neural	O
cell	O
differentiation.	O

Notably,	O
the	O
downregulation	O
of	O
this	O
Env	O
led	O
to	O
the	O
dissociation	O
of	O
the	O
stem	B
cell	I
colonies	O
and	O
prompted	O
their	O
differentiation	O
along	O
neuronal	O
pathways,	O
up	O
to	O
the	O
production	O
of	O
neurons,	O
suggesting	O
a	O
role	O
in	O
the	O
regulation	O
of	O
embryonic	O
neurodevelopment	O
[235]..	O

In	O
particular,	O
we	O
discuss	O
the	O
pro-	O
and	O
anti-tumorigenic	O
roles	O
of	O
RB	O
during	O
the	O
early	O
stages	O
of	O
cancer,	O
as	O
well	O
as	O
the	O
importance	O
of	O
the	O
RB	O
pathway	O
in	O
stem	B
cells	I
and	O
cell	O
fate	O
decisions..	O

Research	O
performed	O
in	O
Arabidopsis	O
thaliana,	O
in	O
which	O
there	O
is	O
only	O
one	O
member	O
of	O
the	O
RB	O
family,	O
shows	O
that	O
RB	O
inactivation	O
prevents	O
differentiation	O
and	O
leads	O
to	O
an	O
expansion	O
of	O
the	O
stem	B
cell	I
pool,	O
suggesting	O
that	O
RB	O
loss	O
induces	O
uncontrolled	O
proliferation	O
without	O
decreasing	O
self-renewing	O
capacity	O
(Chen,	O
Z.	O

Clearly,	O
different	O
mechanisms	O
exist	O
in	O
different	O
populations	O
of	O
stem	B
cells	I
and	O
progenitors	O
to	O
ensure	O
the	O
maintenance	O
of	O
quiescence	O
and	O
the	O
control	O
of	O
the	O
cell	O
cycle..	O

In	O
spite	O
of	O
the	O
well-known	O
role	O
of	O
WNT	O
signaling	O
in	O
inflammatory	O
processes	O
and	O
in	O
the	O
regulation	O
of	O
stem	B
cell	I
proliferation	O
and	O
differentiation,	O
they	O
have	O
so	O
far	O
only	O
marginally	O
been	O
analyzed	O
in	O
psoriasis.	O

Epigenetic	O
dynamics	O
of	O
stem	B
cells	I
and	O
cell	O
lineage	O
commitment:	O
digging	O
Waddington’s	O
canal.	O

Tumor	B
stem	I
cells	I
derived	O
from	O
glioblastomas	O
cultured	O
in	O
bFGF	O
and	O
EGF	O
more	O
closely	O
mirror	O
the	O
phenotype	O
and	O
genotype	O
of	O
primary	O
tumors	O
than	O
do	O
serum-cultured	O
cell	O
lines.	O

Roles	O
for	O
the	O
stem	B
cell	I
associated	O
intermediate	O
filament	O
Nestin	O
in	O
prostate	O
cancer	O
migration	O
and	O
metastasis.	O

Enhancement	O
of	O
NF-kappaB	O
expression	O
and	O
activity	O
upon	O
differentiation	O
of	O
human	B
embryonic	I
stem	I
cell	I
line	O
SNUhES3.	O

Our	O
technique	O
uncovers	O
a	O
diverse	O
set	O
of	O
patterns	O
that	O
are	O
conserved	O
across	O
embryonic	B
stem	I
cell	I
and	O
cancer	O
data	O
sets.	O

However,	O
focusing	O
on	O
in	O
vitro	O
hallmarks	O
of	O
stem	B
cell	I
aging,	O
we	O
demonstrated	O
that,	O
when	O
cultured	O
for	O
prolonged	O
time	O
(one	O
year),	O
iPSCs	O
display	O
altered	O
mitochondrial	O
number,	O
functionality	O
and	O
biogenesis,	O
and	O
fail	O
to	O
undergo	O
neurogenesis	O
[20].	O

Focusing	O
on	O
in	O
vitro	O
hallmarks	O
of	O
stem	B
cell	I
age,	O
we	O
previously	O
demonstrated	O
that	O
iPSCs	O
kept	O
in	O
culture	O
for	O
prolonged	O
time	O
present	O
altered	O
mitochondrial	O
number	O
and	O
functionality,	O
altered	O
expression	O
of	O
genes	O
relevant	O
to	O
mitochondria	O
biogenesis,	O
and	O
fail	O
to	O
properly	O
undergo	O
neurogenesis	O
[20].	O

to	O
induce	O
aging	O
with	O
progerin	O
overexpression	O
in	O
human	O
iPSC-derived	O
lineages,	O
we	O
obtained	O
aging	O
in	O
pluripotent	B
stem	I
cell	I
by	O
long	O
term	O
culturing.	O

It	O
will	O
be	O
interesting	O
to	O
learn,	O
however,	O
whether	O
treatment	O
of	O
Wnt-high	O
disorders	O
with	O
PORCN	O
inhibitors	O
could	O
maintain	O
a	O
therapeutic	O
window,	O
considering	O
the	O
role	O
that	O
Wnt/β-catenin	O
signaling	O
plays	O
in	O
adult	B
stem	I
cell	I
homeostasis	O
(43)..	O

Our	O
prior	O
work	O
has	O
shown	O
that	O
MSC-EVs	O
can	O
abate	O
the	O
effects	O
of	O
toxic	O
chemo/radiation	O
and	O
serve	O
to	O
protect	B
stem	I
cell	I
allowing	O
for	O
quicker	O
recover	O
in	O
cell	O
blood	O
counts..	O

Results:	O
The	O
overexpression	O
of	O
HIF-1α	O
was	O
demonstrated	O
in	O
MM	O
cells	O
under	O
long-term	O
hypoxia,	O
and	O
the	O
expression	O
of	O
stem	B
cell	I
markers	O
were	O
more	O
increased	O
in	O
MM	O
cells	O
under	O
hypoxic	O
condition	O
compared	O
to	O
normal	O
oxygen	O
concentration	O
The	O
RNA	O
sequencing	O
showed	O
up-regulation	O
of	O
gene	O
associated	O
with	O
production	O
of	O
EV	O
in	O
hypoxic	O
cultured	O
cells.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
role	O
of	O
apoptotic	O
EVs	O
on	O
mesenchymal	B
stem	I
cell	I
immunomodulatory	O
function	O
in	O
a	O
tumour	O
microenvironment..	O

Comprehensive	O
proteomics	O
and	O
microRNA	O
analyses	O
of	O
adult	B
neural	I
stem	I
cell	I
derived	O
exosomes	O
after	O
stroke.	O

Exosomes-derived	O
from	O
mesenchymal	B
stem	I
cell	I
is	O
thought	O
to	O
contain	O
plenty	O
of	O
unique	O
microRNA,	O
which	O
is	O
specific	O
for	O
boosting	O
cellular	O
repair	O
and	O
regeneration.	O

EVs	O
for	O
cell	O
free	O
therapy	O
are	O
less	O
potential	O
risk	O
compared	O
to	O
stem	B
cell	I
transplantation	O
and	O
could	O
be	O
promising	O
tool	O
for	O
patients	O
suffering	O
from	O
lymphedema..	O

Introduction:	O
Mesenchymal	B
Stem	I
Cell	I
is	O
a	O
multipotent	O
cell	O
that	O
works	O
in	O
two	O
ways,	O
replacing	O
the	O
injured	O
cells	O
and	O
releasing	O
active	O
biomolecules	O
that	O
work	O
as	O
a	O
paracrine	O
signal	O
for	O
cell	O
migration	O
and	O
proliferation.	O

Natural	O
and	O
synthetic	O
biomaterial	O
mediated	O
delivery	O
of	O
Mesenchymal	B
Stem	I
Cell	I
derived	O
exosomes.	O

These	O
miRNAs	O
were	O
enriched	O
in	O
signalling	O
pathways	O
that	O
involve	O
TGF-β	O
(p	O
=	O
0.004)	O
and	O
TNF-α	O
(p	O
=	O
0.03)	O
and	O
the	O
maintenance	O
of	O
stem	B
cell	I
pluripotency	O
(p	O
=	O
0.0001).	O

Therapeutic	O
effects	O
of	O
mesenchymal	B
stem	I
cell	I
exosomes	O
in	O
myocardial	O
ischemia/reperfusion	O
injury	O
in	O
a	O
porcine	O
model.	O

Our	O
prior	O
work	O
has	O
shown	O
that	O
MSC-EVs	O
can	O
abate	O
the	O
effects	O
of	O
toxic	O
chemo/radiation	O
and	O
serve	O
to	O
protect	B
stem	I
cell	I
allowing	O
for	O
quicker	O
recover	O
in	O
cell	O
blood	O
counts..	O

Methods:	O
Here,	O
we	O
attempted	O
to	O
elucidate	O
tumour-derived	O
exosomes	O
bearing	O
miR-27b	O
in	O
regulating	O
tumour	O
microenvironments	O
via	O
modulation	O
of	O
cancer	B
stem	I
cell	I
growth	O
and	O
migration..	O

Intranasal	O
delivery	O
of	O
mesenchymal	B
stem	I
cell	I
derived	O
exosomes	O
loaded	O
with	O
PTEN	O
siRNA	O
repairs	O
complete	O
spinal	O
cord	O
injury.	O

Control	O
of	O
neural	B
stem	I
cell	I
differentiation	O
to	O
generate	O
defined	O
exosome	O
populations.	O

It	O
can	O
be	O
confirmed	O
that	O
the	O
stem	B
cell	I
membrane	O
is	O
well-coated	O
on	O
the	O
surface	O
of	O
gold	O
nanorod	O
through	O
various	O
analysis	O
including,	O
zeta	O
potential,	O
TEM,	O
PAGE	O
gel	O
and	O
Western	O
blotting,	O
etc..	O

Further	O
investigation	O
to	O
elucidate	O
regulatory	O
roles	O
of	O
these	O
three	O
transcription	O
factors	O
in	O
mesenchymal	B
stem	I
cell	I
reprogramming	O
will	O
provide	O
a	O
critical	O
foundation	O
for	O
a	O
novel	O
cell-based	O
regenerative	O
therapy	O
for	O
patients	O
with	O
xerostomia..	O

(2011)	O
Opposing	O
effects	O
of	O
Tcf3	O
and	O
Tcf1	O
control	O
Wnt	O
stimulation	O
of	O
embryonic	B
stem	I
cell	I
self-renewal.	O

In	O
this	O
regard,	O
most	O
work	O
addressed	O
structure,	O
function,	O
and	O
maintenance	B
on	I
stem	I
cell	I
niches	O
located	O
in	O
the	O
subventricular	O
zone	O
(SVZ)	O
of	O
the	O
lateral	O
brain	O
ventricles	O
as	O
well	O
as	O
in	O
the	O
subgranular	O
zone	O
(SGZ)	O
of	O
the	O
dentate	O
gyrus.	O

While	O
the	O
large	O
degree	O
of	O
heterogeneity	O
of	O
applied	O
NSCs,	O
even	O
when	O
isolated	O
from	O
defined	B
stem	I
cell	I
niches	O
[8,9],	O
is	O
likely	O
to	O
affect	O
reproducibility,	O
standardization,	O
and	O
clinical	O
translation,	O
different	O
brain	O
regions	O
and	O
injury	O
types	O
additionally	O
contribute	O
to	O
the	O
number	O
of	O
parameters	O
affecting	O
cell	O
fate	O
acquisition.	O

Neural	B
stem	I
cell	I
survival	O
rates	O
were	O
largely	O
comparable	O
between	O
striatum,	O
cortex,	O
and	O
olfactory	O
bulb	O
indicating	O
that	O
no	O
preferential	O
survival	O
cues	O
are	O
expressed	O
and	O
secreted	O
in	O
these	O
brain	O
regions.	O

Thus,	O
despite	O
a	O
lowered	O
survival	O
rate,	O
the	O
chronic	O
lesion	O
environment	O
appears	O
to	O
still	O
exert	O
a	O
beneficial	O
influence	O
on	O
the	O
differentiation	O
of	O
human	O
NSCs	O
and	O
of	O
iPSC-NPCs	O
as	O
two	O
groups	O
reported	O
a	O
more	O
mature	O
oligodendrocyte	O
phenotype	O
in	O
stem	B
cell	I
derivatives	O
upon	O
transplantation	O
into	O
early	O
chronic-	O
or	O
chronic	O
lesions	O
[98,99]..	O

The	O
discovery	O
of	O
neural	B
stem	I
cells	I
and	O
their	O
potential	O
to	O
give	O
rise	O
to	O
all	O
cell	O
lineages	O
of	O
the	O
CNS	O
has	O
revived	O
the	O
field	O
in	O
terms	O
of	O
functional	O
cell	O
replacement.	O

Applicability	O
and	O
limitations	O
of	O
MR	O
tracking	O
of	O
neural	B
stem	I
cells	I
with	O
asymmetric	O
cell	O
division	O
and	O
rapid	O
turnover:	O
The	O
case	O
of	O
the	O
shiverer	O
dysmyelinated	O
mouse	O
brain.	O

Increasing	O
Human	O
Neural	B
Stem	I
Cell	I
Transplantation	O
Dose	O
Alters	O
Oligodendroglial	O
and	O
Neuronal	O
Differentiation	O
after	O
Spinal	O
Cord	O
Injury.	O

(2004)	O
Characteristics	O
of	O
stem	B
cells	I
from	O
human	O
neuroblastoma	O
cell	O
lines	O
and	O
in	O
tumors.	O

The	O
advancement	O
of	O
stem	B
cell	I
technologies	O
has	O
allowed	O
the	O
culturing	O
of	O
patient-derived	O
cells	O
and	O
their	O
differentiation	O
into	O
various	O
cell	O
types,	O
including	O
oligodendrocytes.	O

Recent	O
developments	O
in	O
stem	B
cell	I
technologies	O
have	O
allowed	O
the	O
growth	O
of	O
MSA-derived	O
iPSCs	O
and	O
their	O
differentiation	O
into	O
oligodendrocytes.	O

Interestingly,	O
our	O
pathway	O
analysis	O
identified	O
molecular	O
mechanisms	O
of	O
cancer	O
and	O
human	B
embryonic	I
stem	I
cell	I
pluripotency	O
as	O
two	O
of	O
the	O
major	O
canonical	O
pathways	O
highly	O
represented	O
in	O
the	O
PLEKHA7-enriched	O
mRNAs	O
(Fig.	O

Recently,	O
the	O
protein	O
expression	O
of	O
the	O
stem	B
cell	I
marker	O
Nestin	O
has	O
been	O
used	O
to	O
identify	O
progenitor	O
cells	O
in	O
several	O
tissues	O
and	O
was	O
investigated	O
its	O
association	O
with	O
tumor	O
staging	O
and	O
metastasis	O
formation	O
in	O
several	O
cancers	O
comprising	O
PC	O
[56].	O

Immunosuppressive	O
therapy	O
mitigates	O
immunological	O
rejection	O
of	O
human	B
embryonic	I
stem	I
cell	I
xenografts.	O

A	O
Novel	O
Regulatory	O
Axis,	O
CHD1L-MicroRNA	O
486-Matrix	O
Metalloproteinase	O
2,	O
Controls	O
Spermatogonial	B
Stem	I
Cell	I
Properties.	O

The	O
SP	O
phenotype	O
has	O
been	O
proven	O
to	O
be	O
invaluable	O
for	O
stem	B
cell	I
isolation	O
in	O
the	O
absence	O
of	O
definitive	O
cell	O
surface	O
markers24.	O

[52]	O
Wang	O
J,	O
Chu	O
R,	O
Ni	O
N,	O
Nan	O
G,	O
The	O
effect	O
of	O
Matrigel	O
as	O
scaffold	O
material	O
for	O
neural	B
stem	I
cell	I
transplantation	O
for	O
treating	O
spinal	O
cord	O
injury,	O
Sci.	O

Nonhuman	O
primate	O
model	O
in	O
clinical	O
modeling	O
of	O
diseases	O
for	O
stem	B
cell	I
therapy.	O

Nonhuman	O
primate	O
model	O
in	O
clinical	O
modeling	O
of	O
diseases	O
for	O
stem	B
cell	I
therapy.	O

In	O
addition,	O
we	O
suggest	O
that	O
applying	O
a	O
directed	O
and	O
collaborative	O
approach,	O
as	O
seen	O
in	O
the	O
evolution	O
of	O
stroke	O
NHP	O
models,	O
will	O
greatly	O
benefit	O
the	O
translation	O
of	O
stem	B
cell	I
therapy	O
in	O
other	O
NHP	O
disease	O
models..	O

In	O
this	O
current	O
report,	O
we	O
suggest	O
that	O
a	O
robust	O
dialog	O
within	O
each	O
disease-specific	O
research	O
community	O
focused	O
on	O
the	O
development	O
of	O
relevant	O
NHP	O
models	O
will	O
greatly	O
benefit	O
the	O
advance	O
of	O
the	O
translation	O
of	O
stem	B
cell	I
research..	O

The	O
majority	O
of	O
this	O
duality	O
appears	O
to	O
stem	O
from	O
the	O
necessity	O
of	O
a	O
cell	O
to	O
regulate	O
centrosome	O
duplication	O
and	O
mitotic	O
spindle	O
integrity,	O
with	O
several	O
DDR	O
proteins	O
localising	O
to	O
the	O
centrosome	O
and/or	O
regulating	O
cell	O
cycle	O
progression	O
and,	O
in	O
turn,	O
centriole	O
duplication	O
events.	O
Outcome	O
of	O
relapsed	O
adult	O
lymphoblastic	O
leukemia	O
depends	O
on	O
response	O
to	O
salvage	O
chemotherapy,	O
prognostic	O
factors,	O
and	O
performance	O
of	O
stem	B
cell	I
transplantation.	O

The	O
role	O
of	O
bioactive	O
lipids	O
in	O
stem	B
cell	I
mobilization	O
and	O
homing:	O
novel	O
therapeutics	O
for	O
myocardial	O
ischemia.	O

MMP-9	O
is	O
already	O
known	O
in	O
the	O
Duchenne	O
field	O
due	O
to	O
its	O
role	O
in	O
disease	O
pathogenesis35	O
and	O
for	O
the	O
ability	O
to	O
modulate	O
the	O
capacity	O
of	O
stem	B
cell	I
to	O
correctly	O
engraft	O
in	O
a	O
dystrophic	O
muscle36.	O

Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

Delta-like	O
(Dll)	O
binding	O
to	O
the	O
Notch	O
receptor	O
drives	O
the	O
expression	O
of	O
Hes1	O
to	O
maintain	B
stem	I
cell	I
pluripotency	O
and	O
suppress	O
differentiation	O
(Ishibashi	O
et	O
al.,	O
1995).	O

Hedgehog-induced	O
maintenance	O
of	O
stem	B
cell	I
pluripotency	O
relies	O
in	O
part	O
on	O
the	O
activation	O
of	O
Notch	O
to	O
balance	O
proliferation	O
with	O
differentiation	O
(Dave	O
et	O
al.,	O
2011;	O
Kong	O
et	O
al.,	O
2015).	O

(2006)	O
Regulation	O
of	O
SDF-1	O
(CXCL12)	O
production	O
by	O
osteoblasts;	O
a	O
possible	O
mechanism	O
for	O
stem	B
cell	I
homing.	O

A	O
novel	O
target	O
cell	O
for	O
c-fos-induced	O
oncogenesis:	O
development	O
of	O
chondrogenic	O
tumours	O
in	O
embryonic	B
stem	I
cell	I
chimeras.	O

Immunomodulatory	O
effects	O
of	O
the	O
Agaricus	O
blazei	O
Murrill-based	O
mushroom	O
extract	O
AndoSan	O
in	O
patients	O
with	O
multiple	O
myeloma	O
undergoing	O
high	O
dose	O
chemotherapy	O
and	O
autologous	B
stem	I
cell	I
transplantation:	O
A	O
randomized,	O
double	O
blinded	O
clinical	O
study.	O

Activation	O
of	O
an	O
IL6	O
inflammatory	O
loop	O
mediates	O
trastuzumab	O
resistance	O
in	O
HER2+	O
breast	O
cancer	O
by	O
expanding	O
the	O
cancer	B
stem	I
cell	I
population.	O

Variation	O
in	O
cancer	O
risk	O
among	O
tissues	O
can	O
be	O
explained	O
by	O
the	O
number	O
of	O
stem	B
cell	I
divisions.	O

The	O
calvarium	O
has	O
been	O
demonstrated	O
to	O
be	O
equivalent	O
to	O
the	O
long	O
bones	O
such	O
as	O
the	O
femur	O
with	O
regards	O
to	O
haematopoietic	B
stem	I
cell	I
frequency,	O
function	O
and	O
localisation14,22,	O
and	O
is	O
the	O
only	O
bone	O
marrow	O
compartment	O
that	O
allows	O
longitudinal	O
imaging	O
through	O
minimally	O
invasive	O
surgery16,32.	O

Based	O
on	O
this	O
integrative	O
analysis,	O
we	O
identified	O
lncRNAs	O
that	O
are	O
regulated	O
during	O
Oligodendrocyte	O
Precursor	O
Cell	O
(OPC)	O
differentiation	O
from	O
Neural	O
Stem	B
Cells	I
(NSCs)	I
and	O
that	O
are	O
likely	O
to	O
be	O
involved	O
in	O
oligodendrogenesis.	O

A	O
previous	O
study	O
employing	O
a	O
custom-designed	O
microarray	O
also	O
showed	O
that	O
a	O
number	O
of	O
known	O
lncRNAs	O
exhibit	O
dynamic	O
expression	O
patterns	O
during	O
oligodendrocyte	O
lineage	O
specification,	O
suggesting	O
that	O
they	O
may	O
play	O
a	O
role	O
in	O
neural	B
stem	I
cell	I
fate	O
decisions	O
and	O
oligodendrocyte	O
lineage	O
maturation	O
[6].	O

It	O
has	O
been	O
reported	O
that	O
miR221/222affect	O
cell	O
migration	O
and	O
proliferation	O
by	O
reducing	O
the	O
expression	O
of	O
c-kit	O
and	O
of	O
the	O
receptor	O
for	O
stem	B
cell	I
factor[13],	O
and,	O
indirectly,	O
by	O
inhibiting	O
endothelial	O
nitric	O
oxide	O
(NO)	O
synthase	O
expression[26].	O

Human	B
embryonic	I
stem	I
cell	I
lines	O
HUES8	O
(NIHhESC-09–0021,	O
male)	O
and	O
H1	O
(NIHhESC-10–0043,	O
male)	O
were	O
authenticated	O
by	O
the	O
standard	O
short	O
tandem	O
repeat	O
(STR)	O
profiling	O
using	O
the	O
MSK	O
Integrated	O
Genomics	O
Operation	O
core	O
facility.	O

This	O
displaced	O
the	O
goals	O
of	O
the	O
Edinburgh	O
scientists	O
from	O
the	O
production	O
of	O
transgenic	O
sheep	O
to	O
stem	B
cell	I
research	O
and	O
human	O
regenerative	O
medicine.	O

A	O
history	O
of	O
embryonic	B
stem	I
cell	I
research:	O
Concepts,	O
laboratory	O
work,	O
and	O
contexts.	O

Moreover,	O
the	O
effects	O
of	O
stem	B
cell	I
paracrine	O
secretion	O
have	O
been	O
reported.	O

To	O
analyze	O
the	O
mesenchymal	B
stem	I
cell	I
markers,	O
105	O
cells	O
were	O
stained	O
with	O
antibodies,	O
particularly	O
PE-conjugated	O
CD105	O
(Bio-Rad,	O
Hercules,	O
CA,	O
USA,	O
MCA1557,),	O
PE-conjugated	O
CD90	O
(BioLegend,	O
San	O
Diego,	O
CA,	O
USA,	O
555596),	O
PE-conjugated	O
CD73	O
(BioLegend,	O
344004),	O
FITC-conjugated	O
CD45	O
(BioLegend,	O
555482),	O
FITC-conjugated	O
CD34	O
(BioLegend,	O
343504),	O
and	O
PE-conjugated	O
CD14	O
(Bio-Rad,	O
MCA1568).	O

Epidural	O
Fat-Derived	O
Mesenchymal	O
Stem	O
Cell:	O
First	O
Report	O
of	O
Epidural	O
Fat-Derived	O
Mesenchymal	O
Stem	O
Cell.	O
Isolation	O
and	O
Characterization	O
of	O
an	O
Adult	O
Stem	B
Cell	I
Population	O
from	O
Human	O
Epidural	O
Fat.	O

Epidural	O
Adipose	O
Tissue-Derived	O
Mesenchymal	B
Stem	I
Cell	I
Activation	O
Induced	O
by	O
Lung	O
Cancer	O
Cells	O
Promotes	O
Malignancy	O
and	O
EMT	O
of	O
Lung	O
Cancer.	O

Most	O
cell	O
biologists	O
are	O
unfamiliar	O
with	O
the	O
techniques	O
and	O
procedures	O
necessary	O
to	O
work	O
with	O
stem	O
cells.	O
Such	O
resources	O
will	O
be	O
particularly	O
important	O
for	O
stem	O
cells	O
in	O
part	O
because	O
of	O
the	O
current	O
costs	O
involved	O
and	O
partly	O
because	O
of	O
the	O
care	O
needed	O
to	O
maintain	O
the	O
stem	B
cell	I
state	O
while	O
modifying	O
their	O
genome.	O

A	O
particularly	O
promising	O
development	O
in	O
this	O
direction	O
is	O
the	O
efforts	O
of	O
the	O
Allen	O
Institute	O
for	O
Cell	O
Science	O
to	O
use	O
genome	O
editing	O
in	O
stem	B
cells	I
to	O
construct	O
a	O
collection	O
of	O
isogenic	O
cell	O
lines	O
endogenously	O
expressing	O
fluorescent	O
protein	O
fusions.	O

The	O
presence	O
of	O
H3.3	O
at	O
bivalent	O
promoters	O
is	O
of	O
particular	O
interest	O
in	O
the	O
context	O
of	O
stem	O
cell	O
biology	O
as	O
a	O
possible	O
mechanism	O
regulating	O
differentiation	O
potential	O
of	O
stem	B
cells	I
and	O
occurs	O
through	O
recruitment	O
of	O
PRC2	O
by	O
HIRA	O
(Banaszynski	O
et	O
al.,	O
2013).	O

Control	O
of	O
Embryonic	B
Stem	I
Cell	I
Identity	O
by	O
BRD4-Dependent	O
Transcriptional	O
Elongation	O
of	O
Super-Enhancer-Associated	O
Pluripotency	O
Genes.	O

Cell	O
renewing	O
in	O
neuroblastoma:	O
electrophysiological	O
and	O
immunocytochemical	O
characterization	O
of	O
stem	B
cells	I
and	O
derivatives.	O

Role	O
of	O
p75	O
neurotrophin	O
receptor	O
in	O
stem	B
cell	I
biology:	O
more	O
than	O
just	O
a	O
marker.	O

To	O
generate	O
enteroids,	O
the	O
intestinal	O
crypts	O
containing	O
the	O
intestinal	B
stem	I
cell	I
niches	O
are	O
separated	O
from	O
intestinal	O
tissues	O
by	O
EDTA	O
treatment.	O

Moreover,	O
Salmonella	O
infection	O
significantly	O
decreased	O
the	O
expression	O
of	O
intestinal	B
stem	I
cell	I
markers,	O
Lgr5	O
and	O
Bmi	O
1	O
(Forbester	O
et	O
al.,	O
2015).	O

Recent	O
advances	O
in	O
stem	B
cell	I
research	O
have	O
helped	O
to	O
establish	O
organoids	O
and	O
enteroids	O
as	O
viable	O
alternatives	O
to	O
many	O
established	O
infection	O
models.	O

The	O
most	O
important	O
lesson	O
from	O
these	O
epithelial	O
therapies	O
is	O
that	O
of	O
stem	B
cell	I
retention	O
during	O
culture.	O

However,	O
the	O
functionality	O
of	O
the	O
engrafted	O
cells,	O
including	O
their	O
contribution	O
to	O
the	O
hepatic	B
stem	I
cell	I
pool,	O
was	O
not	O
analyzed..	O

A	O
commonality	O
between	O
3T3	O
co‐culture	O
and	O
organoid	O
culture	O
systems	O
is	O
that	O
the	O
gold	O
standard	O
protocols	O
for	O
stem	B
cell	I
culture	O
depend	O
on	O
murine‐derived	O
products.	O

Attempts	O
to	O
replace	O
3T3	O
cells	O
with	O
human	O
feeder	O
cells	O
and/or	O
defined	O
media	O
have	O
been	O
largely	O
unsuccessful	O
in	O
terms	O
of	O
stem	B
cell	I
maintenance,	O
while	O
the	O
regulatory	O
environment	O
for	O
cell	O
therapies	O
has	O
changed	O
substantially.	O

The	O
complex	O
ECM	O
is	O
known	O
to	O
contain	O
fibronectin,	O
laminin,	O
and	O
collagen	O
types	O
I,	O
IV,	O
and	O
V	O
(Alitalo	O
et	O
al,	O
1982),	O
but	O
their	O
relative	O
importance	O
for	O
epithelial	B
stem	I
cell	I
retention	O
is	O
not	O
known.	O

In	O
epidermal	O
3T3	O
co‐cultures,	O
partial	O
differentiation	O
of	O
colonies	O
occurs	O
during	O
their	O
expansion,	O
while	O
the	O
stem	O
cell	O
population	O
is	O
retained	O
by	O
balanced	O
self‐renewal	O
of	O
stem	B
cells.	I

Gjorevski	O
N,	O
Sachs	O
N,	O
Manfrin	O
A,	O
Giger	O
S,	O
Bragina	O
ME,	O
Ordonez‐Moran	O
P,	O
Clevers	O
H,	O
Lutolf	O
MP	O
(2016)	O
Designer	O
matrices	O
for	O
intestinal	B
stem	I
cell	I
and	O
organoid	O
culture.	O

Kretzschmar	O
K,	O
Clevers	O
H	O
(2016)	O
Organoids:	O
modeling	O
development	O
and	O
the	O
stem	B
cell	I
niche	O
in	O
a	O
dish.	O

Senescence	O
can	O
be	O
inflicted	O
by	O
many	O
intrinsic	O
stimuli,	O
oncogenes,	O
as	O
well	O
as	O
by	O
natural	O
and	O
pathological	O
changes	O
in	O
stem	B
cell	I
microenvironment	O
(Rao	O
and	O
Mattson,	O
2001;	O
Janzen	O
et	O
al.,	O
2006;	O
Wang	O
et	O
al.,	O
2011;	O
Signer	O
and	O
Morrison,	O
2013).	O

Importantly,	O
new	O
findings	O
demonstrate	O
that	O
INK4b-ARF-INK4a	O
locus	O
is	O
playing	O
an	O
important	O
role	O
not	O
only	O
in	O
senescence,	O
but	O
also	O
in	O
stem	B
cell	I
self-renewal	O
(Gil	O
and	O
Peters,	O
2006).	O

The	O
new	O
line	O
of	O
evidence	O
demonstrates	O
that	O
primary	O
mouse	O
keratinocytes	O
transiently	O
exposed	O
to	O
the	O
SMS	O
exhibit	O
upregulated	O
expression	O
of	O
stem	B
cell	I
markers	O
and	O
boost	O
regenerative	O
capacity	O
in	O
vivo.	O

Embryonic	B
stem	I
cell	I
therapies	O
are	O
currently	O
being	O
developed	O
for	O
therapeutic	O
applications	O
and	O
have	O
already	O
entered	O
the	O
clinic	O
for	O
the	O
treatment	O
of	O
multiple	O
diseases.	O

These	O
emerging	O
technologies	O
supported	O
by	O
recent	O
advances	O
in	O
the	O
world	O
of	O
stem	B
cell	I
biology	O
hold	O
the	O
promise	O
for	O
a	O
further	O
understanding	O
of	O
N.	O

Previous	O
efforts	O
of	O
mesenchymal	B
stem	I
cell	I
differentiation	O
toward	O
SMCs	O
have	O
mainly	O
focused	O
on	O
MSCs	O
originating	O
from	O
bone	O
marrow	O
and	O
adipose	O
tissue	O
(10,	O
11).	O

However,	O
little	O
is	O
known	O
about	O
the	O
involvement	O
of	O
miRNAs	O
in	O
mesenchymal	B
stem	I
cell	I
differentiation	O
to	O
SMCs.	O

Stage-specific	O
optimization	O
of	O
activin/nodal	O
and	O
BMP	O
signaling	O
promotes	O
cardiac	O
differentiation	O
of	O
mouse	O
and	O
human	B
pluripotent	I
stem	I
cell	I
lines.	O

CCR5	O
governs	O
DNA	O
damage	O
repair	O
and	O
breast	B
cancer	I
stem	I
cell	I
expansion.	O

In	O
addition,	O
to	O
prepare	O
for	O
cell-based	O
therapies,	O
new	O
technologies	O
for	O
the	O
generation	O
of	O
stem	B
cell	I
lines	O
that	O
are	O
histocompatible	O
with	O
or	O
specific	O
to	O
individual	O
patients	O
will	O
provide	O
a	O
strategy	O
to	O
overcome	O
the	O
challenges	O
of	O
immune	O
rejection..	O

Of	O
critical	O
importance	O
for	O
the	O
utility	O
of	O
stem	B
cells	I
is	O
their	O
reliable	O
and	O
efficient	O
differentiation	O
into	O
specific	O
cell	O
types	O
such	O
as	O
disease-linked	O
types	O
of	O
neurons	O
or	O
blood	O
lineage	O
cells.	O

Techniques	O
for	O
directed	O
differentiation	O
of	O
stem	B
cells	I
into	O
specific	O
neuronal	O
or	O
blood	O
cells	O
are	O
invariably	O
based	O
on	O
reconstructing	O
in	O
the	O
culture	O
dish	O
the	O
sequential	O
conditions	O
that	O
lead	O
during	O
normal	O
development	O
to	O
the	O
generation	O
of	O
the	O
cell	O
type	O
in	O
question.	O

Young;	O
n = 4	O
(21.8	O
years ± 2.4SD),	O
Old;	O
n = 4	O
(65.5	O
years ± 8.3SD)	O
MSCs	O
21.8–65.5	O
years	O
Mesenchymal	B
stem	I
cell	I
450	O
k	O
Illumina	O
methylation	O
array	O
50%	O
of	O
the	O
top	O
20	O
differentially	O
methylated	O
loci	O
contained	O
transcription	O
factors,	O
suggesting	O
altered	O
transcriptional	O
regulation	O
and	O
ageing	O
may	O
be	O
controlled	O
through	O
methylation	O
events.	O

Different	O
origins	O
may	O
be	O
associated	O
with	O
different	O
functions,	O
and	O
due	O
to	O
the	O
localization	O
of	O
the	O
embryonic	O
F4/80Pos	O
macrophages,	O
it	O
is	O
easy	O
to	O
speculate	O
a	O
role	O
for	O
these	O
cells	O
in	O
stem	B
cell	I
renewal,	O
combined	O
with	O
growth	O
factor	O
secretion..	O

Prior	O
to	O
stem	B
cell	I
isolation,	O
MNCs	O
were	O
resuspended	O
in	O
an	O
isolation	O
HBSS	O
(iHBSS)	O
consisting	O
of	O
0.5%	O
FBS	O
and	O
2	O
mM	O
EDTA	O
in	O
HBSS..	O

Conditioning	O
prior	O
to	O
stem	B
cell	I
transplantation	O
has	O
helped	O
improve	O
B	O
cell	O
reconstitution	O
in	O
some	O
cases	O
(63),	O
although	O
such	O
conditioning	O
procedures	O
would	O
be	O
difficult	O
prior	O
to	O
in	O
utero	O
cell	O
transplantation.	O

15	O
Mouse	B
embryonic	I
stem	I
cells	I
Cultured	O
cell	O
line	O
1000	O
ng	O
14	O
h	O
99.3%	O
2	O
17,887,273	O
6,304,523	O
35.2%	O
9,004,532	O
888,836	O
10.1×.	O

16	O
Mouse	B
embryonic	I
stem	I
cells	I
Cultured	O
cell	O
line	O
300	O
ng	O
14	O
h	O
99.3%	O
2	O
14,791,120	O
4,592,225	O
31.0%	O
6,196,115	O
761,891	O
8.1×.	O

17	O
Mouse	B
embryonic	I
stem	I
cells	I
Cultured	O
cell	O
line	O
100	O
ng	O
14	O
h	O
97.7%	O
2	O
25,020,175	O
6,950,681	O
27.8%	O
9,261,527	O
870,409	O
10.6×.	O

18	O
Mouse	B
embryonic	I
stem	I
cells	I
Cultured	O
cell	O
line	O
30	O
ng	O
14	O
h	O
98.4%	O
2	O
26,698,038	O
8,521,733	O
31.9%	O
12,548,800	O
931,932	O
13.5×.	O

Depletion	O
of	O
RMST	O
prevents	O
cells	O
from	O
exiting	O
the	O
embryonic	B
stem	I
cell	I
state	O
and	O
inhibits	O
the	O
initiation	O
of	O
neural	O
differentiation.	O

Pnky	O
Divergent	O
Pou3f2	O
Decoy	O
for	O
splicing	O
factors	O
Neural	B
Stem	I
Cell	I
self-renewal	O
N/A	O
Ramos	O
et	O
al.,	O
2015.	O

Developments	O
in	O
stem	B
cell	I
therapy	O
have	O
introduced	O
renewed	O
hope	O
to	O
patients	O
with	O
ischemic	O
stroke	O
due	O
to	O
its	O
potential	O
effect	O
for	O
reversing	O
the	O
neurological	O
sequelae.	O

Nearly	O
four	O
decades	O
of	O
experimental	O
evidence	O
have	O
proven	O
the	O
efficacy	O
and	O
safety	O
of	O
stem	B
cell	I
therapies	O
in	O
pre-clinical	O
animal	O
tests	O
and	O
clinical	O
trials	O
(Borlongan,	O
2019).	O

In	O
this	O
review,	O
we	O
discuss	O
the	O
potential	O
mechanisms,	O
cell	O
types,	O
methods,	O
and	O
time	O
for	O
stem	B
cell	I
transplantation,	O
current	O
trends	O
in	O
stem	O
cell-based	O
therapy,	O
and	O
the	O
challenges	O
that	O
need	O
to	O
be	O
overcome..	O

Overview	O
of	O
the	O
potential	O
mechanisms	O
of	O
stem	B
cell	I
therapy	O
for	O
ischemic	O
stroke.	O

The	O
underlying	O
mechanisms	O
of	O
stem	B
cell	I
therapy	O
for	O
ischemic	O
stroke	O
may	O
be	O
to	O
reverse	O
these	O
processes,	O
including	O
cell	O
migration	O
and	O
differentiation	O
into	O
various	O
cells	O
to	O
replace	O
damaged	O
neurons,	O
neurotrophic	O
secretion,	O
apoptosis	O
and	O
inflammation	O
inhibition,	O
angiogenesis,	O
and	O
enhancement	O
of	O
neural	O
circuit	O
reconstruction.	O

Axonal	O
plasticity	O
may	O
be	O
the	O
basic	O
mechanism	O
of	O
stem	B
cell	I
therapy	O
(Boshuizen	O
and	O
Steinberg,	O
2018).	O

iPSC	O
are	O
a	O
type	O
of	O
pluripotent	B
stem	I
cell	I
that	O
can	O
be	O
generated	O
directly	O
from	O
somatic	O
cells.	O

However,	O
some	O
studies	O
promote	O
the	O
use	O
of	O
IA	O
for	O
stem	B
cell	I
administration	O
as	O
the	O
shortest	O
route	O
toward	O
the	O
lesion,	O
with	O
improving	O
cell	O
engraftment	O
and	O
survival	O
(Na	O
Kim	O
et	O
al.,	O
2017).	O

Further	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
best	O
route	O
for	O
stem	B
cell	I
transplantation	O
in	O
treating	O
stroke	O
patients..	O

In	O
clinical	O
trials,	O
the	O
time	O
window	O
of	O
stem	B
cell	I
transplant	O
administration	O
ranged	O
from	O
24 h	O
to	O
2 years.	O

The	O
integration	O
of	O
gene	O
therapy,	O
tissue	O
engineering	O
scaffolds,	O
and	O
the	O
use	O
of	O
various	O
stem	O
cell	O
types	O
are	O
the	O
current	O
trends	O
in	O
stem	B
cell	I
therapy..	O

Using	O
a	O
combination	O
of	O
multiple	O
types	O
of	O
stem	B
cells	I
is	O
another	O
trend	O
in	O
cell	O
therapy.	O

SUMOylation	O
promotes	O
survival	O
and	O
integration	O
of	O
neural	B
stem	I
cell	I
grafts	O
in	O
ischemic	O
stroke.	O

Intravenous	O
autologous	O
bone	B
marrow	I
mononuclear	I
stem	I
cell	I
therapy	O
for	O
ischemic	O
stroke:	O
a	O
multicentric,	O
randomized	O
trial.	O

Mesenchymal	B
stem	I
cell	I
therapy	O
in	O
stroke:	O
a	O
systematic	O
review	O
of	O
literature	O
in	O
pre-clinical	O
and	O
clinical	O
research.	O

A	O
simple	O
genotyping	O
assay	O
for	O
the	O
Hprt	O
null	O
allele	O
in	O
mice	O
produced	O
from	O
the	O
HM-1	O
and	O
E14TG2a	O
mouse	B
embryonic	I
stem	I
cell	I
lines.	O

A	O
new	O
mouse	B
embryonic	I
stem	I
cell	I
line	O
with	O
good	O
germ	O
line	O
contribution	O
and	O
gene	O
targeting	O
frequency.	O

De	O
novo	O
alterations	O
that	O
confer	O
a	O
proliferative	O
advantage	O
to	O
the	O
spermatogonial	B
stem	I
cell	I
would	O
lead	O
to	O
the	O
expansion	O
of	O
this	O
cell	O
clone	O
(and	O
consequently	O
sperm	O
carrying	O
this	O
mutation	O
or	O
epimutation)..	O

One	O
of	O
the	O
main	O
questions	O
in	O
the	O
stem	B
cell	I
field	O
is	O
how	O
tissues	O
and	O
organs	O
balance	O
these	O
opposing	O
processes.	O

The	O
adult	O
Drosophila	O
midgut	O
has	O
been	O
established	O
as	O
a	O
simple	O
and	O
useful	O
system	O
for	O
the	O
study	O
of	O
the	O
stem	B
cell	I
behavior	O
during	O
homeostatic	O
tissue	O
renewal	O
and	O
in	O
response	O
to	O
environmental	O
changes	O
(Biteau	O
et	O
al.,	O
2011;	O
Jiang	O
and	O
Edgar,	O
2012).	O

A	O
sox	O
transcription	O
factor	O
is	O
a	O
critical	O
regulator	O
of	O
adult	B
stem	I
cell	I
proliferation	O
in	O
the	O
Drosophila	O
intestine.	O

Olfactory	O
mucosa	O
is	O
a	O
potential	O
source	O
for	O
autologous	B
stem	I
cell	I
therapy	O
for	O
Parkinson's	O
disease.	O

Variation	O
in	O
cancer	O
risk	O
among	O
tissues	O
can	O
be	O
explained	O
by	O
the	O
number	O
of	O
stem	B
cell	I
divisions.	O

Patient-derived	O
xenografts,	O
the	O
cancer	B
stem	I
cell	I
paradigm,	O
and	O
cancer	O
pathobiology	O
in	O
the	O
21st	O
century.	O

The	O
hypoxic	O
tumor	O
microenvironment	O
in	O
vivo	O
selects	O
the	O
cancer	B
stem	I
cell	I
fate	O
of	O
breast	O
cancer	O
cells.	O

Dysregulation	O
in	O
stem	B
cell	I
recruitment	O
and	O
differentiation	O
during	O
adipogenesis	O
is	O
linked	O
to	O
a	O
chronic	O
low-grade	O
inflammation	O
and	O
macrophage	O
infiltration	O
inside	O
the	O
adipose	O
tissue,	O
insulin	O
resistance,	O
cardiovascular	O
disease	O
and	O
obesity.	O

Furthermore,	O
HSP70	O
interacts	O
with	O
several	O
transcription	O
factors	O
in	O
order	O
to	O
modulate	B
stem	I
cell	I
behavior	O
and	O
autophagy	O
[24,25].	O

In	O
the	O
present	O
study,	O
we	O
evaluated	O
the	O
effects	O
of	O
these	O
two	O
molecules,	O
alone	O
or	O
in	O
combination,	O
in	O
modulating	B
stem	I
cell	I
behavior	O
during	O
adipogenic	O
commitment,	O
with	O
particular	O
attention	O
to	O
cytokine	O
release	O
and	O
autophagosome	O
formation,	O
in	O
the	O
attempt	O
to	O
balance	O
WAT/BAT	O
differentiation	O
and	O
counteract	O
uncontrolled	O
lipogenesis..	O

Dual	O
Role	O
of	O
Autophagy	O
in	O
Regulation	O
of	O
Mesenchymal	B
Stem	I
Cell	I
Senescence.	O

Severe	O
polyposis	O
in	O
Apc1322T	O
mice	O
is	O
associated	O
with	O
submaximal	O
Wnt	O
signalling	O
and	O
increased	O
expression	O
of	O
the	O
stem	B
cell	I
marker	O
Lgr5.	O

To	O
address	O
these	O
challenges,	O
we	O
developed	O
and	O
applied	O
a	O
straightforward,	O
clinically	O
amenable	O
assay	O
to	O
validate	O
and	O
quantify	O
RNA	O
recoding	O
in	O
stem	B
cell	I
regulatory	O
transcripts	O
identified	O
through	O
whole	O
transcriptome	O
RNA-seq	O
analysis	O
of	O
purified	O
primary	O
LSC	O
[1].	O

Previous	O
whole	O
transcriptome	O
analysis	O
(Figure	O
1A)	O
revealed	O
widespread	O
A-to-I	O
RNA	O
changes	O
in	O
CML	O
LSC	O
that	O
were	O
associated	O
with	O
malignant	O
progenitor	O
reprogramming	O
typified	O
by	O
mis-splicing	O
of	O
key	B
stem	I
cell	I
regulatory	O
transcripts	O
in	O
selective	O
niches	O
during	O
CML	O
progression	O
[1,27].	O

An	O
additional	O
known	O
editing	O
site	O
within	O
exon	O
10	O
of	O
the	O
stem	B
cell	I
self-renewal	O
factor	O
GLI1	O
was	O
included	O
because	O
ADAR-directed	O
RNA	O
editing	O
of	O
this	O
site	O
promotes	O
transcriptional	O
activity	O
of	O
GLI1	O
protein.	O

Glycogen	O
synthase	O
kinase	O
3beta	O
missplicing	O
contributes	O
to	O
leukemia	B
stem	I
cell	I
generation.	O

Complementing	O
these	O
therapies	O
are	O
advances	O
in	O
innate	O
host	O
defense:	O
a	O
pioneering	O
clinical	O
study	O
using	O
adoptive	O
transfer	O
of	O
Aspergillus-stimulated	O
T	O
cells	O
showed	O
significant	O
efficacy	O
in	O
treating	B
stem	I
cell	I
transplant	O
recipients	O
with	O
invasive	O
aspergillosis.	O

Complementing	O
these	O
therapies	O
are	O
advances	O
in	O
innate	O
host	O
defense:	O
a	O
pioneering	O
clinical	O
study	O
using	O
adoptive	O
transfer	O
of	O
Aspergillus-stimulated	O
T	O
cells	O
showed	O
significant	O
efficacy	O
in	O
treating	B
stem	I
cell	I
transplant	O
recipients	O
with	O
invasive	O
aspergillosis.	O

RT-qPCR	O
analysis	O
also	O
demonstrated	O
that	O
knockdown	O
of	O
HOXD-AS1	O
decreased	O
the	O
expression	O
levels	O
of	O
stem	B
cell	I
markers	O
(CD44,	O
CD133,	O
CD24,	O
CD166,	O
Oct4,	O
Lgr5,	O
Sox2	O
and	O
Nanog)	O
in	O
HCT116	O
and	O
LoVo	O
cells	O
(P<0.05;	O
Fig.	O

(D)	O
RT-qPCR	O
analysis	O
demonstrated	O
that	O
knockdown	O
of	O
HOXD-AS1	O
decreased	O
the	O
expression	O
levels	O
of	O
stem	B
cell	I
markers	O
(CD44,	O
CD133,	O
CD24,	O
CD166,	O
Oct4,	O
Lgr5,	O
Sox2	O
and	O
Nanog)	O
in	O
HCT116	O
and	O
LoVo	O
cells	O
(*P<0.05	O
vs.	O

Along	O
the	O
same	O
lines,	O
the	O
California	O
Institute	O
for	O
Regenerative	O
Medicine	O
(CIRM)	O
has	O
adopted	O
WikiPathways	O
to	O
highlight	O
a	O
subset	O
of	O
pathways	O
contributed	O
by	O
the	O
stem	B
cell	I
research	O
community.	O

Later,	O
in	O
development	O
and	O
adult	O
life,	O
telomerase	O
becomes	O
the	O
dominant	O
telomere	O
maintenance	O
mechanism	O
for	O
the	O
inner	O
cell	O
mass	O
and	O
in	O
tissue-specific	O
telomere	O
replenishment	O
in	O
stem	B
cell	I
niches.	O

Characterization	O
of	O
cancer	B
stem	I
cell	I
properties	O
of	O
CD24	O
and	O
CD26-positive	O
human	O
malignant	O
mesothelioma	O
cells.	O

For	O
instance,	O
hESCs	O
express	O
the	O
stem	B
cell	I
marker	O
REX1,	O
similarly	O
to	O
mESCs,	O
and	O
mEpiSCs	O
express	O
the	O
Fgf5,	O
which	O
is	O
absent	O
in	O
hESCs	O
and	O
mESCs	O
(Tesar	O
et	O
al.,	O
2007).	O

Distinct	O
developmental	O
ground	O
states	O
of	O
epiblast	B
stem	I
cell	I
lines	O
determine	O
different	O
pluripotency	O
features.	O

Most	O
recent	O
studies	O
on	O
mice	O
deficient	O
in	O
stem	B
cell	I
factor	O
in	O
the	O
transcription	O
factor	O
called	O
krox20	O
lineage	O
that	O
exhibit	O
hair	O
graying	O
exposed	O
the	O
identities	O
of	O
hair	O
matrix	O
progenitors	O
which	O
regulate	O
hair	O
growth	O
and	O
pigmentation36.	O

A	O
new	O
complication	O
of	O
stem	B
cell	I
transplantation:	O
measles	O
inclusion	O
body	O
encephalitis.	O

A	O
fatal	O
case	O
of	O
measles	O
pneumonia	O
complicating	O
an	O
adult	O
recipient	O
of	O
hemopoietic	B
stem	I
cell	I
transplantation	O
during	O
the	O
nationwide	O
epidemic	O
in	O
Korea.	O

Cohen	O
for	O
EM	O
technical	O
assistance;	O
National	O
Heart,	O
Lung,	O
and	O
Blood	O
Institute	O
FACS	O
core	O
and	O
National	O
Cancer	O
Institute	O
Center	O
for	O
Cancer	O
Research	O
Genomics	O
core	O
for	O
technical	O
support;	O
Bloomington	O
Drosophila	O
Stock	O
Center,	O
Vienna	O
Drosophila	O
Resource	O
Center,	O
Kyoto	O
Drosophila	O
Genomics	O
and	O
Genetics	O
Resources	O
for	O
fly	O
stocks;	O
Drosophila	O
Genomics	O
Resource	O
Center	O
for	O
Dm	B
stem	I
cell	I
cultures;	O
and	O
Developmental	O
Studies	O
Hybridoma	O
Bank	O
for	O
antibodies.	O

The	O
upregulation	O
of	O
miR-302	O
cluster	O
and	O
miR-520	O
cluster	O
in	O
hES	O
cells	O
suggests	O
their	O
ability	O
to	O
modulate	O
local	O
chromatin	O
states	O
which	O
is	O
necessary	O
for	O
stem	B
cell	I
pluripotency	O
[58,59]..	O

Recently,	O
it	O
was	O
reported	O
that	O
the	O
downregulation	O
of	O
let-7	O
is	O
essential	O
for	O
self-renewal	O
and	O
maintenance	O
of	O
the	O
undifferentiated	O
state	O
of	O
cancer	O
stem	O
cells	O
[72],	O
indicating	O
that	O
this	O
family	O
of	O
miRNAs	O
has	O
a	O
greater	O
role	O
in	O
stem	B
cell	I
function	O
than	O
previously	O
described..	O

Human	B
embryonic	I
stem	I
cell	I
lines	O
WA09	O
(H9),	O
TE06	O
(I6),	O
and	O
BG01v	O
from	O
WiCell	O
Research	O
Institute	O
(Madison,	O
WI),	O
Technion-Israel	O
Institute	O
of	O
Technology	O
(Haifa,	O
Israel)	O
and	O
ATCC	O
(Manassas,	O
VA)	O
were	O
cultured	O
on	O
mitotically	O
inactivated	O
mouse	O
embryonic	O
fibroblast	O
(MEF)	O
feeders	O
using	O
DMEM/F12	O
medium	O
optimized	O
for	O
human	O
ESC	O
culture	O
(GlobalStem	O
Inc,	O
Rockville,	O
MD)	O
supplemented	O
with	O
20%	O
knockout	O
serum	O
replacement	O
and	O
4	O
ng/ml	O
bFGF	O
(both	O
from	O
Invitrogen,	O
Gaithersburg,	O
MD).	O

GeneChip	O
analysis	O
of	O
human	B
embryonic	I
stem	I
cell	I
differentiation	O
into	O
hemangioblasts:	O
an	O
in	O
silico	O
dissection	O
of	O
mixed	O
phenotypes.	O

Gene	O
expression	O
patterns	O
in	O
human	B
embryonic	I
stem	I
cells	I
and	O
human	O
pluripotent	O
germ	O
cell	O
tumors.	O

Sonic	O
hedgehog	O
stimulates	O
mouse	B
embryonic	I
stem	I
cell	I
proliferation	O
by	O
cooperation	O
of	O
Ca2+/protein	O
kinase	O
C	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
as	O
well	O
as	O
Gli1	O
activation.	O

With	O
the	O
reemergence	O
of	O
the	O
cancer	B
stem	I
cell	I
hypothesis	O
initially	O
suggested	O
more	O
than	O
100	O
years	O
ago,77,78	O
new	O
cell	O
culture	O
tools	O
have	O
been	O
developed	O
for	O
propagating	O
cancer	O
stem-like	O
cells	O
in	O
serum-free	O
growth	O
media,	O
supplemented	O
with	O
epidermal	O
growth	O
factor	O
(EGF),	O
fibroblast	O
growth	O
factor,	O
and	O
insulin	O
(neurobasal	O
media).79–81	O
The	O
establishment	O
of	O
such	O
spheres	O
from	O
gliomas	O
has	O
provided	O
novel	O
insight	O
into	O
tumor	O
cells	O
that	O
show	O
stem-cell	O
characteristics82–85	O
and	O
has	O
proven	O
to	O
be	O
highly	O
successful	O
from	O
a	O
variety	O
of	O
tumors,	O
including	O
pediatric	O
gliomas83	O
and	O
GBM.86.	O

Tumor	B
stem	I
cells	I
derived	O
from	O
glioblastomas	O
cultured	O
in	O
bFGF	O
and	O
EGF	O
more	O
closely	O
mirror	O
the	O
phenotype	O
and	O
genotype	O
of	O
primary	O
tumors	O
than	O
do	O
serum-cultured	O
cell	O
lines.	O

Glioma	B
stem	I
cell	I
lines	O
expanded	O
in	O
adherent	O
culture	O
have	O
tumor-specific	O
phenotypes	O
and	O
are	O
suitable	O
for	O
chemical	O
and	O
genetic	O
screens.	O

Importantly,	O
caspases	O
are	O
emerging	O
as	O
potent	O
controllers	O
of	O
stem	B
cell	I
properties,	O
as	O
well	O
as	O
differentiation	O
factors	O
[12,	O
13].	O

An	O
expanded	O
Oct4	O
interaction	O
network:	O
implications	O
for	O
stem	B
cell	I
biology,	O
development,	O
and	O
disease.	O

Transient	O
pairing	O
of	O
homologous	O
Oct4	O
alleles	O
accompanies	O
the	O
onset	O
of	O
embryonic	B
stem	I
cell	I
differentiation.	O

The	O
mechanisms	O
behind	O
the	O
EAE-induced	O
derangement	O
of	O
the	O
normal	O
villus-crypt	O
structure	O
is	O
not	O
clear	O
but	O
could	O
be	O
related	O
to	O
differentiation	O
of	O
the	O
intestinal	O
subepithelial	O
myofibroblasts,	O
cell-volume	O
changes	O
in	O
the	O
enterocytes,	O
or	O
alteration	O
of	O
crypt	B
stem	I
cell	I
proliferation..	O

Here	O
we	O
talk	O
about	O
stem	B
cell	I
therapy	O
for	O
the	O
treatment	O
of	O
RA	O
in	O
basic	O
experiments	O
and	O
clinical	O
applications..	O

Inhibition	O
of	O
immune	O
synapse	O
by	O
altered	O
dendritic	O
cell	O
actin	O
distribution:	O
a	O
new	O
pathway	O
of	O
mesenchymal	B
stem	I
cell	I
immune	O
regulation.	O

Mesenchymal	B
stem	I
cells	I
inhibit	O
dendritic	O
cell	O
differentiation	O
and	O
function	O
by	O
preventing	O
entry	O
into	O
the	O
cell	O
cycle.	O

Mesenchymal	B
stem	I
cells	I
induce	O
mature	O
dendritic	O
cells	O
into	O
a	O
novel	O
Jagged-2-dependent	O
regulatory	O
dendritic	O
cell	O
population.	O

Thus,	O
the	O
stem	B
cell	I
hierarchy	O
within	O
GBM	O
cell	O
populations,	O
in	O
part,	O
resembles	O
the	O
program	O
dynamics	O
during	O
normal	O
brain	O
development.	O

Within	O
this	O
heterogeneous	O
GSC	O
compartment	O
is	O
a	O
particularly	O
invasive	O
subpopulation	O
that	O
transcriptionally	O
resembles	O
outer	O
radial	O
glia,	O
a	O
fetal	O
cell	O
type	O
that	O
expands	O
the	O
stem	B
cell	I
niche	O
in	O
normal	O
human	O
cortex.	O

Adaptive	O
Chromatin	O
Remodeling	O
Drives	O
Glioblastoma	B
Stem	I
Cell	I
Plasticity	O
and	O
Drug	O
Tolerance.	O

Browsing	O
(epi)genomes:	O
a	O
guide	O
to	O
data	O
resources	O
and	O
epigenome	O
browsers	O
for	O
stem	B
cell	I
researchers.	O

Generating	O
hepatic	O
cell	O
lineages	O
from	O
pluripotent	B
stem	I
cells	I
for	O
drug	O
toxicity	O
screening.	O

(2009)	O
Genetic	O
variation	O
in	O
the	O
prostate	B
stem	I
cell	I
antigen	O
gene	O
PSCA	O
confers	O
susceptibility	O
to	O
urinary	O
bladder	O
cancer.	O

In	O
Japan,	O
regulation	O
is	O
the	O
responsibility	O
of	O
the	O
Pharmaceuticals	O
and	O
Medical	O
Devices	O
Agency	O
(PMDA),	O
which	O
recently	O
prioritized	O
biologics,	O
thus	O
enabling	O
the	O
approval	O
of	O
stem	B
cell	I
therapies	O
with	O
only	O
basic	O
demonstrations	O
of	O
safety	O
and	O
trends	O
toward	O
efficacy	O
(phase	O
II	O
clinical	O
trials).	O

Clinical	O
trials	O
of	O
adult	B
stem	I
cell	I
therapy	O
for	O
peripheral	O
artery	O
disease.	O

Human	O
relevance	O
of	O
pre-clinical	O
studies	O
in	O
stem	B
cell	I
therapy:	O
systematic	O
review	O
and	O
meta-analysis	O
of	O
large	O
animal	O
models	O
of	O
ischaemic	O
heart	O
disease.	O

Cardiac	B
stem	I
cell	I
treatment	O
in	O
myocardial	O
infarction:	O
a	O
systematic	O
review	O
and	O
meta-analysis	O
of	O
preclinical	O
studies.	O

Granulocyte	O
colony-stimulating	O
factor	O
therapy	O
for	O
stem	B
cell	I
mobilization	O
following	O
anterior	O
wall	O
myocardial	O
infarction:	O
the	O
CAPITAL	O
STEM	O
MI	O
randomized	O
trial.	O

Effects	O
of	O
intracoronary	B
stem	I
cell	I
transplantation	O
in	O
patients	O
with	O
dilated	O
cardiomyopathy.	O

Granulocyte-colony	O
stimulating	O
factor	O
or	O
granulocyte-colony	O
stimulating	O
factor	O
associated	O
to	O
stem	B
cell	I
intracoronary	O
infusion	O
effects	O
in	O
non	O
ischemic	O
refractory	O
heart	O
failure.	O

A	O
quantitative,	O
randomized	O
study	O
evaluating	O
three	O
methods	O
of	O
mesenchymal	B
stem	I
cell	I
delivery	O
following	O
myocardial	O
infarction.	O

A	O
high-throughput	O
platform	O
for	O
stem	B
cell	I
niche	O
co-cultures	O
and	O
downstream	O
gene	O
expression	O
analysis.	O

Mitochondria	O
also	O
play	O
a	O
critical	O
role	O
in	O
the	O
neurogenesis,	O
the	O
process	O
of	O
neural	B
stem	I
cell	I
proliferation	O
and	O
differentiation	O
into	O
new	O
neurons.	O

Since	O
the	O
derivation	O
of	O
mESCs	O
from	O
the	O
blastocyst-stage	O
embryo,	O
significant	O
advances	O
have	O
been	O
made	O
in	O
extending	O
the	O
repertoire	O
of	O
stem	B
cell	I
types	O
in	O
the	O
mouse	O
(reviewed	O
in	O
Rossant,	O
2008),	O
as	O
well	O
as	O
other	O
mammalian	O
species,	O
notably	O
humans	O
(reviewed	O
in	O
Wu	O
et	O
al.,	O
2016).	O

trophoblast	B
stem	I
cells	I
blastocyst	O
TE,	O
postimplantation	O
ExE	O
TE	O
lineage	O
(detailed	O
analysis	O
of	O
differentiation	O
into	O
all	O
cell	O
types	O
not	O
available)	O
Tanaka	O
et	O
al.	O

These	O
observations	O
have	O
led	O
to	O
a	O
renewed	O
interest	O
in	O
the	O
development	O
of	O
more	O
complex,	O
often	O
3D,	O
models	O
of	O
stem	B
cell	I
differentiation,	O
which	O
are	O
designed	O
to	O
more	O
accurately	O
recapitulate	O
the	O
spatial	O
interactions	O
among	O
cells	O
observed	O
in	O
early	O
embryonic	O
development	O
(Figure	O
1	O
and	O
Table	O
2).	O

Regular	O
screening	O
of	O
stem	B
cell	I
lines	O
may	O
well	O
be	O
needed	O
to	O
ensure	O
their	O
ongoing	O
fidelity.	O

Alternatively,	O
the	O
use	O
of	O
stem	B
cell	I
lines	O
with	O
known	O
chromosomal	O
abnormalities	O
may	O
provide	O
a	O
system	O
to	O
study	O
how	O
the	O
resulting	O
developmental	O
defects	O
subsequently	O
emerge..	O

Comparing	O
gene	O
expression	O
of	O
stem	B
cell	I
types,	O
whether	O
by	O
a	O
handful	O
of	O
key	O
marker	O
genes	O
or	O
by	O
genome-wide	O
expression	O
profiling,	O
to	O
representative	O
embryo	O
stages	O
is	O
a	O
good	O
first	O
approximation	O
of	O
cell	O
identity.	O

It	O
is	O
important	O
to	O
note,	O
however,	O
that	O
in	O
species	O
such	O
as	O
nonhuman	O
primates	O
(NHPs)	O
and	O
humans,	O
where	O
functional	O
assays	O
are	O
limited,	O
a	O
transcriptional	O
comparison	O
remains	O
a	O
major	O
pillar	O
of	O
stem	B
cell	I
quality	O
control,	O
given	O
proper	O
in	O
vivo	O
comparisons	O
are	O
available	O
(discussed	O
later)..	O

The	O
disadvantages	O
of	O
this	O
approach	O
include	O
low	O
throughput	O
capacity,	O
the	O
differential	O
ability	O
of	O
stem	O
cell	O
types	O
to	O
colonize	O
the	O
host	O
embryo,	O
especially	O
in	O
situations	O
where	O
the	O
stem	O
cell	O
is	O
developmentally	O
(Cohen	O
et	O
al.,	O
2018)	O
or	O
phylogenetically	O
(Masaki	O
and	O
Nakauchi,	O
2017)	O
not	O
matched	O
to	O
the	O
host	O
embryo,	O
and	O
the	O
increased	O
difficulty	O
of	O
characterizing	O
the	O
cellular	O
identities	O
of	O
stem	B
cell	I
progeny	O
within	O
a	O
complex	O
tissue.	O

Recent	O
studies	O
have	O
reported	O
capture	O
of	O
a	O
formative	O
state	O
in	O
self-renewing	B
stem	I
cell	I
lines	O
(Kinoshita	O
et	O
al.,	O
2020).	O

The	O
focus	O
on	O
this	O
work,	O
however,	O
has	O
left	O
improvements	O
on	O
extraembryonic	B
stem	I
cell	I
types	O
trailing	O
behind.	O

Embryonic	B
stem	I
cell	I
culture	O
conditions	O
support	O
distinct	O
states	O
associated	O
with	O
different	O
developmental	O
stages	O
and	O
potency.	O

Inhibition	O
of	O
phosphoinositide-3-kinase	O
signaling	O
promotes	O
the	O
stem	B
cell	I
state	O
of	O
trophoblast.	O

The	O
chromosome	O
make-up	O
of	O
mouse	B
embryonic	I
stem	I
cells	I
is	O
predictive	O
of	O
somatic	O
and	O
germ	O
cell	O
chimaerism.	O

Pluri-IQ:	O
Quantification	O
of	O
embryonic	B
stem	I
cell	I
pluripotency	O
through	O
an	O
image-based	O
analysis	O
software.	O

Tracing	O
the	O
derivation	O
of	O
embryonic	O
stem	B
cells	I
from	O
the	O
inner	O
cell	O
mass	O
by	O
single-cell	O
RNA-Seq	O
analysis.	O

Deep	O
learning	O
neural	O
networks	O
highly	O
predict	O
very	O
early	O
onset	O
of	O
pluripotent	B
stem	I
cell	I
differentiation.	O

Cell	O
Tracking	O
Profiler	O
(analysis	O
of	O
muscle	B
stem	I
cell	I
responses	O
to	O
injury)—semi-automated	O
image	O
analysis	O
pipeline,	O
based	O
on	O
cell	O
tracking	O
(3D	O
time-lapse	O
datasets)	O
Accurate	O
measurement	O
of	O
cell	O
shape	O
and	O
movement	O
[173].	O

Embryonic	B
stem	I
cell	I
marker	O
expression	O
and	O
differentiation	O
potential	O
of	O
SS-AF-MPCs	O
and	O
RS-AF-MPCs.	O

The	O
role	O
of	O
the	O
hyaluronan	O
receptor	O
CD44	O
in	O
mesenchymal	B
stem	I
cell	I
migration	O
in	O
the	O
extracellular	O
matrix.	O

The	O
mRNA	O
expression	O
of	O
stem	B
cell	I
markers	O
in	O
CRC	O
cells	O
with	O
upregulated	O
or	O
downregulated	O
SATB2	O
expression	O
was	O
detected	O
by	O
quantitative	O
real-time	O
polymerase	O
chain	O
reaction.	O

Chromatin	O
immunoprecipitation	O
(ChIP)	O
was	O
used	O
to	O
verify	O
the	O
binding	O
loci	O
of	O
SATB2	O
on	O
genomic	O
sequences	O
of	O
stem	B
cell	I
markers.	O

Primer	O
sequences	O
used	O
in	O
quantitative	O
real-time	O
polymerase	O
chain	O
reaction	O
for	O
detection	O
of	O
stem	B
cell	I
marker	O
mRNA	O
expression.	O

Primer	O
sequences	O
used	O
in	O
polymerase	O
chain	O
reaction	O
for	O
detecting	O
genomic	O
binding	O
sites	O
for	O
stem	B
cell	I
markers.	O

A-B:	O
The	O
mRNA	O
expression	O
of	O
a	O
series	O
of	O
stem	B
cell	I
markers	O
was	O
detected	O
in	O
SATB2	O
overexpressing	O
cells	O
(A)	O
and	O
SATB2	O
knockdown	O
cells	O
(B)	O
by	O
qRT-PCR;	O
C-D:	O
CD133	O
expression	O
level	O
in	O
cells	O
with	O
stable	O
SATB2	O
knockdown	O
was	O
increased	O
when	O
detected	O
by	O
Western	O
blot	O
(C)	O
and	O
immunofluorescence	O
(D).	O

As	O
a	O
transcriptional	O
factor,	O
SATB2	O
may	O
affect	O
gene	O
expression	O
of	O
stem	B
cell	I
markers	O
by	O
directly	O
binding	O
to	O
regulatory	O
elements	O
of	O
those	O
genes.	O

Brca1	O
breast	O
tumors	O
contain	O
distinct	O
CD44+/CD24-	O
and	O
CD133+	O
cells	O
with	O
cancer	B
stem	I
cell	I
characteristics.	O

Furthermore,	O
enriching	O
multiple	O
breast	O
cancer	O
cell	O
lines	O
for	O
stem	B
cells	I
in	O
vitro	O
not	O
only	O
resulted	O
in	O
an	O
increase	O
in	O
stemness	O
markers,	O
but	O
also	O
resulted	O
in	O
increased	O
miR-221	O
expression,	O
suggesting	O
that	O
miR-221	O
is	O
involved	O
in	O
regulating	O
BCSCs.	O

The	O
tumor	O
secretion	O
of	O
stem	B
cell	I
factor	O
functions	O
as	O
a	O
chemoattracting	O
signal	O
for	O
mast	O
cells;	O
then	O
mast	O
cells	O
produce	O
angiogenic	O
factors	O
and	O
MMPs	O
(MMP-2	O
and	O
MMP-9)	O
to	O
promote	O
tumor	O
vascularization..	O

Furthermore,	O
in	O
females,	O
Pdcd4	O
genetically	O
interacts	O
with	O
the	O
key	O
differentiation	O
gene	O
bag	O
of	O
marbles	O
(bam)	O
and	O
the	O
stem	B
cell	I
renewal	O
factor	O
eIF4A,	O
suggesting	O
a	O
possible	O
pathway	O
for	O
its	O
function	O
in	O
differentiation..	O

An	O
excess	O
of	O
differentiation	O
can	O
lead	O
to	O
stem	B
cell	I
depletion	O
and	O
tissue	O
senescence,	O
whereas	O
an	O
excess	O
of	O
self-renewal,	O
and/or	O
a	O
deficiency	O
of	O
differentiation,	O
can	O
lead	O
to	O
an	O
accumulation	O
of	O
undifferentiated	O
proliferative	O
cells.	O

With	O
the	O
aim	O
of	O
identifying	O
new	O
candidate	O
genes	O
with	O
putative	O
functions	O
in	O
stem	B
cell	I
maintenance	O
and	O
the	O
early	O
differentiation	O
programs	O
of	O
female	O
and	O
male	O
germ	O
cells,	O
we	O
sought	O
to	O
identify	O
genes	O
whose	O
expression	O
is	O
enriched	O
in	O
specific	O
cell	O
populations	O
in	O
adult	O
gonadal	O
tissue	O
containing	O
GSCs,	O
early	O
differentiating	O
germ	O
cells,	O
and	O
somatic	O
cells.	O

In	O
the	O
second	O
approach	O
of	O
our	O
study,	O
we	O
analyzed	O
our	O
data	O
with	O
respect	O
to	O
data	O
from	O
previous	O
studies	O
of	O
gene	O
expression	O
in	O
stem	B
cells	I
and	O
their	O
daughter	O
cells	O
in	O
order	O
to	O
begin	O
to	O
analyze	O
the	O
expression	O
patterns	O
in	O
different	O
cell	O
types.	O

For	O
example,	O
the	O
first	O
rank	O
ordered	O
gene	O
is	O
piwi,	O
which	O
is	O
expressed	O
in	O
the	O
germarium	O
and	O
apex	O
of	O
testis	O
and	O
is	O
an	O
essential	O
factor	O
in	O
germline	B
stem	I
cell	I
maintenance	O
in	O
both	O
females	O
and	O
males	O
[57-59].	O

The	O
gene	O
ovo	O
is	O
expressed	O
in	O
the	O
germline	B
stem	I
cell	I
niches	O
of	O
both	O
females	O
and	O
males	O
although	O
it	O
doesn't	O
appear	O
to	O
play	O
a	O
role	O
in	O
the	O
male	O
germline	O
[60,61].	O

Regulation	O
of	O
self-renewal	O
and	O
differentiation	O
in	O
adult	B
stem	I
cell	I
lineages:	O
lessons	O
from	O
the	O
Drosophila	O
male	O
germ	O
line.	O

A	O
novel	O
class	O
of	O
evolutionarily	O
conserved	O
genes	O
defined	O
by	O
piwi	O
are	O
essential	O
for	O
stem	B
cell	I
self-renewal.	O

These	O
results	O
indicate	O
that	O
FREM2	O
was	O
significantly	O
over-expressed	O
in	O
glioblastoma	O
stem-like	O
cell	O
line	O
(NCH)	O
in	O
comparison	O
to	O
mature	O
glioblastoma	O
cells	O
of	O
the	O
U87MG	O
cell	O
line	O
representing	O
relatively	O
less	O
aggressive	O
neuronal	O
type	O
GB	O
[40],	O
and	O
in	O
comparison	O
to	B
neural	I
stem	I
cells	I
and	O
astrocytes.	O

Epidermal	O
growth	O
factor	O
receptor	O
and	O
ink4a/arf:	O
Convergent	O
mechanisms	O
governing	O
terminal	O
differentiation	O
and	O
transformation	O
along	O
the	O
neural	B
stem	I
cell	I
to	O
astrocyte	O
axis.	O

In	O
mammals,	O
subsets	O
of	O
tanycytes	O
also	O
express	O
Sox2,	O
a	O
transcription	O
factor	O
essential	O
for	O
neural	B
stem	I
cell	I
differentiation	O
and	O
consistent	O
with	O
the	O
observations	O
that	O
tanycytes	O
can	O
also	O
act	O
as	O
neural	O
stem/progenitor	O
cells.	O

Neural	B
stem	I
cells	I
and	O
neurogenesis	O
in	O
the	O
adult	O
zebrafish	O
brain:	O
Origin,	O
proliferation	O
dynamics,	O
migration	O
and	O
cell	O
fate.	O

Subcellular	O
localisation	O
of	O
the	O
stem	B
cell	I
markers	O
OCT4,	O
SOX2,	O
NANOG,	O
KLF4	O
and	O
c-MYC	O
in	O
cancer:	O
A	O
review.	O

Tissue	O
mass	O
growth	O
following	O
transplantation	O
of	O
autologous	B
stem	I
cell	I
from	O
blood	O
41,	O
42	O
and	O
olfactory	O
mucosa	O
43	O
has	O
been	O
reported	O
in	O
patients.	O

Mesenchymal	B
stem	I
cell	I
1	O
(MSC1)‐based	O
therapy	O
attenuates	O
tumor	O
growth	O
whereas	O
MSC2‐treatment	O
promotes	O
tumor	O
growth	O
and	O
metastasis.	O

Teratomas	O
provide	O
a	O
microenvironment	O
that	O
is	O
more	O
suitable	O
for	O
stem	B
cell	I
growth.	O

The	O
teratoma	O
system	O
facilitates	O
the	O
formation	O
of	O
embryoid-body-like	O
aggregates	O
from	O
stem	B
cells	I
with	O
poor	O
ability	O
to	O
differentiate	O
and	O
could	O
also	O
be	O
used	O
to	O
enrich	O
specific	O
cell	O
lineages	O
(Lee	O
et	O
al.,	O
2020).	O

Is	O
teratoma	O
formation	O
in	O
stem	B
cell	I
research	O
a	O
characterization	O
tool	O
or	O
a	O
window	O
to	O
developmental	O
biology?	O
Reprod.	O

Embryonic	B
stem	I
cell	I
lines	O
from	O
human	O
blastocysts:	O
somatic	O
differentiation	O
in	O
vitro.	O

Nuclear	O
AURKA	O
acquires	O
kinase-independent	O
transactivating	O
function	O
to	O
enhance	O
breast	B
cancer	I
stem	I
cell	I
phenotype.	O

Paneth	O
cells,	O
located	O
in	O
the	O
intestinal	O
crypts	O
of	O
the	O
ileum,	O
secrete	O
a	O
host	O
of	O
cytokines	O
and	O
antimicrobial	O
peptides	O
to	O
directly	O
impact	O
the	O
homeostasis	O
of	O
the	O
stem	B
cell	I
niche	O
and	O
the	O
host-microbial	O
axis	O
(Bevins	O
and	O
Salzman,	O
2011;	O
Clevers	O
and	O
Bevins,	O
2013).	O

Paneth	O
cells	O
are	O
also	O
central	O
to	O
regulating	O
mucosal	O
development,	O
providing	O
key	O
cellular	O
factors	O
critical	O
to	O
maintenance	O
of	O
the	O
intestinal	B
stem	I
cell	I
niche,	O
and	O
providing	O
host	O
defense	O
(Bevins	O
and	O
Salzman,	O
2011;	O
Clevers,	O
2013;	O
Sailaja	O
et	O
al.,	O
2016).	O

Gene	O
editing	O
in	O
hiPSC	O
further	O
helps	O
to	O
reverse	O
disease	O
phenotype	O
by	O
correction	O
of	O
the	O
pathogenic	O
mutation	O
or	O
variant,	O
raising	O
the	O
possibility	O
of	O
personalized	O
therapies	O
for	O
autologous	B
stem	I
cell	I
transplantation..	O

The	O
effect	O
of	O
romiplostim,	O
which	O
is	O
a	O
drug	O
already	O
approved	O
for	O
some	O
patients	O
suffering	O
from	O
chronic	O
idiopathic	O
thrombocytopenia	O
purpura,	O
but	O
was	O
also	O
reported	O
in	O
off-label	O
uses	O
such	O
as	O
treatment	O
of	O
persistent	O
thrombocytopenia	O
associated	O
with	O
stem	B
cell	I
transplantation	O
or	O
congenital	O
amegakaryocytic	O
thrombocytopenia,48-50	O
confirmed	O
that	O
heterozygous	O
Gfi1b-DN	O
mutant	O
MK	O
are	O
still	O
functional.	O

Although	O
this	O
locus	O
has	O
well-characterized	O
functions	O
in	O
stem	B
cell	I
and	O
tumor	O
contexts,	O
its	O
role	O
during	O
neural	O
development	O
is	O
unknown.	O

Ouyang	O
A,	O
Cerchiari	O
AE,	O
Tang	O
X,	O
Liebenberg	O
E,	O
Alliston	O
T,	O
Gartner	O
ZJ,	O
Lotz	O
JC	O
(2017a)	O
Effects	O
of	O
cell	O
type	O
and	O
configuration	O
on	O
anabolic	O
and	O
catabolic	O
activity	O
in	O
3D	O
co-culture	O
of	O
mesenchymal	B
stem	I
cells	I
and	O
nucleus	O
pulposus	O
cells.	O

Velpula	O
KK,	O
Rehman	O
AA,	O
Chelluboina	O
B,	O
Dasari	O
VR,	O
Gondi	O
CS,	O
Rao	O
JS,	O
Veeravalli	O
KK	O
(2012)	O
Glioma	B
stem	I
cell	I
invasion	O
through	O
regulation	O
of	O
the	O
interconnected	O
ERK,	O
integrin	O
α6	O
and	O
N-cadherin	O
signaling	O
pathway.	O

Protein	O
citrullination	O
also	O
participates	O
in	O
the	O
regulation	O
of	O
stem	B
cell	I
pluripotency,	O
cancer-related	O
genes,	O
and	O
immune	O
responses	O
(24–27).	O

A	O
comparative	O
study	O
of	O
protocols	O
for	O
mouse	B
embryonic	I
stem	I
cell	I
culturing.	O

Gold	O
Nanoparticle-Based	O
Surface-Enhanced	O
Raman	O
Scattering	O
for	O
Noninvasive	O
Molecular	O
Probing	O
of	O
Embryonic	B
Stem	I
Cell	I
Differentiation.	O

We	O
cloned	O
the	O
mouse	O
equivalents	O
of	O
these	O
mutants	O
(L191A/L193A,	O
Y376A/Y378A,	O
R393A/L394A)	O
in	O
mouse	B
stem	I
cell	I
virus–based	O
(MSCV-based)	O
retroviral	O
vectors	O
(Figure	O
4A).	O

Takahashi	O
and	O
Yamanaka	O
reported	O
a	O
significant	O
advance	O
in	O
the	O
stem	B
cell	I
field	O
with	O
the	O
reprogramming	O
of	O
somatic	O
cells	O
into	O
ESC-like	O
cells	O
(Figure.	O

Recent	O
advances	O
in	O
stem	B
cell	I
technology	O
have	O
led	O
to	O
the	O
emergence	O
of	O
methods	O
for	O
differentiation	O
of	O
PSCs	O
into	O
multipotent	O
retinal	O
progenitor	O
cells	O
(RPCs),	O
retinal	O
pigment	O
epithelium	O
(RPE),	O
and	O
photoreceptor-like	O
cells	O
(Buchholz	O
et	O
al.,	O
2009;	O
Meyer	O
et	O
al.,	O
2009,	O
2011;	O
Osakada	O
et	O
al.,	O
2009;	O
Lamba	O
and	O
Reh,	O
2011).	O

How	O
to	O
cross	O
immunogenetic	O
hurdles	O
to	O
human	B
embryonic	I
stem	I
cell	I
transplantation.	O

Human	O
embryonic	O
stem	O
cell-derived	O
oligodendrocyte	O
progenitor	O
cell	O
transplants	O
remyelinate	O
and	O
restore	O
locomotion	O
after	O
spinal	O
cord	O
injury.	B
Embryonic	I
stem	I
cell	I
differentiation:	O
emergence	O
of	O
a	O
new	O
era	O
in	O
biology	O
and	O
medicine.	O

Regulation	O
of	O
human	B
embryonic	I
stem	I
cell	I
differentiation	O
by	O
BMP-2	O
and	O
its	O
antagonist	O
noggin.	O

Manipulation	O
of	O
stem	B
cell	I
proliferation	O
and	O
lineage	O
commitment:	O
visualisation	O
of	O
label-retaining	O
cells	O
in	O
wholemounts	O
of	O
mouse	O
epidermis.	O

Role	O
of	O
beta-catenin	O
in	O
epidermal	B
stem	I
cell	I
expansion,	O
lineage	O
selection,	O
and	O
cancer.	O

Immunostaining	O
shows	O
expression	O
of	O
embryonic	B
stem	I
cell	I
surface	O
antigen	O
SSEA4,	O
Tra-1-60,	O
Tra-1-81,	O
and	O
nuclear	O
Oct4.	O

This	O
would	O
suggest	O
that	O
in	O
this	O
SMA	B
stem	I
cell	I
model,	O
the	O
patient	O
iPSC	O
lines	O
are	O
competent	O
in	O
generating	O
MN	O
progenitors	O
at	O
early	O
stages	O
of	O
differentiation	O
and	O
argue	O
against	O
a	O
serious	O
fetal	O
developmental	O
maturation	O
error	O
as	O
suggested	O
in	O
a	O
recent	O
study	O
examining	O
post-mortem	O
pathological	O
analyses	O
from	O
spinal	O
cords	O
of	O
SMA	O
patients	O
[40].	O

(B)	O
Immunostaining	O
of	O
three	O
clones	O
from	O
77iSMA	O
iPSCs	O
shows	O
expression	O
of	O
embryonic	B
stem	I
cell	I
surface	O
antigen	O
SSEA3	O
and	O
nuclear	O
Oct4.	O

Immunocytochemical	O
staining	O
of	O
embryonic	B
stem	I
cell	I
surface	O
antigens	O
SSEA-4,	O
TRA-1-60	O
and	O
nuclear	O
Oct4.	O

Zebrafish	B
adult	I
pigment	I
stem	I
cells	I
are	O
multipotent	O
and	O
form	O
pigment	O
cells	O
by	O
a	O
progressive	O
fate	O
restriction	O
process:	O
clonal	O
analysis	O
identifies	O
shared	O
origin	O
of	O
all	O
pigment	O
cell	O
types.	O

Thus,	O
comprehension	O
of	O
stem	B
cell	I
proteomes	O
and	O
their	O
dynamics	O
may	O
provide	O
detailed	O
systems	O
understanding	O
of	O
pluripotency,	O
how	O
it	O
differs	O
from	O
somatic	O
cell	O
states,	O
and	O
may	O
yield	O
important	O
clues	O
into	O
mechanistic	O
understanding	O
of	O
progenitor	O
cells	O
for	O
therapeutic	O
and	O
diagnostic	O
applications..	O

This	O
fundamental	O
work	O
has	O
laid	O
the	O
groundwork	O
for	O
application	O
of	O
stem	B
cell	I
metabolomics	O
as	O
a	O
platform	O
for	O
pharmaceutical	O
toxicity	O
screening	O
and	O
identification	O
of	O
predictive	O
biomarkers	O
of	O
toxicity.	O

Furthermore,	O
development	O
of	O
a	O
prototype	O
platform	O
for	O
stem	B
cell	I
diagnostics,	O
which	O
incorporates	O
major	O
“-omic”	O
layers	O
discussed	O
here,	O
provides	O
the	O
premise	O
for	O
incorporating	O
other	O
“-omes”	O
for	O
enhanced	O
systems	O
biology	O
deconvolution	O
of	O
disease	O
states.	O

The	O
participation	O
of	O
merlin	O
in	O
the	O
mammalian	O
hippo	O
pathway	O
might	O
suggest	O
a	O
role	O
in	O
stem	O
cell	O
maintenance,	O
differentiation	O
or	O
regulation	O
of	O
the	O
stem	B
cell	I
niche	O
(156–160)..	O

Another	O
provocative	O
issue	O
emerging	O
from	O
work	O
on	O
O-GlcNAc	O
and	O
epigenetics	O
is	O
its	O
role	O
in	O
stem	B
cell	I
biology.	O

Reducing	O
O-GlcNAylation	O
through	O
inhibition	O
of	O
OGT	O
or	O
reducing	O
glucose	O
concentrations	O
interferes	O
with	O
embryonic	B
stem	I
cell	I
self-renewal	O
and	O
nuclear	O
reprogramming.	O

Cancer	O
Stem	O
Cells	O
(CSC)	O
represent	O
exactly	O
the	O
kind	O
of	O
tumor	O
cells	O
that	O
possess	B
all	I
of	I
these	O
fundamental	O
requisites	O
for	O
cancer	O
cell	O
invasion	O
and	O
metastasis	O
[9]..	O

Mesenchymal	B
stem	I
cell	I
transplantation	O
has	O
become	O
a	O
promising	O
treatment	O
for	O
many	O
diseases	O
such	O
as	O
diabetes,	O
liver	O
fibrosis,	O
and	O
myocardial	O
infarction	O
[6-8].	O

Labeling	O
and	O
tracking	O
of	O
stem	B
cells	I
are	O
crucial	O
for	O
assessing	O
cell	O
distribution	O
and	O
homing.	O

Thibault	O
RA,	O
Scott	O
Baggett	O
L,	O
Mikos	O
AG,	O
Kasper	O
FK	O
(2010)	O
Osteogenic	O
differentiation	O
of	O
mesenchymal	B
stem	I
cells	I
on	O
pregenerated	O
extracellular	O
matrix	O
scaffolds	O
in	O
the	O
absence	O
of	O
osteogenic	O
cell	O
culture	O
supplements.	O

This	O
supports	O
a	O
similar	O
finding	O
of	O
human	B
embryonic	I
stem	I
cell	I
hematopoietic	O
differentiation	O
(Reid	O
et	O
al.,	O
2018).	O

Cancer	B
stem	I
cell	I
mediated	O
acquired	O
chemoresistance	O
in	O
head	O
and	O
neck	O
cancer	O
can	O
be	O
abrogated	O
by	O
aldehyde	O
dehydrogenase	O
1	O
A1	O
inhibition.	O

A	O
genome-wide	O
RNAi	O
screen	O
reveals	O
determinants	O
of	O
human	B
embryonic	I
stem	I
cell	I
identity.	O

Specific	O
deletion	O
of	O
Myh9	O
in	O
LGR5+	O
cells	O
also	O
reduced	O
their	O
cell	O
number,	O
suggesting	O
that	O
Myh9	O
is	O
critical	B
to	I
protect	I
stem	I
cells	I
from	O
necroptosis.	O

ZNF671	O
re-expression	O
in	O
UC	O
cell	O
lines,	O
via	O
ectopic	O
expression,	O
inhibited	O
tumor	O
growth	O
and	O
invasion,	O
in	O
possible	O
conjunction	O
with	O
downregulation	O
of	O
cancer	B
stem	I
cell	I
markers	O
(c-KIT,	O
NANOG,	O
OCT4).	O

Over-expression	O
of	O
ZNF671	O
down-regulates	O
the	O
expression	O
of	O
cancer	B
stem	I
cell	I
markers	O
in	O
bladder	O
urothelial	O
carcinoma.	O

Expression	O
of	O
stem	B
cell	I
markers	O
(c-KIT,	O
NANOG	O
and	O
OCT4)	O
were	O
detected	O
by	O
qRT-PCR	O
in	O
A.	O

Mesenchymal	B
stem	I
cell	I
therapy	O
promotes	O
the	O
improvement	O
and	O
recovery	O
of	O
renal	O
function	O
in	O
a	O
preclinical	O
model.	O

Senescence	O
reduces	O
the	O
number	O
of	O
stem	B
cell	I
lineages,	O
requiring	O
the	O
remaining	O
lineages	O
to	O
divide	O
more	O
frequently	O
to	O
maintain	O
the	O
tissue,	O
thus	O
providing	O
an	O
opportunity	O
to	O
further	O
increase	O
the	O
somatic	O
mutation	O
burden	O
in	O
those	O
cells.	O

Repeated	O
exposure	O
of	O
human	O
fibroblasts	O
to	O
UVR	O
induces	O
secretion	O
of	O
stem	B
cell	I
factor	O
and	O
senescence.	O

A	O
quantitative,	O
randomized	O
study	O
evaluating	O
three	O
methods	O
of	O
mesenchymal	B
stem	I
cell	I
delivery	O
following	O
myocardial	O
infarction.	O

Micropatterning	O
of	O
the	O
culture	O
surface	O
is	O
one	O
strategy	O
that	O
has	O
been	O
used	O
to	O
manipulate	O
the	O
physical	O
organization	O
of	O
2D	O
stem	B
cell	I
colonies	O
and	O
the	O
resulting	O
mechanical	O
environment	O
individual	O
cells	O
experience	O
within	O
the	O
cell	O
sheet.	O

Niche-mediated	O
BMP/SMAD	O
signaling	O
regulates	O
lung	O
alveolar	B
stem	I
cell	I
proliferation	O
and	O
differentiation.	O

The	O
opposing	O
effects	O
of	O
the	O
Polycomb	O
group	O
(PcG,	O
associated	O
with	O
gene	O
repression)	O
and	O
Trithorax	O
group	O
(associated	O
with	O
gene	O
activation)	O
remodelling	O
proteins	O
regulate	O
many	O
cellular	O
decisions	O
in	O
stem	B
cell	I
biology,	O
development,	O
and	O
cancer.	O

This	O
suggests	O
that	O
β-catenin	O
plays	O
a	O
key	O
role	O
in	O
stem	B
cell	I
renewal	O
and	O
differentiation	O
to	O
the	O
smooth-muscle	O
phenotype	O
observed	O
in	O
myometrial	O
and	O
leiomyoma	O
tissues,	O
and	O
that	O
the	O
WNT/β-catenin	O
pathway	O
may	O
be	O
promising	O
target	O
for	O
new	O
therapeutics	O
(48)..	O

Boutet	O
SC,	O
Cheung	O
TH,	O
Quach	O
NL,	O
et	O
al.Alternative	O
polyadenylation	O
mediates	O
microRNA	O
regulation	O
of	O
muscle	B
stem	I
cell	I
function.	O

The	O
role	O
of	O
mesenchymal	B
stem	I
cell	I
derived	O
sEVs	O
in	O
promoting	O
immune	O
suppression	O
as	O
well	O
as	O
chemo	O
resistance	O
of	O
gastric	O
cancer	O
is	O
studied	O
[307].	O

Hypoxia	O
induces	O
EMT	O
in	O
low	O
and	O
highly	O
aggressive	O
pancreatic	O
tumor	O
cells	O
but	O
only	O
cells	O
with	O
cancer	B
stem	I
cell	I
characteristics	O
acquire	O
pronounced	O
migratory	O
potential.	O

[105]	O
used	O
multimodal	O
imaging	O
for	O
early	O
monitoring	O
for	O
the	O
stem	B
cell	I
gene	O
therapy.	O

Molecular	O
imaging	O
of	O
embryonic	B
stem	I
cell	I
misbehavior	O
and	O
suicide	O
gene	O
ablation.	O

A	O
low-shear	O
stress	O
has	O
also	O
played	O
an	O
increasingly	O
important	O
role	O
in	O
EB-to-organoid	O
differentiation	O
because	O
the	O
fluid	O
dynamics	O
in	O
a	O
spin-culture	O
system	O
not	O
only	O
promotes	O
nutrient	O
diffusion	O
but	O
also	O
maximizes	O
pluripotent	B
stem	I
cell	I
propagation	O
by	O
keeping	O
cell	O
aggregates	O
below	O
the	O
critical	O
size	O
of	O
a	O
diffusion	O
limit	O
[22,30].	O

Particularly,	O
AFCs	O
resemble	O
characteristically	O
the	O
mesenchymal	B
stem	I
cells	I
and	O
harbor	O
pluripotency	O
to	O
differentiate	O
into	O
a	O
wide	O
range	O
of	O
cell	O
types	O
[44].	O

Organoids:	O
Modeling	O
development	O
and	O
the	O
stem	B
cell	I
niche	O
in	O
a	O
dish.	O

They	O
demonstrated	O
that	O
GASC1	O
is	O
amplified	O
and	O
overexpressed	O
in	O
multiple	O
breast	O
cancer	O
cell	O
lines,	O
it	O
causes	O
transformation	O
of	O
immortalized,	O
non-transformed	O
mammary	O
epithelial	O
cells,	O
regulates	O
expression	O
of	O
genes	O
responsible	O
for	O
stem	O
cells	O
self-renewal	O
and	O
may	O
be	O
linked	O
to	O
the	O
stem	B
cell	I
phenotypes	O
in	O
breast	O
cancer.	O

GASC1	O
demethylase	O
activity	O
has	O
been	O
shown	O
to	O
regulate	O
the	O
expression	O
of	O
genes	O
critical	O
for	O
stem	O
cell	O
self-renewal,	O
including	O
NOTCH1	O
and	O
NANOG,	O
and	O
possibly	O
to	O
be	O
linked	O
to	O
the	O
stem	B
cell	I
phenotypes	O
in	O
breast	O
cancer	O
[13,17,18].	O

Astrocytes	O
are	O
a	O
brain	O
and	O
spinal	O
cord	O
specific	O
cell	O
type	O
essential	O
for	O
mounting	O
an	O
immune	O
response	O
in	O
these	O
tissues,	O
and	O
are	O
derived	O
from	O
neural	B
stem	I
cells	I
which	O
go	O
through	O
an	O
astrocyte	O
precursor	O
stage	O
before	O
becoming	O
fully	O
mature	O
astrocytes	O
(For	O
interpretation	O
of	O
the	O
references	O
to	O
colour	O
in	O
this	O
figure	O
legend,	O
the	O
reader	O
is	O
referred	O
to	O
the	O
web	O
version	O
of	O
this	O
article.).	O

Most	O
of	O
the	O
studies	O
reported	O
on	O
the	O
effect	O
of	O
microRNA	O
(miRNA)	O
in	O
stem	B
cell	I
differentiation	O
were	O
limited	O
to	O
in	O
vitro	O
analysis.	O

This	O
approach	O
would	O
be	O
a	O
useful	O
addition	O
to	O
the	O
currently	O
available	O
methods	O
in	O
the	O
field	O
of	O
miRNA	O
analysis	O
in	O
stem	B
cell	I
differentiation	O
and	O
lineage	O
specification..	O

These	O
small	O
RNAs	O
are	O
known	O
to	O
regulate	O
gene	O
expression	O
through	O
complementary	O
base	O
pairing	O
to	O
the	O
3′‐untranslated	O
region	O
(UTR)	O
of	O
target	O
messenger	O
RNAs	O
(mRNAs)	O
and	O
are	O
important	O
regulators	O
of	O
fundamental	O
cellular	O
processes,	O
including	O
proliferation,	O
differentiation,	O
and	O
apoptosis.4,	O
5,	O
6,	O
7	O
Growing	O
evidence	O
has	O
shown	O
that	O
miRNA	O
plays	O
a	O
critical	O
role	O
in	O
fine‐tuning	O
the	O
expression	O
levels	O
of	O
genes	O
involved	O
in	O
stem	B
cell	I
self‐renewal	O
and	O
differentiation.	O

Efficient	O
definitive	O
endoderm	O
induction	O
from	O
mouse	B
embryonic	I
stem	I
cell	I
adherent	O
cultures:	O
a	O
rapid	O
screening	O
model	O
for	O
differentiation	O
studies.	O

All	O
the	O
experiments	O
with	O
iPSCs	O
in	O
this	O
study	O
were	O
approved	O
by	O
institutional	O
Embryonic	B
Stem	I
Cell	I
Research	O
Oversight	O
(ESCRO)	O
at	O
Cincinnati	O
Children’s	O
Hospital	O
Medical	O
Center..	O

The	O
resulting	O
neural	O
aggregates	O
were	O
plated	O
on	O
poly-L-ornithine/laminin	O
(PLO/L)	O
coated	O
tissue	O
culture	O
plates	O
and	O
within	O
a	O
day,	O
rosette	O
structures	O
formed	O
NPCs	O
that	O
grew	O
out	O
of	O
the	O
isolated	O
rosettes	O
were	O
self-renewing	O
and	O
expressed	O
signals	O
for	O
the	O
neural	B
stem	I
cell	I
markers,	O
nestin	O
and	O
sox2	O
(Fig.	O

Here	O
we	O
review	O
the	O
role	O
of	O
microRNAs	O
in	O
the	O
control	O
of	O
stem	B
cell	I
and	O
cardiomyocyte	O
dependent	O
cardiac	O
regeneration	O
processes,	O
and	O
discuss	O
potential	O
applications	O
for	O
the	O
treatment	O
of	O
cardiac	O
injury..	O

A	O
related	O
field	O
with	O
high	O
potential	O
for	O
cardiac	O
repair	O
–	O
cell	O
therapy	O
involving	O
the	O
transplantation	O
and	O
in	O
situ	O
differentiation	O
of	O
stem	B
cells	I
[13,14]—in	O
which	O
miRNAs	O
play	O
a	O
relevant	O
role	O
as	O
modulators	O
of	O
both	O
pluripotency	O
and	O
differentiation	O
[15],	O
will	O
not	O
be	O
discussed	O
here	O
in	O
detail..	O

In	O
addition	O
to	O
this,	O
miRs	O
have	O
also	O
been	O
shown	O
to	O
play	O
critical	O
roles	O
in	O
the	O
establishment	O
of	O
stem	B
cell	I
properties,	O
in	O
particular	O
in	O
the	O
maintenance	O
of	O
the	O
pluripotent	O
state	O
(reviewed	O
by	O
[84])..	O

miR-449a-5p	O
is	O
involved	O
in	O
different	O
pathways,	O
such	O
as	O
TGF-β,	O
TNF,	O
MAPK,	O
Wnt,	O
FoxO,	O
PI3K-Akt,	O
and	O
Hippo	O
signalling	O
pathway	O
and	O
was	O
proposed	O
to	O
be	O
linked	O
to	O
stem	B
cell	I
pluripotency	O
[57]..	O

However,	O
data	O
from	O
the	O
experimental	O
models	O
and	O
clinical	O
samples,	O
suggest	O
IL-30′s	O
engagement	O
in	O
the	O
relationship	O
between	O
cancer	O
and	O
myeloid	O
cells,	O
which	O
fosters	O
the	O
tumor	O
microenvironment	O
and	O
the	O
cancer	B
stem	I
cell	I
niche,	O
boosting	O
the	O
disease	O
progression.	O

Tumor-	O
and	O
Myeloid	O
Cell-Derived	O
IL-30	O
Contributes	O
to	O
the	O
Maintenance	O
of	O
the	O
Cancer	B
Stem	I
Cell	I
Niche.	O

The	O
immunoregulatory	O
molecule,	O
IL-30,	O
which	O
has	O
been	O
recently	O
identified	O
in	O
the	O
context	O
of	O
the	O
TME,	O
specifically	O
in	O
BCs	O
and	O
PCs,	O
has	O
proven	O
to	O
mediate,	O
directly	O
or	O
through	O
second-level	O
cytokines,	O
the	O
crosstalk	O
between	O
cancer	O
and	O
myeloid	O
cells	O
and	O
to	O
foster	O
the	O
cancer	B
stem	I
cell	I
niche,	O
thus,	O
promoting	O
tumor	O
immune	O
escape	O
and	O
disease	O
progression	O
[15,16,81].	O

Mesenchymal	B
stem	I
cells	I
generate	O
distinct	O
functional	O
hybrids	O
in	O
vitro	O
via	O
cell	O
fusion	O
or	O
entosis.	O

This	O
hypothesis	O
is	O
supported	O
by	O
the	O
demonstration	O
that	O
miR-125b	O
increases	O
the	O
size	O
of	O
the	O
hematopoietic	B
stem	I
cell	I
compartment	O
in	O
mice,	O
targeting	O
several	O
component	O
of	O
the	O
pro-apoptotic	O
pathway,	O
as	O
well	O
as	O
genes	O
coding	O
molecules	O
involved	O
in	O
both	O
B-	O
and	O
T-cell	O
differentiation	O
[29,31–33]..	O

The	O
authors	O
suggested	O
that	O
the	O
acquisition	O
of	O
the	O
genetic	O
translocations	O
had	O
occurred	O
at	O
the	O
stem	B
cell	I
stage,	O
as	O
these	O
cells	O
were	O
able	O
to	O
differentiate	O
into	O
B	O
cells	O
and	O
cells	O
from	O
the	O
myeloid	O
lineage,	O
and	O
some	O
of	O
which	O
acquired	O
additional	O
mutations	O
that	O
ultimately	O
resulted	O
in	O
AML	O
[72].	O

Indeed,	O
it	O
is	O
widely	O
accepted	O
that	O
aging	O
is	O
associated	O
with	O
stem	B
cell	I
pool	O
depletion,	O
as	O
a	O
consequence	O
of	O
cellular	O
senescence	O
or	O
apoptotic	O
death,	O
and/or	O
their	O
reduced	O
functionality,	O
leading	O
to	O
reduced	O
tissue	O
regeneration	O
potential	O
and	O
impaired	O
homeostasis	O
[11,89,90].	O

Deregulation	O
of	O
stem	B
cell	I
function	O
or	O
decrease	O
of	O
their	O
population,	O
due	O
to	O
cell	O
senescence	O
and	O
apoptotic	O
death,	O
are	O
the	O
main	O
factors	O
for	O
these	O
age-related	O
observations.	O

UV	O
light,	O
chemical,	O
chemotherapeutic	O
and	O
radioactive	O
compounds,	O
X-rays,	O
ionizing	O
radiation,	O
etc.)	O
damage	O
may	O
occur,	O
thus	O
affecting	O
the	O
stem	B
cell	I
population..	O

For	O
example,	O
the	O
resistance	O
of	O
stem	B
cells	I
to	O
cell	O
death	O
and	O
senescence	O
was	O
shown	O
to	O
be	O
mediated	O
by	O
age-associated	O
self-renewal	O
deregulation	O
and	O
genetic	O
and/or	O
epigenetic	O
alterations,	O
inducing	O
their	O
transformation	O
into	O
CSCs	O
and	O
skin	O
tumour	O
[98].	O

These	O
observations	O
are	O
consistent	O
with	O
the	O
model	O
of	O
pre-tumour	O
progression	O
proposed	O
by	O
Calabrese	O
et	O
al	O
(2004)	O
that	O
during	O
the	O
period	O
preceding	O
tumorigenesis,	O
neutral	O
mutations	O
accumulate	O
in	O
stem	B
cells	I
without	O
apparent	O
effects	O
on	O
cell	O
morphology	O
or	O
tumorigenesis.	O

Since	O
the	O
stem	B
cell	I
population	O
is	O
very	O
small,	O
benign	O
mutations	O
can	O
be	O
maintained	O
and	O
accumulated	O
over	O
time	O
due	O
to	O
genetic	O
drift.	O

Unlike	O
germ	O
cells,	O
telomerase	O
expression	O
in	O
adult	B
stem	I
cells	I
decreases	O
with	O
age,	O
causing	O
telomere	O
shortening	O
with	O
each	O
cell	O
division	O
[114].	O

This	O
fact	O
demonstrates	O
its	O
importance	O
for	O
stem	O
cell	O
maintenance,	O
although	O
a	O
role	O
in	O
regulating	O
the	O
balance	O
between	O
self-renewal	O
and	O
differentiation	O
of	O
stem	B
cells	I
has	O
also	O
been	O
described	O
[129].	O

If	O
Wnt/β-catenin	O
functionality	O
is	O
decreased,	O
the	O
progenitor	O
compartment	O
is	O
compromised	O
due	O
to	O
a	O
decline	O
of	O
the	O
stem	B
cell	I
self-renewal	O
ability	O
[138].	O

et	O
al.Cancer	O
induction	O
by	O
restriction	O
of	O
oncogene	O
expression	O
to	O
the	O
stem	B
cell	I
compartment.	O

et	O
al.Epidermal	O
growth	O
factor	O
receptor	O
and	O
Ink4a/Arf:	O
convergent	O
mechanisms	O
governing	O
terminal	O
differentiation	O
and	O
transformation	O
along	O
the	O
neural	B
stem	I
cell	I
to	O
astrocyte	O
axis.	O

The	O
longest	O
telomeres:	O
a	O
general	O
signature	O
of	O
adult	B
stem	I
cell	I
compartments.	O

Organ	O
aging	O
and	O
susceptibility	O
to	O
cancer	O
may	O
be	O
related	O
to	O
the	O
geometry	O
of	O
the	O
stem	B
cell	I
niche.	O

Bmi1	O
Enhances	O
Tumorigenicity	O
and	O
Cancer	B
Stem	I
Cell	I
Function	O
in	O
Pancreatic	O
Adenocarcinoma.	O

Bmi-1	O
Is	O
a	O
Crucial	O
Regulator	O
of	O
Prostate	B
Stem	I
Cell	I
Self-Renewal	O
and	O
Malignant	O
Transformation.	O

Tightrope	O
act:	O
autophagy	O
in	O
stem	B
cell	I
renewal,	O
differentiation,	O
proliferation,	O
and	O
aging.	O

Jang	O
HK,	O
Kim	O
BS	O
(2010)	O
Modulation	O
of	O
stem	B
cell	I
differentiation	O
with	O
biomaterials.	O

In	O
addition,	O
Pin1	O
is	O
required	O
not	O
only	O
for	O
the	O
stability	O
of	O
the	O
stem	B
cell	I
reprogramming	O
factors	O
Nanog,	O
Oct4,	O
and	O
MYC	O
but	O
also	O
for	O
inducing	O
and	O
maintaining	O
pluripotency	O
[28,	O
30–33].	O

This	O
implies	O
that	O
Pin1	O
can	O
maintain	O
the	O
leukemia	B
stem	I
cell	I
population	O
and	O
therefore	O
represent	O
an	O
ideal	O
target	O
for	O
the	O
effective	O
treatment	O
of	O
AML..	O

Changes	O
in	O
phenotype	O
and	O
proliferative	O
potential	O
of	O
human	O
acute	O
myeloblastic	O
leukemia	O
cells	O
in	O
culture	O
with	O
stem	B
cell	I
factor.	O

Aberrant	O
telomere	O
function	O
seems	O
to	O
directly	O
contribute	O
to	O
alveolar	B
stem	I
cell	I
failure,	O
defective	O
alveolar	O
repair	O
and	O
fibrosis	O
possibly	O
because	O
the	O
rate	O
of	O
cell	O
loss	O
exceeds	O
the	O
rate	O
of	O
replacement	O
[46–48].	O

Nintedanib	O
can	O
ameliorate	O
a	O
decline	O
in	O
forced	O
vital	O
capacity	O
(FVC)	O
in	O
patients	O
with	O
SSc	O
and	O
lung	O
fibrosis	O
[167],	O
and	O
autologous	B
stem	I
cell	I
transplantation	O
can	O
favorably	O
modify	O
disease	O
course	O
in	O
some	O
patients,	O
leading	O
to	O
remission	O
or	O
even	O
“cure”	O
[168].	O

Repair	O
and	O
regeneration	O
of	O
the	O
respiratory	O
system:	O
complexity,	O
plasticity,	O
and	O
mechanisms	O
of	O
lung	B
stem	I
cell	I
function.	O

reported	O
a	O
positive	O
role	O
of	O
stem	B
cell	I
factor	O
(SCF)	O
and	O
its	O
receptor	O
c-kit	O
in	O
promoting	O
ES	O
metastasis	O
(116).	O

ABCG2:	O
a	O
potential	O
marker	O
of	O
stem	O
cells	O
and	O
novel	O
target	O
in	O
stem	B
cell	I
and	O
cancer	O
therapy.	O

With	O
the	O
advance	O
of	O
m6A	O
sequence	O
technology,	O
m6A	O
modification	O
has	O
been	O
identified	O
in	O
the	O
mRNAs	O
of	O
more	O
than	O
7,000	O
genes	O
in	O
mammalian	O
organisms.8,9	O
Recently,	O
an	O
increasing	O
number	O
of	O
studies	O
have	O
revealed	O
that	O
m6A	O
modification	O
in	O
mRNAs	O
or	O
non-coding	O
RNAs	O
plays	O
pivotal	O
roles	O
in	O
stem	B
cell	I
self-renewal	O
and	O
tumorigenesis;	O
in	O
cell	O
growth	O
in	O
cancer;	O
and	O
in	O
the	O
fate	O
and	O
functions	O
of	O
RNA,	O
including	O
mRNA	O
stability,	O
splicing,	O
location,	O
and	O
translation,	O
RNA-protein	O
interactions,	O
and	O
primiRNA	O
processes.16,17,27,	O
28,	O
29,	O
30,	O
31	O
Li	O
et	O
al.32	O
verified	O
that	O
FTO,	O
a	O
key	O
RNA	O
demethylase,	O
was	O
highly	O
expressed	O
and	O
functioned	O
as	O
an	O
oncogene	O
via	O
regulation	O
of	O
ASB2	O
and	O
RARA	O
in	O
certain	O
subtypes	O
of	O
acute	O
myeloid	O
leukemia	O
(AML).	O

Tumor	B
stem	I
cells	I
derived	O
from	O
glioblastomas	O
cultured	O
in	O
bFGF	O
and	O
EGF	O
more	O
closely	O
mirror	O
the	O
phenotype	O
and	O
genotype	O
of	O
primary	O
tumors	O
than	O
do	O
serum-cultured	O
cell	O
lines.	O

More	O
recently,	O
ABC	O
drug	O
transporters	O
have	O
crossed	O
paths	O
with	O
models	O
of	O
cellular	O
selection	O
and	O
the	O
tumor	O
stem	B
cell	I
theory	O
(Dean	O
et	O
al.,	O
2005).	O

Further	O
evidence	O
favoring	O
the	O
concept	O
of	O
the	O
stem	B
cell	I
in	O
ascites	O
tumors	O
of	O
rats.	O

The	O
H2bΔIEC	O
mice	O
had	O
DNA	O
damage	O
to	O
intestinal	O
epithelial	O
cells	O
and	O
proliferative	O
exhaustion	O
of	O
the	O
intestinal	B
stem	I
cell	I
compartment	O
compared	O
with	O
controls	O
and	O
H2b/p53ΔIEC	O
mice.	O

Intestinal	O
epithelial	O
RNase	O
H2	O
deficiency	O
leads	O
to	O
a	O
p53-dependent	O
proliferative	O
exhaustion	O
of	O
the	O
intestinal	B
stem	I
cell	I
compartment	O
and	O
concomitant	O
deletion	O
of	O
p53	O
instigates	O
spontaneous	O
carcinogenesis.	O

CRC	O
originates	O
from	O
adult	O
stem	O
cells	O
that	O
maintain	O
lifelong	O
proliferation	O
and	O
are	O
particularly	O
prone	O
to	O
accumulate	O
hazardous	O
mutations.3,	O
4	O
A	O
direct	O
correlation	O
between	O
the	O
number	O
of	O
stem	B
cell	I
divisions	O
and	O
cancer	O
risk	O
over	O
a	O
range	O
of	O
tissues	O
has	O
been	O
reported.5.	O

Note	O
the	O
lack	O
of	O
cellular	O
proliferation	O
in	O
the	O
intestinal	B
stem	I
cell	I
niche	O
located	O
at	O
the	O
crypt	O
base	O
(arrow).	O

Note	O
the	O
lack	O
of	O
cellular	O
proliferation	O
in	O
the	O
intestinal	B
stem	I
cell	I
niche	O
located	O
at	O
the	O
crypt	O
base	O
(arrows).	O

Clobetasol	O
modulates	O
adult	B
neural	I
stem	I
cell	I
growth	O
via	O
canonical	O
hedgehog	O
pathway	O
activation.	O

However,	O
where	O
did	O
cancer	O
heterogeneity	O
come	O
from?	O
Several	O
hypotheses	O
have	O
been	O
proposed	O
in	O
an	O
attempt	O
to	O
explain	O
the	O
mechanisms	O
involved	O
in	O
the	O
cancer	O
heterogeneity,	O
and	O
all	O
of	O
them	O
are	O
related,	O
at	O
least	O
in	O
part,	O
to	O
the	O
prevalence	O
of	O
cancer	B
stem	I
cell	I
in	O
tumor	O
bulk,	O
asymmetric	O
division	O
presented	O
by	O
cancer	O
cells,	O
variations	O
in	O
the	O
genetic	O
signature,	O
modulation	O
of	O
gene	O
expression,	O
and	O
posttranslational	O
modifications	O
[11]..	O

Just	O
as	O
only	O
a	O
small	O
subpopulation	O
of	O
cancer	O
cells	O
resist	O
to	O
therapies,	O
a	O
small	O
portion	O
of	O
cancer	B
stem	I
cells	I
determine	O
cell	O
differentiation.	O

The	O
potential	O
use	O
of	O
mesenchymal	O
stem	O
cells	O
in	O
hematopoietic	O
stem	B
cell	I
transplantation.	O

These	O
pioneer	O
studies	O
suggested	O
that	O
AAV	O
vectors	O
could	O
be	O
also	O
used	O
for	O
stem	B
cell	I
correction	O
and	O
consequently	O
studies	O
of	O
biological	O
mechanisms	O
in	O
vitro	O
and	O
eventually	O
for	O
therapeutic	O
purposes	O
in	O
cell	O
therapy	O
approaches..	O

Polycomb	O
Cbx	O
Family	O
Members	O
Mediate	O
the	O
Balance	O
between	O
Haematopoietic	B
Stem	I
Cell	I
Self-Renewal	O
and	O
Differentiation.	O

These	O
cells	O
remain	O
the	O
gold	O
standard	O
for	O
all	O
studies	O
in	O
the	O
pluripotent	B
stem	I
cell	I
field,	O
although	O
their	O
use	O
has	O
been	O
restricted	O
by	O
ethical	O
concerns,	O
and	O
two	O
clinical	O
trials	O
have	O
been	O
launched	O
by	O
Advanced	O
Cell	O
Technology.	O

Differentiation	O
of	O
mouse	B
embryonic	I
stem	I
cells	I
to	O
hepatocyte-like	O
cells	O
by	O
co-culture	O
with	O
human	O
liver	O
nonparenchymal	O
cell	O
lines.	O

In	O
lola	O
mutants,	O
neurons	O
dedifferentiate,	O
turn	O
on	O
neural	B
stem	I
cell	I
genes,	O
and	O
begin	O
to	O
divide,	O
forming	O
tumors.	O

At	O
each	O
division,	O
cell-fate	O
determinants	O
are	O
segregated	O
from	O
the	O
neural	B
stem	I
cell	I
to	O
the	O
GMC.	O

Here,	O
we	O
show	O
that	O
the	O
BTB-Zn	O
finger	O
transcription	O
factor,	O
Lola	O
(Seeger	O
et	O
al.,	O
1993;	O
Giniger	O
et	O
al.,	O
1994),	O
binds	O
to	O
a	O
large	O
number	O
of	O
Prospero’s	O
targets,	O
including	O
genes	O
involved	O
both	O
in	O
stem	B
cell	I
self-renewal	O
and	O
differentiation.	O

This	O
is	O
intriguing	O
as	O
Lola-N	O
is	O
first	O
expressed	O
just	O
prior	O
to	O
the	O
GMC’s	O
terminal	O
division	O
(Figure	O
2F),	O
at	O
which	O
point	O
Prospero	O
would	O
already	O
have	O
repressed	O
neural	B
stem	I
cell	I
genes.	O

It	O
is	O
conceivable	O
that	O
Prospero	O
is	O
able	O
to	O
maintain	O
the	O
repression	O
of	O
neural	B
stem	I
cell	I
genes	O
in	O
the	O
central	O
brain	O
in	O
the	O
absence	O
of	O
Lola.	O

Lola-N	O
is	O
expressed	O
in	O
postmitotic	O
neurons,	O
implying	O
that	O
there	O
is	O
active	O
repression	O
of	O
stem	B
cell	I
genes	O
in	O
postmitotic	O
neurons	O
and	O
raising	O
the	O
possibility	O
that	O
lola	O
mutant	O
tumors	O
arise	O
through	O
the	O
dedifferentiation	O
of	O
neurons.	O

First,	O
Prospero	O
enters	O
the	O
nucleus	O
of	O
the	O
newly	O
born	O
GMC	O
and	O
initiates	O
the	O
repression	O
of	O
neural	B
stem	I
cell	I
genes.	O

We	O
show	O
that	O
Lola-N	O
is	O
a	O
potent	O
repressor	O
of	O
neural	B
stem	I
cell	I
genes.	O

We	O
hypothesize	O
that	O
Lola	O
maintains	O
the	O
repression	O
of	O
neural	B
stem	I
cell	I
genes	O
until	O
they	O
transition	O
to	O
a	O
more	O
permanent	O
“off	O
state.”	O
BTB-zinc	O
finger	O
proteins	O
are	O
known	O
to	O
recruit	O
HDACs,	O
and	O
this	O
may	O
be	O
the	O
mechanism	O
by	O
which	O
target	O
genes	O
are	O
more	O
permanently	O
locked	O
down.	O

Dividing	O
cellular	O
asymmetry:	O
asymmetric	O
cell	O
division	O
and	O
its	O
implications	O
for	O
stem	B
cells	I
and	O
cancer.	O

Increased	O
expression	O
of	O
the	O
adult	B
stem	I
cell	I
marker	O
Musashi-1	O
in	O
endometriosis	O
and	O
endometrial	O
carcinoma.	O

On	O
the	O
concept	O
of	O
stem	B
cell	I
and	O
a	O
model	O
of	O
functional-morphological	O
structure	O
of	O
the	O
endometrium.	O

Activity	O
of	O
the	O
GCS	O
has	O
been	O
shown	O
to	O
be	O
important	O
for	O
the	O
maintenance	O
of	O
stem	B
cell	I
pluripotency	O
through	O
epigenetic	O
regulation	O
[128].	O

Adipocyte	O
lineage	O
cells	O
contribute	O
to	O
the	O
skin	B
stem	I
cell	I
niche	O
to	O
drive	O
hair	O
cycling.	O

It	O
is	O
also	O
known	O
to	O
upregulate	O
the	O
expression	O
of	O
cancer	B
stem	I
cell	I
markers	O
leading	O
to	O
high	O
metastatic	O
features	O
in	O
NPCs	O
(1).	O

Adoptive	O
transfer	O
of	O
cytomegalovirus-specific	O
CTL	O
to	O
stem	B
cell	I
transplant	O
patients	O
after	O
selection	O
by	O
HLA-peptide	O
tetramers.	O

Objectives:	O
This	O
study	O
aimed	O
analysing	O
high‐risk	O
neuroblastoma	O
recurrence	O
after	O
high	O
dose	O
chemotherapy	O
(HDC)	O
and	O
autologous	B
stem	I
cell	I
transplantation	O
(ASCT).	O

Bone‐marrow	O
of	O
10	O
healthy	O
pediatric	O
controls	O
was	O
collected	O
at	O
time	O
of	O
stem	B
cell	I
donation.	O

Methods:	O
Children	O
received	O
as	O
postoperative	O
induction	O
chemotherapy	O
two	O
cycles	O
of	O
etoposide	O
(500	O
mg/m2)	O
‐	O
carboplatine	O
(800	O
mg/m2),	O
followed	O
by	O
two	O
courses	O
of	O
thiotepa	O
(600mg/m2	O
per	O
course)	O
with	O
autologous	B
stem	I
cell	I
rescue.	O

Mouse	B
embryonic	I
stem	I
cells	I
cultured	O
under	O
serum‐free	O
of	O
embryoid	O
body‐like	O
aggregates	O
(SFEBq)	O
conditions	O
can	O
differentiate	O
into	O
many	O
cell	O
types	O
of	O
the	O
brain	O
including	O
cerebellar	O
progenitor	O
cells.	O

Nine	O
patients	O
received	O
multiagent	O
intensive	O
chemotherapy	O
per	O
the	O
Dana	O
Farber	O
Cancer	O
Institute	O
regimen	O
while	O
4	O
had	O
treatment	O
either	O
on	O
or	O
per	O
ACNS	O
0333	O
protocol	O
with	O
intensive	O
multiagent	O
chemotherapy	O
along	O
with	O
stem	B
cell	I
transplants.	O

Objectives:	O
To	O
examine	O
the	O
health	O
related	O
quality	O
of	O
life	O
(HRQL)	O
of	O
survivors	O
of	O
advanced	O
neuroblastoma	O
(AN)	O
who	O
underwent	O
intensive	O
chemotherapy	O
followed	O
by	O
myeloablative	O
therapy	O
with	O
autologous	B
stem	I
cell	I
transplant	O
(SCT)..	O

These	O
children	O
are	O
diagnosed	O
and	O
treated	O
in	O
5	O
paediatric	O
oncology	O
centres	O
(POC's)	O
and	O
2	O
centres	O
for	O
allogenic	B
stem	I
cell	I
transplantation.	O

Methods:	O
We	O
report	O
3	O
refractory	O
Langerhans	O
Cell	O
Histiocytosis	O
patient	O
who	O
were	O
treated	O
successfully	O
with	O
hematopoetic	B
stem	I
cell	I
transplantation	O
using	O
non	O
myeloablative	O
conditioning	O
regimen..	O

At	O
the	O
end	O
of	O
induction	O
therapy,	O
myeloablative	O
chemotherapy	O
with	O
autologous	B
stem	I
cell	I
rescue	O
followed	O
by	O
local	O
therapy	O
was	O
given.	O

Objectives:	O
In	O
the	O
recent	O
years	O
in	O
Japan,	O
an	O
increasing	O
number	O
of	O
patients	O
with	O
neuroblastoma	O
(NB)	O
are	O
being	O
treated	O
by	O
the	O
“delayed	O
local	O
treatment	O
(DL)	O
”	O
policy,	O
undergoing	O
surgery	O
after	O
the	O
completion	O
of	O
high‐dose	O
chemotherapy	O
with	O
hematopoietic	B
stem	I
cell	I
rescue	O
(HDC).	O

With	O
the	O
advent	O
of	O
comprehensive	O
treatment	O
approaches	O
that	O
include	O
intensive	O
induction	O
chemotherapy,	O
myeloablative	O
consolidation	O
therapy	O
with	O
stem	B
cell	I
rescue	O
and	O
targeted	O
therapy,	O
OS	O
rates	O
have	O
improved.	O

Currently,	O
the	O
OS	O
is	O
69.2%	O
for	O
patients	O
who	O
were	O
treated	O
with	O
tandem	O
HDHT	O
with	O
autologous	O
stem	B
cell	I
support.	O

Objectives:	O
Based	O
on	O
the	O
results	O
recent	O
of	O
investigations,	O
application	O
of	O
autologous	B
stem	I
cell	I
tandem	O
transplantation	O
(TT)	O
could	O
improve	O
the	O
treatment	O
results	O
of	O
patients	O
with	O
some	O
malignant	O
solid	O
tumors.	O

Post	O
rapid	O
cojec	O
mass	O
was	O
resected	O
followed	O
by	O
autologous	B
stem	I
cell	I
therapy	O
as	O
it	O
was	O
N	O
myc	O
amplified..	O

The	O
entire	O
cohort	O
(100%)	O
received	O
chemotherapy,	O
and	O
4	O
patients	O
(36%)	O
underwent	O
additional	O
high	O
dose	O
chemotherapy	O
with	O
autologous	B
stem	I
cell	I
rescue	O
(HDCT	O
&	O
ASCR)	O
with	O
melphalan,	O
etoposide,	O
and	O
carboplatin	O
(MECb).	O

Methods:	O
Children	O
were	O
eligible	O
for	O
early	O
palliative	O
care	O
consultation	O
if	O
they	O
had	O
a	O
high	O
risk	O
malignancy,	O
defined	O
as:	O
1)	O
relapsed	O
disease,	O
2)	O
need	O
for	O
stem	B
cell	I
transplantation	O
(SCT),	O
or	O
3)	O
newly	O
diagnosed	O
with	O
an	O
estimated	O
overall	O
survival	O
of	O
<	O
50%.	O

However,	O
its	O
ubiquitous	O
expression	O
and	O
high	O
degree	O
of	O
sequence	O
conservation	O
underline	O
a	O
wider	O
role,	O
which	O
has	O
been	O
recently	O
associated	O
with	O
the	O
regulation	O
of	O
stem	B
cell	I
differentiation24,	O
hepatic	O
cholesterol	O
uptake25,	O
haem	O
synthesis6,	O
cell	O
proliferation	O
and	O
programmed	O
demise26,27..	O

Taken	O
together,	O
the	O
RNA	O
sequencing	O
(RNA-seq)	O
and	O
5′	O
CAGE	O
data	O
from	O
the	O
ENCODE	O
Consortium	O
suggest	O
that	O
an	O
antisense	O
transcript,	O
hereafter	O
referred	O
to	O
as	O
the	O
hTERT	O
antisense	O
promoter-associated	O
(hTAPAS)	O
RNA,	O
was	O
detected	O
in	O
the	O
hTERT	O
promoter	O
region	O
in	O
human	B
embryonic	I
stem	I
cells	I
and	O
in	O
some	O
but	O
not	O
all	O
cancer	O
cell	O
lines.	O

Importantly,	O
an	O
early	O
study	O
also	O
indicated	O
that	O
miR-181c-5p	O
might	O
have	O
a	O
key	O
role	O
in	O
the	O
cancer	B
stem	I
cell	I
formation19..	O

A	O
subset	O
of	O
gene	O
pool	O
shared	O
by	O
regulatory	O
networks	O
of	O
both	O
MYC	O
and	O
STAT3	O
was	O
found	O
to	O
participate,	O
in	O
part,	O
in	O
maintaining	B
stem	I
cell	I
phenotype,	O
cell	O
proliferation,	O
Warburg	O
effect	O
and	O
sustained	O
angiogenesis.	O

Compared	O
to	O
H1	B
embryonic	I
stem	I
cell	I
derived	O
neurons	O
and	O
an	O
unrelated	O
CAMK2A	O
wild-type	O
iPSC	O
control,	O
the	O
patient’s	O
iPSCs	O
were	O
equally	O
efficient	O
in	O
differentiating	O
into	O
mature	O
neurons	O
expressing	O
neuronal	O
markers	O
TUJ1	O
and	O
MAP2	O
after	O
21	O
days	O
of	O
in	O
vitro	O
differentiation	O
(Figure	O
2B).	O

There	O
is	O
potential	O
however,	O
as	O
effective	O
grafting	O
of	O
human	O
microglia	O
was	O
recently	O
accomplished	O
in	O
a	O
humanized	O
bone	O
marrow	O
chimera	O
in	O
which	O
human	O
interleukin-34	O
under	O
the	O
control	O
of	O
the	O
cytomegalovirus	O
promoter	O
drove	O
brain	O
reconstitution	O
of	O
human	B
stem	I
cell	I
derived	O
peripheral	O
macrophages	O
to	O
differentiate	O
into	O
human	O
microglial-like	O
cells	O
in	O
the	O
mouse	O
brain	O
[82].	O

The	O
major	O
advantage	O
in	O
the	O
use	O
of	O
the	O
direct	O
reprogramming	O
stays	O
in	O
controlling	O
the	O
resident	O
support	O
cells	O
of	O
adult	B
stem	I
cell	I
niches	O
inside	O
eventual	O
damaged	O
organs	O
or	O
old	O
tissues.	O

(2008)	O
Regulatory	O
networks	O
define	O
phenotypic	O
classes	O
of	O
human	B
stem	I
cell	I
lines.	O

Furthermore,	O
such	O
knowledge	O
may	O
also	O
increase	O
our	O
understanding	O
of	O
the	O
factors	O
involved	O
in	O
cardiomyogenic	B
stem	I
cell	I
differentiation,	O
and	O
may	O
thus	O
aid	O
in	O
the	O
development	O
of	O
regenerative	O
therapy	O
for	O
treatment	O
of	O
myocardial	O
infarction.	O

However,	O
one	O
of	O
the	O
main	O
challenges	O
is	O
cardiac	O
arrhythmias	O
associated	O
with	O
stem	B
cell	I
transplantation.	O

A	O
high	O
rate	O
of	O
transplanted	B
stem	I
cell	I
loss	O
(90%	O
within	O
the	O
first	O
few	O
days)	O
has	O
been	O
observed	O
[4,	O
5].	O

With	O
the	O
advances	O
in	O
3-D	O
culture	O
system,	O
aggregates	O
of	O
stem	B
cells	I
can	O
self-organize	O
into	O
retinal	O
organoids,	O
forming	O
optic	O
vesicles	O
or	O
optic	O
cups,	O
with	O
major	O
cell	O
types	O
self-patterning	O
into	O
a	O
polarized,	O
laminated	O
cytoarchitecture	O
highly	O
reminiscent	O
of	O
the	O
human	O
retina	O
in	O
vivo	O
[23,	O
24,	O
124–126].	O

and	O
Yamanaka	O
S.,	O
Induction	O
of	O
pluripotent	B
stem	I
cells	I
from	O
mouse	O
embryonic	O
and	O
adult	O
fibroblast	O
cultures	O
by	O
defined	O
factors,	O
Cell	O
126(4)	O
(2006),	O
663–676.	O

[123]	O
Yin	O
X.,	O
et	O
al.,	O
Engineering	O
Stem	O
Cell	O
Organoids,	O
Cell	B
Stem	I
Cell	I
18(1)	O
(2016),	O
25–38.	O

Cancer	B
stem	I
cells	I
of	O
CNS	O
origin	O
have	O
the	O
ability	O
to	O
grow	O
on	O
non-adherent	O
surfaces	O
and	O
give	O
rise	O
to	O
spherical	O
cell	O
colonies	O
known	O
as	O
neurospheres.	O

The	O
reliance	O
of	O
tumors	O
on	O
stem	B
cell	I
renewal	O
and	O
differentiation	O
potential	O
strongly	O
parallels	O
the	O
cellular	O
growth	O
and	O
differentiation	O
pathways	O
found	O
in	O
the	O
developing	O
CNS.	O

In	O
particular,	O
they	O
are	O
important	O
for	O
stem	B
cell	I
maintenance	O
and	O
have	O
been	O
attributed	O
roles	O
in	O
tissue	O
regeneration	O
and	O
tumorigenesis	O
(Kamachi	O
and	O
Kondoh,	O
2013).	O

Tumor	B
stem	I
cells	I
derived	O
from	O
glioblastomas	O
cultured	O
in	O
bFGF	O
and	O
EGF	O
more	O
closely	O
mirror	O
the	O
phenotype	O
and	O
genotype	O
of	O
primary	O
tumors	O
than	O
do	O
serum-cultured	O
cell	O
lines.	O

Roles	O
of	O
TGF-beta	O
family	O
signaling	O
in	O
stem	B
cell	I
renewal	O
and	O
differentiation.	O

Adhesive	O
and	O
mechanical	O
regulation	O
of	O
mesenchymal	B
stem	I
cell	I
differentiation	O
in	O
human	O
bone	O
marrow	O
and	O
periosteum-derived	O
progenitor	O
cells.	O

We	O
then	O
further	O
detected	O
the	O
expression	O
of	O
stem	B
cell	I
factors	O
involved	O
in	O
HCC.	O

b	O
GSK5959	O
reduced	O
the	O
expression	O
of	O
stem	B
cell	I
factors	O
in	O
Huh-7	O
cells	O
after	O
24-h	O
treatment.	O

More	O
importantly,	O
BRPF1	O
contributed	O
to	O
liver	O
cancer	O
stemness	O
by	O
increasing	O
the	O
expression	B
of	I
stem	I
cell	I
factors	O
and	O
promoting	O
self-renewal	O
ability.	O

Ki-67	O
is	O
required	O
for	O
maintenance	O
of	O
cancer	B
stem	I
cells	I
but	O
not	O
cell	O
proliferation.	O

In	O
many	O
muscle	O
disorders,	O
the	O
repeated	O
cycles	O
of	O
damage	O
and	O
repair	O
lead	O
to	O
stem	B
cell	I
dysfunction.	O

A	O
recent	O
hypothesis	O
to	O
explain	O
such	O
an	O
outcome	O
is	O
that	O
the	O
MuSC	O
pool	O
responsible	O
for	O
muscle	O
regeneration	O
gradually	O
becomes	O
less	O
efficient	O
at	O
responding	O
to	O
and	O
repairing	O
damage	O
as	O
a	O
result	O
of	O
stem	B
cell	I
defects	O
(Dumont	O
et	O
al.,	O
2015,	O
Sacco	O
et	O
al.,	O
2010).	O

An	O
optimized	O
technique	O
that	O
is	O
able	O
to	O
measure	O
telomere	O
length	O
in	O
a	O
muscle	O
cell	O
type-specific	O
way	O
would	O
be	O
an	O
invaluable	O
tool	O
to	O
study	O
the	O
involvement	O
of	O
stem	B
cells	I
in	O
the	O
onset	O
and	O
progression	O
of	O
DMD	O
as	O
well	O
as	O
other	O
skeletal	O
muscle	O
diseases..	O

However,	O
in	O
the	O
skeletal	O
muscle	O
field,	O
existing	O
methods	O
are	O
not	O
well	O
suited	O
for	O
stem	B
cell	I
analysis	O
due	O
to	O
technical	O
and	O
biological	O
limitations	O
of	O
the	O
muscles	O
(rare	O
population,	O
fragile	O
cells,	O
no	O
MuSC	O
expansion,	O
and	O
small	O
tissue	O
sample	O
availability).	O

While	O
similar	O
numbers	O
of	O
MuSCs	O
were	O
isolated	O
between	O
wild-type,	O
mdx,	O
and	O
mTRG2	O
mice	O
(Figure	O
4A),	O
a	O
comparison	O
of	O
mTRG2	O
mice	O
with	O
mdx/mTRG2	O
mice	O
did	O
show	O
a	O
decrease	O
in	O
MuSC	O
numbers	O
in	O
the	O
dystrophic	O
mice,	O
consistent	O
with	O
the	O
reported	O
difference	O
in	O
stem	B
cell	I
reserves	O
available	O
for	O
regeneration	O
during	O
the	O
progression	O
of	O
the	O
dystrophic	O
disease	O
(Sacco	O
et	O
al.,	O
2010)..	O

These	O
effects,	O
either	O
individually	O
or	O
in	O
combination,	O
contribute	O
to	O
stem	B
cell	I
dysfunction..	O

These	O
findings	O
support	O
the	O
notion	O
that	O
telomere	O
shortening	O
contributes	O
to	O
the	O
stem	B
cell	I
dysfunction	O
and	O
impaired	O
regeneration	O
observed	O
in	O
muscular	O
dystrophy.	O

Importantly,	O
utilizing	O
MuQ-FISH	O
will	O
allow	O
for	O
further	O
investigation	O
of	O
the	O
developmental	O
and	O
self-renewal	O
processes	O
and	O
pathways	O
involved	O
in	O
stem	B
cell	I
dysfunction	O
in	O
various	O
skeletal	O
muscle	O
disorders.	O

The	O
longest	O
telomeres:	O
a	O
general	O
signature	O
of	O
adult	B
stem	I
cell	I
compartments.	O

The	O
NOTCH	O
pathway	O
contributes	O
to	O
the	O
inhibition	O
of	O
cell	O
differentiation,	O
whereas	O
WNT	O
promotes	O
the	O
development	O
of	O
CSCs	O
originating	O
from	O
normal	B
stem	I
cells	I
and	O
non-stem	O
cancer	O
cells	O
[35,	O
36].	O

Chemoresistant	O
colorectal	O
cancer	O
cells,	O
the	O
cancer	B
stem	I
cell	I
phenotype,	O
and	O
increased	O
sensitivity	O
to	O
insulin-like	O
growth	O
factor-I	O
receptor	O
inhibition.	O

A	O
retinoic	O
acid-enhanced,	O
multicellular	O
human	O
blood-brain	O
barrier	O
model	O
derived	O
from	O
stem	B
cell	I
sources.	O

A	O
subset	O
of	O
midbrain	O
dopaminergic	O
neurons	O
degenerate	O
in	O
Parkinson’s	O
disease	O
and	O
are	O
therefore	O
of	O
particular	O
interest	O
for	O
neuro-regenerative	B
stem	I
cell	I
research	O
(reviewed	O
by,	O
e.g.,	O
Lindvall	O
2013;	O
Arenas	O
2014).	O

They	O
express	O
the	O
neural	B
stem	I
cell	I
markers	O
Nestin	O
(b),	O
SOX2	O
(c)	O
and	O
PLZF	O
(d).	O

The	O
generation	O
of	O
authentic	O
neuronal	O
cell	O
types	O
that	O
fully	O
resemble	O
their	O
in	O
vivo	O
counterparts	O
is	O
still	O
one	O
of	O
the	O
main	O
challenges	O
in	O
stem	B
cell	I
research.	O

Neural	B
stem	I
cell	I
systems:	O
physiological	O
players	O
or	O
in	O
vitro	O
entities?	O
Nat	O
Rev	O
Neurosci.	O

Human	O
ES	O
cell-derived	O
neural	O
rosettes	O
reveal	O
a	O
functionally	O
distinct	O
early	O
neural	B
stem	I
cell	I
stage.	O

Emerging	O
concepts	O
in	O
neural	B
stem	I
cell	I
research:	O
autologous	O
repair	O
and	O
cell-based	O
disease	O
modelling.	O

Dicer	O
is	O
required	O
for	O
neural	B
stem	I
cell	I
multipotency	O
and	O
lineage	O
progression	O
during	O
cerebral	O
cortex	O
development.	O

DGCR8	O
is	O
essential	O
for	O
microRNA	O
biogenesis	O
and	O
silencing	O
of	O
embryonic	B
stem	I
cell	I
self-renewal.	O

A	O
feedback	O
regulatory	O
loop	O
involving	O
microRNA-9	O
and	O
nuclear	O
receptor	O
TLX	O
in	O
neural	B
stem	I
cell	I
fate	O
determination.	O

Alternatively,	O
the	O
emergence	O
of	O
CRISPR/Cas9	O
gene	O
editing	O
has	O
enabled	O
researchers	O
to	O
further	B
manipulate	I
stem	I
cell	I
systems	O
for	O
mechanistic	O
study.	O

Canine	O
Bone	O
Marrow	O
Mesenchymal	B
Stem	I
Cell	I
Conditioned	O
Media	O
Affect	O
Bacterial	O
Growth,	O
Biofilm-Associated	O
Staphylococcus	O
aureus	O
and	O
AHL-Dependent	O
Quorum	O
Sensing.	O

Thus,	O
research	O
on	O
canine-derived	O
MSCs	O
may	O
provide	O
insight	O
into	O
stem	B
cell	I
therapy	O
not	O
just	O
for	O
canines,	O
but	O
for	O
humans	O
as	O
well	O
[13]..	O

Although	O
these	O
MSCs	O
can	O
be	O
derived	O
from	O
several	O
sources,	O
clinical	O
use	O
has	O
favored	O
bone	O
marrow	O
and	O
adipose	O
tissue	O
because	O
of	O
their	O
relative	O
ease	O
of	O
stem	B
cell	I
recovery	O
in	O
large	O
numbers	O
and	O
their	O
minimal	O
donor-site	O
morbidity	O
[10].	O

Human	O
Mesenchymal	B
Stem	I
Cell	I
Microvesicles	O
for	O
Treatment	O
of	O
Escherichia	O
Coli	O
Endotoxin-Induced	O
Acute	O
Lung	O
Injury	O
in	O
Mice:	O
MSC	O
MV	O
Attenuates	O
ALI	O
in	O
Part	O
Through	O
KGF.	O

Mutant	O
IDH	O
inhibition	O
resulted	O
in	O
enhanced	O
progenitor	O
cell	O
differentiation,	O
which	O
was	O
associated	O
with	O
an	O
increase	O
in	O
differentiation	O
and	O
a	O
decrease	O
in	O
stem	B
cell	I
marker	O
expression,	O
as	O
shown	O
in	O
AML	O
blast	O
cells	O
ex	O
vivo	O
(82)	O
and	O
in	O
glioma-initiating	O
cells	O
in	O
vitro	O
and	O
derivative	O
tumors	O
in	O
vivo	O
(87).	O

After	O
conditioning	O
with	O
whole-body	O
irradiation	O
or	O
high-dose	O
chemotherapy	O
to	O
ablate	O
endogenous	O
HSCs,	O
investigators	O
transplant	O
transduced	O
HSCs	O
intravenously	O
into	O
recipient	O
mice	O
which	O
hone	O
to	O
bone	O
marrow	O
niches	O
through	O
signaling	O
pathways	O
analogous	O
to	O
stem	B
cell	I
transplants	O
in	O
humans.	O

Treatment	O
of	O
nasopharyngeal	O
sphere-derived	O
cells	O
with	O
(−)EGCG,	O
a	O
major	O
bioactive	O
compound	O
in	O
green	O
tea,	O
failed	O
to	O
inhibit	O
growth	O
and	O
apoptosis	O
but	O
induced	O
the	O
formation	O
of	O
a	O
sphere,	O
suggesting	O
that	O
EGCG	O
potently	O
eliminates	O
the	O
stem	B
cell	I
character	O
of	O
nasopharyngeal	O
cancer	O
cells.[137]	O
EGCG	O
inhibits	O
the	O
self-renewing	O
capacity	O
of	O
human	O
prostate	O
cancer	O
cell	O
lines	O
(PC-3	O
and	O
LNCaP)	O
containing	O
a	O
small	O
population	O
of	O
CSCs	O
presenting	O
CD44+	O
CD133+.	O

Antagonism	O
of	O
stem	B
cell	I
factor/c-kit	O
signaling	O
attenuates	O
neonatal	O
chronic	O
hypoxia-induced	O
pulmonary	O
vascular	O
remodeling.	O

The	O
long	O
non-coding	O
RNA-ORLNC1	O
regulates	O
bone	O
mass	O
by	O
directing	O
mesenchymal	B
stem	I
cell	I
fate.	O

Unfortunately,	O
few	O
studies	O
have	O
directly	O
compared	O
engraftment	O
in	O
relation	O
to	O
the	O
engineered	O
T	O
cell	O
dose,	O
and	O
those	O
studies	O
have	O
shown	O
conflicting	O
results.24,	O
25,	O
26	O
In	O
many	O
ways,	O
T	O
cell	O
therapy	O
is	O
akin	O
to	O
hematopoietic	B
stem	I
cell	I
transplantation,	O
in	O
which	O
the	O
number	O
of	O
CD34+	O
cells	O
transferred	O
is	O
correlated	O
with	O
both	O
the	O
engraftment	O
success	O
as	O
well	O
as	O
the	O
time	O
to	O
recovery	O
of	O
mature	O
hematopoietic	O
cells.27	O
However,	O
it	O
is	O
still	O
challenging	O
to	O
identify	O
the	O
T	O
cells	O
within	O
an	O
infused	O
product	O
with	O
the	O
greatest	O
“stemness.”	O
Studies	O
in	O
both	O
murine	O
and	O
primate	O
models	O
of	O
adoptive	O
cellular	O
therapy	O
(ACT)	O
over	O
the	O
past	O
decade	O
have	O
shown	O
that	O
T	O
cells	O
vary	O
in	O
their	O
ability	O
to	O
support	O
long-term	O
engraftment	O
following	O
adoptive	O
transfer.	O

Inflammatory	O
cytokine-induced	O
intercellular	O
adhesion	O
molecule-1	O
and	O
vascular	O
cell	O
adhesion	O
molecule-1	O
in	O
mesenchymal	B
stem	I
cells	I
are	O
critical	O
for	O
immunosuppression.	O

DDX3	O
directly	O
regulates	O
m6A	O
through	O
the	O
methylase	O
ALKBH5	O
and	O
reduces	O
the	O
transcription	O
of	O
cancer	B
stem	I
cell	I
transcription	O
factor	O
FOXM1	O
(Fork	O
head	O
box	O
protein	O
M1)	O
and	O
Nanog	O
homeobox,	O
resulting	O
in	O
chemotherapy	O
drug	O
resistance	O
(Shriwas	O
et	O
al.,	O
2020).	O

Under	O
physiological	O
conditions,	O
MSC	O
have	O
a	O
major	O
role	O
in	O
the	O
maintenance	O
of	O
stem	B
cell	I
niches,	O
like	O
for	O
the	O
hematopoietic	O
niche	O
(8).	O

Cancer	B
stem	I
cell	I
niche	O
models	O
and	O
contribution	O
by	O
mesenchymal	O
stroma/stem	O
cells.	O

Mesenchymal	B
stem	I
cells	I
generate	O
distinct	O
functional	O
hybrids	O
in	O
vitro	O
via	O
cell	O
fusion	O
or	O
entosis.	O

Cancer	B
stem	I
cell	I
dynamics	O
in	O
tumor	O
progression	O
and	O
metastasis:	O
is	O
the	O
microenvironment	O
to	O
blame?	O
Cancer	O
Lett.	O

Sphere-forming	O
cell	O
subsets	O
with	O
cancer	B
stem	I
cell	I
properties	O
in	O
human	O
musculoskeletal	O
sarcomas.	O

Tumor	O
promotion	O
through	O
the	O
mesenchymal	B
stem	I
cell	I
compartment	O
in	O
human	O
hepatocellular	O
carcinoma.	O

Mesenchymal	B
stem	I
cell	I
secretion	O
of	O
chemokines	O
during	O
differentiation	O
into	O
osteoblasts,	O
and	O
their	O
potential	O
role	O
in	O
mediating	O
interactions	O
with	O
breast	O
cancer	O
cells.	O

Mesenchymal	B
stem	I
cell	I
targeting	O
of	O
microscopic	O
tumors	O
and	O
tumor	O
stroma	O
development	O
monitored	O
by	O
noninvasive	O
in	O
vivo	O
positron	O
emission	O
tomography	O
imaging.	O

Direct	O
evidence	O
of	O
mesenchymal	B
stem	I
cell	I
tropism	O
for	O
tumor	O
and	O
wounding	O
microenvironments	O
using	O
in	O
vivo	O
bioluminescent	O
imaging.	O

Mesenchymal	B
stem	I
cells	I
enhance	O
ovarian	O
cancer	O
cell	O
infiltration	O
through	O
IL6	O
secretion	O
in	O
an	O
amniochorionic	O
membrane	O
based	O
3D	O
model.	O

Mesenchymal	B
stem	I
cell	I
secretome:	O
toward	O
cell-free	O
therapeutic	O
strategies	O
in	O
regenerative	O
medicine.	O

EZH2	O
regulates	O
expression	O
of	O
numerous	O
genes	O
critical	O
for	O
stem	B
cell	I
renewal	O
by	O
mediating	O
a	O
H3K27	O
methylation.21	O
EZH2	O
mutations	O
were	O
found	O
in	O
9	O
of	O
12	O
patients	O
with	O
chromosome	O
7q	O
acquired	O
uniparental	O
disomy,	O
and	O
the	O
majority	O
of	O
EZH2	O
mutations	O
resulted	O
in	O
loss	O
of	O
its	O
H3K27	O
methyltransferase	O
activity,22	O
which	O
is	O
in	O
contrast	O
with	O
its	O
gain	O
of	O
function	O
mutation	O
in	O
B-cell	O
lymphoma.23	O
Deletion	O
of	O
EZH2	O
was	O
able	O
to	O
induce	O
a	O
myelodysplastic	O
syndrome-like	O
disease	O
in	O
a	O
mouse	O
model,	O
suggesting	O
the	O
tumour	O
suppressor	O
function	O
of	O
EZH2	O
in	O
certain	O
myeloid	O
malignancies.24,	O
25,	O
26	O
On	O
the	O
other	O
hand,	O
loss-of-function	O
mutations	O
of	O
ASXL1,	O
another	O
polycomb	O
group	O
protein,	O
are	O
usually	O
associated	O
with	O
unfavourable	O
OS	O
and	O
poor	O
complete	O
remission	O
rate	O
in	O
AML.27	O
Although	O
its	O
molecular	O
function	O
in	O
leukaemic	O
transformation	O
is	O
still	O
unclear,	O
depletion	O
of	O
ASXL1	O
showed	O
loss	O
of	O
PRC2-mediated	O
H3K27	O
trimethylation	O
and	O
led	O
to	O
upregulation	O
of	O
HOXA	O
genes	O
including	O
HOXA5	O
and	O
HOXA9.	O

Tissue	O
transglutaminase	O
induces	O
Epithelial-Mesenchymal-Transition	O
and	O
the	O
acquisition	O
of	O
stem	B
cell	I
like	O
characteristics	O
in	O
colorectal	O
cancer	O
cells.	O

In	O
conclusion,	O
organoid	O
technology	O
is	O
one	O
of	O
the	O
most	O
important	O
advances	O
in	O
stem	B
cell	I
research.	O

It	O
is	O
known	O
that	O
Muse	O
cells	O
can	O
be	O
isolated	O
from	O
cultured	O
ASCs	O
based	O
on	O
the	O
positive	O
expression	O
of	O
embryonic	B
stem	I
cell	I
surface	O
marker	O
SSEA3	O
and	O
MSC	O
marker	O
CD105	O
[77,78].	O

Mesenchymal	B
stem	I
cell	I
alterations	O
in	O
bone	O
marrow	O
lesions	O
in	O
patients	O
with	O
hip	O
osteoarthritis.	O

The	O
developing	O
organoid	O
model	O
system	O
of	O
in	O
vitro	O
cell	O
culture	O
has	O
been	O
a	O
game-changer	O
for	O
stem	B
cell	I
and	O
cancer	O
biologists,	O
with	O
infectious	O
disease	O
studies	O
following	O
closely	O
behind	O
[for	O
a	O
comprehensive	O
review	O
see	O
Rossi	O
et	O
al.	O

Hyaluronan–CD44	O
interaction	O
with	O
protein	O
kinase	O
C	O
(epsilon)	O
promotes	O
oncogenic	O
signaling	O
by	O
the	O
stem	B
cell	I
marker	O
Nanog	O
and	O
the	O
production	O
of	O
microRNA-21,	O
leading	O
to	O
down-regulation	O
of	O
the	O
tumor	O
suppressor	O
protein	O
PDCD4,	O
anti-apoptosis,	O
and	O
chemotherapy	O
resistance	O
in	O
breast	O
tumor	O
cells.	O

Targeting	O
miRNAs	O
involved	O
in	O
cancer	B
stem	I
cell	I
and	O
EMT	O
regulation:	O
an	O
emerging	O
concept	O
in	O
overcoming	O
drug	O
resistance.	O

Notch	O
reporter	O
activity	O
in	O
breast	O
cancer	O
cell	O
lines	O
identifies	O
a	O
subset	O
of	O
cells	O
with	O
stem	B
cell	I
activity.	O

The	O
same	O
oncogenic	O
combination	O
(Ras/p53)	O
in	O
hair	B
follicle	I
stem	I
cells	I
can	O
directly	O
induce	O
a	O
more	O
invasive	O
form	O
of	O
SCC,	O
mesenchymal-like	O
spindle	O
cell	O
carcinoma.	O

Multiple	O
resident	O
stem	O
cell	O
populations	O
within	O
the	O
skin	O
layers	O
can	O
be	O
involved	O
in	O
nonmelanoma	O
and	O
melanoma	O
skin	O
cancer	O
development;	O
however,	O
each	O
population	O
located	O
in	O
distinct	O
stem	B
cell	I
niches	O
has	O
different	O
tumorigenic	O
potential	O
that	O
can	O
correlate	O
with	O
distinct	O
tumor	O
phenotypes.	O

Cox-2	O
is	O
known	O
to	O
be	O
involved	O
in	O
the	O
re-epithelialization	O
of	O
early	O
phases	O
of	O
wound	O
healing;67	O
hence,	O
it	O
is	O
also	O
be	O
important	O
to	O
determine	O
whether	O
selective	O
Cox-2	O
inhibition	O
can	O
regulate	O
wound	O
healing-mediated	O
hair	B
follicle	I
stem	I
cell	I
migration	O
and	O
SCC	O
formation..	O

It	O
is	O
also	O
possible	O
that	O
all-trans	O
retinoic	O
acid	O
and	O
Cox-2	O
may	O
have	O
opposite	O
roles	O
or	O
act	O
synergistically	O
in	O
stem	B
cell	I
differentiation,	O
although	O
this	O
has	O
not	O
been	O
documented	O
in	O
cutaneous	O
and	O
esophageal	O
stem/progenitor	O
cells96.	O

While	O
Cox-2	O
may	O
be	O
a	O
promising	O
molecular	O
target	O
to	O
prevent	O
stem/progenitor	O
cell-originating	O
tumor	O
formation,	O
it	O
is	O
important	O
to	O
clarify	O
whether	O
and	O
how	O
Cox-2	O
expression	O
in	O
stem	O
cells	O
is	O
required	O
for	O
their	O
normal	O
function	O
and	O
how	O
they	O
regulate	O
the	O
stem	B
cell	I
niche.	O

This	O
phenomenon	O
may	O
prove	O
to	O
be	O
associated	O
with	O
stem	B
cell	I
aging	O
and	O
Cox-2	O
expression98,99.	O

Basal	O
cell	O
carcinoma	O
preferentially	O
arises	O
from	O
stem	B
cells	I
within	O
hair	O
follicle	O
and	O
mechanosensory	O
niches.	O

Basal	O
cell	O
carcinomas	O
in	O
mice	O
arise	O
from	O
hair	B
follicle	I
stem	I
cells	I
and	O
multiple	O
epithelial	O
progenitor	O
populations.	O

Conditional	O
expression	O
of	O
K-ras	O
in	O
an	O
epithelial	O
compartment	O
that	O
includes	O
the	O
stem	B
cells	I
is	O
sufficient	O
to	O
promote	O
squamous	O
cell	O
carcinogenesis.	O

Therefore,	O
in	O
the	O
cellular	O
hierarchy	O
of	O
a	O
tumor,	O
there	O
is	O
a	O
differentiation	O
mechanism	O
from	O
tumor	B
stem	I
cell	I
to	O
tumor	O
progenitor	O
cell	O
to	O
mature	O
tumor	O
cell	O
which	O
ends	O
in	O
apoptosis	O
and	O
turnover	O
[6].	O

Bmi1	O
is	O
a	O
transcriptional	O
receptor	O
in	O
the	O
polycomb	O
group	O
(PcG)	O
gene	O
family	O
and	O
is	O
involved	O
in	O
stem	B
cell	I
maintenance,	O
proliferation,	O
differentiation	O
to	O
more	O
committed	O
cells,	O
malignant	O
transformation,	O
and	O
biologic	O
aggressiveness	O
of	O
human	O
carcinomas	O
[18,19].	O

By	O
suppressing	O
a	O
tumor	O
suppressor,	O
a	O
double-negative	O
results	O
in	O
a	O
positive	O
for	O
cancer	O
growth	O
as	O
well	O
as	O
for	O
the	O
expansion	O
of	O
cells	O
with	O
stem	B
cell	I
properties.	O

Therefore,	O
Bmi1	O
became	O
an	O
interesting	O
endeavor	O
for	O
the	O
cancer	B
stem	I
cell	I
biologist.	O

If	O
it	O
is	O
not	O
an	O
initiating	O
event,	O
GI	O
may	O
be	O
the	O
result	O
of	O
other	O
alterations,	O
thus	O
steering	O
the	O
stem	B
cell	I
population	O
into	O
cancer.	O

However,	O
much	O
still	O
needs	O
to	O
be	O
understood	O
about	O
normal	B
stem	I
cell	I
versus	O
CSC	O
function	O
and	O
maintenance	O
before	O
effective	O
treatments	O
can	O
be	O
generated	O
for	O
such	O
defiant	O
cellular	O
mechanisms..	O

A	O
stochastic	O
model	O
for	O
cancer	O
stem	B
cell	I
origin	O
in	O
metastatic	O
colon	O
cancer.	O

The	O
first	O
extracellular	O
domain	O
of	O
the	O
tumour	B
stem	I
cell	I
marker	O
CD133	O
contains	O
an	O
antigenic	O
ganglioside-binding	O
motif.	O

Prognostic	O
significance	O
of	O
the	O
cancer	B
stem	I
cell	I
markers	O
CD133,	O
CD44,	O
and	O
CD166	O
in	O
colorectal	O
cancer.	O

We	O
speculate	O
that	O
exposure	O
to	O
toxic	O
agents	O
leads	O
to	O
clonal	O
expansion	O
of	O
cells	O
that	O
are	O
hypomethylated	O
in	O
CpGs	O
of	O
genes	O
involved	O
in	O
activation	O
of	O
a	O
pathway	O
reactive	O
to	O
environmental	O
insults,	O
and	O
this	O
imbalance	O
in	O
the	O
proportion	O
of	O
methylated	O
DNA	O
in	O
stem	B
cells	I
persists,	O
remaining	O
mitotically	O
stable	O
through	O
subsequent	O
cell	O
divisions..	O

Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

Summary/Conclusion:	O
In	O
conclusion,	O
by	O
combining	O
the	O
beneficial	O
effects	O
of	O
stem	B
cell	I
therapies	O
and	O
protein	O
therapeutics,	O
engineered	O
decoy	O
EVs	O
may	O
have	O
great	O
potential	O
to	O
be	O
the	O
next	O
generation	O
of	O
biotherapeutics..	O

Immunomodulatory	O
treatment	O
approach	O
to	O
CNS	O
injury:	O
role	O
of	O
mesenchymal	B
stem	I
cell	I
derived	O
extracellular	O
vesicles.	O

Results:	O
Our	O
results	O
show	O
that	O
the	O
flow	O
of	O
exosomes	O
between	O
subpopulations	O
of	O
pancreatic	O
cancer	O
cells	O
occurs	O
in	O
a	O
non-random	O
way,	O
and	O
that	O
preferential	O
routes	O
of	O
communication	O
are	O
established	O
from	O
cancer	O
stem	O
cells	O
to	O
non-cancer	B
stem	I
cell	I
subpopulations.	O

Cell	O
secretion	O
is	O
an	O
important	O
mechanism	O
for	O
stem	O
cell-based	O
therapeutic	O
angiogenesis	O
along	O
with	O
cell	O
differentiation	O
to	O
vascular	O
endothelial	O
cell	O
or	O
smooth	O
muscle	O
cell.	O
Neural	O
differentiation	O
of	O
stem	B
cell	I
provides	O
alternative	O
source	O
for	O
neural	O
lineage	O
cells	O
(NLCs)..	O

restorative	O
properties	O
of	O
stem	B
cell	I
EVs)	O
or	O
injurious,	O
as	O
represented	O
in	O
pre-eclampsia	O
(caused	O
by	O
placental	O
vesicle	O
shedding)	O
and	O
acute	O
traumatic	O
brain	O
injury	O
(exacerbated	O
by	O
EV	O
release	O
into	O
circulation).	O

(2009)	O
Genetic	O
variation	O
in	O
the	O
prostate	B
stem	I
cell	I
antigen	O
gene	O
PSCA	O
confers	O
susceptibility	O
to	O
urinary	O
bladder	O
cancer.	O

The	O
defect	O
has	O
been	O
shown	O
to	O
be	O
a	O
mutation	O
in	O
the	O
gene	O
encoding	O
c-kit	O
tyrosine	O
kinase	O
receptor,	O
or	O
a	O
mutation	O
in	O
the	O
gene	O
for	O
stem	B
cell	I
factor,	O
which	O
is	O
the	O
receptor	O
ligand.	O

Experimental	O
verification	O
of	O
this	O
hypothesis	O
has	O
come	O
from	O
mouse	O
models,	O
where	O
APC	O
loss	O
in	O
the	O
intestinal	B
stem	I
cell	I
compartments	O
results	O
in	O
rapid	O
induction	O
of	O
colon	O
adenomas,	O
indicating	O
that	O
these	O
cells	O
can	O
be	O
the	O
cells	O
of	O
origin	O
of	O
cancer	O
(Barker	O
et	O
al.,	O
2009;	O
Powell	O
et	O
al.,	O
2012).	O

To	O
determine	O
the	O
evolution	O
of	O
genetic	O
diversity	O
in	O
the	O
context	O
of	O
functional	O
heterogeneity,	O
an	O
analysis	O
of	O
the	O
Philadelphia	O
Chromosome	O
copy	O
number	O
variations	O
in	O
primary	O
human	O
BCR-ABL+	O
ALL	O
samples	O
was	O
performed	O
to	O
define	O
the	O
ancestry	O
of	O
functional	B
stem	I
cell	I
populations	O
(Notta	O
et	O
al.,	O
2011).	O

Key	O
studies	O
using	O
in	O
vitro	O
breast	O
cancer	O
cells	O
have	O
shown	O
that	O
the	O
acquisition	O
of	O
EMT	O
is	O
accompanied	O
by	O
a	O
transcriptional	O
program	O
indicative	O
of	O
the	O
stem	B
cell	I
state	O
(Mani	O
et	O
al.,	O
2008).	O

Importantly,	O
the	O
progression	O
of	O
EMT	O
could	O
be	O
halted	O
by	O
disrupting	O
oncogenic	O
developmental	O
signals,	O
such	O
as	O
Ras	O
(McFaline-Figueroa	O
et	O
al.,	O
2019),	O
suggesting	O
that	O
the	O
signals	O
sustaining	O
these	O
distinct	O
metastatic	O
populations	O
may	O
all	O
rely	O
on	O
a	O
core	O
network	O
of	O
stem	B
cell	I
programs.	O

Generating	O
hepatic	O
cell	O
lineages	O
from	O
pluripotent	B
stem	I
cells	I
for	O
drug	O
toxicity	O
screening.	O

Researchers	O
working	O
in	O
the	O
burgeoning	O
field	O
of	O
adult	O
stem	O
cell	O
biology	O
seek	O
to	O
understand	O
the	O
signals	O
that	O
regulate	O
the	O
behavior	O
and	O
function	O
of	O
stem	B
cells	I
during	O
normal	O
homeostasis	O
and	O
disease	O
states.	O

For	O
example,	O
better	O
knowledge	O
about	O
adult	B
stem	I
cell	I
biology	O
can	O
facilitate	O
the	O
design	O
of	O
therapeutic	O
strategies	O
in	O
which	O
organs	O
are	O
triggered	O
to	O
heal	O
themselves	O
or	O
even	O
the	O
creation	O
of	O
methods	O
for	O
growing	O
organs	O
in	O
vitro	O
that	O
can	O
be	O
transplanted	O
into	O
humans1.	O

For	O
example,	O
there	O
are	O
expanding	O
interests	O
in	O
using	O
zebrafish	O
to	O
investigate	O
the	O
biology	O
of	O
adult	B
stem	I
cell	I
populations	O
and	O
make	O
sophisticated	O
adult	O
models	O
of	O
diseases	O
such	O
as	O
cancer5.	O

In	O
light	O
of	O
this	O
new	O
discovery,	O
the	O
zebrafish	O
kidney	O
is	O
one	O
organ	O
that	O
houses	O
the	O
location	O
of	O
two	O
exciting	O
opportunities	O
for	O
adult	B
stem	I
cell	I
biology	O
studies.	O

There	O
is	O
great	O
interest	O
in	O
understanding	O
the	O
pathways	O
that	O
regulate	O
the	O
cell	O
fate	O
decisions	O
and	O
potency	O
of	O
adult	B
stem	I
cells	I
because	O
of	O
their	O
important	O
roles	O
in	O
tissue	O
homeostasis1.	O

It	O
should	O
be	O
noted	O
that	O
the	O
method	O
we	O
describe	O
for	O
isolating	O
and	O
working	O
with	O
the	O
zebrafish	O
adult	O
kidney	O
is	O
certainly	O
not	O
limited	O
to	O
scientists	O
who	O
wish	O
to	O
pursue	O
questions	O
of	O
adult	B
stem	I
cell	I
biology,	O
as	O
the	O
dissection	O
of	O
this	O
organ	O
can	O
facilitate	O
studies	O
for	O
those	O
researchers	O
pursuing	O
investigations	O
on	O
topics	O
ranging	O
from	O
physiology	O
to	O
aging.	O

Arsenic	O
trioxide	O
alters	O
the	O
differentiation	O
of	O
mouse	B
embryonic	I
stem	I
cell	I
into	O
cardiomyocytes.	O

Arsenic	O
trioxide	O
alters	O
the	O
differentiation	O
of	O
mouse	B
embryonic	I
stem	I
cell	I
into	O
cardiomyocytes.	O

Arsenic	O
trioxide	O
alters	O
the	O
differentiation	O
of	O
mouse	B
embryonic	I
stem	I
cell	I
into	O
cardiomyocytes.	O

Recently,	O
one	O
group	O
has	O
taken	O
advantage	O
of	O
the	O
singular	O
ability	O
of	O
stem	B
cells	I
to	O
efflux	O
drugs,	O
as	O
well	O
as	O
the	O
fluorescent	O
Hoechst	O
dye,	O
to	O
isolate	O
CSCs	O
from	O
a	O
PDGF‐driven	O
glioma	O
model	O
by	O
fluorescent‐activated	O
cell	O
sorting	O
(Bleau,	O
AM	O
and	O
Holland,	O
EC,	O
unpub.	O

Expression	O
of	O
pluripotent	B
stem	I
cell	I
reprogramming	O
factors	O
by	O
prostate	O
tumor	O
initiating	O
cells.	O

Cyclin‐dependent	O
kinase	O
7	O
may	O
be	O
involved	O
in	O
cancer	B
stem	I
cell	I
self‐proliferation	O
and	O
differentiation.42,	O
43	O
Our	O
research	O
on	O
MPM	O
also	O
supports	O
this	O
view.	O

Nanotopographical	O
surfaces	O
for	O
stem	B
cell	I
fate	O
control:	O
Engineering	O
mechanobiology	O
from	O
the	O
bottom.	O

Effects	O
of	O
mechanical	O
stretch	O
on	O
cell	O
proliferation	O
and	O
matrix	O
formation	O
of	O
mesenchymal	B
stem	I
cell	I
and	O
anterior	O
cruciate	O
ligament	O
fibroblast.	O

The	O
use	O
of	O
all	O
WISCB-donated	O
hESC	O
lines	O
in	O
these	O
studies	O
was	O
approved	O
by	O
the	O
Johns	O
Hopkins	O
Embryonic	O
Stem	O
Cell	O
Research	O
Oversight	O
(JHU-ESCRO)	O
Committee	O
and	O
the	O
University	O
of	O
Maryland	O
School	O
of	O
Medicine	B
Embryonic	I
Stem	I
Cell	I
Research	O
Oversight	O
Committee	O
(UMSOM-ESCRO)	O
and	O
conforms	O
strictly	O
to	O
standards	O
of	O
both	O
institutions,	O
including	O
written	O
informed	O
consent.	O

Zambidis),	O
NIH/NCI	O
(T32CA60441,	O
Jeffrey	O
S	O
Huo),	O
and	O
the	O
Maryland	B
Stem	I
Cell	I
Research	O
Fund	O
(2011-MSCRF-II-0008-00,	O
Elias	O
T.	O

The	O
principal	O
mechanisms	O
of	O
action	O
of	O
hyperbaric	O
oxygenation	O
are	O
based	O
on	O
antioxidant	O
enzymes	O
induction,	O
inflammatory	O
cytokine	O
suppression,	O
angiogenesis,	O
vasculogenesis,	O
and	O
enhancement	O
of	O
stem	B
cell	I
mobilization	O
[38–45].	O

NF1	O
inactivation	O
in	O
Schwann	O
cells	O
leads	O
to	O
an	O
increase	O
in	O
the	O
stem	B
cell	I
factor,	O
a	O
mast	O
cell-activating	O
factor	O
[65].	O

The	O
presence	O
of	O
mast	O
cells	O
is	O
a	O
neurofibroma	O
hallmark	O
and	O
can	O
be	O
identified	O
by	O
staining	O
for	O
the	O
stem	B
cell	I
factor	O
receptor	O
(KIT).	O

—Possible	O
function	O
in	O
chronic	B
stem	I
cell	I
recruitment	O
to	O
the	O
infarct	O
site	O
(Wang	O
et	O
al.,	O
2002).	O

The	O
mouse	O
strain	O
with	O
high-grade	O
glioma	O
(Arf−/−)	O
displayed	O
a	O
significantly	O
higher	O
infiltration	O
of	O
MCs	O
than	O
Ink4a−/−	O
mice	O
developing	O
low-grade	O
gliomas	O
and	O
exhibited	O
also	O
a	O
strong	O
expression	O
of	O
stem	B
cell	I
factor	O
(SCF),	O
the	O
main	O
growth	O
factor	O
for	O
MCs,	O
around	O
tumor	O
blood	O
vessels	O
[42].	O

Mast	O
cell	O
accumulation	O
in	O
glioblastoma	O
with	O
a	O
potential	O
role	O
for	O
stem	B
cell	I
factor	O
and	O
chemokine	O
CXCL12.	O

Hemberger	O
M,	O
Dean	O
W,	O
Reik	O
W	O
(2009)	O
Epigenetic	O
dynamics	O
of	O
stem	B
cells	I
and	O
cell	O
lineage	O
commitment:	O
digging	O
Waddington's	O
canal.	O

Certainly,	O
exosome	O
therapy	O
reduces	O
the	O
formation	O
of	O
any	O
endogenous	O
abnormal	O
differentiation	O
and	O
adverse	O
reactions	O
(e.g.,	O
fever	O
and	O
allergic	O
reactions)	O
compared	O
to	O
stem	B
cell	I
transplantation,	O
even	O
if	O
some	O
challenges	O
often	O
limit	O
the	O
application	O
of	O
exosomes	O
because	O
it	O
is	O
difficult	O
to	O
determine	O
their	O
specific	O
cell	O
source,	O
their	O
extraction	O
methods	O
are	O
not	O
yet	O
standardized,	O
their	O
amount	O
is	O
limited,	O
and	O
content	O
is	O
variable	O
based	O
on	O
the	O
pathophysiological	O
conditions.	O

Comprehensive	O
Proteomic	O
Analysis	O
of	O
Mesenchymal	B
Stem	I
Cell	I
Exosomes	O
Reveals	O
Modulation	O
of	O
Angiogenesis	O
via	O
Nuclear	O
Factor-KappaB	O
Signaling.	O

Patient-derived	O
xenografts,	O
the	O
cancer	B
stem	I
cell	I
paradigm,	O
and	O
cancer	O
pathobiology	O
in	O
the	O
21st	O
century.	O

The	O
transcription	O
factor	O
Krüppel-like	O
factor	O
4	O
(KLF4)	O
has	O
been	O
implicated	O
in	O
regulating	O
cell	O
proliferation,	O
migration	O
and	O
differentiation	O
in	O
a	O
variety	O
of	O
human	O
cells	O
and	O
is	O
one	O
of	O
four	O
factors	O
required	O
for	O
the	O
induction	O
of	O
pluripotent	B
stem	I
cell	I
reprogramming.	O

Cross-talk	O
between	O
the	O
dipeptidyl	O
peptidase-4	O
and	O
stromal	O
cell-derived	O
factor-1	O
in	O
stem	B
cell	I
homing	O
and	O
myocardial	O
repair:	O
potential	O
impact	O
of	O
dipeptidyl	O
peptidase-4	O
inhibitors.	O

Molecular	O
mechanisms	O
for	O
cardiovascular	B
stem	I
cell	I
apoptosis	O
and	O
growth	O
in	O
the	O
hearts	O
with	O
atherosclerotic	O
coronary	O
disease	O
and	O
ischemic	O
heart	O
failure.	O

Targeting	O
CSCs	O
integrins	O
to	O
modulate	O
their	O
interaction	O
with	O
the	O
ECM	O
of	O
the	O
stem	B
cell	I
niche	O
may	O
be	O
of	O
therapeutic	O
potential.	O

Evaluation	O
of	O
the	O
expression	O
of	O
stem	B
cell	I
markers	O
in	O
human	O
breast	O
cancer	O
reveals	O
a	O
correlation	O
with	O
clinical	O
progression	O
and	O
metastatic	O
disease	O
in	O
ductal	O
carcinoma.	O

Validation	O
of	O
stem	B
cell	I
markers	O
in	O
clinical	O
prostate	O
cancer:	O
alpha6-integrin	O
is	O
predictive	O
for	O
non-aggressive	O
disease.	O

MPC1	O
is	O
necessary	O
for	O
intestinal	O
stem	O
cell	O
differentiation	O
in	O
zebrafish,	O
and	O
loss	O
of	O
the	O
tumor	O
suppressor	O
Adenomatous	O
Polyposis	O
Coli	O
(APC)	O
downregulates	O
MPC	O
expression	O
to	O
favor	O
stem	B
cell	I
growth	O
over	O
differentiation	O
[23].	O

In	O
MPC-deficient	O
lung,	O
colon,	O
and	O
prostate	O
cancers,	O
an	O
increase	O
in	O
stem	O
cell	O
markers	O
suggests	O
that	O
MPC	O
loss	O
may	O
increase	O
resistance	O
to	O
chemo/radiation	O
therapy	O
and	O
expand	O
the	O
stem	B
cell	I
compartment	O
to	O
shift	O
tumor	O
metabolism	O
toward	O
a	O
growth-promoting,	O
glycolytic	O
state..	O

Regulation	O
of	O
Drosophila	O
Intestinal	B
Stem	I
Cell	I
Proliferation	O
by	O
Enterocyte	O
Mitochondrial	O
Pyruvate	O
Metabolism.	O

Similarly,	O
when	O
threonine	O
metabolism	O
was	O
attenuated	O
in	O
mouse	B
embryonic	I
stem	I
cells	I
by	O
threonine	O
restriction	O
in	O
culture	O
medium	O
or	O
by	O
genetic	O
depletion	O
of	O
TDH	O
(threonine	O
dehydrogenase),	O
the	O
levels	O
of	O
cellular	O
SAM	O
and	O
H3K4me3	O
decreased,	O
affecting	O
cell	O
growth	O
and	O
differentiation	O
(Shyh-Chang	O
et	O
al.,	O
2013).	O

Due	O
to	O
immunological	O
considerations,	O
the	O
essential	O
starting	O
point	O
for	O
work	O
in	O
stem	B
cell	I
transplantation	O
is	O
deriving	O
and	O
characterizing	O
allogeneic	O
cells.	O

The	O
transient	O
quality	O
of	O
CXCR4	O
expression,	O
a	O
receptor	O
involved	O
in	O
stem	B
cell	I
homing,	O
is	O
of	O
particular	O
interest	O
in	O
that	O
it	O
has	O
potential	O
implications	O
for	O
the	O
timing	O
of	O
transplantation	O
and	O
successful	O
integration	O
of	O
grafted	O
cells..	O

A	O
mouse	O
model	O
of	O
acrodermatitis	O
enteropathica:	O
Loss	O
of	O
intestine	O
zinc	O
transporter	O
zip4	O
(slc39a4)	O
disrupts	O
the	O
stem	B
cell	I
niche	O
and	O
intestine	O
integrity.	O

Such	O
residual	O
cell	O
populations	O
appear	O
to	O
be	O
enriched	O
for	O
cancer	B
stem	I
cells	I
[34].	O

Most	O
importantly,	O
the	O
stem	B
cell	I
field	O
continues	O
to	O
advance	O
rapidly	O
in	O
both	O
mechanistic	O
understanding	O
of	O
disease	O
and	O
the	O
translation	O
of	O
discovery	O
into	O
new	O
therapies	O
for	O
so	O
many	O
devastating	O
yet	O
unsolved	O
human	O
diseases.	O

Revised	O
guidelines	O
will	O
be	O
available	O
in	O
early	O
2021,	O
once	O
again	O
setting	O
an	O
international	O
standard	O
for	O
excellence	O
in	O
stem	B
cell	I
research	O
and	O
clinical	O
translation..	O

In	O
the	O
last	O
12	O
months,	O
the	O
journal	O
has	O
published	O
primary	O
research	O
Articles,	O
Reviews,	O
and	O
Perspectives	O
across	O
a	O
breadth	O
of	O
stem	B
cell	I
science—from	O
fundamental	O
research	O
to	O
translational	O
discoveries	O
happening	O
in	O
laboratories	O
across	O
the	O
world..	O

The	O
journal	O
also	O
has	O
expanded	O
its	O
efforts	O
to	O
identify	O
and	O
highlight	O
important	O
ethical,	O
political,	O
or	O
scientific	O
issues	O
within	O
the	O
stem	B
cell	I
or	O
broader	O
scientific	O
community	O
through	O
Commentaries	O
and	O
Forum	O
articles	O
in	O
our	O
Society	O
Pages.	O

These	O
important	O
activities	O
on	O
behalf	O
of	O
members	O
and	O
the	O
stem	B
cell	I
community	O
could	O
not	O
take	O
place	O
without	O
this	O
vital	O
support..	O

The	O
2019	O
annual	O
meeting	O
drew	O
nearly	O
4,000	O
attendees,	O
207	O
plenary	O
and	O
concurrent	O
talks,	O
and	O
1,400	O
poster	O
presentations	O
that	O
covered	O
the	O
breadth	O
of	O
stem	B
cell	I
science	O
and	O
its	O
applications..	O

Supporting	O
the	O
next	O
generation	O
of	O
stem	B
cell	I
scientists	O
through	O
meaningful	O
education	O
and	O
leadership	O
opportunities	O
remains	O
a	O
vital	O
component	O
of	O
the	O
society’s	O
mission..	O

Led	O
by	O
incoming	O
ISSCR	O
President	O
Christine	O
Mummery,	O
Leiden	O
University	O
Medical	O
Center,	O
the	O
Netherlands,	O
and	O
Lucy	O
O’Brien,	O
Stanford	O
University,	O
US,	O
the	O
group	O
met	O
in	O
2019	O
to	O
evaluate	O
how	O
to	O
continue	O
to	O
adapt	O
our	O
meeting	O
as	O
the	O
field	O
and	O
the	O
needs	O
of	O
the	O
stem	B
cell	I
community	O
evolve.	O

Further,	O
consistent	O
with	O
the	O
society’s	O
investment	O
in	O
recognizing	O
excellence	O
in	O
stem	B
cell	I
science,	O
the	O
board	O
of	O
directors	O
established	O
two	O
new	O
awards	O
that	O
will	O
be	O
given	O
for	O
the	O
first	O
time	O
during	O
this	O
year’s	O
meeting.	O

The	O
ISSCR	O
met	O
with	O
policymakers	O
to	O
voice	O
concerns	O
regarding	O
the	O
new	O
restrictions	O
on	O
research	O
using	O
fetal	O
tissue	O
and	O
the	O
proliferation	O
of	O
clinics	B
selling	I
unproven	I
stem	I
cell	I
“treatments”	O
and	O
to	O
support	O
biomedical	O
research	O
funding.	O

In	O
2019,	O
the	O
ISSCR	O
launched	O
an	O
Education	O
Committee	O
that	O
is	O
assembling	O
a	O
syllabus	O
and	O
learning	O
guide	O
to	O
teach	O
undergraduate	O
students,	O
early	O
graduate	O
students,	O
and	O
medical	O
students	O
the	O
core	O
concepts	O
of	O
stem	B
cell	I
biology.	O

It	O
has	O
been	O
a	O
year	O
full	O
of	O
exciting	O
achievements	O
in	O
stem	O
cell	O
research	O
and	O
new	O
firsts	O
for	O
the	O
society	O
as	O
we	O
adapt	O
to	O
ensure	O
that	O
connections	O
and	O
communication	O
continues	O
in	O
our	O
field	O
despite	O
the	O
new	O
“normal.”	O
I	O
am	O
confident	O
our	O
brightest	O
days	O
are	O
ahead	O
and	O
together	O
we	O
will	O
achieve	O
our	O
goal	O
of	O
stem	B
cell	I
biology	O
and	O
regenerative	O
medicine	O
alleviating	O
human	O
suffering.	O

(2000)	O
Herpesvirus	O
saimiri-based	O
gene	O
delivery	O
vectors	O
maintain	O
heterologous	O
expression	O
throughout	O
mouse	B
embryonic	I
stem	I
cell	I
differentiation	O
in	O
vitro.	O

Various	O
niches	O
have	O
been	O
proposed,	O
including	O
the	O
perivascular	O
niche	O
associated	O
with	O
the	O
vasculature22,	O
the	O
haematopoietic	B
stem	I
cell	I
niche	O
of	O
the	O
bone	O
marrow175	O
and	O
the	O
osteoblastic	O
niche	O
in	O
bone176.	O

Effects	O
of	O
autologous	O
bone	B
marrow	I
stem	I
cell	I
transplantation	O
on	O
beta-adrenoceptor	O
density	O
and	O
electrical	O
activation	O
pattern	O
in	O
a	O
rabbit	O
model	O
of	O
non-ischemic	O
heart	O
failure.	O

A	O
recent	O
work	O
discussed	O
novel	O
associations	O
in	O
drug	O
therapies	O
that	O
have	O
been	O
examined	O
together	O
with	O
stem	O
cells	O
to	O
overcome	O
the	O
restrictions	O
allied	O
with	O
stem	B
cell	I
transplantation	O
and	O
to	O
progress	O
functional	O
recuperation	O
and	O
brain	O
repair	O
post-TBI.	O

Zc3h13	O
regulates	O
nuclear	O
RNA	O
m(6)A	O
methylation	O
and	O
mouse	B
embryonic	I
stem	I
cell	I
self-renewal.	O

Prostate	B
stem	I
cell	I
antigen	O
as	O
therapy	O
target:	O
tissue	O
expression	O
and	O
in	O
vivo	O
efficacy	O
of	O
an	O
immunoconjugate.	O

Prostate	B
stem	I
cell	I
antigen	O
vaccination	O
induces	O
a	O
long-term	O
protective	O
immune	O
response	O
against	O
prostate	O
cancer	O
in	O
the	O
absence	O
of	O
autoimmunity.	O

Prostate	B
stem	I
cell	I
antigen	O
DNA	O
vaccination	O
breaks	O
tolerance	O
to	O
self-antigen	O
and	O
inhibits	O
prostate	O
cancer	O
growth.	O

In	O
general,	O
Hh	O
pathway	O
activity	O
has	O
been	O
associated	O
with	O
brain	O
size	O
(see	O
above),	O
which	O
might	O
be	O
caused	O
by	O
its	O
positive	O
effects	O
on	O
neural	B
stem	I
cell	I
pools.	O

Rapid	O
endothelial	O
turnover	O
in	O
atherosclerosis-prone	O
areas	O
coincides	O
with	O
stem	B
cell	I
repair	O
in	O
apolipoprotein	O
E-deficient	O
mice.	O

Regulation	O
of	O
myogenic	B
stem	I
cell	I
behavior	O
by	O
vessel	O
cells:	O
the	O
“menage	O
a	O
trois”	O
of	O
satellite	O
cells,	O
periendothelial	O
cells	O
and	O
endothelial	O
cells.	O

Human	O
embryonic	O
stem	O
(hES)	O
cells,	O
typically	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
(ICM)	O
of	O
the	O
blastocyst,	O
proliferate	O
by	O
self	O
renewal	O
and	O
have	O
the	O
potential	O
to	O
differentiate	O
into	O
all	O
cells	O
of	O
the	O
body	O
(Thomson	O
et	O
al.	O
However,	O
HIF2A	O
has	O
been	O
found	O
to	O
be	O
a	O
direct	O
upstream	O
regulator	O
of	O
POU5F1	O
(OCT4)	O
in	O
mouse	O
ES	O
cells,	O
suggesting	O
that	O
HIF2A	O
is	O
involved	O
in	O
the	O
regulation	B
of	I
stem	I
cell	I
maintanence	O
(Covello	O
et	O
al.	O

Application	O
of	O
stem	B
cell	I
derived	O
neuronal	O
cells	O
to	O
evaluate	O
neurotoxic	O
chemotherapy.	O

Muscular	O
dystrophy	O
begins	O
early	O
in	O
embryonic	O
development	O
deriving	O
from	O
stem	B
cell	I
loss	O
and	O
disrupted	O
skeletal	O
muscle	O
formation.	O

MyoD	O
is	O
required	O
for	O
myogenic	B
stem	I
cell	I
function	O
in	O
adult	O
skeletal	O
muscle.	O

Whilst	O
the	O
stem	B
cell	I
chemotactic	O
properties	O
capture	O
the	O
imagination,	O
the	O
absence	O
of	O
release	O
of	O
SDF-1a	O
from	O
the	O
human	O
heart	O
suggest	O
that	O
this	O
may	O
not	O
be	O
its	O
primary	O
mechanism	O
of	O
action	O
following	O
MI.	O

Autologous	O
Haematopoietic	B
Stem	I
Cell	I
Transplantation	O
and	O
Other	O
Cellular	O
Therapy	O
in	O
Multiple	O
Sclerosis	O
and	O
Immune-Mediated	O
Neurological	O
Diseases:	O
Updated	O
Guidelines	O
and	O
Recommendations	O
from	O
the	O
EBMT	O
Autoimmune	O
Diseases	O
Working	O
Party	O
(ADWP)	O
and	O
the	O
Joint	O
Accreditation	O
Committee	O
of	O
EBMT	O
and	O
ISCT	O
(JACIE)	O
Bone	O
Marrow	O
Transplant.	O

Allogeneic	O
Haematopoietic	B
Stem	I
Cell	I
Transplantation	O
in	O
a	O
Refractory	O
Case	O
of	O
Neuromyelitis	O
Optica	O
Spectrum	O
Disorder.	O

Danica	O
Chen	O
from	O
the	O
University	O
of	O
California,	O
Berkeley,	O
USA	O
highlighted	O
the	O
Sirtuins,	O
a	O
NAD+-dependent	O
protein	O
deacetylase	O
protein	O
family,	O
as	O
key	O
players	O
during	O
the	O
aging	O
process	O
and	O
as	O
a	O
promising	O
target	O
for	B
stem	I
cell	I
rejuvenation	O
[23].	O

Ana	O
Martin-Villalba	O
from	O
the	O
German	O
Cancer	O
Research	O
Center,	O
Heidelberg,	O
Germany,	O
introduced	O
the	O
audience	O
to	O
the	O
world	O
of	O
neuronal	B
stem	I
cell	I
regeneration.	O

In	O
line	O
with	O
this,	O
recent	O
work	O
from	O
his	O
group	O
revealed	O
targeting	O
of	O
the	O
muscle	B
stem	I
cell	I
niche	O
as	O
a	O
promising	O
intervention	O
strategy	O
[32].	O

Quiescence	O
Modulates	B
Stem	I
Cell	I
Maintenance	O
and	O
Regenerative	O
Capacity	O
in	O
the	O
Aging	O
Brain.	O

Research	O
in	O
the	O
stem	B
cell	I
field	O
has	O
traditionally	O
focused	O
on	O
understanding	O
key	O
transcriptional	O
factors	O
that	O
provide	O
pluripotent	O
cell	O
identity.	O

Thus,	O
maintaining	O
functional	O
respiratory	O
complexes	O
may	O
be	O
critical	O
for	O
generating	O
endogenous	O
levels	O
of	O
ROS	O
critical	O
for	O
stem	B
cell	I
renewal	O
and	O
pluripotency.	O

Recent	O
advances	O
in	O
the	O
field	O
of	O
stem	B
cell	I
biology	O
and	O
in	O
cellular	O
reprogramming	O
technology	O
in	O
particular,	O
have	O
created	O
new	O
opportunities	O
in	O
understanding	O
human	O
disease,	O
drug	O
discovery,	O
and	O
regenerative	O
medicine.	O

Pioneer	O
work	O
from	O
Ruth	O
Slack's	O
group	O
[11]	O
highlighted	O
the	O
physiological	O
significance	O
of	O
mitochondrial	O
dynamics	O
for	O
stem	B
cell	I
identity	O
and	O
fate	O
during	O
mouse	O
brain	O
development.	O

Recent	O
studies	O
shed	O
light	O
into	O
the	O
essential	O
requirement	O
for	O
a	O
fine-tuned	O
regulation	O
of	O
mitochondrial	O
morphology	O
and	O
function	O
for	O
the	O
maintenance	O
of	O
stem	B
cell	I
properties.	O

Mitochondrial	O
dysfunction	O
underlies	O
cognitive	O
defects	O
as	O
a	O
result	O
of	O
neural	B
stem	I
cell	I
depletion	O
and	O
impaired	O
neurogenesis.	O

Glycolytic	O
network	O
restructuring	O
integral	O
to	O
the	O
energetics	O
of	O
embryonic	B
stem	I
cell	I
cardiac	O
differentiation.	O

Such	O
cultures	O
usually	O
rely	O
on	O
cell-cell	O
interactions	O
between	O
the	O
stem	B
cells	I
and	O
a	O
putative	O
niche	O
cell	O
for	O
their	O
growth	O
and	O
differentiation..	O

Organoids	O
are	O
defined	O
as	O
three-dimensional	O
(3D)	O
structures	B
derived	I
from	I
stem	I
cells	I
and	O
consist	O
of	O
organ-specific	O
cell	O
types	O
which	O
self-organise	O
through	O
cell	O
sorting	O
and	O
spatially	O
restricted	O
lineage	O
commitment	O
in	O
a	O
manner	O
reminiscent	O
of	O
the	O
native	O
organ	O
with	O
some	O
degree	O
of	O
organ	O
functionality	O
[1,	O
2].	O

Multiple	O
in	O
vivo	O
and	O
in	O
vitro	O
experiments	O
have	O
shown	O
that,	O
at	O
steady	O
state,	O
the	O
AC2	O
cells	O
are	O
the	O
primary	B
stem	I
cell	I
for	O
the	O
alveolar	O
epithelium	O
[28,	O
51].	O

This	O
is	O
the	O
first	O
description	O
of	O
a	O
spheroid	O
co-culture	O
system	O
for	O
the	O
distal	B
lung	I
stem	I
cell	I
population	O
and,	O
although	O
it	O
has	O
not	O
yet	O
been	O
demonstrated	O
to	O
support	O
self-renewal	O
or	O
differentiation,	O
it	O
is	O
likely	O
to	O
prove	O
highly	O
useful	O
for	O
future	O
mechanistic	O
studies..	O

Lung	B
stem	I
cell	I
differentiation	O
in	O
mice	O
directed	O
by	O
endothelial	O
cells	O
via	O
a	O
BMP4-NFATc1-thrombospondin-1	O
axis.	O

Repair	O
and	O
regeneration	O
of	O
the	O
respiratory	O
system:	O
complexity,	O
plasticity,	O
and	O
mechanisms	O
of	O
lung	B
stem	I
cell	I
function.	O

A	O
bioengineered	O
niche	O
promotes	O
in	O
vivo	O
engraftment	O
and	O
maturation	O
of	O
pluripotent	B
stem	I
cell	I
derived	O
human	O
lung	O
organoids.	O

Targeting	O
the	O
Mechanisms	O
of	O
Resistance	O
to	O
Chemotherapy	O
and	O
Radiotherapy	O
with	O
the	O
Cancer	B
Stem	I
Cell	I
Hypothesis.	O

Targeting	O
the	O
Mechanisms	O
of	O
Resistance	O
to	O
Chemotherapy	O
and	O
Radiotherapy	O
with	O
the	O
Cancer	B
Stem	I
Cell	I
Hypothesis.	O

Schematic	O
diagram	O
of	O
the	O
mechanisms	O
leading	O
to	O
cancer	B
stem	I
cell	I
resistance	O
to	O
chemo-	O
and	O
radiation	O
therapy.	O

Cancer	B
stem	I
cells	I
have	O
been	O
found	O
to	O
exhibit	O
a	O
number	O
of	O
genetic	O
and	O
cellular	O
adaptations	O
that	O
confer	O
resistance	O
to	O
classical	O
therapeutic	O
approaches,	O
including	O
relative	O
dormancy/slow	O
cell	O
cycle	O
kinetics,	O
efficient	O
DNA	O
repair,	O
high	O
expression	O
of	O
multidrug-resistance-type	O
membrane	O
transporters,	O
resistance	O
to	O
apoptosis,	O
and	O
protection	O
by	O
a	O
hypoxic	O
niche	O
environment..	O

The	O
hedgehog	O
signaling	O
pathway	O
is	O
a	O
potential	O
modulator	O
of	O
cancer	B
stem	I
cell	I
carcinogenesis	O
with	O
significant	O
therapeutic	O
implications.	O

Cancer	O
induction	O
by	O
restriction	O
of	O
oncogene	O
expression	O
to	O
the	O
stem	B
cell	I
compartment.	O

Identification	O
of	O
a	O
subpopulation	O
of	O
cells	O
with	O
cancer	B
stem	I
cell	I
properties	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma.	O

Acute	O
myeloid	O
leukemia	O
originates	O
from	O
a	O
hierarchy	O
of	O
leukemic	B
stem	I
cell	I
classes	O
that	O
differ	O
in	O
self-renewal	O
capacity.	O

Gene	O
expression	O
profiling	O
of	O
cancer	B
stem	I
cell	I
in	O
human	O
lung	O
adenocarcinoma	O
A549	O
cells.	O

Rapid	O
endothelial	O
turnover	O
in	O
atherosclerosis-prone	O
areas	O
coincides	O
with	O
stem	B
cell	I
repair	O
in	O
apolipoprotein	O
E-deficient	O
mice.	O

Regulation	O
of	O
myogenic	B
stem	I
cell	I
behavior	O
by	O
vessel	O
cells:	O
the	O
“menage	O
a	O
trois”	O
of	O
satellite	O
cells,	O
periendothelial	O
cells	O
and	O
endothelial	O
cells.	O

Intrinsic	O
changes	O
and	O
extrinsic	O
influences	O
of	O
myogenic	B
stem	I
cell	I
function	O
during	O
aging.	O

Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

Wdr5	O
mediates	O
self-renewal	O
and	O
reprogramming	O
via	O
the	O
embryonic	B
stem	I
cell	I
core	O
transcriptional	O
network.	O

Persistent	O
sonic	O
hedgehog	O
signaling	O
in	O
adult	O
brain	O
determines	O
neural	B
stem	I
cell	I
positional	O
identity.	O

Neural	B
stem	I
cell	I
heterogeneity	O
through	O
time	O
and	O
space	O
in	O
the	O
ventricular-subventricular	O
zone.	O

Soon,	O
it	O
will	O
be	O
important	O
to	O
ethically	O
discuss	O
genome	O
editing	O
with	O
stem	B
cell	I
technology.	O

27	O
via	O
tissue	O
removal	O
surgery	O
triggers	O
a	O
signal	O
that	O
extends	O
the	O
stem	B
cell	I
multipotency	O
of	O
RPCs	O
in	O
order	O
to	O
restore	O
normal	O
size.	O

We	O
also	O
have	O
little	O
understanding	O
of	O
how	O
early	O
pregnancy	O
and	O
functional	O
differentiation	O
of	O
the	O
breast	O
protects	O
against	O
cancer,	O
and	O
whether	O
this	O
is	O
related	O
to	O
stem	B
cell	I
dynamics	O
[41]..	O

L1td1	O
LINE-1	O
type	O
transposase	O
domain	O
containing	O
1	O
Embryonic	B
stem	I
cell	I
renewal	O
and	O
identity	O
33	O
59	O
27	O
0.0241.	O

RNA	O
polymerase-associated	O
protein	O
LEO1	O
(upregulated	O
during	O
cold-stoarge)	O
is	O
a	O
component	O
of	O
the	O
PAF1	O
complex	O
(PAF1C)	O
which	O
has	O
multiple	O
functions	O
during	O
transcription	O
and	O
is	O
implicated	O
in	O
regulation	O
of	O
development	O
and	O
maintenance	O
of	O
embryonic	B
stem	I
cell	I
pluripotency	O
and	O
required	O
for	O
transcription	O
of	O
Hox	O
and	O
Wnt	O
target	O
genes62.	O

A	O
transient	O
increase	O
in	O
Lgr5+	O
stem	O
cells	O
suggests	O
compensatory	O
responses	O
in	O
the	O
stem	B
cell	I
niche	O
during	O
early	O
time	O
points	O
of	O
protein	O
deficiency.	O

Tumor	B
stem	I
cells	I
derived	O
from	O
glioblastomas	O
cultured	O
in	O
bFGF	O
and	O
EGF	O
more	O
closely	O
mirror	O
the	O
phenotype	O
and	O
genotype	O
of	O
primary	O
tumors	O
than	O
do	O
serum-cultured	O
cell	O
lines.	O

Son	O
MJ,	O
Kwon	O
Y,	O
Son	O
T,	O
Cho	O
YS	O
(2016)	O
Restoration	O
of	O
mitochondrial	B
NAD(+)	I
levels	I
delays	I
stem	I
cell	I
senescence	O
and	O
facilitates	O
reprogramming	O
of	O
aged	O
somatic	O
cells.	O

(2017)	O
Decoupling	O
the	O
functional	O
pleiotropy	O
of	O
stem	B
cell	I
factor	O
by	O
tuning	O
c-Kit	O
signaling.	O

These	O
observations	O
demonstrate	O
that	O
direct	O
delivery	O
of	O
transcription	O
factors	O
by	O
protein	O
transduction	O
can	O
be	O
used	O
as	O
alternative	O
modality	O
to	O
specify	O
fate	O
decision	O
in	O
differentiating	B
stem	I
cell	I
cultures	O
without	O
genetic	O
modification..	O

Neural	B
stem	I
cells	I
have	O
the	O
capacity	O
to	O
self‐renew	O
and	O
generate	O
different	O
cell	O
types.	O

Our	O
aim	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
multiple	O
sclerosis	O
(MS)	O
‐like	O
pathology	O
on	O
this	O
stem	B
cell	I
niche..	O

SIRPβ1,	O
TREM2	O
and	O
DAP12	O
gene	O
transcripts	O
were	O
up‐regulation	B
in	I
embryonic	I
stem	I
cell	I
derived	O
microglia	O
(ESdM)	O
subsequent	O
to	O
treatment	O
by	O
interferon‐α	O
(IFNα),	O
interferon‐β	O
(IFNβ)	O
or	O
lipopolysaccharides	O
(LPS).	O

This	O
increase	O
of	O
NPs	O
is	O
noticeable	O
by	O
an	O
up‐regulation	O
of	O
the	O
stem	B
cell	I
marker	O
Prominin1.	O

Indeed,	O
proliferation	O
was	O
rather	O
impaired	O
in	O
the	O
adult	B
neural	I
stem	I
cell	I
niche	O
as	O
well	O
as	O
after	O
brain	O
injury..	O

Our	O
project	O
now	O
focused	O
on	O
exploring	O
the	O
mechanisms	O
by	O
which	O
brain	O
endothelial	O
cells	O
might	O
modulate	O
the	O
stem	B
cell	I
properties	O
through	O
the	O
mTor	O
signalling	O
axis..	O

Cancer	O
cells	O
with	O
stem	B
cell	I
properties	O
have	O
been	O
isolated	O
from	O
these	O
tumours.	O

showed	O
that	O
HDAC	O
inhibitors	O
determine	O
changes	O
in	O
CD34+	O
phenotype	O
due	O
to	O
activation	O
of	O
different	O
pathways	O
involved	O
in	O
cell	O
proliferation	O
and	O
clonogenicity,	O
and	O
in	O
modulation	O
of	O
stem	B
cells	I
markers	O
such	O
as	O
CD34,	O
CD38,	O
CD133	O
and	O
KDR	O
[28].	O

Moreover,	O
recent	O
research	O
revealed	O
that	O
during	O
differentiation	O
of	O
pluripotent	B
stem	I
cell	I
lines	O
from	O
HD	O
patients	O
into	O
neurons,	O
there	O
is	O
a	O
loss	O
of	O
expression	O
in	O
DNAJB6,	O
which	O
leads	O
to	O
aggregation	O
of	O
polyQ	O
(Thiruvalluvan	O
et	O
al.,	O
2020).	O

Lung	B
stem	I
cell	I
differentiation	O
in	O
mice	O
directed	O
by	O
endothelial	O
cells	O
via	O
a	O
BMP4‐NFATc1‐thrombospondin‐1	O
axis.	O

Increased	O
levels	O
of	O
NO	O
have	O
been	O
associated	O
with	O
increased	O
HSPC	O
motility	O
and	O
egress	O
from	O
the	O
BM,	O
leading	O
to	O
a	O
lower	O
repopulation	O
capacity	O
of	O
the	O
BM	B
stem	I
cell	I
pool	O
after	O
injuries	O
(Aicher	O
et	O
al.,	O
2003,	O
Gur-Cohen	O
et	O
al.,	O
2015).	O

Not	O
only	O
the	O
number	O
but	O
also	O
the	O
stem	B
cell	I
function	O
of	O
these	O
SLAM+	O
cells	O
was	O
increased,	O
as	O
shown	O
by	O
their	O
repopulation	O
ability	O
in	O
secondary	O
recipients	O
(Figures	O
S7C	O
and.	O

Hence,	O
we	O
treated	O
mice	O
engrafted	O
with	O
normal	O
HSPCs	O
with	O
NOS	O
inhibitors	O
and	O
analyzed	O
the	O
effect	O
on	O
the	O
stem	B
cell	I
pool	O
(Figure	O
7H).	O

Leukaemogenic	O
effects	O
of	O
Ptpn11	O
activating	O
mutations	O
in	O
the	O
stem	B
cell	I
microenvironment.	O

Deep	O
learning	O
neural	O
networks	O
highly	O
predict	O
very	O
early	O
onset	O
of	O
pluripotent	B
stem	I
cell	I
differentiation.	O

Aging	O
phenotype	O
is	O
represented	O
by	O
expanded	O
cellular	O
senescence,	O
reduction	O
of	O
stem	B
cell	I
population,	O
altered	O
proteostasis	O
(which	O
activates	O
the	O
inflammasome	O
-	O
a	O
multiprotein	O
oligomer	O
responsible	O
for	O
inflammation),	O
change	O
in	O
intercellular	O
communication	O
and	O
loss	O
of	O
telomere	O
function	O
[2,	O
3]..	O

Mettl1/Wdr4-Mediated	O
m7G	O
tRNA	O
Methylome	O
Is	O
Required	O
for	O
Normal	O
mRNA	O
Translation	O
and	O
Embryonic	B
Stem	I
Cell	I
Self-Renewal	O
and	O
Differentiation.	O

1,	O
flow	O
cytometric	O
analysis	O
revealed	O
that	O
hAdSCs	O
are	O
positive	O
for	O
mesenchymal	B
stem	I
cell	I
markers	O
CD29,	O
CD90,	O
and	O
CD105,	O
but	O
are	O
persistently	O
negative	O
for	O
CD31,	O
CD34,	O
and	O
CD45,	O
which	O
precludes	O
contamination	O
with	O
endothelial	O
cells	O
and	O
hematopoietic	O
cells,	O
as	O
previous	O
reported	O
[26,	O
27]..	O

Flow	O
cytometric	O
analysis	O
revealed	O
that	O
hAdSCs	O
are	O
positive	O
for	O
mesenchymal	B
stem	I
cell	I
markers	O
CD29,	O
CD90,	O
and	O
CD105.	O

A	O
multisubunit	O
protein	O
complex	O
known	O
as	O
Mediator	O
interacts	O
with	O
the	O
RNA	O
polymerase	O
II	O
enzyme	O
and	O
control	O
of	O
gene	O
expression.45	O
ChIP-seq	O
results	O
showed	O
that	O
Mediator,	O
cohesin,	O
and	O
the	O
cohesin	O
loading	O
factor,	O
SCC2/NIPBL,	O
co-occupy	O
thousands	O
of	O
sites	O
in	O
the	O
embryonic	B
stem	I
cell	I
genome.	O

These	O
changes	O
could	O
be	O
partially	O
explained	O
by	O
age-related	O
alterations	O
of	O
the	O
stem	B
cell	I
niche,	O
such	O
as	O
decreased	O
tenascin-C	O
expression	O
in	O
bone	O
marrow	O
(66)..	O

Elevated	O
Id2	O
expression	O
results	O
in	O
precocious	O
neural	B
stem	I
cell	I
depletion	O
and	O
abnormal	O
brain	O
development.	O

In	O
addition,	O
recent	O
studies	O
demonstrated	O
a	O
major	O
role	O
for	O
the	O
Janus	O
kinase-	O
(JAK-)	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(STAT)	O
signaling	O
pathway	O
in	O
epithelial	O
host	O
defense	O
via	O
regulation	O
of	O
stem	B
cell	I
proliferation	O
and	O
epithelial	O
cell	O
homeostasis	O
[38]..	O

Furthermore,	O
VSELS	O
may	O
be	O
useful	O
in	O
stem	B
cell	I
therapies	O
for	O
leukemia,	O
lymphoma,	O
hereditary	O
blood	O
diseases	O
and	O
bone	O
marrow	O
failure)	O
[211].	O

So	O
far,	O
peripheral	O
blood	O
as	O
a	O
source	O
of	O
VSELS	O
in	O
stem	B
cell	I
therapy	O
may	O
need	O
elaborate	O
investigations	O
as	O
the	O
number	O
of	O
cells	O
may	O
be	O
still	O
too	O
low..	O

In	O
contrast	O
to	O
any	O
other	O
rare	O
cell	O
type,	O
stringent	O
standardization	O
efforts	O
of	O
HSC	O
quantification	O
was	O
pursued	O
and	O
enabled	O
clinical	O
use	O
in	O
stem	B
cell	I
transplantation	O
therapy	O
[250,251,252,253,254].	O

Hypoxia-Inducible	O
Factor-1α	O
Is	O
Essential	O
for	O
Hypoxia-Induced	O
Mesenchymal	B
Stem	I
Cell	I
Mobilization	O
into	O
the	O
Peripheral	O
Blood.	O

Bone	O
Marrow-Derived	O
Myofibroblasts	O
Contribute	O
to	O
the	O
Mesenchymal	B
Stem	I
Cell	I
Niche	O
and	O
Promote	O
Tumor	O
Growth.	O

Thus	O
PcG	O
silencing	O
appears	O
to	O
maintain	O
the	O
stem	B
cell	I
state	O
via	O
repression	O
of	O
cytodifferentiation	O
genes;	O
this	O
repression	O
is	O
not	O
permanent	O
and	O
can	O
be	O
lifted	O
upon	O
receipt	O
of	O
differentiation	O
signals..	O

Cancer	B
stem	I
cell	I
heterogeneity:	O
Origin	O
and	O
new	O
perspectives	O
on	O
CSC	O
targeting.	O

It	O
will	O
be	O
of	O
future	O
interest	O
to	O
investigate	O
whether	O
the	O
intracellular	O
C-terminal	O
of	O
Fzd7	O
is	O
required	O
for	O
its	O
baso-lateral	O
localisation	O
and	O
how	O
this	O
may	O
impact	O
on	O
intestinal	B
stem	I
cell	I
function..	O

These	O
findings	O
are	O
supported	O
by	O
previous	O
studies	O
demonstrating	O
a	O
central	O
role	O
for	O
Fzd7	O
in	O
skeletal	B
stem	I
cell	I
maintenance	O
in	O
muscular	O
dystrophy	O
animal	O
models	O
via	O
activation	O
of	O
Akt/mTOR	O
signalling	O
[21]..	O

Effect	O
of	O
Comedications	O
and	O
Endotoxins	O
on	O
Mesenchymal	B
Stem	I
Cell	I
Secretomes,	O
Migratory	O
and	O
Immunomodulatory	O
Capacity.	O

In	O
vitro	O
expression	O
of	O
cytokeratin	O
18,	O
19	O
and	O
tube	O
formation	O
of	O
adipose-derived	B
stem	I
cells	I
induced	O
by	O
the	O
breast	O
epithelial	O
cell	O
line	O
HBL-100.	O

TM4SF1	O
and	O
SerpinB2	O
were	O
previously	O
implicated	O
in	O
cancer	O
development	O
particularly	O
in	O
cancer	B
stem	I
cell	I
biology.	O

An	O
expanded	O
Oct4	O
interaction	O
network:	O
implications	O
for	O
stem	B
cell	I
biology,	O
development,	O
and	O
disease.	O

Interaction	O
domains	O
of	O
Sos1/Grb2	O
are	O
finely	O
tuned	O
for	O
cooperative	O
control	O
of	O
embryonic	B
stem	I
cell	I
fate.	O

The	O
understanding	O
of	O
how	O
indirect	O
cancer	O
cell	O
targeting	O
can	O
affect	O
the	O
tumor	O
cell	O
environment	O
may	O
be	O
the	O
link	O
in	O
providing	O
more	O
effective	O
treatment,	O
which	O
stops	O
the	O
initiation	O
of	O
further	O
tumor	O
mutations	O
at	O
the	O
stem	B
cell	I
level.	O

The	O
potential	O
product	O
of	O
1334,	O
721	O
bp	O
from	O
the	O
breakpoint,	O
did	O
not	O
match	O
any	O
known	O
conserved	O
domains	O
and	O
has	O
an	O
unknown	O
function,	O
but	O
was	O
similar	O
to	O
mesenchymal	B
stem	I
cell	I
protein	O
DSC92.	O

To	O
check	O
the	O
expression	O
of	O
stem	B
cell	I
markers	O
on	O
the	O
surface,	O
the	O
cells	O
at	O
passage	O
3	O
were	O
harvested	O
and	O
fixed	O
with	O
70	O
%	O
EtOH	O
overnight	O
at	O
4°C.	O

To	O
examine	O
the	O
expression	O
of	O
stem	B
cell	I
surface	O
markers	O
in	O
hUDSCs,	O
we	O
performed	O
fluorescence-activated	O
cell	O
sorter	O
(FACS)	O
analysis	O
after	O
staining	O
hUDSCs	O
with	O
antibodies	O
against	O
CD44,	O
CD90,	O
CD105,	O
or	O
SSEA-4.	O

The	O
cells	O
obtained	O
from	O
urine	O
were	O
positive	O
for	O
mesenchymal	B
stem	I
cell	I
antigens,	O
such	O
as	O
CD44,	O
CD90,	O
and	O
CD105.	O

Mesenchymal	B
stem	I
cells	I
are	O
found	O
in	O
a	O
number	O
of	O
tissues,	O
and	O
may	O
have	O
the	O
ability	O
to	O
trans-differentiate	O
into	O
multiple	O
cell	O
types	O
including	O
adipocytes,	O
osteocytes,	O
myocytes	O
neuronal	O
cells,	O
and	O
islets-like	O
cells	O
20.	O

We	O
demonstrated	O
that	O
the	O
isolated	O
hUDSCs	O
expressed	O
the	O
mesenchymal	B
stem	I
cell	I
markers	O
and	O
can	O
be	O
directly	O
differentiated	O
into	O
IPCs.	O

Thus,	O
with	O
the	O
introduction	O
of	O
a	O
combination	O
of	O
3	O
or	O
4	O
transcription	O
factors,	O
somatic	O
cells	O
can	O
be	O
transformed	O
into	O
stem	B
cells	I
with	O
unlimited	O
capacity	O
for	O
cell	O
division	O
and	O
differentiation	O
(Takahashi	O
et	O
al.,	O
2007).	O

B,C,	O
The	O
cells	O
in	O
the	O
colony	O
are	O
all	O
positive	O
for	O
stem	B
cell	I
surface	O
markers	O
SSEA4	O
and	O
TRA-1–60	O
when	O
stained	O
with	O
the	O
marker	O
for	O
each	O
in	O
live-cell	O
imaging.	O

D,	O
All	O
cells	O
in	O
the	O
colony	O
are	O
also	O
positive	O
for	O
stem	B
cell	I
nuclear	O
markers	O
Oct4	O
and	O
Nanog	O
when	O
stained	O
after	O
fixation.	O

A	O
feedback	O
regulatory	O
loop	O
involving	O
microRNA-9	O
and	O
nuclear	O
receptor	O
TLX	O
in	O
neural	B
stem	I
cell	I
fate	O
determination.	O

In	O
ESCs,	O
PRDM14	O
supports	O
the	O
maintenance	O
of	O
self-renewal	O
by	O
promoting	O
expression	O
of	O
stem	B
cell	I
markers	O
while	O
also	O
repressing	O
differentiation	O
factors	O
(Chia	O
et	O
al.,	O
2010;	O
Ma	O
et	O
al.,	O
2011;	O
Tsuneyoshi	O
et	O
al.,	O
2008).	O

Thus,	O
there	O
is	O
a	O
definitive	O
need	O
in	O
the	O
field	O
to	O
identify,	O
characterize	O
and	O
develop	O
novel	O
therapeutics	O
that	O
directly	O
target	O
CICs	O
while	O
sparing	O
the	O
normal	B
stem	I
cell	I
compartment.	O

A	O
genome-wide	O
RNAi	O
screen	O
reveals	O
determinants	O
of	O
human	B
embryonic	I
stem	I
cell	I
identity.	O

This	O
phenotype	O
is	O
the	O
result	O
of	O
two	O
distinct	O
spontaneous	O
mutations	O
located	O
within	O
the	O
“white	O
spotting	O
locus,”	O
termed	O
W	O
and	O
Wv,	O
in	O
Kit,	O
the	O
gene	O
that	O
encodes	O
the	O
stem	B
cell	I
factor	O
receptor	O
c-kit	O
(66).	O

Specifically,	O
Mukherjee’s	O
group	O
established	O
that	O
CDK5	O
pharmacological	O
inhibition	O
restrains	O
glioma	B
stem	I
cell	I
renewal	O
in	O
xenografted	O
drosophila	O
models,	O
partially	O
by	O
reducing	O
PKA-independent	O
CREB	O
activation.	O

One	O
of	O
the	O
advantages	O
of	O
iPSCs	O
compared	O
with	O
other	O
kinds	O
of	O
stem	B
cells	I
is	O
the	O
availability	O
to	O
create	O
cell	O
models	O
for	O
diseases	O
and	O
based	O
on	O
that	O
the	O
pathophysiological	O
research	O
of	O
diseases	O
and	O
drug	O
discovery	O
can	O
be	O
developed	O
by	O
reprograming	O
cells	O
from	O
diseased	O
patients	O
and	O
inducing	O
cell	O
differentiation	O
suitable	O
for	O
evaluation.2	O
In	O
this	O
study,	O
we	O
searched	O
and	O
selected	O
research	O
articles	O
that	O
described	O
work	O
using	O
iPSCs	O
and	O
were	O
published	O
between	O
2006	O
and	O
recent	O
years	O
from	O
the	O
PubMed	O
database	O
and	O
classified	O
these	O
publications	O
according	O
to	O
their	O
themes	O
into	O
reprogramming,	O
differentiation	O
protocols	O
for	O
specific	O
cells	O
and/or	O
tissues,	O
pathophysiological	O
research	O
of	O
diseases,	O
discovery	O
of	O
new	O
drugs,	O
and	O
cell	O
therapy,	O
and	O
then	O
the	O
trends	O
over	O
the	O
years	O
were	O
analyzed.	O

The	O
most	O
promising	O
effect	O
of	O
icariin	O
at	O
cardiovascular	O
level	O
is	O
the	O
promotion	O
of	O
stem	B
cell	I
differentiation	O
into	O
beating	O
cardiomyocytes,	O
making	O
it	O
apply	O
in	O
cardiac	O
cell	O
therapy	O
[20,	O
21].	O

Results	O
showed	O
that	O
transplanted	O
DFAT	O
cells	O
converted	O
into	O
smooth	O
muscle	O
cells,	O
promoting	O
sphincter	O
muscle	O
regeneration	O
and	O
improving	O
leak	O
point	O
pressure	O
in	O
the	O
rat	O
vaginal	O
distension	O
model.14	O
Jumabay	O
et	O
al.10	O
found	O
the	O
DFAT	O
cells	O
expressed	O
cardiac	O
markers	O
when	O
co-cultured	O
with	O
cardiomyocytes	O
and	O
also	O
when	O
grown	O
in	O
stem	B
cell	I
methylcellulose	O
medium	O
with	O
the	O
absence	O
of	O
cardiomyocytes.	O

A	O
recent	O
review	O
showed	O
that	O
changes	O
in	O
culture	O
conditions	O
might	O
alter	O
the	O
fate	O
and/or	O
potency	O
of	O
stem	B
cells	I
or	O
reprogram	O
adult	O
stem/progenitor	O
cells	O
to	O
assume	O
a	O
broader	O
range	O
of	O
multipotency.45	O
The	O
examination	O
of	O
microenvironment	O
(including	O
the	O
cell	O
density,	O
the	O
oxygen	O
demand,	O
the	O
amount	O
and	O
type	O
of	O
serum,	O
the	O
basic	O
medium,	O
and	O
proper	O
inducer)	O
of	O
DFAT	O
cells	O
might	O
allow	O
a	O
better	O
understanding	O
of	O
the	O
range	O
of	O
cellular	O
potential.	O

With	O
easy	O
access	O
from	O
patients	O
per	O
se	O
and	O
homogeneous	O
traits	O
of	O
progeny	O
cells,	O
multipotent	O
DFAT	O
cells	O
may	O
provide	O
an	O
excellent	O
source	O
of	O
cells	O
for	O
tissue	O
regeneration	O
and	O
disease	O
treatment,	O
expanding	O
the	O
stem	B
cell	I
repertoire	O
used	O
in	O
research	O
and	O
clinical	O
applications..	O

Expression	O
pattern	O
of	O
embryonic	B
stem	I
cell	I
markers	O
in	O
DFAT	O
cells	O
and	O
ADSCs.	O

Several	O
mechanisms	O
of	O
action	O
have	O
been	O
suggested	O
for	O
the	O
anti-GBM	O
effect	O
of	O
bevacizumab,	O
including	O
direct	O
inhibition	O
of	O
tumor-associated	O
angiogenesis,	O
a	O
direct	O
anti-GBM	O
effect	O
on	O
VEGF	O
receptor-expressing	O
GBM	O
cells,	O
disruption	O
of	O
the	O
glioma	B
stem	I
cell	I
microvascular	O
niche,	O
and	O
improved	O
vascular	O
function	O
or	O
normalization	O
[19].	O

It	O
has	O
also	O
been	O
found	O
that	O
after	O
treating	O
with	O
Hedgehog-Gli	O
signaling	O
inhibitor,	O
the	O
GBM-derived	O
neurosphere	O
cells	O
lost	O
their	O
tumorigenicity,	O
and	O
the	O
expression	O
of	O
stem	B
cell	I
markers	O
including	O
CD133	O
were	O
also	O
reduced	O
[132].	O

We	O
may	O
be	O
entering	O
a	O
new	O
phase	O
in	O
cancer	O
research	O
based	O
on	O
the	O
cancer	B
stem	I
cell	I
paradigm	O
in	O
the	O
following	O
5	O
years..	O

In	O
this	O
study	O
metformin	O
treatment	O
also	O
resulted	O
in	O
an	O
increase	O
of	O
cells	O
expressing	O
the	O
muscle	B
stem	I
cell	I
marker	O
Pax7+,	O
7	O
days	O
post-burn	O
injury	O
in	O
conjunction	O
with	O
an	O
increase	O
in	O
total	O
Pax7	O
protein	O
levels	O
[131].	O

Various	O
theoretical	O
models	O
have	O
been	O
developed	O
to	O
explain	O
how	O
SSCs	O
concomitantly	O
maintain	O
the	O
stem	B
cell	I
population	O
through	O
self-renewal	O
while	O
providing	O
sufficient	O
numbers	O
of	O
differentiating	O
progeny.	O

For	O
example,	O
although	O
they	O
showed	O
a	O
large	O
relative	O
increase	O
in	O
stem	O
cell	O
activity	O
over	O
time,	O
the	O
absolute	O
number	O
of	O
stem	B
cells	I
expanded	O
and	O
the	O
ability	O
to	O
freeze–thaw	O
the	O
long-term	O
SSCs	O
was	O
not	O
addressed.	O

As	O
an	O
extension	O
of	O
the	O
seminal	O
Brinster	O
study,	O
which	O
used	O
freshly	O
isolated	O
testis	O
cell	O
suspensions,	O
many	O
studies	O
currently	O
employ	O
this	O
method	O
to	O
verify	O
the	O
presence	O
of	O
stem	B
cells	I
in	O
culture	O
[25,26].	O

Second,	O
given	O
recent	O
improvements	O
in	O
experimental	O
derivation	O
of	O
gametes	O
in	O
vitro	O
from	O
stem	B
cell	I
precursors,	O
it	O
is	O
likely	O
that	O
production	O
of	O
functional	O
sperm	O
from	O
hSSCs	O
will	O
eventually	O
become	O
feasible.	O

Quantitative	O
detection	O
of	O
human	O
spermatogonia	O
for	O
optimization	O
of	O
spermatogonial	B
stem	I
cell	I
culture.	O

Spermatogonial	B
stem	I
cell	I
transplantation	O
into	O
rhesus	O
testes	O
regenerates	O
spermatogenesis	O
producing	O
functional	O
sperm.	O

A	O
most	O
exciting	O
role	O
for	O
plucked	O
hair	O
shafts	O
is	O
developing	O
in	O
the	O
field	O
of	O
stem	B
cell	I
reprogramming	O
and	O
the	O
development	O
of	O
autologous	O
epidermal	O
equivalents.	O

In	O
vitro	O
studies	O
on	O
breast	O
cancer	O
cells	O
show	O
that	O
Doxycycline	O
inhibits	O
cancer	O
cell	O
proliferation/viability	O
and	O
downregulates	O
the	O
expression	O
of	O
stem	B
cell	I
factors	O
(Oct4,	O
Sox2,	O
Nanog,	O
and	O
CD44)	O
and	O
autophagy	O
markers	O
(LC-3BI	O
and	O
LC-3BII)	O
[54,55].	O

Doxycycline	O
inhibits	O
the	O
cancer	B
stem	I
cell	I
phenotype	O
and	O
epithelial-to-mesenchymal	O
transition	O
in	O
breast	O
cancer.	O

Mammospheres	O
of	O
SUM149	O
and	O
IPC-366	O
cell	O
lines	O
exhibit	O
a	O
very	O
similar	O
immunophenotype	O
for	O
the	O
expression	O
of	O
stem	B
cells	I
markers	O
[15].	O

The	O
present	O
descriptive	O
study	O
can	O
only	O
address	O
the	O
morphology	O
of	O
the	O
cells,	O
however,	O
there	O
are	O
previous	O
studies	O
on	O
these	O
two	O
cell	O
lines	O
that	O
support	O
the	O
molecular	O
transformation	O
of	O
these	O
cultured	O
cells,	O
with	O
stem	B
cells	I
phenotype,	O
into	O
ELCs	O
[15,	O
25].	O

As	O
previously	O
reported,	O
SUM149	O
and	O
IPC-366	O
cell	O
lines	O
in	O
non-adherent	O
(3D)	O
cultures,	O
exhibited	O
similar	O
immunophenotype	O
for	O
the	O
expression	O
of	O
stem	B
cells	I
markers.	O

Exosomes	O
from	O
mesenchymal	B
stem	I
cells	I
modulate	O
endoplasmic	O
reticulum	O
stress	O
to	O
protect	O
against	O
nucleus	O
pulposus	O
cell	O
death	O
and	O
ameliorate	O
intervertebral	O
disc	O
degeneration	O
in	O
vivo.	O

Cocultures	O
with	O
U87MG	O
cells	O
for	O
videomicroscopy	O
were	O
done	O
in	O
neural	B
stem	I
cell	I
media	O
on	O
either	O
Matrigel-	O
or	O
laminin-coated	O
plates	O
(results	O
were	O
similar	O
on	O
both	O
substrates)..	O

Identification	O
of	O
brain	O
tumour	O
initiating	O
cells	O
using	O
the	O
stem	B
cell	I
marker	O
aldehyde	O
dehydrogenase.	O

Pathway	O
analysis	O
of	O
the	O
highly	O
over-representative	O
cluster	O
demonstrated	O
enrichment	O
of	O
mostly	O
cell	O
cycle	O
processes,	O
cytokine-cytokine	O
receptor	O
interaction,	O
signaling	O
pathways	O
regulating	O
pluripotency	O
of	O
stem	O
cells,	O
chemokine	O
signaling	O
pathway	O
(Fig	O
4A).	O
Differential	O
expression	O
of	O
stem	B
cell	I
mobilization-associated	O
molecules	O
on	O
multi-lineage	O
cells	O
from	O
adipose	O
tissue	O
and	O
bone	O
marrow.	O

In	O
addition	O
to	O
model	O
organisms,	O
human	O
cell	O
lines	O
from	O
the	O
differentiation	O
of	O
stem	B
cells	I
and	O
other	O
sources	O
provide	O
unique	O
opportunities	O
to	O
perform	O
cellular	O
studies	O
and	O
test	O
therapeutic	O
compounds	O
for	O
neurodegenerative	O
disease	O
(Ordonez	O
et	O
al.,	O
2012).	O

Two	O
paired	O
box	O
transcription	O
factors,	O
Pax3	O
and	O
Pax7,	O
are	O
essential	O
for	O
maintaining	O
this	O
muscle	B
stem	I
cell	I
status	O
through	O
their	O
antidifferentiation	O
capacity,	O
owing	O
to	O
their	O
negative	O
regulation	O
of	O
MyoD	O
[4,	O
6,	O
8].	O

Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

Variation	O
in	O
cancer	O
risk	O
among	O
tissues	O
can	O
be	O
explained	O
by	O
the	O
number	O
of	O
stem	B
cell	I
divisions.	O

Regulation	O
of	O
the	O
breast	B
cancer	I
stem	I
cell	I
phenotype	O
by	O
hypoxia-inducible	O
factors.	O

The	O
advent	O
of	O
stem	B
cell	I
therapy	O
has	O
opened	O
new	O
horizons	O
for	O
both	O
researchers	O
and	O
ALS	O
patients,	O
desperately	O
looking	O
for	O
a	O
treatment.	O

Mesenchymal	B
Stem	I
Cell	I
Transplantation	O
In	O
Amyotrophic	O
Lateral	O
Sclerosis:	O
A	O
Phase	O
I	O
Clinical	O
Trial.	O

cp	O
GO:2000648	O
positive	O
regulation	O
of	O
stem	B
cell	I
proliferation	O
6	O
40	O
0.0089.	O

The	O
RNA-binding	O
protein,	O
cold	O
shock	O
domain-containing	O
protein	O
E1	O
(CSDE1,	O
also	O
known	O
as	O
N-ras	O
upstream	O
gene	O
protein,	O
UNR),	O
could	O
function	O
as	O
a	O
target	O
of	O
the	O
anti-glioma	B
stem	I
cell	I
drug,	O
clofoctol,	O
for	O
tumor	O
growth	O
[25].	O

Several	O
of	O
the	O
seven	O
isoforms	O
participate	O
in	O
each	O
process,	O
Nox4	O
plays	O
a	O
crucial	O
role	O
in	O
O2·−	O
and	O
H2O2	O
generation,	O
and	O
the	O
Nox2	O
and	O
Nox4	O
activities	O
were	O
found	O
to	O
be	O
increased	O
in	O
majority	O
of	O
stem	B
cell	I
types	O
[105].	O

Embryonic	B
stem	I
cell	I
differentiation	O
into	O
smooth	O
muscle	O
cells	O
is	O
mediated	O
by	O
Nox4-produced	O
H2O2.	O

Reactive	O
oxygen	O
species	O
and	O
mitochondrial	O
homeostasis	O
as	O
regulators	O
of	O
stem	B
cell	I
fate	O
and	O
function.	O

Nuclear	O
Nox4	O
interaction	O
with	O
prelamin	O
A	O
is	O
associated	O
with	O
nuclear	O
redox	O
control	O
of	O
stem	B
cell	I
aging.	O

BCL6-mediated	O
repression	O
of	O
p53	O
is	O
critical	O
for	O
leukemia	B
stem	I
cell	I
survival	O
in	O
chronic	O
myeloid	O
leukemia.	O

Notes:	O
(A)	O
GSEA	O
plot	O
showing	O
that	O
PRR11	O
expression	O
positively	O
correlated	O
with	O
cancer	B
stem	I
cell	I
signaling	O
pathway.	O

Cancer	B
stem	I
cells	I
in	O
oesophageal	O
squamous	O
cell	O
carcinoma:	O
identification,	O
prognostic	O
and	O
treatment	O
perspectives.	O

In	O
the	O
embryonic	B
stem	I
cell	I
model,	O
Mef2c	O
expression	O
was	O
induced	O
under	O
10	O
dyn/cm2	O
shear	O
stress	O
(Kudo	O
et	O
al.,	O
2000).	O

Alternatively,	O
M2	O
(Arg1+,	O
CD36+,	O
CD206+,	O
Ym1+)	O
phenotypes,	O
mostly	O
found	O
in	O
the	O
ischemic	O
core	O
region,	O
secrete	O
IL4,	O
IL10,	O
and	O
IL13	O
and	O
TGFβ,	O
IGF1,	O
NGF,	O
and	O
BDNF	O
for	O
neuroprotection,	O
inhibition	O
of	O
apoptosis	O
and	O
necrosis,	O
tissue	O
and	O
ECM	O
repair	O
and	O
cleanup	O
of	O
debris	O
via	O
phagocytosis.177–180	O
Transformation	O
of	O
these	O
microglia	O
from	O
M1	O
(tumor	O
suppressive)	O
to	O
M2	O
(tumor	O
promoting)	O
form	O
initiates	O
immune	O
suppression	O
in	O
the	O
tumor	O
area	O
and	O
also	O
promotes	O
tumor	O
expansion,	O
metastasis,	O
angiogenesis,	O
and	O
glioma	B
stem	I
cell	I
maintenance	O
via	O
the	O
secretion	O
of	O
several	O
factors	O
(viz.	O

Glioma	B
stem	I
cell	I
proliferation	O
and	O
tumor	O
growth	O
are	O
promoted	O
by	O
nitric	O
oxide	O
synthase-2.	O

Cardiac	B
stem	I
cell	I
and	O
myocyte	O
aging,	O
heart	O
failure,	O
and	O
insulin-like	O
growth	O
factor-1	O
overexpression.	O

A	O
nucleolar	O
mechanism	O
controlling	O
cell	O
proliferation	O
in	O
stem	B
cells	I
and	O
cancer	O
cells.	O

Successful	O
regeneration	O
of	O
the	O
periodontium	O
has	O
been	O
accomplished	O
using	O
a	O
combination	O
of	O
stem	B
cell	I
engineered	O
by	O
adenovirus	O
to	O
express	O
the	O
BMP-2	O
gene	O
[72]..	O

In	O
comparison,	O
Panx1	O
showed	O
the	O
highest	O
expression	O
in	O
all	B
of	I
the	I
stem	I
cell	I
lines:	O
a	O
in	O
hCBiPS2	O
cells,	O
Panx2	O
expression	O
was	O
8.26-fold	O
lower	O
and	O
Panx3	O
expression	O
was	O
6.25-fold	O
lower	O
than	O
Panx1	O
expression;	O
b	O
in	O
HSC-1285	O
cells,	O
Panx2	O
expression	O
was	O
12.82-fold	O
lower	O
and	O
Panx3	O
expression	O
was	O
8.06-fold	O
lower	O
as	O
compared	O
to	O
Panx1;	O
c	O
in	O
HES-3	O
cells,	O
Panx2	O
expression	O
was	O
7.75-fold	O
lower	O
and	O
Panx3	O
expression	O
was	O
2.98-fold	O
lower	O
than	O
Panx1	O
expression.	O

The	O
histone	O
acetyltransferase	O
MOF	O
is	O
a	O
key	O
regulator	O
of	O
the	O
embryonic	B
stem	I
cell	I
core	O
transcriptional	O
network.	O

Interplay	O
of	O
geometric	O
cues	O
and	O
RGD/BMP-2	O
crosstalk	O
in	O
directing	B
stem	I
cell	I
fate.	O

Dynamic	O
surfaces	O
for	O
the	O
study	O
of	O
mesenchymal	B
stem	I
cell	I
growth	O
through	O
adhesion	O
regulation.	O

Evaluating	O
the	O
Endocytosis	O
and	O
Lineage-Specification	O
Properties	O
of	O
Mesenchymal	B
Stem	I
Cell	I
Derived	O
Extracellular	O
Vesicles	O
for	O
Targeted	O
Therapeutic	O
Applications.	O

Evaluating	O
the	O
Endocytosis	O
and	O
Lineage-Specification	O
Properties	O
of	O
Mesenchymal	B
Stem	I
Cell	I
Derived	O
Extracellular	O
Vesicles	O
for	O
Targeted	O
Therapeutic	O
Applications.	O

Quantitative	O
and	O
Qualitative	O
Endocytosis	O
of	O
Human	O
Mesenchymal	B
Stem	I
Cell	I
Extracellular	O
Vesicles.	O

Exosomes	O
as	O
biomimetic	O
tools	O
for	O
stem	B
cell	I
differentiation:	O
applications	O
in	O
dental	O
pulp	O
tissue	O
regeneration.	O

Repair	O
and	O
regeneration	O
of	O
the	O
respiratory	O
system:	O
complexity,	O
plasticity,	O
and	O
mechanisms	O
of	O
lung	B
stem	I
cell	I
function.	O

Dysfunctional	O
autophagy	O
is	O
a	O
driver	O
of	O
muscle	B
stem	I
cell	I
functional	O
decline	O
with	O
aging.	O

In	O
some	O
tumor	O
studies,	O
hyaluronan	O
binding	O
to	O
tumor	O
cells	O
promoted	O
Nanog	O
protein	O
in	O
association	O
with	O
CD44	O
followed	O
by	O
Nanog	O
activation	O
and	O
the	O
expression	O
of	O
pluripotent	B
stem	I
cell	I
regulators	O
such	O
as	O
Rex1	O
and	O
Sox2.	O

Many	O
reports	O
have	O
experimentally	O
confirmed	O
this	O
idea,	O
demonstrating	O
the	O
acceleration	O
of	O
stem	B
cell	I
proliferation	O
by	O
hyaluronan.	O

Previous	O
studies	O
have	O
reported	O
that	O
MDR	O
is	O
an	O
important	O
regulator	O
of	O
stem	B
cell	I
commitment	O
[77].	O

Hyaluronan-containing	O
hydrogels	O
provide	O
a	O
suitable	O
environment	O
for	O
neural	B
stem	I
cell	I
growth	O
and	O
differentiation	O
[84,	O
85]..	O

The	O
role	O
of	O
the	O
hyaluronan	O
receptor	O
CD44	O
in	O
mesenchymal	B
stem	I
cell	I
migration	O
in	O
the	O
extracellular	O
matrix.	O

Hyalomatrix:	O
a	O
temporary	O
epidermal	O
barrier,	O
hyaluronan	O
delivery,	O
and	O
neodermis	O
induction	O
system	O
for	O
keratinocyte	B
stem	I
cell	I
therapy.	O

e	O
The	O
GSCs	O
in	O
T1454	O
expressed	O
the	O
stem	B
cell	I
markers	O
CD133	O
and	O
CD15.	O

Tumor	B
stem	I
cells	I
derived	O
from	O
glioblastomas	O
cultured	O
in	O
bFGF	O
and	O
EGF	O
more	O
closely	O
mirror	O
the	O
phenotype	O
and	O
genotype	O
of	O
primary	O
tumors	O
than	O
do	O
serum-cultured	O
cell	O
lines.	O

Defining	O
the	O
actual	O
sensitivity	O
and	O
specificity	O
of	O
the	O
neurosphere	O
assay	O
in	O
stem	B
cell	I
biology.	O

identified	O
ALDH+	O
pancreatic	O
cancer	O
cells	O
with	O
stem	B
cell	I
like	O
tumorigenicity,	O
clonogenic	O
potential	O
and	O
characteristics	O
of	O
epithelial-mesenchymal	O
transition	O
(EMT)	O
[11]..	O

It	O
has	O
been	O
demonstrated	O
that	O
the	O
miR-200	O
family	O
members	O
(miR-141,	O
miR-200a,	O
b,	O
c	O
and	O
miR-429)	O
are	O
able	O
to	O
repress	O
the	O
expression	O
of	O
stem	B
cell	I
factors	O
such	O
as	O
Sox2	O
and	O
Klf4.	O

A	O
direct	O
pancreatic	O
cancer	O
xenograft	O
model	O
as	O
a	O
platform	O
for	O
cancer	B
stem	I
cell	I
therapeutic	O
development.	O

Detection	O
of	O
tumor	B
stem	I
cell	I
markers	O
in	O
pancreatic	O
carcinoma	O
cell	O
lines.	O

PSC	O
markers	O
also	O
characterize	O
several	O
other	O
cell	O
types	O
such	O
as	O
desmin	O
that	O
is	O
seen	O
in	O
monocytes,	O
GFAP	O
of	O
astrocytes,	O
vimentin	O
that	O
also	O
characterizes	O
leukocytes	O
and	O
endothelial	O
cells,	O
and	O
nestin	O
of	O
neuroepithelial	B
stem	I
cells	I
[10].	O

INTRODUCTION:	O
With	O
advances	O
in	O
stem	B
cell	I
research,	O
molecular	O
markers	O
of	O
stem	O
and	O
early	O
progenitor	O
cells	O
have	O
been	O
discovered	O
in	O
the	O
small	O
intestine	O
and	O
colon.	O

CONCLUSION:	O
In	O
conclusion,	O
we	O
established	O
a	O
3D	O
culture	O
system	O
to	O
allow	O
long-term	O
culture	O
of	O
primary	O
stomach	O
cells	O
within	O
the	O
stem	B
cell	I
niche.	O

This	O
culture	O
method	O
should	O
be	O
useful	O
for	O
stem	B
cell	I
research	O
and	O
elucidating	O
the	O
cause	O
of	O
gastric	O
diseases..	O

To	O
date,	O
the	O
use	O
of	O
a	O
novel	O
therapeutic	O
approach	O
of	O
high-dose	O
chemotherapy	O
followed	O
by	O
autologous	B
stem	I
cell	I
transplant	O
(ASCT)	O
in	O
a	O
small	O
cohort	O
of	O
patients	O
with	O
RCD	O
II	O
has	O
stimulated	O
great	O
interest	O
world	O
wide	O
with	O
promising	O
results..	O

We	O
also	O
tested	O
and	O
validated	O
the	O
FATS	O
on	O
adipogenesis	O
of	O
three	O
MSC-like	O
cell	O
lines	O
derived	O
from	O
pluripotent	B
stem	I
cell	I
lines	O
including	O
iPSCs	O
and	O
ESCs	O
(26.67–40.14%;	O
Fig.	O

FATS	O
is	O
particularly	O
useful	O
for	O
characterising	O
adipogenesis	O
of	O
pluripotent	B
stem	I
cell	I
lines.	O

CIC	O
is	O
also	O
involved	O
in	O
the	O
control	O
of	O
cancer	B
stem	I
cell	I
properties.	O

CIC	O
deficiency	O
promotes	O
the	O
self-renewal	O
capacity	O
and	O
increases	O
the	O
expression	O
of	O
cancer	B
stem	I
cell	I
markers,	O
including	O
EpCAM+/CD44hi/CD24lo	O
and	O
ALDH47,48,	O
via	O
derepression	O
of	O
ETV4,	O
ETV5,	O
and	O
SOX2	O
in	O
breast	O
cancer	O
cell	O
lines49.	O

Mesenchymal	B
stem	I
cell	I
exosomes	O
promote	O
immunosuppression	O
of	O
regulatory	O
T	O
cells	O
in	O
asthma.	O

The	O
wnt	O
family	O
pathways,	O
which	O
are	O
important	O
in	O
mammary	O
development	O
and	O
renewal	O
of	O
stem	B
cell	I
in	O
the	O
adult	O
tissue	O
(Brennan	O
and	O
Brown	O
2004,	O
Clevers	O
2006),	O
are	O
often	O
perturbed	O
in	O
tumors.	O

Since	O
the	O
unique	O
anatomy	O
of	O
the	O
intestinal	O
crypt	O
epithelium	O
makes	O
it	O
one	O
of	O
the	O
most	O
accessible	O
models	O
for	O
the	O
study	O
of	O
adult	B
stem	I
cell	I
biology,	O
the	O
research	O
on	O
this	O
subject	O
started	O
almost	O
four	O
decades	O
ago	O
(8).	O

Experimental	O
strategies	O
should	O
be	O
aimed	O
at	O
‘hijacking’	O
the	O
crypt	B
stem	I
cell	I
niche	O
biology	O
by	O
transforming	O
the	O
function	O
of	O
the	O
Paneth	O
cell	O
from	O
homeostasis	O
keeper	O
to	O
local	O
inducer	O
of	O
chronic	O
inflammation.	O

Conversely,	O
Paneth	O
cell-targeted	O
overexpression	O
of	O
an	O
anti-inflammatory	O
cytokine,	O
such	O
as	O
IL-10,	O
could	O
create	O
a	O
‘shield’,	O
protecting	O
the	O
stem	B
cell	I
niche	O
and	O
attenuating	O
the	O
oncogenic	O
potential	O
of	O
a	O
CAC-inducing	O
regimen	O
on	O
the	O
whole	O
mucosa.	O

In	O
this	O
respect,	O
the	O
small	O
intestine	O
crypt	O
represents	O
an	O
outstanding	O
model,	O
due	O
to	O
the	O
unique	O
role	O
of	O
Paneth	O
cells	O
in	O
the	O
fine-tuning	O
of	O
stem	B
cell	I
niche	O
homeostasis.	O

In	O
addition	O
and	O
intriguingly,	O
Paneth	O
cells	O
secrete	O
factors	O
that	O
sustain	O
and	O
fuel	O
the	O
crypt	B
stem	I
cell	I
compartment	O
(93)..	O

This	O
is	O
particularly	O
true	O
for	O
stem	B
cell	I
therapies	O
(which	O
have	O
been	O
used	O
for,	O
among	O
many	O
diseases,	O
the	O
treatment	O
of	O
canine	O
fistulizing	O
IBD).9,	O
10,	O
11	O
Pet	O
owners	O
increasingly	O
demand	O
state-of-the	O
art	O
care	O
for	O
their	O
animals,	O
and	O
thus	O
there	O
are	O
increasing	O
numbers	O
of	O
veterinary	O
clinical	O
trials	O
that	O
ultimately	O
may	O
have	O
human	O
relevance.	O

The	O
biological	O
pathway	O
enrichment	O
analysis	O
of	O
the	O
62	O
predicted	O
target	O
genes	O
showed	O
that	O
hsa-miR-223-3p	O
was	O
significantly	O
enriched	O
in	O
the	O
AMP-activated	O
protein	O
kinase	O
(AMPK)	O
signaling	O
pathway,	O
mineral	O
absorption	O
pathway	O
and	O
signaling	O
pathways	O
regulating	O
pluripotency	O
of	O
stem	B
cell	I
(Fig.	O

Distinct	O
expression	O
levels	O
and	O
patterns	O
of	O
stem	B
cell	I
marker,	O
aldehyde	O
dehydrogenase	O
isoform	O
1	O
(ALDH1),	O
in	O
human	O
epithelial	O
cancers.	O

Finally,	O
we	O
will	O
discuss	O
the	O
clinical	O
implications	O
of	O
stem	B
cell	I
modeling	O
of	O
CBF	O
AML	O
for	O
the	O
therapy	O
of	O
the	O
disease..	O

Acute	O
myeloid	O
leukemia	O
fusion	O
proteins	O
deregulate	O
genes	O
involved	O
in	O
stem	B
cell	I
maintenance	O
and	O
DNA	O
repair.	O

Identification	O
of	O
the	O
haematopoietic	B
stem	I
cell	I
niche	O
and	O
control	O
of	O
the	O
niche	O
size.	O

A	O
number	O
of	O
stem	B
cell	I
clinical	O
trials	O
[19,	O
154]	O
have	O
shown	O
that	O
some	O
cell-based	O
protocols	O
could	O
be	O
safe	O
and	O
produce	O
promising	O
though	O
modest	O
effects.	O

The	O
past,	O
present	O
and	O
future	O
of	O
stem	B
cell	I
clinical	O
trials	O
for	O
ALS.	O

Cell	O
cycle	O
restriction	O
by	O
histone	O
H2AX	O
limits	O
proliferation	O
of	O
adult	O
neural	O
stem	O
cells.	O
Concise	O
review:	O
epigenetic	O
mechanisms	O
contribute	O
to	O
pluripotency	O
and	O
cell	O
lineage	O
determination	O
of	O
embryonic	O
stem	O
cells.	O
Release	O
of	O
extracellular	O
membrane	O
particles	O
carrying	O
the	O
stem	B
cell	I
marker	O
prominin-1	O
(CD133)	O
from	O
neural	O
progenitors	O
and	O
other	O
epithelial	O
cells.	O

Mesenchymal	B
stem	I
cells	I
are	O
multipotent	O
cells	O
with	O
the	O
potential	O
to	O
differentiate	O
into	O
a	O
variety	O
of	O
cell	O
lineages	O
including	O
fat,	O
bone,	O
cartilage,	O
muscle,	O
and	O
marrow	O
stroma	O
[4].	O

Although	O
there	O
are	O
still	O
unresolved	O
concerns	O
about	O
the	O
safety	O
and	O
the	O
efficacy	O
of	O
stem	B
cell	I
therapy,	O
these	O
data	O
suggest	O
that	O
MSCs	O
are	O
a	O
promising	O
therapeutic	O
option	O
for	O
treatment	O
of	O
diabetes	O
in	O
the	O
future..	O

While	O
A-type	O
lamins	O
are	O
rarely	O
expressed	O
in	O
pluripotent	B
stem	I
cells	I
or	O
embryos	O
during	O
early	O
development	O
[67,68,69],	O
at	O
least	O
one	O
B-type	O
lamin	O
is	O
expressed	O
in	O
most	O
embryonic	O
and	O
somatic	O
cell	O
types.	O

The	O
frequency	O
of	O
germ	O
line	O
epimutations	O
or	O
imprinting	O
errors—estimated	O
to	O
be	O
an	O
order	O
of	O
magnitude	O
higher	O
than	O
that	O
of	O
germ	O
line	O
mutations	O
(Horsthemke	O
2006)—can	O
be	O
either	O
environmentally	O
regulated	O
(Dolinoy	O
and	O
Jirtle	O
2008),	O
as	O
illustrated	O
by	O
the	O
inducibility	O
of	O
spermatogonial	B
stem	I
cell	I
DNA	O
hypermethylation	O
by	O
air	O
pollution	O
(Yauk	O
et	O
al.	O

As	O
an	O
extension	O
of	O
the	O
“immortal	O
strand”	O
hypothesis	O
of	O
stem	B
cell	I
fidelity	O
(Cairns	O
2006),	O
our	O
findings	O
raise	O
the	O
notion	O
that	O
the	O
transcribed	O
(well	O
repaired,	O
CpG-demethylated)	O
DNA	O
strand	O
represents	O
the	O
“immovable	O
object”	O
of	O
negative	O
selection,	O
whereas	O
the	O
untranscribed	O
(poorly	O
repaired,	O
CpG-methylated)	O
strand	O
provides	O
the	O
“irresistible	O
force”	O
of	O
positive	O
selection.	O

Stability	O
of	O
colon	B
stem	I
cell	I
methylation	O
after	O
neo-adjuvant	O
therapy	O
in	O
a	O
patient	O
with	O
attenuated	O
familial	O
adenomatous	O
polyposis.	O

In	O
GBM,	O
Notch	O
activity	O
is	O
associated	O
with	O
the	O
control	O
of	O
Glioma	O
Stem	O
Cell	O
(GSC),	O
since	O
its	O
activity	O
regulates	O
asymmetric	O
cell	O
division	O
and	O
Notch	O
unbalanced	O
expression	O
leads	O
to	O
uncontrolled	O
growth	O
and	O
high	O
malignancy	O
(Mukherjee	O
et	O
al.,	O
2016),	O
Several	O
studies	O
demonstrate	O
a	O
role	O
for	O
Notch	O
signal	O
in	O
controlling	O
growth	O
and	O
stem	B
cell	I
maintenance	O
of	O
the	O
brain	O
also	O
in	O
flies	O
(Song	O
and	O
Lu,	O
2011).	O

Glioma	B
stem	I
cells	I
divide	O
asymmetrically	O
under	O
the	O
guidance	O
of	O
cell	O
polarity	O
complexes	O
that	O
control	O
the	O
proper	O
apical	O
and	O
basolateral	O
polarization	O
and	O
cell	O
division,	O
a	O
process	O
that	O
was	O
originally	O
identified	O
in	O
Drosophila	O
and	O
later	O
confirmed	O
for	O
the	O
mechanism	O
driving	O
differentiation	O
in	O
human	O
glia	O
for	O
members	O
of	O
the	O
Hugl-1/Llgl-1	O
complexes	O
(Prehoda,	O
2009).	O

Several	O
Drosophila	O
models	O
of	O
stem	B
cell	I
tumors	O
are	O
now	O
available,	O
and	O
a	O
drug	O
screening	O
was	O
successfully	O
carried	O
out	O
highlighting	O
several	O
compounds	O
active	O
on	O
the	O
signaling	O
promoting	O
cancer	O
growth	O
(Markstein	O
et	O
al.,	O
2014)..	O

Melatonin	O
treatment	O
improves	O
adipose-derived	B
mesenchymal	I
stem	I
cell	I
therapy	O
for	O
acute	O
lung	O
ischemia-reperfusion	O
injury.	O

The	O
BMSCs	O
reside	O
in	O
the	O
stem	B
cell	I
niches	O
at	O
bone	O
marrow	O
and	O
it	O
is	O
necessary	O
for	O
them	O
to	O
migrate	O
to	O
the	O
damaged	O
area	O
and	O
differentiate	O
into	O
osteoblasts	O
to	O
regenerate	O
new	O
tissues.	O

A	O
mouse	O
bone	O
marrow	O
stromal	O
cell	O
line	O
with	O
skeletal	B
stem	I
cell	I
characteristics	O
to	O
study	O
osteogenesis	O
in	O
vitro	O
and	O
in	O
vivo.	O

This	O
is	O
a	O
novel	O
way	O
to	O
understand	O
the	O
signaling	O
architecture	O
of	O
mesenchymal	B
stem	I
cell	I
differentiation	O
and	O
might	O
be	O
useful	O
in	O
developing	O
network-targeted	O
therapies	O
for	O
clinical	O
applications.	O

Dynamic	O
protein	O
pathway	O
activation	O
mapping	O
of	O
adipose-derived	B
stem	I
cell	I
differentiation	O
implicates	O
novel	O
regulators	O
of	O
adipocyte	O
differentiation.	O

Vascular-derived	O
TGF-β	O
increases	O
in	O
the	O
stem	B
cell	I
niche	O
and	O
perturbs	O
neurogenesis	O
during	O
aging	O
and	O
following	O
irradiation	O
in	O
the	O
adult	O
mouse.	O

Man	O
SM,	O
Zhu	O
Q,	O
Zhu	O
L,	O
Liu	O
Z,	O
Karki	O
R,	O
Malik	O
A,	O
Sharma	O
D,	O
Li	O
L,	O
Malireddi	O
RK,	O
Gurung	O
P,	O
Neale	O
G,	O
Olsen	O
SR,	O
Carter	O
RA,	O
McGoldrick	O
DJ,	O
Wu	O
G,	O
Finkelstein	O
D,	O
Vogel	O
P,	O
Gilbertson	O
RJ,	O
Kanneganti	O
TD	O
(2015)	O
Critical	O
role	O
for	O
the	O
DNA	O
sensor	O
AIM2	O
in	O
stem	B
cell	I
proliferation	O
and	O
cancer.	O

The	O
emerging	O
role	O
of	O
the	O
phosphatidylinositol	O
3-kinase/	O
akt/mammalian	O
target	O
of	O
rapamycin	O
signaling	O
network	O
in	O
cancer	B
stem	I
cell	I
biology.	O

Conversely,	O
they	O
also	O
display	O
a	O
decrease	O
in	O
OCT4,	O
a	O
marker	O
of	O
stem	B
cell	I
pluripotency	O
(Supplementary	O
Material,	O
Fig.	O

While	O
this	O
demonstrates	O
utility	O
in	O
stem	B
cell	I
application,	O
there	O
is	O
now	O
a	O
need	O
for	O
a	O
consolidation	O
of	O
methodologies	O
as	O
we	O
move	O
towards	O
clinical	O
translation..	O

Time-dependent	O
changes	O
in	O
the	O
microenvironment	O
of	O
injured	O
spinal	O
cord	O
affects	O
the	O
therapeutic	O
potential	O
of	O
neural	B
stem	I
cell	I
transplantation	O
for	O
spinal	O
cord	O
injury.	O

Accordingly,	O
XBP1	O
expression	O
was	O
correlated	O
to	O
cancer	B
stem	I
cell	I
expansion	O
and	O
tumor	O
relapse	O
post	O
therapy	O
(Chen	O
et	O
al.,	O
2014)..	O

Identification	O
of	O
prognostic	O
model	O
and	O
biomarkers	O
for	O
cancer	B
stem	I
cell	I
characteristics	O
in	O
glioblastoma	O
by	O
network	O
analysis	O
of	O
multi-omics	O
data	O
and	O
stemness	O
indices.	O

3F),	O
suggesting	O
HOTAIR	O
inhibition	O
with	O
PNA	O
could	O
reduce	O
the	O
cancer	B
stem	I
cell	I
population..	O

Abstract	O
A57:	O
Platinum	O
induces	O
IL-6-signaling	O
mediated	O
activation	O
of	O
ALDH1A1	O
and	O
enriches	O
the	O
cancer	B
stem	I
cell	I
population	O
in	O
ovarian	O
cancer.	O

In	O
addition,	O
it	O
was	O
reported	O
that	O
miR-377	O
can	O
target	O
chromobox	O
protein	O
homolog	O
3	O
(CBX3)	O
and	O
contributes	O
to	O
maintenance	O
of	O
stem	B
cell	I
potential	O
in	O
ESCC[39],	O
which	O
further	O
emphasized	O
the	O
importance	O
of	O
miR-377	O
as	O
a	O
critical	O
tumor	O
suppressor	O
in	O
ESCC..	O

Identification	O
of	O
Cancer	B
Stem	I
Cell	I
Molecular	O
Markers	O
and	O
Effects	O
of	O
hsa-miR-21-3p	O
on	O
Stemness	O
in	O
Esophageal	O
Squamous	O
Cell	O
Carcinoma.	O

Effects	O
of	O
telomerase	O
and	O
telomere	O
length	O
on	O
epidermal	B
stem	I
cell	I
behavior.	O

Application	O
of	O
the	O
Cas9	O
tool	O
in	O
hPSCs	O
offers	O
a	O
powerful	O
way	O
to	O
study	B
stem	I
cell	I
signaling,	O
particularly	O
in	O
multicellular	O
autocrine	O
and	O
paracrine	O
contexts	O
that	O
involve	O
reprogramming	O
and	O
differentiation..	O

Laminin-511	O
but	O
not	O
-332,	O
-111,	O
or	O
-411	O
enables	O
mouse	B
embryonic	I
stem	I
cell	I
self-renewal	O
in	O
vitro.	O

Influence	O
of	O
substrate	O
composition	O
on	O
human	B
embryonic	I
stem	I
cell	I
differentiation	O
and	O
extracellular	O
matrix	O
production	O
in	O
embryoid	O
bodies.	O

Matrix	O
assembly,	O
regulation,	O
and	O
survival	O
functions	O
of	O
laminin	O
and	O
its	O
receptors	O
in	O
embryonic	B
stem	I
cell	I
differentiation.	O

Dysfunctional	O
autophagy	O
is	O
a	O
driver	O
of	O
muscle	B
stem	I
cell	I
functional	O
decline	O
with	O
aging.	O

The	O
development	O
of	O
the	O
organoid	O
methodology	O
counts	O
today	O
as	O
a	O
major	O
technological	O
breakthrough	O
in	O
stem	B
cell	I
research.	O

The	O
use	O
of	O
BMP	O
antagonists	O
Noggin,	O
LDN,	O
and	O
DM	O
has	O
been	O
shown	O
in	O
2D	O
(Chambers	O
et	O
al.,	O
2009;	O
Kriks	O
et	O
al.,	O
2011;	O
Reinhardt	O
et	O
al.,	O
2013a)	O
and	O
applied	O
in	O
3D	B
stem	I
cell	I
cultures	O
(Table	O
1).	O

Typically,	O
brain	O
organoids	O
are	O
generated	O
from	O
PSCs	O
by	O
exploiting	O
developmental	O
processes	O
(Lancaster	O
et	O
al.,	O
2013;	O
Clevers,	O
2016)	O
or	O
by	O
creating	O
an	O
environment	O
favoring	O
specific	B
stem	I
cell	I
niches	O
(Tieng	O
et	O
al.,	O
2014;	O
Jo	O
et	O
al.,	O
2016;	O
Qian	O
et	O
al.,	O
2016;	O
Kim	O
et	O
al.,	O
2019).	O

Similarly,	O
the	O
presence	O
of	O
midbrain-specific	B
stem	I
cell	I
niches	O
and	O
clusters	O
of	O
mDANs	O
was	O
shown	O
in	O
a	O
NSC-derived	O
hMO	O
model	O
and	O
approaches	O
to	O
efficiently	O
differentiate	O
mDANs	O
within	O
hMOs	O
by	O
starting	O
from	O
expandable	O
neural	O
precursor	O
cells	O
(NPCs)	O
were	O
reported	O
(Monzel	O
et	O
al.,	O
2017;	O
Smits	O
et	O
al.,	O
2019a,	O
b;	O
Tables	O
2,.	O

Prox1	O
is	O
required	O
for	O
oligodendrocyte	O
cell	O
identity	O
in	O
adult	B
neural	I
stem	I
cells	I
of	O
the	O
subventricular	O
zone.	O

TCF7	O
has	O
been	O
observed	O
in	O
long	O
lived	O
Th17	O
cells	O
[56]	O
as	O
a	O
marker	O
of	O
stem	B
cell	I
memory	O
[57].	O

Messenger	O
RNAs	O
localized	O
to	O
distal	O
projections	O
of	O
human	B
stem	I
cell	I
derived	O
neurons.	O

The	O
functional	O
role	O
of	O
piRNAs	O
in	O
somatic	O
tissues	O
—	O
from	O
stem	B
cell	I
maintenance,	O
to	O
memory-related	O
synaptic	O
plasticity,	O
to	O
whole	O
body	O
regeneration	O
in	O
diverse	O
species	O
—	O
is	O
a	O
rapidly	O
emerging	O
field	O
of	O
research8,33,34,35,36.	O

To	O
functionally	O
assess	O
the	O
effect	O
of	O
these	O
drugs	O
on	B
stem	I
cell	I
activity,	O
we	O
performed	O
a	O
competitive	O
transplant	O
with	O
total	O
bone	O
marrow	O
cells	O
from	O
treated	O
mice	O
(Supplementary	O
Fig.	O

ELDA:	O
extreme	O
limiting	O
dilution	O
analysis	O
for	O
comparing	O
depleted	O
and	O
enriched	O
populations	O
in	O
stem	B
cell	I
and	O
other	O
assays.	O

Effect	O
of	O
5‐FU	O
and	O
MTX	O
on	O
the	O
Expression	O
of	O
Drug‐resistance	O
Related	O
Cancer	B
Stem	I
Cell	I
Markers	O
in	O
Non‐small	O
Cell	O
Lung	O
Cancer	O
Cells.	O

The	O
intention	O
is	O
then	O
to	O
clarify	O
whether	O
(i)	O
the	O
risk	O
of	O
severe	O
toxicity	O
when	O
trying	O
intensive	O
and	O
potentially	O
curative	O
intensive	O
chemotherapy	O
possibly	O
combined	O
with	O
autologous	B
stem	I
cell	I
transplantation	O
(AuSCT)	O
is	O
acceptable/low;	O
and	O
(ii)	O
conventional	O
intensive	O
therapy	O
can	O
be	O
used	O
or	O
the	O
risk	O
of	O
a	O
chemoresistant	O
relapse	O
is	O
so	O
high	O
that	O
one	O
should	O
recommend	O
the	O
much	O
more	O
toxic	O
but	O
at	O
the	O
same	O
time	O
more	O
effective	O
ASCT	O
as	O
part	O
of	O
the	O
treatment..	O

Leukemic	B
stem	I
cell	I
frequency:	O
A	O
strong	O
biomarker	O
for	O
clinical	O
outcome	O
in	O
acute	O
myeloid	O
leukemia.	O

However,	O
ALK+	O
cells	O
are	O
present	O
in	O
stem	O
cell-enriched	O
cord	O
blood,	O
and	O
a	O
study	O
has	O
identified	O
a	O
side	O
population	O
of	O
cells	O
in	O
ALK+	O
ALCL	O
cell	O
lines	O
and	O
tumors	O
with	O
signatures	O
similar	O
to	O
early	O
thymic	O
progenitors	O
(ETPs),	O
suggesting	O
that	O
transformation	O
of	O
T	O
cells	O
by	O
NPM-ALK	O
might	O
occur	O
early	O
during	O
thymic	O
T	O
cell	O
development	O
(Laurent	O
et	O
al.,	O
2012;	O
Moti	O
et	O
al.,	O
2015).	O
DNA	O
methylation	O
at	O
these	O
bivalent	O
chromatin	O
domains	O
has	O
been	O
observed	O
in	O
a	O
multitude	O
of	O
cancers	O
and	O
has	O
been	O
discussed	O
as	O
an	O
epigenetic	O
stem	B
cell	I
signature	O
of	O
cancer,	O
resembling	O
reprogramming	O
of	O
the	O
cancer	O
cell	O
epigenome	O
to	O
a	O
more	O
dedifferentiated	O
state	O
(Gal-Yam	O
et	O
al.,	O
2008;	O
Lehnertz	O
et	O
al.,	O
2003;	O
Ohm	O
et	O
al.,	O
2007;	O
Tachibana	O
et	O
al.,	O
2008;	O
Viré	O
et	O
al.,	O
2006;	O
Widschwendter	O
et	O
al.,	O
2007).	O

ZBP1	O
has	O
also	O
been	O
implicated	O
IL-17-mediated	O
skin	O
inflammation	O
(101)	O
and	O
regulation	O
of	O
stem	B
cell	I
differentiation	O
(102)..	O

Neuroprotective	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
through	O
complement	O
component	O
3	O
downregulation	O
after	O
transient	O
focal	O
cerebral	O
ischemia	O
in	O
mice.	O

Li	O
Y,	O
Zhao	O
X	O
(2014)	O
Concise	O
review:	O
fragile	O
X	O
proteins	O
in	O
stem	B
cell	I
maintenance	O
and	O
differentiation.	O

The	O
proapoptotic	O
activities	O
of	O
Bax	O
and	O
Bak	O
limit	O
the	O
size	O
of	O
the	O
neural	B
stem	I
cell	I
pool.	O

Concise	O
review:	O
growing	O
hearts	O
in	O
the	O
right	O
place:	O
on	O
the	O
design	O
of	O
biomimetic	O
materials	O
for	O
cardiac	B
stem	I
cell	I
differentiation.	O

Amplification	O
of	O
neural	B
stem	I
cell	I
proliferation	O
by	O
intermediate	O
progenitor	O
cells	O
in	O
Drosophila	O
brain	O
development.	O

The	O
role	O
of	O
controlled	O
surface	O
topography	O
and	O
chemistry	O
on	O
mouse	B
embryonic	I
stem	I
cell	I
attachment,	O
growth	O
and	O
self-renewal.	O

Comparative	O
effects	O
of	O
N-cadherin	O
protein	O
and	O
peptide	O
fragments	O
on	O
mesenchymal	B
stem	I
cell	I
mechanotransduction	O
and	O
paracrine	O
function.	O

Interplay	O
of	O
matrix	O
stiffness	O
and	O
protein	O
tethering	O
in	O
stem	B
cell	I
differentiation.	O

We	O
have	O
tested	O
two	O
types	O
of	O
stem	B
cells	I
in	O
the	O
marmoset	O
EAE	O
model,	O
namely	O
human	O
NPC,	O
grown	O
as	O
homogenous	O
cell	O
line,	O
and	O
iPS	O
cells	O
derived	O
from	O
reprogrammed	O
human	O
skin	O
fibroblasts,	O
differentiated	O
into	O
oligodendrocyte	O
precursor	O
cells	O
(OPCs)..	O

The	O
scientific	O
impact	O
of	O
the	O
Nobel	O
Prize-winning	O
new	O
technology	O
for	O
reprogramming	O
of	O
committed	O
somatic	O
cells	O
into	O
pluripotent	B
stem	I
cells	I
from	O
which	O
other	O
cell	O
lineages	O
can	O
be	O
generated	O
has	O
been	O
immense	O
(Takahashi	O
and	O
Yamanaka,	O
2006).	O

Early	O
life	O
stress	O
delays	O
hippocampal	O
development	O
and	O
diminishes	O
the	O
adult	B
stem	I
cell	I
pool	O
in	O
mice.	O

Interestingly,	O
the	O
innexin	O
gap	O
junction	O
genes	O
ogre	O
(inx1)	O
and	O
inx2	O
are	O
enriched	O
in	O
the	O
surface	O
glia	O
and	O
Drosophila	O
inx1	O
and	O
inx2	O
have	O
recently	O
been	O
linked	O
to	O
coordination	O
of	O
neural	B
stem	I
cell	I
proliferation	O
in	O
response	O
to	O
the	O
metabolic	O
status	O
of	O
the	O
animal	O
(Spéder	O
and	O
Brand,	O
2014).	O

Accumulating	O
evidence	O
in	O
vitro	O
and	O
in	O
vivo	O
suggests	O
this	O
interaction	O
plays	O
a	O
dominant	O
role	O
in	O
embryonic	B
stem	I
cell	I
self-renewal	O
and	O
tumorigenesis.	O

Oxygen	O
in	O
stem	O
cell	O
biology:	O
a	O
critical	O
component	O
of	O
the	O
stem	B
cell	I
niche.	O

have	O
previously	O
developed	O
murine	O
OSCC	O
models	O
with	O
varying	O
immunogenicity	O
to	O
demonstrate	O
the	O
therapeutic	O
potential	O
of	O
photoimmunotherapy	O
targeting	O
the	O
stem	B
cell	I
marker	O
CD44	O
[20].	O

Cultured	O
cells	O
were	O
sorted	O
using	O
flow	O
cytometry	O
based	O
on	O
expression	O
of	O
the	O
stem	B
cell	I
marker	O
(CD44)	O
and	O
epithelial	O
cell	O
adhesion	O
molecule,	O
EpCAM	O
(CD326).	O

(B)	O
Flow	O
cytometry	O
was	O
used	O
to	O
sort	O
cells	O
co-expressing	O
the	O
stem	B
cell	I
marker	O
(CD44)	O
and	O
epithelial	O
cell	O
adhesion	O
molecule,	O
EpCAM	O
(CD326).	O

To	O
generate	O
the	O
OSCC	O
cell	O
line,	O
donor	O
tongue	O
tissue	O
from	O
a	O
4NQO	O
exposed	O
mouse	O
was	O
stained	O
for	O
the	O
cancer	B
stem	I
cell	I
marker,	O
CD44	O
and	O
the	O
membrane	O
glycoprotein,	O
EpCAM	O
and	O
subsequently	O
sorted	O
using	O
flow	O
cytometry.	O

Cancer	B
stem	I
cells	I
in	O
squamous	O
cell	O
carcinoma	O
switch	O
between	O
two	O
distinct	O
phenotypes	O
that	O
are	O
preferentially	O
migratory	O
or	O
proliferative.	O

Phenotypic	O
Plasticity	O
Determines	O
Cancer	B
Stem	I
Cell	I
Therapeutic	O
Resistance	O
in	O
Oral	O
Squamous	O
Cell	O
Carcinoma.	O

XPC	O
also	O
mediates	O
initiation	O
of	O
the	O
transcription	O
of	O
the	O
stem	B
cell	I
inducer	O
Nanog	O
together	O
with	O
Oct4/Sox2	O
(Fong	O
et	O
al.,	O
2011).	O

With	O
the	O
recognition	O
that	O
adult	O
skeletal	O
muscles	O
contain	O
rare	O
cells	O
with	O
stem	B
cell	I
properties,	O
a	O
number	O
of	O
markers,	O
including	O
Sca-1,	O
CD34,	O
CD45,	O
Bcl-2,	O
and	O
c-kit,	O
have	O
been	O
used	O
alone	O
or	O
in	O
combination	O
to	O
identify	O
and	O
purify	O
the	O
cells	O
[1,18,19,28,34-37].	O

We	O
have	O
demonstrated	O
that	O
DclK-1	O
(DCAMKL-1),	O
is	O
a	O
novel	O
putative	O
pancreatic	B
stem	I
cell	I
marker	O
and	O
identified	O
DclK-1	O
as	O
potent	O
target	O
for	O
pancreatic	O
tumor	O
eradication.	O

DCLK1	O
marks	O
a	O
morphologically	O
distinct	O
subpopulation	O
of	O
cells	O
with	O
stem	B
cell	I
properties	O
in	O
preinvasive	O
pancreatic	O
cancer.	O

Cardiomyocyte	O
precursors	O
and	O
telocytes	O
in	O
epicardial	B
stem	I
cell	I
niche:	O
electron	O
microscope	O
images.	O

Gene	O
expression	O
profiling	O
of	O
cancer	B
stem	I
cell	I
in	O
human	O
lung	O
adenocarcinoma	O
A549	O
cells.	O

The	O
re-expression	O
of	O
the	O
pyruvate	O
transporters	O
MCP1	O
and	O
MCP2	O
was	B
associated	I
with	I
impaired	I
stem	I
cell	I
properties	O
in	O
vitro	O
and	O
in	O
a	O
mouse	O
xenograft	O
model	O
[30].	O

The	O
genetic	O
hallmark	O
of	O
invasive	O
TGCT	O
is	O
the	O
amplification	O
of	O
the	O
short	O
arm	O
of	O
chromosome	O
12,	O
usually	O
in	O
the	O
form	O
of	O
isochromosome	O
i(12p),	O
which	O
may	O
lead	O
to	O
the	O
activation	O
of	O
genes	O
located	O
here,	O
most	O
importantly	O
the	O
core	B
stem	I
cell	I
gene	O
NANOG	O
or	O
the	O
oncogene	O
KRAS.	O

Understanding	O
the	O
basis	O
for	O
specificity	O
in	O
KIR	O
binding	O
to	O
HLA-C	O
allotypes	O
is	O
also	O
relevant	O
to	O
hematopoietic	B
stem	I
cell	I
transplantation	O
for	O
the	O
treatment	O
of	O
certain	O
leukemias,	O
as	O
the	O
clinical	O
outcome	O
is	O
improved	O
when	O
donor	O
KIR	O
and	O
recipient	O
HLA-C	O
genes	O
are	O
mismatched	O
according	O
to	O
the	O
C1–C2	O
model	O
for	O
KIR	O
specificity	O
(16–18)..	O

Mitochondria	O
in	O
mesenchymal	B
stem	I
cell	I
biology	O
and	O
cell	O
therapy:	O
from	O
cellular	O
differentiation	O
to	O
mitochondrial	O
transfer.	O

Recent	O
advances	O
in	O
mesenchymal	B
stem	I
cell	I
immunomodulation:	O
the	O
role	O
of	O
microvesicles.	O

We	O
observed	O
that	O
excessive	O
ROS	O
production	O
via	O
an	O
oxidant	O
or	O
altered	O
Keap1/Nrf2	O
activity	O
can	O
effectively	O
disturb	O
the	O
equilibrium	O
of	O
stem	B
cell	I
fate,	O
favoring	O
GSC	O
differentiation	O
at	O
the	O
expense	O
of	O
GSC	O
self-renewal.	O

Foxo3a	O
is	O
essential	O
for	O
maintenance	O
of	O
the	O
hematopoietic	O
stem	B
cell	I
pool.	O

Regulation	O
of	O
stem	B
cell	I
maintenance	O
and	O
transit	O
amplifying	O
cell	O
proliferation	O
by	O
TGF-beta	O
signaling	O
in	O
Drosophila	O
spermatogenesis.	O

Somatic	O
control	O
over	O
the	O
germline	B
stem	I
cell	I
lineage	O
during	O
Drosophila	O
spermatogenesis.	O

Control	O
of	O
stem	B
cell	I
self-renewal	O
in	O
Drosophila	O
spermatogenesis	O
by	O
JAK-STAT	O
signaling.	O

AdSC-derived	O
organoids	O
require	O
segregation	O
of	O
tissue-specific	B
stem	I
cell	I
populations,	O
which	O
are	O
at	O
that	O
point	O
implanted	O
in	O
extracellular	O
matrix	O
(ECM)	O
and	O
engendered	O
in	O
combination	O
with	O
particular	O
tissue	O
development	O
components..	O

Cend1,	O
a	O
Story	O
with	O
Many	O
Tales:	B
From	I
Regulation	I
of	O
Cell	O
Cycle	O
Progression/Exit	O
of	O
Neural	O
Stem	O
Cells	O
to	O
Brain	O
Structure	O
and	O
Function.	O

Cend1,	O
a	O
Story	O
with	O
Many	O
Tales:	B
From	I
Regulation	I
of	O
Cell	O
Cycle	O
Progression/Exit	O
of	O
Neural	O
Stem	O
Cells	O
to	O
Brain	O
Structure	O
and	O
Function.	O

b	O
Bone	O
marrow	O
neutrophil	O
lineage	O
cells	O
can	O
be	O
divided	O
into	O
three	O
compartments:	O
the	O
stem	B
cell	I
pool	O
(stem	O
cells	O
and	O
pluripotent	O
progenitors),	O
the	O
mitotic	O
pool	O
and	O
the	O
post-mitotic	O
pool.	O

Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

PTTG1	O
oncogene	O
promotes	O
tumor	O
malignancy	O
via	O
epithelial	O
to	O
mesenchymal	O
transition	O
and	O
expansion	O
of	O
cancer	B
stem	I
cell	I
population.	O

Global	O
analysis	O
of	O
proliferation	O
and	O
cell	O
cycle	O
gene	O
expression	O
in	O
the	O
regulation	O
of	O
hematopoietic	O
stem	O
and	O
progenitor	O
cell	O
fates.	O
Deletion	O
of	O
the	O
NF-kappaB	O
subunit	O
p65/RelA	O
in	O
the	O
hematopoietic	O
compartment	O
leads	O
to	O
defects	O
in	O
hematopoietic	B
stem	I
cell	I
function.	O

For	O
the	O
gene	O
targeting	O
and	O
germline	O
transmission	O
to	O
generate	O
the	O
CftrTgH(neoim)Hgu	O
mice,	O
the	O
embryonal	B
stem	I
cell	I
line	O
E14	O
was	O
used	O
[2].	O

IL-9	O
enhances	O
the	O
growth	O
of	O
human	O
mast	O
cell	O
progenitors	O
under	O
stimulation	O
with	O
stem	B
cell	I
factor.	O

Association	O
of	O
stem	B
cell	I
factor	O
expression	O
in	O
nasal	O
polyp	O
epithelial	O
cells	O
with	O
aspirin	O
sensitivity	O
and	O
asthma.	O

Recently	O
lncRNAs	O
have	O
also	O
been	O
associated	O
with	O
the	O
maintenance	O
of	O
embryonic	B
stem	I
cell	I
pluripotency	O
[24,25].	O

Small	O
molecule	O
inhibitors	O
of	O
glycogen	O
synthase	O
kinase	O
beta	O
(GSK3β)	O
and	O
the	O
mitogen-activated	O
protein	O
kinase	O
(MAPK)	O
signaling	O
pathway	O
can	O
replace	O
some	O
of	O
the	O
reprogramming	O
factors	O
during	O
iPS	O
cell	O
generation	O
[7],	O
and	O
these	O
inhibitors	O
can	O
similarly	O
stabilize	O
the	O
LIF/serum-dependent	O
pluripotent	O
state	O
in	O
blastocyst-derived	B
stem	I
cells	I
or	O
iPS	O
cells	O
from	O
the	O
the	O
non-permissive	O
NOD	O
mouse	O
strain	O
[4],	O
[8],	O
[9],	O
[10].	O

GDF3,	O
a	O
BMP	O
inhibitor,	O
regulates	O
cell	O
fate	O
in	O
stem	B
cells	I
and	O
early	O
embryos.	O

The	O
RBP	O
Lin28	O
and	O
its	O
miRNA	O
target	O
let-7	O
are	O
important	O
players	O
in	O
stem	B
cell	I
differentiation	O
and	O
in	O
development	O
(reviewed	O
in	O
[66,103]).	O

Regulation	O
of	O
microRNA	O
function	O
in	O
somatic	B
stem	I
cell	I
proliferation	O
and	O
differentiation.	O

=	O
unavailable	O
;	O
CPX	O
=	O
copaxone;	O
NTZ	O
=	O
natalizumab;	O
IV-IgG	O
=	O
bi-monthly	O
pulsed	O
intravenous	O
immunoglobulin;	O
PE	O
=	O
plasma-exchange	O
2	O
months	O
before	O
lumbar	O
puncture;	O
ASCT	O
=	O
autologous	B
stem	I
cell	I
transplant	O
one	O
year	O
before	O
LP;	O
Cy	O
=	O
Cyclophosphamide;	O
RTX	O
=	O
rituximab	O
five	O
months	O
before	O
lumbar	O
puncture..	O

As	O
a	O
highly	O
conserved	O
signaling	O
system,	O
the	O
Wnt/Wg	O
pathway	O
holds	O
important	O
roles	O
throughout	O
development	O
from	O
stem	B
cell	I
maintenance	O
and	O
proliferation	O
to	O
differentiation	O
and	O
cell	O
fate	O
specification	O
[5].	O

The	O
most	O
definitive	O
studies	O
implicating	O
mast	O
cells	O
have	O
relied	O
on	O
the	O
use	O
of	O
mast	O
cell	O
deficient	O
mice,	O
most	O
commonly	O
those	O
with	O
mutations	O
in	O
Kit,	O
the	O
gene	O
encoding	O
c-kit,	O
the	O
stem	B
cell	I
factor	O
(SCF)	O
receptor	O
(W/Wv,	O
W−sh	O
mice)	O
or	O
in	O
Kitlg,	O
the	O
gene	O
encoding	O
the	O
c-kit	O
ligand,	O
SCF	O
(Sl/Sld	O
mice).	O

The	O
expression	O
of	O
stem	B
cell	I
protein	O
Piwil2	O
and	O
piR-932	O
in	O
breast	O
cancer.	O

These	O
small	O
pieces	O
of	O
RNAs	O
are	O
noncoding	O
nucleotides	O
that	O
modulate	O
transcriptional	O
and	O
post-transcriptional	O
variations	O
of	O
oncogene	O
and	O
tumor	O
suppressor	O
genes,	O
also	O
not	O
in	O
physiologic	O
processes	O
such	O
as	O
cell	O
differentiation,	O
proliferation,	O
cell	O
cycle	O
regulation,	O
self-renewal	O
capacity	O
of	O
stem	B
cells	I
and	O
apoptosis,	O
but	O
also	O
in	O
the	O
chemo-	O
and	O
radioresistance	O
ability	O
of	O
tumors	O
[16,17]..	O

For	O
instance,	O
HOXA1	O
and	O
TCF7L,	O
which	O
are	O
involved	O
in	O
stem	B
cell	I
maintenance,	O
are	O
hypomethylated	O
and	O
highly	O
expressed	O
[60],	O
while	O
epigenetic	O
silencing	O
(mediated	O
by	O
promoter	O
methylation	O
in	O
stem/progenitor	O
cells)	O
and	O
gene	O
body	O
methylation	O
(associated	O
with	O
expressed	O
genes	O
as	O
the	O
luminal-driving	O
transcription	O
factor	O
GATA3)	O
are	O
preferentially	O
found	O
in	O
luminal	O
cells	O
[60,61]..	O

Recently,	O
this	O
self-organizing	O
potential	O
has	O
been	O
highlighted	O
by	O
a	O
number	O
of	O
stem	B
cell	I
models	O
known	O
as	O
embryoids	O
that	O
can	O
recapitulate	O
different	O
aspects	O
of	O
embryogenesis	O
in	O
vitro.	O

Connexin	O
31	O
(GJB3)	O
deficiency	O
in	O
mouse	B
trophoblast	I
stem	I
cells	I
alters	O
giant	O
cell	O
differentiation	O
and	O
leads	O
to	O
loss	O
of	O
oxygen	O
sensing.	O

As	O
a	O
proof	O
of	O
principle	O
we	O
successfully	O
applied	O
this	O
approach	O
to	O
two	O
Arabidopsis	O
mutants	O
and	O
identified	O
a	O
novel	O
factor	O
required	O
for	O
stem	B
cell	I
activity..	O

SCHIZORIZA	O
encodes	O
a	O
nuclear	O
factor	O
regulating	O
asymmetry	O
of	O
stem	B
cell	I
divisions	O
in	O
the	O
Arabidopsis	O
root.	O

SCARECROW	O
is	O
involved	O
in	O
positioning	O
the	O
stem	B
cell	I
niche	O
in	O
the	O
Arabidopsis	O
root	O
meristem.	O

Infusion	O
of	O
haplo-identical	O
killer	O
immunoglobulin-like	O
receptor	O
ligand	O
mismatched	O
NK	O
cells	O
for	O
relapsed	O
myeloma	O
in	O
the	O
setting	O
of	O
autologous	B
stem	I
cell	I
transplantation.	O

Human	O
NIAM	O
is	O
involved	O
in	O
chromosome	O
segregation,	O
p53	O
regulation	O
and	O
cell	O
proliferation	O
in	O
somatic	O
cells,	O
but	O
its	O
role	O
in	O
embryonic	B
stem	I
cells	I
is	O
unknown.	O

Niam	O
is	O
easily	O
detected	O
in	O
whole	O
cell	O
extracts	O
of	O
mouse	B
embryonic	I
stem	I
cells	I
by	O
western	O
blot	O
using	O
monoclonal	O
antibodies,	O
indicating	O
that	O
it	O
is	O
reasonably	O
well	O
expressed	O
in	O
this	O
cell	O
type	O
(Fig.	O

The	O
histone	O
acetyltransferase	O
MOF	O
is	O
a	O
key	O
regulator	O
of	O
the	O
embryonic	B
stem	I
cell	I
core	O
transcriptional	O
network.	O

An	O
expanded	O
Oct4	O
interaction	O
network:	O
implications	O
for	O
stem	B
cell	I
biology,	O
development,	O
and	O
disease.	O

CSF1R	O
is	O
a	O
type	O
III	O
receptor	O
tyrosine	O
kinase	O
belonging	O
to	O
the	O
platelet-derived	O
growth	O
factor	O
(PDGF)	O
receptor	O
family	O
whose	O
members	O
include	O
PDGF-α	O
and	O
–β,	O
the	O
FMS-like	O
tyrosine	O
kinase	O
3	O
(FLT3)	O
and	O
the	O
receptor	O
for	O
stem	B
cell	I
factor	O
(c-KIT)6.	O

Concise	O
review:	O
fragile	O
X	O
proteins	O
in	O
stem	B
cell	I
maintenance	O
and	O
differentiation.	O

hEBs	O
are	O
spherical	O
colonies	O
of	O
differentiating	B
stem	I
cells	I
that	O
contain	O
cell	O
types	O
representative	O
of	O
all	O
three	O
embryonic	O
germ	O
layers	O
[4].	O

Some	O
of	O
the	O
most	O
effective	O
strategies	O
for	O
directing	O
the	O
differentiation	O
of	O
pluripotent	B
stem	I
cells	I
into	O
specific	O
cell	O
types	O
have	O
taken	O
advantage	O
of	O
our	O
understanding	O
of	O
human	O
development	O
(Table.	O

Examples	O
of	O
directed	O
differentiation	O
of	O
human	B
embryonic	I
stem	I
cells	I
into	O
specific	O
cell	O
types.	O

The	O
biological	O
importance	O
of	O
these	O
RNAs	O
in	O
stem	B
cell	I
biology	O
is	O
underscored	O
by	O
recent	O
studies	O
demonstrating	O
that	O
mESCs	O
lacking	O
the	O
miRNA-processing	O
enzyme	O
Dicer	O
display	O
differentiation	O
and	O
proliferation	O
defects	O
[53-56].	O

Although	O
detection	O
of	O
lineage-specific	O
genes	O
underlies	O
most	O
methods	O
for	O
selecting	O
specific	O
cell	O
types	O
from	O
differentiating	B
stem	I
cell	I
cultures,	O
a	O
few	O
cell	O
types,	O
such	O
as	O
cardiac	O
muscle	O
cells,	O
bear	O
unique	O
biochemical	O
properties	O
that	O
aid	O
in	O
their	O
isolation.	O

These	O
investigators	O
showed	O
that	O
appropriately	O
designed,	O
dual-FRET	O
molecular	O
beacon	O
pairs	O
can	O
identify	O
the	O
expression	O
of	O
specific	O
mRNAs	O
by	O
microscopy	O
and	O
flow	O
cytometry	O
and	O
facilitate	O
the	O
collection	O
of	O
specific	O
stem	O
cell	O
populations	O
by	O
cell	O
sorting	O
while	O
leaving	O
the	O
stem	B
cell	I
genome	O
intact	O
[6]..	O

Hydrodynamic	O
modulation	O
of	O
embryonic	B
stem	I
cell	I
differentiation	O
by	O
rotary	O
orbital	O
suspension	O
culture.	O

DGCR8	O
is	O
essential	O
for	O
microRNA	O
biogenesis	O
and	O
silencing	O
of	O
embryonic	B
stem	I
cell	I
self-renewal.	O

Developmental	O
expression	O
of	O
fibroblast	O
growth	O
factor	O
(FGF)	O
receptors	O
in	O
neural	B
stem	I
cell	I
progeny.	O

Effect	O
of	O
epithelial	B
stem	I
cell	I
transplantation	O
on	O
noise-induced	O
hearing	O
loss	O
in	O
adult	O
mice.	O

Klf4	O
is	O
a	O
zinc	O
finger	O
protein	O
that	O
also	O
functions	O
in	O
pluripotent	B
stem	I
cell	I
induction	O
but	O
it	O
is	O
also	O
a	O
regulator	O
of	O
endothelial	O
activation	O
in	O
response	O
to	O
pro-inflammatory	O
stimuli	O
and	O
TGFβ	O
signalling127,129.	O

Dendritic	O
cells,	O
MC3T3	O
cells,	O
patients’	O
serum	O
miR-146a	O
Osteoblasts,	O
bone	B
marrow	I
mesenchymal	I
stem	I
cells	I
Induction	O
of	O
cell	O
growth	O
arrest	O
and	O
senescence	O
of	O
osteogenic	O
cells.	O

Mesenchymal	B
stem	I
cells	I
adopt	O
lung	O
cell	O
phenotype	O
in	O
normal	O
and	O
radiation-induced	O
lung	O
injury	O
conditions.	O

Mesenchymal	B
stem	I
cell	I
therapy	O
protects	O
lungs	O
from	O
radiation-induced	O
endothelial	O
cell	O
loss	O
by	O
restoring	O
superoxide	O
dismutase	O
1	O
expression.	O

Cardiac	B
stem	I
cell	I
and	O
myocyte	O
aging,	O
heart	O
failure,	O
and	O
insulin-like	O
growth	O
factor-1	O
overexpression.	O

For	O
analysis	O
of	O
the	O
expression	O
profiles	O
of	O
key	O
genes	O
involved	O
in	O
stem	B
cell	I
properties	O
and	O
pluripotency,	O
total	O
RNA	O
was	O
extracted	O
with	O
the	O
mirVana™	O
RNA	O
isolation	O
kit	O
(Ambion).	O

Human	O
ES	O
cell-derived	O
neural	O
rosettes	O
reveal	O
a	O
functionally	O
distinct	O
early	O
neural	B
stem	I
cell	I
stage.	O

SISTEMA:	O
A	O
large	O
and	O
standardized	O
collection	O
of	O
transcriptome	O
data	O
sets	O
for	O
human	B
pluripotent	I
stem	I
cell	I
research.	O

SISTEMA:	O
A	O
large	O
and	O
standardized	O
collection	O
of	O
transcriptome	O
data	O
sets	O
for	O
human	B
pluripotent	I
stem	I
cell	I
research.	O

In	O
this	O
context,	O
we	O
present	O
SISTEMA,	O
a	O
quality-controlled	O
curated	O
gene	O
expression	O
database,	O
built	O
on	O
a	O
valuable	O
catalog	O
of	O
human	B
pluripotent	I
stem	I
cell	I
lines,	O
and	O
their	O
derivatives	O
for	O
which	O
transcriptomic	O
analyses	O
have	O
been	O
generated	O
using	O
a	O
single	O
experimental	O
pipeline.	O

SISTEMA	O
functions	O
as	O
a	O
one-step	O
resource	O
that	O
will	O
assist	O
the	O
stem	B
cell	I
community	O
to	O
easily	O
evaluate	O
the	O
expression	O
level	O
for	O
genes	O
of	O
interest,	O
while	O
comparing	O
them	O
across	O
different	O
hPSC	O
lines,	O
cell	O
types,	O
pathological	O
conditions,	O
or	O
after	O
pharmacological	O
treatments..	O

Other	O
genes	O
have	O
been	O
selected	O
based	O
on	O
the	O
literature	O
such	O
as	O
the	O
example	O
of	O
ID1	O
gene	O
that	O
belongs	O
to	O
a	O
family	O
called	O
“inhibitors	O
of	O
the	O
differentiation”	O
and	O
previously	O
described	O
to	O
be	O
specific	O
of	O
human	B
pluripotent	I
stem	I
cell	I
lines	O
(Aloia	O
et	O
al.,	O
2015;	O
Hong	O
et	O
al.,	O
2011)..	O

Since	O
the	O
derivation	O
of	O
the	O
first	O
human	O
embryonic	O
stem	O
cell	O
line	O
more	O
than	O
two	O
decades	O
ago	O
(Thomson	O
et	O
al.,	O
1998),	O
human	O
pluripotent	O
stem	O
cells	O
have	O
ushered	O
in	O
an	O
exciting	O
new	O
era	O
for	O
the	O
fields	O
of	O
stem	B
cell	I
biology	O
and	O
biomedical	O
research.	O

SISTEMA	O
functions	O
as	O
a	O
one-step	O
resource	O
that	O
will	O
assist	O
the	O
stem	B
cell	I
community	O
to	O
easily	O
evaluate	O
the	O
expression	O
level	O
for	O
their	O
genes	O
of	O
interest,	O
while	O
comparing	O
them	O
across	O
different	O
hPSC	O
lines,	O
cell	O
types,	O
pathological	O
conditions,	O
or	O
after	O
pharmacological	O
treatments	O
(Figure	O
6).	O

All	O
the	O
Human	B
embryonic	I
stem	I
cell	I
lines	O
indicated	O
in	O
SISTEMA	O
database	O
are	O
referenced	O
on	O
hPSCreg	O
and	O
listed	O
here:.	O

StemMapper:	O
a	O
curated	O
gene	O
expression	O
database	B
for	I
stem	I
cell	I
lineage	O
analysis.	O

To	O
achieve	O
this,	O
we	O
submit	O
that	O
a	O
better	O
understanding	O
of	O
stem	B
cell	I
trafficking	O
through	O
the	O
microvasculature	O
prior	O
to	O
incorporation	O
is	O
necessary	O
and	O
that	O
computational	O
modeling	O
techniques	O
could	O
speed	O
the	O
rate	O
of	O
discovery;	O
current	O
investigations	O
however	O
are	O
hampered	O
by	O
the	O
processes'	O
inherent	O
complexity.	O

Towards	O
this	O
end,	O
we	O
present	O
an	O
agent-based	O
computational	O
model	O
(ABM)	O
of	O
therapeutic	B
stem	I
cell	I
trafficking	O
during	O
skeletal	O
muscle	O
ischemia	O
that	O
is	O
capable	O
of	O
generating	O
new	O
hypotheses	O
quickly	O
and	O
cost-effectively..	O

Based	O
on	O
independent	O
in	O
vivo	O
experiments	O
wherein	O
hASCs	O
were	O
delivered	O
intravenously	O
to	O
ischemic	O
mouse	O
hindlimbs	O
and	O
a	O
review	O
of	O
relevant	B
stem	I
cell	I
literature	O
(Text	O
S1),	O
we	O
expected	O
the	O
efficiency	O
of	O
hASC	O
incorporation	O
into	O
ischemic	O
tissue	O
to	O
be	O
approximately	O
10%	O
of	O
the	O
total	O
cells	O
delivered,	O
which	O
would	O
also	O
be	O
3–5×	O
that	O
of	O
levels	O
quantified	O
in	O
non-ischemic	O
tissue.	O

The	O
ABM	O
of	O
therapeutic	B
stem	I
cell	I
trafficking	O
during	O
acute	O
skeletal	O
muscle	O
ischemia	O
was	O
created	O
through	O
modification	O
of	O
a	O
previously	O
developed	O
ABM	O
of	O
monocyte	O
trafficking	O
in	O
healthy	O
skeletal	O
muscle	O
microvasculature	O
[23].	O

Subsequently,	O
Neo-deleted	O
mESC	O
clones	O
were	O
isolated,	O
screened	O
by	O
PCR	O
(primers	O
F2	O
and	O
R2,	O
respectively:	O
5'-CGGCCTCGACTCTACGATACCGTCGATCC-3',	O
R2	O
5'-GGATCGAGATCTGATAACTTCGTA-3')	O
and	O
injected	O
into	O
B6	O
blastocysts,	O
which	O
were	O
subsequently	O
transferred	O
into	O
pseudo-pregnant	O
females	O
to	O
produce	O
chimeric	O
animals	O
at	O
the	O
Embryonic	B
Stem	I
Cell	I
Facility	O
of	O
IRGS	O
(Ariano	O
Irpino,	O
Avellino,	O
Italy).	O

Giangreco	O
A,	O
Reynolds	O
SD,	O
Stripp	O
BR	O
(2002)	O
Terminal	O
bronchioles	O
harbor	O
a	O
unique	O
airway	B
stem	I
cell	I
population	O
that	O
localizes	O
to	O
the	O
bronchoalveolar	O
duct	O
junction.	O

Ma	O
J,	O
Liu	O
Y,	O
Zhou	O
W,	O
Zhu	O
Y,	O
Dong	O
A	O
and	O
Shen	O
WH	O
(2018)	O
Histone	O
chaperones	O
play	O
crucial	O
roles	O
in	O
maintenance	O
of	O
stem	B
cell	I
niche	O
during	O
plant	O
root	O
development.	O

showed	O
that	O
the	O
self-renewal	O
and	O
phenotypic	O
properties	O
of	O
leukemia-initiating	O
cells	O
(SL-ICs)	O
in	O
BCR-ABL	O
p190	O
Ph-ALL	O
were	O
similar	O
to	O
those	O
of	O
normal	O
stem	O
cells,	O
suggesting	O
that	O
HSCs	O
act	O
as	O
cell	O
of	O
origin	O
in	O
CML	O
[10].	O
Upon	O
progression	O
to	O
BC-AML,	O
it	O
has	O
been	O
shown	O
that	O
the	O
phenotype	O
of	O
the	O
leukemia-maintaining	B
stem	I
cell	I
changes	O
and	O
starts	O
to	O
resemble	O
the	O
phenotype	O
of	O
granulocyte/macrophage	O
progenitors	O
(GMPs).	O

Later	O
studies	O
from	O
the	O
same	O
group	O
further	O
modified	O
this	O
tet-off	O
inducible	O
transgenic	O
model	O
by	O
placing	O
tTA	O
expression	O
under	O
control	O
of	O
the	O
3′	O
enhancer	O
of	O
the	O
murine	B
stem	I
cell	I
leukemia	O
(scl)	O
gene	O
[33].	O

NOD/SCID	O
mice	O
engineered	O
to	O
express	O
human	O
IL-3,	O
GM-CSF	O
and	O
steel	O
factor	O
constitutively	O
mobilize	O
engrafted	O
human	O
progenitors	O
and	O
compromise	O
human	B
stem	I
cell	I
regeneration.	O

In	O
addition	O
to	O
stem	B
cell	I
self‐renewal	O
and	O
the	O
maintenance	O
of	O
pluripotency,	O
defined	O
culture	O
is	O
essential	O
for	O
cellular	O
differentiation,	O
scale‐up,	O
and	O
biomedical	O
application.	O

Gene	O
networks	O
and	O
transcription	O
factor	O
motifs	O
defining	O
the	O
differentiation	O
of	O
stem	B
cell	I
into	O
hepatocyte‐like	O
cells.	O

In	O
the	O
context	O
of	O
regeneration,	O
this	O
can	O
result	O
in	O
depletion	O
of	O
stem/progenitor	O
cell	O
pools	O
[58],	O
loss	O
of	O
stem	B
cell	I
quiescence	O
[59],	O
premature	O
differentiation	O
[60]	O
and,	O
when	O
the	O
checkpoint	O
mechanisms	O
fail	O
and	O
the	O
DNA	O
damage	O
remains,	O
neoplastic	O
transformation..	O

Additionally,	O
DNA	O
repair	O
defects	O
such	O
as	O
those	O
found	O
in	O
cells	O
derived	O
from	O
Fanconi	O
anemia	O
patients	O
(which	O
have	O
defects	O
in	O
crosslink	O
repair	O
and	O
homologous	O
recombination	O
proteins)	O
can	O
predispose	O
cells	O
to	O
catastrophe	O
during	O
proliferation	O
bursts,	O
as	O
shown	O
in	O
the	O
case	O
of	O
haematopoietic	B
stem	I
cells	I
which	O
undergo	O
cell	O
death	O
following	O
physiological	O
challenges	O
such	O
as	O
substantial	O
blood	O
loss..	O

In	O
mice,	O
genetic	O
disruption	O
of	O
ATM	O
or	O
another	O
DNA	O
damage	O
sensor,	O
ATR,	O
causes	O
significant	O
age-dependent	O
perturbation	O
in	O
stem	B
cell	I
compartments.	O

Recently,	O
various	O
studies	O
have	O
found	O
age-dependent	O
abnormalities	O
in	O
expression	O
of	O
DNA	O
repair	O
genes	O
[65,66],	O
which	O
correlate	O
with	O
defects	O
in	O
stem	B
cell	I
functionality.	O

Many	O
reports	O
suggest	O
that	O
an	O
increase	O
in	O
p53	O
expression	O
or	O
activity	O
levels	O
can	O
lead	O
to	O
aging	O
and	O
reduced	O
lifespan,	O
and	O
lead	O
to	O
stem	B
cell	I
death	O
in	O
response	O
to	O
telomere	O
attrition	O
[74,75,76].	O

Interestingly,	O
the	O
effects	O
on	O
stem	B
cell	I
populations	O
vary	O
according	O
to	O
the	O
tissue.	O

ROS	O
could	O
then	O
trigger	O
stress	O
responses	O
such	O
as	O
apoptosis,	O
senescence	O
and	O
functional	O
changes	O
leading	O
to	O
stem	B
cell	I
dysfunction.	O

In	O
agreement	O
with	O
this,	O
accumulation	O
of	O
oxidative	O
damage	O
has	O
been	O
observed	O
in	O
mice	O
and	O
human	O
HSC	O
after	O
serial	O
transplantations,	O
which	O
leads	O
to	O
expression	O
of	O
cell	O
cycle	O
inhibitors	O
and	O
premature	O
senescence,	O
causing	O
loss	O
of	O
stem	B
cell	I
function	O
[117]..	O

In	O
addition,	O
a	O
recent	O
study	O
suggests	O
a	O
role	O
for	O
the	O
mitochondrial	O
unfolded	O
protein	O
response	O
(mtUPR)	O
in	O
stem	B
cell	I
aging	O
(see	O
below).	O

By	O
disrupting	O
Sirt7	O
in	O
mice,	O
they	O
showed	O
that	O
SIRT7	O
regulates	O
the	O
level	O
of	O
mUPR,	O
proliferation,	O
differentiation	O
and	O
reconstitution	O
abilities	O
in	O
the	O
haematopoietic	B
stem	I
cell	I
compartment.	O

For	O
example,	O
deletion	O
of	O
the	O
mTOR	O
regulator	O
TSC1,	O
which	O
enhances	O
mTOR	O
signalling,	O
leads	O
to	O
loss	O
of	O
quiescence	O
in	O
HSC	O
due	O
to	O
enhanced	O
proliferation	O
in	O
the	O
stem	B
cell	I
compartment	O
[162].	O

Likewise,	O
increased	O
mTOR	O
signalling	O
leads	O
to	O
epidermal	B
stem	I
cell	I
depletion	O
through	O
promotion	O
of	O
proliferation	O
[163],	O
which	O
can	O
be	O
counteracted	O
by	O
treatment	O
with	O
the	O
mTOR	O
inhibitor	O
rapamycin	O
[159].	O

melanogaster	O
have	O
uncovered	O
a	O
role	O
for	O
the	O
gut	O
microbiota	O
in	O
the	O
modulation	O
of	O
regenerative	O
responses,	O
by	O
showing	O
that	O
gut	O
bacteria	O
promote	O
intestinal	O
epithelium	O
renewal	O
through	O
the	O
induction	O
of	O
intestinal	B
stem	I
cell	I
proliferation	O
[212].	O

The	O
longest	O
telomeres:	O
A	O
general	O
signature	O
of	O
adult	B
stem	I
cell	I
compartments.	O

Accumulating	O
mitochondrial	O
DNA	O
mutations	O
drive	O
premature	O
hematopoietic	O
aging	O
phenotypes	O
distinct	O
from	O
physiological	B
stem	I
cell	I
aging.	O

P38	O
mapk	O
signaling	O
underlies	O
a	O
cell-autonomous	O
loss	O
of	O
stem	B
cell	I
self-renewal	O
in	O
skeletal	O
muscle	O
of	O
aged	O
mice.	O

Control	O
of	O
stem	B
cell	I
fate	O
by	O
physical	O
interactions	O
with	O
the	O
extracellular	O
matrix.	O

Rejuvenation	O
of	O
the	O
muscle	B
stem	I
cell	I
population	O
restores	O
strength	O
to	O
injured	O
aged	O
muscles.	O

The	O
planarian	O
flatworm:	O
An	O
in	O
vivo	O
model	O
for	O
stem	B
cell	I
biology	O
and	O
nervous	O
system	O
regeneration.	O

The	O
commitment	O
of	O
mesenchymal	B
stem	I
cells	I
to	O
osteogenic	O
progenitor	O
cells	O
is	O
influenced	O
by	O
Runx2,	O
FGF,	O
Wnt,	O
as	O
well	O
as	O
MITF	O
and	O
SATB2,	O
while	O
Osx,	O
Runx2,	O
NFATc1	O
promote	O
osteogenic	O
progenitor	O
cell	O
proliferation	O
to	O
preosteoblasts,	O
which	O
is	O
then	O
muture	O
into	O
mature	O
and	O
functional	O
osteoblasts	O
by	O
the	O
action	O
of	O
Runx2,	O
FGF,	O
Wnt,	O
NFATc1,	O
MITF	O
as	O
well	O
as	O
ATF4..	O

The	O
Wnt-β-catenin	O
signaling	O
pathway	O
is	O
an	O
evolutionarily	O
conserved	O
system	O
of	O
cell-cell	O
communication	O
that	O
plays	O
an	O
important	O
role	O
in	O
stem	B
cell	I
renewal,	O
cell	O
proliferation,	O
and	O
cell	O
differentiation.	O

Effects	O
of	O
low-level	O
laser	O
irradiation	O
on	O
mesenchymal	B
stem	I
cell	I
proliferation:	O
a	O
microarray	O
analysis.	O

Charron	O
D,	O
Suberbielle-Boissel	O
C,	O
Al-Daccak	O
R	O
(2009)	O
Immunogenicity	O
and	O
allogenicity:	O
a	O
challenge	O
of	O
stem	B
cell	I
therapy.	O

The	O
small	O
GTPase	O
RhoA	O
is	O
required	O
to	O
maintain	O
spinal	O
cord	O
neuroepithelium	O
organization	O
and	O
the	O
neural	B
stem	I
cell	I
pool.	O

miR-205	O
mimics	O
could	O
promote	O
the	O
restoration	O
of	O
chemosensitivity	O
to	O
gemcitabine	O
and	O
a	O
minimized	O
expression	O
of	O
stem	B
cell	I
markers	O
OCT3/4	O
and	O
CD44	O
[81].	O

The	O
other	O
face	O
of	O
ROS:	O
a	O
driver	O
of	O
stem	B
cell	I
expansion	O
in	O
colorectal	O
cancer.	O

Most	O
importantly,	O
these	O
cells	O
also	O
express	O
a	O
relatively	O
large	O
set	O
of	O
stem	B
cell	I
markers	O
(e.g.,	O
Cd44,	O
Id1,	O
Slug,	O
Klf4,	O
Sca1)10–14.	O

While	O
evidence	O
exists	O
for	O
both	O
the	O
mechanical	O
stress	O
and	O
gene	O
expression	O
models,	O
it	O
is	O
also	O
possible	O
that	O
lamins	O
are	O
required	O
for	O
adult	B
stem	I
cell	I
homeostasis	O
[8]..	O

Gesson	O
K,	O
Vidak	O
S,	O
Foisner	O
R	O
(2014)	O
Lamina-associated	O
polypeptide	O
(LAP)2alpha	O
and	O
nucleoplasmic	O
lamins	O
in	O
adult	B
stem	I
cell	I
regulation	O
and	O
disease.	O

Organoid	O
models	O
have	O
the	O
potential	O
to	O
contribute	O
to	O
the	O
ongoing	O
development	O
of	O
novel	O
treatments	O
and	O
to	O
the	O
identification	O
of	O
the	O
GEP-NEN	B
stem	I
cell	I
of	O
origin,	O
which	O
could	O
lead	O
to	O
the	O
eventual	O
eradication	O
of	O
these	O
diseases.	O

MicroRNAs	O
(miRNAs)	O
are	O
differentially	O
expressed	O
between	O
CSCs	O
and	O
non-tumorigenic	O
cancer	O
cells,	O
and	O
play	O
important	O
roles	O
in	O
the	O
maintenance	O
and	O
regulation	O
of	O
stem	B
cell	I
properties	O
of	O
CSCs.	O

Existence	O
of	O
interplay	O
between	O
RBPs	O
and	O
RNAs	O
is	O
crucial	O
for	O
various	O
biological	O
processes,	O
such	O
as	O
development	O
and	O
maintenance	O
of	O
stem	B
cell	I
phenotypes..	O

Colorectal	O
CSCs	O
share	O
a	O
part	O
of	O
the	O
stem	B
cell	I
properties	O
with	O
normal	O
intestinal	O
stem/progenitor	O
cells,	O
and	O
cellular	O
composition	O
shows	O
some	O
similarities	O
between	O
colorectal	O
tumors	O
and	O
the	O
normal	O
colorectal	O
epithelium.	O

A	O
subset	O
of	O
CD166-positive	O
CBCs	O
co-express	O
the	O
stem	B
cell	I
markers,	O
LGR5,	O
Musashi-1(MSI1),	O
or	O
doublecortin-like	O
kinase	O
1(DCLK1).	O

In	O
addition,	O
the	O
number	O
of	O
Lgr5+	B
stem	I
cell	I
is	O
decreased	O
and	O
architecture	O
of	O
the	O
intestinal	O
epithelium	O
is	O
disrupted	O
in	O
the	O
intestinal	O
crypts	O
of	O
CD166−/−	O
mice	O
[70].	O

Although	O
the	O
number	O
of	O
studies	O
that	O
analyzed	O
the	O
miRNA	O
expression	O
and/or	O
functions	O
in	O
colorectal	O
CSCs	O
is	O
still	O
limited,	O
miRNAs,	O
such	O
as	O
miR-200	O
family	O
miRNAs,	O
miR-203,	O
miR-137,	O
miR-34a	O
and	O
miR-221,	O
function	O
as	O
the	B
regulator	I
of	I
stem	I
cell	I
properties	O
in	O
colorectal	O
CSCs	O
by	O
targeting	O
various	O
genes	O
involved	O
in	O
the	O
regulation	O
of	O
CSC	O
properties	O
(Figure	O
2A).	O

miR-34a,	O
miR-200b/c,	O
miR-203	O
and	O
miR-137	O
are	O
downregulated	O
in	O
colorectal	O
CSCs	O
and	O
suppress	O
the	O
stem	B
cell	I
properties	O
of	O
CSCs.	O

Among	O
them,	O
the	O
expression	O
of	O
miR-200bc	O
and	O
miR-203	O
is	O
coordinately	O
regulated,	O
and	O
these	O
miRNAs	O
coordinately	O
function	O
for	O
the	O
suppression	O
of	O
the	O
stem	B
cell	I
properties	O
of	O
CSCs.	O

In	O
contrast,	O
miR-221	O
is	O
highly	O
expressed	O
in	O
CSCs	O
and	O
enhances	O
the	O
stem	B
cell	I
properties	O
of	O
CSCs.	O

Among	O
them,	O
miR-200bc	O
and	O
miR-203	O
coordinately	O
suppressed	O
the	O
stem	B
cell	I
properties	O
of	O
colorectal	O
CSCs	O
and	O
normal	O
intestinal	O
stem/progenitor	O
cells.	O

These	O
miRNAs	O
regulate	O
the	O
genes	O
involved	O
in	O
shaping	O
the	O
self-renewal	O
and	O
proliferative	O
properties	O
of	O
stem	B
cell	I
populations,	O
such	O
as	O
BMI1and	O
ZEB1,	O
and	O
the	O
expression	O
of	O
these	O
miRNAs	O
is	O
negatively	O
regulated	O
by	O
ZEB1.	O

miR-203	O
plays	O
important	O
role	O
in	O
stem	B
cell	I
regulation	O
by	O
targeting	O
p63	O
and/or	O
BMI1.	O

p63	O
is	O
an	O
essential	O
regulator	O
of	O
stem	B
cell	I
maintenance	O
in	O
the	O
skin	O
epithelium,	O
and	O
promotes	O
epidermal	O
differentiation	O
[88].	O

Several	O
studies	O
showed	O
that	O
LIN28A/B	O
are	O
among	O
the	O
stem	B
cell	I
pluripotency	O
factors.	O

In	O
colon	O
cancer,	O
tumors	O
with	O
constitutive	O
LIN28B	O
expression	O
exhibit	O
increased	O
expression	O
of	O
colorectal	B
stem	I
cell	I
markers,	O
LGR5,	O
KIT	O
and	O
PROM1	O
(CD133)	O
[145].	O

Several	O
lines	O
of	O
evidence	O
support	O
that	O
QKI	O
will	O
be	O
a	O
novel	O
regulator	O
of	O
stem	B
cell	I
properties.	O

QKI	O
epigenetically	O
regulates	O
the	O
expression	O
of	O
multiple	O
genes	O
involved	O
in	O
stem	B
cell	I
maintenance	O
and	O
differentiation,	O
such	O
as	O
SOX2,	O
NANOG	O
and	O
OCT4	O
[208,215].	O

QKI	O
deletion	O
on	O
a	O
Pten−/−;	O
Trp53−/−	O
background	O
enhances	O
the	O
maintenance	O
of	O
neural	B
stem	I
cell	I
function	O
and	O
results	O
in	O
glioblastoma	O
formation	O
with	O
a	O
penetrance	O
of	O
92%..	O

Increased	O
expression	O
of	O
the	O
adult	B
stem	I
cell	I
marker	O
musashi-1	O
in	O
endometriosis	O
and	O
endometrial	O
carcinoma.	O

The	O
promise(s)	O
of	O
mesenchymal	B
stem	I
cell	I
therapy	O
in	O
averting	O
preclinical	O
diabetes:	O
lessons	O
from	O
in	O
vivo	O
and	O
in	O
vitro	O
model	O
systems.	O

Obesity	O
(Ob)	O
poses	O
a	O
significant	O
risk	O
factor	O
for	O
the	O
onset	O
of	O
metabolic	O
syndrome	O
with	O
associated	O
complications,	O
wherein	O
the	O
Mesenchymal	B
Stem	I
Cell	I
(MSC)	O
therapy	O
shows	O
pre-clinical	O
success.	O

Schematic	O
representation	O
of	O
Human	O
Placental	O
Mesenchymal	B
Stem	I
Cell	I
Therapy	O
in	O
obesity-induced	O
diabetes.	O

Age-associated	O
inflammation	O
connects	O
RAS-induced	O
senescence	O
to	O
stem	B
cell	I
dysfunction	O
and	O
epidermal	O
malignancy.	O

The	O
timing	O
and	O
pattern	O
of	O
Serping1	O
expression	O
suggested	O
that	O
this	O
gene	O
may	O
participate	O
in	O
neuronal	B
stem	I
cell	I
proliferation..	O

To	O
investigate	O
the	O
role	O
of	O
Serping1	O
in	O
regulation	O
of	O
neuronal	B
stem	I
cell	I
proliferation	O
during	O
mouse	O
embryonic	O
brain	O
development	O
two	O
models	O
were	O
used.	O

Neuronal	B
stem	I
cell	I
proliferation	O
was	O
tested	O
by	O
application	O
of	O
a	O
short	O
IdU	O
pulse,	O
which	O
is	O
incorporated	O
during	O
S	O
phase	O
following	O
by	O
immunostaining	O
of	O
embryonic	O
brain	O
sections	O
using	O
the	O
respective	O
antibodies.	O

Serping1	O
has	O
been	O
reported	O
to	O
be	O
expressed	O
in	O
the	O
SVZ	O
basal	O
progenitors	O
(Kawaguchi	O
et	O
al.,	O
2008),	O
yet	O
our	O
study	O
is	O
the	O
first	O
demonstrating	O
a	O
direct	O
role	O
for	O
this	O
gene	O
product	O
in	O
neuronal	B
stem	I
cell	I
proliferation.	O

On	O
the	O
other	O
hand,	O
subpopulations	O
of	O
cancer	O
stems	O
cells	O
have	O
been	O
previously	O
identified	O
in	O
head	O
and	O
neck	O
cancers,	O
by	O
the	O
application	O
of	O
stem	B
cell	I
science	O
[208].	O

Identification	O
of	O
a	O
subpopulation	O
of	O
cells	O
with	O
cancer	B
stem	I
cell	I
properties	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma.	O

Moreover,	O
pre-miR-137	O
significantly	O
decreased	O
the	O
self-renewal	O
of	O
GSCs	O
and	O
the	O
stem	B
cell	I
markers	O
Oct4,	O
Nanog,	O
Sox2	O
and	O
Shh.	O

Moreover,	O
miR-137	O
decreased	O
the	O
self-renewal	O
ability	O
of	O
the	O
GSCs	O
and	O
the	O
expression	O
of	O
the	O
stem	B
cell	I
associated	O
proteins	O
Nanog,	O
Shh,	O
Oct4	O
and	O
Sox2.	O

We	O
found	O
that	O
silencing	O
of	O
RTVP-1	O
decreased	O
the	O
expression	O
of	O
CXCR4	O
which	O
has	O
been	O
associated	O
with	O
cancer	B
stem	I
cell	I
characteristics	O
in	O
various	O
types	O
of	O
tumors	O
[38,	O
39].	O

The	O
core	O
signaling	O
pathways	O
involved	O
in	O
cancer	B
stem	I
cell	I
self-renewal	O
include	O
the	O
WNT,	O
Hedgehog,	O
Notch,	O
BMI,	O
PTEN,	O
BMP	O
and	O
TGF-β	O
pathways	O
[6].	O

Tumor	O
suppressors	O
that	O
inhibit	O
cancer	O
cell	O
proliferation,	O
such	O
as	O
p53,p16INK4a	O
and	O
p19ARF,	O
also	O
inhibit	B
stem	I
cell	I
self-renewal	O
[41].	O

In	O
the	O
SCLtTA/BCR-ABL	O
transgenic	O
mouse	O
model	O
of	O
leukemogenesis	O
the	O
expression	O
of	O
P210	O
BCR-ABL	O
is	O
regulated	O
by	O
a	O
tetracycline-controlled	O
transactivator	O
(tTA)	O
under	O
the	O
control	O
of	O
the	O
murine	B
stem	I
cell	I
leukaemia	O
gene	O
3’	O
enhancer	O
(SCL),	O
specifically	O
driving	O
expression	O
of	O
BCR-ABL	O
in	O
the	O
stem	O
and	O
progenitor	O
cells	O
of	O
the	O
hematopoietic	O
system	O
when	O
tetracycline	O
is	O
removed	O
from	O
the	O
drinking	O
water	O
[42]	O
(Fig.	O

Analysis	O
of	O
common	O
insertion	O
sites	O
revealed	O
disruption	O
of	O
a	O
number	O
of	O
genes	O
with	O
known	O
associations	O
with	O
CML	O
progression,	O
particularly	O
genes	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
the	O
stem	B
cell	I
compartment,	O
and	O
progression	O
to	O
BC	O
in	O
the	O
model	O
displayed	O
gene	O
expression	O
profiles	O
comparable	O
to	O
those	O
of	O
human	O
BC.	O

Impact	O
of	O
malignant	B
stem	I
cell	I
burden	O
on	O
therapy	O
outcome	O
in	O
newly	O
diagnosed	O
chronic	O
myeloid	O
leukemia	O
patients.	O

Enhanced	O
ADCC	O
activity	O
of	O
affinity	O
maturated	O
and	O
Fc-engineered	O
mini-antibodies	O
directed	O
against	O
the	O
AML	B
stem	I
cell	I
antigen	O
CD96.	O

Identification	O
of	O
the	O
haematopoietic	B
stem	I
cell	I
niche	O
and	O
control	O
of	O
the	O
niche	O
size.	O

Increasing	O
evidence	O
suggests	O
that	O
miRNA	O
regulation	O
and	O
function	O
in	O
pluripotent	B
stem	I
cells	I
and	O
somatic	O
cell	O
reprogramming	O
is	O
vital	O
for	O
the	O
advancement	O
of	O
regenerative	O
medicine.	O

microRNAs	O
as	O
novel	O
regulators	O
of	O
stem	B
cell	I
pluripotency	O
and	O
somatic	O
cell	O
reprogramming.	O

p18Ink4c	O
Collaborates	O
with	O
Men1	O
to	O
Constrain	O
Lung	B
Stem	I
Cell	I
Expansion	O
and	O
Suppress	O
Non-Small-Cell	O
Lung	O
Cancers.	O

The	O
CRISPR/Cas	O
system	O
could	O
efficient	O
manipulate	O
the	O
genome	O
without	O
complicated	O
procedures	O
[129],	O
which	O
accelerates	O
the	O
stem	B
cell	I
study.	O

The	O
iPSCs	O
are	O
originally	O
generated	O
by	O
reprogramming	O
of	O
somatic	O
cells	O
with	O
Yamanaka	O
factors	O
into	O
ESCs-like	O
cells	O
that	O
resemble	O
their	O
pluripotency	O
and	O
epigenetic	O
status,	O
thus	O
iPSCs	O
are	O
considered	O
as	O
the	O
ideal	O
objects	O
to	O
perform	B
stem	I
cell	I
therapy	O
without	O
the	O
ethic	O
concerns.	O

Therefore,	O
genome	O
editing	O
with	O
CRISPR/Cas	O
system	O
accelerates	O
the	O
generation	O
of	O
stem	B
cell	I
lines,	O
especially	O
disease	O
models..	O

From	O
the	O
table,	O
we	O
observe	O
that	O
the	O
network	O
specific	O
to	O
stem	B
cell	I
has	O
the	O
largest	O
in-degree	O
and	O
out-degree.	O

These	O
genes	O
have	O
diverse	O
functions	O
ranging	O
from	O
embryonic	B
stem	I
cell	I
co-activator	O
(UTF1)	O
to	O
osmoregulation	O
(SCT).	O

The	O
mouse	O
cells	O
were	O
then	O
prestimulated	O
in	O
StemSpam	O
SFEM	O
(serum-free	O
expansion	O
medium,	O
StemCells	O
Technologies,	O
Canada)	O
with	O
50ng/mL	O
mouse	B
Stem	I
Cell	I
Factor	O
(mSCF)	O
(R&D	O
Systems,	O
Minneapolis,	O
USA),	O
100ng/mL	O
human	O
Interleukin-11	O
(hIL-11),	O
100ng/mL	O
human	O
Flt-3	O
Ligand	O
(hFlt-3L)	O
and	O
10ng/mL	O
human	O
Interleukin-3	O
(hIL-3)	O
(PeproTech,	O
Rocky	O
Hill,	O
NJ,	O
USA)	O
for	O
4-6	O
hours.	O

Comparative	O
Analysis	O
Between	O
Flaviviruses	O
Reveals	O
Specific	O
Neural	B
Stem	I
Cell	I
Tropism	O
for	O
Zika	O
Virus	O
in	O
the	O
Mouse	O
Developing	O
Neocortex.	O

This	O
mutation	O
accelerates	O
HSC	O
cycling,	O
thereby	O
increasing	O
the	O
stem	B
cell	I
pool	O
and	O
elevating	O
short-term	O
and	O
long-term	O
repopulating	O
capabilities	O
[73].	O

Pioneer	O
factors	O
govern	O
super-enhancer	O
dynamics	O
in	O
stem	B
cell	I
plasticity	O
and	O
lineage	O
choice.	O

Cell	O
therapy	O
applies	O
the	O
biochemical	O
and	O
biophysical	O
properties	O
of	O
stem	B
cells	I
to	O
generate	O
healthy	O
tissues	O
and	O
repair	O
damaged	O
organs,	O
preventing	O
them	O
from	O
further	O
damage[20].	O

Further	O
advancement	O
in	O
stem	B
cell	I
therapy	O
happened	O
with	O
identifying	O
pluripotency	O
of	O
ESCs	O
in	O
1998[22].	O

First	O
trimester	O
fetal	O
MSCs	O
express	O
baseline	O
levels	O
of	O
pluripotent	B
stem	I
cell	I
markers	O
such	O
as	O
Oct4,	O
Nanog,	O
Rex1	O
SSEA3,	O
SSEA4,	O
Tra-1-60,	O
and	O
Tra-1-81.	O

Overcomes	O
the	O
ethical	O
concerns	O
associated	O
with	O
embryonic	B
stem	I
cell	I
research	O
and	O
clinical	O
use.	O

It	O
could	O
find	O
out	O
the	O
equivalent	O
stage	O
of	O
human	O
PSC	O
differentiation	O
products	O
along	O
with	O
the	O
identification	O
of	O
stem	B
cell	I
derivatives.	O

Nevertheless,	O
AI-driven	O
methods	O
have	O
emerged	O
as	O
an	O
important	O
component	O
of	O
stem	B
cell	I
research.	O

Mesenchymal	B
Stem	I
Cell	I
Secretome:	O
Toward	O
Cell-Free	O
Therapeutic	O
Strategies	O
in	O
Regenerative	O
Medicine.	O

Trends	O
in	O
mesenchymal	B
stem	I
cell	I
clinical	O
trials	O
2004-2018:	O
Is	O
efficacy	O
optimal	O
in	O
a	O
narrow	O
dose	O
range?	O
Stem	O
Cells	O
Transl	O
Med.	O

In	O
this	O
review,	O
we	O
summarize	O
the	O
structural	O
and	O
functional	O
properties	O
of	O
astrocytes,	O
including	O
the	O
unique	O
features	O
of	O
human	O
astrocytes;	O
demonstrate	O
the	O
necessity	O
of	O
the	O
stem	B
cell	I
platform;	O
and	O
discuss	O
how	O
this	O
platform	O
has	O
been	O
applied	O
to	O
the	O
research	O
of	O
neurodevelopmental	O
and	O
neuropsychiatric	O
diseases..	O

These	O
important	O
studies	O
demonstrated	O
the	O
feasibility	O
of	O
studying	O
DS	O
using	O
the	O
stem	B
cell	I
model	O
and	O
partially	O
verified	O
observations	O
from	O
mouse	O
models..	O

In	O
conclusion,	O
the	O
observed	O
advantageous	O
qualities	O
of	O
stem	B
cells	I
and	O
oligodendroglia‐biased	O
progenitors	O
significantly	O
contribute	O
to	O
anticipating	O
a	O
clinical	O
improvement	O
in	O
cell	O
replacement	O
therapies..	O

Currently	O
our	O
research	O
focuses	O
on	O
rescuing	O
the	O
maturation	O
inhibition	O
in	O
vitro,	O
which	O
can	O
aid	O
the	O
development	O
of	O
stem	B
cell	I
therapy	O
for	O
VWM..	O

Thus,	O
we	O
tested	O
the	O
ability	O
of	O
ADPβS,	O
a	O
stable	O
P2Y1	O
agonist,	O
to	O
modulate	B
stem	I
cell	I
properties	O
in	O
the	O
adult	O
brain,	O
with	O
a	O
focus	O
on	O
the	O
possible	O
modulatory	O
effects	O
exerted	O
by	O
reactive	O
astrocytes.	O

Methods:	O
To	O
this	O
end	O
we	O
analyzed	O
cellular	O
morphologies,	O
expression	O
and	O
regulation	O
of	O
key	O
genes/proteins	O
involved	O
in	O
oligodendroglial	O
cell	O
fate	O
and	O
maturation	O
upon	O
incubation	O
with	O
mesenchymal	B
stem	I
cell	I
conditioned	O
medium..	O

Using	O
this	O
system,	O
we	O
removed	O
microglia	O
from	O
the	O
adult	O
hippocampal	O
neurogenic	O
niche	O
and	O
evaluated	O
the	O
effects	O
of	O
this	O
manipulation	O
on	O
neurogenesis	O
and	O
hippocampal	O
homeostasis,	O
including	O
immunohistochemical	O
analyses	O
of	O
stem	B
cell	I
survival	O
and	O
proliferation,	O
as	O
well	O
as	O
analyses	O
of	O
neuroblast	O
development,	O
migration	O
and	O
electrophysiological	O
activity.	O

Among	O
these,	O
astrocytes	O
within	O
the	O
injury	O
site	O
may	O
represent	O
a	O
novel	O
source	O
of	O
cells	O
with	O
stem	B
cell	I
potential.	O

The	O
treatment	O
was	O
devised	O
to	O
accomplish	O
an	O
optimal	O
effect	O
on	O
the	O
stem	B
cell	I
regeneration.	O

Here	O
we	O
addressed	O
first	O
the	O
question	O
to	O
which	O
extent	O
the	O
type	O
of	O
injury	O
selectively	O
affects	O
the	O
proliferative	O
response	O
of	O
NG2	O
glia	O
and	O
astrocytes	O
and	O
to	O
which	O
extent	O
the	O
proliferative	O
reaction	O
of	O
astrocytes	O
may	O
be	O
linked	O
to	O
the	O
stem	B
cell	I
response.	O

There	O
has	O
been	O
much	O
recent	O
interest	O
in	O
the	O
use	O
of	O
intraocular	B
stem	I
cell	I
transplantation	O
to	O
slow	O
or	O
reverse	O
visual	O
loss	O
in	O
glaucoma.	O

Mesenchymal	B
stem	I
cell	I
transplantation	O
has	O
been	O
proven	O
to	O
have	O
beneficial	O
effects	O
in	O
various	O
degenerative	O
diseases,	O
including	O
demyelinating	O
models.	O

Alternatively,	O
random	O
gene	O
insertion,	O
by	O
lenti-viruses	O
for	O
instance,	O
can	O
reduce	O
cloning	O
cycles	O
significantly,	O
yet	O
transgenes	O
that	O
are	O
integrated	O
during	O
the	O
stem	B
cell	I
stage	O
may	O
be	O
downregulated	O
during	O
differentiation	O
(Xia	O
et	O
al.,	O
2007).	O

An	O
overview	O
of	O
human	B
stem	I
cell	I
models	O
utilized	O
to	O
study	O
the	O
cellular	O
pathology	O
of	O
MND	O
in	O
vitro.	O

As	O
expected,	O
various	O
molecular	O
and	O
cellular	O
manipulations	O
did	O
demonstrate	O
that	O
TERT	O
and	O
BRG1	O
depend	O
on	O
each	O
other	O
to	O
stimulate	O
β-catenin-mediated	O
promoter	O
activation	O
and	O
target	O
gene	O
transcription,	O
through	O
which	O
the	O
β-catenin-regulated	B
stem	I
cell	I
program	O
of	O
self-renewal,	O
proliferation	O
or	O
survival	O
are	O
achieved	O
[8].	O

NS	O
is	O
a	O
self-renewal	O
factor	O
involved	O
in	O
stem	B
cell	I
self-renewal	O
and	O
proliferation	O
[66].	O

Appropriate	O
TERT/telomerase	O
expression	O
is	O
required	O
for	O
stem	B
cell	I
biology,	O
tissue	O
homeostasis,	O
and	O
physiological	O
aging,	O
while	O
the	O
aberrant	O
TERT	O
gene	O
de-repression/telomerase	O
reactivation	O
is	O
essential	O
to	O
malignant	O
transformation	O
of	O
human	O
cells.	O

Human	B
embryonic	I
stem	I
cells	I
were	O
first	O
derived	O
by	O
Thompson's	O
group	O
in	O
1998	O
[3]	O
and	O
are	O
usually	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
(ICM)	O
of	O
blastocyst	O
stage	O
embryos	O
that	O
are	O
left	O
over	O
after	O
in	O
vitro	O
fertilization	O
(IVF)	O
and	O
after	O
embryo	O
donations	O
[4].	O

Also	O
the	O
derivation	O
of	O
embryonic	B
stem	I
cell	I
lines	O
that	O
are	O
"HLA-homozygous,"	O
now	O
provides	O
avenues	O
to	O
overcome	O
the	O
problem	O
of	O
immune	O
rejection	O
and	O
may	O
pave	O
way	O
to	O
utilize	O
ESCs	O
as	O
therapeutics	O
[67].	O

Adult	B
stem	I
cell	I
plasticity:	O
fact	O
or	O
artifact?	O
Annu	O
Rev	O
Cell	O
Dev	O
Biol.	O

Restriction	O
landmark	O
genome	O
scanning	O
identifies	O
culture-induced	O
DNA	O
methylation	O
instability	O
in	O
the	O
human	B
embryonic	I
stem	I
cell	I
epigenome.	O

Embryonic	O
stem	O
cell	O
derived	O
and	O
adult	O
hematopoietic	O
stem	B
cell	I
transplantation	O
for	O
tolerance	O
induction	O
in	O
a	O
renal	O
allograft	O
recipient:	O
–	O
a	O
case	O
report.	O

Rac1	O
is	O
required	O
for	O
epithelial	B
stem	I
cell	I
function	O
during	O
dermal	O
and	O
oral	O
mucosal	O
wound	O
healing	O
but	O
not	O
for	O
tissue	O
homeostasis	O
in	O
mice.	O

The	O
in	O
vivo	O
approaches	O
in	O
Ciona	O
overcome	O
major	O
shortcomings	O
of	O
classical	O
model	O
organisms	O
in	O
the	O
quest	O
of	O
unraveling	O
conserved	O
mechanisms	O
in	O
the	O
chordate	O
developmental	O
program,	O
relevant	O
to	O
stem	B
cell	I
research,	O
drug	O
discovery,	O
and	O
subsequent	O
clinical	O
application..	O

Circ-Foxo3	O
Knockdown	O
Mesenchymal	O
Stem	O
Cells	O
Promotes	O
cell	O
proliferation	O
Du	O
et	O
al	O
(2016)	O
7.	O

This	O
is	O
possible	O
due	O
to	O
recent	O
technological	O
leaps	O
in	O
stem	B
cell	I
research,	O
which	O
enable	O
lab-grown	O
human	O
mini-brains	O
that	O
reproduce	O
the	O
hallmarks	O
of	O
AD.375,376	O
The	O
mini-brains	O
(as	O
an	O
alternative	O
AD	O
model)	O
allow	O
for	O
testing	O
of	O
various	O
invivo-based	O
hypotheses	O
and	O
to	O
gather	O
complementary	O
and	O
complex	O
information	O
that	O
perhaps	O
is	O
missed	O
in	O
transgenic	O
animal	O
models.	O

A	O
novel	O
class	O
of	O
evolutionarily	O
conserved	O
genes	O
defined	O
by	O
piwi	O
are	O
essential	O
for	O
stem	B
cell	I
self-renewal.	O

Germline	B
stem	I
cell	I
gene	O
PIWIL2	O
mediates	O
DNA	O
repair	O
through	O
relaxation	O
of	O
chromatin.	O

The	O
expression	O
of	O
stem	B
cell	I
protein	O
Piwil2	O
and	O
piR-932	O
in	O
breast	O
cancer.	O

The	O
identification	O
of	O
the	O
cell	O
type	O
from	O
which	O
cancer	O
arises	O
may	O
provide	O
some	O
key	O
insights	O
into	O
the	O
sensitivity	O
of	O
cancer	O
cells	O
to	O
targeted	O
therapies	O
(for	O
example,	O
if	O
cancer	O
cells	O
retain	O
similar	O
signaling	O
networks	O
with	O
the	O
cell	O
of	O
origin)	O
and	O
may	O
help	O
researchers	O
understand	O
how	O
tumors	O
gain	O
heterogeneous	O
features,	O
including	O
the	O
evolution	O
of	O
cancer	B
stem	I
cells	I
and	O
their	O
progeny	O
within	O
tumors	O
(reviewed	O
by	O
Gilbertson	O
2011	O
and	O
Visvader	O
2011)..	O

It	O
is	O
also	O
sometimes	O
difficult	O
to	O
tease	O
apart	O
heterogeneity	O
related	O
to	O
epigenetic	O
differences	O
(following	O
the	O
cancer	B
stem	I
cell	I
model)	O
and	O
heterogeneity	O
related	O
to	O
genetic	O
differences	O
(following	O
a	O
clonal	O
evolution	O
model)	O
(Shackleton	O
et	O
al.	O

lupus	O
nephritis,	O
GVHD	O
complication	O
of	O
stem	B
cell	I
transplant	O
and	O
pregnancy)	O
as	O
aHUS	O
(when	O
the	O
differential	O
diagnoses	O
have	O
been	O
excluded)	O
can	O
result	O
in	O
significantly	O
improved	O
outcomes	O
when	O
treating	O
the	O
primary	O
disease	O
fails	O
to	O
resolve	O
the	O
TMA	O
[11–13,	O
69–72].	O

This	O
switch	O
from	O
canonical	O
to	O
noncanonical	O
WNT	O
signalling	O
also	O
occurs	O
in	O
haematopoietic	B
stem	I
cell	I
ageing	O
[23].	O

Cell	O
cultures	O
can	O
be	O
guided	O
from	O
the	O
pluripotent	B
stem	I
cell	I
stage	O
to	O
alveolar	O
epithelium	O
by	O
recapitulating	O
normal	O
development	O
in	O
a	O
stepwise	O
process	O
termed	O
directed	O
differentiation.	O

In	O
our	O
cell-fate	O
mapping	O
and	O
in	O
vivo	O
retinal	O
imaging	O
experiments,	O
we	O
ascertained	O
that	O
microglial	O
repopulation	O
originated	O
from	O
residual	O
CX3CR1-expressing	O
microglia	O
and	O
that	O
microglial	O
proliferation	O
occurred	O
in	O
situ	O
within	O
the	O
retina	O
proper,	O
rather	O
than	O
arising	O
from	O
CX3CR1-negative	B
stem	I
cell	I
precursors	O
that	O
subsequently	O
differentiated	O
into	O
microglia	O
(5).	O

Role	O
of	O
stem	B
cell	I
proteins	O
and	O
microRNAs	O
in	O
embryogenesis	O
and	O
germ	O
cell	O
cancer.	O

Selective	O
purging	O
of	O
human	O
multiple	O
myeloma	O
cells	O
from	O
autologous	B
stem	I
cell	I
transplantation	O
grafts	O
using	O
oncolytic	O
myxoma	O
virus.	O

Modulation	O
of	O
embryonic	B
stem	I
cell	I
fate	O
and	O
somatic	O
cell	O
reprogramming	O
by	O
small	O
molecules.	O

Direct	O
cocultures	O
of	O
CFBE41o–	O
cells	O
with	O
mesenchymal	B
stem	I
cells	I
obtained	O
from	O
the	O
amniotic	O
membrane	O
(hAMSCs)	O
allowed	O
us	O
to	O
investigate	O
the	O
functionality	O
of	O
the	O
CFTR	O
channel	O
and	O
the	O
tightness	O
of	O
the	O
epithelial	O
barrier,	O
which	O
are	O
altered	O
in	O
CF	O
cell	O
monolayers	O
[95].	O

Cardiac	B
Stem	I
Cell	I
Treatment	O
in	O
Myocardial	O
Infarction:	O
A	O
Systematic	O
Review	O
and	O
Meta-Analysis	O
of	O
Preclinical	O
Studies.	O

Although	O
other	O
upregulated	O
genes	O
also	O
promoted	O
cell	O
differentiation	O
and	O
proliferation,	O
downregulated	O
IRF8,	O
which	O
mediates	O
apoptosis	O
of	O
cancerous	O
nonhematopoietic	O
cells	O
via	O
Fas,	O
Bax,	O
FLIP,	O
Jak1,	O
and	O
STAT1,	O
availed	O
the	O
proliferation	O
of	O
stem	B
cells	I
in	O
the	O
spleen	O
[50,	O
51].	O

Jacques	O
TS,	O
Swales	O
A,	O
Brzozowski	O
MJ,	O
Henriquez	O
NV,	O
Linehan	O
JM,	O
Mirzadeh	O
Z,	O
et	O
al.Combinations	O
of	O
genetic	O
mutations	O
in	O
the	O
adult	B
neural	I
stem	I
cell	I
compartment	O
determine	O
brain	O
tumour	O
phenotypes.	O

Furthermore,	O
BD-MSCs	O
seem	O
to	O
be	O
unaffected	O
by	O
the	O
thermal	O
damage	O
in	O
regard	O
to	O
key	O
cell	O
functions	O
and	O
are	O
comparable	O
to	O
mesenchymal	B
stem	I
cells	I
extracted	O
from	O
Wharton’s	O
jelly	O
of	O
human	O
umbilical	O
cords	O
(UC-MSCs).	O

This	O
sample	O
size,	O
however,	O
is	O
not	O
uncommon	O
in	O
stem	B
cell	I
research	O
due	O
to	O
limited	O
cell	O
availabilities	O
and	O
high	O
costs	O
[64–67].	O

Many	O
research	O
questions	O
remain	O
unknown;	O
this	O
study	O
opens	O
the	O
discussion	O
for	O
new	O
avenues	O
throughout	O
the	O
stem	B
cell	I
and	O
burn	O
community.	O

Mesenchymal	B
stem	I
cell	I
therapy	O
for	O
attenuation	O
of	O
scar	O
formation	O
during	O
wound	O
healing.	O

In	O
breast	O
cancer	O
it	O
has	O
been	O
shown	O
that	O
the	O
cancer	B
stem	I
cell	I
population	O
makes	O
up	O
the	O
more	O
oxidative,	O
more	O
resistant	O
subset	O
of	O
cells	O
in	O
a	O
tumor,	O
which,	O
in	O
this	O
study,	O
was	O
found	O
to	O
be	O
driven	O
by	O
co-overexpression	O
of	O
Myc	O
and	O
MCL-1	O
[242].	O

Hypoxic	O
culture	O
conditions	O
as	O
a	O
solution	O
for	O
mesenchymal	B
stem	I
cell	I
based	O
regenerative	O
therapy.	O

Dsh	O
plays	O
a	O
key	O
role	O
in	O
Wnt	O
signaling,	O
thus	O
affecting	O
cell	O
proliferation,	O
migration,	O
polarity,	O
terminal	O
differentiation,	O
and	O
the	O
self-renewal	O
of	O
stem	B
cells	I
(Boutros	O
and	O
Mlodzik	O
1999;	O
Gao	O
and	O
Chen	O
2010;	O
Sugimura	O
et	O
al.	O

(D)	O
The	O
(mother)	O
centrosome	O
derived	O
from	O
the	O
mother	O
centriole	O
of	O
the	O
basal	O
body	O
of	O
the	O
PC	O
is	O
typically	O
retained	O
by	O
the	O
stem	B
cell	I
during	O
asymmetric	O
division.	O

While	O
similar	O
observations	O
for	O
iPSC	O
were	O
made	O
with	O
N-Ras	O
[57],	O
again	O
only	O
KRAS–G12D,	O
but	O
not	O
the	O
other	O
two	O
Ras	O
isoforms,	O
was	O
able	O
to	O
increase	O
the	O
neural	B
stem	I
cell	I
pool	O
when	O
expressed	O
in	O
the	O
mouse	O
ventricular	O
zone	O
[58].	O

The	O
most	O
frequent	O
RASopathy,	O
neurofibromatosis	O
type	O
I	O
(occurrence	O
1:	O
3000),	O
is	O
caused	O
by	O
mutations	O
of	O
the	O
NF1	O
tumor	O
suppressor	O
gene,	O
which	O
in	O
mice	O
was	O
also	O
linked	O
to	O
neural	B
stem	I
cell	I
hyperproliferation	O
[67].	O

(2014)	O
Role	O
of	O
oncogenic	O
K-Ras	O
in	O
cancer	B
stem	I
cell	I
activation	O
by	O
aberrant	O
Wnt/β-Catenin	O
signaling.	O

Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

The	O
involvement	O
of	O
histone	O
methylation	O
in	O
the	O
transition	O
from	O
stem	B
cell	I
to	O
OPC	O
is	O
also	O
suggested	O
by	O
evidence	O
on	O
the	O
role	O
of	O
Enhancer	O
of	O
zeste	O
homolog	O
2	O
(Ezh2),	O
a	O
polycomb	O
group	O
protein	O
involved	O
in	O
gene	O
silencing	O
via	O
histone	O
methylation.	O

Fibroblast	O
growth	O
factor	O
2	O
is	O
required	O
for	O
maintaining	O
the	O
neural	B
stem	I
cell	I
pool	O
in	O
the	O
mouse	O
brain	O
subventricular	O
zone.	O

Human	O
pancreatic	O
tumor	O
organoids	O
reveal	O
loss	O
of	O
stem	B
cell	I
Niche	O
factor	O
dependence	O
during	O
disease	O
progression.	O

Following	O
melanocyte	O
ablation	O
by	O
MoTP,	O
regeneration	O
melanocytes	O
arise	O
from	O
cell	O
division	O
of	O
the	O
otherwise	O
quiescent	O
melanocyte	O
precursors	O
that	O
we	O
suggest	O
are	O
equivalent	O
to	O
adult	B
stem	I
cells	I
[9].	O

Glycogen	O
synthase	O
kinase	O
3beta	O
missplicing	O
contributes	O
to	O
leukemia	B
stem	I
cell	I
generation.	O

Gene	O
Delivery	O
Approaches	O
for	O
Mesenchymal	B
Stem	I
Cell	I
Therapy:	O
Strategies	O
to	O
Increase	O
Efficiency	O
and	O
Specificity.	O

(*)	O
Biomineralized	O
Recombinant	O
Collagen‐Based	O
Scaffold	O
Mimicking	O
Native	O
Bone	O
Enhances	O
Mesenchymal	B
Stem	I
Cell	I
Interaction	O
and	O
Differentiation.	O

Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

Although	O
much	O
has	O
been	O
reported	O
about	O
the	O
stem	B
cell	I
and	O
MSC-EV	O
role,	O
less	O
is	O
known	O
about	O
the	O
influence	O
of	O
BM-EVs	O
on	O
HSCs	O
and	O
MSCs	O
in	O
physiological	O
conditions	O
and	O
in	O
malignancy	O
onset,	O
progression,	O
and	O
therapy	O
resistance.	O

Interleukin-6	O
maintains	O
bone	B
marrow-derived	I
mesenchymal	I
stem	I
cell	I
stemness	O
by	O
an	O
ERK1/2-dependent	O
mechanism.	O

Comprehensive	O
proteomic	O
analysis	O
of	O
mesenchymal	B
stem	I
cell	I
exosomes	O
reveals	O
modulation	O
of	O
angiogenesis	O
via	O
nuclear	O
factor-KappaB	O
signaling.	O

Furthermore,	O
we	O
showed	O
that	O
amphiregulin,	O
present	O
on	O
fibroblast-derived	O
EV,	O
contributed	O
to	O
the	O
maintenance	O
of	O
the	O
intestinal	B
stem	I
cell	I
pool	O
and	O
to	O
cell	O
proliferation	O
in	O
epidermal	O
growth	O
factor-dependent	O
CRC	O
organoids..	O

MiRNA-192	O
and	O
−432	O
depleted	O
c-kit+	O
progenitor	O
cell	O
exosomes	O
promotes	O
the	O
proliferation,	O
migration	O
of	O
mesenchymal	B
stem	I
cells	I
and	O
regulates	O
inflammation.	O

Exosomes	O
have	O
been	O
implicated	O
as	O
the	O
mechanistic	O
unit	O
in	O
stem	B
cell	I
therapy,	O
as	O
inhibition	O
of	O
exosome	O
synthesis	O
abrogates	O
the	O
effects	O
of	O
cell	O
therapy	O
following	O
cardiac	O
injury.	O

Computational	O
Modelling	O
of	O
Mesenchymal	B
Stem	I
Cell	I
Exosomes	O
Predicts	O
Cardiac	O
Improvements	O
in	O
Preclinical	O
and	O
Clinical	O
Models	O
of	O
Hypoplastic	O
Left	O
Heart	O
Syndrome.	O

Summary/Conclusion:	O
This	O
proof	O
of	O
concept	O
study	O
shows	O
that	O
antenatal	O
administration	O
of	O
stem	B
cell	I
EVs	O
is	O
feasible	O
with	O
different	O
routes.	O

Summary/Conclusion:	O
In	O
summary,	O
cAD-MSCs	O
exosomes	O
display	O
structural	O
and	O
functional	O
features	O
comparable	O
to	O
stem	B
cell	I
derived	O
exosomes	O
from	O
other	O
species.	O

Natural	O
killer	O
cell-derived	O
extracellular	O
vesicles	O
have	O
a	O
potent	O
anti-leukaemic	O
effect	O
and	O
selectively	O
target	O
the	O
cancer	B
stem	I
cell	I
subpopulation.	O

Use	O
of	O
stem	B
cell	I
extracellular	O
vesicles	O
as	O
a	O
holistic	O
approach	O
towards	O
CNS	O
repair.	O

The	O
diverse	O
biological	O
cargo	O
contained	O
within	O
these	O
vesicles	O
are	O
proposed	O
to	O
mediate	O
their	O
effects	O
and,	O
to	O
date,	O
the	O
reparative	O
and	O
regenerative	O
effects	O
of	O
stem	B
cell	I
EVs	O
have	O
been	O
demonstrated	O
in	O
a	O
wide	O
range	O
of	O
cell	O
types.	O

Lastly,	O
utilizing	O
an	O
iPSC-derived	O
neurosphere	O
model,	O
we	O
have	O
observed	O
a	O
robust	O
uptake	O
of	O
stem	B
cell	I
EVs	O
and	O
have	O
found	O
that	O
these	O
EVs	O
are	O
able	O
to	O
effectively	O
penetrate	O
these	O
3D	O
structures..	O

Summary/Conclusion:	O
Collectively,	O
these	O
results	O
highlight	O
the	O
“holistic”	O
properties	O
of	O
stem	B
cell	I
EVs	O
by	O
demonstrating	O
their	O
ability	O
to	O
partially	O
reverse	O
or	O
reduce	O
damage	O
in	O
various	O
cell	O
types..	O

Comprehensive	O
analysis	O
of	O
methods	O
and	O
outcome	O
reporting	O
in	O
preclinical	O
animal	O
studies	O
of	O
mesenchymal	B
stem	I
cell	I
derived	O
extracellular	O
vesicles:	O
A	O
systematic	O
review.	O

One	O
of	O
them	O
is	O
epithelial-mesenchymal	O
transition	O
(EMT)	O
which	O
is	O
associated	O
with	O
cell	O
acquisition	O
of	O
invasiveness,	O
stem	B
cell	I
characteristics	O
and	O
resistance	O
to	O
apoptosis	O
and	O
therapy.	O

Introduction:	O
Over	O
the	O
last	O
2	O
decades,	O
Mesenchymal	O
Stem	O
Cell-derived	O
exosomes	O
have	O
been	O
shown	O
to	O
play	O
a	O
crucial	O
role	O
in	O
a	O
myriad	O
of	O
cell	O
function	O
such	O
as	O
extracellular	O
matrix	O
synthesis,	O
proliferation,	O
differentiation	O
or	O
cell	O
migration.	O
Administration	O
of	O
human	O
Mesenchymal	B
Stem	I
Cell	I
derived	O
extracellular	O
vesicles	O
modulates	O
the	O
abnormal	O
plasticity	O
of	O
newly	O
born	O
neurons	O
and	O
neuroinflammation	O
in	O
a	O
rat	O
model	O
of	O
status	O
epilepticus.	O

By	O
altering	O
the	O
miRNA	O
profile,	O
Dsg2	O
contributes	O
to	O
the	O
pathogenicity	O
of	O
these	O
EVs	O
by	O
increasing	O
levels	O
of	O
cytokines	O
important	O
for	O
cancer	B
stem	I
cell	I
renewal	O
and	O
metastasis.	O

Summary/Conclusion:	O
Monolith	O
chromatography	O
can	O
achieve	O
scalable	O
and	O
reproducible	O
purification	O
of	O
stem	B
cell	I
derived	O
exosomes,	O
whilst	O
maintaining	O
their	O
functional	O
capacity..	O

In	O
recent	O
years,	O
lncRNAs	O
have	O
merged	O
as	O
regulators	O
of	O
somatic	O
cell	O
differentiation	O
in	O
tissues	O
ranging	O
from	O
epidermal	O
to	O
adipose	O
tissues	O
[82,83],	O
as	O
well	O
as	O
osteogenic	O
differentiation	O
of	O
mesenchymal	B
stem	I
cells	I
[84],	O
while	O
their	O
biology	O
and	O
function	O
in	O
the	O
development,	O
differentiation,	O
and	O
maturation	O
of	O
professional	O
innate	O
immune	O
cells	O
are	O
only	O
beginning	O
to	O
be	O
explored.	O

Otherwise,	O
Sox2	O
and	O
Oct4	O
transcription	O
factors	O
regulate	O
the	O
embryonic	B
stem	I
cell	I
pluripotency	O
and	O
the	O
fate	O
of	O
cell	O
lineages	O
by	O
a	O
narrow	O
range	O
of	O
dose-effect	O
(131).	O

The	O
absence	O
and	O
deregulation	O
of	O
these	O
microRNAs	O
generate	O
early	O
maturation	O
of	O
the	O
progenitor	B
stem	I
cells	I
and	O
an	O
increase	O
in	O
cell	O
apoptosis,	O
producing	O
severe	O
impairments	O
in	O
fetal	O
brain	O
development	O
(230).	O

Comparison	O
of	O
adult	O
stem	O
cells	O
derived	O
from	O
multiple	O
stem	B
cell	I
niches.	O

It	O
is	O
generally	O
believed	O
that	O
aging	O
results	O
in	O
the	O
progressive	O
decrease	O
of	O
stem	B
cell	I
reservoirs;	O
although,	O
when	O
looking	O
at	O
the	O
hematopoietic	O
system,	O
aging	O
entails	O
complex	O
and	O
somehow	O
counterintuitive	O
alterations.	O

Identification	O
of	O
the	O
haematopoietic	B
stem	I
cell	I
niche	O
and	O
control	O
of	O
the	O
niche	O
size.	O

Leukaemogenic	O
effects	O
of	O
Ptpn11	O
activating	O
mutations	O
in	O
the	O
stem	B
cell	I
microenvironment.	O

Moreover,	O
YAP1	O
also	O
possesses	O
the	O
ability	O
to	O
modulate	B
stem	I
cell	I
self-renewal	O
and	O
differentiation	O
and	O
tissue	O
homeostasis,	O
as	O
well	O
as	O
upregulate	O
p73-dependent	O
pro-apoptotic	O
gene	O
transcription44.	O

Besides	O
these	O
steps	O
that	O
follow	O
implantation	O
of	O
the	O
blastocyst,	O
a	O
recent	O
addition	O
to	O
the	O
cabinet	O
filled	O
with	O
technological	O
breakthroughs	O
in	O
stem	B
cell	I
biology	O
is	O
the	O
three-channel	O
microfluidic	O
device	O
with	O
matrix	O
pouches	O
as	O
a	O
hESCs-	O
or	O
hiPSCs-based	O
advanced	O
model	O
of	O
the	O
spatial	O
events	O
at	O
the	O
peri-implantation	O
stage	O
[91].	O

Human	B
embryonic	I
stem	I
cell	I
lines	O
originate	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
human	O
blastocysts,	O
which	O
were	O
derived	O
through	O
cultivation	O
of	O
embryos	O
donated	O
by	O
participants	O
of	O
in	O
vitro	O
fertilization	O
programs	O
[92].	O

But	O
both	O
microcomputed	O
tomography	O
evaluation	O
and	O
biopsy	O
evaluation	O
indicated	O
significantly	O
more	O
osteogenesis	O
in	O
the	O
stem	B
cell	I
transplanted	O
side.42).	O

In	O
histological	O
examination,	O
the	O
sign	O
of	O
stem	B
cell	I
grafting	O
on	O
cartilage	O
surface	O
was	O
only	O
observed	O
in	O
one	O
patient.44).	O

Mesenchymal	B
stem	I
cell	I
implantation	O
in	O
atrophic	O
nonunion	O
of	O
the	O
long	O
bones:	O
a	O
translational	O
study.	O

Using	O
our	O
experimental	O
design,	O
we	O
found	O
that	O
the	O
rates	O
of	O
stem	B
cell	I
division	O
measured	O
in	O
the	O
intestines	O
of	O
uninfected	O
control	O
flies	O
were	O
somewhat	O
higher	O
than	O
previously	O
reported.	O

Neural	B
stem	I
cells	I
and	O
neurogenesis	O
in	O
the	O
adult	O
zebrafish	O
brain:	O
origin,	O
proliferation	O
dynamics,	O
migration	O
and	O
cell	O
fate.	O

However,	O
the	O
dominance	O
of	O
gene-centric	O
views	O
has	O
been	O
challenged	O
with	O
the	O
rapid	O
development	O
of	O
research	O
within	O
the	O
cancer	B
stem	I
cell	I
hypothesis,	O
thus	O
bringing	O
non-genetic	O
sources	O
of	O
phenotypic	O
variability	O
into	O
focus	O
[20].	O

Small	O
non-coding	O
RNAs	O
in	O
particular	O
have	O
emerged	O
as	O
potential	O
candidates	O
as	O
they	O
can	O
exert	O
a	O
broad	O
influence	O
on	O
functional	O
networks	O
and	O
have	O
been	O
found	O
to	O
be	O
dysregulated	O
in	O
SCZ	O
postmortem	O
brains.11,	O
12,	O
13,	O
14	O
The	O
possibility	O
that	O
miRNA	O
may	O
also	O
be	O
directly	O
involved	O
in	O
the	O
pathogenesis	O
of	O
SCZ	O
was	O
highlighted	O
in	O
the	O
most	O
recent	O
international	O
genome	O
wide	O
association	O
studies	O
coordinated	O
by	O
the	O
Schizophrenia	O
Working	O
Group	O
of	O
the	O
PGC.15	O
These	O
studies	O
strongly	O
implicate	O
the	O
MIR137	O
locus	O
in	O
the	O
susceptibility	O
for	O
schizophrenia	O
and	O
suggest	O
that	O
the	O
encoded	O
miRNA	O
may	O
be	O
involved	O
in	O
the	O
disorder	O
through	O
a	O
role	O
in	O
shaping	O
neurodevelopment.1,	O
16,	O
17,	O
18,	O
19	O
MiR-137	O
is	O
highly	O
expressed	O
in	O
the	O
brain20,	O
21	O
and	O
has	O
been	O
associated	O
with	O
neuronal	O
differentiation,	O
maturation	O
and	O
transmission,	O
dendritic	O
spine	O
morphogenesis	O
and	O
synaptogenesis.20,	O
21,	O
22,	O
23,	O
24	O
It	O
has	O
also	O
been	O
linked	O
to	O
murine	O
adult	B
neural	I
stem	I
cell	I
proliferation	O
and	O
differentiation.25	O
While	O
miR-137	O
seems	O
to	O
have	O
important	O
diverse	O
biological	O
functions,	O
particularly	O
in	O
the	O
brain,	O
this	O
has	O
not	O
yet	O
been	O
fully	O
elaborated	O
in	O
molecular	O
or	O
genetic	O
intervention	O
studies	O
in	O
vivo.	O

3D-Printed	O
microrobotic	O
transporters	O
with	O
recapitulated	B
stem	I
cell	I
niche	O
for	O
programmable	O
and	O
active	O
cell	O
delivery.	O

Reduced	O
insulin	O
sensitivity	O
in	O
childhood	O
survivors	O
of	O
haematopoietic	B
stem	I
cell	I
transplantation	O
is	O
associated	O
with	O
lipodystropic	O
and	O
sarcopenic	O
phenotypes.	O

The	O
clonal	O
expansions	O
presumably	O
involve	O
altered	O
dynamics	O
of	O
stem	B
cell	I
self-renewal,	O
through	O
a	O
proliferative	O
advantage	O
(possibly	O
enhanced	O
by	O
preferential	O
survival)49	O
compared	O
to	O
neighboring	O
non-mutant	O
cells,	O
analogous	O
to	O
the	O
role	O
of	O
oncogenes	O
in	O
cancer.	O

Finally,	O
we	O
showcase	O
a	O
methylation-sensitive	O
method	O
of	O
correcting	O
for	O
GC-content	O
bias	O
by	O
applying	O
it	O
to	O
high-coverage	O
bisulfite-treated	O
data	O
from	O
the	O
H1	B
embryonic	I
stem	I
cell	I
line..	O

We	O
started	O
with	O
over	O
1.5	O
billion	O
such	O
reads	O
from	O
the	O
H1	B
embryonic	I
stem	I
cell	I
line	O
generated	O
on	O
the	O
Illumina	O
GAII	O
sequencer	O
[21].	O

Of	O
particular	O
interest	O
was	O
research	O
on	O
embryonic	O
carcinoma	O
cells	O
(EC),	O
a	O
type	O
of	O
stem	B
cell	I
derived	O
from	O
teratocarcinoma.	O

Finally,	O
the	O
most	O
promising	O
emerging	O
approaches	O
for	O
overcoming	O
the	O
challenges	O
of	O
stem	B
cell	I
tumorigenicity	O
are	O
highlighted..	O

However,	O
it	O
has	O
only	O
been	O
more	O
recently	O
that	O
the	O
normal	O
role	O
of	O
Myc	O
in	O
stem	B
cell	I
biology	O
has	O
been	O
discerned.	O

Part	O
of	O
the	O
challenge	O
of	O
resolving	O
issues	O
related	O
to	O
stem	B
cell	I
safety	O
is	O
that	O
only	O
few	O
in	O
vivo	O
studies	O
have	O
been	O
reported,	O
particularly	O
on	O
human	O
cells	O
such	O
as	O
human	O
ESC	O
(hESC).	O

Thus,	O
other	O
than	O
their	O
robust	O
teratoma	O
inducing	O
abilities,	O
the	O
reality	O
is	O
that	O
the	O
stem	B
cell	I
field	O
knows	O
almost	O
nothing	O
about	O
the	O
tumorigenicity	O
of	O
mouse	O
IPSC	O
and	O
essentially	O
nothing	O
about	O
that	O
of	O
human	O
IPSC	O
in	O
a	O
context	O
relevant	O
to	O
regenerative	O
medicine..	O

Mostly	O
under	O
the	O
radar	O
in	O
the	O
field	O
of	O
stem	B
cell	I
safety	O
are	O
potential	O
undesirable	O
side	O
effects	O
of	O
epigenetic	O
changes	O
in	O
IPSC	O
and	O
hESC	O
that	O
are	O
undetectable	O
by	O
karyotyping,	O
but	O
could	O
have	O
profound	O
effects	O
on	O
cell	O
biology	O
as	O
the	O
biology	O
of	O
normal	O
hESC	O
is	O
regulated	O
by	O
epigenetic	O
programming	O
[38].	O

Of	O
concern	O
is	O
the	O
fact	O
that	O
it	O
remains	O
unknown	O
if	O
all	O
hESC	O
express	O
what	O
are	O
thought	O
of	O
as	O
the	O
key	B
stem	I
cell	I
factors	O
such	O
as	O
oct3	O
and	O
nanog.	O

From	O
teratocarcinomas	O
to	O
embryonic	O
stem	O
cells	O
and	O
beyond:	O
A	O
history	O
of	O
embryonic	B
stem	I
cell	I
research.	O

Restriction	O
landmark	O
genome	O
scanning	O
identifies	O
culture-induced	O
DNA	O
methylation	O
instability	O
in	O
the	O
human	B
embryonic	I
stem	I
cell	I
epigenome.	O

Safety	O
and	O
efficacy	O
of	O
adult	B
stem	I
cell	I
therapy	O
for	O
acute	O
myocardial	O
infarction	O
and	O
ischemic	O
heart	O
failure	O
(safecell	O
heart):	O
A	O
systematic	O
review	O
and	O
meta-analysis.	O

Embryonic	B
stem	I
cell	I
immunogenicity	O
increases	O
upon	O
differentiation	O
after	O
transplantation	O
into	O
ischemic	O
myocardium.	O

Embryonic	B
stem	I
cell	I
transplantation	O
after	O
experimental	O
traumatic	O
brain	O
injury	O
dramatically	O
improves	O
neurological	O
outcome,	O
but	O
may	O
cause	O
tumors.	O

Second	O
malignancy	O
following	O
high-dose	O
therapy	O
and	O
autologous	B
stem	I
cell	I
transplantation:	O
incidence	O
and	O
risk	O
factor	O
analysis.	O

Inflamm-aging	O
of	O
the	O
stem	B
cell	I
niche:	O
Breast	O
cancer	O
as	O
a	O
paradigmatic	O
example:	O
Breakdown	O
of	O
the	O
multi-shell	O
cytokine	O
network	O
fuels	O
cancer	O
in	O
aged	O
people.	O

Bone	O
marrow-derived	O
myofibroblasts	O
contribute	O
to	O
the	O
mesenchymal	B
stem	I
cell	I
niche	O
and	O
promote	O
tumor	O
growth.	O

The	O
novel	O
CXCR4	O
antagonist,	O
PRX177561,	O
reduces	O
tumor	O
cell	O
proliferation	O
and	O
accelerates	O
cancer	B
stem	I
cell	I
differentiation	O
in	O
glioblastoma	O
preclinical	O
models.	O

Intravascular	O
delivery	O
of	O
neural	B
stem	I
cell	I
lines	O
to	O
target	O
intracranial	O
and	O
extracranial	O
tumors	O
of	O
neural	O
and	O
non-neural	O
origin.	O

Furthermore,	O
the	O
absence	O
of	O
lamin	O
A/C	O
from	O
embryonic	B
stem	I
cells	I
has	O
been	O
suggested	O
as	O
an	O
explanation	O
for	O
the	O
more	O
malleable	O
and	O
deformable	O
nuclei	O
of	O
this	O
cell	O
type	O
[65].	O

Haematopoietic	B
stem	I
cell	I
transplantation	O
corrects	O
the	O
metabolic	O
defect	O
in	O
Krabbe	O
disease,	O
which	O
indicates	O
the	O
importance	O
of	O
dysfunctional	O
GALC	O
in	O
leukocytes	O
in	O
disease	O
pathogenesis	O
[109].	O

Lipofibroblasts	O
have	O
been	O
reported	O
to	O
contribute	O
to	O
AECII	B
stem	I
cell	I
niche	O
[34]	O
and	O
we	O
showed	O
HBO	O
exposure	O
resulted	O
in	O
reduction	O
of	O
lipofibroblasts,	O
which	O
could	O
be	O
detrimental	O
for	O
AECII	O
stemness	O
maintenance.	O

Different	O
from	O
previously	O
described	O
β2	O
integrin	O
agonists,	O
THI0019	O
is	O
a	O
full	O
agonist	O
and	O
promotes	O
rolling,	O
migration	O
and	O
cell	O
homing,	O
and,	O
in	O
this	O
case,	O
the	O
up-regulation	O
of	O
integrin	O
activity	O
should	O
be	O
useful	O
for	O
cell	O
retention	O
in	O
stem	B
cell	I
therapy.	O

The	O
Ptf1alox	O
allele	O
(Ptf1atm3Cvw)	O
was	O
generated	O
using	O
homologous	O
recombination	O
in	O
mouse	O
ES	O
cells	O
at	O
the	O
Vanderbilt	O
Transgenic	B
Mouse/Embryonic	I
Stem	I
Cell	I
Shared	O
Resource.	O

Activation	O
of	O
the	O
PI3K/AKT	O
signaling	O
may	O
have	O
dynamic	O
roles	O
in	O
maintaining	O
the	O
pluripotency	O
of	O
stem	B
cells	I
[48],	O
which	O
is	O
also	O
involved	O
in	O
enhanced	O
cell	O
proliferation	O
[49]	O
(Figure	O
2).	O

In	O
addition,	O
it	O
has	O
been	O
reported	O
that	O
PI3K/AKT	O
is	O
associated	O
with	O
the	O
regulation	O
of	O
stem	B
cell	I
fate	O
[50].	O

Stromal	O
cell-derived	O
factor	O
1	O
(SDF1)	O
is	O
an	O
important	O
chemokine	O
in	O
stem	B
cell	I
mobilization,	O
and	O
plays	O
a	O
critical	O
role	O
in	O
the	O
biological	O
functions	O
of	O
MSCs	O
by	O
enhancing	O
PI3K	O
expression	O
[51].	O

The	O
role	O
of	O
reactive	O
oxygen	O
species	O
in	O
mesenchymal	B
stem	I
cell	I
adipogenic	O
and	O
osteogenic	O
differentiation:	O
A	O
review.	O

These	O
intergenic	O
transcripts	O
are	O
involved	O
in	O
diverse	O
cellular	O
processes,	O
including	O
proliferation,	O
migration,	O
invasion,	O
apoptosis	O
and	O
the	O
reprogramming	O
of	O
stem	B
cell	I
pluripotency	O
(10–13).	O

Repair	O
and	O
regeneration	O
of	O
the	O
respiratory	O
system:	O
Complexity,	O
plasticity,	O
and	O
mechanisms	O
of	O
lung	B
stem	I
cell	I
function.	O

Paternal	O
age	O
and	O
telomere	O
length	O
in	O
twins:	O
the	O
germ	B
stem	I
cell	I
selection	O
paradigm.	O

Role	O
of	O
neuregulin-1/ErbB	O
signaling	O
in	O
stem	B
cell	I
therapy	O
for	O
spinal	O
cord	O
injury-induced	O
chronic	O
neuropathic	O
pain.	O

Deriving	O
and	O
propagating	O
mouse	B
embryonic	I
stem	I
cell	I
lines	O
for	O
studying	O
genomic	O
imprinting.	O

SGBC	O
are	O
presumed	O
to	O
be	O
similar	O
to	O
CSC,	O
as	O
they	O
show	O
increased	O
positivity	O
for	O
stem	B
cell	I
markers	O
[71],	O
but	O
whether	O
they	O
represent	O
an	O
enrichment,	O
a	O
subset	O
or	O
what	O
exactly	O
the	O
relationship	O
between	O
those	O
two	O
terms	O
is,	O
remains	O
open	O
for	O
debate.	O

The	O
inevitable	O
re-emergence	O
of	O
GB	O
after	O
surgical	O
resection,	O
radiation	O
and	O
chemotherapy	O
suggests	O
that	O
within	O
GB	O
a	O
subpopulation	O
exists	O
that	O
is	O
resistant	O
to	O
these	O
therapies	O
and	O
based	O
on	O
the	O
stem	B
cell	I
model,	O
CSCs	O
are	O
often	O
proposed	O
to	O
be	O
the	O
underlying	O
cause	O
[141].	O

Tumor	B
stem	I
cells	I
derived	O
from	O
glioblastomas	O
cultured	O
in	O
bFGF	O
and	O
EGF	O
more	O
closely	O
mirror	O
the	O
phenotype	O
and	O
genotype	O
of	O
primary	O
tumors	O
than	O
do	O
serum-cultured	O
cell	O
lines.	O

Cancer	B
stem	I
cell	I
analysis	O
and	O
clinical	O
outcome	O
in	O
patients	O
with	O
glioblastoma	O
multiforme.	O

Glioma	B
stem	I
cell	I
lines	O
expanded	O
in	O
adherent	O
culture	O
have	O
tumor-specific	O
phenotypes	O
and	O
are	O
suitable	O
for	O
chemical	O
and	O
genetic	O
screens.	O

High	O
levels	O
of	O
purine	O
and	O
pyrimidine	O
biosynthesis	O
may	O
be	O
a	O
reflection	O
of	O
the	O
high	O
rate	O
of	O
stem	B
cell	I
formation	O
in	O
this	O
tissue..	O

Park	O
JS,	O
Kim	O
YS,	O
Yoo	O
MA	O
(2009)	O
The	O
role	O
of	O
p38b	O
MAPK	O
in	O
age-related	O
modulation	O
of	O
intestinal	B
stem	I
cell	I
proliferation	O
and	O
differentiation	O
in	O
Drosophila.	O

Recently,	O
it	O
has	O
been	O
shown	O
that	O
extensive	O
de	O
novo	O
and	O
recurrent	O
CNV	O
occurs	O
in	O
vitro	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
lines	O
derived	O
from	O
common	O
parental	O
lines,	O
leading	O
to	O
mosaic	O
animals	O
containing	O
variants	O
of	O
the	O
zygote	O
genome	O
[12].	O

Functional	O
effects	O
of	O
TGF-beta1	O
on	O
mesenchymal	B
stem	I
cell	I
mobilization	O
in	O
cockroach	O
allergen-induced	O
asthma.	O

A	O
bioengineered	O
niche	O
promotes	O
in	O
vivo	O
engraftment	O
and	O
maturation	O
of	O
pluripotent	B
stem	I
cell	I
derived	O
human	O
lung	O
organoids.	O

A	O
molecular	O
scheme	O
for	O
improved	O
characterization	O
of	O
human	B
embryonic	I
stem	I
cell	I
lines.	O

It	O
is	O
accepted	O
that	O
enteroids	O
are	O
3	O
dimensional	O
structures,	O
and	O
the	O
study	O
has	O
been	O
productive	O
in	O
the	O
evaluation	O
of	O
stem	B
cell	I
dynamics	O
and	O
other	O
tissue	O
level	O
events.	O

It	O
is	O
accepted	O
that	O
enteroids	O
are	O
3	O
dimensional	O
structures,	O
and	O
the	O
study	O
has	O
been	O
productive	O
in	O
the	O
evaluation	O
of	O
stem	B
cell	I
dynamics	O
and	O
other	O
tissue	O
level	O
events.	O

Recent	O
advances	O
have	O
highlighted	O
the	O
importance	O
of	O
gene/protein	O
network	O
maintaining	O
the	O
identity	O
of	O
cell	O
phenotype,	O
especially	O
from	O
the	O
study	O
of	O
embryonic	B
stem	I
cells	I
[137,	O
138].	O

Dividing	O
cellular	O
asymmetry:	O
asymmetric	O
cell	O
division	O
and	O
its	O
implications	O
for	O
stem	B
cells	I
and	O
cancer.	O

These	O
results	O
suggest	O
that	O
NCSCs	O
derived	O
from	O
pluripotent	B
stem	I
cells	I
could	O
be	O
a	O
safe	O
and	O
unlimited	O
cell	O
source	O
to	O
generate	O
odontoblasts	O
for	O
tooth	O
regeneration.	O

Multiple	O
actions	O
of	O
stem	B
cell	I
factor	O
in	O
neural	O
crest	O
cell	O
differentiation	O
in	O
vitro.	O

Therefore,	O
another	O
therapeutic	O
option	O
will	O
be	O
to	O
inject	O
the	O
stem	O
cell	O
secretome	O
for	O
repair	O
of	O
the	O
damaged	O
tissue,	O
which	O
may	O
even	O
be	O
improved	O
through	O
the	O
use	O
of	O
gene	O
expression	O
methodologies	O
or	O
culture	O
preconditioning	O
of	O
modified	O
stem	B
cells	I
increasing	O
the	O
ability	O
to	O
secrete	O
pro-regenerative	O
factors	O
(Drago	O
et	O
al.,	O
2013)..	O

Mesenchymal	B
stem	I
cells	I
rescue	O
the	O
Alzheimer’s	O
disease	O
cell	O
model	O
from	O
cell	O
death	O
induced	O
by	O
misfolded	O
truncated	O
tau.	O

Notch	O
signaling	O
plays	O
a	O
pivotal	O
role	O
in	O
biological	O
processes	O
including	O
apoptosis,	O
cell	O
proliferation,	O
differentiation,	O
and	O
cell	O
lineage	O
decision	O
in	O
stem	O
cells.	O
More	O
differentiated	O
cells	O
were	O
also	O
investigated:	O
experiments	O
with	O
mosaic	O
inactivation	O
of	O
Tp53	O
and	O
Nf1	O
in	O
NSCs	O
showed	O
that	O
the	O
most	O
rapid	O
phase	O
of	O
tumor	O
growth	O
occurs	O
when	O
the	O
cells	O
migrate	O
out	O
of	O
the	O
stem	B
cell	I
niche	O
and	O
become	O
Olig2-positive	O
oligodendroglial	O
progenitor	O
cells	O
(106).	O

Although	O
Numb4d7	O
opposes	O
growth-inhibitory	O
effect	O
of	O
Numb4,	O
both	O
isoforms	O
promote	O
expression	O
of	O
stem	B
cell	I
markers	O
in	O
BTPCs.	O

However,	O
they	O
seem	O
equally	O
sensitive	O
to	O
treatments	B
targeting	I
stem	I
cell	I
pathways	O
such	O
as	O
Notch	O
(146,	O
147).	O

Tumor	B
stem	I
cells	I
derived	O
from	O
glioblastomas	O
cultured	O
in	O
bFGF	O
and	O
EGF	O
more	O
closely	O
mirror	O
the	O
phenotype	O
and	O
genotype	O
of	O
primary	O
tumors	O
than	O
do	O
serum-cultured	O
cell	O
lines.	O

PTTG1	O
oncogene	O
promotes	O
tumor	O
malignancy	O
via	O
epithelial	O
to	O
mesenchymal	O
transition	O
and	O
expansion	O
of	O
cancer	B
stem	I
cell	I
population.	O

Therefore,	O
this	O
project	O
performs	O
a	O
genomic	O
analysis	O
of	O
CSC-like	O
by	O
array-CGH	O
and	O
expression	O
array,	O
with	O
special	O
focus	O
on	O
altered	O
signalling	O
pathways	O
that	O
might	O
explain	O
the	O
stem	B
cell	I
phenotype	O
of	O
the	O
CSC	O
subpopulation.	O

As	O
a	O
result,	O
we	O
observed	O
significant	O
alteration	O
in	O
representative	O
signalling	O
pathways	O
known	O
to	O
be	O
also	O
involved	O
in	O
stem	B
cell	I
self-renewal,	O
as	O
Wnt,	O
Notch,	O
Hh	O
and	O
TGF-β	O
(Figure	O
3)..	O

This	O
gene	O
could	O
interact	O
with	O
members	O
from	O
other	O
pathways	O
as	O
TGF-β,	O
Notch	O
and	O
Wnt	O
[65],	O
[66]	O
working	O
together	O
in	O
the	O
regulation	O
of	O
stem	B
cell	I
pluripotency.	O

This	O
might	O
happen	O
because	O
in	O
neuroblastoma	O
as	O
in	O
other	O
tumors,	O
the	O
CSC	O
subpopulation	O
seems	O
to	O
be	O
especially	O
sensitive	B
to	I
inhibition	I
of	I
stem	I
cell	I
pathways	O
as	O
Notch	O
[73]..	O

In	O
conclusion,	O
we	O
found	O
that	O
the	O
expression	O
profile	O
of	O
neuroblastoma	O
CSC-like	O
cells	O
differs	O
significantly	O
from	O
the	O
expression	O
profile	O
in	O
standard	O
neuroblastoma	O
cell	O
lines,	O
which	O
is	O
seen	O
as	O
altered	O
signalling	O
pathways	O
involved	O
in	O
stem	B
cell	I
proliferation	O
pathways	O
as	O
Wnt,	O
Notch,	O
Hh	O
and	O
TGF-β,	O
suggesting	O
a	O
cross	O
talk	O
among	O
them	O
and	O
with	O
other	O
pathways.	O

(2010)	O
The	O
utility	O
and	O
limitations	O
of	O
neurosphere	O
assay,	O
CD133	O
immunophenotyping	O
and	O
side	O
population	O
assay	O
in	O
glioma	B
stem	I
cell	I
research.	O

Rahman	O
R,	O
Heath	O
R,	O
Grundy	O
R	O
(2009)	O
Cellular	O
immortality	O
in	O
brain	O
tumours:	O
an	O
integration	O
of	O
the	O
cancer	B
stem	I
cell	I
paradigm.	O

Distinct	O
histone	O
modifications	O
in	O
stem	B
cell	I
lines	O
and	O
tissue	O
lineages	O
from	O
the	O
early	O
mouse	O
embryo.	O

Furthermore,	O
autophagy	O
may	O
be	O
an	O
important	O
determinant	O
of	O
stem	B
cell	I
pluripotency	O
(Phadwal	O
et	O
al.	O

Similarly,	O
increasing	O
mitochondrial	O
oxidative	O
stress	O
in	O
stem	B
cells	I
leads	O
to	O
senescence,	O
cell	O
cycle	O
arrest	O
and	O
loss	O
of	O
stemness	O
(Velarde	O
et	O
al.	O

Tightrope	O
act:	O
autophagy	O
in	O
stem	B
cell	I
renewal,	O
differentiation,	O
proliferation,	O
and	O
aging.	O

Mesenchymal	B
stem	I
cell	I
secreted	O
vesicles	O
provide	O
novel	O
opportunities	O
in	O
(stem)	O
cell-free	O
therapy.	O

Cell	O
Shape,	O
Cytoskeletal	O
Tension,	O
and	O
RhoA	O
Regulate	B
Stem	I
Cell	I
Lineage	O
Commitment	O
several	O
studies	O
have	O
noted	O
that	O
changes	O
in	O
cell	O
shape	O
themselves	O
can	O
alter	O
the	O
differentiation	O
of	O
precommitted	O
mesenchymal	O
lineages.	O

A	O
feedback	O
regulatory	O
loop	O
involving	O
microRNA-9	O
and	O
nuclear	O
receptor	O
TLX	O
in	O
neural	B
stem	I
cell	I
fate	O
determination.	O

Neoplastic	O
transformation	O
of	O
the	O
peribiliary	B
stem	I
cell	I
niche	O
in	O
cholangiocarcinoma	O
arisen	O
in	O
primary	O
sclerosing	O
cholangitis.	O

miR-138	O
is	O
a	O
highly	O
conserved	O
miRNA	O
abundantly	O
expressed	O
in	O
neuronal	O
cells	O
and	O
important	O
for	O
neuronal	B
stem	I
cell	I
proliferation	O
and	O
differentiation,	O
and	O
frequently	O
found	O
downregulated	O
in	O
various	O
cancers	O
(reviewed	O
in	O
[63]).	O

This	O
loss	O
of	O
Prrx1	O
was	O
associated	O
with	O
a	O
reversion	O
of	O
EMT	O
and	O
induction	O
of	O
stem	B
cell	I
properties,	O
suggesting	O
that	O
plasticity	O
and	O
EMT	O
are	O
not	O
inextricably	O
linked	O
and	O
the	O
process	O
of	O
metastasis	O
may	O
require	O
dynamic	O
fluctuations	O
between	O
epithelial	O
and	O
mesenchymal	O
states	O
in	O
cancer	O
cells	O
(Ocana	O
et	O
al.,	O
2012)..	O

EMP	O
and	O
cancer	O
stemness	O
may	O
act	O
cooperatively	O
to	O
enhance	O
anoikis	O
resistance,	O
as	O
Frisch	O
and	O
colleagues	O
showed	O
that	O
in	O
breast	O
cancer,	O
the	O
cancer	B
stem	I
cell	I
marker	O
CD44S,	O
which	O
is	O
up-regulated	O
in	O
response	O
to	O
an	O
EMT,	O
can	O
enhance	O
cell	O
survival	O
under	O
detached	O
conditions	O
(Cieply	O
et	O
al.,	O
2015)..	O

As	O
early	O
as	O
the	O
1990s,	O
and	O
well	O
before	O
ALDH	O
was	O
associated	O
with	O
cancer	B
stem	I
cell	I
phenotypes,	O
it	O
was	O
known	O
to	O
be	O
associated	O
with	O
chemoresistance	O
due	O
at	O
least	O
in	O
part	O
to	O
its	O
ability	O
to	O
metabolically	O
inactivate	O
chemotherapeutic	O
agents	O
such	O
as	O
cyclophosphamide	O
(Mirkes	O
et	O
al.,	O
1991).	O

For	O
example,	O
Zolkiewska	O
and	O
colleagues	O
found	O
that	O
selumetinib	O
blocked	O
EGF-induced	O
expansion	O
of	O
CD44+/CD24–	O
breast	B
cancer	I
stem	I
cell	I
associated	O
populations	O
(Wise	O
and	O
Zolkiewska,	O
2017).	O

Similarly,	O
the	O
Ueno	O
laboratory	O
found	O
that	O
selumetinib	O
inhibits	O
the	O
acquisition	O
of	O
breast	B
cancer	I
stem	I
cell	I
phenotypes	O
and	O
protects	O
mice	O
from	O
lung	O
metastasis	O
after	O
transplantation	O
with	O
TNBC	O
cells	O
(Bartholomeusz	O
et	O
al.,	O
2015)..	O

Interplay	O
of	O
stem	B
cell	I
characteristics,	O
EMT,	O
and	O
microtentacles	O
in	O
circulating	O
breast	O
tumor	O
cells.	O

Regulation	O
of	O
breast	B
cancer	I
stem	I
cell	I
activity	O
by	O
signaling	O
through	O
the	O
Notch4	O
receptor.	O

Transforming	O
growth	O
factor-β1-induced	O
epithelial-mesenchymal	O
transition	O
generates	O
ALDH-positive	O
cells	O
with	O
stem	B
cell	I
properties	O
in	O
cholangiocarcinoma.	O

The	O
clonogenic	O
expansion	O
of	O
hPEOs	O
from	O
single	O
cells	O
can	O
therefore	O
provide	O
an	O
ideal	O
model	O
to	O
study	O
the	O
epidermal	B
stem	I
cell	I
homeostasis	O
and	O
mechanism	O
of	O
stratification	O
at	O
the	O
single	O
cells	O
level.	O

Analysis	O
of	O
different	O
promoter	O
systems	O
for	O
efficient	O
transgene	O
expression	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
lines.	O

Stable	O
isotope	O
labeling	O
by	O
amino	O
acids	O
in	O
cell	O
culture	O
(SILAC)	O
and	O
proteome	O
quantitation	O
of	O
mouse	B
embryonic	I
stem	I
cells	I
to	O
a	O
depth	O
of	O
5,111	O
proteins.	O

In	O
a	O
murine	O
study	O
on	O
the	O
topic,	O
it	O
was	O
suggested	O
that	O
donor	O
B	O
cell	O
depletion	O
protected	O
mice	O
from	O
CGVHD	O
[32],	O
and	O
therefore,	O
it	O
is	O
conceivable	O
that	O
alloreactive	O
donor	O
CD4+	O
T	O
cells	O
could	O
be	O
activated	O
by	O
host	O
B	O
cells,	O
and	O
that	O
this,	O
in	O
turn,	O
promotes	O
the	O
activation	O
and	O
expansion	O
of	O
quiescent	O
autoreactive	O
donor	O
B	O
cells	O
in	O
stem	B
cell	I
grafts.	O

Accumulating	O
evidence	O
has	O
shown	O
that	O
the	O
miR-302/367	O
cluster	O
is	O
highly	O
expressed	O
in	O
embryonic	B
stem	I
cells	I
and	O
plays	O
a	O
crucial	O
role	O
in	O
their	O
self-renewal	O
and	O
somatic	O
cell	O
reprogramming	O
(34,	O
35).	O

Changes	O
of	O
mitochondrial	O
mass	O
in	O
the	O
hemopoietic	B
stem	I
cell	I
line	O
FDCP-mix	O
after	O
treatment	O
with	O
etoposide:	O
a	O
correlative	O
study	O
by	O
multiparameter	O
flow	O
cytometry	O
and	O
confocal	O
and	O
electron	O
microscopy.	O

Study	O
of	O
Taf4b	O
KO	O
mice	O
showed	O
that	O
homozygous	O
mutant	O
males	O
are	O
subfertile	O
with	O
extensive	O
pre‐meiotic	O
germ	O
cell	O
loss	O
due	O
to	O
altered	O
differentiation	O
and	O
self‐renewal	O
of	O
the	O
spermatogonial	B
stem	I
cell	I
pool,	O
thus	O
illustrating	O
that	O
pre‐meiotic	O
block	O
induces	O
NOA.	O

Despite	O
widespread	O
use	O
of	O
high-dose	O
chemotherapy	O
in	O
combination	O
with	O
autologous	B
stem	I
cell	I
transplantation	O
(ASCT)	O
and	O
the	O
introduction	O
of	O
novel	O
agents	O
(immunomodulatory	O
drugs,	O
IMiDs,	O
and	O
proteasome	O
inhibitors,	O
PIs),	O
the	O
prognosis	O
of	O
MM	O
patients	O
is	O
still	O
poor.	O

Phenotypic	O
Plasticity	O
Determines	O
Cancer	B
Stem	I
Cell	I
Therapeutic	O
Resistance	O
in	O
Oral	O
Squamous	O
Cell	O
Carcinoma.	O

Recent	O
advances	O
in	O
stem	B
cell	I
biology	O
have	O
led	O
to	O
the	O
development	O
of	O
organoids	O
as	O
a	O
powerful,	O
alternative	O
model	O
of	O
intestinal	O
physiology	O
[23,24••].	O

Decreased	O
expression	O
levels	O
of	O
intestinal	B
stem	I
cell	I
markers	O
Lgr5	O
and	O
Sox9	O
observed	O
by	O
real	O
time-PCR	O
and	O
immunohistochemistry	O
suggested	O
that	O
parasite	O
infection	O
could	O
involve	O
inhibition	O
of	O
ISC	O
function	O
through	O
attenuation	O
of	O
the	O
Wnt/B-catenin	O
signaling	O
resulting	O
in	O
apoptotic	O
cell	O
death	O
and	O
senescence.	O

p53	O
gene	O
deletion	O
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
is	O
an	O
adverse	O
prognostic	O
factor	O
for	O
patients	O
with	O
multiple	O
myeloma	O
following	O
autologous	B
stem	I
cell	I
transplantation.	O

PTTG1	O
oncogene	O
promotes	O
tumor	O
malignancy	O
via	O
epithelial	O
to	O
mesenchymal	O
transition	O
and	O
expansion	O
of	O
cancer	B
stem	I
cell	I
population.	O

Embryonic	B
stem	I
cell	I
specific	O
“master”	O
replication	O
origins	O
at	O
the	O
heart	O
of	O
the	O
loss	O
of	O
pluripotency.	O

The	O
morphogen	O
diffusion	O
and	O
the	O
release	O
of	O
cell-secreted	O
soluble	O
factors	O
create	O
a	O
biochemical	O
gradient	O
in	O
the	O
stem	B
cell	I
niche	O
[188,195].	O

Organoids:	O
Modeling	O
development	O
and	O
the	O
stem	B
cell	I
niche	O
in	O
a	O
dish.	O

Phobol	O
ester	O
induces	O
c-sis	O
gene	O
transcription	O
in	O
stem	B
cell	I
line	O
K-562.	O

Hypoxia-inducible	O
factors:	O
Coupling	O
glucose	O
metabolism	O
and	O
redox	O
regulation	O
with	O
induction	O
of	O
the	O
breast	B
cancer	I
stem	I
cell	I
phenotype.	O

Redox	O
Modulating	O
NRF2:	O
A	O
Potential	O
Mediator	O
of	O
Cancer	B
Stem	I
Cell	I
Resistance.	O

Mesenchymal	B
stem	I
cell	I
extracellular	O
vesicles	O
(MSCEVs)	O
obtained	O
from	O
MSCs	O
can	O
have	O
numerous	O
therapeutic	O
applications	O
via	O
regeneration	O
of	O
various	O
body	O
tissues.	O

Mesenchymal	B
stem	I
cell	I
extracellular	O
vesicles	O
(MSCEVs)	O
offer	O
therapeutic	O
benefits	O
for	O
various	O
pathophysiological	O
ailments	O
by	O
restoring	O
tissues.	O

Mesenchymal	B
stem	I
cell	I
extracellular	O
vesicle	O
(MSCEV)	O
treatment	O
approaches	O
in	O
clinical	O
trials.	O

Translational	O
Cardiac	B
Stem	I
Cell	I
Therapy:	O
Advancing	O
from	O
First-Generation	O
to	O
next-Generation	O
Cell	O
Types.	O

Mesenchymal	B
Stem	I
Cell	I
Therapy	O
Ameliorates	O
Diabetic	O
Nephropathy	O
via	O
the	O
Paracrine	O
Effect	O
of	O
Renal	O
Trophic	O
Factors	O
Including	O
Exosomes.	O

Mesenchymal	B
Stem	I
Cell	I
Exosomes	O
Induce	O
Proliferation	O
and	O
Migration	O
of	O
Normal	O
and	O
Chronic	O
Wound	O
Fibroblasts,	O
and	O
Enhance	O
Angiogenesis	O
in	O
vitro.	O

Circulating	O
Apoptotic	O
Bodies	O
Maintain	O
Mesenchymal	B
Stem	I
Cell	I
Homeostasis	O
and	O
Ameliorate	O
Osteopenia	O
via	O
Transferring	O
Multiple	O
Cellular	O
Factors.	O

However,	O
analysis	O
of	O
conditional	O
SHIP1	O
mutant	O
mice	O
showed	O
that	O
osteoporosis	O
results	O
from	O
SHIP1	O
deficiency	O
in	O
the	O
mesenchymal	B
stem	I
cell	I
compartment	O
that	O
is	O
defective	O
for	O
differentiation	O
to	O
bone-forming	O
osteoblasts	O
in	O
the	O
absence	O
of	O
SHIP1	O
expression	O
and	O
increased	O
PI3K/AKT	O
signaling	O
that	O
promotes	O
a	O
β-Catenin/Id2	O
transcriptional	O
circuit	O
[85].	O

SHIP1-Expressing	O
Mesenchymal	O
Stem	O
Cells	O
Regulate	O
Hematopoietic	B
Stem	I
Cell	I
Homeostasis	O
and	O
Lineage	O
Commitment	O
During	O
Aging.	O

Coordinate	O
Expansion	O
of	O
Murine	O
Hematopoietic	O
and	O
Mesenchymal	B
Stem	I
Cell	I
Compartments	O
by	O
SHIPi.	O

Cancer	B
stem	I
cell	I
definitions	O
and	O
terminology:	O
The	O
devil	O
is	O
in	O
the	O
details.	O

:	O
Genome-wide	O
surveillance	O
of	O
mismatched	O
alleles	O
for	O
graft-versus-host	O
disease	O
in	O
stem	B
cell	I
transplantation.	O

The	O
second	O
commonly	O
used	O
method	O
is	O
co-culture	O
of	O
pluripotent	B
stem	I
cell	I
with	O
a	O
feeder	O
layer	O
of	O
mesenchymal	O
cells	O
such	O
as	O
bone	O
marrow	O
stromal	O
cells.	O

Similarly,	O
NOTCH1	O
mutations	O
have	O
also	O
been	O
studied	O
with	O
pluripotent	B
stem	I
cell	I
platforms	O
(160).	O

This	O
triculture	O
demonstrated	O
more	O
complex	O
vascular	O
networks	O
compared	O
to	O
culture	O
with	O
mesenchymal	B
stem	I
cell	I
and	O
endothelial	O
cells	O
alone.	O

Improved	O
understanding	O
of	O
vascular	O
development	O
will	O
also	O
provide	O
useful	O
in	O
the	O
field	O
of	O
regenerative	O
medicine	O
where	O
ensuring	O
perfusion	O
of	O
stem	B
cell	I
derived	O
tissue	O
is	O
one	O
of	O
the	O
key	O
challenges	O
in	O
producing	O
viable	O
implantable	O
grafts.	O

microRNAs	O
from	O
the	O
Planarian	O
Schmidtea	O
mediterranea:	O
a	O
model	O
system	O
for	O
stem	B
cell	I
biology.	O

A	O
gata6-wnt	O
pathway	O
required	O
for	O
epithelial	B
stem	I
cell	I
development	O
and	O
airway	O
regeneration.	O

In	O
addition,	O
components	O
of	O
the	O
piRNA	O
pathway	O
are	O
associated	O
with	O
stem	B
cell	I
self-renewal	O
and	O
are	O
aberrantly	O
expressed	O
in	O
several	O
types	O
of	O
somatic	O
tumors50,	O
suggesting	O
that	O
dysregulation	O
of	O
the	O
piRNA	O
pathway	O
leads	O
to	O
loss	O
of	O
proliferative	O
control.	O

We	O
selected	O
genes	O
expressed	O
in	O
PGCs:	O
Dead	O
end	O
(dnd),	O
crucial	O
to	O
PGC	O
survival	O
and	O
migration	O
[27],	O
vasa	O
(vasa)	O
relevant	O
in	O
germ	O
cell	O
lineage	O
and	O
PGC	O
development	O
[28],	O
chemokine	O
(C-X-C	O
motif)	O
receptor	O
4b	O
(cxcr4b)	O
involved	O
in	O
PGCs	O
migration	O
[29];	O
genes	O
with	O
important	O
functions	O
in	O
stem	B
cells	I
pluripotency:	O
POU	O
domain,	O
class	O
5,	O
transcription	O
factor	O
1	O
(pou5f1)	O
[30];	O
and	O
genes	O
involved	O
in	O
differentiation	O
processes	O
in	O
early	O
embryo	O
development:	O
SRY-box	O
containing	O
gene	O
2	O
[31]	O
and	O
3	O
[32]	O
(sox2	O
and	O
3)	O
(Supplementary	O
Table	O
1	O
(Figure	O
S1))..	O

Four	O
genes,	O
either	O
involved	O
in	O
neural	B
stem	I
cell	I
proliferation	O
and/or	O
neuronal	O
activity	O
that	O
have	O
been	O
reported	O
to	O
be	O
regulated	O
by	O
PTEN39,40,41,42,43	O
and	O
DAXX35,38,	O
were	O
analysed	O
(CCND1,	O
MYC,	O
FOS	O
and	O
BCL2).	O

Four	O
tumour-related	O
genes	O
associated	O
with	O
neural	B
stem	I
cell	I
proliferation	O
and	O
neuronal	O
activity,	O
and	O
regulated	O
by	O
PTEN39,40,41,42,43	O
and	O
DAXX35,38	O
were	O
studied.	O

Furthermore,	O
organoid	O
ability	O
to	O
replicate	O
the	O
microanatomy	O
of	O
organ-specific	O
stem	O
cell	O
niches	O
opens	O
gateways	O
to	O
research	O
EV	O
communication	O
within	O
the	O
stem	B
cell	I
microenvironment	O
along	O
with	O
the	O
TME.	O

CSCs	O
exhibit	O
many	O
defining	O
characteristics	O
such	O
as	O
self-renewal,	O
continuous	O
proliferation	O
capacity,	O
tumor	O
initiation	O
and	O
progression,	O
a	O
relatively	O
slow	O
cell	O
cycle	O
and	O
entrance	O
into	O
dormancy,	O
chemoresistance,	O
expression	O
of	O
stem	B
cell	I
markers	O
and	O
pluripotency	O
[113].	O

Culturing	O
tumor	O
cells	O
in	O
stem	B
cell	I
medium	O
often	O
results	O
in	O
characteristics	O
of	O
a	O
3D	O
microenvironment	O
including	O
heterogeneous	O
cell	O
populations.	O

For	O
instance,	O
human	O
prostate	O
neuroendocrine	O
adenocarcinoma	O
PC-3	O
cells	O
cultured	O
with	O
stem	B
cell	I
medium	O
in	O
3D	O
cell	O
culture	O
plates	O
formed	O
large	O
grape-like	O
aggregates	O
with	O
more	O
intercellular	O
space,	O
fewer	O
areas	O
of	O
intercellular	O
adhesion,	O
a	O
reduced	O
cell	O
proliferation	O
rate	O
and	O
cell	O
differentiation	O
[117].	O

Compared	O
with	O
2D	O
cultures	O
or	O
spheroids	O
in	O
serum-containing	O
medium,	O
the	O
PC-3	O
cell	O
aggregates	O
in	O
stem	O
cell	O
medium	O
formed	O
larger	O
cellular	O
aggregations	O
with	O
increased	O
intercellular	O
adhesion,	O
expression	O
of	O
stem	B
cell	I
markers	O
and	O
oncogenes,	O
increased	O
hypoxia	O
levels	O
and	O
slower	O
cellular	O
proliferation	O
rate,	O
better	O
representing	O
in	O
vivo	O
tumor	O
status.	O

When	O
cultured	O
in	O
stem	B
cell	I
medium,	O
murine	O
CRC	O
CT26	O
cells	O
grow	O
as	O
CSCs	O
in	O
spheroids	O
(colonospheres)	O
that	O
exhibit	O
increased	O
chemoresistance	O
and	O
orthotopic	O
tumorigenicity	O
[66].	O

This	O
can	O
be	O
attributed	O
to	O
the	O
stem	B
cell	I
factor,	O
Wnt,	O
which	O
activates	O
the	O
β-catenin/TCF-4	O
transcription	O
factor	O
complex	O
and	O
increases	O
Rab27B	O
expression	O
which	O
regulates	O
CRCSC	O
secretion	O
of	O
exosomes	O
and	O
the	O
inflammatory	O
chemokine	O
IL-8.	O

These	O
are	O
associated	O
with	O
stem	B
cell	I
functions	O
such	O
as	O
self-renewal	O
capacity	O
and	O
tumor	O
growth.	O

Human	O
ovarian	O
cancer	O
HeyA8	O
cells	O
cultured	O
under	O
hypoxic	O
conditions	O
in	O
stem	B
cell	I
medium	O
were	O
found	O
to	O
grow	O
as	O
spheroids	O
and	O
were	O
enriched	O
in	O
CSCs	O
[69].	O

Effect	O
of	O
cell	O
number	O
on	O
mesenchymal	B
stem	I
cell	I
transplantation	O
in	O
a	O
canine	O
disc	O
degeneration	O
model.	O

Surgery,	O
chemotherapy,	O
radiotherapy,	O
high-dose	O
chemotherapy	O
with	O
autologous	B
stem	I
cell	I
rescue,	O
biologic	O
and	O
immunotherapeutic	O
maintenance	O
therapy,	O
retinoids	O
40%–50%.	O

Activation	O
of	O
an	O
IL6	O
inflammatory	O
loop	O
mediates	O
trastuzumab	O
resistance	O
in	O
HER2+	O
breast	O
cancer	O
by	O
expanding	O
the	O
cancer	B
stem	I
cell	I
population.	O

For	O
a	O
detailed	O
description	O
of	O
stem	B
cell	I
culture	O
and	O
differentiation	O
protocols,	O
see	O
Supplemental	O
Information..	O

TGF-β	O
is	O
a	O
potent	O
chemokine	O
essential	O
for	O
the	O
recruitment	O
of	O
MSCs	O
and	O
plays	O
a	O
critical	O
role	O
in	O
stem	B
cell	I
proliferation	O
and	O
differentiation	O
[75].	O

LKB1	O
localization	O
to	O
the	O
primary	O
cilia	O
is	O
needed	O
to	O
inhibit	O
CCL2	O
expression	O
[88]	O
and	O
potentially	O
exert	O
its	O
inhibitory	O
function	O
on	O
mTORC1	O
and	O
thus	O
sustain	O
a	O
low	O
level	O
of	O
mTORC1	O
activity	O
needed	O
for	O
stem	B
cell	I
renewal	O
and	O
proliferation.	O

Role	O
of	O
Autophagy	O
and	O
primary	O
cilia	O
in	O
embryonic	B
stem	I
cell	I
lineage	O
specification.	O

It	O
is	O
believed	O
to	O
arise	O
from	O
neural	B
stem	I
cell	I
precursors	O
[115]	O
through	O
aberrant	O
activation	O
of	O
Shh	O
signaling	O
[115].	O

The	O
primary	O
cilium	O
is	O
an	O
essential	O
organelle	O
for	O
stem	B
cell	I
development	O
and	O
differentiation.	O

Understanding	O
how	O
the	O
primary	O
cilium	O
is	O
involved	O
in	O
stem	B
cell	I
biology	O
is	O
crucial	O
to	O
develop	O
new	O
ciliotherapies	O
[25]	O
to	O
eliminate	O
developmental	O
ciliopathy	O
diseases	O
such	O
as	O
Meckel	O
Syndrome..	O

Deciphering	O
the	O
role	O
of	O
the	O
primary	O
cilium	O
in	O
cancer	B
stem	I
cell	I
biology	O
will	O
likely	O
improve	O
our	O
knowledge	O
and	O
diversify	O
the	O
cancer	O
treatment	O
options	O
as	O
the	O
majority	O
of	O
the	O
signaling	O
pathways	O
are	O
dysregulated	O
in	O
cancers..	O

The	O
Notch	O
pathway	O
is	O
important	O
in	O
maintaining	O
the	O
cancer	B
stem	I
cell	I
population	O
in	O
pancreatic	O
cancer.	O

Recent	O
reports	O
have	O
characterised	O
a	O
subpopulation	O
of	O
mouse	O
AT2	O
cells	O
that	O
preferentially	O
act	O
as	O
the	O
alveolar	B
stem	I
cell	I
during	O
steady-state	O
turnover	O
(Nabhan	O
et	O
al.,	O
2018;	O
Zacharias	O
et	O
al.,	O
2018)	O
and	O
also	O
suggest	O
that	O
a	O
similar	O
subpopulation	O
can	O
be	O
identified	O
in	O
adult	O
human	O
alveoli.	O

A	O
bioengineered	O
niche	O
promotes	O
in	O
vivo	O
engraftment	O
and	O
maturation	O
of	O
pluripotent	B
stem	I
cell	I
derived	O
human	O
lung	O
organoids.	O

Terminal	O
bronchioles	O
harbor	O
a	O
unique	O
airway	B
stem	I
cell	I
population	O
that	O
localizes	O
to	O
the	O
bronchoalveolar	O
duct	O
junction.	O

Repair	O
and	O
regeneration	O
of	O
the	O
respiratory	O
system:	O
complexity,	O
plasticity,	O
and	O
mechanisms	O
of	O
lung	B
stem	I
cell	I
function.	O

Lung	B
stem	I
cell	I
differentiation	O
in	O
mice	O
directed	O
by	O
endothelial	O
cells	O
via	O
a	O
BMP4-NFATc1-thrombospondin-1	O
axis.	O

The	O
effect	O
of	O
FGF-2	O
withdrawal	O
in	O
promoting	O
neuronal	B
differentiation	I
from	I
stem	I
cells	I
is	O
mediated	O
by	O
IGF-I,56	O
and	O
pre-treatment	O
with	O
FGF-2	O
increases	O
IGF1R	O
expression.57	O
In	O
rodent	O
astrocytes,	O
IGF-I	O
secretion	O
is	O
stimulated	O
by	O
epidermal	O
growth	O
factor	O
(EGF)	O
and	O
IGF1R	O
blockade	O
reduces	O
the	O
action	O
of	O
EGF	O
on	O
cell	O
replication.58,59	O
In	O
a	O
human	O
neuroblastoma	O
cell	O
line,	O
IGF-II	O
stimulates	O
cell	O
growth	O
in	O
the	O
presence	O
of	O
EGF.60	O
Insulin-like	O
growth	O
factor	O
I	O
signalling	O
pathways	O
interact	O
with	O
those	O
of	O
sex	O
steroids	O
in	O
the	O
neuroendocrine	O
hypothalamus	O
and	O
also	O
in	O
the	O
hippocampus	O
in	O
the	O
control	O
of	O
neurogenesis	O
and	O
synaptic	O
plasticity.61	O
The	O
effect	O
of	O
IGF-I	O
on	O
oestrogen	O
signalling	O
in	O
brain	O
is	O
cell	O
type-specific	O
and	O
oestrogen	O
receptor	O
isoform-specific.62	O
When	O
the	O
IGF-I	O
gene	O
is	O
delivered	O
to	O
the	O
medial	O
basal	O
hypothalamus	O
in	O
female	O
rats,	O
serum	O
luteinising	O
hormone	O
levels	O
are	O
higher,	O
probably	O
due	O
to	O
enhanced	O
oestrogen	O
positive	O
feedback	O
on	O
GnRH	O
production,	O
and	O
ovarian	O
function	O
is	O
prolonged.63	O
The	O
IGF	O
system	O
interfaces	O
with	O
the	O
brain-derived	O
neurotrophic	O
factor	O
(BDNF)	O
system.	O

Neural	B
stem	I
cell	I
differentiation	O
into	O
mature	O
neurons:	O
mechanisms	O
of	O
regulation	O
and	O
biotechnological	O
applications.	O

These	O
lineage-committed	O
progenitors	O
are	O
defined	O
as	O
CD34+CD38+IL-3Rα+CD45RA−IL-5Rα+	O
and	O
generate	O
only	O
eosinophils	O
under	O
ex	O
vivo	O
culture	O
conditions	O
that	O
are	O
enriched	O
in	O
stem	B
cell	I
factor,	O
IL-3,	O
IL-5,	O
GM-CSF,	O
erythropoietin	O
and	O
thrombopoietin.	O

Expression	O
of	O
the	O
cancer	B
stem	I
cell	I
markers	O
ABCG2	O
and	O
OCT-4	O
in	O
right-sided	O
colon	O
cancer	O
predicts	O
recurrence	O
and	O
poor	O
outcomes.	O

Furthermore,	O
Wnt	O
is	O
involved	O
in	O
the	O
up-regulation	O
of	O
neuronal	B
stem	I
cell	I
growth	O
through	O
HIF-1a	O
signaling	O
[43]..	O

The	O
goal	O
of	O
myogenic	O
stem	O
cell	O
transplant	O
therapy	O
for	O
DMD	O
is	O
to	O
increase	O
dystrophin	O
expression	O
in	O
existing	O
muscle	O
fibers	O
and	O
to	O
provide	O
a	O
source	O
of	O
stem	B
cells	I
for	O
future	O
muscle	O
generation.	O

New	O
insights	O
to	O
vascular	O
smooth	O
muscle	O
cell	O
and	O
pericyte	O
differentiation	O
of	O
mouse	B
embryonic	I
stem	I
cells	I
in	O
vitro.	O

The	O
phase	O
I	O
oligodendrocyte	O
trial	O
recently	O
ceased	O
taking	O
new	O
enrolments	O
due	O
to	O
Geron's	O
controversial	O
strategic	O
financial	O
decision	O
to	O
move	O
out	O
of	O
the	O
stem	B
cell	I
field	O
in	O
favour	O
of	O
developing	O
in-house	O
anti-cancer	O
drugs	O
[60].	O

Innovative	O
approaches	O
in	O
the	O
embryonic	B
stem	I
cell	I
test	O
(EST)	O
Front	O
Biosci.	O

The	O
application	O
of	O
human	B
embryonic	I
stem	I
cell	I
technologies	O
to	O
drug	O
discovery.	O

Validation	O
of	O
the	O
embryonic	B
stem	I
cell	I
test	O
in	O
the	O
international	O
ECVAM	O
validation	O
study	O
on	O
three	O
in	O
vitro	O
embryotoxicity	O
tests.	O

Three-dimensional	O
culture	O
of	O
human	B
embryonic	I
stem	I
cell	I
derived	O
hepatic	O
endoderm	O
and	O
its	O
role	O
in	O
bioartificial	O
liver	O
construction.	O

Mesenchymal	B
stem	I
cell	I
therapy	O
targeting	O
mitochondrial	O
dysfunction	O
in	O
acute	O
kidney	O
injury.	O

DeltaNp63alpha	O
is	O
an	O
oncogene	O
that	O
targets	O
chromatin	O
remodeler	O
Lsh	O
to	O
drive	B
skin	I
stem	I
cell	I
proliferation	O
and	O
tumorigenesis.	O

(e)	O
Quantitative	O
PCR	O
analysis	O
of	O
stem	B
cell	I
markers	O
OCT4,	O
SOX2,	O
L-MYC	O
and	O
LIN28.	O

Wang	O
L,	O
Zeng	O
X,	O
Ryoo	O
HD,	O
Jasper	O
H	O
(2014)	O
Integration	O
of	O
UPRER	O
and	O
oxidative	O
stress	O
signaling	O
in	O
the	O
control	O
of	O
intestinal	B
stem	I
cell	I
proliferation.	O

Mesenchymal	B
stem	I
cell	I
carriers	O
protect	O
oncolytic	O
measles	O
viruses	O
from	O
antibody	O
neutralization	O
in	O
an	O
orthotopic	O
ovarian	O
cancer	O
therapy	O
model.	O

Recent	O
studies	O
in	O
embryonic	B
stem	I
cells	I
in	O
which	O
O-fut1	O
was	O
removed,	O
and	O
Chinese	O
hamster	O
ovary	O
cell	O
lines	O
in	O
which	O
O-fut1	O
was	O
knocked	O
down,	O
show	O
that	O
Notch–ligand	O
interaction	O
and	O
ligand-induced	O
Notch	O
activation	O
are	O
impaired	O
in	O
biochemical	O
assays,	O
highlighting	O
the	O
role	O
of	O
O-fucosylation	O
in	O
optimizing	O
the	O
Notch–ligand	O
binding	O
(Stahl	O
et	O
al.,	O
2008).	O

Similarly,	O
an	O
equivalent	O
level	O
of	O
the	O
proliferation	O
marker	O
Ki67,	O
in	O
combination	O
with	O
the	O
stem	B
cell	I
marker	O
Pax7	O
was	O
found	O
in	O
injured	O
control	O
and	O
IKK2CAMuSC	O
muscles	O
(Figures	O
3D	O
and.	O

4E),	O
as	O
identified	O
by	O
the	O
stem	B
cell	I
marker,	O
vascular	O
cell	O
adhesion	O
molecule	O
(VCAM)	O
(Figure	O
S3G).	O

We	O
found	O
that	O
the	O
number	O
of	O
MuSCs	O
decreases	O
over	O
time	O
in	O
Pax7EGFP/IKK2CAMuSC	O
skeletal	O
muscles	O
(Figure	O
4F),	O
indicative	O
of	O
an	O
exhaustion	O
of	O
the	O
stem	B
cell	I
pool	O
under	O
chronic	O
injury..	O

The	O
potential	O
mechanisms	O
underlying	O
the	O
protective	O
role	O
of	O
stem	B
cells	I
have	O
been	O
extensively	O
studied,	O
such	O
as	O
the	O
promotion	O
of	O
angiogenesis	O
and	O
endogenous	O
neurogenesis,	O
immunomodulatory	O
functions,	O
differentiation	O
into	O
cells	O
that	O
facilitate	O
repair	O
or	O
replacement	O
of	O
a	O
damaged	O
tissue,	O
secretion	O
of	O
cytokines	O
helping	O
to	O
restore	O
neural	O
injury,	O
and	O
cell	O
migration	O
(Gutiérrez-Fernández	O
et	O
al.,	O
2013;	O
Shichinohe	O
et	O
al.,	O
2015;	O
Tan	O
et	O
al.,	O
2018;	O
Rikhtegar	O
et	O
al.,	O
2019;	O
Kikuchi-Taura	O
et	O
al.,	O
2020).	O

This	O
review	O
summarizes	O
and	O
discusses	O
the	O
pathophysiological	O
changes	O
after	O
IS,	O
which	O
are	O
also	O
the	O
treatment	O
targets	O
of	O
stem	O
cell	O
therapy,	O
the	O
current	O
types	O
of	O
cell	O
therapy,	O
the	O
stem	B
cell	I
used,	O
and	O
the	O
neuroprotective	O
mechanisms.	O

Neurotrophic	O
factor	O
secretion	O
is	O
an	O
important	O
mechanism	O
underlying	O
the	O
function	O
of	O
stem	B
cell	I
therapy	O
in	O
IS.	O

Mesenchymal	B
stem	I
cells	I
have	O
the	O
capacity	O
for	O
self-renewal	O
and	O
potential	O
multidirectional	O
differentiation	O
into	O
different	O
cell	O
types	O
and	O
are	O
available	O
from	O
almost	O
any	O
tissue	O
type.	O

The	O
first	O
step	O
in	O
restoring	O
damaged	O
cells	O
following	O
stroke	O
is	O
the	O
migration	O
of	O
stem	O
cells	O
into	O
the	O
damaged	O
brain	O
regions	O
(De	O
Feo	O
et	O
al.,	O
2012);	O
however,	O
it	O
is	O
not	O
yet	O
clear	O
how	O
the	O
stem	O
cells	O
enter	O
the	O
infarct	O
core	O
or	O
boundary	O
area	O
after	O
IS;	O
therefore,	O
modulating	O
their	O
migration	O
remains	O
a	O
challenge	O
in	O
translating	O
stem	B
cell	I
therapy	O
from	O
the	O
laboratory	O
to	O
clinical	O
practice	O
(Sullivan	O
et	O
al.,	O
2015).	O

Understanding	O
this	O
mechanism	O
should	O
be	O
a	O
critical	O
part	O
of	O
future	O
studies	O
on	O
the	O
protective	O
effects	O
of	O
stem	B
cell	I
therapy..	O

Due	O
to	O
the	O
role	O
of	O
BDNF	O
in	O
stem	B
cell	I
migration,	O
recent	O
research	O
has	O
shown	O
that	O
a	O
certain	O
level	O
of	O
BDNF	O
can	O
serve	O
as	O
a	O
minimum	O
predictive	O
value	O
for	O
the	O
recovery	O
of	O
motor	O
function	O
after	O
IS	O
(Luo	O
et	O
al.,	O
2019).	O

Some	O
recent	O
studies	O
have	O
found	O
a	O
lower	O
density	O
of	O
transplanted	B
stem	I
cells	I
in	O
the	O
stroke	O
core	O
compared	O
with	O
the	O
penumbra	O
or	O
surrounding	O
area,	O
suggesting	O
that	O
functional	O
improvements	O
are	O
more	O
likely	O
mediated	O
by	O
the	O
release	O
of	O
trophic	O
factors	O
rather	O
than	O
cell	O
replacement	O
and	O
differentiation,	O
a	O
phenomenon	O
known	O
as	O
the	O
“bystander	O
effect.”.	O

The	O
bystander	O
effect	O
is	O
common	O
in	O
the	O
protective	O
mechanisms	O
of	O
stem	B
cell	I
used	O
in	O
the	O
IS	O
therapy.	O

It	O
is	O
that	O
revealed	O
the	O
functional	O
network	O
sharply	O
decreased	O
for	O
the	O
entire	O
3	O
months,	O
while	O
it	O
was	O
previously	O
stabilized	O
in	O
mice	O
with	O
NSC	O
transplantation,	O
indicating	O
the	O
important	O
paracrine	O
role	O
of	O
stem	B
cell	I
treatment	O
in	O
IS	O
therapy	O
(Green	O
et	O
al.,	O
2018).	O

The	O
beneficial	O
paracrine	O
effect	O
of	O
stem	B
cell	I
support	O
and	O
protect	O
neurons	O
in	O
ischemic	O
conditions,	O
which	O
is	O
largely	O
attributed	O
to	O
the	O
release	O
of	O
neurotrophic	O
factors	O
such	O
as	O
SDF,	O
NGF,	O
BDNF,	O
GDNF,	O
and	O
FGF	O
(Wakabayashi	O
et	O
al.,	O
2010).	O

More	O
than	O
50%	O
of	O
transplanted	B
stem	I
cells	I
in	O
the	O
ischemic	O
brain	O
express	O
a	O
neuronal	O
phenotype	O
at	O
2	O
months	O
after	O
cell	O
transplantation	O
(Kawabori	O
et	O
al.,	O
2012,	O
2013)..	O

There	O
has	O
been	O
a	O
lot	O
of	O
fundamental	O
research	O
into	O
exosomes	O
and	O
their	O
related	O
secreted	O
factors,	O
as	O
a	O
medium	O
for	O
information	O
exchange	O
between	O
cells,	O
in	O
stem	B
cell	I
therapy.	O

Over	O
the	O
last	O
decades,	O
a	O
large	O
number	O
of	O
preclinical	O
studies	O
have	O
been	O
carried	O
out	O
on	O
the	O
role	O
of	O
stem	B
cell	I
therapy	O
in	O
IS	O
treatment.	O

During	O
IS,	O
the	O
pathophysiological	O
changes	O
after	O
stroke	O
are	O
due	O
to	O
a	O
dynamic	O
process,	O
which	O
in	O
turn	O
requires	O
a	O
flexibility	O
in	O
stem	B
cell	I
choice	O
dependent	O
on	O
individual	O
patient’s	O
conditions.	O

Based	O
on	O
the	O
different	O
features	O
of	O
stem	O
cell	O
types	O
and	O
the	O
pathophysiological	O
change	O
in	O
each	O
phase	O
of	O
IS,	O
it	O
is	O
advisable	O
that	O
the	O
stem	B
cell	I
therapeutic	O
strategy	O
should	O
be	O
adjusted	O
to	O
the	O
pathophysiology	O
features	O
according	O
to	O
further	O
clinical	O
studies..	O

Nevertheless,	O
the	O
intravascular	O
routes	O
(intravenous	O
and	O
intra-arterial	O
route)	O
mainly	O
contribute	O
to	O
the	O
functional	O
recovery	O
that	O
may	O
mainly	O
rely	O
on	O
the	O
bystander	O
effect,	O
while	O
the	O
intrathecal,	O
intracerebroventricular,	O
intracerebral,	O
and	O
subarachnoid	O
routes	O
are	O
invasive	O
routes	O
that	O
can	O
directly	O
deliver	O
the	O
stem	B
cell	I
into	O
the	O
CNS,	O
thus	O
facilitating	O
the	O
reconstruction	O
of	O
the	O
neural	O
circuit	O
and	O
the	O
replacement	O
of	O
the	O
damaged	O
brain	O
tissues	O
in	O
IS	O
(Kelly	O
et	O
al.,	O
2004).	O

So	O
far,	O
the	O
strong	O
connection	O
between	O
routes	O
of	O
administration	O
and	O
the	O
target	O
of	O
stem	B
cell	I
therapy	O
is	O
quite	O
evident.	O

It	O
is	O
therefore	O
important	O
to	O
take	O
these	O
aspects	O
into	O
consideration	O
when	O
assessing	O
the	O
effect	O
of	O
stem	B
cell	I
therapy	O
in	O
future	O
clinical	O
studies.	O

The	O
purpose	O
of	O
stem	B
cell	I
therapy	O
in	O
the	O
chronic	O
phase	O
is	O
totally	O
different	O
because	O
it	O
focuses	O
mainly	O
on	O
neurogenesis,	O
angiogenesis,	O
and	O
synaptic	O
plasticity	O
in	O
peri-ischemic	O
areas	O
to	O
restore	O
neuronal	O
functions.	O

Some	O
clinical	O
trials	O
have	O
reported	O
the	O
efficacy	O
of	O
stem	B
cell	I
therapy	O
in	O
the	O
chronic	O
phase	O
of	O
IS	O
by	O
intracerebral	O
and	O
intravascular	O
routes	O
(Chen	O
D.C.	O

This	O
improves	O
the	O
survival	O
and	O
migration	O
of	O
stem	O
cells,	O
finally	O
differentially	O
modulating	O
the	O
transplanted	O
cell	O
fate	O
(Moshayedi	O
et	O
al.,	O
2016;	O
Gopalakrishnan	O
et	O
al.,	O
2019).	O
Only	O
few	O
studies	O
are	O
available	O
discussing	O
the	O
appropriate	O
cell	O
dose	O
in	O
stem	O
cell	O
therapy	O
and	O
considering	O
the	O
risk	O
of	O
formation	O
of	O
tumors	O
and	O
thrombosis,	O
and	O
thus,	O
further	O
studies	O
should	O
investigate	O
these	O
issues	O
before	O
the	O
widespread	O
use	O
of	O
stem	B
cell	I
therapy	O
in	O
clinical	O
practice..	O

Our	O
review	O
summarizes	O
the	O
mechanisms	O
of	O
stem	B
cell	I
therapy	O
in	O
detail,	O
as	O
well	O
as	O
several	O
key	O
parameters	O
elucidated	O
by	O
the	O
current	O
clinical	O
research,	O
providing	O
a	O
reference	O
and	O
a	O
guide	O
in	O
the	O
direction	O
of	O
further	O
research.	O

In	O
addition,	O
many	O
preclinical	O
and	O
clinical	O
trials	O
have	O
revealed	O
promising	O
prospects	O
in	O
the	O
administration	O
of	O
stem	B
cell	I
therapy	O
to	O
cure	O
IS.	O

However,	O
much	O
research	O
still	O
needs	O
to	O
be	O
performed,	O
and	O
new	O
discoveries	O
may	O
help	O
develop	O
a	O
better	O
use	O
or	O
modification	O
of	O
stem	B
cell	I
therapy	O
or	O
the	O
treatment	O
methods	O
derived	O
from	O
it.	O

The	O
next	O
step	O
may	O
require	O
exploration	O
of	O
more	O
clinically	O
suited	O
issues,	O
such	O
as	O
the	O
choice	O
of	O
stem	O
cell	O
types,	O
the	O
route	O
of	O
stem	B
cell	I
administration,	O
the	O
administration	O
time,	O
and	O
the	O
cell	O
dose.	O

Restriction	O
landmark	O
genome	O
scanning	O
identifies	O
culture-induced	O
DNA	O
methylation	O
instability	O
in	O
the	O
human	B
embryonic	I
stem	I
cell	I
epigenome.	O

Clinical	O
trials	O
of	O
adult	B
stem	I
cell	I
therapy	O
in	O
patients	O
with	O
ischemic	O
stroke.	O

Neural	B
stem	I
cell	I
transplantation	O
in	O
central	O
nervous	O
system	O
disorders:	O
from	O
cell	O
replacement	O
to	O
neuroprotection.	O

Efficacy	O
and	O
safety	O
of	O
stem	B
cell	I
therapies	O
for	O
patients	O
with	O
stroke:	O
a	O
systematic	O
review	O
and	O
single	O
arm	O
meta-analysis.	O

Mesenchymal	B
stem	I
cell	I
therapy	O
for	O
ischemic	O
stroke:	O
a	O
look	O
into	O
treatment	O
mechanism	O
and	O
therapeutic	O
potential.	O

Intravenous	O
autologous	O
bone	B
marrow	I
mononuclear	I
stem	I
cell	I
therapy	O
for	O
ischemic	O
stroke:	O
a	O
multicentric,	O
randomized	O
trial.	O

Delayed	O
intranasal	O
delivery	O
of	O
hypoxic-preconditioned	B
bone	I
marrow	I
mesenchymal	I
stem	I
cells	I
enhanced	O
cell	O
homing	O
and	O
therapeutic	O
benefits	O
after	O
ischemic	O
stroke	O
in	O
mice.	O

Transplantation	O
of	O
neural	B
stem	I
cells	I
overexpressing	O
glial	O
cell	O
line-derived	O
neurotrophic	O
factor	O
enhances	O
Akt	O
and	O
Erk1/2	O
signaling	O
and	O
neurogenesis	O
in	O
rats	O
after	O
stroke.	O

With	O
regard	O
to	O
that,	O
3D	O
quantitative	O
DNA	O
methylation	O
imaging	O
(3D-qDMI)	O
has	O
been	O
particularly	O
developed	O
as	O
a	O
tool	O
towards	O
the	O
causal	O
assessment	O
of	O
global	O
DNA	O
demethylation,	O
heterochromatin	O
decondensation,	O
and	O
relevant	O
genome	O
reorganization	O
in	O
cell	O
nuclei	O
to	O
characterize	O
cells	O
in	O
response	O
to	O
environmental	O
changes,	O
for	O
directed	O
differentiation	O
of	O
stem	B
cells	I
and	O
therapeutic	O
reprogramming	O
by	O
demethylating	O
agents	O
[18–24].	O

The	O
importance	O
of	O
retrotransposons	O
in	O
aging	O
was	O
supported	O
by	O
recent	O
evidences	O
in	O
which	O
the	O
class	O
of	O
Alu	O
sequences	O
—	O
the	O
most	O
abundant	O
primate	O
SINE	O
—	O
was	O
found	O
demethylated	O
in	O
the	O
context	O
of	O
adult	B
stem	I
cell	I
aging,	O
due	O
to	O
elevation	O
in	O
DNA	O
damage	O
as	O
a	O
result	O
of	O
demethylation-induced	O
increase	O
in	O
Alu	O
transcription	O
[58].	O

Expression	O
of	O
the	O
neural	B
stem	I
cell	I
marker	O
(PAX6),	O
neural	O
precursor	O
markers	O
(S100	O
and	O
SOX2),	O
and	O
early	O
neural	O
markers	O
(MAP2	O
and	O
Nestin)	O
were	O
confirmed	O
by	O
immunofluorescence	O
staining.	O

In	O
addition,	O
expression	O
of	O
MAP2,	O
the	O
neural	B
stem	I
cell	I
marker	O
PAX6,	O
neural	O
progenitor	O
markers	O
S100	O
and	O
SOX2,	O
and	O
the	O
early	O
neuronal	O
marker	O
Nestin	O
was	O
confirmed	O
by	O
enlarging	O
individual	O
neuro-organoids	O
(Figure	O
6D)..	O

FGF	O
signalling	O
as	O
a	O
mediator	O
of	O
lineage	O
transitions—evidence	O
from	O
embryonic	B
stem	I
cell	I
differentiation.	O

Piwi-like	O
genes/proteins	O
are	O
essential	O
for	O
stem	B
cell	I
self-renewal	O
and	O
are	O
expressed	O
predominantly	O
in	O
the	O
germline5–7.	O

A	O
novel	O
class	O
of	O
evolutionarily	O
conserved	O
genes	O
defined	O
by	O
piwi	O
are	O
essential	O
for	O
stem	B
cell	I
self-renewal.	O

Additionally,	O
physiological	O
response	O
markers	O
can	O
offer	O
an	O
opportunity	O
to	O
get	O
a	O
better	O
understanding	O
of	O
an	O
intervention’s	O
potential	O
effects	O
when	O
no	O
direct	O
molecular	O
target	O
is	O
involved	O
or	O
when	O
the	O
exact	O
mechanism	O
of	O
action	O
is	O
not	O
yet	O
fully	O
understood,	O
e.g.,	O
in	O
the	O
case	O
of	O
stem	B
cell	I
trials	O
in	O
ALS	O
patients	O
[101,104]	O
(Table	O
2)..	O

Mesenchymal	B
stem	I
cell	I
transplantation	O
in	O
amyotrophic	O
lateral	O
sclerosis:	O
A	O
Phase	O
I	O
clinical	O
trial.	O

Intraspinal	B
stem	I
cell	I
transplantation	O
in	O
amyotrophic	O
lateral	O
sclerosis:	O
A	O
phase	O
I	O
trial,	O
cervical	O
microinjection,	O
and	O
final	O
surgical	O
safety	O
outcomes.	O

Safety	O
and	O
immunological	O
effects	O
of	O
mesenchymal	B
stem	I
cell	I
transplantation	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
and	O
amyotrophic	O
lateral	O
sclerosis.	O

Several	O
studies	O
have	O
shown	O
that	O
YAP/TAZ	O
play	O
a	O
functional	O
role	O
in	O
cancer	B
stem	I
cell	I
maintenance	O
and	O
proliferation	O
[26,27].	O

Indeed,	O
relapse	O
ineluctably	O
occurs,	O
principally	O
due	O
to	O
local	O
invasiveness,	O
therapeutic	O
failure	O
in	O
radiation	O
therapy,	O
and	O
drug	O
response,	O
as	O
well	O
as	O
the	O
existence	O
of	O
cancer	B
stem	I
cell	I
population.	O

Following	O
10	O
days	O
of	O
directed	O
differentiation,	O
iPS	O
podocytes	O
had	O
an	O
up-regulated	O
expression	O
of	O
mRNA	O
and	O
protein	O
localization	O
for	O
podocyte	O
markers	O
including	O
synaptopodin,	O
nephrin	O
and	O
Wilm’s	O
tumour	O
protein	O
(WT1),	O
combined	O
with	O
a	O
down-regulation	O
of	O
the	O
stem	B
cell	I
marker	O
OCT3/4.	O

Murine	O
cutaneous	O
mastocytosis	O
and	O
epidermal	O
melanocytosis	O
induced	O
by	O
keratinocyte	O
expression	O
of	O
transgenic	B
stem	I
cell	I
factor.	O

Sept4/ARTS‐Null	O
mice	O
show	O
accelerated	O
spontaneous	O
tumor	O
development,	O
elevated	O
XIAP	O
(but	O
not	O
cIAP1)	O
levels,	O
and	O
increased	O
numbers	O
of	O
stem	B
cells	I
that	O
are	O
resistant	O
to	O
cell	O
death.	O

Utilizing	O
breast	O
cancer	O
cell	O
lines,	O
mouse	O
xenograft	O
models,	O
we	O
demonstrate	O
that	O
HER2	O
is	O
selectively	O
expressed	O
in	O
the	O
cancer	B
stem	I
cell	I
population	O
(CSCs)	O
of	O
ER+,	O
HER2‐	O
luminal	O
breast	O
cancers	O
and	O
were	O
responsive	O
to	O
Trastuzumab	O
treatment.	O

N6‐methyladenosine	O
landscape	O
of	O
mRNAs	O
in	O
glioma:	O
Essential	O
role	O
of	O
METTL3	O
and	O
m6A	O
modification	O
in	O
glioma	B
stem	I
cell	I
growth.	O

We	O
found	O
that	O
METTL3	O
and	O
the	O
associated	O
m6A	O
modification	O
are	O
essential	O
for	O
glioma	B
stem	I
cell	I
growth.	O

Thus	O
our	O
study	O
reports	O
the	O
importance	O
of	O
m6A	O
modification	O
in	O
glioma	B
stem	I
cell	I
growth	O
and	O
uncovers	O
METTL3	O
as	O
a	O
potential	O
molecular	O
target	O
in	O
GBM	O
therapy..	O

Chemokine	O
receptor	O
CXCR4	O
and	O
its	O
ligand	O
CXCL12	O
(SDF‐1)	O
have	O
shown	O
to	O
be	O
overexpressed	O
in	O
more	O
than	O
20	O
solid	O
tumors	O
and	O
CXCR4	O
serves	O
as	O
a	O
Cancer	B
Stem	I
Cell	I
(CSC)	O
marker	O
in	O
multiple	O
cancers.	O

We	O
have	O
found	O
the	O
role	O
of	O
epigenetic	O
regulation	O
in	O
programmed	O
cell	O
death	O
as	O
well	O
as	O
in	O
differentiation	O
of	O
neural	O
stem	O
cells.	O
Amity	O
Institute	O
of	O
Molecular	O
Medicine	O
and	O
Stem	B
Cell	I
Research	O
(AIMMSCR),	O
Amity	O
University,	O
Noida,	O
Uttar	O
Pradesh,	O
India.	O

Primary	O
OSCC	O
cells	O
expressed	O
combination	O
of	O
stem	B
cell	I
markers	O
that	O
did	O
not	O
change	O
in	O
series	O
of	O
cell	O
passages.	O

Modulation	O
of	O
mammary	B
stem	I
cell	I
properties	O
by	O
the	O
transcription	O
factor	O
Nrf2.	O

However,	O
the	O
molecular	O
and	O
physiological	O
requirements	O
for	O
germline	B
stem	I
cell	I
homeostasis	O
remain	O
largely	O
elusive.	O

The	O
staining	O
was	O
much	O
weaker	O
at	O
the	O
core	O
of	O
the	O
stem	B
cell	I
colonies	O
and	O
progressively	O
increased	O
as	O
cells	O
differentiated	O
and	O
extended	O
membrane	O
projections	O
typical	O
of	O
differentiated	O
cells.	O

Mammalian	B
stem	I
cell	I
differentiation	O
upon	O
LIF	O
removal	O
is	O
accompanied	O
by	O
an	O
increase	O
in	O
POLRMT	O
expression.	O

Hence,	O
a	O
switch	O
to	O
enhanced	O
mitochondrial	O
respiration	O
is	O
a	O
prerequisite	O
for	O
stem	B
cell	I
differentiation	O
across	O
species..	O

For	O
instance,	O
Insulin/IGF-1	O
promotes	O
germ	O
cell	O
proliferation,	O
while	O
DAF-16/FOXO	O
is	O
beneficial	O
for	O
stem	B
cell	I
pool	O
maintenance	O
during	O
ageing	O
[29,	O
59].	O

Analysis	O
of	O
germline	B
stem	I
cell	I
differentiation	O
following	O
loss	O
of	O
GLP-1	O
notch	O
activity	O
in	O
Caenorhabditis	O
elegans.	O

Sensory	O
regulation	O
of	O
reproduction	O
via	O
TGFβ	O
signaling	O
through	O
the	O
stem	B
cell	I
niche.	O

Cancer	B
stem	I
cells	I
–	O
new	O
and	O
potentially	O
important	O
targets	O
for	O
the	O
therapy	O
of	O
oral	O
squamous	O
cell	O
carcinoma.	O

Metastatic	O
potential	O
of	O
cancer	B
stem	I
cells	I
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma.	O

Identification	O
and	O
characterization	O
of	O
cancer	B
stem	I
cells	I
in	O
human	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma.	O

Acute	O
myeloid	O
leukemia	O
originates	O
from	O
a	O
hierarchy	O
of	O
leukemic	B
stem	I
cell	I
classes	O
that	O
differ	O
in	O
self-renewal	O
capacity.	O

Cancer	B
stem	I
cell	I
mediated	O
acquired	O
chemoresistance	O
in	O
head	O
and	O
neck	O
cancer	O
can	O
be	O
abrogated	O
by	O
aldehyde	O
dehydrogenase	O
1	O
A1	O
inhibition.	O

Targeting	O
the	O
mechanisms	O
of	O
resistance	O
to	O
chemotherapy	O
and	O
radiotherapy	O
with	O
the	O
cancer	B
stem	I
cell	I
hypothesis.	O

Identification	O
of	O
a	O
subpopulation	O
of	O
cells	O
with	O
cancer	B
stem	I
cell	I
properties	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma.	O

Cancer	B
stem	I
cells	I
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma:	O
a	O
review.	O

The	O
evolving	O
concepts	O
of	O
cancer	B
stem	I
cells	I
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma.	O

Interestingly,	O
the	O
loss	O
of	O
the	O
AKT1	O
or	O
AKT2	O
isoform	O
had	O
only	O
a	O
minimal	O
effect	O
on	O
hematopoietic	B
stem	I
cell	I
function,	O
whereas	O
AKT1/2	O
double-deficient	O
cells	O
exhibited	O
long-term	O
functional	O
defects	O
that	O
were	O
caused	O
by	O
decreased	O
reactive	O
oxygen	O
species	O
production	O
and	O
survival	O
[113].	O

This	O
increase	O
in	O
cell	O
proliferation	O
is	O
accompanied	O
by	O
the	O
up	O
regulation	O
of	O
stem	B
cell	I
markers	O
and	O
a	O
decrease	O
in	O
Notch	O
signaling	O
(66).	O

Mesenchymal	B
stem	I
cells	I
enhance	O
ovarian	O
cancer	O
cell	O
infiltration	O
through	O
IL6	O
secretion	O
in	O
an	O
amniochorionic	O
membrane	O
based	O
3D	O
model.	O

The	O
fibroblast	O
growth	O
factor	O
receptor	O
1	O
(FGFR1)	O
gene	O
on	O
chromosome	O
8	O
is	O
involved	O
in	O
translocations	O
with	O
at	O
least	O
14	O
partner	O
genes	O
in	O
stem	B
cell	I
myeloproliferative	O
disorder	O
and	O
other	O
myeloid	O
and	O
lymphoid	O
cancers	O
[202].	O

The	O
retrovirus	O
HERVH	O
is	O
a	O
long	O
noncoding	O
RNA	O
required	O
for	O
human	B
embryonic	I
stem	I
cell	I
identity.	O

Platelets	O
are	O
widely	O
recognized	O
as	O
inducers	O
of	O
cell	O
proliferation,	O
and	O
are	O
also	O
involved	O
in	O
stem	B
cell	I
differentiation,	O
cell	O
migration,	O
and	O
revascularization	O
of	O
damaged	O
tissue	O
via	O
increased	O
release	O
of	O
growth	O
factors	O
during	O
tissue	O
regeneration.	O

Since	O
then,	O
there	O
have	O
been	O
slow	O
but	O
steady	O
attempts	O
at	O
understanding	O
the	O
regenerative	O
capabilities	O
of	O
human	O
being	O
and	O
it	O
is	O
only	O
in	O
the	O
last	O
decade	O
that	O
we	O
have	O
seen	O
an	O
information	O
explosion	O
in	O
the	O
area	O
of	O
stem	B
cell	I
research.	O

Further,	O
it	O
is	O
difficult	O
to	O
control	O
the	O
growth	O
and	O
differentiation	O
of	O
the	O
embryonic	B
stem	I
cell	I
posing	O
risk	O
of	O
tumorogenicity	O
and	O
teratoma	O
formation.	O

Advances	O
in	O
stem	B
cell	I
research	O
have	O
explored	O
many	O
therapeutic	O
avenues	O
and	O
the	O
insight	O
gained	O
by	O
a	O
pilot	O
proof	O
of	O
concept	O
studies	O
promises	O
a	O
plethora	O
of	O
unimaginable	O
benefits:.	O

Recent	O
developments	O
in	O
the	O
technique	O
of	O
stem	B
cell	I
isolation	O
and	O
expansion	O
together	O
with	O
advances	O
in	O
growth	O
factor	O
biology	O
and	O
biodegradable	O
polymer	O
constructs	O
have	O
set	O
a	O
stage	O
for	O
successful	O
tissue	O
engineering	O
of	O
tooth/tooth-related	O
tissues.	O

Integration	O
of	O
exogenous	O
DNA	O
into	O
mouse	B
embryonic	I
stem	I
cell	I
chromosomes	O
shows	O
preference	O
into	O
genes	O
and	O
frequent	O
modification	O
at	O
junctions.	O

The	O
Notch	O
signaling	O
pathway	O
encourages	O
pancreatic	O
lineage	O
commitment	O
and	O
pancreatic	O
progenitor	O
cell	O
differentiation,	O
whereas	O
WNT	O
signaling	O
controls	O
the	O
stem	B
cell	I
state	O
[128,129].	O

The	O
Ever-Evolving	O
Concept	O
of	O
the	O
Cancer	B
Stem	I
Cell	I
in	O
Pancreatic	O
Cancer.	O

Cancer	B
stem	I
cell	I
drugs	O
target	O
K-ras	O
signaling	O
in	O
a	O
stemness	O
context.	O

The	O
Notch	O
pathway	O
is	O
important	O
in	O
maintaining	O
the	O
cancer	B
stem	I
cell	I
population	O
in	O
pancreatic	O
cancer.	O

DCLK1	O
marks	O
a	O
morphologically	O
distinct	O
subpopulation	O
of	O
cells	O
with	O
stem	B
cell	I
properties	O
in	O
preinvasive	O
pancreatic	O
cancer.	O

Comparative	O
evaluation	O
of	O
cancer	B
stem	I
cell	I
markers	O
in	O
normal	O
pancreas	O
and	O
pancreatic	O
ductal	O
adenocarcinoma.	O

Photochemical	O
internalization	O
(PCI)	O
of	O
immunotoxins	O
targeting	O
CD133	O
is	O
specific	O
and	O
highly	O
potent	O
at	O
femtomolar	O
levels	O
in	O
cells	O
with	O
cancer	B
stem	I
cell	I
properties.	O

A	O
stochastic	O
model	O
for	O
cancer	O
stem	B
cell	I
origin	O
in	O
metastatic	O
colon	O
cancer.	O

Stage-specific	O
control	O
of	O
neural	B
crest	I
stem	I
cell	I
proliferation	O
by	O
the	O
small	O
Rho	O
GTPases	O
Cdc42	O
and	O
Rac1.	O

Neural	B
stem	I
cell	I
transplantation	O
in	O
the	O
stomach	O
rescues	O
gastric	O
function	O
in	O
neuronal	O
nitric	O
oxide	O
synthase-deficient	O
mice.	O

The	O
down-regulation	O
of	O
the	O
stem	B
cell	I
markers	O
Sca-1	O
and	O
c-KIT	O
and	O
the	O
up-regulation	O
of	O
IL-7	O
receptor	O
(IL-7R)	O
characterize	O
the	O
common	O
lymphoid	O
progenitor	O
(CLP)	O
(10,	O
11).	O

Changes	O
of	O
neural	B
stem	I
cell	I
proliferation	O
and	O
differentiation-related	O
proteins	O
in	O
L-monosodium	O
glutamate	O
rats.	O

Embryonic	B
stem	I
cell	I
differentiation:	O
emergence	O
of	O
a	O
new	O
era	O
in	O
biology	O
and	O
medicine.	O

miRNAs	O
are	O
also	O
required	O
for	O
stem	B
cells	I
to	O
bypass	O
the	O
normal	O
G1/S	O
checkpoint	O
in	O
cell	O
cycle	O
[69].	O

Intravenous	O
delivery	O
of	O
the	O
γtcPNA/DNA	O
NPs	O
after	O
pretreatment	O
with	O
stem	B
cell	I
factor	O
(SCF),	O
the	O
ligand	O
for	O
the	O
c-Kit	O
pathway,	O
yielded	O
levels	O
of	O
gene	O
editing	O
over	O
6%	O
in	O
sorted	O
bone	O
marrow	O
HSCs	O
(Lin-	O
Sca1+	O
cKit+	O
CD150+	O
CD135-)	O
in	O
the	O
β-thalassemia	O
mouse.	O

Mesenchymal	B
stem	I
cell	I
homing	O
towards	O
cancer	O
cells	O
is	O
increased	O
by	O
enzyme	O
activity	O
of	O
cathepsin	O
D.	O

New	O
Insights	O
into	O
the	O
Mechanisms	O
of	O
Embryonic	B
Stem	I
Cell	I
Self-Renewal	O
under	O
Hypoxia:	O
A	O
Multifactorial	O
Analysis	O
Approach.	O

Serum-Free	O
Manufacturing	O
of	O
Mesenchymal	O
Stem	O
Cell	O
Tissue	O
Rings	O
Using	O
Human-Induced	O
Pluripotent	B
Stem	I
Cells.	I

The	O
use	O
of	O
HLA-matched	O
unrelated	O
donors	O
for	O
stem	B
cell	I
transplantation	O
drastically	O
increased	O
the	O
number	O
of	O
patients	O
who	O
could	O
be	O
treated	O
(26).	O

*Chemotherapy	O
consolidation	O
includes	O
option	O
of	O
high-dose	O
chemotherapy	O
and	O
autologous	B
stem	I
cell	I
rescue.	O

Depletion	O
of	O
T	O
cells	O
may	O
be	O
achieved	O
by	O
manipulating	O
the	O
stem	B
cell	I
graft	O
ex	O
vivo	O
or	O
by	O
administering	O
treatment	O
to	O
the	O
transplant	O
recipient	O
in	O
vivo..	O

Indications	O
for	O
haematopoietic	B
stem	I
cell	I
transplantation	O
for	O
haematological	O
diseases,	O
solid	O
tumours	O
and	O
immune	O
disorders:	O
current	O
practice	O
in	O
Europe,	O
2019.	O

Impact	O
of	O
in	O
vivo	O
alemtuzumab	O
dose	O
before	O
reduced	O
intensity	O
conditioning	O
and	O
HLA-identical	O
sibling	B
stem	I
cell	I
transplantation:	O
pharmacokinetics,	O
GVHD,	O
and	O
immune	O
reconstitution.	O

Identification	O
of	O
gastric	O
cancer	B
stem	I
cells	I
using	O
the	O
cell	O
surface	O
marker	O
CD44.	O

Stem	O
cell	O
conditioned	O
medium	O
improves	O
acute	O
lung	O
injury	O
in	O
mice:	O
in	O
vivo	O
evidence	O
for	O
stem	B
cell	I
paracrine	O
action.	O

Intravital	O
imaging	O
of	O
mesenchymal	B
stem	I
cell	I
trafficking	O
and	O
association	O
with	O
platelets	O
and	O
neutrophils.	O

Fischer	O
UM,	O
Harting	O
MT,	O
Jimenez	O
F,	O
Monzon-Posadas	O
WO,	O
Xue	O
H,	O
Savitz	O
SI,	O
Laine	O
GA,	O
Cox	O
CS.,	O
Jr	O
Pulmonary	O
passage	O
is	O
a	O
major	O
obstacle	O
for	O
intravenous	B
stem	I
cell	I
delivery:	O
the	O
pulmonary	O
first-pass	O
effect.	O

A	O
quantitative,	O
randomized	O
study	O
evaluating	O
three	O
methods	O
of	O
mesenchymal	B
stem	I
cell	I
delivery	O
following	O
myocardial	O
infarction.	O

Cancer	B
stem	I
cells	I
and	O
cisplatin-resistant	O
cells	O
isolated	O
from	O
non-small-lung	O
cancer	O
cell	O
lines	O
constitute	O
related	O
cell	O
populations.	O

Spermatogonial	B
stem	I
cell	I
enrichment	O
using	O
simple	O
grafting	O
of	O
testis	O
and	O
in	O
vitro	O
cultivation.	O

Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

Clones	O
were	O
selected	O
for	O
growth	O
in	O
400	O
µg/ml	O
G418,	O
and	O
multiple	O
clonal	O
cell	O
lines	O
were	O
isolated	O
for	O
each	O
genotype	O
that	O
expressed	O
the	O
neural	B
stem	I
cell	I
marker,	O
nestin,	O
but	O
lacked	O
glial	O
fibrillary	O
acidic	O
protein	O
(GFAP)	O
expression	O
by	O
immunofluorescence	O
and,	O
in	O
some	O
cases,	O
also	O
confirmed	O
by	O
Western	O
blot,	O
to	O
verify	O
a	O
neuronal	O
lineage	O
(Figure	O
S1	O
and	O
[20]).	O

The	O
Complexity	O
of	O
Targeting	O
PI3K-Akt-mTOR	O
Signalling	O
in	O
Human	O
Acute	O
Myeloid	O
Leukaemia:	O
The	O
Importance	O
of	O
Leukemic	O
Cell	O
Heterogeneity,	O
Neighbouring	O
Mesenchymal	O
Stem	O
Cells	O
and	O
Immunocompetent	B
Cells.	I

In	O
particular,	O
33454	O
developed	O
anti-CMV	O
T	O
cell	O
responses	O
directed	O
against	O
epitopes	O
not	O
recognized	O
pre-HSCT	O
or	O
in	O
the	O
stem	B
cell	I
donor.	O

Experimental	O
approaches	O
to	O
limit	O
GvHD	O
through	O
modulation	O
of	O
the	O
T	O
cell	O
content	O
in	O
stem	B
cell	I
grafts	O
such	O
as	O
depletion	O
of	O
naive	O
cells	O
can	O
also	O
be	O
tested26.	O

The	O
effects	O
of	O
TKi	O
on	O
the	O
expression	O
of	O
stem	B
cell	I
related	O
genes	O
were	O
compared	O
by	O
quantitative	O
PCR.	O

Both	O
drugs	O
strongly	O
upregulated	O
NANOG	O
and	O
SOX2	O
in	O
CML	O
cell	O
lines,	O
but	O
in	O
KCL22	O
cells	O
this	O
upregulation	O
was	O
significantly	O
lower	O
with	O
ponatinib	O
than	O
with	O
imatinib,	O
an	O
outcome	O
compatible	O
with	O
a	O
lower	O
level	O
of	O
enrichment	O
of	O
the	O
stem	B
cell	I
compartment	O
upon	O
ponatinib	O
treatment..	O

This	O
set	O
of	O
markers	O
also	O
includes	O
c-MYC,	O
a	O
proto-oncogene	O
important	O
for	O
the	O
regulation	O
of	O
the	O
stem	B
cell	I
compartment	O
[36,	O
37]..	O

This	O
is	O
in	O
agreement	O
with	O
the	O
overall	O
antiproliferative	O
effect	O
of	O
TKi	O
and	O
with	O
the	O
fact	O
that	O
c-MYC	O
plays	O
multiple	O
roles,	O
including	O
the	O
control	O
of	O
stem	O
cell	O
clonal	O
expansion,	O
while	O
NANOG	O
and	O
SOX2	O
are	O
upregulated	O
in	O
association	O
with	O
the	O
maintenance	O
of	O
cancer	B
stem	I
cell	I
pool	O
[26,	O
72].	O

The	O
enhanced	O
NANOG	O
and	O
SOX2	O
expression	O
is	O
also	O
in	O
keeping	O
with	O
the	O
preferential	O
effects	O
of	O
TKi	O
on	O
relatively	O
less	O
immature	O
CML	O
cell	O
subsets,	O
resulting	O
in	O
an	O
apparent	O
enrichment	O
of	O
stem	B
cell	I
phenotype	O
[11].	O

We	O
addressed	O
in	O
detail	O
elsewhere	O
the	O
question	O
of	O
the	O
phenotypical	O
heterogeneity	O
of	O
the	O
CML	B
stem	I
cell	I
compartment	O
in	O
terms	O
of	O
the	O
sensitivity	O
or	O
resistance	O
to	O
TKi	O
[78–80].	O

Nevertheless,	O
this	O
work	O
provides	O
a	O
sizeable	O
contribution	O
to	O
the	O
discussion	O
of	O
whether	O
or	O
not	O
TKi	O
are	O
capable	O
of	O
targeting	O
the	O
CML	B
stem	I
cell	I
compartment.	O

Single-cell	O
molecular	O
analysis	O
defines	O
therapy	O
response	O
and	O
immunophenotype	O
of	O
stem	B
cell	I
subpopulations	O
in	O
CML.	O

Human	B
embryonic	I
stem	I
cell	I
genes	O
OCT4,	O
NANOG,	O
STELLAR,	O
and	O
GDF3	O
are	O
expressed	O
in	O
both	O
seminoma	O
and	O
breast	O
carcinoma.	O

Quantitative	O
assessment	O
of	O
the	O
CD26 + leukemic	B
stem	I
cell	I
compartment	O
in	O
chronic	O
myeloid	O
leukemia:	O
patient-subgroups,	O
prognostic	O
impact,	O
and	O
technical	O
aspects.	O

Surveillance	O
of	O
cancer	B
stem	I
cell	I
plasticity	O
using	O
an	O
isoform-selective	O
fluorescent	O
probe	O
for	O
aldehyde	O
dehydrogenase	O
1A1.	O

Several	O
preclinical	O
investigations	O
conducted	O
so	O
far	O
indicated	O
the	O
extensive	O
potential	O
of	O
the	O
stem	B
cell	I
in	O
tissue	O
repair	O
and	O
regeneration	O
of	O
dental	O
tissues,	O
as	O
well	O
as	O
other	O
organs.	O

SP	O
cells	O
have	O
been	O
identified	O
in	O
human	O
PDL	O
cells	O
and	O
porcine	O
dental	O
pulp	O
tissues.92	O
SP	O
cells	O
are	O
highly	O
enriched	O
for	O
stem	B
cell	I
activity.93,94	O
Iohara	O
et	O
al.70	O
have	O
shown	O
that	O
SP	O
of	O
dental	O
pulp	O
cells	O
has	O
a	O
property	O
of	O
vasculogenesis.	O

These	O
observations	O
suggested	O
the	O
use	O
of	O
dental	O
pulp	O
as	O
an	O
autologous	B
stem	I
cell	I
therapy	O
in	O
diabetic	O
patients.76,100.	O

Huang	O
et	O
al.103	O
reported	O
that	O
the	O
inhibition	O
of	O
Wnt	O
and	O
bone	O
morphogenetic	O
protein	O
signaling	O
induced	O
retinal	O
cell	O
differentiation	O
from	B
stem	I
cells	I
isolated	O
from	O
the	O
PDL.	O

We	O
anticipate	O
that	O
the	O
next	O
decade	O
will	O
bring	O
great	O
advances	O
in	O
stem	B
cell	I
and	O
tissue	O
engineering	O
therapies..	O

A	O
DTC	O
niche	O
plexus	O
surrounds	O
the	O
germline	B
stem	I
cell	I
pool	O
in	O
Caenorhabditis	O
elegans.	O

A	O
comparative	O
transcriptomic	O
analysis	O
reveals	O
conserved	O
features	O
of	O
stem	B
cell	I
pluripotency	O
in	O
planarians	O
and	O
mammals.	O

From	O
our	O
perspective,	O
the	O
interest	O
in	O
stem	B
cell	I
biology	O
as	O
a	O
route	O
to	O
novel	O
therapeutic	O
drugs	O
arose	O
from	O
the	O
convergence	O
of	O
three	O
separate	O
lines	O
of	O
investigation.	O

In	O
an	O
attempt	O
to	O
provide	O
a	O
systematic	O
basis	O
for	O
characterizing	B
stem	I
cell	I
lines,	O
Bock	O
and	O
colleagues	O
[25]	O
carried	O
out	O
an	O
extensive	O
bioinformatics	O
comparison	O
of	O
20	O
human	O
iPSC	O
and	O
12	O
human	O
ESC	O
lines,	O
including	O
DNA	O
methylation	O
patterns,	O
microarray	O
analyses,	O
and	O
a	O
general	O
differentiation	O
assay	O
in	O
which	O
gene	O
expression	O
was	O
analyzed	O
in	O
embryoid	O
bodies	O
derived	O
from	O
each	O
line.	O

Geron	O
trial	O
resumes,	O
but	O
standards	O
for	O
stem	B
cell	I
trials	O
remain	O
elusive.	O

Stage-specific	O
optimization	O
of	O
activin/nodal	O
and	O
BMP	O
signaling	O
promotes	O
cardiac	O
differentiation	O
of	O
mouse	O
and	O
human	B
pluripotent	I
stem	I
cell	I
lines.	O

von	O
Willebrand	O
factor-cleaving	O
protease	O
(ADAMTS13)	O
in	O
the	O
course	O
of	O
stem	B
cell	I
transplantation.	O

The	O
modulation	O
of	O
HIF	O
by	O
HSP90	O
leads	O
to	O
increased	O
expression	O
of	O
stem	B
cell	I
markers,	O
as	O
CD133	O
and	O
HIF	O
target	O
genes	O
as	O
VEGF	O
affecting	O
in	O
vivo	O
tumor	O
growth	O
[100].	O

It	O
has	O
also	O
been	O
observed	O
that	O
HSP90	O
expression	O
is	O
located	O
in	O
necrotic	O
areas	O
of	O
biopsies,	O
co-localizing	O
with	O
stem	B
cell	I
markers	O
and	O
HIF	O
[100].	O

Indeed,	O
HSP90	O
was	O
correlated	O
with	O
the	O
GSC	O
phenotype,	O
since	O
it	O
is	O
co-expressed	O
with	O
stem	B
cell	I
markers	O
and	O
predominantly	O
observed	O
in	O
hypoxic	O
niches,	O
where	O
it	O
induces	O
HIF	O
transcription	O
factors	O
during	O
acidosis.	O

Reduction	O
of	O
nestin	O
expression	O
impairs	O
sphere	O
formation,	O
in	O
vivo	O
tumor	O
growth,	O
and	O
the	O
expression	O
of	O
stem	B
cell	I
markers	O
such	O
as	O
NANOG,	O
N-cadherin,	O
CD133,	O
and	O
Oct4.	O

FACT	O
is	O
a	O
histone	O
chaperone	O
with	O
essential	O
functions	O
in	O
GSCs,	O
and	O
its	O
expression	O
is	O
associated	O
with	O
high	O
grade	O
of	O
gliomas	O
and	O
poor	O
prognosis,	O
being	O
co-expressed	O
with	O
stem	B
cell	I
markers	O
[106].	O

Targeting	O
of	O
replicating	O
CD133	O
and	O
OCT4/SOX2	O
expressing	O
glioma	B
stem	I
cells	I
selects	O
a	O
cell	O
population	O
that	O
reinitiates	O
tumors	O
upon	O
release	O
of	O
therapeutic	O
pressure.	O

However,	O
while	O
the	O
rapid	O
effect	O
of	O
LPS	O
upon	O
brain	O
homeostasis	O
is	O
clear,	O
a	O
single	O
sublethal	O
injection	O
of	O
LPS	O
(5 mg/kg)	O
is	O
sufficient	O
to	O
impair	O
behavior	O
and	O
memory,	O
mediated	O
by	O
a	O
reduction	O
in	O
neural	B
stem	I
cell	I
proliferation	O
in	O
the	O
dentate	O
gyrus,	O
as	O
well	O
as	O
inducing	O
microglia	O
invasion	O
and	O
activation	O
to	O
the	O
hippocampus,	O
all	O
lasting	O
for	O
at	O
least	O
30 days	O
(Anderson	O
et	O
al.,	O
2015).	O

Nitric	O
oxide-dependence	O
of	O
satellite	B
stem	I
cell	I
activation	O
and	O
quiescence	O
on	O
normal	O
skeletal	O
muscle	O
fibers.	O

Chromatin	O
modifications	O
as	O
determinants	O
of	O
muscle	B
stem	I
cell	I
quiescence	O
and	O
chronological	O
aging.	O

Autophagy	O
supports	O
breast	B
cancer	I
stem	I
cell	I
maintenance	O
by	O
regulating	O
il6	O
secretion.	O

Down-regulation	O
of	O
prostate	B
stem	I
cell	I
antigen	O
(PSCA)	O
by	O
Slug	O
promotes	O
metastasis	O
in	O
nasopharyngeal	O
carcinoma.	O

Determination	O
of	O
mesenchymal	B
stem	I
cell	I
fate	O
by	O
pigment	O
epithelium-derived	O
factor	O
(PEDF)	O
results	O
in	O
increased	O
adiposity	O
and	O
reduced	O
bone	O
mineral	O
content.	O

Single-cell	O
transcriptomic	O
analysis	O
defines	O
heterogeneity	O
and	O
transcriptional	O
dynamics	O
in	O
the	O
adult	B
neural	I
stem	I
cell	I
lineage.	O

Recent	O
studies	O
demonstrated	O
that	O
Snail,	O
a	O
potent	O
oncogene	O
which	O
can	O
induce	O
epithelial-mesenchymal	O
transition	O
(EMT),	O
contributes	O
to	O
the	O
acquisition	O
of	O
stem	B
cell	I
traits	O
in	O
breast	O
cancer	O
cells	O
[14,15].	O

A	O
broad	O
description	O
of	O
stem	B
cell	I
traits	O
reminiscent	O
in	O
EECs	O
is	O
therefore	O
crucial..	O

The	O
degree	O
of	O
stem	B
cell	I
gene	O
expression	O
correlates	O
with	O
pivotal	O
tumor	O
features	O
and	O
patient	O
prognosis	O
[10,11,13].	O

Recent	O
studies	O
demonstrated	O
that	O
EMT	O
contributes	O
to	O
the	O
acquisition	O
of	O
stem	B
cell	I
traits	O
in	O
cancer	O
cells	O
and	O
the	O
induction	O
of	O
EMT	O
inducer	O
Snail	O
results	O
in	O
stemness	O
gene	O
expression	O
[14,15].	O

Tumor	B
stem	I
cells	I
derived	O
from	O
glioblastomas	O
cultured	O
in	O
bFGF	O
and	O
EGF	O
more	O
closely	O
mirror	O
the	O
phenotype	O
and	O
genotype	O
of	O
primary	O
tumors	O
than	O
do	O
serum-cultured	O
cell	O
lines.	O

Cancer	O
induction	O
by	O
restriction	O
of	O
oncogene	O
expression	O
to	O
the	O
stem	B
cell	I
compartment.	O

SUMO-specific	O
protease	O
2	O
is	O
essential	O
for	O
modulating	O
p53-Mdm2	O
in	O
development	O
of	O
trophoblast	B
stem	I
cell	I
niches	O
and	O
lineages.	O

The	O
hormone	O
injection	O
stimulates	O
muscle	O
regeneration,	O
activation	O
of	O
muscle	B
stem	I
cell	I
proliferation	O
in	O
aged	O
mice	O
via	O
MAPK/ERK	O
(mitogen-activated	O
protein	O
kinases/	O
extracellular	O
signal-regulated	O
kinases)	O
signaling	O
pathway	O
activation	O
[197].	O

Thus,	O
monitoring	O
blood	O
levels	O
of	O
such	O
factors	O
as	O
IL27,	O
Il35,	O
and	O
TNF	O
will	O
stimulate	O
the	O
development	O
of	O
new	O
approaches	O
to	O
examining	O
the	O
blood	B
stem	I
cell	I
aging..	O

Therefore,	O
establishing	O
a	O
stable	O
and	O
efficient	O
protocol	O
for	O
the	O
derivation	O
of	O
NCSCs	O
from	O
pluripotent	B
stem	I
cells	I
will	O
provide	O
an	O
ideal	O
cell	O
resource	O
for	O
the	O
generation	O
of	O
enteric	O
neurons.	O

[17]),	O
ERRβsf	O
requires	O
nuclear	O
receptor	O
coactivator	O
3	O
(NCOA3	O
or	O
AIB1)	O
to	O
perform	O
transcription-dependent	O
functions	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
self-renewal	O
[21],	O
and	O
cooperates	O
with	O
AIB1	O
to	O
modulate	O
G1/S	O
checkpoint	O
integrity	O
in	O
this	O
context	O
[23,	O
24].	O

High	O
levels	O
of	O
superoxide	O
have	O
been	O
shown	O
to	O
modulate	O
neuronal	O
plasticity	O
in	O
the	O
hippocampus	O
[205],	O
a	O
region	O
of	O
the	O
brain	O
that	O
relies	O
on	O
neural	B
stem	I
cell	I
turnover	O
of	O
neural	O
tissue	O
to	O
facilitate	O
memory	O
and	O
learning	O
[206].	O

The	O
ETS	O
genes	O
ETV2,	O
FLI-1	O
and	O
ERG1	O
specify	O
the	O
differentiation	O
of	O
pluripotent	B
stem	I
cells	I
into	O
induced	O
vascular	O
endothelial	O
cells	O
(iVECs).44,52,53	O
EC	O
specification	O
by	O
these	O
ETS	O
proteins	O
requires	O
cooperation	O
with	O
other	O
TFs	O
including	O
SCL/TAL1,	O
GATA2	O
and	O
LMO2.52	O
These	O
iVECs	O
are	O
unstable	O
and	O
drift	O
toward	O
nonvascular	O
cell	O
fate.	O

These	O
studies	O
reveal	O
an	O
essential	O
role	O
of	O
Fli-1	O
in	O
stem	B
cell	I
maintenance	O
and	O
differentiation,	O
hematopoiesis,	O
vasculogenesis	O
and	O
angiogenesis.	O

Establishing	O
the	O
stem	O
cell	O
state:	O
insights	O
from	O
regulatory	O
network	O
analysis	O
of	O
blood	B
stem	I
cell	I
development.	O

Establishing	O
the	O
transcriptional	O
programme	O
for	O
blood:	O
the	O
SCL	B
stem	I
cell	I
enhancer	O
is	O
regulated	O
by	O
a	O
multiprotein	O
complex	O
containing	O
Ets	O
and	O
GATA	O
factors.	O

In	O
addition,	O
BMP	O
signaling	O
has	O
an	O
inhibitory	O
effect	O
on	O
gastric	B
Lgr5+	I
stem	I
cells	I
as	O
the	O
combination	O
of	O
inflammation	O
leads	O
to	O
enhanced	O
cell	O
proliferation	O
and	O
development	O
of	O
metaplasia	O
and	O
dysplasia	O
in	O
BMP	O
receptor	O
Bmpr1a	O
knockout	O
mice	O
(Ye	O
et	O
al.,	O
2018).	O

If	O
the	O
mechanical	O
method	O
is	O
not	O
sufficient	O
for	O
stem	B
cell	I
isolation,	O
mild	O
proteases	O
such	O
as	O
dispase	O
or	O
collagenase	O
can	O
be	O
used	O
for	O
tissue	O
digestion.	O

The	O
beauty	O
of	O
organoids	O
is	O
the	O
mimic	O
of	O
tissue	O
structures	O
and	O
functions	O
by	O
sustaining	O
the	O
self-renewal	O
of	O
tissue	B
stem	I
cells	I
while	O
retaining	O
the	O
diversity	O
of	O
tissue	O
cell	O
types.	O

Exposure	O
of	O
the	O
surface	O
in	O
2D	O
culture	O
provides	O
a	O
suitable	O
system	O
to	O
investigate	O
the	O
interactions	O
between	O
different	O
cell	O
types,	O
the	O
dynamics	O
of	O
resident	B
stem	I
cells	I
and	O
the	O
pathogen-host	O
cell	O
interaction.	O

Aberrant	O
epithelial	O
GREM1	O
expression	O
initiates	O
colonic	O
tumorigenesis	O
from	O
cells	O
outside	O
the	O
stem	B
cell	I
niche.	O

Isolation	O
and	O
characterization	O
of	O
human	O
salivary	O
gland	O
cells	O
for	O
stem	B
cell	I
transplantation	O
to	O
reduce	O
radiation-induced	O
hyposalivation.	O

Quantitative	O
PCR	O
was	O
used	O
to	O
assess	O
the	O
expression	O
levels	O
of	O
endogenous	B
stem	I
cell	I
markers	O
and	O
to	O
confirm	O
removal	O
of	O
transgene	O
vectors.	O

DGCR8	O
is	O
essential	O
for	O
microRNA	O
biogenesis	O
and	O
silencing	O
of	O
embryonic	B
stem	I
cell	I
self-renewal.	O

One	O
thousand	O
single	O
cells	O
were	O
plated	O
in	O
methocult	O
(catalogue	O
number	O
04100,	O
Stem	O
Cell	O
Technology,	O
Grenoble,	O
France)	O
supplemented	O
with	O
stem	O
cell	O
medium	O
(final	O
concentration	O
1x	O
B27;	O
penicillin/streptomycin;	O
glutaMAX	O
(all	O
Life	O
Technologies);	O
20 ng/mL	O
basic	O
fibroblast	O
growth	O
factor;	O
20 ng/mL	O
epidermal	O
growth	O
factor	O
(both	O
PeproTech,	O
Stockholm,	O
Sweden);	O
as	O
recommended	O
by	O
Stem	B
Cell	I
Technology.	O

Cell	O
lines	O
considered	O
highly	O
aggressive	O
displayed	O
a	O
high	O
proliferation	O
rate;	O
ability	O
to	O
form	O
tumor;	O
resistance	O
towards	O
differentiation;	O
high	O
capacity	O
for	O
colony	O
formation,	O
migration	O
and	O
invasion;	O
low	O
expression	O
of	O
differentiation	O
markers	O
(CEBPB,	O
CEBPA,	O
PPARG,	O
FABP4);	O
high	O
expression	O
of	O
pluripotency	O
markers	O
NANOG,	O
OCT4,	O
SOX2;	O
high	O
expression	O
of	O
stem	O
cell	O
surface	O
markers	O
CD90,	O
CD105,	O
CD73,	O
and	O
CD44;	O
expression	O
of	O
cancer	B
stem	I
cell	I
marker	O
CD133	O
and	O
Aldefluor	O
in	O
more	O
than	O
3%	O
of	O
the	O
cells.	O

Cell	O
lines	O
considered	O
non-aggressive	O
displayed	O
a	O
low	O
proliferation	O
rate,	O
did	O
not	O
form	O
tumors	O
in  vivo;	O
adipocytic	O
differentiated	O
at	O
basal	O
level;	O
low	O
capacity	O
for	O
colony	O
formation,	O
migration	O
and	O
invasion;	O
high	O
expression	O
of	O
differentiation	O
markers	O
CEBPB,	O
CEBPA,	O
PPARG,	O
FABP4;	O
low	O
expression	O
of	O
pluripotency	O
markers	O
NANOG,	O
OCT4,	O
SOX2;	O
expression	O
of	O
stem	O
cell	O
surface	O
markers	O
CD90,	O
CD105,	O
CD73,	O
and	O
CD44	O
in	O
a	O
low	O
percentage	O
of	O
the	O
cells	O
and	O
undetectable	O
expression	O
of	O
the	O
cancer	B
stem	I
cell	I
markers..	O

Re-expression	O
of	O
the	O
embryonic	B
stem	I
cell	I
and	O
pluripotency	O
factors	O
OCT4,	O
SOX2,	O
and	O
NANOG	O
has	O
been	O
associated	O
with	O
poorly	O
differentiated	O
and	O
aggressive	O
cancers,	O
such	O
as	O
high-grade	O
breast	O
cancer,	O
glioblastomas,	O
and	O
bladder	O
carcinomas	O
[29].	O

Aldehyde	O
dehydrogenase	O
activity	O
among	O
primary	O
leukemia	O
cells	O
is	O
associated	O
with	O
stem	B
cell	I
features	O
and	O
correlates	O
with	O
adverse	O
clinical	O
outcomes.	O

Circumventing	O
senescence	O
is	O
associated	O
with	O
stem	B
cell	I
properties	O
and	O
metformin	O
sensitivity.	O

Mice	O
transfected	O
with	O
CD133+	O
NSCLC	O
cells	O
harboring	O
the	O
siRNA-SNORA80E	O
are	O
unable	O
to	O
develop	O
tumors	O
compared	O
to	O
control	O
mice,	O
underlining	O
the	O
pivotal	O
function	O
of	O
SNORA80E	O
in	O
cancer	B
stem	I
cell	I
properties,	O
thus	O
contributing	O
to	O
NSCLC	O
malignancies	O
[59]..	O

Systematic	O
gene	O
tagging	O
using	O
CRISPR/Cas9	O
in	O
human	B
stem	I
cells	I
to	O
illuminate	O
cell	O
organization.	O

To	O
address	O
the	O
limitations	O
of	O
conventional	O
two	O
dimensional	O
cell	O
culture	O
techniques,	O
researchers	O
in	O
stem	B
cell	I
and	O
developmental	O
biology	O
have	O
been	O
making	O
efforts	O
with	O
engineers	O
and	O
physical	O
scientists	O
to	O
develop	O
advanced	O
in	O
vitro	O
technologies	O
for	O
three	O
dimensional	O
(3D)	O
cell	O
culture	O
models.	O

For	O
example,	O
SMAD	O
family	O
member	O
3	O
(SMAD3),	O
a	O
downstream	O
TF	O
of	O
transforming	O
growth	O
factor	O
β	O
(TGFβ)	O
signaling,	O
has	O
many	O
cell-type-specific	O
effects	O
due	O
to	O
interacting	O
with	O
different	O
cofactors	O
in	O
different	O
cell	O
types,	O
such	O
as	O
octamer-binding	O
transcription	O
factor	O
4	O
in	O
embryonic	B
stem	I
cells	I
and	O
MYOD1	O
in	O
myotubes	O
[32].	O

This	O
was	O
correlated	O
with	O
the	O
observations	O
that,	O
in	O
the	O
sensitive	O
cells,	O
MYXV	O
infection	O
decreased	O
the	O
expression	O
of	O
stem	B
cell	I
markers	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
[86].	O

Selective	O
purging	O
of	O
human	O
multiple	O
myeloma	O
cells	O
from	O
autologous	B
stem	I
cell	I
transplantation	O
grafts	O
using	O
oncolytic	O
myxoma	O
virus.	O

In	O
the	O
adult,	O
deregulation	O
of	O
the	O
Wnt	O
pathway	O
cause	O
several	O
cancers	O
and	O
Wnt-signalling	O
is	O
required	O
for	O
stem	B
cell	I
self	O
renewal	O
[51,	O
52].	O

Effect	O
of	O
THz	O
irradiation	O
on	O
gene	O
expression	O
in	O
mouse	B
stem	I
cell	I
cultures.	O

Gene	O
specific	O
effect	O
of	O
THz	O
irradiation	O
in	O
mouse	B
stem	I
cell	I
cultures..	O

In	O
cooperation	O
with	O
other	O
polycomb	O
group	O
(PcG)	O
proteins,	O
CBX7	O
maintain	O
target	O
genes,	O
which	O
participate	O
in	O
stem	B
cell	I
self-renewal	O
and	O
developmental	O
regulation,	O
in	O
a	O
silenced	O
state	O
[1–4].	O

Role	O
of	O
polycomb	O
group	O
proteins	O
in	O
stem	B
cell	I
self-renewal	O
and	O
cancer.	O

Therefore,	O
a	O
deeper	O
understanding	O
of	O
adult	B
stem	I
cell	I
biology	O
is	O
required	O
to	O
determine	O
a	O
therapeutic	O
window	O
for	O
anti-CSC	O
agents.	O

Prolonged	O
drug	O
selection	O
of	O
breast	O
cancer	O
cells	O
and	O
enrichment	O
of	O
cancer	B
stem	I
cell	I
characteristics.	O

Genetic	O
aberrations,	O
such	O
as	O
Pik3ca	O
mutations,	O
can	O
have	O
a	O
profound	O
effect	O
on	O
the	O
stem	B
cell	I
pool,	O
as	O
was	O
demonstrated	O
recently	O
by	O
two	O
independent	O
laboratories.	O

Neural	B
stem	I
cell	I
proliferation	O
is	O
decreased	O
in	O
schizophrenia,	O
but	O
not	O
in	O
depression.	O

In	O
leukemia,	O
ERG	O
targets	O
transcription	O
factors	O
such	O
as	O
GATA2,	O
which	O
is	O
an	O
important	O
regulator	O
of	O
hematopoietic	B
stem	I
cell	I
and	O
megakaryocyte	O
development	O
and,	O
RUNX1,	O
which	O
is	O
involved	O
in	O
the	O
development	O
of	O
normal	O
hematopoiesis.	O

Functional	O
analyses	O
conducted	O
in	O
mice	O
and	O
human	O
CD34	O
normal	O
and	O
leukemic	O
cells	O
have	O
demonstrated	O
the	O
role	O
of	O
ERG	O
in	O
the	O
induction	O
of	O
early	O
myeloid	O
progenitors	O
in	O
leukemia	B
stem	I
cell	I
through	O
the	O
activation	O
of	O
RAS	O
pathway	O
and	O
Pim1	O
[20–24].	O

Rupp	O
and	O
coworkers	O
could	O
impressively	O
show	O
first	O
results	O
of	O
stem	B
cell	I
therapy	O
in	O
children.	O

For	O
example,	O
the	O
G12D	O
mutation	O
of	O
K-Ras	O
leads	O
to	O
bronchioalveolar	O
stem	O
cell	O
expansion	O
and	O
lung	O
tumorigenesis	O
(Kim	O
et	O
al.,	O
2005),	O
and	O
the	O
combined	O
inactivation	O
of	O
p53	O
and	O
Rb	O
in	O
stem	B
cells	I
of	O
the	O
ovarian	O
surface	O
epithelium	O
results	O
in	O
ovarian	O
adenocarcinoma	O
in	O
mice	O
(Flesken-Nikitin	O
et	O
al.,	O
2013).	O

Since	O
it	O
may	O
allow	O
quiescent	O
cells	O
to	O
acquire	O
new	O
oncogenic	O
mutations,	O
TM	O
may	O
serve	O
as	O
one	O
possible	O
route	O
to	O
tumor	O
initiation	O
for	O
cancers	O
with	O
stem	B
cell	I
origins,	O
following	O
RM,	O
but	O
it	O
may	O
also	O
play	O
a	O
role	O
in	O
cancers	O
that	O
originate	O
from	O
highly	O
proliferative	O
cells,	O
such	O
as	O
progenitors.	O

Loss	O
of	O
let-7	O
upregulates	O
EZH2	O
in	O
prostate	O
cancer	O
consistent	O
with	O
the	O
acquisition	O
of	O
cancer	B
stem	I
cell	I
signatures	O
that	O
are	O
attenuated	O
by	O
BR-DIM.	O

Selection	O
and	O
dynamics	O
of	O
embryonic	B
stem	I
cell	I
integration	O
into	O
early	O
mouse	O
embryos.	O

Distinct	O
developmental	O
ground	O
states	O
of	O
epiblast	B
stem	I
cell	I
lines	O
determine	O
different	O
pluripotency	O
features.	O

Epiblast	B
stem	I
cell	I
subpopulations	O
represent	O
mouse	O
embryos	O
of	O
distinct	O
pregastrulation	O
stages.	O

Expression	O
of	O
pluripotent	B
stem	I
cell	I
markers	O
in	O
the	O
human	O
fetal	O
testis.	O

Expression	O
of	O
pluripotent	B
stem	I
cell	I
markers	O
in	O
the	O
human	O
fetal	O
ovary.	O

Studies	O
have	O
also	O
shown	O
that	O
the	O
stem	B
cell	I
marker,	O
CD44	O
is	O
a	O
miR-34a	O
target	O
in	O
UC	O
[17].	O

Emerging	O
roles	O
of	O
Myc	O
in	O
stem	B
cell	I
biology	O
and	O
novel	O
tumor	O
therapies.	O

Subcellular	O
localisation	O
of	O
the	O
stem	B
cell	I
markers	O
OCT4,	O
SOX2,	O
NANOG,	O
KLF4	O
and	O
c-MYC	O
in	O
cancer:	O
A	O
review.	O

Mouse	B
embryonic	I
stem	I
cell	I
culture	O
for	O
generation	O
of	O
three-dimensional	O
retinal	O
and	O
cortical	O
tissues.	O

Human	O
ES	O
cell-derived	O
neural	O
rosettes	O
reveal	O
a	O
functionally	O
distinct	O
early	O
neural	B
stem	I
cell	I
stage.	O

GATA2	O
GATA2	O
is	O
a	O
TF	O
involved	O
in	O
stem	B
cell	I
maintenance	O
with	O
important	O
roles	O
in	O
hematopoietic	O
development..	O

Interaction	O
of	O
stem	B
cell	I
factor	O
and	O
its	O
receptor	O
c-kit	O
mediates	O
lodgment	O
and	O
acute	O
expansion	O
of	O
hematopoietic	O
cells	O
in	O
the	O
murine	O
spleen.	O

Igbp1	O
is	O
part	O
of	O
a	O
positive	O
feedback	O
loop	O
in	O
stem	B
cell	I
factor–dependent,	O
selective	O
mRNA	O
translation	O
initiation	O
inhibiting	O
erythroid	O
differentiation.	O

Embryonic	B
stem	I
cell	I
differentiation	O
into	O
smooth	O
muscle	O
cells	O
is	O
mediated	O
by	O
Nox4-produced	O
H2O2.	O

The	O
expression	O
of	O
stem	B
cell	I
protein	O
Piwil2	O
and	O
piR-932	O
in	O
breast	O
cancer.	O

Although	O
there	O
is	O
a	O
broad	O
consensus	O
that	O
DC	O
results	O
from	O
stem	B
cell	I
renewal	O
failure	O
due	O
to	O
defective	O
telomere	O
maintenance,	O
some	O
mutated	O
genes	O
(e.g.	O

An	O
important	O
up-regulated	O
gene	O
in	O
the	O
A375	O
cell	O
line	O
is	O
EZH2	O
(Enhancer	O
of	O
zeste	O
homolog	O
2),	O
a	O
member	O
of	O
polycomb	O
protein	O
and	O
a	O
part	O
of	O
polycomb	O
repressive	O
complex,	O
implicated	O
in	O
cancer	B
stem	I
cell	I
maintenance	O
and	O
metastasis	O
in	O
breast	O
and	O
pancreatic	O
cancer	O
[77,78],	O
and	O
it	O
could	O
be	O
considered	O
as	O
a	O
prognostic	O
marker	O
in	O
renal	O
cell	O
carcinoma	O
[79].	O

Radix	O
ginseng	O
(Ren	O
shen)	O
Harmonizes	O
and	O
tonifies	O
the	O
qi,	O
raises	O
the	O
qi,	O
generates	O
fluids	O
Ginsenosides	O
Rb1,	O
Rg1,	O
Rg3,	O
Rh1,	O
Re,	O
and	O
Rd	O
Rb1	O
suppresses	O
neurotoxicity	O
and	O
breast	B
cancer	I
stem	I
cells	I
[148],	O
Re	O
enhances	O
cardiac	O
muscle	O
cell	O
survival	O
through	O
autophagy	O
[149].	O

One	O
such	O
organ-specific	O
biomarker	O
may	O
be	O
doublecortin-like	O
kinase	O
1	O
(Dclk1),	O
found	O
in	O
the	O
Notch	O
signaling	O
pathway.[57]	O
This	O
protein	O
can	O
be	O
used	O
to	O
evaluate	O
and	O
correlated	O
to	O
intestinal	B
stem	I
cell	I
survival	O
shortly	O
after	O
radiation	O
injury.	O

In	O
the	O
life	O
science	O
literature,	O
there	O
are	O
numerous	O
reports	O
on	O
DPSC	O
properties	O
from	O
in	O
vitro	O
and	O
in	O
vivo	O
studies,	O
such	O
as	O
cell	O
growth,	O
capacity	O
for	O
differentiation,	O
competence	O
in	O
assays,	O
and	O
potential	O
for	O
pioneering	B
stem	I
cell	I
functions.	O

In	O
addition,	O
the	O
secretion	O
of	O
PDGF-BB	O
by	O
DPSCs	O
can	O
increase	O
the	O
likelihood	O
of	O
stem	B
cell	I
homing	O
via	O
the	O
PI3K/Akt	O
pathway	O
and	O
improve	O
the	O
DPSC-mediated	O
dentin–pulp	O
complex	O
regeneration	O
in	O
vivo.71	O
Moreover,	O
separated	O
PDGFRβ+	O
and	O
PDGFRβ+/c-kit+	O
dental	O
pulp	O
cells	O
show	O
faster	O
proliferation	O
than	O
whole	O
pulp	O
cells	O
and	O
PDGFRβ−	O
cells.	O

According	O
to	O
the	O
literature,	O
mitochondrial	O
functions	O
and	O
dynamics	O
are	O
particularly	O
related	O
to	O
the	O
direction	O
of	O
stem	B
cell	I
differentiation,	O
including	O
for	O
DPSCs..	O

DPSCs	O
are	O
a	O
promising	O
cell	O
source	O
in	O
the	O
cutting-edge	O
research	O
field	O
of	O
stem	B
cells	I
and	O
for	O
developing	O
regenerative	O
medicine	O
applications.	O

A	O
common	O
molecular	O
logic	O
determines	O
embryonic	B
stem	I
cell	I
self-renewal	O
and	O
reprogramming.	O

Functional	O
impacts	O
of	O
NRXN1	O
knockdown	O
on	O
neurodevelopment	O
in	O
stem	B
cell	I
models.	O

Determination	O
of	O
mesenchymal	B
stem	I
cell	I
fate	O
by	O
pigment	O
epithelium	O
derived	O
factor	O
(PEDF)	O
results	O
in	O
increased	O
adiposity	O
and	O
reduced	O
bone	O
mineral	O
content.	O

IGF2	O
is	O
expressed	O
in	O
the	O
subgranular	O
zone	O
of	O
the	O
dentate	O
gyrus,	O
and	O
endogenous	O
IGF2	O
upregulates	O
the	O
proliferation	O
of	O
neural	B
stem	I
cells	I
in	O
this	O
brain	O
region	O
[15]	O
and,	O
moreover,	O
intrahippocampal	O
injections	O
of	O
IGF2	O
promote	O
the	O
survival	O
of	O
adult-born	O
neurons	O
in	O
the	O
dentate	O
granule	O
cell	O
layer	O
[12],	O
[13].	O

Consistent	O
with	O
the	O
role	O
of	O
Sox2	O
as	O
a	O
core	O
pluripotency	O
factor,	O
down-regulated	O
signature	O
genes	O
are	O
key	O
genes	O
involved	O
in	O
stem	B
cell	I
maintenance	O
and	O
early	O
development,	O
including	O
Nanog,	O
Klf4,	O
Esrrb,	O
Tet1,	O
and	O
Kit.	O

TET	O
family	O
proteins	O
and	O
their	O
role	O
in	O
stem	B
cell	I
differentiation	O
and	O
transformation.	O

Studies	O
have	O
found	O
that	O
a	O
series	O
of	O
miRNAs	O
participate	O
in	O
the	O
processes	O
of	O
muscle	B
stem	I
cell	I
proliferation	O
and	O
differentiation	O
and	O
promote	O
the	O
activation	O
and	O
proliferation	O
of	O
MuSCs.6,68,69	O
MiR-195,	O
miR-489	O
and	O
miR-497	O
control	O
the	O
resting	O
state	O
of	O
skeletal	O
MuSCs	O
by	O
inhibiting	O
cell	O
division	O
cycle	O
25A	O
(CDC25A),	O
cyclin	O
D2	O
(CCND2)	O
and	O
Dek,	O
respectively.	O

The	O
impact	O
of	O
aerobic	O
exercise	O
on	O
the	O
muscle	B
stem	I
cell	I
response.	O

This	O
model	O
feature	O
suggested	O
that	O
ovarian	O
cancer	O
cells	O
could	O
turn	O
on	O
or	O
off	O
the	O
stem	B
cell	I
marker	O
(c-KIT)	O
to	O
promote	O
or	O
repress	O
cell	O
growth	O
in	O
response	O
to	O
changes	O
in	O
intracellular	O
E2F6	O
activation,	O
which	O
could	O
be	O
significantly	O
regulated	O
by	O
cancer-specific	O
signals	O
such	O
as	O
estrogen	O
signaling	O
and	O
miR-193a	O
expression	O
[33]..	O

This	O
is	O
an	O
area	O
that	O
clearly	O
requires	O
more	O
detailed	O
investigation,	O
although	O
it	O
has	O
been	O
suggested	O
that	O
mutations	O
in	O
mitochondrial	O
DNA	O
are	O
not	O
a	O
primary	O
driver	O
of	O
stem	B
cell	I
aging	O
[145]..	O

The	O
role	O
of	O
the	O
sirtuin	O
SIRT1	O
in	O
stem	B
cell	I
biology,	O
the	O
aging	O
process	O
and	O
in	O
HSC	O
function	O
in	O
old	O
mice	O
had	O
been	O
reviewed	O
[219].	O

It	O
was	O
observed	O
that	O
the	O
genetic,	O
hormonal,	O
or	O
drug	O
manipulation	O
of	O
stem	B
cell	I
mitochondria	O
may	O
be	O
useful	O
as	O
an	O
intervening	O
tool	O
for	O
manipulating	O
HSCs	O
from	O
old	O
mice.	O

Beyond	O
its	O
role	O
in	O
immunity,	O
lepR-expressing	O
MSCs	O
in	O
murine	O
hematopoiesis	O
have	O
been	O
well-characterized	O
as	O
an	O
indispensable	O
source	O
of	O
stem	B
cell	I
factor	O
for	O
maintenance	O
of	O
both	O
HSCs	O
and	O
more	O
differentiated	O
progenitor	O
cells	O
[279–282].	O

Epigenetic	O
control	O
of	O
stem	B
cell	I
potential	O
during	O
homeostasis,	O
aging,	O
and	O
disease.	O

Metabolic	O
regulation	O
of	O
stem	B
cell	I
function	O
in	O
tissue	O
homeostasis	O
and	O
organismal	O
ageing.	O

Can	O
metabolic	O
mechanisms	O
of	O
stem	O
cell	O
maintenance	O
explain	O
aging	O
and	O
the	O
immortal	O
germline?	O
Cell	O
Stem	B
Cell.	I

Accumulating	O
mitochondrial	O
DNA	O
mutations	O
drive	O
premature	O
hematopoietic	O
aging	O
phenotypes	O
distinct	O
from	O
physiological	B
stem	I
cell	I
aging.	O

Reactive	O
oxygen	O
species	O
in	O
mesenchymal	B
stem	I
cell	I
aging:	O
implication	O
to	O
lung	O
diseases.	O

Permanent	O
loss	O
in	O
stem	B
cell	I
self	O
renewal	O
capacity	O
following	O
stress	O
to	O
the	O
marrow.	O

The	O
retina,	O
particularly	O
the	O
subretinal	O
space,	O
is	O
advantageous	O
to	O
stem	B
cell	I
transplantation	O
as	O
the	O
eye	O
is	O
relatively	O
immune	O
privileged.	O

The	O
dietary	O
bioflavonoid	O
quercetin	O
synergizes	O
with	O
epigallocatechin	O
gallate	O
(EGCG)	O
to	O
inhibit	B
prostate	I
cancer	I
stem	I
cell	I
characterstic,	O
invasion	O
migration	O
and	O
epithelial-mesenchymal	O
transition.	O

The	O
skeletal	O
muscle	O
satellite	O
cell:	O
the	O
stem	B
cell	I
that	O
came	O
in	O
from	O
the	O
cold.	O

Variation	O
in	O
cancer	O
risk	O
among	O
tissues	O
can	O
be	O
explained	O
by	O
the	O
number	O
of	O
stem	B
cell	I
divisions.	O

Umbilical	O
cord	O
tissue	O
is	O
another	B
source	I
of	I
multipotent	I
stem	I
cells	I
that	O
have	O
the	O
potency	O
to	O
develop	O
into	O
a	O
variety	O
of	O
somatic	O
cell	O
types	O
[26].	O

As	O
the	O
suspected	O
cellular	O
origin	O
of	O
primary	O
AMD	O
pathology,	O
the	O
RPE	O
has	O
attracted	O
particular	O
interest	O
in	O
the	O
field	O
of	O
stem	B
cell	I
differentiation	O
and	O
in	O
vitro	O
modelling.	O

Accumulating	O
studies	O
in	O
animal	O
models	O
of	O
retinal	O
degeneration	O
showed	O
promising	O
results	O
[79],	O
and	O
in	O
2012,	O
the	O
first	B
therapeutic	I
stem	I
cell	I
application	O
in	O
a	O
human	O
clinical	O
trial	O
was	O
reported	O
by	O
Schwartz	O
et	O
al.	O

Importantly,	O
this	O
implies	O
that	O
therapeutic	O
application	O
of	O
stem	B
cell	I
technology	O
for	O
AMD	O
may	O
require	O
not	O
only	O
development	O
of	O
the	O
appropriate	O
mature	O
cell	O
type,	O
but	O
also	O
management	O
of	O
the	O
extracellular	O
milieu.	O

A	O
number	O
of	O
proof-of-concept	O
studies	O
have	O
been	O
published	O
and	O
have	O
further	O
underscored	O
the	O
advancements	O
and	O
the	O
power	O
of	O
stem	B
cell	I
technology	O
[47,79,115],	O
heralding	O
a	O
new	O
era	O
in	O
biomedical	O
research,	O
as	O
well	O
as	O
drug	O
discovery	O
and	O
development..	O

Emerging	O
concepts	O
in	O
neural	B
stem	I
cell	I
research:	O
Autologous	O
repair	O
and	O
cell-based	O
disease	O
modelling.	O

Mesenchymal	B
stem	I
cell	I
secreted	O
vesicles	O
provide	O
novel	O
opportunities	O
in	O
(stem)	O
cell-free	O
therapy.	O

ST6Gal-I	O
protein	O
expression	O
is	O
upregulated	O
in	O
human	O
epithelial	O
tumors	O
and	O
correlates	O
with	O
stem	B
cell	I
markers	O
in	O
normal	O
tissues	O
and	O
colon	O
cancer	O
cell	O
lines.	O

GATA2	O
is	O
a	O
zinc	O
finger	O
transcription	O
factor	O
that	O
is	O
required	O
for	O
embryonic	O
hematopoiesis,	O
and	O
maintenance	O
of	O
the	O
stem	B
cell	I
pool	O
in	O
adults	O
(42,	O
43)	O
and	O
GATA2	O
haploinsufficiency	O
can	O
also	O
lead	O
to	O
loss	O
of	O
dendritic	O
cell	O
subsets	O
and	O
B	O
cell	O
cytopenias.	O

Therefore,	O
given	O
its	O
important	O
role	O
in	O
stem	B
cell	I
maintenance	O
and	O
hematopoiesis,	O
GATA2	O
deficiency	O
may	O
affect	O
multiple	O
immune	O
cell	O
lineages,	O
which	O
are	O
again	O
highly	O
variable	O
from	O
patient	O
to	O
patient.	O

Our	O
contribution	O
focuses	O
on	O
the	O
histopathology	O
of	O
the	O
characteristic	O
Peutz-Jeghers	O
polyp	O
and	O
recent	B
research	I
on	I
stem	I
cell	I
dynamics	O
and	O
how	O
these	O
concepts	O
relate	O
to	O
Peutz-Jeghers	O
polyposis.	O

My	O
contribution	O
(as	O
a	O
surgical	O
pathologist)	O
deals	O
with	O
two	O
aspects,	O
the	O
histopathology	O
of	O
the	O
characteristic	O
Peutz-Jeghers	O
polyps	O
and,	O
secondly,	O
recent	B
research	I
on	I
stem	I
cell	I
dynamics	O
and	O
how	O
this	O
relates	O
to	O
Peutz-Jeghers	O
polyposis..	O

Both	O
research	O
groups	O
inferred	O
that	O
contrary	O
to	O
previous	O
thinking	O
the	O
dominant	O
mode	O
of	O
stem	B
cell	I
division	O
in	O
the	O
crypt	O
is	O
symmetric,	O
not	O
asymmetric.	O

Individual	O
mutations	O
without	O
selective	O
advantage	O
may	O
thus	O
initially	O
‘hitchhike’	O
along	O
with	O
the	O
inherent	O
clonal	O
evolution	O
of	O
stem	B
cell	I
niches.	O

Incipient	O
polyps	O
might	O
be	O
created	O
by	O
stochastic	O
deviations	O
from	O
the	O
normal	O
equilibrium	O
of	O
stem	B
cell	I
divisions.	O

This	O
lottery-like	O
process	O
of	O
accumulating	O
and	O
selecting	O
pathogenic	O
hits	O
in	O
stem	B
cell	I
niches	O
is	O
played	O
out	O
in	O
each	O
of	O
the	O
approximately	O
15	O
million	O
crypts	O
that	O
constitute	O
the	O
human	O
colon..	O

This	O
diagram	O
illustrates	O
the	O
consequences	O
of	O
differences	O
in	O
clonal	O
evolution	O
in	O
stem	B
cell	I
compartments	O
such	O
as	O
the	O
intestinal	O
crypt.	O

Definitively	O
testing	O
the	O
impact	O
of	O
LKB1	O
hemizygosity	O
in	O
lineage	O
succession	O
in	O
the	O
intestinal	B
stem	I
cell	I
compartment	O
will	O
require	O
lineage	O
tracing	O
experiments	O
where	O
multiple	O
individual	O
lineages	O
can	O
be	O
traced	O
competing	O
over	O
time	O
in	O
individual	O
crypts.	O

This	O
would	O
provide	O
important	O
impetus	O
to	O
begin	O
studying	O
the	O
impact	O
of	O
LKB1	O
hemizygosity	O
on	O
lineage	O
competition	O
in	O
stem	B
cell	I
niches.	O

DUBs	O
can	O
deubiquitylate	O
a	O
broad	O
range	O
of	O
substrates	O
in	O
fundamental	O
cellular	O
processes	O
including	O
transcription,	O
translation,	O
cell	O
cycle	O
progression,	O
vesicular	O
trafficking,	O
autophagy,	O
proteasomal	O
degradation,	O
and	O
intracellular	O
signaling	O
to	O
control	O
various	O
aspects	O
of	O
stem	B
cell	I
maintenance,	O
differentiation,	O
and	O
development	O
[1,	O
3,	O
25–30].	O

Ubiquitylation	O
frequently	O
orchestrates	O
core	O
signaling	O
networks	O
essential	O
for	O
stem	B
cell	I
maintenance	O
and	O
differentiation.	O

For	O
example,	O
USP44	O
(through	O
the	O
N-CoR	O
complex	O
[106]),	O
USP51,	O
USP27X,	O
and	O
USP22	O
(through	O
ATXN7L3	O
and	O
ENY2	O
[107]),	O
and	O
BAP1	O
(through	O
FOXK1/2	O
and	O
ASXL1/2/3	O
[37,	O
108,	O
109])	O
are	O
recruited	O
to	O
specific	O
regions	O
on	O
chromatin,	O
where	O
they	O
counteract	O
monoubiquitylation	O
of	O
H2A	O
and	O
H2B	O
to	O
regulate	O
gene	O
expression	O
changes	O
required	O
for	O
various	O
aspects	O
of	O
stem	B
cell	I
maintenance	O
and	O
differentiation	O
(see	O
below).	O

In	O
a	O
different	O
example,	O
USP7,	O
a	O
DUB	O
with	O
pivotal	O
roles	O
in	O
stem	B
cell	I
self-renewal	O
and	O
differentiation	O
(see	O
below),	O
requires	O
its	O
C-terminal	O
ubiquitin-like	O
domains	O
to	O
fold	O
onto	O
the	O
catalytic	O
USP	O
domain	O
[115,	O
116]	O
resulting	O
in	O
increased	O
intrinsic	O
USP7	O
activity,	O
which	O
can	O
be	O
further	O
stimulated	O
by	O
binding	O
of	O
an	O
interacting	O
protein	O
in	O
the	O
form	O
of	O
GMP-synthase	O
[115,	O
117].	O

Such	O
allosteric	O
regulation	O
is	O
also	O
well	O
described	O
for	O
DUBs	O
that	O
are	O
incorporated	O
into	O
large	O
macromolecular	O
complexes	O
such	O
as	O
the	O
proteasome	O
[122–126]	O
and	O
the	O
SAGA	O
histone	O
acetyltransferase	O
complex	O
[127–129]	O
(i.e.,	O
USP22,	O
an	O
essential	O
regulator	O
of	O
stem	B
cell	I
differentiation	O
[36,	O
81]).	O

BAP1	O
and	O
USP21	O
activity	O
are	O
required	O
for	O
stem	B
cell	I
self-renewal	O
by	O
ensuring	O
the	O
expression	O
of	O
genes	O
that	O
are	O
involved	O
in	O
basic	O
cellular	O
functions	O
and	O
that	O
are	O
under	O
the	O
control	O
of	O
the	O
pluripotency	O
factor	O
NANOG,	O
respectively	O
[108,	O
143].	O

In	O
contrast,	O
the	O
Down	O
Syndrome-associated	O
USP16	O
is	O
not	O
essential	O
for	O
stem	B
cell	I
maintenance,	O
but	O
its	O
activity	O
was	O
proposed	O
to	O
alleviate	O
H2A	O
ubiquitylation-imposed	O
repression	O
of	O
lineage-specific	O
genes	O
during	O
differentiation	O
[35,	O
154,	O
160].	O

A	O
complex	O
of	O
the	O
ubiquitin	O
ligase	O
TRIM32	O
and	O
the	O
deubiquitinase	O
USP7	O
balances	O
the	O
level	O
of	O
c-Myc	O
ubiquitination	O
and	O
thereby	O
determines	O
neural	B
stem	I
cell	I
fate	O
specification.	O

But	O
recently,	O
tumor	O
proteome	O
profiling	O
studies	O
based	O
on	O
mass	O
spectrometry	O
have	O
shown	O
that	O
ORF2p	O
was	O
difficult	O
to	O
be	O
detected,	O
and	O
after	O
affinity	O
capture	O
of	O
ORF1p,	O
ORF2p	O
has	O
not	O
been	O
detected	O
in	O
stem	B
cell	I
LINE-1	O
proteome	O
analysis	O
(Vuong	O
et	O
al.,	O
2019;	O
Ardeljan	O
et	O
al.,	O
2020).	O

Epigenetic	O
Regulation	O
in	O
Mesenchymal	B
Stem	I
Cell	I
Aging	O
and	O
Differentiation	O
and	O
Osteoporosis.	O

Epigenetic	O
Regulation	O
in	O
Mesenchymal	B
Stem	I
Cell	I
Aging	O
and	O
Differentiation	O
and	O
Osteoporosis.	O

These	O
properties	O
signify	O
that	O
MSCs	O
could	O
perform	O
extensive	O
and	O
active	O
interactions	O
with	O
tissue-specific	B
stem	I
cell	I
niches	O
and	O
represent	O
an	O
ideal	O
and	O
promising	O
tool	O
for	O
tissue	O
regeneration..	O

Accumulation	O
of	O
reactive	O
oxygen	O
species	O
(ROS)	O
is	O
another	O
important	O
mechanism	O
of	O
stem	B
cell	I
aging.	O

Mesenchymal	B
stem	I
cell	I
therapy	O
induces	O
glucocorticoid	O
synthesis	O
in	O
colonic	O
mucosa	O
and	O
suppresses	O
radiation-activated	O
T	O
cells:	O
new	O
insights	O
into	O
MSC	O
immunomodulation.	O

Epigenetic	O
control	O
of	O
mesenchymal	B
stem	I
cell	I
fate	O
decision	O
via	O
histone	O
methyltransferase	O
ASH1L.	O

The	O
BRG1	O
ATPase	O
of	O
chromatin	O
remodeling	O
complexes	O
is	O
involved	O
in	O
modulation	O
of	O
mesenchymal	B
stem	I
cell	I
senescence	O
through	O
RB-P53	O
pathways.	O

Redundant	O
miR-3077-5p	O
and	O
miR-705	O
mediate	O
the	O
shift	O
of	O
mesenchymal	B
stem	I
cell	I
lineage	O
commitment	O
to	O
adipocyte	O
in	O
osteoporosis	O
bone	O
marrow.	O

Tumor	O
necrosis	O
factor	O
α	O
suppresses	O
the	O
mesenchymal	B
stem	I
cell	I
osteogenesis	O
promoter	O
miR-21	O
in	O
estrogen	O
deficiency-induced	O
osteoporosis.	O

The	O
long	O
non-coding	O
RNA-ORLNC1	O
regulates	O
bone	O
mass	O
by	O
directing	O
mesenchymal	B
stem	I
cell	I
fate.	O

Fibroadipogenic	O
progenitors	O
(FAPs)	O
are	O
interstitially	O
located	O
between	O
muscle	O
fibers	O
and	O
contribute	O
to	O
the	O
stem	B
cell	I
niche.	O

Up-regulation	O
of	O
histone	O
methyltransferase,	O
dot1l,	O
by	O
matrix	O
hyaluronan	O
promotes	O
microrna-10	O
expression	O
leading	O
to	O
tumor	O
cell	O
invasion	O
and	O
chemoresistance	O
in	O
cancer	B
stem	I
cells	I
from	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma.	O

Functional	O
but	O
abnormal	O
adult	O
erythropoiesis	O
in	O
the	O
absence	O
of	O
the	O
stem	B
cell	I
leukemia	O
gene.	O

The	O
transcriptional	O
program	O
controlled	O
by	O
the	O
stem	B
cell	I
leukemia	O
gene	O
Scl/Tal1	O
during	O
early	O
embryonic	O
hematopoietic	O
development.	O

The	O
ECM	O
is	O
known	O
to	O
modulate	O
cell	O
signaling	O
and	O
differentiation	O
cues,	O
for	O
example,	O
ECM-integrin	O
signaling	O
has	O
roles	O
both	O
in	O
early-stage	O
differentiation	O
of	O
iPSCs	O
as	O
well	O
as	O
through	O
later	O
stages	O
of	O
cardiomyocyte	O
differentiation	O
and	O
maturation.198	O
ECM	O
studies	O
open	O
the	O
possibility	O
of	O
biomimetic	O
approaches	O
to	O
stem	B
cell	I
differentiation	O
methods,	O
which	O
could	O
be	O
controlled	O
in	O
microsystems	O
designed	O
to	O
generate	O
specific	O
lineages.199.	O

Deep	O
learning	O
neural	O
networks	O
highly	O
predict	O
very	O
early	O
onset	O
of	O
pluripotent	B
stem	I
cell	I
differentiation.	O

Systematic	O
gene	O
tagging	O
using	O
CRISPR/Cas9	O
in	O
human	B
stem	I
cells	I
to	O
illuminate	O
cell	O
organization.	O

We	O
would	O
like	O
to	O
thank	O
Drs	O
Amanda	O
Swain	O
and	O
Jeffrey	O
Francis	O
(Division	O
of	O
Cancer	O
Biology,	O
Institute	O
of	O
Cancer	O
Research,	O
London)	O
and	O
Professor	O
Alan	O
Clarke	O
and	O
Dr	O
Boris	O
Shorning	O
(European	O
Cancer	B
Stem	I
Cell	I
Research	O
Institute,	O
Cardiff	O
University,	O
UK)	O
for	O
supplying	O
wild	O
type	O
and	O
PTen	O
−/−	O
mouse	O
tissues	O
and	O
for	O
their	O
assistance	O
with	O
this	O
work.	O

In	O
this	O
regard,	O
it	O
is	O
interesting	O
to	O
note	O
that,	O
in	O
addition	O
to	O
its	O
well-established	O
role	O
in	O
neurogenesis,	O
NURR1	O
has	O
recently	O
been	O
implicated	O
in	O
control	O
of	O
hematopoietic	O
stem	B
cell	I
proliferation	O
(Sirin	O
et	O
al.,	O
2010).	O

Bone	O
Marrow-Derived	O
Myofibroblasts	O
Contribute	O
to	O
the	O
Mesenchymal	B
Stem	I
Cell	I
Niche	O
and	O
Promote	O
Tumor	O
Growth.	O

Quantitative	O
temporal	O
proteomic	O
analysis	O
of	O
human	B
embryonic	I
stem	I
cell	I
differentiation	O
into	O
oligodendrocyte	O
progenitor	O
cells.	O

Transient	O
pairing	O
of	O
homologous	O
Oct4	O
alleles	O
accompanies	O
the	O
onset	O
of	O
embryonic	B
stem	I
cell	I
differentiation.	O

Efficient	O
establishment	O
of	O
human	B
embryonic	I
stem	I
cell	I
lines	O
and	O
long-term	O
maintenance	O
with	O
stable	O
karyotype	O
by	O
enzymatic	O
bulk	O
passage.	O

Embryoglycan	O
is	O
a	O
highly	O
branched	O
mucin-like	O
sialylated	O
cell	O
surface	O
glycoprotein	O
of	O
embryonic	B
pluripotent	I
stem	I
cells	I
that	O
contains	O
a	O
number	O
of	O
developmentally	O
regulated	O
carbohydrate	O
motifs	O
and	O
small	O
non-sulfated	O
poly-N-acetyllactosamine	O
residues	O
similar	O
to	O
in	O
corneal	O
KS	O
(Figure.	O

Characterization	O
of	O
human	O
embryonic	O
stem	O
cell	O
lines	O
by	O
the	O
International	O
Stem	B
Cell	I
Initiative.	O

Neuroepithelial	B
stem	I
cell	I
marker	O
nestin	O
regulates	O
the	O
migration,	O
invasion	O
and	O
growth	O
of	O
human	O
gliomas.	O

show	O
that	O
in	O
an	O
EGF-rich	O
environment	O
needed	O
for	O
adult	B
neural	I
stem	I
cell	I
proliferation,	O
a	O
subpopulation	O
of	O
postnatal	O
progenitors	O
downregulates	O
EGFR	O
signaling	O
via	O
targeted	O
receptor	O
trafficking,	O
promoting	O
multiciliated	O
ependymal	O
niche	O
cell	O
differentiation..	O

Although	O
much	O
is	O
known	O
about	O
the	O
cellular	O
identities	O
of	O
stem	B
cell	I
niche	O
components,	O
the	O
principles	O
governing	O
their	O
differentiation	O
from	O
specified	O
precursors	O
into	O
three-dimensional	O
(3D)	O
environments	O
in	O
adult	O
tissues	O
remain	O
unclear.	O

Repair	O
and	O
regeneration	O
of	O
the	O
respiratory	O
system:	O
complexity,	O
plasticity,	O
and	O
mechanisms	O
of	O
lung	B
stem	I
cell	I
function.	O

Creating	O
permissive	O
microenvironments	O
for	O
stem	B
cell	I
transplantation	O
into	O
the	O
central	O
nervous	O
system.	O

Variation	O
in	O
cancer	O
risk	O
among	O
tissues	O
can	O
be	O
explained	O
by	O
the	O
number	O
of	O
stem	B
cell	I
divisions.	O

The	O
directed	O
differentiation	O
of	O
stem	B
cells	I
to	O
specific	O
cell	O
phenotypes	O
is	O
facilitated	O
by	O
the	O
precisely	O
timed	O
addition	O
of	O
molecules	O
influencing	O
cell	O
fate	O
during	O
various	O
stages	O
of	O
neurodevelopment	O
[79]..	O

In	O
addition,	O
advances	O
in	O
stem	B
cell	I
technology	O
now	O
facilitate	O
the	O
creation	O
of	O
3D	O
brain	O
structures	O
or	O
organoids	O
and	O
co-culture	O
of	O
multiple	O
cell	O
types	O
to	O
partially	O
reconstruct	O
the	O
complex	O
network	O
of	O
the	O
human	O
brain,	O
which	O
may	O
ultimately	O
aid	O
in	O
identifying	O
druggable	O
targets	O
and	O
their	O
implications	O
in	O
a	O
more	O
sophisticated	O
context,	O
even	O
though	O
it	O
may	O
not	O
be	O
able	O
to	O
replace,	O
but	O
rather	O
complement,	O
functional	O
readouts	O
in	O
in	O
vivo	O
models	O
of	O
neurodegeneration.	O

Optimal	O
timing	O
of	O
inner	O
cell	O
mass	O
isolation	O
increases	O
the	O
efficiency	O
of	O
human	B
embryonic	I
stem	I
cell	I
derivation	O
and	O
allows	O
generation	O
of	O
sibling	O
cell	O
lines.	O

(2012)	O
A	O
comparative	O
transcriptomic	O
analysis	O
reveals	O
conserved	B
features	I
of	I
stem	I
cell	I
pluripotency	O
in	O
planarians	O
and	O
mammals.	O

Among	O
them,	O
the	O
stem	B
cell	I
leukemia	O
gene	O
(Scl/Tal1)	O
is	O
a	O
central	O
regulator	O
of	O
primitive	O
hematopoiesis8,9.	O

Mesenchymal	B
Stem	I
Cell	I
1	O
(MSC1)-Based	O
Therapy	O
Attenuates	O
Tumor	O
Growth	O
Whereas	O
MSC2-Treatment	O
Promotes	O
Tumor	O
Growth	O
and	O
Metastasis.	O

Mesenchymal	B
Stem	I
Cell	I
1	O
(MSC1)-Based	O
Therapy	O
Attenuates	O
Tumor	O
Growth	O
Whereas	O
MSC2-Treatment	O
Promotes	O
Tumor	O
Growth	O
and	O
Metastasis.	O

Mesenchymal	B
stem	I
cell	I
administration	O
in	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease:	O
State	O
of	O
the	O
science.	O

Journey	O
of	O
mesenchymal	O
stem	O
cells	O
for	O
homing:	O
Strategies	O
to	O
enhance	O
efficacy	O
and	O
safety	O
of	O
stem	B
cell	I
therapy.	O

Mesenchymal	B
stem	I
cell	I
transplantation	O
increases	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
in	O
papain-induced	O
emphysematous	O
lungs	O
and	O
inhibits	O
apoptosis	O
of	O
lung	O
cells.	O

Inflammatory	O
cytokine-induced	O
intercellular	O
adhesion	O
molecule-1	O
and	O
vascular	O
cell	O
adhesion	O
molecule-1	O
in	O
mesenchymal	B
stem	I
cells	I
are	O
critical	O
for	O
immunosuppression.	O

In	O
this	O
study	O
we	O
observed	O
a	O
threshold	O
for	O
effective	O
transplantation	O
of	O
HO-1	O
knockout	O
bone	O
marrow;	O
too	O
few	O
cells	O
led	O
to	O
hematopoietic	O
failure	O
due	O
to	O
stem	B
cell	I
depletion,	O
transplantation	O
using	O
cell	O
numbers	O
above	O
this	O
threshold	O
were	O
successful,	O
but	O
serial	O
transplants	O
from	O
these	O
recipient	O
animals	O
also	O
resulted	O
in	O
hematopoietic	O
failure..	O

Interaction	O
of	O
stem	B
cell	I
factor	O
and	O
its	O
receptor	O
c-kit	O
mediates	O
lodgment	O
and	O
acute	O
expansion	O
of	O
hematopoietic	O
cells	O
in	O
the	O
murine	O
spleen.	O

Identifying	O
Tmem59	O
related	O
gene	O
regulatory	O
network	O
of	O
mouse	O
neural	B
stem	I
cell	I
from	O
a	O
compendium	O
of	O
expression	O
profiles.	O

Adding	O
additional	O
agents	O
to	O
the	O
ex	O
vivo	O
T-cell	O
expansion	O
process	O
to	O
improve	O
T-cell	O
selection	O
and	O
expansion	O
are	O
also	O
under	O
consideration,	O
including	O
Bruton’s	O
tyrosine	O
kinase	O
(BTK)	O
inhibitors	O
and	O
homeostatic	O
cytokines	O
like	O
IL-7,	O
IL-15,	O
and	O
IL-21	O
to	O
promote	O
the	O
memory	B
stem	I
cell	I
phenotype	O
(165,	O
166)..	O

Most	O
FDA	O
approved	O
indications	O
for	O
CART	O
include	O
patients	O
with	O
relapsed	O
or	O
refractory	O
aggressive	O
B	O
cell	O
lymphomas,	O
and	O
therapy	O
for	O
such	O
patients	O
often	O
involve	O
high	O
dose	O
chemotherapy	O
with	O
stem	B
cell	I
transplantation.	O

However,	O
not	O
all	O
damage	O
can	O
be	O
prevented,	O
resulting	O
in	O
a	O
decline	O
in	O
stem	B
cell	I
function	O
with	O
age.	O

The	O
previously	O
discussed	O
hallmarks	O
are	O
involved	O
in	O
the	O
decline	O
of	O
stem	O
cell	O
function	O
with	O
age,	O
as	O
for	O
example	O
the	O
accumulation	O
of	O
DNA	O
damage	O
[251]	O
and	O
telomere	O
shortening	O
[252,	O
253]	O
were	O
shown	O
to	O
attribute	O
to	O
stem	B
cell	I
exhaustion.	O

Effects	O
of	O
telomerase	O
and	O
telomere	O
length	O
on	O
epidermal	B
stem	I
cell	I
behavior.	O

Additionally,	O
a	O
previous	O
study	O
shows	O
that	O
the	O
EZH2	O
"loss-of-function"	O
mutation	O
contributes	O
to	O
formation	O
of	O
the	O
leukemic	B
stem	I
cell	I
by	O
mediating	O
self-renewal	O
of	O
myeloid	O
progenitors	O
[9],	O
indicating	O
that	O
the	O
loss	O
of	O
EZH2	O
silencing	O
on	O
SEMA3A	O
contributes	O
to	O
leukemogenesis	O
in	O
t-AML..	O

Direct	O
evidence	O
of	O
mesenchymal	B
stem	I
cell	I
tropism	O
for	O
tumor	O
and	O
wounding	O
microenvironments	O
using	O
in	O
vivo	O
bioluminescent	O
imaging.	O

Mesenchymal	B
stem	I
cell	I
transplantation	O
and	O
DMEM	O
administration	O
in	O
a	O
3NP	O
rat	O
model	O
of	O
Huntington’s	O
disease:	O
morphological	O
and	O
behavioral	O
outcomes.	O

Safety	O
and	O
immunological	O
effects	O
of	O
mesenchymal	B
stem	I
cell	I
transplantation	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
and	O
amyotrophic	O
lateral	O
sclerosis.	O

Open-labeled	O
study	O
of	O
unilateral	B
autologous	I
bone-marrow-derived	I
mesenchymal	I
stem	I
cell	I
transplantation	O
in	O
Parkinson’s	O
disease.	O

Numerous	O
appraisals	O
of	O
stem	B
cell	I
transplantation	O
for	O
cardiac	O
diseases	O
have	O
concluded	O
that	O
although	O
safe,	O
cell	O
transplantation	O
does	O
not	O
promote	O
significant	O
gains	O
in	O
cardiac	O
functions	O
and	O
therefore	O
further	O
investigations	O
are	O
needed	O
in	O
forthcoming	O
trials	O
[11–13].	O

However,	O
continued	O
innovations	O
are	O
needed	O
to	O
maximise	O
the	O
proposed	O
power	O
of	O
stem	B
cell	I
derived	O
cardiomyocytes	O
as	O
cell	O
products	O
and	O
laboratory	O
tools..	O

Embryonic	B
stem	I
cell	I
differentiation	O
to	O
cardiomyocytes	O
on	O
nanostructured	O
scaffolds	O
for	O
myocardial	O
tissue	O
regeneration.	O

The	O
effect	O
of	O
matrix	O
composition	O
of	O
3D	O
constructs	O
on	O
embryonic	B
stem	I
cell	I
differentiation.	O

However,	O
this	O
role	O
of	O
macroH2A1	O
is	O
not	O
exclusive	O
to	O
CSCs,	O
as	O
it	O
is	O
implied	O
in	O
stem	B
cell	I
fate	O
and	O
reprogramming	O
[36–41]	O
among	O
others.	O

Multiple	O
studies	O
have	O
demonstrated	O
that	O
hypoxia	O
promotes	O
self-renewal	O
and	O
pluripotency	O
maintenance	O
in	O
ESCs	O
and	O
other	O
types	O
of	O
stem	B
cell	I
cultures.	O

It	O
is	O
known	O
that	O
self-renewal,	O
pluripotency	O
and	O
the	O
expression	O
of	O
stem	B
cell	I
markers	O
and	O
effectors	O
such	O
as	O
Nanog,	O
Oct3/4	O
and	O
Sox2	O
are	O
promoted	O
by	O
hypoxia,	O
either	O
dependent	O
or	O
independent	O
of	O
HIFα.	O

Chemotherapy-induced	O
senescence	O
mediated	O
by	O
p53	O
and	O
the	O
epigenetic	O
marker	O
H2K9me3	O
contributes	O
to	O
the	O
acquisition	O
of	O
stem	B
cell	I
properties	O
in	O
tumoral	O
cells	O
in	O
vivo	O
[203].	O

Additionally,	O
CSCs	O
can	O
modulate	O
the	O
microenvironment	O
secreting	O
TGFβ	O
to	O
mimic	O
the	O
stem	B
cell	I
niche	O
microenvironment,	O
promote	O
epithelial-mesenchymal	O
transition	O
(EMT)	O
and	O
modify	O
distal	O
niches	O
secreting	O
VGFA,	O
TGFβ,	O
TNFα	O
and	O
LOX..	O

Similarly,	O
it	O
is	O
still	O
under	O
discussion	O
whether	O
hypoxia	O
promotes	O
differentiation	O
or	O
helps	O
to	O
maintain	B
stem	I
cell	I
identity	O
under	O
certain	O
conditions.	O

The	O
histone	O
variant	O
macroH2A	O
confers	O
functional	O
robustness	O
to	O
the	O
intestinal	B
stem	I
cell	I
compartment.	O

Oxygen	O
in	O
stem	O
cell	O
biology:	O
A	O
critical	O
component	O
of	O
the	O
stem	B
cell	I
niche.	O

Molecular	O
basis	O
of	O
embryonic	B
stem	I
cell	I
self-renewal:	O
From	O
signaling	O
pathways	O
to	O
pluripotency	O
network.	O

Two	O
faces	O
of	O
the	O
coin:	O
Minireview	O
for	O
dissecting	O
the	O
role	O
of	O
reactive	O
oxygen	O
species	O
in	O
stem	B
cell	I
potency	O
and	O
lineage	O
commitment	O
[Internet]	O
J	O
Adv	O
Res	O
Elsevier	O
BV.	O

Hypoxia	B
promotes	I
stem	I
cell	I
phenotypes	O
and	O
poor	O
prognosis	O
through	O
epigenetic	O
regulation	O
of	O
DICER.	O

However,	O
minimal	O
changes	O
in	O
Fis1	O
expression	O
occur	O
during	O
mouse	B
embryonic	I
stem	I
cell	I
differentiation	O
(149),	O
suggesting	O
further	O
work	O
needs	O
to	O
be	O
done	O
to	O
elucidate	O
the	O
role	O
of	O
Fis1	O
during	O
cellular	O
differentiation..	O

Fatty	O
acid	O
synthesis	O
is	O
critical	O
for	O
stem	B
cell	I
pluripotency	O
via	O
promoting	O
mitochondrial	O
fission.	O

High-resolution	O
DNA	O
analysis	O
of	O
human	B
embryonic	I
stem	I
cell	I
lines	O
reveals	O
culture-induced	O
copy	O
number	O
changes	O
and	O
loss	O
of	O
heterozygosity.	O

Several	O
risk	O
factors	O
predispose	O
to	O
NTM	O
infections	O
in	O
recipients	O
of	O
stem	B
cell	I
transplantation	O
and	O
these	O
are	O
related	O
to	O
the	O
underlying	O
medical	O
condition	O
and	O
its	O
treatment,	O
the	O
pre-transplant	O
conditioning	O
therapies	O
as	O
well	O
as	O
the	O
transplant	O
procedure	O
and	O
its	O
complications.	O

Currently,	O
there	O
are	O
no	O
guidelines	O
for	O
the	O
treatment	O
of	O
NTM	O
infections	O
in	O
recipients	O
of	O
stem	B
cell	I
transplantation,	O
but	O
such	O
infections	O
have	O
been	O
successfully	O
treated	O
with	O
surgical	O
debridement,	O
removal	O
of	O
infected	O
or	O
colonized	O
indwelling	O
intravascular	O
devices,	O
and	O
administration	O
of	O
various	O
combinations	O
of	O
antimicrobials.	O

The	O
npBAF	O
complex	O
incorporated	O
with	O
SS18	O
is	O
required	O
for	O
neural	B
stem	I
cell	I
self-renewal.	O

The	O
increased	O
LRBA	O
protein	O
expression	O
after	O
stimulation	O
(black)	O
compared	O
with	O
that	O
in	O
unstimulated	O
cells	O
(gray)	O
is	O
shown	O
in	O
the	O
in-house	O
control	O
and	O
in	O
a	O
travel	O
control	O
(1	O
and	O
2	O
asterisks,	O
respectively;	O
upper	O
panel);	O
is	O
reduced	O
in	O
the	O
LRBA-heterozygous	O
mother,	O
who	O
was	O
the	O
stem	B
cell	I
donor,	O
in	O
patient	O
1	O
after	O
HSCT;	O
and	O
is	O
absent	O
in	O
patient	O
2	O
(lower	O
panel).	O

Although	O
certain	O
refractory	O
courses	O
of	O
systemic	O
sclerosis,	O
multiple	O
sclerosis,	O
systemic	O
lupus,	O
Crohn	O
disease,	O
and	O
other	O
autoimmune	O
diseases	O
are	O
becoming	O
a	O
standard	O
indication	O
for	O
autologous	O
stem	O
cell	O
transplantation,E30	O
the	O
indications	O
for	O
allogeneic	O
HSCT	O
in	O
patients	O
with	O
autoimmune	O
diseases	O
remain	O
controversial,	O
given	O
the	O
risk	O
of	O
histoincompatibility	O
reactions,	O
such	O
as	O
GvHD,	O
and	O
the	O
increased	O
incidence	O
of	O
life-threatening	O
infections	O
in	O
the	O
allogeneic	O
setting	O
compared	O
with	O
autologous	B
stem	I
cell	I
reinfusion.	O

The	O
younger	O
sibling	O
has	O
been	O
considered	O
a	O
candidate	O
for	O
stem	B
cell	I
transplantation	O
since	O
the	O
first	O
presentation	O
after	O
the	O
experience	O
of	O
patient	O
1,	O
but	O
3	O
factors	O
have	O
argued	O
against	O
it.	O

We	O
experimentally	O
validate	O
several	O
of	O
these	O
newly	O
discovered	O
dimorphisms,	O
including	O
the	O
first	O
reported	O
instance	O
of	O
an	O
unfixed	O
HERV-W	O
provirus	O
and	O
an	O
HERV-H	O
locus	O
driving	O
a	O
transcript	O
(ESRG)	O
implicated	O
in	O
the	O
maintenance	O
of	O
embryonic	B
stem	I
cell	I
pluripotency..	O

3f)	O
corresponds	O
to	O
the	O
RefSeq	O
gene	O
Embryonic	B
Stem	I
cell	I
Related	O
Gene	O
(ESRG),	O
which	O
has	O
been	O
identified	O
as	O
a	O
marker	O
of	O
pluripotency	O
[63–66].	O

The	O
retrovirus	O
HERVH	O
is	O
a	O
long	O
noncoding	O
RNA	O
required	O
for	O
human	B
embryonic	I
stem	I
cell	I
identity.	O

Multilineage	O
hematopoietic	O
reconstitution	O
without	O
clonal	O
selection	O
in	O
ADA-SCID	O
patients	O
treated	O
with	O
stem	B
cell	I
gene	O
therapy.	O

DGCR8	O
is	O
essential	O
for	O
microRNA	O
biogenesis	O
and	O
silencing	O
of	O
embryonic	B
stem	I
cell	I
self-renewal.	O

a	O
Neurogenesis	O
in	O
the	O
hippocampus	O
comprises	O
several	O
steps,	O
including	O
proliferation	O
of	O
neural	B
stem	I
cells	I
and	O
transit	O
amplifying	O
neural	O
progenitors	O
in	O
the	O
subgranular	O
zone	O
(SGZ),	O
cell	O
cycle	O
exit,	O
neuroblasts	O
migration	O
throughout	O
the	O
granule	O
cell	O
layer	O
(GCL),	O
and	O
maturation	O
of	O
the	O
newborn	O
neurons.	O

Thus,	O
signaling	O
from	O
the	O
niche	O
is	O
suggested	O
to	O
be	O
responsible	O
for	O
key	O
processes	O
in	O
the	O
regulation	O
of	O
adult	O
neurogenesis	O
homeostasis,	O
including:	O
the	O
balance	O
between	O
quiescence	O
versus	O
proliferation,	O
the	O
mode	O
of	O
cell	O
division,	O
and	O
the	O
prevention	O
of	O
stem	B
cell	I
depletion	O
[75,	O
76].	O

Neural	B
stem	I
cell	I
proliferation	O
is	O
decreased	O
in	O
schizophrenia,	O
but	O
not	O
in	O
depression.	O

This	O
review	O
article	O
will	O
also	O
focus	O
on	O
recent	O
advances	O
in	O
stem	B
cell	I
therapies	O
that	O
aim	O
at	O
repopulation	O
or	O
regeneration	O
of	O
a	O
degenerating	O
vascular	O
system	O
for	O
neural	O
diseases..	O

Herein,	O
we	O
discuss	O
these	O
and	O
also	O
explore	O
the	O
recent	O
advance	O
of	O
stem	B
cell	I
therapy	O
that	O
targets	O
neovascularization	O
during	O
neural	O
diseases..	O

An	O
appropriate	O
balance	O
between	O
self-renewal	O
and	O
differentiation	O
is	O
crucial	O
for	O
stem	B
cell	I
functions	O
to	O
generate	O
precise	O
cellular	O
diversity	O
in	O
the	O
neocortex	O
(Mizutani	O
et	O
al.,	O
2007;	O
Franco	O
and	O
Müller,	O
2013;	O
Inoue	O
et	O
al.,	O
2017).	O

Hypoxia	O
inducible	O
factor-1α	O
(HIF-1α)	O
is	O
required	O
for	O
neural	B
stem	I
cell	I
maintenance	O
and	O
vascular	O
stability	O
in	O
the	O
adult	O
mouse	O
SVZ.	O

Along	O
with	O
the	O
multiple	O
cellular	O
processes	O
and	O
functions	O
known	O
to	O
be	O
derived	O
from	O
HH	O
cascade	O
activation,	O
recent	O
findings	O
showing	O
that	O
the	O
HH	O
pathway	O
plays	O
a	O
pivotal	O
role	O
in	O
stem	B
cell	I
maintenance	O
have	O
attracted	O
great	O
attention,	O
especially	O
in	O
the	O
field	O
of	O
cancer	O
research	O
as	O
a	O
new	O
potential	O
therapeutic	O
target	O
pathway	O
for	O
the	O
treatment	O
of	O
various	O
types	O
of	O
cancers	O
[5,11,12].	O

Recent	O
advances	O
in	O
stem	B
cell	I
biology	O
have	O
also	O
presented	O
cross-talk	O
between	O
the	O
HH	O
pathway	O
and	O
other	O
developmental	O
pathways	O
such	O
as	O
Wnt,	O
Hox	O
and	O
Notch	O
signaling	O
[34,35].	O

Gene	O
expression	O
profiling	O
indicated	O
that	O
the	O
Pou3f1	O
expression	O
peak	O
occurred	O
between	O
the	O
epiblast	O
marker	O
Fgf5	O
and	O
the	O
neural	B
stem	I
cell	I
marker	O
Sox1	O
(Figure	O
1A,	O
Figure	O
1—figure	O
supplement	O
1A).	O

These	O
results	O
indicate	O
that	O
the	O
increase	O
of	O
CoAM,	O
which	O
inhibits	O
CoAA	O
transcriptional	O
activity,	O
might	O
be	O
common	O
in	O
different	O
type	O
of	O
stem	B
cell	I
differentiation	O
at	O
the	O
EB	O
stage..	O

Cell	O
fate	O
determination	O
in	O
stem	B
cell	I
differentiation	O
involves	O
a	O
complex	O
pattern	O
of	O
gene	O
regulation	O
including	O
alternative	O
splicing	O
(54,55).	O

Together,	O
these	O
results	O
show	O
successful	O
prime	O
editing	O
of	O
primary	B
stem	I
cells	I
with	O
similar	O
efficiency	O
and	O
accuracy	O
as	O
in	O
human	O
cancer	O
cell	O
lines..	O

Tumor-initiating	B
stem	I
cells	I
of	O
squamous	O
cell	O
carcinomas	O
and	O
their	O
control	O
by	O
TGF-β	O
and	O
integrin/focal	O
adhesion	O
kinase	O
(FAK)	O
signaling.	O

They	O
report	O
the	O
repression	O
of	O
miR-203	O
by	O
oncogenic	O
H-Ras	O
in	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
skin,	O
purporting	O
that	O
the	O
stem	B
cell	I
pool	O
is	O
affected.	O

This	O
work	O
emanates	O
from	O
previous	O
work	O
connecting	O
miR-203	O
to	O
skin	B
stem	I
cell	I
biology.	O

Mesenchymal	B
Stem	I
Cell	I
Secretome:	O
Toward	O
Cell-Free	O
Therapeutic	O
Strategies	O
in	O
Regenerative	O
Medicine.	O

Mesenchymal	B
Stem	I
Cell	I
Secretome:	O
Toward	O
Cell-Free	O
Therapeutic	O
Strategies	O
in	O
Regenerative	O
Medicine.	O

On	O
the	O
other	O
hand,	O
culture	O
of	O
DPSCs	O
in	O
5%	O
O2	O
significantly	O
increases	O
their	O
migration	O
and	O
proliferation	O
rate,	O
but	O
also	O
the	O
expression	O
of	O
stem	B
cell	I
markers	O
and	O
BDNF,	O
NGF,	O
SOX2	O
and	O
VEGF	O
[222].	O

As	O
mentioned	O
above,	O
oxygen	O
concentration	O
is	O
a	O
critical	O
environmental	O
factor	O
that	O
affects	O
the	O
maintenance	O
of	O
stem	B
cell	I
plasticity	O
and	O
proliferation	O
[232].	O

Differential	O
expression	O
of	O
stem	B
cell	I
mobilization-associated	O
molecules	O
on	O
multi-lineage	O
cells	O
from	O
adipose	O
tissue	O
and	O
bone	O
marrow.	O

A	O
review	O
of	O
therapeutic	O
effects	O
of	O
mesenchymal	B
stem	I
cell	I
secretions	O
and	O
induction	O
of	O
secretory	O
modification	O
by	O
different	O
culture	O
methods.	O

Mesenchymal	B
stem	I
cell	I
secreted	O
vesicles	O
provide	O
novel	O
opportunities	O
in	O
(stem)	O
cell-free	O
therapy.	O

Stem	O
cell	O
conditioned	O
medium	O
improves	O
acute	O
lung	O
injury	O
in	O
mice:	O
In	O
vivo	O
evidence	O
for	O
stem	B
cell	I
paracrine	O
action.	O

Mesenchymal	B
stem	I
cell	I
secretome:	O
A	O
potential	O
tool	O
for	O
the	O
prevention	O
of	O
muscle	O
degenerative	O
changes	O
associated	O
with	O
chronic	O
rotator	O
cuff	O
tears.	O

Identification	O
of	O
MFGE8	O
in	O
mesenchymal	B
stem	I
cell	I
secretome	O
as	O
an	O
anti-fibrotic	O
factor	O
in	O
liver	O
fibrosis.	O

Harnessing	O
the	O
mesenchymal	B
stem	I
cell	I
secretome	O
for	O
the	O
treatment	O
of	O
cardiovascular	O
disease.	O

Mesenchymal	B
stem	I
cell	I
microvesicles	O
attenuate	O
acute	O
lung	O
injury	O
in	O
mice	O
partly	O
mediated	O
by	O
Ang-1	O
mRNA.	O

Hypoxic	O
culture	O
conditions	O
as	O
a	O
solution	O
for	O
mesenchymal	B
stem	I
cell	I
based	O
regenerative	O
therapy.	O

D54	O
cells	O
expressing	O
the	O
stem	B
cell	I
marker	O
CD133,	O
had	O
an	O
intrinsic	O
resistance	O
to	O
a	O
variety	O
of	O
compounds	O
confirming	O
prior	O
findings	O
[25],	O
[26].	O

Based	O
on	O
these	O
histological	O
differences,	O
we	O
expected	O
that	O
lentivirus	O
microinjected	O
into	O
immature	O
seminiferous	O
tubules	O
would	O
have	O
a	O
higher	O
probability	O
of	O
successfully	O
targeting	O
the	O
stem	B
cell	I
population,	O
than	O
lentivirus	O
injected	O
into	O
mature	O
seminiferous	O
tubules.	O

Spermatogonial	B
stem	I
cell	I
enrichment	O
by	O
multiparameter	O
selection	O
of	O
mouse	O
testis	O
cells.	O

Adenoviruses	O
play	O
a	O
major	O
role	O
in	O
solid-organ	O
transplant	O
recipients	O
but	O
occur	O
less	O
often	O
in	O
stem	B
cell	I
recipients	O
[46,	O
62,	O
71,	O
92,	O
130,	O
131,	O
135],	O
However,	O
novel	O
and	O
more	O
aggressive	O
adenovirus	O
strains	O
may	O
meet	O
the	O
definition	O
for	O
emerging	O
pathogens	O
and	O
may	O
play	O
a	O
future	O
role	O
in	O
patients	O
with	O
hematological	O
malignancies.	O

Hippo	O
pathway	O
in	O
combination	O
with	O
Notch	O
was	O
also	O
seen	O
to	O
play	O
a	O
role	O
in	O
the	O
cancer	B
stem	I
cell	I
population	O
in	O
ERMS.	O

Notch	O
pathway	O
is	O
implicated	O
in	O
cancer	B
stem	I
cell	I
maintenance	O
and	O
expansion	O
in	O
various	O
cancers	O
[136]	O
including	O
RMS	O
[45],	O
[137].	O

Blastema	O
formation	O
requires	O
a	O
large	O
number	O
of	O
progenitor	O
cells	O
derived	O
from	O
quiescent	B
stem	I
cells	I
or	O
differentiated	O
cell	O
types.	O

Actin	O
cytoskeleton	O
regulation	O
has	O
been	O
implicated	O
in	O
modulating	B
stem	I
cell	I
signaling	O
and	O
responsiveness	O
(Müller	O
et	O
al.,	O
2013).	O

The	O
effect	O
of	O
matrix	O
composition	O
of	O
3D	O
constructs	O
on	O
embryonic	B
stem	I
cell	I
differentiation.	O

Mitochondria	O
in	O
mesenchymal	B
stem	I
cell	I
biology	O
and	O
cell	O
therapy:	O
from	O
cellular	O
differentiation	O
to	O
mitochondrial	O
transfer.	O

Enhanced	B
stem	I
cell	I
engraftment	O
and	O
modulation	O
of	O
hepatic	O
reactive	O
oxygen	O
species	O
production	O
in	O
diet-induced	O
obesity.	O

Fascin	O
is	O
critical	O
for	O
the	O
maintenance	O
of	O
breast	B
cancer	I
stem	I
cell	I
pool	O
predominantly	O
via	O
the	O
activation	O
of	O
the	O
notch	O
self-renewal	O
pathway.	O

Disequilibrium	O
of	O
BMP2	O
levels	O
in	O
the	O
breast	B
stem	I
cell	I
niche	O
launches	O
epithelial	O
transformation	O
by	O
overamplifying	O
BMPR1B	O
cell	O
response.	O

Epigenetic	O
dynamics	O
of	O
stem	B
cells	I
and	O
cell	O
lineage	O
commitment:	O
Digging	O
waddington’s	O
canal.	O

New	O
insights	O
into	O
the	O
role	O
of	O
Runx1	O
in	O
epithelial	B
stem	I
cell	I
biology	O
and	O
pathology.	O

Directed	O
differentiation	O
of	O
stem	B
cells	I
offers	O
a	O
scalable	O
solution	O
to	O
the	O
need	O
for	O
human	O
cell	O
models	O
recapitulating	O
islet	O
biology	O
and	O
T2D	O
pathogenesis.	O

Principal	O
component	O
analysis	O
of	O
the	O
different	O
developmental	O
stages	O
and	O
human	O
FACS-enriched	O
β-cells57	O
showed	O
an	O
inverted-U	O
shape	O
from	O
stem	B
cell	I
through	O
to	O
adult	O
β-cells.	O

Gene	O
expression	O
patterns	O
in	O
human	B
embryonic	I
stem	I
cells	I
and	O
human	O
pluripotent	O
germ	O
cell	O
tumors.	O

Here,	O
we	O
show	O
that	O
the	O
Cox-2	O
and	O
Wnt	O
signaling	O
pathways	O
are	O
aberrantly	O
activated	O
in	O
GSCs	O
and	O
interact	O
to	O
maintain	O
the	O
cancer	B
stem	I
cell	I
identity.	O

Interestingly,	O
the	O
activating	O
effect	O
of	O
Wnt	O
on	O
embryonic	B
stem	I
cell	I
self-renewal	O
has	O
been	O
found	O
to	O
depend	O
on	O
its	O
induction	O
of	O
Egr1	O
[22],	O
which	O
has	O
also	O
been	O
implicated	O
as	O
a	O
downstream	O
target	O
of	O
the	O
Cox-2	O
pathway	O
[23]..	O

As	O
Cox-2	O
has	O
been	O
implicated	O
as	O
a	O
mediator	O
of	O
the	O
cancer	B
stem	I
cell	I
phenotype	O
in	O
mouse	O
glioblastoma,	O
we	O
sought	O
to	O
determine	O
if	O
it	O
has	O
an	O
analogous	O
role	O
in	O
the	O
human	O
disease.	O

Glioma	B
stem	I
cell	I
lines	O
expanded	O
in	O
adherent	O
culture	O
have	O
tumor-specific	O
phenotypes	O
and	O
are	O
suitable	O
for	O
chemical	O
and	O
genetic	O
screens.	O

Personalized	O
busulfan	O
and	O
treosulfan	O
conditioning	O
for	O
pediatric	B
stem	I
cell	I
transplantation:	O
the	O
role	O
of	O
pharmacogenetics	O
and	O
pharmacokinetics.	O

Mechanical	O
stimulation	O
of	O
mesenchymal	B
stem	I
cell	I
proliferation	O
and	O
differentiation	O
promotes	O
osteogenesis	O
while	O
preventing	O
dietary-induced	O
obesity.	O

In	O
parallel	O
with	O
the	O
above	O
experiments,	O
TLR4/MyD88	O
expression	O
was	O
assessed	O
in	O
undifferentiated	O
and	O
differentiated	O
embryonal	O
carcinoma	O
cells	O
to	O
provide	O
further	O
evidence	O
of	O
the	O
cancer	B
stem	I
cell	I
hypothesis	O
in	O
ovarian	O
cancer..	O

Here,	O
we	O
report	O
that	O
CSDE1,	O
an	O
RNA-binding	O
protein	O
linked	O
to	O
stem	B
cell	I
maintenance	O
and	O
metastasis	O
in	O
cancer,	O
interacts	O
with	O
AGO2	O
within	O
miRNA-induced	O
silencing	O
complex	O
and	O
mediates	O
gene	O
silencing	O
through	O
its	O
N-terminal	O
domains.	O

Further	O
research	O
is	O
required	O
to	O
determine	O
the	O
mechanism,	O
which	O
may	O
generate	O
important	O
knowledge	O
on	O
new	O
ways	O
to	O
manipulate	O
the	O
cell	O
fate	O
potential	O
of	O
stem	B
cells	I
and	O
mature	O
adult	O
cells.	O

Basal	O
cell	O
carcinomas	O
arise	O
from	O
hair	B
follicle	I
stem	I
cells	I
in	O
Ptch1(+/-)	O
mice.	O

Induction	O
of	O
cells	O
with	O
cancer	B
stem	I
cell	I
properties	O
from	O
nontumorigenic	O
human	O
mammary	O
epithelial	O
cells	O
by	O
defined	O
reprogramming	O
factors.	O

Mesenchymal	B
stem	I
cell	I
graft	O
improves	O
recovery	O
after	O
spinal	O
cord	O
injury	O
in	O
adult	O
rats	O
through	O
neurotrophic	O
and	O
pro-angiogenic	O
actions.	O

Finally,	O
we	O
speculate	O
upon	O
the	O
potential	O
role	O
for	O
stem	B
cell	I
based	O
therapies	O
in	O
MS..	O

A	O
common	O
taxonomy	O
of	O
stem	B
cells	I
is	O
based	O
on	O
the	O
developmental	O
stage	O
of	O
isolation,	O
which	O
in	O
turn	O
determines	O
the	O
repertoire	O
of	O
specialised	O
cell	O
types	O
they	O
can	O
generate	O
(or	O
their	O
“potency”).	O

Multiple	O
specific	O
genetic	O
steps	O
contribute	O
to	O
the	O
transition	O
from	O
stem	B
cell	I
to	O
a	O
terminally	O
differentiated	O
state,	O
raising	O
the	O
question	O
of	O
which	O
specific	O
point	O
in	O
the	O
differentiation	O
process	O
provides	O
cells	O
best	O
suited	O
to	O
the	O
desired	O
therapeutic	O
goal.	O

Recent	O
advances	O
in	O
human	B
stem	I
cell	I
biology	O
have	O
given	O
rise	O
to	O
unprecedented	O
experimental	O
opportunities	O
to	O
study	O
neurodegenerative	O
disease	O
using	O
clinically	O
relevant	O
model	O
systems,	O
and	O
patient-derived	O
iPSCs	O
now	O
offer	O
an	O
unparalleled	O
human	O
system	O
for	O
in	O
vitro	O
modeling	O
of	O
disease	O
mechanisms	O
and	O
discovering	O
new	O
therapeutic	O
strategies.	O

At	O
present,	O
the	O
main	O
utility	O
of	O
human	B
stem	I
cell	I
approaches	O
therapeutically	O
would	O
appear	O
to	O
be	O
indirect,	O
through	O
the	O
promotion	O
of	O
endogenous	O
repair	O
mechanisms,	O
rather	O
than	O
direct	O
cellular	O
replacement.	O

Human	B
embryonic	I
stem	I
cell	I
derived	O
astrocytes	O
mediate	O
non-cell-autonomous	O
neuroprotection	O
through	O
endogenous	O
and	O
drug-induced	O
mechanisms.	O

Preprocessed	O
microarray	O
datasets	O
of	O
normal	O
hematopoiesis	O
(GSE24759)	O
[31],	O
paired	O
diagnosis	O
and	O
relapse	O
AML	O
samples	O
(GSE65625)	O
[32],	O
and	O
functionally	O
annotated	O
leukemic	B
stem	I
cell	I
enriched	O
(LSC+)	O
and	O
depleted	O
(LSC−)	O
AML	O
populations	O
(GSE76009)	O
[33]	O
were	O
also	O
downloaded	O
from	O
the	O
GEO	O
Omnibus.	O

A	O
gene	O
expression	O
profile	O
associated	O
with	O
relapse	O
of	O
cytogenetically	O
normal	O
acute	O
myeloid	O
leukemia	O
is	O
enriched	O
for	O
leukemia	B
stem	I
cell	I
genes.	O

It	O
is	O
still	O
unknown	O
whether	O
clock	O
factors	O
expressed	O
in	O
ES	O
exert	O
a	O
role	O
in	O
stem	B
cell	I
maintenance.	O

Dysregulation	O
of	O
the	O
circadian	O
network	O
has	O
also	O
been	O
implicated	O
in	O
cancer	B
stem	I
cell	I
biology..	O

The	O
oncogenic	O
role	O
for	O
circadian	O
clock	O
activity	O
in	O
the	O
cancer	B
stem	I
cell	I
compartment	O
has	O
been	O
confirmed	O
by	O
other	O
observations.	O

Circadian	O
clock-mediated	O
control	O
of	O
stem	B
cell	I
division	O
and	O
differentiation:	O
Beyond	O
night	O
and	O
day.	O

We	O
found	O
that	O
down-regulation	O
of	O
p53	O
reduces	O
OCIAD1	O
expression	O
level,	O
in	O
contrast	O
to	O
the	O
report	O
that	O
OCIAD1	O
regulates	O
p53	O
in	O
mouse	O
HSC	O
[74],	O
suggesting	O
that	O
interplay	O
between	O
OCIAD1	O
and	O
p53	O
may	O
be	O
different	O
in	O
stem	B
cell	I
and	O
non-stem	O
cells..	O

Embryonic	B
stem	I
cell	I
and	O
tissue	O
specific	O
expression	O
of	O
a	O
novel	O
conserved	O
gene,	O
asrij.	O

We	O
define	O
the	O
effects	O
of	O
TDCM	O
on	O
the	O
expression	O
of	O
stem	B
cell	I
markers,	O
and	O
on	O
proliferation	O
and	O
differentiation,	O
and	O
compare	O
the	O
TDCM	O
cells	O
to	O
both	O
CRCs	O
grown	O
in	O
conventional	O
two-dimensional	O
cultures	O
(i.e.	O

Effects	O
of	O
ethanol	O
on	O
transforming	O
growth	O
factor	O
Beta1-dependent	O
and-independent	O
mechanisms	O
of	O
neural	B
stem	I
cell	I
apoptosis.	O

Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

Cells	O
were	O
cultured	O
and	O
validated	O
for	O
stem	B
cell	I
properties	O
as	O
described	O
[12].	O

This	O
is	O
particularly	O
interesting	O
in	O
the	O
context	O
of	O
HF	O
stem	B
cell	I
contribution	O
to	O
healing,	O
which	O
seems	O
o	O
be	O
influenced	O
by	O
the	O
stage	O
of	O
repair..	O

An	O
extended	O
epidermal	O
response	O
heals	O
cutaneous	O
wounds	O
in	O
the	O
absence	O
of	O
a	O
hair	B
follicle	I
stem	I
cell	I
contribution.	O

Pioneer	O
factors	O
govern	O
super-enhancer	O
dynamics	O
in	O
stem	B
cell	I
plasticity	O
and	O
lineage	O
choice.	O

Moreover,	O
there	O
is	O
growing	O
evidence	O
that	O
substantial	O
person-to-person	O
differences	O
in	O
the	O
outcome	O
of	O
stem	B
cell	I
therapy	O
exists.	O

Therefore,	O
the	O
precise	O
planning	O
of	O
stem	B
cell	I
therapy	O
must	O
be	O
coordinated	O
ideally	O
with	O
the	O
characteristics	O
of	O
individual	O
patient	O
profiles	O
to	O
fully	O
harness	O
its	O
therapeutic	O
potential	O
[4]..	O

The	O
relatively	O
small	O
number	O
of	O
patients,	O
the	O
absence	O
of	O
a	O
control	O
group	O
undergoing	O
repeat	O
coronary	O
infusions,	O
and	O
the	O
relatively	O
mild	O
improvements	O
in	O
LV	O
function	O
after	O
the	O
index	O
infarction	O
challenged	O
distinct	O
interpretation	O
of	O
these	O
results	O
concerning	O
identification	O
of	O
patient	O
populations	O
with	O
particular	O
benefit	O
of	O
stem	B
cell	I
interventions..	O

Through	O
this	O
information,	O
therapeutic	O
outcome	O
of	O
stem	B
cell	I
therapies	O
would	O
be	O
better	O
predicted.	O

Patient	O
specific	O
genomic	O
profiling	O
and	O
molecular	O
understanding	O
of	O
stem	B
cell	I
biology	O
are	O
therefore	O
the	O
major	O
tasks	O
for	O
clinicians	O
and	O
scientists	O
in	O
order	O
to	O
reach	O
desirable	O
results	O
in	O
future	O
approaches,	O
reminding	O
us	O
that	O
a	O
complete	O
understanding	O
of	O
basic	O
science	O
is	O
fundamental	O
prior	O
to	O
and	O
during	O
implementation	O
of	O
these	O
cell-based	O
interventions..	O

However,	O
recent	O
evidence	O
suggests	O
that	O
the	O
adult	O
myocardium	O
contains	O
a	O
small	O
population	O
of	O
endogenous	B
stem	I
cells	I
that	O
most	O
likely	O
facilitate	O
minor	O
repair	O
and	O
turnover-mediated	O
cell	O
replacement	O
[63].	O

While	O
cell	O
tracking	O
methodologies	O
allow	O
researchers	O
to	O
determine	O
migration	O
patterns,	O
the	O
stem	B
cells	I
must	O
target	O
their	O
desired	O
destination	O
and	O
be	O
retained	O
there	O
for	O
a	O
sufficient	O
amount	O
of	O
time	O
to	O
achieve	O
benefit.	O

Clearly,	O
the	O
field	O
of	O
stem	B
cell	I
therapy	O
needs	O
research	O
that	O
would	O
serve	O
towards	O
the	O
purpose	O
of	O
individualized	O
treatments.	O

Effect	O
on	O
left	O
ventricular	O
function	O
of	O
intracoronary	O
transplantation	O
of	O
autologous	B
bone	I
marrow	I
mesenchymal	I
stem	I
cell	I
in	O
patients	O
with	O
acute	O
myocardial	O
infarction.	O

To	O
the	O
best	O
of	O
our	O
knowledge,	O
this	O
is	O
first	O
report	O
to	O
examine	O
the	O
detrimental	O
effect	O
of	O
PM2.5-stimulated	O
inflammatory	O
cytokines	O
secreted	O
from	O
respiratory	O
tract	O
on	O
stem	B
cell	I
differentiation.	O

Human	B
embryonic	I
stem	I
cell	I
derived	O
Mouse	O
green	O
fluorescent	O
protein-labeleda	O
Guinea	O
pig	O
Hypothalamusb	O
Mouse	O
Olfactory	O
placode	O
derivedc.	O

Perhaps,	O
hKP10	O
supplementation	O
during	O
days	O
0	O
to	O
5	O
is	O
less	O
effective,	O
because	O
kisspeptin	O
in	O
stem	B
cell	I
cultures	O
is	O
already	O
high,	O
whereas	O
KISS1R	O
between	O
days	O
0	O
and	O
8	O
is	O
low	O
(Fig.	O

Generation	O
of	O
mCh-GnRH	O
carrying	O
hESC	O
allowed	O
us	O
to	O
find	O
the	O
exact	O
time	O
course	O
necessary	O
for	O
stem	B
cell	I
transformation	O
into	O
GnRH	O
neurons,	O
to	O
count	O
GnRH	O
producing	O
cells	O
more	O
accurately,	O
and	O
to	O
conduct	O
experiments	O
for	O
physiological	O
characterization	O
of	O
GnRH	O
neurons.	O

Additionally,	O
while	O
for	O
the	O
RNAseq	O
analysis	O
we	O
used	O
mixed	O
cell	O
groups	O
throughout	O
the	O
stem	B
cell	I
differentiation	O
by	O
FGF8	O
exposure	O
(ie,	O
days	O
0,	O
8,	O
15,	O
and	O
28),	O
Lund	O
et	O
al	O
(50)	O
used	O
mixed	O
cell	O
groups	O
for	O
their	O
day	O
20	O
(day	O
10	O
of	O
FGF8	O
exposure)	O
and	O
Td-Tomato-labeled	O
GnRH	O
neurons	O
only	O
for	O
day	O
27	O
(day	O
17	O
of	O
FGF8	O
exposure)	O
in	O
the	O
RNAseq	O
analysis.	O

On	O
the	O
other	O
hand,	O
ROS	O
levels	O
are	O
indirectly	O
controlled	O
via	O
signalling	O
mechanisms	O
during	O
the	O
quiescent	B
stem	I
cell	I
mode,	O
to	O
maintain	O
low	O
ROS	O
levels.	O

Increased	O
levels	O
of	O
ROS	O
can	O
either	O
be	O
removed	O
directly	O
through	O
induction	O
of	O
antioxidative	O
mechanisms	O
or	O
indirectly	O
through	O
induction	O
of	O
the	O
quiescent	B
stem	I
cell	I
model.	O

In	O
this	O
manuscript,	O
the	O
authors	O
hypothesize	O
an	O
important	O
role	O
for	O
HSPs	O
in	O
the	O
stem	B
cell	I
defence,	O
guiding	O
survival	O
and	O
proliferation	O
during	O
Cd	O
stress.	O

Here,	O
we	O
will	O
briefly	O
summarize	O
recent	O
studies	O
that	O
afforded	O
a	O
glance	O
behind	O
the	O
scenes	O
of	O
this	O
stem	B
cell	I
connection.	O

CSC	O
possess	O
the	O
stem	B
cell	I
characteristics	O
of	O
self-renewal	O
and	O
differentiation	O
potential	O
to	O
(re-)grow	O
the	O
heterogeneous	O
tumor.	O

Expression	O
of	O
the	O
pituitary	B
stem	I
cell	I
markers	O
SOX2,	O
SOX9,	O
OCT4,	O
and	O
KLF4,	O
as	O
identified	O
in	O
normal	O
human	O
pituitaries,	O
was	O
also	O
observed	O
in	O
human	O
ACP	O
(and	O
PCP)	O
samples	O
(5,	O
33)	O
(Table.	O

Transgenic	O
overexpression	O
of	O
the	O
pituitary	B
stem	I
cell	I
marker	O
PROP1	O
under	O
control	O
of	O
the	O
αGSU	O
promoter	O
also	O
leads	O
(after	O
1 year)	O
to	O
pituitary	O
tumors	O
including	O
non-hormonal,	O
GH-,	O
PRL-,	O
GH/PRL-,	O
PRL/αGSU-,	O
and	O
TSH-producing	O
adenomas	O
(38,	O
39).	O

Ectopic	O
overexpression	O
of	O
the	O
pituitary	B
stem	I
cell	I
protein	O
BMI1	O
(45)	O
caused	O
after	O
1 year	O
the	O
development	O
of	O
both	O
IL	O
and	O
AP	O
tumors	O
that	O
were	O
positive	O
for	O
ACTH	O
and	O
β-endorphin	O
(40).	O

Here,	O
we	O
summarize	O
what	O
is	B
known	I
about	I
the	I
major	I
stem	I
cell	I
signaling	O
pathways	O
(i.e.,	O
NOTCH,	O
WNT,	O
EMT,	O
SHH,	O
Hippo,	O
and	O
epidermal	O
growth	O
factor-EGF/FGF)	O
in	O
pituitary	O
tumors,	O
and	O
where	O
investigations	O
have	O
been	O
conducted,	O
in	O
the	O
candidate	O
TSC	O
populations	O
(Table.	O

Taken	O
together,	O
information	O
on	O
stem	B
cell	I
signaling	O
pathways	O
in	O
pituitary	O
tumorigenesis	O
is	O
presently	O
very	O
limited.	O

Cancer	B
stem	I
cell	I
niche	O
models	O
and	O
contribution	O
by	O
mesenchymal	O
stroma/stem	O
cells.	O

Introduction	O
of	O
these	O
agents,	O
including	O
proteasome	O
inhibitors	O
(bortezomib,	O
ixazomib,	O
carfilzomib),	O
immunomodulatory	O
agents	O
(thalidomide,	O
lenalidomide,	O
and	O
pomalidomide)	O
together	O
with	O
consolidation	O
using	O
high-dose	O
melphalan	O
followed	O
by	O
autologous	B
stem	I
cell	I
salvage	O
in	O
fit	O
patients,	O
has	O
already	O
led	O
to	O
an	O
immense	O
improvement	O
of	O
overall	O
survival	O
in	O
MM	O
patients.	O

Expression	O
of	O
the	O
stem	B
cell	I
self-renewal	O
gene	O
Hiwi	O
and	O
risk	O
of	O
tumour-related	O
death	O
in	O
patients	O
with	O
soft-tissue	O
sarcoma.	O

Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

Mesenchymal	B
stem	I
cell	I
deficiency	O
influences	O
megakaryocytopoiesis	O
through	O
the	O
TNFAIP3/NF-kappaB/SMAD	O
pathway	O
in	O
patients	O
with	O
immune	O
thrombocytopenia.	O

Methods	O
have	O
been	O
developed	O
to	O
isolate	B
stem	I
cells	I
using	O
antibodies	O
that	O
specifically	O
bind	O
to	O
cell	O
surface	O
marker	O
proteins	O
[12-14],	O
or	O
based	O
on	O
transfection	O
of	O
plasmid	O
with	O
the	O
promoter	O
and	O
reporter	O
genes	O
[15,16].	O

Therefore,	O
it	O
is	O
necessary	O
to	O
develop	O
new	O
methods	O
for	O
stem	B
cell	I
detection	O
and	O
isolation	O
with	O
better	O
robustness	O
and	O
safety..	O

In	O
this	O
work,	O
we	O
have	O
developed	O
a	O
new	O
method	O
for	O
detection	O
and	O
isolation	O
of	O
stem	B
cells	I
by	O
targeting	O
both	O
an	O
intracellular	O
marker	O
(mRNA)	O
and	O
a	O
cell	O
surface	O
marker	O
(SSEA-1	O
protein),	O
using	O
mouse	O
EC	O
cells	O
as	O
a	O
model	O
system.	O

The	O
efficiency	O
and	O
specificity	O
of	O
stem	B
cell	I
detection	O
and	O
isolation	O
can	O
be	O
further	O
enhanced	O
by	O
targeting	O
mRNAs	O
using	O
multiple	O
molecular	O
beacons	O
and	O
cell	O
surface	O
markers	O
using	O
antibodies..	O

A	O
particular	O
issue	O
is	O
whether	O
the	O
biology	O
of	O
cancer	B
stem	I
cells	I
is	O
affected	O
by	O
the	O
detection	O
method,	O
including	O
the	O
delivery	O
approach	O
and	O
the	O
probes	O
inside	O
the	O
living	O
cell.	O

RT-PCR	O
results	O
and	O
cell	O
morphologies	O
of	O
differentiated	O
cells	O
with	O
and	O
without	O
beacon	O
indicated	O
that	O
there	O
was	O
no	O
change	O
in	O
the	O
ability	O
of	O
stem	B
cell	I
differentiation	O
(unpublished	O
data).	O

Tuning	O
Cancer	O
Fate:	O
Tumor	O
Microenvironment's	O
Role	O
in	O
Cancer	B
Stem	I
Cell	I
Quiescence	O
and	O
Reawakening.	O

Tuning	O
Cancer	O
Fate:	O
Tumor	O
Microenvironment's	O
Role	O
in	O
Cancer	B
Stem	I
Cell	I
Quiescence	O
and	O
Reawakening.	O

Cancer	B
stem	I
cell	I
chemotherapeutics	O
assay	O
for	O
prospective	O
treatment	O
of	O
recurrent	O
glioblastoma	O
and	O
progressive	O
anaplastic	O
glioma:	O
a	O
single-institution	O
case	O
series.	O

The	O
marrow	O
niche	O
controls	O
the	O
cancer	B
stem	I
cell	I
phenotype	O
of	O
disseminated	O
prostate	O
cancer.	O

The	O
Notch	O
pathway	O
is	O
important	O
in	O
maintaining	O
the	O
cancer	B
stem	I
cell	I
population	O
in	O
pancreatic	O
cancer.	O

Notch2	O
pathway	O
mediates	O
breast	O
cancer	O
cellular	O
dormancy	O
and	O
mobilisation	O
in	O
bone	O
and	O
contributes	O
to	O
haematopoietic	B
stem	I
cell	I
mimicry.	O

An	O
alternative	O
brain	O
model	O
that	O
utilizes	O
3D	O
culture	O
involves	O
the	O
use	O
of	O
stem	B
cell	I
technology	O
to	O
engineer	O
neural	O
tissues	O
which	O
grow	O
directly	O
from	O
neurospheres,	O
yielding	O
organoids	O
(Lancaster	O
et	O
al.,	O
2013).	O

Impact	O
of	O
the	O
hypoxic	O
tumor	O
microenvironment	O
on	O
the	O
regulation	O
of	O
cancer	B
stem	I
cell	I
characteristics.	O

The	O
hypoxic	O
tumor	O
microenvironment	O
in	O
vivo	O
selects	O
the	O
cancer	B
stem	I
cell	I
fate	O
of	O
breast	O
cancer	O
cells.	O

Those	O
with	O
unrelated	O
RS	O
to	O
DLBCL	O
have	O
survivals	O
similar	O
to	O
de	O
novo	O
DLBCL	O
and	O
seem	O
to	O
be	O
able	O
to	O
safely	O
be	O
treated	O
with	O
standard	O
anthracycline-based	O
regimens	O
combined	O
with	O
anti-CD20	O
therapy;	O
still,	O
the	O
role	O
of	O
consolidative	O
therapy	O
with	O
stem	B
cell	I
transplant	O
in	O
this	O
population	O
remains	O
unclear.	O

DR	O
reduces	O
cancer	O
risk	O
in	O
model	O
organisms	O
[23],	O
induces	O
autophagy	O
[24],	O
changes	O
DNA	O
methylation	O
[25]	O
and	O
even	O
ameliorates	O
loss	O
of	O
stem	B
cell	I
function	O
with	O
age	O
[26].	O

In	O
view	O
of	O
the	O
co-localization	O
of	O
the	O
osteochondroreticular	B
stem	I
cell	I
population	O
with	O
sites	O
associated	O
with	O
MM	O
PC	O
growth	O
[17,18],	O
the	O
expression	O
of	O
GREM1	O
was	O
analyzed	O
in	O
messenger	O
RNA	O
(mRNA)	O
samples	O
obtained	O
from	O
healthy	O
and	O
MM	O
patient-derived	O
BM	O
stromal	O
cell	O
cultures.	O

Clinical	O
significance	O
of	O
Gremlin	O
1	O
in	O
cervical	O
cancer	O
and	O
its	O
effects	O
on	O
cancer	B
stem	I
cell	I
maintenance.	O

Aberrant	O
epithelial	O
GREM1	O
expression	O
initiates	O
colonic	O
tumorigenesis	O
from	O
cells	O
outside	O
the	O
stem	B
cell	I
niche.	O

Engineered	O
composite	O
fascia	O
for	O
stem	B
cell	I
therapy	O
in	O
tissue	O
repair	O
applications.	O

Characterization	O
of	O
an	O
immunodeficient	O
mouse	O
model	O
of	O
mucopolysaccharidosis	O
type	O
I	O
suitable	O
for	O
preclinical	O
testing	O
of	O
human	B
stem	I
cell	I
and	O
gene	O
therapy.	O

Thus,	O
researchers	O
hypothesized	O
that	O
the	O
addition	O
or	O
removal	O
of	O
specific	O
cytokines	O
was	O
able	O
to	O
regulate	O
the	O
survival	O
and	O
expansion	O
of	O
the	O
stem	B
cell	I
population	O
[2,3].	O

These	O
findings	O
may	O
suggest	O
a	O
possible	O
new	O
venue	O
for	O
investigating	O
mechanisms	O
of	O
stem	B
cell	I
self-renewal	O
and	O
achieving	O
clinically	O
significant	O
expansion	O
of	O
human	O
HSCs.	O

Studies	O
have	O
shown	O
that	O
overexpression	O
of	O
BMI1	O
in	O
cord	O
blood	O
CD34+	O
cells	O
resulted	O
in	O
stem	B
cell	I
maintenance[32].	O

Mesenchymal	O
Stem	O
Cell	O
Fate:	O
Applying	O
Biomaterials	O
for	O
Control	O
of	O
Stem	B
Cell	I
Behavior.	O

The	O
effect	O
of	O
matrix	O
composition	O
of	O
3D	O
constructs	O
on	O
embryonic	B
stem	I
cell	I
differentiation.	O

Differential	O
expression	O
of	O
stem	B
cell	I
mobilization-associated	O
molecules	O
on	O
multi-lineage	O
cells	O
from	O
adipose	O
tissue	O
and	O
bone	O
marrow.	O

Mesenchymal	B
stem	I
cell	I
inhibition	O
of	O
T-helper	O
17	O
cell-	O
differentiation	O
is	O
triggered	O
by	O
cell–cell	O
contact	O
and	O
mediated	O
by	O
prostaglandin	O
E2	O
via	O
the	O
EP4	O
receptor.	O

Mesenchymal	B
Stem	I
Cells	I
Inhibit	O
Human	O
Th17	O
Cell	O
Differentiation	O
and	O
Function	O
and	O
Induce	O
a	O
T	O
Regulatory	O
Cell	O
Phenotype.	O

Direct	O
Evidence	O
of	O
Mesenchymal	B
Stem	I
Cell	I
Tropism	O
for	O
Tumor	O
and	O
Wounding	O
Microenvironments	O
Using	O
In	O
Vivo	O
Bioluminescent	O
Imaging.	O

Effect	O
of	O
the	O
Microenvironment	O
on	O
Mesenchymal	B
Stem	I
Cell	I
Paracrine	O
Signaling:	O
Opportunities	O
to	O
Engineer	O
the	O
Therapeutic	O
Effect.	O

Mesenchymal	B
stem	I
cells	I
inhibit	O
T	O
cell	O
activation	O
by	O
releasing	O
TGF-β1	O
from	O
TGF-β1/GARP	O
complex.	O

Inflammatory	O
cytokine-induced	O
intercellular	O
adhesion	O
molecule-1	O
and	O
vascular	O
cell	O
adhesion	O
molecule-1	O
in	O
mesenchymal	B
stem	I
cells	I
are	O
critical	O
for	O
immunosuppression.	O

Production	O
of	O
Oncolytic	O
Adenovirus	O
and	O
Human	O
Mesenchymal	O
Stem	O
Cells	O
in	O
a	O
Single-Use,	B
Vertical-Wheel	I
Bioreactor	I
System:	O
Impact	O
of	O
Bioreactor	O
Design	O
on	O
Performance	O
of	O
Microcarrier-Based	O
Cell	O
Culture	O
Processes.	O

Modulation	O
of	O
the	O
Mesenchymal	B
Stem	I
Cell	I
Secretome	O
Using	O
Computer-Controlled	O
Bioreactors:	O
Impact	O
on	O
Neuronal	O
Cell	O
Proliferation,	O
Survival	O
and	O
Differentiation.	O

Mesenchymal	B
Stem	I
Cell	I
Secretome:	O
Toward	O
Cell-Free	O
Therapeutic	O
Strategies	O
in	O
Regenerative	O
Medicine.	O

A	O
New	O
Mesenchymal	B
Stem	I
Cell	I
(MSC)	O
Paradigm:	O
Polarization	O
into	O
a	O
Pro-Inflammatory	O
MSC1	O
or	O
an	O
Immunosuppressive	O
MSC2	O
Phenotype.	O

Soluble	O
mediators	O
from	O
mesenchymal	B
stem	I
cells	I
suppress	O
T	O
cell	O
proliferation	O
by	O
inducing	O
IL-10.	O

Erythropoietin	O
combined	O
with	O
granulocyte	O
colony−stimulating	O
factor	O
enhances	O
MMP-2	O
expression	O
in	O
mesenchymal	B
stem	I
cells	I
and	O
promotes	O
cell	O
migration.	O

They	O
found	O
that	O
all	O
of	O
these	O
cell	O
types	O
generated	O
malignant	O
gliomas	O
in	O
mice	O
with	O
these	O
genetic	O
alterations	O
and	O
concluded	O
that	O
the	O
mature	O
cell	O
types	O
undergo	O
dedifferentiation	O
in	O
response	O
to	O
defined	O
oncogenic	O
mutations	O
to	O
neural	B
stem	I
cells	I
or	O
progenitors,	O
enabling	O
tumour	O
initiation	O
and	O
maintenance	O
[46].	O

Combinations	O
of	O
genetic	O
mutations	O
in	O
the	O
adult	B
neural	I
stem	I
cell	I
compartment	O
determine	O
brain	O
tumour	O
phenotypes.	O

Epidermal	O
growth	O
factor	O
receptor	O
and	O
Ink4a/Arf:	O
Convergent	O
mechanisms	O
governing	O
terminal	O
differentiation	O
and	O
transformation	O
along	O
the	O
neural	B
stem	I
cell	I
to	O
astrocyte	O
axis.	O

TGFβ	O
also	O
plays	O
a	O
crucial	O
role	O
in	O
stem	B
cell	I
differentiation,	O
as	O
well	O
as	O
in	O
T	O
cell	O
regulation	O
and	O
differentiation	O
[20].	O

Work	O
on	O
cell	O
lines	O
suggests	O
that	O
downregulation	O
of	O
the	O
RCOR2	O
transcription	O
factor	O
promotes	O
hypermethylation,	O
whereas	O
expression	O
of	O
RCOR2	O
promotes	O
reprogramming	O
to	O
stem	B
cell	I
pluripotency.25,	O
26.	O

RUNX1	O
is	O
essential	O
for	O
mesenchymal	B
stem	I
cell	I
proliferation	O
and	O
myofibroblast	O
differentiation.	O

Stage-specific	O
optimization	O
of	O
activin/nodal	O
and	O
BMP	O
signaling	O
promotes	O
cardiac	O
differentiation	O
of	O
mouse	O
and	O
human	B
pluripotent	I
stem	I
cell	I
lines.	O

The	O
cell	O
line	O
developed	O
characteristics	O
of	O
breast	B
cancer	I
stem	I
cells	I
and	O
exhibited	O
a	O
transformed	O
phenotype.	O

One	O
of	O
the	O
challenges	O
of	O
the	O
hESCs	O
was	O
the	O
method	O
of	O
isolation	O
of	O
stem	B
cells	I
from	O
the	O
human	O
embryo,	O
as	O
hESCs	O
can	O
only	O
be	O
obtained	O
from	O
the	O
inner	O
cell	O
mass	O
(ICM)	O
of	O
human	O
embryos	O
[5].	O

Furthermore,	O
some	O
researchers	O
have	O
used	O
bovine	O
serum	O
to	O
culture	O
hESCs,	O
but	O
the	O
use	O
of	O
animal-derived	O
serum	O
can	O
transmit	O
prion	O
and	O
animal	B
viruses	I
in	I
embryonic	I
stem	I
cell	I
culture	O
[26].	O

Another	O
way	O
to	O
eliminate	O
the	O
risk	O
of	O
animal	O
pathogen	O
contamination	O
is	O
the	O
use	O
of	O
feeder	O
layers	O
derived	O
from	O
the	O
human	B
stem	I
cell	I
line	O
[43,	O
44].	O

One	O
of	O
the	O
first	O
approaches	O
tried	O
for	O
feeder-free	O
growth	O
media	O
was	O
the	O
use	O
of	O
extracellular	O
matrix	O
proteins	O
along	O
with	O
growth	O
factors	O
to	O
create	O
an	O
in	O
vitro	O
culture	O
condition	O
for	O
the	O
stem	B
cell	I
proliferation	O
and	O
renewal	O
(Figure	O
2).	O

Among	O
large	O
animals,	O
dogs,	O
goats,	O
sheep,	O
and	O
nonhuman	O
primates	O
are	O
considered	O
better	O
models	O
than	O
mice/rats	O
for	O
the	O
stem	B
cell	I
testing	O
[70].	O

The	O
chemicals,	O
reagents,	O
cells,	O
and	O
machines	O
and	O
instrumentations	O
used	O
in	O
the	O
stem	B
cell	I
culture	O
should	O
undergo	O
safety	O
and	O
health	O
checks,	O
and	O
all	O
manufacturing	O
processes	O
must	O
be	O
monitored	O
and	O
documented	O
as	O
per	O
cGMP	O
guidelines.	O

Human	B
embryonic	I
stem	I
cell	I
lines	O
and	O
their	O
use	O
in	O
international	O
research.	O

Embryonic	B
stem	I
cell	I
lines	O
from	O
human	O
blastocysts:	O
somatic	O
differentiation	O
in	O
vitro.	O

Human	B
embryonic	I
stem	I
cell	I
cultivation:	O
historical	O
perspective	O
and	O
evolution	O
of	O
xeno-free	O
culture	O
systems.	O

Electron	O
microscopy	O
reveals	O
the	O
presence	O
of	O
viruses	O
in	O
mouse	O
embryonic	O
fibroblasts	O
but	O
neither	O
in	O
human	O
embryonic	O
fibroblasts	O
nor	O
in	O
human	O
mesenchymal	O
cells	O
used	O
for	O
hESC	O
maintenance:	O
toward	O
an	O
implementation	O
of	O
microbiological	O
quality	O
assurance	O
program	O
in	O
stem	B
cell	I
banks.	O

Establishment	O
and	O
maintenance	O
of	O
human	B
embryonic	I
stem	I
cell	I
lines	O
on	O
human	O
feeder	O
cells	O
derived	O
from	O
uterine	O
endometrium	O
under	O
serum-free	O
condition.	O

Development	O
of	O
a	O
xeno-free	O
non-contact	O
co-culture	O
system	O
for	O
derivation	O
and	O
maintenance	O
of	O
embryonic	B
stem	I
cells	I
using	O
a	O
novel	O
human	O
endometrial	O
cell	O
line.	O

Scale-up	O
of	O
human	B
embryonic	I
stem	I
cell	I
culture	O
using	O
a	O
hollow	O
fibre	O
bioreactor.	O

Human	O
embryonic	O
stem	O
cell-derived	O
oligodendrocyte	O
progenitor	O
cell	O
transplants	O
remyelinate	O
and	O
restore	O
locomotion	O
after	O
spinal	O
cord	O
injury.	O
World’s	O
first	O
clinical	O
trial	O
of	O
human	B
embryonic	I
stem	I
cell	I
therapy	O
cleared.	O

Geron	O
trial	O
resumes,	O
but	O
standards	O
for	O
stem	B
cell	I
trials	O
remain	O
elusive.	O

However,	O
the	O
detailed	O
mechanism	O
remains	O
to	O
be	O
expounded	O
in	O
further	O
studies.49	O
In	O
another	O
example,	O
Wang	O
et	O
al	O
identified	O
a	O
long	O
non‐coding	O
RNA,	O
lncTCF7,	O
which	O
contributes	O
to	O
liver	B
cancer	I
stem	I
cell	I
self‐renewal	O
and	O
tumour	O
proliferation	O
by	O
activating	O
Wnt	O
signalling.	O

Wnt/β‐catenin	O
signaling	O
in	O
embryonic	B
stem	I
cell	I
self‐renewal	O
and	O
somatic	O
cell	O
reprogramming.	O

β‐Catenin	O
is	O
important	O
for	O
cancer	B
stem	I
cell	I
generation	O
and	O
tumorigenic	O
activity	O
in	O
nasopharyngeal	O
carcinoma.	O

(I)	O
mRNA	O
expression	O
of	O
stem	B
cell	I
markers	O
from	O
colon	O
epithelial	O
isolates	O
at	O
baseline	O
quantified	O
by	O
qPCR:	O
cMyc	O
(Bves−/−	O
vs.	O

rodentium	O
infection,	O
expression	O
of	O
stem	B
cell	I
markers	O
relative	O
to	O
baseline	O
was	O
quantified	O
by	O
qPCR.	O

As	O
such,	O
we	O
compared	O
mRNA	O
expression	O
of	O
stem	B
cell	I
markers	O
from	O
colon	O
epithelial	O
isolates	O
both	O
before	O
and	O
after	O
C.	O

At	O
baseline,	O
cMyc	O
was	O
significantly	O
upregulated	O
in	O
Bves−/−	O
colon	O
epithelium	O
while	O
there	O
was	O
a	O
trend	O
towards	O
an	O
increase	O
in	O
stem	B
cell	I
markers	O
Lgr5	O
and	O
Lrig1	O
(Figure	O
4I).	O

While	O
we	O
don’t	O
have	O
a	O
unifying	O
explanation	O
for	O
this	O
phenotype	O
at	O
this	O
time,	O
one	O
hypothesis	O
is	O
that	O
injury	O
resulted	O
in	O
a	O
relative	O
depletion	O
of	O
stem	B
cells	I
in	O
Bves−/−	O
mice	O
resulting	O
in	O
reduced	O
inflow	O
into	O
the	O
transit	O
amplifying	O
cell	O
compartment.	O

This	O
suggests	O
that	O
a	O
role	O
for	O
BVES	O
in	O
stem	B
cell	I
preservation	O
after	O
injury.	O

DeltaNp63alpha	O
is	O
an	O
oncogene	O
that	O
targets	O
chromatin	O
remodeler	O
Lsh	O
to	O
drive	B
skin	I
stem	I
cell	I
proliferation	O
and	O
tumorigenesis.	O

The	O
upregulation	O
of	O
stem	B
cell	I
marker	O
genes	O
like	O
Etv5	O
is	O
also	O
associated	O
with	O
both	O
an	O
increase	O
in	O
unspliced	O
transcript	O
counts	O
(Figure	O
S7K)	O
and	O
unspliced	O
to	O
spliced	O
ratio	O
of	O
these	O
genes	O
(Figure	O
S7H),	O
suggesting	O
that	O
the	O
observed	O
increase	O
in	O
gene	O
expression	O
is	O
due	O
to	O
enhanced	O
transcription.	O

However,	O
FGF2	O
has	O
also	O
been	O
reported	O
to	O
stimulate	O
germ	O
cell	O
p38	O
MAPK	O
phosphorylation,	O
and	O
p38	O
MAPK	O
is	O
essential	O
for	O
mouse	B
male	I
germline	I
stem	I
cell	I
self‐renewal.	O

Spermatogonial	B
stem	I
cell	I
self‐renewal	O
requires	O
ETV5‐mediated	O
downstream	O
activation	O
of	O
Brachyury	O
in	O
mice.	O

Plzf	O
is	O
required	O
in	O
adult	O
male	O
germ	O
cells	O
for	O
stem	B
cell	I
self‐renewal.	O

ERM	O
is	O
required	O
for	O
transcriptional	O
control	O
of	O
the	O
spermatogonial	B
stem	I
cell	I
niche.	O

Mesenchymal	B
stem	I
cell	I
therapy	O
ameliorates	O
diabetic	O
nephropathy	O
via	O
the	O
paracrine	O
effect	O
of	O
renal	O
trophic	O
factors	O
including	O
exosomes.	O

New	O
means	O
of	O
drug	O
discovery	O
–	O
such	O
as	O
the	O
use	O
of	O
stem	O
cells	O
–	O
have	O
elicited	O
debate	O
about	O
the	O
relative	O
values	O
placed	O
on	O
the	O
status	O
of	O
the	O
embryo	O
and	O
the	O
potential	O
treatment	O
for	O
intractable	O
conditions	O
that	O
could	O
result	O
from	O
stem	B
cell	I
research.	O

Identification	O
of	O
human	B
embryonic	I
stem	I
cell	I
surface	O
markers	O
by	O
combined	O
membrane-polysome	O
translation	O
state	O
array	O
analysis	O
and	O
immunotranscriptional	O
profiling.	O

For	O
example,	O
binding	O
sites	O
have	O
been	O
mapped	O
for	O
the	O
stem	B
cell	I
regulator	O
Scl	O
in	O
normal	O
HSPCs	O
[18]	O
as	O
well	O
as	O
the	O
PML-RARA	O
oncoprotein	O
in	O
promyelocytic	O
leukaemia	O
cells	O
[19].	O

The	O
transcriptional	O
program	O
controlled	O
by	O
the	O
stem	B
cell	I
leukemia	O
gene	O
Scl/Tal1	O
during	O
early	O
embryonic	O
hematopoietic	O
development.	O

Wang	O
L,	O
Zeng	O
X,	O
Ryoo	O
HD,	O
Jasper	O
H	O
(2014)	O
Integration	O
of	O
UPRER	O
and	O
oxidative	O
stress	O
signaling	O
in	O
the	O
control	O
of	O
intestinal	B
stem	I
cell	I
proliferation.	O

SHIP2	O
is	O
tyrosine	O
phosphorylated	O
upon	O
stimulation	O
with	O
stem	B
cell	I
factor	O
(SCF),	O
interleukin-3	O
(IL-3),	O
and	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(GM-CSF),	O
which	O
results	O
in	O
its	O
association	O
with	O
SHC	O
(src	O
homologous	O
and	O
collagen	O
gene).	O

Effect	O
of	O
mesenchymal	B
stem	I
cell	I
penile	O
transplantation	O
on	O
erectile	O
signaling	O
of	O
aged	O
rats.	O

The	O
mechanisms	O
and	O
potential	O
of	O
stem	B
cell	I
therapy	O
for	O
penile	O
fibrosis.	O

Mesenchymal	B
stem	I
cell	I
therapy	O
improves	O
erectile	O
dysfunction	O
in	O
experimental	O
spinal	O
cord	O
injury.	O

Cancer	B
stem	I
cell	I
and	O
epithelial–mesenchymal	O
transition	O
markers	O
predict	O
worse	O
outcome	O
in	O
metaplastic	O
carcinoma	O
of	O
the	O
breast.	O

The	O
retrovirus	O
HERVH	O
is	O
a	O
long	O
noncoding	O
RNA	O
required	O
for	O
human	B
embryonic	I
stem	I
cell	I
identity.	O

J	O
Fertil	O
In	O
Vitro	O
IVF	O
Worldw	O
Reprod	O
Med	B
Genet	I
Stem	I
Cell	I
Biol.	O

These	O
phytochemicals	O
also	O
appear	O
to	O
display	O
beneficial	O
effects	O
on	O
stem	B
cell	I
function	O
and	O
have	O
been	O
documented	O
as	O
significant	O
vital	O
promoters	O
of	O
tissue	O
regeneration	O
both	O
in	O
vitro	O
and	O
in	O
vivo.	O

Alterations	O
in	O
the	O
epithelial	B
stem	I
cell	I
compartment	O
could	O
contribute	O
to	O
permanent	O
changes	O
in	O
the	O
mucosa	O
of	O
patients	O
with	O
ulcerative	O
colitis.	O

Single	O
cell	O
analysis	O
of	O
Crohn’s	O
disease	O
patient-derived	O
small	O
intestinal	O
organoids	O
reveals	O
disease	O
activity-dependent	O
modification	O
of	O
stem	B
cell	I
properties.	O

Continuous	O
live	O
imaging	O
of	O
adult	B
neural	I
stem	I
cell	I
division	O
and	O
lineage	O
progression	O
in	O
vitro.	O

A	O
Fatty	O
Acid	O
Oxidation-Dependent	O
Metabolic	O
Shift	O
Regulates	O
Adult	O
Neural	B
Stem	I
Cell	I
Activity.	O

Selective	O
purging	O
of	O
human	O
multiple	O
myeloma	O
cells	O
from	O
autologous	B
stem	I
cell	I
transplantation	O
grafts	O
using	O
oncolytic	O
myxoma	O
virus.	O

MPP(+)	O
decreases	O
store-operated	O
calcium	O
entry	O
and	O
TRPC1	O
expression	O
in	O
Mesenchymal	B
Stem	I
Cell	I
derived	O
dopaminergic	O
neurons.	O

Sphingosine	O
Phosphate	O
Lyase	O
Regulates	O
Murine	O
Embryonic	B
Stem	I
Cell	I
Proliferation	O
and	O
Pluripotency	O
through	O
an	O
S1P2/STAT3	O
Signaling	O
Pathway.	O

Human	O
ESCs	O
identified	O
by	O
expression	O
of	O
extracellular	B
stem	I
cell	I
marker	O
Tra-1-60	O
were	O
shown	O
to	O
express	O
S1P1-3	O
[15],	O
whereas	O
mouse	O
ESCs	O
were	O
found	O
to	O
express	O
S1P1-3	O
and	O
S1P5	O
but	O
not	O
S1P4	O
[14]..	O

It	O
became	O
important	O
to	O
determine	O
whether	O
inhibition	O
of	O
SPL	O
hinders	O
the	O
capacity	O
of	O
mESCs	O
to	O
give	O
rise	O
to	O
tissue	B
stem	I
cells	I
and	O
thus	O
be	O
of	O
utility	O
in	O
cell	O
therapy	O
schemes.	O

Our	O
finding	O
of	O
increased	O
SSEA1	O
and	O
OCT4	O
expression	O
but	O
no	O
detectible	O
impact	O
on	O
SOX2	O
and	O
NANOG	O
expression	O
in	O
response	O
to	O
SPL	O
silencing	O
suggests	O
that	O
SPL	O
differentially	O
regulates	O
factors	O
critical	O
to	O
stem	B
cell	I
homeostasis.	O

This	O
report	O
is	O
in	O
line	O
with	O
previous	O
studies	O
where	O
reported	O
mutations	O
in	O
either	O
in	O
PAX6	O
[84]	O
or	O
p63	O
[85]	O
lead	O
to	O
blindness	O
resulting	O
from	O
limbal	B
stem	I
cell	I
deficiency..	O

Embryonic	B
stem	I
cell	I
enhancers	O
median	O
size	O
has	O
been	O
reported	O
to	O
be	O
around	O
800	O
bp	O
(Parker	O
et	O
al.,	O
2013);	O
therefore,	O
the	O
initial	O
search	O
was	O
performed	O
with	O
a	O
maximum	O
length	O
restriction	O
of	O
either	O
600,	O
700	O
or	O
800	O
bp.	O

DGCR8	O
is	O
essential	O
for	O
microRNA	O
biogenesis	O
and	O
silencing	O
of	O
embryonic	B
stem	I
cell	I
self-renewal.	O

Effects	O
of	O
telomerase	O
and	O
telomere	O
length	O
on	O
epidermal	B
stem	I
cell	I
behavior.	O

The	O
longest	O
telomeres:	O
a	O
general	O
signature	O
of	O
adult	B
stem	I
cell	I
compartments.	O

miRNAs	O
regulate	O
SIRT1	O
expression	O
during	O
mouse	B
embryonic	I
stem	I
cell	I
differentiation	O
and	O
in	O
adult	O
mouse	O
tissues.	O

TERT	O
executes	O
this	O
stem	B
cell	I
activation	O
program	O
by	O
interacting	O
with	O
the	O
chromatin	O
remodeling	O
protein	O
Brg1,	O
at	O
target	O
gene	O
chromatin,	O
including	O
the	O
promoter	O
of	O
the	O
c-Myc	O
gene24.	O

Meanwhile,	O
the	O
potential	O
of	O
short-term	O
microgravity	O
exposure	O
for	O
cardiovascular	B
stem	I
cell	I
expansion	O
and	O
age-related	O
disease	O
modeling	O
needs	O
to	O
be	O
investigated	O
for	O
future	O
application.	O

Pluripotency	O
is	O
a	O
defining	O
characteristic	O
of	O
stem	B
cells	I
and	O
refers	O
to	O
a	O
cell’s	O
ability	O
to	O
self-renew	O
and	O
differentiate	O
into	O
other	O
cell	O
lineages.	O

In	O
order	O
to	O
do	O
this,	O
we	O
uploaded	O
our	O
list	O
of	O
significantly	O
upregulated	O
transcripts	O
into	O
StemChecker,	O
a	O
powerful	O
online	O
tool	O
comprised	O
of	O
genes	B
associated	I
with	I
stem	I
cell	I
function	O
and	O
characteristics	O
[25].	O

In	O
order	O
to	O
validate	O
this,	O
we	O
next	O
assessed	O
the	O
expression	O
of	O
specific	O
genes	O
related	O
to	O
stem	B
cell	I
maintenance	O
(Figure	O
2B).	O

Activation	O
of	O
these	O
GPCRs	O
in	O
response	O
to	O
spaceflight	O
is	O
suggestive	O
of	O
stem	B
cell	I
maintenance	O
and	O
proliferative	O
capacity.	O

Interestingly,	O
EHF	O
is	O
also	O
known	O
to	O
play	O
a	O
role	O
in	O
stem	B
cell	I
maintenance	O
and	O
proliferation	O
[33,34].	O

Genes	O
involved	O
in	O
stem	B
cell	I
differentiation	O
were	O
significantly	O
induced	O
in	O
our	O
flown	O
samples	O
(Figure	O
5B).	O

Pim1	O
Kinase	O
Overexpression	O
Enhances	O
Ckit+	O
Cardiac	B
Stem	I
Cell	I
Cardiac	O
Repair	O
Following	O
Myocardial	O
Infarction	O
in	O
Swine.	O

Transforming	O
growth	O
factor-β1	O
(TGF-β1)	O
is	O
a	O
pleiotropic	O
molecule	O
involved	O
in	O
various	O
biological	B
processes,	I
including	I
development,	I
regulation	I
of	I
stem	I
cell	I
behavior,	O
carcinogenesis,	O
tissue	O
homeostasis,	O
and	O
immune	O
responses.26,27	O
Of	O
the	O
three	O
known	O
isoforms	O
expressed	O
by	O
mammalian	O
cells	O
(TGF-β1,	O
TGF-β2,	O
TGF-β3),	O
TGF-β1	O
is	O
the	O
isoform	O
predominantly	O
expressed	O
by	O
immune	O
cells.28	O
Studies	O
have	O
shown	O
that	O
MSCs	O
can	O
secrete	O
TGF-β1,	O
which	O
also	O
plays	O
a	O
well-documented	O
role	O
in	O
MSC	O
immunomodulation,	O
including	O
a	O
role	O
in	O
regulatory	O
T	O
cell	O
(Treg)	O
induction	O
and/or	O
expansion.29,	O
30,	O
31,	O
32	O
TGF-β1	O
is	O
also	O
known	O
to	O
directly	O
influence	O
MSCs,	O
modulating	O
their	O
differentiation	O
and	O
migration.33,34	O
The	O
vast	O
majority	O
of	O
published	O
studies	O
investigating	O
TGF-β	O
pre-treatment	O
in	O
the	O
context	O
of	O
MSCs	O
either	O
focus	O
on	O
the	O
effects	O
of	O
TGF-β	O
treatment	O
on	O
MSC	O
differentiation	O
capacity	O
or	O
on	O
the	O
use	O
MSCs	O
as	O
a	O
“carrier”	O
for	O
delivery	O
of	O
therapeutic	O
levels	O
of	O
the	O
cytokine	O
to	O
sites	O
of	O
injury	O
via	O
virus-mediated	O
overexpression	O
protocols.35,	O
36,	O
37,	O
38	O
These	O
studies	O
have	O
identified	O
a	O
role	O
for	O
TGF-β1	O
in	O
osteoblast	O
differentiation	O
and	O
increased	O
migratory	O
capacity	O
into	O
remodeling	O
sites	O
following	O
pre-activation	O
with	O
TGF-β,	O
leading	O
to	O
synergistic	O
bone	O
formation	O
and	O
reabsorption.36	O
Lentivirus-mediated	O
overexpression	O
of	O
TGF-β1	O
on	O
MSCs	O
showed	O
improved	O
renal	O
function	O
and	O
reduced	O
epithelial	O
apoptosis	O
and	O
subsequent	O
inflammation	O
in	O
a	O
rat	O
model	O
of	O
renal	O
ischemia/reperfusion	O
(I/R)	O
injury	O
via	O
a	O
mechanism	O
not	O
involving	O
the	O
direct	O
canonical	O
TGF-β1/Smad	O
pathway.37	O
While	O
such	O
studies	O
as	O
highlighted	O
above	O
comprise	O
the	O
majority	O
of	O
published	O
work	O
related	O
to	O
TGF-β1-licensed	O
MSCs,	O
there	O
are	O
some	O
reports	O
investigating	O
their	O
immunomodulatory	O
capacity.	O

This	O
finding	O
is	O
in	O
contrast	O
to	O
the	O
reported	O
effects	O
of	O
licensing	O
strategies	O
using	O
pro-inflammatory	O
cytokines	O
on	O
MHC-I	O
expression.40	O
We	O
also	O
noted	O
that	O
TGF-β-licensed	O
MSCs	O
expressed	O
significantly	O
lower	O
levels	O
of	O
the	O
identification	B
marker	I
stem	I
cell	I
antigen	O
(SCA)-1.	O

Mesenchymal	B
stem	I
cell	I
therapy	O
promotes	O
corneal	O
allograft	O
survival	O
in	O
rats	O
by	O
local	O
and	O
systemic	O
immunomodulation.	O

Cell	O
therapy	O
using	O
allogeneic	O
bone	B
marrow	I
mesenchymal	I
stem	I
cells	I
prevents	O
tissue	O
damage	O
in	O
collagen-induced	O
arthritis.	O

Mesenchymal	B
stem	I
cell	I
therapy	O
to	O
promote	O
corneal	O
allograft	O
survival:	O
current	O
status	O
and	O
pathway	O
to	O
clinical	O
translation.	O

C-Kit,	O
the	O
receptor	O
for	O
stem	B
cell	I
factor,	O
is	O
expressed	O
on	O
hematopoietic	O
cells	O
and	O
is	O
required	O
for	O
hematopoiesis.	O

Besides	O
the	O
magnitude	O
of	O
the	O
horse	O
industry,	O
the	O
possibility	O
of	O
using	O
these	O
animals	O
as	O
models	O
for	O
human	O
musculoskeletal	O
injuries	O
or	O
diseases[99]	O
has	O
contributed	O
to	O
intensify	O
the	O
stem	B
cell	I
and	O
regenerative	O
research	O
in	O
the	O
last	O
few	O
years..	O

Pioneer	O
factors	O
govern	O
super-enhancer	O
dynamics	O
in	O
stem	B
cell	I
plasticity	O
and	O
lineage	O
choice.	O

Tumor-initiating	B
stem	I
cells	I
of	O
squamous	O
cell	O
carcinomas	O
and	O
their	O
control	O
by	O
TGF-	O
and	O
integrin/focal	O
adhesion	O
kinase	O
(FAK)	O
signaling.	O

[205]	O
discovered	O
that	O
JAG	O
regulates	O
the	O
transition	O
between	O
tight	O
coordination	O
of	O
cell	O
volume	O
with	O
initiation	O
of	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
in	O
the	O
stem	B
cells	I
of	O
the	O
meristem	O
and	O
loose	O
coordination	O
in	O
the	O
initiating	O
organ	O
primordium.	O

The	O
miRNA-34c	O
inhibited	O
VSMC	O
proliferation	O
and	O
neointimal	O
hyperplasia	O
by	O
targeting	O
the	O
stem	B
cell	I
factor	O
(SCF),	O
a	O
cytokine	O
that	O
binds	O
to	O
the	O
c-kit	O
receptor	O
[35].	O

We	O
tracked	O
changes	O
in	O
replication	O
timing,	O
gene	O
expression,	O
and	O
chromatin	O
conformation	O
capture	O
(Hi-C)	O
A/B	O
compartments	O
over	O
the	O
first	O
two	O
cell	O
cycles	O
during	O
differentiation	O
of	O
human	B
embryonic	I
stem	I
cells	I
to	O
definitive	O
endoderm.	O

Indeed,	O
depletion	O
and	O
overexpression	O
of	O
numerous	O
chromatin	O
and	O
transcription	O
regulators	O
has	O
little	O
to	O
no	O
effect	O
on	O
RT,	O
whereas	O
the	O
induction	O
of	O
a	O
cell	O
fate	O
change	O
in	O
stem	B
cells	I
induces	O
rapid	O
and	O
widespread	O
alterations	O
in	O
RT	O
(Dileep	O
et	O
al.,	O
2015b).	O

We	O
reasoned	O
cells	O
that	O
did	O
not	O
stably	O
initiate	O
transcriptional	O
reprograming	O
toward	O
endoderm	O
would	O
reacquire	O
an	O
ESC-like	O
transcriptome	O
when	O
returned	O
to	O
stem	B
cell	I
medium.	O

The	O
transcriptome	O
after	O
6	O
or	O
12	O
h	O
in	O
differentiation	O
medium	O
followed	O
by	O
24	O
h	O
of	O
reversal	O
in	O
stem	B
cell	I
medium	O
is	O
strikingly	O
similar	O
to	O
expression	O
after	O
24	O
h	O
of	O
forward	O
differentiation	O
for	O
all	O
K-clusters	O
(Figures	O
1B	O
and	O
S1).	O

At	O
each	O
time	O
point	O
half	O
the	O
cells	O
were	O
washed	O
and	O
returned	O
to	O
stem	B
cell	I
medium	O
for	O
24	O
h.	O

These	O
cells	O
continued	O
to	O
progress	O
toward	O
the	O
endoderm	O
lineage	O
even	O
after	O
returning	O
to	O
stem	B
cell	I
medium	O
for	O
up	O
to	O
24	O
h	O
suggests	O
that	O
these	O
cells	O
have	O
become	O
committed.	O

Our	O
experimental	O
conditions	O
cannot	O
rule	O
out	O
the	O
possibility	O
that	O
some	O
cells	O
in	O
the	O
population	O
secrete	O
factors	O
that	O
drive	O
differentiation	O
forward	O
even	O
after	O
return	O
to	O
stem	B
cell	I
medium.	O

Nonetheless,	O
before	O
the	O
experiments	O
reported	O
here,	O
there	O
was	O
no	O
expectation	O
that	O
early	B
stem	I
cell	I
lineage	O
specification	O
would	O
be	O
so	O
rapid	O
and	O
irreversible.	O

Initiation	O
of	O
stem	B
cell	I
differentiation	O
involves	O
cell	O
cycle-dependent	O
regulation	O
of	O
developmental	O
genes	O
by	O
Cyclin	O
D.	O

In	O
this	O
regard,	O
a	O
recent	O
study	O
on	O
mouse	B
stem	I
cells	I
has	O
shown	O
that	O
CNVs	O
involving	O
gains	O
or	O
losses	O
of	O
millions	O
of	O
base	O
pairs	O
occur	O
frequently	O
during	O
mitotic	O
cell	O
culture	O
divisions,	O
supporting	O
the	O
idea	O
that	O
somatic	O
tissues	O
are	O
composed	O
of	O
variants	O
of	O
the	O
mitotic	O
genome	O
[34].	O

Studies	O
in	O
RMD	O
events	O
in	O
MSH2	O
KO	O
mouse	B
embryonic	I
stem	I
cells	I
had	O
previously	O
shown	O
similar	O
stimulation	O
of	O
RMDs	O
(Mendez‐Dorantes	O
et	O
al.,	O
2018;	O
2020)	O
suggesting	O
that	O
Alu	O
elements	O
are	O
likely	O
to	O
play	O
a	O
bigger	O
role	O
in	O
resolution	O
of	O
DSBs	O
in	O
this	O
specific	O
cell	O
background.	O

Additionally,	O
animal	O
studies	O
demonstrated	O
that	O
the	O
disruption	O
of	O
REX1	O
influences	O
differentiation	O
and	O
cell	O
cycle	O
regulation	O
of	O
embryonic	B
stem	I
cells	I
59..	O

Mesenchymal	B
stem	I
cell	I
targeting	O
of	O
microscopic	O
tumors	O
and	O
tumor	O
stroma	O
development	O
monitored	O
by	O
noninvasive	O
in	O
vivo	O
positron	O
emission	O
tomography	O
imaging	O
[published	O
correction	O
appears	O
in	O
Clin	O
Cancer	O
Res	O
2006;12:4364].	O

Recent	O
studies	O
have	O
highlighted	O
histone	O
methylation	O
state	O
as	O
an	O
important	O
modulator	O
in	O
stem	B
cell	I
differentiation.24	O
Regulation	O
of	O
these	O
methylation	O
states	O
is	O
tightly	O
controlled	O
by	O
the	O
opposing	O
activities	O
of	O
histone	O
lysine	O
methyltransferases	O
(KMTs)	O
and	O
histone	O
lysine	O
demethylases	O
(KDMs),25	O
which	O
are	O
recruited	O
to	O
specific	O
histone	O
lysine	O
residues	O
and	O
are	O
responsible	O
for	O
the	O
establishment	O
and	O
regulation	O
of	O
histone	O
methylation	O
and	O
demethylation,	O
respectively.	O

Ubiquitous	O
deletion	O
of	O
any	O
of	O
these	O
components	O
causes	O
embryonic	O
death	O
during	O
the	O
post-implantation	O
period.38,39,40	O
For	O
decades,	O
EZH2	O
has	O
been	O
known	O
to	O
be	O
important	O
for	O
stem	B
cell	I
maintenance	O
and	O
differentiation.36,41.	O

Depletion	O
of	O
histone	O
demethylase	O
KDM2A	O
inhibited	O
cell	O
proliferation	O
of	O
stem	B
cells	I
from	O
apical	O
papilla	O
by	O
de-repression	O
of	O
p15INK4B	O
and	O
p27Kip1.	O

Several	O
methods	O
have	O
been	O
developed	O
to	O
isolate	O
and/or	O
enrich	O
subpopulations	O
with	O
stem	B
cell	I
properties	O
within	O
the	O
tumors	O
[82–85].	O

These	O
CSC	O
commonly	O
show	O
increased	O
expression	O
of	O
the	O
pluripotent	B
stem	I
cell	I
markers	O
OCT3/4,	O
NANOG,	O
and	O
SOX2	O
[87,	O
89,	O
105,	O
106].	O

Advances	O
in	O
osteosarcoma	B
stem	I
cell	I
research	O
and	O
opportunities	O
for	O
novel	O
therapeutic	O
targets.	O

Aberrant	O
Wnt/β-catenin	O
signaling	O
and	O
elevated	O
expression	O
of	O
stem	B
cell	I
proteins	O
are	O
associated	O
with	O
osteosarcoma	O
side	O
population	O
cells	O
of	O
high	O
tumorigenicity.	O

CHD7	O
is	O
involved	O
in	O
a	O
variety	O
of	O
stem	B
cell	I
differentiation	O
and	O
cell‐fate	O
decisions.	O

Another	O
interesting	O
study	O
showed	O
that	O
CHD7	O
cooperates	O
with	O
SOX2	O
to	O
regulate	O
a	O
small	O
set	O
of	O
genes,	O
such	O
as	O
NOTCH	O
and	O
Sonic	O
Hedgehog	O
pathway	O
genes	O
and	O
classical	O
oncogenes	O
NRAS	O
and	O
SRC;	O
these	O
genes	O
play	O
critical	O
roles	O
in	O
stem	B
cell	I
development	O
and	O
tumorigenesis	O
(Engelen	O
et	O
al.,	O
2011;	O
Puc	O
and	O
Rosenfeld,	O
2011).	O

KLF4,	O
a	O
member	O
of	O
the	O
KLF	O
family,	O
plays	O
significant	O
roles	O
in	O
stem	B
cell	I
function,	O
cell	O
survival,	O
proliferation,	O
and	O
differentiation	O
(3–5).	O

Kruppel-like	O
factor	O
4	O
(KLF4)	O
is	O
required	O
for	O
maintenance	O
of	O
breast	B
cancer	I
stem	I
cells	I
and	O
for	O
cell	O
migration	O
and	O
invasion.	O

For	O
instance,	O
recent	O
studies	O
of	O
the	O
interaction	O
between	O
HCP5	O
and	O
Runx	O
family	O
proteins	O
suggests	O
that	O
they	O
may	O
play	O
key	O
roles	O
in	O
stem	B
cell	I
biology,	O
particularly	O
in	O
regulating	O
apoptosis	O
and	O
the	O
G0/G1	O
transition	O
by	O
way	O
of	O
the	O
ceRNA	O
networks	O
[150].	O

Embryonic	B
stem	I
cell	I
markers	O
Sox-2	O
and	O
OCT4	O
expression	O
and	O
their	O
correlation	O
with	O
WNT	O
signal	O
pathway	O
in	O
cervical	O
squamous	O
cell	O
carcinoma.	O

(2012)	O
Metabolomics:	O
A	O
valuable	O
tool	O
for	O
stem	B
cell	I
monitoring	O
in	O
regenerative	O
medicine.	O

For	O
example,	O
lncRNA	O
ANRIL	O
can	O
interact	O
with	O
polycomb	O
repressive	O
complexes	O
1	O
(PRC1)	O
and	O
polycomb	O
repressive	O
complexes	O
2	O
(PRC2)	O
to	O
inhibit	O
the	O
expression	O
of	O
INK4b-ARF-INK4a,	O
resist	O
the	O
aging	O
mechanism,	O
and	O
enhance	O
the	O
stem	B
cell	I
characteristics	O
of	O
cancer	O
cells	O
[14].	O

Role	O
of	O
the	O
testis	O
interstitial	O
compartment	O
in	O
spermatogonial	B
stem	I
cell	I
function.	O

Pax3	O
functions	O
at	O
a	O
nodal	O
point	O
in	O
melanocyte	B
stem	I
cell	I
differentiation.	O

Syntenin-1	O
promotes	O
colorectal	B
cancer	I
stem	I
cell	I
expansion	O
and	O
chemoresistance	O
by	O
regulating	O
prostaglandin	O
E2	O
receptor.	O

ABHD11	O
is	O
critical	O
for	O
embryonic	B
stem	I
cell	I
expansion,	O
differentiation	O
and	O
lipid	O
metabolic	O
homeostasis.	O

The	O
concentration	O
and	O
time	O
of	O
Oligomycin	O
have	O
been	O
established	O
in	O
many	O
Agilent	O
Seahorse	O
assays	O
and	O
and	O
human	O
pluripotent	O
stem	O
cell	O
energy-profiling	O
studies	O
to	O
inhibit	O
OXPHOS-linked	O
ATP	O
production	O
by	O
blocking	O
complex	O
V,	O
without	O
inducing	O
cell	O
death	O
in	O
stem	B
cells	I
and	O
cultured	O
neurons27,28,48.	O

This	O
has	O
resulted	O
in	O
the	O
dramatic	O
expansion	O
of	O
the	O
stem	B
cell	I
field,	O
with	O
development	O
and	O
improvements	O
in	O
reprogramming	O
protocols	O
and	O
directed	O
cellular	O
differentiation.	O

Release	O
of	O
extracellular	O
membrane	O
particles	O
carrying	O
the	O
stem	B
cell	I
marker	O
prominin-1	O
(CD133)	O
from	O
neural	O
progenitors	O
and	O
other	O
epithelial	O
cells.	O

Currently	O
there	O
is	O
no	O
therapy	O
to	O
treat	O
this	O
advanced	O
stage	O
of	O
AMD	O
that	O
is	O
characterized	O
by	O
RPE	O
atrophy	O
[9,	O
10],	O
although	O
a	O
number	O
of	O
embryonic	B
stem	I
cell	I
based	O
RPE	O
therapies	O
are	O
being	O
evaluated	O
to	O
replace	O
sick	O
or	O
lost	O
RPE	O
cells	O
[11-14]..	O

Expression	O
is	O
elevated	O
in	O
induced	B
stem	I
cell	I
derived	O
neurons	O
from	O
ALS	O
patient	O
ALS/cell	O
line	O
(Human)	O
Zhang	O
et	O
al.	O

DGCR8	O
is	O
essential	O
for	O
microRNA	O
biogenesis	O
and	O
silencing	O
of	O
embryonic	B
stem	I
cell	I
self-renewal.	O

Remarkably,	O
in	O
F1	O
males	O
H3K4me3	O
peaks	O
show	O
increased	O
occupancy	O
in	O
F1	O
males	O
proximal	O
to	O
genes	O
encoding	O
key	O
pluripotency	O
factors	O
such	O
as	O
Sox2,	O
Pou5f1	O
and	O
Nanos2	O
and	O
transcription	O
factors	O
such	O
as	O
Sox9	O
and	O
decreased	O
occupancy	O
at	O
genes	O
encoding	O
factors	O
of	O
stem	B
cell	I
differentiation	O
factors	O
such	O
as	O
Cyp26a1,	O
Eomes,	O
Hey1,	O
Isl1,	O
Jarid2,	O
Med10,	O
Msi2	O
and	O
Nog.	O

Mesenchymal	B
stem	I
cell	I
therapy	O
modulates	O
the	O
inflammatory	O
response	O
in	O
experimental	O
traumatic	O
brain	O
injury.	O

Anti-inflammatory	O
and	O
immunomodulatory	O
mechanisms	O
of	O
mesenchymal	B
stem	I
cell	I
transplantation	O
in	O
experimental	O
traumatic	O
brain	O
injury.	O

CSN	O
maintains	O
the	O
germline	O
cellular	O
microenvironment	O
and	O
controls	O
the	O
level	O
of	O
stem	B
cell	I
genes	O
via	O
distinct	O
CRLs	O
in	O
testes	O
of	O
Drosophila	O
melanogaster.	O

Interaction	O
of	O
sonic	O
hedgehog	O
(SHH)	O
pathway	O
with	O
cancer	B
stem	I
cell	I
genes	O
in	O
gastric	O
cancer.	O

In	O
this	O
Review,	O
we	O
highlight	O
recent	O
insights	O
into	O
the	O
maintenance	O
of	O
GI	O
compartmentalization	O
and	O
regulation	O
of	O
diverse	B
stem	I
cell	I
lineages,	O
focusing	O
on	O
advances	O
made	O
by	O
analysis	O
of	O
the	O
GI	O
tract	O
of	O
Drosophila	O
and	O
mice.	O

Although	O
regeneration	O
of	O
the	O
small	O
intestine	O
is	O
thus	O
better	O
understood	O
than	O
regeneration	O
of	O
other	O
compartments	O
of	O
the	O
mammalian	O
GI	O
tract,	O
recent	O
studies	O
have	O
made	O
headway	O
in	O
characterizing	B
stem	I
cell	I
populations	O
in	O
the	O
esophagus	O
and	O
stomach,	O
as	O
discussed	O
below..	O

Overall,	O
our	O
understanding	O
of	O
the	O
organization	O
of	O
regenerative	O
processes	O
and	O
of	O
stem	B
cell	I
lineage	O
relationships	O
in	O
the	O
mammalian	O
GI	O
tract	O
has	O
made	O
substantial	O
progress	O
in	O
recent	O
years.	O

(A)	O
Regulation	O
of	O
stem	B
cell	I
functions	O
in	O
the	O
Drosophila	O
GI	O
tract.	O

(B)	O
Regulation	O
of	O
stem	B
cell	I
functions	O
in	O
the	O
mouse	O
GI	O
tract.	O

To	O
date,	O
most	O
studies	O
characterizing	O
the	O
regulation	O
of	O
stem	B
cell	I
function	O
in	O
the	O
Drosophila	O
GI	O
tract	O
have	O
focused	O
on	O
the	O
PM.	O

In	O
the	O
mammalian	O
small	O
intestine,	O
ISC	O
functions	O
are	O
maintained	O
and	O
regulated	O
by	O
factors	O
from	O
the	O
stem	B
cell	I
niche	O
(see	O
Box	O
1),	O
which	O
comprises	O
adjacent	O
epithelial	O
cells,	O
pericryptal	O
myofibroblasts,	O
enteric	O
neurons,	O
endothelial	O
cells,	O
intraepithelial	O
lymphocytes	O
and	O
the	O
basement	O
membrane	O
(Walker	O
et	O
al.,	O
2009).	O

Overall,	O
the	O
regulation	O
of	O
stem	B
cell	I
function	O
in	O
the	O
mammalian	O
stomach	O
and	O
esophagus	O
in	O
homeostatic	O
conditions	O
remains	O
poorly	O
understood.	O

Although	O
recent	O
studies	O
have	O
provided	O
new	O
information	O
on	O
the	O
regulation	O
of	O
stem	B
cell	I
function	O
by	O
different	O
signaling	O
pathways	O
both	O
in	O
Drosophila	O
and	O
mouse	O
GI	O
tracts,	O
several	O
interesting	O
questions	O
remain	O
and	O
warrant	O
further	O
exploration.	O

More	O
precise	O
characterization	O
of	O
stem	B
cell	I
markers	O
and	O
cell	O
lineages	O
in	O
the	O
gastric	O
region	O
are	O
expected	O
to	O
advance	O
future	O
studies	O
that	O
test	O
this	O
hypothesis..	O

The	O
rich	O
mechanistic	O
insight	O
provided	O
by	O
the	O
fly	O
system	O
is	O
thus	O
expected	O
to	O
complement	O
studies	O
made	O
in	O
mice	O
to	O
enhance	O
our	O
understanding	O
of	O
stem	B
cell	I
function	O
in	O
the	O
GI	O
tract	O
of	O
humans.	O

Slit/Robo	O
signaling	O
regulates	O
cell	O
fate	O
decisions	O
in	O
the	O
intestinal	B
stem	I
cell	I
lineage	O
of	O
Drosophila.	O

Mesenchymal	B
stem	I
cell	I
therapy	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases:	O
challenges,	O
opportunities,	O
and	O
future	O
perspectives.	O

However,	O
some	O
patient	O
populations	O
(e.g.,	O
the	O
elderly,	O
diabetic,	O
or	O
immunocompromized)	O
likely	O
possess	O
limited	O
stores	O
of	O
stem	B
cell	I
populations	O
that	O
exhibit	O
adequate	O
regenerative	O
responses.	O

Adult	B
stem	I
cell	I
therapy	O
and	O
heart	O
failure,	O
2000	O
to	O
2016:	O
a	O
systematic	O
review.	O

Senescent	O
cells	O
can	O
acquire	O
a	O
distinct	O
phenotype	O
of	O
wide	O
range	O
of	O
characteristics,	O
closely	O
relating	O
them	O
to	O
cancer	B
stem	I
cell	I
status	O
(senescence-associated	O
reprogramming/stemness),	O
and	O
this	O
requires	O
a	O
better	O
understanding	O
as	O
to	O
the	O
exact	O
role	O
that	O
senescent	O
cells	O
play	O
in	O
pre-mature	O
aging	O
tissues	O
such	O
as	O
atherosclerotic	O
plaques.	O

Moreover,	O
the	O
subcellular	O
localization	O
of	O
a	O
given	O
protein	O
is	O
also	O
of	O
interest	O
in	O
stem	B
cell	I
biology,	O
mainly	O
for	O
network	O
investigation	O
and	O
protein	O
function	O
understanding,	O
and	O
innovative	O
proteomics	O
approaches	O
can	O
also	O
perform	O
that.	O

This	O
is	O
of	O
crucial	O
importance	O
for	O
stem	B
cell	I
research	O
since	O
it	O
is	O
known	O
that	O
protein	O
isoforms	O
might	O
perform	O
different	O
biological	O
roles	O
and	O
that	O
the	O
isoform	O
profile	O
of	O
specific	O
cells	O
can	O
vary	O
among	O
species	O
and	O
during	O
pathological	O
processes.	O

Stable	O
isotope	O
labeling	O
by	O
amino	O
acids	O
in	O
cell	O
culture	O
(SILAC)	O
and	O
proteome	O
quantitation	O
of	O
mouse	B
embryonic	I
stem	I
cells	I
to	O
a	O
depth	O
of	O
5,111	O
proteins.	O

A	O
GLI1-P53	O
Inhibitory	O
Loop	O
Controls	O
Neural	B
Stem	I
Cell	I
and	O
Tumour	O
Cell	O
Numbers.	O

Hedgehog	O
Signaling	O
Antagonist	O
GDC-0449	O
(Vismodegib)	O
Inhibits	O
Pancreatic	B
Cancer	I
Stem	I
Cell	I
Characteristics:	O
Molecular	O
Mechanisms.	O

More	O
recently,	O
PTEN	O
loss	O
has	O
been	O
analyzed	O
in	O
human	O
T-ALL	O
samples	O
displaying	O
the	O
stem	B
cell	I
leukemia	O
(SCL)/TAL1	O
interrupting	O
locus	O
(STIL)	O
protein/TAL1	O
fusion	O
product	O
[67]	O
that	O
were	O
xenografted	O
in	O
mice	O
and	O
compared	O
with	O
specimens	O
collected	O
at	O
diagnosis	O
[68].	O

Phenotypic	O
traits	O
of	O
mesenchymal	B
stem	I
cell	I
sheets	O
fabricated	O
by	O
temperature-responsive	O
cell	O
culture	O
plate:	O
Structural	O
characteristics	O
of	O
MSC	O
sheets.	O

To	O
investigate	O
a	O
role	O
for	O
Kcnq1	O
in	O
the	O
intestinal	B
stem	I
cell	I
compartment	O
we	O
created	O
intestinal	O
organoids	O
from	O
the	O
colons	O
of	O
a	O
group	O
of	O
Kcnq1+/+	O
and	O
Kcnq1−/−	O
age	O
and	O
gender	O
matched	O
littermate	O
mice.	O

Loss	O
of	O
Kcnq1	O
increased	O
the	O
number	O
of	O
colon	O
organoids	O
by	O
greater	O
than	O
3-fold,	O
confirming	O
a	O
potential	O
regulatory	O
effect	O
of	O
Kcnq1	O
on	O
the	O
intestinal	B
stem	I
cell	I
compartment22	O
(Fig.	O

Neural	B
stem	I
cell	I
lineages	O
are	O
regionally	O
specified,	O
but	O
not	O
committed,	O
within	O
distinct	O
compartments	O
of	O
the	O
developing	O
brain.	O

This	O
phenotype	O
was	O
linked	O
to	O
the	O
evidence	O
of	O
chromatin	O
decompaction	O
specifically	O
at	O
target	O
genes	O
of	O
stem	B
cell	I
factors	O
(e.g.	O

In	O
addition,	O
parthenogenetic	O
blastocysts	O
and	O
haploid	O
mouse	O
embryos	O
have	O
been	O
used	O
for	O
the	O
establishment	O
of	O
stem	B
cell	I
lines,	O
confirming	O
that	O
lack	O
of	O
dosage	O
compensation	O
can	O
be	O
tolerated	O
to	O
a	O
large	O
extent	O
in	O
early	O
embryonic	O
cell	O
types	O
[81,	O
82].	O

Even	O
if	O
side-effects	O
are	O
not	O
immediate,	O
impaired	O
epigenetic	O
regulation	O
could	O
have	O
long-term	O
effects	O
and	O
could	O
lead	O
to	O
problems	O
associated	O
with	O
stem	B
cell	I
maintenance	O
or	O
cell	O
transformation.	O

A	O
HAT	O
complex	O
GCN5	O
is	O
essential	O
for	O
maintaining	O
of	O
root	B
stem	I
cell	I
niche	O
through	O
the	O
attenuation	O
of	O
Plt.96	O
In	O
animals,	O
the	O
proto-oncogene	O
c-Myc	O
has	O
a	O
very	O
similar	O
function.	O

This	O
occurs	O
when	O
fully	O
differentiated	O
plant	O
cells	O
undergo	O
cell	O
wall	O
degradation	O
generating	O
protoplasts	O
which	O
are	O
totipotent.163	O
In	O
vitro	O
experiments	O
suggest	O
that	O
cell	O
shape	O
can	O
influence	O
cell	O
fate	O
determination	O
of	O
mesenchymal	B
stem	I
cells	I
between	O
chondrogenic	O
and	O
smooth	O
muscle	O
cell	O
lineages	O
through	O
cell	O
adhesion	O
molecules-mediated	O
pathways.164	O
Thus,	O
extracellular	O
stimuli,	O
adhesion,	O
and	O
cell	O
shape	O
properties	O
are	O
critical	O
determinants	O
of	O
cell	O
fate	O
and	O
differentiation..	O

Control	O
of	O
stem	B
cell	I
fate	O
by	O
physical	O
interactions	O
with	O
the	O
extracellular	O
matrix.	O

Pax3	O
functions	O
at	O
a	O
nodal	O
point	O
in	O
melanocyte	B
stem	I
cell	I
differentiation.	O

As	O
Bmi-1	O
is	O
also	O
known	O
to	O
promote	O
the	O
stem	B
cell	I
renewal,	O
a	O
process	O
that	O
is	O
important	O
in	O
glioma,	O
hence	O
miRNA-128	O
may	O
be	O
used	O
against	O
the	O
"stem	O
cell-like"	O
characteristics	O
of	O
glioma	O
cells	O
[237].	O

A	O
feedback	O
regulatory	O
loop	O
involving	O
microRNA-9	O
and	O
nuclear	O
receptor	O
TLX	O
in	O
neural	B
stem	I
cell	I
fate	O
determination.	O

Resident	O
interstitial	O
lung	O
fibroblasts	O
and	O
their	O
role	O
in	O
alveolar	B
stem	I
cell	I
niche	O
development,	O
homeostasis,	O
injury,	O
and	O
regeneration.	O

Resident	O
interstitial	O
lung	O
fibroblasts	O
and	O
their	O
role	O
in	O
alveolar	B
stem	I
cell	I
niche	O
development,	O
homeostasis,	O
injury,	O
and	O
regeneration.	O

Developing,	O
regenerating,	O
and	O
repairing	O
a	O
lung	O
all	O
require	O
interstitial	O
resident	O
fibroblasts	O
(iReFs)	O
to	O
direct	O
the	O
behavior	O
of	O
the	O
epithelial	B
stem	I
cell	I
niche.	O

This	O
article	O
summarizes	O
the	O
fibroblast	O
stages	O
during	O
lung	O
development,	O
regeneration,	O
and	O
repair,	O
with	O
a	O
focus	O
on	O
their	O
role	O
in	O
supporting	O
the	O
alveolar	B
stem	I
cell	I
niche	O
and	O
their	O
potential	O
to	O
function	O
as	O
stromal	O
progenitor	O
cells.	O

Resident	O
interstitial	O
lung	O
fibroblasts	O
and	O
their	O
role	O
in	O
alveolar	B
stem	I
cell	I
niche	O
development,	O
homeostasis,	O
injury,	O
and	O
regeneration.	O

To	O
modify	O
primed-state	O
iPSCs	O
so	O
that	O
they	O
can	O
contribute	O
to	O
host	O
embryos	O
as	O
chimera	O
seems	O
to	O
require	O
naïve	O
conversion	O
or	O
adjustment	O
of	O
stem	B
cell	I
status	O
to	O
have	O
region	O
specificity	O
(30,	O
31).	O

Ying	O
Q.-L.,	O
Wray	O
J.,	O
Nichols	O
J.,	O
Batlle-Morera	O
L.,	O
Doble	O
B.,	O
Woodgett	O
J.,	O
Cohen	O
P.,	O
Smith	O
A.,	O
The	O
ground	O
state	O
of	O
embryonic	B
stem	I
cell	I
self-renewal.	O

Expression	O
of	O
the	O
cancer	B
stem	I
cell	I
marker	O
CD133	O
in	O
CTCs	O
of	O
metastatic	O
breast,	O
colon,	O
colorectal,	O
renal	O
cell,	O
hepatocellular	O
and	O
non-small	O
cell	O
lung	O
cancer	O
patients	O
[266,	O
269–257].	O

Cancer	B
stem	I
cells	I
in	O
squamous	O
cell	O
carcinoma	O
switch	O
between	O
two	O
distinct	O
phenotypes	O
that	O
are	O
preferentially	O
migratory	O
or	O
proliferative.	O

Hyaluronan-CD44	O
interaction	O
with	O
protein	O
kinase	O
C(epsilon)	O
promotes	O
oncogenic	O
signaling	O
by	O
the	O
stem	B
cell	I
marker	O
Nanog	O
and	O
the	O
Production	O
of	O
microRNA-21,	O
leading	O
to	O
down-regulation	O
of	O
the	O
tumor	O
suppressor	O
protein	O
PDCD4,	O
anti-apoptosis,	O
and	O
chemotherapy	O
resistance	O
in	O
breast	O
tumor	O
cells.	O

Identification	O
of	O
a	O
subpopulation	O
of	O
cells	O
with	O
cancer	B
stem	I
cell	I
properties	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma.	O

Precise	O
regulation	O
of	O
the	O
activity	O
and	O
maintenance	O
of	O
the	O
fidelity	O
of	O
gene	O
expression	O
is	O
vital	O
for	O
stem	B
cell	I
self-renewal,	O
differentiation,	O
and	O
development.	O

An	O
RNAi	O
screen	O
of	O
chromatin	O
proteins	O
identifies	O
Tip60-p400	O
as	O
a	O
regulator	O
of	O
embryonic	B
stem	I
cell	I
identity.	O

Based	O
on	O
the	O
concepts	O
of	O
stem	B
cells	I
in	O
healthy	O
tissues,	O
these	O
glioma	O
stem-like	O
cells	O
(GSLCs),	O
also	O
called	O
glioma-initiating	O
cells	O
(GICs),	O
are	O
believed	O
to	O
divide	O
asymmetrically,	O
yielding	O
a	O
novel	O
stem-like	O
cell	O
that	O
is	O
resistant	O
to	O
chemotherapy	O
and	O
radiotherapy	O
and	O
is	O
responsible	O
for	O
tumor	O
progression,	O
and	O
a	O
non-stem-like	O
daughter	O
cell	O
[136].	O

GEMMs	O
(conditional	O
expression	O
of	O
oncogenes/loss	O
of	O
tumor	O
suppressor	O
genes)	O
Partly	O
relevant,	O
only	O
few	O
known	O
driver	O
mutations	O
used	O
(among	O
others	O
loss	O
of	O
p53/pten,CDKN2A,	O
krasV12)	O
[38]	O
Existing	O
models	O
expressing	O
IDH1-R132H	O
in	O
neural	B
stem	I
cells	I
have	O
epigenetic	O
alterations	O
but	O
are	O
not	O
tumor	O
models	O
[7]	O
Genetically	O
homogeneous,	O
initiator	O
cell	O
type	O
dependent	O
on	O
promoter	O
driving	O
Cre	O
expression	O
(CMV/nestin/GFAP)	O
Yes	O
Relevant	O
when	O
Cre	O
expression	O
is	O
induced	O
in	O
the	O
CNS	O
(intracerebral	O
injection	O
of	O
Cre-lentivirus,	O
crossing	O
mice	O
with	O
developmental	O
CNS-	O
expression	O
of	O
Cre	O
Yes	O
Yes.	O

A	O
variety	O
of	O
different	O
humanized	O
mouse	O
models	O
have	O
been	O
developed	O
and	O
fall	O
into	O
two	O
distinct	O
categories:	O
(1)	O
those	O
with	O
a	O
slow	O
but	O
more	O
extensive	O
immune	O
reconstitution	O
resulting	B
from	I
stem	I
cell	I
transfer	O
(Lapidot	O
et	O
al.	O

The	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
pathway	O
enrichment	O
analysis	O
revealed	O
that	O
the	O
DECs	O
are	O
markedly	O
enriched	O
to	O
stem	B
cell	I
pluripotency	O
regulation,	O
tight	O
junctions,	O
adhesion	O
junctions,	O
and	O
cAMP	O
signaling	O
pathway.	O

Under	O
asymmetric	O
strand	O
segregation,	O
the	O
double-stranded	O
molecule	O
that	O
contains	O
the	O
oldest	O
DNA	O
strand	O
is	O
preferentially	O
targeted	O
to	O
the	O
somatic	B
stem	I
cell	I
after	O
each	O
round	O
of	O
DNA	O
replication.	O

When	O
strand	O
segregation	O
is	O
symmetric	O
(B),	O
the	O
oldest	O
strand	O
is	O
assigned	O
at	O
random	O
to	O
the	O
stem	B
cell	I
or	O
to	O
the	O
differentiated	O
cell,	O
and	O
is	O
eventually	O
lost	O
when	O
the	O
terminally	O
differentiated	O
cell	O
that	O
contains	O
it	O
is	O
sloughed	O
off	O
at	O
the	O
epithelial	O
surface..	O

Stability	O
of	O
colon	B
stem	I
cell	I
methylation	O
after	O
neo-adjuvant	O
therapy	O
in	O
a	O
patient	O
with	O
attenuated	O
familial	O
adenomatous	O
polyposis.	O

In	O
the	O
central	O
nervous	O
system	O
(CNS),	O
JNKs	O
are	O
involved	O
in	O
neuronal	O
polarization,	O
starting	O
from	O
the	O
cell	O
division	O
of	O
neural	B
stem	I
cells	I
and	O
ending	O
with	O
their	O
final	O
positioning	O
when	O
migrating	O
and	O
maturing.	O

Expression	O
of	O
pluripotent	B
stem	I
cell	I
markers	O
in	O
the	O
human	O
fetal	O
testis.	O

Identification	O
of	O
somatic	B
stem	I
cell	I
populations	O
has	O
made	O
possible	O
the	O
study	O
of	O
heterologous	O
cells	O
comprising	O
their	O
niche.	O

These	O
studies	O
were	O
initiated	O
focusing	O
on	O
the	O
stem	O
cell	O
niche,	O
but	O
the	O
results	O
indicate	O
that	O
individual	O
microenvironment	O
constituents	O
can	O
serve	O
as	O
regulators	O
of	O
tissue	O
functions	O
beyond	O
that	O
of	O
stem	B
cell	I
support.	O

Identification	O
of	O
the	O
haematopoietic	B
stem	I
cell	I
niche	O
and	O
control	O
of	O
the	O
niche	O
size.	O

On	O
the	O
other	O
hand,	O
if	O
these	O
Müller	O
cell	O
processes	O
create	O
a	O
scar	O
with	O
extracellular	O
matrix	O
proteins	O
(such	O
as	O
proteoglycans,	O
collagen,	O
and	O
laminin)	O
then	O
the	O
diffusion	O
of	O
therapeutics	O
and	O
migration	O
of	O
progenitors	O
in	O
stem	B
cell	I
therapy	O
into	O
the	O
retina	O
could	O
also	O
be	O
significantly	O
reduced.	O

This	O
strategy	O
could	O
be	O
applied	O
to	O
the	O
production	O
of	O
many	O
other	O
cell	O
lineages	O
from	O
pluripotent	B
stem	I
cells	I
with	O
the	O
integration	O
of	O
programming	O
factors	O
into	O
a	O
safer	O
harbor	O
locus	O
providing	O
a	O
safer	O
and	O
more	O
reproducible	O
route	O
to	O
the	O
clinic..	O

A	O
new	O
complication	O
of	O
stem	B
cell	I
transplantation:	O
measles	O
inclusion	O
body	O
encephalitis.	O

In	O
order	O
to	O
compensate	O
for	O
stem	B
cell	I
loss	O
and	O
low	O
blood	O
cell	O
counts	O
[38]	O
this	O
quantitative	O
defect	O
leads	O
to	O
a	O
limited	O
replicative	O
capacity	O
of	O
the	O
remaining	O
HSPC	O
pool	O
and	O
results	O
in	O
the	O
penetrance	O
of	O
the	O
short	O
telomere	O
phenotype	O
in	O
peripheral	O
blood	O
cells.	O

Organoid	O
culture	O
is	O
also	O
feasible	O
for	O
human	O
intestinal	O
cells.62	O
Normal	O
small	O
intestinal	O
cells	O
and	O
colon	O
cells	O
were	O
genetically	O
engineered	O
by	O
CRISPR/Cas9	O
to	O
reconstitute	O
triple	O
mutations	O
in	O
APC,	O
TP53	O
and	O
KRAS,	O
followed	O
by	O
depletion	O
of	O
factors	O
or	O
addition	O
of	O
inhibitors	O
to	O
enrich	O
cells	O
that	O
acquired	O
independency	O
of	O
the	O
stem	B
cell	I
niches	O
through	O
introduced	O
mutations.57	O
Engineered	O
organoids	O
from	O
intestine	O
and	O
colon	O
developed	O
adenomas	O
and	O
well‐differentiated	O
adenocarcinomas,	O
respectively.	O

Fully	O
functional	O
ALDH	O
activity	O
counteracts	O
the	O
toxic	O
effect	O
induced	O
by	O
acetaldehyde	O
and	O
is	O
involved	O
in	O
stem	B
cell	I
protection,	O
maintenance,	O
and	O
differentiation	O
[269,274].	O

Alcohol	O
also	O
altered	O
the	O
stem	B
cell	I
niche’s	O
microenvironment	O
and	O
disturbed	O
cell	O
fate	O
determination	O
by	O
dysregulating	O
the	O
extracellular	O
matrix	O
deposition	O
and	O
changing	O
the	O
plasma	O
membrane’s	O
fluidity	O
(reviewed	O
in	O
[269]).	O

As	O
mentioned	O
above,	O
the	O
accumulation	O
of	O
stem	B
cell	I
divisions	O
is	O
a	O
significant	O
cause	O
of	O
cancer.	O

Ethanol	O
and	O
its	O
metabolites	O
Changes	O
in	O
stem	B
cell	I
niche’s	O
microenvironment,	O
modification	O
of	O
membrane	O
fluidity,	O
and	O
derangement	O
of	O
the	O
extracellular	O
matrix	O
composition	O
and	O
organization	O
Block	O
of	O
cell	O
differentiation,	O
DNA	O
damage,	O
and	O
promotion	O
of	O
apoptosis	O
[268].	O

Acute	O
and	O
chronic	O
treatments	O
Activation	O
of	O
intestinal	B
stem	I
cell	I
divisions	O
and	O
dysregulation	O
of	O
β-catenin	O
signaling	O
More	O
frequent	O
divisions	O
cause	O
mutations	O
and	O
malignant	O
cell	O
transformation	O
[284].	O

Cancer	B
stem	I
cell	I
definitions	O
and	O
terminology:	O
The	O
devil	O
is	O
in	O
the	O
details.	O

Cancer	B
stem	I
cell	I
quiescence	O
and	O
plasticity	O
as	O
major	O
challenges	O
in	O
cancer	O
therapy.	O

Induction	O
of	O
immunogenic	O
cell	O
death	O
in	O
radiation-resistant	O
breast	B
cancer	I
stem	I
cells	I
by	O
repurposing	O
anti-alcoholism	O
drug	O
disulfiram.	O

Variation	O
in	O
cancer	O
risk	O
among	O
tissues	O
can	O
be	O
explained	O
by	O
the	O
number	O
of	O
stem	B
cell	I
divisions.	O

Molecular	O
basis	O
of	O
embryonic	B
stem	I
cell	I
self-renewal:	O
From	O
signaling	O
pathways	O
to	O
pluripotency	O
network.	O

The	O
discovery	O
of	O
the	O
cancer	O
stem	O
cell	O
[6-8]	O
lent	O
support	O
to	O
the	O
theory	O
that	O
cancer	O
may	O
develop	O
out	O
of	O
a	O
single	O
cell,	O
and	O
raised	O
the	O
question	O
of	O
cancer	O
stem	O
cells	O
arising	O
from	O
normal	B
stem	I
cells	I
[9].	O

Translation:	O
Screening	O
for	O
novel	O
therapeutics	O
with	O
disease-relevant	O
cell	O
types	O
derived	O
from	O
human	B
stem	I
cell	I
models.	O

Although	O
telomerase	O
is	O
expressed	O
in	O
adult	B
stem	I
cell	I
compartments,	O
this	O
is	O
not	O
sufficient	O
to	O
counteract	O
telomere	O
attrition	O
associated	O
with	O
cell	O
division	O
throughout	O
life,	O
and	O
therefore	O
telomeres	O
shorten	O
with	O
age	O
in	O
vitro	O
and	O
in	O
vivo	O
(Harley	O
et	O
al.,	O
1990;	O
Hastie	O
et	O
al.,	O
1990;	O
Lindsey	O
et	O
al.,	O
1991;	O
Collado	O
et	O
al.,	O
2007;	O
Liu	O
et	O
al.,	O
2007;	O
Flores	O
et	O
al.,	O
2008;	O
Marion	O
et	O
al.,	O
2009).	O

Telomere	O
attrition	O
in	O
stem	B
cell	I
compartments	O
impairs	O
their	O
tissue	O
and	O
self-renewal	O
capacity	O
and	O
is	O
considered	O
to	O
be	O
one	O
of	O
the	O
primary	O
molecular	O
causes	O
of	O
aging	O
and	O
the	O
onset	O
of	O
aging-associated	O
diseases	O
(Flores	O
et	O
al.,	O
2005;	O
Sharpless	O
and	O
DePinho,	O
2007).	O

The	O
aplastic	O
anemia	O
phenotypes	O
in	O
mouse	O
(see	O
text	O
box)	O
are	O
provoked	O
either	O
by	O
partially	O
depleting	O
TRF1	O
in	O
the	O
BM	B
stem	I
cell	I
and	O
progenitor	O
compartments	O
(hematopoietic	O
stem/progenitor	O
cells	O
[HSPCs])	O
or	O
by	O
transplanting	O
irradiated	O
wild-type	O
mice	O
with	O
BM	O
from	O
late-generation	O
telomerase-deficient	O
Tert	O
knockout	O
mice	O
presenting	O
with	O
short	O
telomeres	O
(Beier	O
et	O
al.,	O
2012;	O
Bär	O
and	O
Blasco,	O
2016).	O

We	O
showed	O
that	O
a	O
DNA-damaged	O
burden	O
above	O
a	O
certain	O
threshold,	O
combined	O
with	O
defective	B
stem	I
cell	I
regeneration	O
ability,	O
lead	O
to	O
the	O
development	O
of	O
PF	O
(Povedano	O
et	O
al.,	O
2015).	O

Telomere	O
attrition	O
in	O
stem	B
cell	I
compartments	O
impairs	O
their	O
tissue	O
and	O
self-renewal	O
capacity	O
and	O
is	O
considered	O
to	O
be	O
one	O
of	O
the	O
primary	O
molecular	O
causes	O
of	O
aging	O
and	O
the	O
onset	O
of	O
aging-associated	O
diseases.	O

Effects	O
of	O
telomerase	O
and	O
telomere	O
length	O
on	O
epidermal	B
stem	I
cell	I
behavior.	O

The	O
longest	O
telomeres:	O
A	O
general	O
signature	O
of	O
adult	B
stem	I
cell	I
compartments.	O

The	O
presence	O
of	O
efflux	O
transporters	O
such	O
as	O
ABC	O
transporters	O
on	O
the	O
cell	O
membrane	O
is	O
an	O
important	O
mechanism	O
that	O
protects	O
the	O
cellular	O
homeostasis	O
of	O
stem	B
cells	I
[40].	O

For	O
instance,	O
the	O
surface	O
marker	O
CD44	O
is	O
associated	O
with	O
the	O
maintenance	O
of	O
stem	B
cell	I
characteristics	O
[126].	O

Additionally,	O
BRMC	O
was	O
also	O
able	O
to	O
inhibit	O
self-renewal	O
and	O
proliferation	O
of	O
liver	B
stem	I
cells	I
isolated	O
from	O
the	O
MHCC97	O
cell	O
line.	O

Sensitivity	O
to	O
imatinib	O
plus	O
SFN	O
was	O
higher	O
in	O
the	O
CD34+CD38+	O
cell	O
population,	O
and	O
the	O
expression	O
of	O
β-catenin	O
and	O
MRD1	O
proteins,	O
important	O
proteins	O
that	O
confer	O
drug	O
resistance	O
of	O
leukemia	B
stem	I
cells	I
to	O
imatinib,	O
was	O
reduced	O
by	O
treatment	O
with	O
SFN	O
[143]..	O

Maintenance	O
of	O
stem	B
cell	I
self-renewal	O
in	O
head	O
and	O
neck	O
cancers	O
requires	O
actions	O
of	O
GSK3beta	O
influenced	O
by	O
CD44	O
and	O
RHAMM.	O

Notch	O
signaling	O
in	O
the	O
regulation	O
of	O
stem	B
cell	I
self-renewal	O
and	O
differentiation.	O

Notch-1	O
induces	O
epithelial-mesenchymal	O
transition	O
consistent	O
with	O
cancer	B
stem	I
cell	I
phenotype	O
in	O
pancreatic	O
cancer	O
cells.	O

Atractylenolide	O
I-mediated	O
Notch	O
pathway	O
inhibition	O
attenuates	O
gastric	B
cancer	I
stem	I
cell	I
traits.	O

Curcumin	O
and	O
epigallocatechin	O
gallate	O
inhibit	O
the	O
cancer	B
stem	I
cell	I
phenotype	O
via	O
down-regulation	O
of	O
STAT3-NFkappaB	O
signaling.	O

The	O
tissue-specific	O
outcome	O
of	O
genotoxic	O
stress	O
imposed	O
by	O
the	O
DNA-PKcs3A	O
mutant	O
protein	O
or	O
DNA-PKcs	O
dysfunction	O
may	O
depend	O
on	O
cell	O
type–specific	O
apoptosis/senescence	O
and	O
the	O
compensation	O
capacity	O
from	O
varied	O
sizes	O
of	O
stem	B
cell	I
pools	O
in	O
different	O
tissues	O
and	O
organs..	O

The	O
hallmarks	O
of	O
FA,	O
including	O
aplastic	O
anemia,	O
abnormal	O
skin	O
pigmentation,	O
MMC	O
sensitivity,	O
and	O
radial	O
chromosome	O
formation	O
with	O
MMC	O
treatment,	O
are	O
all	O
observed	O
in	O
DNA-PKcs3A/3A	O
mice,	O
suggesting	O
that,	O
in	O
human	O
patients,	O
FA	O
mutations	O
also	O
likely	O
affect	O
the	O
stem	B
cell	I
compartment	O
during	O
embryo	O
development	O
and	O
activate	O
p53,	O
which	O
generates	O
pathological	O
changes	O
in	O
multiple	O
organs.	O

MYC	O
controls	O
numerous	O
genes	O
involved	O
in	O
stem	B
cell	I
functions,	O
differentiation,	O
growth,	O
immortalization,	O
metabolism,	O
survival	O
and	O
other	O
fundamental	O
cellular	O
processes,	O
and	O
deregulated	O
expression	O
of	O
MYC	O
is	O
very	O
often	O
implicated	O
in	O
human	O
tumor	O
development	O
including	O
hematological	O
malignancies	O
[5],	O
[6].	O

Age	O
Is	O
Relative-Impact	O
of	O
Donor	O
Age	O
on	O
Induced	O
Pluripotent	O
Stem	O
Cell-Derived	O
Cell	O
Functionality.	O
Castration	O
of	O
Ptenp−/−	O
mice	O
led	O
to	O
massive	O
apoptosis	O
of	O
prostate	O
epithelial	O
cells,	O
yet	O
unlike	O
in	O
prostates	O
of	O
wild-type	O
mice,	O
a	O
population	O
of	O
proliferative	O
prostate	O
cells	O
positive	O
for	B
stem	I
cell	I
markers	O
(p63	O
and	O
casein	O
kinase	O
5)	O
in	O
primary	O
tumors	O
were	O
detected.65	O
A	O
better	O
response	O
was	O
achieved	O
when	O
anti-androgen	O
therapy	O
(MDV3100	O
or	O
castration)	O
was	O
combined	O
with	O
an	O
mTOR	O
inhibitor.66	O
In	O
the	O
compound	O
Pten+/−;Nkx3.1−/−	O
mice,	O
prostates	O
were	O
completely	O
resistant	O
to	O
castration.	O

Therefore,	O
it	O
is	O
crucial	O
to	O
target	O
the	O
stem	B
cell	I
compartment	O
using	O
a	O
different	O
promoter.136	O
Cre	O
expression	O
was	O
detectable	O
in	O
tissue	O
lysates	O
from	O
the	O
small	O
intestine,	O
but	O
to	O
a	O
lesser	O
extent	O
in	O
the	O
large	O
intestine,	O
which	O
must	O
be	O
addressed	O
before	O
this	O
system	O
can	O
be	O
used	O
as	O
an	O
inducible	O
mouse	O
model	O
for	O
human	O
colon	O
cancer	O
by	O
crossing	O
with	O
Apcflox/flox	O
mice..	O

In	O
situ-synthesized	O
novel	O
microarray	O
optimized	O
for	O
mouse	B
stem	I
cell	I
and	O
early	O
developmental	O
expression	O
profiling.	O

Since	O
the	O
p38	O
MAPK	O
signaling	O
pathway	O
has	O
fundamental	O
roles	O
on	O
the	O
regulation	O
of	O
muscle	O
stem	O
cell	O
functions	O
is	O
important	O
to	O
elucidate	O
the	O
molecular	O
regulation	O
of	O
p38	O
by	O
Nilotinib	O
and	O
to	O
evaluate	O
the	O
extent	O
of	O
this	O
regulation	O
on	O
muscle	B
stem	I
cell	I
biology	O
[58]..	O

Regulation	O
of	O
muscle	B
stem	I
cell	I
functions:	O
a	O
focus	O
on	O
the	O
p38	O
MAPK	O
signaling	O
pathway.	O

We	O
conducted	O
a	O
systematic	O
review	O
and	O
meta-analysis	O
of	O
studies	O
that	O
were	O
published	O
between	O
March	O
2009	O
and	O
March	O
2015	O
on	O
stem	B
cell	I
therapy	O
and	O
survival	O
in	O
animal	O
models	O
and	O
patients	O
with	O
ALS.	O

The	O
results	O
of	O
studies	O
on	O
the	O
use	O
of	O
stem	B
cell	I
therapy	O
to	O
preserve	O
motor	O
neuron	O
function	O
have	O
been	O
considered	O
without	O
any	O
evidence	O
of	O
their	O
effectiveness	O
in	O
humans,	O
although	O
the	O
use	O
of	O
this	O
therapeutic	O
approach	O
has	O
been	O
fairly	O
efficacious	O
in	O
experimental	O
animal	O
models	O
[9]..	O

Given	O
the	O
need	O
to	O
identify	O
new	O
alternatives	O
to	O
treat	O
ALS,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
conduct	O
a	O
systematic	O
literature	O
review	O
to	O
assess	O
the	O
efficacy	O
of	O
stem	B
cell	I
therapy	O
in	O
clinical	O
and	O
preclinical	O
studies..	O

The	O
inclusion	O
criteria	O
were	O
the	O
following:	O
1)	O
clinical,	O
prospective	O
or	O
retrospective	O
studies	O
of	O
patients	O
diagnosed	O
with	O
a	O
motor	O
neuron	O
disease	O
by	O
means	O
of	O
anamnesis	O
and	O
electromyography	O
according	O
to	O
the	O
El	O
Escorial	O
[10]	O
and	O
Awaji	O
criteria	O
[11];	O
2)	O
preclinical	O
and	O
in	O
vivo	O
studies	O
with	O
assessment	O
of	O
survival	O
compared	O
to	O
a	O
control	O
group,	O
and	O
studies	O
of	O
treatment	O
after	O
the	O
onset	O
of	O
weakness;	O
and	O
3)	O
studies	O
based	O
on	O
the	O
use	O
of	O
stem	B
cell	I
therapy	O
to	O
increase	O
survival	O
time	O
compared	O
to	O
placebo	O
or	O
other	O
treatments	O
used	O
by	O
the	O
control	O
group..	O

Preclinical	O
studies	O
in	O
amyotrophic	O
lateral	O
sclerosis	O
model	O
with	O
stem	B
cell	I
therapy,	O
2009	O
-	O
2015..	O

This	O
systematic	O
review	O
uses	O
a	O
meta-analysis	O
to	O
show	O
the	O
efficacy	O
of	O
stem	B
cell	I
therapy	O
in	O
improving	O
survival	O
in	O
preclinical	O
trials,	O
whereas	O
the	O
number	O
of	O
clinical	O
studies	O
is	O
still	O
insufficient	O
to	O
assess	O
their	O
effectiveness	O
and	O
demonstrates	O
only	O
the	O
absence	O
of	O
serious	O
adverse	O
events.	O

The	O
development	O
of	O
iPSCs	O
has	O
led	O
to	O
remarkable	O
changes	O
in	O
stem	B
cell	I
science.	O

These	O
recent	O
studies	O
in	O
humans	O
with	O
ALS	O
are	O
summarized	O
in	O
Table	O
1	O
and	O
include	O
many	O
differences,	O
such	O
as	O
the	O
number	O
of	O
patients,	O
cell	O
type,	O
delivery	O
method	O
and	O
outcome	O
measurement	O
strategies;	O
however,	O
each	O
study	O
has	O
the	O
potential	O
to	O
contribute	O
to	O
increasing	O
our	O
current	O
understanding	O
of	O
the	O
safety	O
and	O
feasibility	O
of	O
stem	B
cell	I
therapies	O
for	O
ALS.	O

Preclinical	O
studies	O
of	O
stem	B
cell	I
therapy	O
show	O
great	O
efficacy,	O
whereas	O
more	O
prospective	O
and	O
controlled	O
studies	O
are	O
needed	O
to	O
establish	O
the	O
effectiveness	O
of	O
clinical	O
studies	O
in	O
improving	O
survival.	O

Safety	O
and	O
immunological	O
effects	O
of	O
mesenchymal	B
stem	I
cell	I
transplantation	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
and	O
amyotrophic	O
lateral	O
sclerosis.	O

Intraspinal	B
stem	I
cell	I
transplantation	O
in	O
amyotrophic	O
lateral	O
sclerosis:	O
a	O
phase	O
I	O
trial,	O
cervical	O
microinjection,	O
and	O
final	O
surgical	O
safety	O
outcomes.	O

Intraspinal	B
stem	I
cell	I
transplantation	O
in	O
amyotrophic	O
lateral	O
sclerosis:	O
a	O
phase	O
I	O
safety	O
trial,	O
technical	O
note,	O
and	O
lumbar	O
safety	O
outcomes.	O

In	O
the	O
animal	O
infection	O
models,	O
the	O
bacteria	O
counts	O
were	O
compared	O
using	O
stratified	O
log-rank	O
tests,	O
with	O
the	O
stem	B
cell	I
donors	O
being	O
correlated	O
with	O
the	O
outcomes	O
of	O
the	O
in	O
vivo	O
resolution	O
of	O
bacteria	O
load	O
posttreatment.	O

Evidence	O
for	O
epithelial-mesenchymal	O
transition	O
in	O
cancer	B
stem	I
cells	I
of	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma.	O

Additional	O
signaling	O
molecules	O
showed	O
reduced	O
expression	O
in	O
A‐AML;	O
they	O
included	O
the	O
inositol	O
1,4,5‐trisphosphate	O
receptor	O
ITPR2,	O
the	O
leukemia	B
stem	I
cell	I
marker	O
CD47,	O
the	O
CALM/AF10‐related	O
gene	O
COMMD3,	O
and	O
the	O
RAS	O
pathway	O
genes	O
BRAF,	O
PIK3CB,	O
SOS1,	O
and	O
PIK3C3.	O

Similarly,	O
Kumar	O
and	O
colleagues	O
reported	O
that	O
high	O
basal	O
expression	O
of	O
TG2	O
in	O
breast	O
cancer	O
cells	O
promotes	O
the	O
development	O
of	O
stem	B
cell	I
features	O
but	O
did	O
not	O
mediate	O
their	O
terminal	O
differentiation	O
[111].	O

Efficient	O
cardiomyogenic	O
differentiation	O
of	O
embryonic	B
stem	I
cell	I
by	O
fibroblast	O
growth	O
factor	O
2	O
and	O
bone	O
morphogenetic	O
protein	O
2.	O

(d)	O
TRF2	O
maintains	O
the	O
characteristics	O
of	O
tumor	B
stem	I
cells	I
by	O
regulating	O
the	O
gene	O
expression	O
and	O
stability	O
of	O
tumor	O
cell	O
stemness-related	O
transcription	O
factors	O
and	O
related	O
proteins,	O
thereby	O
promoting	O
tumor	O
cell	O
proliferation	O
and	O
cancer	O
metastasis.	O

It	O
was	O
previously	O
demonstrated	O
that,	O
after	O
radiation	O
treatment,	O
the	O
expression	O
level	O
of	O
TRF2	O
and	O
RAP1	O
in	O
the	O
stem	B
cell	I
cloning	O
sphere	O
increased,	O
and	O
the	O
interaction	O
between	O
the	O
2	O
could	O
also	O
regulate	O
the	O
activity	O
of	O
hTERT,	O
which	O
was	O
essential	O
for	O
the	O
maintenance	O
of	O
telomeres	O
(151).	O

Enhanced	O
expression	O
of	O
TRF2,	O
RAP1	O
and	O
hTERT	O
in	O
stem	B
cell	I
clone	O
spheres	O
could	O
improve	O
telomere	O
DNA	O
repair	O
and	O
protection,	O
and	O
counteract	O
genomic	O
instability	O
caused	O
by	O
telomere	O
shortening	O
or	O
DSB,	O
thereby	O
effectively	O
resisting	O
cell	O
death	O
induced	O
by	O
DNA	O
damage	O
caused	O
by	O
radiotherapy,	O
chemotherapy	O
and	O
other	O
factors	O
(such	O
as	O
aging),	O
maintain	O
the	O
survival	O
of	O
tumor	O
cells,	O
and	O
produce	O
tolerance	O
to	O
treatment	O
(152)..	O

The	O
tortoise	O
and	O
the	O
hair:	O
Slow-cycling	O
cells	O
in	O
the	O
stem	B
cell	I
race.	O

The	O
development	O
of	O
autoimmunity	O
in	O
C57BL/6	O
lpr	O
mice	O
correlates	O
with	O
the	O
disappearance	O
of	O
natural	O
killer	O
type	O
1-positive	O
cells:	O
evidence	O
for	O
their	O
suppressive	O
action	O
on	O
bone	B
marrow	I
stem	I
cell	I
proliferation,	O
B	O
cell	O
immunoglobulin	O
secretion,	O
and	O
autoimmune	O
symptoms.	O

The	O
knockout	O
Sam68	O
mice	O
are	O
protected	O
against	O
the	O
development	O
of	O
osteoporosis	O
pointing	O
towards	O
an	O
enhancement	O
of	O
the	O
mesenchymal	B
stem	I
cell	I
differentiation	O
along	O
the	O
osteogenic	O
rather	O
than	O
the	O
adipocyte	O
pathway	O
[34].	O

They	O
proposed	O
that	O
reduced	O
HAT	O
activity	O
in	O
diabetic	O
hearts	O
was	O
responsible	O
for	O
increased	O
DNA	O
CpG	O
methylation	O
resulting	O
in	O
decreased	O
cell	O
differentiation	O
and	O
proliferation	O
of	O
cardiac	B
mesenchymal	I
stem	I
cells	I
in	O
diabetic	O
cardiomyopathy.	O

The	O
Wnt	O
signaling	O
pathway	O
plays	O
a	O
critical	O
role	O
in	O
stem	B
cell	I
renewal,	O
survival,	O
and	O
differentiation,	O
as	O
well	O
as	O
in	O
the	O
normal	O
development	O
and	O
homeostasis	O
of	O
tissues	O
including	O
the	O
mammary	O
gland	O
(Boras-Granic	O
and	O
Wysolmerski,	O
2008).	O

To	O
date,	O
many	O
lncRNAs	O
have	O
been	O
demonstrated	O
to	O
be	O
involved	O
in	O
PC,	O
such	O
as	O
HOTAIR,	O
HOTTIP,	O
MALAT-1,	O
AFAP1-AS1,	O
H19,	O
PVT1,	O
and	O
AF339813.15	O
Upregulated	O
HOTAIR	O
could	O
promote	O
resistance	O
to	O
tumor	O
necrosis	O
factor-related	O
apoptosis	O
inducing	O
ligands	O
in	O
PC	O
cell	O
lines.16	O
HOTTIP	O
changes	O
the	O
biological	O
characteristics	O
of	O
cancer	B
stem	I
cells	I
in	O
PC	O
by	O
regulating	O
HOXA9.17	O
Enhancer	O
of	O
zeste	O
homolog	O
2	O
(EZH2)	O
binds	O
to	O
MALAT-1,	O
a	O
combination	O
that	O
inhibits	O
E-cadherin	O
and	O
promotes	O
cell	O
migration	O
and	O
invasion	O
without	O
altering	O
cell	O
proliferation.18	O
H19	O
promotes	O
metastasis	O
of	O
PC	O
cells	O
by	O
inhibiting	O
let-7	O
against	O
its	O
target	O
HMGA2-mediated	O
epithelial–mesenchymal	O
transition	O
(EMT)	O
inhibition.19	O
lncRNA-PVT1	O
competitively	O
binds	O
miR-448	O
to	O
regulate	O
translation	O
of	O
downstream	O
target	O
genes	O
to	O
promote	O
proliferation	O
and	O
migration	O
of	O
PC	O
cells.20	O
As	O
we	O
look	O
into	O
the	O
future,	O
we	O
recognize	O
the	O
imperative	O
need	O
for	O
further	O
study	O
on	O
the	O
PC-related	O
lncRNAs..	O

Mutant	O
KRAS	O
promotes	O
hyperplasia	O
and	O
alters	O
differentiation	O
in	O
the	O
colon	O
epithelium	O
but	O
does	O
not	O
expand	O
the	O
presumptive	B
stem	I
cell	I
pool.	O

PIWI	O
was	O
first	O
discovered	O
in	O
Drosophila	O
melanogaster	O
in	O
relation	O
to	O
germline	B
stem	I
cell	I
self-renewal;	O
therefore,	O
much	O
of	O
the	O
focus	O
has	O
been	O
on	O
the	O
piRNA/PIWI	O
complex’s	O
role	O
in	O
the	O
germline	O
[34].	O

The	O
expression	O
of	O
stem	B
cell	I
protein	O
Piwil2	O
and	O
piR-932	O
in	O
breast	O
cancer.	O

Functional	O
analysis	O
revealed	O
enrichment	O
in	O
stem	B
cell	I
related	O
genes	O
and	O
mesenchymal	O
regulatory	O
transcription	O
factors	O
(TFs).	O

Genes	O
included	O
in	O
this	O
stem	B
cell	I
signature	O
are	O
involved	O
in	O
cell	O
cycle	O
regulation,	O
DNA	O
repair,	O
or	O
apoptosis	O
control,	O
as	O
part	O
of	O
the	O
machinery	O
associated	O
to	O
self-renewal.	O

Interestingly	O
KLF4,	O
as	O
indicated	O
above,	O
is	O
implicated	B
in	I
maintaining	I
stem	I
cell	I
pluripotency	O
and	O
has	O
been	O
reported	O
to	O
perform	O
a	O
cooperative	O
activation	O
with	O
MEIS2	O
and	O
PBX1	O
[75]	O
resulting	O
in	O
the	O
fine-tuning	O
of	O
the	O
KLF4	O
response.	O

Optimization	O
of	O
mesenchymal	B
stem	I
cell	I
expansion	O
procedures	O
by	O
cell	O
separation	O
and	O
culture	O
conditions	O
modification.	O

Kruppel-like	O
factor	O
4	O
(KLF4)	O
is	O
required	O
for	O
maintenance	O
of	O
breast	B
cancer	I
stem	I
cells	I
and	O
for	O
cell	O
migration	O
and	O
invasion.	O

The	O
cells	O
in	O
the	O
mesenchymal	B
stem	I
cell	I
and	O
osteoblast	O
cultures	O
were	O
harvested	O
after	O
3	O
or	O
5	O
weeks,	O
respectively,	O
for	O
the	O
calcium	O
and	O
DNA	O
assay..	O

Exosomes	O
secreted	O
from	O
stem	B
cells	I
carry	O
many	O
bioactive	O
molecules,	O
which	O
not	O
only	O
prevent	O
cell	O
apoptosis	O
and	O
promote	O
cell	O
proliferation,	O
but	O
also	O
improve	O
neovascularization	O
9	O
10	O
11	O
12.	O

Inflammatory	O
cytokine-induced	O
intercellular	O
adhesion	O
molecule-1	O
and	O
vascular	O
cell	O
adhesion	O
molecule-1	O
in	O
mesenchymal	B
stem	I
cells	I
are	O
critical	O
for	O
immunosuppression.	O

The	O
inhibitory	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
on	O
blood–brain	O
barrier	O
disruption	O
following	O
intracerebral	O
hemorrhage	O
in	O
rats:	O
contribution	O
of	O
TSG-6.	O

Inactivation	O
of	O
TGFbeta	O
receptors	O
in	O
stem	B
cells	I
drives	O
cutaneous	O
squamous	O
cell	O
carcinoma.	O

Synteny	O
is	O
maintained	O
with	O
distantly	O
related	O
blood	O
flukes	O
but	O
we	O
find	O
extreme	O
losses	O
of	O
genes	O
and	O
pathways	O
ubiquitous	O
in	O
other	O
animals,	O
including	O
34	O
homeobox	O
families	O
and	O
several	O
determinants	O
of	O
stem	B
cell	I
fate.	O

Echinococcus	O
multilocularis	O
as	O
an	O
experimental	O
model	O
in	O
stem	B
cell	I
research	O
and	O
molecular	O
host-parasite	O
interaction.	O

Several	O
ECM	O
components	O
are	O
involved	O
in	O
key	O
cellular	O
pathways	O
other	O
than	O
the	O
mere	O
cell-matrix	O
adhesion,	O
such	O
as	O
activation	O
and	O
presentation	O
of	O
soluble	O
factors,	O
preservation	O
of	O
the	O
stem	B
cell	I
niche,	O
and	O
signal	O
transduction	O
into	O
cells	O
(Hynes,	O
2009;	O
Gattazzo	O
et	O
al.,	O
2014).	O

Lysine	O
4	O
of	O
histone	O
H3.3	O
is	O
required	O
for	O
embryonic	B
stem	I
cell	I
differentiation,	O
histone	O
enrichment	O
at	O
regulatory	O
regions	O
and	O
transcription	O
accuracy.	O

Cell-ECM	O
adhesion	O
transmits	O
mechanical	O
forces	O
bi-directionally	O
between	O
the	O
cellular	O
microenvironment	O
and	O
the	O
cytoskeleton,	O
with	O
broad	O
implications	O
in	O
stem	B
cell	I
differentiation	O
and	O
cancer	O
progression2,3,4.	O

Tumors	O
modeled	O
using	O
the	O
cancer	O
stem	O
cell	O
model	O
have	O
been	O
found	O
to	O
more	O
accurately	O
represent	O
the	O
heterogeneity	O
and	O
invasiveness	O
of	O
human	O
cancer	O
when	O
compared	O
to	O
tumors	O
without	O
the	O
cancer	B
stem	I
cell	I
hierarchy	O
(52,	O
53).	O

Besides	O
blocking	O
apoptosis,	O
IL-6	O
promotes	O
HCC	O
progression	O
by	O
upregulating	O
osteopontin	O
(OPN),	O
a	O
secretory	O
extracellular	O
matrix	O
protein	O
involved	O
in	O
stem	B
cell	I
maintenance	O
and	O
metastasis	O
[129]..	O

Screening	O
for	O
genes	O
essential	O
for	O
mouse	B
embryonic	I
stem	I
cell	I
self-renewal	O
using	O
a	O
subtractive	O
RNA	O
interference	O
library.	O

POU5F1	O
(POU	O
class	O
5	O
homeobox	O
1	O
gene)	O
that	O
is	O
important	O
for	O
stem	B
cell	I
function..	O

Three-dimensional	O
flow	O
perfusion	O
culture	O
system	O
for	O
stem	B
cell	I
proliferation	O
inside	O
the	O
critical-size	O
beta-tricalcium	O
phosphate	O
scaffold.	O

The	O
role	O
of	O
cytotoxic	O
therapy	O
with	O
hematopoietic	B
stem	I
cell	I
transplantation	O
in	O
the	O
treatment	O
of	O
adult	O
acute	O
lymphoblastic	O
leukemia:	O
update	O
of	O
the	O
2006	O
evidence-based	O
review.	O

The	O
role	O
of	O
collagen	O
in	O
cardiomyogenesis	O
keeps	O
on	O
unfolding	O
with	O
the	O
current	O
attention	O
it	O
gets	O
from	O
researchers,	O
and	O
it	O
remains	O
one	O
of	O
the	O
most	O
studied	O
biomaterials	O
concerned	O
with	O
stem	B
cell	I
differentiation..	O

The	O
use	O
of	O
synthetic	O
biomaterials	O
in	O
cardiomyogenesis	O
was	O
prompted	O
because	O
of	O
the	O
need	O
to	O
develop	O
polymers	O
that	O
are	O
easy	O
to	O
fabricate	O
and	O
manipulate,	O
thus	O
enabling	O
the	O
production	O
of	O
biomaterials	O
for	O
specific	B
stem	I
cell	I
response	O
[9].	O

Other	O
studies	O
have	O
gone	O
on	O
to	O
demonstrate	O
that	O
embedding	O
carbon	O
nanotubes	O
in	O
mouse	O
embryoid	O
bodies	O
to	O
control	O
mechanical	O
and	O
electrical	O
activity	O
in	O
stem	B
cell	I
niches	O
led	O
to	O
cardiac	O
differentiation	O
and	O
beating	O
activity	O
[154].	O

However,	O
the	O
study	O
did	O
not	O
look	O
into	O
the	O
effects	O
of	O
structural	O
parameters	O
like	O
the	O
line	O
width	O
of	O
the	O
construct,	O
the	O
number	O
of	O
required	O
cells	O
and	O
ratio	O
of	O
cells,	O
and	O
the	O
in	O
vitro	O
conditioning	O
of	O
the	O
prevascularized	B
stem	I
cell	I
patch..	O

A	O
major	O
limitation	O
to	O
the	O
therapeutic	O
effect	O
of	O
stem	B
cell	I
transplantation	O
is	O
the	O
prevalence	O
of	O
low	O
retention	O
and	O
engraftment	O
rates	O
[113].	O

Decellularized	O
extracellular	O
matrix	O
as	O
an	O
in	O
vitro	O
model	O
to	O
study	O
the	O
comprehensive	O
roles	O
of	O
the	O
ECM	O
in	O
stem	B
cell	I
differentiation.	O

The	O
intestinal	O
epithelium	O
represents	O
an	O
exquisite	O
model	O
for	O
the	O
study	O
of	O
stem	B
cell	I
biology	O
especially	O
for	O
investigating	O
the	O
relationship	O
between	O
inflammatory	O
disorders	O
and	O
cell	O
proliferation	O
[1].	O

Epithelial	O
damage	O
also	O
induces	O
a	O
localized	O
repair	O
response	O
characterized	O
by	O
enhancing	O
division	O
of	O
stem	B
cell	I
at	O
the	O
base	O
of	O
crypts	O
to	O
replace	O
the	O
damaged	O
epithelial	O
cells	O
[1].	O

In	O
order	O
to	O
elucidate	O
whether	O
the	O
increase	O
of	O
cholesterol	O
contributes	O
to	O
the	O
division	O
of	O
stem	B
cells	I
in	O
the	O
duodenum	O
epithelium,	O
cell	O
proliferative	O
marker	O
proliferating	O
cell	O
nuclear	O
antigen	O
(PCNA)	O
mRNA	O
and	O
protein	O
expression	O
were	O
detected	O
by	O
real-time	O
PCR,	O
western	O
blot	O
and	O
immunohistochemical	O
(IHC)	O
analysis,	O
respectively	O
(Figure.	O

It's	O
very	O
important	O
to	O
note	O
that	O
besides	O
the	O
similarity	O
of	O
histological	O
features	O
of	O
intestine	O
epithelia	O
between	O
avian	O
and	O
mammals,	O
cell	O
proliferation	O
mainly	O
occurs	O
in	O
the	O
stem	B
cell	I
zone	O
located	O
in	O
the	O
intestinal	O
crypt.	O

Although	O
these	O
experiments	O
did	O
not	O
produce	O
an	O
experimental	O
model	O
of	O
osteosarcoma,	O
some	O
insights	O
into	O
the	O
role	O
of	O
β-catenin	O
in	O
mesenchymal	B
stem	I
cell	I
differentiation	O
may	O
be	O
inferred.	O

Current	O
descriptions	O
of	O
mesenchymal	B
stem	I
cell	I
do	O
not	O
describe	O
intermediate	O
stages	O
of	O
differentiation	O
in	O
which	O
cells	O
have	O
become	O
committed	O
to	O
a	O
restricted	O
set	O
of	O
final	O
lineages.	O

Expression	O
of	O
the	O
chemokine	O
receptor	O
CXCR2,	O
and	O
the	B
stem	I
cell	I
factor	O
(SCF)	O
receptor	O
c-Kit,	O
markers	O
of	O
neutrophil	O
maturity	O
and	O
immaturity	O
respectively27,	O
identified	O
two	O
distinct	O
populations	O
of	O
Ly-6G+	O
cells	O
(Fig.	O

Musashi	O
proteins	O
also	O
participate	O
in	O
stem	B
cell	I
maintenance	O
by	O
suppressing	O
the	O
translation	O
of	O
mRNAs	O
that	O
encode	O
proteins	O
involved	O
in	O
cellular	O
differentiation.	O

Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

p53	O
positively	O
regulates	O
the	O
expression	O
of	O
cancer	B
stem	I
cell	I
marker	O
CD133	O
in	O
HCT116	O
colon	O
cancer	O
cells.	O

In	O
this	O
light,	O
the	O
contribution	O
of	O
resident	B
stem	I
cell	I
populations	O
to	O
the	O
renewal	O
of	O
liver	O
parenchyma	O
remained	O
an	O
open	O
question,	O
and	O
controversial	O
evidence	O
is	O
present	O
in	O
the	O
literature	O
[3,9,12].	O

In	O
summary,	O
findings	O
obtained	O
in	O
rodents	O
suggested	O
that	O
a	O
significant	O
role	O
for	O
stem	B
cell	I
populations	O
in	O
liver	O
physiological	O
renewal	O
could	O
be	O
excluded;	O
however,	O
severe	O
damage	O
and	O
deterioration	O
of	O
mature	O
cell	O
function	O
are	O
compensated	O
by	O
the	O
activation	O
of	O
stem/progenitor	O
cell	O
niche	O
within	O
the	O
biliary	O
tree..	O

Accordingly,	O
the	O
activation	O
of	O
stem	B
cell	I
populations	O
has	O
been	O
described	O
in	O
all	O
human	O
liver	O
and	O
biliary	O
pathologies,	O
and	O
has	O
a	O
critical	O
role	O
in	O
fibrogenesis,	O
progression	O
to	O
cirrhosis,	O
clinical	O
manifestations,	O
and	O
prognosis	O
[1,23]..	O

HpSCs	O
express	O
the	O
stem	B
cell	I
marker	O
Sox9	O
(purple	O
arrows)	O
and	O
are	O
surrounded	O
by	O
α-Smooth	O
Muscle	O
Actin	O
(αSMA)+	O
myofibroblast-like	O
cells	O
(red	O
arrows).	O

In	O
PBGs,	O
BTSCs	O
can	O
be	O
identified	O
by	O
the	O
positivity	O
to	O
stem	B
cell	I
markers,	O
such	O
as	O
Sox9	O
and	O
EpCAM.	O

In	O
addition	O
to	O
the	O
expression	O
of	O
stem	B
cell	I
markers	O
observed	O
in	O
situ,	O
the	O
stemness	O
of	O
BTSCs	O
has	O
been	O
also	O
demonstrated	O
in	O
vitro.	O

Moreover,	O
PBGs	O
within	O
bile	O
ducts	O
in	O
samples	O
obtained	O
from	O
patients	O
affected	O
by	O
hepatolithiasis	O
were	O
characterized	O
by	O
increased	O
expression	O
of	O
Sox9	O
and	O
EpCAM,	O
along	O
with	O
stem	B
cell	I
markers	O
CD44s	O
and	O
CXCR4,	O
compared	O
to	O
normal	O
ducts	O
[74]..	O

Neoplastic	O
transformation	O
of	O
peribiliary	B
stem	I
cell	I
niche	O
in	O
cholangiocarcinoma	O
arisen	O
in	O
primary	O
sclerosing	O
cholangitis.	O

Thus,	O
the	O
treatment	O
of	O
patients	O
with	O
APDS	O
has	O
varied	O
considerably	O
from	O
simple	O
observation	O
to	O
haematopoietic	B
stem	I
cell	I
transplant	O
(HSCT)	O
in	O
childhood	O
(4,	O
5).	O

To	O
effectively	O
utilize	O
these	O
cells,	O
novel	O
differentiation	O
stage	O
and	O
lineage	O
specific	B
stem	I
cell	I
markers	O
are	O
required.	O

We	O
analyzed	O
N-glycan	O
profiles	O
of	O
all	O
the	O
biological	O
materials	O
that	O
were	O
in	O
contact	O
with	O
the	O
stem	B
cells	I
and	O
could	O
potentially	O
contaminate	O
the	O
samples	O
with	O
glycoproteins,	O
including	O
hEF	O
and	O
mEF	O
feeder	O
cells,	O
cell	O
culture	O
media,	O
and	O
culture	O
media	O
supplements.	O

Human	O
embryonic	O
stem	O
cell	O
lines	O
have	O
previously	O
been	O
demonstrated	O
to	O
have	O
a	O
common	B
genetic	I
stem	I
cell	I
signature	O
that	O
can	O
be	O
identified	O
using	O
gene	O
expression	O
profiling	O
techniques	O
[41-44].	O

For	O
example,	O
we	O
have	O
previously	O
shown	O
that	O
minor	O
cell	O
culture	O
reagents	O
may	O
cause	O
glycan	O
contamination	O
of	O
stem	B
cells	I
[21]..	O

This	O
straightforward	O
method	O
could	O
be	O
widely	O
applicable	O
to	O
analysis	O
and	O
monitoring	O
of	O
stem	B
cell	I
lines.	O

Gene	O
expression	O
in	O
human	B
embryonic	I
stem	I
cell	I
lines:	O
unique	O
molecular	O
signature.	O

Cell	O
surface	O
sialylation	O
and	O
fucosylation	O
are	O
regulated	O
by	O
the	O
cell	O
recognition	O
molecule	O
L1	O
via	O
PLCγ	O
and	O
cooperate	O
to	O
modulate	B
embryonic	I
stem	I
cell	I
survival	O
and	O
proliferation.	O

TGFβ	O
also	O
participates	O
in	O
the	O
regulation	O
of	O
temporal	O
transition	O
between	O
early	O
and	O
late	O
phases	O
of	O
neurogenesis	O
and	O
the	O
regulation	O
of	O
the	O
stem	B
cell	I
potency	O
(Dias	O
et	O
al.,	O
2014).	O

As	O
the	O
brain	O
ages,	O
TGFβ	O
has	O
important	O
roles	O
both	O
in	O
neuronal	O
survival	O
and	O
in	O
the	O
promotion	O
of	O
stem	B
cell	I
quiescence	O
(Kandasamy	O
et	O
al.,	O
2014).	O

Vascular-derived	O
TGF-beta	O
increases	O
in	O
the	O
stem	B
cell	I
niche	O
and	O
perturbs	O
neurogenesis	O
during	O
aging	O
and	O
following	O
irradiation	O
in	O
the	O
adult	O
mouse	O
brain.	O

Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

The	O
water	O
supply	O
system	O
as	O
a	O
potential	O
source	O
of	O
fungal	O
infection	O
in	O
paediatric	B
haematopoietic	I
stem	I
cell	I
units.	O

Exploring	O
biological	O
processes	O
involved	O
in	O
embryonic	B
stem	I
cell	I
differentiation	O
by	O
analyzing	O
proteomic	O
data.	O

Despite	O
the	O
extensive	O
involvement	O
of	O
chemokines	O
in	O
many	O
pathological	O
conditions,	O
except	O
for	O
selective	O
CCR5	O
antagonists	O
for	O
HIV	O
and	O
a	O
selective	O
CXCR4	O
antagonist	O
for	O
stem	B
cell	I
mobilization,	O
obtaining	O
new	O
therapeutics	O
related	O
to	O
targeting	O
single	O
chemokine	O
receptors	O
and	O
chemokines	O
against	O
autoimmunity,	O
therapies	O
for	O
inflammation	O
and	O
cancer	O
has	O
been	O
unsuccessful	O
(5,	O
9).	O

Quantifying	O
the	O
Landscape	O
for	O
Development	O
and	O
Cancer	O
from	O
a	O
Core	O
Cancer	B
Stem	I
Cell	I
Circuit.	O

The	O
potential	O
landscape	O
of	O
genetic	O
circuits	O
imposes	O
the	O
arrow	O
of	O
time	O
in	O
stem	B
cell	I
differentiation.	O

Mesenchymal	B
Stem	I
Cell	I
Transplantation	O
Reduces	O
Glial	O
Cyst	O
and	O
Improves	O
Functional	O
Outcome	O
After	O
Spinal	O
Cord	O
Compression.	O

Mesenchymal	B
stem	I
cell	I
graft	O
improves	O
recovery	O
after	O
spinal	O
cord	O
injury	O
in	O
adult	O
rats	O
through	O
neurotrophic	O
and	O
pro-angiogenic	O
actions.	O

Time-dependent	O
changes	O
in	O
the	O
microenvironment	O
of	O
injured	O
spinal	O
cord	O
affects	O
the	O
therapeutic	O
potential	O
of	O
neural	B
stem	I
cell	I
transplantation	O
for	O
spinal	O
cord	O
injury.	O

(A)	O
Shown	O
are	O
the	O
fraction	O
of	O
modules	O
from	O
all	O
six	O
cancer	O
data	O
sets	O
that	O
are	O
enriched	O
for	O
curated	O
gene	O
sets	O
from	O
Gene	O
ontology	O
(GO),	O
KEGG,	O
REACTOME,	O
NCI	O
cancer	O
pathways,	O
and	O
DNase	O
I	O
motif	O
accessibility	O
networks	O
for	O
six	O
cancer	O
cell	O
lines	O
and	O
the	O
H1	B
embryonic	I
stem	I
cell	I
line,	O
respectively.	O

We	O
next	O
focused	O
on	O
the	O
enrichment	O
of	O
consensus	O
modules	O
for	O
motif	O
instances	O
of	O
sequence-specific	O
TFs	O
in	O
cell	O
line–specific	O
DNase	O
I	O
footprints14,22	O
from	O
six	O
cancer	O
cell	O
lines	O
and	O
the	O
H1	B
embryonic	I
stem	I
cell	I
line	O
(Supplementary	O
Figs.	O

Finally,	O
we	O
investigated	O
the	O
consensus	O
modules	O
for	O
enrichments	O
of	O
TF	O
target	O
genes	O
from	O
the	O
H1	B
embryonic	I
stem	I
cell	I
line	O
DNase	O
I	O
accessibility	O
network	O
(Supplementary	O
Fig.	O

It	O
has	O
been	O
reported	O
that	O
Sirtuin	O
6	O
(Sirt6),	O
a	O
member	O
of	O
the	O
sirtuin	O
family	O
of	O
NAD+-dependent	O
protein	O
deacetylases,	O
is	O
involved	O
in	O
embryonic	B
stem	I
cell	I
differentiation.	O

We	O
hypothesized	O
that	O
another	O
nuclear	O
member	O
Sirt6	O
may	O
also	O
involve	O
in	O
the	O
stem	B
cell	I
regulation.	O

Mammalian	O
leucine-rich	O
repeat-containing	O
G	O
protein-coupled	O
receptors	O
(LGRs)	O
have	O
emerged	O
as	O
central	O
players	O
in	O
stem	B
cell	I
biology	O
in	O
the	O
recent	O
years.	O

Our	O
results	O
demonstrate	O
a	O
novel,	O
local	O
role	O
for	O
enteroendocrine	O
cells	O
as	O
paracrine	O
regulators	O
of	O
stem	B
cell	I
proliferation.	O

Forced	O
expression	O
of	O
various	O
combinations	O
of	O
members	O
of	O
two	O
of	O
these	O
gene	O
families	O
with	O
POU5F1	O
and	O
SOX2	O
have	O
all	O
led	O
to	O
pluripotent	B
stem	I
cell	I
induction	O
from	O
human	O
somatic	O
cells	O
(46,47)..	O

Neural	O
crest-derived	O
cells	O
with	O
stem	B
cell	I
features	O
can	O
be	O
traced	O
back	O
to	O
multiple	O
lineages	O
in	O
the	O
adult	O
skin.	O

miR-23b	O
Bone	B
marrow	I
mesenchymal	I
stem	I
cells	I
Breast	O
cancer	O
cells	O
MARCKS	O
Decreases	O
MARCKS	O
expression	O
and	O
promotes	O
breast	O
cancer	O
cell	O
dormancy	O
in	O
the	O
metastatic	O
niche.	O

Targeting	O
exosomes	O
from	O
preadipocytes	O
inhibits	O
preadipocyte	O
to	O
cancer	B
stem	I
cell	I
signaling	O
in	O
early-stage	O
breast	O
cancer.	O

Lamin	O
A/C	O
Acts	O
as	O
an	O
Essential	O
Factor	O
in	O
Mesenchymal	B
Stem	I
Cell	I
Differentiation	O
Through	O
the	O
Regulation	O
of	O
the	O
Dynamics	O
of	O
the	O
Wnt/beta-Catenin	O
Pathway.	O

piRNA-823	O
is	O
involved	O
in	O
cancer	B
stem	I
cell	I
regulation	O
through	O
altering	O
dna	O
methylation	O
in	O
association	O
with	O
luminal	O
breast	O
cancer.	O

WNT-5A	O
belongs	O
to	O
the	O
WNT	O
family	O
of	O
secreted	O
lipoglycoproteins	O
which	O
is	O
composed	O
of	O
19	O
WNTs	O
in	O
mammals	O
and	O
is	O
crucial	O
for	O
stem	B
cell	I
proliferation	O
and	O
differentiation	O
during	O
embryonic	O
development	O
[1-3].	O

Although	O
NK	O
cell	O
education	O
in-vitro	O
and	O
the	O
impact	O
of	O
stem	B
cell	I
sources	O
need	O
to	O
be	O
evaluated	O
further,	O
these	O
results	O
demonstrate	O
that	O
CD56bright	O
NK	O
cells	O
are	O
able	O
to	O
acquire	O
KIR	O
expression	O
to	O
some	O
extent..	O

Background:	O
Autologous	O
Hematopoietic	O
Stem	B
Cell	I
Transplantation	O
(AHSCT)	O
is	O
the	O
only	O
treatment	O
so	O
far	O
which	O
improved	O
mortality	O
in	O
severe	O
Systemic	O
Sclerosis	O
(SSc)	O
(level	O
I	O
EBMT-evidence).	O

Lentiviral	O
Haematopoietic	B
Stem	I
Cell	I
Therapy	O
in	O
Patients	O
With	O
Wiskott	O
Aldrich	O
Syndrome	O
(WAS):	O
London	O
Experience.	O

Donor	O
Characteristics	O
Predict	O
The	O
Success	O
of	O
Allogeneic	O
Haematopoietic	B
Stem	I
Cell	I
Transplantation	O
in	O
Thalassaemia	O
Major:	O
A	O
Single	O
Centre	O
Analysis	O
of	O
250	O
Patients.	O

Background:	O
The	O
outcome	O
of	O
haematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
in	O
thalassaemia	O
major	O
has	O
been	O
linked	O
to	O
comorbidity	O
in	O
the	O
recipient	O
and	O
published	O
risk	O
groups	O
like	O
Lucarelli	O
and	O
Vellore	O
high-risk	O
help	O
modify	O
HSCT	O
algorithms.	O

National	O
Health	O
Service	O
England	O
(NHSE)	O
Program	O
for	O
Selection	O
of	O
Adult	O
Primary	O
Immunodeficiency	O
Patients	O
For	O
Allogeneic	O
Haematopoietic	B
Stem	I
Cell	I
Transplantation.	O

Most	O
patients	O
(n	O
=	O
67)	O
received	O
conditioning	O
chemotherapy	O
(81%)	O
prior	O
to	O
stem	B
cell	I
infusion.	O

Our	O
study	O
aimed	O
to	O
examine	O
the	O
conditional	O
survival	O
and	O
standardized	O
mortality	O
ratio	O
(SMR)	O
among	O
patients	O
with	O
relapsed	O
de	O
novo	O
diffuse	O
large	O
B	O
cell	O
(DLBCL)	O
successfully	O
undergoing	O
an	O
autologous	B
stem	I
cell	I
transplant	O
(ASCT)	O
after	O
first	O
relapse..	O

Background:	O
Patients	O
with	O
Hodgkin	O
Lymphoma	O
(HL)	O
who	O
relapse/progress	O
after	O
primary	O
therapy	O
can	O
be	O
successfully	O
treated	O
with	O
salvage	O
chemotherapy	O
and	O
consolidation	O
with	O
an	O
autologous	B
stem	I
cell	I
transplant	O
(ASCT).	O

Primary	O
endpoint	O
was	O
sCR	O
post	O
consolidation	O
(Day	O
100	O
post	O
autologous	B
stem	I
cell	I
transplant),	O
per	O
International	O
Myeloma	O
Working	O
Group	O
(IMWG)	O
criteria.	O

Analysis	O
of	O
clinical	O
practice	O
in	O
stem	B
cell	I
collection	O
revealed	O
increasing	O
use	O
of	O
cylophosphamide-based	O
mobilisation	O
from	O
(1)	O
31%	O
to	O
(5)	O
65%;	O
the	O
use	O
of	O
single	O
agent	O
G-CSF	O
declined	O
from	O
(1)	O
69%	O
to	O
(5)	O
28%.	O

The	O
median	O
number	O
of	O
stem	B
cells	I
collected	O
(CD34+cells	O
×	O
10^6/kg)	O
has	O
gradually	O
increased	O
from	O
(1)	O
5.1	O
to	O
(5)	O
6.5,	O
though	O
the	O
median	O
cell	O
dose	O
infused	O
is	O
essentially	O
unchanged:	O
(1)	O
3.6,	O
(2)	O
4.1,	O
(3)	O
4.0,	O
(4)	O
3.8,	O
and	O
(5)	O
3.8.	O

Background:	O
The	O
EBMT	O
risk	O
score	O
uses	O
5	O
factors	O
to	O
estimate	O
risks	O
associated	O
with	O
haematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
in	O
patients.	O

Gene	O
Ontology	O
analysis	O
to	O
categorize	O
overrepresented	O
genes	O
has	O
led	O
to	O
the	O
identification	O
of	O
themes	O
which	O
may	O
prove	O
essential	O
to	O
stem	B
cell	I
identity,	O
including	O
chromatin	O
structure,	O
nuclear	O
architecture,	O
cell	O
cycle	O
control,	O
DNA	O
repair,	O
and	O
apoptosis.	O

Embryonic	O
Stem	O
Cells	O
(ESCs)	O
are	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
the	O
pre-implantation	O
embryo	O
and	O
are	O
characterized	O
by	O
their	B
unlimited	I
capacity	O
for	O
self-renewal	O
and	O
their	O
ability	O
to	O
contribute	O
to	O
all	O
cell	O
lineages.	O

Furthermore,	O
several	O
signaling	O
pathways	O
including	O
LIF/JAK/STAT,	O
BMP,	O
WNT,	O
PI3K,	O
MAPK/ERK,	O
TGFβ	O
and	O
Notch	O
[13],	O
[14],	O
[15],	O
[16]	O
have	O
been	O
shown	O
to	O
modulate	B
stem	I
cell	I
function.	O

We	O
hypothesized	O
that	O
by	O
using	O
Oct4	O
as	O
a	O
marker	O
gene	O
for	O
self-renewal,	O
pluripotency,	O
and	O
early	O
lineage	O
commitment,	O
this	O
analysis	O
would	O
lead	O
to	O
the	O
identification	O
of	O
1)	O
Genes	O
that	O
are	O
central	O
to	O
stem	B
cell	I
identity;	O
2)	O
Oct4	O
target	O
genes;	O
and	O
3)	O
Genes	O
that	O
modulate	O
Oct4	O
function.	O

The	O
validity	O
of	O
this	O
method	O
for	O
the	O
identification	O
of	O
genes	O
related	O
to	O
stem	B
cell	I
identity	O
is	O
assured	O
by	O
the	O
presence	O
of	O
genes	O
which	O
have	O
previously	O
defined	O
roles	O
in	O
ESCs	O
such	O
as	O
Utf1,	O
Fgf4,	O
Nanog,	O
and	O
Sox2	O
which	O
were	O
correlated	O
to	O
Oct4	O
in	O
100%,	O
99%,	O
97%	O
and	O
49%	O
of	O
the	O
trials	O
respectively.	O

Therefore	O
it	O
is	O
predicted	O
that	O
alterations	O
in	O
the	O
balance	O
of	O
PcG	O
members	O
would	O
have	O
profound	O
implications	O
for	O
maintenance	O
of	O
the	O
stem	B
cell	I
state.	O

Carefully	O
regulated	O
execution	O
of	O
cell	O
cycle	O
progression	O
is	O
accomplished	O
in	O
stem	B
cells	I
by	O
a	O
unique	O
constellation	O
of	O
genes	O
which	O
impact	O
self-renewal	O
and	O
lineage	O
commitment.	O

An	O
imbalance	O
in	O
either	O
of	O
these	O
processes,	O
possibly	O
emanating	O
from	O
deregulated	O
signaling	O
from	O
the	O
stem	B
cell	I
niche	O
or	O
mutations	O
in	O
the	O
key	O
regulators	O
would	O
lead	O
to	O
unrestrained	O
cellular	O
proliferation..	O

Analysis	O
of	O
the	O
Oct4	O
gene	O
list	O
revealed	O
an	O
important	O
emerging	O
theme;	O
mechanisms	O
to	O
actively	O
repress	O
apoptotic	O
pathways	O
are	O
involved	O
in	O
maintaining	O
the	O
stem	B
cell	I
state.	O

The	O
validation	O
of	O
Trp53,	O
Tdrd7,	O
Brca1,	O
and	O
Parp1	O
as	O
direct	O
Oct4	O
targets	O
strengthens	O
the	O
importance	O
of	O
this	O
group	O
of	O
genes	O
in	O
stem	B
cell	I
function..	O

The	O
high	O
frequency	O
at	O
which	O
apoptotic	O
genes	O
were	O
negatively	O
correlated	O
to	O
Oct4	O
and	O
anti-apoptotic	O
genes	O
were	O
positively	O
correlated	O
to	O
Oct4	O
implies	O
that	O
‘anti-apoptosis’	O
is	O
an	O
important	O
theme	O
for	O
maintaining	O
the	O
stem	B
cell	I
state.	O

While	O
the	O
stem	B
cell	I
state	O
is	O
guarded	O
by	O
highly	O
dynamic,	O
complex,	O
and	O
interrelated	O
mechanisms	O
which	O
impact	O
the	O
repertoire,	O
location,	O
and	O
functional	O
state	O
of	O
expressed	O
genes,	O
lineage	O
commitment	O
can	O
be	O
described	O
as	O
a	O
process	O
whereby	O
the	O
unlimited	O
ability	O
for	O
self-renewal	O
and	O
potency	O
are	O
gradually	O
restricted	O
as	O
a	O
cell	O
progresses	O
from	O
one	O
steady	O
state	O
of	O
gene	O
expression	O
to	O
the	O
next.	O

Importantly,	O
our	O
experiments	O
have	O
defined	O
how	O
Oct4,	O
as	O
the	O
master	O
regulator	O
of	O
embryonic	B
stem	I
cell	I
function,	O
plays	O
a	O
central	O
role	O
in	O
regulating	O
key	O
genes	O
in	O
pivotal	O
pathways	O
involved	O
in	O
controlling	O
pluripotency,	O
self-renewal	O
and	O
differentiation..	O

Maturation	O
arrest	O
of	O
stem	B
cell	I
differentiation	O
is	O
a	O
common	O
pathway	O
for	O
the	O
cellular	O
origin	O
of	O
teratocarcinomas	O
and	O
epithelial	O
cancers.	O

The	B
stem	I
cell	I
factor	O
receptor	O
c-Kit	O
is	O
an	O
active	O
participant	O
in	O
many	O
vital	O
functions	O
in	O
humans	O
and	O
animals,	O
such	O
as	O
homeostasis,	O
cell	O
maintenance,	O
differentiation,	O
and	O
melanogenesis,	O
in	O
a	O
wide	O
variety	O
of	O
cells	O
(180).	O

Cancer	B
stem	I
cells	I
are	O
also	O
characterized	O
by	O
the	O
presence	O
of	O
multidrug-resistant	O
(MDR)	O
adenosine	O
triphosphate-binding	O
cassette	O
(ABC)	O
transporter	O
efflux	O
pumps,	O
influencing	O
chemotherapy	O
resistance	O
in	O
cancer	O
due	O
to	O
their	O
capacity	O
to	O
export	O
a	O
wide	O
variety	O
of	O
cell	O
substances	O
(276).	O

Effect	O
of	O
melatonin	O
in	O
epithelial	O
mesenchymal	O
transition	O
markers	O
and	O
invasive	O
properties	O
of	O
breast	B
cancer	I
stem	I
cells	I
of	O
canine	O
and	O
human	O
cell	O
lines.	O

Nectin-4	O
is	O
a	O
breast	B
cancer	I
stem	I
cell	I
marker	O
that	O
induces	O
WNT/β-catenin	O
signaling	O
via	O
Pi3k/Akt	O
axis.	O

hMSC	O
cells	O
were	O
cultured	O
in	O
mesenchymal	B
stem	I
cell	I
growth	O
medium	O
(Cambrex/Clonetics)	O
according	O
to	O
the	O
manufacturer's	O
directions.	O

Control	O
of	O
embryonic	B
stem	I
cell	I
identity	O
by	O
BRD4-dependent	O
transcriptional	O
elongation	O
of	O
super-enhancer-associated	O
pluripotency	O
genes.	O

Furthermore,	O
drugs	O
that	O
perturb	O
global	O
DNA	O
demethylation	O
and/or	O
normal	O
histone	O
modifications	O
can	O
potentially	O
harm	O
the	O
function	O
of	O
adult	B
stem	I
cell	I
populations	O
in	O
cancer	O
patients	O
[9].	O

These	O
proteins	O
are	O
involved	O
in	O
stem	B
cell	I
maintenance	O
and	O
can	O
slow	O
the	O
aging	O
process.	O

et	O
al.Treatment	O
of	O
adenovirus	O
disease	O
in	O
stem	B
cell	I
transplant	O
recipients	O
with	O
cidofovir.	O

Quantification	O
of	O
adenovirus	O
DNA	O
in	O
plasma	O
for	O
management	O
of	O
infection	O
in	O
stem	B
cell	I
graft	O
recipients.	O

Adenovirus	O
infections	O
in	O
stem	B
cell	I
transplant	O
recipients:	O
recent	O
developments	O
in	O
understanding	O
of	O
pathogenesis,	O
diagnosis	O
and	O
management.	O

et	O
al.Frequent	O
detection	O
of	O
respiratory	O
viruses	O
in	O
adult	O
recipients	O
of	O
stem	B
cell	I
transplants	O
with	O
the	O
use	O
of	O
real-time	O
polymerase	O
chain	O
reaction,	O
compared	O
with	O
viral	O
culture.	O

PTTG1	O
oncogene	O
promotes	O
tumor	O
malignancy	O
via	O
epithelial	O
to	O
mesenchymal	O
transition	O
and	O
expansion	O
of	O
cancer	B
stem	I
cell	I
population.	O

Mesenchymal	B
stem	I
cell	I
attenuates	O
neutrophil‐predominant	O
inflammation	O
and	O
acute	O
lung	O
injury	O
in	O
an	O
in	O
vivo	O
rat	O
model	O
of	O
ventilator‐induced	O
lung	O
injury.	O

Opposing	O
effect	O
of	O
mesenchymal	B
stem	I
cells	I
on	O
Th1	O
and	O
Th17	O
cell	O
polarization	O
according	O
to	O
the	O
state	O
of	O
CD4+	O
T	O
cell	O
activation.	O

Overall,	O
the	O
tests	O
are	O
based	O
on	O
stem	B
cell	I
and	O
omics	O
technologies	O
and	O
have	O
a	O
high	O
predictive	O
potency	O
for	O
discriminating	O
between	O
general	O
and	O
developmental	O
toxicity.	O

The	O
biological	O
and	O
ethical	O
basis	O
of	O
the	O
use	O
of	O
human	B
embryonic	I
stem	I
cells	I
for	O
in	O
vitro	O
test	O
systems	O
or	O
cell	O
therapy.	O

Genomic	O
instability	O
of	O
human	B
embryonic	I
stem	I
cell	I
lines	O
using	O
different	O
passaging	O
culture	O
methods.	O

Genomic	O
instability	O
of	O
human	B
embryonic	I
stem	I
cell	I
lines	O
using	O
different	O
passaging	O
culture	O
methods.	O

Human	B
embryonic	I
stem	I
cells	I
exhibit	O
genomic	O
instability	O
that	O
can	O
be	O
related	O
to	O
culture	O
duration	O
or	O
to	O
the	O
passaging	O
methods	O
used	O
for	O
cell	O
dissociation.	O

Human	B
embryonic	I
stem	I
cell	I
lines	O
H1	O
and	O
H9	O
derived	O
from	O
46,XY	O
and	O
46,XX	O
embryos,	O
respectively	O
(Wicell	O
Research	O
Institute,	O
http://www.wicell.org)	O
were	O
maintained	O
into	O
undifferentiated	O
state	O
by	O
continuous	O
culture	O
on	O
a	O
feeder	O
layer	O
of	O
mitomycin	O
C	O
inactivated	O
mouse	O
embryonic	O
fibroblasts	O
in	O
DMEM/F12	O
supplemented	O
with	O
20%	O
Knock	O
Out	O
Serum	O
Replacer,	O
1	O
mM	O
L-glutamine,	O
0.5%	O
penicillin/streptomycin,	O
100	O
μM	O
2-mercaptoethanol	O
and	O
10	O
ng/ml	O
basic	O
FGF	O
(all	O
of	O
them	O
from	O
Invitrogen,	O
Saint-Aubin,	O
France).	O

High-resolution	O
DNA	O
analysis	O
of	O
human	B
embryonic	I
stem	I
cell	I
lines	O
reveals	O
culture-induced	O
copy	O
number	O
changes	O
and	O
loss	O
of	O
heterozygosity.	O

Preventing	O
aging	O
with	O
stem	B
cell	I
rejuvenation:	O
Feasible	O
or	O
infeasible?	O
World	O
J.	O

In	O
addition,	O
the	O
liver	O
or	O
other	O
non-intestinal	O
sources	O
of	O
exogenous	O
ketone	O
bodies	O
increase	O
the	O
stem	B
cell	I
numbers	O
and	O
thereby	O
upregulate	O
regenerative	O
activities	O
after	O
injury.	O

Sirtuin-2	O
activity	O
is	O
required	O
for	O
glioma	B
stem	I
cell	I
proliferation	O
arrest	O
but	O
not	O
necrosis	O
induced	O
by	O
resveratrol.	O

However,	O
there	O
is	O
a	O
clear	O
requirement	O
for	O
the	O
combined	O
effects	O
of:	O
(1)	O
homozygous	O
loss	O
of	O
neurofibromin	O
function	O
in	O
tumor	O
progenitors,	O
(2)	O
heterozygous	O
loss	O
of	O
neurofibromin	O
function	O
in	O
stromal	O
cells	O
of	O
the	O
microenvironment,	O
and	O
(3)	O
other	O
factors	O
specific	O
to	O
the	O
most	O
commonly	O
affected	O
brain	O
regions,	O
such	O
as	O
differences	O
in	O
stem	B
cell	I
populations	O
or	O
growth	O
regulatory/differentiation	O
pathways.	O

Key	O
to	O
CXCR4	O
antagonism	O
is	O
the	O
blockade	O
of	O
critical	O
tumor-stromal	O
interactions	O
that	O
occur	O
within	O
the	O
specialized	B
perivascular	I
stem	I
cell	I
niche	O
(PVN)	O
(Rao	O
et	O
al.,	O
2012).	O

Upregulation	O
of	O
genes	O
involved	O
in	O
the	O
EMT	O
suggests	O
a	O
phenotype	O
of	O
cancer	B
stem	I
cell	I
activation,	O
tumor	O
invasiveness,	O
increased	O
metastasis,	O
and	O
increased	O
drug	O
resistance	O
(Hennessy	O
et	O
al	O
2009,	O
Singh	O
and	O
Settleman	O
2010).	O

A	O
genome-wide	O
RNAi	O
screen	O
reveals	O
determinants	O
of	O
human	B
embryonic	I
stem	I
cell	I
identity.	O

revealed	O
that	O
the	O
identified	O
specific	O
lncRNAs	O
in	O
spermatogonial	B
stem	I
cells	I
play	O
important	O
roles	O
in	O
maintaining	O
these	O
cells,	O
and	O
some	O
of	O
them	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
differentiation	O
of	O
specific	O
stages	O
of	O
testicular	O
spermatogenesis	O
and	O
germ	O
cell	O
meiosis	O
[80].	O

LncRNA	O
AK015322	O
promotes	O
proliferation	O
of	O
spermatogonial	B
stem	I
cell	I
C18-4	O
by	O
acting	O
as	O
a	O
decoy	O
for	O
microRNA-19b-3p.	O

An	O
RNAi	O
screen	O
of	O
chromatin	O
proteins	O
identifies	O
Tip60-p400	O
as	O
a	O
regulator	O
of	O
embryonic	B
stem	I
cell	I
identity.	O

Essential	O
roles	O
of	O
FoxM1	O
in	O
Ras-induced	O
liver	O
cancer	O
progression	O
and	O
in	O
cancer	O
cells	O
with	O
stem	B
cell	I
features.	O

Finally,	O
we	O
established	O
an	O
IEC-specific	O
5-FU-induced	O
mucosal	O
injury	O
model	O
to	O
investigate	O
the	O
reserve	B
stem	I
cell	I
capacity	O
of	O
long-lived	O
secretory	O
IECs	O
in	O
vivo..	O

Prostate	B
stem	I
cell	I
antigen	O
(PSCA)	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
and	O
its	O
decreased	O
expression	O
are	O
associated	O
with	O
gastric	O
cancer1.	O

Dave	O
M,	O
Mehta	O
K,	O
Luther	O
J,	O
et	O
al.,	O
Mesenchymal	B
Stem	I
Cell	I
Therapy	O
for	O
Inflammatory	O
Bowel	O
Disease:	O
A	O
Systematic	O
Review	O
and	O
Meta-analysis.	O

Mouse	B
embryonic	I
stem	I
cells	I
were	O
differentiated	O
to	O
definitive	O
endoderm,	O
the	O
progenitor	O
cell	O
of	O
intestinal	O
epithelia,	O
as	O
a	O
model	O
of	O
the	O
cell	O
of	O
origin	O
of	O
BE.	O

Results:	O
H2bΔIEC	O
mice	O
display	O
chronic	O
epithelial	O
DNA	O
damage	O
and	O
develop	O
a	O
p53-dependent	O
proliferative	O
exhaustion	O
of	O
the	O
intestinal	B
stem	I
cell	I
compartment.	O

SOX2	O
was	O
the	O
most	O
upregulated	O
TF	O
(Boumahdi	O
et	O
al.,	O
2014)	O
in	O
cancer	B
stem	I
cells	I
from	O
skin	O
squamous	O
cell	O
carcinoma	O
(SCC)	O
and	O
was	O
shown	O
to	O
control	O
self-renewal	O
(Sastre-Perona	O
et	O
al.,	O
2019)..	O

Induction	O
of	O
cells	O
with	O
cancer	B
stem	I
cell	I
properties	O
from	O
nontumorigenic	O
human	O
mammary	O
epithelial	O
cells	O
by	O
defined	O
reprogramming	O
factors.	O

Hepatic	O
oval	O
cells:	O
helping	O
redefine	O
a	O
paradigm	O
in	O
stem	B
cell	I
biology.	O

So	O
much	O
so,	O
that	O
the	O
dependence	O
of	O
HSCs	O
from	O
the	O
in	O
vivo	O
environment	O
for	O
their	O
self-renewal	O
became	O
incorporated	O
into	O
another	O
totemic	O
notion	O
of	O
stem	B
cell	I
biology,	O
the	O
concept	O
of	O
a	O
“niche”	O
[Schofield,	O
1978]..	O

The	O
ability	O
of	O
“MSCs”	O
to	O
act	O
as	O
dynamic	O
organizers	O
of	O
the	O
hematopoietic	O
microenvironment	O
[Sacchetti	O
et	O
al.,	O
2007]	O
paved	O
the	O
way	O
for	O
a	O
number	O
of	O
studies	O
that	O
redirected	O
attention	O
from	O
osteoblasts	O
and	O
endothelial	O
cells	O
of	O
sinusoids	O
(first	O
cell	O
types	O
to	O
be	O
implicated	O
as	O
“niche”	O
cells	O
in	O
bone	O
marrow,	O
reviewed	O
in	O
Bianco,	O
in	O
press)	O
to	O
“MSCs”	O
or	O
osteoprogenitors	O
as	O
providers	O
of	O
the	O
“niche”	O
effect	O
for	O
hematopoietic	B
stem	I
cells	I
[Chan	O
et	O
al.,	O
2009;	O
Mendez-Ferrer	O
et	O
al.,	O
2010;	O
Omatsu	O
et	O
al.,	O
2010;	O
Raaijmakers	O
et	O
al.,	O
2010].	O

These	O
two	O
treatments	O
similarly	O
affected	O
the	O
expression	O
of	O
stem	B
cell	I
markers	O
nestin	O
and	O
CD133,	O
and	O
multiple	O
oligodendrocyte	O
lineage	O
markers	O
2′,3′-cyclic-nucleotide	O
3′-phosphodiesterase	O
(CNPase),	O
myelin-basic	O
protein	O
(MBP),	O
oligodendrocyte	O
myelin	O
glycoprotein	O
(OMG),	O
and	O
proteolipid	O
protein	O
1	O
(plp1)	O
(Figures	O
S	O
7	O
and	O
S	O
8).	O

GBM4	O
and	O
GBM8	O
patient-derived	O
tumor	O
neurosphere	O
lines	O
were	O
cultured	O
in	O
stem	B
cell	I
medium	O
supplemented	O
with	O
FGF	O
and	O
EGF.	O

To	O
this	O
day	O
there	O
are	O
multiple	O
important	O
unanswered	O
questions	O
about	O
the	O
pituitary	O
gland	O
development	O
and	O
maintenance	O
during	O
adult	O
life,	O
in	O
particular	O
regarding	O
the	O
participation	O
of	O
embryonic	O
and	O
adult	B
stem	I
cell	I
population	O
in	O
this	O
process.	O

The	O
pluripotent	O
state	O
of	O
the	O
stem	B
cells	I
allows	O
them	O
to	O
differentiate	O
into	O
several	O
other	O
cell	O
types,	O
both	O
in	O
vivo	O
and	O
in	O
vitro.	O

A	O
combination	O
of	O
BMP4,	O
SHH,	O
FGF8,	O
and	O
FGF10	O
stimuli	O
was	O
used	O
to	O
obtain	O
hormone	O
producing	O
cells	O
in	O
monolayer	B
stem	I
cells	I
in	O
shorter	O
times	O
than	O
3D	O
cultures;	O
however,	O
this	O
approach	O
relies	O
on	O
cell	O
sorting	O
based	O
on	O
GFP	O
expression	O
coupled	O
to	O
SIX1,	O
challenging	O
the	O
process	O
to	O
adapt	O
this	O
protocol	O
into	O
obtaining	O
pituitary	O
cells	O
from	O
patients’	O
iPSCs	O
(48,	O
49)..	O

Regenerative	O
medicine,	O
mostly	O
involves	O
the	O
transplant	O
of	O
differentiated	O
stem	B
cells	I
to	O
correct	O
the	O
genetic	O
or	O
cell	O
defects	O
in	O
patients,	O
thus	O
is	O
a	O
promising	O
future	O
treatment	O
approach.	O

Organoids	O
from	O
pituitary	O
as	O
a	O
novel	O
research	O
model	O
toward	O
pituitary	B
stem	I
cell	I
exploration.	O

Induced	B
neural	I
stem	I
cell	I
grafts	O
exert	O
neuroprotection	O
through	O
an	O
interaction	O
between	O
Crry	O
and	O
Akt	O
in	O
a	O
mouse	O
model	O
of	O
closed	O
head	O
injury.	O

Growing	O
evidence	O
indicates	O
that	O
neuronal	O
replacement	O
using	O
stem	B
cell	I
transplantation	O
can	O
play	O
a	O
positive	O
role	O
in	O
the	O
treatment	O
of	O
neuronal	O
damage	O
[15,	O
16].	O

However,	O
complement-mediated	O
cytolysis	O
also	O
exerts	O
deleterious	O
effects	O
on	O
these	O
stem	B
cell	I
grafts	O
[20–22].	O

2)	O
Before	O
NK	O
cells	O
are	O
fully	O
developed,	O
there	O
is	O
always	O
a	O
mixture	O
of	O
cell	O
populations	O
with	O
stem	O
cells,	O
NKP	O
cells,	O
iNK	O
cells,	O
mature	O
NK	O
cells,	O
and	O
other	O
cell	O
types	O
that	O
we	O
are	O
unable	O
to	O
delineate	O
at	O
this	O
moment,	O
since	O
any	O
bulk	O
cell-based	O
analysis	O
may	O
neglect	O
the	O
huge	O
heterogeneity	O
between	O
cells	O
by	O
default.	O
The	O
discovery	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
and	O
the	O
subsequent	O
establishment	O
of	O
long-term	O
organotypic	O
intestinal	O
and	O
brain	O
cultures	O
derived	O
from	O
human	O
subjects	O
enabled	O
the	O
development	O
of	O
novel	O
cell	O
systems,	O
opening	O
new	O
avenues	O
for	O
expanding	O
our	O
scientific	O
knowledge	O
on	O
host-microbiome	O
interactions,	O
among	O
other	O
applications	O
[10,29].	O

Cell	B
Stem	I
Cell	I
22,	O
310–324	O
10.1016/j.stem.2018.02.011	O
[PMC	O
free	O
article]	O
[PubMed]	O
[CrossRef]	O
[Google	O
Scholar].	O

Intestinal	B
stem	I
cell	I
growth	O
and	O
differentiation	O
on	O
a	O
tubular	O
scaffold	O
with	O
evaluation	O
in	O
small	O
and	O
large	O
animals.	O

Haemophagocytic	O
lymphohistiocytosis	O
(HLH)	O
following	O
allogeneic	B
haematopoietic	I
stem	I
cell	I
transplantation	O
(HSCT)	O
—	O
time	O
to	O
reappraise	O
with	O
modern	O
diagnostic	O
and	O
treatment	O
strategies?	O
Bone	O
Marrow	O
Transplant.	O

The	O
molecular	O
profiling	O
of	O
CSCs	O
are	O
based	O
on	O
the	O
expression	O
of	O
stem	B
cell	I
markers	O
(CD34,	O
CD44,	O
CD133,	O
ALDH,	O
etc)	O
and	O
EMT	O
gene	O
drivers	O
such	O
as	O
ETV5	O
(Ets	O
Variant	O
5),	O
NOTCH1,	O
SNAI1	O
(Snail	O
family	O
zinc	O
finger	O
1),	O
TGFB1,	O
among	O
other	O
genes	O
(Chaffer	O
and	O
Weinberg,	O
2011;	O
Clevers,	O
2011).	O

Patient-derived	O
xenografts,	O
the	O
cancer	B
stem	I
cell	I
paradigm	O
and	O
cancer	O
pathobiology	O
in	O
the	O
21st	O
century.	O

High	O
dose	O
chemotherapy	O
with	O
stem	B
cell	I
rescue	O
may	O
cure	O
a	O
proportion	O
of	O
these	O
children	O
but	O
when	O
CNS	O
dissemination	O
occurs[13],	O
survival	O
is	O
uncommon.	O

High-dose	O
chemotherapy	O
with	O
autologous	B
hematopoietic	I
stem	I
cell	I
rescue	O
for	O
stage	O
4B	O
retinoblastoma.	O

In	O
addition,	O
E2	O
along	O
with	O
TGF	B
enrich	I
cancer	I
stem	I
cell	I
populations	O
in	O
BC,	O
leading	O
to	O
increased	O
migration	O
and	O
resistance	O
to	O
therapy	O
[16]..	O

Organelle	O
cooperation	O
in	O
stem	B
cell	I
fate:	O
Lysosomes	O
as	O
emerging	O
regulators	O
of	O
cell	O
identity.	O

Over	O
the	O
past	O
30	O
years,	O
basic	O
and	O
translational	O
research	O
has	O
identified	O
several	O
molecular	O
pathways	O
of	O
aging	O
defined	O
as	O
the	O
challmarks	O
of	O
aging,	O
i.e.,	O
genomic	O
instability,	O
telomere	O
attrition,	O
epigenetic	O
alterations,	O
loss	O
of	O
proteostasis,	O
deregulated	O
nutrient	O
sensing,	O
mitochondrial	O
dysfunction,	O
cellular	O
senescence,	O
altered	O
intercellular	O
communication,	O
and	O
stem	B
cell	I
exhaustion,	O
which	O
provide	O
a	O
molecular	O
foundation	O
for	O
organismal	O
aging	O
[11].	O

These	O
data	O
suggest	O
that	O
the	O
CDK5-SCFFbw7-Nde1	O
pathway	O
is	O
not	O
only	O
important	O
for	O
the	O
regulation	O
of	O
ciliary	O
length	O
by	O
cell	O
cycle	O
but	O
also	O
critical	O
for	O
crosstalk	O
between	O
cilia	O
and	O
the	O
cell	O
cycle	O
in	O
normal	O
and	O
cancer	O
stem	O
cells.	O
This	O
work	O
was	O
supported	O
by	O
PBBEP3-141439	O
from	O
the	O
Swiss	O
National	O
Science	O
Foundation	O
(DM);	O
by	O
DK59599	O
from	O
the	O
National	O
Institutes	O
of	O
Health,	O
from	O
the	O
Oklahoma	O
Center	O
for	O
the	O
Advancement	O
of	O
Science	O
and	O
Technology,	O
the	O
Oklahoma	O
Center	O
for	O
Adult	B
Stem	I
Cell	I
Research,	O
and	O
from	O
the	O
John	O
S.	O

The	O
possible	O
mechanism	O
may	O
be	O
that	O
the	O
induction	O
of	O
EMT	O
in	O
normal	O
epithelial	O
cell	O
populations	O
generates	O
cancer	O
stem	O
cells,	O
which	O
have	O
increased	O
resistance	O
to	O
chemotherapy	O
[22–23].	O
The	O
replenishing	O
of	O
stem	O
cell	O
niches	O
may	O
enhance	O
maternal	O
survival	O
through	O
counteracting	O
some	O
of	O
the	O
negative	O
effects	O
of	O
stem	B
cell	I
loss	O
and	O
damage	O
due	O
to	O
aging	O
39.	O

This	O
predicts	O
that	O
fetal	O
cells	O
may	O
take	O
over	O
stem	B
cell	I
niches,	O
which	O
may	O
be	O
associated	O
with	O
greater	O
survival	O
and	O
reduced	O
aging	O
of	O
mothers.	O

Mouse	O
fetal	O
fibroblast	O
cells	O
have	O
been	O
shown	O
to	O
differentiate	O
into	O
mammary	O
epithelioid	O
cells	O
when	O
exposed	O
to	O
lactation	O
hormones	O
(insulin,	O
progesterone,	O
and	O
oxytocin)	O
in	O
vitro	O
61	O
and	O
a	O
functional	O
mammary	O
gland	O
has	O
been	O
generated	O
from	O
a	O
single	O
stem	B
cell	I
in	O
an	O
pregnancy	O
mouse	O
model	O
62.	O

Generation	O
of	O
a	O
functional	O
mammary	O
gland	O
from	O
a	O
single	O
stem	O
cell.	O
Application	O
and	O
assessment	O
of	O
optical	O
clearing	O
methods	O
for	O
imaging	O
of	O
tissue-engineered	B
neural	I
stem	I
cell	I
spheres.	O

Myf-5	O
and	O
myoD	O
genes	O
are	O
activated	O
in	O
distinct	O
mesenchymal	B
stem	I
cells	I
and	O
determine	O
different	O
skeletal	O
muscle	O
cell	O
lineages.	O

A	O
prosurvival	B
and	I
proangiogenic	I
stem	I
cell	I
delivery	O
system	O
to	O
promote	O
ischemic	O
limb	O
regeneration.	O

Mendez-Ferrer	O
S,	O
Lucas	O
D,	O
Battista	O
M,	O
Frenette	O
PS	O
(2008)	O
Haematopoietic	B
stem	I
cell	I
release	O
is	O
regulated	O
by	O
circadian	O
oscillations.	O

Epigenetic	O
characterization	O
of	O
hematopoietic	B
stem	I
cell	I
differentiation	O
using	O
miniChIP	O
and	O
bisulfite	O
sequencing	O
analysis.	O

Short	O
telomeres	O
and	O
stem	B
cell	I
exhaustion	O
model	O
duchenne	O
muscular	O
dystrophy	O
in	O
mdx/mTR	O
mice.	O

A	O
small	O
clinical	O
trial	O
was	O
conducted	O
on	O
41	O
patients	O
with	O
severe	O
COVID-19	O
infection,	O
12	O
of	O
them	O
received	O
human	B
umbilical	I
cord	I
mesenchymal	I
stem	I
cell	I
(hUC-MSC)	O
infusion,	O
and	O
29	O
received	O
standard	O
of	O
care	O
therapies	O
only.	O

The	O
FDA	O
has	O
recently	O
issued	O
several	O
warnings	O
about	O
patients	O
being	O
potentially	O
vulnerable	O
to	O
stem	B
cell	I
treatments	O
that	O
are	O
illegal	O
and	O
potentially	O
harmful	O
(Food	O
and	O
Drug	O
Administration,	O
2019b).	O

Clinical	O
study	O
of	O
mesenchymal	B
stem	I
cell	I
treatment	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
induced	O
by	O
epidemic	O
influenza	O
A	O
(H7N9)	O
infection:	O
a	O
hint	O
for	O
COVID-19	O
treatment.	O

Genetically	B
modified	I
mesenchymal	I
stem	I
cell	I
therapy	O
for	O
acute	O
respiratory	O
distress	O
syndrome.	O

Mesenchymal	B
stem	I
cell	I
therapies	O
for	O
COVID-19:	O
current	O
status	O
and	O
mechanism	O
of	O
action.	O

Mesenchymal	B
stem	I
cell	I
infusion	O
shows	O
promise	O
for	O
combating	O
coronavirus	O
(COVID-19)-	O
induced	O
pneumonia.	O

Differentiation	B
and	I
maturation	I
of	O
Neural	O
Stem	O
Cells	O
into	O
distinct	O
neuronal	O
cell	O
types	O
Yes	O
mTORC1/C2,	O
prostaglandin,	O
Histone	O
acetylation/deacetylation,	O
miRNA-9,	O
miRNA-17-92	O
cluster,	O
miRNA-124,	O
Notch	O
signalling,	O
Wnt,	O
BDNF,	O
retinoic	O
acid	O
signaling.	O

Generation,	O
expansion,	O
and	O
differentiation	O
of	O
human	B
pluripotent	I
stem	I
cell	I
derived	O
neural	O
progenitor	O
cells	O
(NPCs)	O
Methods	O
Mol.	O

Neurogenic	O
transdifferentiation	O
of	O
human	O
adipose-derived	O
stem	O
cells.	O
A	O
critical	O
protocol	O
reevaluation	O
with	O
special	O
emphasis	O
on	O
cell	O
proliferation	O
and	O
cell	O
cycle	O
alterations.	O
Human	O
ES	O
cell-derived	O
neural	O
rosettes	O
reveal	O
a	O
functionally	O
distinct	O
early	O
neural	B
stem	I
cell	I
stage.	O

The	O
role	O
of	O
MiR-132	O
in	O
regulating	O
neural	B
stem	I
cell	I
proliferation,	O
differentiation	O
and	O
neuronal	O
maturation.	O

Fibrinogen	O
induces	O
neural	B
stem	I
cell	I
differentiation	O
into	O
astrocytes	O
in	O
the	O
subventricular	O
zone	O
via	O
BMP	O
signaling.	O

A	O
xeno-free	O
culturing	O
protocol	O
for	O
pluripotent	O
stem	O
cell	O
derived	O
oligodendrocyte	O
precursor	O
cell	O
production.	O
Despite	O
improvements	O
in	O
multi-agent	O
chemotherapy,	O
chemoimmunotherapy,	O
targeted	O
therapy	O
and	O
allogeneic	B
stem	I
cell	I
transplantation	O
for	O
clinical	O
management	O
of	O
leukemia,	O
the	O
5-year	O
relative	O
survival	O
was	O
only	O
29.5%	O
(2011–2017)	O
due	O
to	O
chemotherapy	O
resistance,	O
immune	O
rejection,	O
and	O
poor	O
adherence	O
to	O
treatment16.	O

Triptolide	O
inhibits	O
CD133+/CD44+	B
colon	I
cancer	I
stem	I
cell	I
growth	O
and	O
migration	O
through	O
triggering	O
apoptosis	O
and	O
represses	O
epithelial-mesenchymal	O
transition	O
via	O
downregulating	O
expressions	O
of	O
snail,	O
slug,	O
and	O
twist.	O

Previous	O
characterization	O
of	O
these	O
cells	O
demonstrated	O
the	O
presence	O
of	O
p75,	O
a	O
Schwann/neural	B
stem	I
cell	I
marker,	O
but	O
also	O
the	O
lack	O
of	O
expression	O
of	O
any	O
proteins	O
associated	O
with	O
myelinating	O
Schwann	O
cells	O
7.	O

This	O
finding	O
suggests	O
the	O
potential	B
stem	I
cell	I
nature	O
of	O
these	O
endoneurial	O
cells.	O

Neural	B
crest	I
stem	I
cell	I
maintenance	O
by	O
combinatorial	O
Wnt	O
and	O
BMP	O
signaling.	O

Interestingly,	O
mesenchymal	O
stem	O
cells,	O
which	O
express	O
only	O
very	O
low	O
MHC-I	O
level	O
and	O
do	O
not	O
induce	O
T	O
cell	O
activation	O
are	O
able	O
to	O
induce	O
differentiation	O
of	O
na	O
T	O
cells	O
into	O
Tregs	O
in	O
the	O
presence	O
of	O
HLA-G	O
(245).	O
Hematol	B
Oncol	I
Stem	I
Cell	I
Ther	O
(2015)	O
8(2):47.10.1016/j.hemonc.2014.11.006	O
[PubMed]	O
[CrossRef]	O
[Google	O
Scholar].	O

For	O
instance,	O
Exo	O
present	O
in	O
the	O
urine	O
of	O
T1DM	O
patients	O
have	O
a	O
miRNA	O
cargo	O
that	O
could	O
be	O
protective	O
for	O
diabetic	O
glomerulopathy	O
[75],	O
and	O
microvesicles	O
from	O
a	O
human	B
mesenchymal	I
stem	I
cell	I
line	O
exert	O
an	O
anti-inflammatory	O
effect	O
in	O
mononuclear	O
blood	O
cells	O
isolated	O
from	O
T1DM	O
patients	O
[82].	O

Isolated	O
mouse	O
mammary	O
epithelial	O
cells	O
were	O
transduced	O
with	O
a	O
lentivirus	O
encoding	O
PyMT	O
during	O
an	O
overnight	O
infection	O
and	O
then	O
sorted	O
into	O
hormone	O
receptor	O
positive	O
luminal	O
(CD133+),	O
hormone	O
receptor	O
negative	O
luminal	O
(CD133),	O
basal,	O
and	O
stem	B
cell	I
populations	O
using	O
the	O
cell	O
surface	O
markers	O
CD24,	O
CD49f,	O
and	O
CD133.	O

Interestingly,	O
both	O
molecularly	O
basal	O
and	O
luminal	O
tumors	O
developed	O
from	O
luminal	O
CD133+,	O
basal,	O
and	O
stem	B
cell	I
populations;	O
however,	O
luminal	O
CD133	O
cells	O
gave	O
rise	O
exclusively	O
to	O
molecularly	O
basal	O
tumors.	O

Tumors	O
arising	O
from	O
the	O
luminal	O
CD133,	O
basal,	O
and	O
stem	B
cell	I
populations	O
were	O
highly	O
metastatic;	O
however,	O
luminal	O
CD133+	O
cells	O
generated	O
tumors	O
that	O
were	O
significantly	O
less	O
metastatic,	O
possibly	O
due	O
to	O
an	O
inability	O
of	O
these	O
tumor	O
cells	O
to	O
escape	O
the	O
primary	O
tumor	O
site..	O

The	O
data	O
demonstrate	O
that	O
luminal	O
CD133+	O
cells	O
give	O
rise	O
to	O
less	O
metastatic	O
tumors,	O
luminal	O
CD133	O
cells	O
preferentially	O
establish	O
basal	O
tumors,	O
and	O
the	O
cell	O
of	O
origin	O
for	O
squamous	O
metaplasia	O
likely	O
resides	O
in	O
the	O
basal	O
and	O
stem	B
cell	I
populations..	O

The	O
results	O
suggest	O
that	O
the	O
originating	O
cell	O
population	O
influences	O
several	O
tumor	O
characteristics	O
and	O
further	O
implicates	O
a	O
cell	O
residing	O
predominantly	O
in	O
the	O
basal	O
and	O
stem	B
cell	I
compartment	O
as	O
the	O
cellular	O
origin	O
for	O
squamous	O
metaplasia..	O

Stained	O
MECs	O
were	O
then	O
resuspended	O
in	O
wash	O
buffer	O
and	O
sorted	O
into	O
luminal	O
CD133+,	O
luminal	O
CD133,	O
basal,	O
and	O
stem	B
cell	I
populations	O
as	O
described	O
previously	O
[32]	O
on	O
a	O
BD	O
FACSAria	O
Cell	O
Sorter	O
using	O
FACSDiva	O
version	O
6.1.3	O
software	O
for	O
analysis	O
(BD	O
Biosciences,	O
San	O
Jose,	O
CA,	O
USA).	O

To	O
extend	O
upon	O
these	O
studies,	O
we	O
asked	O
whether	O
PyMT	O
oncogenesis	O
within	O
specific	O
luminal,	O
basal,	O
and	O
stem	B
cell	I
populations	O
would	O
affect	O
tumor	O
latency,	O
pathology,	O
metastasis,	O
and	O
molecular	O
subgroup.	O

b	O
Transduced	O
MECs	O
were	O
sorted	O
into	O
basal,	O
luminal,	O
and	O
stem	B
cell	I
populations	O
based	O
on	O
the	O
expression	O
of	O
the	O
cell	O
surface	O
markers	O
CD49f	O
and	O
CD24	O
(right).	O

Inset	O
shows	O
representative	O
K14/K8	O
double-positive	O
cells	O
from	O
the	O
stem	B
cell	I
enriched	O
population	O
(scale	O
bar=10bcm).	O

g	O
RT-qPCR	O
quantification	O
of	O
relative	O
PyMT	O
mRNA	O
expression	O
levels	O
in	O
averaged	O
luminal	O
CD133+	O
cell,	O
luminal	O
CD133	O
cell,	O
basal	O
cell,	O
and	O
stem	B
cell	I
tumors	O
normalized	O
to	O
the	O
Rplp0	O
housekeeping	O
gene.	O

h	O
Average	O
ratio	O
of	O
phosphorylated	O
(pAKT)	O
to	O
AKT,	O
phosphorylated	O
extracellular	O
signal-regulated	O
kinase	O
(pERK)	O
to	O
ERK,	O
and	O
phosphorylated	O
SRC	O
(pSRC)	O
to	O
Src	O
protein	O
expression	O
in	O
luminal	O
CD133+,	O
luminal	O
CD133,	O
basal,	O
and	O
stem	B
cell	I
tumors	O
normalized	O
to	O
the	O
b2-actin.	O

Freshly	O
isolated	O
primary	O
MECs	O
were	O
infected	O
with	O
the	O
EF1b1-PyMT-ZsGreen	O
lentivirus	O
overnight	O
in	O
suspension	O
[12]	O
and	O
then	O
stained	O
and	O
sorted	O
for	O
the	O
cell	O
surface	O
proteins	O
CD24,	O
CD49f,	O
and	O
CD133,	O
which	O
are	O
markers	O
known	O
to	O
delineate	O
luminal,	O
basal,	O
and	O
stem	B
cell	I
populations	O
[34,	O
35].	O

The	O
gene	O
expression	O
patterns	O
we	O
observed	O
confirmed	O
the	O
enriched	O
expression	O
of	O
hormone	O
receptors	O
Esr1	O
and	O
Pgr	O
within	O
the	O
luminal	O
CD133+	O
population	O
[34],	O
whereas	O
the	O
stem	O
cell	O
markers	O
p63	O
and	O
Slug	O
were	O
highly	O
expressed	O
in	O
the	O
enriched	O
stem	B
cell	I
population	O
[9,	O
48].	O

Although	O
both	O
basal	O
and	O
stem	B
cell	I
populations	O
expressed	O
K14	O
protein	O
(Fig.	O

1c),	O
the	O
mRNA	O
was	O
expressed	O
in	O
basal	O
cells	O
at	O
a	O
level	O
similar	O
to	O
that	O
of	O
unsorted	O
MECs,	O
suggesting	O
a	O
difference	O
in	O
the	O
transcriptional	O
regulation	O
of	O
this	O
gene	O
between	O
basal	O
and	O
stem	B
cell	I
populations..	O

Second,	O
although	O
papillary	O
features	O
were	O
observed	O
in	O
tumors	O
derived	O
from	O
all	O
cell	O
types,	O
they	O
were	O
significantly	O
more	O
prevalent	O
in	O
tumors	O
arising	O
from	O
luminal	O
CD133+	O
cells	O
than	O
in	O
the	O
stem	O
cell	O
enriched	O
population	O
(Fig.	O
Lipid-rich	O
tumors	O
arose	O
primarily	O
from	O
the	O
luminal	O
CD133+	O
cell	O
population,	O
whereas	O
sebaceous-like	O
carcinomas	O
developed	O
primarily	O
from	O
basal	O
and	O
stem	B
cells	I
(Fig.	O

On	O
the	O
basis	O
of	O
this	O
analysis,	O
we	O
found	O
that	O
luminal	O
CD133+,	O
basal	O
cell,	O
and	O
stem	B
cell	I
enriched	O
MECs	O
were	O
able	O
to	O
give	O
rise	O
to	O
tumors	O
of	O
both	O
basal	O
and	O
luminal	O
subgroups	O
(Fig.	O

The	O
data	O
in	O
our	O
present	O
study	O
expand	O
upon	O
those	O
previous	O
studies	O
by	O
demonstrating	O
that	O
squamous	O
metaplasia	O
was	O
observed	O
more	O
frequently	O
when	O
basal	O
and	O
stem	B
cell	I
populations	O
were	O
infected	O
with	O
the	O
EF1b1-PyMT-ZsGreen	O
lentivirus.	O

Collectively,	O
these	O
studies	O
provide	O
strong	O
support	O
that	O
a	O
cell	O
within	O
the	O
basal	O
lineage,	O
either	O
a	O
myoepithelial	O
cell	O
or	O
a	O
stem	O
cell,	O
is	O
the	O
origin	O
of	O
squamous	O
metaplasia	O
in	O
mammary	O
tumors..	O
The	O
ability	O
to	O
fractionate	O
primary	O
mouse	O
mammary	O
cells	O
into	O
luminal,	O
basal,	O
and	O
stem	B
cell	I
populations,	O
and	O
their	O
receptiveness	O
to	O
ex	O
vivo	O
manipulation	O
and	O
outgrowth	O
following	O
transplantation,	O
provides	O
a	O
unique	O
method	O
to	O
study	O
how	O
cellular	O
context	O
affects	O
oncogenesis	O
[12].	O

We	O
report	O
that	O
differentiated	O
luminal	O
(CD133+),	O
luminal	O
progenitor	O
(CD133),	O
basal,	O
and	O
stem	B
cell	I
enriched	O
populations	O
have	O
the	O
capacity	O
to	O
give	O
rise	O
to	O
mammary	O
tumors	O
at	O
equivalent	O
frequency	O
and	O
latency	O
when	O
transformed	O
with	O
PyMT	O
oncogene.	O

Basal	O
and	O
stem	B
cell	I
enriched	O
populations	O
predominantly	O
established	O
poorly	O
differentiated	O
squamous	O
tumors,	O
whereas	O
differentiated	O
luminal	O
cells	O
gave	O
rise	O
to	O
a	O
high	O
proportion	O
of	O
ER+	O
papillary	O
tumors.	O

In	O
addition,	O
the	O
data	O
provide	O
support	O
that	O
the	O
cellular	O
origin	O
of	O
squamous	O
metaplasia	O
resides	O
within	O
the	O
basal	O
or	O
mammary	B
stem	I
cell	I
population..	O

a	O
Half-maximal	O
inhibitory	O
concentration	O
values	O
of	O
wild-type	O
MECs	O
and	O
cells	O
isolated	O
from	O
luminal	O
CD133+,	O
luminal	O
CD133,	O
basal,	O
and	O
stem	B
cell	I
tumors	O
treated	O
for	O
48	O
h	O
with	O
4-hydroxytamoxifen	O
(4-OHT).	O

a	O
RT-qPCR	O
quantification	O
of	O
relative	O
PyMT	O
mRNA	O
expression	O
levels	O
in	O
individual	O
MMTV-PyMT,	O
luminal	O
CD133+	O
cell,	O
luminal	O
CD133	O
cell,	O
basal	O
cell,	O
and	O
stem	B
cell	I
tumors	O
normalized	O
to	O
the	O
Rplp0	O
housekeeping	O
gene.	O

b	O
Western	O
blot	O
quantification	O
of	O
relative	O
ratio	O
of	O
pAKT	O
to	O
AKT	O
protein	O
expression	O
in	O
individual	O
MMTV-PyMT,	O
luminal	O
CD133+	O
cell,	O
luminal	O
CD133	O
cell,	O
basal	O
cell,	O
and	O
stem	B
cell	I
tumors	O
normalized	O
to	O
b2-actin.	O

Characterization	O
of	O
a	O
naturally	O
occurring	O
breast	O
cancer	O
subset	O
enriched	O
in	O
epithelial-to-mesenchymal	O
transition	O
and	O
stem	B
cell	I
characteristics.	O

Generation	O
of	O
a	O
functional	O
mammary	O
gland	O
from	O
a	O
single	O
stem	O
cell.	O
Dissociation	O
of	O
estrogen	O
receptor	O
expression	O
and	O
in	O
vivo	B
stem	I
cell	I
activity	O
in	O
the	O
mammary	O
gland.	O

b2-catenin	O
is	O
a	O
pivotal	O
transcriptional	O
factor	O
for	O
Wnt	O
signaling	O
and	O
plays	O
an	O
important	O
role	O
in	O
stem	B
cell	I
self-renewal	O
and	O
organ	O
regeneration,	O
in	O
addition	O
to	O
cancer	O
development	O
and	O
drug	O
resistance	O
(16).	O

For	O
example,	O
b2-catenin	O
has	O
been	O
discovered	O
to	O
promote	O
tumorigenesis,	O
cancer	B
stem	I
cell	I
self-renewal,	O
drug	O
resistance	O
and	O
metastasis	O
in	O
lung	O
cancer	O
cells	O
by	O
promoting	O
the	O
activation	O
of	O
Wnt	O
signaling	O
and	O
the	O
expression	O
of	O
downstream	O
target	O
genes	O
(17,18).	O

Patients	O
with	O
a	O
severe	O
type	O
die	O
of	O
airway	O
compromise,	O
cervical	O
spinal	O
cord	O
complications,	O
or	O
heart	O
valve	O
disease	O
in	O
their	O
20s	O
or	O
30s	O
if	O
untreated.4,7,9,	O
10,	O
11	O
Enzyme	O
replacement	O
therapy	O
(ERT),	O
hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT),	O
and	O
various	O
surgical	O
interventions	O
are	O
currently	O
available	O
for	O
patients	O
with	O
MPS	O
IVA	O
in	O
clinical	O
practice.	O

Impact	O
of	O
enzyme	O
replacement	O
therapy	O
and	O
hematopoietic	B
stem	I
cell	I
transplantation	O
in	O
patients	O
with	O
Morquio	O
A	O
syndrome.	O

Allogeneic	B
hematopoietic	I
stem	I
cell	I
transplantation	O
in	O
thirty-four	O
pediatric	O
cases	O
of	O
mucopolysaccharidosis	O
a	O
ten-year	O
report	O
from	O
the	O
China	O
Children	O
Transplant	O
Group.	O

5-AZA,	O
5-azacitidine;	O
AML,	O
acute	O
myeloid	O
leukemia;	O
CML,	O
chronic	O
myelogenous	O
leukemia;	O
CR,	O
complete	O
remission;	O
CRi,	O
complete	O
remission	O
with	O
incomplete	O
cell	O
count	O
recovery;	O
HR-MDS,	O
high-risk	O
myelodysplastic	O
syndrome;	O
HSCT,	O
hematopoietic	B
stem	I
cell	I
transplant;	O
NCT,	O
ClinicalTrials.gov	O
identifier;	O
ND,	O
new	O
diagnosis;	O
ORR,	O
overall	O
response	O
rate;	O
OS,	O
overall	O
survival;	O
Ref,	O
reference;	O
RR,	O
relapsed/refractory.	O

B-cell	O
leukemia/lymphoma-2	O
(BCL-2)	O
is	O
an	O
anti-apoptotic	O
protein	O
that	O
inhibits	O
cell	O
death	O
by	O
blocking	O
permeability	O
of	O
the	O
mitochondrial	O
outer	O
membrane.106	O
Though	O
first	O
identified	O
in	O
follicular	O
lymphoma,	O
BCL-2	O
is	O
also	O
overexpressed	O
in	O
other	O
hematologic	O
malignancies	O
including	O
AML	O
and	O
has	O
been	O
implicated	O
in	O
leukemia	B
stem	I
cell	I
survival.107,108	O
BCL-2	O
activity	O
is	O
regulated	O
by	O
a	O
group	O
of	O
small	O
molecules	O
known	O
as	O
BH3-mimetics	O
that	O
bind	O
to	O
and	O
inhibit	O
the	O
BH3	O
domain	O
of	O
BCL-2	O
proteins	O
which	O
releases	O
proapoptotic	O
factors	O
from	O
their	O
BCL-2	O
binding	O
site	O
and	O
triggers	O
apoptosis.109.	O

These	O
cells	O
show	O
a	O
stable	O
epithelial	O
morphology	O
and	O
differentiated	O
cytokeratin	O
isoforms	O
after	O
over	O
100	O
population	O
doublings,	O
express	O
the	O
stem	B
cell	I
marker	O
p63	O
and	O
high	O
levels	O
of	O
p16INK4a,	O
and	O
have	O
an	O
intact	O
p53	O
checkpoint	O
pathway	O
[33]..	O

We	O
utilized	O
extracts	O
from	O
MEL-1	B
human	I
embryonic	I
stem	I
cell	I
line	O
with	O
CRISPR/Cas9	O
KO	O
of	O
RAB39B	O
(MEL-1	O
30.3)	O
[13]	O
and	O
Rab39b	O
KO	O
mice,	O
along	O
with	O
corresponding	O
unmodified	O
parental	O
lines.	O

In	O
order	O
to	O
definitively	O
define	O
the	O
specific	O
intracellular	O
localization	O
of	O
endogenous	O
RAB39B,	O
further	O
studies	O
are	O
required,	O
which	O
will	O
be	O
facilitated	O
by	O
the	O
mouse	O
models	O
generated	O
in	O
this	O
study,	O
in	O
addition	O
to	O
previously	O
generated	O
stem	B
cell	I
models	O
[13]..	O

Generation	O
of	O
RAB39B	O
knockout	O
isogenic	O
human	B
embryonic	I
stem	I
cell	I
lines	O
to	O
model	O
RAB39B-mediated	O
Parkinson’s	O
disease.	O

Here,	O
we	O
discuss	O
the	O
contributions	O
of	O
the	O
zebrafish	O
model	O
to	O
the	O
understanding	O
of	O
hematopoiesis,	O
hematopoietic	B
stem	I
cell	I
development,	O
and	O
disease-related	O
discovery.	O

Embryos	O
were	O
then	O
stained	O
for	O
the	O
stem	B
cell	I
markers	O
Runx1	O
and	O
c-Myb.	O

We	O
recently	O
used	O
this	O
technique	O
[45]	O
to	O
identify	O
82	O
compounds	O
that	O
influence	O
hematopoietic	B
stem	I
cell	I
differentiation,	O
the	O
most	O
prominent	O
of	O
which	O
was	O
dimethyl	O
prostaglandin	O
E2	O
(dmPGE2).	O

These	O
studies	O
demonstrate	O
the	O
advantages	O
provided	O
by	O
the	O
zebrafish	O
model	O
as	O
a	O
platform	O
for	O
conducting	O
large-scale	O
screens	O
for	O
potential	O
molecules	O
that	O
target	B
stem	I
cell	I
development,	O
hematopoietic	O
differentiation,	O
and	O
disease-related	O
mechanisms.	O

The	O
derivation	O
of	O
green	O
cells	O
adjacent	O
to	O
the	O
red	O
endothelial	O
cells	O
indicates	O
autonomous	O
effects	O
of	O
stem	B
cell	I
production.	O

A	O
clinical	O
trial	O
is	O
currently	O
analyzing	O
dmPGE2	O
and	O
its	O
potential	O
for	O
enhancing	O
engraftment	O
in	O
cord	B
stem	I
cell	I
transplants.	O

Prostaglandin	O
E2	O
enhances	O
human	B
cord	I
blood	I
stem	I
cell	I
xenotransplants	O
and	O
shows	O
long-term	O
safety	O
in	O
preclinical	O
nonhuman	O
primate	O
transplant	O
models.	O

Establishment	O
of	O
a	O
new	O
embryonic	B
stem	I
cell	I
line	O
derived	O
from	O
C57BL/6	O
mouse	O
expressing	O
EGFP	O
ubiquitously.	O

Furthermore,	O
the	O
regulatory	O
pathways	O
that	O
underpin	O
the	O
maintenance	O
of	O
stem	B
cell	I
pluripotency	O
also	O
rely	O
on	O
chromatin-based	O
epigenetic	O
memory	O
systems..	O

Cell	B
Stem	I
Cell	I
3,	O
265	O
278	O
[PMC	O
free	O
article]	O
[PubMed]	O
[Google	O
Scholar].	O

The	O
third	O
model	O
suggests	O
that	O
lamins	O
A	O
and	O
C	O
are	O
involved	O
in	O
regulating	O
cell	O
type	O
specific	O
gene	O
expression	O
during	O
adult	B
stem	I
cell	I
differentiation	O
(Gotzmann	O
and	O
Foisner,	O
2006	O
).	O

Mutant	O
mice	O
in	O
which	O
ASAH1	O
is	O
deleted	O
by	O
homologous	O
recombination	O
do	O
not	O
survive	O
beyond	O
the	O
embryonic	O
2-cell	O
stage	O
and	O
undergo	O
apoptotic	O
cell	O
death,	O
while	O
treatment	O
with	O
exogenous	O
S1P	O
rescues	O
embryonic	B
AC-null	I
stem	I
cells	I
and	O
permits	O
their	O
survival24.	O

Melanoma	B
stem	I
cells	I
and	O
metastasis:	O
mimicking	O
hematopoietic	O
cell	O
trafficking?	O
Lab	O
Invest.	O

Essential	O
role	O
of	O
aldehyde	O
dehydrogenase	O
1A3	O
for	O
the	O
maintenance	O
of	O
non-small	O
cell	O
lung	O
cancer	B
stem	I
cells	I
is	O
associated	O
with	O
the	O
STAT3	O
pathway.	O

Loss	O
of	O
let-7	O
up-regulates	O
EZH2	O
in	O
prostate	O
cancer	O
consistent	O
with	O
the	O
acquisition	O
of	O
cancer	B
stem	I
cell	I
signatures	O
that	O
are	O
attenuated	O
by	O
BR-DIM.	O

Adipose-derived	B
mesenchymal	I
stem	I
cells	I
promote	O
cell	O
proliferation	O
and	O
invasion	O
of	O
epithelial	O
ovarian	O
cancer.	O

Multiple	O
myeloma	O
treatment	O
at	O
relapse	O
after	O
autologous	B
stem	I
cell	I
transplantation:	O
A	O
practical	O
analysis.	O

Polycomb-Like	O
3	O
Promotes	O
Polycomb	O
Repressive	O
Complex	O
2	O
Binding	O
to	O
CpG	O
Islands	O
and	O
Embryonic	B
Stem	I
Cell	I
Self-Renewal.	O

Polycomb	O
repressive	O
complex	O
2	O
(PRC2)	O
trimethylates	O
lysine	O
27	O
of	O
histone	O
H3	O
(H3K27me3)	O
to	O
regulate	O
gene	O
expression	O
during	O
diverse	O
biological	O
transitions	O
in	O
development,	O
embryonic	B
stem	I
cell	I
differentiation,	O
and	O
cancer.	O

Consistent	O
with	O
roles	O
for	O
PRC2	O
in	O
regulating	O
stem	B
cell	I
behaviors,	O
Pcl3	O
is	O
important	O
for	O
embryonic	O
stem	O
cell	O
self-renewal.	O

Thus,	O
Pcl3	O
is	O
a	O
critical	O
regulator	O
of	O
gene	O
repression	O
and	O
stem	B
cell	I
self-renewal	O
that	O
acts	O
by	O
controlling	O
PRC2	O
binding	O
to	O
target	O
genes..	O

Polycomb	O
repressive	O
complex	O
2	O
is	O
dispensable	O
for	O
maintenance	O
of	O
embryonic	B
stem	I
cell	I
pluripotency.	O

The	O
polycomb	O
group	O
protein	O
Suz12	O
is	O
required	O
for	O
embryonic	B
stem	I
cell	I
differentiation.	O

EZH1	O
mediates	O
methylation	O
on	O
histone	O
H3	O
lysine	O
27	O
and	O
complements	O
EZH2	O
in	O
maintaining	O
stem	B
cell	I
identity	O
and	O
executing	O
pluripotency.	O

Polycomb-like	O
2	O
associates	O
with	O
PRC2	O
and	O
regulates	O
transcriptional	O
networks	O
during	O
mouse	B
embryonic	I
stem	I
cell	I
self-renewal	O
and	O
differentiation.	O

An	O
RNAi	O
screen	O
of	O
chromatin	O
proteins	O
identifies	O
Tip60-p400	O
as	O
a	O
regulator	O
of	O
embryonic	B
stem	I
cell	I
identity.	O

The	O
environmental	O
sensor	O
AHR	O
protects	O
from	O
inflammatory	O
damage	O
by	O
maintaining	O
intestinal	B
stem	I
cell	I
homeostasis	O
and	O
barrier	O
integrity.	O

Stem	B
cell	I
therapy	O
has	O
recently	O
been	O
shown	O
to	O
be	O
a	O
potential	O
treatment	O
for	O
damaged	O
brain	O
cells,	O
allowing	O
for	O
the	O
reversibility	O
of	O
the	O
damages	O
caused	O
by	O
the	O
disease	O
[28].	O

Design/Method:	O
Retrospective	O
chart	O
review	O
was	O
performed	O
in	O
all	O
patients	O
with	O
neuroblastoma	O
undergoing	O
high	O
dose	O
chemotherapy	O
and	O
autologous	B
stem	I
cell	I
transplantation	O
(2005	O
2015)	O
to	O
identify	O
incidence	O
of	O
transplant	O
associated	O
TMA,	O
outcome	O
and	O
therapy	O
used..	O

Division	O
of	O
Pediatric	O
Hematology,	O
Oncology,	O
and	O
Stem	B
Cell	I
Transplantation,	O
Massey	O
Cancer	O
Center	O
and	O
Children's	O
Hospital	O
of	O
Richmond	O
at	O
Virginia	O
Commonwealth	O
University;	O
2Program	O
in	O
Developmental	O
Biology,	O
Stanley	O
Manne	O
Children's	O
Research	O
Institute,	O
Northwestern	O
University	O
Feinberg	O
School	O
of	O
Medicine,	O
Chicago,	O
Illinois,	O
Richmond,	O
Virginia,	O
United	O
States.	O

In	O
the	O
largest	O
international	O
retrospective	O
survey	O
of	O
patients	O
with	O
DIDS,	O
36	O
underwent	O
hematopoietic	B
stem	I
cell	I
transplant	O
(HSCT),	O
suggesting	O
a	O
potential	O
curative	O
measure.	O

However,	O
there	O
remains	O
a	O
challenging	O
subset	O
of	O
patients	O
with	O
relapsed	O
or	O
refractory	O
disease	O
who	O
fail	O
first	O
line	O
therapy	O
and	O
require	O
salvage	O
therapy	O
prior	O
to	O
consolidation	O
with	O
autologous	B
stem	I
cell	I
transplant	O
(ASCT).	O

The	O
combination	O
of	O
ifosfamide,	O
gemcitabine,	O
and	O
vinorelbine	O
(IGEV)	O
has	O
been	O
used	O
as	O
a	O
salvage	O
regimen	O
in	O
adults	O
with	O
relapsed	O
and	O
refractory	O
HL	O
with	O
high	O
rates	O
of	O
disease	O
response	O
and	O
of	O
successful	O
stem	B
cell	I
mobilization.	O

All	O
patients	O
had	O
successful	O
CD34+	B
stem	I
cell	I
mobilization	O
after	O
a	O
single	O
apheresis	O
procedure.	O

Conclusion:	O
IGEV	O
is	O
an	O
effective	O
salvage	O
regimen	O
for	O
children	O
with	O
relapsed	O
or	O
refractory	O
Hodgkin	O
Lymphoma	O
due	O
to	O
high	O
rates	O
of	O
disease	O
response	O
and	O
successful	O
facilitation	O
of	O
autologous	B
stem	I
cell	I
collection,	O
with	O
an	O
acceptable	O
toxicity	O
profile.	O

Background:	O
As	O
hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
techniques	O
and	O
supportive	O
care	O
have	O
improved,	O
more	O
children	O
are	O
surviving	O
their	O
transplants.	O

Other	O
factors,	O
including	O
age,	O
race,	O
ethnicity,	O
gender,	O
underlying	O
diagnosis,	O
stem	B
cell	I
source,	O
and	O
ABO	O
incompatibility,	O
were	O
not	O
associated	O
with	O
risk	O
of	O
iron	O
overload.	O

Background:	O
Hematopoietic	B
stem	I
cell	I
transplant	O
(HSCT)	O
is	O
the	O
only	O
potential	O
curative	O
therapy	O
for	O
sickle	O
cell	O
disease	O
(SCD)	O
currently.	O

Background:	O
Cord	O
blood	O
is	O
used	O
as	O
an	O
alternative	O
stem	B
cell	I
source	O
for	O
hematopoietic	O
stem	O
cell	O
transplantation	O
(HSCT)..	O

Design/Method:	O
This	O
is	O
a	O
retrospective	O
chart	O
review	O
of	O
all	O
pediatric	O
hematopoietic	B
stem	I
cell	I
transplants	O
over	O
a	O
20	O
year	O
period..	O

Ninety	O
five	O
were	O
performed	O
using	O
cord	O
blood	O
as	O
the	O
stem	B
cell	I
source.	O

Background:	O
Total	O
body	O
irradiation	O
(TBI)	O
is	O
associated	O
with	O
many	O
acute	O
and	O
chronic	O
complications	O
but	O
is	O
the	O
standard	O
therapy	O
as	O
conditioning	O
for	O
allogeneic	B
stem	I
cell	I
transplantation	O
(AlloSCT)	O
in	O
children	O
acute	O
lymphoblastic	O
leukemia	O
(ALL).	O

Design/Method:	O
We	O
performed	O
a	O
retrospective	O
analysis	O
of	O
consecutive	O
patients	O
with	O
ALL,	O
transplanted	O
with	O
TT	O
BU	O
FLU	O
conditioning	O
in	O
a	O
single	O
pediatric	B
stem	I
cell	I
transplantation	O
center	O
with	O
a	O
median	O
follow	O
of	O
8.3	O
months	O
(1	O
28).	O

Stem	B
cell	I
transplant	O
was	O
advised	O
to	O
all	O
patients	O
once	O
HLH	O
was	O
under	O
control	O
but	O
the	O
only	O
child	O
who	O
underwent	O
SCT	O
at	O
another	O
centre,	O
succumbed	O
to	O
sepsis.	O

While	O
therapy	O
with	O
HLH	O
2004	O
protocol	O
is	O
successful	O
in	O
the	O
majority	O
of	O
cases,	O
access	O
to	O
stem	B
cell	I
transplant	O
is	O
still	O
a	O
challenge	O
in	O
the	O
developing	O
world.	O

Background:	O
Stem	B
cell	I
transplant	O
(SCT)	O
is	O
an	O
established	O
therapy	O
for	O
numerous	O
malignant	O
and	O
non	O
malignant	O
conditions	O
in	O
the	O
pediatric	O
population.	O

Objectives:	O
To	O
assess	O
risk	O
factors	O
for	O
pericardial	O
effusion	O
in	O
pediatric	O
patients	O
after	O
hematopoietic	B
stem	I
cell	I
transplant	O
and	O
its	O
impact	O
on	O
mortality.	O

Overall,	O
there	O
was	O
22.5%	O
mortality	O
rate	O
during	O
the	O
initial	O
admission	O
for	O
conditioning	O
and	O
stem	B
cell	I
infusion.	O

Background:	O
Children	O
undergoing	O
hematopoietic	B
stem	I
cell	I
transplant	O
(HSCT)	O
are	O
at	O
increased	O
risk	O
of	O
having	O
potentially	O
fatal	O
viral	O
infections	O
including	O
adenovirus	O
which	O
is	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
this	O
population.	O

Objectives:	O
To	O
report	O
the	O
case	O
of	O
a	O
pediatric	B
hematopoietic	I
stem	I
cell	I
transplant	O
recipient	O
treated	O
with	O
inhaled	O
cidofovir	O
for	O
adenovirus	O
pneumonitis.	O

Results:	O
A	O
5	O
year	O
old	O
Hispanic	O
female	O
with	O
past	O
medical	O
history	O
of	O
Fanconi	O
anemia	O
who	O
developed	O
multi	O
organ	O
failure	O
requiring	O
dialysis	O
and	O
respiratory	O
support	O
for	O
adenovirus	O
pneumonitis	O
90	O
days	O
after	O
umbilical	B
cord	I
stem	I
cell	I
transplant.	O

A	O
number	O
of	O
secretory	O
related	O
molecules	O
like	O
stem	B
cell	I
factor	O
(SCF),	O
CXCL12	O
and	O
Angiopoietin	O
mediate	O
this	O
maintenance	O
function.	O

Objectives:	O
The	O
primary	O
objective	O
was	O
to	O
evaluate	O
the	O
proportion	O
of	O
patients	O
who	O
achieved	O
a	O
plasma	O
trough	O
concentration	O
of	O
	O
1bcg/mL	O
with	O
the	O
initial	O
dosing	O
of	O
voriconazole	O
for	O
fungal	O
prophylaxis	O
or	O
treatment	O
in	O
pediatric	B
oncology	I
and	I
hematopoietic	I
stem	I
cell	I
transplant	O
(HSCT).	O

Results:	O
Themes	O
identified	O
by	O
all	O
ages	O
about	O
the	O
effect	O
of	O
SCD	O
on	O
work	O
and	O
school	O
included	O
Disability,	O
School	O
absence,	O
and	O
Motivation	O
to	O
disprove	O
odds.	O
Thematic	O
analysis	O
identified	O
that	O
patients	O
would	O
live	O
their	O
lives	O
differently	O
if	O
cured:	O
More	O
energy	O
to	O
improve	O
myself,	O
New	O
educational	O
goals	O
Career	O
aspirations.	O
The	O
potential	O
that	O
stem	B
cell	I
transplant	O
would	O
relieve	O
their	O
disability	O
was	O
recognized	O
by	O
nearly	O
all	O
subjects.	O

This	O
survey	O
is	O
the	O
first	O
to	O
examine	O
perception	O
of	O
disability	O
among	O
the	O
factors	O
that	O
patients	O
consider	O
in	O
their	O
decision	O
about	O
stem	B
cell	I
transplant	O
for	O
sickle	O
cell.	O

Further,	O
few	O
studies	O
include	O
both	O
adolescent	O
and	O
adult	O
sickle	O
cell	O
patients	O
in	O
a	O
single	O
survey,	O
and	O
this	O
opens	O
the	O
door	O
on	O
age	O
related	O
differences	O
in	O
perception	O
of	O
stem	B
cell	I
transplantation.	O

Background:	O
Bloodstream	O
infections	O
(BSI)	O
are	O
serious	O
complications	O
in	O
children	O
receiving	O
chemotherapy	O
and	O
undergoing	O
stem	B
cell	I
transplantation	O
(SCT).	O

Patients	O
with	O
nonmalignant	O
marrow	O
dysfunction,	O
histiocytosis,	O
FN	O
as	O
a	O
symptom	O
of	O
cancer	O
relapse,	O
previous	B
hematopoietic	I
stem	I
cell	I
transplantation,	O
and	O
patients	O
receiving	O
induction	O
chemotherapy	O
for	O
acute	O
lymphoblastic	O
leukemia	O
were	O
excluded.	O

The	O
only	O
available	O
cure	O
for	O
SCA	O
is	O
hematopoeitic	B
stem	I
cell	I
transplant	O
(HSCT).	O

Background:	O
Oncology	O
and	O
Stem	B
cell	I
transplant	O
(SCT)	O
inpatients	O
require	O
frequent	O
complete	O
blood	O
count	O
(CBC)	O
monitoring	O
and	O
blood	O
product	O
transfusions.	O

Intent	O
was	O
palliative	O
in	O
21patients	O
(total	O
28courses);	O
most	O
were	O
high	O
risk	O
NB	O
and	O
had	O
received	O
multiple	O
courses	O
of	O
treatment,	O
including	O
Autologous	B
Stem	I
Cell	I
Transplant	O
in	O
3/21.	O

Not	O
included	O
in	O
our	O
analysis	O
are	O
3	O
patients	O
who	O
developed	O
colorectal	O
cancer	O
in	O
two	O
and	O
OS	O
in	O
one,	O
respectively,	O
following	O
hematopoietic	B
stem	I
cell	I
transplantation..	O

Results:	O
We	O
found	O
that	O
PPP1R1A	O
is	O
highly	O
expressed	O
in	O
ES	O
but	O
not	O
the	O
putative	O
cell	O
of	O
origin,	O
mesenchymal	O
stem	O
cells.	O
Background:	O
Cytomegalovirus	O
(CMV)	O
retinitis	O
is	O
a	O
complication	O
of	O
immunosuppressed	O
hosts	O
that	O
is	O
typically	O
seen	O
in	O
acquired	O
immunodeficiency	O
syndrome	O
and	O
hematopoietic	B
stem	I
cell	I
transplant	O
patients.	O

These	O
tumors	O
may	O
be	O
arising	O
from	O
a	O
common	O
pleuripotent	O
mesenchymal	O
stem	O
cell.	O
Aggressive	O
surgical	O
resection	O
combined	O
with	O
high	O
dose	O
chemotherapy	O
and	O
stem	B
cell	I
rescue	O
was	O
suggested	O
as	O
a	O
curative	O
option	O
by	O
the	O
treating	O
team	O
but	O
the	O
family	O
opted	O
for	O
a	O
palliative	O
approach	O
with	O
metronomic	O
chemotherapy	O
using	O
cyclophosphamide	O
and	O
etoposide.	O

Objectives:	O
To	O
report	O
the	O
treatment	O
of	O
two	O
GCTs	O
that	O
underwent	O
SMT	O
into	O
a	O
PNET	O
with	O
a	O
modified	O
Head	O
Start	O
II	O
regimen	O
followed	O
by	O
high	O
dose	O
chemotherapy	O
with	O
stem	B
cell	I
rescue..	O

Both	O
patients	O
underwent	O
consolidation	O
with	O
high	O
dose	O
chemotherapy	O
(HDCT)	O
with	O
carboplatin	O
16.7	O
mg/kg,	O
thiotepa	O
10	O
mg/kg	O
and	O
etoposide	O
8.3	O
mg/kg	O
followed	O
by	O
autologous	B
peripheral	I
stem	I
cell	I
rescue.	O

Both	O
failed	O
induction	O
therapy	O
and	O
received	O
investigational	O
131I	O
MIBG	O
followed	O
by	O
consolidation	O
chemotherapy	O
and	O
stem	B
cell	I
rescue,	O
local	O
radiation	O
therapy,	O
and	O
13cisRA.	O

Currently,	O
treatment	O
approaches	O
include	O
steroids	O
alone,	O
immunosuppressive	O
agents,	O
multi	O
agent	O
chemotherapy	O
and	O
even	O
autologous	B
stem	I
cell	I
transplant.	O

Background:	O
Donors	O
for	O
patients	O
of	O
African	O
descent	O
requiring	O
a	O
hematopoietic	B
stem	I
cell	I
transplant	O
(HSCT)	O
are	O
limited	O
in	O
national	O
registries.	O

Background:	O
Infants	O
and	O
young	O
children	O
who	O
undergo	O
hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
are	O
at	O
increased	O
risk	O
for	O
late	O
effects	O
due	O
to	O
exposure	O
of	O
developing	O
organs	O
to	O
chemotherapy	O
and	O
radiation	O
therapy	O
typically	O
utilized	O
as	O
part	O
of	O
conditioning	O
regimens.	O

Background:	O
Pediatric	O
patients	O
undergoing	O
hematopoietic	B
stem	I
cell	I
transplant	O
(HSCT)	O
are	O
at	O
increased	O
risk	O
for	O
invasive	O
fungal	O
disease	O
(IFD).	O

We	O
hypothesize	O
that	O
Cdk5	O
inhibition	O
in	O
donor	O
T	O
cells	O
leads	O
to	O
reduced	O
migration	O
into	O
secondary	O
lymphoid	O
organs	O
(SLOs)	O
and	O
reduced	O
severity	O
of	O
aGvHD	O
in	O
murine	O
models	O
of	O
allogeneic	B
hematopoietic	I
stem	I
cell	I
transplant	O
(allo	O
HSCT)..	O

Background:	O
VOD/SOS	O
is	O
typically	O
considered	O
an	O
unpredictable,	O
potentially	O
life	O
threatening	O
hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
complication;	O
however,	O
there	O
is	O
a	O
known	O
risk	O
post	O
chemotherapy	O
without	O
HSCT.	O

Background:	O
There	O
is	O
no	O
FDA	O
approved	O
treatment	O
for	O
hepatic	O
VOD/SOS,	O
a	O
potentially	O
life	O
threatening	O
complication	O
of	O
conditioning	O
regimens	O
for	O
stem	B
cell	I
transplantation	O
(SCT).	O

Modern	O
treatment	O
protocols	O
utilizing	O
intense	O
induction	O
followed	O
by	O
myeloablative	O
consolidation	O
chemotherapy	O
with	O
autologous	B
stem	I
cell	I
rescue	O
(ASCR)	O
have	O
improved	O
survival	O
rates,	O
but	O
long	O
term	O
sequelae	O
emerge	O
over	O
time..	O

However,	O
late	O
effects	O
of	O
the	O
skin	O
after	O
pediatric	B
hematopoietic	I
stem	I
cell	I
transplantation	O
(HSCT)	O
have	O
not	O
been	O
well	O
described.	O

Background:	O
Hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
for	O
patients	O
with	O
sickle	O
cell	O
disease	O
(SCD)	O
is	O
curative,	O
though	O
significant	O
toxicity	O
from	O
myeloablative	O
conditioning	O
has	O
limited	O
its	O
utility.	O

Background:	O
Most	O
patients	O
that	O
could	O
be	O
cured	O
of	O
sickle	O
cell	O
disease	O
(SCD)	O
with	O
stem	B
cell	I
transplantation	O
do	O
not	O
have	O
a	O
matched	O
sibling	O
donor	O
and	O
many	O
do	O
not	O
have	O
a	O
matched	O
unrelated	O
donor.	O

Objectives:	O
The	O
use	O
of	O
a	O
reduced‐intensity	O
conditioning	O
regimen	O
and	O
a	O
CD34+	O
selected,	O
T	O
cell	O
depleted	O
peripheral	B
blood	I
stem	I
cell	I
graft	O
will	O
allow	O
engraftment	O
with	O
a	O
low	O
incidence	O
of	O
graft	O
versus	O
host	O
disease	O
(GVHD)..	O

Background:	O
Rapid	O
availability,	O
allowance	O
for	O
greater	O
HLA	O
mismatch	O
and	O
low	O
rates	O
of	O
GVHD	O
make	O
UCB	O
an	O
attractive	B
stem	I
cell	I
source	O
.	O

Background:	O
Allogeneic	B
Hematopoietic	I
stem	I
cell	I
transplant	O
(HSCT)	O
relies	O
on	O
the	O
availability	O
of	O
suitable	O
donor,	O
with	O
only	O
30%	O
of	O
the	O
patients	O
having	O
matched	O
sibling	O
donor.	O

Background:	O
Hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
can	O
halt	O
the	O
progression	O
of	O
Krabbe	O
disease	O
(KD)	O
via	O
engraftment	O
of	O
donor	O
derived,	O
enzyme	O
producing	O
cells	O
in	O
the	O
bone	O
marrow,	O
brain,	O
and	O
other	O
organs.	O

Background:	O
Unrelated	O
cord	O
blood	O
transplant	O
(UCBT)	O
offers	O
a	O
readily	O
available	O
stem	B
cell	I
source	O
for	O
individuals	O
lacking	O
a	O
suitable	O
related	O
donor.	O

Background:	O
Increased	O
numbers	O
of	O
human	O
leukocyte	O
antigen	O
(HLA)	O
mismatched	O
allogeneic	B
hematopoietic	I
stem	I
cell	I
transplants	O
(HSCTs)	O
are	O
now	O
being	O
performed.	O

Anti	O
HLA	O
antibodies	O
in	O
the	O
recipient	O
are	O
routinely	O
tested	O
prior	O
to	O
stem	B
cell	I
transplant,	O
and	O
may	O
be	O
donor	O
specific	O
or	O
non	O
donor	O
specific.	O

There	O
are	O
few	O
data	O
regarding	O
general	O
anti	O
HLA	O
antibodies	O
and	O
their	O
role	O
in	O
stem	B
cell	I
transplant	O
outcomes..	O

Objectives:	O
To	O
determine	O
the	O
incidence	O
and	O
risk	O
factors	O
for	O
the	O
development	O
of	O
anti	O
HLA	O
antibodies	O
in	O
stem	B
cell	I
transplant	O
recipients	O
and	O
association	O
with	O
outcomes..	O

Conclusion:	O
Anti	O
HLA	O
antibodies	O
are	O
detectable	O
in	O
a	O
significant	O
portion	O
of	O
stem	B
cell	I
transplant	O
recipients.	O

The	O
presence	O
of	O
general	O
anti	O
HLA	O
antibodies	O
in	O
the	O
recipient	O
does	O
not	O
correlate	O
with	O
patient	O
outcomes	O
after	O
stem	B
cell	I
transplantation..	O

Background:	O
Reduced	O
intensity	O
conditioning	O
(RIC)	O
is	O
increasingly	O
used	O
for	O
hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
with	O
the	O
goal	O
of	O
maintaining	O
therapeutic	O
efficacy	O
while	O
limiting	O
toxicity.	O

Background:	O
Cidofovir	O
is	O
the	O
only	O
treatment	O
for	O
disseminated	O
adenovirus	O
infection,	O
a	O
life	O
threatening	O
complication	O
of	O
hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT).	O

Background:	O
Cardiac	O
dysfunction	O
is	O
an	O
increasingly	O
recognized	O
complication	O
for	O
long	O
term	O
survivors	O
of	O
pediatric	B
Stem	I
Cell	I
Transplant	O
(SCT).	O

Background:	O
Hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
provides	O
potential	O
curative	O
treatment	O
for	O
various	O
conditions.	O

Little	O
is	O
reported	O
of	O
the	O
utility	O
of	O
donor	O
DLI	O
following	O
hematopoietic	B
stem	I
cell	I
transplantation	O
(HCT)	O
for	O
non	O
malignant	O
disorders	O
(NMD)..	O

Background:	O
Neurologic	O
functional	O
outcomes	O
are	O
unpredictable	O
and	O
varied	O
following	O
allogeneic	B
hematopoietic	I
stem	I
cell	I
transplantation	O
(HSCT)	O
for	O
advanced,	O
childhood‐onset	O
cerebral	O
adrenoleukodystrophy	O
(cALD).	O

Allogenic	B
hematopoietic	I
stem	I
cell	I
transplantation	O
is	O
the	O
sole	O
curative	O
therapy	O
to	O
prevent	O
AP..	O

Background:	O
Allogeneic	B
hematopoietic	I
stem	I
cell	I
transplantation	O
(HSCT)	O
remains	O
standard	O
treatment	O
for	O
Hurler	O
syndrome	O
and	O
other	O
inherited	O
metabolic	O
disorders	O
(IMD).	O

Background:	O
Increased	O
risk	O
factors	O
for	O
invasive	O
mold	O
infections	O
led	O
to	O
a	O
change	O
in	O
primary	O
fungal	O
prophylaxis	O
from	O
fluconazole	O
to	O
voriconazole	O
for	O
allogeneic	B
stem	I
cell	I
transplant	O
patients	O
at	O
our	O
institution.	O

All	O
patients	O
that	O
achieved	O
negative	O
minimal	O
residual	O
disease	O
received	O
an	O
allogenic	B
stem	I
cell	I
transplantation.	O

Background:	O
Haploidentical	B
hematopoietic	I
stem	I
cell	I
transplantation	O
using	O
T‐cell	O
depleted	O
grafts	O
is	O
a	O
valid	O
option	O
for	O
pediatric	O
patients	O
with	O
hematological	O
malignancies	O
in	O
need	O
of	O
an	O
allogeneic	O
transplantation	O
and	O
lacking	O
an	O
HLA‐identical	O
donor.	O

Objectives:	O
Haploidentical	B
stem	I
cell	I
transplantation	O
(haplo	O
HCT)	O
has	O
become	O
an	O
interesting	O
strategy	O
to	O
avoid	O
this	O
problem,	O
but	O
the	O
required	O
T	O
cell	O
depletion	O
produce	O
a	O
profund	O
and	O
long	O
lasting	O
inmunosupression,	O
as	O
well	O
as	O
graft	O
failure	O
and	O
rejection.	O

Background:	O
Hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
is	O
proven	O
to	O
be	O
curative	O
for	O
severe	O
combined	O
immunodeficiency	O
(SCID)..	O

Background:	O
Reports	O
indicate	O
that	O
pediatric	O
patients	O
undergoing	O
hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
are	O
frequency	O
afflicted	O
by	O
vitamin	O
D	O
deficiency.	O

Prevalence	O
did	O
not	O
change	O
after	O
hematopoietic	B
stem	I
cell	I
transplantation	O
(p	O
value	O
=	O
0.7)	O
with	O
63%	O
of	O
the	O
patients	O
having	O
suboptimal	O
(<	O
30ng/mL)	O
vitamin	O
D	O
levels	O
and	O
45%	O
having	O
severe	O
vitamin	O
D	O
deficiency	O
(<20ng/mL)	O
at	O
100	O
days	O
after	O
transplantation	O
despite	O
supplemental	O
therapy	O
in	O
74%	O
of	O
subjects.	O

Attractor	O
serves	O
as	O
a	O
driving	O
force	O
to	O
drive	O
a	O
stem	B
cell	I
towards	O
a	O
particular	O
differentiated	O
state	O
upon	O
receiving	O
a	O
differentiation	O
factor.	O

Importantly,	O
we	O
unveiled	O
novel	O
and	O
druggable	O
metastatic	O
biomarkering	O
(systemic)	O
signatures	O
such	O
as	O
hybrid	O
epithelial-to-mesenchymal	O
transition	O
(EMT)/mesenchymal-to-epithelial	O
transition	O
(MET)	O
[31,33,36,37]	O
and	O
neural	B
crest	I
stem	I
cell	I
[37,38,39,40,41,42,43,44,45]	O
oncogenic	O
programs	O
for	O
mutant	O
(e.g.,	O
V600D)	O
BRAF-dependent	O
human	O
cutaneous	O
melanomagenesis..	O

Melanocytes	O
derive	O
from	O
neural	B
crest	I
stem	I
cells	I
that	O
disseminate	O
into	O
the	O
embryo	O
to	O
form	O
an	O
array	O
of	O
diverse	O
cell	O
lineages	O
[139].	O

Strikingly,	O
besides	O
elevated	O
autophagy,	O
increased	O
levels	O
of	O
the	O
SOX2	B
(NC)	I
stem	I
cell	I
marker	O
are	O
also	O
associated	O
with	O
anthracycline(s)	O
resistance	O
[340,349,350,351,352].	O

Differential	O
effect	O
of	O
long-term	O
drug	O
selection	O
with	O
doxorubicin	O
and	O
vorinostat	O
on	O
neuroblastoma	O
cells	O
with	O
cancer	B
stem	I
cell	I
characteristics.	O

Small	O
molecules	O
that	O
improve	O
reprogramming,	O
stem	B
cell	I
properties,	O
and	O
regeneration	O
can	O
be	O
widely	O
applied	O
in	O
regenerative	O
medicine.	O

Here,	O
we	O
tested	O
3695	O
extracts	O
from	O
native	O
plants	O
to	O
examine	O
whether	O
they	O
can	O
improve	O
induced	B
pluripotent	I
stem	I
cell	I
generation	O
using	O
genetically	O
homogeneous	O
secondary	O
mouse	O
embryonic	O
fibroblasts	O
(MEFs)	O
harboring	O
doxycycline	O
(dox)-inducible	O
reprograming	O
transgenes.	O

The	O
generation	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
by	O
somatic	O
cellular	O
reprogramming	O
technology	O
using	O
a	O
combination	O
of	O
defined	O
reprogramming	O
factors	O
termed	O
the	O
Yamanaka	O
factors	O
(Oct-4,	O
Sox-2,	O
Klf-4,	O
and	O
c-Myc	O
(OSKM))	O
represents	O
a	O
major	O
breakthrough	O
in	O
stem	O
cell	O
biology	O
and	O
regenerative	O
medicine	O
[10,11].	O

Subsequently,	O
we	O
evaluated	O
cellular	O
reprogramming	O
efficiency	O
by	O
counting	O
the	O
number	O
of	O
alkaline	O
phosphatase	O
(AP)-positive	B
mouse	I
embryonic	I
stem	I
cell	I
-like	O
colonies	O
15	O
days	O
later	O
(Figure	O
1a).	O

The	O
aging	O
signature:	O
A	O
hallmark	O
of	O
induced	O
pluripotent	O
stem	O
cells	O
Aging	O
Cell.	O
Small	O
molecules,	O
big	O
roles	O
The	O
chemical	O
manipulation	O
of	O
stem	B
cell	I
fate	O
and	O
somatic	O
cell	O
reprogramming.	O

Techniques	O
of	O
human	O
embryonic	O
stem	O
cell	O
and	O
induced	B
pluripotent	I
stem	I
cell	I
derivation.	O

Stem	B
cell	I
derived	O
phenotypic	O
human	O
neuromuscular	O
junction	O
model	O
for	O
dose	O
response	O
evaluation	O
of	O
therapeutics.	O

High	O
risk	O
of	O
death	O
due	O
to	O
bacterial	O
and	O
fungal	O
infection	O
among	O
cytomegalovirus	O
(CMV)-seronegative	O
recipients	O
of	O
stem	B
cell	I
transplants	O
from	O
seropositive	O
donors:	O
evidence	O
for	O
indirect	O
effects	O
of	O
primary	O
CMV	O
infection.	O

et	O
al.Donor	O
cytomegalovirus	O
status	O
influences	O
the	O
outcome	O
of	O
allogeneic	B
stem	I
cell	I
transplant:	O
a	O
study	O
by	O
the	O
European	O
group	O
for	O
blood	O
and	O
marrow	O
transplantation.	O

et	O
al.Use	O
of	O
cytomegalovirus	O
intravenous	O
immune	O
globulin	O
for	O
the	O
adjunctive	O
treatment	O
of	O
cytomegalovirus	O
in	O
hematopoietic	B
stem	I
cell	I
transplant	O
recipients.	O

et	O
al.Safety	O
and	O
clinical	O
efficacy	O
of	O
rapidly-generated	O
trivirus-directed	O
T	O
cells	O
as	O
treatment	O
for	O
adenovirus,	O
EBV,	O
and	O
CMV	O
infections	O
after	O
allogeneic	B
hematopoietic	I
stem	I
cell	I
transplant.	O

Detection	O
and	O
pharmacokinetics	O
of	O
a	O
cytomegalovirus	O
(CMV)	O
DNA	O
plasmid	O
in	O
human	O
plasma	O
during	O
a	O
clinical	O
trial	O
of	O
an	O
intramuscular	O
CMV	O
vaccine	O
in	O
hematopoietic	B
stem	I
cell	I
transplant	O
recipients.	O

Is	O
there	O
a	O
difference	O
in	O
post-transplant	O
lymphoproliferative	O
disorder	O
in	O
adults	O
after	O
solid	O
organ	O
and	O
haematologic	B
stem	I
cell	I
transplantation?	O
Experience	O
in	O
41	O
patients.	O

Epstein-Barr	O
virus-associated	O
pneumonia	O
in	O
patients	O
with	O
post-transplant	O
lymphoproliferative	O
disease	O
after	O
hematopoietic	B
stem	I
cell	I
transplantation.	O

et	O
al.The	O
role	O
of	O
HLA	O
mismatch,	O
splenectomy	O
and	O
recipient	O
Epstein-Barr	O
virus	O
seronegativity	O
as	O
risk	O
factors	O
in	O
post-transplant	O
lymphoproliferative	O
disorder	O
following	O
allogeneic	B
hematopoietic	I
stem	I
cell	I
transplantation.	O

Outcome	O
of	O
treatment	O
of	O
Epstein-Barr	O
virus-related	O
post-transplant	O
lymphoproliferative	O
disorder	O
in	O
hematopoietic	B
stem	I
cell	I
recipients:	O
a	O
comprehensive	O
review	O
of	O
reported	O
cases.	O

Successful	O
clearance	O
of	O
cutaneous	O
acyclovir-resistant,	O
foscarnet-refractory	O
herpes	O
virus	O
lesions	O
with	O
topical	O
cidofovir	O
in	O
an	O
allogeneic	B
hematopoietic	I
stem	I
cell	I
transplant	O
patient.	O

et	O
al.High	O
incidence	O
of	O
herpes	O
zoster	O
in	O
nonmyeloablative	B
hematopoietic	I
stem	I
cell	I
transplantation.	O

et	O
al.Incidence,	O
risk	O
factors	O
and	O
outcome	O
of	O
varicella-zoster	O
virus	O
infection	O
in	O
children	O
after	O
haematopoietic	B
stem	I
cell	I
transplantation.	O

et	O
al.Infectious	O
pulmonary	O
complications	O
after	O
stem	B
cell	I
transplantation	O
or	O
chemotherapy:	O
diagnostic	O
yield	O
of	O
bronchoalveolar	O
lavage.	O

et	O
al.Large-scale	O
multiplex	O
polymerase	O
chain	O
reaction	O
assay	O
for	O
diagnosis	O
of	O
viral	O
reactivations	O
after	O
allogeneic	B
hematopoietic	I
stem	I
cell	I
transplantation.	O

et	O
al.Reactivation	O
of	O
human	O
herpes	O
virus-6	O
after	O
pediatric	B
stem	I
cell	I
transplantation:	O
risk	O
factors,	O
onset,	O
clinical	O
symptoms	O
and	O
association	O
with	O
severity	O
of	O
acute	O
graft-versus-host	O
disease.	O

Clinical	O
outcomes	O
of	O
human	O
herpesvirus	O
6	O
reactivation	O
after	O
hematopoietic	B
stem	I
cell	I
transplantation.	O

et	O
al.Early	O
human	O
herpesvirus	O
type	O
6	O
reactivation	O
after	O
allogeneic	B
stem	I
cell	I
transplantation:	O
a	O
large-scale	O
clinical	O
study.	O

et	O
al.Plasma	O
HHV-6	O
viral	O
load-guided	O
preemptive	O
therapy	O
against	O
HHV-6	O
encephalopathy	O
after	O
allogeneic	B
stem	I
cell	I
transplantation:	O
a	O
prospective	O
evaluation.	O

et	O
al.Correlations	O
of	O
HHV-6	O
viral	O
load	O
and	O
plasma	O
IL-6	O
concentration	O
with	O
HHV-6	O
encephalitis	O
in	O
allogeneic	B
stem	I
cell	I
transplant	O
recipients.	O

Cord-blood	B
hematopoietic	I
stem	I
cell	I
transplant	O
confers	O
an	O
increased	O
risk	O
for	O
human	O
herpesvirus-6-associated	O
acute	O
limbic	O
encephalitis:	O
a	O
cohort	O
analysis.	O

et	O
al.Human	O
herpes	O
6	O
virus	O
encephalitis	O
complicating	O
allogeneic	B
hematopoietic	I
stem	I
cell	I
transplantation.	O

et	O
al.Immunotherapeutic	O
strategies	O
to	O
prevent	O
and	O
treat	O
human	O
herpesvirus	O
6	O
reactivation	O
after	O
allogeneic	B
stem	I
cell	I
transplantation.	O

(2016)	O
Autophagy	O
regulates	O
Notch	O
degradation	O
and	O
modulates	O
stem	B
cell	I
development	O
and	O
neurogenesis.	O

The	O
targets	O
of	O
these	O
cytokines	O
are	O
not	O
limited	O
to	O
the	O
immune	O
system,	O
and	O
LT	O
was	O
recently	O
shown	O
to	O
influence	O
CNS	B
neural	I
stem	I
cell	I
fate	O
by	O
promoting	O
glial	O
cell	O
differentiation	O
and	O
suppressing	O
neurogenesis	O
through	O
LTβR	O
signaling.	O

Co-stimulation	O
with	O
IL-1	O
2	O
and	O
TNF-	O
b1	O
induces	O
an	O
inflammatory	O
reactive	O
astrocyte	O
phenotype	O
with	O
neurosupportive	O
characteristics	O
in	O
a	O
human	B
pluripotent	I
stem	I
cell	I
model	O
system.	O

Bone	O
marrow-derived	O
myofibroblasts	O
contribute	O
to	O
the	O
mesenchymal	B
stem	I
cell	I
niche	O
and	O
promote	O
tumor	O
growth.	O

The	O
Stem	B
Cell	I
Revolution	O
Revealing	O
Protozoan	O
Parasites	O
Secrets	O
and	O
Paving	O
the	O
Way	O
towards	O
Vaccine	O
Development.	O

The	O
advent	O
of	O
stem	B
cell	I
technology	O
has	O
opened	O
exciting	O
new	O
possibilities	O
to	O
advance	O
our	O
knowledge	O
in	O
this	O
field.	O

A	O
further	O
crucial	O
development,	O
particularly	O
for	O
the	O
study	O
of	O
invasive	O
parasites,	O
was	O
the	O
discovery	O
that	O
stem	B
cells	I
can	O
organise	O
themselves	O
into	O
complex	O
structures	O
with	O
all	O
the	O
cell	O
types	O
and	O
characteristics	O
of	O
an	O
organ.	O

This	O
review	O
summarises	O
the	O
application	O
of	O
stem	B
cell	I
technology	O
for	O
the	O
understanding	O
of	O
protozoan	O
infectious	O
diseases	O
so	O
far.	O

Embryonic	O
Stem	O
Cells	O
are	O
derived	O
from	O
the	B
inner	I
cell	O
mass	O
of	O
the	O
blastocyst	O
at	O
the	O
early	O
stages	O
of	O
embryogenesis.	O

Malaria	O
is	O
perhaps	O
the	O
infectious	O
disease	O
with	O
the	O
widest	O
application	O
of	O
stem	B
cell	I
technology	O
to	O
answer	O
some	O
of	O
the	O
outstanding	O
questions.	O

Stem	B
cell	I
technology	O
has	O
provided	O
novel	O
avenues	O
to	O
address	O
this	O
stage.	O

Though	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
highlight	O
the	O
necessity	O
for	O
screening	O
for	O
this	O
parasite	O
before	O
stem	O
cell	O
transplantation	O
in	O
endemic	O
countries,	O
it	O
showed	O
that	O
stem	B
cells	I
can	O
be	O
a	O
versatile	O
model	O
to	O
study	O
this	O
parasite	O
[60].	O

Stem	B
cell	I
technology	O
offers	O
the	O
possibility	O
to	O
re-create	O
multicellular	O
structures	O
that	O
mimic	O
specific	O
organs.	O

As	O
stem	B
cells	I
are	O
pluripotent,	O
they	O
can	O
be	O
induced	O
to	O
generate	O
the	O
diverse	O
cell	O
types	O
of	O
an	O
organ	O
that	O
assemble	O
into	O
complex,	O
three-dimensional	O
clusters	O
and	O
organise	O
themselves	O
into	O
the	O
architecture	O
and	O
functionality	O
of	O
the	O
desired	O
organ	O
[61,62].	O

Murine	O
enteroids	O
have	O
also	O
been	O
used	O
to	O
understand	O
the	O
impact	O
of	O
the	O
parasite	O
on	O
the	O
intestinal	O
environment	O
[87],	O
showing	O
that	O
infection	O
leads	O
to	O
a	O
decrease	O
in	O
proliferation	O
and	O
expression	O
of	O
intestinal	B
stem	I
cell	I
markers	O
Lgr5	O
and	O
Sox9.	O

This	O
suggested	O
that	O
the	O
parasite	O
could	O
inhibit	O
intestinal	B
stem	I
cell	I
function	O
through	O
attenuation	O
of	O
the	O
Wnt/Beta-cat	O
signalling	O
pathway	O
resulting	O
in	O
apoptosis	O
and	O
senescence.	O

The	O
advances	O
in	O
stem	B
cell	I
technology	O
have	O
opened	O
new	O
avenues	O
to	O
develop	O
in	O
vitro	O
cellular	O
systems	O
[63,64]	O
that	O
can	O
be	O
adapted	O
to	O
provide	O
more	O
physiological	O
environments	O
to	O
grow	O
protozoan	O
parasites.	O

A	O
variety	O
of	O
stem	B
cell	I
lines	O
(ESC	O
or	O
iPS)	O
have	O
been	O
established	O
that	O
can	O
be	O
expanded,	O
cultured,	O
stored,	O
genetically	O
edited	O
and	O
differentiated	O
into	O
any	O
desired	O
cell	O
type,	O
providing	O
unlimited	O
access	O
to	O
cell	O
types	O
as	O
well	O
as	O
mini-organs	O
for	O
modelling	O
infectious	O
diseases.	O

As	O
any	O
in	O
vitro	O
system,	O
stem	B
cell	I
models	O
also	O
have	O
some	O
limitations	O
that	O
need	O
to	O
be	O
taken	O
into	O
consideration.	O

Stem	B
cell	I
technologies	O
are	O
in	O
line	O
with	O
the	O
3Rs	O
(Replacement,	O
Reduction	O
and	O
Refinement)	O
principles	O
avoiding	O
and	O
reducing	O
costly	O
animal	O
experimentation,	O
at	O
the	O
same	O
time	O
providing	O
stable	O
and	O
more	O
physiological	O
models	O
for	O
the	O
study	O
of	O
infectious	O
diseases.	O

Adipose	B
tissue-derived	I
mesenchymal	I
stem	I
cells	I
as	O
a	O
new	O
host	O
cell	O
in	O
latent	O
leishmaniasis.	O

Vicente-Due	O
as,	O
S	O
nchez-Garc	O
eda,	O
and	O
colleagues	O
review	O
the	O
notion	O
of	O
epigenetic	B
stem	I
cell	I
rewiring	O
as	O
a	O
driver	O
of	O
cancer,	O
emphasising	O
that	O
this	O
mechanism	O
represents	O
a	O
common	O
mechanism	O
at	O
work	O
in	O
epithelial	O
tumours	O
[8].	O

As	O
emphasized	O
in	O
the	O
review	O
by	O
S	O
1nchez-Garc	O
da,	O
a	O
new	O
view	O
on	O
normal	O
haematopoiesis	O
also	O
has	O
important	O
implications	O
for	O
the	O
way	O
we	O
view	O
the	O
initiation	O
of	O
cancer,	O
perhaps	O
as	O
a	O
fixed	O
lineage-choice	O
in	O
a	O
LSC/cancer	B
stem	I
cell	I
that	O
an	O
oncogenic	O
event	O
wires.	O

In	O
the	O
germline,	O
stem	B
cells	I
adopt	O
one	O
of	O
three	O
possible	O
fates:	O
mitotic	O
cell	O
cycle,	O
or	O
gamete	O
formation	O
via	O
meiosis,	O
producing	O
either	O
sperm	O
or	O
oocytes.	O

Thus,	O
it	O
is	O
likely	O
that	O
trd-1,	O
in	O
common	O
with	O
other	O
factors,	O
was	O
recruited	O
to	O
the	O
germline	O
sex	O
determination	O
pathway	O
while	O
retaining	O
a	O
role	O
in	O
germline	B
stem	I
cell	I
maintenance,	O
thus	O
two	O
very	O
distinct	O
pathways	O
have	O
evolved	O
in	O
the	O
same	O
tissue	O
to	O
control	O
the	O
balance	O
between	O
proliferation	O
and	O
differentiation	O
[11].	O

elegans	O
CBFbeta	O
homologue	O
BRO-1	O
interacts	O
with	O
the	O
Runx	O
factor,	O
RNT-1,	O
to	O
promote	B
stem	I
cell	I
proliferation	O
and	O
self-renewal.	O

Byrd	O
DT,	O
Knobel	O
K,	O
Affeldt	O
K,	O
Crittenden	O
SL,	O
Kimble	O
J	O
(2014)	O
A	O
DTC	O
Niche	O
Plexus	O
Surrounds	O
the	O
Germline	B
Stem	I
Cell	I
Pool	O
in	O
Caenorhabditis	O
elegans	O
.	O

Isolating	O
intestinal	B
stem	I
cells	I
from	O
adult	O
Drosophila	O
midguts	O
by	O
FACS	O
to	O
study	O
stem	O
cell	O
behavior	O
during	O
aging.	O

Between	O
January	O
2013	O
and	O
June	O
2016,	O
2,714,110	O
samples	O
largely	O
from	O
German,	O
Polish	O
and	O
UK-based	O
potential	O
stem	B
cell	I
donors	O
have	O
been	O
processed.	O

During	O
registration	O
donors	O
sign	O
an	O
informed	O
consent	O
approving	O
HLA	O
genotyping	O
and	O
other	O
analyses	O
to	O
facilitate	O
or	O
improve	O
donor	O
search	O
for	O
stem	B
cell	I
transplantation.	O

HLA	O
association	O
with	O
hematopoietic	B
stem	I
cell	I
transplantation	O
outcome:	O
the	O
number	O
of	O
mismatches	O
at	O
HLA-A,	O
-B,	O
-C,	O
-DRB1,	O
or	O
-DQB1	O
is	O
strongly	O
associated	O
with	O
overall	O
survival.	O

Simulation	O
shows	O
that	O
HLA-matched	B
stem	I
cell	I
donors	O
can	O
remain	O
unidentified	O
in	O
donor	O
searches.	O

Immunogenetics	O
of	O
HLA	O
null	O
alleles:	O
implications	O
for	O
blood	B
stem	I
cell	I
transplantation.	O

Ion	O
channelopathies	O
in	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
derived	O
cardiomyocytes:	O
a	O
dynamic	O
clamp	O
study	O
with	O
virtual	O
IK1.	O

Allele-specific	O
RNA	O
interference	O
rescues	O
the	O
long-QT	O
syndrome	O
phenotype	O
in	O
human-induced	B
pluripotency	I
stem	I
cell	I
cardiomyocytes.	O

Isogenic	B
human	I
pluripotent	I
stem	I
cell	I
pairs	O
reveal	O
the	O
role	O
of	O
a	O
KCNH2	O
mutation	O
in	O
long-QT	O
syndrome.	O

Recessive	O
cardiac	O
phenotypes	O
in	O
induced	B
pluripotent	I
stem	I
cell	I
models	O
of	O
Jervell	O
and	O
Lange-Nielsen	O
syndrome:	O
disease	O
mechanisms	O
and	O
pharmacological	O
rescue.	O

Dantrolene	O
rescues	O
arrhythmogenic	O
RYR2	O
defect	O
in	O
a	O
patient-specific	O
stem	B
cell	I
model	O
of	O
catecholaminergic	O
polymorphic	O
ventricular	O
tachycardia.	O

A	O
human	B
pluripotent	I
stem	I
cell	I
model	O
of	O
catecholaminergic	O
polymorphic	O
ventricular	O
tachycardia	O
recapitulates	O
patient-specific	O
drug	O
responses.	O

Patient-specific	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
model	O
assessed	O
with	O
electrical	O
pacing	O
validates	O
S107	O
as	O
a	O
potential	O
therapeutic	O
agent	O
for	O
catecholaminergic	O
polymorphic	O
ventricular	O
tachycardia.	O

Cardiolipin	O
deficiency	O
affects	O
respiratory	O
chain	O
function	O
and	O
organization	O
in	O
an	O
induced	B
pluripotent	I
stem	I
cell	I
model	O
of	O
Barth	O
syndrome.	O

Modeling	O
the	O
mitochondrial	O
cardiomyopathy	O
of	O
Barth	O
syndrome	O
with	O
induced	B
pluripotent	I
stem	I
cell	I
and	O
heart-on-chip	O
technologies.	O

An	O
induced	B
pluripotent	I
stem	I
cell	I
model	O
of	O
hypoplastic	O
left	O
heart	O
syndrome	O
(HLHS)	O
reveals	O
multiple	O
expression	O
and	O
functional	O
differences	O
in	O
HLHS-derived	O
cardiac	O
myocytes.	O

Characterization	O
of	O
the	O
molecular	O
mechanisms	O
underlying	O
increased	O
ischemic	O
damage	O
in	O
the	O
aldehyde	O
dehydrogenase	O
2	O
genetic	O
polymorphism	O
using	O
a	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
model	O
system.	O

Concise	O
review:	O
measuring	O
physiological	O
responses	O
of	O
human	B
pluripotent	I
stem	I
cell	I
derived	O
cardiomyocytes	O
to	O
drugs	O
and	O
disease.	O

Cardiac	O
non-myocyte	O
cells	O
show	O
enhanced	O
pharmacological	O
function	O
suggestive	O
of	O
contractile	O
maturity	O
in	O
stem	B
cell	I
derived	O
cardiomyocyte	O
microtissues.	O

Stage-specific	O
optimization	O
of	O
activin/nodal	O
and	O
BMP	O
signaling	O
promotes	O
cardiac	O
differentiation	O
of	O
mouse	B
and	I
human	I
pluripotent	I
stem	I
cell	I
lines.	O

Recent	O
studies	O
indicate	O
that	O
pericytes	O
in	O
blood	O
vessel	O
walls	O
have	O
adipogenic	O
potential,	O
express	O
mesenchymal	B
stem	I
cell	I
markers	O
and	O
are	O
multipotent	O
[4].	O

HBMSCs	O
are	O
more	O
difficult	O
to	O
handle	O
than	O
mouse	B
stem	I
cell	I
lines	O
but	O
their	O
importance	O
and	O
therapeutic	O
potential	O
necessitate	O
their	O
use	O
in	O
research	O
of	O
the	O
type	O
outlined	O
herein.	O

The	O
previous	O
studies	O
are	O
focused	O
on	O
the	O
mouse	B
stem	I
cell	I
lines	O
but	O
the	O
regulation	O
of	O
them	O
could	O
be	O
different	O
in	O
some	O
aspects,	O
and	O
results	O
of	O
murine	O
cells	O
would	O
be	O
less	O
convincing	O
in	O
interpreting	O
the	O
onset	O
of	O
human	O
disease.	O

The	O
use	O
of	O
extra-cellular	O
matrix	O
(ECM)-coated	O
media	O
such	O
as	O
collagen	O
Type	O
IV	O
helps	O
to	O
mimic	O
the	O
microenvironment	O
found	O
within	O
mammalian	O
tissues	O
and	O
has	O
been	O
demonstrated	O
to	O
drive	O
stem	B
cell	I
differentiation	O
towards	O
functional	O
SMCs	O
[86,	O
87].	O

Immortalized	O
primary	O
neural	B
crest	I
stem	I
cell	I
lines	O
have	O
long	O
been	O
used	O
as	O
a	O
model	O
to	O
study	O
SMC	O
differentiation	O
in	O
vitro	O
[96].	O

Regenerating	O
diseased	O
tissues	O
and	O
organs,	O
once	O
thought	O
to	O
belong	O
in	O
the	O
realms	O
of	O
science	O
fiction,	O
is	O
now	O
gaining	O
widespread	O
acceptance	O
as	O
one	O
of	O
the	O
most	O
exciting	O
future	O
applications	O
of	O
stem	B
cell	I
technology.	O

Clinical	O
trials	O
for	O
cardiovascular	O
regeneration	O
to	O
date	O
have	O
used	O
adult	O
stem	O
cell	O
populations	O
such	O
as	O
bone	O
marrow	O
cells	O
or	O
mesenchymal	B
stem	I
cells	I
with	O
mixed	O
results	O
[131].	O

Nevertheless,	O
the	O
rapid	O
progress	O
in	O
this	O
field	O
to	O
date	O
is	O
a	O
reflection	O
of	O
the	O
synergy	O
in	O
bringing	O
together	O
the	O
complementary	O
fields	O
of	O
stem	B
cell	I
biology	O
and	O
vascular	O
biology,	O
and	O
bodes	O
well	O
for	O
further	O
major	O
advances..	O

Defining	O
pathways	O
that	O
enforce	O
cell	O
lineage	O
specification	O
in	O
early	O
development	O
and	O
stem	O
cells.	O
BMP	O
induction	O
of	O
Id	O
proteins	O
suppresses	O
differentiation	O
and	O
sustains	O
embryonic	B
stem	I
cell	I
self-renewal	O
in	O
collaboration	O
with	O
STAT3.	O

Embryonic	B
stem	I
cell	I
strategies	O
to	O
explore	O
neural	O
crest	O
development	O
in	O
human	O
embryos.	O

Pathway	O
for	O
differentiation	O
of	O
human	B
embryonic	I
stem	I
cells	I
to	O
vascular	O
cell	O
components	O
and	O
their	O
potential	O
for	O
vascular	O
regeneration.	O

Embryoid	O
body	O
morphology	O
influences	O
diffusive	O
transport	O
of	O
inductive	O
biochemicals:	O
a	O
strategy	O
for	O
stem	B
cell	I
differentiation.	O

Pluripotent	B
stem	I
cell	I
differentiation	O
into	O
vascular	O
cells:	O
a	O
novel	O
technology	O
with	O
promises	O
for	O
vascular	O
re(generation)	O
Pharmacol	O
Ther.	O

Transforming	O
growth	O
factor-beta-induced	O
differentiation	O
of	O
smooth	O
muscle	O
from	O
a	O
neural	B
crest	I
stem	I
cell	I
line.	O

A	O
human	O
iPSC	O
model	O
of	O
Hutchinson	O
Gilford	O
Progeria	O
reveals	O
vascular	O
smooth	O
muscle	O
and	O
mesenchymal	B
stem	I
cell	I
defects.	O

Stage-specific	O
optimization	O
of	O
activin/nodal	O
and	O
BMP	O
signaling	O
promotes	O
cardiac	O
differentiation	O
of	O
mouse	B
and	I
human	I
pluripotent	I
stem	I
cell	I
lines.	O

Gene	O
body	O
methylation	O
of	O
the	O
dimethylarginine	O
dimethylamino-hydrolase	O
2	O
(Ddah2)	O
gene	O
is	O
an	O
epigenetic	O
biomarker	O
for	O
neural	B
stem	I
cell	I
differentiation.	O

However,	O
different	O
therapeutic	O
approaches	O
are	O
in	O
the	O
early	O
clinical	O
phase	O
including	O
stem	B
cell	I
therapy,4	O
gene	O
therapy	O
(ClinicalTrials.gov	O
identifier	O
NCT01736592,	O
NCT01367444)	O
and	O
medical	O
therapy	O
that	O
markedly	O
slow	O
the	O
formation	O
of	O
toxic	O
components	O
(ClinicalTrials.gov	O
identifier	O
NCT02402660).	O

A	O
novel	O
immunodeficient	O
mouse	O
model	O
RAG2	O
common	O
cytokine	O
receptor	O
gamma	O
chain	O
double	O
mutants	O
requiring	O
exogenous	O
cytokine	O
administration	O
for	O
human	B
hematopoietic	I
stem	I
cell	I
engraftment.	O

Beta2	O
microglobulin-deficient	O
(B2m(null))	O
NOD/SCID	O
mice	O
are	O
excellent	O
recipients	O
for	O
studying	O
human	B
stem	I
cell	I
function.	O

Parameters	O
for	O
establishing	O
humanized	O
mouse	O
models	O
to	O
study	O
human	O
immunity:	O
analysis	O
of	O
human	B
hematopoietic	I
stem	I
cell	I
engraftment	O
in	O
three	O
immunodeficient	O
strains	O
of	O
mice	O
bearing	O
the	O
IL2rgamma(null)	O
mutation.	O

In	O
this	O
article,	O
we	O
review	O
the	O
insight	O
into	O
the	O
mTOR	O
activity	O
in	O
neural	B
stem	I
cell	I
functions	O
thereby	O
illustrating	O
the	O
close	O
relationship	O
between	O
mTOR	O
and	O
the	O
pathological	O
events	O
which	O
are	O
mainly	O
occurred	O
in	O
brain	O
developmental	O
disorders	O
and	O
pediatric	O
brain	O
tumors..	O

Innate	O
neural	B
stem	I
cell	I
heterogeneity	O
determines	O
the	O
patterning	O
of	O
glioma	O
formation	O
in	O
children.	O

Neurofibromin	O
regulates	O
neural	B
stem	I
cell	I
proliferation,	O
survival,	O
and	O
astroglial	O
differentiation	O
in	O
vitro	O
and	O
in	O
vivo.	O

The	O
only	O
curative	O
therapy	O
for	O
most	O
high	O
risk	O
AML	O
and	O
MDS	O
patients	O
is	O
allogeneic	B
hematopoietic	I
stem	I
cell	I
transplant	O
(allo	O
HSCT).	O

Background/Case	O
Studies:	O
Lymphoma	O
patients	O
receiving	O
>0.5x109	O
lymphocytes(lymph)/Kg	O
during	O
peripheral	B
blood	I
stem	I
cell	I
transplant	O
have	O
superior	O
survival.	O

The	O
impact	O
of	O
such	O
delay	O
on	O
hematopoietic	B
stem	I
cell	I
function	O
is	O
unclear	O
since	O
most	O
studies	O
have	O
not	O
used	O
transplantation	O
assays	O
that	O
measure	O
HSC	O
key	O
properties	O
and	O
activities.	O

A	O
Streamlined	O
Mixed	O
Lymphocyte	O
Reaction	O
(MLR)	O
Assay	O
for	O
Evaluation	O
of	O
Human	B
Mesenchymal	I
Stem	I
Cell	I
Immunomodulation	O
Activity.	O

Biosimilar	O
Based	O
Mobilization	O
Of	O
Peripheral	O
Blood	O
Hematopoietic	O
Stem	O
Cells	B
For	I
Autologous	I
Stem	I
Cell	I
Transplantation.	O

Two	O
patients	O
could	O
not	O
undergo	O
hematopoietic	B
stem	I
cell	I
transplantation	O
due	O
low	O
CD34+	O
cellularity..	O

Comparison	O
of	O
the	O
Terumo	O
BCT	O
MNC	O
and	O
Cmnc	O
Protocols	O
for	O
Peripheral	B
Blood	I
Stem	I
Cell	I
Collections.	O

Background/Case	O
Studies:	O
Terumo	O
BCT	O
recently	O
offered	O
a	O
new	O
method	O
of	O
peripheral	B
blood	I
stem	I
cell	I
collection	O
using	O
the	O
Spectra	O
Optia,	O
an	O
apheresis	O
instrument.	O

Conundrums	O
Surrounding	O
Organ	O
Transplant	O
in	O
a	O
Hematopoietic	B
Stem	I
Cell	I
Transplant	O
Recipient.	O

Background/Case	O
Studies:	O
Hematopoietic	B
stem	I
cell	I
donors	O
and	O
their	O
recipients	O
need	O
not	O
have	O
a	O
matching	O
blood	O
type.	O

Viability,	O
Hematopoietic	B
stem	I
cell	I
(CD34+CD38	O
CD45RA	O
CD90+CD49f+	O
cells)	O
phenotyping	O
and	O
CFU	O
assays	O
were	O
done	O
following	O
first	O
thaw	O
(PT1),	O
post	O
transduction	O
(PTxn)	O
and	O
second	O
cryopreservation	O
thaw	O
(PT2)..	O

Background/Case	O
Studies:	O
Autologous	B
peripheral	I
blood	I
stem	I
cell	I
transplantation	O
has	O
been	O
used	O
as	O
a	O
powerful	O
resource	O
during	O
the	O
treatment	O
of	O
some	O
hematological	O
malignancies.	O

Evaluation	O
of	O
Efficacy	O
of	O
Peripheral	B
Blood	I
Stem	I
Cell	I
Collection	O
Endpoint	O
with	O
Prediction	O
Algorithm.	O

Background/Case	O
Studies:	O
Hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
is	O
a	O
therapeutic	O
strategy	O
used	O
to	O
treat	O
patients	O
with	O
onco	O
hematological	O
diseases.	O

As	O
such,	O
a	O
growing	O
number	O
of	O
stem	B
cell	I
banks	O
have	O
established	O
UC	O
storage	O
programs	O
based	O
on	O
mounting	O
preclinical	O
evidence	O
of	O
its	O
therapeutic	O
potential.	O

This	O
work	O
describes	O
and	O
characterizes	O
the	O
isolation	O
of	O
MSCs	O
from	O
UC	O
tissue	O
cryopreserved	O
as	O
a	O
composite	O
material	O
at	O
a	O
family	B
stem	I
cell	I
bank	O
for	O
5	O
years..	O

Background/Case	O
Studies:	O
Steroid	O
refractory	O
acute	O
graft	O
versus	O
host	O
disease	O
(GvHD)	O
is	O
a	O
serious	O
complication	O
of	O
allogeneic	B
hematopoietic	I
stem	I
cell	I
transplantation	O
(HSCT).	O

More	O
experience	O
accumulates	O
in	O
the	O
immunomodulatory	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
infusion	O
in	O
numerous	O
immunopathological	O
disorders	O
such	O
as	O
GvHD	O
and	O
signals.	O

The	O
median	O
time	O
of	O
MSC's	O
first	O
infusion	O
was	O
274	O
(114	O
1981)	O
days	O
after	O
the	O
stem	B
cell	I
transplantation	O
(HSCT)	O
and	O
165	O
(19	O
1974)	O
days	O
after	O
the	O
first	O
episode	O
of	O
GvHD.	O

Background/Case	O
Studies:	O
Stem	B
cell	I
collection	O
by	O
leukapheresis	O
for	O
transplantation	O
is	O
a	O
significant	O
endeavor	O
for	O
the	O
patient	O
and	O
the	O
clinical	O
team.	O

Data	O
was	O
collected	O
over	O
6	O
months	O
from	O
every	O
patient	O
who	O
underwent	O
a	O
stem	B
cell	I
collection.	O

The	O
Effect	O
of	O
Unrelated	B
Allogeneic	I
Peripheral	I
Blood	I
Stem	I
Cell	I
Donor	O
Ethnicity	O
on	O
Mobilization	O
and	O
Apheresis	O
Collection	O
of	O
CD34+	O
Cells.	O

This	O
small	O
data	O
set	O
would	O
suggest	O
that	O
people	O
of	O
Hispanic	O
ethnicity	O
maintain	O
a	O
more	O
robust	O
and	O
quickly	O
responsive	B
stem	I
cell	I
pool,	O
even	O
as	O
they	O
age.	O

If	O
proven,	O
this	O
has	O
far	O
reaching	O
implications	O
within	O
the	O
stem	B
cell	I
research	O
and	O
therapy	O
arena..	O

Use	O
of	O
Buffy	O
Coat	O
Derived	O
Leukocyte	O
Enriched	O
Products	O
for	O
Evaluation	O
of	O
a	O
Plasma	B
Reduction	I
Stem	I
Cell	I
Manufacturing	O
Protocol.	O

Infusion	O
pumps	O
are	O
routinely	O
used	O
for	O
blood	O
products,	O
but	O
are	O
not	O
commonly	O
used	O
for	O
administration	O
of	O
Peripheral	B
Blood	I
Stem	I
Cell	I
products	O
(PBSCs).	O

Therapeutic	O
plasmapheresis	O
was	O
the	O
most	O
frequent	O
procedure	O
(50.4%)	O
followed	O
by	O
autologous	B
peripheral	I
blood	I
stem	I
cell	I
collection	O
(23.9%),	O
allogeneic	O
PBSC	O
collection	O
(11.0%),	O
donor	O
leukapheresis	O
(4.0%),	O
and	O
therapeutic	O
leukapheresis	O
(3.9%).	O

Background/Case	O
Studies:	O
Viral	O
infections	O
(Adenovirus,	O
EBV,	O
CMV,	O
BK,	O
HHV6,	O
and	O
RSV	O
etc.)	O
have	O
been	O
implicated	O
as	O
major	O
contributors	O
to	O
post	O
transplant	O
morbidity	O
and	O
mortality	O
in	O
Hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
from	O
unrelated	O
donors.	O

The	O
buffy	O
coats	O
were	O
submitted	O
to	O
the	O
GMP	B
Stem	I
Cell	I
Lab	O
for	O
processing	O
of	O
Cytomegalovirus	O
specific	O
CTLs.	O

All	O
of	O
the	O
buffy	O
coats	O
received	O
by	O
the	O
GMP	B
Stem	I
Cell	I
Lab	O
were	O
adequate	O
in	O
cell	O
numbers	O
to	O
be	O
processed..	O

We	O
have	O
active	O
programs	O
in	O
high	O
risk	O
OB,	O
stem	B
cell	I
transplant,	O
solid	O
organ	O
transplant	O
(heart,	O
liver,	O
and	O
kidney),	O
CT	O
surgery,	O
ECMO,	O
oncology	O
and	O
critical	O
care.	O

Granulocyte	O
Transfusion	O
for	O
Pediatric	O
Patients	O
Non	O
Responsive	O
to	O
Antibiotic	O
and	O
Antifungal	O
Undergoing	O
High	O
Dose	O
Chemotherapy	O
and	O
Hematopoietic	B
Stem	I
Cell	I
Transplantation.	O

Background/Case	O
Studies:	O
Bacterial	O
and	O
fungal	O
infections	O
remain	O
a	O
significant	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
severely	O
neutropenic	O
patients	O
with	O
hematological	O
disease	O
receiving	O
high	O
dose	O
chemotherapy	O
and	O
hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT).	O

A	O
Retrospective	O
Analysis	O
of	O
the	O
HLA	O
DPB1	O
Frequency	O
in	O
10/10	O
HLA	O
Matched	O
Unrelated	B
Hematopoietic	I
Stem	I
Cell	I
Transplantation.	O

Background/Case	O
Studies:	O
Hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
from	O
matched	O
unrelated	O
donors	O
is	O
increasingly	O
being	O
used	O
all	O
over	O
the	O
world.	O

The	O
impact	O
of	O
HLA	O
DPB1	O
mismatches	O
after	O
unrelated	B
hematopoietic	I
stem	I
cell	I
transplantation	O
(HSCT)	O
remains	O
controversial..	O

On	O
the	O
suspicion	O
that	O
the	O
patient	O
had	O
non	O
erythroid	O
cells	O
producing	O
B	O
reactive	O
type	O
1	O
chains,	O
a	O
sample	O
from	O
a	O
hematopoietic	B
stem	I
cell	I
transplant	O
(HSCT)	O
patient	O
(group	O
B	O
secretor	O
receiving	O
group	O
O	O
donor	O
cells)	O
was	O
included	O
as	O
a	O
control	O
and	O
gave	O
the	O
same	O
type	O
of	O
reactions..	O

Study	O
Design/Method:	O
Patients	O
who	O
had	O
not	O
undergone	O
hematopoietic	B
stem	I
cell	I
transplantation	O
were	O
tested	O
using	O
a	O
flow	O
based	O
assay	O
for	O
anti	O
HLA	O
Class	O
I	O
antibodies.	O

However,	O
whether	O
a	O
hematopoietic	B
stem	I
cell	I
or	O
organ	O
transplant	O
recipient	O
experiences	O
hemolysis	O
when	O
a	O
transplant	O
contains	O
unintended	O
antibody	O
forming	O
passenger	O
lymphocytes	O
depends,	O
by	O
chance,	O
on	O
the	O
recipient's	O
blood	O
group	O
phenotype.	O

Results/Finding:	O
Of	O
63	O
published	O
cases	O
(31	O
reports)	O
of	O
TA	O
PLS,	O
8	O
(4	O
reports)	O
were	O
stem	B
cell	I
and	O
55	O
(27	O
reports)	O
were	O
organ	O
transplants.	O

All	O
8(100%)	O
stem	B
cell	I
transplants	O
and	O
52	O
(95%)	O
organ	O
transplants	O
were	O
associated	O
with	O
hemolysis,	O
reflecting	O
an	O
overwhelming	O
bias	O
for	O
identifying	O
TA	O
PLS	O
associated	O
with	O
hemolysis.	O

Of	O
the	O
4	O
reports	O
of	O
stem	B
cell	I
TA	O
PLS,	O
3	O
actively	O
screened	O
for	O
antibodies	O
in	O
the	O
immediate	O
post	O
transplant	O
period,	O
and	O
of	O
the	O
27	O
reports	O
of	O
organ	O
TA	O
PLS,	O
1	O
actively	O
screened	O
for	O
antibodies.	O

These	O
screens	O
detected	O
5	O
cases	O
of	O
stem	B
cell	I
TA	O
PLS	O
before	O
hemolysis	O
became	O
apparent	O
and	O
2	O
cases	O
of	O
organ	O
TA	O
PLS	O
with	O
antibodies	O
without	O
hemolysis.	O

Recent	O
data	O
in	O
leukemia	O
and	O
hematopoietic	B
stem	I
cell	I
recipients	O
transfused	O
exclusively	O
with	O
leukoreduced	O
products	O
show	O
that	O
4%	O
to	O
8%	O
develop	O
Alloimmune	O
platelet	O
refractoriness..	O

tests	O
for	O
hemostasis	O
and	O
tissue	O
typing	O
for	O
possible	O
donors	O
as	O
well	O
as	O
patients	O
waiting	O
for	O
organ	O
or	O
stem	B
cell	I
transplantation.	O

Our	O
hospital	O
based	O
TS	O
supports	O
a	O
full	O
range	O
of	O
services:	O
a	O
Level	O
I	O
trauma	O
service;	O
stem	B
cell	I
and	O
solid	O
organ	O
transplant	O
services;	O
a	O
brisk	O
cardiothoracic	O
surgical	O
program;	O
a	O
high	O
risk	O
obstetrical	O
service;	O
and	O
high	O
acuity	O
medical/surgical	O
services.	O

Advances	O
of	O
stem	B
cell	I
therapeutics	O
in	O
cutaneous	O
wound	O
healing	O
and	O
regeneration.	O

IMI	O
projects	O
have	O
already	O
developed	O
over	O
35	O
new	O
validated	O
drug	O
targets;	O
over	O
30	O
new	O
in	O
vitro	O
models	O
and	O
tools;	O
over	O
300	O
new	O
in	O
silico	O
(computer-based)	O
models;	O
over	O
70	O
new	O
animal	O
models;	O
over	O
1500	O
new	O
stem	B
cell	I
lines;	O
a	O
dozen	O
novel	O
imaging	O
techniques;	O
over	O
300	O
biomarkers	O
in	O
development,	O
of	O
which	O
more	O
than	O
130	O
have	O
been	O
validated,	O
promising	O
better	O
diagnosis	O
and	O
treatment	O
design	O
for	O
patients;	O
and	O
close	O
to	O
40	O
cohorts	O
and	O
registries	O
[14].	O

In	O
support	O
of	O
this,	O
IL-15	O
has	O
been	O
shown	O
to	O
costimulate	B
stem	I
cell	I
proliferation	O
7,	O
and	O
extend	O
the	O
survival	O
of	O
normal	O
NK	O
cells	O
8	O
and	O
T	O
cells	O
50	O
by	O
preventing	O
apoptosis.	O

Over	O
the	O
past	O
45	O
years,	O
our	O
understanding	O
of	O
NK	O
cell	O
biology	O
has	O
grown	O
and	O
evolved,	O
and	O
it	O
is	O
now	O
clear	O
that	O
NK	O
cells	O
play	O
important	O
roles	O
in	O
diverse	O
biological	O
processes,	O
ranging	O
from	O
tumor	O
surveillance	O
and	O
anti-pathogen	O
defense	O
to	O
metabolic	O
disorders,	O
inflammatory	O
diseases,	O
stem	B
cell	I
transplantation,	O
neuronal	O
pruning,	O
and	O
pregnancy	O
(3)..	O

NK	O
cells	O
and	O
other	O
innate	O
lymphoid	O
cells	O
in	O
hematopoietic	B
stem	I
cell	I
transplantation.	O

Under	O
such	O
conditions,	O
endogenous	O
BCL-XL	O
might	O
be	O
required	O
to	O
counteract	O
BH3-only	O
proteins	O
exclusively	O
engaged	O
in	O
the	O
imperfect	O
microenvironment	O
but	O
not	O
during	O
clinical	O
hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT).	O

Haematopoietic	B
stem	I
cell	I
survival	O
and	O
transplantation	O
efficacy	O
is	O
limited	O
by	O
the	O
BH3-only	O
proteins	O
Bim	O
and	O
Bmf.	O

Stem	B
cell	I
factor	O
protects	O
erythroid	O
precursor	O
cells	O
from	O
chemotherapeutic	O
agents	O
via	O
up-regulation	O
of	O
BCL-2	O
family	O
proteins.	O

Transient	O
apoptosis	O
inhibition	O
in	O
donor	B
stem	I
cells	I
improves	O
hematopoietic	O
stem	O
cell	O
transplantation.	O

Leukemias	O
represent	O
abnormal	O
and	O
poorly	O
regulated	O
hematopoiesis,	O
with	O
leukemia	B
stem	I
cells	I
capable	O
of	O
self-renewal	O
as	O
well	O
as	O
the	O
generation	O
of	O
multiple	O
cell	O
types	O
[1].	O

The	O
CML-associated	O
p210	O
Bcr-Abl	O
gene	O
is	O
found	O
in	O
myeloid,	O
erythroid,	O
and	O
lymphoid	O
lineage	O
cells	O
in	O
CML	O
patients,	O
suggesting	O
that	O
the	O
translocation	O
originally	O
occurred	O
in	O
a	O
pluripotent	B
stem	I
cell	I
[3].	O

For	O
most	O
experiments,	O
we	O
limited	O
transduction	O
with	O
mouse	B
stem	I
cell	I
viruses	O
(MSCVs)	O
encoding	O
Bcr-Abl	O
and/or	O
green	O
fluorescent	O
protein	O
(GFP)	O
to	O
only	O
a	O
small	O
percentage	O
of	O
progenitors	O
to	O
more	O
accurately	O
reflect	O
the	O
rare	O
occurrence	O
of	O
oncogenic	O
initiating	O
events	O
in	O
a	O
background	O
of	O
unmutated	O
cells,	O
allowing	O
for	O
competition	O
between	O
Bcr-Abl-positive	O
and	O
-negative	O
progenitor	O
cells.	O

In	O
this	O
regard,	O
it	O
is	O
unlikely	O
that	O
all	O
conditions	O
that	O
globally	O
impair	O
cell	O
cycle	O
progression	O
in	O
a	O
stem	B
cell	I
pool	O
will	O
promote	O
tumorigenesis,	O
particularly	O
if	O
these	O
impaired	O
contexts	O
cannot	O
be	O
easily	O
overcome	O
by	O
oncogenic	O
mutation	O
or	O
do	O
not	O
sufficiently	O
promote	O
mutation	O
accumulation.	O

Indeed,	O
for	O
surviving	O
mice,	O
GFP	O
expression	O
in	O
peripheral	O
blood	O
became	O
undetectable	O
(unpublished	O
data),	O
indicating	O
that	O
Bcr-Abl	O
expression	O
is	O
disfavored	O
in	O
stem	B
cell	I
pools	O
in	O
the	O
long-term.	O

These	O
contexts	O
of	O
dNTP	O
restriction	O
are	O
thought	O
to	O
promote	O
cancer	O
in	O
part	O
by	O
increasing	O
mutation	O
rates,	O
and	O
our	O
results	O
suggest	O
that	O
poorly	O
competitive	O
stem	B
cell	I
pools	O
also	O
play	O
an	O
important	O
role.	O

Thus,	O
as	O
with	O
the	O
natural	O
selection	O
of	O
species,	O
poor	O
fitness	O
selects	O
for	O
adaptive	O
mutations	O
in	O
stem	B
cell	I
pools..	O

Harvested	O
donor	O
BM	O
cells	O
were	O
enriched	O
for	O
c-Kit+	O
cells	O
by	O
MACS	O
(Miltenyi	O
Biotec,	O
Bad	O
Gladbach,	O
Germany)	O
and	O
then	O
cultured	O
overnight	O
in	O
IMDM	O
plus	O
15%	O
defined	O
fetal	O
bovine	O
serum	O
(HyClone,	O
South	O
Logan,	O
Utah,	O
United	O
States)	O
and	O
0.1%	O
bovine	O
serum	O
antigen	O
(Sigma),	O
with	O
the	O
cytokines	O
100	O
ng/ml	O
human	B
stem	I
cell	I
factor	O
(gift	O
from	O
Dr.	O

Normal	O
and	O
leukemic	O
hematopoiesis:	O
Are	O
leukemias	O
a	O
stem	B
cell	I
disorder	O
or	O
a	O
reacquisition	O
of	O
stem	O
cell	O
characteristics?	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A.	O

Distinct	O
patterns	O
of	O
hematopoietic	B
stem	I
cell	I
involvement	O
in	O
acute	O
lymphoblastic	O
leukemia.	O

Mouse	O
strain	O
variability	O
in	O
the	O
expression	O
of	O
the	O
hematopoietic	B
stem	I
cell	I
antigen	O
Ly-6A/E	O
by	O
bone	O
marrow	O
cells.	O

Neural	B
stem	I
cells	I
with	O
self-renewal	O
and	O
multipotent	O
properties	O
serve	O
as	O
an	O
ideal	O
cell	O
source	O
for	O
transplantation	O
to	O
treat	O
neurodegenerative	O
insults	O
such	O
as	O
Parkinson's	O
disease.	O

Philip	O
Schwartz	O
at	O
National	B
Human	I
Neural	I
Stem	I
Cell	I
Resource,	O
Children's	O
Hospital	O
of	O
Orange	O
County	O
Research	O
Institute,	O
CA	O
(NIH	O
grant	O
HD059967).	O

We	O
started	O
our	O
DNA	O
microarray	O
data	O
analysis	O
by	O
studying	O
expression	O
level	O
of	O
the	O
generally	O
accepted	O
stem	B
cell	I
markers	O
such	O
as	O
POU,	O
transcription	O
factor	O
1	O
(Oct3/4),	O
teratocarcinoma-derived	O
growth	O
factor	O
(Tdgf1),	O
Enk-pending	O
(Nanog),	O
undifferentiated	O
embryonic	O
cell	O
transcription	O
factor	O
1	O
(Utf1),	O
and	O
DNA	O
methyltransferase	O
3B	O
(Dnmt3b)	O
in	O
samples	O
of	O
hENSCs.	O

To	O
further	O
test	O
for	O
the	O
presence	O
of	O
undifferentiated	O
embryonic	B
stem	I
cell	I
markers,	O
samples	O
from	O
hENSC	O
were	O
assayed	O
for	O
the	O
presence	O
of	O
the	O
endodermal	O
gene	O
AFP	O
and	O
the	O
mesodermal	O
gene	O
Eomes.	O

In	O
an	O
attempt	O
to	O
confirm	O
the	O
results	O
obtained	O
in	O
the	O
present	O
study,	O
we	O
correlated	O
the	O
expression	O
profiles	O
of	O
our	O
studies	O
hENSC	O
with	O
that	O
of	O
adult	O
and	O
fetal	O
human	O
neuroprogenitors	O
available	O
in	O
public	O
databases	O
such	O
as	O
human	O
hippocampal	O
adult	O
NPCs,	O
human	O
fetal	O
NPCs	O
from	O
frontal	O
cortex,	O
multipotent	O
adult	O
human	B
mesenchymal	I
stem	I
cells	I
as	O
a	O
multipotent	O
adult	O
stem	O
cell	O
control	O
and	O
adult	O
(differentiated)	O
human	O
hippocampal	O
tissue.	O

In	O
accordance	O
with	O
the	O
previously	O
studied	O
individual	O
chips	O
[44],	O
[45],	O
[46],	O
the	O
enrichment	O
encountered	O
in	O
most	O
of	O
known	O
stem	B
cell	I
markers	O
that	O
had	O
been	O
revealed	O
in	O
the	O
present	O
study	O
fit	O
well	O
with	O
that	O
observed	O
in	O
their	O
respective	O
progenitor	O
cell	O
population	O
providing	O
additional	O
validation	O
of	O
our	O
protocol.	O

Similar	O
to	O
our	O
results,	O
the	O
human	O
brain-derived	O
adult	O
neuroprogenitors	O
cells	O
(NPCs)	O
showed	O
high	O
expression	O
of	O
the	O
neural	B
stem	I
cell	I
marker	O
NES	O
(nestin),	O
as	O
well	O
as	O
of	O
OLIG2,	O
MSl1,	O
NKX2-2,	O
and	O
CD44.	O

Such	O
finding	O
might	O
point	O
to	O
unrestricted	B
stem	I
cell	I
potential	O
of	O
our	O
examined	O
hENSC	O
line	O
in	O
contrast	O
to	O
adult	O
NPC	O
where	O
CD44	O
and	O
GDF1/LASS1	O
were	O
overexpressed	O
[48]..	O

A	O
better	O
understanding	O
of	O
these	O
signaling	O
pathways	O
at	O
a	O
cellular	O
level	O
would	O
be	O
of	O
great	O
assistance	O
to	O
the	O
elucidation	O
of	O
the	O
mechanisms	O
underlying	O
stem	O
cell	O
lineage	O
specification	O
and	O
to	O
the	O
discovery	O
of	O
potential	O
targets	O
for	O
stem	B
cell	I
therapy,	O
gene	O
therapy	O
and	O
pharmaceuticals.	O

Clonal	O
and	O
population	O
analyses	O
demonstrate	O
that	O
an	O
EGF-responsive	O
mammalian	O
embryonic	O
CNS	O
precursor	O
is	O
a	O
stem	O
cell.	O
FGF-2-responsive	O
neural	B
stem	I
cell	I
proliferation	O
requires	O
CCg,	O
a	O
novel	O
autocrine/paracrine	O
cofactor.	O

Gene	O
expression	O
in	O
human	B
embryonic	I
stem	I
cell	I
lines:	O
unique	O
molecular	O
signature.	O

Wnt	O
proteins	O
are	O
lipid-modified	O
and	O
can	O
act	O
as	O
stem	B
cell	I
growth	O
factors.	O

Olig2-induced	B
neural	I
stem	I
cell	I
differentiation	O
involves	O
downregulation	O
of	O
Wnt	O
signaling	O
and	O
induction	O
of	O
Dickkopf-1	O
expression.	O

A	O
Wnt	O
signal	O
regulates	B
stem	I
cell	I
fate	O
and	O
differentiation	O
in	O
vivo.	O

On	O
the	O
contrary,	O
it	O
has	O
been	O
reported	O
that	O
constitutive	O
activation	O
of	O
df-catenin	O
causes	O
a	O
multilineage	O
block	O
in	O
differentiation	O
and	O
compromises	O
HSC	O
maintenance	O
by	O
enforcing	O
the	O
cycling	O
of	O
HSCs,	O
with	O
the	O
consequence	O
of	O
exhausting	O
the	O
long-term	O
stem	B
cell	I
pool16-17..	O

Wnt	O
proteins	O
are	O
lipid-modified	O
and	O
can	O
act	O
as	O
stem	B
cell	I
growth	O
factors.	O

Activation	O
of	O
the	O
canonical	O
Wnt	O
pathway	O
leads	O
to	O
loss	O
of	O
hematopoietic	B
stem	I
cell	I
repopulation	O
and	O
multilineage	O
differentiation	O
block.	O

Hematopoietic	B
stem	I
cell	I
and	O
multilineage	O
defects	O
generated	O
by	O
constitutive	O
df-catenin	O
activation.	O

Glycogen	O
synthase	O
kinase	O
3df	O
missplicing	O
contributes	O
to	O
leukemia	B
stem	I
cell	I
generation.	O

Dynamic	O
tracking	O
of	O
human	B
hematopoietic	I
stem	I
cell	I
engraftment	O
using	O
in	O
vivo	O
bioluminescence	O
imaging.	O

Taken	O
together,	O
Fgf5-P2A-Venus	O
BAC	O
Tg	O
mice	O
and	O
mEpiSCs	O
generated	O
in	O
this	O
study	O
will	O
be	O
useful	O
for	O
developmental	O
biology	O
as	O
well	O
as	O
stem	B
cell	I
biology	O
research..	O

Mouse	O
embryonic	O
stem	O
cells	O
are	O
the	O
first	O
pluripotent	B
stem	I
cell	I
type	O
that	O
was	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
the	O
developing	O
blastocyst	O
[1,2].	O

Embryonic	B
stem	I
cells	I
expressing	O
both	O
platelet	O
endothelial	O
cell	O
adhesion	O
molecule-1	O
and	O
stage-specific	O
embryonic	O
antigen-1	O
differentiate	O
predominantly	O
into	O
epiblast	O
cells	O
in	O
a	O
chimeric	O
embryo.	O

Distinct	O
developmental	O
ground	O
states	O
of	O
epiblast	B
stem	I
cell	I
lines	O
determine	O
different	O
pluripotency	O
features.	O

Single	O
cell	O
lineage	O
analysis	O
of	O
mouse	B
embryonic	I
stem	I
cells	I
at	O
the	O
exit	O
from	O
pluripotency.	O

The	O
Seckel	O
syndrome	O
and	O
centrosomal	O
protein	O
Ninein	O
localizes	O
asymmetrically	O
to	O
stem	B
cell	I
centrosomes	O
but	O
is	O
not	O
required	O
for	O
normal	O
development,	O
behavior,	O
or	O
DNA	O
damage	O
response	O
in	O
Drosophila.	O

Guan	O
P,	O
Bassiri	O
H,	O
Patel	O
NP,	O
Nichols	O
KE,	O
Das	O
R	O
(2016)	O
Invariant	O
natural	O
killer	O
T	O
cells	O
in	O
hematopoietic	B
stem	I
cell	I
transplantation:	O
killer	O
choice	O
for	O
natural	O
suppression.	O

Amelioration	O
of	O
ductular	O
reaction	O
by	O
stem	B
cell	I
derived	O
extracellular	O
vesicles	O
in	O
MDR2	O
knockout	O
mice	O
via	O
lethal-7	O
microRNA.	O

Furthermore,	O
glioma	B
cancer	I
stem	I
cells	I
have	O
been	O
shown	O
to	O
express	O
c-Myc	O
at	O
much	O
higher	O
levels	O
than	O
non	O
glioma	O
cells,	O
and	O
c-Myc	O
knockdown	O
was	O
shown	O
to	O
reduce	O
proliferation	O
and	O
cause	O
cell	O
cycle	O
arrest	O
in	O
glioma	O
stem	O
cells	O
[21].	O

Distinct	O
roles	O
for	O
CREB-binding	O
protein	O
and	O
p300	O
in	O
hematopoietic	B
stem	I
cell	I
self-renewal.	O

Cells	O
derived	O
from	O
induced	B
pluripotent	I
stem	I
cell	I
(iPSC)	O
sources	O
(HM,	O
HO,	O
and	O
HN)	O
were	O
utilized	O
in	O
several	O
instances	O
to	O
establish	O
potential	O
patient-specific	O
and	O
disease	O
applications.	O

Application	O
of	O
the	O
software	O
to	O
stem	B
cell	I
and	O
breast	O
cancer	O
demonstrates	O
that	O
it	O
is	O
an	O
effective	O
tool	O
for	O
understanding	O
regulatory	O
mechanisms	O
in	O
biological	O
complex	O
systems.	O

Cell	O
lysates	O
derived	O
from	O
our	O
laboratory	O
are	O
as	O
follows:	O
human	B
embryonic	I
stem	I
cell	I
line	O
H1	O
(undifferentiated),	O
H1	O
endoderm	O
(differentiated	O
to	O
pancreatic	O
progenitors),	O
H1	O
mesoderm	O
(cardiac	O
progenitors),	O
H1	O
ectoderm	O
(neuronal	O
progenitors),	O
H1	O
embryoid	O
body,	O
and	O
human	O
gingival	O
fibroblasts	O
(two	O
different	O
patients).	O

The	O
interplay	O
of	O
epigenetic	O
marks	O
during	O
stem	B
cell	I
differentiation	O
and	O
development.	O

Hybrid	O
strain	O
(C57B6xDBA2)	O
F1	O
mice	O
(436-week-old	O
females)	O
were	O
purchased	O
from	O
Jackson	O
Laboratory	O
and	O
maintained	O
in	O
the	O
animal	O
facility	O
in	O
the	O
Lorry	B
Lokey	I
Stem	I
Cell	I
Research	O
Building.	O

The	O
use	O
of	O
human	B
stem	I
cell	I
or	O
induced	O
pluripotent	O
stem	O
cells	O
may	O
represent	O
an	O
alternative,	O
but	O
a	O
lot	O
of	O
works	O
are	O
still	O
remaining	O
in	O
order	O
to	O
control	O
and	O
optimize	O
the	O
differentiation	O
of	O
these	O
cells	O
and	O
to	O
resolve	O
the	O
safety	O
aspects,	O
for	O
example,	O
the	O
transcription	O
factor	O
regulation	O
[28]..	O

The	O
combination	O
of	O
recent	O
advances	O
in	O
stem	O
cell	O
biology,	O
such	O
as	O
induced	B
pluripotent	I
stem	I
cells	I
(Moreno	O
et	O
al.,	O
2015)	O
and	O
organoid	O
technology	O
(Astashkina	O
et	O
al.,	O
2012),	O
with	O
microfluidic	O
3D	O
cell	O
culture	O
will	O
lead	O
to	O
the	O
implementation	O
of	O
personalized	O
medicine	O
and	O
companion	O
diagnostics	O
in	O
the	O
next	O
5	O
years	O
(van	O
Duinen	O
et	O
al.,	O
2015)..	O

Differentiation	O
of	O
neuroepithelial	B
stem	I
cells	I
into	O
functional	O
dopaminergic	O
neurons	O
in	O
3D	O
microfluidic	O
cell	O
culture.	O

Mesenchymal	B
stem	I
cell	I
derived	O
exosome	O
plays	O
a	O
central	O
role	O
in	O
the	O
cell-free	O
therapeutics	O
involving	O
MSCs	O
and	O
the	O
contents	O
can	O
be	O
customized	O
under	O
disease-associated	O
microenvironments.	O

Therapeutic	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
largely	O
depends	O
on	O
the	O
paracrine	O
efficiency	O
of	O
MSC,	O
and	O
gingiva-derived	O
MSC	O
(GMSC)	O
have	O
unique	O
capacity	O
to	O
secret	O
large	O
amount	O
of	O
exosomes	O
and,	O
moreover,	O
are	O
easier	O
to	O
isolate.	O

[5]	O
Bernardo	O
ME,	O
Fibbe	O
WE,	O
Mesenchymal	O
stromal	O
cells:	O
sensors	O
and	O
switchers	O
of	O
inflammation,	O
Cell	B
Stem	I
Cell	I
13	O
(4)	O
(2013)	O
392–402,	O
doi:	O
10.1016/j.stem.2013.09.006.	O

[24]	O
Kong	O
L,	O
Wang	O
Y,	O
Smith	O
W,	O
Hao	O
D,	O
Macrophages	O
in	O
Bone	O
Homeostasis,	O
Curr	B
Stem	I
Cell	I
Res.	O

[48]	O
Giacomelli	O
C,	O
Natali	O
L,	O
Nisi	O
M,	O
De	O
Leo	O
M,	O
Daniele	O
S,	O
Costa	O
B,	O
Graziani	O
F,	O
Gabriele	O
M,	O
Braca	O
A,	O
Trincavelli	O
ML,	O
Martini	O
C,	O
Negative	O
effects	O
of	O
a	O
high	O
tumour	O
necrosis	O
factor-alpha	O
concentration	O
on	O
human	O
gingival	O
mesenchymal	O
stem	O
cell	O
trophism:	O
the	O
use	O
of	O
natural	O
compounds	O
as	O
modulatory	O
agents,	O
Stem	B
Cell	I
Res.	O

[56]	O
Yamaza	O
T,	O
Miura	O
Y,	O
Bi	O
Y,	O
Liu	O
Y,	O
Akiyama	O
K,	O
Sonoyama	O
W,	O
Patel	O
V,	O
Gutkind	O
S,	O
Young	O
M,	O
Gronthos	O
S,	O
Le	O
A,	O
Wang	O
CY,	O
Chen	O
W,	O
Shi	O
S,	O
Pharmacologic	B
stem	I
cell	I
based	O
intervention	O
as	O
a	O
new	O
approach	O
to	O
osteoporosis	O
treatment	O
in	O
rodents,	O
PLoS	O
One	O
3	O
(7)	O
(2008)	O
e2615,	O
doi:	O
10.1371/journal.pone.0002615.	O

[87]	O
Xiang	O
L,	O
Chen	O
M,	O
He	O
L,	O
Cai	O
B,	O
Du	O
Y,	O
Zhang	O
X,	O
Zhou	O
C,	O
Wang	O
C,	O
Mao	O
JJ,	O
Ling	O
J,	O
Wnt5a	O
regulates	O
dental	O
follicle	O
stem/progenitor	O
cells	O
of	O
the	O
periodontium,	O
Stem	B
Cell	I
Res.	O

Autocrine	O
TNF-b1	O
production	O
supports	O
CML	O
stem	O
and	O
progenitor	O
cell	O
survival	O
and	O
enhances	O
their	O
proliferation.	O
MicroRNAs	O
to	O
Nanog,	O
Oct4	O
and	O
Sox2	O
coding	O
regions	O
modulate	O
embryonic	B
stem	I
cell	I
differentiation.	O

POLG	O
mice	O
develop	O
progressive,	O
ultimately	O
fatal	O
megaloblastic	O
anemia	O
due	O
to	O
hematopoietic	B
stem	I
cell	I
deficits,	O
impaired	O
erythrocyte	O
maturation,	O
and	O
increased	O
erythrocyte	O
destruction	O
by	O
splenic	O
macrophages	O
(30,	O
69,	O
70).	O

P.,	O
Suomalainen	O
A.,	O
mtDNA	O
mutagenesis	O
disrupts	O
pluripotent	B
stem	I
cell	I
function	O
by	O
altering	O
redox	O
signaling.	O

J.,	O
Wahlestedt	O
M.,	O
Sten	O
G.,	O
Ugale	O
A.,	O
Sigvardsson	O
M.,	O
Bryder	O
D.,	O
Accumulating	O
mitochondrial	O
DNA	O
mutations	O
drive	O
premature	O
hematopoietic	O
aging	O
phenotypes	O
distinct	O
from	O
physiological	B
stem	I
cell	I
aging.	O

Y.,	O
DNA-damage-induced	O
type	O
I	O
interferon	O
promotes	O
senescence	O
and	O
inhibits	B
stem	I
cell	I
function.	O

However,	O
in	O
contrast	O
to	O
DENV,	O
where	O
NS4A-induced	O
autophagy	O
confers	O
protection	O
from	O
cell	O
death,	O
NS4A	O
and	O
NS4B	O
of	O
ZIKV	O
dysregulate	O
autophagy	O
through	O
AKT1-mTOR	O
inhibition,	O
leading	O
to	O
increased	O
cell	O
death	O
and	O
impeded	O
neurogenesis	O
in	O
fetal	B
neural	I
stem	I
cells	I
[178].	O

To	O
regenerate	O
cardiac	O
tissue	O
after	O
the	O
Myocardial	O
Infarction,	O
Stem	B
cell	I
based	O
transplantation	O
ideas	O
are	O
currently	O
hindered	O
within	O
the	O
affected	O
area	O
and	O
inflated	O
fibrosis	O
by	O
the	O
ischemic	O
environment.	O

Functional	O
redundancy	O
of	O
GSK-3b1	O
and	O
GSK-3b2	O
in	O
Wnt/beta-catenin	O
signaling	O
shown	O
by	O
using	O
an	O
allelic	O
series	O
of	O
embryonic	B
stem	I
cell	I
lines.	O

Pivotal	O
role	O
for	O
glycogen	O
synthase	O
kinase-3	O
in	O
hematopoietic	B
stem	I
cell	I
homeostasis	O
in	O
mice.	O

Glycogen	O
synthase	O
kinase	O
3b2	O
missplicing	O
contributes	O
to	O
leukemia	B
stem	I
cell	I
generation.	O

Targeted	O
gene	O
correction	O
minimally	O
impacts	O
whole-genome	O
mutational	O
load	O
in	O
human-disease-specific	B
induced	I
pluripotent	I
stem	I
cell	I
clones.	O

Low	O
incidence	O
of	O
off-target	O
mutations	O
in	O
individual	O
CRISPR-Cas9	O
and	O
TALEN	O
targeted	O
human	B
stem	I
cell	I
clones	O
detected	O
by	O
whole-genome	O
sequencing.	O

Compatibility	O
in	O
the	O
HLA	O
system	O
is	O
vital	O
in	O
hematopoietic	B
stem	I
cell	I
transplantation	O
[4]..	O

Russia	O
A,	O
B,	O
C,	O
DRB1	O
=	O
2,650	O
Lebedeva,	O
2009,	O
Moscow	B
Stem	I
Cell	I
Bank	O
—.	O

Impact	O
of	O
HLA	O
diversity	O
on	O
donor	O
selection	O
in	O
organ	O
and	O
stem	B
cell	I
transplantation.	O

Submucosal	O
glands	O
lie	O
below	O
the	O
luminal	O
surface	O
and	O
secrete	O
mucus	O
and	O
other	O
antimicrobial	O
factors	O
into	O
the	O
airway	O
but	O
also	O
act	O
as	O
a	O
stem	B
cell	I
niche	O
containing	O
myoepithelial	O
basal	O
cells142,143.	O

Taking	O
advantage	O
of	O
genetic	O
lineage-tracing	O
techniques,	O
performed	O
mainly	O
on	O
genetically	O
engineered	O
mouse	O
models	O
(GEMMs),	O
multiple	O
cell	O
types	O
in	O
the	O
CNS	O
have	O
been	O
suggested	O
as	O
potential	O
cells	O
of	O
origin	O
for	O
glioblastoma,	O
among	O
which	O
adult	B
neural	I
stem	I
cells	I
and	O
oligodendrocyte	O
precursor	O
cells	O
(OPCs)	O
are	O
the	O
major	O
candidates.	O

Keywords:	O
cell	O
of	O
origin,	O
high-grade	O
glioma,	O
glioblastoma,	O
adult	B
neural	I
stem	I
cells,	I
oligodendrocyte	O
precursor	O
cells	O
(OPC),	O
genetically	O
engineered	O
mouse	O
models	O
(GEMMs),	O
lineage	O
tracing.	O

Recent	O
progress	O
in	O
the	O
biology	O
of	O
neural	B
stem	I
cells	I
and	O
oligodendrocyte	O
precursor	O
cells	O
(OPCs)	O
provides	O
new	O
insights	O
into	O
their	O
candidacy	O
as	O
the	O
cell	O
of	O
origin	O
for	O
human	O
glioblastoma.	O

This	O
work	O
was	O
supported	O
by	O
the	O
National	O
Key	O
Research	O
and	O
Development	O
Program	O
of	O
China,	O
Stem	B
Cell	I
and	O
Translational	O
Research	O
(2016YFA0101201	O
to	O
CL),	O
Science	O
Foundation	O
for	O
Distinguished	O
Young	O
Scientists	O
of	O
Zhejiang	O
Province	O
(LR17H160001	O
to	O
CL),	O
National	O
Natural	O
Science	O
Foundation	O
of	O
China	O
(81673035	O
to	O
CL),	O
and	O
Thousand	O
Talent	O
Program	O
for	O
Young	O
Outstanding	O
Scientists,	O
China	O
(to	O
CL)..	O

Epidermal	O
growth	O
factor	O
receptor	O
and	O
Ink4a/Arf:	O
convergent	O
mechanisms	O
governing	O
terminal	O
differentiation	O
and	O
transformation	O
along	O
the	O
neural	B
stem	I
cell	I
to	O
astrocyte	O
axis.	O

Ets	O
factors	O
regulate	O
neural	B
stem	I
cell	I
depletion	O
and	O
gliogenesis	O
in	O
Ras	O
pathway	O
glioma.	O

A	O
mosaic	O
world:	O
puzzles	O
revealed	O
by	O
adult	O
neural	B
stem	I
cell	I
heterogeneity.	O

The	O
putative	O
neural	B
stem	I
cell	I
marker,	O
nestin,	O
is	O
expressed	O
in	O
heterogeneous	O
cell	O
types	O
in	O
the	O
adult	O
rat	O
neocortex.	O

Combinations	O
of	O
genetic	O
mutations	O
in	O
the	O
adult	B
neural	I
stem	I
cell	I
compartment	O
determine	O
brain	O
tumour	O
phenotypes.	O

S100B	O
expression	O
defines	O
a	O
state	O
in	O
which	O
GFAP-expressing	O
cells	O
lose	O
their	O
neural	B
stem	I
cell	I
potential	O
and	O
acquire	O
a	O
more	O
mature	O
developmental	O
stage.	O

Thus,	O
an	O
intestinal	O
phenotype	O
in	O
the	O
stomach	O
would	O
be	O
not	O
just	O
a	O
differentiated	O
metaplasia	O
in	O
the	O
stomach,	O
but	O
a	O
phenotype	O
of	O
stem	B
cell	I
abnormality	O
with	O
precancerous	O
lesion	O
susceptible	O
to	O
gastric	O
carcinogenesis	O
after	O
chronic	O
inflammation	O
[92]..	O

Recent	O
data	O
on	O
gastric	B
cancer	I
stem	I
cell	I
involvement	O
may	O
provide	O
insights	O
into	O
the	O
molecular	O
pathway	O
of	O
carcinogenesis,	O
eventually	O
leading	O
to	O
development	O
of	O
new	O
therapeutic	O
approaches	O
to	O
target	O
early-stage	O
gastric	O
cancer..	O

Drosophila	O
oogenesis	O
has	O
been	O
used	O
extensively	O
as	O
a	O
genetically	O
tractable	O
model	O
to	O
study	O
organogenesis,	O
niche-germline	O
stem	O
cell	O
communication,	O
and	O
more	O
recently	O
reproductive	O
aging	O
including	O
germline	B
stem	I
cell	I
aging.	O

Cell	O
stem	O
cell	O
mechanisms	O
that	O
regulate	O
stem	B
cell	I
aging	O
and	O
life	O
span.	O

Acute	O
depletion	O
of	O
Tet1-dependent	O
5-hydroxymethylcytosine	O
levels	O
impairs	O
LIF/Stat3	O
signaling	O
and	O
results	O
in	O
loss	O
of	O
embryonic	B
stem	I
cell	I
identity.	O

In	O
human	O
cell	O
models	O
that	O
mimic	O
first-trimester	O
brain	O
development	O
in	O
vitro,	O
ZIKV	O
infection	O
has	O
been	O
shown	O
to	O
cause	O
cell	O
death	O
in	O
neural	B
stem	I
cells	I
and	O
to	O
reduce	O
the	O
growth	O
of	O
brain	O
organoids,	O
as	O
well	O
as	O
to	O
disrupt	O
the	O
development	O
of	O
neurospheres	O
(17)..	O

The	O
dynamic	O
role	O
of	O
bone	O
morphogenetic	O
proteins	O
in	O
neural	B
stem	I
cell	I
fate	O
and	O
maturation.	O

Two	O
standard	O
tumor	O
brain	O
cell	O
lines	O
from	O
the	O
American	O
Type	O
Culture	O
Collection,	O
LN18,	O
derived	O
from	O
glial	O
cells	O
(supportive	O
tissue	O
of	O
the	O
brain)	O
and	O
Daoy,	O
derived	O
from	O
the	O
neural	B
stem	I
cell	I
precursors,	O
are	O
widely	O
used	O
in	O
studies	O
that	O
employ	O
experimental	O
models	O
of	O
brain	O
neoplastic	O
disease..	O

The	O
Effect	O
of	O
miR-210	O
Up-regulation	O
on	O
Proliferation	O
and	O
Survival	O
of	O
Mouse	O
Bone	O
Marrow	O
Derived	O
Mesenchymal	O
Stem	O
Cell.	O
miR-17	O
family	O
miRNAs	O
are	O
expressed	O
during	O
early	O
mammalian	O
development	O
and	O
regulate	O
stem	B
cell	I
differentiation.	O

An	O
early	O
study	O
on	O
ICF	O
patient-derived	O
peripheral	O
blood	O
found	O
a	O
lack	O
of	O
memory	O
B	O
and	O
plasma	O
cells	O
that	O
could	O
explain	O
the	O
hypo-	O
and	O
agammaglobulinemia	O
phenotype	O
[53],	O
and	O
hematopoietic	B
stem	I
cell	I
transplantation	O
has	O
been	O
used	O
to	O
treat	O
ICF	O
patients	O
[51,54].	O

(2007)	O
Hematopoietic	B
stem	I
cell	I
transplantation	O
corrects	O
the	O
immunologic	O
abnormalities	O
associated	O
with	O
immunodeficiency-centromeric	O
instability-facial	O
dysmorphism	O
syndrome.	O

Hematopoietic	B
stem	I
cells	I
and	O
CD14+	O
monocytes	O
are	O
thought	O
to	O
be	O
the	O
main	O
source	O
of	O
reactivation.5	O
The	O
trafficking	O
of	O
human	O
b2-herpesviruses	O
from	O
among	O
different	O
cell	O
types	O
is	O
an	O
active	O
area	O
of	O
research,	O
particularly	O
for	O
human	O
cytomegalovirus.6.	O

Embryonic	B
stem	I
cells	I
are	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
the	O
blastocysts	O
and	O
are	O
characterized	O
by	O
the	O
ability	O
to	O
renew	O
themselves	O
(self-renewal)	O
and	O
the	O
capability	O
to	O
generate	O
all	O
the	O
cells	O
within	O
the	O
human	O
body.	O

In	O
this	O
review,	O
we	O
revisit	O
stem	B
cell	I
biology	O
and	O
add	O
a	O
new	O
layer	O
of	O
complexity.	O

In	O
particular,	O
we	O
will	O
highlight	O
some	O
of	O
the	O
complexities	O
of	O
the	O
system,	O
but	O
also	O
where	O
there	O
may	O
be	O
therapeutic	O
potential	O
for	O
modulation	O
of	O
intrinsic	B
stem	I
cells	I
and	O
where	O
particular	O
caution	O
may	O
be	O
needed	O
in	O
terms	O
of	O
cell	O
transplantation	O
therapies..	O

The	O
following	O
definition	O
of	O
a	O
stem	O
cell	O
is	O
now	O
widely	O
accepted:	O
stem	B
cells	I
are	O
characterized	O
by	O
their	O
ability	O
to	O
renew	O
themselves	O
through	O
mitotic	O
cell	O
division	O
(self-renewal)	O
and	O
the	O
ability	O
to	O
differentiate	O
into	O
diverse	O
range	O
of	O
specialized	O
cell	O
types.	O

Thus,	O
the	O
Oct4,	O
Sox2	O
and	O
Nanog	O
transcription	O
factors	O
control	O
the	O
expression	O
of	O
genes,	O
including	O
further	O
transcription	O
factors	O
(such	O
as	O
STAT3,	O
HESX1,	O
FGF-2	O
and	O
TCF)	O
[31]	O
and	O
other	O
signaling	O
components	O
necessary	O
to	O
maintain	O
the	O
stem	B
cell	I
state.	O

Recently,	O
several	O
observations	O
indicate	O
that	O
the	O
p53	O
family	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
stem	B
cell	I
biology	O
[42].	O

With	O
the	O
discoveries	O
of	O
microRNAs	O
(miRs),	O
a	O
new	O
layer	O
of	O
complexity	O
has	O
been	O
added	O
to	O
stem	B
cell	I
biology	O
[54,	O
55].	O

In	O
contrast,	O
the	O
expression	O
of	O
other	O
miRs	O
(miR-21,	O
miR-22	O
and	O
miR-29)	O
increases	O
during	O
the	O
differentiation	O
of	O
ESCs	O
indicating	O
a	O
possible	O
role	O
for	O
them	O
in	O
stem	B
cell	I
differentiation	O
[57,	O
58].	O

A	O
second	O
message	O
is	O
the	O
use	O
of	O
mesenchymal	O
stem	O
cells	O
as	O
alternatives	O
to	O
the	O
stem	B
cell	I
sources	O
described	O
above.	O

Prospects	O
and	O
challenges	O
for	O
the	O
use	O
of	O
stem	B
cell	I
technologies	O
to	O
develop	O
novel	O
therapies	O
for	O
Parkinson	O
disease.	O

Stem	B
cell	I
induced	O
cardiac	O
regeneration:	O
fusion/mitochondrial	O
exchange	O
and/or	O
transdifferentiation?	O
Cell	O
Cycle.	O

Absolute	O
requirement	O
for	O
STAT3	O
function	O
in	O
small-intestine	B
crypt	I
stem	I
cell	I
survival.	O

BMP	O
induction	O
of	O
Id	O
proteins	O
suppresses	O
differentiation	O
and	O
sustains	O
embryonic	B
stem	I
cell	I
self-renewal	O
in	O
collaboration	O
with	O
STAT3.	O

Nitric	O
oxide	O
repression	O
of	O
Nanog	O
promotes	O
mouse	B
embryonic	I
stem	I
cell	I
differentiation.	O

p73	O
is	O
an	O
essential	O
regulator	O
of	O
neural	B
stem	I
cell	I
maintenance	O
in	O
embryonal	O
and	O
adult	O
CNS	O
neurogenesis.	O

miRNAs	O
regulate	O
SIRT1	O
expression	O
during	O
mouse	B
embryonic	I
stem	I
cell	I
differentiation	O
and	O
in	O
adult	O
mouse	O
tissues.	O

Suppression	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
generation	O
by	O
the	O
p53-p21	O
pathway.	O

Mesenchymal	B
stem	I
cells	I
improve	O
small	O
intestinal	O
integrity	O
through	O
regulation	O
of	O
endogenous	O
epithelial	O
cell	O
homeostasis.	O

miR-335	O
orchestrates	O
cell	O
proliferation,	O
migration	O
and	O
differentiation	O
in	O
human	O
mesenchymal	O
stem	O
cells	O
Cell	O
reprogramming:	O
expectations	O
and	O
challenges	O
for	O
chemistry	O
in	O
stem	B
cell	I
biology	O
and	O
regenerative	O
medicine.	O

Generation	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
lines	O
from	O
3	O
distinct	O
laminopathies	O
bearing	O
heterogeneous	O
mutations	O
in	O
lamin	O
A/C.	O

De	O
novo	O
generation	O
of	O
HSCs	O
from	O
somatic	O
and	O
pluripotent	B
stem	I
cell	I
sources.	O

Development	O
of	O
human	O
CD4+FoxP3+	O
regulatory	O
T	O
cells	O
in	O
human	B
stem	I
cell	I
factor-,	O
granulocyte-macrophage	O
colony-stimulating	O
factor-,	O
and	O
interleukin-3-expressing	O
NOD-SCID	O
IL2Rb3(null)	O
humanized	O
mice.	O

See	O
"Polycomb	O
Group	O
Genes:	O
Keeping	O
Stem	B
Cell	I
Activity	O
in	O
Balance",	O
e113..	O

Using	O
mice	O
with	O
an	O
N-ethyl-N-nitrosourea	O
(ENU)-induced	O
mutation	O
in	O
Suppressor	O
of	O
Zeste	O
12	O
(Suz12),	O
a	O
core	O
component	O
of	O
Polycomb	O
Repressive	O
Complex	O
2	O
(PRC2),	O
we	O
show	O
here	O
that	O
loss	O
of	O
Suz12	O
function	O
enhances	O
hematopoietic	B
stem	I
cell	I
activity.	O

In	O
addition	O
to	O
these	O
effects	O
on	O
a	O
wild-type	O
genetic	O
background,	O
mutations	O
in	O
Suz12	O
are	O
sufficient	O
to	O
ameliorate	O
the	O
stem	B
cell	I
defect	O
and	O
thrombocytopenia	O
present	O
in	O
mice	O
that	O
lack	O
the	O
thrombopoietin	O
receptor	O
(c-Mpl).	O

These	O
data	O
suggest	O
that	O
PRC2	O
is	O
required	O
to	O
maintain	O
a	O
specific	O
gene	O
expression	O
pattern	O
in	O
hematopoiesis	O
that	O
is	O
indispensable	O
to	O
normal	B
stem	I
cell	I
function..	O

An	O
ENU	O
mutagenesis	O
screen	O
was	O
performed	O
with	O
c-Mpl	O
mice	O
to	O
identify	O
mutations	O
that	O
suppress	O
thrombocytopenia	O
and/or	O
stem	B
cell	I
defects.	O

In	O
agreement	O
with	O
previous	O
studies	O
that	O
detailed	O
a	O
reduction	O
in	O
stem	B
cell	I
function	O
in	O
c-Mpl/	O
mice,	O
these	O
animals	O
show	O
a	O
dramatic	O
reduction	O
in	O
CFU-S	O
compared	O
with	O
c-Mpl+/+	O
mice	O
(Figure	O
4)	O
[45].	O

The	O
number	O
of	O
immunophenotypic	O
HSCs	O
was	O
quantified	O
to	O
determine	O
whether	O
the	O
stem	B
cell	I
compartment	O
was	O
expanded	O
in	O
Suz12Plt8/+	O
mice.	O

The	O
stem	B
cell	I
phenotype	O
was	O
exacerbated	O
when	O
Suz12	O
was	O
inhibited	O
by	O
shRNA-mediated	O
silencing,	O
providing	O
independent	O
confirmation	O
that	O
the	O
mutant	O
phenotype	O
is	O
a	O
direct	O
result	O
of	O
impaired	O
Suz12	O
expression.	O

Kamminga	O
and	O
colleagues	O
recently	O
demonstrated	O
that	O
exogenous	O
expression	O
of	O
Ezh2	B
preserves	I
stem	I
cell	I
function	O
during	O
serial	O
bone	O
marrow	O
transplantation	O
and	O
suggested	O
that	O
PRC2	O
prevents	O
replicative	O
senescence	O
within	O
the	O
HSC	O
compartment	O
[36].	O

Hematopoietic	B
stem	I
cell	I
deficiencies	O
in	O
mice	O
lacking	O
c-Mpl,	O
the	O
receptor	O
for	O
thrombopoietin.	O

The	O
polycomb	O
group	O
protein	O
suz12	O
is	O
required	O
for	O
embryonic	B
stem	I
cell	I
differentiation.	O

This	O
type	O
of	O
bone	O
simulation	O
with	O
microfluidics	O
was	O
supportive	O
in	O
learning	O
about	O
drug	O
discovery	O
research,	O
transplantation	O
of	O
BM,	O
and	O
hematopoietic	B
stem	I
cell	I
diseases.	O

This	O
study	O
detected	O
a	O
number	O
of	O
genes	O
silenced	O
by	O
DNA	O
methylation,	O
including	O
genes	O
involved	O
in	O
stem	B
cell	I
pluripotency	O
(BMI1,	O
BMP3,	O
FOXD3),	O
WNT	O
signaling	O
(WNT5A,	O
APC2,	O
SOX1)	O
and	O
cell	O
adhesion	O
(CDH2,	O
CDH4,	O
PCDH1,	O
and	O
PCDH10)	O
[46].	O

In	O
contrast,	O
depletion	O
of	O
EZH2	O
by	O
RNAi	O
in	O
PDAC	O
cells	O
inhibits	O
cell	O
growth,	O
increases	O
chemosensitivity,	O
and	O
decreases	O
the	O
growth	O
of	O
PDAC	B
cancer	I
stem	I
cells	I
[87,91].	O

EZH2	O
is	O
required	O
for	O
breast	O
and	O
pancreatic	O
cancer	O
stem	O
cell	O
maintenance	O
and	O
can	O
be	O
used	O
as	O
a	O
functional	O
cancer	B
stem	I
cell	I
reporter.	O

Bmi1	O
enhances	O
tumorigenicity	O
and	O
cancer	B
stem	I
cell	I
function	O
in	O
pancreatic	O
adenocarcinoma.	O

The	O
c-kit	O
Ligand,	O
Stem	B
Cell	I
Factor,	O
Can	O
Enhance	O
Innate	O
Immunity	O
Through	O
Effects	O
on	O
Mast	O
Cells.	O

We	O
previously	O
reported	O
that	O
repetitive	O
administration	O
of	O
the	O
c-kit	O
ligand,	O
stem	B
cell	I
factor	O
(SCF),	O
can	O
increase	O
mast	O
cell	O
numbers	O
in	O
normal	O
mice	O
in	O
vivo.	O

Keywords:	O
c-kit,	O
innate	O
immunity,	O
mast	O
cells,	O
stem	B
cell	I
factor,	O
tumor	O
necrosis	O
factor-b1.	O

We	O
therefore	O
investigated	O
whether	O
repetitive	O
administration	O
of	O
the	O
c-kit	O
ligand,	O
stem	B
cell	I
factor	O
(SCF	O
[references	O
6,	O
7];	O
also	O
known	O
as	O
kit	O
ligand	O
[reference	O
8],	O
mast	O
cell	O
growth	O
factor	O
[MGF,	O
reference	O
9],	O
or	O
steel	O
factor	O
[reference	O
10]),	O
could	O
influence	O
the	O
survival	O
of	O
mice	O
subjected	O
to	O
CLP.	O

The	O
c-kit	O
ligand,	O
stem	B
cell	I
factor,	O
promotes	O
mast	O
cell	O
survival	O
by	O
suppressing	O
apoptosis.	O

Induction	O
of	O
mast	O
cell	O
proliferation,	O
maturation	O
and	O
heparin	O
synthesis	O
by	O
the	O
rat	O
c-kit	O
ligand,	O
stem	B
cell	I
factor.	O

The	O
rat	O
c-kitligand,	O
stem	B
cell	I
factor,	O
induces	O
the	O
development	O
of	O
connective	O
tissue-type	O
and	O
mucosal	O
mast	O
cells	O
in	O
vivo.	O

Effects	O
of	O
chronic	O
treatment	O
with	O
the	O
c-kit	O
ligand,	O
stem	B
cell	I
factor,	O
on	O
immunoglobulin	O
E-dependent	O
anaphylaxis	O
in	O
mice:	O
genetically	O
mast	O
cell	O
deficient	O
Sl/Sldmice	O
acquire	O
anaphylactic	O
responsiveness,	O
but	O
the	O
congenic	O
normal	O
mice	O
do	O
not	O
exhibit	O
augmented	O
responses.	O

Stem	B
cell	I
factor	O
(SCF)	O
is	O
encoded	O
at	O
the	O
Sl	O
locus	O
of	O
the	O
mouse	O
and	O
is	O
the	O
ligand	O
for	O
the	O
c-kit	O
tyrosine	O
kinase	O
receptor.	O

What	O
sample	O
sizes	O
are	O
reasonable?	O
What	O
derivation	O
and	O
purification	O
protocols	O
should	O
be	O
used	O
to	O
make	O
human	O
neurons?	O
In	O
what	O
way	O
should	O
gene	O
editing	O
technologies	O
be	O
used	O
to	O
support	O
discoveries?	O
What	O
kinds	O
of	O
preclinical	O
studies	O
are	O
the	O
most	O
feasible?	O
It	O
is	O
hoped	O
that	O
this	O
roadmap	O
will	O
provide	O
the	O
necessary	O
details	O
for	O
experimental	O
planning	O
and	O
execution	O
for	O
those	O
less	O
familiar	O
in	O
the	O
area	O
of	O
stem	B
cell	I
disease	O
modeling.	O

Difficulties	O
arise,	O
however,	O
in	O
the	O
accurate	O
ability	O
to	O
maintain	O
stem	B
cells	I
in	O
an	O
undifferentiated	O
state,	O
in	O
differentiating	O
CNS	O
cell	O
types,	O
and	O
in	O
achieving	O
consistency	O
in	O
postmitotic	O
cell	O
population	O
types,	O
all	O
problems	O
compounded	O
by	O
the	O
fact	O
that	O
cells	O
are	O
derived	O
from	O
different	O
individuals,	O
meaning	O
that	O
while	O
genetic	O
background	O
contributes	O
to	O
disease	O
by	O
interactions	O
with	O
pathogenic	O
mutations,	O
it	O
also	O
leads	O
to	O
significant	O
increases	O
in	O
technical	O
variability	O
(ie,	O
experimental	O
noise).	O

Even	O
for	O
those	O
with	O
these	O
facilities,	O
the	O
expertise	O
required	O
for	O
differentiation	O
from	O
a	O
stem	O
cell	O
state	O
to	O
a	O
more	O
differentiated	O
state	O
is	O
unlikely	O
to	O
be	O
performed	O
at	O
these	O
centers,	O
which	O
usually	O
focus	O
on	O
making	O
stem	B
cells	I
themselves.	O

Minimization	O
of	O
variation	O
in	O
an	O
experimental	O
system,	O
desirable	O
in	O
all	O
scientific	O
studies,	O
is	O
paramount	O
in	O
a	O
iPSC	O
based	O
NDD	B
stem	I
cell	I
study	O
since	O
conclusions	O
are	O
necessarily	O
drawn	O
from	O
few,	O
often	O
unrelated	O
subjects.	O

The	O
focus	O
on	O
a	O
single	O
case/control	O
pair	O
allows	O
for	O
in	O
depth	O
characterization	O
and	O
the	O
creation	O
of	O
multiple	O
replicates	O
(eg,	O
many	O
stem	B
cell	I
clones).	O

Difficulties	O
and	O
troubleshooting	O
for	O
stem	B
cell	I
derivation	O
have	O
been	O
reviewed	O
and	O
more	O
information	O
can	O
be	O
found	O
here.17	O
While	O
routine,	O
it	O
requires	O
significant	O
infrastructure	O
and	O
expertise	O
to	O
do	O
properly	O
to	O
avoid	O
common,	O
preventable	O
problems.	O

Reprogramming	O
cells	O
with	O
Yamanaka	O
factors,	O
OCT4,	O
SOX2,	O
KLF4,	O
and	O
CMYC	O
returns	O
cells	O
to	O
a	O
stem	B
cell	I
state	O
that	O
is	O
indistinguishable	O
from	O
ES	O
cells	O
after	O
4	O
to	O
5	O
passages.	O

Stem	B
cell	I
derivation22,	O
23	O
and	O
quality	O
control24	O
options	O
including	O
the	O
best	O
ways	O
to	O
assess	O
genomic	O
integrity25	O
have	O
been	O
reviewed	O
many	O
times,	O
so	O
I	O
focus	O
here	O
on	O
neural	O
differentiation	O
and	O
issues	O
for	O
neurodevelopmental	O
disease	O
research.	O

Once	O
a	O
stem	B
cell	I
state	O
has	O
been	O
achieved,	O
cells	O
can	O
be	O
maintained	O
or	O
differentiated	O
into	O
different	O
neural	O
cell	O
types.	O

Transdifferentiation	O
refers	O
to	O
the	O
induction	O
of	O
a	O
somatic	O
cell	O
directly	O
to	O
a	O
cell	O
of	O
interest	O
while	O
developmental	O
reprograming	O
refers	O
to	O
recapitulating	O
developmental	O
timing	O
and	O
factors	O
in	O
stem	B
cells	I
to	O
make	O
a	O
cell	O
type	O
of	O
interest.	O

Studying	O
NDDs	O
can	O
be	O
difficult	O
because	O
mutations	O
in	O
some	O
genes	O
that	O
cause	O
neurodevelopmental	O
disorders	O
can	O
be	O
important	O
in	O
multiple	O
biological	O
systems,	O
and	O
may	O
even	O
be	O
important	O
in	O
cell	O
reprogramming,	O
stem	B
cell	I
maintenance,	O
or	O
cell	O
differentiation.	O

Becoming	O
aware	O
of	O
the	O
molecular	O
machinery	O
important	O
for	O
stem	B
cell	I
reprogramming,	O
maintenance,	O
and	O
induction	O
is	O
essential..	O

Neurodevelopmental	O
diseases	O
are	O
a	O
specialized	O
category	O
of	O
stem	B
cell	I
modeling	O
and	O
therefore	O
require	O
specialized	O
experimental	O
design.	O

Low	O
incidence	O
of	O
off	O
target	O
mutations	O
in	O
individual	O
CRISPR	O
Cas9	O
and	O
TALEN	O
targeted	O
human	B
stem	I
cell	I
clones	O
detected	O
by	O
whole	O
genome	O
sequencing.	O

Human	O
ES	O
cell	O
derived	O
neural	O
rosettes	O
reveal	O
a	O
functionally	O
distinct	O
early	O
neural	B
stem	I
cell	I
stage.	O

The	O
methylation	O
of	O
H3K27	O
serves	O
as	O
an	O
anchorage	O
point	O
for	O
the	O
recruitment	O
of	O
other	O
PcG	O
proteins	O
contributing	O
to	O
gene	O
repression	O
impacting	O
development	O
and	O
regulation	O
of	O
stem	B
cell	I
lineage	O
development	O
[61]..	O

The	O
action	O
of	O
high	O
dose	O
ascorbate	O
treatment	O
promoted	O
DNA	O
demethylation	O
inducing	O
stem	B
cell	I
maturation	O
while	O
suppression	O
of	O
leukaemic	O
cells	O
providing	O
a	O
potential	O
alternative	O
treatment	O
options	O
for	O
AML	O
patients	O
[87].	O

Mutations	O
occurring	O
at	O
Y641	O
result	O
in	O
altered	O
function,	O
mutants	O
show	O
increased	O
affinity	O
for	O
H3K27me2/	O
H3K27me3	O
enabling	O
uncontrolled	O
development	O
of	O
stem	B
cell	I
lineages	O
due	O
to	O
loss	O
of	O
histone	O
methyltransferase	O
activity.	O

DNMT3A	O
R882	O
mutants	O
interact	O
with	O
polycomb	O
proteins	O
to	O
block	O
haematopoietic	O
stem	O
and	O
leukaemic	O
cell	O
differentiation.	O
Tet2	O
Loss	O
Leads	O
to	O
Increased	O
Hematopoietic	B
Stem	I
Cell	I
Self-Renewal	O
and	O
Myeloid	O
Transformation.	O

EZH1	O
Mediates	O
Methylation	O
on	O
Histone	O
H3	O
Lysine	O
27	O
and	O
Complements	O
EZH2	O
in	O
Maintaining	O
Stem	B
Cell	I
Identity	O
and	O
Executing	O
Pluripotency.	O

The	O
murine	O
homolog	O
of	O
SALL4,	O
a	O
causative	O
gene	O
in	O
Okihiro	O
syndrome,	O
is	O
essential	O
for	O
embryonic	B
stem	I
cell	I
proliferation,	O
and	O
cooperates	O
with	O
Sall1	O
in	O
anorectal,	O
heart,	O
brain	O
and	O
kidney	O
development.	O

The	O
MPTP	O
mouse	O
model:	O
cues	O
on	O
DA	O
release	O
and	O
neural	B
stem	I
cell	I
restorative	O
role.	O

The	O
Wnt	O
pathway	O
acts	O
as	O
a	O
common	O
element	O
in	O
regulation	O
of	O
stem	B
cell	I
renewal	O
and	O
maintenance	O
of	O
many	O
systems.	O

Currently,	O
other	O
models	O
based	O
on	O
a	O
wider	O
number	O
of	O
mouse	O
backgrounds	O
(https://www.model-ad.org/strain-table/)	O
and	O
human-induced	B
pluripotent	I
stem	I
cell	I
culture	O
models	O
([188,189,190]	O
among	O
others)	O
are	O
being	O
used	O
and	O
developed	O
to	O
better	O
understand	O
human	O
AD	O
pathology..	O

Common	O
pitfalls	O
of	O
stem	B
cell	I
differentiation:	O
A	O
guide	O
to	O
improving	O
protocols	O
for	O
neurodegenerative	O
disease	O
models	O
and	O
research.	O

The	O
two	O
stem	B
cell	I
microRNA	O
gene	O
clusters	O
C19MC	O
and	O
miR-371-3	O
are	O
activated	O
by	O
specific	O
chromosomal	O
rearrangements	O
in	O
a	O
subgroup	O
of	O
thyroid	O
adenomas.	O

Stem	B
cell	I
factor	O
induces	O
eosinophil	O
activation	O
and	O
degranulation:	O
mediator	O
release	O
and	O
gene	O
array	O
analysis.	O

Human	O
peripheral	O
blood	O
eosinophils	O
express	O
a	O
functional	O
c-kit	O
receptor	O
for	O
stem	B
cell	I
factor	O
that	O
stimulates	O
very	O
late	O
antigen	O
4	O
(VLA-4)	O
mediated	O
cell	O
adhesion	O
to	O
fibronectin	O
and	O
vascular	O
cell	O
adhesion	O
molecule	O
1	O
(VCAM-1)	O
J	O
Exp	O
Med.	O

Active	O
NOTCH	O
signaling	O
is	O
required	O
for	O
normal	O
mammary	B
stem	I
cell	I
function	O
[92],	O
implying	O
that	O
the	O
development	O
of	O
endocrine	O
therapy	O
resistance	O
in	O
breast	O
cancer	O
cells	O
may	O
rely	O
on	O
the	O
reversion	O
or	O
reactivation	O
of	O
stemness	O
pathways	O
and	O
a	O
loss	O
of	O
estrogen	O
responsiveness	O
that	O
is	O
typical	O
of	O
luminal	O
breast	O
cancer	O
cell	O
identity..	O

PAX6	O
+/	O
heterozygotes	O
suffer	O
from	O
aniridia	O
and	O
aniridia-related	O
keratopathy	O
(ARK),	O
a	O
corneal	O
deterioration	O
that	O
probably	O
involves	O
a	O
limbal	B
epithelial	I
stem	I
cell	I
deficiency.	O

It	O
is	O
widely	O
accepted	O
that,	O
during	O
adult	O
corneal	O
epithelial	O
homeostasis,	O
cell	O
production	O
is	O
initiated	O
by	O
limbal	B
epithelial	I
stem	I
cells	I
(LESCs)	O
in	O
the	O
limbus	O
at	O
the	O
corneoscleral	O
junction	O
[10]	O
[14].	O

Although	O
stripe	O
patterns	O
in	O
PAX77Tg/,	O
XLacZTg/	O
mosaics	O
appeared	O
normal,	O
a	O
quantitative	O
analysis	O
was	O
undertaken	O
to	O
identify	O
any	O
subtle	O
differences	O
that	O
might	O
suggest	O
that	O
stem	B
cell	I
clones	O
were	O
affected.	O

Evidence	O
for	O
effects	O
of	O
Pax6	O
dose	O
on	O
limbal	B
stem	I
cell	I
clones.	O

If	O
LESCs	O
can	O
divide	O
either	O
symmetrically	O
to	O
produce	O
one	O
LESC	O
and	O
one	O
TAC	O
or	O
asymmetrically	O
to	O
produce	O
either	O
two	O
LESCs	O
or	O
two	O
TACs	O
then	O
the	O
pattern	O
of	O
active	B
stem	I
cell	I
clones	O
may	O
follow	O
a	O
pattern	O
of	O
neutral	O
drift	O
as	O
suggested	O
for	O
some	O
other	O
stem	O
cell	O
systems,	O
including	O
spermatogonial	O
stem	O
cells	O
[61]	O
and	O
intestinal	O
crypts	O
[62],	O
[63].	O

It	O
is	O
widely	O
believed	O
that	O
stem	B
cell	I
deficiency	O
causes	O
most	O
corneal	O
abnormalities	O
in	O
ARK.	O

Strategies	O
of	O
epithelial	O
repair:	O
modulation	O
of	O
stem	B
cell	I
and	O
transit	O
amplifying	O
cell	O
proliferation.	O

Clonal	O
analysis	O
of	O
patterns	O
of	O
growth,	O
stem	B
cell	I
activity,	O
and	O
cell	O
movement	O
during	O
the	O
development	O
and	O
maintenance	O
of	O
the	O
murine	O
corneal	O
epithelium.	O

Mosaic	O
analysis	O
of	O
stem	B
cell	I
function	O
and	O
wound	O
healing	O
in	O
the	O
mouse	O
corneal	O
epithelium.	O

Management	O
of	O
aniridic	O
keratopathy	O
with	O
keratolimbal	O
allograft:	O
A	O
limbal	B
stem	I
cell	I
transplantation	O
technique.	O

Corneal	O
development,	O
limbal	B
stem	I
cell	I
function,	O
and	O
corneal	O
epithelial	O
cell	O
migration	O
in	O
the	O
Pax6+/−	O
mouse.	O

Functional	O
identification	O
of	O
the	O
actual	O
and	O
potential	O
stem	B
cell	I
compartments	O
in	O
mouse	O
spermatogenesis.	O

Differential	O
Rates	O
of	O
Replacement	O
of	O
Human	O
Dermal	O
Dendritic	O
Cells	O
and	O
Macrophages	O
During	O
Hematopoietic	B
Stem	I
Cell	I
Transplantation.	O

JMML	O
is	O
usually	O
rapidly	O
fatal	O
due	O
to	O
multiorgan	O
failure	O
or	O
progression	O
towards	O
acute	O
myeloid	O
leukemia	O
(AML)	O
unless	O
allogeneic	B
hematopoietic	I
stem	I
cell	I
transplantation	O
(HSCT)	O
is	O
performed	O
[5].	O

WBC	O
whole	O
blood	O
cell	O
count,	O
HbF	O
fetal	O
hemoglobin,	O
HSCT	O
hematopoietic	B
stem	I
cell	I
transplantation,	O
ND	O
not	O
done,	O
N/A	O
not	O
applicable,	O
SNV	O
single-nucleotide	O
variation,	O
CNV	O
copy	O
number	O
variation,	O
aUPD	O
acquired	O
uniparental	O
disomy,	O
VAF	O
variant	O
allele	O
frequency.	O

This	O
suggests	O
that	O
clonal	O
selection	O
occurred	O
within	O
the	O
HSC/MPP	O
compartment	O
very	O
early	O
in	O
the	O
oncogenic	O
process	O
and	O
was	O
not	O
affected	O
by	O
hematopoietic	O
differentiation	O
or	O
expansion,	O
highlighting	O
the	O
stem	B
cell	I
origin	O
of	O
the	O
JMML	O
despite	O
the	O
complexity	O
of	O
JMML-PCs..	O

Hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
in	O
children	O
with	O
juvenile	O
myelomonocytic	O
leukemia	O
(JMML):	O
results	O
of	O
the	O
EWOG-MDS/EBMT	O
trial.	O

Several	O
articles	O
report	O
alteration	O
in	O
redox	O
environment	O
and	O
link	O
this	O
phenomenon	O
to	O
impaired	O
hematopoietic	O
progenitor	O
and	O
stem	B
cell	I
function	O
improved	O
by	O
treatment	O
with	O
n-acetyl	O
cysteine	O
in	O
transgenic	O
SCD	O
mice,	O
reduced	O
migration	O
of	O
endothelial	O
progenitors	O
cells	O
derived	O
from	O
children	O
who	O
have	O
SCD,	O
and	O
lastly	O
an	O
association	O
of	O
oxidative	O
stress	O
markers	O
with	O
an	O
atherogenic	O
index	O
in	O
adults	O
with	O
sickle	O
nephropathy.	O

The	O
wide	O
variety	O
of	O
experimental	O
studies	O
in	O
this	O
special	O
issue	O
represents	O
potentially	O
new	O
therapeutic	O
tools,	O
ranging	O
from	O
novel	O
approaches	O
for	O
Hb	O
F	O
induction,	O
improved	O
stem	B
cell	I
function	O
and	O
a	O
biomarker	O
to	O
predict	O
risk	O
for	O
SCD	O
nephropathy.	O

The	O
cancer	O
stem	O
cell	O
hypothesis	O
proposes	O
that	O
a	O
subset	O
of	O
cells	O
with	O
stem	B
cell	I
properties	O
of	O
indefinite	O
self-renewal	O
drive	O
tumor	O
initiation	O
and	O
progression.	O

Recently,	O
the	O
first	O
induced	B
pluripotent	I
stem	I
cell	I
-derived	O
motor	O
neurons	O
were	O
generated	O
from	O
fibroblasts	O
of	O
patients	O
carrying	O
a	O
M337V	O
TARDBP	O
mutation	O
[22].	O

Mutant	B
induced	I
pluripotent	I
stem	I
cell	I
lines	O
recapitulate	O
aspects	O
of	O
TDP-43	O
proteinopathies	O
and	O
reveal	O
cell-specific	O
vulnerability.	O

Evidence	O
of	O
the	O
importance	O
of	O
NK	O
cells	O
in	O
tumor	O
regulation	O
has	O
primarily	O
been	O
based	O
on	O
clinical	O
studies	O
of	O
patients	O
with	O
leukemia	O
who	O
have	O
undergone	O
allogeneic	B
hematopoietic	I
stem	I
cell	I
transplantation	O
(cell	O
therapy)	O
(77).	O

Stem	B
cell	I
trafficking	O
during	O
endometriosis:	O
may	O
epigenetics	O
play	O
a	O
pivotal	O
role?	O
Reprod	O
Sci	O
2018;	O
25:978979..	O

The	O
Hedgehog	O
pathway	O
(HH),	O
plays	O
a	O
key	O
role	O
in	O
stem	B
cell	I
differentiation	O
and	O
neuroendocrine	O
fate	O
and	O
has	O
been	O
found	O
to	O
be	O
activated	O
in	O
SCLC	O
[32,33].	O

A	O
multipotent	O
subpopulation	O
of	O
adult	O
pancreatic	O
ductal	O
cells	O
capable	O
of	O
reprogramming	O
towards	O
the	O
endocrine	O
lineage	O
was	O
recently	O
described,	O
arguing	O
for	O
a	O
stem	B
cell	I
population	O
in	O
the	O
ductal	O
compartment	O
35.	O

Certain	O
cell	O
types,	O
such	O
as	O
embryonic	B
stem	I
cells,	I
cells	O
in	O
the	O
germ	O
line,	O
and	O
cells	O
of	O
highly	O
proliferative	O
tissues,	O
can	O
counteract	O
telomere	O
loss	O
by	O
expressing	O
the	O
reverse	O
transcriptase	O
telomerase	O
that	O
adds	O
telomeric	O
repeats	O
onto	O
the	O
32	O
ends	O
of	O
chromosomes	O
(Greider	O
and	O
Blackburn,	O
1985	O
).	O

Drosophila	O
intestinal	O
response	O
to	O
bacterial	O
infection:	O
activation	O
of	O
host	O
defense	O
and	O
stem	B
cell	I
proliferation.	O

Live	O
imaging	O
of	O
stem	B
cell	I
and	O
progeny	O
behaviour	O
in	O
physiological	O
hair-follicle	O
regeneration.	O

Keywords:	O
cancer	O
stem	O
cells,	O
ITG	O
b24,	O
dendritic	O
cell	O
vaccine,	O
bispecific	O
antibody,	O
T	O
cells.	O
This	O
finding	O
is	O
particularly	O
interesting	O
in	O
the	O
context	O
of	O
cancer	B
stem	I
cells	I
(CSCs),	O
a	O
highly	O
tumorigenic,	O
self-renewing	O
tumor	O
cell	O
sub-population	O
resistant	O
to	O
traditional	O
radiation	O
and	O
chemotherapy	O
[22].	O

Cancer	B
stem	I
cell	I
vaccine	O
inhibits	O
metastases	O
of	O
primary	O
tumors	O
and	O
induces	O
humoral	O
immune	O
responses	O
against	O
cancer	O
stem	O
cells.	O

Single-marker	O
identification	O
of	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	B
cancer	I
stem	I
cells	I
with	O
aldehyde	O
dehydrogenase.	O

Induction	O
of	O
metastatic	B
cancer	I
stem	I
cells	I
from	O
the	O
NK/LAK-resistant	O
floating,	O
but	O
not	O
adherent,	O
subset	O
of	O
the	O
UP-LN1	O
carcinoma	O
cell	O
line	O
by	O
IFN-	O
b3.	O

Keywords:	O
cholangiocarcinoma,	O
experimental	O
models,	O
animal	O
models,	O
cell	O
lines,	O
tumor	O
microenvironment,	O
spheroids,	O
cancer	O
stem	O
cells,	O
organoids.	O
In	O
addition,	O
the	O
culture	O
conditions	O
of	O
primary	O
cells	O
are	O
designed	O
to	O
limit	O
cell	O
differentiation	O
and	O
partially	O
preserve	O
the	O
cancer	B
stem	I
cell	I
(CSC)	O
subpopulation,	O
reflecting	O
tumor	O
heterogeneity..	O

The	O
absence	O
of	O
serum	O
and	O
the	O
addition	O
of	O
growth	O
factors	O
that	O
stimulate	O
stem	B
cell	I
proliferation	O
(EGF	O
and	O
FGFs,	O
insulin,	O
and	O
hydrocortisone)	O
promote	O
the	O
enrichment	O
of	O
a	O
CSC-like	O
population.	O

They	O
originate	O
from	O
stem	B
cell	I
progenitors	O
cultured	O
in	O
the	O
presence	O
of	O
a	O
scaffold	O
(a	O
synthetic	O
basement	O
membrane)	O
that	O
reproduces	O
the	O
in	O
vivo	O
ECM	O
[127].	O

Three	O
techniques	O
are	O
mainly	O
used	O
to	O
create	O
transgenic	O
mice:	O
(i)	O
DNA	O
delivery	O
by	O
retroviral	O
vectors;	O
(ii)	O
microinjection	O
of	O
exogenous	O
DNA	O
into	O
the	O
pro-nuclei	O
of	O
fertilized	O
one-cell	O
embryos	O
subsequently	O
transferred	O
into	O
the	O
oviduct	O
of	O
a	O
pseudo-pregnant	O
surrogate	O
mother;	O
and	O
(iii)	O
DNA	O
introduction	O
into	O
embryonic	B
stem	I
cells	I
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
the	O
blastocysts	O
[157].	O

In	O
particular,	O
ideal	O
animal	O
models	O
should	O
be	O
developed	O
and	O
fully	O
characterized,	O
accounting	O
for	O
the	O
CCA	O
site	O
of	O
origin	O
and	O
sub-classification,	O
their	O
stem	B
cell	I
origin,	O
and	O
genetic,	O
epigenetic,	O
and	O
molecular	O
alterations.	O

Suppression	O
of	O
cholangiocarcinoma	O
cell	O
growth	O
by	O
human	O
umbilical	O
cord	O
mesenchymal	O
stem	O
cells	O
:	O
A	O
possible	O
role	O
of	O
Wnt	O
and	O
Akt	O
signaling.	O
Engineering	O
three-dimensional	O
stem	B
cell	I
morphogenesis	O
for	O
the	O
development	O
of	O
tissue	O
models	O
and	O
scalable	O
regenerative	O
therapeutics.	O

Damonte	O
et	O
al	O
employing	O
the	O
MINO	O
(mammary	O
intraepithelial	O
neoplasia	O
outgrowth)	O
mouse	O
model	O
of	O
DCIS	O
concluded	O
that	O
malignant	O
aggressiveness	O
is	O
pre-programmed	O
in	O
the	O
pre-cancer	B
stem	I
cell	I
[6].	O

Consequently	O
we	O
used	O
Reverse	O
Phase	O
Protein	O
Microarray	O
(RPMA)	O
analysis	O
of	O
59	O
cell	O
signaling	O
kinase	O
endpoints,	O
representing	O
stem	B
cell	I
markers,	O
autophagy,	O
adhesion,	O
invasion,	O
and	O
pro-survival	O
pathways	O
(Table	O
S1).	O

The	O
spheroids	O
exhibited	O
progenitor	O
cell	O
characteristics	O
as	O
evidenced	O
by	O
up-regulation	O
of	O
stem	B
cell	I
markers	O
(CD44),	O
down-regulation	O
of	O
cell	O
adhesion	O
markers	O
(E-Cadherin),	O
up-regulation	O
of	O
invasion	O
related	O
metalloproteinases	O
(MMP14),	O
and	O
up-regulation	O
of	O
COX-2	O
(Figure	O
2)..	O

Chloroquine	O
has	O
been	O
shown	O
to	O
suppress	O
N-methyl-N-nitrosurea	O
induced	O
mouse	O
breast	O
carcinomagenesis	O
[39],	O
enhances	O
the	O
effectiveness	O
of	O
tyrosine	O
kinase	O
inhibitor	O
treatment	O
of	O
primary	B
CML	I
stem	I
cells	I
[40],	O
and	O
has	O
been	O
proposed	O
as	O
a	O
potential	O
means	O
to	O
enhance	O
the	O
effectiveness	O
of	O
tamoxifen	O
in	O
vitro	O
in	O
tamoxifen	O
resistant	O
breast	O
carcinoma	O
cells	O
by	O
blocking	O
autophagy	O
dependent	O
cell	O
survival	O
[17],	O
[28].	O

Derivation	O
of	O
oocyte-like	O
cells	O
from	O
a	O
clonal	B
pancreatic	I
stem	I
cell	I
line.	O

Adoptive	O
transfer	O
of	O
pp65-specific	O
T	O
cells	O
for	O
the	O
treatment	O
of	O
chemorefractory	O
cytomegalovirus	O
disease	O
or	O
reactivation	O
after	O
haploidentical	O
and	O
matched	O
unrelated	B
stem	I
cell	I
transplantation.	O

Adoptive	O
immunotherapy	O
with	O
CMV-specific	O
cytotoxic	O
T	O
lymphocytes	O
for	O
stem	B
cell	I
transplant	O
patients	O
with	O
refractory	O
CMV	O
infections.	O

Cytomegalovirus-specific	O
T-cell	O
transfer	O
for	O
refractory	O
cytomegalovirus	O
infection	O
after	O
haploidentical	B
stem	I
cell	I
transplantation:	O
The	O
quantitative	O
and	O
qualitative	O
immune	O
recovery	O
for	O
cytomegalovirus.	O

Strategies	O
of	O
adoptive	O
T	O
-cell	O
transfer	O
to	O
treat	O
refractory	O
viral	O
infections	O
post	O
allogeneic	B
stem	I
cell	I
transplantation.	O

Human	O
cytomegalovirus	O
latency	O
and	O
reactivation	O
in	O
allogeneic	B
hematopoietic	I
stem	I
cell	I
transplant	O
recipients.	O

Tetramer-based	O
quantification	O
of	O
cytomegalovirus	O
(CMV)-specific	O
CD8+	O
T	O
lymphocytes	O
in	O
T-cell-depleted	B
stem	I
cell	I
grafts	O
and	O
after	O
transplantation	O
may	O
identify	O
patients	O
at	O
risk	O
for	O
progressive	O
CMV	O
infection.	O

Direct	O
visualization	O
of	O
cytomegalovirus-specific	O
T-cell	O
reconstitution	O
after	O
allogeneic	B
stem	I
cell	I
transplantation.	O

Models	O
of	O
astrocyte	O
infection	O
of	O
HIV	O
have	O
been	O
established,	O
including	O
the	O
use	O
of	O
the	O
multipotent	B
human	I
neural	I
stem	I
cell	I
line	O
HNSC.100,	O
in	O
which	O
astrocytes	O
can	O
be	O
differentiated	O
and	O
productively	O
infected	O
with	O
HIV	O
long-term	O
[45].	O

This	O
treatment	O
disrupts	O
HIV	O
transcription	O
with	O
a	O
variety	O
of	O
small	O
molecule	O
compounds,	O
and	O
is	O
incredibly	O
scalable	O
compared	O
to	O
expensive	O
and	O
time-consuming	O
treatments	O
such	O
as	O
stem	B
cell	I
transplants	O
[63].	O

Antiretroviral-Free	O
HIV-1	O
Remission	O
and	O
Viral	O
Rebound	O
Following	O
Allogeneic	B
Stem	I
Cell	I
Transplantation:	O
A	O
Report	O
of	O
Two	O
Cases.	O

:	O
2D	B
and	I
3D	I
Stem	I
Cell	I
Models	O
of	O
Primate	O
Cortical	O
Development	O
Identify	O
Species-Specific	O
Differences	O
in	O
Progenitor	O
Behavior	O
Contributing	O
to	O
Brain	O
Size.	O

Furthermore,	O
in	O
lineage	O
tracing	O
studies,	O
Schepers	O
and	O
colleagues	O
showed	O
that	O
these	O
adenomas	O
maintain	O
Lgr5+	B
stem	I
cell	I
activity	O
[22,23]..	O

The	O
authors	O
found	O
that	O
metastatic	O
PDOs	O
show	O
decreased	O
expression	O
of	O
differentiated	O
markers	O
and,	O
curiously,	O
also	O
of	O
intestinal	B
stem	I
cell	I
markers,	O
demonstrating	O
that	O
primary	O
and	O
metastatic	O
lesions	O
have	O
distinct	O
cellular	O
composition	O
[93]..	O

In	O
addition,	O
Engel	O
and	O
colleagues	O
examined	O
the	O
expression	O
of	O
stem	B
cell	I
markers	O
in	O
a	O
cohort	O
of	O
CRC	O
PDTOs	O
and	O
their	O
correlation	O
with	O
sensitivity	O
to	O
5-FU	O
treatment.	O

Lineage	O
tracing	O
reveals	O
Lgr5+	B
stem	I
cell	I
activity	O
in	O
mouse	O
intestinal	O
adenomas.	O

Organoids:	O
Modeling	O
Development	O
and	O
the	O
Stem	B
Cell	I
Niche	O
in	O
a	O
Dish.	O

Specific	O
Labeling	O
of	O
Stem	B
Cell	I
Activity	O
in	O
Human	O
Colorectal	O
Organoids	O
Using	O
an	O
ASCL2-Responsive	O
Minigene.	O

Regenerative	O
Reprogramming	O
of	O
the	O
Intestinal	B
Stem	I
Cell	I
State	O
via	O
Hippo	O
Signaling	O
Suppresses	O
Metastatic	O
Colorectal	O
Cancer.	O

MET	O
Signaling	O
Mediates	O
Intestinal	O
Crypt-Villus	O
Development,	O
Regeneration,	O
and	O
Adenoma	O
Formation	O
and	O
Is	O
Promoted	O
by	O
Stem	B
Cell	I
CD44	O
Isoforms.	O

Patient-Derived	O
Colorectal	O
Cancer	O
Organoids	O
Upregulate	O
Revival	O
Stem	B
Cell	I
Marker	O
Genes	O
following	O
Chemotherapeutic	O
Treatment.	O

Functional	O
repair	O
of	O
CFTR	O
by	O
CRISPR/Cas9	O
in	O
intestinal	B
stem	I
cell	I
organoids	O
of	O
cystic	O
fibrosis	O
patients.	O

Sustained	O
in	O
vitro	O
intestinal	O
epithelial	O
culture	O
within	O
a	O
Wnt-dependent	B
stem	I
cell	I
niche.	O

Three-Dimensional	O
Gastrointestinal	O
Organoid	O
Culture	O
in	O
Combination	O
with	O
Nerves	O
or	O
Fibroblasts:	O
A	O
Method	O
to	O
Characterize	O
the	O
Gastrointestinal	B
Stem	I
Cell	I
Niche.	O

Stroma	O
provides	O
an	O
intestinal	B
stem	I
cell	I
niche	O
in	O
the	O
absence	O
of	O
epithelial	O
Wnts.	O

Extracellular	O
vesicles	O
transmit	O
epithelial	O
growth	O
factor	O
activity	O
in	O
the	O
intestinal	B
stem	I
cell	I
niche.	O

Alterations	O
in	O
the	O
epithelial	B
stem	I
cell	I
compartment	O
could	O
contribute	O
to	O
permanent	O
changes	O
in	O
the	O
mucosa	O
of	O
patients	O
with	O
ulcerative	O
colitis.	O

These	O
results	O
emphasize	O
a	O
key	O
function	O
of	O
the	O
BRG1	O
bromodomain	O
in	O
stem	B
cell	I
maintenance	O
and	O
differentiation.	O

Selective	O
targeting	O
of	O
the	O
BRG/PB1	O
bromodomains	O
impairs	O
embryonic	O
and	O
trophoblast	B
stem	I
cell	I
maintenance.	O

Enhancement	O
of	O
hematopoietic	B
stem	I
cell	I
repopulating	O
capacity	O
and	O
self-renewal	O
in	O
the	O
absence	O
of	O
the	O
transcription	O
factor	O
C/EBP	O
alpha.	O

Chlorogenic	O
acid	O
regulates	O
apoptosis	O
and	O
stem	B
cell	I
marker-related	O
gene	O
expression	O
in	O
A549	O
human	O
lung	O
cancer	O
cells.	O

Sonic	O
hedgehog	O
(Shh)	O
signaling	O
plays	O
a	O
crucial	O
role	O
in	O
growth	O
and	O
patterning	O
during	O
embryonic	O
development,	O
and	O
also	O
in	O
stem	B
cell	I
maintenance	O
and	O
tissue	O
regeneration	O
in	O
adults.	O

Some	O
studies	O
have	O
revealed	O
that	O
high	O
glucose	O
can	O
reduce	O
proliferation	O
of	O
rat	O
BMMSCs	O
[17]	O
but	O
enhance	O
the	O
adipogenic	O
differentiation	O
of	O
mouse	O
BMMSCs	O
[18],	O
human	O
osteosarcoma	O
cell	O
MG63	O
[19],	O
and	O
human	B
muscle-derived	I
stem	I
cells	I
[20]..	O

Differentiation	O
potential	O
of	O
STRO-1+	B
dental	I
pulp	I
stem	I
cells	I
changes	O
during	O
cell	O
passaging.	O

High	O
glucose	O
suppresses	O
embryonic	B
stem	I
cell	I
differentiation	O
into	O
neural	O
lineage	O
cells.	O

For	O
instance,	O
HIFs	O
promote	O
the	O
expression	O
of	O
genes	O
associated	O
to	O
angiogenesis	O
and	O
modulate	O
the	O
differentiation	O
of	O
stem	B
cells	I
onto	O
certain	O
cell	O
phenotypes	O
[42].	O

Regarding	O
other	O
tissues	O
and	O
organs,	O
O2	O
monitoring	O
is	O
important	O
for	O
tissue	B
engineering	I
and	I
regenerative	I
medicine	I
because	I
stem	I
cell	I
differentiation,	O
cell	O
therapy	O
and	O
engraftment	O
of	O
progenitor	O
cells	O
into	O
the	O
target	O
tissue	O
seem	O
to	O
be	O
more	O
efficient	O
at	O
specific	O
levels	O
of	O
oxygen	O
[117,118].	O

Hyperbaric	O
Oxygen	O
Increases	O
Stem	B
Cell	I
Proliferation,	O
Angiogenesis	O
and	O
Wound-Healing	O
Ability	O
of	O
WJ-MSCs	O
in	O
Diabetic	O
Mice.	O

Assessing	O
glucose	O
and	O
oxygen	O
diffusion	O
in	O
hydrogels	O
for	O
the	O
rational	O
design	O
of	O
3D	B
stem	I
cell	I
scaffolds	O
in	O
regenerative	O
medicine.	O

Real-time	O
monitoring	O
of	O
specific	O
oxygen	O
uptake	O
rates	O
of	O
embryonic	B
stem	I
cells	I
in	O
a	O
microfluidic	O
cell	O
culture	O
device.	O

Monoclonal	O
antibodies	O
for	O
murine	O
CD3	O
(clone	O
145-2C11),	O
CD4	O
(clone	O
GK	O
1.5),	O
CD8	O
(clone	O
53–6.72),	O
CD44	O
(clone	O
IM7),	O
CD48	O
(clone	O
HM48-1),	O
CD62L	O
(clone	O
MEL-14),	O
CD117	O
(c-Kit,	O
clone	O
2B8),	O
CD150	O
(SLAM,	O
clone	O
TC15-12F12.2),	O
erythroid	O
cells	O
(clone	O
Ter119),	O
granulocytes	O
(Gr1/Ly6-G,	O
clone	O
RB6-8C5),	O
stem	B
cell	I
antigen-1	O
(Sca-1,	O
clone	O
E13-161),	O
and	O
IFN-γ	O
(clone	O
XMG1.2)	O
were	O
all	O
from	O
BioLegend	O
(San	O
Diego,	O
CA).	O

Hematopoietic	B
stem	I
cell	I
loss	O
and	O
hematopoietic	O
failure	O
in	O
severe	O
aplastic	O
anemia	O
is	O
driven	O
by	O
macrophages	O
and	O
aberrant	O
podoplanin	O
expression.	O

Inhibition	O
of	O
endosteal	O
vascular	O
niche	O
remodeling	O
rescues	O
hematopoietic	B
stem	I
cell	I
loss	O
in	O
AML.	O

A	O
third	O
hypothesis	O
proposes	O
that	O
LMNA	O
mutation	O
could	O
cause	O
impairments	O
in	O
muscle	B
stem	I
cell	I
function.	O

Lamina-associated	O
polypeptide	O
(LAP)2	O
b1	O
and	O
nucleoplasmic	O
lamins	O
in	O
adult	B
stem	I
cell	I
regulation	O
and	O
disease.	O

CSF	O
flow	O
is	O
also	O
suggested	O
to	O
support	O
neural	B
stem	I
cell	I
proliferation	O
[18]	O
and	O
directional	O
neuronal	O
migration	O
[19].	O

Epithelial	O
sodium	O
channel	O
regulates	O
adult	O
neural	B
stem	I
cell	I
proliferation	O
in	O
a	O
flow-dependent	O
manner.	O

Single-cell	O
transcriptomics	O
and	O
fate	O
mapping	O
of	O
ependymal	O
cells	O
reveals	O
an	O
absence	O
of	O
neural	B
stem	I
cell	I
function.	O

MACF1	O
also	O
sustains	O
directional	O
cell	O
migration	O
in	O
stem	B
cells	I
responsible	O
for	O
homeostasis	O
and	O
wound	O
healing	O
(7).	O

Moreover,	O
a	O
link	O
between	O
MACF1	O
and	O
GSK3	O
b2	O
controlling	O
skin	B
stem	I
cell	I
migration	O
and	O
polarized	O
locomotion	O
upon	O
injury	O
was	O
identified	O
(7).	O

WNT-signaling	O
regulates	O
a	O
range	O
of	O
physiological	O
processes	O
including	O
embryonic	O
development,	O
cell	O
proliferation,	O
stem	B
cell	I
maintenance,	O
epithelial	O
mesenchymal	O
interactions	O
but	O
is	O
also	O
linked	O
to	O
human	O
carcinogenesis	O
[9	O
11].	O

The	O
neural	B
stem	I
cell	I
tumors	O
in	O
the	O
tumor	O
model	O
also	O
had	O
high	O
oxidation,	O
which	O
promotes	O
tumor	O
immortality;	O
however,	O
the	O
underlying	O
mechanisms	O
remain	O
unclear	O
(Bonnay	O
et	O
al.,	O
2020)..	O

The	O
noncoding	O
RNA	O
Mistral	O
activates	O
Hoxa6	O
and	O
Hoxa7	O
expression	O
and	O
stem	B
cell	I
differentiation	O
by	O
recruiting	O
MLL1	O
to	O
chromatin.	O

Epigenetic	O
regulation	O
of	O
NANOG	O
by	O
miR-302	O
cluster-MBD2	O
completes	O
induced	B
pluripotent	I
stem	I
cell	I
reprogramming.	O

Previous	O
studies	O
have	O
used	O
chromatin-state	O
maps	O
to	O
identify	O
3,019	O
lncRNAs	O
with	O
a	O
clear	O
evolutionary	O
conservation,	O
which	O
are	O
associated	O
with	O
distinct	O
and	O
diverse	O
biological	O
processes	O
(such	O
as	O
cell	O
proliferation),	O
RNA	O
binding	O
complexes,	O
immune	O
surveillance,	O
embryonic	B
stem	I
cell	I
pluripotency,	O
neuronal	O
processes,	O
morphogenesis,	O
gametogenesis	O
and	O
muscle	O
development	O
(29,30).	O

Oxidative	O
stress	O
in	O
HSC	O
can	O
lead	O
to	O
DNA	O
damage,	O
premature	O
senescence,	O
and	O
loss	O
of	O
stem	B
cell	I
function	O
[18].	O

Stein	O
SJ,	O
Baldwin	O
AS	O
(2013)	O
Deletion	O
of	O
the	O
NF-baB	O
subunit	O
p65/RelA	O
in	O
the	O
hematopoietic	O
compartment	O
leads	O
to	O
defects	O
in	O
hematopoietic	B
stem	I
cell	I
function.	O

The	O
mood	O
stabilizers	O
valproic	O
acid	O
and	O
lithium	O
enhance	O
mesenchymal	B
stem	I
cell	I
migration	O
via	O
distinct	O
mechanisms.	O

Indeed,	O
a	O
growing	O
body	O
of	O
evidence	O
now	O
suggests	O
that	O
the	O
metabolism	O
epigenetics	O
axis	O
optimizes	O
adaptive	O
responses	O
to	O
changes	O
in	O
environment	O
in	O
normal	O
(e.g.,	O
development	O
and	O
stem	B
cell	I
differentiation)	O
and	O
disease	O
states	O
(e.g.,	O
cancer),	O
thus	O
linking	O
metabolic	O
stress	O
to	O
cellular	O
functions	O
[4].	O

We	O
have	O
previously	O
demonstrated	O
that	O
tumors	O
depleted	O
of	O
VDAC1	O
undergo	O
metabolic	O
reprograming	O
(Figure	O
1),	O
leading	O
to	O
a	O
reduction	O
of	O
tumor	O
growth,	O
invasiveness,	O
and	O
angiogenesis,	O
and	O
the	O
disappearance	O
of	O
cancer	O
stem	O
cells,	O
while	O
inducing	O
tumor	O
cell	O
differentiation	O
[49].	O
The	O
polycomb	O
group	O
protein	O
Suz12	O
is	O
required	O
for	O
embryonic	B
stem	I
cell	I
differentiation.	O

Although	O
KIR2DL2/L3	O
polymorphism	O
is	O
known	O
to	O
be	O
associated	O
with	O
many	O
human	O
diseases	O
and	O
is	O
an	O
important	O
factor	O
for	O
donor	O
selection	O
in	O
allogeneic	B
hematopoietic	I
stem	I
cell	I
transplantation,	O
the	O
molecular	O
determinant	O
of	O
functional	O
diversity	O
among	O
various	O
alleles	O
is	O
unclear.	O

The	O
results	O
of	O
this	O
study	O
will	O
be	O
important	O
for	O
future	O
studies	O
of	O
KIR2DL2/L3-associated	O
diseases	O
as	O
well	O
as	O
for	O
donor	O
selection	O
in	O
allogeneic	B
stem	I
cell	I
transplantation..	O

Moreover,	O
KIR2DL2/L3	O
are	O
important	O
determinant	O
for	O
donor	O
selection	O
in	O
hematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT).	O

Hematopoietic	B
stem	I
cell	I
differentiation	O
is	O
a	O
prominent	O
example	O
of	O
a	O
dynamic	O
process	O
that	O
is	O
heavily	O
genetically	O
regulated	O
[9],	O
[29]	O
[32].	O

Van	O
Zant	O
G,	O
Eldridge	O
PW,	O
Behringer	O
RR,	O
Dewey	O
MJ	O
(1983)	O
Genetic	O
control	O
of	O
hematopoietic	O
kinetics	O
revealed	O
by	O
analyses	O
of	O
allophenic	O
mice	O
and	O
stem	B
cell	I
suicide.	O

Dybedal	O
I,	O
Larsen	O
S,	O
Jacobsen	O
SE	O
(1995)	O
IL-12	O
directly	O
enhances	O
in	O
vitro	O
murine	O
erythropoiesis	O
in	O
combination	O
with	O
IL-4	O
and	O
stem	B
cell	I
factor.	O

Transitions	O
between	O
epithelial	O
and	O
mesenchymal	O
states:	O
acquisition	O
of	O
malignant	O
and	O
stem	B
cell	I
traits.	O

The	O
Effect	O
of	O
Adipose	B
Stem	I
Cell	I
Therapy	O
on	O
Pulmonary	O
Fibrosis	O
Induced	O
by	O
Repetitive	O
Intratracheal	O
Bleomycin	O
in	O
Mice.	O

Injured	O
Microenvironment	O
Directly	O
Guides	O
the	O
Differentiation	O
of	O
Engrafted	O
Flk-1+	O
Mesenchymal	B
Stem	I
Cell	I
in	O
Lung.	O

Optimization	O
of	O
the	O
Adipose-Derived	B
Mesenchymal	I
Stem	I
Cell	I
Delivery	O
Time	O
for	O
Radiation-Induced	O
Lung	O
Fibrosis	O
Treatment	O
in	O
Rats.	O

A	O
recent	O
study	O
has	O
shown	O
that	O
extracellular	O
vesicles	O
(EVs)	O
released	O
by	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
-derived	O
cardiomyocytes	O
(iCMs)	O
exposed	O
to	O
hypoxic	O
conditions	O
are	O
enriched	O
with	O
miR-106a-363	O
cluster.	O

As	O
a	O
master	O
transcriptional	O
regulator,	O
FOXM1	O
promotes	O
critical	O
oncogenic	O
phenotypes	O
in	O
ovarian	O
cancer,	O
including:	O
(1)	O
cell	O
proliferation,	O
(2)	O
invasion	O
and	O
metastasis,	O
(3)	O
chemotherapy	O
resistance,	O
(4)	O
cancer	B
stem	I
cell	I
(CSC)	O
properties,	O
(5)	O
genomic	O
instability,	O
and	O
(6)	O
altered	O
cellular	O
metabolism.	O

Cancer	B
stem	I
cells	I
(CSC)	O
have	O
enhanced	O
capacities	O
for	O
self-renewal,	O
cell	O
plasticity,	O
and	O
the	O
ability	O
to	O
adapt	O
to	O
harsh	O
environments	O
[277,278,279].	O

Temporal	O
expression	O
changes	O
during	O
differentiation	O
of	O
neural	O
stem	O
cells	O
derived	O
from	O
mouse	B
embryonic	I
stem	I
cell.	I

The	O
Forkhead	O
box	O
transcription	O
factor	O
FOXM1	O
is	O
required	O
for	O
the	O
maintenance	O
of	O
cell	O
proliferation	O
and	O
protection	O
against	O
oxidative	O
stress	O
in	O
human	O
embryonic	O
stem	O
cells.	O
FOXM1	O
in	O
sarcoma:	O
Role	O
in	O
cell	O
cycle,	O
pluripotency	O
genes	O
and	O
stem	B
cell	I
pathways.	O

7-difluoromethoxyl-5,4-di-n-octyl	O
genistein	O
inhibits	O
ovarian	O
cancer	B
stem	I
cell	I
characteristics	O
through	O
the	O
downregulation	O
of	O
FOXM1.	O

Essential	O
roles	O
of	O
FoxM1	O
in	O
Ras-induced	O
liver	O
cancer	O
progression	O
and	O
in	O
cancer	O
cells	O
with	O
stem	B
cell	I
features.	O

FoxM1	O
Promotes	O
Stemness	O
and	O
Radio-Resistance	O
of	O
Glioblastoma	O
by	O
Regulating	O
the	O
Master	B
Stem	I
Cell	I
Regulator	O
Sox2.	O

Maintenance	O
of	O
the	O
hematopoietic	B
stem	I
cell	I
pool	O
by	O
CXCL12-CXCR4	O
chemokine	O
signaling	O
in	O
bone	O
marrow	O
stromal	O
cell	O
niches.	O

Overexpression	O
of	O
cMyc,	O
a	O
global	O
regulator	O
of	O
transcription50	O
and	O
a	O
known	O
Wnt	O
target	O
gene,51	O
has	O
previously	O
been	O
reported	O
to	O
induce	O
mammary	O
carcinomas	O
in	O
mice52	O
and	O
found	O
to	O
be	O
overexpressed	O
in	O
the	O
majority	O
of	O
human	O
breast	O
tumors.53	O
Given	O
Wnt	O
pathway	O
activation	O
was	O
only	O
apparent	O
in	O
a	O
subset	O
of	O
epithelial	O
cells	O
at	O
an	O
early	O
time	O
point,	O
it	O
is	O
unclear	O
whether	O
these	O
tumors	O
arise	O
because	O
of	O
Wnt	O
activation	O
in	O
specific	O
cell	O
types,	O
which	O
one	O
could	O
speculate	O
to	O
be	O
mammary	B
stem	I
cells	I
or	O
because	O
of	O
accumulation	O
of	O
other	O
oncogenic	O
mutations..	O

Emodin	O
reduces	O
breast	O
cancer	O
lung	O
metastasis	O
by	O
suppressing	O
macrophage-induced	O
breast	O
cancer	O
cell	O
epithelial-mesenchymal	O
transition	O
and	O
cancer	B
stem	I
cell	I
formation.	O

Here,	O
we	O
show	O
that	O
porcine	O
c-kit+	O
bone	O
marrow	O
cells	O
(c-kit+	O
BM	O
cells)	O
develop	O
into	O
NK	O
cells	O
in	O
vitro	O
in	O
the	O
presence	O
of	O
various	O
cytokines	O
[interleukin	O
(IL)-2,	O
IL-7,	O
IL-15,	O
IL-21,	O
stem	B
cell	I
factor	O
(SCF),	O
and	O
fms-like	O
tyrosine	O
kinase-3	O
ligand	O
(FLT3L)].	O

Porcine	O
c-kit+	O
cell	O
colony	O
obtained	O
from	O
porcine	O
BM	O
cells	O
was	O
photographed	O
in	O
stem	B
cell	I
medium	O
(B,	O
Bar:	O
50	O
b5m)..	O

The	O
authenticated	O
short	O
tandem	O
repeat-profiled	O
RCC	O
786-O,	O
normal	O
renal	O
tubular	O
epithelial	O
HK-2,	O
and	O
prostate	O
cancer	O
PC-3	O
cell	O
lines	O
were	O
purchased	O
from	O
the	O
Stem	B
Cell	I
Bank,	O
Chinese	O
Academy	O
of	O
Sciences.	O

Stem	B
cell	I
factor	O
and	O
its	O
receptor	O
c-KIT	O
are	O
essential	O
for	O
mast	O
cell	O
survival	O
and	O
inhibition	O
of	O
apoptosis,	O
and	O
gain-of-function	O
mutations	O
are	O
present	O
in	O
human	O
and	O
canine	O
mast	O
cell	O
tumors	O
[137,138,139,140,141,142].	O

The	O
c-kit	O
ligand,	O
stem	B
cell	I
factor,	O
promotes	O
mast	O
cell	O
survival	O
by	O
suppressing	O
apoptosis.	O

Stem	B
cell	I
factor	O
promotes	O
mast	O
cell	O
survival	O
via	O
inactivation	O
of	O
FOXO3a-mediated	O
transcriptional	O
induction	O
and	O
MEK-regulated	O
phosphorylation	O
of	O
the	O
proapoptotic	O
protein	O
Bim.	O

The	O
TLX-miR-219	O
cascade	O
regulates	O
neural	B
stem	I
cell	I
proliferation	O
in	O
neurodevelopment	O
and	O
schizophrenia	O
iPSC	O
model.	O

MicroRNAs	O
to	O
Nanog,	O
Oct4	O
and	O
Sox2	O
coding	O
regions	O
modulate	O
embryonic	B
stem	I
cell	I
differentiation.	O

Mice	O
with	O
high	O
chimeric	O
ratio	O
develop	O
anemia	O
after	O
engraftment	O
Human	O
cell	O
engraftment	O
does	O
not	O
last	O
more	O
than	O
five	O
months	O
Low	O
tolerance	O
for	O
irradiation	O
Low	O
CD45+	O
human	O
cell	O
engraftment	O
compared	O
to	O
NSG	O
mice	O
Short	O
lifespan	O
post-engraftment	O
(~	O
weeks)	O
but	O
may	O
be	O
prolonged	O
by	O
avoiding	O
irradiation,	O
using	O
less	O
potent	O
and	O
lower	O
number	O
of	O
stem	B
cells	I
Not	O
reported.	O

Second,	O
NOD.Cg-Prkdcscid	O
Il2rgtm1Wjl	O
Tg	O
(CMV-IL3,	O
CSF2,	O
KITLG)	O
1Eav/MloySzJ	O
(NSG-SGM3	O
mouse)	O
are	O
knock-in	O
mice	O
expressing	O
IL-3,	O
GM-CSF	O
and	O
stem	B
cell	I
factor	O
(SCF)	O
under	O
the	O
control	O
of	O
human-specific	O
cytomegalovirus	O
(CMV)	O
(Billerbeck	O
et	O
al.	O

Even	O
though	O
this	O
combination	O
of	O
genes	O
supports	O
human	O
HSC	O
engraftment,	O
formation	O
of	O
myeloid	O
leukocytes,	O
and	O
reduces	O
B-lymphopoiesis	O
post-BM	O
transplantation	O
this	O
model	O
lacks	O
an	O
improved	O
red	O
blood	O
cell	O
(RBC)	O
reconstitution	O
and	O
the	O
presence	O
of	O
SCF	O
may	O
destructively	O
affect	O
human	B
stem	I
cell	I
compartments	O
by	O
supporting	O
the	O
growth	O
and	O
competitive	O
repopulation	O
of	O
mouse	O
cells	O
(Billerbeck	O
et	O
al.	O

A	O
solution	O
for	O
this	O
limitation	O
is	O
underway	O
as	O
teams	O
around	O
the	O
world	O
perfect	O
induced	B
pluripotent	I
stem	I
cell	I
technology,	O
which	O
enables	O
the	O
use	O
of	O
patient-specific	O
iPSCs	O
allowing	O
a	O
renewable	O
source	O
of	O
autologous	O
cells	O
sans	O
immune	O
rejection	O
(Shi	O
et	O
al.	O

NK	O
cells	O
preferentially	O
target	O
tumor	O
cells	O
with	O
a	O
cancer	B
stem	I
cell	I
phenotype.	O

Immunodeficient	O
mouse	O
model	O
for	O
human	B
hematopoietic	I
stem	I
cell	I
engraftment	O
and	O
immune	O
system	O
development.	O

Development	O
of	O
human	O
CD4(+)FoxP3(+)	O
regulatory	O
T	O
cells	O
in	O
human	B
stem	I
cell	I
factor-,	O
granulocyte-macrophage	O
colony-stimulating	O
factor-,	O
and	O
interleukin-3-expressing	O
NOD-SCID	O
IL2R(null)	O
humanized	O
mice.	O

Parameters	O
for	O
establishing	O
humanized	O
mouse	O
models	O
to	O
study	O
human	O
immunity:	O
Analysis	O
of	O
human	B
hematopoietic	I
stem	I
cell	I
engraftment	O
in	O
three	O
immunodeficient	O
strains	O
of	O
mice	O
bearing	O
the	O
IL2r3(null)	O
mutation.	O

Long-term	O
human	O
immune	O
system	O
reconstitution	O
in	O
non-obese	O
diabetic	O
(NOD)-Rag	O
()-	O
chain	O
()	O
(NRG)	O
mice	O
is	O
similar	O
but	O
not	O
identical	O
to	O
the	O
original	B
stem	I
cell	I
donor.	O

Zinc	O
finger	O
nuclease-mediated	O
CCR5	O
knockout	O
hematopoietic	B
stem	I
cell	I
transplantation	O
controls	O
HIV-1	O
in	O
vivo.	O

Improved	O
B	O
cell	O
development	O
in	O
humanized	O
NOD-scid	O
IL2R	O
null	O
mice	O
transgenically	O
expressing	O
human	B
stem	I
cell	I
factor,	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
and	O
interleukin-3.	O

NOD//SCID	O
mice	O
engineered	O
to	O
express	O
human	O
IL-3,	O
GM-CSF	O
and	O
Steel	O
factor	O
constitutively	O
mobilize	O
engrafted	O
human	O
progenitors	O
and	O
compromise	O
human	B
stem	I
cell	I
regeneration.	O

Co-transplantation	O
of	O
human	B
hematopoietic	I
stem	I
cells	I
and	O
human	O
breast	O
cancer	O
cells	O
in	O
NSG	O
mice:	O
A	O
novel	O
approach	O
to	O
generate	O
tumor	O
cell	O
specific	O
human	O
antibodies.	O

This	O
idea	O
that	O
osteoblasts	O
in	O
fibrous	O
dysplasia	O
lesions	O
may	O
have	O
reacquired	O
the	O
characteristics	O
of	O
a	O
perinatal	O
osteoblast	O
correlates	O
with	O
suggestions	O
that	O
fibrous	O
dysplasia	O
may	O
be	O
a	O
stem	B
cell	I
disease.(37)	O
Furthermore,	O
a	O
non-cell	O
autonomous	O
mechanism	O
may	O
contribute	O
to	O
the	O
development	O
of	O
fibrous	O
dysplasia	O
lesions(38)	O
and	O
may	O
similarly	O
modify	O
the	O
osteoblast	O
response	O
to	O
Rs1-mediated	O
Gs	O
activation	O
in	O
an	O
age-dependent	O
manner..	O

Treatment	O
for	O
AML	O
may	O
include	O
chemotherapy,	O
radiation	O
therapy,	O
stem	B
cell	I
transplant	O
and/or	O
immunotherapy	O
[81],[89]..	O

Treatment	O
for	O
CML	O
may	O
include	O
radiation	O
therapy,	O
chemotherapy,	O
stem	B
cell	I
transplant	O
and/or	O
immunotherapy.	O

The	O
p53	O
tumor	O
suppressor	O
protein	O
is	O
a	O
critical	O
regulator	O
of	O
hematopoietic	B
stem	I
cell	I
behavior.	O

Quiescent,	O
slow-cycling	B
stem	I
cell	I
populations	O
in	O
cancer:	O
A	O
review	O
of	O
the	O
evidence	O
and	O
discussion	O
of	O
significance.	O

SNAI1	O
induces	O
resistance	O
to	O
apoptosis,	O
confers	O
tumor	O
recurrence,	O
generates	O
breast	B
cancer	I
stem	I
cell	I
(CSC)-like	O
properties,	O
and	O
induces	O
aerobic	O
glycolysis	O
14-16.	O

Among	O
the	O
hallmarks	O
of	O
aging	O
are	O
genomic	O
instability,	O
telomere	O
attrition,	O
epigenetic	O
alterations,	O
loss	O
of	O
proteostasis,	O
deregulated	O
nutrient	O
sensing,	O
mitochondrial	O
dysfunction,	O
cellular	O
senescence,	O
stem	B
cell	I
exhaustion,	O
and	O
altered	O
intercellular	O
communication	O
[1].	O

Phytochemicals	O
have	O
also	O
successfully	O
been	O
applied	O
for	O
regenerative	O
medicine	O
and	O
cancer	B
stem	I
cell	I
therapy	O
[248-253].	O

Snail,	O
one	O
of	O
the	O
downstream	O
targets	O
of	O
TGF-	O
b2	O
induction,	O
is	O
highly	O
expressed	O
during	O
embryogenesis	O
and	O
plays	O
a	O
critical	O
role	O
in	O
the	O
stem	B
cell	I
division.	O

Pluripotent	O
cells	O
have	O
been	O
established	O
from	O
several	O
embryonic	O
and	O
adult	O
tissues	O
using	O
cell	O
culture	O
systems.10	O
For	O
example,	O
embryonic	O
germ	O
cells	O
have	O
been	O
isolated	O
from	O
the	O
primordial	O
germ	O
cells	O
of	O
midgestation	O
embryos,	O
while	O
multipotent	B
germline	I
stem	I
cells	I
have	O
been	O
generated	O
from	O
explanted	O
neonatal	O
and	O
adult	O
mouse	O
testicular	O
cells,	O
albeit	O
at	O
a	O
very	O
low	O
efficiency.11,	O
12,	O
13	O
iPSCs	O
have	O
been	O
generated	O
by	O
the	O
addition	O
of	O
various	O
combinations	O
of	O
transcription	O
factors	O
(octamer-binding	O
transcription	O
factor	O
4	O
(OCT4),	O
MYC,	O
KLF4,	O
and	O
SOX2).14.	O

Oct4	O
expression	O
is	O
not	O
required	O
for	O
mouse	B
somatic	I
stem	I
cell	I
self-renewal.	O

A	O
definitive	O
role	O
of	O
Shp-2	O
tyrosine	O
phosphatase	O
in	O
mediating	O
embryonic	B
stem	I
cell	I
differentiation	O
and	O
hematopoiesis.	O

Shp2-mediated	O
molecular	O
signaling	O
in	O
control	O
of	O
embryonic	B
stem	I
cell	I
self-renewal	O
and	O
differentiation.	O

Deletion	O
of	O
the	O
developmentally	O
essential	O
gene	O
ATR	O
in	O
adult	O
mice	O
leads	O
to	O
age-related	O
phenotypes	O
and	O
stem	B
cell	I
loss.	O

Cell	B
Stem	I
Cell	I
1,	O
113	O
126	O
[PMC	O
free	O
article]	O
[PubMed]	O
[Google	O
Scholar].	O

A-FABP	O
activates	O
the	O
Interleukin	O
6/Signal	O
Transducer	O
and	O
Activator	O
of	O
Transcription	O
3/ALDH1	O
pathway	O
within	O
breast	O
tumor	O
cells	O
which	O
promotes	O
a	O
stem	B
cell	I
phenotype	O
that	O
enhances	O
the	O
aggressiveness	O
of	O
these	O
tumor	O
cells	O
[54].	O

Nevertheless,	O
human	O
epithelial	O
and	O
stem	B
cell	I
cancers	O
have	O
been	O
successfully	O
modeled	O
in	O
Drosophila	O
[26].	O

Endogenous	O
miRNA	O
sponge	O
lincRNA-RoR	O
regulates	O
Oct4,	O
Nanog,	O
and	O
Sox2	O
in	O
human	B
embryonic	I
stem	I
cell	I
self-renewal.	O

Enhanced	O
expression	O
of	O
stem	B
cell	I
antigen-1	O
(Ly-6A/E)	O
in	O
lymphocytes	O
from	O
lupus	O
prone	O
mice	O
correlates	O
with	O
disease	O
severity.	O

SMAD	O
signaling	O
pathways	O
have	O
been	O
implicated	O
in	O
stem	B
cell	I
regulation	O
and	O
control	O
cell	O
fate	O
decisions.	O

BMPs	O
promote	O
an	O
undifferentiated	O
state	O
by	O
upregulating	O
inhibitor	O
of	O
differentiation	O
(Id)	O
proteins	O
through	O
SMAD1	O
activation,	O
whereas	O
Actvin/Nodal/TGF	O
b2-regulated	O
SMAD2/3	O
promotes	O
stem	B
cell	I
self-renewal.	O

Proteomic	O
investigations	O
have	O
identified	O
VEPH1	O
as	O
a	O
component	O
of	O
exosomes	O
originating	O
from	O
various	O
cell	O
types	O
including	O
trophoblast	O
cells,	O
cancer	O
associated	O
fibroblasts,	O
and	O
mesenchymal	B
stem	I
cells	I
[33].	O

Placental	B
mesenchymal	I
stem	I
cells	I
similarly	O
produce	O
exosomes	O
that	O
promote	O
placental	O
microvascular	O
endothelial	O
cell	O
migration	O
and	O
tube	O
formation,	O
with	O
exosome	O
production	O
augmented	O
under	O
hypoxic	O
conditions.	O

Changes	O
to	O
the	O
microenvironment	O
within	O
tissue	B
stem	I
cell	I
niches	O
can	O
have	O
determining	O
effects	O
on	O
renewal	O
vs.	O

Telomerase,	O
the	O
dedicated	O
reverse	O
transcriptase	O
that	O
adds	O
telomeric	O
repeats	O
de	O
novo	O
to	O
the	O
3	O
end,	O
is	O
highly	O
active	O
during	O
development	O
and	O
its	O
activity	O
persists	O
in	O
stem	B
cell	I
compartments,	O
where	O
it	O
ensures	O
the	O
cell	O
replication	O
potential	O
of	O
highly	O
proliferative	O
tissues	O
[17][19].	O

Implications	O
of	O
cellular	O
senescence	O
in	O
tissue	O
damage	O
response,	O
tumor	O
suppression,	O
and	O
stem	B
cell	I
biology.	O

Deletion	O
of	O
the	O
Dicer	O
gene	O
in	O
mice	O
results	O
in	O
embryonic	O
lethality	O
and	O
a	O
depletion	O
of	O
the	O
stem	B
cell	I
population	O
[32].	O

An	O
analysis	O
of	O
chromatin	O
accessibility,	O
histone	O
modifications,	O
and	O
transcription	O
factor	O
binding	O
in	O
a	O
mouse	B
embryonic	I
stem	I
cell	I
model	O
of	O
hematopoiesis	O
has	O
revealed	O
a	O
complex	O
regulatory	O
network	O
that	O
drives	O
changes	O
in	O
the	O
transcriptome	O
during	O
differentiation	O
12.	O

Physiological	O
Srsf2	O
P95H	O
expression	O
causes	O
impaired	O
hematopoietic	B
stem	I
cell	I
functions	O
and	O
aberrant	O
RNA	O
splicing	O
in	O
mice.	O

These	O
are	O
likely	O
at	O
work	O
in	O
cells	O
with	O
stem	B
cell	I
properties,	O
leading	O
to	O
the	O
appearance	O
of	O
metastasis	O
initiating	O
cells,	O
and	O
at	O
least	O
in	O
colon	O
and	O
breast	O
cancers	O
there	O
is	O
little	O
correlation	O
of	O
the	O
time	O
of	O
metastatic	O
spread	O
with	O
primary	O
tumor	O
size	O
[2,	O
3].	O

WNT	O
and	O
TGF	O
b1	O
participate	O
in	O
the	O
architecture	O
of	O
normal	O
and	O
regenerating	O
crypt-villus	O
axes	O
of	O
the	O
intestine	O
and	O
are	O
expressed	O
at	O
opposite	O
ends:	O
canonical	O
WNT	O
ligands	O
are	O
made	O
in	O
the	O
bottom	O
part	O
of	O
the	O
crypt	O
and	O
promote	O
crypt	B
stem	I
cell	I
self-renewal	O
[91].	O

Human	O
colon	O
cancer	O
epithelial	O
cells	O
harbour	O
active	O
HEDGEHOG-GLI	O
signalling	O
that	O
is	O
essential	O
for	O
tumour	O
growth,	O
recurrence,	O
metastasis	O
and	O
stem	B
cell	I
survival	O
and	O
expansion.	O

HEDGEHOG-GLI1	O
signaling	O
regulates	O
human	O
glioma	O
growth,	O
cancer	B
stem	I
cell	I
self-renewal,	O
and	O
tumorigenicity.	O

This	O
may	O
primarily	O
be	O
due	O
to	O
the	O
interaction	O
of	O
c-Kit	O
receptor	O
present	O
on	O
mast	O
cells	O
and	O
stem	B
cell	I
factor	O
(SCF,	O
the	O
ligand	O
for	O
ckit)	O
expressed	O
on	O
tumor	O
cells.	O

The	O
expression	O
of	O
stem	B
cell	I
factor	O
(SCF)	O
on	O
the	O
4T1	O
and	O
PyV	O
MT	O
cells	O
in	O
vivo	O
and	O
in	O
vitro.	O

The	O
expression	O
of	O
stem	B
cell	I
factor	O
(SCF)	O
on	O
the	O
4T1	O
and	O
PyV	O
MT	O
tumors	O
in	O
vivo	O
from	O
arthritic	O
BC	O
mice	O
b1	O
anti-SCF	O
treatment.	O

Expression	O
of	O
stem	B
cell	I
factor	O
(SCF)	O
and	O
SCF	O
receptor	O
(c-kit)	O
in	O
synovial	O
membrane	O
in	O
arthritis:	O
correlation	O
with	O
synovial	O
mast	O
cell	O
hyperplasia	O
and	O
inflammation.	O

The	O
c-kit	O
receptor,	O
stem	B
cell	I
factor,	O
and	O
mast	O
cells:	O
what	O
each	O
is	O
teaching	O
us	O
about	O
the	O
others.	O

Antioxidant	O
Role	O
for	O
Lipid	O
Droplets	O
in	O
a	O
Stem	B
Cell	I
Niche	O
of	O
Drosophila.	O

We	O
describe	O
novel	O
murine	O
immunocompetent	O
glioblastoma	B
stem	I
cell	I
lines	O
derived	O
from	O
Nestin-CreERT2	O
Quaking	O
(QKI)L/L;	O
P53L/L;	O
PTENL/L	O
(QPP)	O
mice	O
[5]	O
and	O
determine	O
their	O
sensitivities	O
to	O
immunotherapies..	O

Fifteen	O
10-12-week-old	O
NSG	O
mice	O
were	O
sub-lethally	O
(1.5Gy)	O
irradiated	O
and	O
then	O
implanted	O
with	O
fetal	O
thymic	O
tissue	O
and	O
CD34+	B
stem	I
cells	I
that	O
had	O
been	O
harvested	O
from	O
a	O
fetus,	O
whose	O
HLA-types	O
were	O
partially-matched	O
with	O
those	O
of	O
the	O
U-CH1	O
chordoma	O
cell	O
line.	O

Patients	O
with	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
(HNSCC)	O
were	O
consented	O
for	O
tumor	O
and	O
IRB	O
approved	O
apheresis	O
for	O
stem	B
cell	I
collection	O
at	O
Winship	O
Cancer	O
Institute	O
of	O
Emory	O
University.	O

NK	O
cells	O
have	O
been	O
implicated	O
in	O
the	O
clinical	O
efficacy	O
of	O
several	O
therapies	O
against	O
MM	O
and	O
may	O
contribute	O
to	O
the	O
success	O
of	O
stem	B
cell	I
transplantation	O
(SCT)	O
by	O
clearing	O
residual	O
cancer	O
cells	O
[2].	O

Strategies	O
to	O
activate	O
NK	O
cells	O
to	O
prevent	O
relapse	O
and	O
induce	O
remission	O
following	O
hematopoietic	B
stem	I
cell	I
transplantation.	O

P644	O
Checkpoint	O
inhibitor	O
therapy	O
in	O
solid	O
organ	O
and	O
allogeneic	B
stem	I
cell	I
transplantation:	O
data	O
mining	O
of	O
The	O
Truven	O
Health	O
Marketscan	O
Research	O
Database.	O

Directed	O
differentiation	O
of	O
pluripotent	B
stem	I
cells	I
produces	O
many	O
specific	O
cell	O
types	O
including	O
dopaminergic	O
neurons.	O

Genetically	O
labeling	O
a	O
lineage	O
specific	O
gene	O
in	O
pluripotent	B
stem	I
cells	I
combined	O
with	O
a	O
robust	O
lineage	O
direct	O
differentiation	O
protocol	O
enables	O
one	O
to	O
easily	O
build	O
in	O
vitro	O
quantitative	O
assays	O
for	O
specific	O
terminal	O
cell	O
types.	O

We	O
suggest	O
that	O
stem	B
cell	I
derived	O
functional	O
cells	O
have	O
the	O
potential	O
to	O
contribute	O
to	O
a	O
highly	O
specific	O
and	O
robust	O
in	O
vitro	O
cell-based	O
platform	O
for	O
the	O
purposes	O
of	O
drug	O
testing	O
and	O
screening	O
studies..	O

Generation	O
of	O
human	B
embryonic	I
stem	I
cell	I
reporter	O
lines	O
expressing	O
GFP	O
specifically	O
in	O
neural	O
progenitors.	O

Genetic	O
approach	O
to	O
track	O
neural	O
cell	O
fate	O
decisions	O
using	O
human	O
embryonic	O
stem	O
cells.	O
Three-Dimensional	O
Human	B
Alveolar	I
Stem	I
Cell	I
Culture	O
Models	O
Reveal	O
Infection	O
Response	O
to	O
SARS-CoV-2.	O

A	O
bioengineered	O
niche	O
promotes	O
in	O
vivo	O
engraftment	O
and	O
maturation	O
of	O
pluripotent	B
stem	I
cell	I
derived	O
human	O
lung	O
organoids.	O

Revealing	O
tissue-specific	O
SARS-CoV-2	O
infection	O
and	O
host	O
responses	O
using	O
human	B
stem	I
cell	I
derived	O
lung	O
and	O
cerebral	O
organoids.	O

Therapeutic	O
Effects	O
of	O
Human	B
Mesenchymal	I
Stem	I
Cell	I
Microvesicles	O
in	O
an	O
Ex	O
Vivo	O
Perfused	O
Human	O
Lung	O
Injured	O
with	O
Severe	O
E.coli	O
Pneumonia.	O

Likewise	O
there	O
has	O
also	O
been	O
increased	O
interest	O
in	O
the	O
use	O
of	O
pluripotent	B
stem	I
cells	I
capable	O
of	O
differentiating	O
into	O
multiple	O
cell	O
types.	O

Stem	B
cell	I
therapy	O
for	O
SCI	O
is	O
based	O
on	O
a	O
strategy	O
to	O
treat	O
the	O
injuries	O
and	O
to	O
restore	O
lost	O
functions	O
by	O
replacing	O
lost	O
or	O
damaged	O
cell	O
populations	O
[3]..	O

In	O
order	O
to	O
promote	O
functional	O
recovery,	O
stem	B
cell	I
transplantation	O
must	O
suppress	O
the	O
inflammatory	O
response,	O
inhibit	O
neuronal	O
apoptosis	O
and	O
necrosis,	O
enhance	O
neuronal	O
regeneration,	O
and	O
promote	O
axon	O
regeneration	O
and	O
remyelination	O
[23]..	O

An	O
early	O
stem	B
cell	I
transplantation	O
study	O
in	O
humans	O
was	O
reported	O
as	O
a	O
one	O
patient	O
case	O
report	O
by	O
a	O
Korean	O
research	O
team	O
in	O
2005.	O

In	O
recent	O
years,	O
the	O
advancement	O
of	O
stem	B
cell	I
therapy	O
for	O
SCI	O
has	O
been	O
encouraging	O
and	O
inspiring	O
[30–32].	O

Embryonic	O
stem	O
cells	O
are	O
a	O
kind	O
of	O
pluripotent	B
stem	I
cells	I
that	O
can	O
be	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
the	O
early	O
embryo	O
[5].	O

Compared	O
with	O
the	O
adult	B
stem	I
cells	I
found	O
in	O
adults,	O
ESCs	O
are	O
able	O
to	O
replicate	O
indefinitely	O
and	O
to	O
differentiate	O
into	O
all	O
three	O
primary	O
germ	O
layers	O
cell	O
lines	O
and	O
eventually	O
generate	O
all	O
cell	O
types	O
in	O
the	O
body	O
[37].	O

In	O
stem	B
cell	I
therapy	O
research	O
for	O
SCI,	O
the	O
application	O
of	O
MSCs	O
is	O
favored	O
by	O
some	O
researchers	O
because	O
of	O
the	O
following	O
excellent	O
properties.	O

Neurospheres	O
are	O
mainly	O
composed	O
of	O
two	O
sorts	O
of	O
cells,	O
one	O
which	O
is	O
an	O
electron-dense	O
and	O
slowly	O
dividing	O
neural	B
stem	I
cell	I
population	O
and	O
their	O
progeny	O
which	O
are	O
immunopositive	O
to	O
actin,	O
weakly	O
positive	O
to	O
vimentin,	O
and	O
nestin-negative,	O
and	O
another	O
population	O
of	O
electron-lucent	O
and	O
fast-dividing	O
progenitor	O
cells	O
which	O
are	O
actin,	O
vimentin	O
and	O
nestin	O
positive	O
[155,	O
157].	O

Epidermal	O
growth	O
factor	O
(EGF)	O
and	O
fibroblast	O
growth	O
factor	O
(FGF)	O
are	O
two	O
vital	O
nutritional	O
growth	O
factors	O
that	O
can	O
promote	O
neural	O
progenitor	O
and	O
stem	B
cell	I
growth	O
in	O
vitro	O
and	O
in	O
vivo	O
[158,	O
159].	O

Based	O
on	O
this	O
study,	O
the	O
neurospheres	O
culture	O
system	O
is	O
able	O
to	O
provide	O
a	O
pure	O
population	O
of	O
astrocytes,	O
which	O
have	O
been	O
extensively	O
utilized	O
for	O
stem	B
cell	I
research.	O

developed	O
a	O
novel	O
assay	O
for	O
neural	B
stem	I
cells	I
research,	O
the	O
Neural	O
Colony-Forming	O
Cell	O
Assay,	O
which	O
is	O
capable	O
of	O
discriminating	O
NSCs	O
from	O
various	O
progenitor	O
cells,	O
and	O
more	O
accurate	O
regulating	O
of	O
NSCs	O
for	O
specific	O
applications	O
in	O
further	O
experiments	O
or	O
therapeutic	O
use	O
[163]..	O

They	O
claimed	O
that	O
human	B
neural	I
stem	I
cell	I
fate	O
determination	O
in	O
vivo	O
might	O
be	O
influenced	O
by	O
the	O
predifferentiation	O
treatment	O
prior	O
to	O
grafting,	O
and	O
furthermore	O
the	O
functional	O
improvement	O
is	O
related	O
with	O
the	O
transplantation	O
time	O
point	O
after	O
injury,	O
and	O
the	O
newly	O
differentiated	O
neurons	O
and	O
oligodendrocytes.	O

medu.:	O
intramedullary	O
injection;	O
SCI:	O
spinal	O
cord	O
injury;	O
SCs:	O
Schwann	O
cells;	O
SKP:	O
skin-derived	O
precursors;	O
SCPs:	O
Schwann	O
cell	O
precursors;	O
dbCAMP,	O
dibutyryl	O
CAMP;	O
MSCs:	O
mesenchymal	O
stem	O
cells.	O
There	O
are	O
several	O
issues	O
concerning	O
the	O
safety	O
and	O
the	O
efficacy	O
of	O
these	O
stem	B
cell	I
strategies,	O
which	O
may	O
range	O
from	O
target	O
population	O
selection,	O
long-term	O
tumor	O
genesis,	O
to	O
a	O
series	O
of	O
ethical	O
problems	O
[199	O
201].	O

In	O
November	O
2011,	O
Geron	O
announced	O
that	O
it	O
had	O
ended	O
its	O
SCI	B
stem	I
cell	I
research	O
program	O
largely	O
due	O
to	O
financial	O
reasons	O
[204].	O

Because	O
of	O
this	O
reason,	O
they	O
coated	O
SPION	O
with	O
citrate,	O
and	O
then	O
compared	O
the	O
labeling	O
efficiencies	O
effects	O
on	O
stem	B
cell	I
functionality,	O
and	O
the	O
in	O
vivo	O
MRI	O
visualization	O
of	O
new	O
citrate-coated	O
SPION	O
with	O
commercial	O
Endorem	O
and	O
Resovist	O
SPION.	O

Isolation	O
of	O
a	O
stem	B
cell	I
for	O
neurons	O
and	O
glia	O
from	O
the	O
mammalian	O
neural	O
crest.	O

Adult	B
stem	I
cell	I
transplants	O
for	O
spinal	O
cord	O
injury	O
repair:	O
current	O
state	O
in	O
preclinical	O
research.	O

Prospects	O
for	O
pluripotent	B
stem	I
cell	I
therapies:	O
into	O
the	O
clinic	O
and	O
back	O
to	O
the	O
bench.	O

Feasibility	O
of	O
combination	O
allogeneic	B
stem	I
cell	I
therapy	O
for	O
spinal	O
cord	O
injury:	O
a	O
case	O
report.	O

Cell	O
adhesion	O
molecule	O
L1-transfected	O
embryonic	B
stem	I
cells	I
with	O
enhanced	O
survival	O
support	O
regrowth	O
of	O
corticospinal	O
tract	O
axons	O
in	O
mice	O
after	O
spinal	O
cord	O
injury.	O

The	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
transplantation	O
on	O
the	O
recovery	O
of	O
bladder	O
and	O
hindlimb	O
function	O
after	O
spinal	O
cord	O
contusion	O
in	O
rats.	O

Mesenchymal	B
stem	I
cell	I
transplantation	O
reduces	O
glial	O
cyst	O
and	O
improves	O
functional	O
outcome	O
following	O
spinal	O
cord	O
compression.	O

Combination	O
of	O
activated	O
Schwann	O
cells	O
with	O
bone	O
mesenchymal	O
stem	O
cells	O
the	O
best	O
cell	O
strategy	O
for	O
repair	O
after	O
spinal	O
cord	O
injury	O
in	O
rats.	O
Extensive	O
neuronal	O
differentiation	O
of	O
human	B
neural	I
stem	I
cell	I
grafts	O
in	O
adult	O
rat	O
spinal	O
cord.	O

A	O
rosette-type,	O
self-renewing	O
human	B
ES	I
cell-derived	I
neural	I
stem	I
cell	I
with	O
potential	O
for	O
in	O
vitro	O
instruction	O
and	O
synaptic	O
integration.	O

Comparison	O
of	O
canine	B
umbilical	I
cord	I
blood-derived	I
mesenchymal	I
stem	I
cell	I
transplantation	O
times:	O
involvement	O
of	O
astrogliosis,	O
inflammation,	O
intracellular	O
actin	O
cytoskeleton	O
pathways,	O
and	O
neurotrophin.	O

Risk	O
of	O
tumorigenesis	O
in	O
first-in-human	O
trials	O
of	O
embryonic	B
stem	I
cell	I
neural	O
derivatives:	O
ethics	O
in	O
the	O
face	O
of	O
long-term	O
uncertainty.	O

Case	O
control	O
series	O
of	O
intrathecal	O
autologous	B
bone	I
marrow	I
mesenchymal	I
stem	I
cell	I
therapy	O
for	O
chronic	O
spinal	O
cord	O
injury.	O

Intravenous	O
ferumoxytol	O
allows	O
noninvasive	O
MR	O
imaging	O
monitoring	O
of	O
macrophage	O
migration	O
into	O
stem	B
cell	I
transplants.	O

Efficient	O
in	O
vitro	O
labeling	O
rabbit	B
neural	I
stem	I
cell	I
with	O
paramagnetic	O
Gd-DTPA	O
and	O
fluorescent	O
substance.	O

Highly	O
efficient	O
magnetic	B
stem	I
cell	I
labeling	O
with	O
citrate-coated	O
superparamagnetic	O
iron	O
oxide	O
nanoparticles	O
for	O
MRI	O
tracking.	O

Evaluation	O
of	O
cell	O
tracking	O
effects	O
for	O
transplanted	O
mesenchymal	B
stem	I
cells	I
with	O
jetPEI/Gd-DTPA	O
complexes	O
in	O
animal	O
models	O
of	O
hemorrhagic	O
spinal	O
cord	O
injury.	O

Long-term	O
MR	O
cell	O
tracking	O
of	O
neural	B
stem	I
cells	I
grafted	O
in	O
immunocompetent	O
versus	O
immunodeficient	O
mice	O
reveals	O
distinct	O
differences	O
in	O
contrast	O
between	O
live	O
and	O
dead	O
cells.	O

Human-induced	B
pluripotent	I
stem	I
cells	I
are	O
generated	O
by	O
the	O
nuclear	O
reprogramming	O
of	O
any	O
somatic	O
cell	O
using	O
a	O
variety	O
of	O
established	O
but	O
evolving	O
methods.	O

Human-induced	B
pluripotent	I
stem	I
cells	I
are	O
generated	O
by	O
the	O
nuclear	O
reprogramming	O
of	O
any	O
somatic	O
cell	O
using	O
either	O
genome	O
integrating	O
or	O
non-integrating	O
footprint-free	O
methods	O
(reviewed	O
in	O
Gonzalez	O
et	O
al.	O

Line-to-line	O
variability	O
continues	O
to	O
be	O
a	O
concern	O
among	O
stem	B
cell	I
biologists.	O

Such	O
an	O
approach	O
would	O
not	O
only	O
provide	O
an	O
invaluable	O
resource	O
but	O
would	O
also	O
significantly	O
reduce	O
costs	O
for	O
stem	B
cell	I
researchers.	O

Indeed,	O
the	O
hiPSC	O
field	O
has	O
begun	O
to	O
achieve	O
such	O
stem	B
cell	I
repositories	O
and	O
had	O
the	O
foresight	O
to	O
include	O
secondary	O
products	O
(e.g.,	O
reporter	O
lines).	O

Further	O
attributes	O
including	O
integration-free	O
lines,	O
equal	O
male	O
and	O
female	O
line	O
representation,	O
and	O
the	O
prospect	O
of	O
intensively	O
characterized	O
cryopreservable	O
differentiated	O
precursors	O
make	O
such	O
stem	B
cell	I
repositories	O
an	O
attractive	O
prospect.	O

A	O
workflow	O
for	O
using	O
human-induced	B
pluripotent	I
stem	I
cell	I
derivatives	O
for	O
disease	O
modeling,	O
drug	O
discovery,	O
and	O
toxicity	O
assays	O
in	O
high	O
throughput.	O

Geron	O
Corporation	O
initiated	O
the	O
first	O
human	B
stem	I
cell	I
trial	O
for	O
spinal	O
cord	O
injuries	O
in	O
2010,	O
but	O
unfortunately	O
this	O
was	O
discontinued	O
shortly	O
afterwards	O
for	O
business-related	O
strategic	O
(rather	O
than	O
scientific)	O
reasons	O
(Scott	O
and	O
Magnus	O
2014;	O
Lebkowski	O
2011).	O

Multiple	O
sclerosis	O
Mouse	O
with	O
experimental	O
autoimmune	O
encephalomyelitis	O
hiPSC	O
neural	B
stem	I
cell	I
Intraventricular	O
injection	O
(lateral	O
ventricle)	O
Donor	O
cells	O
localized	O
to	O
lesions.	O

Such	O
spread	O
of	O
disease	O
into	O
stem	B
cell	I
grafts	O
has	O
already	O
been	O
demonstrated	O
in	O
the	O
context	O
of	O
fetal	O
ventral	O
mesencephalic	O
transplantation	O
in	O
Parkinsons	O
disease	O
(Li	O
et	O
al.	O

Mutant	B
induced	I
pluripotent	I
stem	I
cell	I
lines	O
recapitulate	O
aspects	O
of	O
TDP-43	O
proteinopathies	O
and	O
reveal	O
cell-specific	O
vulnerability.	O

Intraspinal	B
neural	I
stem	I
cell	I
transplantation	O
in	O
amyotrophic	O
lateral	O
sclerosis:	O
phase	O
1	O
trial	O
outcomes.	O

Pluripotent	B
stem	I
cell	I
derived	O
hepatocyte	O
like	O
cells	O
and	O
their	O
potential	O
in	O
toxicity	O
screening.	O

Compounds	O
with	O
species	O
and	O
cell	O
type	O
specific	O
toxicity	O
identified	O
in	O
a	O
2000	O
compound	O
drug	O
screen	O
of	O
neural	B
stem	I
cells	I
and	O
rat	O
mixed	O
cortical	O
neurons.	O

Stem	B
cells	I
and	O
drug	O
discovery:	O
the	O
beginning	O
of	O
a	O
new	O
era?	O
Cell.	O

Astrocyte	O
pathology	O
and	O
the	O
absence	O
of	O
non-cell	O
autonomy	O
in	O
an	O
induced	B
pluripotent	I
stem	I
cell	I
model	O
of	O
TDP-43	O
proteinopathy.	O

Modeling	O
a	O
genetic	O
risk	O
for	O
schizophrenia	O
in	O
iPSCs	O
and	O
mice	O
reveals	O
neural	B
stem	I
cell	I
deficits	O
associated	O
with	O
adherens	O
junctions	O
and	O
polarity.	O

A	O
certified	O
culture	O
of	O
human	O
foreskin	O
dermal	O
fibroblasts	O
was	O
obtained	O
from	O
the	O
Stem	B
Cell	I
Bank	O
Pokrovsky	O
(St.	O

Phase	O
I/II	O
dose-escalation	O
trials	O
in	O
HIV-infected	O
men	O
with	O
asymptomatic	O
CMV	O
shedding	O
further	O
indicated	O
that	O
maribavir	O
is	O
rapidly	O
absorbed	O
following	O
oral	O
dosing	O
and	O
reduces	O
CMV	O
titers	O
in	O
semen.93	O
Maribavir	O
is	O
currently	O
in	O
a	O
prophylaxis	O
study	O
in	O
allogenic	B
stem	I
cell	I
transplant	O
recipients	O
with	O
results	O
expected	O
in	O
2006	O
[to	O
be	O
divulged	O
by	O
ViroPharma	O
Inc.,	O
according	O
to	O
Biron14].	O

Activating	O
mutations	O
of	O
the	O
tyrosine	O
kinase	O
receptor	O
c-KIT,	O
which	O
binds	O
to	O
stem	B
cell	I
factor	O
(SCF),	O
a	O
known	O
hematopoietic	O
cytokine,	O
have	O
been	O
described	O
in	O
canine	O
MCTs.	O

Tet2	O
loss	O
leads	O
to	O
increased	O
hematopoietic	B
stem	I
cell	I
self-renewal	O
and	O
myeloid	O
transformation.	O

Targeting	O
miRNAs	O
involved	O
in	O
cancer	B
stem	I
cell	I
and	O
EMT	O
regulation:	O
an	O
emerging	O
concept	O
in	O
overcoming	O
drug	O
resistance.	O

Allogeneic	B
hematopoietic	I
stem	I
cell	I
transplantation	O
(allo-HSCT)	O
is	O
a	O
potentially	O
curative	O
therapy	O
for	O
many	O
hematological	O
disorders	O
and	O
autoimmune	O
diseases,	O
but	O
acute	O
graft-versus-host	O
disease	O
(aGVHD)	O
has	O
remained	O
a	O
major	O
obstacle	O
that	O
limits	O
allo-HSCT	O
and	O
exhibits	O
a	O
daunting	O
mortality	O
rate.	O

NCT03727113	O
Optimization	O
of	O
antibiotic	O
treatment	O
in	O
hematopoietic	B
stem	I
cell	I
receptors	O
Antibiotics	O
To	O
demonstrate	O
that	O
in	O
ASCT	O
receptors	O
a	O
predefined	O
protocol	O
of	O
optimization	O
of	O
the	O
antibacterial	O
treatment	O
will	O
preserve	O
the	O
intestinal	O
microbiota	O
diversity	O
which	O
will	O
correlate	O
with	O
decrease	O
incidence	O
of	O
acute	O
GVHD.	O

NCT03727113	O
Choosing	O
the	O
Best	O
Antibiotic	O
to	O
Protect	O
Friendly	O
Gut	O
Bacteria	O
During	O
the	O
Course	O
of	O
Stem	B
Cell	I
Transplant	O
Piperacillin-tazobactam	O
To	O
compare	O
the	O
effects	O
of	O
different	O
antibiotics	O
on	O
the	O
community	O
of	O
friendly	O
bacteria	O
in	O
the	O
gut	O
Randomized.	O

T	O
Cell	O
Recruitment	O
to	O
the	O
Intestinal	B
Stem	I
Cell	I
Compartment	O
Drives	O
Immune-Mediated	O
Intestinal	O
Damage	O
after	O
Allogeneic	O
Transplantation.	O

Microbiota	O
Disruption	O
Induced	O
by	O
Early	O
Use	O
of	O
Broad-Spectrum	O
Antibiotics	O
Is	O
an	O
Independent	O
Risk	O
Factor	O
of	O
Outcome	O
after	O
Allogeneic	B
Stem	I
Cell	I
Transplantation.	O

The	O
effects	O
of	O
intestinal	O
tract	O
bacterial	O
diversity	O
on	O
mortality	O
following	O
allogeneic	B
hematopoietic	I
stem	I
cell	I
transplantation.	O

Antibiotic-Induced	O
Depletion	O
of	O
Anti-inflammatory	O
Clostridia	O
Is	O
Associated	O
with	O
the	O
Development	O
of	O
Graft-versus-Host	O
Disease	O
in	O
Pediatric	B
Stem	I
Cell	I
Transplantation	O
Patients.	O

Metagenomic	O
analysis	O
of	O
the	O
stool	O
microbiome	O
in	O
patients	O
receiving	O
allogeneic	B
stem	I
cell	I
transplantation:	O
loss	O
of	O
diversity	O
is	O
associated	O
with	O
use	O
of	O
systemic	O
antibiotics	O
and	O
more	O
pronounced	O
in	O
gastrointestinal	O
graft-versus-host	O
disease.	O

Poor	O
oral	O
nutrition	O
after	O
allogeneic	B
stem	I
cell	I
transplantation	O
correlates	O
significantly	O
with	O
severe	O
graft-versus-host	O
disease.	O

Enteral	O
feeding	O
and	O
early	O
outcomes	O
of	O
patients	O
undergoing	O
allogeneic	B
stem	I
cell	I
transplantation	O
following	O
myeloablative	O
conditioning.	O

Questioning	O
the	O
role	O
of	O
a	O
neutropenic	O
diet	O
following	O
hematopoetic	B
stem	I
cell	I
transplantation.	O

Prebiotics	O
protect	O
against	O
acute	O
graft-versus-host	O
disease	O
and	O
preserve	O
the	O
gut	O
microbiota	O
in	O
stem	B
cell	I
transplantation.	O

Rifaximin	O
preserves	O
intestinal	O
microbiota	O
balance	O
in	O
patients	O
undergoing	O
allogeneic	B
stem	I
cell	I
transplantation.	O

Impact	O
of	O
choice,	O
timing,	O
sequence	O
and	O
combination	O
of	O
broad-spectrum	O
antibiotics	O
on	O
the	O
outcome	O
of	O
allogeneic	B
haematopoietic	I
stem	I
cell	I
transplantation.	O

CCSP+	O
cells	O
express	O
the	O
chemokine	O
receptors	O
CCR2,	O
CCR4,	O
CXCR3,	O
and	O
CXCR4,	O
and	O
significantly	O
migrated	O
in	O
vitro	O
toward	O
Stromal	O
Derived	O
Factor-1	O
(SDF-1)	O
and	O
Stem	B
Cell	I
Growth	O
Factor-	O
b2	O
(SCGF-	O
b2).	O

The	O
number	O
of	O
CCSP+	O
cells	O
in	O
the	O
bone	O
marrow	O
and	O
peripheral	O
blood	O
significantly	O
correlated	O
with	O
the	O
plasma	O
concentration	O
of	O
Stem	B
Cell	I
Growth	O
Factor-beta	O
SCGF-	O
b2	O
(Figure	O
8A)	O
in	O
a	O
range	O
of	O
samples,	O
including	O
lung	O
transplant	O
recipients,	O
donors,	O
and	O
control	O
samples.	O

(A)	O
The	O
relationship	O
between	O
plasma	B
Stem	I
Cell	I
Growth	O
Factor	O
(SCGF)-	O
b2	O
levels	O
and	O
the	O
percentage	O
of	O
CCSP+	O
bone	O
marrow	O
cells	O
(BMCs)	O
(n	O
=	O
44)	O
or	O
CCSP+	O
peripheral	O
blood	O
mononuclear	O
cells	O
(PBMCs)	O
in	O
lung	O
transplant	O
recipients	O
(R)	O
and	O
donors	O
(D),	O
and	O
healthy	O
controls	O
(BMC:	O
n	O
=	O
35R,	O
9D.	O

Alterations	O
in	O
circulating	O
inflammatory	O
and	O
stem	B
cell	I
recruitment	O
factors	O
are	O
likely	O
an	O
important	O
element	O
in	O
the	O
control	O
of	O
progenitor	O
cell	O
trafficking	O
and	O
in	O
the	O
ultimate	O
ability	O
to	O
influence	O
lung	O
tissue	O
repair	O
or	O
pathology.	O

Mesenchymal	B
stem	I
cell	I
engraftment	O
in	O
lung	O
is	O
enhanced	O
in	O
response	O
to	O
bleomycin	O
exposure	O
and	O
ameliorates	O
its	O
fibrotic	O
effects.	O

et	O
al.Serum	O
stem	B
cell	I
growth	O
factor	O
for	O
monitoring	O
hematopoietic	O
recovery	O
following	O
stem	O
cell	O
transplantation.	O

It	O
is	O
primate-specific	O
and	O
is	O
expressed	O
in	O
placenta,	O
embryonic	B
stem	I
cell	I
,	O
and	O
certain	O
tumors	O
[69	O
71].	O

miR-26b-3p	O
regulates	O
human	B
umbilical	I
cord-derived	I
mesenchymal	I
stem	I
cell	I
proliferation	O
by	O
targeting	O
estrogen	O
receptor.	O

ADAR1	O
activation	O
drives	O
leukemia	B
stem	I
cell	I
self-renewal	O
by	O
impairing	O
Let-7	O
biogenesis.	O

Are	O
globoseries	O
glycosphingolipids	O
SSEA-3	O
and	O
-4	O
markers	O
for	O
stem	B
cells	I
derived	O
from	O
human	O
umbilical	O
cord	O
blood?	O
Journal	O
of	O
Molecular	O
Cell	O
Biology.	O

Roles	O
of	O
gangliosides	O
in	O
mouse	O
embryogenesis	O
and	O
embryonic	B
stem	I
cell	I
differentiation.	O

Neural	B
stem	I
cell	I
transplantation	O
benefits	O
a	O
monogenic	O
neurometabolic	O
disorder	O
during	O
the	O
symptomatic	O
phase	O
of	O
disease.	O

Cobalt	O
chloride	O
Down-regulation	O
of	O
stem	B
cell	I
markers	O
Reduced	O
number	O
of	O
osteoblasts	O
and	O
subsequent	O
mineralization	O
of	O
the	O
operculum,	O
without	O
affecting	O
its	O
size.	O

We	O
returned	O
to	O
animal	O
caps,	O
Xenopus	B
stem	I
cell	I
explants	O
that	O
auto-differentiate	O
into	O
an	O
embryonic	O
multiciliated	O
epidermis	O
and	O
raised	O
them	O
in	O
two	O
different	O
conditions.	O

It	O
is	O
reported	O
that	O
lincRNA-ROR	O
regulates	O
the	O
expression	O
of	O
core	O
transcription	O
factors	O
and	O
differentiation-related	O
miRNAs	O
involving	O
in	O
human	B
embryonic	I
stem	I
cell	I
self-renewal.[34]	O
Moreover,	O
lincRNA-ROR	O
induces	O
EMT	O
by	O
regulation	O
the	O
degradation	O
of	O
microRNA-205	O
target	O
genes	O
ZEB2	O
in	O
breast	O
cancer.[35]	O
On	O
other	O
hand,	O
lincRNA-ROR	O
mediates	O
multiple	O
signaling	O
pathways	O
involving	O
in	O
the	O
growth	O
and	O
progression	O
of	O
various	O
tumors.	O

Interaction	O
of	O
lincRNA	O
ROR	O
and	O
p53/miR-145	O
correlates	O
with	O
lung	B
cancer	I
stem	I
cell	I
signatures.	O

Endogenous	O
miRNA	O
sponge	O
lincRNA-RoR	O
regulates	O
Oct4,	O
Nanog,	O
and	O
Sox2	O
in	O
human	B
embryonic	I
stem	I
cell	I
self-renewal.	O

This	O
medium	O
is	O
supplemented	O
with	O
key	O
niche	O
signals,	O
R-Spondin	O
(a	O
Wnt	O
agonist	O
that	O
maintains	O
stem	B
cell	I
population),	O
Noggin	O
(a	O
BMP	O
inhibitor	O
that	O
limits	O
differentiation)	O
and	O
EGF	O
(epidermal	O
growth	O
factor,	O
to	O
promote	O
cell	O
proliferation)	O
that	O
allow	O
reproducing	O
the	O
proliferation	O
and	O
differentiation	O
program	O
that	O
generates	O
the	O
intestinal	O
epithelium.	O

This	O
type	O
of	O
system	O
has	O
been	O
used	O
to	O
study	O
various	O
mechanisms,	O
such	O
as	O
the	O
impact	O
of	O
biochemical	O
gradients,106	O
stem	B
cell	I
differentiation107	O
or	O
axon	O
guidance.108	O
Since	O
then,	O
more	O
sophisticated	O
systems	O
have	O
been	O
developed,	O
composed	O
of	O
several	O
channels	O
interconnected	O
with	O
porous	O
membranes,	O
and	O
including	O
several	O
cell	O
types	O
to	O
mimic	O
the	O
interface	O
between	O
tissues.83.	O

Bioengineered	O
systems	O
and	O
designer	O
matrices	O
that	O
recapitulate	O
the	O
intestinal	B
stem	I
cell	I
niche.	O

BMP	O
signaling	O
inhibits	O
intestinal	B
stem	I
cell	I
self-renewal	O
through	O
suppression	O
of	O
Wnt-beta-catenin	O
signaling.	O

Synthesis	O
and	O
characterization	O
of	O
well-defined	O
hydrogel	O
matrices	O
and	O
their	O
application	O
to	O
intestinal	B
stem	I
cell	I
and	O
organoid	O
culture.	O

Human	B
neural	I
stem	I
cell	I
growth	O
and	O
differentiation	O
in	O
a	O
gradient-generating	O
microfluidic	O
device.	O

Stroma	O
provides	O
an	O
intestinal	B
stem	I
cell	I
niche	O
in	O
the	O
absence	O
of	O
epithelial	O
Wnts.	O

Recent	O
work	O
demonstrating	O
that	O
H2A.Z	O
is	O
necessary	O
for	O
the	O
proper	O
execution	O
of	O
developmental	O
programs	O
during	O
embryonic	B
stem	I
cell	I
differentiation	O
[638]	O
as	O
well	O
as	O
for	O
regulating	O
the	O
activation	O
of	O
gene	O
expression	O
patterns	O
during	O
muscle	O
differentiation,	O
T	O
cell	O
activation,	O
and	O
hormone-mediated	O
gene	O
activation	O
[9312]	O
has	O
led	O
to	O
a	O
model	O
whereby	O
H2A.Z	O
functions	O
to	O
mediate	O
gene	O
induction	O
in	O
response	O
to	O
diverse	O
cellular	O
cues..	O

H2A.Z	O
facilitates	O
access	O
of	O
active	O
and	O
repressive	O
complexes	O
to	O
chromatin	O
in	O
embryonic	B
stem	I
cell	I
self-renewal	O
and	O
differentiation.	O

Foxa2	O
and	O
H2A.Z	O
mediate	O
nucleosome	O
depletion	O
during	O
embryonic	B
stem	I
cell	I
differentiation.	O

Many	O
strategies	O
for	O
COVID-19	O
treatment	O
have	O
been	O
and	O
still	O
are	O
under	O
investigation:	O
several	O
antiviral	O
drugs,	O
among	O
them	O
Favipiravir	O
(ClinicalTrials.gov	O
Identifier:	O
NCT04336904),	O
Umifenovir	O
(CTI:	O
NCT04476719)	O
or	O
Lopinavir/Ritonavir	O
(CTI:	O
NCT04386876),	O
alone	O
or	O
in	O
combination	O
with	O
other	O
chemicals	O
such	O
as	O
the	O
antimalarial	O
chloroquine/hydroxychloroquine	O
(e.g.,	O
CTI:	O
NCT04328285);	O
biologicals,	O
such	O
as	O
convalescent	O
plasma	O
(e.g.,	O
CTI:	O
NCT04321421)	O
or	O
mesenchymal	B
stem	I
cell	I
and	O
MSC-derived	O
exosomes	O
(CTI:	O
NCT04276987);	O
Chinese	O
traditional	O
medicines	O
(e.g.,	O
CTI:	O
NCT04544605)	O
and	O
supplementation	O
with	O
Vitamins	O
C	O
and	O
D	O
(CTI:	O
NCT03680274	O
and	O
NCT04449718;	O
https://www.clinicaltrials.gov/)	O
[79–82].	O

A	O
Werner	B
syndrome	I
stem	I
cell	I
model	O
unveils	O
heterochromatin	O
alterations	O
as	O
a	O
driver	O
of	O
human	O
aging.	O

Candidate	O
b2-catenin-activated	O
pathways	O
were	O
involved	O
in	O
Wnt/b2-catenin,	O
embryonic	B
stem	I
cell	I
pluripotency,	O
basal	O
cell	O
carcinoma	O
signaling,	O
and	O
TGF-b2	O
signaling.	O

From	O
the	O
pathway	O
analysis	O
using	O
Ingenuity	O
Systems	O
Software,	O
we	O
found	O
altered	O
pathways,	O
including	O
Wnt/b2-catenin	O
signaling,	O
TGF-b2	O
signaling,	O
embryonic	B
stem	I
cell	I
pluripotency,	O
basal	O
cell	O
carcinoma	O
signaling,	O
ErbB	O
signaling,	O
and	O
ERK/MAPK	O
signaling.	O

Transitions	O
between	O
epithelial	O
and	O
mesenchymal	O
states:	O
acquisition	O
of	O
malignant	O
and	O
stem	B
cell	I
traits.	O

B	O
cell	O
development	O
occurs	O
in	O
the	O
bone	O
marrow	O
(BM)	O
and	O
involves	O
the	O
progressive	O
maturation	O
of	O
pluripotent	B
hematopoietic	I
stem	I
cells	I
into	O
populations	O
of	O
progenitor	O
(pro-B),	O
precursor	O
(preB),	O
and	O
immature	O
B	O
cells	O
(Uckun,	O
1990;	O
LeBien	O
and	O
Tedder,	O
2008).	O

B	O
cell	O
development	O
occurs	O
in	O
the	O
BM,	O
where	O
hematopoietic	B
stem	I
cells	I
undergo	O
progressive	O
steps	O
to	O
yield	O
pro-B,	O
pre-B,	O
and	O
immature	O
B	O
cells	O
before	O
being	O
exported	O
to	O
the	O
periphery	O
as	O
transitional	O
cells	O
(Uckun,	O
1990).	O

Effects	O
of	O
Exendin-4	O
on	O
bone	B
marrow	I
mesenchymal	I
stem	I
cell	I
proliferation,	O
migration	O
and	O
apoptosis	O
in	O
vitro.	O

Despite	O
all	O
the	O
implication	O
of	O
the	O
Wnt	O
signal	O
in	O
AP	O
patterning	O
and	O
midbrain	O
specification	O
in	O
both	O
animal	O
and	O
human	O
systems,	O
the	O
detailed	O
molecular	O
mechanism	O
underlying	O
how	O
the	O
Wnt	O
signal	O
drives	O
posterior	O
fate	O
during	O
neural	O
differentiation	O
and	O
how	O
inhibitors	O
of	O
glycogen	O
synthase	O
kinase	O
3	O
(GSK3),	O
a	O
key	O
enzyme	O
mediating	O
the	O
canonical	O
Wnt	O
signal,	O
facilitate	O
midbrain	O
specification	O
during	O
human	B
stem	I
cell	I
differentiation	O
remained	O
unclear..	O

As	O
such,	O
the	O
molecular	O
mechanism	O
by	O
which	O
FGF8	O
contributes	O
to	O
fate	O
determination	O
or	O
regional	O
identity	O
of	O
developing	O
neural	O
cells	O
in	O
the	O
midbrain	O
area	O
has	O
been	O
of	O
interest	O
in	O
both	O
developmental	O
and	O
stem	B
cell	I
biology..	O

Human	O
ES	O
cell-derived	O
neural	O
rosettes	O
reveal	O
a	O
functionally	O
distinct	O
early	O
neural	B
stem	I
cell	I
stage.	O

MicroRNAs	O
to	O
Nanog,	O
Oct4	O
and	O
Sox2	O
coding	O
regions	O
modulate	O
embryonic	B
stem	I
cell	I
differentiation.	O

Buchon	O
N,	O
Broderick	O
NA,	O
Chakrabarti	O
S,	O
Lemaitre	O
B	O
(2009)	O
Invasive	O
and	O
indigenous	O
microbiota	O
impact	O
intestinal	B
stem	I
cell	I
activity	O
through	O
multiple	O
pathways	O
in	O
Drosophila.	O

Marianes	O
A,	O
Spradling	O
AC	O
(2013)	O
Physiological	O
and	O
stem	B
cell	I
compartmentalization	O
within	O
the	O
Drosophila	O
midgut.	O

Buchon	O
N,	O
Broderick	O
NA,	O
Poidevin	O
M,	O
Pradervand	O
S,	O
Lemaitre	O
B	O
(2009)	O
Drosophila	O
intestinal	O
response	O
to	O
bacterial	O
infection:	O
activation	O
of	O
host	O
defense	O
and	O
stem	B
cell	I
proliferation.	O

A	O
Patient-Specific	O
Stem	B
Cell	I
Model	O
to	O
Investigate	O
the	O
Neurological	O
Phenotype	O
Observed	O
in	O
Ataxia-Telangiectasia.	O

Phasor	O
fluorescence	O
lifetime	O
microscopy	O
of	O
free	O
and	O
protein-bound	O
NADH	O
reveals	O
neural	B
stem	I
cell	I
differentiation	O
potential.	O

However,	O
very	O
recent	O
observations	O
provide	O
opposite	O
evidence	O
showing	O
that	O
melanoma	O
cells	O
are	O
critically	O
dependent	O
on	O
oxidative	O
phosphorylation	O
(OXPHOS)	O
rather	O
than	O
glycolysis1,	O
2	O
and	O
that	O
respiratory	O
function	O
is	O
essential	O
for	O
tumorigenic	O
and	O
metastatic	O
potential	O
of	O
breast	O
cancer	O
and	O
melanoma	O
cells.3,	O
4	O
Notably,	O
it	O
has	O
been	O
shown	O
that	O
the	O
most	O
aggressive	O
ovarian	O
cancer	O
(OC)	O
cell	O
lines	O
show	O
a	O
marked	O
dependence	O
on	O
glutamine	O
rather	O
than	O
on	O
glucose,5	O
and	O
cancer	B
stem	I
cells	I
from	O
epithelial	O
OC	O
(EOC)	O
patients	O
privilege	O
OXPHOS	O
and	O
resist	O
glucose	O
deprivation,6	O
suggesting	O
that	O
glycolysis	O
is	O
not	O
the	O
main	O
pathway	O
sustaining	O
tumour	O
growth	O
in	O
these	O
systems.	O

For	O
decades,	O
decreased	O
capacity	O
for	O
OXPHOS	O
because	O
of	O
dysfunctional	O
mitochondria	O
and	O
increased	O
glycolysis	O
have	O
been	O
considered	O
as	O
dominant	O
in	O
neoplastic	O
cells;	O
however,	O
very	O
recent	O
observations	O
challenge	O
this	O
view	O
in	O
a	O
growing	O
number	O
of	O
tumour	O
systems,	O
especially	O
melanoma.49	O
Remarkably,	O
recent	O
data	O
suggested	O
that	O
OC	O
could	O
be	O
included	O
in	O
the	O
list,	O
showing	O
that	O
the	O
most	O
aggressive	O
OC	O
cell	O
lines	O
mostly	O
depend	O
on	O
glutamine	O
rather	O
than	O
on	O
glucose5	O
and	O
cancer	B
stem	I
cells	I
from	O
EOC	O
patients	O
privilege	O
OXPHOS	O
and	O
resist	O
glucose	O
deprivation.6	O
Intriguingly,	O
the	O
first	O
inverse	O
correlations	O
between	O
TRAP1	O
and	O
tumour	O
stage	O
was	O
reported	O
in	O
bladder,	O
clear	O
cell	O
renal	O
cell	O
and	O
cervical	O
carcinoma,18	O
with	O
the	O
latter	O
mostly	O
relying	O
on	O
OXPHOS	O
for	O
its	O
energetic	O
metabolism.19	O
In	O
agreement,	O
previous	O
data	O
correlated	O
TRAP1	O
expression	O
with	O
favourable	O
chemotherapy	O
response	O
and	O
overall	O
survival	O
in	O
a	O
subset	O
of	O
ERb1-positive	O
OC	O
patients.22.	O

The	O
versatility	O
of	O
the	O
OOC	O
platform	O
enables	O
users	O
not	O
only	O
to	O
study	O
the	O
mechanism	O
of	O
disease	O
(for	O
example,	O
metastatic	O
dissemination	O
or	O
immune	O
cell	O
infiltration)	O
but	O
also	O
permits	O
the	O
study	O
of	O
normal	O
human	O
physiological	O
process	O
(such	O
as	O
the	O
gut	O
hormonal	O
axis	O
or	O
stem	B
cell	I
differentiation)	O
[46].	O

It	O
is	O
used	O
in	O
B-cell	O
lymphoma,	O
allogeneic	B
stem	I
cell	I
transplantation,	O
and	O
renal	O
transplantation.	O

Lastly,	O
stem	B
cell	I
transplantation	O
aims	O
to	O
restore	O
immunologic	O
tolerance	O
by	O
eliminating	O
autoreactive	O
clones	O
followed	O
by	O
T-cell	O
reconstitution.	O

Haematopoietic	B
stem	I
cell	I
transplantation	O
for	O
vasculitis	O
including	O
Behcet’s	O
disease	O
and	O
polychondritis:	O
A	O
retrospective	O
analysis	O
of	O
patients	O
recorded	O
in	O
the	O
European	O
Bone	O
Marrow	O
Transplantation	O
and	O
European	O
League	O
Against	O
Rheumatism	O
databases	O
and	O
a	O
review	O
of	O
the	O
literature.	O

Cell	O
Stem	O
Cell	O
15,	O
27330	O
(2014).Corrected	O
in:	O
Cell	B
Stem	I
Cell	I
15,	O
254	O
(2014).	O

System-wide	O
temporal	O
characterization	O
of	O
the	O
proteome	O
and	O
phosphoproteome	O
of	O
human	B
embryonic	I
stem	I
cell	I
differentiation.	O

This	O
cell	O
fate	O
decision	O
core	O
represents	O
a	O
major	O
target	O
for	O
SCI	O
therapeutics,	O
especially	O
with	O
current	O
interest	O
in	O
the	O
use	O
of	O
growth	O
factor	O
therapies	O
and	O
stem	B
cell	I
transplantation	O
for	O
treating	O
SCI.	O

Case	O
Western	O
Reserve	O
University	O
acknowledges	O
the	O
contribution	O
of	O
the	O
State	O
of	O
Ohio,	O
Department	O
of	O
Development,	O
which	O
provided	O
funding	O
in	O
support	O
of	O
Center	O
for	O
Stem	B
Cell	I
and	O
Regenerative	O
Medicine:	O
Commercial	O
and	O
Clinical	O
Application	O
project..	O

Journey	O
of	O
mesenchymal	O
stem	O
cells	O
for	O
homing:	O
strategies	O
to	O
enhance	O
efficacy	O
and	O
safety	O
of	O
stem	B
cell	I
therapy.	O

Noninvasive	O
in	O
vivo	O
tracking	O
of	O
mesenchymal	B
stem	I
cells	I
and	O
evaluation	O
of	O
cell	O
therapeutic	O
effects	O
in	O
a	O
murine	O
model	O
using	O
a	O
clinical	O
3.0	O
T	O
MRI.	O

Stem	O
cell	O
therapy	O
in	O
spinal	O
cord	O
injury:	O
in	O
vivo	O
and	O
postmortem	O
tracking	O
of	O
bone	O
marrow	O
mononuclear	O
or	O
mesenchymal	B
stem	I
cells.	I

Chondrogenic	O
differentiation	O
of	O
human	B
mesenchymal	I
stem	I
cell	I
aggregates	O
via	O
controlled	O
release	O
of	O
TGF-b21	O
from	O
incorporated	O
polymer	O
microspheres.	O

Spatiotemporal	O
regulation	O
of	O
chondrogenic	O
differentiation	O
with	O
controlled	O
delivery	O
of	O
transforming	O
growth	O
factor-beta1	O
from	O
gelatin	O
microspheres	O
in	O
mesenchymal	B
stem	I
cell	I
aggregates.	O

A	O
new	O
mesenchymal	B
stem	I
cell	I
paradigm:	O
Polarization	O
into	O
a	O
pro-inflammatory	O
MSC1	O
or	O
an	O
immunosuppressive	O
MSC2	O
phenotype.	O

Reversal	O
of	O
serologic,	O
immunologic,	O
and	O
histologic	O
dysfunction	O
in	O
mice	O
with	O
systemic	O
lupus	O
erythematosus	O
by	O
long-term	O
serial	O
adipose	O
tissue-derived	O
mesenchymal	B
stem	I
cell	I
transplantation.	O

These	O
gene	O
variants	O
were	O
characterised	O
by	O
various	O
aforementioned	O
immune	O
abnormalities;	O
among	O
them,	O
P17,	O
who	O
was	O
diagnosed	O
with	O
leucocyte	O
adhesion	O
deficiency	O
type	O
1	O
(LAD1)	O
(OMIM:	O
600065),	O
received	O
haematopoietic	B
stem	I
cell	I
transplantation	O
(HSCT)	O
and	O
survived	O
at	O
180	O
days	O
of	O
interview.	O

Haploidentical	B
stem	I
cell	I
transplantation	O
with	O
post	O
transplant	O
cyclophosphamide	O
for	O
primary	O
immune	O
deficiency	O
disorders	O
in	O
children:	O
challenges	O
and	O
outcome	O
from	O
a	O
tertiary	O
care	O
center	O
in	O
south	O
India.	O

Leukocyte	O
adhesion	O
deficiency	O
type	O
III:	O
clinical	O
features	O
and	O
treatment	O
with	O
stem	B
cell	I
transplantation.	O

C-kit	O
is	O
a	O
growth	O
factor	O
receptor	O
of	O
the	O
tyrosine	O
kinase	O
subclass	O
III	O
family,	O
the	O
ligand	O
of	O
which	O
is	O
Stem	B
Cell	I
Factor,	O
and	O
is	O
normally	O
expressed	O
in	O
many	O
cell	O
lines,	O
including	O
gametocytes	O
[29].	O

Of	O
note,	O
rs94308	O
is	O
not	O
an	O
expression	O
quantitative	O
trait	O
locus	O
for	O
any	O
GTEx	O
tissues	O
(GTEx	O
Consortium	O
et	O
al.,	O
2017),	O
but	O
this	O
could	O
be	O
due	O
to	O
the	O
fact	O
that	O
the	O
interval	O
around	O
the	O
SNP	O
is	O
only	O
annotated	O
as	O
an	O
enhancer	O
region	O
in	O
Roadmap	O
(Roadmap	O
Epigenomics	O
et	O
al.,	O
2015)	O
in	O
a	O
small	O
number	O
of	O
stem	B
cell	I
or	O
fetal	O
tissues.	O

Identification	O
of	O
differentially	O
expressed	O
non-coding	O
RNAs	O
in	O
embryonic	B
stem	I
cell	I
neural	O
differentiation.	O

Restriction	O
of	O
intestinal	B
stem	I
cell	I
expansion	O
and	O
the	O
regenerative	O
response	O
by	O
YAP.	O

Nuclear	O
shape	O
change	O
during	O
mouse	B
embryonic	I
stem	I
cell	I
differentiation	O
in	O
culture.	O

Lamin	O
A/C	O
and/or	O
emerin	O
mediate	O
nuclear	O
shape	O
changes	O
in	O
embryonic	B
stem	I
cell	I
differentiation.	O

Lamin	O
A/C	O
expression	O
is	O
a	O
marker	O
of	O
mouse	B
and	I
human	I
embryonic	I
stem	I
cell	I
differentiation.	O

Increased	O
expression	O
of	O
Syne-1/Nesprin-1	O
facilitates	O
nuclear	O
envelope	O
structure	O
changes	O
in	O
embryonic	B
stem	I
cell	I
differentiation.	O

Nuclear	O
and	O
chromatin	O
reorganization	O
in	O
the	O
MHC-Oct3/4	O
locus	O
at	O
developmental	O
phases	O
of	O
embryonic	B
stem	I
cell	I
differentiation.	O

Histone	O
modifications	O
and	O
lamin	O
A	O
regulate	O
chromatin	O
protein	O
dynamics	O
in	O
early	B
embryonic	I
stem	I
cell	I
differentiation.	O

Embryonic	B
stem	I
cell	I
differentiation:	O
emergence	O
of	O
a	O
new	O
era	O
in	O
biology	O
and	O
medicine.	O

(2013)	O
ECM-Dependent	O
HIF	O
Induction	O
Directs	O
Trophoblast	B
Stem	I
Cell	I
Fate	O
via	O
LIMK1-Mediated	O
Cytoskeletal	O
Rearrangement.	O

Patients	O
could	O
alternatively	O
proceed	O
to	O
allogeneic	B
stem	I
cell	I
transplantation	O
at	O
any	O
point,	O
but	O
in	O
that	O
case,	O
went	O
off-protocol.	O

The	O
latter	O
is	O
compatible	O
with	O
findings	O
that	O
rapamycin,	O
by	O
inhibiting	O
mTOR,	O
decreases	O
neurogenesis	O
[58],	O
neural	B
stem	I
cell	I
proliferation	O
[59]	O
and	O
mitochondrial	O
respiration	O
[60].	O

The	O
most	O
recent	O
organoid	O
methods	O
used	O
in	O
the	O
pneumological	O
field	O
and	O
based	O
on	O
human	O
tissue	O
are	O
described	O
below,	O
according	O
to	O
the	O
origin	O
cell	O
lineage	O
used	O
to	O
start	O
the	O
culture	O
(PS,	O
MS,	O
or	O
adult	O
stem	O
cells/progenitors)..	O
In	O
Vitro	O
Generation	O
of	O
Human	B
Pluripotent	I
Stem	I
Cell	I
Derived	O
Lung	O
Organoids.	O

A	O
Bioengineered	O
Niche	O
Promotes	O
in	O
Vivo	O
Engraftment	O
and	O
Maturation	O
of	O
Pluripotent	B
Stem	I
Cell	I
Derived	O
Human	O
Lung	O
Organoids.	O

Reversal	O
of	O
Surfactant	O
Protein	O
B	O
Deficiency	O
in	O
Patient	O
Specific	O
Human	B
Induced	I
Pluripotent	I
Stem	I
Cell	I
Derived	O
Lung	O
Organoids	O
by	O
Gene	O
Therapy.	O

The	O
limitations	O
of	O
2D	O
cultures	O
have	O
encouraged	O
the	O
development	O
of	O
3D	O
models	O
of	O
AD,	O
the	O
first	O
of	O
which	O
was	O
based	O
on	O
an	O
immortalized	B
human	I
neural	I
stem	I
cell	I
line	O
(ReN)	O
containing	O
mutations	O
in	O
the	O
APP	O
(K670N/M671L	O
and	O
V717I)	O
and	O
PSEN1	O
(ΔE9)	O
genes	O
(Choi	O
et	O
al.,	O
2014).	O

Generation	O
of	O
induced	B
pluripotent	I
stem	I
cell	I
line,	O
CSSi004-A	O
(2962),	O
from	O
a	O
patient	O
diagnosed	O
with	O
Huntingtons	O
disease	O
at	O
the	O
presymptomatic	O
stage.	O

The	O
first	O
reported	O
generation	O
of	O
several	O
induced	B
pluripotent	I
stem	I
cell	I
lines	O
from	O
homozygous	O
and	O
heterozygous	O
Huntingtons	O
disease	O
patients	O
demonstrates	O
mutation	O
related	O
enhanced	O
lysosomal	O
activity.	O

Differentiation	O
of	O
neuroepithelial	B
stem	I
cells	I
into	O
functional	O
dopaminergic	O
neurons	O
in	O
3D	O
microfluidic	O
cell	O
culture.	O

A	O
human	B
stem	I
cell	I
model	O
of	O
early	O
Alzheimer’s	O
disease	O
pathology	O
in	O
Down	O
syndrome.	O

Generation	O
of	O
six	O
induced	B
pluripotent	I
stem	I
cell	I
lines	O
from	O
two	O
patients	O
with	O
amyotrophic	O
lateral	O
sclerosis	O
(NUIGi043-A,	O
NUIGi043-B,	O
NUIGi043-C,	O
NUIGi044-A,	O
NUIGi044-B,	O
NUIGi044-C).	O

Therefore,	O
these	O
results	O
establish	O
the	O
efficacy	O
of	O
diprotin	O
A	O
in	O
stimulating	O
muscle	O
cell	O
engraftment,	O
and	O
highlight	O
the	O
pre-clinical	O
utility	O
of	O
a	O
xenotransplantation	O
model	O
in	O
assessing	O
the	O
relative	O
efficacy	O
of	O
muscle	B
stem	I
cell	I
populations..	O

Furthermore,	O
our	O
results	O
suggest	O
the	O
potential	O
pre-clinical	O
utility	O
of	O
a	O
human-to-mouse	O
xenotransplantation	O
model	O
in	O
assessing	O
the	O
relative	O
efficacy	O
of	O
human	B
muscle	I
stem	I
cell	I
populations..	O

MSCs	O
are	O
the	O
major	O
stem	B
cells	I
for	O
cell	O
therapy	O
and	O
have	O
been	O
used	O
in	O
the	O
clinic	O
for	O
approximately	O
10	O
years	O
[3].	O

Volcano	O
plots	O
of	O
human	B
mesenchymal	I
stem	I
cell	I
related	O
gene	O
A.,	O
cellular	O
senescence	O
related	O
gene	O
B.	O

Proliferation	O
is	O
a	O
fundamental	O
property	O
of	O
stem	O
cells	O
necessary	O
for	O
self-renewal	O
and	O
expansion	O
and	O
defining	O
stem	B
cell	I
degree	O
of	O
stemness	O
[33].	O

hBM-MSC	O
samples	O
of	O
P3-P4	O
and	O
P6-P7	O
were	O
analyzed	O
using	O
Human	B
Mesenchymal	I
Stem	I
Cell	I
RT2	O
Profiler	O
PCR	O
Array	O
(PAHS-082Z,	O
SABiosciences,	O
Qiagen)	O
and	O
Human	O
Cellular	O
Senescence	O
RT2	O
Profiler	O
PCR	O
Array	O
(PAHS-050Z).	O

Cell	O
senescence	O
abrogates	O
the	O
therapeutic	O
potential	O
of	O
human	B
mesenchymal	I
stem	I
cells	I
in	O
the	O
lethal	O
endotoxemia	O
model.	O

Quick	O
and	O
effective	O
method	O
of	O
bone	B
marrow	I
mesenchymal	I
stem	I
cell	I
extraction.	O

Genetic	O
evaluation	O
of	O
mesenchymal	B
stem	I
cells	I
by	O
G-banded	O
karyotyping	O
in	O
a	O
Cell	O
Technology	O
Center.	O

The	O
pluripotency	O
regulator	O
Oct4:	O
a	O
role	O
in	O
somatic	O
stem	O
cells	O
Cell	O
Cycle.	O
Human	O
mesenchymal	B
stem	I
cell	I
expression	O
program	O
upon	O
extended	O
ex-vivo	O
cultivation,	O
as	O
revealed	O
by	O
2-DE-based	O
quantitative	O
proteomics.	O

Human	B
induced	I
pluripotent	I
stem	I
cell	I
-derived	O
hepatocytes	O
(hiPSC-Heps)	O
have	O
the	O
potential	O
to	O
overcome	O
the	O
limitations	O
of	O
pHeps	O
and	O
human	O
cell	O
lines.	O

Inversion	O
and	O
Computational	O
Maturation	O
of	O
Drug	O
Response	O
Using	O
Human	B
Stem	I
Cell	I
Derived	O
Cardiomyocytes	O
in	O
Microphysiological	O
Systems.	O

Modulation	O
of	O
mouse	B
embryonic	I
stem	I
cell	I
proliferation	O
and	O
neural	O
differentiation	O
by	O
the	O
P2X7	O
receptor.	O

ATP	O
and	O
spontaneous	O
calcium	O
oscillations	O
control	O
neural	B
stem	I
cell	I
fate	O
determination	O
in	O
Huntington’s	O
disease:	O
a	O
novel	O
approach	O
for	O
cell	O
clock	O
research.	O

In	O
recent	O
years,	O
the	O
incredible	O
boost	O
in	O
stem	B
cell	I
research	O
has	O
kindled	O
the	O
expectations	O
of	O
both	O
patients	O
and	O
physicians.	O

Among	O
the	O
cell	O
types	O
studied,	O
mesenchymal	B
stem	I
cells	I
are	O
strong	O
candidates	O
for	O
success	O
in	O
the	O
MI	O
setting.	O

Similarly,	O
but	O
adding	O
simple	O
mechanical	O
and	O
enzymatic	O
processing,	O
a	O
mixed	O
cell	O
population	O
(called	O
stromal	O
vascular	O
fraction,	O
SVF)	O
can	O
be	O
isolated	O
from	O
adipose	O
depots,	O
which,	O
after	O
in	O
vitro	O
culture	O
and	O
homogenization,	O
gives	O
rise	O
to	O
the	O
mesenchymal	O
progenitors	O
from	O
this	O
tissue,	O
also	O
termed	O
adipose-derived	B
stem	I
cells	I
[12].	O

Despite	O
all	O
the	O
optimism,	O
stem	B
cell	I
therapy	O
shows	O
certain	O
caveats	O
that	O
are	O
amenable	O
to	O
improvement,	O
namely,	O
lack	O
of	O
substantial	O
engraftment	O
and	O
cell	O
persistence,	O
high	O
levels	O
of	O
death,	O
and	O
low	O
in	O
vivo	O
differentiation	O
capacity.	O

In	O
view	O
of	O
the	O
encouraging	O
results	O
of	O
the	O
previous	O
clinical	O
trials,	O
new	O
phase-I/II	O
studies	O
have	O
been	O
initiated,	O
including	O
the	O
transendocardial	O
autologous	O
cells	O
(hMSC	O
or	O
hBMC)	O
in	O
Ischemic	O
Heart	O
Failure	O
Trial	O
(TAC-HFT;	O
http://www.clinicaltrials.org/NCT00768066/),	O
the	O
Prospective	O
Randomised	O
study	O
Of	O
MSC	O
THErapy	O
in	O
patients	O
Undergoing	O
cardiac	O
Surgery	O
(PROMETHEUS)	O
trial	O
(http://www.clinicaltrials.org/NCT00587990/),	O
and	O
the	O
Percutaneous	B
Stem	I
Cell	I
Injection	O
Delivery	O
Effects	O
on	O
Neomyogenesis	O
(POSEIDON)	O
pilot	O
study	O
(http://www.clinicaltrials.org/NCT01087996/)	O
[121],	O
among	O
others..	O

In	O
general,	O
the	O
results	O
obtained	O
from	O
the	O
many	O
clinical	O
trials	O
performed,	O
either	O
with	O
MSC	O
or	O
other	O
stem	B
cell	I
populations	O
(mainly	O
BM-derived	O
cells	O
and	O
skeletal	O
myoblasts),	O
have	O
taught	O
us	O
several	O
important	O
lessons	O
that	O
will	O
help	O
to	O
design	O
and	O
interpret	O
the	O
following	O
clinical	O
trials.	O

These	O
positive	O
results	O
will	O
probably	O
promote	O
new	O
larger	O
randomized	O
controlled	O
trials,	O
where	O
mesenchymal	O
and	O
other	O
stem	B
cell	I
populations	O
might	O
be	O
tested	O
in	O
combination	O
with	O
scaffolds,	O
thus	O
leading	O
to	O
a	O
further	O
step	O
in	O
the	O
therapeutic	O
use	O
of	O
stem	O
cells..	O

Stem	O
cells	O
and	O
cardiac	O
disease:	O
where	O
are	O
we	O
going?	O
Current	O
Stem	B
Cell	I
Research	O
&amp;	O
Therapy.	O

No	O
place	O
like	O
home:	O
anatomy	O
and	O
function	O
of	O
the	O
stem	B
cell	I
niche.	O

Mesenchymal	B
stem	I
cell	I
modification	O
of	O
endothelial	O
matrix	O
regulates	O
their	O
vascular	O
differentiation.	O

Synergistic	O
effect	O
of	O
adipose-derived	B
stem	I
cell	I
therapy	O
and	O
bone	O
marrow	O
progenitor	O
recruitment	O
in	O
ischemic	O
heart.	O

Cell	O
origin	O
of	O
human	B
mesenchymal	I
stem	I
cells	I
determines	O
a	O
different	O
healing	O
performance	O
in	O
cardiac	O
regeneration.	O

Comparison	O
of	O
different	O
adult	B
stem	I
cell	I
types	O
for	O
treatment	O
of	O
myocardial	O
ischemia.	O

Allogenic	B
mesenchymal	I
stem	I
cell	I
transplantation	O
has	O
a	O
therapeutic	O
effect	O
in	O
acute	O
myocardial	O
infarction	O
in	O
rats.	O

Mesenchymal	B
stem	I
cell	I
administration	O
at	O
coronary	O
artery	O
reperfusion	O
in	O
the	O
rat	O
by	O
two	O
delivery	O
routes:	O
a	O
quantitative	O
assessment.	O

Cell	O
therapy	O
generates	O
a	O
favourable	O
chemokine	O
gradient	O
for	O
stem	B
cell	I
recruitment	O
into	O
the	O
infarcted	O
heart	O
in	O
rabbits.	O

Adipose-derived	B
stem	I
cells	I
are	O
an	O
effective	O
cell	O
candidate	O
for	O
treatment	O
of	O
heart	O
failure:	O
an	O
MR	O
imaging	O
study	O
of	O
rat	O
hearts.	O

Multimodality	O
noninvasive	O
imaging	O
demonstrates	O
in	O
vivo	O
cardiac	O
regeneration	O
after	O
mesenchymal	B
stem	I
cell	I
therapy.	O

Effects	O
of	O
adipose	B
tissue-derived	I
stem	I
cell	I
therapy	O
after	O
myocardial	O
infarction:	O
impact	O
of	O
the	O
route	O
of	O
administration.	O

Genetic	O
modification	O
of	O
mesenchymal	B
stem	I
cells	I
overexpressing	O
ccr1	O
increases	O
cell	O
viability,	O
migration,	O
engraftment,	O
and	O
capillary	O
density	O
in	O
the	O
injured	O
myocardium.	O

Repair	O
of	O
infarcted	O
myocardium	O
using	O
mesenchymal	B
stem	I
cell	I
seeded	O
small	O
intestinal	O
submucosa	O
in	O
rabbits.	O

Cancer	B
stem	I
cell	I
drugs	O
target	O
k-ras	O
signaling	O
in	O
a	O
stemness	O
context.	O

Identification	O
of	O
thioridazine,	O
an	O
antipsychotic	O
drug,	O
as	O
an	O
antiglioblastoma	O
and	O
anticancer	B
stem	I
cell	I
agent	O
using	O
public	O
gene	O
expression	O
data.	O

Identification	O
of	O
antipsychotic	O
drug	O
fluspirilene	O
as	O
a	O
potential	O
anti-glioma	B
stem	I
cell	I
drug.	O

Repositioning	O
CEP-1347,	O
a	O
chemical	O
agent	O
originally	O
developed	O
for	O
the	O
treatment	O
of	O
Parkinsons	O
disease,	O
as	O
an	O
anti-cancer	B
stem	I
cell	I
drug.	O

Nicardipine	O
sensitizes	O
temozolomide	O
by	O
inhibiting	O
autophagy	O
and	O
promoting	O
cell	O
apoptosis	O
in	O
glioma	O
stem	O
cells.	O
In	O
fact,	O
the	O
isolation	O
of	O
spheroid-forming	O
cells	O
is	O
crucial	O
for	O
cancer	B
stem	I
cell	I
(CSC)	O
characteristics	O
investigation.	O

These	O
obtained	O
cells	O
demonstrated	O
higher	O
self-renewal,	O
enhanced	O
stem	B
cell	I
markers	O
expression	O
and	O
resistance	O
to	O
apoptosis	O
compared	O
with	O
spheroid	O
cells	O
made	O
by	O
the	O
traditional	O
method.	O

Thus,	O
single	O
cell	O
isolation	O
technology	O
is	O
considered	O
a	O
novel	O
approach	O
representing	O
a	O
step	O
forward	O
in	O
cancer	B
stem	I
cell	I
studies..	O

This	O
obtained	O
spheroid	O
technique	O
is	O
characterized	O
by	O
cellular	O
enrichment	O
with	O
stem	B
cell	I
markers	O
and	O
emergence	O
of	O
platinum-resistance	O
phenotype	O
[172].	O

revealed	O
the	O
inhibitory	O
effect	O
of	O
Rho	O
kinase	O
ROCK	O
inhibition	O
in	O
ovarian	O
cancer	O
as	O
a	O
promoter	O
to	O
ovarian	O
cancer	B
stem	I
cell	I
(CSC)	O
proliferation	O
and	O
malignant	O
progression	O
[183].	O

The	O
cell	O
environment	O
may	O
be	O
adjusted	O
in	O
3D-cell	O
culture	O
procedures	O
to	O
imitate	O
that	O
of	O
a	O
cell	O
in	O
vivo	O
and	O
offer	O
more	O
precise	O
data	O
regarding	O
cell-to-cell	O
interactions,	O
tumor	O
features,	O
drug	O
discovery,	O
metabolic	O
profiling,	O
stem	B
cell	I
research,	O
and	O
other	O
sorts	O
of	O
disorders	O
[198].	O

A	O
Breast	B
Cancer	I
Stem	I
Cell	I
Niche	O
Supported	O
by	O
Juxtacrine	O
Signalling	O
From	O
Monocytes	O
and	O
Macrophages.	O

Human	O
pancreatic	O
tumor	O
organoids	O
reveal	O
loss	O
of	O
stem	B
cell	I
niche	O
factor	O
dependence	O
during	O
disease	O
progression.	O

Cancer	B
stem	I
cell	I
definitions	O
and	O
terminology:	O
The	O
devil	O
is	O
in	O
the	O
details.	O

The	O
effect	O
of	O
2D	O
and	O
3D	O
cell	O
cultures	O
on	O
treatment	O
response,	O
EMT	O
profile	O
and	O
stem	B
cell	I
features	O
in	O
head	O
and	O
neck	O
cancer.	O

Personalized	O
medicine	O
based	O
approach	O
to	O
model	O
patterns	O
of	O
chemoresistance	O
and	O
tumor	O
recurrence	O
using	O
ovarian	O
cancer	B
stem	I
cell	I
spheroids.	O

The	O
hematopoietic	O
cells	O
characterized	O
as	O
CD34+	O
are	O
a	O
cell	O
population	O
with	O
functional	O
heterogeneity	O
and	O
variability,	O
involving	O
stem	B
cells	I
and	O
progenitor	O
cells	O
that	O
retain	O
both	O
proliferation	O
and	O
differentiation	O
potential	O
(a	O
proportion	O
of	O
these	O
cells	O
are	O
in	O
cell	O
cycle	O
or	O
in	O
G0	O
phase/dormant	O
cells)	O
[30]..	O

Single	O
administration	O
of	O
stem	B
cell	I
factor,	O
FLT-3	O
ligand,	O
megakaryocyte	O
growth	O
and	O
development	O
factor,	O
and	O
interleukin-3	O
in	O
combination	O
soon	O
after	O
irradiation	O
prevents	O
nonhuman	O
primates	O
from	O
myelosuppression:	O
long-term	O
follow-up	O
of	O
hematopoiesis.	O

Hematopoietic	B
stem	I
cell	I
compartment:	O
acute	O
and	O
late	O
effects	O
of	O
radiation	O
therapy	O
and	O
chemotherapy.	O

More	O
systematic	O
analysis	O
of	O
the	O
morphology	O
and	O
dynamics	O
of	O
the	O
mitochondrial	O
network	O
is	O
necessary;	O
changes	O
in	O
mitochondrial	O
morphology	O
during	O
corticogenesis	O
have	O
physiological	O
implications	O
for	O
stem	B
cell	I
commitment	O
and	O
metabolic	O
adaptations.	O

The	O
authors	O
research	O
is	O
supported	O
by	O
the	O
National	O
Institutes	O
of	O
Health	O
(1R35GM128915-01,	O
1R21CA227483-01A1	O
and	O
1RF1MH123971-01	O
to	O
V.G.)	O
and	O
by	O
a	O
Stem	B
Cell	I
and	O
Regenerative	O
Developmental	O
Biology	O
Training	O
Grant	O
from	O
the	O
Eunice	O
Kennedy	O
Shriver	O
National	O
Institute	O
of	O
Child	O
Health	O
and	O
Human	O
Development	O
(5T32HD007502-23	O
to	O
T.B.).	O

Mitochondrial	O
dynamics:	O
biogenesis,	O
fission,	O
fusion,	O
and	O
mitophagy	O
in	O
the	O
regulation	O
of	O
stem	B
cell	I
behaviors.	O

Mitochondrial	O
dynamics	O
impacts	O
stem	B
cell	I
identity	O
and	O
fate	O
decisions	O
by	O
regulating	O
a	O
nuclear	O
transcriptional	O
program.	O

The	O
clinical	O
response	O
to	O
treatment	O
was	O
initially	O
very	O
satisfying;	O
however	O
after	O
two	O
years	O
the	O
child	O
presented	O
severe	O
infections	O
requiring	O
prolonged	O
hospitalisation;	O
stem	B
cell	I
transplantation	O
was	O
then	O
performed	O
with	O
a	O
complete	O
normalization	O
of	O
both	O
clinical	O
and	O
immunological	O
features..	O

Quantitative	O
analysis	O
of	O
chimerism	O
after	O
allogeneic	B
stem	I
cell	I
transplantation	O
by	O
PCR	O
amplification	O
of	O
microsatellite	O
markers	O
and	O
capillary	O
electrophoresis	O
with	O
fluorescence	O
detection:	O
the	O
Geneva	O
experience.	O

reported	O
that	O
bone	O
marrow-derived	O
MSCs	O
could	O
encapsulate	O
miRNAs,	O
such	O
as	O
miR-124a,	O
into	O
exosomes,	O
and	O
these	O
engineered	O
exosomes	O
could	O
be	O
used	O
to	O
treat	O
mice	O
harboring	O
intracranial	O
glioma	O
stem	O
cell.	O
Neural	B
stem	I
cells	I
and	O
neurogenesis	O
in	O
the	O
adult	O
zebrafish	O
brain:	O
origin,	O
proliferation	O
dynamics,	O
migration	O
and	O
cell	O
fate.	O

b22M	O
predicts	O
not	O
only	O
the	O
prognosis	O
but	O
also	O
the	O
progression	O
of	O
asymptomatic	O
disease	O
(HR	O
3.30;	O
P	O
=	O
0.002)	O
(280)	O
and	O
even	O
outcomes	O
after	O
stem	B
cell	I
transplantation	O
(281,	O
282).	O

Cytomegalovirus	O
pp71	O
protein	O
is	O
expressed	O
in	O
human	O
glioblastoma	O
and	O
promotes	O
pro-angiogenic	O
signaling	O
by	O
activation	O
of	O
stem	B
cell	I
factor.	O

HIF-2b1	O
promotes	O
conversion	O
to	O
a	O
stem	B
cell	I
phenotype	O
and	O
induces	O
chemoresistance	O
in	O
breast	O
cancer	O
cells	O
by	O
activating	O
wnt	O
and	O
notch	O
pathways.	O

ERG	O
promotes	O
T-acute	O
lymphoblastic	O
leukemia	O
and	O
is	O
transcriptionally	O
regulated	O
in	O
leukemic	O
cells	O
by	O
a	O
stem	B
cell	I
enhancer.	O

Taken	O
together,	O
these	O
studies	O
suggest	O
that	O
the	O
essential	O
role	O
of	O
Dicer	O
in	O
the	O
production	O
of	O
mature	O
microRNAs	O
is	O
central	O
for	O
biological	O
processes	O
in	O
mammalian	O
organisms,	O
ranging	O
from	O
stem	B
cell	I
differentiation	O
to	O
the	O
integrity	O
and	O
function	O
of	O
centromeric	O
heterochromatin	O
(Kanellopoulou	O
et	O
al.	O

DGCR8	O
is	O
essential	O
for	O
MicroRNA	O
biogenesis	O
and	O
silencing	O
of	O
embryonic	B
stem	I
cell	I
self-renewal.	O

Stem	B
cell	I
aging	O
is	O
controlled	O
both	O
intrinsically	O
and	O
extrinsically	O
in	O
the	O
Drosophila	O
ovary.	O

(A)	O
RNA-sequencing	O
and	O
quantitative	O
real-time	O
polymerase	O
chain	O
reaction	O
(qRT-PCR)	O
validation	O
revealed	O
that	O
~45%	O
(11/25)	O
of	O
the	O
patients	O
with	O
t(4;11)+	O
B-cell	O
precursor	O
acute	O
lymphoblastic	O
leukemia	O
do	O
not	O
express	O
the	O
reciprocal	O
fusion	O
A4M.18	O
(B)	O
Left,	O
Phase-contrast	O
morphology	O
of	O
representative	O
colonies	O
from	O
each	O
transgenic	B
human	I
embryonic	I
stem	I
cell	I
line.	O

hESC	O
(AND1	O
cell	O
line)	O
were	O
maintained	O
undifferentiated	O
on	O
a	O
layer	O
of	O
irradiated	O
human	B
mesenchymal	I
stem	I
cells	I
in	O
complete	O
knockout	O
Dulbecco	O
modified	O
Eagle	O
medium	O
containing	O
20%	O
knockout	O
serum	O
replacement	O
and	O
8	O
ng/mL	O
basic	O
fibroblast	O
growth	O
factor.34,35	O
The	O
medium	O
was	O
changed	O
daily,	O
and	O
cells	O
were	O
passaged	O
weekly	O
by	O
dissociation	O
with	O
1:1	O
collagenase	O
IV:dispase.	O

FACS-purified	O
HEP	O
(CD29CD34+CD31+CD45)	O
were	O
plated	O
onto	O
MS5	O
stroma	O
or	O
in	O
liquid	O
culture	O
for	O
30	O
or	O
16	O
days,	O
respectively,	O
in	O
differentiation	O
medium	O
with	O
hematopoietic	O
cytokines	O
(50	O
ng/mL	O
stem	B
cell	I
factor,	O
50	O
ng/mL	O
Flt3L,	O
10	O
ng/mL	O
interleukin-3,	O
20	O
ng/mL	O
interleukin-7).	O

EB:	O
erythroid	O
body;	O
bFGF:	O
basic	O
fibroblast	O
growth	O
factor;	O
BMP4:	O
bone	O
morphogenetic	O
protein-4;	O
SCF:	O
stem	B
cell	I
factor;	O
IL:	O
interleukin;	O
G-CSF:	O
granulocyte	O
colony-stimulating	O
factor;	O
CFU:	O
colony-forming	O
unit;	O
EV:	O
empty	O
vector;	O
IBMT;	O
intra-bone	O
marrow	O
transplantation;	O
C+:	O
positive	O
control;	O
CB:	O
cord	O
blood..	O

(A)	O
Experimental	O
design	O
of	O
OP9-based	O
human	B
embryonic	I
stem	I
cell	I
differentiation	O
towards	O
hemato-endothelial	O
precursors	O
(HEP)	O
and	O
further	O
hematopoietic	O
commitment	O
of	O
HEP	O
maintained	O
in	O
either	O
liquid	O
culture	O
for	O
16	O
days	O
or	O
in	O
MS5	O
co-culture	O
for	O
30	O
days.	O

bFGF:	O
basic	O
fibroblast	O
growth	O
factor;	O
MTG:	O
monothioglycerol;	O
SCF:	O
stem	B
cell	I
factor;	O
IL:	O
interleukin;	O
G-CSF:	O
granulocyte	O
colony-stimulating	O
factor;	O
EV:	O
empty	O
vector..	O

Mechanistically,	O
a	O
putative	O
function	O
of	O
A4M	O
is	O
to	O
activate	O
chromatin,	O
rendering	O
a	O
chromatin	O
landscape	O
similar	O
to	O
that	O
present	O
during	O
stem	B
cell	I
development.	O

Endothelial	O
and	O
hematopoietic	O
cell	O
fate	O
of	O
human	B
embryonic	I
stem	I
cells	I
originates	O
from	O
primitive	O
endothelium	O
with	O
hemangioblastic	O
properties.	O

Aberrant	O
chromatin	O
at	O
genes	O
encoding	O
stem	B
cell	I
regulators	O
in	O
human	O
mixed-lineage	O
leukemia.	O

Mechanical	O
Properties	O
of	O
Stem	O
Cells	O
from	B
Different	I
Sources	O
During	O
Vascular	O
Smooth	O
Muscle	O
Cell	O
Differentiation.	O

Integrin	O
activation	O
and	O
internalization	O
on	O
soft	O
ECM	O
as	O
a	O
mechanism	O
of	O
induction	O
of	O
stem	B
cell	I
differentiation	O
by	O
ECM	O
elasticity.	O

Epithelial	O
to	O
mesenchymal	O
transition	O
is	O
mechanistically	O
linked	O
with	O
stem	B
cell	I
signatures	O
in	O
prostate	O
cancer	O
cells.	O

A	O
hierarchical	O
network	O
controls	O
protein	O
translation	O
during	O
murine	B
embryonic	I
stem	I
cell	I
self-renewal	O
and	O
differentiation.	O

Polysome	O
profiling	O
shows	O
extensive	O
posttranscriptional	O
regulation	O
during	O
human	B
adipocyte	I
stem	I
cell	I
differentiation	O
into	O
adipocytes.	O

Ultra	O
Low-Dose	O
IL-2	O
for	O
GVHD	O
Prophylaxis	O
after	O
Allogeneic	B
Hematopoietic	I
Stem	I
Cell	I
Transplantation	O
Mediates	O
Expansion	O
of	O
Regulatory	O
T	O
Cells	O
without	O
Diminishing	O
Antiviral	O
and	O
Antileukemic	O
Activity.	O

For	O
consolidation	O
therapy,	O
114	O
patients	O
were	O
treated	O
with	O
a	O
high-dose	O
cytarabine-based	O
chemotherapy,	O
and	O
10	O
young	O
patients	O
received	O
bone	B
marrow	I
stem	I
cell	I
transplantation.	O

Knockdown	O
of	O
miR-210	O
decreases	O
hypoxic	O
glioma	B
stem	I
cells	I
stemness	O
and	O
radioresistance,	O
Exp	O
Cell	O
Res	O
2014;	O
326:	O
22–35.	O

In	O
addition,	O
correlated	O
with	O
the	O
expression	O
of	O
pluripotency	O
markers,	O
lncRNAs	O
play	O
role	O
in	O
the	O
embryonic	B
stem	I
cell	I
regulatory	O
(5).	O

Further	O
analysis	O
suggested	O
that	O
the	O
absence	O
of	O
Dnmt3a	O
caused	O
both	O
hypermethylation	O
and	O
hypomethylation	O
of	O
promoter	O
regions,	O
and	O
deregulation	O
of	O
stem	B
cell	I
and	O
differentiation	O
genes	O
[17]..	O

Sources	O
and	O
in	O
vitro	O
growth	O
protocols	O
for	O
neural	B
stem	I
cell	I
generation	O
and	O
expansion..	O

Indeed,	O
grafted	O
pluripotent	O
cells	O
can	O
form	O
teratomas,	O
implying	O
that	O
in	O
a	O
clinical	O
setting	O
residual	O
undifferentiated	O
pluripotent	B
stem	I
cells	I
should	O
be	O
excluded	O
from	O
the	O
cell	O
preparation	O
before	O
grafting.	O

If	O
restricting	O
the	O
search	O
to	O
non-tumor	O
diseases,	O
the	O
database	O
returns	O
51	O
studies	O
(query	O
terms:	O
neural	B
stem	I
cell	I
AND	O
injection	O
AND	O
nervous	O
system	O
disease	O
NOT	O
tumor)	O
with	O
only	O
27	O
of	O
these	O
currently	O
open.	O

In	O
2009,	O
the	O
Company	O
completed	O
the	O
Phase	O
I	O
safety	O
study	O
and	O
in	O
October	O
2010	O
embarked	O
on	O
a	O
Phase	O
Ib	O
safety	O
and	O
efficacy	O
trial	O
(clinicaltrials.gov	O
identifier	O
no.NCT01238315)	O
in	O
6	O
children	O
with	O
less	O
advanced	O
Battens	O
disease	O
and	O
therefore	O
most	O
likely	O
to	O
benefit	O
from	O
a	O
timely	O
neural	B
stem	I
cell	I
transplant.	O

The	O
enthusiasm	O
about	O
this	O
study	O
was	O
abated	O
only	O
a	O
year	O
later,	O
when	O
Geron	O
suddenly	O
and	O
surprisingly	O
stopped	O
the	O
trial	O
and	O
decided	O
to	O
give	O
up	O
on	O
the	O
stem	B
cell	I
division.	O

On	O
the	O
contrary,	O
current	O
research	O
does	O
not	O
support	O
the	O
idea	O
that	O
stem	B
cell	I
transplantation	O
may	O
work	O
in	O
the	O
case	O
of	O
other	O
neurodevelopmental	O
disorders	O
such	O
as	O
autism,	O
since	O
no	O
massive	O
cell	O
loss	O
is	O
observed	O
in	O
the	O
brain	O
of	O
autistic	O
patients.	O

NCT01343511	O
Safety	O
and	O
Efficacy	O
of	O
Stem	O
Cell	O
Therapy	O
in	O
Patients	O
With	O
Autism	O
Completed	O
Autism	O
Biological:	O
human	O
cord	O
blood	O
mononuclear	O
cells	O
implantation|Biological:	O
human	O
cord	O
blood	O
mononuclear	O
cells	O
and	O
human	B
umbilical	I
cord	I
mesenchymal	I
stem	I
cells	I
Injection	O
Shenzhen	O
Beike	O
Bio-Technology	O
Co.,	O
Ltd.|Shandong	O
Jiaotong	O
Hospital|Association	O
for	O
the	O
Handicapped	O
Of	O
Jinan	O
Phase	O
1-2	O
37	O
March	O
2009	O
May	O
2011.	O

Another	O
field	O
in	O
which	O
a	O
strong	O
interest	O
has	O
been	O
raised	O
for	O
cell	O
treatments	O
based	O
on	O
NSCs	O
or	O
cell	O
derivatives	O
of	O
human	B
pluripotent	I
stem	I
cells	I
is	O
represented	O
by	O
retinopathies.	O

Among	O
these,	O
an	O
age	O
related	O
macular	O
degneration	O
(AMD)	O
Phase	O
I/II	O
trial	O
sponsored	O
by	O
Stem	B
Cell	I
Inc.	O

This	O
represents	O
the	O
first	O
time	O
that	O
orphan	O
drug	O
status	O
has	O
been	O
granted	O
for	O
the	O
use	O
of	O
an	O
embryonic	B
stem	I
cell	I
derived	O
therapy	O
in	O
treating	O
an	O
unmet	O
medical	O
need.	O

NCT01469832	O
Safety	O
and	O
Tolerability	O
of	O
Sub-retinal	O
Transplantation	O
of	O
Human	B
Embryonic	I
Stem	I
Cell	I
Derived	O
Retinal	O
Pigmented	O
Epithelial	O
(hESC-RPE)	O
Cells	O
in	O
Patients	O
With	O
Stargardts	O
Macular	O
Dystrophy	O
(SMD)	O
Recruiting	O
Stargardts	O
Macular	O
Dystrophy|Fundus	O
Flavimaculatus|Juvenile	O
Macular	O
Dystrophy	O
Biological:	O
MA09-hRPE	O
implantation	O
Advanced	O
Cell	O
Technology	O
Phase	O
1-2	O
16	O
November	O
2011	O
December	O
2014.	O

NCT01674829	O
A	O
Phase	O
I/IIa,	O
Open-Label,	O
Single-Center,	O
Prospective	O
Study	O
to	O
Determine	O
the	O
Safety	O
and	O
Tolerability	O
of	O
Sub-retinal	O
Transplantation	O
of	O
Human	B
Embryonic	I
Stem	I
Cell	I
Derived	O
Retinal	O
Pigmented	O
Epithelial	O
(MA09-hRPE)	O
Cells	O
in	O
Patients	O
With	O
Advanced	O
Dry	O
Age-related	O
Macular	O
Degeneration	O
(AMD)	O
Recruiting	O
Dry	O
Age	O
Related	O
Macular	O
Degeneration	O
Biological:	O
MA09-hRPE	O
implantation	O
CHA	O
Bio	O
&	O
Diostech	O
Phase	O
1-2	O
12	O
September	O
2012	O
April	O
2016.	O

NCT01691261	O
A	O
Study	O
Of	O
Implantation	O
Of	O
Human	B
Embryonic	I
Stem	I
Cell	I
Derived	O
Retinal	O
Pigment	O
Epithelium	O
In	O
Subjects	O
With	O
Acute	O
Wet	O
Age	O
Related	O
Macular	O
Degeneration	O
And	O
Recent	O
Rapid	O
Vision	O
Decline	O
Not	O
yet	O
recruiting	O
Age	O
Related	O
Macular	O
Degeneration	O
Biological:	O
PF-05206388	O
implantation	O
Pfizer|University	O
College,	O
London	O
Phase	O
1	O
10	O
April	O
2014	O
July	O
2016.	O

NCT02122159	O
Research	O
With	O
Retinal	O
Cells	O
Derived	O
From	B
Stem	I
Cells	I
for	I
Myopic	O
Macular	O
Degeneration	O
Not	O
yet	O
recruiting	O
Myopic	O
Macular	O
Degeneration	O
Biological:	O
MA09-hRPE	O
implantation	O
University	O
of	O
California,	O
Los	O
Angeles|Advanced	O
Cell	O
Technology,	O
Inc.	O

The	O
growing	O
interest	O
and	O
participation	O
in	O
stem	B
cell	I
therapies	O
of	O
big	O
pharmaceutical	O
companies	O
and	O
their	O
collaborating	O
partners	O
worldwide	O
will	O
represent	O
an	O
important	O
step	O
in	O
order	O
to	O
increase	O
the	O
number	O
of	O
new	O
well-defined	O
clinical	O
trials	O
in	O
the	O
next	O
few	O
years.	O

The	O
real	O
risk	O
is	O
that	O
the	O
entire	O
field	O
of	O
stem	O
cell	O
research	O
and	O
therapies	O
might	O
become	O
a	O
fertile	O
ground	O
for	O
commercially	O
driven	O
illusion	O
sellers	O
that	O
peddle	O
the	O
poisoning	O
concept	O
of	O
stem	B
cell	I
research	O
as	O
an	O
alchemic	O
science..	O

Neural	B
stem	I
cell	I
systems:	O
physiological	O
players	O
or	O
in	O
vitro	O
entities?	O
Nat	O
Rev	O
Neurosci.	O

Opinion:	O
neural	B
stem	I
cell	I
therapy	O
for	O
neurological	O
diseases:	O
dreams	O
and	O
reality.	O

Gene	O
expression	O
profile	O
of	O
adult	O
human	O
olfactory	O
bulb	O
and	O
embryonic	O
neural	B
stem	I
cell	I
suggests	O
distinct	O
signaling	O
pathways	O
and	O
epigenetic	O
control.	O

Neuro-immune	O
interactions	O
of	O
neural	B
stem	I
cell	I
transplants:	O
from	O
animal	O
disease	O
models	O
to	O
human	O
trials.	O

Central	B
nervous	I
system	I
stem	I
cell	I
transplantation	O
for	O
children	O
with	O
neuronal	O
ceroid	O
lipofuscinosis.	O

Characterization	O
of	O
a	O
human	B
fetal	I
spinal	I
cord	I
stem	I
cell	I
line,	O
NSI-566RSC,	O
and	O
its	O
induction	O
to	O
functional	O
motoneurons.	O

A	O
conditionally	O
immortal	O
clonal	B
stem	I
cell	I
line	O
from	O
human	O
cortical	O
neuroepithelium	O
for	O
the	O
treatment	O
of	O
ischemic	O
stroke.	O

Long-term	O
survival	O
and	O
differentiation	O
of	O
retinal	O
neurons	O
derived	O
from	O
human	B
embryonic	I
stem	I
cell	I
lines	O
in	O
un-immunosuppressed	O
mouse	O
retina.	O

Hematopoietic	B
stem	I
cell	I
gene	O
therapy	O
with	O
a	O
lentiviral	O
vector	O
in	O
X-linked	O
adrenoleukodystrophy.	O

Bone	O
marrow-derived	O
myofibroblasts	O
contribute	O
to	O
the	O
mesenchymal	B
stem	I
cell	I
niche	O
and	O
promote	O
tumor	O
growth.	O

GBM	B
cancer	I
stem	I
cells	I
or	O
tumor-initiating	O
cells	O
are	O
the	O
cell	O
population	O
within	O
the	O
tumor-driving	O
therapy	O
resistance	O
and	O
recurrence.	O

Using	O
CRISPRi	O
to	O
downregulate	O
our	O
candidate	O
lncRNA	O
in	O
gCSC,	O
we	O
demonstrate	O
that	O
TP73-AS1	O
promotes	O
TMZ	O
resistance	O
in	O
gCSC	O
and	O
is	O
linked	O
to	O
regulation	O
of	O
the	O
expression	O
of	O
metabolism-	O
related	O
genes	O
and	O
ALDH1A1,	O
a	O
protein	O
known	O
to	O
be	O
expressed	O
in	O
cancer	B
stem	I
cell	I
markers	O
and	O
protects	O
gCSC	O
from	O
TMZ	O
treatment.	O

The	O
estimate	O
depicts	O
the	O
confidence	O
interval	O
for	O
one	O
per	O
stem	B
cell	I
frequency.	O

Glioma	B
stem	I
cell	I
lines	O
expanded	O
in	O
adherent	O
culture	O
have	O
tumor-specific	O
phenotypes	O
and	O
are	O
suitable	O
for	O
chemical	O
and	O
genetic	O
screens.	O

The	O
cancer	B
stem	I
cell	I
marker	O
aldehyde	O
dehydrogenase	O
is	O
required	O
to	O
maintain	O
a	O
drug-tolerant	O
tumor	O
cell	O
subpopulation.	O

Aldehyde	O
dehydrogenase	O
1	O
positive	O
glioblastoma	O
cells	O
show	O
brain	O
tumor	B
stem	I
cell	I
capacity.	O

In	O
this	O
study,	O
melatonin	O
significantly	O
increased	O
mRNA	O
expression	O
for	O
various	O
HDAC	O
isoforms	O
and	O
increased	O
histone	O
H3	O
acetylation	O
in	O
neural	B
stem	I
cell	I
lines..	O

Finally,	O
the	O
purpose	O
of	O
cell	O
culturing	O
should	O
be	O
taken	O
into	O
consideration	O
as	O
many	O
clinical	O
approaches	O
such	O
as	O
stem	B
cell	I
therapy,	O
gene	O
therapy,	O
xeno-	O
or	O
allotransplantation	O
involve	O
cell	O
culturing	O
ex	O
vivo	O
for	O
therapeutic	O
purposes.	O

For	O
example	O
a	O
long-term	O
cell	O
culture	O
device	O
ensuring	O
both	O
the	O
protection	O
of	O
the	O
product	O
and	O
the	O
operator	O
has	O
been	O
designed	O
for	O
the	O
culturing	O
of	O
embryonic	B
stem	I
cells	I
in	O
an	O
antibiotic-free	O
medium	O
by	O
means	O
of	O
an	O
integrated	O
automation	O
platform	O
using	O
a	O
class	O
II	O
BSC	O
confining	O
the	O
microwells	O
(liquid	O
handling	O
robot	O
contained	O
in	O
a	O
BSC)	O
(Hussain	O
et	O
al.	O

In	O
allogeneic	O
HSCT	O
a	O
stem	B
cell	I
donor	O
can	O
be	O
a	O
matched	O
related	O
sibling	O
or	O
a	O
haploidentical	O
(partially	O
matched)	O
family	O
relative.	O

Stem	B
cell	I
grafts	O
can	O
also	O
be	O
obtained	O
from	O
an	O
unrelated	O
volunteer	O
or	O
from	O
a	O
cryopreserved	O
cord	O
blood	O
unit.	O

Allogeneic	B
stem	I
cell	I
transplantation	O
is	O
performed	O
by	O
qualified	O
medical	O
staff	O
in	O
a	O
facility	O
with	O
adequate	O
conditions	O
(patients	O
environmental	O
isolation,	O
cellular	O
processing	O
transplantation	O
laboratory,	O
apheresis	O
unit).	O

As	O
in	O
solid	O
organ	O
transplantations,	O
the	O
process	O
involves	O
the	O
preparation	O
and	O
care	O
of	O
a	O
healthy	O
donor	O
volunteer	O
who	O
should	O
undergo	O
a	O
medical	O
procedure	O
of	O
stem	B
cell	I
collection.	O

The	O
preparative	O
regimen	O
of	O
chemotherapy	O
or	O
combined	O
chemotherapy	O
and	O
radiotherapy	O
prior	O
to	O
stem	B
cell	I
transfusion	O
has	O
a	O
role	O
in	O
eradicating	O
residual	O
tumor	O
and	O
suppressing	O
the	O
patients	O
immune	O
system	O
to	O
prevent	O
graft	O
rejection.	O

Excessive	O
stem	B
cell	I
production	O
is	O
stimulated	O
by	O
injecting	O
recombinant	O
granulocyte	O
colony-stimulating	O
factor	O
(G-CSF)	O
to	O
the	O
donor.	O

Stem	B
cells	I
are	O
then	O
collected	O
by	O
leukopheresis	O
using	O
an	O
apheresis	O
machine,	O
which	O
is	O
an	O
automated,	O
continuous	O
flow	O
blood	O
cell	O
and	O
plasma	O
components	O
separator.	O

The	O
procedure	O
was	O
shown	O
to	O
be	O
safe	O
with	O
no	O
increased	O
rates	O
of	O
GVHD,	O
infections,	O
or	O
disease	O
relapse.56	O
In	O
another	O
study	O
pre-emptive	O
Treg	O
DLI	O
was	O
performed	O
after	O
stopping	O
immunosuppression,	O
in	O
order	O
to	O
prevent	O
relapse	O
after	O
allogeneic	O
HSCT	O
in	O
high-risk	O
patients.57	O
In	O
one	O
study,	O
Treg	O
DLI	O
from	O
a	O
donor	O
was	O
given	O
as	O
treatment	O
for	O
active	O
chronic	O
GVHD	O
after	O
allogeneic	O
HSCT.58	O
In	O
two	O
other	O
studies	O
in	O
the	O
haploidentical	O
HSCT	O
setting,	O
Tregs	O
were	O
infused	O
a	O
few	O
days	O
prior	O
to	O
the	O
transfusion	O
of	O
a	O
TCD	B
stem	I
cell	I
graft	O
combined	O
with	O
Tcon	O
infusion.	O

Many	O
trials	O
have	O
tested	O
augmenting	O
the	O
patient	O
immune	O
response	O
against	O
the	O
tumor	O
in	O
the	O
autologous	O
setting.68,69	O
In	O
two	O
trials,	O
autologous	O
inactivated	O
leukemia	O
cells	O
were	O
transfused	O
to	O
patients	O
following	O
allogeneic	B
stem	I
cell	I
transplantation	O
to	O
induce	O
in	O
vivo	O
immunity.	O

In	O
one	O
case	O
the	O
donor	O
was	O
immunized	O
prior	O
to	O
DLI	O
collection	O
to	O
treat	O
relapsed	O
disease	O
after	O
the	O
HSCT.72	O
In	O
the	O
other	O
cases	O
the	O
donor	O
was	O
immunized	O
before	B
stem	I
cell	I
collection,	O
and	O
the	O
recipient	O
showed	O
immunogenic	O
response	O
with	O
long-term	O
remission.73,74	O
Further	O
trials	O
are	O
required	O
to	O
find	O
immunogenic	O
targets	O
and	O
immunization	O
strategies	O
in	O
the	O
allogeneic	O
HSCT	O
setting.	O

The	O
graft	O
is	O
then	O
T	O
cell-depleted	O
by	O
positive	O
stem	B
cell	I
selection.	O

In	O
December	O
2012,	O
the	O
one-millionth	O
blood	B
stem	I
cell	I
transplant	O
worldwide	O
was	O
performed.	O

Nonmyeloablative	B
stem	I
cell	I
transplantation	O
and	O
cell	O
therapy	O
as	O
an	O
alternative	O
to	O
conventional	O
bone	O
marrow	O
transplantation	O
with	O
lethal	O
cytoreduction	O
for	O
the	O
treatment	O
of	O
malignant	O
and	O
nonmalignant	O
hematologic	O
diseases.	O

Allogeneic	B
peripheral	I
blood	I
stem	I
cell	I
transplantation	O
using	O
a	O
fludarabine-based	O
low	O
intensity	O
conditioning	O
regimen	O
for	O
malignant	O
lymphoma.	O

Reduced-intensity	O
allogeneic	B
stem	I
cell	I
transplantation	O
as	O
salvage	O
treatment	O
for	O
patients	O
with	O
indolent	O
lymphoma	O
or	O
CLL	O
after	O
failure	O
of	O
autologous	O
SCT.	O

Regulatory	O
T	O
cells	O
in	O
stem	B
cell	I
transplantation:	O
strategies	O
and	O
first	O
clinical	O
experiences.	O

HLA	B
haploidentical	I
stem	I
cell	I
transplantation	O
after	O
removal	O
of	O
alpha	O
beta	O
+	O
T	O
lymphocytes	O
and	O
B	O
lymphocytes	O
is	O
an	O
effective	O
treatment	O
for	O
children	O
with	O
life-threatening,	O
non-malignant	O
disorders.	O

Biologic	O
activity	O
of	O
irradiated,	O
autologous,	O
GM-CSF-secreting	O
leukemia	O
cell	O
vaccines	O
early	O
after	O
allogeneic	B
stem	I
cell	I
transplantation.	O

Tumor	O
antigen	O
immunization	O
of	O
sibling	B
stem	I
cell	I
transplant	O
donors	O
in	O
multiple	O
myeloma.	O

Metformin	O
and	O
phenformin	O
deplete	O
tricarboxylic	O
acid	O
cycle	O
and	O
glycolytic	O
intermediates	O
during	O
cell	O
transformation	O
and	O
ntps	O
in	O
cancer	O
stem	O
cells.	O
(2008)	O
Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

In	O
addition,	O
xenograft	O
models	O
have	O
been	O
recently	O
used	O
to	O
understand	O
the	O
metabolic	O
and/or	O
stem	B
cell	I
properties	O
of	O
cancer	O
cells	O
and	O
they	O
also	O
offer	O
the	O
possibility	O
to	O
study	O
patient-derived	O
cancer	O
cells	O
in	O
vivo	O
[110,111]..	O

JAK/STAT3-regulated	O
fatty	O
acid	O
b2-oxidation	O
is	O
critical	O
for	O
breast	B
cancer	I
stem	I
cell	I
self-renewal	O
and	O
chemoresistance.	O

Targeting	O
multiple	O
pathways	O
in	O
gliomas	O
with	O
stem	B
cell	I
and	O
viral	O
delivered	O
s-TRAILl	O
and	O
temozolomide.	O

Variation	O
in	O
cancer	O
risk	O
among	O
tissues	O
can	O
be	O
explained	O
by	O
the	O
number	O
of	O
stem	B
cell	I
divisions.	O

et	O
al.A	O
novel	O
mode	O
of	O
enhancer	O
evolution:	O
the	O
Tal1	B
stem	I
cell	I
enhancer	O
recruited	O
a	O
MIR	O
element	O
to	O
specifically	O
boost	O
its	O
activity.	O

Meanwhile,	O
the	O
small-molecule-inhibitor-based	O
interference	O
with	O
DDR	O
function	O
might	O
also	O
offer	O
the	O
possibility	O
to	O
specifically	O
target	O
cancer	B
stem	I
cells	I
(CSCs)	O
a	O
small	O
subset	O
of	O
the	O
tumor	O
cell	O
population	O
that	O
shares	O
several	O
features	O
with	O
normal	O
stem	O
cells,	O
e.g.,	O
the	O
potential	O
to	O
self-renew,	O
to	O
proliferate	O
excessively,	O
to	O
differentiate	O
into	O
multiple	O
cellular	O
lineages,	O
and	O
to	O
induce	O
de	O
novo	O
formation	O
of	O
blood	O
vessels	O
(Reya	O
et	O
al.	O

Even	O
administration	O
of	O
stem	B
cell	I
transplantation	O
that	O
serves	O
as	O
a	O
potential	O
curative	O
option	O
for	O
HGBL-DHL	O
cases,	O
the	O
prognosis	O
of	O
this	O
patient	O
population	O
still	O
has	O
not	O
been	O
largely	O
improved	O
with	O
median	O
overall	O
survival	O
inferior	O
to	O
2	O
years	O
(6).	O

Impact	O
of	O
induction	O
regimen	O
and	O
stem	B
cell	I
transplantation	O
on	O
outcomes	O
in	O
double-hit	O
lymphoma:	O
a	O
multicenter	O
retrospective	O
analysis.	O

The	O
authors	O
have	O
proposed	O
that	O
this	O
interaction	O
may	O
provide	O
a	O
mechanism	O
for	O
Wnt5a	O
to	O
regulate	O
the	O
localization	O
and	O
timing	O
of	O
TGF	O
b2	O
signalling	O
during	O
stem	B
cell	I
proliferation47.	O

A	O
long-term	O
serial	O
cell	O
expansion	O
can	O
potentially	O
induce	O
replicative	O
senescence,	O
which	O
leads	O
to	O
a	O
progressive	O
decline	O
in	O
stem	B
cell	I
function	O
and	O
stemness,	O
losing	O
multipotent	O
characteristics.	O

To	O
improve	O
the	O
therapeutic	O
efficiency	O
of	O
stem	B
cell	I
therapy,	O
it	O
would	O
be	O
important	O
to	O
identify	O
specific	O
biomarkers	O
for	O
senescent	O
cells..	O

Our	O
data	O
suggest	O
that	O
activation	O
of	O
ECM-receptor	O
signaling,	O
specifically	O
involved	O
with	O
integrin	O
family-mediated	O
activation	O
of	O
the	O
intracellular	O
cell	O
survival-signaling	O
molecule	O
AKT,	O
can	O
regulate	O
stem	B
cell	I
senescence	O
in	O
TMSCs.	O

Nevertheless,	O
MSCs	O
are	O
generally	O
considered	O
as	O
a	O
more	O
practical	O
option	O
for	O
cell	O
therapies	O
since	O
transplanted	O
stem	O
cells	O
derived	O
from	O
MSCs	O
have	O
a	O
much	O
lower	O
risk	O
of	O
forming	O
tumors	O
and	O
are	O
relatively	O
safer	O
compared	O
with	O
pluripotent	B
stem	I
cells	I
[1,	O
3].	O

Senescent	O
MSCs	O
secrete	O
numerous	O
factors	O
that	O
decrease	O
proliferation	O
[8]	O
and	O
migration	O
of	O
a	O
stem	B
cell	I
[911]	O
but	O
increase	O
inflammatory	O
responses	O
[12].	O

The	O
complex	O
milieu	O
composed	O
of	O
cells	O
and	O
extracellular	O
matrix	O
(ECM),	O
as	O
well	O
as	O
signaling	O
molecules	O
associated	O
with	O
stem	O
cells,	O
are	O
collectively	O
referred	O
to	O
as	O
a	O
stem	O
cell	O
niche	O
[10,	O
26].	O
Stem	O
cell	O
self-renewal	O
is	O
tightly	O
regulated	O
by	O
the	O
concerted	O
action	O
of	O
intrinsic	O
factors	O
and	O
signals	O
from	O
stem	B
cells	I
within	O
the	O
niche.	O

Aging	O
of	O
stem	B
cells	I
could	O
likely	O
decrease	O
the	O
expression	O
of	O
cell	O
adhesion	O
molecules,	O
such	O
as	O
members	O
of	O
the	O
integrin	O
family	O
and	O
related	O
signaling	O
pathways	O
[29].	O

We	O
next	O
investigated	O
changes	O
in	O
expression	O
of	O
the	O
stem	B
cell	I
markers,	O
Nanog,	O
Oct4,	O
and	O
Sox2,	O
between	O
the	O
control	O
and	O
culture-aged	O
TMSCs.	O

a	O
Protein	O
expression	O
of	O
the	O
embryonic	B
stem	I
cell	I
markers,	O
Nanog,	O
Oct4,	O
and	O
Sox2,	O
in	O
TMSCs	O
was	O
investigated	O
using	O
Western	O
blot	O
analyses.	O

Changes	O
in	O
expression	O
of	O
stem	B
cell	I
surface	O
markers	O
in	O
TMSCs	O
with	O
serial	O
passaging.	O

Percent	O
changes	O
in	O
the	O
expression	O
of	O
stem	B
cell	I
surface	O
markers	O
in	O
TMSCs	O
with	O
serial	O
passaging.	O

However,	O
there	O
is	O
a	O
possible	O
risk	O
of	O
stem	B
cell	I
heterogeneity,	O
where	O
senescent	O
cells	O
within	O
a	O
TMSC	O
pool	O
might	O
have	O
lost	O
their	O
stemness,	O
decreasing	O
therapeutic	O
efficacy.	O

Our	O
inability	O
to	O
detect	O
changes	O
in	O
the	O
expression	O
of	O
stem	B
cell	I
surface	O
markers	O
with	O
senescence	O
(Fig.	O

Articles	O
from	O
Stem	B
Cell	I
Research	O
&	O
Therapy	O
are	O
provided	O
here	O
courtesy	O
of	O
BioMed	O
Central.	O

Microtubule-dependent	O
positive	O
feedback	O
between	O
Par-3	O
and	O
centrosomes	O
may	O
be	O
important	O
for	O
many	O
processes	O
within	O
cells,	O
including	O
the	O
establishment	O
of	O
apical	O
basal	O
polarity	O
(Feldman	O
and	O
Priess,	O
2012;	O
Jiang	O
et	O
al.,	O
2015)	O
and	O
oriented	O
cell	O
division	O
in	O
the	O
stem	B
cell	I
niche	O
(Inaba	O
et	O
al.,	O
2015)..	O

The	O
polarity	O
protein	O
Baz	O
forms	O
a	O
platform	O
for	O
the	O
centrosome	O
orientation	O
during	O
asymmetric	B
stem	I
cell	I
division	O
in	O
the	O
Drosophila	O
male	O
germline.	O

Role	O
of	O
the	O
Transcriptional	O
Corepressor	O
Bcor	O
in	O
Embryonic	B
Stem	I
Cell	I
Differentiation	O
and	O
Early	O
Embryonic	O
Development.	O

Polycomb	O
group	O
proteins	O
(PcG)	O
have	O
been	O
shown	O
to	O
play	O
a	O
central	O
role	O
in	O
stem	B
cell	I
maintenance	O
and	O
lineage	O
specification	O
[60].	O

The	O
in	O
vitro	O
development	O
of	O
blastocyst-derived	B
embryonic	I
stem	I
cell	I
lines:	O
formation	O
of	O
visceral	O
yolk	O
sac,	O
blood	O
islands	O
and	O
myocardium.	O

All	O
stages	O
of	O
spermatogenesis,	O
from	O
germline	B
stem	I
cell	I
division	O
to	O
functional	O
sperm	O
production,	O
are	O
present	O
in	O
adult	O
Drosophila	O
testes	O
[25].	O

APP	O
has	O
a	O
trophic	O
function	O
and	O
may	O
be	O
involved	O
in	O
neuronal	B
stem	I
cell	I
development,	O
neuronal	O
survival,	O
neurite	O
outgrowth	O
and	O
neurorepair	O
[21,22,37]..	O

WW6:	O
an	O
embryonic	B
stem	I
cell	I
line	O
with	O
an	O
inert	O
genetic	O
marker	O
that	O
can	O
be	O
traced	O
in	O
chimeras.	O

Chinese	O
researchers	O
are	O
now	O
setting	O
up	O
programs	O
in	O
everything	O
from	O
stem	B
cell	I
research,	O
through	O
large-scale	O
efforts	O
to	O
determine	O
protein	O
structures,	O
to	O
population	O
studies	O
to	O
hunt	O
for	O
human	O
disease	O
genes	O
[87].	O

In	O
recent	O
years,	O
the	O
CAM	O
has	O
been	O
used	O
in	O
innovative	O
stem	B
cell	I
research.	O

Using	O
CAM	O
or	O
chick	O
embryo	O
to	O
study	O
biocompatible	O
materials	O
and	O
stem	B
cell	I
integration	O
has	O
become	O
a	O
new	O
future	O
trend	O
[15].	O

Indeed,	O
many	O
of	O
the	O
cellular	O
THAP	O
proteins	O
studied	O
to	O
date	O
act	O
as	O
transcription	O
factors	O
that	O
control	O
the	O
expression	O
of	O
diverse	O
sets	O
of	O
genes	O
implicated	O
in	O
angiogenesis,	O
apoptosis,	O
cell	O
cycle	O
regulation,	O
stem	B
cell	I
pluripotency,	O
and	O
epigenetic	O
gene	O
silencing8,14,15,17,19-21.	O

Focusing	O
on	O
clonal	O
heterogeneity	O
instead	O
of	O
cellular	O
heterogeneity	O
eliminates	O
some	O
of	O
the	O
noise	O
of	O
tumor	O
evolution,	O
as	O
many	O
of	O
the	O
variants	O
detectable	O
at	O
the	O
level	O
of	O
individual	O
cells	O
fail	O
to	O
clonally	O
expand	O
because	O
of	O
their	O
occurrence	O
in	O
a	O
cell	O
that	O
has	O
lost	O
stem	B
cell	I
properties,	O
unfavorable	O
effects	O
on	O
fitness,	O
or	O
simple	O
stochastic	O
reasons.	O

The	O
implication	O
is	O
that	O
phenotypic	O
and	O
genetic	O
heterogeneity,	O
associated	O
with	O
tumor	O
stem	O
cell	O
differentiation,	O
are	O
irrelevant	O
for	O
tumor	O
progression	O
(as	O
long	O
as	O
they	O
do	O
not	O
affect	O
the	O
tumor	O
stem	O
cell	O
subpopulation	O
or	O
lead	O
to	O
stem	B
cell	I
conversion),	O
as	O
selection	O
can	O
only	O
work	O
on	O
the	O
heritable	O
phenotypes	O
of	O
CSCs	O
(Figure	O
2)..	O

This	O
hypothesis	O
proposes	O
that	O
the	O
majority	O
of	O
tumor	B
cells	I
reveals	I
stem	I
cell	I
features	O
with	O
varying	O
degrees	O
of	O
“stemness”,	O
where	O
the	O
“stemness”	O
is	O
influenced	O
by	O
microenvironmental	O
cues	O
and	O
some	O
stochastic	O
cell-autonomous	O
mechanisms	O
[44].	O

Importantly,	O
mathematical	O
models	O
that	O
involve	O
plasticity	O
of	O
the	O
stem	O
cell	O
phenotype	O
provide	O
a	O
much	O
better	O
match	O
to	O
experimental	O
data	O
on	O
stem	B
cell	I
dynamics	O
than	O
does	O
the	O
concept	O
of	O
rigid	O
differentiation	O
hierarchy	O
[14,41,48].	O

The	O
loss	O
of	O
epithelial	O
characteristics	O
(i.e.,	O
lack	O
of	O
intercellular	O
adhesion	O
molecules)	O
results	O
in	O
breakdown	O
of	O
epithelial-cell	O
homeostasis,	O
correlates	O
with	O
the	O
acquisition	O
of	O
a	O
migratory	O
and	O
stem	B
cell	I
phenotype	O
that	O
leads	O
to	O
progression,	O
and	O
it	O
is	O
regulated	O
by	O
CXCR4-CXCL12	O
[237].	O

Supporting	O
this	O
concept,	O
topographic	O
analysis	O
of	O
HIF1	O
and	O
stem	B
cell	I
markers	O
in	O
follicular	O
thyroid	O
neoplasms	O
has	O
shown	O
direct	O
correlation.	O

The	O
molecular	O
mechanisms	O
led	O
by	O
hypoxia	O
explain	O
the	O
general	O
phenotype	O
associated	O
with	O
progression	O
(metastatic	O
capability):	O
spindle-shaped	O
cellularity,	O
necrosis	O
and	O
stem	B
cell	I
phenotype.	O

CXCR4-CXCL12	O
and	O
hypoxia	O
play	O
a	O
central	O
role	O
on	O
the	O
metastatic	O
process	O
(stromal	O
interaction	O
and	O
digestion,	O
angiogenesis),	O
maintaining	O
stem	B
cell	I
features	O
in	O
the	O
tumor	O
cells.	O

The	O
central	O
role	O
of	O
hypoxia	O
in	O
tumor	O
progression-metastasis	O
would	O
also	O
explain	O
the	O
general	O
phenotype	O
associated	O
with	O
progression	O
(metastatic	O
capability):	O
spindle-shaped	O
cellularity,	O
necrosis	O
and	O
stem	B
cell	I
phenotype.	O

Among	O
the	O
chemokines	O
involved	O
in	O
tumor	O
metastasis,	O
the	O
CXCL12	O
(also	O
known	O
as	O
SDF-1	O
or	O
stromal-derived	O
factor)/CXCR4	O
axis	O
plays	O
a	O
critical	O
role	O
in	O
stem	B
cell	I
migration.	O

Context,	O
tissue	O
plasticity,	O
and	O
cancer:	O
Are	O
tumor	B
stem	I
cells	I
also	O
regulated	O
by	O
the	O
microenvironment?	O
Cancer	O
Cell.	O

High	O
aldehyde	O
dehydrogenase	O
and	O
expression	O
of	O
cancer	B
stem	I
cell	I
markers	O
selects	O
for	O
breast	O
cancer	O
cells	O
with	O
enhanced	O
malignant	O
and	O
metastatic	O
ability.	O

Feedback	O
mechanisms	O
control	O
coexistence	O
in	O
a	O
stem	B
cell	I
model	O
of	O
acute	O
myeloid	O
leukaemia.	O

Instead,	O
a	O
distinct	O
cancer	O
cell	O
subpopulation,	O
often	O
referred	O
to	O
as	O
cancer	B
stem	I
cells	I
(CSC)	O
or	O
tumor	O
initiating	O
cells,	O
may	O
uniquely	O
possess	O
the	O
requisite	O
genetic	O
repertoire	O
to	O
accomplish	O
this	O
task.4	O
Their	O
identity	O
and	O
complex	O
behavior	O
remains	O
an	O
intensely	O
studied	O
area.	O

In	O
addition,	O
this	O
tumor	O
initiating	O
cell	O
population	O
displayed	O
characteristics	O
that	O
were	O
similar	O
to	O
those	O
of	O
normal	B
stem	I
cells	I
in	O
that	O
they	O
were	O
able	O
to	O
produce	O
secondary	O
tumors	O
with	O
similar	O
heterogeneous	O
phenotypes	O
with	O
differentiated	O
tumor	O
cells	O
and	O
reduced	O
proliferative	O
capacity.	O

Breast	O
tumor	O
heterogeneity:	O
cancer	B
stem	I
cells	I
or	O
clonal	O
evolution?	O
Cell	O
Cycle.	O

Molecular	O
heterogeneity	O
of	O
breast	O
carcinomas	O
and	O
the	O
cancer	B
stem	I
cell	I
hypothesis.	O

Multiplexing	O
spheroid	O
volume,	O
resazurin	O
and	O
acid	O
phosphatase	O
viability	O
assays	O
for	O
high-throughput	O
screening	O
of	O
tumour	O
spheroids	O
and	O
stem	B
cell	I
neurospheres.	O

Sphere-forming	O
cell	O
subpopulations	O
with	O
cancer	B
stem	I
cell	I
properties	O
in	O
human	O
hepatoma	O
cell	O
lines.	O

Aspirin	O
counteracts	O
cancer	B
stem	I
cell	I
features,	O
desmoplasia	O
and	O
gemcitabine	O
resistance	O
in	O
pancreatic	O
cancer.	O

We	O
meta-analyzed	O
publically-available	O
gene	O
expression	O
data	O
sets	O
and	O
evaluated	O
signaling	O
and	O
metabolic	O
pathway	O
activation	O
profiles	O
for	O
20	O
human	B
embryonic	I
stem	I
cell	I
lines,	O
12	O
human	O
iPSC	O
lines,	O
five	O
embryonic	O
body	O
lines,	O
and	O
six	O
fibroblast	O
cell	O
lines.	O

fibroblast	O
characteristics,	O
and	O
that	O
the	O
cAMP	O
pathway	O
was	O
also	O
among	O
the	O
top	O
20	O
least	O
variable	O
pathways	O
in	O
ESC	O
and	O
iPSC	O
lines,	O
thus,	O
defining	O
a	O
key	O
role	O
of	O
this	O
pathway	O
in	O
stem	B
cell	I
differentiation.	O

Stem	B
cell	I
frequency	O
was	O
calculated	O
using	O
extreme	O
limiting	O
dilution	O
analysis	O
(http://bioinf.wehi.edu.au/software/elda/)..	O

For	O
example,	O
the	O
Stem	B
Cell	I
Commons	O
(Ho	O
Sui	O
et	O
al.,	O
2013)	O
data	O
collection	O
(Section	O
3.5)	O
uses	O
only	O
142	O
out	O
of	O
1	O
269	O
955	O
ontology	O
terms.	O

For	O
example,	O
Stem	B
Cell	I
Commons	O
(Ho	O
Sui	O
et	O
al.,	O
2013)	O
includes	O
datasets	O
with	O
files	O
sampled	O
from	O
three	O
species:	O
human,	O
mouse	O
and	O
zebrafish,	O
which	O
have	O
all	O
been	O
annotated	O
with	O
NCBITaxon	O
(Federhen,	O
2012).	O

In	O
this	O
section,	O
we	O
illustrate	O
three	O
usage	O
scenarios	O
for	O
SATORI	O
using	O
the	O
Stem	B
Cell	I
Commons	O
(Ho	O
Sui	O
et	O
al.,	O
2013)	O
and	O
MetaboLights	O
(Haug	O
et	O
al.,	O
2013)	O
data	O
collections,	O
which	O
are	O
comprised	O
of	O
119	O
public	O
and	O
a	O
selection	O
of	O
200	O
datasets	O
respectively.	O

Datasets	O
of	O
Stem	B
Cell	I
Commons	O
are	O
annotated	O
with	O
12	O
ontologies	O
(Supplementary	O
Table	O
S1)	O
and	O
datasets	O
of	O
MetaboLights	O
are	O
annotated	O
with	O
more	O
than	O
40	O
ontologies	O
(Supplementary	O
Table	O
S2).	O

Assume	O
a	O
data	O
analyst	O
is	O
searching	O
for	O
datasets	O
related	O
to	O
leukocytes	O
in	O
Stem	B
Cell	I
Commons.	O

Assume	O
a	O
data	O
curator	O
wants	O
to	O
evaluate	O
the	O
curation	O
state	O
of	O
Stem	B
Cell	I
Commons.	O

Zooming	O
into	O
biotin	O
reveals	O
that	O
69	O
out	O
of	O
119	O
public	O
Stem	B
Cell	I
Commons	O
datasets	O
are	O
annotated	O
with	O
it,	O
which	O
is	O
not	O
surprising	O
given	O
that	O
many	O
datasets	O
contain	O
microarray	O
or	O
RNA-Seq	O
experiments.	O

We	O
conducted	O
a	O
field	O
study	O
with	O
six	O
bioinformaticians	O
and	O
data	O
curators	O
on	O
the	O
Stem	B
Cell	I
Commons	O
data	O
collection	O
(Section	O
3.4)	O
to	O
evaluate	O
the	O
general	O
utility	O
of	O
SATORI	O
in	O
exploring	O
a	O
biomedical	O
data	O
repository.	O

The	O
study	O
consisted	O
of	O
a	O
brief	O
introduction	O
to	O
SATORI,	O
a	O
set	O
of	O
kick-off	O
tasks	O
for	O
browsing	O
of	O
the	O
Stem	B
Cell	I
Commons	O
data	O
collection	O
(Supplementary	O
Table	O
S5)	O
and	O
open-ended	O
exploration.	O

This	O
work	O
was	O
funded	O
by	O
the	O
National	O
Institutes	O
of	O
Health	O
[R00	O
HG007583]	O
and	O
the	O
Harvard	B
Stem	I
Cell	I
Institute..	O

(2013)	O
The	O
Stem	B
Cell	I
Commons:	O
an	O
exemplar	O
for	O
data	O
integration	O
in	O
the	O
biomedical	O
domain	O
driven	O
by	O
the	O
ISA	O
framework.	O

Neurodegenerative	O
diseases	O
cause	O
a	O
progressive	O
deterioration	O
of	O
neuronal	O
circuits	O
and	O
pronounced	O
hampering	O
of	O
the	O
stem	B
cell	I
proliferation32.	O

We	O
specifically	O
chose	O
her4.1	O
promoter	O
because	O
we	O
hypothesized	O
that	O
if	O
the	O
expression	O
of	O
TAUP301L	O
started	O
from	O
the	O
stem	O
cell	O
stage,	O
all	O
neurons	O
produced	O
by	O
those	O
stem	B
cells	I
after	O
the	O
recombination	O
would	O
express	O
the	O
protein.	O

In	O
contrast	O
to	O
conditional	O
expression	O
systems	O
that	O
use	O
mature	O
neuronal	O
promoters	O
such	O
as	O
HuC/D41,	O
enolase36	O
or	O
neural	O
beta	O
tubulin	O
(NBT)42,	O
using	O
a	O
stem	B
cell	I
promoter	O
would	O
increase	O
the	O
number	O
of	O
neurons	O
expressing	O
the	O
transgene	O
throughout	O
the	O
life	O
of	O
the	O
fish.	O

These	O
results	O
indicate	O
that	O
TAUP301L	O
is	O
successfully	O
expressed	O
throughout	O
the	O
entire	O
axis	O
of	O
zebrafish	O
brain	O
using	O
a	O
stem	B
cell	I
promoter.	O

Phosphorylated	O
TAUP301L	O
does	O
not	O
cause	O
cell	O
death,	O
inflammation	O
and	O
stem	B
cell	I
activation	O
in	O
adult	O
zebrafish	O
brain.	O

Additionally,	O
similar	O
to	O
her4.1,	O
nbt-driven	O
TAU	O
did	O
not	O
alter	O
neural	B
stem	I
cell	I
proliferation	O
(S100	O
b2-PCNA	O
stainings)	O
or	O
microglial	O
activation	O
in	O
adult	O
zebrafish	O
brain	O
(L-Plastin	O
stainings)	O
(Supplementary	O
Fig.	O

Since	O
TAUP301L	O
expression	O
and	O
its	O
hyperphosphorylation	O
did	O
not	O
lead	O
to	O
changes	O
in	O
cell	O
death	O
and	O
stem	B
cell	I
proliferation,	O
we	O
hypothesized	O
that	O
in	O
our	O
TAU	O
model,	O
we	O
would	O
not	O
see	O
the	O
neurodegeneration	O
induced	O
IL4	O
expression.	O

Since	O
zebrafish	O
brain	O
is	O
highly	O
regenerative	O
after	O
various	O
type	O
of	O
neuronal	O
loss33,45,67,79,	O
we	O
believe	O
that	O
the	O
lack	O
of	O
stem	B
cell	I
proliferation	O
response	O
and	O
activation	O
of	O
regenerative	O
programs	O
is	O
an	O
indication	O
that	O
adult	O
zebrafish	O
brain	O
can	O
cope	O
well	O
with	O
the	O
phosphorylated	O
forms	O
of	O
TAUP301L..	O

IL4/STAT6	O
signaling	O
activates	O
neural	B
stem	I
cell	I
proliferation	O
and	O
neurogenesis	O
upon	O
Amyloid-β42	O
aggregation	O
in	O
adult	O
zebrafish	O
brain.	O

Live	O
imaging	O
of	O
adult	B
neural	I
stem	I
cell	I
behavior	O
in	O
the	O
intact	O
and	O
injured	O
zebrafish	O
brain.	O

MSCs	O
have	O
also	O
been	O
shown	O
to	O
cause	O
aberrant	O
expression	O
of	O
micro-RNAs	O
by	O
BCCs,	O
providing	O
BCCs	O
with	O
enhanced	O
cancer	B
stem	I
cell	I
properties	O
[8],	O
and	O
to	O
promote	O
the	O
production	O
of	O
lysyl	O
oxidase	O
by	O
BCCs,	O
which	O
was	O
found	O
to	O
enhance	O
the	O
metastasis	O
of	O
weakly	O
metastatic	O
cancer	O
cells	O
to	O
the	O
lungs	O
and	O
bones	O
[11]..	O

This	O
is	O
consistent	O
with	O
a	O
previous	O
report	O
that	O
one	O
of	O
the	O
effects	O
of	O
POSTN	O
is	O
to	O
increase	O
the	O
prevalence	O
of	O
breast	B
cancer	I
stem	I
cell	I
phenotypes	O
[38].	O

Direct	O
Evidence	O
of	O
Mesenchymal	B
Stem	I
Cell	I
Tropism	O
for	O
Tumor	O
and	O
Wounding	O
Microenvironments	O
Using	O
In	O
Vivo	O
Bioluminescent	O
Imaging.	O

Since	O
its	O
discovery	O
as	O
a	O
master	O
regulator	O
of	O
EMT,	O
the	O
miR-200	O
family	O
was	O
subsequently	O
found	O
to	O
regulate	O
a	O
number	O
of	O
complementary	O
cellular	O
functions	O
relevant	O
to	O
tumor	O
growth	O
and	O
metastasis,	O
including	O
stem	B
cell	I
properties,	O
sensitivity	O
to	O
chemotherapeutic	O
agents,	O
reduction	O
in	O
angiogenesis,	O
and	O
responsiveness	O
to	O
pro-apoptotic	O
signals.	O

Epithelial	O
to	O
mesenchymal	O
transition	O
is	O
mechanistically	O
linked	O
with	O
stem	B
cell	I
signatures	O
in	O
prostate	O
cancer	O
cells.	O

For	O
example,	O
Lakshmikanth	O
and	O
colleagues	O
[79]	O
recently	O
showed	O
in	O
a	O
combination	O
serum	O
protein	O
and	O
mass	O
cytometry	O
phenotyping	O
study	O
of	O
leukemia	O
patients	O
receiving	O
allogeneic	B
stem	I
cell	I
transplants	O
that	O
they	O
could	O
identify	O
early	O
immune	O
features	O
associated	O
with	O
patient	O
outcome..	O

The	O
use	O
of	O
the	O
term	O
'organoid'	O
varies	O
substantially	O
by	O
field;	O
although	O
in	O
many	O
instances	O
they	O
are	O
derived	O
from	O
an	O
originating	B
stem	I
cell	I
population,	O
the	O
consistent	O
features	O
of	O
different	O
organoid	O
systems	O
are	O
relevant	O
tissue	O
patterning	O
and	O
retention	O
of	O
in	O
vivo	O
function.	O

Mass	O
cytometry	O
and	O
topological	O
data	O
analysis	O
reveal	O
immune	O
parameters	O
associated	O
with	O
complications	O
after	O
allogeneic	B
stem	I
cell	I
transplantation.	O

For	O
low-risk	O
papillomavirus	O
types	O
such	O
as	O
ROPV	O
or	O
HPV11,	O
it	O
has	O
been	O
suggested	O
that	O
papilloma	O
formation	O
requires	O
virus	O
entry	O
and	O
genome	O
maintenance	O
in	O
an	O
epithelial	B
stem	I
cell	I
[57].	O

the	O
infected	O
transiently	O
amplifying	O
cells)	O
populating	O
the	O
epithelial	O
basal	O
layer	O
around	O
the	O
infected	O
stem	B
cell	I
as	O
it	O
undergoes	O
normal	O
cell-division.	O

via	O
the	O
squamo-columnar	O
junction	O
or	O
via	O
hair	O
follicles),	O
in	O
many	O
cases	O
it	O
is	O
thought	O
that	O
papillomaviruses	O
gain	O
access	O
to	O
basal	O
cells	O
of	O
the	O
epithelium	O
via	O
cuts	O
or	O
abrasions,	O
and	O
that	O
the	O
establishment	O
and	O
maintenance	O
of	O
infection	O
requires	O
entry	O
into	O
a	O
long-lived	O
cell	O
such	O
as	O
the	O
epithelial	B
stem	I
cell	I
[57].	O

Increased	O
risk	O
of	O
cervical	O
dysplasia	O
in	O
long-term	O
survivors	O
of	O
allogeneic	B
stem	I
cell	I
transplantation--implications	O
for	O
screening	O
and	O
HPV	O
vaccination.	O

Can	O
routine	O
posttransplant	O
HPV	O
vaccination	O
prevent	O
commonly	O
occurring	O
epithelial	O
cancers	O
after	O
allogeneic	B
stem	I
cell	I
transplantation?	O
Clin	O
Cancer	O
Res.	O

Fbx15	O
is	O
a	O
novel	O
target	O
of	O
Oct3/4	O
but	O
is	O
dispensable	O
for	O
embryonic	B
stem	I
cell	I
self-renewal	O
and	O
mouse	O
development.	O

TRIM32	O
regulates	O
skeletal	B
muscle	I
stem	I
cell	I
differentiation	O
and	O
is	O
necessary	O
for	O
normal	O
adult	O
muscle	O
regeneration.	O

Depending	O
on	O
which	O
cell	O
proceeds	O
to	O
form	O
myoblasts	O
and	O
which	O
returns	O
to	O
repopulate	O
the	O
stem	B
cell	I
pool,	O
the	O
mutation	O
may	O
be	O
maintained	O
or	O
lost	O
from	O
the	O
regenerating	O
muscle	O
cells.	O

Vascular	O
endothelial	O
growth	O
factor	O
promotes	O
cardiac	B
stem	I
cell	I
migration	O
via	O
the	O
PI3K/Akt	O
pathway.	O

Some	O
attempts	O
have	O
been	O
made	O
to	O
treat	O
XLA	O
patients	O
by	O
stem	B
cell	I
transplantation,	O
but	O
the	O
results	O
have	O
not	O
been	O
satisfactory	O
due	O
to	O
transplantation	O
complications	O
[27].	O

Recently,	O
stem	B
cell	I
technology	O
has	O
shown	O
promise	O
in	O
drug	O
development	O
and	O
has	O
been	O
proposed	O
as	O
an	O
alternative	O
to	O
current	O
industrial	O
systems.	O

Stem	B
cell	I
technology	O
has	O
shown	O
promise	O
in	O
drug	O
screening	O
(5,6)	O
and	O
has	O
been	O
proposed	O
as	O
a	O
suitable	O
alternative	O
to	O
overcome	O
the	O
above-mentioned	O
limitations	O
with	O
primary	O
cell	O
types.	O

For	O
screening	O
proposes,	O
stem	B
cell	I
differentiation	O
procedures	O
must	O
be	O
fully	O
reproducible,	O
display	O
low	O
levels	O
of	O
variation	O
between	O
wells	O
and	O
plates	O
and	O
be	O
amenable	O
to	O
high	O
content	O
analysis	O
and	O
multiplexing.	O

Recent	O
studies	O
have	O
probed	O
the	O
practical	O
use	O
of	O
stem	B
cell	I
technology	O
for	O
high	O
content	O
screening	O
for	O
toxic	O
drugs	O
by	O
a	O
combination	O
of	O
high	O
content	O
microscopy	O
and	O
single	O
endpoint	O
assays	O
(6,102).	O

We	O
believe	O
that	O
with	O
the	O
recent	O
advances	O
in	O
stem	B
cell	I
differentiation,	O
scale	O
up,	O
and	O
performance,	O
it	O
is	O
possible	O
to	O
create	O
more	O
accurate	O
human	O
tissue	O
models	O
for	O
drug	O
development.	O

Advances	O
in	O
stem	B
cell	I
biology	O
over	O
the	O
last	O
decade	O
has	O
provided	O
the	O
field	O
with	O
more	O
accurate	O
human	O
cell-based	O
models	O
that	O
recapitulate	O
key	O
aspects	O
of	O
human	O
drug	O
metabolism,	O
with	O
better	O
precision	O
than	O
cancer	O
lines.	O

Concise	O
review:	O
measuring	O
physiological	O
responses	O
of	O
human	B
pluripotent	I
stem	I
cell	I
derived	O
cardiomyocytes	O
to	O
drugs	O
and	O
disease.	O

High	O
content	O
analysis	O
of	O
human	B
pluripotent	I
stem	I
cell	I
derived	O
hepatocytes	O
reveals	O
drug	O
induced	O
steatosis	O
and	O
phospholipidosis.	O

Organoids	O
from	O
adult	O
liver	O
and	O
pancreas:	O
stem	B
cell	I
biology	O
and	O
biomedical	O
utility.	O

Functionally	O
enhanced	O
human	B
stem	I
cell	I
derived	O
hepatocytes	O
in	O
galactosylated	O
cellulosic	O
sponges	O
for	O
hepatotoxicity	O
testing.	O

Surface-engineered	O
substrates	O
for	O
improved	B
human	I
pluripotent	I
stem	I
cell	I
culture	O
under	O
fully	O
defined	O
conditions.	O

Pluripotent	B
stem	I
cell	I
derived	O
hepatocytes:	O
using	O
materials	O
to	O
define	O
cellular	O
differentiation	O
and	O
tissue	O
engineering.	O

A	O
defined	O
synthetic	O
substrate	O
for	O
serum-free	O
culture	O
of	O
human	B
stem	I
cell	I
derived	O
cardiomyocytes	O
with	O
improved	O
functional	O
maturity	O
identified	O
using	O
combinatorial	O
materials	O
microarrays.	O

The	O
growing	O
interest	O
in	O
hydrogels	O
as	O
biomaterials	O
for	O
bioinks	O
has	O
resulted	O
in	O
numerous	O
detailed	O
reviews	O
covering	O
polymer	O
chemistries	O
and	O
their	O
applications.6,22,28,30	O
Recent	O
progress	O
in	O
stem	B
cell	I
technology	O
is	O
likely	O
to	O
drive	O
a	O
paradigm	O
shift	O
in	O
RM	O
and	O
disease	O
modeling.	O

We	O
then	O
outline	O
how	O
the	O
combination	O
of	O
stem	B
cell	I
technology	O
with	O
bioprinting	O
opens	O
new	O
avenues	O
for	O
the	O
development	O
of	O
personalized	O
therapies	O
while	O
placing	O
additional	O
requirements	O
on	O
the	O
materials	O
and	O
techniques	O
used	O
for	O
the	O
fabrication	O
of	O
patient-specific	O
tissue	O
models.	O

utilized	O
oxidized	O
alginate	O
to	O
extrude	O
encapsulated	O
human	B
adipose-derived	I
stem	I
cells	I
and	O
found	O
that	O
the	O
level	O
of	O
oxidation	O
greatly	O
influenced	O
the	O
cell	O
proliferation	O
and	O
spreading,	O
assumed	O
to	O
be	O
due	O
to	O
an	O
increase	O
in	O
porosity	O
with	O
degradation.344	O
The	O
process	O
to	O
create	O
oxidized	O
alginate	O
was	O
originally	O
reported	O
by	O
Bouhadir	O
et	O
al.	O

Many	O
of	O
the	O
challenges	O
experienced	O
by	O
those	O
attempting	O
to	O
print	B
stem	I
cells	I
are	O
similar	O
to	O
those	O
affecting	O
other	O
cell	O
types.	O

Mesenchymal	B
Stem	I
Cell	I
3D	O
Encapsulation	O
Technologies	O
for	O
Biomimetic	O
Microenvironment	O
in	O
Tissue	O
Regeneration.	O

Directing	B
Stem	I
Cell	I
Fate	O
on	O
Hydrogel	O
Substrates	O
by	O
Controlling	O
Cell	O
Geometry,	O
Matrix	O
Mechanics	O
and	O
Adhesion	O
Ligand	O
Composition.	O

Combinatorial	O
Screening	O
of	O
Nanoclay-Reinforced	O
Hydrogels:	O
A	O
Glimpse	O
of	O
the	O
Holy	O
Grail	O
in	O
Orthopedic	B
Stem	I
Cell	I
Therapy?.	O

Screening	O
of	O
Rat	B
Mesenchymal	I
Stem	I
Cell	I
Behaviour	O
on	O
Polydimethylsiloxane	O
Stiffness	O
Gradients.	O

Generation	O
of	O
KCL018	O
Research	O
Grade	O
Human	B
Embryonic	I
Stem	I
Cell	I
Line	O
Carrying	O
a	O
Mutation	O
in	O
the	O
DMPK	O
Gene.	O

Recombinant	O
Vitronectin	O
Is	O
a	O
Functionally	O
Defined	O
Substrate	O
That	O
Supports	O
Human	B
Embryonic	I
Stem	I
Cell	I
Self-Renewal	O
via	O
AVβ5	O
Integrin.	O

Analysis	O
of	O
the	O
Distinct	O
Functions	O
of	O
Growth	O
Factors	O
and	O
Tissue	O
Culture	O
Substrates	O
Necessary	O
for	O
the	O
Long-Term	O
Self-Renewal	O
of	O
Human	B
Embryonic	I
Stem	I
Cell	I
Lines.	O

Bioprinting	O
Organotypic	O
Hydrogels	O
with	O
Improved	O
Mesenchymal	B
Stem	I
Cell	I
Remodeling	O
and	O
Mineralization	O
Properties	O
for	O
Bone	O
Tissue	O
Engineering.	O

Effects	O
of	O
telomerase	O
and	O
telomere	O
length	O
on	O
epidermal	B
stem	I
cell	I
behavior.	O

A	O
protocol	O
describing	O
the	O
use	O
of	O
a	O
recombinant	O
protein-based,	O
animal	O
product-free	O
medium	O
(APEL)	O
for	O
human	B
embryonic	I
stem	I
cell	I
differentiation	O
as	O
spin	O
embryoid	O
bodies.	O

Hematopoietic	B
stem	I
cell	I
senescence	O
and	O
cancer	O
therapy-induced	O
long-term	O
bone	O
marrow	O
injury.	O

Some	O
mitochondrial	O
miRNAs	O
were	O
shown	O
to	O
modulate	O
the	O
differentiation	O
of	O
muscle	B
stem	I
cell	I
into	O
functional	O
muscle	O
cells	O
by	O
regulating	O
mitochondria	O
biogenesis	O
(Table	O
1).	O

miR-127	O
was	O
shown	O
to	O
mediate	O
muscle	B
stem	I
cell	I
differentiation	O
through	O
direct	O
targeting	O
sphingosine-1-phosphate	O
receptor	O
3	O
(S1P3).	O

In	O
a	O
miR-127	O
transgenic	O
mouse	O
suffering	O
Duchenne	O
muscular	O
dystrophy,	O
administration	O
of	O
this	O
biomolecule	O
induced	O
skeletal	O
muscle	O
regeneration	O
and	O
improved	O
muscular	O
dystrophy	O
through	O
stem	B
cell	I
differentiation	O
[73].	O

Overexpression	O
of	O
other	O
mitochondrial	O
miRNAs,	O
such	O
as	O
miR-125b	O
and	O
miR-128,	O
was	O
also	O
correlated	O
with	O
inhibition	O
of	O
muscle	B
stem	I
cell	I
differentiation	O
and	O
consequently	O
impaired	O
muscle	O
regeneration	O
[74].	O

A	O
study	O
demonstrated	O
that	O
age	O
was	O
correlated	O
with	O
reduced	O
stem	B
cell	I
numbers	O
and	O
self-renewal	O
throughout	O
the	O
central	O
and	O
peripheral	O
nervous	O
systems	O
in	O
Hmga2-deficient	O
mice.	O

This	O
evidence	O
suggests	O
an	O
important	O
role	O
of	O
let-7b	O
miRNA	O
in	O
the	O
decline	O
in	O
neural	B
stem	I
cell	I
function	O
whose	O
inhibition	O
would	O
potentiate	O
the	O
maintenance	O
of	O
stemness	O
[98].	O

The	O
stem	B
cell	I
gene	O
therapy	O
has	O
proven	O
to	O
be	O
efficient	O
in	O
pre-clinical	O
studies	O
and	O
is	O
now	O
being	O
applied	O
in	O
patients	O
with	O
different	O
regenerative	O
contexts	O
(diabetic	O
foot	O
ulcer,	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa,	O
peripheral	O
nerve	O
injury),	O
being	O
a	O
promising	O
tool	O
for	O
the	O
regenerative	O
medicine	O
field..	O

Metabolic	O
Maturation	O
during	O
Muscle	B
Stem	I
Cell	I
Differentiation	O
Is	O
Achieved	O
by	O
miR-1/133a-Mediated	O
Inhibition	O
of	O
the	O
Dlk1-Dio3	O
Mega	O
Gene	O
Cluster.	O

Hmga2	O
Promotes	O
Neural	B
Stem	I
Cell	I
Self-Renewal	O
in	O
Young	O
but	O
Not	O
Old	O
Mice	O
by	O
Reducing	O
p16Ink4a	O
and	O
p19Arf	O
Expression.	O

H1-hESC	B
Human	I
embryonic	I
stem	I
cell	I
1	O
NcoI	O
In	O
situ	O
4DNES4DGHDMX	O
(35).	O

hESC	B
Human	I
embryonic	I
stem	I
cell	I
2	O
HindIII	O
Dilution	O
SRX378271,	O
SRX378272	O
(39).	O

Long	O
noncoding	O
RNAs	O
in	O
mouse	B
embryonic	I
stem	I
cell	I
pluripotency	O
and	O
differentiation.	O

We	O
demonstrate	O
protocols	O
for	O
controlled	O
cell	O
seeding,	O
splitting	O
and	O
expansion	O
of	O
human	O
fibroblasts,	O
induced	B
pluripotent	I
stem	I
cells,	I
and	O
neural	O
progenitor	O
cells	O
(NPC)	O
that	O
allow	O
for	O
subsequent	O
differentiation	O
into	O
different	O
cell	O
types	O
and	O
image-based	O
multiparametric	O
screening.	O

Phenotypic	O
screening	O
is	O
experiencing	O
a	O
renaissance,	O
which	O
is	O
mainly	O
driven	O
by	O
the	O
availability	O
of	O
advanced	O
patient-derived	O
cellular	O
models	O
due	O
to	O
the	O
recent	O
advances	O
of	O
stem	B
cell	I
technology.	O

The	O
ability	O
of	O
iPSC	O
to	O
differentiate	O
into	O
all	O
three	O
germ	O
layers	O
was	O
tested	O
after	O
10	O
passages	O
by	O
using	O
the	O
Human	B
Pluripotent	I
Stem	I
Cell	I
Functional	O
Identification	O
Kit	O
(R&D	O
Systems)	O
according	O
to	O
manufacturers	O
instructions.	O

Large-scale	O
cell	O
production	O
of	O
stem	B
cells	I
for	O
clinical	O
application	O
using	O
the	O
automated	O
cell	O
processing	O
machine.	O

Manufacture	O
of	O
a	O
human	B
mesenchymal	I
stem	I
cell	I
population	O
using	O
an	O
automated	O
cell	O
culture	O
platform.	O

Automated	O
mechanical	O
passaging:	O
A	O
novel	O
and	O
efficient	O
method	O
for	O
human	B
embryonic	I
stem	I
cell	I
expansion.	O

Serum	O
neutrophil	O
extracellular	O
trap	O
levels	O
predict	O
thrombotic	O
microangiopathy	O
after	O
allogeneic	B
stem	I
cell	I
transplantation.	O

Cellular	O
senescence	O
induced	O
loss	O
of	O
stem	B
cell	I
proportion	O
in	O
the	O
skin	O
in	O
vitro.	O

A	O
human	B
stem	I
cell	I
model	O
of	O
FND	O
was	O
generated	O
in	O
order	O
to	O
investigate	O
the	O
effect	O
of	O
ALX1	O
mutations	O
on	O
NCC	O
behavior.	O

Lamplot	O
JD,	O
Qin	O
J,	O
Nan	O
G,	O
Wang	O
J,	O
Liu	O
X,	O
Yin	O
L,	O
Tomal	O
J,	O
Li	O
R,	O
Shui	O
W,	O
Zhang	O
H	O
et	O
al	O
(2013)	O
BMP9	O
signaling	O
in	O
stem	B
cell	I
differentiation	O
and	O
osteogenesis.	O

Cell	B
Stem	I
Cell	I
11:	O
633,648	O
[PMC	O
free	O
article]	O
[PubMed]	O
[Google	O
Scholar].	O

The	O
comparative	O
histopathology	O
is	O
an	O
important	O
element	O
in	O
validating	O
a	O
mouse	O
model	O
and	O
has	O
implications	O
for	O
deducing	O
the	O
stem	B
cell	I
of	O
origin,	O
and	O
predicting	O
future	O
behaviour	O
of	O
the	O
tumour.	O

Pax3	O
functions	O
at	O
a	O
nodal	O
point	O
in	O
melanocyte	B
stem	I
cell	I
differentiation.	O

Characteristics	O
of	O
stem	B
cells	I
from	O
human	O
neuroblastoma	O
cell	O
lines	O
and	O
in	O
tumors.	O

Hosoda	O
T,	O
Zheng	O
H,	O
Cabral-da-Silva	O
M,	O
Sanada	O
F,	O
Ide-Iwata	O
N,	O
Ogrek	O
B,	O
Ferreira-Martins	O
J,	O
Arranto	O
C,	O
D'Amario	O
D,	O
del	O
Monte	O
F	O
(2011)	O
Human	O
cardiac	B
stem	I
cell	I
differentiation	O
is	O
regulated	O
by	O
a	O
mircrine	O
mechanism.	O

It	O
should	O
be	O
noted	O
that	O
the	O
authors	O
repeated	O
the	O
experiment	O
using	O
human	B
pluripotent	I
stem	I
cells	I
differentiated	O
into	O
neurons	O
and	O
also	O
showed	O
the	O
transynaptic	O
spread	O
of	O
mHTT	O
from	O
R6/2	O
host	O
tissue	O
to	O
human	O
grafts,	O
indicating	O
that	O
this	O
was	O
common	O
to	O
different	O
cell	O
types..	O

A	O
phase	O
1	O
clinical	O
trial	O
examining	O
the	O
efficacy	O
of	O
fetal-derived	B
neural	I
stem	I
cell	I
transplantation	O
in	O
multiple	O
sclerosis	O
patients	O
is	O
currently	O
on-going	O
(clinicaltrials.gov,	O
NCT03269071).	O

For	O
stem	B
cell	I
clinical	O
applications,	O
large	O
numbers	O
of	O
well-characterized	O
cells	O
will	O
be	O
needed,	O
leading	O
to	O
the	O
consideration	O
of	O
more	O
easily	O
accessible	O
cell	O
types.	O

Current	O
status	O
of	O
mesenchymal	B
stem	I
cell	I
therapy	O
for	O
immune/inflammatory	O
lung	O
disorders:	O
gleaning	O
insights	O
for	O
possible	O
use	O
in	O
COVID-19.	O

Mesenchymal	B
stem	I
cell	I
transplantation	O
in	O
polytrauma:	O
evaluation	O
of	O
bone	O
and	O
liver	O
healing	O
response	O
in	O
an	O
experimental	O
rat	O
model.	O

Efficacy	O
and	O
safety	O
of	O
autologous	B
bone	I
marrow-derived	I
stem	I
cell	I
transplantation	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus:	O
a	O
randomized	O
placebo-controlled	O
study.	O

Stem	B
cell	I
therapy:	O
a	O
novel	O
&	O
futuristic	O
treatment	O
modality	O
for	O
disaster	O
injuries.	O

Neural	B
stem	I
cell	I
transplantation	O
is	O
associated	O
with	O
inhibition	O
of	O
apoptosis,	O
Bcl-xL	O
upregulation,	O
and	O
recovery	O
of	O
neurological	O
function	O
in	O
a	O
rat	O
model	O
of	O
traumatic	O
brain	O
injury.	O

Neural	B
stem	I
cell	I
transplantation	O
promotes	O
functional	O
recovery	O
from	O
traumatic	O
brain	O
injury	O
via	O
brain	O
derived	O
neurotrophic	O
factor-mediated	O
neuroplasticity.	O

A	O
first-in-human,	O
phase	O
i	O
study	O
of	O
neural	B
stem	I
cell	I
transplantation	O
for	O
chronic	O
spinal	O
cord	O
injury.	O

The	O
role	O
of	O
mesenchymal	O
stem	O
cells	O
in	O
hematopoietic	B
stem	I
cell	I
transplantation:	O
prevention	O
and	O
treatment	O
of	O
graft-versus-host	O
disease.	O

Comparative	O
analysis	O
of	O
human	B
mesenchymal	I
stem	I
cells	I
from	O
bone	O
marrow	O
and	O
adipose	O
tissue	O
under	O
xeno-free	O
conditions	O
for	O
cell	O
therapy.	O

Safety	O
and	O
immunological	O
effects	O
of	O
mesenchymal	B
stem	I
cell	I
transplantation	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
and	O
amyotrophic	O
lateral	O
sclerosis.	O

Safety	O
and	O
effect	O
of	O
adipose	B
tissue-derived	I
stem	I
cell	I
implantation	O
in	O
patients	O
with	O
critical	O
limb	O
ischemia:	O
a	O
pilot	O
study.	O

A	O
phase	O
I	O
clinical	O
trial	O
of	O
the	O
treatment	O
of	O
Crohn's	O
fistula	O
by	O
adipose	B
mesenchymal	I
stem	I
cell	I
transplantation.	O

Long-term	O
insulin	O
independence	O
in	O
type	O
1	O
diabetes	O
mellitus	O
using	O
a	O
simplified	O
autologous	B
stem	I
cell	I
transplant.	O

Human	B
mesenchymal	I
stem	I
cell	I
secretome	O
from	O
bone	O
marrow	O
or	O
adipose-derived	O
tissue	O
sources	O
for	O
treatment	O
of	O
hypoxia-induced	O
pulmonary	O
epithelial	O
injury.	O

Hydra	O
is	O
a	O
unique	O
model	O
for	O
studying	O
the	O
mechanisms	O
underlying	O
stem	B
cell	I
biology.	O

The	O
activity	O
of	O
the	O
three	O
stem	B
cell	I
lineages	O
structuring	O
its	O
body	O
constantly	O
replenishes	O
mature	O
cells	O
lost	O
due	O
to	O
normal	O
tissue	O
turnover.	O

In	O
vertebrates,	O
one	O
of	O
many	O
genes	O
that	O
participate	O
in	O
regulating	O
stem	B
cell	I
homeostasis	O
is	O
the	O
protooncogene	O
c-myc,	O
which	O
has	O
been	O
recently	O
identified	O
also	O
in	O
Hydra,	O
and	O
found	O
expressed	O
in	O
the	O
interstitial	O
stem	O
cell	O
lineage.	O

In	O
the	O
present	O
paper,	O
by	O
developing	O
a	O
novel	O
strategy	O
of	O
RNA	O
interference-mediated	O
gene	O
silencing	O
(RNAi)	O
based	O
on	O
an	O
enhanced	O
uptake	O
of	O
small	O
interfering	O
RNAi	O
(siRNA),	O
we	O
provide	O
molecular	O
and	O
biological	O
evidence	O
for	O
an	O
unexpected	O
function	O
of	O
the	O
Hydra	O
myc	O
gene	O
(Hymyc1)	O
in	O
the	O
homeostasis	O
of	O
the	O
interstitial	B
stem	I
cell	I
lineage.	O

Our	O
results	O
show	O
the	O
involvement	O
of	O
Hymyc1	O
in	O
the	O
control	O
of	O
interstitial	B
stem	I
cell	I
dynamics,	O
provide	O
new	O
clues	O
to	O
decipher	O
the	O
molecular	O
control	O
of	O
the	O
cell	O
and	O
tissue	O
plasticity	O
in	O
Hydra,	O
and	O
also	O
provide	O
further	O
insights	O
into	O
the	O
complex	O
myc	O
network	O
in	O
higher	O
organisms.	O

Despite	O
its	O
simple	O
body	O
plan	O
and	O
structural	O
anatomy,	O
the	O
Cnidaria	O
Hydra,	O
a	O
dipoblastic	O
animal	O
at	O
the	O
base	O
of	O
metazoan	O
evolution,	O
is	O
an	O
excellent	O
model	O
system	O
to	O
investigate	O
the	O
mechanisms	O
controlling	O
stem	B
cell	I
proliferation	O
and	O
differentiation	O
and	O
the	O
balance	O
between	O
the	O
two	O
phenomena.	O

By	O
contrast,	O
the	O
functional	O
role	O
played	O
in	O
the	O
interstitial	B
stem	I
cell	I
lineage	O
in	O
Hydra	O
is	O
unknown.	O

By	O
contrast,	O
proliferation	O
of	O
single	O
and	O
pairs	O
of	O
interstitial	O
cells	O
(1	O
s+2	O
s)	O
was	O
enhanced	O
in	O
myc-RNAi	O
animals,	O
indicating	O
an	O
effect	O
of	O
myc	O
downregulation	O
on	O
the	O
stem	B
cell	I
cycling	O
activity	O
(Figure	O
4B).	O

B)	O
Cell	O
cycling	O
activity	O
of	O
1	O
s+2	O
s	O
stem	B
cells	I
were	O
obtained	O
in	O
control	O
and	O
treated	O
animals	O
(as	O
above,	O
10058-F4	O
90	O
5M)	O
by	O
continuous	O
incubation	O
with	O
BrdU,	O
followed	O
by	O
maceration	O
of	O
ten	O
animals	O
at	O
the	O
indicated	O
time	O
points	O
and	O
fluorescence	O
immunostaining.	O

Treatment	O
with	O
10058-F4	O
enhances	O
stem	B
cell	I
proliferation	O
and	O
determinates	O
the	O
accumulation	O
of	O
intermediate	O
and	O
terminal	O
differentiation	O
products.	O

As	O
Hymyc1	O
is	O
expressed	O
in	O
proliferating	B
stem	I
cells	I
of	O
the	O
interstitial	O
cell	O
lineage,	O
we	O
also	O
evaluated	O
its	O
expression	O
profile	O
during	O
regeneration,	O
a	O
complex	O
phenomena	O
involving	O
extensive	O
cell	O
reprogramming,	O
proliferation	O
and	O
differentiation	O
processes	O
to	O
rebuild	O
a	O
new	O
organism	O
from	O
an	O
amputated	O
moiety	O
[32]..	O

While	O
not	O
affecting	O
the	O
epithelial	O
cell	O
proliferation	O
rate,	O
Hymyc1	O
downregulation	O
induced	O
a	O
moderate	O
increase	O
in	O
the	O
stem	B
cell	I
proliferation	O
rate	O
and	O
density,	O
which	O
produced	O
dramatic	O
effects	O
on	O
the	O
related	O
cell	O
population	O
sizes.	O

1	O
s	O
and	O
2	O
s:	O
large	O
interstitial	B
stem	I
cells	I
(note	O
that	O
1	O
s	O
is	O
in	O
mitosis);	O
ecto:	O
ectodermal	O
epithelial	O
cell;	O
endo:	O
endodermal	O
epithelial	O
cell;	O
gc:	O
gland	O
cell.	O

The	O
interstitial	O
cell	O
lineage	O
of	O
hydra:	O
a	O
stem	B
cell	I
system	O
that	O
arose	O
early	O
in	O
evolution.	O

Pioneer	O
factors	O
govern	O
super-enhancer	O
dynamics	O
in	O
stem	B
cell	I
plasticity	O
and	O
lineage	O
choice.	O

Apparently,	O
stem	B
cell	I
regulatory	O
pathways	O
are	O
the	O
same	O
as	O
cancer	O
stem	O
cell	O
regulatory	O
pathways	O
(Dirks	O
2009;	O
Shimono	O
et	O
al.	O

The	O
balance	O
between	O
these	O
alternative	O
pathways	O
apparently	O
depends	O
on	O
association	O
of	O
the	O
stem	B
cell	I
with	O
the	O
niche	O
(Clarke	O
and	O
Fuller	O
2006;	O
Li	O
and	O
Neaves	O
2006;	O
Walkley	O
et	O
al.	O

On	O
the	O
other	O
hand,	O
recent	O
data	O
obtained	O
on	O
the	O
model	O
of	O
immortalized	O
human	O
mammary	O
epithelial	O
cells	O
(both	O
normal	O
and	O
transformed),	O
have	O
demonstrated	O
an	O
unexpected	O
linkage	O
between	O
the	O
epithelial	O
mesenchymal	O
transition,	O
a	O
key	O
developmental	O
program,	O
and	O
acquisition	O
of	O
stem	B
cell	I
properties	O
(Mani	O
et	O
al.	O

An	O
important	O
example	O
is	O
the	O
coupling	O
of	O
metastases	O
with	O
downregulation	O
of	O
the	O
miR-200	O
family,	O
which	O
interferes,	O
as	O
was	O
mentioned	O
above,	O
with	O
acquisition	O
by	O
cells	O
of	O
stem	B
cell	I
properties	O
(Olson	O
et	O
al.	O

Transitions	O
between	O
epithelial	O
and	O
mesenchymal	O
states:	O
acquisition	O
of	O
malignant	O
and	O
stem	B
cell	I
traits.	O

A	O
luminal	B
epithelial	I
stem	I
cell	I
that	O
is	O
a	O
cell	O
of	O
origin	O
for	O
prostate	O
cancer.	O

We	O
demonstrate	O
that	O
adult	B
human	I
muscle	I
stem	I
cells	I
undergo	O
apicobasal	O
and	O
planar	O
cell	O
divisions	O
and	O
express	O
polarized	O
dystrophin	O
and	O
EGFR.	O

Here,	O
we	O
report	O
that	O
by	O
utilizing	O
primary	O
human	O
myofibers,	O
we	O
can	O
model	O
human	O
muscle	B
stem	I
cell	I
dynamics	O
in	O
a	O
chemically,	O
physically,	O
and	O
cellularly	O
relevant	O
context.	O

In	O
rodents,	O
this	O
can	O
be	O
achieved	O
by	O
experimental	O
models	O
of	O
injury,	O
muscle	O
digestion	O
for	O
stem	B
cell	I
isolation	O
[52,	O
53]	O
or	O
in	O
the	O
case	O
of	O
myofiber	O
preparation,	O
digestion	O
with	O
collagenase	O
and	O
exposure	O
to	O
growth	O
factors	O
in	O
cell	O
culture	O
[21].	O

Evaluating	O
human	B
stem	I
cell	I
dynamics	O
in	O
a	O
relevant	O
context	O
is	O
critical	O
to	O
model	O
biological	O
phenomena	O
and	O
generalize	O
results	O
to	O
benefit	O
human	O
health.	O

from	O
the	O
US	O
National	O
Institutes	O
for	O
Health	O
(R01AR044031),	O
the	O
Canadian	O
Institutes	O
for	O
Health	O
Research	O
(FDN-148387),	O
E-Rare-2:	O
Canadian	O
Institutes	O
of	O
Health	O
Research/Muscular	O
Dystrophy	O
Canada,	O
and	O
the	O
Stem	B
Cell	I
Network..	O

Increased	O
Wnt	O
Signaling	O
During	O
Aging	O
Alters	O
Muscle	B
Stem	I
Cell	I
Fate	O
and	O
Increases	O
Fibrosis.	O

Intrinsic	O
changes	O
and	O
extrinsic	O
influences	O
of	O
myogenic	B
stem	I
cell	I
function	O
during	O
aging.	O

P38	O
MAPK	O
signaling	O
underlies	O
a	O
cell	O
autonomous	O
loss	O
of	O
stem	B
cell	I
self-renewal	O
in	O
aged	O
skeletal	O
muscle.	O

Rejuvenation	O
of	O
the	O
aged	O
muscle	B
stem	I
cell	I
population	O
restores	O
strength	O
to	O
injured	O
aged	O
muscles.	O

Isolation	O
of	O
muscle	B
stem	I
cells	I
by	O
fluorescence	O
activated	O
cell	O
sorting	O
cytometry.	O

Stem	B
cell	I
function,	O
self-renewal,	O
and	O
behavioral	O
heterogeneity	O
of	O
cells	O
from	O
the	O
adult	O
muscle	O
satellite	O
cell	O
niche.	O

M.,	O
Wang	O
H.,	O
The	O
histone	O
H2A	O
deubiquitinase	O
Usp16	O
regulates	O
embryonic	B
stem	I
cell	I
gene	O
expression	O
and	O
lineage	O
commitment.	O

Shp2-deficient	O
blastocysts	O
exhibited	O
inner	O
cell	O
mass	O
cell	O
death	O
and	O
no	O
trophoblast	B
stem	I
cells	I
were	O
developed	O
in	O
these	O
embryos	O
(Yang	O
et	O
al.,	O
2006).	O

To	O
further	O
understand	O
the	O
mechanism	O
by	O
which	O
Ptpn11E76K/+	O
mutation	O
induces	O
MPD,	O
a	O
clonal	B
stem	I
cell	I
disorder,	O
we	O
assessed	O
the	O
effects	O
of	O
Ptpn11E76K/+	O
mutation	O
on	O
HSCs.	O

3	O
B),	O
similar	O
to	O
those	O
seen	O
in	O
PTEN-deficient	O
mice	O
(Yilmaz	O
et	O
al.,	O
2006;	O
Zhang	O
et	O
al.,	O
2006),	O
reflecting	O
extramedullary	O
hematopoiesis	O
in	O
the	O
mutant	O
mice	O
and	O
potential	O
microenvironmental	O
impact	O
on	O
mutant	B
stem	I
cell	I
homeostasis.	O

The	O
decrease	O
in	O
the	O
stem	B
cell	I
pool	O
in	O
the	O
BM	O
of	O
mutant	O
mice	O
is	O
not	O
caused	O
by	O
any	O
defects	O
in	O
cell	O
survival.	O

More	O
likely,	O
aberrant	O
activation	O
of	O
mutant	O
stem	O
cells	O
eventually	O
led	O
to	O
the	O
depletion	O
of	O
the	O
stem	B
cell	I
population	O
caused	O
by	O
exhaustion	O
of	O
the	O
reserve	O
capacity.	O

Assessment	O
of	O
cell	O
signaling	O
activities	O
confirmed	O
that	O
in	O
response	O
to	O
stem	B
cell	I
factor	O
(SCF)	O
stimulation,	O
activation	O
of	O
ERK	O
(Fig.	O

Of	O
these	O
B220+	O
cells,	O
70,80%	O
cells	O
were	O
also	O
positive	O
for	O
an	O
early	O
B	O
lineage	O
marker	O
CD43	O
and	O
the	O
stem	B
cell	I
marker	O
Sca-1,	O
but	O
negative	O
for	O
the	O
mature	O
B	O
cell	O
marker	O
IgM,	O
indicating	O
a	O
B	O
lineage	O
maturation	O
arrest	O
at	O
around	O
the	O
pro	O
B	O
stage.	O

To	O
investigate	O
the	O
mechanisms	O
underlying	O
the	O
observed	O
effects	O
of	O
L3MBTL1	O
on	O
stem	B
cell	I
biology,	O
we	O
utilized	O
an	O
unbiased,	O
genome-wide	O
approach	O
to	O
analyze	O
the	O
gene	O
expression	O
profile	O
(GEP)	O
of	O
two	O
independent	O
clones	O
of	O
undifferentiated	O
L3MBTL1-KD	O
iPSCs.	O

Stem	B
cell	I
colonies	O
were	O
dissociated	O
into	O
single	O
cells	O
using	O
accutase	O
and	O
cultured	O
in	O
suspension,	O
without	O
any	O
differentiation	O
factors,	O
for	O
7	O
to	O
8	O
days	O
until	O
they	O
formed	O
three-dimensional	O
multicellular	O
aggregates.	O

From	O
stem	B
cell	I
to	O
red	O
cell:	O
regulation	O
of	O
erythropoiesis	O
at	O
multiple	O
levels	O
by	O
multiple	O
proteins,	O
RNAs,	O
and	O
chromatin	O
modifications.	O

The	O
polycomb	O
group	O
protein	O
Suz12	O
is	O
required	O
for	O
embryonic	B
stem	I
cell	I
differentiation.	O

Endothelial	O
and	O
hematopoietic	O
cell	O
fate	O
of	O
human	B
embryonic	I
stem	I
cells	I
originates	O
from	O
primitive	O
endothelium	O
with	O
hemangioblastic	O
properties.	O

Articles	O
from	O
Stem	B
Cell	I
Reports	O
are	O
provided	O
here	O
courtesy	O
of	O
Elsevier.	O

The	O
process	O
is	O
characterized	O
in	O
cells	O
by	O
telomere	O
erosion,	O
genomic	O
instability,	O
mitochondrial	O
dysfunction	O
and	O
stem	B
cell	I
exhaustion	O
[1].	O

Current	O
knowledge	O
about	O
biological	O
functions	O
of	O
CTCF	O
sites	O
has	O
been	O
obtained	O
mainly	O
from	O
studies	O
on	O
cell	O
lines	O
and	O
embryonic	B
stem	I
cells	I
(ESCs)7,10,15,16,18,23,24,25,26.	O

The	O
murine	O
clusters	O
did	O
not	O
express	O
markers	O
of	O
hormone	O
producing	O
cell	O
differentiation	O
and	O
a	O
proportion	O
expressed	O
the	O
pituitary	B
stem	I
cell	I
marker	O
SOX2	O
15.	O

The	O
SOX2	O
cell	O
population	O
was	O
confirmed	O
to	O
have	O
both	O
self	O
renewal	O
and	O
differentiation	O
capacity	O
into	O
all	O
lineages	O
of	O
the	O
anterior	O
pituitary,	O
thus	O
demonstrating	O
that	O
stem	B
cells	I
are	O
contained	O
within	O
the	O
Sox2	O
expressing	O
cell	O
compartment	O
2.	O

Holsken	O
A,	O
Stache	O
C,	O
Schlaffer	O
SM,	O
Flitsch	O
J,	O
Fahlbusch	O
R,	O
Buchfelder	O
M,	O
Buslei	O
R	O
(2014)	O
Adamantinomatous	O
craniopharyngiomas	O
express	O
tumor	O
stem	O
cell	O
markers	O
in	O
cells	O
with	O
activated	O
Wnt	O
signaling:	O
further	O
evidence	O
for	O
the	O
existence	O
of	O
a	O
tumor	B
stem	I
cell	I
niche?	O
Pituitary	O
17:546:556.	O

Reduced	O
immunomodulation	O
potential	O
of	O
bone	B
marrow-derived	I
mesenchymal	I
stem	I
cells	I
induced	O
CCR4+CCR6+	O
Th/Treg	O
cell	O
subset	O
imbalance	O
in	O
ankylosing	O
spondylitis.	O

Alternatively,	O
redundant	O
signaling	O
through	O
noncanonical	O
Wnt	O
or	O
hedgehog	O
signaling	O
pathways	O
may	O
compensate	O
for	O
decreased	O
NOTCH	O
signaling	O
in	O
the	O
stem	B
cell	I
compartment	O
(Fleming	O
et	O
al.,	O
2008;	O
Gao	O
et	O
al.,	O
2009;	O
Kokolus	O
and	O
Nemeth,	O
2010)..	O

Autophagy	O
is	O
critical	O
for	O
the	O
regulation	O
and	O
coordination	O
of	O
cellular	O
homeostasis,	O
epithelial	O
barrier	O
integrity,	O
stem	B
cell	I
maintenance	O
and	O
differentiation,	O
lifespan,	O
and	O
immunity	O
[17]	O
[21].	O

Vessoni	O
AT,	O
Muotri	O
AR,	O
Okamoto	O
OK	O
(2012)	O
Autophagy	O
in	O
stem	B
cell	I
maintenance	O
and	O
differentiation.	O

Widespread	O
influence	O
of	O
miRNAs	O
is	O
also	O
observed	O
in	O
different	O
physiological	O
responses,	O
like	O
cardiovascular	O
development	O
[5],	O
stem	B
cell	I
differentiation	O
[6],	O
immune	O
response	O
[7],	O
insulin	O
secretion	O
[8]	O
and	O
anti-viral	O
defense	O
[9].	O

Furthermore,	O
overexpression	O
of	O
miR-7,	O
a	O
miRNA	O
involved	O
in	O
the	O
repression	O
of	O
the	O
pro-oncogenic	O
Akt	O
pathway,	O
reduced	O
the	O
proliferation	O
and	O
invasion	O
in	O
different	O
GBM	O
cell	O
lines	O
and	O
in	O
one	O
GBM	B
stem	I
cell	I
line	O
[128],	O
while	O
expression	O
of	O
miR-128	O
inhibited	O
the	O
proliferation	O
of	O
glioma	O
cells	O
by	O
decreasing	O
the	O
levels	O
of	O
E2F3a	O
[129].	O

Some	O
of	O
them	O
can	O
participate	O
in	O
cell	O
signal	O
transduction	O
and	O
epigenetic	O
regulation,	O
some	O
can	O
negatively	O
regulate	O
cell	O
cycle,	O
some	O
can	O
lead	O
to	O
DNA	O
mismatch	O
repair,	O
some	O
can	O
regulate	O
development	O
and	O
stem	B
cell	I
proliferation,	O
and	O
some	O
can	O
be	O
used	O
as	O
negative	O
transcriptional	O
factors.	O

Recently,	O
it	O
has	O
been	O
suggested	O
that	O
SOX2	O
promotes	O
tumor	O
initiation	O
and	O
controls	O
cancer	B
stem	I
cell	I
properties	O
in	O
squamous	O
cell	O
carcinoma	O
(SCC)	O
of	O
the	O
skin	O
tumors	O
(Boumahdi	O
et	O
al.,	O
2014).	O

By	O
acting	O
as	O
a	O
transcriptional	O
coregulator,	O
RMST	O
helps	O
SOX2	O
to	O
bind	O
to	O
regulatory	O
regions	O
of	O
that	O
of	O
target	O
genes	O
which	O
have	O
a	O
role	O
in	O
the	O
regulation	O
of	O
neural	B
stem	I
cell	I
fate	O
(Ng	O
et	O
al.,	O
2013).	O

Furthermore,	O
the	O
expression	O
patterns	O
of	O
its	O
variants	O
and	O
their	O
emerging	O
roles	O
in	O
stem	B
cell	I
biology	O
and	O
tumorigenesis	O
is	O
discussed.	O

This	O
work	O
was	O
supported	O
by	O
a	O
research	O
grant	O
from	O
the	O
Iranian	O
Council	O
of	O
Stem	B
Cell	I
Technology,	O
and	O
Deputy	O
of	O
Research	O
and	O
Technology	O
of	O
Golestan	O
University	O
of	O
Medical	O
Sciences..	O

The	O
stem	B
cell	I
factor	O
SOX2	O
regulates	O
the	O
tumorigenic	O
potential	O
in	O
human	O
gastric	O
cancer	O
cells.	O

Rajasimha	O
HK,	O
Chinnery	O
PF,	O
Samuels	O
DC	O
(2008)	O
Selection	O
against	O
pathogenic	O
mtDNA	O
mutations	O
in	O
a	O
stem	B
cell	I
population	O
leads	O
to	O
the	O
loss	O
of	O
the	O
3243A–>G	O
mutation	O
in	O
blood.	O

Stem	B
cell	I
regulatory	O
gene	O
expression	O
in	O
human	O
adult	O
dental	O
pulp	O
and	O
periodontal	O
ligament	O
cells	O
undergoing	O
odontogenic/osteogenic	O
differentiation.	O

This	O
is	O
in	O
fact	O
true	O
in	O
the	O
case	O
of	O
all	O
stem	B
cell	I
type	O
(reviewed	O
by	O
[50,	O
51]).	O

Although	O
high	O
in	O
vitro	O
proliferation	O
capacity	O
is	O
often	O
regarded	O
as	O
a	O
cancer	B
stem	I
cell	I
property	O
(reviewed	O
by	O
[48,	O
49,	O
56]),	O
the	O
link	O
between	O
this	O
property	O
and	O
the	O
capacity	O
to	O
form	O
tumors	O
is	O
not	O
apparent.	O

It	O
is	O
of	O
great	O
importance	O
that	O
a	O
distinction	O
between	O
stem	B
cell	I
niches	O
in	O
particular,	O
and	O
microenvironments	O
in	O
general	O
(Box-2)	O
be	O
made.	O

Some	O
of	O
these	O
are	O
designed	O
to	O
support	O
differentiation,	O
others	O
promote	O
release	O
from	O
the	O
bone	O
marrow	O
compartment	O
and	O
only	O
the	O
highly	O
specialized	O
and	O
rare	O
ones	O
are	O
designed	O
to	O
support	O
stem	B
cell	I
renewal.	O

The	O
function	O
of	O
the	O
stem	O
cell	O
niche	O
is	O
to	O
maintain	O
the	O
stem	B
cell	I
phenotype.	O

The	O
release	O
of	O
the	O
stem	B
cell	I
from	O
the	O
niche	O
will	O
result	O
in	O
differentiation.	O

Clearly,	O
stem	B
cell	I
niches	O
are	O
engaged	O
in	O
antagonism	O
with	O
differentiation	O
rather	O
than	O
with	O
promotion	O
of	O
this	O
process	O
[58–60].	O

Differentiation	O
inducing	O
domains	O
should	O
therefore	O
not	O
be	O
confused	O
with	O
stem	B
cell	I
maintenance	O
niches.	O

The	O
general	O
structure	O
of	O
the	O
HSC	O
niche:	O
Self-renewal	O
divisions	O
occurs	O
as	O
long	O
as	O
the	O
stem	B
cell	I
remains	O
within	O
the	O
niche	O
a.	O

It	O
was	O
later	O
found	O
that	O
HSCs	O
are	O
specifically	O
localized	O
to	O
the	O
region	O
close	O
to	O
the	O
endosteal	O
bone	O
that	O
was	O
termed	O
the	O
stem	B
cell	I
niche	O
[62,	O
63]..	O

A	O
long	O
list	O
of	O
molecules	O
is	O
supposed	O
to	O
contribute,	O
in	O
varying	O
degrees,	O
to	O
the	O
stem	B
cell	I
maintaining	O
capacity	O
of	O
the	O
HSC	O
niche.	O

Notably,	O
several	O
of	O
the	O
factors	O
that	O
emanate	O
from	O
the	O
stem	B
cell	I
niche,	O
listed	O
above	O
as	O
regulators	O
of	O
HSCs,	O
operate	O
in	O
a	O
restrictive	O
manner	O
and	O
do	O
not	O
promote	O
growth.	O

The	O
latter	O
family	O
in	O
addition	O
to	O
other	O
molecules,	O
were	O
all	O
proposed	O
to	O
take	O
part	O
in	O
the	O
formation	O
of	O
bone	B
marrow	I
stem	I
cell	I
niches..	O

Detachment	O
from	O
the	O
niche	O
releases	O
the	O
stem	B
cell	I
from	O
the	O
effect	O
of	O
the	O
antagonist	O
b.	O

The	O
role	O
of	O
differentiation	O
antagonists,	O
in	O
the	O
creation	O
of	O
stem	B
cell	I
niches,	O
has	O
now	O
been	O
well	O
established	O
through	O
studies	O
of	O
Drosophila	O
Melanogaster	O
[60].	O

This	O
is	O
completely	O
different	O
from	O
mammalian	O
HSCs,	O
and	O
in	O
fact	O
differs	O
from	O
all	O
other	O
mammalian	B
stem	I
cell	I
systems,	O
which	O
are	O
hard	O
to	O
detect	O
and	O
do	O
not	O
have	O
specific	O
markers	O
that	O
identify	O
them	O
unequivocally.	O

First	O
and	O
foremost,	O
the	O
direct	O
contact	O
of	O
the	O
stem	B
cell	I
with	O
the	O
niche	O
cell	O
is	O
obligatory.	O

The	O
earlier	O
studies	O
on	O
hemopoietic	O
cells	O
and	O
the	O
later	O
on	O
gonadal	O
cells	O
of	O
the	O
fruit	O
fly,	O
taken	O
together,	O
strongly	O
suggest	O
that	O
the	O
stem	B
cell	I
niche	O
provides	O
antagonism	O
with	O
differentiation.	O

The	O
reprogramming	O
of	O
skin	O
fibroblasts,	O
liver	O
and	O
gut	O
cells	O
and	O
B	O
lymphocytes,	O
requires	O
the	O
forced	O
expression	O
of	O
3-4	O
genes	O
[90,93]	O
whereas	O
the	O
de-differentiation	O
of	O
neuronal	B
stem	I
cell	I
into	O
induced	O
pluripotent	O
cells	O
requires	O
the	O
overexpression	O
of	O
oct-4	O
and	O
Klf4	O
only	O
[94].	O

De-differentiation	O
in	O
Drosophila	O
gonads:	O
The	O
gonadal	B
stem	I
cell	I
that	O
remain	O
attached	O
to	O
their	O
niche	O
following	O
division,	O
remain	O
undifferentiated	O
(I)	O
whereas	O
they	O
differentiate	O
upon	O
release	O
from	O
the	O
niche	O
(I).	O

The	O
discussion	O
above	O
highlighted	O
the	O
major	O
features	O
of	O
the	O
HSC	O
niche	O
that	O
maintains	O
the	O
stem	B
cell	I
phenotype.	O

The	O
author	O
is	O
indebted	O
to	O
the	O
Helen	O
and	O
Martin	O
Kimmel	O
Institute	O
for	O
Stem	B
Cell	I
Research	O
and	O
the	O
M.D.	O

Blasts	O
from	O
the	O
past:	O
new	O
lessons	O
in	O
stem	B
cell	I
biology	O
from	O
chronic	O
myelogenous	O
leukemia.	O

Support	O
of	O
human	O
hematopoiesis	O
in	O
long-term	O
bone	O
marrow	O
cultures	O
by	O
murine	O
stromal	O
cells	O
selectively	O
expressing	O
the	O
membrane-bound	O
and	O
secreted	O
forms	O
of	O
the	O
human	O
homolog	O
of	O
the	O
steel	O
gene	O
product,	O
stem	B
cell	I
factor.	O

HSCs	O
also	O
make	O
use	O
of	O
the	O
ISR	O
and	O
ATF4	O
to	O
protect	O
against	O
homeostatic	O
cellular	O
stress	O
and	O
to	O
preserve	O
the	O
integrity	O
of	O
the	O
stem	B
cell	I
pool	O
(25).	O

Activity	O
of	O
a	O
heptad	O
of	O
transcription	O
factors	O
is	O
associated	O
with	O
stem	B
cell	I
programs	O
and	O
clinical	O
outcome	O
in	O
acute	O
myeloid	O
leukemia.	O

A	O
leukemic	B
stem	I
cell	I
with	O
intrinsic	O
drug	O
efflux	O
capacity	O
in	O
acute	O
myeloid	O
leukemia.	O

High	O
stem	B
cell	I
frequency	O
in	O
acute	O
myeloid	O
leukemia	O
at	O
diagnosis	O
predicts	O
high	O
minimal	O
residual	O
disease	O
and	O
poor	O
survival.	O

Secreted	O
phospholipases	O
A2	O
are	O
intestinal	B
stem	I
cell	I
niche	O
factors	O
with	O
distinct	O
roles	O
in	O
homeostasis,	O
inflammation	O
and	O
cancer.	O

overexpression	O
of	O
secretory	O
phospholipase	O
A2-IIa	O
supports	O
cancer	B
stem	I
cell	I
phenotype	O
via	O
HER/ERBB-elicited	O
signaling	O
in	O
lung	O
and	O
prostate	O
cancer	O
cells.	O

In	O
the	O
next	O
series	O
of	O
experiments,	O
we	O
derived	O
embryonic	B
stem	I
cell	I
clones	O
expressing	O
lamin	O
A/C	O
short	O
hairpin	O
RNA	O
and	O
examined	O
their	O
differentiation	O
potential.	O

We	O
have	O
observed	O
significant	O
effects	O
on	O
embryonic	B
stem	I
cell	I
differentiation	O
to	O
visceral	O
endoderm,	O
neuronal	O
and	O
myogenic	O
lineages	O
upon	O
depletion	O
of	O
lamin	O
A/C.	O

During	O
early	O
differentiation,	O
ES	O
cells	O
give	O
rise	O
to	O
a	O
number	O
of	O
stem	O
cell	O
lineages,	O
some	O
of	O
which	O
contribute	O
to	O
adult	B
stem	I
cells	I
later	O
in	O
life.	O

Defective	O
stem	O
cell	O
differentiation	O
and	O
proliferation	O
early	O
in	O
development	O
is	O
likely	O
to	O
be	O
lethal,	O
whereas	O
defects	O
in	O
adult	B
stem	I
cell	I
proliferation	O
and	O
differentiation	O
may	O
lead	O
to	O
tissue	O
degenerative	O
diseases	O
such	O
as	O
the	O
laminopathies	O
[65],	O
[66].	O

Solter	O
D	O
(2006)	O
From	O
teratocarcinomas	O
to	O
embryonic	O
stem	O
cells	O
and	O
beyond:	O
a	O
history	O
of	O
embryonic	B
stem	I
cell	I
research.	O

Constantinescu	O
D,	O
Gray	O
HL,	O
Sammak	O
PJ,	O
Schatten	O
GP,	O
Csoka	O
AB	O
(2006)	O
Lamin	O
A/C	O
expression	O
is	O
a	O
marker	O
of	O
mouse	B
and	I
human	I
embryonic	I
stem	I
cell	I
differentiation.	O

(1988)	O
Inhibition	O
of	O
pluripotential	B
embryonic	I
stem	I
cell	I
differentiation	O
by	O
purified	O
polypeptides.	O

Doetschman	O
TC,	O
Eistetter	O
H,	O
Katz	O
M,	O
Schmidt	O
W,	O
Kemler	O
R	O
(1985)	O
The	O
in	O
vitro	O
development	O
of	O
blastocyst-derived	B
embryonic	I
stem	I
cell	I
lines:	O
formation	O
of	O
visceral	O
yolk	O
sac,	O
blood	O
islands	O
and	O
myocardium.	O

Nagy	O
A,	O
Rossant	O
J,	O
Nagy	O
R,	O
Abramow-Newerly	O
W,	O
Roder	O
JC	O
(1993)	O
Derivation	O
of	O
completely	O
cell	O
culture-derived	O
mice	O
from	O
early-passage	O
embryonic	B
stem	I
cells.	I
Metzger	O
JM,	O
Lin	O
WI,	O
Samuelson	O
LC	O
(1996)	O
Vital	O
staining	O
of	O
cardiac	O
myocytes	O
during	O
embryonic	O
stem	O
cell	O
cardiogenesis	O
in	O
vitro	O
.	O

Characterization	O
of	O
novel	B
stem	I
cell	I
factor	O
responsive	O
human	O
mast	O
cell	O
lines	O
LAD	O
1	O
and	O
2	O
established	O
from	O
a	O
patient	O
with	O
mast	O
cell	O
sarcoma/leukemia;	O
activation	O
following	O
aggregation	O
of	O
FcRI	O
or	O
FcRI.	O

For	O
example,	O
high	O
level	O
of	O
miR-17-92	O
cluster	O
was	O
investigated	O
to	O
have	O
the	O
ability	O
of	O
increasing	O
the	O
number	O
of	O
leukemia	B
stem	I
cells	I
by	O
enhancing	O
cell	O
proliferation	O
and	O
inhibiting	O
cell	O
differentiation,	O
while	O
low	O
level	O
of	O
miR-17-92	O
cluster	O
had	O
the	O
opposite	O
effect	O
[23].	O

The	O
stimulatory	O
process	O
implicates	O
the	O
specific	O
activation	O
of	O
the	O
hair	O
follicle	O
stem	O
cell	O
niche,	O
encompassing	O
the	O
induction	O
of	O
stem	B
cell	I
differentiation	O
markers	O
(Ck15),	O
overall	O
cell	O
proliferation	O
and	O
sustained	O
growth	O
of	O
the	O
tissue	O
associated	O
with	O
expression	O
of	O
gen	O
targets	O
(Ccnd1)	O
concomitant	O
with	O
the	O
inhibition	O
of	O
Wnt	O
signaling	O
antagonists	O
and	O
repressors	O
(Dkk1,	O
Gsk3)	O
of	O
Wnt	O
signaling.	O

As	O
a	O
whole,	O
this	O
observation	O
indicates	O
that,	O
once	O
activated,	O
ROS	O
signalling	O
is	O
an	O
intrinsic	O
mechanism	O
regulating	O
the	O
hair	B
follicle	I
stem	I
cell	I
niche	O
independently	O
of	O
any	O
external	O
signal..	O

Interestingly,	O
a	O
transient	O
and	O
differential	O
ROS	O
production	O
has	O
been	O
associated	O
also	O
with	O
the	O
deregulation	O
of	O
intestinal	B
stem	I
cell	I
function	O
during	O
colorectal	O
cancer	O
initiation13..	O

More	O
recently,	O
we	O
have	O
provided	O
a	O
straightforward	O
demonstration	O
of	O
the	O
physiological	O
roles	O
of	O
ROS	O
in	O
vivo	O
in	O
the	O
regulation	O
of	O
skin	O
homeostasis	O
and	O
regeneration	O
and	O
of	O
the	O
hair	B
follicle	I
stem	I
cell	I
niche	O
activity15,16.	O

Using	O
Protoporphyrin	O
IX	O
as	O
an	O
endogenous	O
photosensitizer	O
and	O
subsequent	O
irradiation	O
of	O
the	O
tissue	O
with	O
red	O
light	O
to	O
promote	O
a	O
local,	O
spatially	O
restricted	O
photodynamic	O
effect,	O
we	O
have	O
reported	O
that	O
a	O
transient	O
activation	O
of	O
non-lethal	O
endogenous	O
ROS	O
levels	O
activates	O
the	O
hair	B
follicle	I
stem	I
cell	I
niche,	O
promoting	O
wound	O
healing	O
and	O
hair	O
growth	O
in	O
a	O
ROS-dependent	O
process.	O

In	O
a	O
step	O
forward,	O
our	O
aim	O
here,	O
using	O
human	O
hair	O
follicles	O
growth	O
ex	O
vivo	O
as	O
experimental	O
model,	O
was	O
to	O
provide	O
a	O
concise	O
report	O
supporting	O
the	O
notion	O
that	O
the	O
ROS-dependent	O
activation	O
of	O
the	O
hair	B
follicle	I
stem	I
cell	I
niche	O
is	O
an	O
intrinsic	O
event	O
that	O
does	O
not	O
depend	O
on	O
signals	O
from	O
the	O
surrounding	O
tissue..	O

The	O
proliferation	O
and	O
mobilization	O
of	O
skin	B
stem	I
cell	I
progenitors	O
was	O
monitored	O
by	O
the	O
expression	O
of	O
the	O
specific	O
CK15	O
marker	O
in	O
the	O
tissue	O
(Fig.	O

3D),	O
showing	O
that	O
an	O
activation	O
of	O
proliferation	O
and	O
differentiation	O
programs	O
occurred	O
in	O
the	O
hair	B
follicle	I
stem	I
cell	I
niche	O
in	O
response	O
to	O
ROS	O
signaling.	O

For	O
the	O
most	O
part,	O
these	O
external	O
signals	O
regulate	O
the	O
activity	O
of	O
the	O
hair	B
follicle	I
stem	I
cell	I
niche.	O

In	O
this	O
sense,	O
the	O
results	O
shown	O
here	O
strongly	O
support	O
an	O
active	O
role	O
for	O
ROS	O
in	O
the	O
functional	O
regulation	O
of	O
stem	B
cell	I
niches,	O
in	O
agreement	O
with	O
previous	O
reports.	O

ROS	O
production	O
and	O
NF-B	O
activation	O
triggered	O
by	O
RAC1	O
facilitate	O
WNT-driven	O
intestinal	B
stem	I
cell	I
proliferation	O
and	O
colorectal	O
cancer	O
initiation.	O

Photoactivation	O
of	O
ROS	O
Production	O
in	O
Situ	O
Transiently	O
Activates	O
Cell	O
Proliferation	O
in	O
Mouse	O
Skin	O
and	O
in	O
the	O
hair	B
Follicle	I
Stem	I
Cell	I
Niche	O
Promoting	O
Hair	O
Growth	O
and	O
Wound	O
Healing.	O

Many	O
studies	O
that	O
investigate	O
the	O
potential	O
use	O
of	O
stem	B
cell	I
or	O
gene	O
therapy	O
for	O
DMD	O
use	O
hind	O
limb	O
muscles,	O
such	O
as	O
the	O
gastrocnemius	O
muscle	O
(GM),	O
for	O
sites	O
of	O
injection	O
[27].	O

Newly	O
generated	O
NPCs	O
were	O
immunopositive	O
for	O
the	O
neural	B
stem	I
cell	I
markers	O
Nestin,	O
SOX2,	O
and	O
Musashi-1,	O
and	O
the	O
neuroepithelial	O
marker	O
PAX6	O
(Figure	O
1B),	O
and	O
were	O
maintained	O
in	O
proliferative	O
state	O
under	O
defined	O
growth	O
media	O
with	O
EGF	O
(epidermal	O
growth	O
factor)	O
and	O
FGF	O
(fibroblast	O
growth	O
factor	O
)	O
(Figure	O
1A)	O
(Nemati	O
et	O
al.,	O
2011,	O
Sheridan	O
et	O
al.,	O
2011,	O
Yuan	O
et	O
al.,	O
2011).	O

Epigenetic	O
characterization	O
of	O
the	O
FMR1	O
gene	O
and	O
aberrant	O
neurodevelopment	O
in	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
models	O
of	O
fragile	O
X	O
syndrome.	O

Articles	O
from	O
Stem	B
Cell	I
Reports	O
are	O
provided	O
here	O
courtesy	O
of	O
Elsevier.	O

Previously,	O
we	O
[8],	O
[9]	O
and	O
others	O
[10],	O
[11]	O
demonstrated	O
that	O
adult	O
bone	O
marrow-derived,	O
hematopoietic	B
stem	I
cells	I
(HSCs)	O
give	O
rise	O
to	O
functional	O
vascular	O
endothelial	O
cells	O
in	O
the	O
mouse	O
at	O
the	O
clonal	O
level	O
through	O
differentiation	O
in	O
the	O
absence	O
of	O
cell	O
fusion.	O

Influence	O
of	O
polymorphism	O
within	O
the	O
heme	O
oxygenase-I	O
promoter	O
on	O
overall	O
survival	O
and	O
transplantation-related	O
mortality	O
after	O
allogeneic	B
stem	I
cell	I
transplantation.	O

Muscle	B
stem	I
cell	I
behavior	O
is	O
modified	O
by	O
microRNA-27	O
regulation	O
of	O
Pax3	O
expression.	O

Embryonic	B
stem	I
cell	I
aggregation	O
was	O
performed	O
with	O
CD1	O
morula	O
and	O
the	O
resulting	O
chimeric	O
mice	O
were	O
screened	O
for	O
germline	O
transmission	O
of	O
the	O
targeting	O
vector.	O

hMSCs-Ad	O
are	O
a	O
well-characterized	O
type	O
of	O
adult	B
stem	I
cell	I
that	O
may	O
differentiate	O
into	O
adipocytes,	O
osteoblasts	O
and	O
chondrocytes	O
under	O
various	O
conditions	O
(34).	O

These	O
studies	O
are	O
very	O
important	O
advances	O
in	O
the	O
treatment	O
of	O
leukemia	O
patients	O
as	O
ex	O
vivo	O
expansion	O
of	O
HSCs	O
prior	O
to	O
stem	B
cell	I
transplantation	O
may	O
improve	O
reconstitution	O
of	O
hematopoiesis	O
and	O
immune	O
functions	O
in	O
patients..	O

The	O
movement	O
of	O
engrafted	O
CD133+	O
U87	O
cells	O
from	O
the	O
injection	O
point	O
showed	O
that	O
GBM	O
cells	O
with	O
stem	B
cell	I
properties	O
were	O
more	O
invasive	O
than	O
were	O
the	O
cells	O
that	O
lacked	O
these	O
properties..	O

Prostaglandin	O
E2	O
enhances	O
human	B
cord	I
blood	I
stem	I
cell	I
xenotransplants	O
and	O
shows	O
long-term	O
safety	O
in	O
preclinical	O
nonhuman	O
primate	O
transplant	O
models.	O

A	O
novel	O
zebrafish	O
xenotransplantation	O
model	O
for	O
study	O
of	O
glioma	B
stem	I
cell	I
invasion.	O

Stem	B
cell	I
cultures	O
derived	O
from	O
pediatric	O
brain	O
tumors	O
accurately	O
model	O
the	O
originating	O
tumors.	O

Mesenchymal	B
stem	I
cells	I
differentially	O
affect	O
the	O
invasion	O
of	O
distinct	O
glioblastoma	O
cell	O
lines.	O

In	O
differentiating	O
stem	B
cell	I
cultures,	O
VEGFR3	O
is	O
expressed	O
by	O
subpopulations	O
of	O
endothelial	O
cells	O
in	O
growing	O
vessels,	O
some	O
of	O
which	O
may	O
transdifferentiate	O
to	O
become	O
early	O
lymphatic	O
structures	O
(Kreuger	O
et	O
al,	O
2006;	O
Adams	O
and	O
Alitalo,	O
2007).	O

These	O
patterns	O
apparently	O
derive,	O
at	O
least	O
in	O
part,	O
from	O
the	O
fact	O
that	O
mesenchymal	O
stem	O
cells	O
within	O
bone	O
marrow	O
can	O
develop	O
into	O
either	O
bone	O
forming	O
osteoblasts	O
or	O
fat	O
storing	O
adipocytes	O
[261],	O
such	O
that	O
stem	B
cell	I
up-	O
or	O
down-regulation	O
should	O
affect	O
both	O
tissues..	O

Identification	O
of	O
a	O
subpopulation	O
of	O
cells	O
with	O
cancer	B
stem	I
cell	I
properties	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma.	O

Transitions	O
between	O
epithelial	O
and	O
mesenchymal	O
states:	O
acquisition	O
of	O
malignant	O
and	O
stem	B
cell	I
traits.	O

Mesenchymal	B
stem	I
cells	I
deliver	O
synthetic	O
microRNA	O
mimics	O
to	O
glioma	O
cells	O
and	O
glioma	O
stem	O
cells	O
and	O
inhibit	O
their	O
cell	O
migration	O
and	O
self-renewal.	O

MicroRNA-145	O
Regulates	O
Neural	B
Stem	I
Cell	I
Differentiation	O
Through	O
the	O
Sox2-Lin28/let-7	O
Signaling	O
Pathway.	O

SNP-based	O
Bayesian	O
networks	O
can	O
predict	O
oral	O
mucositis	O
risk	O
in	O
autologous	B
stem	I
cell	I
transplant	O
recipients.	O

It	O
was	O
observed	O
that	O
HA	O
played	O
a	O
role	O
in	O
maintaining	O
PDMSC	O
in	O
slow-cell	O
cycling	O
mode	O
similar	O
to	O
stem	B
cell	I
quiescence	O
[15].	O

However,	O
the	O
MSC	O
eventually	O
lose	O
their	O
stem	B
cell	I
functions	O
as	O
cells	O
are	O
passaged	O
for	O
a	O
prolonged	O
period	O
of	O
time.	O

It	O
is	O
known	O
that	O
nuclear	O
structure	O
integrity	O
is	O
important	O
for	O
stem	B
cell	I
maintenance.	O

Apart	O
from	O
this,	O
HA	O
presence	O
provided	O
stem	O
cells	O
with	O
a	O
hypoxic	O
microenvironment	O
upon	O
cell	O
culture	O
for	O
embryonic	B
stem	I
cells	I
[69].	O

HMGA1	O
reprograms	O
somatic	O
cells	O
into	O
pluripotent	B
stem	I
cells	I
by	O
inducing	O
stem	O
cell	O
transcriptional	O
networks.	O

Oxygen	O
in	O
stem	O
cell	O
biology:	O
a	O
critical	O
component	O
of	O
the	O
stem	B
cell	I
niche.	O

This	O
work	O
was	O
supported	O
by	O
grants	O
from	O
the	O
Korea	O
Research	O
Institute	O
of	O
Bioscience	O
and	O
Biotechnology,	O
the	O
Korea	O
Research	O
Council	O
of	O
Fundamental	O
Science	O
and	O
Technology	O
(National	O
Agenda	O
Project),	O
and	O
the	O
Stem	B
Cell	I
Research	O
Program	O
(Grants	O
2010-0020549,	O
2010-0020305,	O
and	O
2011-0030028)	O
of	O
the	O
Korea	O
National	O
Research	O
Foundation..	O

The	O
correlation	O
between	O
human	B
adipose-derived	I
stem	I
cells	I
differentiation	O
and	O
cell	O
adhesion	O
mechanism.	O

Bmi-1	O
is	O
a	O
crucial	O
regulator	O
of	O
prostate	B
stem	I
cell	I
self-renewal	O
and	O
malignant	O
transformation.	O

This	O
obtaining	O
of	O
cells	O
was	O
funded	O
through	O
the	O
Maryland	B
Stem	I
Cell	I
Research	O
Act	O
of	O
2006.	O

With	O
this	O
in	O
mind,	O
cell	O
therapeutic	O
strategies	O
have	O
turned	O
to	O
non-neuronal	O
cells	O
(including	O
astrocytes,	O
but	O
also	O
myocytes,	O
oligodendrocytes,	O
microglia,	O
and	O
mesenchymal	O
stem	O
cells,	O
amongst	O
others)	O
for	O
their	O
potential	O
in	O
providing	O
motor	O
neuron	O
protection	O
and	O
slowing	O
disease	O
progression..	O
Funding:	O
The	O
work	O
was	O
supported	O
by:	O
National	O
Institutes	O
of	O
Health	O
(NIH)	O
F32-NS059155	O
(AL),	O
NIH	O
U01	O
NS062713	O
(NM,	O
JC,	O
LK),	O
The	O
Robert	O
Packard	O
Center	O
for	O
Lou	O
Gehrig's	O
Disease	O
(ALS)	O
Research	O
(NM),	O
Muscular	O
Dystrophy	O
Association	O
(NM),	O
The	O
ALS	O
Association	O
(NM),	O
The	O
Maryland	B
Stem	I
Cell	I
Research	O
Fund	O
(NM).	O

Combined	O
immunosuppressive	O
agents	O
or	O
CD4	O
antibodies	O
prolong	O
survival	O
of	O
human	B
neural	I
stem	I
cell	I
grafts	O
and	O
improve	O
disease	O
outcomes	O
in	O
amyotrophic	O
lateral	O
sclerosis	O
transgenic	O
mice.	O

Moreover,	O
a	O
very	O
recent	O
study	O
from	O
our	O
lab	O
performed	O
in	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
-derived	O
neurons	O
gives	O
further	O
support	O
to	O
clusterin	O
mediating	O
A	O
toxicity	O
(Robbins	O
et	O
al.,	O
2018),	O
showing	O
neurite	O
length	O
after	O
Aβ-insult	O
is	O
preserved	O
in	O
CLU-KO	O
cells.	O

Cell	B
Stem	I
Cell	I
24:	O
363.375	O
[PMC	O
free	O
article]	O
[PubMed]	O
[Google	O
Scholar].	O

(2007)	O
Induced	B
pluripotent	I
stem	I
cell	I
lines	O
derived	O
from	O
human	O
somatic	O
cells.	O

Collectively,	O
this	O
findings	O
indicate	O
that	O
the	O
tested	O
nanostructure	O
impair	O
invasiveness	O
and	O
breast	B
cancer	I
stem	I
cell	I
population..	O

Ki-67	O
depletion	O
showed	O
a	O
reduction	O
of	O
this	O
CSCs	O
subpopulation,	O
displayed	O
reduced	O
ability	O
of	O
tumour	O
formation,	O
suggesting	O
that	O
Ki-67	O
is	O
required	O
to	O
maintain	O
cancer	B
stem	I
cell	I
niche21.	O

Ki-67	O
is	O
required	O
for	O
maintenance	O
of	O
cancer	B
stem	I
cells	I
but	O
not	O
cell	O
proliferation.	O

Human	O
telomerase	O
is	O
not	O
active	O
in	O
most	O
somatic	O
cells,	O
but	O
is	O
critical	O
for	O
stem	B
cell	I
longevity.	O

Southern	O
blot	O
and	O
PCR	O
analysis	O
were	O
used	O
to	O
identify	O
homologous	O
recombinants	O
and	O
to	O
follow	O
the	O
Fatp4	O
mutant	O
alleles	O
during	O
the	O
generation	O
of	O
the	O
two	O
mouse	O
lines	O
F12K	O
and	O
F13K	O
derived	O
from	O
two	O
separate	O
embryonic	B
stem	I
cell	I
clones	O
(Fig.	O

Other	O
model	O
systems	O
have	O
more	O
robust	O
engraftment,	O
including	O
NOD/SCID/	O
2mnull	O
mice	O
and	O
NOD/SCID	O
mice	O
with	O
transgenic	O
expression	O
of	O
stem	B
cell	I
factor	O
(SCF),	O
granulocyte/macrophage-colony	O
stimulating	O
factor	O
(GM-CSF),	O
and	O
interleukin-3	O
(IL-3)	O
(N/S-SGM3	O
mice),	O
which	O
facilitate	O
AML	O
engraftment	O
and	O
proliferation100.	O

LY6E	O
is	O
a	O
member	O
of	O
the	O
Ly6	O
family	O
of	O
proteins,	O
and	O
the	O
protein	O
has	O
been	O
previously	O
referred	O
to	O
as	O
thymic	O
shared	O
antigen-1	O
(TSA-1)	O
or	O
stem	B
cell	I
antigen-2	O
(SCA-2).	O

A	O
goal	O
in	O
human	B
embryonic	I
stem	I
cell	I
research	O
is	O
the	O
faithful	O
differentiation	O
to	O
given	O
cell	O
types	O
such	O
as	O
neural	O
lineages.	O

The	O
cyst	O
method	O
for	O
neuroepithelial	O
differentiation	O
of	O
pluripotent	B
stem	I
cells	I
is	O
not	O
only	O
of	O
importance	O
for	O
RPE	O
generation	O
but	O
will	O
also	O
be	O
relevant	O
to	O
the	O
production	O
of	O
other	O
neuronal	O
cell	O
types	O
and	O
for	O
reconstituting	O
complex	O
patterning	O
events	O
from	O
three-dimensional	O
neuroepithelia..	O

To	O
reconstitute	O
efficient	O
and	O
faithful	O
differentiation	O
of	O
pluripotent	O
cells	O
toward	O
neural	O
cell	O
types,	O
we	O
sought	O
to	O
reconstitute	O
from	O
pluripotent	B
stem	I
cells	I
in	O
vitro	O
organized,	O
three-dimensional	O
neuroepithelial	O
structures	O
with	O
a	O
single	O
lumen.	O

Our	O
work	O
highlights	O
how	O
considering	O
the	O
cell	O
biological	O
context	O
of	O
pluripotent	B
stem	I
cells	I
while	O
culturing	O
can	O
significantly	O
improve	O
differentiation	O
and	O
the	O
subsequent	O
efficacy	O
of	O
therapeutic	O
outcomes..	O

Differentiation	O
of	O
RPE	O
cells	O
from	O
other	O
human	B
pluripotent	I
stem	I
cell	I
lines.	O

We	O
also	O
determined	O
if	O
our	O
method	O
was	O
effective	O
on	O
the	O
human	O
induced	O
pluripotent	O
stem	O
cell	O
line	O
O27-08,	O
which	O
was	O
reprogrammed	O
from	O
human	B
foetal	I
neural	I
stem	I
cells	I
(CB660)	O
[34].	O

(2012)	O
Embryonic	B
stem	I
cell	I
trials	O
for	O
macular	O
degeneration:	O
a	O
preliminary	O
report.	O

(2008)	O
Human	O
ES	O
cell-derived	O
neural	O
rosettes	O
reveal	O
a	O
functionally	O
distinct	O
early	O
neural	B
stem	I
cell	I
stage.	O

Therapeutic	O
effects	O
of	O
human	B
mesenchymal	I
stem	I
cell	I
microvesicles	O
in	O
an	O
ex	O
vivo	O
perfused	O
human	O
lung	O
injured	O
with	O
severe	O
E.	O

There	O
are	O
numerous	O
adult	O
tissues,	O
if	O
not	O
all,	O
that	O
have	O
the	O
ability	O
to	O
regenerate	O
themselves	O
due	O
to	O
the	O
existence	O
of	O
a	O
specific	O
population	O
of	O
adult	B
stem	I
cells	I
with	O
capacity	O
for	O
self-renewal	O
and	O
specification	O
within	O
their	O
cell	O
lineages	O
[30,31,32].	O

Human	O
germ	O
cell	O
formation	O
in	O
xenotransplants	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
carrying	O
X	O
chromosome	O
aneuploidies.	O

Derivation,	O
characterization,	O
differentiation,	O
and	O
registration	O
of	O
seven	O
human	B
embryonic	I
stem	I
cell	I
lines	O
(VAL-3,	O
-4,	O
-5,	O
-6M,	O
-7,	O
-8,	O
and	O
-9)	O
on	O
human	O
feeder.	O

Plzf	O
is	O
required	O
in	O
adult	O
male	O
germ	O
cells	O
for	O
stem	B
cell	I
self-renewal.	O

KIT	O
ligand	O
and	O
bone	O
morphogenetic	O
protein	O
signaling	O
enhances	O
human	O
embryonic	B
stem	I
cell	I
to	O
germ-like	O
cell	O
differentiation.	O

MPP(+)	O
decreases	O
store-operated	O
calcium	O
entry	O
and	O
TRPC1	O
expression	O
in	O
Mesenchymal	B
Stem	I
Cell	I
derived	O
dopaminergic	O
neurons.	O

The	O
leukemogenic	O
risk	O
of	O
integrating	O
retroviral	O
vectors	O
in	O
hematopoietic	B
stem	I
cell	I
gene	O
therapy	O
applications.	O

Few	O
cell	O
populations	O
such	O
as	O
adipose	B
stem	I
cells	I
[117],	O
adipose	O
tissue	O
stromal	O
cells	O
[161]	O
and	O
fetal	O
skin	O
cells	O
[109],	O
have	O
been	O
investigated.	O

For	O
this,	O
adipose	B
stem	I
cells	I
isolated	O
from	O
patients	O
tissues	O
were	O
integrated	O
within	O
an	O
equine	O
tendon	O
collagen	O
scaffold	O
to	O
provide	O
a	O
better	O
cell	O
delivery	O
system	O
to	O
the	O
burned	O
site.	O

Enhancement	O
of	O
human	B
adipose-derived	I
stem	I
cell	I
expansion	O
and	O
stability	O
for	O
clinical	O
use.	O

Mitochondria	O
as	O
central	O
regulators	O
of	O
neural	B
stem	I
cell	I
fate	O
and	O
cognitive	O
function.	O

Human	B
mesenchymal	I
stem	I
cell	I
and	O
epithelial	O
hepatic	O
carcinoma	O
cell	O
lines	O
in	O
admixture:	O
concurrent	O
stimulation	O
of	O
cancer-associated	O
fibroblasts	O
and	O
epithelial-to-mesenchymal	O
transition	O
markers.	O

The	O
acute	O
myeloid	O
leukemia	O
associated	O
AML1-ETO	O
fusion	O
protein	O
alters	O
the	O
transcriptome	O
and	O
cellular	O
progression	O
in	O
a	O
single-oncogene	O
expressing	O
in	O
vitro	B
induced	I
pluripotent	I
stem	I
cell	I
based	O
granulocyte	O
differentiation	O
model.	O

Here	O
we	O
describe	O
the	O
development	O
and	O
characterization	O
of	O
an	O
induced	B
pluripotent	I
stem	I
cell	I
system	O
that	O
allows	O
in	O
vitro	O
differentiation	O
towards	O
different	O
mature	O
myeloid	O
cell	O
types	O
such	O
as	O
monocytes	O
and	O
granulocytes.	O

In	O
humans,	O
t(8;21)	O
AMLs	O
are	O
characterized	O
by	O
cooperating	O
genetic	O
aberrations,	O
such	O
as	O
mutations	O
of	O
growth	O
factor	O
receptors,	O
proto-oncogenes,	O
and	O
transcription	O
factors	O
such	O
as	O
stem	B
cell	I
factor	O
receptor	O
(c-Kit),	O
FMS-related	O
tyrosine	O
kinase	O
(FLT3),	O
NRAS,	O
PU.1	O
and	O
AML1	O
[7].	O

The	O
acute	O
myeloid	O
leukemia	O
associated	O
AML1-ETO	O
fusion	O
protein	O
alters	O
the	O
transcriptome	O
and	O
cellular	O
progression	O
in	O
a	O
single-oncogene	O
expressing	O
in	O
vitro	B
induced	I
pluripotent	I
stem	I
cell	I
based	O
granulocyte	O
differentiation	O
model.	O

Substantial	O
variation	O
in	O
the	O
cardiac	O
differentiation	O
of	O
human	B
embryonic	I
stem	I
cell	I
lines	O
derived	O
and	O
propagated	O
under	O
the	O
same	O
conditions	O
a	O
comparison	O
of	O
multiple	O
cell	O
lines.	O

Transcriptome	O
variations	O
among	O
human	O
embryonic	B
stem	I
cell	I
lines	O
are	O
associated	O
with	O
their	O
differentiation	O
propensity.	O

As	O
an	O
alternative,	O
adult	O
stem	O
cells	O
and	O
pluripotent	B
stem	I
cells	I
can	O
afford	O
the	O
convenience	O
of	O
a	O
highly	O
expandable	O
and	O
standardized	O
cell	O
source	O
without	O
the	O
need	O
for	O
viral	O
immortalization.	O

Researchers	O
can	O
readily	O
derive	O
adult	B
stem	I
cells	I
from	O
several	O
human	O
tissues	O
[[113],	O
[114],	O
[115]]	O
and	O
pluripotent	O
embryonic	O
stem	O
cells	O
(hESC)	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
a	O
fertilized	O
blastocyst	O
[116].	O

Enteric	B
neural	I
stem	I
cells	I
have	O
been	O
identified	O
as	O
a	O
possible	O
treatment	O
for	O
enteric	O
neuropathies.	O

Increasing	O
evidence	O
indicates	O
that	O
Wnts	O
may	O
function	B
stem	I
cells	I
as	O
key	O
regulators	O
in	O
osteogenic	O
differentiation	O
of	O
mesenchymal	O
stem	O
cells	O
and	O
bone	O
formation.	O

In	O
addition,	O
PCB	O
126	O
suppressed	O
osteoblastogenesis	O
in	O
primary	B
bone	I
marrow	I
mesenchymal	I
stem	I
cell	I
cultures	O
which	O
was	O
blunted	O
by	O
the	O
AhR	O
antagonist	O
CH-223191.	O

Moreover,	O
the	O
calcimimetic	O
promoted	O
the	O
osteogenic	O
differentiation	O
and	O
mineralization	O
of	O
human	B
bone	I
marrow	I
mesenchymal	I
stem	I
cells	I
in	O
vitro.	O

The	O
interaction	O
of	O
paricalcitol	O
with	O
the	O
vitamin	O
D	O
receptor	O
(VDR)	O
in	O
mononuclear	O
spleen	O
cells	O
and	O
myeloid	B
stem	I
cells	I
from	O
wild-type	O
and	O
VDR	O
knockout	O
mice	O
was	O
examined.	O

Paricalcitol	O
induced	O
committed	O
myeloid	B
hematopoietic	I
stem	I
cells	I
from	O
wild-type	O
but	O
not	O
from	O
VDR	O
knockout	O
mice	O
to	O
differentiate	O
as	O
macrophages..	O

A	O
longitudinal	O
study	O
was	O
performed	O
in	O
81	O
patients	O
undergoing	O
bone	O
marrow	O
or	O
peripheral	B
blood	I
stem	I
cell	I
transplantation.	O

If	O
the	O
curative	O
role	O
of	O
bone	B
marrow-derived	I
stem	I
cells	I
was	O
confirmed	O
by	O
more	O
data	O
obtained	O
in	O
experimental	O
animal	O
models,	O
it	O
could	O
be	O
possible	O
to	O
try	O
a	O
cellular-based	O
therapeutic	O
approach	O
in	O
the	O
management	O
of	O
ESRD	O
patients	O
which	O
are	O
in	O
waiting	O
list	O
for	O
a	O
kidney	O
transplant.	O

This	O
study	O
assessed	O
the	O
feasibility	O
of	O
using	O
an	O
ex	B
vivo	I
stem	I
cell	I
antigen-1-positive	O
(Sca-1(+))	O
cell-based	O
systemic	O
fibroblast	O
growth	O
factor-2	O
(FGF-2)	O
gene	O
therapy	O
to	O
promote	O
endosteal	O
bone	O
formation.	O

While	O
human	O
embryonic	O
stem	O
cells	O
have	O
provided	O
the	O
precedent	O
for	O
regenerative	O
medicine,	O
the	O
development	O
of	O
induced	O
pluripotent	B
stem	I
cells	I
revolutionized	O
this	O
field.	O

The	O
aim	O
of	O
the	O
work	O
was	O
to	O
demonstrate	O
possible	O
therapeutic	O
effect	O
of	O
the	O
joined	O
suprachoroidal	O
graft	O
of	O
adipocytes,	O
adipose-derived	B
stem	I
cells	I
in	O
stromal	O
vascular	O
fractions	O
(SVFs)	O
of	O
adipose	O
tissue,	O
and	O
platelet-rich	O
plasma	O
(PRP).	O

This	O
study	O
aimed	O
to	O
utilize	O
human	B
induced	I
pluripotent	I
stem	I
cell	I
technology	O
to	O
create	O
a	O
disease	O
model	O
for	O
the	O
disorder,	O
and	O
to	O
derive	O
clues	O
for	O
retinopathy	O
pathogenesis.	O

To	O
investigate	O
the	O
role	O
of	O
the	O
Fhit	O
gene	O
in	O
carcinogen	O
induction	O
of	O
neoplasia,	O
we	O
have	O
inactivated	O
one	O
Fhit	O
allele	O
in	O
mouse	B
embryonic	I
stem	I
cells	I
and	O
produced	O
(129/SvJ	O
x	O
C57BL/6J)	O
F(1)	O
mice	O
with	O
a	O
Fhit	O
allele	O
inactivated	O
(+/-).	O

The	O
recent	O
advent	O
of	O
induced	B
pluripotent	I
stem	I
cells	I
has	O
provided	O
the	O
ability	O
to	O
generate	O
patient-specific	O
human	O
neurons	O
from	O
somatic	O
cells.	O

They	O
may	O
contribute	O
to	O
the	O
spermatogonial	B
stem	I
cell	I
niche	O
via	O
secreted	O
factors.	O

Mesenchymal	B
stem	I
cell	I
therapy	O
is	O
one	O
of	O
the	O
possible	O
treatments	O
for	O
this	O
disease.	O

Here,	O
we	O
assessed	O
the	O
potential	O
therapeutic	O
effect	O
of	O
HDAC6	O
inhibitors	O
on	O
peripheral	O
neuropathy	O
with	O
<i>HSPB1</i>	O
mutation	O
using	O
in	O
vitro	O
model	O
of	O
motor	O
neurons	O
derived	O
from	O
induced	B
pluripotent	I
stem	I
cells	I
of	O
CMT2F	O
and	O
dHMN2B	O
patients.	O

Multiple	O
CH	O
genes	O
are	O
key	O
regulators	O
of	O
neural	B
stem	I
cell	I
biology	O
and	O
converge	O
in	O
human	O
transcriptional	O
networks	O
and	O
cell	O
types	O
pertinent	O
for	O
fetal	O
neuro-gliogenesis.	O

We	O
previously	O
demonstrated	O
that	O
transplanting	O
mesenchymal	B
stem	I
cells	I
improved	O
recovery	O
from	O
brain	O
injury	O
induced	O
by	O
severe	O
intraventricular	O
hemorrhage	O
(IVH)	O
in	O
newborn	O
rats.	O

Neural	B
stem	I
cells	I
offer	O
the	O
prospect	O
of	O
a	O
cure	O
given	O
their	O
potential	O
ability	O
to	O
replenish	O
missing	O
or	O
dysfunctional	O
neurons.	O

Key	O
milestones	O
include	O
the	O
harvesting	O
of	O
neural	B
stem	I
cells	I
from	O
the	O
human	O
gut	O
and	O
the	O
latest	O
in	O
vivo	O
transplantation	O
studies	O
in	O
animals.	O

This	O
White	O
Paper	O
sets	O
out	O
experts'	O
views	O
on	O
the	O
commonly	O
used	O
methods	O
and	O
approaches	O
to	O
identify,	O
isolate,	O
purify,	O
expand	O
and	O
optimize	O
ENS	B
stem	I
cells,	I
transplant	O
them	O
into	O
the	O
bowel,	O
and	O
assess	O
transplant	O
success,	O
including	O
restoration	O
of	O
gut	O
function.	O

As	O
initial	O
validation	O
of	O
the	O
model,	O
we	O
compared	O
expression	O
ofTAF1and	O
MTS	O
transcripts	O
in	O
XDP	O
versus	O
control	O
fibroblasts	O
and	O
iPSC-derived	B
neural	I
stem	I
cells.	I

Human	B
pluripotent	I
stem	I
cells	I
with	O
knockout	O
or	O
mutant	O
alleles	O
can	O
be	O
generated	O
using	O
custom-engineered	O
nucleases.	O

Neural	B
stem	I
cells	I
are	O
being	O
investigated	O
as	O
potential	O
therapies	O
for	O
neurodegenerative	O
diseases,	O
such	O
as	O
stroke	O
and	O
trauma.	O

Future	O
therapies	O
for	O
AAK	O
may	O
be	O
aimed	O
at	O
the	O
genetic	O
modification	O
of	O
corneal	B
limbal	I
stem	I
cells.	I

Homologous	O
recombination	O
in	O
embryonic	B
stem	I
cells	I
was	O
performed	O
using	O
a	O
plasmid	O
containing	O
the	O
C	O
to	O
T	O
transition	O
in	O
exon	O
1	O
of	O
the	O
cryaa	O
gene.	O

The	O
established	O
patient-derived	O
iPSC	O
displayed	O
all	O
the	O
features	O
of	O
pluripotent	B
stem	I
cell	I
markers	O
and	O
had	O
the	O
ability	O
to	O
differentiate	O
into	O
all	O
of	O
the	O
three	O
germ	O
layers	O
and	O
possessed	O
a	O
normal	O
karyotype.	O

Mesenchymal	B
stem	I
cells	I
inhibit	O
the	O
proliferation	O
or	O
activation	O
of	O
lymphocytes,	O
and	O
their	O
inhibitory	O
effects	O
do	O
not	O
require	O
human	O
leukocyte	O
antigen	O
(HLA)-matching	O
because	O
MSCs	O
express	O
low	O
levels	O
of	O
HLA	O
molecules.	O

Mesenchymal	B
stem	I
cells	I
have	O
immunoregulatory	O
and	O
proangiogenic	O
effects	O
and	O
are	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
pathological	O
processes	O
of	O
immune-related	O
diseases,	O
including	O
psoriasis.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
psoriatic	O
dermal	B
mesenchymal	I
stem	I
cells	I
stimulated	O
keratinocyte	O
(KC)	O
proliferation	O
and	O
that	O
psoriasis	O
exhibited	O
missense	O
SPRED1	O
mutations.	O

Whether	O
dermal-derived	B
mesenchymal	I
stem	I
cells,	I
the	O
main	O
MSCs	O
in	O
the	O
dermis,	O
regulate	O
keratinocyte	O
proliferation	O
and	O
apoptosis	O
remains	O
unknown.	O

Infection	O
of	O
marrow	O
mesenchymal	B
stem	I
cells	I
may	O
abrogate	O
their	O
growth	O
properties	O
and	O
hematopoietic	O
supportive	O
functions.	O

Human	O
embryonic	O
stem	O
cells	O
provide	O
an	O
alternative	O
source	O
for	O
mesenchymal	B
stem	I
cells	I
because	O
of	O
their	O
similarities	O
in	O
phenotype	O
and	O
immunomodulatory	O
and	O
anti-inflammatory	O
characteristics.	O

Cardiac	B
stem	I
cell	I
markers	O
(C-kit(+)	O
and	O
Sca-1(+)	O
cells)	O
were	O
significantly	O
and	O
progressively	O
increased	O
from	O
group	O
1	O
to	O
group	O
3.	O

Mesenchymal	B
stem	I
cells	I
have	O
many	O
properties	O
that	O
make	O
them	O
suitable	O
for	O
preventive	O
and/or	O
regenerative	O
therapies.	O

Here,	O
we	O
show	O
that	O
menstrual-derived	B
stem	I
cells	I
are	O
easy	O
to	O
access	O
and	O
exhibit	O
mesenchymal	O
stem	O
cell-like	O
properties.	O

We	O
present	O
two	O
cases	O
of	O
Wiskott-Aldrich	O
syndrome	O
(WAS),	O
in	O
which	O
nonsense	O
mutations	O
in	O
the	O
WASP	O
gene	O
were	O
corrected	O
phenotypically	O
as	O
well	O
as	O
genotypically	O
by	O
unrelated	O
cord	B
blood	I
stem	I
cell	I
transplantation	O
(CBSCT).	O

Consistent	O
with	O
this	O
finding,	O
we	O
further	O
demonstrate	O
that	O
mouse	B
embryonic	I
stem	I
cells	I
deficient	O
in	O
Notch1	O
(Notch1(-/-))	O
or	O
Pofut1	O
(Pofut1(-/-))	O
fail	O
to	O
generate	O
T	O
lymphocytes	O
but	O
differentiate	O
into	O
myeloid	O
cells	O
while	O
coculturing	O
with	O
Notch	O
ligand-expressing	O
bone	O
marrow	O
stromal	O
cells	O
in	O
vitro.	O

Moreover,	O
in	O
vivo	O
hematopoietic	O
reconstitution	O
of	O
CD34(+)	O
progenitor	O
cells	O
derived	O
from	O
either	O
Notch1(-/-)	O
or	O
Pofut1(-/-)	O
embryonic	B
stem	I
cells	I
show	O
enhanced	O
granulopoiesis	O
with	O
depressed	O
lymphoid	O
lineage	O
development.	O

Antibody	O
to	O
L-selectin	O
decreased	O
the	O
engraftment	O
of	O
BCR-ABL1-transduced	B
stem	I
cells.	I

Notch	O
signaling	O
is	O
required	O
for	O
postnatal	O
hair	O
cycle	O
homeostasis	O
by	O
maintaining	O
proper	O
proliferation	O
and	O
differentiation	O
of	O
hair	B
follicle	I
stem	I
cells.	I

Following	O
homologous	O
recombination	O
in	O
embryonic	B
stem	I
cells	I
and	O
Cre	O
mediated	O
gene	O
deletion,	O
Mgat3-deficient	O
mice	O
were	O
produced	O
that	O
lacked	O
GlcNAc-TIII	O
activity	O
and	O
were	O
deficient	O
in	O
E4-PHA	O
visualized	O
GlcNAc-bisected	O
N-linked	O
oligosaccharides.	O

Pluripotent	B
stem	I
cell	I
technology	O
offers	O
a	O
promising	O
approach	O
for	O
studying	O
human	O
melanocyte	O
development	O
and	O
disease.	O

HOTAIRM1	O
transcripts	O
are	O
induced	O
during	O
renal	O
lineage	O
differentiation	O
of	O
embryonic	B
stem	I
cells	I
and	O
required	O
for	O
expression	O
of	O
specific	O
renal	O
differentiation	O
genes.	O

Consistent	O
with	O
that	O
notion,	O
peri-implantation	O
lethality	O
of	O
E4F1	O
KO	O
embryos	O
is	O
not	O
rescued	O
by	O
concomitant	O
inactivation	O
of	O
p53	O
(unpublished	O
data),	O
and	O
E4F1	B
KO	I
epidermal	I
stem	I
cell	I
defects	O
are	O
partly	O
but	O
not	O
fully	O
rescued	O
upon	O
genetic	O
inactivation	O
of	O
the	O
p53	O
pathway	O
(Lacroix	O
et	O
al.,	O
2010).	O

Transcription	O
factor	O
E4F1	O
is	O
essential	O
for	O
epidermal	B
stem	I
cell	I
maintenance	O
and	O
skin	O
homeostasis.	O

Thus,	O
adequate	O
telomerase	O
activity	O
could	O
maintain	O
tissue	B
stem	I
cell	I
function	O
in	O
WS	O
(Cheung	O
et	O
al.,	O
2014).	O

Effects	O
of	O
telomerase	O
and	O
telomere	O
length	O
on	O
epidermal	B
stem	I
cell	I
behavior.	O

A	O
human	O
iPSC	O
model	O
of	O
Hutchinson	O
Gilford	O
Progeria	O
reveals	O
vascular	O
smooth	O
muscle	O
and	O
mesenchymal	B
stem	I
cell	I
defects.	O

AluY-mediated	O
germline	O
deletion,	O
duplication	O
and	O
somatic	B
stem	I
cell	I
reversion	O
in	O
UBE2T	O
defines	O
a	O
new	O
subtype	O
of	O
Fanconi	O
anemia.	O

coli-derived	O
rhLIF	O
in	O
traditional	O
and	O
embryonic	B
mouse	I
stem	I
cell	I
systems.	O

Development	O
of	O
fully	O
defined	O
xeno-free	O
culture	O
system	O
for	O
the	O
preparation	O
and	O
propagation	O
of	O
cell	O
therapy-compliant	O
human	B
adipose	I
stem	I
cells.	I

Nanog	O
and	O
transcriptional	O
networks	O
in	O
embryonic	B
stem	I
cell	I
pluripotency.	O

Modeling	O
a	O
genetic	O
risk	O
for	O
schizophrenia	O
in	O
iPSCs	O
and	O
mice	O
reveals	O
neural	B
stem	I
cell	I
deficits	O
associated	O
with	O
adherens	O
junctions	O
and	O
polarity.	O

Next	O
to	O
cardiac	O
tissue	O
derived	O
cell	O
types,	O
embryonic	B
stem	I
cell	I
derived-	O
and	O
induced	O
pluripotent	O
derived	O
cardiomyocytes	O
(ESC-CMs	O
and	O
IPCS-CMc)	O
may	O
hold	O
promise	O
for	O
cardiac	O
regenerative	O
therapy.	O

A	O
quantitative,	O
randomized	O
study	O
evaluating	O
three	O
methods	O
of	O
mesenchymal	B
stem	I
cell	I
delivery	O
following	O
myocardial	O
infarction.	O

Human	B
embryonic	I
stem	I
cells	I
hold	O
great	O
promise	O
as	O
cell	O
replacement	O
therapy	O
for	O
lost	O
photoreceptor	O
and	O
RPE	O
cells	O
in	O
GA	O
lesions.	O

Embryonic	B
stem	I
cell	I
trials	O
for	O
macular	O
degeneration:	O
a	O
preliminary	O
report.	O

These	O
data	O
suggest	O
that	O
the	O
development	O
of	O
neural	B
crest	I
stem	I
cells	I
is	O
involved	O
in	O
craniofacial	O
malformations	O
[30],	O
and	O
the	O
malformations	O
observed	O
in	O
individuals	O
with	O
Miller	O
syndrome	O
could	O
be	O
caused	O
by	O
failure	O
of	O
correct	O
neural	O
crest	O
cell	O
development	O
because	O
of	O
loss	O
of	O
DHODH	O
function.	O

Alternatively,	O
IFN	O
response	O
gene	O
expression	O
may	O
confer	O
pathogen	O
resistance	O
and	O
preserve	O
progenitors,	O
analogous	O
to	O
viral	O
resistance	O
of	O
human	O
embryonic	O
stem	O
cells	O
and	O
differentiated	O
neural	B
stem	I
cell	I
progeny	O
(Wu	O
et	O
al.,	O
2018).	O

Effects	O
of	O
Exendin-4	O
on	O
bone	B
marrow	I
mesenchymal	I
stem	I
cell	I
proliferation,	O
migration	O
and	O
apoptosis	O
in	O
vitro.	O

Mesenchymal	B
stem	I
cell	I
delivery	O
strategies	O
to	O
promote	O
cardiac	O
regeneration	O
following	O
ischemic	O
injury.	O

Prolonged	O
hypoxia	O
concomitant	O
with	O
serum	O
deprivation	O
induces	O
massive	O
human	B
mesenchymal	I
stem	I
cell	I
death.	O

Nerve	O
growth	O
factor	O
induces	O
cord	O
formation	O
of	O
mesenchymal	B
stem	I
cell	I
by	O
promoting	O
proliferation	O
and	O
activating	O
the	O
PI3K/Akt	O
signaling	O
pathway.	O

SDF-1/CXCR4	O
axis	O
modulates	O
bone	B
marrow	I
mesenchymal	I
stem	I
cell	I
apoptosis,	O
migration	O
and	O
cytokine	O
secretion.	O

sFRP2	O
suppression	O
of	O
bone	O
morphogenic	O
protein	O
(BMP)	O
and	O
Wnt	O
signaling	O
mediates	O
mesenchymal	B
stem	I
cell	I
self-renewal	O
promoting	O
engraftment	O
and	O
myocardial	O
repair.	O

Reconstitution	O
of	O
B	O
cell	O
subsets	O
in	O
Rag	O
deficient	O
mice	O
by	O
transplantation	O
of	O
in	O
vitro	O
differentiated	O
embryonic	B
stem	I
cells.	I

Human	B
Mesenchymal	I
stem	I
cell	I
suspensions	O
10	O
mM	O
DNPH	O
20%	O
TCA	O
(v/v)	O
360	O
nm	O
20–70	O
µmol/103	O
cells	O
[36,37].	O

Furthermore,	O
BCOR’s	O
major	O
role	O
in	O
embryonic	B
stem	I
cell	I
differentiation	O
may	O
be	O
significantly	O
altered	O
by	O
inheritance	O
of	O
downregulated	O
expression	O
as	O
a	O
result	O
of	O
maternal	O
smoking	O
[43].	O

Role	O
of	O
the	O
transcriptional	O
corepressor	O
Bcor	O
in	O
embryonic	B
stem	I
cell	I
differentiation	O
and	O
early	O
embryonic	O
development.	O

An	O
alternative	O
splicing	O
switch	O
regulates	O
embryonic	B
stem	I
cell	I
pluripotency	O
and	O
reprogramming.	O

MicroRNAs	O
to	O
Nanog,	O
Oct4	O
and	O
Sox2	O
coding	O
regions	O
modulate	O
embryonic	B
stem	I
cell	I
differentiation.	O

Anthracycline	O
cardiomyopathy	O
is	O
mediated	O
by	O
depletion	O
of	O
the	O
cardiac	B
stem	I
cell	I
pool	O
and	O
is	O
rescued	O
by	O
restoration	O
of	O
progenitor	O
cell	O
function.	O

Identification	O
of	O
a	O
neural	B
stem	I
cell	I
in	O
the	O
adult	O
mammalian	O
central	O
nervous	O
system.	O

Mesenchymal	B
stem	I
cells,	I
also	O
referred	O
to	O
as	O
multipotent	O
mesenchymal	O
stromal	O
cells,	O
have	O
been	O
a	O
focus	O
of	O
recent	O
research,	O
partially	O
because	O
they	O
are	O
an	O
extraordinary	O
model	O
for	O
investigating	O
the	O
biological	O
mechanisms	O
that	O
allow	O
a	O
cellular	O
population	O
to	O
generate	O
diverse	O
cell	O
types	O
and	O
because	O
they	O
are	O
a	O
potential	O
tool	O
in	O
cellular	O
therapies	O
for	O
several	O
clinical	O
applications.	O

The	O
immunosuppressive	O
effects	O
of	O
human	B
bone	I
marrow-derived	I
mesenchymal	I
stem	I
cells	I
target	O
T	O
cell	O
proliferation	O
but	O
not	O
its	O
effector	O
function.	O

Mesenchymal	B
stem	I
cells	I
inhibit	O
human	O
Th17	O
cell	O
differentiation	O
and	O
function	O
and	O
induce	O
a	O
T	O
regulatory	O
cell	O
phenotype.	O

Mesenchymal	B
stem	I
cells	I
generate	O
a	O
CD4+CD25+Foxp3+	O
regulatory	O
T	O
cell	O
population	O
during	O
the	O
differentiation	O
process	O
of	O
Th1	O
and	O
Th17	O
cells.	O

Cell	O
contact,	O
prostaglandin	O
E2	O
and	O
transforming	O
growth	O
factor	O
beta	O
1	O
play	O
non-redundant	O
roles	O
in	O
human	B
mesenchymal	I
stem	I
cell	I
induction	O
of	O
CD4+CD25Highforkhead	O
box	O
P3+	O
regulatory	O
T	O
cells.	O

Autologous	B
mesenchymal	I
stem	I
cell	I
treatment	O
increased	O
T	O
regulatory	O
cells	O
with	O
no	O
effect	O
on	O
disease	O
activity	O
in	O
two	O
systemic	O
lupus	O
erythematosus	O
patients.	O

Galectin-1	O
and	O
semaphorin-3A	O
are	O
two	O
soluble	O
factors	O
conferring	O
t-cell	O
immunosuppression	O
to	O
bone	B
marrow	I
mesenchymal	I
stem	I
cell.	I

Evidence	O
for	O
the	O
involvement	O
of	O
galectin-3	O
in	O
mesenchymal	B
stem	I
cell	I
suppression	O
of	O
allogeneic	O
T-cell	O
proliferation.	O

A	O
new	O
mesenchymal	B
stem	I
cell	I
paradigm:	O
polarization	O
into	O
a	O
pro-inflammatory	O
MSC1	O
or	O
an	O
immunosuppressive	O
MSC2	O
phenotype.	O

Mesenchymal	B
stem	I
cells	I
for	O
treatment	O
and	O
prevention	O
of	O
graft-versus-host	O
disease	O
after	O
allogeneic	O
hematopoietic	O
cell	O
transplantation.	O

Mesenchymal	B
stem	I
cell	I
as	O
salvage	O
treatment	O
for	O
refractory	O
chronic	O
GVHD.	O

Allogeneic	B
mesenchymal	I
stem	I
cell	I
transplantation	O
in	O
severe	O
and	O
refractory	O
systemic	O
lupus	O
erythematosus:	O
4	O
years	O
of	O
experience.	O

CD8	O
T	O
cell/indoleamine	O
2,3-dioxygenase	O
axis	O
is	O
required	O
for	O
mesenchymal	B
stem	I
cell	I
suppression	O
of	O
human	O
systemic	O
lupus	O
erythematosus.	O

Umbilical	B
cord	I
mesenchymal	I
stem	I
cell	I
transplantation	O
in	O
active	O
and	O
refractory	O
systemic	O
lupus	O
erythematosus:	O
a	O
multicenter	O
clinical	O
study.	O

The	O
therapeutic	O
effect	O
of	O
mesenchymal	B
stem	I
cell	I
transplantation	O
in	O
experimental	O
autoimmune	O
encephalomyelitis	O
is	O
mediated	O
by	O
peripheral	O
and	O
central	O
mechanisms.	O

Mesenchymal	B
stem	I
cells	I
differentially	O
modulate	O
effector	O
CD8+	O
T	O
cell	O
subsets	O
and	O
exacerbate	O
experimental	O
autoimmune	O
encephalomyelitis.	O

Safety	O
and	O
immunological	O
effects	O
of	O
mesenchymal	B
stem	I
cell	I
transplantation	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
and	O
amyotrophic	O
lateral	O
sclerosis.	O

Mesenchymal	B
stem	I
cell	I
transplantation	O
in	O
amyotrophic	O
lateral	O
sclerosis:	O
a	O
phase	O
I	O
clinical	O
trial.	O

Adoptive	O
transfer	O
of	O
human	B
gingiva-derived	I
mesenchymal	I
stem	I
cells	I
ameliorates	O
collagen-induced	O
arthritis	O
via	O
suppression	O
of	O
Th1	O
and	O
Th17	O
cells	O
and	O
enhancement	O
of	O
regulatory	O
T	O
cell	O
differentiation.	O

In	O
this	O
study,	O
pluripotent	B
stem	I
cell	I
articles	O
published	O
from	O
1991	O
to	O
2012	O
were	O
screened	O
and	O
retrieved	O
from	O
Science	O
Citation	O
Index	O
Expanded	O
(SCI-EXPANDED).	O

In	O
this	O
research,	O
the	O
pluripotent	B
stem	I
cell	I
literature	O
published	O
from	O
1991	O
to	O
2012	O
was	O
screened,	O
and	O
highly	O
cited	O
articles	O
in	O
total	O
citations	O
as	O
well	O
as	O
citations	O
in	O
last	O
year	O
and	O
publication	O
year	O
were	O
identified	O
and	O
compared	O
for	O
impact	O
in	O
literature.	O

In	O
recent	O
years,	O
more	O
pluripotent	B
stem	I
cell	I
related	O
articles	O
have	O
been	O
published	O
and	O
the	O
keywords	O
are	O
not	O
always	O
found	O
in	O
the	O
article	O
titles.	O

The	O
leading	O
institution	O
was	O
Harvard	O
University	O
in	O
the	O
USA,	O
which	O
published	O
147	O
pluripotent	B
stem	I
cell	I
related	O
articles	O
from	O
1991	O
to	O
2012	O
in	O
SCI-EXPANDED.	O

Mir-29b	O
Mediates	O
the	O
Neural	O
Tube	O
versus	O
Neural	O
Crest	O
Fate	O
Decision	O
during	O
Embryonic	B
Stem	I
Cell	I
Neural	O
Differentiation.	O

Cardiac	B
stem	I
cell	I
therapy	O
has	O
shown	O
encouraging	O
initial	O
results	O
in	O
treating	O
heart	O
disease	O
1-3,	O
yet	O
is	O
plagued	O
by	O
poor	O
long-term	O
efficacy	O
because	O
of	O
rapid	O
cell	O
death	O
after	O
implantation	O
2,	O
4.	O